<SEC-DOCUMENT>0000849146-24-000073.txt : 20240828
<SEC-HEADER>0000849146-24-000073.hdr.sgml : 20240828
<ACCEPTANCE-DATETIME>20240828160536
ACCESSION NUMBER:		0000849146-24-000073
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240828
DATE AS OF CHANGE:		20240828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				900224471
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35647
		FILM NUMBER:		241255427

	BUSINESS ADDRESS:	
		STREET 1:		3300 TRIUMPH BLVD
		STREET 2:		SUITE 700
		CITY:			LEHI
		STATE:			UT
		ZIP:			84043
		BUSINESS PHONE:		801-432-9000

	MAIL ADDRESS:	
		STREET 1:		3300 TRIUMPH BLVD
		STREET 2:		SUITE 700
		CITY:			LEHI
		STATE:			UT
		ZIP:			84043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lfvn-20240630.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66,d:e82fc05bf17d40b3a7e7f8db7a0f9606-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:lfvn="http://www.lifevantage.com/20240630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lfvn-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0000849146</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-118">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-119">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-510">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-626">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-627">0.0833</ix:nonFraction><ix:nonNumeric contextRef="c-131" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-747">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lfvn-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>lfvn:lease</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lfvn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="region"><xbrli:measure>lfvn:region</xbrli:measure></xbrli:unit><xbrli:unit id="productline"><xbrli:measure>lfvn:productLine</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">lfvn:CashAccountsHeldPrimarilyAtFinancialInstitutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">lfvn:CashAccountsHeldatOtherFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lfvn:AsiaPacificAndEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lfvn:AsiaPacificAndEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimandTrueScienceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimandTrueScienceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-16</xbrli:startDate><xbrli:endDate>2017-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000849146</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">June&#160;30</ix:nonNumeric>, 2024</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________ to __________ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-35647</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">LIFEVANTAGE CORP</ix:nonNumeric>ORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">90-0224471</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3300 N. Triumph Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 700</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Lehi</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">Utah</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">84043</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, including zip code)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">801</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">432-9000</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">LFVN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.    Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock held by non-affiliates as of December&#160;29, 2023, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-30">68.1</ix:nonFraction> million, based on a closing market price of $6.00 per share. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock (par value $0.0001) outstanding as of August&#160;27, 2024 was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">12,479,185</ix:nonFraction> s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hares.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true">Portions of the registrant&#8217;s definitive proxy statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s fiscal year 2025 annual meeting of stockholders are incorporated by reference into Part III of this report. Such definitive proxy statement will be filed with the Commission not later than 120 days after the end of the registrant&#8217;s fiscal year ended June 30, 2024.</ix:nonNumeric> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements contained in this report and the information incorporated by reference herein may contain &#8220;forward-looking statements&#8221; (as such term is defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). These statements, which involve risks and uncertainties, reflect our current expectations, intentions, or strategies regarding our possible future results of operations, performance, and achievements. Forward-looking statements include, without limitation: statements regarding future products or product development; statements regarding future selling, general and administrative costs and research and development spending; statements regarding the future performance of our network marketing efforts; statements regarding our expectations regarding ongoing litigation; statements regarding international growth; and statements regarding future financial performance, results of operations, capital expenditures and sufficiency of capital resources to fund our operating requirements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable rules of the Securities and Exchange Commission ("SEC") and common law.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements may be identified in this report and the information incorporated by reference by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should&#8221; and similar terms and expressions, including references to assumptions and strategies. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, these statements are subject to certain risks, uncertainties, and contingencies, which could cause our actual results, performance, or achievements to differ materially from those expressed in, or implied by, such statements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following factors are among those that may cause actual results to differ materially from our forward-looking statements:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to properly manage, motivate and retain our independent consultants (which we previously referred to as &#8220;distributors &#8221; in our prior filings) or to attract new customers and independent consultants on an ongoing basis;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-compliance by our independent consultants with applicable legal requirements or our policies and procedures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to our independent consultant compensation plans;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence upon a few products for revenue;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence on third parties to manufacture our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sourcing and pricing of high quality materials for our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions to the transportation channels used to distribute our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of being subject to a product recall;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability claims against us;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition in the dietary supplement and personal care markets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable publicity on our business or products; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actions by activist stockholders;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of or inability to attract key personnel;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of being held responsible for certain taxes or assessments and other obligations relating to the activity of our independent consultants;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk related to Global Not For Resale program;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to comply with evolving laws, regulations, standards, policies, and contractual obligations related to data privacy and security, including cybersecurity; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to manage existing markets, open new international markets or expand our operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability of new products and technological innovations to gain customer or independent consultant or market acceptance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to execute our product launch process due to increased pressure on our supply chain, information systems and management;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to appropriately manage our inventory;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions in our information technology ("IT") systems, including as a result of cybersecurity incidents;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to comply with financial covenants imposed by our credit facility and the impact of debt service obligations and restrictive debt covenants;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International trade or foreign exchange restrictions, increased tariffs, foreign currency exchange fluctuations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to raise additional capital or complete desired acquisitions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strict government regulations on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulations governing the production or marketing of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of investigatory and enforcement action;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of our direct selling program being found non-compliant with current or newly adopted laws or regulations in various markets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laws and regulations prohibiting or severely restricting direct selling;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International regulatory and business risks, including failure to comply with anti-corruption laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to protect our intellectual property rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party intellectual property infringement claims;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility of the market price of our common stock; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of substantial sales of shares negatively impacting the market price of our common stock;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability of share repurchase program enhancing long-term stockholder value;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of additional shares issued diluting voting power of current outstanding common stock or causing decline in stock price;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential delisting of our common stock due to non-compliance with Nasdaq's continued listing requirements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to being a smaller reporting company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limitations for disputes, mergers, tender offers, or proxy contests under Delaware law;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expense and time consuming legal proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ineffectiveness of internal controls over financial reporting;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to tax positions or transfer pricing policies or change in laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Economic, political, foreign exchange and other risks associated with international operations, including consumer discretionary spending habits;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable global economic conditions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Securities class action litigation; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Securities or industry analysts ceasing coverage or publishing inaccurate or unfavorable research.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering these forward-looking statements, you should keep in mind the cautionary statements in this report and the documents incorporated by reference. Except as required by law, we have no obligation and do not undertake to update or revise any such forward-looking statements to reflect events or circumstances after the date of this report.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties associated with our business, many of which are beyond our control. Some of the more significant risks associated with our business that may cause actual results to differ materially from our forward-looking statements include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An inability to properly motivate and incentivize sales from our independent consultants could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain our existing customers and independent consultants or attract additional customers and independent consultants, our revenue will not increase and may decline further.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our independent consultants could fail to comply with applicable legal requirements or our policies and procedures, which could result in claims against us that could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We primarily depend on a few products for our revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent upon third parties to manufacture our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to evolving laws, policies, and contractual obligations related to data privacy and security, including cybersecurity, and our actual or perceived failure to comply with such obligations or the actual or perceived failure to maintain the integrity of our data could expose us to data loss or litigation, harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business, prospects, financial condition, and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to risks related to product recalls.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is susceptible to product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of the markets in which we compete for business, including the dietary supplement and personal care markets, are highly competitive. We may not be able to compete effectively, which may have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actions of activist stockholders have, and could continue to, impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management&#8217;s attention and resources, and adversely affect our business, results of operations, financial condition, and the trading price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to risks related to a Global Not For Resale Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are able to expand our operations, we may experience difficulties in managing our future growth, which could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability of new products and technological innovations to gain market acceptance by customers and/or independent consultants could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be negatively impacted if we fail to execute our product launch process due to increased pressure on our supply chain, information systems and management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our IT systems to manage numerous aspects of our business, and a disruption in these systems, including as a result of cybersecurity incidents, could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A substantial portion of our business is conducted in foreign markets, exposing us to the risks of trade or foreign exchange restrictions, increased tariffs, foreign currency fluctuations, disruptions or conflicts with our third-party importers and similar risks associated with foreign operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to strict government regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our direct selling program could be found to be not in compliance with current or newly adopted laws or regulations in one or more markets, which could prevent us from conducting our business in these markets and harm our financial condition and operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_16">Item&#160;1. Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_178">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_178">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_190">Item&#160;1B. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_190">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">Item&#160;1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">ybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_2914">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_193">Item&#160;2. Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_193">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_196">Item&#160;3. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_196">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_199">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_199">43</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_202">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_205">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_205">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_223">Item&#160;6. Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_223">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_226">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_226">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_256">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_256">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_259">Item&#160;8. Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_259">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_262">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_262">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_265">Item&#160;9A. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_265">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_268">Item&#160;9B. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_268">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_271">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_271">55</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_274">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_277">Item&#160;10. Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_277">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_280">Item&#160;11. Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_280">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_283">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_283">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_286">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_286">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_289">Item&#160;14. Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_289">56</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_292">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_295">Item&#160;15. Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_295">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_301">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_301">59</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_16"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1 &#8212; BUSINESS</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_19"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. We also sell our products in a number of countries to customers for personal consumption only. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. Our line of scientifically validated dietary supplements includes our flagship Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of products, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our line of skin and hair care products and Liquid Collagen. We also market and sell Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our companion pet supplement formulated to combat oxidative stress in dogs; and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our nootropic energy drink mixes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Colorado in June 1988 under the name Andraplex Corporation. We changed our corporate name to Yaak River Resources, Inc. in January 1992 and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, we acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, we changed our name to LifeVantage Corporation. From our fiscal year 2005 until our fiscal year 2009, we marketed and sold a single product, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, through traditional retail stores. In October 2008, we announced that we were transitioning our business model from a traditional retail model to a direct sales model in which Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would be sold primarily through a network of independent consultants. Since entering direct sales, we have increased our geographic reach by entering new international markets and increased our product offering by introducing additional scientifically validated products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we reincorporated from the State of Colorado to the State of Delaware.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_22"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024 Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Product Offerings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, we launched new products in our various markets with the most significant being the global introduction of our reformulated TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care products consisting of TrueClean Refining Cleanser, TrueLift Illuminating Eye Cream, TrueHydrate Brightening Moisturizer and True Renew Daily Firming Complex</span><span style="color:#616060;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With ingredients backed by science and formulas designed to target different visible benefits, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care awakens the skin&#8217;s vitality to reveal natural, youthful radiance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we also launched TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True Protect Daily Mineral Sunstick, a limited-edition TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TruePout Hydrating Lip Oil and Exfoliating Lip Scrub, and four new AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited-edition flavors. In several of our international markets we also introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquid Collagen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the various product introductions by market in fiscal year 2024 is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The United States introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True Protect and, AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited-edition flavors Green Apple, Decaf Orchard Pear, Cherry Limeade, and Decaf Peach Nectarine.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Japan introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care without TrueLift, but included TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueTone Perfecting Lotion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Australia, New Zealand, Taiwan, and Thailand introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Canada introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquid Collagen and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NAD Synergizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mexico, Europe, and the Philippines introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquid Collagen.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Singapore and Hong Kong introduced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated Skin Care without TrueRenew.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology Innovation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to develop, enhance and improve the LifeVantage experience using technology. We pioneered new ways to interact with our independent consultants that give us and our independent consultant leaders valuable insight into the activities of the broader independent consultant base. We provided independent consultants with tools and communications that help simplify business activities, by providing step-by-step instruction for starting their business, and ways to improve the prospecting of potential consultants and customers. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nutrigenomic Culture &amp; Activating Wellness </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have continued to simplify our nutrigenomic story, emphasizing that it activates and empowers the body to work better by using nutrients to turn natural internal processes on or off and help support vibrant health at any age. Nutrigenomics and cellular activation are cutting-edge trends in our industry that support our unique position in the market and leverage our core competencies and existing products. Activation is the guiding principle of our culture and is the key underlying message for our independent consultants and customers. We continue capitalizing on this message by highlighting how LifeVantage has used the concept of activation and expanded it to every aspect of our business, with our brand message of &#8220;activating wellness.&#8221; By focusing on wellness, we are able to apply activation not only to our products, which support physical, mental, and emotional health, but also our business opportunity, which supports financial, social, and spiritual health. The &#8220;activating wellness&#8221; message is featured across our communications with our independent consultants and in our brand and marketing materials. In fiscal year 2024, the brand message of activation and &#8220;activating wellness&#8221; was strengthened by introducing the concepts of &#8220;activation synergies&#8221; and &#8220;inside-out&#8221; activation. At the forefront of &#8220;activating synergies&#8221; was our Healthy Glow Essentials Stack, which consists of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen. Research on this stack revealed that when the activation benefits of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were combined with the activation benefits of TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen the products had a synergistic effect that activated additional health benefits. The pillars of &#8220;inside-out&#8221; activation come from the inner activation of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which offers benefits on the inside, to the inside-out activation of TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen, which offers benefits on the inside, but also visible on the outside, to the outside activation of TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activated Skin Care, which offers visible benefits on the outside. These concepts, as an expansion of our activation message, will continue to be a focus of additional marketing and media assets.    </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Red Carpet Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, we continued to grow through our red-carpet program, which is designed to attract and incentivize experienced direct selling sales leaders to join LifeVantage. Red carpet leaders are identified by our independent consultants who facilitate the relationship between the potential red carpet leader and LifeVantage. Our corporate team does not actively engage in recruiting leaders for the red carpet program. We remain optimistic that this program will help drive long term revenue growth for our business. We have increased red carpet leadership enrollments and hope to see improved retention and active independent consultant and customer counts as a result of this program. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rewards Circle Customer Loyalty Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we launched Rewards Circle, our first-ever customer loyalty program, in the United States, Australia, New Zealand, and Japan (the "Rewards Circle"). In February 2024, Rewards Circle was expanded to Canada, Europe, and Mexico. Rewards Circle rewards customer loyalty through subscription purchases with credits to redeem on future purchases. The program is focused on customer retention, supporting our independent consultants' efforts to grow and maintain their LifeVantage business.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_25"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competitive Advantages</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have a competitive advantage in several key areas:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Our Sales Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We believe our sales compensation plan engineered for our independent consultants is one of the more financially rewarding plans in the direct selling industry and in line with direct selling industry standards.  Our sales compensation plan also enables independent consultants to earn compensation early and often as they sell our products. Some elements of our sales compensation plan are calculated and paid daily to eligible independent consultants and others are calculated and paid weekly or monthly, allowing new independent consultants to receive their sales commissions more quickly. We believe the ease of more frequent sales commission payments helps us attract and then retain new independent consultants by allowing them to receive their commission payments as soon as possible after making qualified product sales. We also offer a variety of incentives to our independent consultants for achieving specified product sales goals. We believe our sales compensation plan provides motivation for our independent consultants to sell our products to customers and share the business opportunity with those entrepreneurs seeking to begin their own sales business. In January 2023, we announced the adoption of a new compensation plan for our independent consultants, which became effective in March 2023, in our United States, Australia, New Zealand </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Japan markets. The new compensation plan is known as our &#8220;Evolve Compensation Plan.&#8221; In February 2024, we launched the Evolve Compensation Plan in the Canada, Mexico, and Europe markets. We plan to roll out this new compensation plan to our remaining markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Our Products:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our focus is on a differentiated approach to health activation through nutrigenomics and the study of how properly formulated and applied nutrition and naturally occurring compounds affect human genes to support good health. We have developed proprietary and exclusive scientifically validated activation products focused on helping individuals look, feel, and perform better. Our products are the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of scientifically validated dietary supplements; LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright&#174;, Rise AM, Reset PM, D3+ and Daily Wellness dietary supplements; PhysIQ Fat Burn and Prebiotic dietary supplements; TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our line of skin and hair care products and Liquid Collagen; Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our companion pet supplement formulated to combat oxidative stress in dogs; and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our nootropic energy drink mixes. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line includes Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body&#8217;s natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective antioxidant enzymes, including superoxide dismutase, catalase, and glutathione synthase. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide), and it has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity, and mood. Use of the three Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products together (marketed as the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tri-Synergizer) has been shown to produce "activation synergies" greater than using the individual products on their own. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+ is a dietary supplement that combines DHA and EPA omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ProBio is a dietary supplement designed to support optimal digestion and immune system function. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Daily Wellness is a dietary supplement designed to support immune health. IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a supplement to help support eye and brain health, reduce eye fatigue and strain, support cognitive functions, and may help support normal sleep patterns. PhysIQ Fat Burn is a dietary supplement designed to support weight-management. PhysIQ Prebiotic is a dietary supplement designed to support a healthy digestive tract. Our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of skin and hair care products includes TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueClean Refining Cleanser, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueLift Illuminating Eye Cream, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueHydrate Brightening Moisturizer, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueTone Perfecting Lotion, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueProtect Daily Mineral Sunstick SPF 30, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Perfecting Lotion, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hand Cream, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Invigorating Shampoo, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nourishing Conditioner, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Scalp Serum, and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquid Collagen. TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquid Collagen activates, replenishes, and maintains collagen to support firmness and elasticity from within. It has been shown to have a synergistic effect with Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, helping to break the cellular stress that prevents cells throughout the body from performing optimally. Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation. AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our line of nootropic energy drink mixes formulated to promote alertness and support mental performance. We believe our significant number of customers who regularly and repeatedly purchase our products is a strong indicator of the health benefits of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Technology-Enabled Consultant Training and Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are committed to providing our independent consultants with resources and training designed to promote productivity and their opportunity for successful sales and resulting commissions. We are dedicated to using technology to facilitate a streamlined approach for independent consultants to manage their businesses and sell our products. The LifeVantage app, which is available for download on the Apple app store and Google Play store, is a custom-developed platform that provides new ways for us to interact with our independent consultants and gives us and our consultant leadership valuable insight into the sales activities of our consultant base. Ultimately, through artificial intelligence and machine learning, we expect that the app will be able to guide independent consultants on what to share, when to share it, and with whom to sell LifeVantage products. In addition, we provide other business and product training materials, and we encourage our independent consultants to participate in company-sponsored events, including conventions and sales promotions and incentives. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Our Culture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are committed to creating a culture for our independent consultants, their customers and our employees that focuses on ethical, legal, and transparent business practices. At enrollment, our independent consultants agree to abide by their contract with us, which includes our policies and procedures. These policies and procedures, when followed, are designed to ensure that our independent consultants comply with applicable laws and regulations. Our consultant compliance department monitors the activities of o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur independent consultants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as part of our effort to enforce our policies and procedures. Similarly, our code of business conduct and ethics sets forth guidelines and expectations for our employees. We believe our ethical, legal, and transparent culture attracts highly qualified employees and independent consultants who share our commitment to these principles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Global Customer Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our global customer acquisition program expands the number of countries where customers can purchase and use our products for personal consumption only. This program allows us to enter additional markets at low incremental cost and enables independent consultants to leverage customer sales through their international relationships outside of their home countries. The program initially launched in eight markets, many of which subsequently became fully open for business on-the-ground through a growing network of resident independent consultants. We have also entered into key strategic agreements with third parties based in the United States that helps customers ship LifeVantage products purchased in the U.S. throughout the world via their customer personal purchase and importation programs. We also expanded our Auto-Assigned Customer Program, which allows new customers to order directly through www.lifevantage.com without being required to go through an independent consultant on their initial order. At the initial order, new customers have an opportunity to be assigned to independent consultants, who may then benefit from the initial sale commission and are then incentivized to provide future product support and sales to the assigned customer. This program provides customers easier access to our innovative products while providing the opportunity of referrals to our independent consultant force.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Our Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We believe that our employees are an essential asset. We have a dedicated team of professionals that support our independent consultants, work to generate long-term value for our stockholders and contribute to the broader society through charitable programs, including the 501(c)(3) LifeVantage Legacy &#8211; an independent charitable organization focused on bettering the lives of children throughout the world. In turn, we offer competitive compensation and direct employee focus toward the short and long-term goals of our stockholders and independent consultants.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_28"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scientific Background</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Normal Aging Process</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aging in humans is a complex process driven by diverse changes in genetic, molecular, biochemical, and cellular events. This multifactorial process is ultimately characterized by a gradual decline in physiological functions and in the effectiveness of the intricate network of internal cellular communication referred to as cellular signaling. Theories as to why humans age include the oxidative stress theory, the mitochondrial theory, and the sirtuin theory. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oxidative Stress Theory of Aging and the Nrf2 Pathway</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The oxidative stress theory of aging states that as humans age, we accumulate free radicals and other oxidants. If left unchecked, this oxidative stress can lead to serious consequences to the cell. Oxidative stress can ultimately lead to oxidative damage from attacks and damage to essential biological structures of the cell which results in compromised cellular function.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antioxidants are the cell&#8217;s primary defense against free radicals and other oxidants. There are two major classes of antioxidants: 1) dietary antioxidants obtained through food and nutritional supplements and 2) endogenous antioxidants produced by the body. A 2013 review of the scientific literature led by the United States National Institutes of Health&#8217;s National Center for Complementary and Integrative Health concluded that &#8220;rigorous trials of antioxidant supplements in large numbers of people have not found that high doses of antioxidant supplements prevent disease.&#8221; Thus, much attention has shifted to the body&#8217;s endogenous antioxidant and detoxification systems. Endogenous antioxidants are antioxidants made by the body and are the primary line of defense against oxidative stress. In general, endogenous antioxidants either prevent oxidants from being formed, or remove them from the body. Endogenous antioxidants form a complex network of antioxidant metabolites and enzymes. These networks work together, throughout the cell, to neutralize oxidants and protect important biological structures from oxidative damage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Endogenous antioxidants can also be upregulated in times of increasing oxidative stress. The Nrf2 cellular signaling pathway is the primary pathway for upregulating endogenous antioxidant and other detoxification pathways. With age, the activity of this Nrf2 cellular signaling pathway has been shown to decrease &#8211; both in its ability to sense oxidative threats and ultimately upregulate its target genes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitochondrial Theory of Aging and the NRF1 Pathway</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mitochondria are membrane-bound cellular organelles that generate most of the chemical energy needed to power the cell's biochemical reactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mitochondria produce energy by breaking down food that has been ingested and capturing high-energy electrons in the process. When mitochondria are functioning properly, they harness the energy of these electrons to produce energy for the cell. At the end of this process, the mitochondria attach these electrons to molecular oxygen that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimately get detoxified to water. However, this process is not perfectly efficient and, even in young, healthy mitochondria, electrons can escape, potentially forming free radicals and other oxidants. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mitochondrial theory of aging states that as humans age, mitochondria function less efficiently, producing less energy and more free radicals and other oxidants. The reduction in energy production compromises cellular function. The increase in free radicals and other oxidants in turn damage structures of the cell, including the mitochondria. This mitochondrial damage goes on to further compromise mitochondrial function leading to a downward spiral of decreased mitochondrial efficiency and increased production of free radicals and other oxidants. This process ultimately contributes to an increase in the overall cellular burden of oxidative stress and otherwise compromises cellular function through decreased energy production.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A major cellular signaling pathway believed to be involved in mitochondrial health is NRF1 (nuclear factor erythroid 2-related factor 1). The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NRF1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cellular signaling pathway, directly or indirectly, regulates a number of genes involved in mitochondrial health, turnover, and biogenesis. Nrf1 (Nuclear Respiratory Factor-1) is a protein believed to activate the expression of key genes involved in metabolism, cellular growth, energy production, and mitochondrial DNA transcription and replication. Together with Nrf2, Nrf1 also provides the essential function of coordinating gene expression between nuclear and mitochondrial genomes. An additional protein shown to support mitochondrial health is PGC1-alpha (peroxisome proliferator activated receptor gamma coactivator-1-alpha). PGC1-alpha has been shown to regulate energy metabolism and is the master regulator of mitochondrial biogenesis and turnover. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sirtuin Theory of Aging and the NAD Pathway</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sirtuin theory of aging developed from studies examining the health benefits of caloric restriction. Caloric restriction is the process whereby caloric intake is restricted by as much as 40 to 60 percent. In numerous experimental models, animals put on calorically restricted diets experienced significant increases in maximum lifespan. Numerous studies have concluded that a family of proteins called the &#8220;sirtuins&#8221; are required for the increase in lifespan brought on by caloric restriction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the physiology of humans undergoing caloric restriction was examined, a number of health benefits were discovered. As researchers began to understand the molecular biology of these sirtuins, they found that the enzymatic activity for most of them required the molecule NAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nicotinamide adenine dinucleotide). NAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an essential molecule for many biochemical reactions, most notably metabolism of food for energy in the mitochondria.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taken together, these findings are intriguing because they establish a direct link between metabolism and healthy longevity. When energy intake is normal, the primary role of NAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is for energy production. However, when NAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> levels increase, either due to restricting calories or increasing the cellular production of NAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it becomes a signaling molecule to activate sirtuins and other health promoting mechanisms within the cell. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_31"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Impacts of Aging - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collagen Depletion</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collagen is a protein that serves as a key structural component in various connective tissues throughout the body.  There are 28 types of collagens, but Type I represents 80%-90% of all skin collagen in healthy adults. Type I collagen is produced by a type of cell called fibroblasts. From early adulthood, fibroblast cells become less active and collagen production declines by about 1.0-1.5% a year. Studies show that collagen levels reach peak levels in an individual&#8217;s late 20&#8217;s to early 30&#8217;s, followed by a gradual decline that continues with age.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decline occurs as collagen fibers accumulate damage over time, decreasing their ability to function correctly. The density of the dermis is reduced as well, so it contains less collagen and elastin. The fibers that remain can become disorganized and abnormal in shape in aged skin compared to young and healthy skin. As a result, there is an upregulation of enzymes that break down and recycle collagen, contributing to declining levels. As collagen fibers become damaged and levels start to decline, collagen becomes more fragile and brittle, leading to a weakening of the skin&#8217;s structural support. The skin loses volume and firmness, and it starts to thin and wrinkle. Hydration, elasticity, and suppleness of the skin also begin to decline. These changes are characteristic hallmarks associated with the appearance of aging. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to holistically address the decline of collagen that impacts structural integrity of both the skin and connective tissue throughout the body, there are three approaches that need to be taken. First, production of new collagen fibers must be activated within the extracellular matrix. Second, the collagen that has been lost must be replenished through supplementation. Third, collagen fibers already present must be maintained through slowing their breakdown or degradation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Factors of Skin Aging</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to declines in collagen, other factors impact the appearance of skin as it ages. Such factors, include skin dullness, hyperpigmentation, and under-eye puffiness and dark circles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Skin dullness can be caused by a buildup of dead skin and impurities caused by the slowdown of skin cell turnover with age, typically beginning in the 30s and early 40s.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hyperpigmentation is caused by excess melanin that can be triggered by factors like sun, pollution, stress, and hormones. Increased tyrosinase and signaling molecules like IL-6 and IL-8 from these factors ultimately lead to an increase of melanin and the appearance of age spots or uneven skin tone.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under-eye dark circles are caused by excess blood vessels under the eye that are more easily visible due to collagen decline and resulting skin thinning under the eye, as well as an increase in vasculature under the eye (angiogenesis triggered by binding of VEGF (vascular endothelial growth factor) on its receptor at the surface of blood vessels).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under-eye puffiness and bags are caused by fat accumulation from weakening tissues around the eye. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All these factors lead to an aging appearance.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have focused our research and development efforts on creating and supporting scientifically validated products under the LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and PhysIQ federation of brands. We anticipate that our future research and development efforts will be focused on creating, developing, and evaluating new products that are consistent with our commitment to provide quality, scientifically validated products that activate and empower the body&#8217;s ability to work better. Through our lens of activation and nutrigenomics, we will explore what categories of products and benefits to target and research new ingredients and combinations thereof to develop new products. As we expand, we intend to build on our foundation of activation and nutrigenomics with products that either activate or support the activation of gene or cell pathways targeting specific benefit areas, provide real results, and are an essential and enjoyable part of everyday life. We also intend to continue exploring the synergies of our products to determine what, if any, enhanced or new benefits appear when multiple products are combined as well as ways to expand our product delivery systems. We remain committed to helping people look and feel healthy and vibrant at any age by combating sources of premature aging or declining health.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Overview</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_37"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a patented dietary supplement that has been shown in clinical trials to reduce the age-dependent increase in markers of oxidative stress and has also been shown to provide substantial benefits to combat the variety of negative health effects linked to oxidative stress.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combats oxidative stress by increasing the body&#8217;s natural antioxidant protection at the gene level. The unique blend of phytonutrients in Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> signals the activation of Nrf2 to increase production of antioxidant enzymes, specifically superoxide dismutase and catalase, and other cell-protective gene products. The body's internally produced antioxidant enzymes provide a better defense against oxidative stress than externally derived sources of antioxidants such as vitamin C and vitamin E. Unlike externally derived sources of antioxidants, these enzymes are &#8220;catalytic,&#8221; which means these enzymes are not used up upon neutralizing free radicals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold multiple U.S. patents related to Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe these patents set Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> apart from other dietary supplements and protect the original formula as well as certain formula modifications we could create to extend our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. We sell Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in three formulas around the world.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been, and is expected to continue to be, the subject of numerous independent scientific studies at various universities and research facilities including Ohio State University, Louisiana State University, University of Colorado Denver, Virginia Commonwealth University, Colorado State University, Texas Tech University and the National Institute on Aging. The results of these studies have been published in a variety of peer-reviewed scientific journals, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Free Radical Biology &amp; Medicine, Enzyme Research, Circulation-the scientific journal of the American Heart Association, American Journal of Physiology-Lung Cellular and Molecular Physiology, PLoS One, Journal of Dietary Supplements, Molecular Aspects of Medicine, Oxidative Medicine and Cell Longevity, Exercise &amp; Sports Science Reviews</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Pharmacology,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the FASEB Journal, and the Journal of Applied Physiology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to perform our own research into Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the synergy with other products in our portfolio.  In fiscal year 2023, we received a patent for the combination of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (marketed as the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tri-Synergizer), continuing to show how our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line is differentiated and unique in the marketplace.  We also filed a U.S. Patent application in fiscal year 2023 which, if granted, will protect the combined effects and synergistic benefits of the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen products when used together.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dietary supplement which was formulated to strengthen the mitochondria, the powerhouse of all cells, for better cellular health. It is designed to work in tandem with our flagship Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and further enhance the body's internal ability to naturally produce antioxidants and reduce the effects of cellular stress. Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> activates NRF1, a protein that regulates the expression of genes involved in mitochondrial DNA transcription, translation and repair. The unique blend of ingredients in Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supports the mitochondria to slow cellular aging and increase cellular energy.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dietary supplement which was specifically formulated to target the biochemical pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide) and has been shown to double sirtuin activity in just 24 hours. Sirtuin activity naturally declines by as much as 60 percent as humans age. Research has long shown that sirtuin activity can be increased by as much as 94 percent through drastic caloric restriction. Sirtuin activity has been linked to multiple health benefits. In addition to being responsible for cellular autophagy (cellular cleanup and renewal process), sirtuins help improve mental focus and concentration, support positive mood and motivation, boost mental and physical energy, aid in maintaining cholesterol levels already in a healthy range, support a healthy vascular system, and promote healthy longevity. A study on the active ingredients in NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also demonstrated a significant increase in NAD+ associated metabolites.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Omega+</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omega+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dietary supplement that combines DHA and EPA omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ProBio</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ProBio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dietary supplement designed to support long-term gut health by restoring healthy gut bacteria to support digestive system health.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_46"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combines macular carotenoids with vitamins and key ingredients that effectively support eye and brain health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It helps reduce eye fatigue and strain from use of digital devices, helps promote healthy levels of essential proteins for the brain, and may help support normal sleep patterns, which can be disrupted by blue light exposure. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_49"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daily Wellness</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Daily Wellness </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a dietary supplement designed to strengthen immune health by supporting and balancing the three essential roles of the immune system: barrier, innate and adaptive.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_52"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rise AM&amp; Reset PM System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Rise AM &amp; Reset PM System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an intelligent approach to a multivitamin that uses Timewise Nutrient Delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to provide the body with the right nutrients in the right amounts at the right time.  Timewise Nutrient Delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was developed in combination with experts in biochemistry, biophysics, and molecular biology and results in nutrition that allows your body to stay in sync with its natural rhythms, delivering energy and focus for a productive day and helping to calm the mind and body at night.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_55"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">D3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">+</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> D3+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a dietary supplement that provides vitamin D3, vitamin K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_58"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PhysIQ Fat Burn</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PhysIQ Fat Burn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a supplement containing naturally derived active ingredients to stimulate the breakdown of abdominal fat, increase energy and support long-term weight management.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PhysIQ Prebiotic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PhysIQ Prebiotic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a dietary supplement designed to support the &#8220;good&#8221; bacteria in the gut and a healthy microbiome, resulting in a healthier digestive tract and a healthier metabolism.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skin Care</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our line of activated anti-aging skin care products under our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Liquid Collagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: our first digestible liquid supplement in fully recyclable glass bottles that activates, replenishes, and maintains the body&#8217;s production of collagen on the cellular level to support skin firmness and elasticity for healthy, glowing skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueRenew Daily Firming Complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">high-performance cosmetic retinol alternative that targets 11 visible signs of aging, providing a more youthful and vibrant complexion in as little as three weeks&#8212;with continued enhancements at six weeks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#616060;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueClean Refining Cleanser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: a rich 2-in-1</span><span style="color:#2e3134;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facial cleanser </span><span style="color:#2e3134;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that cleanses and exfoliates leaving skin clean, soft, and smooth without making it feel tight or dry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2e3134;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueLift Illuminating Eye Cream</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  a silky-smooth formula that targets dark circles and visibly lifts to reveal revitalized eyes. TrueLift supports the skin to improve seven visible signs of aging around the eyes, including dark circles, under eye bags, puffiness, fine lines, wrinkles, sagging eyelids, and crow&#8217;s feet.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueHydrate Brightening Moisturizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: a moisturizing cream that provides hydration equivalent to two weeks&#8217; use of hyaluronic acid, enhanced brightness in seven days and a more even skin tone and visibly faded age spots with continued use.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueProtect Daily Mineral Sunstick SPF 30: </span><span style="color:#2e3134;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A broad-spectrum mineral sunscreen that addresses the appearance of sun-induced hyperpigmentation and wrinkles as it protects against future damage for younger-looking, radiant skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2e3134;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TrueTone Perfecting Lotion (Japan market only):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a toning lotion developed to meet the needs and concerns of Japanese skin care consumers that moisturizes the skin while minimizing the appearance of pores.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Perfecting Lotion: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a hybrid lotion formulated for smoother, radiant, and brighter looking skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Hand Cream:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a cream formulated with Nrf2 ingredients to moisturize skin and decrease the visible signs of premature aging on the hands.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activated Skin Care Collection includes the following products in a TSA-compliant set: TrueClean Refining Cleanser, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  TrueLift Illuminating Eye Cream, and TrueHydrate Brightening Moisturizer. The system varies slightly in some markets and additional products such as TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueProtect Daily Mineral Sunstick SPF 30 and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Perfecting Lotion are available outside of the Collection.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received two composition patents related to our LifeVantage TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">skin care products, which were tested in an independent third-party clinical study and shown to reduce the visible signs of aging by utilizing Nrf2 technology to mitigate the visible effects of skin damage caused by oxidative stress. We also filed a U.S. Patent application in fiscal year 2023 which, if granted, will protect the combined effects and synergistic benefits of the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen products when used together. Our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">skin care products leverage our research on Nrf2 activation and oxidative stress in combination with other clinically tested activating ingredients that work multi-mechanistically to target skin concerns at the source through activation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueRenew Daily Firming Complex was also validated through a third-party clinical trial. Starting at three weeks and continuing over six weeks, subjects experienced significant improvements in 11 visible signs of aging.  </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_64"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hair Care</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our line of hair care products under our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Invigorating Shampoo:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mild surfactant and added amino acid blend that cleans hair without drying out the scalp.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Nourishing Conditioner: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deeply nourishing weightless conditioner that helps hair feel soft and smooth and look fuller and thicker.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Scalp Serum:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A serum that nourishes the scalp to support normal hair growth while soothing all scalp types.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation. Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">builds upon the active ingredients in Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reduce oxidative stress and support joint function, mobility and flexibility in dogs. Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received the Quality Seal from the National Animal Supplement Council ("NASC").</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our line of energy drink mixes, formulated as a nootropic to promote alertness and support mental performance. These energy drink powders deliver sustained energy, as well as improved mental focus and promote a positive mood. Available in regular and decaf formulas, AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is derived from a unique combination of scientifically validated ingredients. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_73"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Stacking</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A stack consists of multiple products bundled together that are designed to achieve a specific result. By studying the effects of nutrients and natural compounds, we have developed scientifically backed nutrigenomics products that promote healthy aging on the cellular level. By stacking these products together, we have created a foundation for synergy from nutrigenomic products to promote a healthier life. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, our stack strategy evolved with a focus on the brand message of Activation with three stacks that tell the unique LifeVantage Activation story from an inside-out approach. This builds upon the synergistic benefits that were demonstrated in fiscal year 2023 with our Healthy Glow Essentials stack. The Inside-Out Activation Duo features Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex. This duo activates antioxidants for good health on the inside and a cleaner, kinder retinol alternative for skin that looks and feels healthy and youthful on the outside. The LifeVantage Activation Essentials Stack contains Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen, and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex. This top-selling trio that boosts your inner wellness while giving you visibly smoother, more youthful skin. Finally, our Healthy Glow + Activated Skin Care Collection contains Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen, and the full Activated Skin Care Collection. This selection of products complement one another with inner Activation power and external benefits you can see and feel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to offer other popular packs such as the Vitality Stack (Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+ and LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ProBio), the Ultimate Stack (Vitality Stack + Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PhysIQ Prebiotic), the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tri-Synergizer&#8482; (Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim&#174; NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_76"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution of Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our products are well suited for independent consultant to customer sales through our direct selling model. This model allows our independent consultants to educate our customers regarding the benefits of our unique products more thoroughly than other business models. Our direct selling model also allows our independent consultants to offer personalized customer service to our customers and encourage regular use of our products.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_79"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Return Policy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All products purchased directly from us include a product guarantee. Subject to some exceptions based on local regulations, we will accept returns of opened and unopened products within 30 days of purchase for a full refund of the purchase price. In addition, our product return program allows independent consultants to return certain unopened, unexpired products for a refund of the purchase price less a 10% restocking fee and any paid commissions. The amount of inventory we will repurchase from an independent consultant is subject to specified policies and procedures.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_82"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally categorize accounts as either independent consultants or customers, both of which may be consumers of our products.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_85"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Consultants</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An independent consultant in our company is an independent contractor who participates in our direct sales opportunity by enrolling through the independent consultant contract process and selling our products. Independent consultants may purchase our products and sell them to others either directly or through our company. We believe our independent consultants are typically entrepreneurs, who believe in our products and desire to earn income through sales commissions and by building their own consulting business. Many of our independent consultants are attracted by the opportunity to sell unique, scientifically validated products without incurring significant start-up costs. Independent consultants sign a contract with us that includes a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement that they adhere to strict policies and procedures. Independent consultants may purchase product from us for individual and family consumption and for demonstrations, samples and retailing opportunities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we provide product development, shipping and logistics support, brochures, magazines, a website, the LifeVantage app and other sales and marketing materials, independent consultants are primarily responsible for their sales to customers and for attracting, enrolling, and educating new independent consultants about the benefits of our products and sales compensation plan. An independent consultant creates multiple levels of compensation by selling our products and enrolling new independent consultants who sell our products. These newly enrolled independent consultants form a &#8220;downline&#8221; or &#8220;group&#8221; for the independent consultant who enrolled them. If downline independent consultants enroll new independent consultants or customers who purchase our products, they create additional levels of compensation, and their downline independent consultants remain in the same downline network as the original enrolling independent consultant We pay commissions only upon the sale of our products. We do not pay commissions for enrolling independent consultants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define &#8220;active indepe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ndent consultants&#8221; as those independent consultants who have purchased product from us for retail sales or personal consumption during the prior three months.  We had approximately 49,000 and 54,000 active independent consultants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of each of the fiscal years ended June&#160;30, 2024 and 2023, respectively.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Consultant Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we launched the Evolve Compensation Plan for our independent consultants in our Mexico, Canada, and European markets, which continued our roll out of the new Evolve Compensation Plan. In March 2023, we launched the Evolve Compensation Plan for our independent consultants in our United States, Australia, New Zealand and Japan markets. We plan to roll out this new compensation plan to our remaining markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our sales compensation plan is one of the more financially rewarding in the direct selling industry and in line with direct selling industry standards. Some elements of our sales compensation plan are paid daily, to eligible independent consultants, and others are paid weekly or monthly. We believe this gives us a competitive advantage and helps retain new independent consultants by allowing them to receive some sales commissions in a more timely manner from their sales efforts. Our sales compensation plan is intended to appeal to a broad cross-section of people, including those seeking to supplement family income, start a home-based business or pursue entrepreneurial opportunities full- or part-time. Through the Evolve Compensation Plan our independent consultants earn bonuses specifically for the sale of products to customers and by growing a customer subscription-based business, creating greater opportunities for independent consultants who are not interested in enrolling other consultants to sell products. Our independent consultants earn sales commissions on product sales to their personally enrolled customers and independent consultants and the product sales to customers and independent consultants within their sales organization, or "downline." Our independent consultants can also earn money by purchasing product from us and selling that product to others at their chosen retail price. We pay sales commissions in the local currency of the independent consultant&#8217;s home country.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Consultant Motivation and Training</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends on the sales success and productivity of our independent consultants. We provide tools, training and technology designed to increase our independent consultants' sales productivity and increase their potential for sales success. We offer training and business development opportunities to our independent consultants, including the opportunities listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Consultant Communications Hub: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A consultant-specific website that has all the latest details on promotions, product launches, and onboarding to help each consultant build a LifeVantage business. Since the launch in October 2023, this site has been widely adopted as a centralized resource for our independent consultants. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Momentum Academy, Global Convention, and other Company-Sponsored Training</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We hold regularly occurring live and virtual company-sponsored events intended to provide sales training and motivation to our independent consultants, in addition to twice-weekly virtual consultant trainings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Promotions and Incentive Trips</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We hold special sales promotions, business incentives and incentive trips from time to time in order to motivate our independent consultants to accomplish specific sales goals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Mobile Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The LifeVantage app was designed to allow users to conduct their business on a single platform from anywhere in the world. Ultimately, through artificial intelligence and machine learning, we expect that the app will be able to guide users on what to share, when to share it, and with whom to maximize their sales potential. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Online Social Media Groups</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Through the use of social media platforms, we host online groups to support the success of our independent consultants. Important announcements, weekly trainings, calls, and documentation are also shared </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through our social media groups to provide our independent consultants many opportunities to find the training and support. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Corporate Support Team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The LifeVantage contact center, VIP Lines, and sales support team are designed to provide support, motivation, training, and resources to our independent consultants through their business journey. As independent consultants advance through the titles in our consultant path, they continue to receive more personalized support.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate new ways in which to incorporate new technology and sales training opportunities to improve consultant product sales.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Consultant Compliance Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that our independent consultants are independent contractors, we do not control or direct their promotional efforts. We do, however, require that our independent consultants abide by policies and procedures that require them to act in an ethical manner and in compliance with applicable laws and regulations. As a member of the United States Direct Selling Association ("US DSA") and similar organizations in many of the markets where we do business, we are also subject to the ethical business practices and consumer service standards required by the industry's code of ethics. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independent consultants represent to us that their receipt of sales commissions is based on their product sales and by product sales of other LifeVantage consultants in their personal marketing organization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must produce or pre-approve all sales aids used by independent consultants, such as brochures and online materials. Products may be promoted only through sales materials produced or approved by us. Independent consultants may not use our trademarks or other intellectual property without our written consent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor and systematically review alleged independent consultant misbehavior through our internal consultant compliance department. If we determine one of our independent consultants has violated any of our policies and procedures, we first attempt to educate, but may discipline or terminate the independent consultant&#8217;s rights to sell or distribute our products when appropriate. When necessary, we have brought legal action against independent consultants, or former consultants, to enforce our policies and procedures. Short of termination or legal action, and in addition to educating, we may impose sanctions against independent consultants whose actions are in violation of our policies and procedures. Such sanctions may include warnings, probation, withdrawal or denial of an award, suspension of privileges of a consultantship, fines and/or withholding of commissions until specified conditions are satisfied, or other appropriate injunctive relief.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers purchase products directly from us at either our retail (list) pricing for one-time purchases or our subscription price on a monthly subscription basis for personal consumption, without the ability to resell or earn commissions from the purchase or sale of such products. Customers who order their items on a subscription also automatically join our Rewards Circle loyalty program, a program that rewards customer loyalty through subscription purchases. A customer may decide to enroll as an independent consultant at any time if they become interested in selling our products. We believe our customers are a great source of word-of-mouth advertising for our products. We also believe our large base of customers validates the health benefits of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define an &#8220;active customer&#8221; as a customer who has purchased product from us within the prior three months. As of June&#160;30, 2024 and 2023, we had approximately 79,000 and 89,000 active customers, respectively.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_100"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Our Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accept orders for our products through our website at www.lifevantage.com and through personalized websites we provide to our independent consultants, which we refer to as &#8220;Virtual Offices.&#8221; Orders placed through Virtual Offices and through our website are processed daily at our fulfillment centers, where orders are shipped directly to the consumer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer toll-free numbers for our independent consultants and our customers to order product or ask questions. Our customer service representatives assist customers in placing orders through our web order processing system, answering questions, tracking packages, and initiating refunds. The customer service representatives receive extensive training about our products and our direct selling business model. LifeVantage customers and independent consultants generally pay for products by credit card, prior to shipment, and as a result, we carry minimal accounts receivable.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_103"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to general economic factors, we are impacted by seasonal factors and trends such as major cultural events and vacation patterns. We believe that direct selling in the United States and Japan is also generally negatively impacted during our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first fiscal quarter, from July 1 through September 30, when many individuals, including our independent consultants, traditionally take vacations. The timing and size of our training events and incentive trips can also cause revenue and expense to fluctuate in the periods that they are held.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our product launch process may vary by market, we may introduce new products to our customers and independent consultants through limited-time offers and promotions. The limited-time offers and promotions typically generate significant activity and a high level of sales and purchasing, which may result in a higher-than-normal increase in revenue during the quarter of the limited-time offer and skew year-over-year and sequential comparisons. Similarly, company events for independent consultants typically generate a higher-than-normal increase in revenue. The timing of these events can also skew year-over-year and sequential comparisons.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our network of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ndependent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onsultants located throughout the United</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines to market and sell our products. We also have in-house sales, marketing, IT, and customer service groups dedicated to supporting our independent consultants. Support includes training and education, personalized assistance, in-person and digital events, recognition, incentives and promotions, digital and social media content, press coverage, regular communications, as well as a full suite of marketing assets, including content for their websites.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials and Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource the primary manufacturing, fulfillment, and shipping components of our business to third-party companies we believe possess a high degree of expertise. We believe outsourcing provides us access to advanced manufacturing process capabilities and expertise without incurring fixed costs associated with manufacturing our own products in house.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently outsource the manufacture of our products to multiple third-party contract manufacturers. Our contract manufacturers have a legal obligation to comply with the current Good Manufacturing Practices ("GMP") regulations that are applicable to those who manufacture, package, label and hold dietary supplements and personal care products. Additionally, we are subject to regulations that, among other things, obligate us to know what and how manufacturing activities are performed so that we can make decisions related to whether the packaged and labeled product conforms to our established specifications and whether to approve and release product for distribution to consumers. We maintain and qualify alternative manufacturing options in order to keep our costs low, maintain the quality of our products, and prepare for unanticipated spikes in demand or manufacturing failure. Our contract manufacturers deliver products to our fulfillment centers based on our purchase orders. We also have a Vendor Code of Conduct that we expect our contract manufacturers and/or vendors to adhere to. This Vendor Code of Conduct requires contract manufacturers and vendors to abide by certain human rights, labor rights, protection of the environment and fight against corruption standards outlined under the United Nations Global Compact. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquire raw materials for our products from third-party suppliers. Although we generally have good relationships with our suppliers, we believe we could replace any of our current suppliers without great difficulty or significant increase to our cost of goods sold. We also have ongoing relationships with secondary and tertiary suppliers. Please refer to "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors - High quality material for our products may be difficult to obtain or expensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for a discussion of the risks and uncertainties associated with our sourcing of raw materials.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. We also sell our products in a number of countries to customers for personal consumption only. In addition, we sold our products in China through our approved e-commerce business model until March 2023, at which time we closed our e-commerce business in China.  In fiscal year 2024, revenue generated in the United States accounted for approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 73% of our total revenue and revenue generated from Japan accounted for approximately 13% of our total revenue. For reporting purposes, we generally divide our markets into two geographic regions: the Americas regio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n and the Asia/Pacific and Europe region. The following table sets forth net revenue information by region for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the fiscal years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional comparative revenue and related financial information is presented in the section captioned "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 2 to our consolidated financial statements.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_115"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability and Other Insurance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product liability insurance coverage for our products that we believe is adequate for our needs. We also maintain commercial property and liability coverage, directors&#8217; and officers&#8217; liability insurance, workers compensation coverage and cyber information security risk insurance policies as well as foreign and other miscellaneous coverage. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_118"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use commercially reasonable efforts to protect our intellectual property through patent protection, trademarks, and trade secrets, licensed rights, and contractual protections, and intend to continue to develop a strong brand identity for our company and our products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary, patented dietary supplement formulation for enhancing antioxidant enzymes including superoxide dismutase and catalase. The patents and patent applications protecting its formulations are held by LifeVantage Corporation or our wholly owned subsidiary, Lifeline Nutraceuticals Corporation. Our intellectual property is covered, in part, by many issued U.S. patents. Our patents and patent applications claim the benefit of priority of multiple U.S. provisional patent applications, the earliest of which was filed on March 23, 2004, and relate to compositions, methods of use, and methods of manufacture of various compositions, including those embodied by the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation. The expected duration of our patent protection via some granted patents for Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at least through approximately March 2025, and we continue to research and file new composition and method patents in the U.S. for enhanced and improved product formulations that will extend our patent protection for a variety of product formulations and methods. During fiscal year 2018, we received other patents for personal care or skin care products. These patents expire approximately February 2036. In fiscal year 2023, we received a patent for the combination of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, collectively called the Tri-Synergizer&#8482; pack. In fiscal year 2023, we filed for a U.S. patent application which, if granted, will protect the combined synergistic effects and benefits of the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen products when these two products are used together.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to protect our products and brands using trademarks. We have filed and successfully procured registered trademarks for our key brands consisting of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in many countries around the world, and we have pending trademark applications for these and other marks in many other countries. We anticipate seeking protection in other countries, as we deem appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect the confidentiality of our intellectual property, including trade secrets, know-how and other proprietary technical and business information, it is our policy to limit access to such information to those who require access in order to perform their functions and to enter into agreements with employees, consultants and vendors to contractually protect such information.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_121"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_124"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Selling Companies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with other direct selling companies, many of which have longer operating histories and greater visibility, name recognition and financial resources than we do. We also compete with newer direct selling companies that may attempt to solicit our independent consultants by offering the possibility of a more financially rewarding opportunity or by being among the company's early consultant base. We compete for new consultants with these companies on the basis of our business opportunity, product offerings, sales compensation plan, management and operations. In order to successfully compete in the direct selling industry and attract and retain quality consultants, we must maintain the attractiveness of our business opportunity, product offerings and sales compensation plan.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_127"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dietary Supplement Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with other companies that sell dietary supplements. We believe the dietary supplement market is highly fragmented and competitive. We believe competition in the dietary supplement market is based primarily on quality, price, efficacy, brand name, and recognition of product benefits. In the dietary supplement industry, our competition includes numerous nutritional supplement companies, pharmaceutical companies and packaged food and beverage companies. Many of these companies have broader product lines, larger sales volumes, and greater financial resources than we do. Additionally, some of these companies are able to compete more effectively due to greater vertical integration. Increased competition in the dietary supplement market could have a material adverse effect on our results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nrf2 Activators</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the last few years, we have seen the number of products marketed as Nrf2 activators increase. We anticipate the number of products that claim to activate Nrf2 will continue to increase as the technology becomes more popular and more broadly accepted. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Direct Antioxidants</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitamin C, vitamin E, other vitamin/mineral antioxidants, and other sources of externally derived antioxidants may be considered competitors of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but they are mechanistically distinct from Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These other sources of antioxidants do not increase the body&#8217;s elimination of oxidants using internal antioxidant enzymes. Our research indicates that Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increases production of anti-fibrotic gene products, including antioxidant enzymes, such as superoxide dismutase and catalase, within the cells of the body. We believe that the body&#8217;s internally produced antioxidant enzymes provide a better defense against oxidative stress than externally derived sources of antioxidants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oral Superoxide Dismutase and Catalase</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies performing research into antioxidants. Several companies sell oral forms of superoxide dismutase and catalase. Although we believe Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a superior alternative to oral forms of superoxide dismutase and catalase, these products do compete with Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the marketplace. We anticipate additional companies will likely develop, purchase or in-license products that are competitive with Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omega Fatty Acid Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies that market omega supplements, including omega-3. Although LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omega+ contains a unique combination of DHA and EPA omega-3 fatty acids, omega-7 fatty acids, and vitamin D3, we anticipate additional companies will likely develop products that are competitive with LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omega+. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Probiotic Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies that market probiotic supplements, and we anticipate additional companies will likely continue to develop products that compete with our LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ProBio supplement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eye Health and Vitamin Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies that market eye health and other vitamin/mineral supplements and we anticipate additional companies will likely continue to develop products that are competitive with our IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daily Wellness,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rise AM &amp; Reset PM System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> D3+. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_130"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Personal Skin Care Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the personal skin care market, we compete principally with large, well-known cosmetics companies that manufacture and sell broad product lines through retail establishments. Many of these competitors have greater financial resources and brand recognition than we do. We believe, however, we can compete with these larger companies by leveraging our direct selling model and emphasizing our unique, science-based, Nrf2 formulas in our personal care products. We also now compete in the growing global liquid collagen market and believe we can compete with our triple-action formula that has been shown to deliver visible results in only 30 days as it activates, replenishes, and maintains collagen levels. Our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen product is a unique blend featuring sustainably sourced, hydrolyzed fish collagen that delivers 10 different types of peptides&#8211;significantly more than most competitive products&#8211;plus a unique red quinoa extract that has been shown to up regulate genes associated with collagen production and down regulate those that produce enzymes that break down collagen.  </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_133"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Personal Hair Care Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the personal hair care market, we compete principally with large, well-known hair care companies that manufacture and sell broad product lines through retail establishments. Many of these competitors have greater financial resources and brand recognition than we do. We believe, however, we can compete with these larger companies by leveraging our direct selling model and emphasizing our unique, science-based hair care products.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_136"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Animal Supplement Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete principally with large, well-known companies in the animal supplement market. Most of the companies we compete with in the animal supplement market have broad distribution channels that include retail establishments. Many of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these competitors have greater financial resources and brand recognition than we do. We believe, however, that we can compete with these larger companies by leveraging our direct selling model and emphasizing our unique, science-based animal supplement product.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Energy Drink Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with large, well-known companies in the energy drink market. Most of the companies we compete with in the energy drink market have broad distribution channels that include big box retail establishments. Many of these competitors have greater financial resources and brand recognition than we do. We intend to compete with these larger companies by leveraging our direct selling model and emphasizing our unique, science-based energy drink product. AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a no sugar, low-carbohydrate and low-calorie energy drink that is also non-GMO, gluten-free and vegan. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_142"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weight Management Market</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with large, well-known companies in the weight management market. Most of the companies we compete with in the weight management market have broad distribution channels that include big box retail establishments. Many of these competitors have greater financial resources and brand recognition than we do. We intend to compete with these larger companies by leveraging our direct selling model and emphasizing our unique, science-based weight management products.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_145"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The formulation, manufacturing, packaging, labeling, and advertising of our products in the United States are subject to regulation by the Food and Drug Administration (&#8220;FDA&#8221;) and the Federal Trade Commission (&#8220;FTC&#8221;), as well as comparable state laws.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_148"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulations and DSHEA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products as &#8220;dietary supplements&#8221; as defined in the Dietary Supplement Health and Education Act of 1994 ("DSHEA"). DSHEA is intended to promote access to safe, quality dietary supplements, and information about dietary supplements. DSHEA established a new framework governing the composition and labeling of dietary supplements. DSHEA does not apply to animal supplements like Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are not required to obtain FDA pre-market approval to sell our products in the United States under current laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DSHEA permits statements of nutritional support, called &#8220;structure-function&#8221; statements, to be included in labeling for dietary supplements without FDA marketing approval. Such statements may claim a benefit related to a classical nutrient deficiency disease and disclose the prevalence of such disease in the United States, describe the role of a nutrient or dietary ingredient intended to affect the structure or function in humans, characterize the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or describe general well-being from consumption of a nutrient or dietary ingredient. Such statements may not expressly o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r impliedly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> claim that a dietary supplement is intended to diagnose, cure, mitigate, treat, or prevent a disease. A company that uses a structure-function statement in labeling must possess evidence substantiating that the statement is truthful and not misleading and is supported by competent and reliable scientific evidence. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may assert that a particular structure-function statement that a company is using is an illegal claim; that assertion, normally, is in the form of a warning letter to that company. We have a duty to send to the FDA a notice that lists each new structure-function statement made by us; we are obligated to send that notice within 30 days after the first marketing of a supplement with such a statement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DSHEA also permits certain scientific literature, for example a reprint of a peer-reviewed scientific publication, to be used in connection with the sale of a dietary supplement to consumers without the literature being subject to regulation as labeling. However, such literature must not be false or misleading, the literature may not promote a particular manufacturer or brand of dietary supplement and it must include a balanced view of the available scientific information on the subject matter, among other requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA's Center for Veterinary Medicine (&#8220;CVM&#8221;) is responsible for enforcing the portion of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;), that relates to animal supplements, like our Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. CVM's primary responsibility in enforcing the FFDCA is to ensure that animal supplements are safe, effective, and can be manufactured to a consistent standard. CVM has taken the position that DSHEA does not apply to products intended for animals, but it is clear that products like Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are under FDA jurisdiction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product follows the labeling rules of the NASC of which LifeVantage is a member. Under the NASC rules, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is classified as a dosage form animal health product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we exercise care in our formulation, manufacturing, packaging, labeling, and advertising of our products, we cannot guarantee the FDA will never inform us that the FDA believes some violation of law has occurred either by us or by our independent consultants. Any allegations of our non-compliance may result in time-consuming and expensive defense of our activities. The FDA&#8217;s normal course of action is to issue a warning letter if it believes that a product is misbranded or adulterated. The responsive action requested by the FDA differs depending upon the nature of the product and claims in question. Typically, the FDA expects a written response within 15 working days of the receipt of a warning letter. The warning letter is public information posted on the FDA&#8217;s web site. That information could affect our relationships with our customers/consumers, investors, independent consultants, vendors, and employees. Warning letters also often spark private class action litigation under state consumer protection statutes. The FDA could also order compliance activities, such as an inspection of our facilities and products, and could file a civil lawsuit in which an arrest warrant (seizure) could be issued as to some or all of our products. In extraordinary cases, we could be named a defendant and sued for declaratory and injunctive relief.  There were no open letters from the FDA to us as of June 30, 2024.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_151"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FTC Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and marketing of our products in the United States are also subject to regulation by the FTC under the Federal Trade Commission Act (&#8220;FTC Act&#8221;). Among other things, the FTC Act prohibits unfair methods of competition and unfair false or deceptive acts or practices in or affecting commerce. The FTC Act also makes it illegal to disseminate or cause to be disseminated any false advertisement for &#8220;food, drugs, devices, services, or cosmetics." The FTC Act provides that disseminating any false advertisement pertaining to foods, which would include dietary supplements, is an unfair or deceptive act or practice. An advertiser is required to have competent and reliable scientific evidence for all express and implied health-related product claims at the time the claims are first made. We are required to have adequate scientific substantiation for all material advertising claims made for our products in the United States. The FTC routinely reviews websites to identify questionable advertising claims and practices. Competitors sometimes inform the FTC when they believe other competitors are violating the FTC Act and consumers may also notify the FTC of what they believe may be wrongful advertising. The FTC may initiate a non-public investigation that focuses on our advertising claims, which usually involves non-public pre-lawsuit extensive formal discovery. Such an investigation may be very expensive to defend, be lengthy, and result in a publicly disclosed Consent Decree, which is a settlement agreement. If no settlement can be reached, the FTC may start an administrative proceeding or a federal court lawsuit against us and/or our principal officers. The FTC often seeks to recover from the defendants, whether in a Consent Decree or a proceeding, any or all of the following: (i) consumer redress in the form of monetary relief or disgorgement of profits; (ii) significant reporting requirements for several years; and (iii) injunctive relief. In addition, most, if not all, states have statutes prohibiting deceptive and unfair acts and practices. The requirements under these state statutes are similar to those of the FTC Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Advertising Division (&#8220;NAD&#8221;), of the national Better Business Bureau, a non-governmental not-for-profit organization through its Advertising Self-Regulatory Council, is also actively engaged in conducting investigations, called inquiries, which are focused on determining whether the requisite claim substantiation standard exists for advertising claims, including specific structure-function claims. Although the results of each inquiry or proceeding are not binding on the recipient, they are posted on NAD&#8217;s website, and the NAD often refers cases to the FTC, if the advertisers do not agree to modify their advertising in conformance with the NAD decision. We have been the subject of a NAD proceeding in 2008 and 2009, which was concluded in 2009.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Direct Selling Self-Regulatory Council (&#8220;DSSRC&#8221;) was introduced. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his program monitors the entire direct selling channel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the US DSA member companies and non-members. The DSSRC provides impartial monitoring, enforcement, and dispute resolution regarding product claims or income representations (including lifestyle claims) disseminated by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">direct selling</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companies and their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> force members (consultants). The failure of a company to resolve DSSRC complaints will ultimately result in the DSSRC reporting the matter to the FTC, which may or may not pursue enforcement action in any given case. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no open letters from the FTC to us as of June 30, 2024.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_154"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Direct Selling Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct selling activities are regulated by the FTC, as well as various federal, state and local governmental agencies in the United States and foreign countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as &#8220;pyramid&#8221; schemes, which compensate participants primarily for recruiting additional participants without sufficient emphasis on product sales. The laws and regulations may often:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us or our independent consultants to register with governmental agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose caps on the amount or type of sales commission we can pay;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose reporting requirements; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that we ensure, among other things, that our independent consultants maintain levels of product sales to qualify to receive sales commissions and that our independent consultants are being compensated primarily for sales of products and not primarily for recruiting additional participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject to government investigations related to our direct selling activities. This may require us to make changes to our business model and our sales compensation plan.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_157"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to United States federal regulation, each state has enacted its own food and drug laws. We may receive requests to supply information regarding our sales or advertising to state regulatory agencies. We remain subject to the risk that, in one or more of our present or future markets, our products, sales, and advertising could be found non-compliant with state laws and regulations. If we fail to comply with these laws and regulations, it could have a material adverse effect on our business in a particular market or in general. In addition, these laws and regulations could affect our ability to enter new markets.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_160"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA Food Safety Modernization Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Food Safety Modernization Act (&#8220;FSMA&#8221;) was enacted in 2011 and is now part of the FFDCA. The FSMA is a comprehensive set of laws that gives the FDA considerable authority with respect to the prevention of food contamination and the serious problems associated with such contamination. Among other things, it does the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gives the FDA explicit authority to compel a recall if the FDA believes there is a reasonable probability of serious adverse health consequences or death;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">places strict obligations on food and dietary supplement importers to verify that food from foreign suppliers is not adulterated or misbranded; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provides whistle blower protection for employees of conventional food or dietary supplement companies who provide information to governmental authorities about violations of the FFDCA.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_163"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations applicable to our activities in the United States, all other markets in which we operate our business regulate our products under a variety of statutory and regulatory schemes. We typically market our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products in international markets as foods, health foods or dietary supplements under applicable regulatory regimes. However, because of varied regulations, some products or ingredients that are recognized as a &#8220;food&#8221; in certain markets may be treated as a &#8220;pharmaceutical&#8221; or equivalent in other markets. In the event a product, or an ingredient in a product, is classified as a drug or pharmaceutical product in any market, we will generally not be able to distribute that product through our independent consultants because of pre-marketing approval requirements and strict regulations applicable to drug and pharmaceutical products. In Japan, for example, ashwagandha was determined to be inappropriate for inclusion in food products. Ashwagandha is one of the ingredients in Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While we disagree with the assessment of ashwagandha by Japanese regulatory authorities, we are restricted from selling a formulation of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains ashwagandha in Japan. As such, we reformulated Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the Japan market to exclude ashwagandha</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and include black pepper extract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This reformulated Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was introduced in Japan in fiscal year 2013.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, our other markets outside the United States regulate advertising and product claims regarding the efficacy of our products and require adequate substantiation of claims. As such, we are unable to claim that any of our products will diagnose, cure, mitigate, treat, or prevent diseases. For example, in Japan, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is considered a food product, which significantly limits our ability to make claims regarding the product. If marketing materials make claims that exceed the scope of allowed claims for dietary supplements, regulatory authorities could deem our products to be unapproved drugs and we could experience substantial harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is also subject to regulatory frameworks that may limit or significantly alter the way business is done in foreign markets vis-&#224;-vis the United States. For example, our marketing of products or business opportunity as a consultant in the United Kingdom differs significantly from marketing to United States customers and independent consultants. Consequently, we may experience additional costs and delays in entering or continuing to do business in foreign markets in order to comply with local regulations.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_166"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential FDA and Other Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could become subject to additional laws or regulations administered by the FDA, FTC, or other federal, state, local or international regulatory authorities, to the repeal or amendment of laws or regulations that we consider favorable, such as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DSHEA, or to more stringent interpretations of current laws or regulations. Because of negative publicity associated with some adulterated or misbranded supplements, including pharmaceutical drugs marketed as dietary supplements, there has been an increased movement in the United States and other markets to expand the regulation of dietary supplements, which could impose additional restrictions or requirements in the future. In recent years, there also has been increased pressure in the United States to further regulate cosmetics. In general, the regulatory environment is becoming more complex with increasingly strict regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dietary Supplement and Nonprescription Drug Consumer Protection Act requires us to report to the FDA all serious adverse events and to maintain for six years, records of all adverse events, whether or not serious. An adverse event is defined as any health-related event associated with the use of a dietary supplement that is adverse. In addition, this law requires the label of each dietary supplement, including our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, to include a domestic address or telephone number by which the company selling the product may receive a report of a serious adverse event associated with such product. The labels of our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products comply with that statutory provision.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_169"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> employees, 217 of which were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">full-time employees. As of June&#160;30, 2024, 167 of our employees were based in the United States, 23 were based in Japan and a total of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were based in the Philippines, Thailand, Taiwan, Mexico, Australia, Singapore, Europe, and Canada. We do not include our independent consultants in our number of employees because our independent consultants are independent contractors and not employees. We outsource our manufacturing, warehousing and shipping operations.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_172"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Responsibility and Sustainability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand that long-term value creation for stockholders is our core responsibility. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are investing in a number of sustainability initiatives, including reducing the environmental impact of our business activities and products, improving the global human condition, providing a positive working environment and engaging with our stakeholders regarding these initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We believe that our employees are an essential asset. We have a dedicated team of professionals that support our customers and independent consultants, work to generate long-term value for our stockholders and contribute to the broader public through charitable programs, including LifeVantage Legacy &#8211; an independent charitable organization focused on bettering the lives of children throughout the world ("LifeVantage Legacy"). In turn, we offer competitive compensation and guide employees to focus on the long-term goals of our stockholders and independent consultants.  We have received many &#8216;best place to work&#8217; awards over the years, most recently being named as "Utah Top Workplaces" by the Salt Lake Tribune for the second year and "Top Places to Work in the Wellness Industry."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are committed to reducing our impact on the environment and creating awareness about sustainability. We strive to improve our environmental footprint over time and to initiate additional projects and activities that will further reduce our impact on the environment. Our commitment to the environment extends to our customers, our independent consultants, our employees, and the global communities in which we operate. We comply with applicable environmental regulations and strive to prevent pollution whenever possible. We are increasing our efforts to train our employees and independent consultants on our environmental program and empower them to contribute and participate. We are committed to continually improving over time by striving to measure our environmental impacts and by setting goals to reduce these impacts each year. Some examples of our efforts include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launching a revamped TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activated Skin Care Collection using only clean ingredients that also score low on the Think Dirty scale; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Using more easily recycled packaging in the relaunch of our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activated Skin Care Collection;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Abiding by our environmental policy using the feedback from our stakeholders to help formalize our focus on sustainability;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Using environmental auditing in our selection process for new partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Switching to more easily recyclable bottles and cartons for product packaging, including replacing plastic bags with paper cartons for our energy drink products and using a fully recyclable glass bottle and cap for our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen product line;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sourcing shipping boxes made from Sustainable Forestry Initiative certified corrugate material; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Redesigning our shipping boxes to reduce the amount of waste created;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changing our shipping process to leverage lower CO2 emissions by 50%; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Creating sharable videos that our independent consultants can use when discussing our sustainability efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Focusing on working with fish oil suppliers and fisheries who are Marine Stewardship Council certified; and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Joining the Roundtable on Sustainable Palm Oil to support sustainable sources of Palm Oil.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Social/Community:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our legacy is not the past, it is the future we create. This belief informed our effort to sponsor the formation of LifeVantage Legacy. LifeVantage Legacy helps the leaders of tomorrow by touching a million lives across the world today. From simply helping a child in need to supporting initiatives that uplift entire communities, our goal is simple - give future generations the support and resources they need to live happier, healthier lives one child at a time. One of the best parts of LifeVantage is our commitment to leaving places better than we found them. Some examples of our efforts include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hosting home building trips over the holidays with our independent consultants and their families in Puerto Penasco, Mexico, where we have built over 30 homes for families in need over the past several years;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Partnering with local refugee foundations to provide help to repair fences, provide habitat upkeep, as well as helped procure needed items for kids and cleaning supplies for people's homes;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hosting Company-sponsored incentive trip where attendees gave back to the local communities, like creating over 1,000 school kits for the local community to aid immigrant children and their families in attending school and after-school education during a recent Company-sponsored trip to Punta Cana;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Formalizing our auditing and commitment to align internationally with human rights philosophies in how we conduct business through our human rights policy and vendor code of conduct, including auditing our key partners each year to ensure we are partnering with those who share our values;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Measuring our employees' engagement levels, requesting anonymous feedback during the fiscal year, and implementing changes to address their feedback; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hosting monthly all hands staff meetings to ensure our employees feel informed and aligned on our priorities and to encourage transparent communication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We endeavor to continue to strengthen and improve our corporate governance and executive compensation practices. We have an equity ownership policy to reinforce our belief that executives and directors who believe in the future of our company should have meaningful equity holdings in LifeVantage. In addition, we have a majority standard for the election of directors on our board. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_175"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal offices are located at 3300 N. Triumph Blvd, Suite 700, Lehi, UT 84043. Our telephone number is (801)&#160;432-9000 and our fax number is (801)&#160;880-0699. Our website address is www.lifevantage.com; however, information found on our website is not incorporated by reference into this report. Our website address is included in this annual report as an inactive textual reference only.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reports filed with the SEC, by us and by our officers, directors, and significant stockholders are available for review on the SEC&#8217;s website at www.sec.gov. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such reports are</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also available free of charge through the investor relations section of our website at </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.lifevantage.com</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are accessible as soon as reasonably practicable after being electronically filed with or furnished to the SEC.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A &#8212; RISK FACTORS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the following risks, as well as other risks affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. The risks described below are those we currently believe could materially affect us. The following risks are not necessarily all of the important factors that could cause our actual results of operations to differ materially from those expressed in the forward-looking statements in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business and Industry</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An inability to properly motivate and incentivize sales from our independent consultants could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Motivating our independent consultants and providing them with appropriate sales resources, including technology, tools, and training, are important to the growth and success of our business. We have faced, and may continue to face, challenges in motivating and incentivizing our independent consultants. In addition, actions we take from time to time to enforce our policies and procedures, may cause discord among some of our independent consultants. The loss of key independent consultants due to various factors including, but not limited to, voluntary termination or involuntary termination or suspension resulting from non-compliance with our policies and procedures, could distract our independent consultants and disrupt our business. For example, in the past, we have experienced discord among our leading independent consultants. If we fail to properly respond to any discord among our leading independent consultants in the United States and other markets, we could lose additional leaders, including to competing direct selling companies, which could have a significant negative impact on our revenue. Further, from time to time, we are involved in legal proceedings with former independent consultants. Such legal proceedings can be a distraction to our active independent consultants and can be expensive, time-consuming and cause a disruption to our business. Our inability to properly respond to these and other distractions may have a negative impact on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain our existing customers and independent consultants or attract additional customers and independent consultants, our revenue will not increase and may decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers may cease purchasing our products at any time and for any reason. Our independent consultants may terminate their services at any time, and we can and have in the past terminated consultants for conduct violative of our policies and procedures. As such, like most direct selling companies, we have experienced and are likely to continue to experience turnover among both customers and independent consultants. We have experienced, and may continue to experience, a decrease in the number of our independent consultants. The departure for any reason of one of our leading independent consultants can be a major disruption to other independent consultants and could have a significant negative impact on our sales and operating results. Independent consultants who join our company to purchase our products for personal consumption or for short-term income goals may only stay with us for a short time. While we take steps to help train, motivate, and retain independent consultants, we cannot accurately predict the number or sales productivity of our independent consultants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results will be harmed if we and our independent consultant leaders do not generate sufficient interest in our business to retain existing customers and independent consultants and attract new customers and independent consultants. The number and sales productivity of our independent consultants could be harmed by several factors, including:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any adverse publicity regarding us, our products, our distribution channel, or our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">non-compliance by our independent consultants with applicable legal requirements or our policies and procedures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of interest in existing or new products or their failure to achieve desired sales results;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a compelling business opportunity sufficient to generate the interest and commitment of new independent consultants;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes we might make to our independent consultant sales compensation plan;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any negative public perception of our company or our products or their ingredients;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any negative public perception of our independent consultants and direct selling business in general;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our actions to enforce our policies and procedures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any efforts to sell our products through competitive channels;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any regulatory actions or charges against us or others in our industry; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and business conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our independent consultants could fail to comply with applicable legal requirements or our policies and procedures, which could result in claims against us that could harm our business.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent consultants are independent contractors and, accordingly, we are not in a position to directly provide the same oversight, direction and motivation as we would if they were our employees. As a result, there can be no assurance that our independent consultants will comply with applicable laws or regulations or our independent consultant policies and procedures, participate in our marketing strategies or plans, or accept our introduction of new products. Despite their independent contractor status, activities by our independent consultants that allegedly violate applicable laws or regulations </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could result in government or third-party actions against us, which could harm our business. Our independent consultants agree to abide by our policies and procedures which are designed to ensure our independent consultants will comply with legal requirements. We have a consultant compliance department that addresses violations of our independent consultants when they become known to us. However, given the size of our independent consultant network, we experience problems with independent consultants violating our policies and procedures from time to time and are not always able to discover or remedy such violations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our most significant areas of risk with respect to independent consultant activities relates to improper product claims and claims regarding the consultant business opportunity of being an independent consultant. Any determination by the FDA, FTC, any state agency, or other similar governmental agency outside the United States that we or our independent consultants are not in compliance with applicable laws could materially harm our business. Even if governmental actions do not result in rulings or orders against us, they could create negative publicity that could detrimentally affect our efforts to recruit or motivate independent consultants and attract customers or lead to consumer lawsuits against us. When we experience growth in the number of our independent consultants, we have seen an increase in sales aids and promotional material being produced by independent consultants and/or consultant groups in some markets. This places an increased burden on us to monitor compliance of such materials and increases the risk that such materials could contain problematic product, marketing, or business opportunity claims in violation of our policies and applicable regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have expanded into foreign countries, our policies and procedures for our independent consultants differ slightly in some countries due to the different legal requirements of each country in which we do business. In addition, as we have expanded internationally, some of our independent consultants have carried or shipped our products into countries in which such products are not registered or that otherwise impose stringent restrictions on our direct selling model. While we have taken steps to stop or restrict these sales from occurring, including through our independent consultant policies and procedures, it can be difficult to enforce these policies and procedures because of the large number of independent consultants and their independent status. If relevant regulatory authorities determined that any such independent consultant activities are not compliant with all regulatory requirements, we could be subject to related fines, penalties, and other assessments or negative publicity, any of which could have an adverse impact on our business. In addition, violations by our independent consultants of our policies and procedures could reflect negatively on our products and operations and harm our business reputation. Further, it is possible that a court could hold us civilly or criminally accountable based on vicarious liability because of the actions of our independent consultants. In the past, some of our independent consultants have been investigated by government agencies for conduct alleged to have violated the law and our policies. This type of investigation can have an adverse effect on us even if we are not involved in the independent consultant&#8217;s activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by changes to our independent consultant compensation plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We modify our compensation plans from time to time to keep them competitive and attractive to existing and potential independent consultants, to address changing market dynamics, to provide incentives to our independent consultants that we believe will help grow our business, to conform to local regulations and to address other business-related considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2023, we launched our new Evolve Compensation Plan for our independent consultants in the United States, Australia, New Zealand, and Japan. Following that launch, in fiscal year 2024, we launched our new Evolve Compensation Plan for our independent consultants in Canada, Mexico Europe, with plans to roll out the new compensation plan to our remaining markets in the future. It is difficult to predict how such changes will be viewed by our independent consultants and whether such changes will achieve their desired results. Such changes could result in unintended or unforeseen negative economic and non-economic consequences to our business, such as higher than anticipated costs or difficulty in attracting and retaining independent consultants, either of which could have a material adverse effect on our results of operations and financial condition. In addition, if regulatory agencies such as the FTC or judicial cases lead to new industry standards or rules, our business could be impacted, and we may need to amend our compensation plan. If we are required to make changes, or if the FTC seeks to enforce similar measures in the industry, either through rulemaking or an enforcement action against our company, our business could be harmed. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We primarily depend on a few products for a majority of our revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we generate revenue through the sale of other products, we primarily rely on our Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product lines for a majority of our revenue, which collectively represent approximately 80.1% of our total revenue. We do not currently have a diversified portfolio of other products that we could rely on to support our operations if we were to experience any difficulty with the manufacture, marketing, sale, or distribution of these product lines. As such, any adverse impact we experience with respect to these two product lines could result in an impact to our overall revenue. For example, if we are unable to sustain or increase the price or sales levels for the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product lines, our business could be harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon third parties to manufacture our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on third parties to manufacture our products. We are dependent on the uninterrupted and efficient operation of third-party manufacturers&#8217; facilities. We currently use multiple third-party manufacturers for our products. If any of our current manufacturers are unable or unwilling to fulfill our manufacturing requirements or seek to impose unfavorable terms, we will likely have to seek out other manufacturers, which could disrupt our operations and we may not be successful in finding alternative manufacturing resources. In addition, competitors who perform their own manufacturing may have an advantage over us with respect to pricing, availability of product, and in other areas through their control of the manufacturing process.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High quality materials for our products may be difficult to obtain or expensive.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials account for a significant portion of our manufacturing costs, and we rely on third-party suppliers to provide raw materials. Suppliers may be unable or unwilling to provide the raw materials our manufacturers need in the quantities requested, at a price we are willing to pay, or that meet our quality standards. We are also subject to potential delays in the delivery of raw materials caused by events beyond our control, including labor disputes, transportation interruptions and changes in government regulations. Our business could be adversely affected if we are unable to obtain a reliable source of any of the raw materials used in the manufacturing of our products that meets our quality standards. Additionally, if demand for our products exceeds our forecasts, we may have difficulties in obtaining additional raw materials in time to meet the excess demand. Any significant delay in or disruption of the supply of raw materials could, among other things, substantially increase the cost of such materials, require reformulation or repackaging of products, require the qualification of new suppliers, or result in our inability to meet customer demands.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to or significantly increased costs associated with transportation and other distribution channels for our products may adversely affect our margins and profitability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally rely on the uninterrupted and efficient operation of third-party logistics companies to transport and deliver our products. These third-party logistics companies may experience disruptions to the transportation channels used to distribute our products, including disruptions caused by increased airport and shipping port congestion, a lack of transportation capacity, increased fuel expenses, and a shortage of manpower. Disruptions to the transportation channels experienced by our third-party logistics companies may result in increased costs, including the additional use of airfreight to meet demand. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to product recalls.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented measures in our manufacturing process that are designed to prevent and detect defects in our products, including contaminants. However, such measures may not prevent or reveal defects or detect contaminants in our products and such defects and contaminants may not become apparent until after our products have been sold into the market. Accordingly, there is a risk that product defects will occur, or that our products will contain foreign contaminants, and that such defects and contaminants will require a product recall. We do not maintain product recall insurance. In the past, we commenced a voluntary recall of certain lots of Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to alleviate safety concerns related to certain batches of turmeric extract, an ingredient in Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we purchase from third-party suppliers. Product recalls and subsequent remedial actions can be expensive to implement and could have a material adverse effect on our business, results of operations and financial condition. In addition, product recalls could result in negative publicity and public concerns regarding the safety of our products, either of which could harm the reputation of our products and our business and could cause the market value of our common stock to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A past voluntary product recall strained our relationships with some of our third-party manufacturers. Additionally, following the voluntary recall we implemented more stringent measures, including several redundant measures, in our manufacturing process to detect contaminants. Third-party manufacturers may be reluctant to implement these redundant measures, may refuse to manufacture our products, and additional safety measures such as these may increase our cost of goods sold and strain our relationships with manufacturers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is susceptible to product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture and sale of any product for human consumption raises the risk of product liability claims. These claims may derive from the product itself or a contaminant found in the product from the manufacturing, packaging, sales process or even due to tampering by unauthorized third parties. Our products consist of vitamins, minerals, herbs, and other ingredients that are classified as foods or dietary supplements and are not subject to pre-market regulatory approval in the United States. Our products could contain contaminated substances, and some of our products contain ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur. In addition, third-party manufacturers produce all of the products we sell. As a distributor of products manufactured by third parties, we may also be liable for various product liability claims for these products despite not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing them. We may be subject to various product liability claims, including, among others, that our products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. Any product liability claim against us could result in increased costs and could adversely affect our reputation with our customers, which in turn could adversely affect our revenue and operating income. Although we maintain insurance coverage, there is a risk that our insurance will not cover our potential exposure completely or would fail to cover a particular claim, in which case we may not have the financial resources to satisfy such claim. In addition, certain types of damages, such as punitive damages, are not covered by our insurance policy.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of the markets in which we compete for business, including the dietary supplement and personal care markets, are highly competitive. We may not be able to compete effectively, which may have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the markets in which we compete for business, including the dietary supplement and personal care markets, are large, highly competitive, and fragmented. Our flagship product line, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen compete in the dietary supplements market and our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Skin Care Collection competes in the personal care market. Participants include specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, online merchants, mail-order companies, and a variety of other smaller participants. Many of our competitors have greater financial and other resources available to them and possess better manufacturing, independent distribution, and marketing capabilities than we do. We believe some of these competitors with greater resources may develop and release products that will compete directly with the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line or the TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line and will be marketed as activation products. One or more of these products could significantly reduce the demand for the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and have a material adverse effect on our revenue. We believe that the market is also highly sensitive to the introduction of new products, including various prescription drugs, which may rapidly capture a significant share of the market. Moreover, because of regulatory restrictions concerning claims about the efficacy of dietary supplements and personal care products, we may have difficulty differentiating our products from our competitors&#8217; products and competing products entering the dietary supplements and personal care markets could harm our revenue. In the United States and Japan, we also compete for sales with heavily advertised national brands manufactured by large pharmaceutical and food companies, as well as other retailers. In addition, as some products become more mainstream, we experience increased competition for those products as more participants enter the market. Our international competitors include large international pharmacy chains, major international supermarket chains, and other large U.S.-based companies with international operations. We may not be able to compete effectively and our attempt to do so may result in increased pricing pressure, which may result in lower margins and have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable publicity could materially harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon consumers' perceptions of the safety, quality, and efficacy of our products, as well as competitive products distributed by other companies. In the past, we have experienced negative publicity that has harmed our business. Critics of our industry and other individuals whose interests are not aligned with our interests, have in the past and may in the future utilize the Internet, the press, and other means to publish criticism of the industry, our company, our products, and our competitors, or make allegations regarding our business and operations, or the business and operations of our competitors. For instance, several prominent companies in our industry have been targeted by short sellers who profit if a company's stock price decreases. One such company was targeted by a short seller who, after taking a significant short position, publicly made allegations regarding the legality of the company's direct selling model. Short sellers have an incentive to publicly criticize our industry and business model and any such criticism may adversely affect our stock price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future scientific research or publicity may not be favorable to our industry or any particular product. Because of our dependence upon consumer perceptions, adverse publicity associated with illness or other adverse effects resulting or claimed to have resulted from the consumption or use of our products or any similar products distributed by other companies could have a material adverse impact on us. Such adverse publicity could arise even if the claims are unsubstantiated or if the adverse effects associated with such products resulted from failure to consume or use such products as directed. Adverse publicity could also increase our product liability exposure, result in increased regulatory scrutiny and lead to the initiation of private lawsuits.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actions of activist stockholders have, and could continue to, impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management&#8217;s attention and resources, and adversely affect our business, results of operations, financial condition, and the trading price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Publicly traded companies have increasingly become subject to campaigns by activist investors advocating for corporate actions such as financial restructurings, increased borrowings, special dividends, stock repurchases or even sales of assets or entire companies to third parties or the activists themselves. Responding to proxy contests and other actions by activist stockholders, including related litigation, has been and can be costly and time consuming, disrupt our operations and divert the attention of our board and senior management from the pursuit of business strategies, which could adversely affect our results </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations and financial condition. For example, in August 2023, we received notice from a stockholder, Bradley L. Radoff, of his intent to nominate three directors for election at our fiscal year 2024 annual meeting of stockholders. We and Mr. Radoff communicated throughout the proxy contest, but could not reach an agreement in connection with Mr. Radoff's nomination. At our fiscal year 2024 annual meeting of stockholders, our stockholders elected the incumbent directors as the directors of our board, each to hold office until our fiscal year 2025 annual meeting of stockholders or until his or her respective successor is elected and qualified. On February 14, 2024, we entered into a cooperation agreement with Mr. Radoff and other relevant persons and entities (the "Cooperation Agreement"). Pursuant to the Cooperation Agreement, we increased the size of our board by one seat, appointed Mr. Dayton Judd to our board, and agreed to other terms and customary standstill provisions. The amount of time, attention, and resources that were required of our Company, board, and executive leadership team to address the proxy contest-related measures were substantial, and the residual impact on the Company's business and financial performance is uncertain. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, perceived uncertainties as to our future direction as a result of future stockholder activism or further changes to the composition of our board may lead to the perception of a change in the direction of our business, instability or lack of continuity. These uncertainties may be more acute or heightened when an activist seeks to change a majority of the board or ultimately desires to acquire the company. If individuals are elected to our board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. Additionally, actions by activist stockholders may be exploited by our competitors, cause concern to our current or potential independent consultants and customers, make it more difficult to attract and retain qualified personnel and may create adverse uncertainty for our employees. In addition, actions of activist stockholders may cause significant fluctuations in our stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business. It is possible that we could become engaged in future proxy contests with other activist stockholders, which could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of or inability to attract key personnel could negatively impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future performance will depend, in part, upon our ability to attract, retain, and motivate our executive and senior management team and scientific staff. Our success depends to a significant extent both upon the continued services of our current executive and senior management team and scientific staff, as well as our ability to attract, hire, motivate, and retain additional qualified management and scientific staff in the future. Specifically, competition for executive and senior staff in the direct selling and dietary supplement markets is intense, and our operations could be adversely affected if we cannot attract and retain qualified personnel. Additionally, former members of our executive and senior management team have in the past, and could in the future, join or form companies that compete against us in the direct selling industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees are &#8220;at will&#8221; employees, which means any employee may quit at any time and we may terminate any employee at any time. We do not carry &#8220;key person&#8221; insurance covering members of senior management or our employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be held responsible for certain taxes or assessments and other obligations relating to the activities of our independent consultants, which could harm our financial condition and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent consultants are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect or withhold taxes, such as value added taxes or income taxes, and to maintain appropriate records. In the event that local laws and regulations or the interpretation of local laws and regulations change to require us to treat our independent consultants as employees, or that our independent consultants are deemed by local regulatory authorities in one or more of the jurisdictions in which we operate to be our employees rather than independent contractors under existing laws and interpretations, or our independent consultants are deemed to be conducting business in countries outside of the country in which they are authorized to do business, we may be held responsible for social security, income, and other related taxes in those jurisdictions, plus any related assessments and penalties, which could harm our financial condition and operating results. If our independent consultants were deemed to be employees rather than independent contractors, we may be obligated to pay certain employee benefits, such as workers compensation and unemployment insurance. Further, if our independent consultants are misclassified as employees, we would also face the threat of increased vicarious liability for their actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to a Global Not For Resale Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Global Not For Resale program, which allows customers from around the world to purchase limited amounts of our products for their individual consumption. Under this program, customers from other countries are able to set up a U.S. customer account and associated U.S. address and payment method to drop-ship their order to a third-party vendor in the U.S., who will then ship the products to the customer&#8217;s global location with any customs and/or duties being the sole responsibility of the ordering customer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This program may raise questions from tax regulators about the appropriate sales tax jurisdiction due to the varied and complex tax regulations in the U.S. and around the world. Further, any regulatory review of our facilitation to ship U.S. product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our existing markets, where such product has not been registered, may raise issues against the local subsidiary from the foreign jurisdiction equivalents of the FDA or FTC or the relevant trade associations, should any agency or association perceive that we or our independent consultants are advertising and/or facilitating the sale of unregistered product in their country.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_181"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Company</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to evolving laws, policies, and contractual obligations related to data privacy and security, including cybersecurity, and our actual or perceived failure to comply with such obligations or perceived failure to maintain the integrity of our data could expose us to data loss or litigation, harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business, prospects, financial condition, and operating results. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and retain large volumes of data relating to our business and from our customers, independent consultants and employees for business purposes, including for transactional and promotional purposes, and our various IT systems enter, process, summarize and report such data. The integrity and protection of this data is critical to our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to or affected by a number of national, state and local laws and regulations, as well as contractual obligations and industry standards, that impose certain obligations and restrictions with respect to data privacy and security, and govern our collection, storage, retention, protection, use, processing, transmission, sharing and disclosure of personal information, including that of our employees, customers and others. We are also subject to requirements imposed by the payment card industry. As we expand our operations, the CCPA, CPRA, and other laws and regulations relating to privacy and data security may increase our compliance costs and potential liability. Compliance with any applicable privacy and data security laws and regulations is a time-intensive and costly process, and we may be required to put in place additional processes to comply with existing and evolving laws and regulations and new laws and regulations as we expand our operations. Many jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities and others of security breaches involving certain types of data. In addition, our agreements with certain customers may require us to notify them in the event of a security breach or incident. Such mandatory disclosures can be costly and could lead to negative publicity, penalties, fines, litigation, and other proceedings or cause our customers to lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security breach or incident. We may not be able to monitor and react to all developments in a timely manner. Maintaining compliance with these evolving regulations and requirements could be difficult and may increase our expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many jurisdictions outside of the United States are considering or have enacted similar or more stringent legislation providing for local storage of data or otherwise imposing privacy, data protection, and data security obligations in connection with the collection, use, and other processing of personal data. Further, the global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. As our international presence expands, we may become subject to additional obligations under laws and regulations in countries outside the United States, such as, for example, the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), legislation in other countries implementing the GDPR or similar versions of the GDPR. As a general matter, compliance with laws, regulations, contractual obligations, industry standards, and any rules or guidance from self-regulatory organizations relating to privacy, data protection, and data security that apply, or are asserted to apply, to our operations may result in substantial costs and may necessitate changes to our business practices, which may compromise our growth strategy, adversely affect our ability to acquire customers, and otherwise adversely affect our business prospects, results of operations, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the security measures we have in place to comply with applicable laws and rules and to protect our security and information systems, there can be no assurance that our cybersecurity risk management program and processes, including our policies, controls, or procedures will be fully implemented, complied with, or effective in protecting our systems and information Further, our vendors and third-party service providers (as well as their third-party service providers), may be vulnerable to security breaches, acts of cyber terrorism or sabotage, vandalism or theft, computer viruses, loss or corruption of data or programming or human errors or other similar events. While we have agreements requiring our third-party service providers to use best practices for data security, we have no operational control over them. Because such attacks are increasing in sophistication and change frequently in nature, we and our third-party service providers may be unable to anticipate these attacks or implement adequate preventative measures, and any compromise of our systems, or those of our third-party vendors (as well as their third-party service providers), may not be discovered and remediated promptly. Changes in consumer behavior following a security breach or perceived security breach, act of cyber terrorism or sabotage, vandalism or theft, computer virus, loss or corruption of data or programming or human error or other similar event affecting a competitor, large retailer or financial institution may materially and adversely affect our business. While we carry cyber insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred, that insurance will continue to be available to us on commercially reasonable terms or at all, or that any insurer will not deny coverage as to any future claim. Any of the foregoing may have an adverse effect on our business, prospects, results of operations, and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in expanding our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in expanding our operations. Although we have been selling our products through our direct selling network since fiscal year 2009, we still may have limited insight into trends, disruptions and other factors that may emerge and affect our business. For example, a widespread pandemic, such as the COVID-19 pandemic, and measures taken in response by governments and businesses worldwide to contain its spread, including quarantines, facility closures, travel and logistics restrictions, border controls, and shelter in place or stay at home and social distancing orders, may adversely impact our supply chain, manufacturing, logistics, workforce and operations, as well as the operations of our customers and suppliers globally. Such adverse impacts on our supply chain could limit our ability to sell our products on a timely and cost-effective basis, which could adversely affect our business and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, from time to time, we are compelled to terminate one or more of our independent consultants for actions contrary to their contractual obligations with us. In the past, some of these terminations have caused disruption among our independent consultants, and such terminations or resulting disruption in the future may negatively impact our revenue. Additionally, we may not be successful in keeping our leading independent consultants focused and motivated or in aligning their goals with our company goals. Although we are seeking to grow our business, if we fail to effectively manage operations in our existing markets and/or expand our operations into additional markets, we may be unable to generate consistent operating profit growth in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are able to expand our operations, we may experience difficulties in managing our future growth, which could adversely affect our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are able to expand our operations in the United States and in other countries where we believe our products will be successful, such expansion could place increased strain on our management, operational, financial and other resources. An inability to leverage our current resources in an efficient manner could have a material adverse effect on our business, operating margins, and results of operations. In addition, if we are able to expand our operations, we expect we will need additional managerial, operational, technical, sales, marketing, financial, legal, and other resources. Our management may need to divert its attention away from its day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure and loss of business opportunities, among others. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not succeed in growing our business in existing markets or opening new markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. We also sell our products in a number of countries to customers for personal consumption only. In fiscal year 2024, we generated approximately 27% of our revenue from our international operations, a majority of which was generated in Japan. We believe that our ability to achieve future growth is dependent in part on our ability to effectively expand into new international markets and grow our existing markets. In some international markets, we have experienced difficulties which have resulted in adverse consequences to our business, including declining revenue in some markets and occasional disruption to our business with supply chain and logistics delays in delivering product to certain markets in a timely manner.  Our business and financial results may be also negatively impacted if a particular market or new business model is not widely accepted and adopted. We must overcome significant regulatory and legal barriers before we can begin marketing in any international market. Also, before marketing commences in a new country or market, it is difficult to assess the extent to which our products and sales techniques will be accepted or successful. In addition to significant regulatory barriers, we may also encounter problems conducting operations in new markets with different cultures and legal systems from those encountered elsewhere. We may be required to reformulate one or more of our products before commencing sales of that product in a given country. Once we have entered a market, we must adhere to the regulatory and legal requirements of that market. We may not be able to obtain and retain necessary permits and approvals in new markets, or we may have insufficient capital to finance our expansion efforts in a timely manner.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inability of new products and technological innovations to gain market acceptance by customers and/or independent consultants could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to introduce new products that gain acceptance among our customers and independent consultants is an important part of our ability to grow our revenue in future periods. However, any new products we introduce may not gain market acceptance by customers and/or independent consultants to the extent we anticipate or project. Factors that could affect our ability to introduce new products include, among others, government regulations, the inability to attract and retain qualified research and development staff, the termination of third-party research and collaborative arrangements, proprietary protections of competitors that may limit our ability to offer comparable products and the difficulties in anticipating changes in consumer tastes and buying preferences. In addition, new products we introduce may not be successful or generate substantial sales </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue. The introduction of a new product could also negatively impact other product lines to the extent our independent consultant leaders focus their sales efforts on the new product instead of an existing product. If any of our products fails to gain customer and/or independent consultant acceptance, we could see an increase in product returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe our ability to introduce new technologies that gain acceptance among our customers and independent consultants is an important part of our ability to grow our sales revenue in future periods. However, these or other new technologies that we introduce may not gain customer and/or independent consultant acceptance to the extent we anticipate or project. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted if we fail to execute any product launch process due to increased pressure on our supply chain, information systems and management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our product launch process may vary by market, we generally introduce new products to our customers and independent consultants through live events or cyber launches, limited-time offers and promotions. The limited-time offers typically generate significant activity and a high level of purchasing, which may result in a higher-than-normal increase in sales revenue during the quarter of the limited-time offer and skew year-over-year and sequential comparisons. We may experience difficulty effectively managing growth associated with these limited-time offers. In addition, the size and condensed schedule of these product launches increases pressure on our supply chain. If we are unable to accurately forecast sales levels in each market, obtain sufficient ingredients or produce a sufficient supply to meet demand, we may incur higher expedited shipping costs and we may temporarily run out of stock of certain products, which could negatively impact the enthusiasm of our independent consultants and their customers. Conversely, if demand does not meet our expectations for a product launch, we could incur increased inventory write-offs. Any inventory write-off would negatively impact our gross margins. In addition, our order processing systems could have difficulties handling the high volume of orders generated by limited-time offers. Although our previous limited-time offers have not materially affected our product return rate, these events may increase our product return rate in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be harmed if we are unable to appropriately manage our inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have experienced difficulties in appropriately managing our inventory. For example, when we launched our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen product in June 2022, we experienced higher than expected demand and did not have sufficient inventory to meet demand. Subsequently, our inventory balances increased significantly, causing us to engage in a deliberate effort to manage our inventory balances down to levels we viewed as appropriate. We review all inventory items quarterly for obsolescence, and when items become obsolete or are expired, we write down our inventory accordingly. If we are unable to sell our inventory in a timely manner, we may experience additional inventory obsolescence charges, including for finished products in inventory that have expired. If we are unable to appropriately manage our inventory balances, our business may be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our IT systems to manage numerous aspects of our business, and a disruption in these systems, including as a result of cybersecurity incidents, could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our IT systems to manage numerous aspects of our business, including our finance and accounting transactions, to manage our independent consultant sales compensation plan and to provide analytical information to management. Our IT systems are an essential component of our business and growth strategies, and a serious disruption to our IT systems, including as a result of cybersecurity incidents, could significantly limit our ability to manage and operate our business efficiently. These systems are vulnerable to, among other things, damage and interruption from power loss or natural disasters, computer system and network failures, loss of telecommunications services, physical and electronic loss of data, security breaches and computer viruses. Any disruption could cause our business and competitive position to suffer and adversely affect our business and operating results. In addition, if we experience future growth, we will need to scale or change some of our systems to accommodate the increasing number of independent consultants and their customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inability to comply with financial covenants imposed by our credit facility and the impact of debt service obligations and restrictive covenants could impede our operations and flexibility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we entered into a loan agreement, which was subsequently amended in May 2018, February 2019, April 2021, and September 2022, that provided for a credit facility consisting of a revolving loan facility in an aggregate principal amount not to exceed $5.0 million (the "2016 Credit Facility"). On March 31, 2024, the 2016 Credit Facility reached its maturity date and was terminated. As of March 31, 2024, there was no outstanding balance on the 2016 Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2024, we entered into a new loan agreement, which provides for a revolving line of credit in an aggregate principal amount not to exceed $5.0 million (the "2024 Credit Facility"). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of June&#160;30, 2024, there is no outstanding balance on the 2024 Credit Facility. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount of any borrowings under the 2024 Credit Facility is repayable, if drawn, on the maturity date of the facility (April 12, 2027). Interest will accrue on outstanding loans, payable monthly. We expect to generate the cash necessary to pay any future principal and interest on the 2024 Credit Facility, if any, from our cash flows provided by operating activities. However, our ability to meet our debt service obligations will depend on our future performance, which may be affected by financial, business, economic, demographic, and other factors. If we do not have enough money to pay our debt service obligations, we may be required to refinance all or part of our debt, sell assets, borrow more money, or raise cash through the sale of equity. In such an event, we may not be able to refinance our debt, sell assets, borrow more money, or raise cash through the sale of equity on terms acceptable to us or at all. Also, our ability to carry out any of these activities on favorable terms, if at all, may be further impacted by any financial or credit crisis which may limit access to the credit markets and increase the cost of capital. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Credit Facility is secured by a lien on substantially all of our assets, and the assets of Lifeline Nutraceuticals, and by a pledge of membership interests of our subsidiaries, and contains customary covenants, both affirmative and negative covenants, that, among other things, restrict our ability to deal with our assets outside of the ordinary course, incur or guarantee additional indebtedness, grant liens on our assets, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, and enter into consolidations, mergers or other combinations. The 2024 Credit Facility requires that we maintain specified financial ratios and satisfy certain financial condition tests and comply with certain informational requirements in order to borrow under the revolving loan facility, if needed. Our ability to comply with these financial ratios and tests and informational requirements can be affected by events beyond our control and we may be unable to meet these ratios and tests and informational requirements. A breach of any of the representations, covenants (including compliance with financial ratios), or other restrictions imposed by the 2024 Credit Facility may result in a default or an event of default giving rise to lender's remedies thereunder, which could result in the lender declaring any portion or all amounts of principal, interest and other related costs and expenses outstanding under the 2024 Credit Facility to be immediately due and payable or limit our ability to draw on the revolving loan facility. Our assets may not be sufficient to repay the indebtedness if the lender accelerates our repayment of the indebtedness under the 2024 Credit Facility. In such circumstances, the lender's remedies would include the ability to foreclose on the collateral securing the loan. We were in compliance with all of the 2024 Credit Facility covenants at the end of fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A substantial portion of our business is conducted in foreign markets, exposing us to the risks of trade or foreign exchange restrictions, increased tariffs, foreign currency fluctuations, disruptions or conflicts with our third-party importers and similar risks associated with foreign operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global economic conditions continue to be challenging and unpredictable. A substantial portion of our sales are generated outside the United States. If we are successful in entering additional foreign markets, we anticipate that the percentage of our sales generated outside the United States will increase. There are substantial risks associated with foreign operations. For example, a foreign government may impose trade or foreign exchange restrictions, increased tariffs or other legal, tax, customs or other financial burdens on us or our independent consultants, due, for example, to the structure of our operations in various markets. Any such actions could negatively impact our operations and financial results. We are also exposed to risks associated with foreign currency fluctuations. For instance, in preparing our financial statements, we translate revenue and expenses in our markets outside the United States from their local currencies into U.S. Dollars using weighted average exchange rates. If the U.S. Dollar strengthens relative to local currencies, our reported revenue, gross profit, and net income will likely be reduced. Foreign currency fluctuations can also result in losses and gains resulting from translation of foreign currency denominated balances on our balance sheet. Additionally, purchases from suppliers are generally made in U.S. Dollars while sales to customers and independent consultants are generally made in local currencies. Accordingly, strengthening of the U.S. Dollar versus a foreign currency could have a negative impact on us. Specifically, because a significant percentage of our revenue is generated in Japan, strengthening of the U.S. Dollar versus the Japanese yen has had and, in the future, could have an adverse impact on our financial results. Although we may engage in transactions intended to reduce our exposure to foreign currency fluctuations, there can be no assurance that these transactions will be effective. Given the complex global political and economic dynamics that affect exchange rate fluctuations, it is difficult to predict future fluctuations and the effect these fluctuations may have upon future reported results or our overall financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be negatively impacted by conflicts with, or disruptions caused or faced by, third party importers, as well as conflicts between such importers and local governments or regulatory agencies. We are required to obtain import licenses in order to sell our products to consumers in countries outside the United States. Our inability to obtain and maintain import licenses could cause delays or disruptions to our business and financial condition. Our operations in some markets also may be adversely affected by political, economic, and social instability in foreign countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development or growth plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current plans, we believe that our current cash and cash equivalents and our ongoing cash flow from operations will be sufficient to satisfy our anticipated cash requirements for at least 12 months from the date of this report. If our available cash resources and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements, we may be required to raise significant additional capital to support our continued operations and the implementation of our business and growth plans. Future funding requirements will depend on many factors, including but not limited to:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with acquiring products from third-party vendors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of the sales and marketing activities of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with commissions and incentives for our independent consultants;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation expenses we incur to defend against claims, including claims that we infringe the intellectual property of others or judgments we must pay to satisfy such claims;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual obligations to third parties;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rate of progress in developing, launching, and selling our current products and any new products we pursue;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to control our operating costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy our outstanding debt obligations; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of responding to the other risks and uncertainties described in this report.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be required to raise additional capital in the future to expand our business and operations to pursue strategic investments or for other reasons including but not limited to:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our sales and marketing efforts to drive market adoption of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scaling up our customer support capabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">funding development and marketing efforts of additional products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding our product portfolio into additional markets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquiring products through licensing rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquiring or investing in complementary businesses or assets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financing capital expenditures and general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek required funding through issuances of equity or convertible debt securities or entering into additional loan facilities. Each of the various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our stockholders would result. If we raise funds by issuing additional debt securities, those debt securities would have rights, preferences, and privileges senior to those of holders of our common stock. Our 2024 Credit Facility restricts our ability to pursue certain transactions that we may believe to be in our best interest, including incurring additional indebtedness without the prior written consent of the lender under the credit facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain adequate financing or financing on terms satisfactory to us, if we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_2924"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory, Compliance, and Legal Matters </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to strict government regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing, packaging, labeling, advertising, sale, and distribution of our products are subject to federal laws and regulations by one or more federal agencies, including, in the United States, the FDA, the FTC, the Consumer Product Safety Commission, and the United States Department of Agriculture (the "U.S. DOA"). These activities are also regulated by various state, local, and international laws, and agencies of the states, localities, and countries in which our products are sold. For instance, the FDA regulates, among other things, the ingredients, composition, manufacture, safety, labeling, and marketing of dietary supplements (including vitamins, minerals, herbs and other dietary ingredients for human use) and cosmetic products. We and our suppliers must comply with FDA regulations with respect to current GMP, which require good manufacturing processes, including ingredient identification, manufacturing controls and record keeping. If our third-party suppliers or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vendors are not able to comply with these regulations, we may experience increased cost or delays in obtaining certain raw materials and third-party products. Complying with applicable legislation could also raise our costs and negatively impact our business. In addition, government regulations may prevent or delay the introduction of our products or require us to reformulate our products or change the claims we make about them, which could result in lost revenue, increased costs, and delayed expansion into new international markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may determine that a particular dietary supplement or ingredient or a particular cosmetic product is adulterated or misbranded or both and may determine that a particular claim or statement of nutritional support that we make to support the marketing of a dietary supplement is an impermissible drug claim or is an unauthorized version of a &#8220;health claim,&#8221; or that a particular benefit claim that we make to support the marketing of a cosmetic product is an impermissible drug claim. The FDA, the FTC, or state attorneys general may also determine that a particular claim we make for our products is not substantiated. Determining whether a claim is improper frequently involves a degree of subjectivity by the regulatory agency or individual regulator. Any of these determinations by the FDA or other regulators could prevent us from marketing that particular dietary supplement product or cosmetic product, or making certain claims for that product. The FDA could also require us to remove a particular product from the market. Any future recall or removal would result in additional costs to us, including lost revenue from any product that we are required to remove from the market, which could be material. Any product recalls or removals could also lead to liability, substantial costs, and reduced growth prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may receive a warning letter from the FDA if it believes some violation of law has occurred either by us or by our independent consultants. Any allegations of our non-compliance may result in time-consuming and expensive defense of our activities. FDA warning letters are available to the public on the FDA&#8217;s website. That information could negatively affect our relationships with our customers, investors, independent consultants, vendors, employees, and consumers. Warning letters may also spark private class action litigation under state consumer protection statutes. The FDA could also order compliance activities, such as an inspection of our facilities and products, and could file a civil lawsuit in which an arrest warrant (seizure) could be issued as to some or all of our products. In extraordinary cases, we could be named a defendant and sued for declaratory and injunctive relief.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional or more stringent regulations of dietary supplements and other products have been considered from time to time. In recent years, there has been increased pressure in the United States and other markets to increase regulation of dietary supplements. New regulations, or new interpretations of those regulations, could impose additional restrictions, including requiring reformulation of some products to meet new standards, recalls or discontinuance of some products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of some products, additional or different labeling, additional scientific substantiation, additional adverse event reporting, or other new requirements. Any of these developments could increase our costs significantly. Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute dietary supplements or impose additional burdens or requirements on dietary supplement companies or require us to reformulate our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over dietary supplements and the FTC over the direct selling industry. The FTC may strengthen the regulation of business opportunity claims and direct selling companies, among other things. The FTC has in recent years investigated and taken enforcement action against direct selling companies for misleading representations relating to the earnings potential of an independent consultant within a company&#8217;s compensation plan, as well as appropriateness of the compensation plans themselves. Our business could be harmed if more restrictive legislation or regulation is successfully introduced and adopted in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, Congress passed the Modernization of Cosmetics Regulation Act, which added significant new requirements for cosmetic products marketed in the United States. For example, we now have to register cosmetic product manufacturing facilities and list all cosmetic products with the FDA, and need to report all &#8220;serious adverse events&#8221; to the FDA and maintain relevant records. We will need to comply with current GMP regulations and fragrance allergen declaration regulations once the FDA implements those requirements. Complying with these requirements could raise our costs and negatively impact our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations governing the production and marketing of our products could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various domestic and foreign laws and regulations that regulate the production and marketing of our products. If, for example, a determination that our dietary supplement products are used to diagnose, treat, cure, or prevent any disease or illness, including due to improper marketing claims by our independent consultants, it may lead to a determination that the LifeVantage supplements require pre-market approval as a drug. Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products. Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or be required to adjust our operations. Our operations also could be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harmed if new laws or regulations are enacted that restrict our ability to market or distribute our products or impose additional burdens or requirements on the contents of our products or require us to reformulate our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the risk of investigatory and enforcement action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the risk of investigatory and enforcement action by various government agencies, both domestic and international. For instance, the FTC and state attorneys general may open an investigation or bring an enforcement action against us based on our advertising claims and marketing practices. The FTC routinely reviews product advertising, including websites, to identify significant questionable advertising claims and practices. The FTC has brought many actions against dietary supplement companies, including some actions that were brought jointly with state attorneys general, based upon allegations that applicable advertising claims or practices were deceptive or not substantiated. If the FTC initiates an investigation, the FTC can initiate pre-complaint discovery that may be nonpublic in nature. In addition, we are subject to the risk of investigatory and enforcement action by other agencies including, but not limited to, the FDA, including warning letters and other sanctions, enforcement actions by the SEC and by other international regulatory agencies. Any investigation may be very expensive to defend and may result in an adverse ruling or in a consent decree.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our direct selling program could be found to be not in compliance with current or newly adopted laws or regulations in one or more markets, which could prevent us from conducting our business in these markets and harm our financial condition and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the legal and regulatory requirements concerning the direct selling business model are ambiguous and subject to interpretation. As a result, regulators and courts have discretion in their application of these laws and regulations, and the enforcement or interpretation of these laws and regulations by governmental agencies or courts can change. Allegations by short sellers regarding the legality of multi-level marketing companies generally have also created intense public scrutiny of our industry and could cause governmental agencies to change their enforcement and interpretation of applicable laws and regulations. The failure of our business to comply with current or newly adopted regulations or interpretations could negatively impact our business in a particular market or in general and may adversely affect our stock price.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations may prohibit or severely restrict direct selling and cause our revenue and profitability to decline, and regulators could adopt new regulations that negatively impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various government agencies throughout the world regulate direct selling practices. The laws and regulations applicable to us and our independent consultants in Japan are particularly stringent. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as &#8220;pyramid&#8221; schemes, which compensate participants primarily for recruiting additional participants without significant emphasis on the sale of product to end consumers. Government agencies, such as the FTC in the United States and similar agencies in foreign jurisdictions, periodically investigate direct selling companies based on such schemes or other claims made by a direct selling company or its independent consultants. Generally, companies that are the subject of an FTC, or similar foreign agency, enforcement action are required to pay monetary fines and/or make updates or changes to their business model. The laws and regulations in some of our markets impose cancellations, product returns, inventory buy-backs and cooling-off rights for our independent consultants and/or customers. Excessive refunds and/or product returns pursuant to local laws and regulations, including being the target of an enforcement action or investigation by the FTC or a similar foreign agency in a foreign jurisdiction, could have a negative impact on our operating results. Complying with these rules and regulations can be difficult and requires the devotion of significant resources on our part. We may not be able to continue business in existing markets or commence operations in new markets if we are unable to comply with these laws or adjust to changes in these laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial condition and results of operations may be adversely affected by international regulatory and business risks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our operations, offering products or contracting with independent contractors and other service providers in various other countries, we are increasingly subject to varied and complex foreign and international laws and regulations. Compliance with these laws and regulations often involves significant costs and may require changes in our business practices that may result in reduced revenues and adversely affect our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent consultants to market our products internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these independent consultants may be deemed to be our agents and we could be held responsible for their actions. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including the United Kingdom&#8217;s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and we could be subject to severe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penalties, including criminal and civil penalties, disgorgement, and other remedial measures, any of which could result in a material adverse effect on our business, prospects, financial condition, or results of operations. Any allegations that we are not in compliance with anti-corruption laws may require us to dedicate time and resources to an internal investigation of the allegations or may result in a government investigation. Any determination that our operations or activities are not in compliance with existing anti-corruption laws or regulations could result in the imposition of substantial fines, and other penalties. Although we have implemented anti-corruption policies and controls to protect against violation of these laws, we cannot be certain that these efforts will be effective. Operating internationally requires significant management attention and financial resources. We cannot be certain that the investment and additional resources required to increase international revenues or expand our international presence will produce desired levels of revenues or profitability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of our intellectual property rights in our products could permit our competitors to manufacture their own version of our products. We have attempted to protect our intellectual property rights in our products through a combination of patents, patent applications, trademarks, trade secrets, confidentiality agreements, non-compete agreements and other contractual protection mechanisms, and we will continue to do so. While we intend to defend against any threats to our intellectual property, our patents or various contractual protections may not adequately protect our intellectual property. In addition, we could be required to expend significant resources to defend our rights to proprietary information and may not be successful in such defense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our intellectual property rights are more limited outside of the United States than they are in the United States. As such, we may not be successful in preventing third parties from copying or misappropriating our intellectual property. There also can be no assurance that pending patent applications owned by us will result in patents being issued to us, that patents issued to or licensed by us in the past or in the future will not be challenged or circumvented by competitors or that such patents will be found to be valid or sufficiently broad to protect our products or to provide us with any competitive advantage. Third parties could also obtain patents that may require us to negotiate to obtain licenses to conduct our business, and any required licenses may not be available on reasonable terms or at all. We also rely on confidentiality and non-compete agreements with certain employees, independent consultants, consultants, and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties might claim that we infringe on their intellectual property rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the dietary supplement industry has historically been characterized by products with naturally occurring ingredients, recently it is becoming more common for suppliers and competitors to apply for patents or develop proprietary technologies and processes. Third parties may assert intellectual property infringement claims against us despite our efforts to avoid such infringement. Such claims could prevent us from offering competitive products or result in litigation or threatened litigation. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_187"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may experience future volatility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has historically been subject to wide fluctuations. The price of our common stock may fluctuate in the future in response to quarter-to-quarter variations in operating results, material announcements by us or competitors, governmental regulatory action, conditions in the dietary supplement industry, or other events or factors, many of which are beyond our control, and some of which do not have a strong correlation to our operating performance. We cannot predict the effect, if any, of future sales of our common stock, or the availability of our common stock for future sales, on the value of our common stock. Sales of substantial amounts of our common stock by any one or more of our stockholders, or the perception that such sales could occur, may adversely affect the market price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substantial sales of shares of our common stock in the public market may impact the market price of our common stock. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we consider appropriate. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock. Significant additional capital may be required in the future to continue our planned operations. To the extent that we raise additional capital through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot guarantee that our share repurchase program will be utilized to the full value approved or that it will enhance long-term stockholder value. Repurchases we consummate could increase the volatility of the price of our common stock and could have a negative impact on our available cash balance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors authorized a share repurchase program pursuant to which we may repurchase up to $60 million of our common stock on or before December 31, 2026. The manner, timing and amount of any share repurchases may fluctuate and will be determined by us based on a variety of factors, including the market price of our common stock, our priorities for the use of cash to support our business operations and plans, general business and market conditions, tax laws, and alternative investment opportunities. The share repurchase program authorization does not obligate us to acquire any specific number or dollar value of shares. Further, our share repurchases could have an impact on our share trading prices, increase the volatility of the price of our common stock, or reduce our available cash balance such that we will be required to seek financing to support our operations. Our share repurchase program may be modified, suspended, or terminated at any time, which may result in a decrease in the trading prices of our common stock. Even if our share repurchase program is fully implemented, it may not enhance long-term stockholder value. Additionally, repurchases are subject to the 1% Share Repurchase Excise Tax enacted by the Inflation Reduction Act, which may be offset by shares newly issued during that fiscal year (the &#8220;Share Repurchase Excise Tax&#8221;). We have and will continue to take the Share Repurchase Excise Tax into account with respect to our decisions to repurchase shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional shares that may be issued upon the exercise of currently outstanding options or upon future vesting of performance restricted stock units, would dilute the voting power of our currently outstanding common stock and could cause our stock price to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had 12.5 million shares of common stock outstanding. As of June&#160;30, 2024, we also had stock options outstanding for an aggregate of 0.1 million shares of common stock. Additionally, the future vesting of time-based and performance restricted stock units will further increase our outstanding shares of common stock. The issuance of these shares will dilute the voting power of our currently outstanding common stock and could cause our stock price to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain compliance with Nasdaq requirements for continued listing, our common stock could be delisted from trading.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our common stock was delisted from the Nasdaq Stock Market for failure to maintain compliance with its listing requirements, then there can be no assurance whether or when it would be listed again for trading on the Nasdaq or any other exchange. In addition, if our common stock were to be delisted, the market price of our shares will likely decline and become more volatile, and our stockholders may find that their ability to trade in our stock will be adversely affected. Furthermore, institutions whose charters do not allow them to hold securities in unlisted companies might sell our shares, which could have a further adverse effect on the price of our stock. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and may take advantage of certain scaled disclosures available to us. We cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. As a smaller reporting company, we are permitted to comply with scaled disclosure obligations in our SEC filings as compared to other issuers who are not smaller reporting companies, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company, the scaled disclosure in our SEC filings will result in less information about our company being available than for public companies that are not smaller reporting companies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700 million as measured on the last business day of our second fiscal quarter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive because we will rely certain scaled disclosures that are available to smaller reporting companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay, or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board to elect a director to fill a vacancy created by the expansion of our board or the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our board;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board, the chairman of our board or our chief executive officer, or by stockholders holding at least 10% of the outstanding shares entitled to vote at such special meeting, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures with which stockholders must comply to nominate candidates to our board or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board or initiate actions that are opposed by our then-current board, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Rights Agreement, pursuant to which we declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of our common stock. The dividend was payable on September 11, 2023 to the stockholders of record at the close of business on September 11, 2023. Each Right initially entitled the registered holder </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of the Company (the "Preferred Stock") at a price of $20 per one one-thousandth of a share of Preferred Stock, subject to adjustment. Also called a "poison pill," the Rights Agreement may have the effect of discouraging or preventing a change of control by, among other things, making it uneconomical for a third party to gain control of us through open market accumulation of shares without paying all stockholders an appropriate control premium or without the consent of our board. The Rights will expire on August 28, 2024 (the "Final Expiration Date").</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_2931"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in legal proceedings that are expensive, time consuming and, if adversely adjudicated or settled, could adversely affect our financial results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation claims can be expensive and time consuming to bring or defend against and could result in settlements or damages that could significantly affect our financial results. It is not possible to predict the final resolution of litigation to which we may become a party, and the impact of litigation proceedings on our business, results of operations and financial condition could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in various legal matters, both as a plaintiff and defendant. While we believe the suits against us are without merit, they are costly to defend, and we cannot be assured that we will ultimately prevail. If we do not prevail and are required to pay damages, it could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) requires, among other things, that we evaluate and determine the effectiveness of our internal controls over financial reporting and provide a management report on the internal controls over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented internal controls to help ensure the completeness and accuracy of our financial reporting and to detect and prevent fraudulent actions within our financial and accounting processes including the development and implementation of control policies and procedures regarding the international business policies, practices, monitoring, and training for each country outside the U.S. in which we do business. However, we cannot be assured that significant deficiencies or material weaknesses in our internal control over financial reporting will not exist in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations and annual auditor attestation reports regarding disclosure controls and the effectiveness of our internal control over financial reporting required under the Sarbanes-Oxley Act and the rules promulgated thereunder. The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to timely meet our reporting obligations, or cause investors to lose confidence in our reported financial information, which could cause a decline in the market price of our stock and we could be subject to sanctions or investigations by the SEC or other regulatory authorities including equivalent foreign authorities. In fiscal year 2024, we did not experience any material weaknesses in our internal control and/or financial reporting processes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government authorities may question our tax positions or transfer pricing policies or change their laws in a manner that could increase our effective tax rate or otherwise harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a U.S. company doing business in international markets through subsidiaries, we are subject to various tax and intercompany pricing laws, including those relating to the flow of funds between our company and our subsidiaries. Tax authorities may disagree with certain positions that we have taken and assess additional taxes. From time to time, we are audited by tax regulators in the United States and in our foreign markets. If regulators challenge our tax positions, corporate structure, transfer pricing mechanisms or intercompany transfers, we may be subject to fines and payment of back taxes, our effective tax rate may increase, and our operations may be harmed. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax positions. However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes of these audits could have a material impact on our business, result of operations, financial condition, and cash flows. Tax rates vary from country to country, and, if tax authorities determine that our profits in one jurisdiction may need to be increased, we may not be able to fully utilize all foreign tax credits that are generated, which will increase our effective tax rate. The various customs, exchange control and transfer pricing laws are continually changing and are subject to the interpretation of government agencies. We may experience increased efforts by customs authorities in foreign countries to reclassify our products or otherwise increase the level of duties we pay on our products. Despite our efforts to be aware of and comply with such laws, and changes to and interpretations thereof, there is a risk that we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not continue to operate in compliance with such laws. We may need to adjust our operating procedures in response to such changes and, as a result, our business may suffer. In addition, due to the international nature of our business, from time to time, we are subject to reviews and audits by taxing authorities of other jurisdictions in which we conduct business throughout the world.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic, political, and other risks associated with our international operations could adversely affect our revenue and international growth prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we intend to continue to expand and grow our international presence. Our international operations are subject to a number of risks inherent to operating in foreign countries, and any expansion or growth of our international operations will increase the effects of these risks. These risks include, among others:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability of foreign markets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign governments&#8217; restrictive trade policies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of well-established or reliable legal systems in certain areas in which we operate;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inconsistent product regulation or sudden policy changes by foreign agencies or governments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the imposition of, or increase in, duties, taxes, government royalties, or non-tariff trade barriers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in collecting international accounts receivable and potentially longer payment cycles;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that a foreign government may limit our ability to repatriate cash;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs in maintaining international marketing efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems entering international markets with different cultural bases and consumer preferences; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these risks could have a material adverse effect on our international operations and our growth strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, including high inflation, and other macroeconomic conditions or trends may have an adverse impact on our business, financial results, and prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing geopolitical matters have contributed to difficult macroeconomic conditions and exacerbated supply chain issues, resulting in significant economic uncertainty as well as volatility in the financial markets, particularly in the United States. Such conditions may adversely impact our business, financial results, and prospects. We rely on consumer discretionary spending. If general economic conditions continue to deteriorate globally or in specific markets where we operate, including with respect to inflation, consumer discretionary spending may decline and demand for our products may be reduced. A decrease in consumer discretionary spending would cause sales in our products to decline and adversely impact our business. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through increases in revenue as increases in core inflation rates may also affect consumers&#8217; willingness to make discretionary purchases on our products. Our inability or failure to do so could harm our business, financial condition, and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such macroeconomic conditions could impact our ability to access the public markets as and when appropriate or necessary to carry out our operations or our strategic goals. We cannot predict the ongoing extent, duration, or severity of these conditions, nor the extent to which we may be impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that there are health epidemics or outbreaks, or a resurgence in the COVID-19 pandemic, our operations could be disrupted and our business adversely impacted. Such disruptions or impacts may be similar to those we faced during the recent COVID-19 pandemic, such as mandated business closures in impacted areas, limitations due to stay at home orders or sickness of employees or their families, reduced demand for certain of our products, or supply constraints.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because dietary supplement companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts cease publishing research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports published by securities or industry analysts about us or our business. Securities and industry analysts currently publish research on our company. If analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_190"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B &#8212; UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_2914"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C &#8212; CYBERSECURITY </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Management and Strategy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain a cybersecurity risk management program through our security steering committee, which is designed to assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and test those systems pursuant to our cybersecurity policies, processes, and practices, which are integrated into our overall risk management program. The members of our security steering committee represent the following functional areas: cybersecurity and infrastructure; corporate risk and privacy; personnel; and finance and fraud management. The security steering committee collaborates with and manages third parties, as appropriate, to assess the effectiveness of our cybersecurity prevention and response systems and processes. These third parties may include cybersecurity assessors, consultants, and other external cybersecurity experts to assist in the identification, verification, and validation of cybersecurity risks, as well as to support associated mitigation plans when necessary. To protect our information systems from cybersecurity threats, we also ask our employees to take periodic cybersecurity training and we use various security tools that are designed to help identify, escalate, investigate, resolve, and recover from security incidents in a timely manner.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified risks from known cybersecurity threats to the business, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect our Company, including our business strategy, results of operations, or financial condition. See our risk factor &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to evolving laws, policies, and contractual obligations related to data privacy and security, including cybersecurity, and our actual or perceived failure to comply with such obligations or perceived failure to maintain the integrity of our data could expose us to data loss or litigation, harm our reputation, subject us to significant fines and liability, or otherwise affect our business, prospects, financial condition, and operating results."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A. (&#8220;Risk Factors&#8221;) for additional details regarding cybersecurity risks and potential impacts on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cybersecurity Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The board carries out its risk oversight and management responsibilities by monitoring risk directly as a full board and, where appropriate, through its committees. Our board has delegated to the audit committee the oversight responsibility for risks and incidents relating to cybersecurity threats, including compliance with disclosure requirements, cooperation with law enforcement, and related effects on financial and other risks. The audit committee reports any material or notable cybersecurity incidents, findings and recommendations, as appropriate, to the full board for consideration. Our Chief Technology Officer ("CTO") also presents to the audit committee and to the board, as appropriate, any updates, changes, or improvements on the Company&#8217;s cybersecurity risk management program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CTO, with over 28 years of experience in IT and operational technology security, has the primary responsibility of overseeing our cybersecurity risk management program and assessing and managing any material risks related to cybersecurity threats. Our CTO supervises efforts to help prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal information systems personnel and reports produced by security tools deployed in the technical environment.    </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2 &#8212; PROPERTIES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Offices</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a lease agreement with Traverse Ridge Center III LLC, a Utah limited liability company, for our new corporate headquarters located at 3300 N. Triumph Blvd., Suite 700, Lehi, Utah 84043. The lease is for approximately 51,674 square feet with a right of first refusal to lease certain additional space in the building when such space becomes available. The term of the lease began on January 1, 2021, and will continue for a period of eleven years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, our subsidiary, LifeVantage Japan K.K., entered into a lease agreement with Sumitomo Mitsui Trust Bank, Limited, for an office located in the Shinagawa Grand Central Tower in Tokyo, Japan.  The lease is for approximately 5,200 square feet and has a lease term from July 1, 2023 through June 30, 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the facilities under our leases are sufficient to meet our needs for the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warehouse Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since fiscal year 2010, Maersk E-Commerce Logistics (formerly Visible Supply Chain Management and IntegraCore, LLC) has provided fulfillment services to us, including services relating to procurement, warehousing, ordering, processing, and shipping. We have also entered into arrangements to receive similar services in each of our international markets.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_196"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3 &#8212; LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 of the Notes to the Consolidated Financial Statements contained within this Annual Report on Form 10-K for a discussion of the company's legal proceedings.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4 &#8212; MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_202"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5 &#8212; MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_208"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Capital Market under the symbol "LFVN".</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is issued in registered form and the following information is taken from the records of our current transfer agent, Computershare Trust Company, Inc. As of June&#160;30, 2024, we ha</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 88 stockholders of record and 12.5 million shares of common stock outstanding. This does not include an unknown number of persons who hold shares in street name </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through brokers and dealers and who are not listed on our stockholder records.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid a one-time cash dividend of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.40 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share of common stock to stockholders of record in September 2023, quarterly cash dividends of $0.035 per share of common stock to stockholders of record in September 2023, December 2023 and March 2024, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock to stockholders in June 2024, which were in the aggregate amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.9 million, or $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.545 per share of common stock for the fiscal year ended June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the fiscal year ended June&#160;30, 2023, we paid to stockholders quarterly cash dividends totaling $1.6 million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.125</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The declaration of dividends is subject to the discretion of our board and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our board of directors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that a comparable cash dividend will be paid each quarter for the foreseeable future.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;27, 2017, our board approved a stock repurchase program. Under this program, we were initially authorized to repurchase up to $15.0 million of the outstanding shares through November&#160;27, 2020. On August&#160;27, 2020, our board approved an amendment to the stock repurchase program to increase the authorized share repurchase amount from $15.0&#160;million to $35.0&#160;million and to extend the duration of the program through </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;30, 2023. Further, on February 17, 2022, our board approved an amendment to the stock repurchase program to increase the authorized share repurchase amount from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.0&#160;million to $60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2023, our board approved an amendment to the stock repurchase program to extend the duration of the program through December 31, 2026. The stock repurchase program permits us to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by our management, in accordance with applicable securities laws. As part of the repurchase program, we may enter into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan would be completed in accordance with the terms of the plan, including specified price, volume, and timing conditions. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he stock repurchase program may be suspended or discontinued at any time. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;three months ended June&#160;30, 2024, we repurchased 0.3 million shares of our common stock&#160;under the stock repurchase plan. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to all purchases&#160;made by the company during the three months ended June 30, 2024. All purchases listed below were made at prevailing market prices.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:23.088%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of the Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1 - April 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,948&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,948&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1 - May 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,991,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1 - June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,421,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">On November&#160;27, 2017, our board approved a stock repurchase program. Under this program, we were initially authorized to repurchase up to $15.0 million of the outstanding shares through November&#160;27, 2020. On August&#160;27, 2020, our board approved an amendment to the stock repurchase program to increase the authorized share repurchase amount from $15.0&#160;million to $35.0&#160;million and to extend the duration of the program through </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">November&#160;30, 2023. Further, on February 17, 2022, our board approved an amendment to the stock repurchase program to increase the authorized share repurchase amount from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">$35.0&#160;million to $60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">On June 13, 2023, our board approved an amendment to the stock repurchase program to extend the duration of the program through December 31, 2026. </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_217"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sale of Unregistered Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_220"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information is incorporated by reference to Part III, Item 12 of this report.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_223"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6 &#8212; [RESERVED]</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_226"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes, which are included in this Annual Report on Form 10-K.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_229"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. We are dedicated to helping people achieve their health, wellness, and financial goals. We provide quality, scientifically validated products to customers an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d independent consultants as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. We currently sell our products to customers and independent consultants in two geographic regions that we have classified as the Americas region and the Asia/Pacific and Europe region.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success and growth of our business is primarily based on the effectiveness of our independent consultants to attract and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retain customers in order to sell our products and our ability to attract and retain independent consultants. When we are successful in attracting and retaining independent consultants and customers, it is largely because of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products, including our flagship Protandim</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scientifically validated dietary supplements, LifeVantage</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rise AM, Reset PM, Daily Wellness, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, our line of TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skin and hair care products and Liquid Collagen, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our companion pet supplement formulated to combat oxidative stress in dogs, and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our nootropic energy drink mixes;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales compensation plan and other sales initiatives and incentives; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our delivery of superior customer service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, it is vital to our success that we leverage our product development resources to develop and introduce compelling and innovative products and provide opportunities for our independent consultants to sell these products in a variety of markets. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. We sold our products in China through a China approved cross-border e-commerce business model until March 15, 2023, at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which time we closed our e-commerce business in China. In addition, we sell our products in a number of countries for personal consumption only. Entering a new market requires a considerable amount of time, resources and continued support. If we are unable to properly support an existing or new market, our revenue growth may be negatively impacted.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_235"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of scientifically validated dietary supplements, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our line of skin and hair care products and Liquid Collagen, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our companion pet supplement formulated to combat oxidative stress in dogs, and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our nootropic energy drink mixes. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line includes Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body&#8217;s natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective antioxidant enzymes, including superoxide dismutase, catalase, and glutathione synthase. The Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide), and it has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity, and mood. Use of the three Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products together, marketed as the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tri-Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has been shown to produce synergistic benefits greater than using the single products on their own. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ProBio is a dietary supplement designed to support optimal digestion and immune system function. LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Daily Wellness is a dietary supplement designed to support immune health. IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dietary supplement to help support eye and brain health, reduce eye fatigue and strain, support cognitive functions, and may help support normal sleep patterns. PhysIQ Fat Burn is a dietary supplement designed to support weight management, and PhysIQ Prebiotic is a dietary supplement designed to support a healthy digestive tract. Our Nrf2 enhanced TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of anti-aging skin and hair care products includes TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueClean Refining Cleanser, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueLift Illuminating Eye Cream, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueHydrate Brightening Moisturizer, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueTone Perfecting Lotion, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueProtect Daily Mineral Sunstick SPF 30, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Perfecting Lotion, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hand Cream, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Invigorating Shampoo, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nourishing Conditioner, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Scalp Serum, and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen. TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen activates, replenishes, and maintains collagen to support firmness and elasticity from within. Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation. AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our line of our nootropic energy drink mixes formulated to promote alertness and support mental performance. We believe our significant number of customers who regularly and repeatedly purchase our products is a strong indicator of the health benefits of our products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products both individually and in stacks. A stack consists of multiple products bundled together that are designed to achieve a specific result. In fiscal year 2024, o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur stack strategy evolved with a focus on the brand message of Activation with three stacks that tell the unique LifeVantage Activation story from an inside-out approach. This builds upon the synergistic benefits that were demonstrated in fiscal year 2023 with our Healthy Glow Essentials stack. The Inside-Out Activation Duo features Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex. This duo activates antioxidants for good health on the inside and a cleaner, kinder retinol alternative for skin that looks and feels healthy and youthful on the outside. The LifeVantage Activation Essentials Stack contains Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen, and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueRenew Daily Firming Complex. Finally our Healthy Glow + Activated Skin Care Collection contains Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen, and the full Activated Skin Care Collection. We continue to offer other popular packs such as the Vitality Stack (Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+ and LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ProBio), the Ultimate Stack (Vitality Stack + Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PhysIQ Prebiotic), and the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tri-Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NRF1 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nrf2 Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NAD Synergizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,135&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,720&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is largely attributed to two product lines, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of which accounted for more than 10% of total revenue for each of the fiscal years ended June&#160;30, 2024 and 2023. On a combined basis, these product lines represent approximately 80.1% and 79.3% of our total net revenue for the fiscal years ended June&#160;30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have additional products in development. Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our ability to attract new independent consultants and customers.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_238"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we primarily utilize a direct selling model for the distribution of a majority of our products, the success and growth of our business depends in large part on the effectiveness of our independent consultants to attract and retain customers to purchase our products, and our ability to attract new and retain existing independent consultants. Changes in our product sales are typically the result of variations in product sales volume relating to fluctuations in the number of active independent consultants and customers purchasing our products. The number of active independent consultants and customers is, therefore, used by management as a key non-financial measure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in our active accounts by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent three-month period, either for personal use or for resale. </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change from Prior Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active Independent Consultants</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Americas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Asia/Pacific &amp; Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Active Independent Consultants</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active Customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Americas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Asia/Pacific &amp; Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Active Customers</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active Accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Americas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Asia/Pacific &amp; Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Active Accounts</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_241"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Statement Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report revenue in two geographic regions, and we translate revenue from each market's local currency into U.S. Dollars using weighted-average exchange rates. Revenue consists primarily of product sales, fee revenue, and shipping and handling fees, net of applicable sales discounts. Revenue is recognized at the time of shipment, which is when the passage of title and risk of loss to customers occurs. Also reflected in revenue is a provision for product returns and allowances, which is estimated based on our historical experience. The following table sets forth net revenue information by region for the years indicated. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following table should be reviewed in connection with the tables presented under "Results of Operations" (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the fiscal years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales primarily consists of costs of products purchased from and manufactured by third-party vendors, shipping and order fulfillment costs, costs of adjustments to inventory carrying value, and costs of marketing materials which we sell to our independent consultant sales force, as well as freight, duties and taxes associated with the import and export of our products. As our international revenue increases as a percentage of total revenue, cost of sales as a percentage of revenue likely will increase as a result of additional duties, freight, and other factors, such as changes in currency exchange rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions and incentives expenses are our most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to our independent consultants, special incentives and costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts we pay to our independent consultants related to their personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue. Our sales compensation plan is an important factor in our ability to attract and retain our independent consultants. Under our sales compensation plan, independent consultants can earn commissions for product sales to their customers as well as the product sales made through the sales networks they have developed and trained. We do not pay commissions on marketing materials that are sold to our independent consultants. Commissions and incentives expenses, as a percentage of net revenue, may be impacted by the timing and magnitude of non-commissionable revenue derived from the sales of marketing materials, event tickets, and promotional items, investment in our red-carpet program, limited-time offers and the timing, magnitude and number of incentive trips and other promotional activities. From time to time, we make modifications and enhancements to our sales compensation plan in an effort to help motivate our sales force and develop leadership characteristics, which can have an impact on commissions and incentives expenses. In fiscal year 2023, we introduced our new compensation plan, called the Evolve Compensation Plan, in four markets &#8211; the United States, Japan, Australia, and New Zea</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">land.  In fiscal year 2024, we introduced the Evolve Compensation Plan to Canada, Mexico, and Europe, with plans to introduce our new compensation plan to the remaining markets in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses include wages and benefits, stock compensation expenses, marketing and event costs, professional fees, rents and utilities, depreciation and amortization, research and development, travel costs and other operating expenses. Wages and benefits and stock compensation expenses represent the largest component of selling, general and administrative expenses. Marketing and event costs include costs of consultant conventions and events held in various markets worldwide, which we expense in the period in which they are incurred. Marketing and event costs also include expenses associated with our sponsorship of the Major League Soccer team, Real Salt Lake. Our agreement with Real Salt Lake ended in December 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to customers outside the United States are transacted in the respective local currencies and are translated to U.S. Dollars at weighted-average currency exchange rates for each monthly accounting period to which they relate. Consequently, our net sales and earnings are affected by changes in currency exchange rates. In general, sales and gross profit are affected positively by a weakening U.S. Dollar and negatively by a strengthening U.S. Dollar. Currency fluctuations, however, have the opposite effect on our commissions paid to independent consultants and selling, and general and administrative expenses. In our revenue discussions that follow, we approximate the impact of currency fluctuations on revenue by translating current year revenue at the average exchange rates in effect during the comparable prior year periods.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_244"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended June&#160;30, 2024 and 2023, we generated net revenue of $200.2 million and $213.4 million, respectively, recognized operating income of $4.3 million and $4.3 million, respectively, and recognized net income of $2.9 million and $2.5 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain consolidated earnings data as a percentage of net revenue for the years indicated:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;fiscal years&#160;ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Comparison of Fiscal Years Ended June&#160;30, 2024 and 2023 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We generated net revenue of $200.2 million and $213.4 million during the fiscal years ended June&#160;30, 2024 and 2023, respectively. The overall decrease in revenue is attributed mainly to a decrease in our total Active Accounts, which declined by 10.5% during fiscal year 2024. The decrease was partially offset by an increase average revenue per account driven by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen product, which is now available in most of our markets. Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen related revenue, including the product when sold as part of a bundle, was $48.5 million for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024 compared to $39.8 million for the fiscal year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We also increased product and shipping prices during the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Offsetting the increase in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen product was a decrease of $15.6 million in sales from our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products as well as decreases in other product lines of approximately $6.3 million, and the negative impacts of foreign currency fluctuations compared to fiscal year ended June&#160;30, 2023.  In fiscal year 2024, f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oreign currency fluctuations negatively impacted our net revenue $2.2 million or 1.0%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Americas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table sets forth revenue for the fiscal years ended June&#160;30, 2024 and 2023 for the Americas region (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:52.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the fiscal years ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,679&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,522&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the Americas region for the fiscal year ended June&#160;30, 2024 decreased $2.5 million, or 1.6%, compared to the prior year. Total Active Accounts decreased 7.8% in the region compared to the prior fiscal year which contributed to the decrease in revenue.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, the decrease in revenue due to the decrease in Active Accounts was partially offset by revenue from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen of $39.5 million for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024 compared to $36.2 million for the fiscal year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue from Mexico, increased $1.0 million in fiscal year 2024 as a result of an increase in Active Accounts in this market by 61.9% and the launch of TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen in this market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Asia/Pacific &amp; Europe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table sets forth revenue for the fiscal years ended June&#160;30, 2024 and 2023 for the Asia/Pacific and Europe region and its principal markets (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:52.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the fiscal years ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,083&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia &amp; New Zealand</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the Asia/Pacific and Europe region for the fiscal year ended June&#160;30, 2024 decreased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $10.8 million, or 18.6%, compared to the prior year. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the region was negatively impacted approximately $2.4 million, or 4.3%, by foreign currency exchange rate fluctuations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in our Japan market decreased 15.9% year over year on a U.S. Dollar basis and decreased 9.0% on a constant currency basis. Contributing to the decrease in revenue on a constant currency basis was revenue related to the decrease in Active Accounts by 11.6% year over year.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Total revenue related to the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen was $4.3 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal year ended June&#160;30, 2024 compared to $2.3 million from the prior year, which partially offset the decrease in revenue.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June&#160;30, 2024, the Japanese yen, on average, weakened against the U.S. Dollar, negatively impacting our revenue in this market by $2.2 million or 6.9%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in our Australia and New Zealand market</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s decreased $0.9 million, or 10.1%, during fiscal year 2024. The decrease in revenue in these markets primarily resulted from a decrease in the number of Active Accounts, partially offset by revenue from the launch of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen in March 2023. Revenue related to the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liquid Collagen was $0.5 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal year ended June&#160;30, 2024 compared to $0.2 million from the prior year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in our Greater China region decreased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by 18.3% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year over year primarily due to a 15.7% decline in our average number of Active Accounts within the market from fiscal year 2023 to fiscal year 2024. Also contributing to the decline in revenue was the closure of our e-commerce business in China in March 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in revenue in our other markets was driven by a decrease in revenue from the Philippines. Revenue from our Philippines market was $2.6 million during fiscal year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to $5.9 million during fiscal year 2023.  Total Active Accounts decreased by 49.0% in the current fiscal year.    </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, our sales and marketing efforts continue to be directed toward strengthening our core business through our fiscal year initiatives and building our worldwide sales. In October 2023, we relaunched our TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Skin Care line with entirely new branding premium packaging, and improved formulas. Rebranded as the TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activated Skin Care Collection, this line includes TrueClean Refining Cleanser, TrueRenew Daily Firming Complex, TrueLift Illuminating Eye Cream, and TrueHydrate Brightening Moisturizer. This was a global launch in all markets. In the United States, we also launched TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TrueProtect Daily Mineral Sunstick, a broad-spectrum, 30 SPF mineral sunscreen that addresses the appearance of sun-induced hyperpigmentation and wrinkles as it protects against future damage. We will continue the refinement and expansion of our product offerings internationally during fiscal year 2025 and beyond. We expect this expansion will continue to drive revenue growth globally through increased average order size and increased ability to attract and retain new independent consultants and customers with a compelling product lineup. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we announced the adoption our Evolve Compensation Plan for our independent consultants, which became effective in March 2023, in our United States, Australia, New Zealand and Japan markets.  In February 2024, we launched the Evolve Compensation Plan in our Canada, Mexico, and Europe markets. This new compensation plan is designed to reward our independent consultants for product sales to their customers as well as the product sales made through the sales networks they have developed and trained. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we launched Rewards Circle, our first-ever customer loyalty program, in the United States, Australia, New Zealand, and Japan. This program was introduced to our Canada, Mexico, and Europe markets in February 2024. Rewards Circle is focused on supporting customer retention for independent consultants, supporting their efforts to grow and maintain their LifeVantage business. We have seen an increase in average revenue per account since the launch of this program and continue to monitor retention trends for our independent consultants and customers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, our main focus will be to increase our average account base through concentrating our efforts on the enrollment of new independent consultants and customers, who will in turn help grow the business through incremental product sales, and on increasing the number of accounts that place an order in the month following their initial enrollment.  This will be achieved through continued focus on our Evolve Compensation Plan and Rewards Circle loyalty program. We will continue investing in our red-carpet program, which we believe has increased our ability to attract and retain strong consultant leadership and is a significant opportunity to drive revenue growth throughout our markets. We remain committed to further expanding the functionality and availability of our digital tools, which we believe will aid independent consultants in initiating and expanding their businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales were $41.4 million for the fiscal year ended June&#160;30, 2024, and $43.4 million for the fiscal year ended June&#160;30, 2023, resulting in a gross margin of $158.7 million, or 79.3%, and $170.0 million, or 79.7%, respectively. The in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">crease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cost of sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percentage of revenue is primarily due to shift in product mix, increased raw material and manufacturing related costs, shipping expenses, and warehouse fulfillment expenses during the current fiscal year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commissions and Incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Commissions and incentives expenses for the fiscal year ended June&#160;30, 2024 were $85.9 million or 42.9% o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f revenue compared to $94.7 million or 44.4% of revenue for the fiscal year ended June&#160;30, 2023. The decrease of $8.8 million in fiscal year 2024 was primarily due to the overall decrease in commissionable sales during fiscal year 2024 compared to fiscal year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 along with decreases in promotion payouts to our independent consultants. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in percentage of commissions and incentives to revenue was primarily due to changes in sales mix and the impact of price increases, as well as the timing and magnitude of promotional and incentive programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions and incentives expenses, as a percentage of revenue, may fluctu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate in future periods based on our ability to hold incentive trips and events and the timing and magnitude of compensation, incentive, and promotional programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses for the fiscal year ended June&#160;30, 2024 were $68.5 million or 34.2% of revenue compared to $71.1 million or 33.3% of revenue for the fiscal year ended June&#160;30, 2023. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in selling, general, and administrative expenses as a percentage of revenue during fiscal year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily was due t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o primarily due to increased proxy contest related expenses of $5.1 million. These increases have been partially offset by decreases in event costs, endorsement agreements, employee compensation related expenses, office lease and professional services expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary factors that may cause our selling, general and administrative expenses to fluctuate in the future include changes in the number of employees, the timing and number of events we hold, the termination of material agreements like our agreement with Real Salt Lake, marketing and branding initiatives and costs related to legal matters, if and as they arise. A fluctuation in our stock price may also impact our stock-based compensation expense relating to equity awards made in future years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest income, net, for the fiscal year ended June&#160;30, 2024 was $0.4 million as compared $0.2 million for the fiscal year ended June&#160;30, 2023.  During the fiscal year ended June&#160;30, 2024, we benefited from higher interest rates earned on our money market accounts.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized other expense, net, for the fiscal year ended June&#160;30, 2024 of $0.4 million as compared to $0.5 million for the fiscal year ended June&#160;30, 2023. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decrease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily due to the impact of foreign currency fluctuations recognized during fiscal year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our income tax expense for the fiscal year ended June&#160;30, 2024 was $1.4 million as compared to income tax expense of $1.5 million for the fiscal year ended June&#160;30, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was&#160;32.5%&#160;of pre-tax income for the fiscal year ended June&#160;30, 2024, compared to&#160;36.5%&#160;for the fiscal year ended June&#160;30, 2023. The decrease in the effectiv</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e tax rate for fiscal year 2024 compared to the prior year is mainly due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the impact of permanent items in relation to pre-tax income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes for the fiscal year ended June&#160;30, 2024 consisted prim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arily of federal, state, and foreign tax on anticipated fiscal year 2024 income which was partially offset by tax benefits. We expect our effective rate to fluctuate in future periods based on the impact of permanent items in relation to pre-tax income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of the foregoing factors, net income for the fiscal year ended June&#160;30, 2024 in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">creased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to $2.9 million compared to $2.5 million for the fiscal year ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Comparison of Fiscal Years Ended June&#160;30, 2023 and 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our results of operations for the fiscal year 2023 compared with fiscal year 2022, refer to &#8220;Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our annual report on Form 10-K for the fiscal year ended June&#160;30, 2023, as filed with the SEC on August 28, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_247"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess our capital allocation strategy to maximize stockholder value. Our current capital allocation strategy follows a balanced approach focused on supporting and re-investing in the business, as well as returning stockholder value through quarterly dividends and opportunistic share repurchases, where appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary liquidity and capital resource requirements are to service our debt, which includes any outstanding balances under the 2024 Credit Facility, and finance the cost of our planned operating expenses and working capital (principally inventory purchases), as well as capital expenditures. We have generally relied on cash flow from operations to fund operating activities and we have, at times, incurred long-term debt in order to fund stock repurchases and strategic transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, our cash and cash equivalents were $16.9 million. This represented a decrease of $4.7 million from the $21.6 million in cash and cash equivalents as of June&#160;30, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June&#160;30, 2024, our net cash provided by operating activities was $12.2 million as compared to $6.8 million during the fiscal year ended June&#160;30, 2023. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n cash provided by operating activities during the fiscal year ended June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily was due to increases in net income, accounts payable, and decreases in prepaid expenses offset by increases in accounts receivable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June&#160;30, 2024, our net cash used in investing activities was $2.2 million, which was attributable to capital expenditures including leasehold improvements related to moving our Tokyo, Japan office. During the fiscal year ended June&#160;30, 2023, our net cash used in investing activities was $3.1 million, as a result of the purchase of fixed assets, primarily from investing in changes to our Evolve Compensation Plan and Rewards Circle loyalty program through software, website, and mobile application development.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the fiscal year ended June&#160;30, 2024 was $14.4 million, as a result of the payment of a one-time cash dividend in September 2023, quarterly cash dividends, the repurchase of company stock, and shares purchased as payment of tax withholding upon vesting of employee equity awards, partially offset by proceeds from purchases of company stock under our employee stock purchase plan. Cash used in financing activities during the fiscal year ended June&#160;30, 2023 was $2.4 million, as a result of the repurchase of company stock, payment of quarterly cash dividends, and shares purchased as payment of tax withholding upon vesting of employee equity awards, partially offset by proceeds from stock option exercises and proceeds from purchases of company stock under our employee stock purchase plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024 and 2023, the total amount of our foreign subsidiary cash was $7.3 million and $6.2 million, respectively. Under current U.S. tax law, in the future, if needed, we expect to be able to repatriate cash from foreign subsidiaries without paying additional U.S. taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, we had working capital (current assets minus current liabilities) of $15.3 million compared to working capital of $24.7 million at June&#160;30, 2023. The de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">crease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in working capital primarily was due to decreases in cash, inventory, and prepaid expenses and increases in accounts payable, partially offset by increase in accounts receivable. We believe that our cash and cash equivalents balances and our ongoing cash flow from operations will be sufficient to satisfy our cash requirements for at least the next 12 months. The majority of our historical expenses have been variable in nature and as such, a potential reduction in the level of revenue would reduce our cash flow. In the event that our current cash balances and future cash flow from operations are not sufficient to meet our obligations or strategic needs, we would consider raising additional funds, which may not be available on terms that are acceptable to us, or at all. Our 2024 Credit Facility, however, contains covenants that in certain circumstances restrict our ability to incur additional indebtedness, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, or transfer any part of the business. Additionally, our 2024 Credit Facility provides for a line of credit in an aggregate principal amount up to $5.0 million. We would also consider realigning our strategic plans including a reduction in capital spending and expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf Registration Statement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, we filed a shelf registration statement on Form S-3 (the &#8220;2023 Shelf Registration&#8221;) with the SEC that was declared effective on April 6, 2023, which permits us to offer up to $75 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. Our 2023 Shelf Registration is intended to provide us with additional flexibility to access capital markets for general corporate purposes, which may include, among other purposes, working capital, capital expenditures, other corporate expenses and acquisitions of assets, licenses, products, technologies, or businesses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;30, 2016, we entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "2016 Security Agreement"). The 2016 Loan Agreement provided for a term loan in an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement and the 2016 Security Agreement, and with the amendments described below, the "2016 Credit Facility"). During the fiscal year ended June 30, 2020, we repaid, in full, the balance of the 2016 Term Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018 and February&#160;1, 2019, we entered into loan modification agreements (&#8220;Amendment No. 1&#8221; and &#8220;Amendment No. 2&#8221;, respectively).  These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;1, 2021, we entered into a loan modification agreement ("Amendment No. 3"), which further amended the 2016 Credit Facility, as previously amended, to provide for an available borrowing amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of 3.00%, with an interest rate floor of 4.00%. Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that we maintain this ratio not in excess of 2.00 to 1.00, measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3).  There were no other changes to the minimum fixed charge coverage ratio of 1.10 to 1.00 or the minimum working capital of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as set forth in previous amendments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the 2016 Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 4) and allowed us to declare and pay dividends, up to $500,000 per quarter, through September 30, 2023. There were no other changes to the covenants or revolving loan facility as set forth in Amendment No. 3.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2023, we received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of $0.40 per share of common stock, to be paid on September 22, 2023. We also received approval to declare and pay dividends, up to $750,000 per quarter, through September 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2024, the 2016 Credit Facility reached the maturity date and was terminated. As of March&#160;31, 2024, there was no balance outstanding under the 2016 Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2024, we entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with Bank of America, N.A., as Lender (the &#8220;Lender&#8221;). In connection with the Loan Agreement and on the same date, we, Lifeline Nutraceuticals Corporation, as Guarantor (the &#8220;Guarantor&#8221;), and the Lender also entered into a Continuing and Unconditional Guaranty (the &#8220;Continuing and Unconditional Guaranty&#8221;) and a Security and Pledge Agreement (the &#8220;Security and Pledge Agreement&#8221;). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed $5.0 million (the &#8220;Line of Credit&#8221;) and collectively with the Loan Agreement, the Continuing and Unconditional Guaranty and the Security and Pledge Agreement, the &#8220;2024 Credit Facility&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we borrow under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the &#8220;Expiration Date&#8221;). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or 0.00%, plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants, including affirmative and negative covenants that in certain circumstances restrict our ability to incur additional indebtedness, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, or transfer any part of the business or any assets of the Company or the Guarantor. The Loan Agreement requires us to maintain specified financial ratios and satisfy certain financial condition tests. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains certain customary events of default, including, among other things, our failure to make required payments under the Loan Agreement, certain breaches of representations made by us or the Guarantor, insolvency or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or our failure to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to us may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will at the option of the Lender bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, there was no outstanding balance under the 2024 Credit Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commitments and Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 13 to the consolidated financial statements contained in this report for information regarding our contingent liabilities.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_250"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare our financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments, and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could differ from these estimates. Our significant accounting policies are described in Note 2 to our consolidated financial statements. Certain of these significant accounting policies require us to make difficult, subjective, or complex judgments or estimates. We consider an accounting estimate to be critical if: (1)&#160;the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made and (2)&#160;changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other items within our financial statements that require estimation but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. Management has discussed the development and selection of these critical accounting estimates with our board, and the audit committee has reviewed the disclosures noted below.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventory Valuation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability equal to the difference between the cost of the inventory and its estimated net realizable value. Factors utilized in the determination of estimated net realizable value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new production introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.  If inventory on hand exceeds projected demand or the expected market value is less than the carrying value, the excess is written down to its net realizable value. If actual demand or the estimate of market value decreases, additional write-downs would be required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June&#160;30, 2024 and 2023, we recognized expenses of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $1.2 million, respectively, related to obsolete and slow-moving inventory. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value approach to account for stock-based compensation in accordance with current accounting guidance. We recognize compensation costs for awards with performance conditions when we conclude it is probable that the performance conditions will be achieved. We reassess the probability of vesting at each balance sheet date and adjust compensation costs based on our probability assessment. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by the employees, regardless of when, if ever, the market-based performance conditions are satisfied. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our estimates and underlying assumptions have not materially deviated from our actual reported results and rates. However, we base assumptions we use on our best estimates, which involves inherent uncertainties based on market conditions that are outside of our control. If actual results are not consistent with the assumptions we use, the stock-based compensation expense reported in our consolidated financial statements may not be representative of the actual economic cost of stock-based compensation. For example, if actual employee forfeitures significantly differ from our estimated forfeitures, we may be required to adjust our consolidated financial statements in future periods. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes income from U.S. and foreign subsidiaries taxed at statutory rates, the accrual or release of amounts for tax uncertainties, and U.S. tax impacts of foreign income in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the carrying amounts of assets and liabilities on the financial statements and their respective tax bases. Deferred tax assets also are recognized for net operating losses and credit carryforwards. Deferred tax assets and liabilities are measured using the enacted rates applicable to taxable income in the years in which the temporary differences are expected to reverse and the credits are expected to be used. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. An assessment is made as to whether or not a valuation allowance is required to offset deferred tax assets. This assessment requires estimates as to future operating results, as well as an evaluation of the effectiveness of our tax planning strategies. These estimates are made on an ongoing basis based upon our business plans and growth strategies in each market and consequently, future material changes in the valuation allowance are possible. The valuation allowance reduces the deferred tax assets to an amount that management determined is more-likely-than-not to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in and file income tax returns in the U.S. and numerous foreign jurisdictions with complex tax laws and regulations, which are subject to examination by tax authorities. The complexity of our global structure requires specialized knowledge and judgment in determining the application of tax laws in various jurisdictions. Years open to examination contain matters that could be subject to differing interpretations of applicable tax laws and regulations related to the amount and/or timing of income, deductions, and tax credits. We account for uncertain tax positions in accordance with Accounting Standards Codification ("ASC) 740, Income Taxes. This guidance prescribes a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to tax contingency or settlement items are recorded as a component of the provision for income taxes in our Consolidated Statements of Operations and Comprehensive Income. We record accruals for tax contingencies as a component of accrued liabilities or other long-term liabilities on our Consolidated Balance Sheet.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_253"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to &#8220;Item 8. Financial Statements and Supplementary Data&#8221; and Note 2 to our consolidated financial statements included in Part IV, Item 15 of this report for discussion regarding the impact of accounting standards that were recently issued but not yet effective, on our consolidated financial statements.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_256"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not required for smaller reporting companies.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_259"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8 &#8212; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is set forth in the consolidated financial statements included in Part IV, Item&#160;15 of this report and is incorporated into this Item&#160;8 by reference.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_262"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9 &#8212; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_265"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A &#8212; CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are designed to ensure that the information required to be disclosed in the reports we file or submit under the Exchange Act is (a) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and (b) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of June&#160;30, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness and design and operation of such disclosure controls and procedures, as defined in Rules 13a-15(e) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 15d-15(e) under the Exchange. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were designed and operating effectively as of&#160;June&#160;30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our system of internal control over financial reporting is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of our consolidated and combined financial statements for external purposes in accordance with generally accepted accounting principles ("GAAP").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of June&#160;30, 2024. In making this assessment, we used the framework included in Internal Control - Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission 2013 (COSO). Based on that evaluation, our management has concluded that internal control over financing reporting was effective as of June&#160;30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June&#160;30, 2024 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, cannot provide absolute assurance that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_268"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B &#8212; OTHER INFORMATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During quarter ended June 30, 2024, none of our officers or directors, as defined in Rule 16a-1(f), informed us of the <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-38">adoption</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-39"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-40">termination</ix:nonNumeric></ix:nonNumeric> of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, each as defined in Regulation S-K Item 408.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_271"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C &#8212; DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_274"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part III of this report is omitted from this report pursuant to General Instruction G(3) of Form 10-K because we will file a definitive proxy statement pursuant to Regulation 14A for our fiscal year 2025 annual meeting of stockholders (the &#8220;Proxy Statement&#8221;) not later than 120 days after the end of the fiscal year covered by this report, and the information included in the Proxy Statement that is required by Part III of this report is incorporated herein by reference.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_277"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10 &#8212; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated herein by reference to the information to be set forth in the Proxy Statement.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_280"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11 &#8212; EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated herein by reference to the information to be set forth in the Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12 &#8212; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated herein by reference to the information to be set forth in the Proxy Statement.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_286"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13 &#8212; CERTAIN RELATIONSHIP AND RELATED TRANSACTIONS, AND DIRECTORS INDEPENDENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated herein by reference to the information to be set forth in the Proxy Statement.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_289"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14 &#8212; PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated herein by reference to the information to be set forth in the Proxy Statement.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_292"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_295"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15 &#8212; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are being filed as part of this report:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(1) Financial Statements. The following consolidated financial statements of LifeVantage Corporation and Report of Independent Registered Public Accounting Firm are included in a separate section of this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(2) All schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions or are inapplicable, or because the required information is included in the financial statements or notes thereto, and therefore have been omitted.</span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_298"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(3) The following exhibits are filed as part of, or incorporated by reference into, the Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith or Incorporated by Reference From</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000046/ex31-certificateofincorpor.htm">Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 3.1 to Form 8-K filed on March 13, 2018.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000066/lifevantage-amendedandrest.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 3.1 to Form 8-K filed on August 15, 2019.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lfvn-certificateofdesign.htm">Certificate of Designation of Series A Junior Participating Preferred Stock of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lfvn-certificateofdesign.htm">the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 3.1 to Form 8-K filed on August 31, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000046/exhibit41formofcommonsto.htm">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 4.1 to Form 8-K filed on March 13, 2018.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000058/ex42descriptionofcapitalst.htm">Description of Capital Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 4.2 to Form 10-K filed on August 23, 2022.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm">Rights Agreement, dated as of August 30, 2023, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm">by and between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm"> the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm">ompany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000114/lifevantage-rightsplanfi.htm"> and Computershare Trust Company, N.A., as Rights Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 4.1 to Form 8-K filed on August 31, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm">Cooperation Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm">dated February 14, 2024, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm">by and among the Company, the entities and person</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm"> listed on Exhibit A thereto, and the entities and person</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/lfvn-cooperationagreemen.htm"> listed on Exhibit B thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 8-K filed on February 15, 2024.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000058/lifevantagesalescompensa.htm">LifeVantage Sales Compensation Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-K filed on August 23, 2022.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000102/evolve-usa.htm">Evolve Compensation Plan (United States)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1.1 to Form 10-K filed on August 28, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000102/evolve-aus.htm">Evolve Compensation Plan (Australia)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1.2 to Form 10-K filed on August 28, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000102/evolve-nzl.htm">Evolve Compensation Plan (New Zealand)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1.3 to Form 10-K filed on August 28, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith or Incorporated by Reference From</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.4#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000102/evolve-jpn.htm">Evolve Compensation Plan (Japan) in US/English Format</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1.4 to Form 10-K filed on August 28, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.5#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000047/evolvecompensationplanca.htm">Evolve Compensation Plan (Canada)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.5 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.6#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000047/evolvecompensationplanme.htm">Evolve Compensation Plan (Mexico)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.6 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.7#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000047/evolvecompensationplanuk.htm">Evolve Compensation Plan (UK)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.7 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.8#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000047/evolvecompensationplaneu.htm">Evolve Compensation Plan (EU)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.8 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2017ltipamended.htm">Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914617000064/ex992restrictedstockgranta.htm">Form of Restricted Stock Grant Agreement for the 2017 Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.2 to the Registration Statement on Form S-8 filed on March 27, 2017.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914617000064/ex993stockunitagreement.htm">Form of Stock Unit Agreement for the 2017 Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.3 to the Registration Statement on Form S-8 filed on March 27, 2017.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000107/espp.htm">LifeVantage Corporation 2019 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.2 to Form 8-K filed on November 19, 2018.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000046/ex991-indemnificationagree.htm">Form of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000046/ex991-indemnificationagree.htm"> Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit to 99.1 to Form 8-K filed on March 13, 2018.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">CEO Offer Letter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">dated January </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">31, 2021, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/lfvnstevefifeceoofferlet.htm"> and Steven R. Fife</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed on April 29, 2021.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex109keyexecutivebenefit.htm">Form of Key Executive Benefits Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm">Loan Agreement, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm"> April 12, 2024, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm">by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm">between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/loanagreement.htm"> and Bank of America, N.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 8-K filed on April 16, 2024.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">Continuing and Unconditional Guaranty, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">April 12, 2024, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">among </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/continuinganduncondition.htm">, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.2 to Form 8-K filed on April 16, 2024.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">Security and Pledge Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">April 12, 2024, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">among </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">he Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/securityandpledgeagreeme.htm">, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.3 to Form 8-K filed on April 16, 2024.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit101zfnb-lifevantage.htm">Loan Agreement, dated March 30, 2016, by and between Z.B., N.A., </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit101zfnb-lifevantage.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit101zfnb-lifevantage.htm">he Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit101zfnb-lifevantage.htm"> and Lifeline Nutraceuticals Corporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 8-K filed on April 4, 2016.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit102zfnb-lifevantage.htm">Security Agreement, dated March 30, 2016, by and between Z.B., N.A., </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit102zfnb-lifevantage.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914616000165/exhibit102zfnb-lifevantage.htm"> and Lifeline Nutraceuticals Corporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.2 to Form 8-K filed on April 4, 2016.<br/></span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000057/ex101-loanmodification.htm">Amended No.1 to Loan Agreement, dated May 4, 2018, by and between Z.B., N.A., </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000057/ex101-loanmodification.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914618000057/ex101-loanmodification.htm"> and Lifeline Nutraceuticals Corporation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2018 filed on May 9, 2018.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">Second Loan Modification Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm"> dated February 1, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm"> by and between Zions Bank and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">he Com</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914619000029/ex101loanmodification.htm">pany</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 8-K filed on February 4, 2019.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith or Incorporated by Reference From</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm">Change in Terms Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm"> dated April 1, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm"> by and between Zions Bank and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914621000047/loandocuments-lifevantag.htm">the Company</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.3 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed on April 29, 2021.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000076/a20220930-zionsrlocadden.htm">Change in Terms Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000076/a20220930-zionsrlocadden.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000076/a20220930-zionsrlocadden.htm"> dated September 30, 2022 by and between the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000076/a20220930-zionsrlocadden.htm">Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914622000076/a20220930-zionsrlocadden.htm"> and Zions Bank</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2022 filed on November 2, 2022.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm">Lease Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm">dated November 14, 2019, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm">by and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm"> between Traverse Ridge Center III and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914620000040/lfvnleasetrciii.htm">the Company</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended December 31, 2019 on January 28, 2020.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000204/leaseagreementshinagawag.htm">Lease Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000204/leaseagreementshinagawag.htm">, dated May 26, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000204/leaseagreementshinagawag.htm">3, by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000204/leaseagreementshinagawag.htm">between Sumitomo Mitsui Trust Bank, Limited and LifeVantage Japan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914623000204/leaseagreementshinagawag.htm"> in US/English Format</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2023 filed on November 9, 2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000027/dlimanufacturingagreement.htm">Commercial Supply Agreement, dated January 31, 2014, by and between the Company and Deseret Laboratories, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.1 to Form 10-Q for the fiscal quarter ended March 31, 2014 filed on May 6, 2014.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm">Service Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm">, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm"> June 1, 2014</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm">, by and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm"> between IntegraCore, LLC and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/integracoreservicesagreeme.htm">he Company</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.29 to Form 10-K for the fiscal year ended June 30, 2014 filed on September 10, 2014. </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">Commercial Supply Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">May 30, 2014</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">, by and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm"> between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">the Company </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/849146/000084914614000062/wasatchmanufagreement.htm">and Wasatch Product Development</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.30 to Form 10-K for the fiscal year ended June 30, 2014 filed on September 10, 2014.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex211listofsubsidiaries063.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231deloitteconsent063020.htm">Consent of Deloitte &amp; Touche, LLP</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature page to this report.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311ceosec302certificatio.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312cfosec302certificatio.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321ceosec906certificatio.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322cfosec906certificatio.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clawbackpolicy.htm">Company Policy for the Recovery of Erroneously A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clawbackpolicy.htm">warded Compensation (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clawbackpolicy.htm">Clawback Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clawbackpolicy.htm">)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from the registrant&#8217;s Annual Report on Form&#160;10-K for the year ended June 30, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets; (ii)&#160;Consolidated Statements of Operations and Other Comprehensive Income; (iii)&#160;Consolidated Statement of Stockholders&#8217; Deficit; (iv)&#160;Consolidated Statements of Cash Flows; and (v)&#160;Notes to Consolidated Financial Statements, tagged as blocks of text.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The company has been granted confidential treatment for portions of this agreement. Accordingly, certain portions of this agreement have been omitted in the version filed with this report and such confidential portions have been filed with the SEC.</span></td></tr></table></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_301"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.871%"><tr><td style="width:1.0%"/><td style="width:14.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFEVANTAGE CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Steven R. Fife</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven R. Fife</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Carl A. Aure</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carl A. Aure</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby constitutes and appoints Steven R. Fife with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Steven R. Fife</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief&#160;Executive&#160;Officer<br/>(Principal&#160;Executive&#160;Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven R. Fife</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Raymond B. Greer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raymond B. Greer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Rajendran Anbalagan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rajendran Anbalagan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael A. Beindorff</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A. Beindorff</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Dayton Judd</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dayton Judd</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Cynthia Latham</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cynthia Latham</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Darwin K. Lewis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darwin K. Lewis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Garry Mauro</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garry Mauro</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_304"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIFEVANTAGE CORPORATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_307">Report of Independent Registered Public Accounting Firm (Deloitte &amp; Touche, LLP, Salt Lake City, UT, Auditor Firm ID: </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-41">34</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_307">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_313">Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_313">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_313">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_316">Consolidated Statements of Operations and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_316">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_319">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_319">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_322">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_322">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_328">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie82fc05bf17d40b3a7e7f8db7a0f9606_328">69</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_307"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of LifeVantage Corporation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of LifeVantage Corporation and subsidiaries (the "Company") as of June 30, 2024 and 2023, the related consolidated statements of operations and comprehensive income, stockholders' equity, and cash flows, for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes&#8212;Refer to Notes 2 and 11 to the financial statements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and is subject to income taxes in the United States (&#8220;U.S.&#8221;) and numerous foreign jurisdictions with complex tax laws and regulations. The complexity of the Company&#8217;s global structure requires specialized knowledge, skills and judgment in determining the application of tax laws in various jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the accounting for income taxes for the U.S. jurisdiction as a critical audit matter because of the complexity of the Company&#8217;s global structure and the application of tax laws in the U.S. jurisdiction. This required an increased extent of effort, including the need to involve our income tax specialists to evaluate the Company&#8217;s U.S. income tax expense, especially the interpretation and application of tax laws in the U.S. and the related impact of the global structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the calculation of U.S. income tax expense, including the interpretation and application of tax laws in the U.S. and evaluation of the Company&#8217;s application of such tax law from its global structure included the following:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtained an understanding of the Company&#8217;s overall legal entity structure by reading and evaluating the Company&#8217;s organizational charts and associated documentation, including legal documents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluated the Company&#8217;s U.S. income tax expense calculation, including: (1) testing the appropriateness of income tax rates applied by agreeing to applicable Federal and state tax laws, (2) testing the accuracy of income allocations and apportionment among the Federal and state taxing jurisdictions based on the Company's structure, (3) testing, on a sample basis, the completeness and accuracy of book to tax differences, and (4) testing the mathematical accuracy of the income tax expense calculation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our income tax specialists, we evaluated management's application of relevant tax laws to its legal entity structure and the effect on the Company&#8217;s U.S. income tax expense, including the Company's calculations of current period income tax expense and adjustments associated with foreign operations, by examining and evaluating management's income tax calculations and assessing the Company's compliance with tax laws. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our income tax specialists, we evaluated management&#8217;s consideration of tax requirements in the U.S. tax jurisdiction in which the Company operates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/<ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-42">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-43">Salt Lake City, Utah</ix:nonNumeric></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;28, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_313"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-44">16,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-45">21,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="f-48">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="f-49">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-50">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-51">16,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">4,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">37,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">44,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-56">7,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-57">9,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-58">9,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-59">8,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="f-60">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="f-61">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-62">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-63">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-64">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-65">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-66">60,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-67">66,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">5,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">6,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="f-72">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">22,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">19,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">11,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">11,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-82">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-83">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-84">34,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-85">31,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies &#8212; Note 13</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-86"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-87"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-88"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-89">0.0001</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-91">5,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-95">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-98"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-99">0.0001</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-101">40,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-103">12,510</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-105">12,622</ix:nonFraction></ix:nonFraction> issued and outstanding as of June&#160;30, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-106">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-107">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-108">136,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-109">134,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-110">108,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-111">98,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-112">1,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-113">1,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">25,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">34,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">60,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">66,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_316"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-118"><span style="-sec-ix-hidden:f-119">Revenue, net</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-120">200,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-122">41,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-123">43,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-124">158,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-125">170,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lfvn:CommissionAndIncentives" format="ixt:num-dot-decimal" scale="3" id="f-126">85,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lfvn:CommissionAndIncentives" format="ixt:num-dot-decimal" scale="3" id="f-127">94,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">68,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">71,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-130">154,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-131">165,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">4,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">4,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestExpense" scale="3" id="f-134">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:InterestExpense" scale="3" id="f-135">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-136">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-137">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-138">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-139">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">4,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-141">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-142">1,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-143">1,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-146">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-150">12,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-151">12,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-152">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-153">12,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-154">555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-155">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-156">555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-157">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_319"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended June&#160;30, 2024 and 2023 </span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:32.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In&#160;Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-160">12,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-161">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-162">131,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-163">98,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">1,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">31,516</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-166">3,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-167">3,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-168">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-169">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-170">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under equity award plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-171">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares canceled or surrendered as payment of tax withholding and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-172">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-173">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-174">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="f-175">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="f-176">822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="f-177">822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="f-178">1,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="f-179">1,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-180">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-181">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances, June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-184">12,622</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-185">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">134,314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">98,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">34,649</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-190">3,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-191">3,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-192">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-193">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-194">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under equity award plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-195">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares canceled or surrendered as payment of tax withholding and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-196">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-197">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-198">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of company stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="f-199">977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-200">6,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-201">6,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="f-202">6,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="f-203">6,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-204">555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-205">555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-207">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances, June 30, 2024</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-208">12,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-209">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">136,644</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">108,738</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">1,916</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-213">25,991</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_322"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.669%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-216">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-217">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-218">3,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-219">3,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-220">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-221">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-222">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-223">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of deferred financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-224">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income tax </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-226">1,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-227">1,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-228">1,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-229">1,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="f-230">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-231">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-232">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-233">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-234">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-235">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-236">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-237">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-238">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-239">3,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="f-240">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="f-241">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-242">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-243">770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-244">1,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-245">1,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-246">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-247">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-248">12,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-249">6,828</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchase of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-250">2,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-251">3,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from sale of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-253">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-254">2,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-255">3,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payment of deferred financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-256">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-258">6,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="f-259">822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payment of cash dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-260">6,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-261">1,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares purchased as payment of tax withholding and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-262">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-263">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" scale="3" id="f-264">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" scale="3" id="f-265">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net Cash Used in Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">14,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-267">2,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Foreign Currency Effect on Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-268">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-269">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Increase (Decrease) in Cash and Cash Equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-270">4,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-271">1,415</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and Cash Equivalents &#8212; beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-272">21,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-273">20,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash and Cash Equivalents &#8212; end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-274">16,886</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-275">21,605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_325"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-276">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-277">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-278">2,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-279">1,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_328"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIFEVANTAGE CORPORATION AND SUBSIDIARIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_331"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-280" continuedAt="f-280-1" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="f-280-1" continuedAt="f-280-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeVantage Corporation (the "Company" or "we" or "our" or "us") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company is dedicated to helping people achieve their health, wellness, and financial goals. The Company provides quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to its independent consultants. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The Company sold its products in China through a China approved cross-border e-commerce business model until March 15, 2023, at which time the Company closed its e-commerce business in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's line of scientifically validated dietary supplements includes its flagship Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of products, LifeVantage&#174; Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the Company's line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, its companion pet supplement formulated to combat oxidative stress in dogs; and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, its nootropic energy drink mixes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Colorado in June 1988 under the name Andraplex Corporation. The Company changed its corporate name to Yaak River Resources, Inc. in January 1992, and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, the Company acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, the Company changed its name to LifeVantage Corporation.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-280-2">In March 2018, the Company reincorporated from the state of Colorado to the state of Delaware. All outstanding shares of common stock, options and share units of the Colorado corporation were converted into an equivalent share, option or share unit of the Delaware corporation and the par value of the Company's common stock was adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-281">0.0001</ix:nonFraction>.</ix:continuation> </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_334"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-282" continuedAt="f-282-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-282-1" continuedAt="f-282-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-283" continuedAt="f-283-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-283-1">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-284" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, stock-based compensation, and loss contingencies.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-285" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company&#8217;s business operations occurs outside the United States.&#160;The local currency of each of the Company&#8217;s subsidiaries generally is its functional currency.&#160;All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders&#8217; equity is recorded at historical exchange rates.&#160;The resulting foreign currency translation adjustments are recorded as a separate component of stockholders&#8217; equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-282-2" continuedAt="f-282-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-286" continuedAt="f-286-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices for identical instruments in active markets; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-286-1">Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-287" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-288" continuedAt="f-288-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-288-1">The Company&#8217;s accounts receivable for the fiscal years ended June&#160;30, 2024 and 2023 consist primarily of credit card receivables. Based on the Company&#8217;s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June&#160;30, 2024 or 2023 is not necessary.</ix:continuation> There was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-289">no</ix:nonFraction> b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad debt expense for the fiscal year ended June&#160;30, 2024. Bad debt expense for the fiscal year ended June&#160;30, 2023 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-290">0.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-291" continuedAt="f-291-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 and 2023, inventory consisted of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-292">11,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="lfvn:InventoryFinishedGoodsPercentOfTotalInventory" scale="-2" id="f-293">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-294">12,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="lfvn:InventoryFinishedGoodsPercentOfTotalInventory" scale="-2" id="f-295">75.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-296">3,214</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="lfvn:RawMaterialsPercentOfTotalInventory" scale="-2" id="f-297">21.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-298">3,920</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="lfvn:RawMaterialsPercentOfTotalInventory" scale="-2" id="f-299">24.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-300">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="lfvn:InventoryPercentOfTotalInventory" scale="-2" id="f-301">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-302">16,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="lfvn:InventoryPercentOfTotalInventory" scale="-2" id="f-303">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-304" escape="true">Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method</ix:nonNumeric>, which includes a reduction in inventory values of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryAdjustments" scale="6" id="f-305">1.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryAdjustments" scale="6" id="f-306">1.3</ix:nonFraction> million at June&#160;30, 2024 and 2023, respectively, related to obsolete and slow-moving inventory. </span></div><ix:continuation id="f-291-1"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves of inventories consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-307">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-308">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="f-309">901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-310">1,199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="f-311">892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-312">1,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-313">1,301</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-314">1,292</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-282-3" continuedAt="f-282-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-315" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-316" continuedAt="f-316-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-34" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-317">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-35" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-318">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-36" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-319">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-37" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-320">5</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-321" continuedAt="f-321-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are stated at cost less accumulated amortization. Finite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset&#8217;s carrying value and estimated fair value. </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-321-1">Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.</ix:continuation> Annual impairment tests on intangible assets were completed for the fiscal years ended June&#160;30, 2024 and 2023, resulting in <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-322"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-323">no</ix:nonFraction></ix:nonFraction> impairment charges.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-324" continuedAt="f-324-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-324-1">Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow.</ix:continuation> For the fiscal years ended June&#160;30, 2024 and 2023, management has concluded that there are no indications of impairment.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-325" continuedAt="f-325-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-325-1">Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents.</ix:continuation> At June&#160;30, 2024, the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> had $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" scale="6" id="f-326">12.6</ix:nonFraction> million in cash accounts at one financial institution and $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" scale="6" id="f-327">4.3</ix:nonFraction> million i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n other financial institutions. As of June&#160;30, 2024 and 2023, and during the years then ended, the Company&#8217;s cash balances exceeded federally insured limits.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommissionsExpensePolicyPolicyTextBlock" id="f-328" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commissions and Incentives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions and incentives expenses are the Company&#8217;s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent consultants, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent consultants for personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-282-4" continuedAt="f-282-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-329" continuedAt="f-329-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with inbound freight and freight out to customers, including independent consultants, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-330" continuedAt="f-330-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-330-1">The Company expenses all costs related to research and development activities as incurred.</ix:continuation> Research and development expenses for the fiscal years ended June&#160;30, 2024 and 2023 were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-331">0.7</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-332">0.6</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-333" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the consolidated balance sheets. The Company does <ix:nonFraction unitRef="lease" contextRef="c-1" decimals="INF" name="lfvn:NumberOfFinanceLeases" format="ixt:fixed-zero" scale="0" id="f-334">no</ix:nonFraction>t have any finance leases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-335" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-336" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-337" continuedAt="f-337-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Per Share</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-282-5"><ix:continuation id="f-337-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended June&#160;30, 2024 and 2023, the effects of approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-338">13,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-339">0.2</ix:nonFraction> million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock, are not included in the computations as their effect was anti-dilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-340" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-341">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-342">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-343">12,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-344">12,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards and options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-345">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-346">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-347">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-348">12,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-349">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-350">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-351">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-352">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-353" continuedAt="f-353-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-353-1">The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operates in an integrated manner from market to market.&#160;Commissions and incentives expenses are the Company&#8217;s largest expense comprised of the commissions paid to its independent consultants.&#160;The Company manages its business primarily by managing its international network of independent consultants.&#160;The Company disaggregates revenue in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="lfvn:NumberOfGeographicSegments" format="ixt-sec:numwordsen" scale="0" id="f-354">two</ix:nonFraction> geographic regions: the Americas region and the Asia/Pacific and Europe region.</ix:continuation> See disaggregated revenue in Note 3.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-355" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-356">19,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-357">20,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-358">1,925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="f-359">354</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-360" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-361" continuedAt="f-361-1" escape="true"><ix:continuation id="f-329-1" continuedAt="f-329-2">Revenue</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-361-1" continuedAt="f-361-2"><ix:continuation id="f-329-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates the majority of its revenue through product sales to customers. These products include the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">line of dietary supplements, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Daily Wellness, Rise AM, Reset PM, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skin and hair care products and Liquid Collagen, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also charges amounts to independent consultants to attend events that it holds. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis, adjusted for the probability of the tickets being redeemed for attendance at a future event. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched its Rewards Circle loyalty program in the United States, Australia, New Zealand, and Japan in March 2023 and in Canada, Europe, and Mexico in February 2024.  Contract liabilities, recorded as deferred revenue, include these loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits are redeemed for additional products at a later date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deferred revenue is included in accrued expenses in the consolidated balance sheets.  The balance of deferred revenue related to contract liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-362">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-363">0.8</ix:nonFraction> million as of June&#160;30, 2024 and 2023, respectively. The contract liabilities impact to revenue for the years ended June&#160;30, 2024 and 2023 was a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="f-364">26,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-365">0.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales Returns and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company&#8217;s return policy is to provide a full refund for product returned within <ix:nonNumeric contextRef="c-1" name="lfvn:MoneyBackGuaranteePeriod" format="ixt-sec:durday" id="f-366">30</ix:nonNumeric> days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a <ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="lfvn:HandlingAndRestockingFeePercentage" scale="-2" id="f-367">10</ix:nonFraction>% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of June&#160;30, 2024 and 2023, the Company&#8217;s return liability reserve, net was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="lfvn:ReturnLiabilityReserve" scale="6" id="f-368">0.1</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="lfvn:ReturnLiabilityReserve" scale="6" id="f-369">0.1</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-370" continuedAt="f-370-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for sales returns consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="f-371">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="f-372">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-373">1,622</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-374">1,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-375">1,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-376">1,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="f-377">133</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="f-378">129</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-361-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports revenue in <ix:nonFraction unitRef="region" contextRef="c-1" decimals="INF" name="lfvn:NumberOfGeographicSegments" format="ixt-sec:numwordsen" scale="0" id="f-379">two</ix:nonFraction>&#160;geographic regions: the Americas region and the Asia/Pacific and Europe region. <ix:continuation id="f-370-1" continuedAt="f-370-2">The following table presents the Company's revenue disaggregated by these <ix:nonFraction unitRef="region" contextRef="c-1" decimals="INF" name="lfvn:NumberOfGeographicSegments" format="ixt-sec:numwordsen" scale="0" id="f-380">two</ix:nonFraction>&#160;geographic regions (in thousands):</ix:continuation></span></div><ix:continuation id="f-370-2"><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-381">152,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-382">155,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-383">47,257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-384">58,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-385">200,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-386">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information as to the Company&#8217;s revenue from operations in the most significant geographical areas is set forth below (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-387">145,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-388">148,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-389">26,989</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-390">32,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue is largely attributed to <ix:nonFraction unitRef="productline" contextRef="c-1" decimals="INF" name="lfvn:NumberOfProductLines" format="ixt-sec:numwordsen" scale="0" id="f-391"><ix:nonFraction unitRef="productline" contextRef="c-6" decimals="INF" name="lfvn:NumberOfProductLines" format="ixt-sec:numwordsen" scale="0" id="f-392">two</ix:nonFraction></ix:nonFraction> product lines, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each of which accounted for more than 10% of total revenue for each of the fiscal years ended June&#160;30, 2024 and 2023. On a combined basis, the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines represent approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-393">80.1</ix:nonFraction>% and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-394">79.3</ix:nonFraction>% of the Company's total revenue for the fiscal years ended June&#160;30, 2024 and 2023, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-395" continuedAt="f-395-1" escape="true">The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023:</ix:nonNumeric></span></div><ix:continuation id="f-395-1"><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-396">104,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-60" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-397">52.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-398">119,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-62" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-399">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-400">56,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-401">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-402">49,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-403">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-404">39,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-405">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-406">44,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-407">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-408">200,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-409">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-410">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-411">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_340"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-412" continuedAt="f-412-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-412-1"><ix:continuation id="f-316-1"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-413">15,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-414">16,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-415">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-416">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-417">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-418">4,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-419">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-420">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-421">14,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-422">14,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-423">7,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-424">9,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-425">3.4</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-426">3.4</ix:nonFraction> million for the fiscal years ended June&#160;30, 2024 and 2023, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_343"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-427" continuedAt="f-427-1" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="f-427-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-428" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent costs</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-429">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-430">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-431">2,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-432">2,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-433">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-434">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-435">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-436">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="f-437">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="f-438">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-439">0.1</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-440">0.1</ix:nonFraction> million for the fiscal years ended June&#160;30, 2024 and 2023, respectively. As of June&#160;30, 2024, the remaining weighted-average amortization period for finite-lived intangible assets was <ix:nonNumeric contextRef="c-4" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-441">0.75</ix:nonNumeric> years. Annual estimated amortization expense is expected to approximate </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-442"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-443">0.1</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the succeeding fiscal year.</span></div></ix:continuation><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_349"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-444" continuedAt="f-444-1" escape="true">Other Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-445" escape="true"><ix:continuation id="f-444-1"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentive compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-446">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-447">3,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="3" id="f-448">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="3" id="f-449">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-450">2,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-451">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payable to vendors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lfvn:AccruedPayableToVendors" scale="3" id="f-452">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lfvn:AccruedPayableToVendors" scale="3" id="f-453">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-454">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-455">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentives and promotions to consultants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-456">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="f-457">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-458">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-459">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-460">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-461">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_352"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-462" continuedAt="f-462-1" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="f-462-1" continuedAt="f-462-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;30, 2016,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "2016 Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-463">10.0</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-464">2.0</ix:nonFraction> million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement, and the 2016 Security Agreement, and together with the amendments described below, the "2016 Credit Facility"). During the fiscal year ended June 30, 2020, the Company repaid, in full, the balance of the 2016 Term Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018 and February&#160;1, 2019, the Company entered into loan modification agreements (&#8220;Amendment No. 1&#8221; and &#8220;Amendment No. 2&#8221;, respectively).  These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2021, the Company entered into a loan modification agreement ("Amendment No. 3"), which amended the 2016 Credit Facility.  Amendment No. 3, with an available borrowing amount of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-465">5.0</ix:nonFraction> million, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-466">2.00</ix:nonFraction>%, with an interest rate floor of <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="lfvn:DebtInstrumentFloorInterestRate" scale="-2" id="f-467">0.00</ix:nonFraction>%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that the Company maintain this ratio not in excess of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="lfvn:DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" scale="0" id="f-468">2.00</ix:nonFraction> to 1.00, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3).  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other changes to the minimum fixed charge coverage ratio of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="lfvn:DebtInstrumentCovenantFixedChargeCoverageRatio" scale="0" id="f-469">1.10</ix:nonFraction> to 1.00 or the minimum working capital of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="INF" name="lfvn:DebtInstrumentCovenantRequiredMinimumWorkingCapital" scale="6" id="f-470">6.0</ix:nonFraction> million as set forth in previous amendments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the 2016 Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-462-2" continuedAt="f-462-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio (as defined in Amendment No. 4) and allowed the Company to declare and pay dividends, up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="lfvn:DebtInstrumentCovenantMaximumDividend" format="ixt:num-dot-decimal" scale="0" id="f-471">500,000</ix:nonFraction> per quarter, through September 30, 2023.  There were no other changes to the covenants or revolving loan facility as set forth in Amendment No. 3.  If the Company borrowed under the 2016 Revolving Loan, interest would have been payable quarterly in arrears on the last day of each fiscal quarter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2023, the Company received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="INF" name="lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend" scale="0" id="f-472">0.40</ix:nonFraction> per share of common stock, to be paid on September 22, 2023. The Company also received approval to declare and pay dividends, up to $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="lfvn:DebtInstrumentCovenantMaximumDividend" format="ixt:num-dot-decimal" scale="0" id="f-473">750,000</ix:nonFraction>, per quarter, through September 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2024, the 2016 Credit Facility reached the maturity date and was terminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with Bank of America, N.A., as Lender (the &#8220;Lender&#8221;). In connection with the Loan Agreement and on the same date, the Company, Lifeline Nutraceuticals Corporation, as Guarantor (the &#8220;Guarantor&#8221;), and the Lender also entered into a Continuing and Unconditional Guaranty (the &#8220;Continuing and Unconditional Guaranty&#8221;) and a Security and Pledge Agreement (the &#8220;Security and Pledge Agreement&#8221;). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-474">5.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Line of Credit&#8221; and collectively with the Loan Agreement, Continuing and Unconditional Guaranty, and the Security and Pledge Agreement, the &#8220;2024 Credit Facility&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company borrows under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the &#8220;Expiration Date&#8221;). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="lfvn:DebtInstrumentFloorInterestRate" scale="-2" id="f-475">0.00</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, plus (ii) <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-476">2.00</ix:nonFraction>%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date. As of June&#160;30, 2024, the effective interest rate is <ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-477">7.34</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, and by a pledge of the membership interests of the Company's subsidiaries, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants, both affirmative and negative, that, among other things, restrict the Company&#8217;s ability to deal with the Company's assets outside of the ordinary course, incur additional indebtedness, grant liens on the Company's assets, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, and enter into consolidations, mergers or other combinations. The Loan Agreement requires that the Company maintain specified financial ratios and satisfy certain financial condition tests. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains certain customary events of default, including, among other things, failure of the Company to make required payments under the Loan Agreement, certain breaches of representations made by the Company or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or failure of the Company to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to the Company may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will, at the option of the Lender, bear interest at a rate which is <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-478">2.00</ix:nonFraction>% higher than the rate of interest otherwise provided under the Loan Agreement. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-462-3">As of June&#160;30, 2024, the Company was in compliance with its financial covenants under the 2024 Credit Facility.  As of June&#160;30, 2024, there was no balance outstanding on the 2024 Credit Facility.</ix:continuation>  </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_355"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-479" continuedAt="f-479-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-479-1" continuedAt="f-479-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-480"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-481">zero</ix:nonFraction></ix:nonFraction> shares of common stock as a result of the exercise of options. During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-482">1.0</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-483">0.3</ix:nonFraction> million shares, respectively, under the Company's equity incentive plans. During the fiscal years ended June&#160;30, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="f-484">0.2</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-485">47,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, respectively, of restricted stock were canceled or surrendered as payment of tax withholding upon vesting.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the fiscal years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-486">0.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-487">0.1</ix:nonFraction> million shares under its 2019 Employee Stock Purchase Plan, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;27, 2017, the Company's board approved a stock repurchase program, which was subsequently amended on February&#160;1, 2019. Under the currently approved stock repurchase program, the Company is authorized to purchase up to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-479-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-488">60</ix:nonFraction>&#160;million through December 31, 2026. The stock repurchase program permits the Company to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the Company's management, in accordance with applicable securities laws. As part of the stock repurchase program, the Company may enter into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan would be completed in accordance with the terms of the plan, including specified price, volume, and timing conditions. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he stock repurchase program may be suspended or discontinued at any time. During the year ended June&#160;30, 2024, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-489">1.0</ix:nonFraction> million&#160;shares of its common stock at an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-490">6.4</ix:nonFraction> million under this repurchase program. During the fiscal year ending June&#160;30, 2023, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-491">0.2</ix:nonFraction> million&#160;shares of its common stock at an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-492">0.8</ix:nonFraction> million under this repurchase program. At&#160;June&#160;30, 2024, there is&#160;$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="f-493">20.4</ix:nonFraction> million&#160;remaining under this stock repurch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ase program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2023, the board approved a stockholder rights agreement (the &#8220;Rights Plan&#8221;) and declared a dividend of one right for each outstanding share of common stock to stockholders of record on September 11, 2023. Each right entitles holders to purchase one newly issued share of preferred stock at an exercise price of $20 per right, subject to adjustment. Initially, the rights are not exercisable and trade with shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the rights become exercisable following a public announcement that a person acquires 12% (or, in the case of passive investors, 20%) or more of the outstanding shares of the Company&#8217;s common stock. If a person becomes an acquiring person, each holder of rights (except the acquiring person) will have the right to purchase, for the purchase price, a number of shares of the Company&#8217;s common stock at a 50% discount to the then-current trading price. Rather than allowing the rights to be exercised in those circumstances, the board may exchange each right, other than the rights owned by the acquiring person, for a share of the Company&#8217;s common stock. The agreement provides for exceptions and additional terms for other certain situations and circumstances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Rights Plan is intended to protect the interests of the Company and its stockholders by reducing the likelihood that any entity, person or group gains control of the Company through open-market accumulation or other means without payment of an adequate control premium and expires August 28, 2024. There is currently no impact to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Certificate of Incorporation authorizes the designation and issuance of shares of preferred stock. However, as of June&#160;30, 2024, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Company&#8217;s board.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid a one-time cash dividend of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="INF" name="lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend" scale="0" id="f-494">0.40</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share of common stock to stockholders of record in September 2023, quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-495"><ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-496"><ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-497">0.035</ix:nonFraction></ix:nonFraction></ix:nonFraction> per share of common stock to stockholders of record in September 2023, December 2023 and March 2024, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-498">0.04</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock in June 2024 which were in the aggregate amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-499">6.9</ix:nonFraction> million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-500">0.545</ix:nonFraction> per share of common stock for the fiscal year ended June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the fiscal year ended June&#160;30, 2023, the Company paid to stockholders quarterly cash dividends totaling $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-501">1.6</ix:nonFraction> million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-502">0.125</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The declaration of dividends is subject to the discretion of the board and will depend upon various factors, including the Company's earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects, and other factors deemed relevant by the board.</span></div></ix:continuation><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_358"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-503" continuedAt="f-503-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Term Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Settled Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted, and the stockholders approved, the 2017 Long-Term Incentive Plan (the &#8220;2017 Plan&#8221;), effective February&#160;16, 2017, to provide incentives to eligible employees, directors, and consultants. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he initial share pool approved was <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-504">650,000</ix:nonFraction> shares. On November 9, 2023, the stockholders approved amendments to the 2017 Plan to increase the number of shares of the Company's common stock that are available for issuance under the 2017 plan by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-505">1,138,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2024, a maximum of&#160;<ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-506">5.1</ix:nonFraction> million&#160;shares of the Company's common stock can be issued under the 2017 Plan in connection with the grant of awards which is calculated as the sum of (i)&#160;<ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-507">4,630,000</ix:nonFraction>&#160;shares and (ii) up to&#160;<ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-508">475,000</ix:nonFraction>&#160;shares previously reserved for issuance under the Company's prior 2010 Long Term Incentive Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. Outstanding stock options awarded under the 2017 Plan have exercise prices of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-509">4.44</ix:nonFraction>&#160;per share, vest over a&#160;<span style="-sec-ix-hidden:f-510">three&#160;year</span> vesting period, and have a contractual term of <ix:nonNumeric contextRef="c-106" name="lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" format="ixt-sec:durwordsen" id="f-511">ten years</ix:nonNumeric>. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-2" continuedAt="f-503-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back to the 2017 Plan. As of June&#160;30, 2024, under the 2017 Plan, there were stock option awards outstanding, net of awards expired, for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-512">0.1</ix:nonFraction> million shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;The Company&#8217;s 2019 Employee Stock Purchase Plan ("ESPP") was adopted by the board in September 2018 and approved by its stockholders in November 2018. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Reserve.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;The Company has reserved <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="f-513">0.4</ix:nonFraction> million shares of its common stock for issuance under the ESPP. As of June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-514">0.1</ix:nonFraction> million shares were available for issuance. The number of shares reserved under the ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Employees may purchase each share of common stock under the ESPP at a price equal to <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-515">85</ix:nonFraction>% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee&#8217;s contributions to the ESPP are limited to <ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-516">15</ix:nonFraction>% of the compensation, and up to a maximum of <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-517">3,000</ix:nonFraction> shares may be purchased by an employee during any offering period. A participant shall not be granted an option under the ESPP if such option would permit the participant&#8217;s rights to purchase stock to accrue at a rate exceeding $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="INF" name="lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" format="ixt:num-dot-decimal" scale="0" id="f-518">25,000</ix:nonFraction> fair market value of stock for each calendar year in which such option is outstanding at any time.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offering Periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Unless otherwise determined by the compensation committee, the ESPP will be operated through a series of successive <ix:nonNumeric contextRef="c-95" name="lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-519">six-month</ix:nonNumeric> offering periods, which will begin each year on March 1 and September 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June&#160;30, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-520">0.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-521">0.1</ix:nonFraction> million shares of common stock were purchased under the ESPP, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with accounting guidance for stock-based compensation, payments in equity instruments for goods or services are accounted for by the fair value method. For the fiscal year ended June&#160;30, 2024 and 2023, stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-522">3.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-523">3.2</ix:nonFraction> million, respectively, was reflected as an increase to additional paid in capital. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-524">2.5</ix:nonFraction> million of unrecognized compensation cost related to non-vested stock-based compensation arrangements under the 2017 Plan, based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over a weighted-average period of <ix:nonNumeric contextRef="c-109" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-525">1.44</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-526"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-527"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-528">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock option grants during the fiscal years ended June&#160;30, 2024 and 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-529" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Remaining<br/>Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-530">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-531">6.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-539">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-540">12.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-541">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-542">4.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="3" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-552">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-553">4.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-554">3.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-555">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="f-556">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-557">4.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-558">3.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-559">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-3" continuedAt="f-503-4"><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-560" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock award activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-561">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-562">6.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-563">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-564">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-565">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-566">6.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-569">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-112" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-570">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-571">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-93" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-572">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-573">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-93" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-574">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-93" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-577">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-578">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:2.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 125,732 shares of restricted stock that were granted in exchange for the cancellation of 48,026 shares of stock units and 77,706 shares of performance restricted stock units on November 6, 2023.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of restricted shares that vested during the fiscal years ended June 30, 2024 and 2023 w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-579">0.7</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-580">0.3</ix:nonFraction> million, respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-581" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-582">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-583">7.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-584">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-585">4.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-586">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-587">8.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-588">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-589">6.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-590">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-591">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-592">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-593">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-594">331</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-595">5.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-596">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-597">4.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-598">338</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-599">4.86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:2.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 48,206 shares of restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-600">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-601">0.6</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Restricted Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June 30, 2024 and 2023, the Company awarded performance restricted stock units (the "FY 2024 PRSUs" and "FY 2023 PRSUs," respectively) to certain employees (the "Recipients"). Each performance restricted stock unit represents a contingent right for the Recipients to receive a distribution of shares of common stock of the Company equal to <ix:nonFraction unitRef="number" contextRef="c-119" decimals="INF" name="lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" scale="-2" id="f-602">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-120" decimals="INF" name="lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" scale="-2" id="f-603">200</ix:nonFraction>% of the target number of performance restricted stock units subject to the award. The actual number of shares distributed will be based on the Company's achievement of specified financial performance metrics. For FY 2024 PRSUs, the performance period for 50% of the FY 2024 PRSUs ended on June&#160;30, 2024, the performance period for 30% of the FY 2024 PRSUs ends on June 30, 2025, and the performance period for the remaining 20% of the FY 2024 PRSUs ends on June 30, 2026. The financial performance metrics for the fiscal year ended June&#160;30, 2024, were deemed achieved at the <ix:nonFraction unitRef="number" contextRef="c-121" decimals="INF" name="lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" scale="-2" id="f-604">0</ix:nonFraction>% achievement level. The performance period for 100% of the FY 2023 PRSUs ended on June 30, 2023, and were deemed achieved at the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-4" continuedAt="f-503-5"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133.13% achievement level. The FY 2024 PRSUs and FY 2023 PRSUs will vest only to the extent the specified financial performance criteria are achieved and subject to the Recipient&#8217;s continued service with the Company, as follows: (i) a portion of the earned award will vest on the first anniversary of the grant date and (ii) an additional portion of the earned award will vest thereafter in a series of quarterly installments. The fair values of the performance restricted stock units are based on the grant date fair value which is the closing price of the Company's common stock on the date of grant.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-605" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-606">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-607">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-608">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-609">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-610">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-611">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-612">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-613">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-614">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-615">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-616">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-617">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-618">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-619">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-620">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-621">4.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-622">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-623">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:2.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes shares added based on achievement of performance goals in excess of target.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 77,706 shares of performance restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><ix:continuation id="f-503-5" continuedAt="f-503-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of performance restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-624">1.6</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="0" id="f-625">4,000</ix:nonFraction></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-503-6">, respectively.</ix:continuation> </span></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_364"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="f-628" continuedAt="f-628-1" escape="true">Other Expense, Net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-629" escape="true"><ix:continuation id="f-628-1"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency transaction loss, net</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-630">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-631">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lfvn:OtherMiscellaneousIncomeExpensesNet" scale="3" id="f-632">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="lfvn:OtherMiscellaneousIncomeExpensesNet" scale="3" id="f-633">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-634">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-635">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_367"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-636" continuedAt="f-636-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-636-1" continuedAt="f-636-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-637" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the fiscal years ended June&#160;30, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Income Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-638">2,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-639">2,464</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-640">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-641">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-642">4,350</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-643">3,999</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-644">1,457</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-645">2,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-646">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-647">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-648">984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-649">686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Income Tax Provision</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-650">2,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-651">3,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-652">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-653">1,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-654">151</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-655">303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-656">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-657">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Deferred Income Tax Provision</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-658">1,274</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-659">1,675</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Tax Provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-660">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-661">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-662" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate for the fiscal years ended June&#160;30, 2024 and 2023 differs from the U.S. Federal statutory income tax rate due to the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-663">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-664">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-665">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-666">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-667">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-668">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax return to provision true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" scale="-2" id="f-669">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" scale="-2" id="f-670">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limit on future stock compensation due to 162(m)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" scale="-2" id="f-671">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" scale="-2" id="f-672">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" scale="-2" id="f-673">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" scale="-2" id="f-674">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-675">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-676">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revalue of deferred for change in federal tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-677">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-678">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-679">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-680">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; current year section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" scale="-2" id="f-681">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" scale="-2" id="f-682">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; foreign derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-683">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-684">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-685">12.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-686">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="f-687">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="f-688">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; removal of additional permanent reinvestment assertions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" scale="-2" id="f-689">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" scale="-2" id="f-690">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; change in uncertain tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="f-691">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="f-692">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; accrual for foreign tax audits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="f-693">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="f-694">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-695">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-696">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-697">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-698">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax provision </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-699">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-700">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-636-2" continuedAt="f-636-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-701" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities as of June&#160;30, 2024 and 2023 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal, state, and foreign net operating loss carryovers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="f-702">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="f-703">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-704">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-705">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-706">2,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="f-707">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lfvn:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-708">3,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lfvn:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-709">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation, allowance for returns, bonuses&#160;&amp; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-710">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-711">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-712">8,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-713">7,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="f-714">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="f-715">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property&#160;&amp; equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-716">798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-717">1,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-718">2,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-719">2,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-720">472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-721">470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-722">3,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-723">4,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-724">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-725">704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-726">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-727">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted accounting guidance for uncertain tax positions ("UTPs") which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position. The measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year ending June&#160;30, 2024, the Company began recording a withholding tax obligation on its rebalanced commission payments to the U.S. parent company it has not obtained treaty rates for. The Company does not believe it will obtain treaty rates, but will also not be able to take a foreign tax credit at this time. Since the Company believes it is unlikely to receive treaty benefits, it has recorded the taxes, the foreign tax credit on those taxes, and a corresponding UTP against the foreign tax credit. The UTP totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lfvn:UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" scale="6" id="f-728">0.1</ix:nonFraction> million was recorded against the foreign tax credit as of June&#160;30, 2024. If the Company is successful with its treaty benefit application or receives an opinion through appeals, competent authority, etc., it will remove the UTP at that time. The UTP recorded is the foreign taxes that will not be credited, but reduced by the benefit the Company will receive from deducting the taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also currently undergoing income tax audits in foreign jurisdictions. For the fiscal year ending June&#160;30, 2024, the Company accrued a total $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lfvn:UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" scale="6" id="f-729">0.3</ix:nonFraction> million related to foreign income tax audits. At this time, the Company believes this amount reflects the amount that is has more than 50% likelihood to be paid upon settlement including interest and penalties. The Company will continue to evaluate as the audits progress.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="lfvn:UnrecognizedTaxPosition" scale="6" id="f-730">0.4</ix:nonFraction> million for taxes related to the UTPs as of June&#160;30, 2024. There were <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-731"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-732">no</ix:nonFraction></ix:nonFraction> changes to the liability for UTPs for the fiscal year ended June&#160;30, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-733"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-734">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits for the fiscal years ended June&#160;30, 2024 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2022, the Company removed its permanent reinvestment assertion in Japan. In fiscal 2024, the Company also removed its permanent reinvestment assertions in Taiwan and Australia and recorded the tax effects of that change.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Taiwan, the Company recorded provisions for withholding tax that it will pay to Taiwan upon payment of dividends. The Company did not record any unborn foreign tax credit related to Taiwan withholding tax. The Company believes any withholding tax paid on dividends will be ineligible for a foreign tax credit.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any withholding tax to Australia upon the payment of dividends. There is a 15% withholding rate on unfranked dividends between Australia and Singapore, but the Company does not anticipate paying any unfranked dividends, so it has not recorded any withholding tax to Australia.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also recorded income taxes to various states when the cash is repatriated from Taiwan and Australia. The Company did not record any federal income tax implications because any withholding tax on dividends will be ineligible for a foreign tax credit.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-636-3"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years open for examination by the Internal Revenue Service (&#8220;IRS&#8221;) include returns for fiscal years June 30, 2021 through present and the open tax years by state tax authorities include returns for fiscal years June 30, 2020 through present. In addition, the IRS and state tax authorities may examine net operating losses ("NOLs") for any previous years if utilized by the Company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-735" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance were as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-736">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-737">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="f-738">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="f-739">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-740">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-741">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in valuation allowance during the fiscal year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on the Company converting from a blended rate to a state-by-state provision. During the fiscal year ended June&#160;30, 2023, the change in valuation allowance related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on updated projections and changes to the blended rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had utilized all of its Federal NOL carry-forwards.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2024, state NOLs were $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-742">5.6</ix:nonFraction> million and foreign NOLs were $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-743">0.4</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total recognized tax benefit from settlement of stock-based awards for the fiscal years ending June&#160;30, 2024 and 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="f-744">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="f-745">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business globally. As a result, the Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions, and are subject to examination for the open tax years of June 30, 2020 through June 30, 2024.</span></div></ix:continuation><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_370"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-746" continuedAt="f-746-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-746-1" continuedAt="f-746-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for current corporate offices and certain equipment. These leases have remaining terms of approximately <span style="-sec-ix-hidden:f-747">one</span> to <ix:nonNumeric contextRef="c-132" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-748">eight years</ix:nonNumeric>. As of June&#160;30, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-749">6.90</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-750">3.46</ix:nonFraction>%, respectively. As of June&#160;30, 2023, the weighted average remaining lease term and weighted average discount rate for operating leases was <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-751">8.27</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-752">3.25</ix:nonFraction>%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, LifeVantage Japan entered into an operating lease agreement with Sumitomo Mitsui Trust Bank, Limited, for a new office located in the Shinagawa Grand Central Tower in Tokyo, Japan.  The lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="c-1" decimals="-2" name="lfvn:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="f-753">5,200</ix:nonFraction> square feet and has a lease term from July 1, 2023 through June 30, 2026 with the option to renew for an additional <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-754">two years</ix:nonNumeric>.  Lease payments began in November 2023 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lfvn:LesseeOperatingLeaseMonthlyPayments" format="ixt:num-dot-decimal" scale="0" id="f-755">28,000</ix:nonFraction> per month, or $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lfvn:LesseeOperatingLeaseAnnualAmount" scale="6" id="f-756">0.3</ix:nonFraction> million per year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June&#160;30, 2024, the Company also entered into new operating leases with previous lessors in Thailand and Taiwan and extended the operating lease Philippines. Each of these leases have a lease term of <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-757">three years</ix:nonNumeric>, expiring in fiscal year 2027.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-758" continuedAt="f-758-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the fiscal years ended June&#160;30, 2024 and 2023, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-759">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-760">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-761">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-762">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-763">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-764">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-765">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-766">2,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-746-2"><ix:continuation id="f-758-1"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-767">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-768">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-769">2,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-771" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities at June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-772">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-773">2,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-774">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-775">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-776">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-777">4,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-778">14,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-779">1,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-780">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie82fc05bf17d40b3a7e7f8db7a0f9606_373"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-781" continuedAt="f-781-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-781-1" continuedAt="f-781-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for contingent liabilities in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of June&#160;30, 2024, and based on the assessment there are no probable loss contingencies requiring accrual or disclosures within its financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Accruals</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable publicity or resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding or publicity related to such could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact of any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.   The Company may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this annual report on Form 10-K, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-781-2">believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>a2017ltipamended.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i760663ace9c2410d895f2a35d6d464f9_40"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">LIFEVANTAGE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2017 LONG-TERM INCENTIVE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(Adopted on December 6, 2016,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Effective on February 16, 2017 and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Amended on November 16, 2017, January 19, 2018, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">September 20, 2018, August 27, 2020, September 19, 2022 and September 21, 2023)</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 1.  INTRODUCTION</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Board adopted the LifeVantage Corporation 2017 Long-Term Incentive Plan on the Adoption Date conditioned upon and subject to obtaining Company stockholder approval. Stockholder approval for the Plan was obtained on February 16, 2017. The Board amended the Plan on November 16, 2017 and January 19, 2018, pursuant to which 425,000 Shares in the aggregate were added to the reserve under the Plan, such that the maximum aggregate number of Shares that may be issued under the Plan (and pursuant to the exercise of Incentive Stock Options) shall be 1,550,000 Shares (the &#8220;2017&#47;2018 Amendment&#8221;). The 2017&#47;2018 Amendment was approved by the Company&#8217;s stockholders on February 2, 2018.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On September 20, 2018, the Board further amended the Plan to add 715,000 Shares to the reserve under the Plan and increase the maximum aggregate number of Shares that may be issued under the Plan (and pursuant to the exercise of Incentive Stock Options) from 1,550,000 Shares to 2,265,000 (the &#8220;September 2018 Amendment&#8221;). The September 2018 Amendment was approved by the Company&#8217;s stockholders on November 15, 2018. On August 27, 2020, the Board further amended the Plan to add 650,000 Shares to the reserve under the Plan to increase the maximum aggregate number of Shares that may be issued under the Plan (and pursuant to the exercise of Incentive Stock Options) from 2,265,000 to 2,915,000 (the &#8220;August 2020 Amendment&#8221;). The August 2020 Amendment was approved by the Company&#8217;s stockholders on November 12, 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On September 19, 2022, the Board further amended the Plan to (i) add 1,052,000 Shares to the reserve under the Plan to increase the maximum aggregate number of Shares that may be issued under the Plan (and pursuant to the exercise of Incentive Stock Options) from 2,915,000 to 3,967,000, (ii) amend the share recycling provisions set forth in Section 5(b) and (iii) amend the vesting acceleration provisions applicable to Awards upon a Change in Control in Section 12 (the &#8220;September 2022 Amendment&#8221;). The September 2022 Amendment was appro</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">ved by the Company&#8217;s stockholders on November 10, 2022. On September 21, 2023, the Board further amended the Plan to add 1,138,000 shares to the reserve under the Plan to increase the maximum aggregate number of Shares that may be issued under the Plan (and pursuant to the exercise of Incentive Stock Options) from 3,967,000 to 5,105,000.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The purposes of the Plan are to (i) attract and retain the services of persons eligible to participate in the Plan&#59; (ii) motivate Selected Employees, by means of appropriate equity and performance based incentives, to achieve long-term performance goals&#59; (iii) provide equity and performance based incentive compensation opportunities that are competitive with those of other similar companies&#59; and (iv) further align Participants&#8217; interests with those of the Company&#8217;s other stockholders and thereby promote the financial interests of the Company and its affiliates and enhancement of stockholder return.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Plan seeks to achieve this purpose by providing for Awards in the form of Options (which may constitute Incentive Stock Options or Non statutory Stock Options), Stock Appreciation Rights, Restricted Stock Grants, Stock Units and&#47;or Cash Awards, as well as any other form of equity award consistent with the terms of the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Capitalized terms shall have the meaning provided in Section 2 unless otherwise provided in this Plan or any related Award Agreement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 2.  DEFINITIONS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)          &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Adoption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means December 6, 2016.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)          &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any entity other than a Subsidiary, if the Company and&#47;or one or more Subsidiaries own not less than 50% of such entity. For purposes of determining an individual&#8217;s &#8220;Service,&#8221; this definition shall include any entity other than a Subsidiary, if the Company, a Parent and&#47;or one or more Subsidiaries own not less than 50% of such entity.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)        &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any award, under this Plan, to a Selected Employee of an Option, SAR, Restricted Stock Grant, Stock Unit or to a Covered Employee of any Cash Award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)      &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a Stock Option Agreement, a SAR Agreement, a Restricted Stock Grant Agreement, a Stock Unit Agreement or such other agreement evidencing an Award granted under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)          &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Board of Directors of the Company, as constituted from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)           &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Cash Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an award of a bonus opportunity, under this Plan, to a Covered Employee that (i) is payable in cash, (ii) is not an Option, SAR, Restricted Stock Grant or Stock Unit, (iii) is paid based on achievement of Performance Goal(s) and (iv) may be intended to qualify as performance-based compensation under Code Section 162(m).</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)          &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, to the extent that a Stock Option Agreement so provides and as permitted by applicable law and in accordance with any procedures established by the Committee, an arrangement whereby payment of some or all of the aggregate Exercise Price may be made all or in part by delivery of an irrevocable direction to a securities broker to sell Shares and to deliver all or part of the sale proceeds to the Company. Cashless Exercise may also be utilized to satisfy an Option&#8217;s tax withholding obligations as provided in Section 14(b).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)          &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, except as may otherwise be provided in a Participant&#8217;s employment agreement or applicable Award Agreement (and in such case the employment agreement or Award Agreement shall govern as to the definition of Cause), (i) dishonesty or fraud, (ii) serious willful misconduct, (iii) unauthorized use or disclosure of confidential information or trade secrets, (iv) conviction or confession of a felony, or (v) any other act or omission by a Participant that, in the opinion of the Company, could reasonably be expected to adversely affect the Company&#8217;s or a Subsidiary&#8217;s or an Affiliate&#8217;s business, financial condition, prospects and&#47;or reputation. In each of the foregoing subclauses (i) through (v), whether or not a &#8220;Cause&#8221; event has occurred will be determined by the Company&#8217;s chief human resources officer or other person performing that function or, in the case of Participants who are Directors or Officers or Section 16 Persons, the Board, each of whose determination shall be final, conclusive and binding. A Participant&#8217;s Service shall be deemed to have terminated for Cause if, after the Participant&#8217;s Service has terminated, facts and circumstances are discovered that would have justified a termination for Cause, including, without limitation, violation of material Company policies or breach of confidentiality or other restrictive covenants that may apply to the Participant.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)           &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, except as may otherwise be provided in a Participant&#8217;s employment agreement or applicable Award Agreement (and in such case the employment agreement or Award Agreement shall govern as to the definition of Change in Control), the occurrence of any one or more of the following&#58; (i) any merger, consolidation or business combination in which the stockholders of the Company immediately prior to the merger, consolidation or business combination do not own at least a majority of the outstanding equity interests of the surviving parent entity, (ii) the sale of all or substantially all of the Company's assets, (iii) the acquisition of beneficial ownership or control of (including, without limitation, power to vote) a majority of the outstanding Shares by any person or entity (including a &#8220;group&#8221; as defined by or under Section 13(d)(3) of the Exchange Act), (iv) the dissolution or liquidation of the Company, or (v) a contested election of directors, as a result of which or in connection with which the persons who were directors of the Company before such election or their nominees cease to constitute a majority of the Board.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transactions. In addition, if a Change in Control constitutes a payment event with respect to any Award which provides for a deferral of compensation and is subject to Code Section 409A, then notwithstanding anything to the contrary in the Plan or applicable Award Agreement the transaction with respect to such Award must also constitute a &#8220;change in control event&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Code Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations and interpretations promulgated thereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a committee described in Section 3.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Company&#8217;s common stock, $0.001 par value per Share, and any other securities into which such shares are changed, for which such shares are exchanged or which may be issued in respect thereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means LifeVantage Corporation, a Colorado corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a consultant or adviser who provides bona fide services to the Company, a Parent, a Subsidiary or an Affiliate, other than as an Employee, Director or Non-Employee Director and who qualifies as a consultant or adviser under Instruction A.1.(a)(1) of Form S-8 under the Securities Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(o)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Covered Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means those individuals whose compensation is subject to the deduction limitations of Code Section 162(m).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(p) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a member of the Board who is also an Employee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, except as may otherwise be provided in a Participant&#8217;s employment agreement or applicable Award Agreement (and in such case the employment agreement or Award Agreement shall govern as to the definition of Disability), that the Participant is classified as disabled under a long-term disability policy of the Company or, if no such policy applies, the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any individual who is a common-law employee of the Company, or of a Parent, or of a Subsidiary or of an Affiliate.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any Award other than a Cash Award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, in the case of an Option, the amount for which a Share may be purchased upon exercise of such Option, as specified in the applicable Stock Option Agreement. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">,&#8221; in the case of a SAR, means an amount, as specified in the applicable SAR Agreement, which is subtracted from the Fair Market Value in determining the amount payable to a Participant upon exercise of such SAR.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the market price of a Share, determined by the Committee as follows&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;If the Shares are traded on a stock exchange (such as the New York Stock Exchange, NYSE MKT, the NASDAQ Global Market or NASDAQ Capital Market) at the time of determination, then the Fair Market Value shall be equal to the regular session closing price for such stock as reported by such exchange (or the exchange or market with the greatest volume of trading in the Shares) on the date of determination, or if there are no sales on such date, on the last date preceding such date on which a closing price was reported&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;If the Shares are traded on the OTC Bulletin Board at the time of determination, then the Fair Market Value shall be equal to the last-sale price reported by the OTC Bulletin Board for such date, or if there are no sales on such date, on the last date preceding such date on which a sale was reported&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii)&#160;&#160;&#160;&#160;If neither of the foregoing provisions is applicable, then the Fair Market Value shall be determined by the Committee in good faith using a reasonable application of a reasonable valuation method as the Committee deems appropriate.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever possible, the determination of Fair Market Value by the Committee shall be based on the prices reported by the applicable exchange or the OTC Bulletin Board, as applicable, or a nationally recognized publisher of stock prices or quotations (including an electronic on-line publication). Such determination shall be conclusive and binding on all persons.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(w)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Company&#8217;s fiscal year.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">ISO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an incentive stock option described in Code Section 422.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Net Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means, to the extent that a Stock Option Agreement so provides and as permitted by applicable law, an arrangement pursuant to which the number of Shares issued to the Optionee in connection with the Optionee&#8217;s exercise of the Option will be reduced by the Company&#8217;s retention of a portion of such Shares. Upon such a net </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">exercise of an Option, the Optionee will receive a net number of Shares that is equal to (i) the number of Shares as to which the Option is being exercised minus (ii) the quotient (rounded down to the nearest whole number) of the aggregate Exercise Price of the Shares being exercised divided by the Fair Market Value of a Share on the Option exercise date. The number of Shares covered by clause (ii) will be retained by the Company and not delivered to the Optionee. No fractional Shares will be created as a result of a Net Exercise and the Optionee must contemporaneously pay for any portion of the aggregate Exercise Price that is not covered by the Shares retained by the Company under clause (ii). The number of Shares delivered to the Optionee may be further reduced if Net Exercise is utilized under Section 14(b) to satisfy applicable tax withholding obligations.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a member of the Board who is not an Employee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Nonstatutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">NSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a stock option that is not an ISO.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(bb)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an individual who is an officer of the Company within the meaning of Rule 16a-1(f) of the Exchange Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(cc)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an ISO or NSO granted under the Plan entitling the Optionee to purchase a specified number of Shares, at such times and applying a specified Exercise Price, as provided in the applicable Stock Option Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(dd)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an individual, estate or other entity that holds an Option.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ee)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the Adoption Date shall be considered a Parent commencing as of such date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ff)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an individual or estate or other entity that holds an Award.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(gg)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means one or more objective performance targets established for a Participant which may be described in terms of Company-wide objectives and&#47;or objectives that are related to the performance of the individual Participant or a Parent, Subsidiary, Affiliate, division, department or function within the Company or entity in which the Participant is employed, and such targets may be applied either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established target, to previous years&#8217; results or to a designated comparison group, in each case as specified by the Committee. Any Performance Goals that are included in an Award in order to make such Award qualify as performance-based compensation under Code Section 162(m) shall be limited to one or more of the following target objectives&#58; (i) operating income&#59; (ii) earnings before interest, taxes, depreciation and amortization, or EBITDA&#59; (iii) earnings&#59; (iv) cash flow&#59; (v) market share&#59; (vi) sales or revenue, including with respect to a particular product, business line, geography or market&#59; (vii) expenses&#59; (viii) cost of goods sold&#59; (ix) profit&#47;loss or profit margin&#59; (x) working capital&#59; (xi) return on equity or assets or investment&#59; (xii) earnings per share&#59; (xiii) economic value added, or EVA&#59; (xiv) stock price including without limitation total stockholder return&#59; (xv) price&#47;earnings ratio&#59; (xvi) debt or debt-to-equity&#59; (xvii) accounts receivable&#59; (xviii) writeoffs&#59; (xix) cash&#59; (xx) assets&#59; (xxi) liquidity&#59; (xxii) operations&#59; (xxiii) research or related milestones&#59; (xxiv) business development&#59; (xxv) intellectual property (e.g., patents)&#59; (xxvi) product development&#59; (xxvii) regulatory activity&#59; (xxviii) information technology&#59; (xxix) financings&#59; (xxx) product quality control&#59; (xxxi) management&#59; (xxxii) human resources&#59; (xxxiii) corporate governance&#59; (xxxiv) compliance program&#59; (xxxv) legal matters&#59; (xxxvi) internal controls&#59; (xxxvii) policies and procedures&#59; (xxxviii) accounting and reporting&#59; (xxxix) strategic alliances, licensing and partnering&#59; (xl) site, plant or building development&#59; (xli) corporate transactions including without limitation mergers, acquisitions, divestitures and&#47;or joint ventures&#59; (xlii) customer satisfaction&#59; (xliii) capital expenditures and&#47;or (xliv) Company advancement milestones. Awards issued to individuals who are not Covered Employees (or which are not intended to qualify as performance-based compensation under Code Section 162(m)) may take into account other (or no) factors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(hh)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any period of time as determined by the Committee, in its sole discretion. The Committee may establish different Performance Periods for different Participants, and the Committee may establish concurrent or overlapping Performance Periods.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means this LifeVantage Corporation 2017 Long-Term Incentive Plan as it may be amended from time to time.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(jj)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Prior Equity Compensation Plan Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an award outstanding under a Prior Equity Compensation Plan as of the September 2022 Amendment. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(kk)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Prior Equity Compensation Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Company&#8217;s 2010 Long-Term Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">2010 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), 2007 Long-Term Incentive Plan (as assumed from Lifeline Therapeutics, Inc., a Colorado corporation) and its predecessor plans and any other Company equity compensation plans.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ll)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Re-Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means that the Company has lowered or reduced the Exercise Price of outstanding Options and&#47;or outstanding SARs for any Participant(s) in a manner described by SEC Regulation S-K Item 402(d)(2)(viii) (or as described in any successor provision(s) or definition(s)).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(mm)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Restricted Stock Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means Shares awarded under the Plan as provided in Section 9.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(nn)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Restricted Stock Grant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the agreement described in Section 9 evidencing each Award of a Restricted Stock Grant.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(oo)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">SAR Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the agreement described in Section 8 evidencing each Award of a Stock Appreciation Right.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(pp)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(qq)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means those officers, directors or other persons who are subject to Section 16 of the Exchange Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(rr)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ss)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Selected Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an Employee, Consultant, Director, or Non-Employee Director who has been selected by the Committee to receive an Award under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(tt)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a Participant&#8217;s separation from service with the Company within the meaning provided to such term under Code Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(uu)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means service as an Employee, Director, Non-Employee Director or Consultant. Service will be deemed terminated as soon as the entity to which Service is being provided is no longer either (i) the Company, (ii) a Parent, (iii) a Subsidiary or (iv) an Affiliate. A Participant&#8217;s Service does not terminate if he or she is a common-law employee with respect to the Company, a Parent, a Subsidiary or an Affiliate and goes on a bona fide leave of absence that was approved by the Company in writing and the terms of the leave provide for continued service crediting, or when continued service crediting is required by applicable law. However, for purposes of determining whether an Option is entitled to continuing ISO status, a common-law employee&#8217;s Service will be treated as terminating ninety (90) days after such Employee went on leave, unless such Employee&#8217;s right to return to active work is guaranteed by law or by a contract. Service terminates in any event when the approved leave ends, unless such Employee immediately returns to active work. The Committee determines which leaves count toward Service, and when Service commences and terminates for all purposes under the Plan. For avoidance of doubt, a Participant&#8217;s Service shall not be deemed terminated if the Committee determines that (i) a transition of employment to service with a partnership, joint venture or corporation not meeting the requirements of a Subsidiary in which the Company or a Subsidiary is a party is not considered a termination of Service, (ii) the Participant transfers between service as an Employee and service as a Consultant or other personal service provider (or vice versa), or (iii) the Participant transfers between service as an Employee and that of a Non-Employee Director (or vice versa). The Committee may determine whether any company transaction, such as a sale or spin-off of a division or subsidiary that employs a Participant, shall be deemed to result in termination of Service for purposes of any affected Awards, and the Committee&#8217;s decision shall be final and binding.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(vv)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means one share of Common Stock.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ww)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stockholder Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the date that the Company&#8217;s stockholders approve this Plan provided that such approval must occur on or before the first anniversary of the Adoption Date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(xx)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a Participant who is considered a &#8220;specified employee&#8221; within the meaning provided to such term under Code Section 409A.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(yy)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a stock appreciation right awarded under the Plan which provides the holder with a right to potentially receive, in cash and&#47;or Shares, value with respect to a specific number of Shares, as provided in Section 8.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(zz)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the agreement described in Section 6 evidencing each Award of an Option.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(aaa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means a bookkeeping entry representing the equivalent of one Share, as awarded under the Plan and as provided in Section 10.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(bbb)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the agreement described in Section 10 evidencing each Award of Stock Units.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ccc)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the Adoption Date shall be considered a Subsidiary commencing as of such date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ddd)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means the date on which a Participant&#8217;s Service terminates as determined by the Committee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(eee)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">10-Percent Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; means an individual who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, its Parent or any of its Subsidiaries. In determining stock ownership, the attribution rules of Section 424(d) of the Code shall be applied.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 3.  ADMINISTRATION</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Committee Composition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  A Committee appointed by the Board shall administer the Plan. Unless the Board provides otherwise, the Board&#8217;s compensation committee (or a comparable committee of the Board) shall be the Committee. The Board may also at any time terminate the functions of the Committee and re-assume all powers and authority previously delegated to the Committee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To the extent required, the Committee shall have membership composition which enables (i) Awards to Section 16 Persons to qualify as exempt from liability under Section 16(b) of the Exchange Act and (ii) Awards to Covered Employees to be able to qualify as performance-based compensation as provided under Code Section 162(m) (to the extent such Awards are intended to qualify as performance-based compensation).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Board may also appoint one or more separate committees of the Board, each composed of directors of the Company who need not qualify under Rule 16b-3 of the Exchange Act or Code Section 162(m), that may administer the Plan with respect to Selected Employees who are not Section 16 Persons or Covered Employees, respectively, may grant Awards under the Plan to such Selected Employees and may determine all terms of such Awards. To the extent permitted by applicable law, the Board may also appoint a committee, composed of one or more Officers, that may authorize Awards to Employees (who are not Section 16 Persons or Covered Employees) within parameters specified by the Board and consistent with any limitations imposed by applicable law.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Committee shall comply with rules and regulations applicable to it, including under the rules of any exchange on which the Shares are traded.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Notwithstanding the foregoing, the Board shall constitute the Committee and shall administer the Plan with respect to all Awards granted to Non-Employee Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Authority of the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Subject to the provisions of the Plan, the Committee shall have full authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan. Such actions shall include without limitation&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;determining Selected Employees who are to receive Awards under the Plan&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;determining the type, number, vesting requirements, Performance Goals (if any) and their degree of satisfaction, and other features and conditions of such Awards and amending such Awards&#59;</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii)&#160;&#160;&#160;&#160;correcting any defect, supplying any omission, or reconciling or clarifying any inconsistency in the Plan or any Award Agreement&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iv)&#160;&#160;&#160;&#160;accelerating the vesting, or extending the post-termination exercise term, or waiving restrictions, of Awards at any time and under such terms and conditions as it deems appropriate&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(v)&#160;&#160;&#160;&#160;interpreting the Plan and any Award Agreements&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(vi)&#160;&#160;&#160;&#160;making all other decisions relating to the operation of the Plan&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(vii)&#160;&#160;&#160;&#160;adopting such plans or subplans as may be deemed necessary or appropriate to provide for the participation by non-U.S. employees of the Company and its Subsidiaries and Affiliates, which plans and&#47;or subplans shall be attached hereto as appendices.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Committee may adopt such rules or guidelines, as it deems appropriate to implement the Plan. The Committee&#8217;s determinations under the Plan shall be final, conclusive and binding on all persons. The Committee&#8217;s decisions and determinations need not be uniform and may be made selectively among Participants in the Committee&#8217;s sole discretion. The Committee&#8217;s decisions and determinations will be afforded the maximum deference provided by applicable law.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the maximum extent permitted by applicable law, each member of the Committee, or of the Board, or any persons (including without limitation Employees and Officers) who are delegated by the Board or Committee to perform oversight or administrative functions in connection with the Plan, shall be indemnified and held harmless by the Company against and from (i) any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or any Award Agreement, and (ii) from any and all amounts paid by him or her in settlement thereof, with the Company&#8217;s approval, or paid by him or her in satisfaction of any judgment in any such claim, action, suit, or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company&#8217;s Articles of Incorporation or Bylaws, by contract, as a matter of law, or otherwise, or under any power that the Company may have to indemnify them or hold them harmless.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 4.  GENERAL</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">General Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Only Employees, Consultants, Directors and Non-Employee Directors shall be eligible for designation as Selected Employees by the Committee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Incentive Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Only Selected Employees who are common-law employees of the Company, a Parent or a Subsidiary shall be eligible for the grant of ISOs. In addition, a Selected Employee who is a 10-Percent Stockholder shall not be eligible for the grant of an ISO unless the requirements set forth in Section 422(c)(5) of the Code are satisfied. If and to the extent that any Shares are issued under a portion of any Option that exceeds the $100,000 limitation of Section 422 of the Code, such Shares shall not be treated as issued under an ISO notwithstanding any designation otherwise. Certain decisions, amendments, interpretations and actions by the Committee and certain actions by a Participant may cause an Option to cease to qualify as an ISO pursuant to the Code and by accepting an Option the Participant agrees in advance to such disqualifying action.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Restrictions on Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Any Shares issued pursuant to an Award shall be subject to such Company policies, rights of repurchase, rights of first refusal and other transfer restrictions as the Committee may determine. Such restrictions shall apply in addition to any restrictions that may apply to holders of Shares generally and shall also comply to the extent necessary with applicable law. In no event shall the Company be required to issue fractional Shares under this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  A Participant may designate one or more beneficiaries with respect to an Award by timely filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Participant&#8217;s death. If no beneficiary was designated or if no designated beneficiary survives the Participant, then after a Participant&#8217;s death any vested Award(s) shall be transferred or distributed to the Participant&#8217;s estate.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Committee may, in its discretion, include Performance Goals or other performance objectives in any Award. If Performance Goals are included in Awards to Covered Employees in order to enable such Awards </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">to qualify as performance-based compensation under Code Section 162(m), then such Awards will be subject to the achievement of such Performance Goals that will be established and administered pursuant to the requirements of Code Section 162(m) and as described in this Section 4(e). If an Award is intended to qualify as performance-based compensation under Code Section 162(m) and to the extent required by Code Section 162(m), the Committee shall certify in writing the degree to which the Performance Goals have been satisfied before any Shares underlying an Award or any Award payments are released to a Covered Employee with respect to a Performance Period. Without limitation, the approved minutes of a Committee meeting shall constitute such written certification. With respect to Awards that are intended to qualify as performance-based compensation under Code Section 162(m), the Committee may adjust the evaluation of performance under a Performance Goal (to the extent permitted by Code Section 162(m)) to remove the effects of certain events including without limitation the following&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;asset write-downs or discontinued operations,</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;litigation or claim judgments or settlements,</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii)&#160;&#160;&#160;&#160;material changes in or provisions under tax law, accounting principles or other such laws or provisions affecting reported results,</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iv)&#160;&#160;&#160;&#160;reorganizations or restructuring programs or divestitures or acquisitions, and&#47;or</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(v)&#160;&#160;&#160;&#160;extraordinary non-recurring items as described in applicable accounting principles and&#47;or items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Notwithstanding satisfaction of any completion of any Performance Goal, to the extent specified at the time of grant of an Award, the number of Shares, Options, SARs, Stock Units or other benefits granted, issued, retainable and&#47;or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further considerations as the Committee in its sole discretion shall determine. Awards with Performance Goals or performance objectives (if any) that are granted to Selected Employees who are not Covered Employees or any Awards to Covered Employees which are not intended to qualify as performance-based compensation under Code Section 162(m) need not comply with the requirements of Code Section 162(m).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">No Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  A Participant, or a transferee of a Participant, shall have no rights as a stockholder (including without limitation voting rights or dividend or distribution rights) with respect to any Common Stock covered by an Award until such person becomes entitled to receive such Common Stock, has satisfied any applicable withholding or tax obligations relating to the Award and the Common Stock has been issued to the Participant. No adjustment shall be made for cash or stock dividends or other rights for which the record date is prior to the date when such Common Stock is issued, except as expressly provided in Section 11. For the avoidance of doubt, no Award shall allow for the payment of dividends with respect to any portion of the Award that does not vest or as to which applicable vesting or performance conditions are not satisfied.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Unless the applicable Award Agreement or employment agreement provides otherwise (and in such case, the Award or employment agreement shall govern as to the consequences of a termination of Service for such Awards), the following rules shall govern the vesting, exercisability and term of outstanding Awards held by a Participant in the event of termination of such Participant&#8217;s Service (in all cases subject to the term of the Option or SAR as applicable)&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;if the Service of a Participant is terminated for Cause, then all of the Participant&#8217;s Options, SARs, unvested portions of Stock Units and unvested portions of Restricted Stock Grants shall terminate and be forfeited immediately without consideration as of the Termination Date (except for repayment of any amounts the Participant had previously paid to the Company to acquire Shares underlying the forfeited Awards)&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;if the Service of Participant is terminated for any reason other than for Cause and other due to the Participant&#8217;s death or Disability, then the vested portion of the Participant&#8217;s then-outstanding Options&#47;SARs may be exercised by such Participant or his or her personal representative within three months after the Termination Date and all unvested portions of the Participant&#8217;s outstanding Awards shall be forfeited without consideration as of the Termination Date (except for </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">repayment of any amounts the Participant had previously paid to the Company to acquire Shares underlying the forfeited Awards)&#59; or</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii)&#160;&#160;&#160;&#160;if the Service of a Participant is terminated due to the Participant&#8217;s death or Disability, the vested portion of the Participant&#8217;s then outstanding Options&#47;SARs may be exercised within twelve months after the Termination Date and all unvested portions of any outstanding Awards shall be forfeited without consideration as of the Termination Date (except for repayment of any amounts the Participant had previously paid to the Company to acquire Shares underlying the forfeited Awards).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Notwithstanding anything in the Plan to the contrary, the Plan and Awards granted hereunder are intended to comply with the requirements of Code Section 409A and shall be interpreted in a manner consistent with such intention. In the event that any provision of the Plan or an Award Agreement is determined by the Committee to not comply with the applicable requirements of Code Section 409A and the Treasury Regulations and other guidance issued thereunder, the Committee shall have the authority to take such actions and to make such changes to the Plan or an Award Agreement as the Committee deems necessary to comply with such requirements, provided that no such action shall adversely affect any outstanding Award without the consent of the affected Participant. Each payment to a Participant made pursuant to this Plan shall be considered a separate payment and not one of a series of payments for purposes of Code Section 409A. Notwithstanding the foregoing or anything elsewhere in the Plan or an Award Agreement to the contrary, if upon a Participant&#8217;s Separation From Service he&#47;she is then a Specified Employee, then solely to the extent necessary to comply with Code Section 409A and avoid the imposition of taxes under Code Section 409A, the Company shall defer payment of &#8220;nonqualified deferred compensation&#8221; subject to Code Section 409A payable as a result of and within six (6) months following such Separation From Service under this Plan until the earlier of (i) the first business day of the seventh month following the Participant&#8217;s Separation From Service, or (ii) ten (10) days after the Company receives written confirmation of the Participant&#8217;s death. Any such delayed payments shall be made without interest. In no event whatsoever shall the Company be liable for any additional tax, interest or penalties that may be imposed on a Participant by Code Section 409A or for any damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Suspension or Termination of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  If at any time (including after a notice of exercise has been delivered) the Committee (or the Board), reasonably believes that a Participant has committed an act of Cause (which includes a failure to act), the Committee (or Board) may suspend the Participant&#8217;s right to exercise any Option or SAR (or payment of a Cash Award or vesting of Restricted Stock Grants or Stock Units) pending a determination of whether there was in fact an act of Cause. If the Committee (or the Board) determines a Participant has committed an act of Cause, neither the Participant nor his or her estate shall be entitled to exercise any outstanding Option or SAR whatsoever and all of Participant&#8217;s outstanding Awards shall then terminate without consideration. Any determination by the Committee (or the Board) with respect to the foregoing shall be final, conclusive and binding on all interested parties.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(j) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Electronic Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Subject to compliance with applicable law and&#47;or regulations, an Award Agreement or other documentation or notices relating to the Plan and&#47;or Awards may be communicated to Participants by electronic media.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Unfunded Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Insofar as it provides for Awards, the Plan shall be unfunded. Although bookkeeping accounts may be established with respect to Participants who are granted Awards under this Plan, any such accounts will be used merely as a bookkeeping convenience. The Company shall not be required to segregate any assets which may at any time be represented by Awards, nor shall this Plan be construed as providing for such segregation, nor shall the Company or the Committee be deemed to be a trustee of stock or cash to be awarded under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Liability of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Company (or members of the Board or Committee) shall not be liable to a Participant or other persons as to&#58; (a) the non-issuance or sale of Shares as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder&#59; and (b) any unexpected or adverse tax consequence or any tax consequence expected, but not realized, by any Participant or other person due to the grant, receipt, exercise or settlement of any Award granted hereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Reformation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  In the event any provision of this Plan shall be held illegal or invalid for any reason, such provisions will be reformed by the Board if possible and to the extent needed in order to be held legal and valid. If it is not </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">possible to reform the illegal or invalid provisions then the illegality or invalidity shall not affect the remaining parts of this Plan, and this Plan shall be construed and enforced as if the illegal or invalid provision had not been included.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(n) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Re-Pricing of Options or SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Notwithstanding anything to the contrary, without the approval of Company stockholders and except as provided in Section 11(a), outstanding Options or SARs may not be re-priced, replaced or regranted (i) through cancellation, whether in exchange for cash or another type of Award, (ii) by lowering the Exercise Price of a previously granted Option or SAR or (iii) by replacing a previously granted Option or SAR with a new Option or SAR with a lower Exercise Price.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Successor Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Any reference to a statute, rule or regulation, or to a section of a statute, rule or regulation, is a reference to that statute, rule, regulation, or section as amended from time to time, both before and after the Adoption Date and including any successor provisions.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  This Plan and all Awards shall be construed in accordance with and governed by the laws of the State of Utah but without regard to its conflict of law provisions. The Committee may provide that any dispute as to any Award shall be presented and determined in such forum as the Committee may specify, including through binding arbitration. Unless otherwise provided in the Award Agreement, recipients of an Award under the Plan are deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of Utah to resolve any and all issues that may arise out of or relate to the Plan or any related Award Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Minimum Vesting Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> No Award granted on or after July 1, 2018 shall vest, become exercisable or be settled on a date that is earlier than the first anniversary of the grant date of the Award&#59; provided however that this minimum vesting and exercisability requirement shall not apply (i) to up to 5% of the aggregate number of shares reserved for issuance hereunder, (ii) if Section 12 applies, or (iii) with respect to an Award held by a Participant whose Service terminates as a result of his or her death or disability. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 5.  SHARES SUBJECT TO PLAN AND SHARE LIMITS</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Basic Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Common Stock issuable under the Plan shall be authorized but unissued Shares or treasury Shares. Subject to adjustment as provided in Section 11, the maximum aggregate number of Shares that may be issued under the Plan shall not exceed the sum of (i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4,630,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> Shares, (ii) the number of Shares reserved under the 2010 Plan that are not issued or subject to outstanding awards under the 2010 Plan on the Stockholder Approval Date, (iii) any Shares subject to outstanding options or other awards under the 2010 Plan on the Stockholder Approval Date that subsequently expire or lapse unexercised and Shares issued pursuant to awards granted under the 2010 Plan that are outstanding on the Stockholder Approval Date and that are subsequently forfeited to or repurchased by the Company, and (iv) the additional Shares described in Section 5(b)&#59; provided, however, that no more than 475,000 Shares, in the aggregate, shall be added to the Plan pursuant to clauses (ii) and (iii). No more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5,105,000 S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">hares plus the additional Shares described in Section 5(b) may be issued under the Plan upon the exercise of ISOs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Share Re-Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  If Equity Awards are forfeited or are terminated for any reason other than being exercised, then the Shares underlying such Equity Awards shall again become available for Equity Awards under the Plan. If SARs are exercised or Stock Units are settled in Shares, then only the number of Shares (if any) actually issued in settlement of such SARs or Stock Units shall reduce the number of Shares available under the Share limits stated in Section 5(a) and the balance shall again become available for Equity Awards under the Plan. If a Participant pays the Exercise Price by Net Exercise or by surrendering previously owned Shares (or by stock attestation) and&#47;or, as permitted by the Committee, pays any withholding tax obligation with respect to an Equity Award by electing to have Shares withheld or surrendering previously owned Shares (or by stock attestation), the surrendered Shares and the Shares withheld to pay taxes shall be available for issuance under the Plan and shall not count toward the Share limits set forth in Section 5(a). Any Shares that are delivered and any Equity Awards that are granted by, or become obligations of, the Company, as a result of the assumption by the Company of, or in substitution for, outstanding awards previously granted by another entity (as provided in Sections 6(e), 8(f), 9(e) or 10(e)) shall not be counted against the Share limits specified in Sections 5(a) and 5(d). Notwithstanding the foregoing, following the September 2022 Amendment, the following Shares shall not become or again be available for grants of Awards under the Plan&#58; (a) Shares delivered (either by actual delivery or stock attestation) to the Company by a Participant or withheld by the Company to satisfy the applicable exercise price of an Option or Prior Equity Compensation Plan Award that is an option and&#47;or satisfy any </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">applicable tax withholding obligation with respect to an Option or Stock Appreciation Right or Prior Equity Compensation Plan Award that is an option or stock appreciation right (including Shares retained by the Company from the Option or Stock Appreciation Right or Prior Equity Compensation Plan Award that is an option or a stock appreciation right being exercised and&#47;or creating the tax obligation), (b) Shares subject to a Stock Appreciation Right that are not issued in connection with the settlement or exercise, as applicable, of the Stock Appreciation Right, and (c) Shares purchased on the open market with the cash proceeds from the exercise of Options.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Any dividend equivalents distributed under the Plan shall not be applied against the number of Shares available for Equity Awards.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Code Section 162(m) Limits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  For so long as&#58; (x) the Company is a &#8220;publicly held corporation&#8221; within the meaning of Code Section 162(m) and (y) the deduction limitations of Code Section 162(m) are applicable to Awards granted to the Company&#8217;s Covered Employees under this Plan, then the limits specified below in this Section 5(d) shall be applicable to Awards issued under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  No Selected Employee shall receive Options to purchase Shares during any Fiscal Year that in the aggregate cover in excess of 300,000 Shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  No Selected Employee shall receive Awards of SARs during any Fiscal Year that in the aggregate cover in excess of 300,000 Shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Restricted Stock Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  No Selected Employee shall receive Restricted Stock Grants during any Fiscal Year that in the aggregate cover in excess of 300,000 Shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Limits on Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  No Selected Employee shall receive Stock Units during any Fiscal Year that in the aggregate cover in excess of 300,000 Shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Limit on Total Amount of All Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Notwithstanding anything to the contrary contained herein, no Selected Employee shall receive Equity Awards during any Fiscal Year in excess of the aggregate amount of 600,000 Shares, whether such Equity Awards are in the form of Options, SARs, Restricted Stock Grants and&#47;or Stock Units.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Increased Limits for First Year of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The numerical limits expressed in the foregoing subparts (i) through (iv) shall in each case be increased to 600,000 Shares with respect to Equity Awards granted to a Selected Employee during the Fiscal Year of the Selected Employee&#8217;s commencement of employment with the Company or during the first Fiscal Year that the Selected Employee becomes a Covered Employee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Dollar Limit for Cash Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The maximum aggregate value of Cash Awards that may be received by any one Selected Employee with respect to any individual Fiscal Year is $5,000,000.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 6.  TERMS AND CONDITIONS OF OPTIONS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Award of an Option under the Plan shall be evidenced by a Stock Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with the Plan (including without limitation any Performance Goals). The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. The Stock Option Agreement shall also specify whether the Option is an ISO and if not specified then the Option shall be an NSO.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and is subject to adjustment of such number in accordance with Section 11.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  An Option&#8217;s Exercise Price shall be established by the Committee and set forth in a Stock Option Agreement. Except with respect to outstanding stock options being assumed or Options being granted in exchange for cancellation of outstanding options granted by another issuer as provided under Section 6(e), the Exercise Price of an Option shall not be less than 100% of the Fair Market Value (110% for ISO Awards to 10-Percent Stockholders) on the date of Award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercisability and Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Stock Option Agreement shall specify the date when all or any installment of the Option is to become vested and&#47;or exercisable. The Stock Option Agreement shall also specify the term of the Option&#59; provided that the term of an Option shall in no event exceed ten years from the date of Award (and may be for a shorter period </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of time than ten years). No Option can be exercised after the expiration date specified in the applicable Stock Option Agreement. A Stock Option Agreement may provide for accelerated vesting in the event of the Participant&#8217;s death, or Disability or other events. Notwithstanding the previous sentence, an ISO that is granted to a 10-Percent Stockholder shall have a maximum term of five years. Notwithstanding any other provision of the Plan, no Option can be exercised after the expiration date provided in the applicable Stock Option Agreement. In no event shall the Company be required to issue fractional Shares upon the exercise of an Option and the Committee may specify a minimum number of Shares that must be purchased in any one Option exercise.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Modifications or Assumption of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Within the limitations of the Plan, the Committee may modify, extend or assume outstanding Options or may accept the cancellation of outstanding stock options (whether granted by the Company or by another issuer) in return for the grant of new Options for the same or a different number of Shares and at the same or a different Exercise Price. For avoidance of doubt, in accordance with Section 4(n), the Committee may not Re-Price outstanding Options without approval from the Company's stockholders, except as provided in Section 11(a). No modification of an Option shall, without the consent of the Optionee, impair his or her rights or increase his or her obligations under such Option.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Assignment or Transfer of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as otherwise provided in the applicable Stock Option Agreement and then only to the extent permitted by applicable law, no Option shall be transferable by the Optionee other than by will or by the laws of descent and distribution. Except as otherwise provided in the applicable Stock Option Agreement, an Option may be exercised during the lifetime of the Optionee only by Optionee or by the guardian or legal representative of the Optionee. No Option or interest therein may be assigned, pledged or hypothecated by the Optionee during his or her lifetime, whether by operation of law or otherwise, or be made subject to execution, attachment or similar process.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 7.  PAYMENT FOR OPTION SHARES</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The entire Exercise Price of Shares issued upon exercise of Options shall be payable in cash at the time when such Shares are purchased by the Optionee, except as follows and if so provided for in an applicable Stock Option Agreement&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;In the case of an ISO granted under the Plan, payment shall be made only pursuant to the express provisions of the applicable Stock Option Agreement. The Stock Option Agreement may specify that payment may be made in any form(s) described in this Section 7.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;In the case of an NSO granted under the Plan, the Committee may, in its discretion at any time, accept payment in any form(s) described in this Section 7.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Surrender of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the extent that the Committee makes this Section 7(b) applicable to an Option in a Stock Option Agreement, payment for all or a part of the Exercise Price may be made with Shares which have already been owned by the Optionee for such duration as shall be specified by the Committee. Such Shares shall be valued at their Fair Market Value on the date when the new Shares are purchased under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the extent that the Committee makes this Section 7(c) applicable to an Option in a Stock Option Agreement, payment for all or a part of the Exercise Price may be made through Cashless Exercise.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Net Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the extent that the Committee makes this Section 7(d) applicable to an Option in a Stock Option Agreement, payment for all or a part of the Exercise Price may be made through Net Exercise.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Other Forms of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the extent that the Committee makes this Section 7(e) applicable to an Option in a Stock Option Agreement, payment may be made in any other form that is consistent with applicable laws, regulations and rules and approved by the Committee.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 8.  TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">SAR Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Award of a SAR under the Plan shall be evidenced by a SAR Agreement between the Participant and the Company. Such SAR shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan (including without limitation any Performance Goals). A SAR Agreement may provide for a maximum limit on the amount of any payout notwithstanding the Fair Market Value on the date of exercise of the SAR. The provisions of the various SAR Agreements entered into under the Plan need not be identical.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each SAR Agreement shall specify the number of Shares to which the SAR pertains and is subject to adjustment of such number in accordance with Section 11.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each SAR Agreement shall specify the Exercise Price. Except with respect to outstanding stock appreciation rights being assumed or SARs being granted in exchange for cancellation of outstanding stock appreciation rights granted by another issuer as provided under Section 8(f), the Exercise Price of a SAR shall not be less than 100% of the Fair Market Value on the date of Award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercisability and Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each SAR Agreement shall specify the date when all or any installment of the SAR is to become exercisable. The SAR Agreement shall also specify the term of the SAR which shall not exceed ten years from the date of Award. No SAR can be exercised after the expiration date specified in the applicable SAR Agreement. A SAR Agreement may provide for accelerated exercisability in the event of the Participant&#8217;s death, or Disability or other events and may provide for expiration prior to the end of its term in the event of the termination of the Participant&#8217;s Service. A SAR may be included in an ISO only at the time of Award but may be included in an NSO at the time of Award or at any subsequent time, but not later than six months before the expiration of such NSO. A SAR granted under the Plan may provide that it will be exercisable only in the event of a Change in Control.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Exercise of SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  If, on the date when a SAR expires, the Exercise Price under such SAR is less than the Fair Market Value on such date but any portion of such SAR has not been exercised or surrendered, then such SAR may automatically be deemed to be exercised as of such date with respect to such portion to the extent so provided in the applicable SAR agreement. Upon exercise of a SAR, the Participant (or any person having the right to exercise the SAR after the Participant&#8217;s death) shall receive from the Company (i) Shares, (ii) cash or (iii) any combination of Shares and cash, as the Committee shall determine. The amount of cash and&#47;or the Fair Market Value of Shares received upon exercise of SARs shall, in the aggregate, be equal to the amount by which the Fair Market Value (on the date of surrender) of the Shares subject to the SARs exceeds the Exercise Price of the Shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Modification or Assumption of SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Within the limitations of the Plan, the Committee may modify, extend or assume outstanding SARs or may accept the cancellation of outstanding SARs (including stock appreciation rights granted by another issuer) in return for the grant of new SARs for the same or a different number of Shares and at the same or a different Exercise Price.  For avoidance of doubt, in accordance with Section 4(n), the Committee may not Re-Price outstanding SARs without approval from the Company's stockholders, except as provided in Section 11(a).  No modification of a SAR shall, without the consent of the Participant, impair his or her rights or increase his or her obligations under such SAR.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Assignment or Transfer of SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as otherwise provided in the applicable SAR Agreement and then only to the extent permitted by applicable law, no SAR shall be transferable by the Participant other than by will or by the laws of descent and distribution. Except as otherwise provided in the applicable SAR Agreement, a SAR may be exercised during the lifetime of the Participant only by the Participant or by the guardian or legal representative of the Participant. No SAR or interest therein may be assigned, pledged or hypothecated by the Participant during his or her lifetime, whether by operation of law or otherwise, or be made subject to execution, attachment or similar process.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 9.  TERMS AND CONDITIONS FOR RESTRICTED STOCK GRANTS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Restricted Stock Grant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Restricted Stock Grant awarded under the Plan shall be evidenced by a Restricted Stock Grant Agreement between the Participant and the Company. Each Restricted Stock Grant shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with the Plan (including without limitation any Performance Goals). The provisions of the Restricted Stock Grant Agreements entered into under the Plan need not be identical.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Number of Shares and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Restricted Stock Grant Agreement shall specify the number of Shares to which the Restricted Stock Grant pertains and is subject to adjustment of such number in accordance with Section 11. Restricted Stock Grants may be issued with or without cash consideration under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Vesting Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Restricted Stock Grant may or may not be subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Restricted Stock Grant Agreement. A Restricted Stock Grant Agreement may provide for accelerated vesting in the event of the Participant&#8217;s death, or Disability or other events.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Voting and Dividend Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The holder of a Restricted Stock Grant (irrespective of whether the Shares subject to the Restricted Stock Grant are vested or unvested) awarded under the Plan shall have the same voting, dividend and other rights as the Company's other stockholders&#59; provided however that any dividends attributed to Shares that are unvested (whether such dividends are in the form of cash or Shares) shall be subject to the same vesting conditions and restrictions as the Restricted Stock Grant with respect to which the dividends relate&#59; and provided further that this sentence is subject to the final sentence of Section 4(f). Such additional Shares issued as dividends that are subject to the Restricted Stock Grant shall not reduce the number of Shares available for issuance under Section 5.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Modification or Assumption of Restricted Stock Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Within the limitations of the Plan, the Committee may modify or assume outstanding Restricted Stock Grants or may accept the cancellation of outstanding Restricted Stock Grants (including stock granted by another issuer) in return for the grant of new Restricted Stock Grants for the same or a different number of Shares. No modification of a Restricted Stock Grant shall, without the consent of the Participant, impair his or her rights or increase his or her obligations under such Restricted Stock Grant.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Assignment or Transfer of Restricted Stock Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as provided in Section 14, or in a Restricted Stock Grant Agreement, or as required by applicable law, a Restricted Stock Grant awarded under the Plan shall not be anticipated, assigned, attached, garnished, optioned, transferred or made subject to any creditor's process, whether voluntarily, involuntarily or by operation of law. Any act in violation of this Section 9(f) shall be void. However, this Section 9(f) shall not preclude a Participant from designating a beneficiary pursuant to Section 4(d) nor shall it preclude a transfer of Restricted Stock Grant Awards by will or pursuant to Section 4(d).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 10.  TERMS AND CONDITIONS OF STOCK UNITS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Stock Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Award of Stock Units under the Plan shall be evidenced by a Stock Unit Agreement between the Participant and the Company. Such Stock Units shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan (including without limitation any Performance Goals). The provisions of the various Stock Unit Agreements entered into under the Plan need not be identical.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Number of Shares and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Stock Unit Agreement shall specify the number of Shares to which the Stock Unit Grant pertains and is subject to adjustment of such number in accordance with Section 11. To the extent that an Award is granted in the form of Stock Units, no cash consideration shall be required of the Award recipients.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Vesting Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Each Award of Stock Units may or may not be subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Stock Unit Agreement. A Stock Unit Agreement may provide for accelerated vesting in the event of the Participant&#8217;s death, or Disability or other events.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Voting and Dividend Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The holders of Stock Units shall have no voting rights. Prior to settlement or forfeiture, any Stock Unit awarded under the Plan may, at the Committee&#8217;s discretion, carry with it a right to dividend equivalents. Such right entitles the holder to be credited with an amount equal to all cash or Common Stock dividends paid on one Share while the Stock Unit is outstanding. Dividend equivalents may be converted into additional Stock Units. Settlement of dividend equivalents may be made in the form of cash, in the form of Shares, or in a combination of both. Prior to vesting of the Stock Units, any dividend equivalents accrued on such unvested Stock Units shall be subject to the same vesting conditions and restrictions as the Stock Units to which they attach, provided that this sentence is subject to the final sentence of Section 4(f).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Modification or Assumption of Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Within the limitations of the Plan, the Committee may modify or assume outstanding Stock Units or may accept the cancellation of outstanding Stock Units (including stock units granted by another issuer) in return for the grant of new Stock Units for the same or a different number of Shares. No modification of a Stock Unit shall, without the consent of the Participant, impair his or her rights or increase his or her obligations under such Stock Unit.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Assignment or Transfer of Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as provided in Section 14, or in a Stock Unit Agreement, or as required by applicable law, Stock Units shall not be anticipated, assigned, attached, garnished, optioned, transferred or made subject to any creditor&#8217;s process, whether voluntarily, involuntarily or by operation of law. Any act in violation of this Section 10(f) shall be void. However, this Section 10(f) shall not preclude a Participant from designating a beneficiary pursuant to Section 4(d) nor shall it preclude a transfer of Stock Units pursuant to Section 4(d).</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Form and Time of Settlement of Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Settlement of vested Stock Units may be made in the form of (a) cash, (b) Shares or (c) any combination of both, as determined by the Committee. The actual number of Stock Units eligible for settlement may be larger or smaller than the number included in the original Award. Methods of converting Stock Units into cash may include (without limitation) a method based on the average Fair Market Value of Shares over a series of trading days. Except as otherwise provided in a Stock Unit Agreement or a timely completed deferral election, vested Stock Units shall be settled within thirty days after vesting. The distribution may occur or commence when all vesting conditions applicable to the Stock Units have been satisfied or have lapsed, or it may be deferred, in accordance with applicable law, to a later specified date. The amount of a deferred distribution may be increased by an interest factor or by dividend equivalents. Until an Award of Stock Units is settled, the number of such Stock Units shall be subject to adjustment pursuant to Section 11.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Creditors' Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  A holder of Stock Units shall have no rights other than those of a general creditor of the Company. Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Stock Unit Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 11.  ADJUSTMENTS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  In the event of a subdivision of the outstanding Shares, a declaration of a dividend payable in Shares, a declaration of a dividend payable in a form other than Shares in an amount that has a material effect on the price of Shares, a combination or consolidation of the outstanding Shares (by reclassification or otherwise) into a lesser number of Shares, a stock split, a reverse stock split, a reclassification or other distribution of the Shares without the receipt of consideration by the Company, of or on the Common Stock, a recapitalization, a combination, a spin-off or a similar occurrence, the Committee shall make equitable and proportionate adjustments to&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;the number and kind of securities available for Equity Awards (and which can be issued as ISOs) under Section 5&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(ii)&#160;&#160;&#160;&#160;the Share limits on Equity Awards issued under the Plan that are intended to qualify as performance-based compensation under Code Section 162(m) under Section 5(d)&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iii)&#160;&#160;&#160;&#160;the number and kind of securities covered by each outstanding Equity Award&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(iv)&#160;&#160;&#160;&#160;the Exercise Price under each outstanding SAR and Option, and the repurchase price, if any, applicable to the unvested portion of Restricted Stock Grants&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(v)&#160;&#160;&#160;&#160;the number and kind of outstanding securities issued under the Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Participant Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as provided in this Section 11, a Participant shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class. If by reason of an adjustment pursuant to this Section 11, a Participant&#8217;s Equity Award covers additional or different shares of stock or securities, then such additional or different shares and the Equity Award in respect thereof shall be subject to all of the terms, conditions and restrictions which were applicable to the Equity Award and the Shares subject to the Equity Award prior to such adjustment.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Any adjustment of Shares pursuant to this Section 11 shall be rounded down to the nearest whole number of Shares. Under no circumstances shall the Company be required to authorize or issue fractional shares. To the extent permitted by applicable law, no consideration shall be provided as a result of any fractional shares not being issued or authorized.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 12.  EFFECT OF A CHANGE IN CONTROL</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Merger or Reorganization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  In the event that the Company is a party to a merger or other reorganization, outstanding Awards shall be subject to the agreement of merger or reorganization. Such agreement may provide, without limitation, that subject to the consummation of the merger or other reorganization, for the assumption (or substitution) of outstanding Awards by the surviving corporation or its parent, for their continuation by the Company (if the Company is a surviving corporation), for their cancellation with or without consideration, in all cases without the consent of the Participant.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Except as otherwise provided in the applicable Award Agreement (and in such case the applicable Award Agreement shall govern), in the event that a Change in Control occurs and there is no assumption, substitution or continuation of Awards pursuant to Section 12(a), (1) with respect to outstanding Awards subject to service-based vesting conditions, 100% of the unvested portion of such Awards shall accelerate and vest immediately upon the Change in Control, and (2) with respect to outstanding Awards subject to performance-based vesting conditions, such Awards shall accelerate and vest upon the Change in Control with respect to the portion of the Award determined based on the greater of (A) target level applicable to the Award or (B) the actual level of achievement measured as of either the end of the applicable Performance Period (if the Performance Period ends prior to the Change in Control but actual performance has not yet been determined) or the effective date of the Change in Control (if the Change in Control occurs prior to the end of the Performance Period), as applicable. For avoidance of doubt, &#8220;substitution&#8221; includes, without limitation, an Award being replaced by a cash award that provides an equivalent intrinsic value (wherein for Equity Awards intrinsic value equals the difference between the market value of a Share and any per Share exercise price).  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 13.  LIMITATIONS ON RIGHTS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Retention Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Neither the Plan nor any Award granted under the Plan shall be deemed to give any individual a right to remain in Service as an Employee, Consultant, Director or Non-Employee Director or to receive any other Awards under the Plan. The Company and its Parents and Subsidiaries and Affiliates reserve the right to terminate the Service of any person at any time, and for any reason, subject to applicable laws, the Company&#8217;s Articles of Incorporation and Bylaws and a written employment agreement (if any).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Regulatory Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  Any other provision of the Plan notwithstanding, the obligation of the Company to issue Shares or other securities under the Plan shall be subject to all applicable laws, rules and regulations and such approval by any regulatory body as may be required. The Company reserves the right to restrict, in whole or in part, the delivery of Shares or other securities pursuant to any Equity Award prior to the satisfaction of all legal requirements relating to the issuance of such Shares or other securities, to their registration, qualification or listing or to an exemption from registration, qualification or listing.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Dissolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  To the extent not previously exercised or settled, Options, SARs, unvested Stock Units and unvested Restricted Stock Grants shall terminate immediately prior to the dissolution or liquidation of the Company and shall be forfeited to the Company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Company may (i) cause the cancellation of any Award, (ii) require reimbursement of any Award by a Participant and (iii) effect any other right of recoupment of equity or other compensation provided under this Plan or otherwise in accordance with Company policies and&#47;or applicable law (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;). In addition, a Participant may be required to repay to the Company certain previously paid compensation, whether provided under this Plan or an Award Agreement or otherwise, in accordance with the Clawback Policy.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 14.  TAXES.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  A Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with his or her Award. The Company shall not be required to issue any Shares or make any cash payment under the Plan until such obligations are satisfied.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Share Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Committee in its discretion may permit or require a Participant to satisfy all or part of his or her withholding or income tax obligations by having the Company withhold all or a portion of any Shares that otherwise would be issued to him or her or by surrendering all or a portion of any Shares that he or she previously acquired (or by stock attestation). Such Shares shall be valued based on the value of the actual trade or, if there is none, the Fair Market Value as of the previous day.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any payment of taxes by assigning Shares to the Company may be subject to restrictions, including, but not limited to, any restrictions required by rules of the SEC. The Committee may also, in its discretion, permit or require a Participant to satisfy withholding or income tax obligations (up to the maximum amount permitted by applicable law) related to an Equity Award through a sale of Shares underlying the Equity Award or, in the case of Options, through Net Exercise or Cashless Exercise.</font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 15.  DURATION AND AMENDMENTS</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Term of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Plan was originally effective on the Adoption Date and was amended on November 16, 2017, January 19, 2018, September 20, 2018, August 27, 2020, September 19, 2022 and September 21, 2023. In any event, the Plan shall terminate no later than on the day before the tenth anniversary of the Adoption Date. The Plan may be terminated by the Board on any earlier date pursuant to Section 15(b). This Plan will not in any way affect outstanding awards that were issued under the Prior Equity Compensation Plans or other Company equity compensation plans.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Right to Amend or Terminate the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.  The Board may amend or terminate the Plan at any time and for any reason. No Awards shall be granted under the Plan after the Plan&#8217;s termination. An amendment of the Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable laws, regulations or rules. In addition, no such amendment or termination shall be made which would impair the rights of any Participant, without such Participant&#8217;s written consent, under any then-outstanding Award, provided that no such Participant consent shall be required with respect to any amendment or alteration if the Committee determines in its sole discretion that such amendment or alteration either (i) is required or advisable in order for the Company, the Plan or the Award to satisfy or conform to any law or regulation or to meet the requirements of any accounting standard, or (ii) is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated. In the event of any conflict in terms between the Plan and any Award Agreement, the terms of the Plan shall prevail and govern.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 16.  EXECUTION</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To record the adoption of this Plan by the Board, the Company has caused its duly authorized Officer to execute this Plan on behalf of the Company.</font></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.292%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">LIFEVANTAGE CORPORATION</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#47;s&#47; Steven R. Fife</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;text-indent:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By&#58; Steven R. Fife</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Title&#58; President and Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>ex109keyexecutivebenefit.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ex109keyexecutivebenefit</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- ex109keyexecutivebenefit001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  1  KEY EXECUTIVE BENEFITS AGREEMENT  LifeVantage Corporation (the &#8220;Company&#8221;) has established this Key Executive Benefits Agreement (the  &#8220;Agreement&#8221;) to attract, motivate and retain certain key executives of the Company.  An employee is  considered a Key Executive upon the recommendation of the CEO and approval by the Company&#8217;s  Compensation Committee.  The terms and conditions of this Agreement are as follows:  1. Position and Responsibilities.  a. As of your hire date or your promotion date as applicable, you will commence serving as  a key management executive of the Company as its [___________________] reporting directly to the  President and CEO.  You shall have the duties, responsibilities and authority that are customarily associated  with such position and such other senior management duties as may reasonably be assigned.  You will  devote your full time, efforts, abilities, and energies to promote the general welfare and interests of the  Company and any related enterprises of the Company.  Unless otherwise approved in writing by the  Company&#8217;s Chief Executive Officer and the Chairman of the Company&#8217;s Board of Directors, your primary  workplace will be located at the Company&#8217;s headquarters located in Lehi, Utah; provided, however, that  you may be required to travel from time to time as reasonably required for business purposes.  b. Nothing herein shall preclude you from (i) serving, with the prior written consent of the  President and CEO, as a member of the board of directors or advisory boards (or their equivalents in the  case of a non-corporate entity) of non-competing businesses and charitable organizations as determined by  the Company in its sole discretion, (ii) engaging in charitable activities and community affairs, and (iii)  managing your personal investments and affairs; provided, however, that the activities set out in clauses (i),  (ii) and (iii) shall be limited by you so as not to materially interfere, individually or in the aggregate, with  the performance of your duties and responsibilities hereunder.  2. Annual Incentive Plan.  As a key executive and during your continued employment as a key  executive, you will be eligible to participate in the Board of Directors&#8217; approved Employee Annual  Incentive Plan, as amended from time to time in the Company&#8217;s sole discretion, at the level indicated in  Exhibit A pursuant to the plan details.  Any Annual Incentive Award (the &#8220;Award&#8221;) shall be paid to you  during the first three months of the fiscal year that follows the applicable performance fiscal year.  The  Award will be deemed to have been earned on the date of payment of such Award and you must remain an  employee of the Company through the date of payment in order to receive the Award.  3. Long Term Incentive Compensation Plan.  As a key executive and during your continued  employment as a key executive, you may be eligible to participate in the Board of Directors&#8217; approved  Employee Equity Plan pursuant to the plan details as amended from time to time in the Company&#8217;s sole  discretion.  Such equity grants, if any, will be made in the sole discretion of the Board of Directors and will  be subject to the terms and conditions specified by the Board of Directors, the Company&#8217;s stock plan, the  award agreement that you must execute as a condition of any grant and the Company&#8217;s insider trading  policy.  If required by applicable law with respect to transactions involving Company equity securities, you  agree that you shall use your best efforts to comply with any duty that you may have to (i) timely report  any such transactions and (ii) to refrain from engaging in certain transactions from time to time.  The  Company has no duty to register under (or otherwise obtain an exemption from) the Securities Act of 1933  (or applicable state securities laws) with respect to any Company equity securities that may be issued to  you.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  2  4. Employee Benefit Programs.    a. During your employment with the Company, and except as may be provided under an  employee stock purchase plan, you will be entitled to participate, in all Company employee benefit plans  and programs at the time or thereafter made available to Key Executives including, without limitation, any  savings or profit sharing plans, deferred compensation plans, stock option incentive plans, group life  insurance, accidental death and dismemberment insurance, hospitalization, surgical, major medical and  dental coverage, vacation, sick leave (including salary continuation arrangements), long-term disability,  holidays and other employee benefit programs sponsored by the Company.    b. LifeVantage will pay all or a portion of the costs associated with the following Company  employee benefit plans:  i. Life Insurance  ii. Long Term Disability  iii. Short Term Disability  iv. Health Insurance  v. Dental Insurance  vi. Vision Insurance  c. The Company may amend, modify or terminate these benefits in its sole discretion at any  time and for any reason.  Any change in any employee benefit program or programs applicable to all  covered key executive employees or all covered employees shall not constitute a material breach of this  Agreement.  5. Termination of Employment.    a. Accrued Pay.  Unless the Company requests otherwise in writing, upon termination of  your employment for any reason, you understand and agree that you shall be deemed to have also  immediately resigned from all positions as a key executive with the Company (and its affiliates) as of your  last day of employment (the &#8220;Termination Date&#8221;).  Upon termination of your employment for any reason,  you shall receive payment or benefits from the Company covering the following: (i) all unpaid salary and  unpaid vacation accrued pursuant to the paid time off policy through the Termination Date, (ii) any  payments/benefits to which you are entitled under the express terms of any applicable Company employee  benefit plan, (iii) any unreimbursed valid business expenses for which you have submitted properly  documented reimbursement requests, and (iv) your then outstanding equity compensation awards as  governed by their applicable terms (collectively, (i) through (iv) are the &#8220;Accrued Pay&#8221;).  You may also be  eligible for other post-employment payments and benefits as provided in this Agreement.  Termination  shall not be made until on or after the date of a &#8220;separation from service&#8221; within the meaning of Code  Section 409A.  b. At-Will Employment.  Your employment with the Company is &#8220;at-will.&#8221; This means that  your employment is not for any specified period of time and can be terminated by you or by the Company  at any time, with or without advance notice or additional payment, and with or without Cause, or for any  reason or no reason at all. It also means that your job duties, title, responsibility and reporting level, and  compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may be changed  at any time, with or without notice, in the Company&#8217;s sole and absolute discretion.  c. For Cause.  For purposes of this Agreement, your employment may be terminated by the  Company for &#8220;Cause&#8221; as a result of the occurrence of one or more of the following:  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  3  i. your refusal, or inability to satisfactorily, in the judgment or your supervisor,  perform in any material respect your duties and responsibilities for the Company (other than any such  failure resulting from incapacity due to physical or mental illness);  ii. willful failure to comply with any valid and legal directive of the Company or the  board;  iii. engagement in dishonesty or conduct (illegal or otherwise), which is, in each case,  materially injurious, or brings public disgrace or disrepute, to the Company or its affiliates;  iv. embezzlement, misappropriation, or fraud, whether or not related to your  employment with the Company;  v. conviction of or plea of guilty or nolo contendere to a crime that constitutes a  felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;  vi. material violation of the Company&#8217;s written policies or codes of conduct,  including, but not limited to, written policies related to discrimination, harassment, performance of illegal  or unethical activities, and ethical misconduct;  vii. unauthorized disclosure of the Company&#8217;s Proprietary Information (as defined in  the Confidentiality Agreement) and/or other confidential, proprietary, and/or trade secret information; or  viii. material breach of any material obligation under this Agreement or any other  written agreement between you and the Company.  In the event your employment is terminated by the Company for Cause you will be entitled only to  your Accrued Pay and you will be entitled to no other compensation from the Company.  d. Without Cause.  The Company may terminate your employment Without Cause at any  time and for any reason.  If your employment is terminated Without Cause then, in addition to your Accrued  Pay, you will be eligible to receive severance consisting of continued base salary (as of your Termination  Date) for a period of [6 / 12] months.  The severance shall be paid to you in cash, less applicable  withholdings, in bi-monthly installments pursuant to the Company&#8217;s normal payroll process beginning on  the first payroll date occurring after expiration of the Release Deadline (as defined below) and revocation  period set forth in the Release (as defined below); provided, however, that if the timeframe from your  Termination Date through the Release Deadline and revocation period spans two calendar years, then the  severance payments shall commence on the first payroll date in the second calendar year.  As a condition  precedent to receiving (and continuing to receive) the payments provided in this Section you must execute  (and not revoke) and deliver to the Company a release of claims set forth in a Separation Agreement and  General Release (the &#8220;Release&#8221;) in a form provided by the Company on or before the date specified by the  Company in such form (the &#8220;Release Deadline&#8221;) and such Release shall include without limitation a release  of all claims against the Company and its affiliates along with a covenant not to sue and (ii) requirements  for you to remain in full compliance with such Release, this Agreement and the Confidentiality Agreement.  e. Good Reason.  For purposes of this Agreement, resigning for &#8220;Good Reason&#8221; shall mean  (a) a material breach of this Agreement by the Company, (b) a material reduction in your base salary other  than a general reduction in base salary that affects all similarly situated executives in substantially the same  proportions, or (c) a material change in your duties or responsibilities; provided, that in each case you must  provide the Company with written notice of the events you indicate constitutes grounds for a Good Reason  resignation within thirty (30) days of the occurrence of such event. Notwithstanding the foregoing, changing  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4  your reporting line shall not constitute Good Reason. Failure to give such notice within thirty (30) days of  the occurrence shall be deemed a waiver by you of your right to terminate for Good Reason with respect to  such circumstances. If you provide such notice, the Company thereafter will have forty-five (45) days to  cure such alleged breach. If the Company does not cure the alleged breach within the forty-five (45) day  notice period, you must thereafter resign within fifteen (15) days of the expiration of the forty-five (45) day  notice period in order to resign for Good Reason.  f. Voluntary Termination.  You may voluntarily terminate your employment without Good  Reason by giving the Company written notice of said resignation.  The Company may elect to pay your  base salary in lieu of notice you provide. In the event you voluntarily terminate your employment with the  Company without Good Reason, you will be entitled to receive only your Accrued Pay.  You will be entitled  to no other compensation from the Company.  g. Death or Disability.  Your employment hereunder shall terminate automatically upon your  death during your employment, and the Company may terminate your employment on account of your  Incapacity. In the event of termination of your employment by reason of your death or Incapacity, you or  your estate will be entitled to receive your Accrued Pay. &#8220;Incapacity&#8221; shall mean your inability, due to  physical or mental incapacity, to substantially perform your duties and responsibilities under this  Agreement for one hundred eighty (180) days out of any three hundred sixty-five (365) day period or one  hundred twenty (120) consecutive days; provided however, in the event the Company temporarily replaces  you, or transfers your duties or responsibilities to another individual on account of your inability to perform  such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a  Incapacity, then your employment shall not be deemed terminated by the Company and you shall not be  able to resign with Good Reason as a result thereof. Any question as to the existence of your Incapacity as  to which you and the Company cannot agree shall be determined in writing by a qualified independent  physician mutually acceptable to you and the Company. If you and the Company cannot agree as to a  qualified independent physician, each shall appoint such a physician and those two physicians shall select  a third who shall make such determination in writing. The determination of Incapacity made in writing to  the Company and Executive shall be final and conclusive for all purposes of this Agreement.  6. Proprietary Information and Inventions Agreement; Confidentiality.  You will be  required, as a condition of your employment with the Company, to timely execute the Company&#8217;s form  Proprietary Information and Inventions Agreement as may be amended from time to time by the Company  (&#8220;Confidentiality Agreement&#8221;). Your duties and obligations pursuant to the Confidentiality Agreement are  in addition to those you agree to herein.  However, to the extent there is a conflict between the terms of the  Confidentiality Agreement and the terms of this Agreement, the terms of this Agreement shall control.  7. Governing Law; Arbitration.   a. To the extent not preempted by federal law, this Agreement will be deemed a contract made  under, and for all purposes shall be construed in accordance with, the laws of Utah.  b. Any and all controversies, claims, or disputes with anyone (including without limitation  Company or its affiliates, and any current or former employee, officer, director, shareholder, member,  manager, or benefit plan of Company or its affiliates in their capacity as such or otherwise) arising out of,  relating to, or resulting from your employment with Company or the termination of your employment with  Company, including any breach of this Agreement, will be subject to private and confidential binding  arbitration to be held in the city of Salt Lake City, State of Utah administered by the American Arbitration  Association (&#8220;AAA&#8221;) in accordance with its rules then in effect for the resolution of employment disputes  (the &#8220;Rules&#8221;).  The AAA&#8217;s optional rules for Emergency Measures or protection are also adopted.  Subject  to section 5.f. below, you covenant and promise that should you commence any action or pursue a claim  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  5  based on a dispute which you agree to arbitrate, you will do so before the AAA as set forth herein and will  not file any complaint or other pleading in a local, state or federal court, acknowledging that doing so would  damage Company and deprive it of the benefits of the private and confidential dispute resolution provided  for herein.  Disputes which you agree to arbitrate, and thereby agree to waive any right to a trial by jury,  include any statutory claims under state or federal law, including, but not limited to, claims under Title VII  of the Civil Rights Act of 1964, the Americans With Disabilities Act of 1990, the Age Discrimination In  Employment Act of 1967, the Older Workers Benefit Protection Act, and any statutory claims.  You further  understand that this agreement to arbitrate also applies to any disputes that Company may have with you  arising during your employment with Company or the termination of your employment with Company.  To  the fullest extent permitted by law, you forego any right to bring claims as a representative or as a member  of a class or in a private attorney general capacity, and expressly disclaim your right to be part of a class,  collective action, or a private attorney general claim.  Nothing in this provision limits or prohibits employees  from engaging in a &#8220;Protected Activity&#8221; as defined in this Agreement or as established under State or  Federal Law. Notwithstanding any other provision of this Agreement, the arbitration will be private and  confidential. The arbitrator will issue an order providing that all pleadings, motions, discovery, responses,  depositions, testimony, case management orders, decisions, and documents exchanged or filed in relation  to the arbitration be kept strictly private and confidential.  The arbitrator will issue the standard protective  order referenced in local rule 26-2 of the United States District Court for the District of Utah.  c. Notwithstanding the foregoing, the following claims are not covered by this arbitration  provision: claims for workers&#8217; compensation benefits, claims for unemployment compensation benefits,  claims under the National Labor Relations Act, claims based upon Company&#8217;s employee benefits and  welfare plans that contain an appeal procedure or other procedure for the resolution of disputes under the  plan, and claims by Company for injunction or other equitable relief, including without limitation claims  for unfair competition and the unauthorized disclosure of trade secrets or confidential information.  d. You agree that any arbitration will be administered by the AAA and that a single neutral  arbitrator will be selected in a manner consistent with the Rules.  You agree that the arbitrator will  administer and conduct any arbitration in accordance with the Federal Arbitration Act and the Federal Rules  of Civil Procedure (the &#8220;FRCP&#8221;), and that arbitrator will apply substantive Utah law to any dispute or  claim, without reference to any conflict of law provisions of any jurisdiction and to the extent that the Rules  conflict with the FRCP, the FRCP will take precedence.  You agree that the arbitrator will have the power  to decide any motions brought by any party to the arbitration, including motions for summary judgment  and adjudication and motions to dismiss and demurrers, prior to any arbitration hearing.  Motions for  summary judgment, partial summary judgment, or summary adjudication will be decided according to Rule  56 of the Federal Rules of Civil Procedure and applicable case law.  Notwithstanding any AAA rules or  arbitration procedure, it is the intent of the parties that the arbitrator will consider and rule on any such  motions as if in a federal court of the United States.  You also agree that the arbitrator will have the power  to award any remedies, including attorneys&#8217; fees and costs, available under applicable law.  The Company  will pay the joint costs and expenses of such arbitration.  Notwithstanding this provision, the Company will  not pay any costs or expenses of the arbitration that are incurred solely by you. Each party will separately  pay for its respective counsel fees and expenses; provided, however, that the arbitrator will award attorneys&#8217;  fees and costs to the prevailing party except as prohibited by law.  Except as set forth herein or as agreed  by the parties in writing, you agree that the arbitrator will administer and conduct any arbitration in a manner  consistent with the Rules.  Employee agrees that the decision of the arbitrator will be in writing and set  forth the reasoning thereof.  e. Except as provided by the Rules and this Agreement, including without limitation Section  7.c. above, arbitration will be the sole, exclusive and final remedy for any dispute between Company and  you.  Accordingly, except as provided for by the Rules and this Agreement, neither Company nor you will  be permitted to pursue court action regarding claims that are subject to arbitration.  Notwithstanding, the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  6  arbitrator will not have the authority to disregard or refuse to enforce any lawful Company policy, and the  arbitrator will not order or require Company to adopt a policy not otherwise required by law which  Company has not adopted. Further, any party may seek a separate order from a court of competent  jurisdiction enforcing the arbitrator&#8217;s order protecting the disclosure of pleadings, motions, discovery  responses, depositions, testimony, case management orders, decisions, and documents exchanged or filed  in the arbitration, provided such motion and responses thereto are filed under seal.  f. In addition to the right under the Rules to petition the court for provisional relief, you agree  that any party may also petition the court for injunctive relief where either party alleges or claims a violation  of this Agreement or any other agreement regarding trade secrets, confidential information, non- competition, or non-solicitation.  Employee understands that any breach or threatened breach of such  agreement will cause irreparable injury and that money damages will not provide an adequate remedy  therefor and both parties hereby consent to the issuance of a temporary restraining order, preliminary  injunction, permanent injunction, or other injunctive relief, without posting any bond or other security,  compelling you to comply with all provisions of such agreements.  The preceding sentence will not be  construed to limit Company from any other relief or damages to which it may be entitled because of your  breach of any provision of this Agreement.  If either party seeks injunctive relief, the prevailing party will  be entitled to recover reasonable costs and attorneys&#8217; fees.  8. Taxes.  The Company shall have the right to withhold and deduct from any payment  hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any  such payment.  The Company shall not be liable to you or other persons as to any unexpected or adverse  tax consequence realized by you and you shall be solely responsible for the timely payment of all taxes  arising from this Agreement that are imposed on you.  This Agreement is intended to comply with the  applicable requirements of Code Section 409A and shall be limited, construed and interpreted in a manner  so as to comply therewith.  Each payment made pursuant to any provision of this Agreement shall be  considered a separate payment and not one of a series of payments for purposes of Code Section 409A.   While it is intended that all payments and benefits provided under this Agreement to you will be exempt  from or comply with Code Section 409A, the Company makes no representation or covenant to ensure that  the payments under this Agreement are exempt from or compliant with Code Section 409A.  The Company  will have no liability to you or any other party if a payment or benefit under this Agreement is challenged  by any taxing authority or is ultimately determined not to be exempt or compliant.  In addition, if upon your  Termination Date, you are then a &#8220;specified employee&#8221; (as defined in Code Section 409A), then solely to  the extent necessary to comply with Code Section 409A and avoid the imposition of taxes under Code  Section 409A, the Company shall defer payment of &#8220;nonqualified deferred compensation&#8221; subject to Code  Section 409A payable as a result of and within six (6) months following your Termination Date until the  earlier of (i) the first business day of the seventh (7th) month following your Termination Date or (ii) ten  (10) days after the Company receives written confirmation of your death.  Any such delayed payments shall  be made without interest.  Additionally, the reimbursement of expenses or in-kind benefits provided  pursuant to this Agreement shall be subject to the following conditions: (1) the expenses eligible for  reimbursement or in-kind benefits in one taxable year shall not affect the expenses eligible for  reimbursement or in-kind benefits in any other taxable year; (2) the reimbursement of eligible expenses or  in-kind benefits shall be made promptly, subject to the Company&#8217;s applicable policies, but in no event later  than the end of the year after the year in which such expense was incurred; and (3) the right to  reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.  9. Entire Agreement.  Except as otherwise specifically provided in this Agreement, this  Agreement (including without limitation the Confidentiality Agreement, the policies referenced in  Section 12.f. and any other agreements referenced herein) contains all the legally binding  understandings and agreements between you and the Company pertaining to the subject matter of this  Agreement and supersedes all such agreements, whether oral or in writing, previously discussed or  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  7  entered into between the parties including without limitation any term sheets regarding your potential  employment with the Company.    10. Key Executive Representations.  As a material condition of this Agreement, you  represent that by entering into this Agreement or by becoming a Company employee you are not  violating the terms of any other contract or agreement or other legal obligations that would prohibit  you from performing your duties for the Company.  You further agree and represent that in providing  your services to the Company you will not utilize or disclose any other entity&#8217;s trade secrets or  confidential information or proprietary information.  You represent that you are not resigning  employment or relocating any residence in reliance on any promise or representation by the Company  regarding the kind, character, or existence of such work, or the length of time such work will last, or  the compensation therefor.  11. Non-Solicitation and Non-Competition.  a. Non-solicitation of employees and consultants.  During your employment and for a  period of two (2) years after your employment terminates, you will not directly or indirectly solicit,  induce, encourage, influence, or persuade, or attempt to solicit, induce, encourage influence or  persuade, any officer, employee, consultant (including without limitation independent contractors) or  agent of the Company (or any of its affiliates) to alter, reduce, or terminate their employment or  relationship with the Company or to any way breach their duties and obligations to the Company.  b. Non-solicitation of Independent Consultants, or Customers.  To the extent  permitted under applicable law, and in order to protect the Proprietary Information of Company as  defined in the Confidentiality Agreement (&#8220;Proprietary Information&#8221;) and preserve the Company&#8217;s  relationships with its current and prospective Independent Consultants (formerly Independent  Distributors) and customers, you agree that during your employment and for a period of two (2) years  after your employment with the Company ends for any reason, you will not directly or indirectly solicit,  induce, encourage, influence, or persuade, or attempt to solicit, induce, encourage, influence or  persuade, any current or prospective Independent Consultant(s) (formerly Independent Distributor(s)),  subscription Customer(s) or retail Customer(s) to (i) join any company, business or entity that  competes with the Company&#8217;s products and services including start-ups even before such begins  selling competing products or services; (ii) join any company, business or entity engaged in direct sales  or network marketing, including start-ups even before such takes on a single distributor, consultant,  subscription customer, preferred customer, or retail customer; or (iii) alter, reduce, or discontinue its  relationship with the Company.  By signing the Agreement, you acknowledge and agree that the  Company is trying to protect legitimate business interests by this prohibition and such prohibition is  reasonable in its scope and duration.  c. Non-Competition.  You shall not, during your employment and for a period of [_____]  months after your employment with the Company ends for any reason, directly or indirectly engage in,  advise or consult with, contribute your knowledge to, own, manage, invest in, operate, control, or  accept employment with any company, business or entity that (i) competes with the Company&#8217;s  products and services including start-ups even before such begins selling competing products or  services or (ii) engages in direct sales or network marketing, including start-ups even before such takes  on a single distributor, consultant, subscription customer, preferred customer, or retail customer.   Following expiration of the aforementioned period, you shall continue to be obligated under the  confidentiality provisions of this Agreement and of the Confidentiality Agreement not to disclose  and/or use Proprietary Information so long as it shall remain proprietary or protectable as confidential  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  8  or trade secret information.  The geographic limitation to this Section 11.c. is any state, county, or  locality in the United States in which the Company conducts business or was planning or preparing to  conduct business and any other country, city, state, province, jurisdiction, or territory in which the  Company conducts business or was planning or preparing to conduct business. Notwithstanding your  obligations under this Section 11.c., you will be entitled to own, as a passive investor, up to five percent  (5%) of any publicly traded company without violating this provision.  The Company and you agree  that: this provision does not impose an undue hardship on you and is not injurious to the public; that  this provision is necessary to protect the business of the Company and its affiliates; the nature of your  responsibilities with the Company under this Agreement require you to have access to confidential  information which is valuable and confidential to the Company; this provision is necessary to protect  the Company&#8217;s confidential information, including but not limited to trade secrets belonging to the  Company; the scope of this Section 11 is reasonable in terms of length of time and geographic scope;  and adequate consideration supports this Section 11, including the consideration herein.  d. Modification By Court.  If any court or arbitrator determines that any post- employment restrictive covenant is unreasonable in any respect, you agree that the Court may modify  any unreasonable terms and enforce the agreement as modified.  e. Extension of Non-Compete.  For any period of time in which you are found to be in  violation of any of the above non-compete or non-solicitation agreements, that period of time shall be  added on to the length of the restriction or period of protection for the Company.  f. Notice to Subsequent Employers.  You agree that the Company may provide notice  of your obligations under any provision of this Agreement and the Confidentiality Agreement to any  company or future employer of yours should the Company consider it necessary for the enforcement  of those obligations.  12. Covenants.  As a condition of this Agreement and to your receipt of any post-employment  benefits, you agree that you will fully and timely comply with all of the covenants set forth in this  Agreement (which shall survive your termination of employment and termination or expiration of this  Agreement):  a. You will fully comply with all obligations under this Agreement and the  Confidentiality Agreement and further agree that the provisions of this Agreement and the  Confidentiality Agreement shall survive any termination or expiration of this Agreement or termination  of your employment or any subsequent service relationship with the Company;  b. Within five (5) days of the Termination Date, you shall return to the Company all  Company Proprietary Information as defined in the Confidentiality Agreement, and you shall not retain  any copies, facsimiles or summaries of any Company Proprietary Information;  c. Except as set forth in Section 18, you will not at any time make or publish (or direct  anyone to make or publish) in any forum or through any medium, including every social media  platform and/or electronic medium any negative or disparaging statements or comments (whether oral  or written) whatsoever about the Company, or any of its affiliated entities, officers, directors,  employees, stockholders, independent distributors, representatives, agents or contractors, or any of the  Company&#8217;s products or services. As used in this paragraph, the term &#8220;disparaging&#8221; means anything  unflattering and/or negative, whether such communication is true or untrue;  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  9  d. You agree that, upon the Company&#8217;s request and without any payment therefore, you  shall reasonably cooperate with the Company (and be available as necessary) after the Termination  Date in connection with any matters involving events that occurred during your period of employment  with the Company;  e. You also agree that you will fully and timely comply with all of the covenants set forth  below (which shall survive your termination of employment and termination or expiration of this  Agreement):  i. You will fully pay off any outstanding amounts owed to the Company no later  than their applicable due date or within thirty days of your Termination Date (if no other due date has  been previously established);  ii. Within five (5) days of the Termination Date, you shall return to the Company  all Company property including, but not limited to, computers and other electronic devices, drives,  data, documents, cell phones, pagers, keys, business cards, passwords necessary to access systems,  websites, cloud services, etc. that contain Company property etc., in good working condition and  without altering or removing items and not retain copies of any such documents, data or information;  iii. Within thirty (30) days of the Termination Date, you will submit any  outstanding expense reports to the Company for expenses incurred prior to the Termination Date; and  iv. As of the Termination Date, you will no longer represent that you are an officer,  director or employee of the Company and you will immediately discontinue using your Company  mailing address, telephone, facsimile machines, voice mail and e-mail and to the extent you resign  with another job in-hand you will disclose the identity of your new employer.  f. You agree that you will strictly adhere to and obey all Company rules, policies,  procedures, regulations and guidelines, including but not limited to those contained in the Company's  Code of Conduct, as well any others that the Company may establish including without limitation any  policy the Company adopts on the recoupment of compensation (&#8220;Clawback Policy&#8221;).  13. Offset.  Any severance or other payments or benefits made to you under this Agreement may  be reduced, in the Company&#8217;s discretion, by any amounts you owe to the Company provided that any  such offsets do not violate Code Section 409A.  14. Notice.  Any notice that the Company is required to or may desire to give you shall be given  by personal delivery, recognized overnight courier service, email, telecopy or registered or certified  mail, return receipt requested, addressed to you at your address of record with the Company, or at such  other place as you may from time to time designate in writing.  Any notice that you are required or  may desire to give to the Company hereunder shall be given by personal delivery, recognized overnight  courier service, email, telecopy or by registered or certified mail, return receipt requested, addressed  to the Company&#8217;s General Counsel at its principal office, or at such other office as the Company may  from time to time designate in writing.  The date of actual delivery of any notice under this Section  shall be deemed to be the date of delivery thereof.  15. Waiver; Severability.  No provision of this Agreement may be amended or waived unless such  amendment or waiver is agreed to by you and the Company in writing and such amendment or waiver  expressly references this Section.  No waiver by you or the Company of the breach of any condition  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  10  or provision of this Agreement will be deemed a waiver of a similar or dissimilar provision or condition  at the same or any prior or subsequent time.  Except as expressly provided herein to the contrary, failure  or delay on the part of either party hereto to enforce any right, power, or privilege hereunder will not  be deemed to constitute a waiver thereof.  In the event any portion of this Agreement is determined to  be invalid or unenforceable for any reason, the remaining portions shall be unaffected thereby and will  remain in full force and effect to the fullest extent permitted by law.  16. Voluntary Agreement.  You acknowledge that you have been advised to review this  Agreement with your own legal counsel and other advisors of your choosing and that prior to entering  into this Agreement, you have had the opportunity to review this Agreement with your attorney and  other advisors and have not asked (or relied upon) the Company or its counsel to represent you or your  counsel in this matter.  You further represent that you have carefully read and understand the scope  and effect of the provisions of this Agreement and that you are fully aware of the legal and binding  effect of this Agreement.  This Agreement is executed voluntarily by you and without any duress or  undue influence on the part or behalf of the Company.  17. Key-Man Insurance.  The Company shall have the right to insure your life for the sole benefit  of the Company, in such amounts, and with such terms, as it may determine.  All premiums payable  thereon shall be the obligation of the Company.  You shall have no interest in any such policy, but you  agree to cooperate with the Company in taking out such insurance by submitting to physical  examinations, supplying all information required by the insurance company, and executing all  necessary documents, provided that no financial obligation is imposed on you by any such documents.  18. Protected Activity Not Prohibited. You understand that nothing in this Agreement shall in any  way limit or prohibit you from engaging in any Protected Activity. For purposes of this Agreement,  &#8220;Protected Activity&#8221; means filing a charge, complaint, or report with, or otherwise communicating,  cooperating, or participating in any investigation or proceeding that may be conducted by, any federal,  state or local government agency or commission, including the Securities and Exchange Commission,  the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration,  and the National Labor Relations Board (&#8220;Government Agencies&#8221;). In addition, Protected Activity  includes any action to (i) form, join or assist a union; (ii) choose a representative to bargain with us on  your behalf; (iii) discuss and act together with other employees for your mutual benefit and protection  with respect to terms and conditions of employment; or (iv) choose not to engage in any of these  protected activities. You understand that in connection with such Protected Activity, you are permitted  to disclose documents or other information as permitted by law, and without giving notice to, or  receiving authorization from, the Company. Notwithstanding the foregoing, you agree to take all  reasonable precautions to prevent any unauthorized use or disclosure of any information that may  constitute Company Proprietary Information under the Confidentiality Agreement to any parties other  than the Government Agencies. You further understand that &#8220;Protected Activity&#8221; does not include the  disclosure of any Company attorney-client privileged communications. Any language in the  Confidentiality Agreement regarding your right to engage in Protected Activity that conflicts with, or  is contrary to, this paragraph is superseded by this Agreement. In addition, pursuant to the Defend  Trade Secrets Act of 2016, you are notified that an individual will not be held criminally or civilly  liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made in  confidence to a federal, state, or local government official (directly or indirectly) or to an attorney  solely for the purpose of reporting or investigating a suspected violation of law, or (b) is made in a  complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made  under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a  suspected violation of law may disclose the trade secret to the individual&#8217;s attorney and use the trade  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  11  secret information in the court proceeding, if the individual files any document containing the trade  secret under seal and does not disclose the trade secret, except pursuant to court order.  ACKNOWLEDGED AND AGREED:  Date: Date:     LIFEVANTAGE CORPORATION          ________________________  BY:       Steven R. Fife  TITLE: President &amp;CEO     KEY EXECUTIVE          ________________________  BY:   TITLE:         </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex109keyexecutivebenefit012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex109keyexecutivebenefit012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  12    EXHIBIT A  TARGET ANNUAL INCENTIVE  Name Title Target Annual Incentive          </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex211listofsubsidiaries063.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i090f3dc7a31745bc89f05754ff52ed6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF LIFEVANTAGE CORPORATION</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a list of all subsidiaries of LifeVantage Corporation, a Delaware corporation, and the state or country of incorporation of each as of June 30, 2024.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">State or Country of Incorporation</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dinng Creative, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Importadora LifeVantage S. de R.L. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LFVN Malaysia SDN. BHD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeLine Nutraceuticals Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Asia Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Australia Pty. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Canada Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage de Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Hong Kong Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Japan Kabushiki Kaisha (KK)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage New Zealand Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Taiwan Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage Thailand Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeVantage UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protandum Philippines Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puyoujian (Guangzhou) Technology Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex231deloitteconsent063020.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6d4ece3d53c641dbb93027c49c5588e6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We consent to the incorporation by reference in Registration Statement Nos. 333-252013, 333-228627, 333-216957, 333-200363, 333-183461, 333-175104, 333-158704, and 333-144247 on Form S-8, and the Registration Statement No. 333-271061 on Form S-3 of our report dated August&#160;28, 2024, relating to the financial statements of LifeVantage Corporation appearing in this Annual Report on Form 10-K for the year ended June&#160;30, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; Deloitte &#38; Touche, LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Salt Lake City, Utah</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">August&#160;28, 2024</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex311ceosec302certificatio.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iafada86f5f1a403e998763a0c7d1d815_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steven R. Fife, certify that&#58;</font></div><div style="margin-top:14pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of LifeVantage Corporation&#59;</font></div><div style="margin-top:14pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:14pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:14pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.57pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:14pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.57pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:14pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:59.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven R. Fife</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven R. Fife</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President&#160;&#38; Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex312cfosec302certificatio.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iea09a2d5723c417f82deae3f30a84f4c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Carl A. Aure, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of LifeVantage Corporation&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.57pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:64.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carl A. Aure</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carl A. Aure<br>Chief Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex321ceosec906certificatio.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iacd3123a2e38416db5bff1f60820326b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the filing of this annual report on Form 10-K of LifeVantage Corporation (the &#8220;Company&#8221;) for the period ended June&#160;30, 2024, with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Steven R. Fife, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:64.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven R. Fife</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven R. Fife<br>President&#160;&#38; Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex322cfosec906certificatio.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i63ae01a5823a4b2698809babe3e27d4e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the filing of this annual report on Form 10-K of LifeVantage Corporation (the &#8220;Company&#8221;) for the period ended June&#160;30, 2024, with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Carl A. Aure, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:66.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carl A. Aure</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carl A. Aure</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>clawbackpolicy.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9767b32f2a5b4dc584038d9b1fa5c4cf_40"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:24.5pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIFEVANTAGE CORPORATION POLICY FOR THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amended and Restated on November 6, 2023 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:11.85pt;padding-left:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group.  This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amended, Rule 10D-1 promulgated thereunder and the Listing Standards.  Each Executive Officer shall be required to sign and return to the Company the Acknowledgment Form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pursuant to which such Executive Officer will agree to be bound by the terms of and comply with this Policy.</font></div><div style="margin-top:11.95pt;padding-left:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Policy shall be administered by the Committee.  The Committee is authorized to interpret and construe this Policy and to make all determinations, and take all actions, necessary, appropriate or advisable for the administration of this Policy. Any determinations and interpretations made by the Committee shall be final and binding on all affected individuals, and need not be uniform with respect to each individual covered by the Policy.</font></div><div style="margin-top:11.95pt;padding-left:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As used in this Policy, the following capitalized terms shall have the meanings set forth below.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean an accounting restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement (i) that corrects an error in previously issued financial statements that is material to the previously issued financial statements (a &#8220;Big R&#8221; restatement), or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;little r&#8221; restatement).  An Accounting Restatement does not include situations in which financial statement changes did not result from material noncompliance with financial reporting requirements, such as, but not limited to, retrospective&#58; (i) application of a change in accounting principles&#59; (ii) revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (iii) reclassification due to a discontinued operation&#59; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control&#59; (v) adjustment to provisional amounts in connection with a prior business combination&#59; and (vi) revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="margin-top:11.95pt;padding-left:36.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Eligible Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean, in connection with an Accounting Restatement and with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-Based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company Group), all Incentive-Based Compensation Received by such Executive Officer (i) on or after the Effective Date (even if such Incentive-Based Compensation was approved, awarded, granted or paid prior to the effective date of the Listing Standards), (ii) after beginning service as an Executive Officer, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the applicable Clawback Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any transition period (that results from a </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Explanatory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58;  Recovery of compensation is not required (1) with respect to any compensation Received while an individual was serving in a non-executive capacity prior to becoming an Executive Officer or (2) from any individual who is an Executive Officer on the Restatement Date but who was not an Executive Officer at any time during the performance period for which the Incentive-Based Compensation is Received.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></div><div style="margin-top:11.25pt;padding-left:36.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Compensation Committee of the Board.</font></div><div style="padding-left:0.05pt"><font><br></font></div><div style="padding-left:0.05pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean LifeVantage Corporation, a Delaware corporation.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Company, together with each of its direct and indirect subsidiaries.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the effective date of this Policy, which date is December 1, 2023.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts as reflected in the Accounting Restatement, computed without regard to any taxes paid.  For Incentive-Based Compensation based on (or derived from) stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to Nasdaq).</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean each individual who is or was designated as an &#8220;officer&#8221; of the Company in accordance with 17 C.F.R. 240.16a-1(f).  Identification of an executive officer for purposes of this Policy would include, at a minimum, executive officers identified pursuant to 17 C.F.R. 229.401(b).  As of the Effective Date (and subject to later amendments to the above-referenced rules), Executive Officer covers the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a significant policy-making function, or any other person (including any executive officer of the Company&#8217;s affiliates including a parent or subsidiary of the Company) who performs similar policy-making functions for the Company.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements (including &#8220;non-GAAP financial measures,&#8221; such as those appearing in earnings releases), and any measures that are derived wholly or in part from such measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented within the Company&#8217;s financial statements or included in a filing with the SEC. Stock price and total shareholder return shall for purposes of this Policy also be considered Financial Reporting Measures.  </font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.  For the sake of clarity, examples of compensation that is not Incentive-Based Compensation include, but are not limited to&#58; (i) base salaries&#59; (ii) discretionary cash bonuses&#59; (iii) awards (either of cash or equity) that are based solely upon subjective, strategic or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational metrics or measures&#59; and (iv) equity awards that vest solely upon continued service or the passage of time.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean Nasdaq Listing Rule 5608.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean The Nasdaq Stock Market.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean this Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall, with respect to any Incentive-Based Compensation, mean actual or deemed receipt, and Incentive-Based Compensation shall be deemed received in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if grant or payment of the Incentive-Based Compensation occurs after the end of that period.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are filed.</font></div><div style="margin-top:11.95pt;padding-left:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the U.S. Securities and Exchange Commission.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required Recovery of Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In the event the Company is required to prepare an Accounting Restatement, the Committee shall determine the amount of any Erroneously Awarded Compensation for each Executive Officer in connection with such Accounting Restatement, shall thereafter provide each Executive Officer with a written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable, and shall take all other actions necessary and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officers reasonably promptly.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Committee shall determine, in its sole discretion, the timing and method for recovering Erroneously Awarded Compensation reasonably promptly based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery.  Such methods may include, without limitation, (i) seeking reimbursement of all or part of any cash or equity-based award, (ii) cancelling prior cash or equity-based awards, whether vested or unvested or paid or unpaid, (iii) cancelling or offsetting against any planned future cash or equity-based awards, (iv) forfeiture of deferred compensation, subject to compliance with Section 409A of the Internal Revenue Code and the regulations promulgated thereunder, and (v) any other method authorized by applicable law or contract.  Subject to compliance with any applicable law, the Committee may effect recovery under this Policy (i) from any amount otherwise payable to the Executive Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, including base salary, bonuses </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Explanatory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58;  The Dodd-Frank statutory language specifies that Incentive-Based Compensation to which recovery must apply under a compliant clawback policy &#8220;includ&#91;es&#93; stock options awarded as compensation.&#8221; Importantly, stock options (and similar equity awards, such as restricted stock, RSUs and SARs) would be treated as Incentive-Based Compensation only if the granting, vesting or earning of the award is based, in whole or in part, on satisfying a Financial Reporting Measure (FRM) performance goal. Therefore, equity awards that are granted irrespective of attaining any FRM performance goal and vest solely on the basis of continued service or the passage of time would not be considered Incentive-Based Compensation. The strike price of an option, on its own, would not make an option Incentive-Based Compensation subject to the clawback policy (even though the option is only in-the-money when the Company&#8217;s stock price is above the strike price). In addition, any incentive awards that are granted, earned or vested solely on the basis of whether nonfinancial (e.g., strategic, operational or subjective) measures have been achieved would not be subject to the clawback policy.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or commissions, and compensation previously deferred by the Executive Officer, and (ii) from any amount of compensation approved, awarded, granted, payable or paid to the Executive Officer prior to, on or after the effective date of the Listing Standards.  For the avoidance of doubt, except as set forth in Section 4(d) below, in no event may the Company Group accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer&#8217;s obligations hereunder.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company Group when due, the Company shall, or shall cause one or more other members of the Company Group to, take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The applicable Executive Officer shall be required to reimburse the Company Group for any and all expenses reasonably incurred (including legal fees) by the Company Group in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Notwithstanding anything herein to the contrary, the Company shall not be required to recover Erroneously Awarded Compensation from any Executive Officer if the following conditions are met and the Committee determines that recovery would be impracticable&#58;</font></div><div style="padding-left:0.05pt;padding-right:0.05pt;text-align:justify"><font><br></font></div><div style="padding-left:36.05pt;padding-right:0.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The direct expenses paid to a third party to assist in enforcing the Policy against an Executive Officer would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation to Nasdaq&#59;</font></div><div style="margin-top:11.95pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Recovery would violate home country law of the Company where that law was adopted prior to November 28, 2022, after the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided to Nasdaq&#59; or</font></div><div style="margin-top:11.95pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reporting and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including the disclosure required by the applicable SEC filings.  The Company shall also file a copy of this Policy and any amendments thereto as an exhibit to its annual report on Form 10-K.</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Indemnification of Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Notwithstanding the terms of any indemnification or insurance policy or any contractual arrangement with any Executive Officer that may be interpreted to the contrary, no member of the Company Group shall be permitted to indemnify any Executive Officer against, or pay or reimburse the premiums for an insurance policy to cover, (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company Group&#8217;s enforcement of its rights under this Policy.  Further, no member of the Company Group shall enter into any agreement that exempts any Incentive-Based Compensation from the application of this Policy or that waives the Company Group&#8217;s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any members of the Committee, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Explanatory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58;  Unpaid amounts will be subject to public disclosure in the Company&#8217;s proxy statement, including (i) the aggregate dollar amount of Erroneously Awarded Compensation that remains outstanding at the end of the last completed fiscal year and (ii) for each current and former Named Executive Officer, the dollar amount of outstanding Erroneously Awarded Compensation still owed that had been outstanding for 180 days or longer since the date the Company determined the amount the officer owed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="margin-top:11.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Policy shall be effective as of the Effective Date.</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may amend, modify, supplement, rescind or replace all or any portion of this Policy at any time and from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed.  The Committee may terminate this Policy at any time. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed.</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Recoupment Rights&#59; Company Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Committee intends that this Policy will be applied to the fullest extent of the law and with respect to all Incentive-Based Compensation granted to an Executive Officer, whether pursuant to a pre-existing contract or arrangement, or one that is entered into after the Effective Date.  Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company Group under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement or similar agreement and any other legal remedies available to the Company Group.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Nothing contained in this Policy, and no recoupment or recovery as contemplated by this Policy, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against an Executive Officer arising out of or resulting from any actions or omissions by the Executive Officer.</font></div><div style="margin-top:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-top:12pt;padding-left:195pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Explanatory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58;  In circumstances in which both the Dodd-Frank and SOX Section 304 clawback provisions could provide for recovery of the same Incentive-Based Compensation, if an Executive Officer reimburses the Company pursuant to SOX, the amount recoverable under the Company&#8217;s Dodd-Frank clawback policy should be deducted by the amount of the reimbursement. The SEC notes that recovery under the Company&#8217;s Dodd-Frank clawback policy would not preclude recovery under SOX to the extent any applicable amounts have not been reimbursed to the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:209.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIFEVANTAGE CORPORATION POLICY FOR THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div><div style="margin-top:12pt;padding-left:146.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACKNOWLEDGMENT FORM</font></div><div style="margin-top:11.9pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the LifeVantage Corporation Policy for the Recovery of Erroneously Awarded Compensation (as may be amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms used but not otherwise defined in this Acknowledgment Form (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acknowledgment Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall have the meanings ascribed to such terms in the Policy.</font></div><div style="margin-top:12pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By signing this Acknowledgment Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment with the Company Group.  Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by promptly returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company Group to the extent required by, and in a manner permitted by, the Policy.  In the event of any inconsistency between the Policy and the terms of any employment agreement to which the undersigned is a party, or the terms of any compensation plan, program or agreement under which any compensation has been granted, awarded, earned or paid, the terms of the Policy shall govern.</font></div><div style="margin-top:30pt;padding-left:216pt;padding-right:60.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________ Signature</font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________ </font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Print Name</font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________ </font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</font></div><div style="padding-left:216pt;padding-right:60.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>lfvn-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lfvn="http://www.lifevantage.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lifevantage.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lfvn-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lfvn-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lfvn-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lfvn-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lifevantage.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.lifevantage.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.lifevantage.com/role/TheCompany">
        <link:definition>9952156 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lifevantage.com/role/Revenue">
        <link:definition>9952158 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNet">
        <link:definition>9952159 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.lifevantage.com/role/IntangibleAssetsNet">
        <link:definition>9952160 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpenses" roleURI="http://www.lifevantage.com/role/OtherAccruedExpenses">
        <link:definition>9952161 - Disclosure - Other Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.lifevantage.com/role/LongTermDebt">
        <link:definition>9952162 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.lifevantage.com/role/StockholdersEquity">
        <link:definition>9952163 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.lifevantage.com/role/ShareBasedCompensation">
        <link:definition>9952164 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseNet" roleURI="http://www.lifevantage.com/role/OtherExpenseNet">
        <link:definition>9952165 - Disclosure - Other Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lifevantage.com/role/IncomeTaxes">
        <link:definition>9952166 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.lifevantage.com/role/Leases">
        <link:definition>9952167 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lifevantage.com/role/CommitmentsandContingencies">
        <link:definition>9952168 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lifevantage.com/role/RevenueTables">
        <link:definition>9954473 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetTables">
        <link:definition>9954474 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetTables">
        <link:definition>9954475 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpensesTables" roleURI="http://www.lifevantage.com/role/OtherAccruedExpensesTables">
        <link:definition>9954476 - Disclosure - Other Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationTables">
        <link:definition>9954477 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseNetTables" roleURI="http://www.lifevantage.com/role/OtherExpenseNetTables">
        <link:definition>9954478 - Disclosure - Other Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lifevantage.com/role/IncomeTaxesTables">
        <link:definition>9954479 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.lifevantage.com/role/LeasesTables">
        <link:definition>9954480 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyDetails" roleURI="http://www.lifevantage.com/role/TheCompanyDetails">
        <link:definition>9954481 - Disclosure - The Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>9954487 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.lifevantage.com/role/RevenueNarrativeDetails">
        <link:definition>9954488 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSalesReturnDetails" roleURI="http://www.lifevantage.com/role/RevenueSalesReturnDetails">
        <link:definition>9954489 - Disclosure - Revenue - Sales Return (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenueDetails" roleURI="http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails">
        <link:definition>9954490 - Disclosure - Revenue - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueMajorProductsDetails" roleURI="http://www.lifevantage.com/role/RevenueMajorProductsDetails">
        <link:definition>9954491 - Disclosure - Revenue - Major Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails">
        <link:definition>9954492 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetDetails" roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetDetails">
        <link:definition>9954493 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpensesDetails" roleURI="http://www.lifevantage.com/role/OtherAccruedExpensesDetails">
        <link:definition>9954494 - Disclosure - Other Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.lifevantage.com/role/LongTermDebtDetails">
        <link:definition>9954495 - Disclosure - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.lifevantage.com/role/StockholdersEquityDetails">
        <link:definition>9954496 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationEquitySettledPlansNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails">
        <link:definition>9954497 - Disclosure - Share-Based Compensation - Equity-Settled Plans, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails">
        <link:definition>9954498 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockBasedCompensationNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails">
        <link:definition>9954499 - Disclosure - Share-Based Compensation - Stock-Based Compensation, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionsNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails">
        <link:definition>9954500 - Disclosure - Share-Based Compensation - Stock Options, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionsDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails">
        <link:definition>9954501 - Disclosure - Share-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedSharesDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails">
        <link:definition>9954502 - Disclosure - Share-Based Compensation - Restricted Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails">
        <link:definition>9954503 - Disclosure - Share-Based Compensation - Restricted Stock, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails">
        <link:definition>9954504 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPerformanceRestrictedStockUnitsDetails" roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails">
        <link:definition>9954505 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseNetDetails" roleURI="http://www.lifevantage.com/role/OtherExpenseNetDetails">
        <link:definition>9954506 - Disclosure - Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>9954507 - Disclosure - Income Taxes - Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateDetails" roleURI="http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails" roleURI="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.lifevantage.com/role/LeasesNarrativeDetails">
        <link:definition>9954512 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseCostDetails" roleURI="http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails">
        <link:definition>9954513 - Disclosure - Leases - Schedule of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>9954514 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>9954515 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>9954515 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lfvn_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lfvn_CommissionAndIncentives" abstract="false" name="CommissionAndIncentives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" abstract="false" name="ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" abstract="true" name="CashAccountsHeldPrimarilyAtFinancialInstitutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" abstract="true" name="CashAccountsHeldatOtherFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lfvn_NumberOfFinanceLeases" abstract="false" name="NumberOfFinanceLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lfvn_NumberOfGeographicSegments" abstract="false" name="NumberOfGeographicSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lfvn_InventoryFinishedGoodsPercentOfTotalInventory" abstract="false" name="InventoryFinishedGoodsPercentOfTotalInventory" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_RawMaterialsPercentOfTotalInventory" abstract="false" name="RawMaterialsPercentOfTotalInventory" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_InventoryPercentOfTotalInventory" abstract="false" name="InventoryPercentOfTotalInventory" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_ProtandimandTrueScienceProductLineMember" abstract="true" name="ProtandimandTrueScienceProductLineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_MoneyBackGuaranteePeriod" abstract="false" name="MoneyBackGuaranteePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lfvn_HandlingAndRestockingFeePercentage" abstract="false" name="HandlingAndRestockingFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_ReturnLiabilityReserve" abstract="false" name="ReturnLiabilityReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_NumberOfProductLines" abstract="false" name="NumberOfProductLines" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lfvn_AsiaPacificAndEuropeMember" abstract="true" name="AsiaPacificAndEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_ProtandimMember" abstract="true" name="ProtandimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_LifeVantageTrueScienceSkinCareRegimenMember" abstract="true" name="LifeVantageTrueScienceSkinCareRegimenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_AccruedPayableToVendors" abstract="false" name="AccruedPayableToVendors" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_March2016RevolvingLoanMember" abstract="true" name="March2016RevolvingLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_March2016TermLoanMember" abstract="true" name="March2016TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_DebtInstrumentFloorInterestRate" abstract="false" name="DebtInstrumentFloorInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" abstract="false" name="DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" abstract="false" name="DebtInstrumentCovenantRequiredMinimumWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_DebtInstrumentCovenantMaximumDividend" abstract="false" name="DebtInstrumentCovenantMaximumDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" abstract="false" name="CommonStockDividendsPerShareCashPaidOneTimeDividend" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lfvn_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lfvn_TwoThousandAndTenLongTermIncentivePlanMember" abstract="true" name="TwoThousandAndTenLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" abstract="true" name="TwoThousandSeventeenLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" abstract="true" name="TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" abstract="true" name="TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lfvn_PerformanceStockUnitsMember" abstract="true" name="PerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_OtherMiscellaneousIncomeExpensesNet" abstract="false" name="OtherMiscellaneousIncomeExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_PermanentDifferencesAbstract" abstract="true" name="PermanentDifferencesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" abstract="false" name="EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lfvn_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" abstract="false" name="UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" abstract="false" name="UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_UnrecognizedTaxPosition" abstract="false" name="UnrecognizedTaxPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="lfvn_LesseeOperatingLeaseMonthlyPayments" abstract="false" name="LesseeOperatingLeaseMonthlyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lfvn_LesseeOperatingLeaseAnnualAmount" abstract="false" name="LesseeOperatingLeaseAnnualAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lfvn-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c81ef-a112-48da-974a-2cc210170cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17df24d0-d473-409a-8d72-de29eb467a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c81ef-a112-48da-974a-2cc210170cd6" xlink:to="loc_us-gaap_Liabilities_17df24d0-d473-409a-8d72-de29eb467a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_61619e70-ab6b-4671-ab11-f4eb797bc062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c81ef-a112-48da-974a-2cc210170cd6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_61619e70-ab6b-4671-ab11-f4eb797bc062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7a823d1e-9d83-47f6-8bb0-3587664049c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c81ef-a112-48da-974a-2cc210170cd6" xlink:to="loc_us-gaap_StockholdersEquity_7a823d1e-9d83-47f6-8bb0-3587664049c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_61e1073a-835c-4774-901b-3937848d8b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:to="loc_us-gaap_AccountsPayableCurrent_61e1073a-835c-4774-901b-3937848d8b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_1c8c49a4-0d7f-40eb-9cfa-e8d87a5ded0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_1c8c49a4-0d7f-40eb-9cfa-e8d87a5ded0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_5f2e93f8-156e-460b-983e-376969cd0403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_5f2e93f8-156e-460b-983e-376969cd0403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_059a207f-8006-47e6-add1-2692548b57fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_059a207f-8006-47e6-add1-2692548b57fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f070add-78f3-4a97-8035-75411cc54051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5398616d-7e0e-41c5-9e8e-58042bb0c36c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f070add-78f3-4a97-8035-75411cc54051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_42755749-6aab-46af-a5dd-8acfff32a4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cdbe223c-6a06-4934-8e09-bbbb718043d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_42755749-6aab-46af-a5dd-8acfff32a4a8" xlink:to="loc_us-gaap_LiabilitiesCurrent_cdbe223c-6a06-4934-8e09-bbbb718043d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c4301a1-b112-4cae-9151-4d655f0474f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_42755749-6aab-46af-a5dd-8acfff32a4a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c4301a1-b112-4cae-9151-4d655f0474f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_069adc92-20ed-462a-8091-0a3b52d615b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_42755749-6aab-46af-a5dd-8acfff32a4a8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_069adc92-20ed-462a-8091-0a3b52d615b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2e38bae6-4041-4054-9a4c-3e5e274bc40c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:to="loc_us-gaap_PreferredStockValue_2e38bae6-4041-4054-9a4c-3e5e274bc40c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1011da79-2e16-47be-b24c-826b5930240e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:to="loc_us-gaap_CommonStockValue_1011da79-2e16-47be-b24c-826b5930240e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_253eb5bb-734a-41d2-b580-811228744555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_253eb5bb-734a-41d2-b580-811228744555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26e92c89-3eae-4905-b3e6-d8f414e9b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26e92c89-3eae-4905-b3e6-d8f414e9b95f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53310574-321c-4ffb-b9ba-03420c626055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_82a106c8-8fcb-4729-8515-9d3171346bd3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53310574-321c-4ffb-b9ba-03420c626055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be4f84a4-ade9-4856-86a9-4b6400c2b328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be4f84a4-ade9-4856-86a9-4b6400c2b328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aaed1bea-7d63-4948-85ba-5455e7b817b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aaed1bea-7d63-4948-85ba-5455e7b817b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_76b84b86-b51e-484e-a249-4c29e42a4c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_76b84b86-b51e-484e-a249-4c29e42a4c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_32f5d7d0-677f-419b-a53b-66bfa8236dee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:to="loc_us-gaap_InventoryNet_32f5d7d0-677f-419b-a53b-66bfa8236dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0182d50-cb0f-4271-aa6e-ea212f85d9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482b64cb-3542-4ad3-bc3b-21baef06c0d6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0182d50-cb0f-4271-aa6e-ea212f85d9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fbdb87dc-5d04-4b71-89da-0a6ccfea3e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_AssetsCurrent_fbdb87dc-5d04-4b71-89da-0a6ccfea3e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff817e7b-43e0-493b-b7eb-1d82a7570cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff817e7b-43e0-493b-b7eb-1d82a7570cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4adbf9cb-5781-4876-9392-3d564abdf845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4adbf9cb-5781-4876-9392-3d564abdf845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ce41d18b-0163-4681-981a-28416480c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ce41d18b-0163-4681-981a-28416480c4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c279ddd8-e3a6-4669-80b4-a21946dd382e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c279ddd8-e3a6-4669-80b4-a21946dd382e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8e1ce698-4103-4f2d-a382-e42b2eaeef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1171beae-fae2-4e5e-82c3-b333a71c5d54" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8e1ce698-4103-4f2d-a382-e42b2eaeef1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56531bea-2e54-48c2-91f3-5256c6286562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71e86e06-24f1-44a1-b738-68a53b847d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56531bea-2e54-48c2-91f3-5256c6286562" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71e86e06-24f1-44a1-b738-68a53b847d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_316410b9-a5b7-496d-b0a1-309b6442dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommissionAndIncentives_af26fbdb-97cd-44bd-9707-ed2ba4863c90" xlink:href="lfvn-20240630.xsd#lfvn_CommissionAndIncentives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_316410b9-a5b7-496d-b0a1-309b6442dc1b" xlink:to="loc_lfvn_CommissionAndIncentives_af26fbdb-97cd-44bd-9707-ed2ba4863c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_024db25e-0d81-4de9-85f3-b285aac5369e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_316410b9-a5b7-496d-b0a1-309b6442dc1b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_024db25e-0d81-4de9-85f3-b285aac5369e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_641fb11a-3569-4979-9f4a-8392c9556df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e62ac61a-761b-4f95-b8eb-8cccefd0d9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_641fb11a-3569-4979-9f4a-8392c9556df1" xlink:to="loc_us-gaap_GrossProfit_e62ac61a-761b-4f95-b8eb-8cccefd0d9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_eee5c247-03bb-4f20-80fb-8398b8285139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_641fb11a-3569-4979-9f4a-8392c9556df1" xlink:to="loc_us-gaap_OperatingExpenses_eee5c247-03bb-4f20-80fb-8398b8285139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e62ff410-00b0-4fbe-90dd-afb1f3be423d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f56f30ba-570a-4930-a220-95cb19b666c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e62ff410-00b0-4fbe-90dd-afb1f3be423d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f56f30ba-570a-4930-a220-95cb19b666c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b98a737e-1be8-4520-8c65-0342989e894d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e62ff410-00b0-4fbe-90dd-afb1f3be423d" xlink:to="loc_us-gaap_InterestExpense_b98a737e-1be8-4520-8c65-0342989e894d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7a39f6b-6e5b-4358-b3ba-143f4b69b079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_053418bb-6b6e-4452-b606-0daa0f3f1143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7a39f6b-6e5b-4358-b3ba-143f4b69b079" xlink:to="loc_us-gaap_OperatingIncomeLoss_053418bb-6b6e-4452-b606-0daa0f3f1143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_977d0628-134f-458a-9c02-7b6ffdcae588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7a39f6b-6e5b-4358-b3ba-143f4b69b079" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_977d0628-134f-458a-9c02-7b6ffdcae588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c9a3398-dcc8-48a9-8d75-1918567fc71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a64750b-c7b5-404b-9ff1-7eed301f6599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c9a3398-dcc8-48a9-8d75-1918567fc71a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a64750b-c7b5-404b-9ff1-7eed301f6599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d84f8c10-5bfc-4abf-8447-9dddc10033dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c9a3398-dcc8-48a9-8d75-1918567fc71a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d84f8c10-5bfc-4abf-8447-9dddc10033dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_00a56b3a-4c44-47c4-b8bb-78c3c0c7fa70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b0bd09-d149-4400-aefa-1d8931eae3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_00a56b3a-4c44-47c4-b8bb-78c3c0c7fa70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b0bd09-d149-4400-aefa-1d8931eae3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7dac4c22-7c86-425b-8110-70e1cd52cb52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_00a56b3a-4c44-47c4-b8bb-78c3c0c7fa70" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7dac4c22-7c86-425b-8110-70e1cd52cb52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ebfb354f-4e9c-429c-a569-573ec8d4bb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00050972-6531-4412-86c7-826a0c9097be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ebfb354f-4e9c-429c-a569-573ec8d4bb8f" xlink:to="loc_us-gaap_NetIncomeLoss_00050972-6531-4412-86c7-826a0c9097be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6ddffc2f-8d1e-4223-b6a8-bb0b0ba44be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ebfb354f-4e9c-429c-a569-573ec8d4bb8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6ddffc2f-8d1e-4223-b6a8-bb0b0ba44be5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d47d29-acbe-47ec-9d71-4e867584d4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccc74e87-732b-44f8-9fa4-01bc5aa2a265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d47d29-acbe-47ec-9d71-4e867584d4c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccc74e87-732b-44f8-9fa4-01bc5aa2a265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382ee810-2a93-4f18-b428-ee5b31d75410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d47d29-acbe-47ec-9d71-4e867584d4c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382ee810-2a93-4f18-b428-ee5b31d75410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f937d41-4d76-4530-8ebf-bfe0747fd82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d47d29-acbe-47ec-9d71-4e867584d4c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f937d41-4d76-4530-8ebf-bfe0747fd82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01d794a2-40cf-4181-9318-ca62f906214b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d47d29-acbe-47ec-9d71-4e867584d4c8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01d794a2-40cf-4181-9318-ca62f906214b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_428bfb11-7911-4cae-9c4f-9ee7ee6efde9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_428bfb11-7911-4cae-9c4f-9ee7ee6efde9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_36ae7e0e-d912-410b-940a-4a99c7ccc438" xlink:href="lfvn-20240630.xsd#lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:to="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_36ae7e0e-d912-410b-940a-4a99c7ccc438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d2967856-4e53-471b-b9d9-0377c3c7acda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d2967856-4e53-471b-b9d9-0377c3c7acda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_91d10a20-6c99-43b4-aa7a-ed01887ed7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:to="loc_us-gaap_PaymentsOfDividends_91d10a20-6c99-43b4-aa7a-ed01887ed7b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_d18373f4-5a5b-4f9d-a438-a8140a13ed33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f9ef202-54db-4faf-98ec-cab12f60a8b2" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_d18373f4-5a5b-4f9d-a438-a8140a13ed33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_41799480-e373-458f-9521-d92bb80dea94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_41799480-e373-458f-9521-d92bb80dea94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b3cdefd1-1cbb-486d-a4c3-47ca94f1d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b3cdefd1-1cbb-486d-a4c3-47ca94f1d1d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2c7cedff-f6d7-4c8d-aa5b-f19d2b7d9e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_ShareBasedCompensation_2c7cedff-f6d7-4c8d-aa5b-f19d2b7d9e86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2a8aaece-da89-4fe9-bef8-a2bddfeb5dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2a8aaece-da89-4fe9-bef8-a2bddfeb5dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f1b0d09-a654-4caa-a5b1-279cb2458580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f1b0d09-a654-4caa-a5b1-279cb2458580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd2b42e2-a168-45c8-a504-9a8f4a141060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd2b42e2-a168-45c8-a504-9a8f4a141060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_01cb8000-d91c-4f7d-b5a2-594ea18242c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_01cb8000-d91c-4f7d-b5a2-594ea18242c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_88ae53be-e883-45eb-a26b-2f847abcfd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_88ae53be-e883-45eb-a26b-2f847abcfd1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_14fdcb9a-b8d7-4554-b708-70e95f872561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_14fdcb9a-b8d7-4554-b708-70e95f872561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1b880d1c-d6e4-4c6f-9f58-dd22eaf1cb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1b880d1c-d6e4-4c6f-9f58-dd22eaf1cb3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cb07d707-1ec4-4d46-9d8e-54f81cfd6a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cb07d707-1ec4-4d46-9d8e-54f81cfd6a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_eed05a2a-4cf9-48be-b69c-c75bcbca2401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_eed05a2a-4cf9-48be-b69c-c75bcbca2401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d71d10b1-c099-4f1a-a365-b72af734a273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_NetIncomeLoss_d71d10b1-c099-4f1a-a365-b72af734a273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_280074f3-ec09-44ea-bdec-8549b61cf61c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_280074f3-ec09-44ea-bdec-8549b61cf61c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5fa5a513-62ae-4efc-81df-0ff45350d2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5fa5a513-62ae-4efc-81df-0ff45350d2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f3ddb2f7-148c-4f4d-a12a-65f9aebd3eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f3ddb2f7-148c-4f4d-a12a-65f9aebd3eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_377f5270-7903-48c5-9a46-d34b96cb3f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3f8d3ca-6dac-40ca-a282-fff848df9c0e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_377f5270-7903-48c5-9a46-d34b96cb3f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7094d404-92a7-4bdc-868c-acafa4c8163a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424cfd91-1746-4cef-819f-8cef8086d346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7094d404-92a7-4bdc-868c-acafa4c8163a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424cfd91-1746-4cef-819f-8cef8086d346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bb20853e-237a-4205-b8d2-811f3bea706d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7094d404-92a7-4bdc-868c-acafa4c8163a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_bb20853e-237a-4205-b8d2-811f3bea706d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryPercentOfTotalInventory_c9d3e1d6-b66e-403a-8dbe-5b253fdedb97" xlink:href="lfvn-20240630.xsd#lfvn_InventoryPercentOfTotalInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_276e51f4-7b98-42dd-aaef-66c0c1eac0e8" xlink:href="lfvn-20240630.xsd#lfvn_InventoryFinishedGoodsPercentOfTotalInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lfvn_InventoryPercentOfTotalInventory_c9d3e1d6-b66e-403a-8dbe-5b253fdedb97" xlink:to="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_276e51f4-7b98-42dd-aaef-66c0c1eac0e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_RawMaterialsPercentOfTotalInventory_8bd299c5-ee98-4bf0-9b46-4c7245bb4f16" xlink:href="lfvn-20240630.xsd#lfvn_RawMaterialsPercentOfTotalInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lfvn_InventoryPercentOfTotalInventory_c9d3e1d6-b66e-403a-8dbe-5b253fdedb97" xlink:to="loc_lfvn_RawMaterialsPercentOfTotalInventory_8bd299c5-ee98-4bf0-9b46-4c7245bb4f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_36ac711f-23b8-40aa-90e6-4063452dd50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_3d221373-6a4e-462f-8d13-28c3638a8854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_36ac711f-23b8-40aa-90e6-4063452dd50b" xlink:to="loc_us-gaap_InventoryFinishedGoods_3d221373-6a4e-462f-8d13-28c3638a8854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0595c0fa-2fe0-4a2b-ad70-6cc405f0a4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_36ac711f-23b8-40aa-90e6-4063452dd50b" xlink:to="loc_us-gaap_InventoryRawMaterials_0595c0fa-2fe0-4a2b-ad70-6cc405f0a4cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4db47c69-18ab-4b53-b46e-423d16eb41e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70a9480a-d2dd-4bd2-839b-bf168c44e603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4db47c69-18ab-4b53-b46e-423d16eb41e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70a9480a-d2dd-4bd2-839b-bf168c44e603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_84eb1337-fa14-4bd8-8b16-9bf1282b7f17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4db47c69-18ab-4b53-b46e-423d16eb41e5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_84eb1337-fa14-4bd8-8b16-9bf1282b7f17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19f7fec5-8562-4e8d-85b4-dfb3e3d89812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1da9224f-d6d7-446f-bfeb-83b4effc3569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_19f7fec5-8562-4e8d-85b4-dfb3e3d89812" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1da9224f-d6d7-446f-bfeb-83b4effc3569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78b4c04c-2b3f-4751-864d-b2db25f63dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_19f7fec5-8562-4e8d-85b4-dfb3e3d89812" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78b4c04c-2b3f-4751-864d-b2db25f63dda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89d84605-c1ef-47d4-9dc9-ec1088c09b73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9faafb8b-032a-471d-8adc-6500f6df94ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89d84605-c1ef-47d4-9dc9-ec1088c09b73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9faafb8b-032a-471d-8adc-6500f6df94ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f80ee753-f209-4770-bb44-2ec9f7f72834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89d84605-c1ef-47d4-9dc9-ec1088c09b73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f80ee753-f209-4770-bb44-2ec9f7f72834" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherAccruedExpensesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/OtherAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_47242900-e342-4348-a0bc-5f0a9f903ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_47242900-e342-4348-a0bc-5f0a9f903ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_355da0ea-5f0f-4bcd-868c-f245470c5908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_355da0ea-5f0f-4bcd-868c-f245470c5908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_62981e3c-1735-4976-aaed-64eb11b65679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_TaxesPayableCurrent_62981e3c-1735-4976-aaed-64eb11b65679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_212d3603-d015-4f97-aadd-507ad886b0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_212d3603-d015-4f97-aadd-507ad886b0f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AccruedPayableToVendors_03eb9797-4008-47ef-98ab-fba766b84721" xlink:href="lfvn-20240630.xsd#lfvn_AccruedPayableToVendors"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_lfvn_AccruedPayableToVendors_03eb9797-4008-47ef-98ab-fba766b84721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1078f783-2377-4c13-9ae5-990cf604f87a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1078f783-2377-4c13-9ae5-990cf604f87a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_21fd759f-1748-4c64-9e74-fac18d53325e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ace70a57-ba78-4b45-8d5e-e9f64d5c5768" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_21fd759f-1748-4c64-9e74-fac18d53325e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherExpenseNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/OtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ce1cdba7-df30-40e8-94cd-778c1b1134e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_dada09c4-cd8b-4ab4-9b09-8d54f8afe05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_ce1cdba7-df30-40e8-94cd-778c1b1134e3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_dada09c4-cd8b-4ab4-9b09-8d54f8afe05f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_OtherMiscellaneousIncomeExpensesNet_ff73686c-6903-43c8-b229-8ce670419060" xlink:href="lfvn-20240630.xsd#lfvn_OtherMiscellaneousIncomeExpensesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_ce1cdba7-df30-40e8-94cd-778c1b1134e3" xlink:to="loc_lfvn_OtherMiscellaneousIncomeExpensesNet_ff73686c-6903-43c8-b229-8ce670419060" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb9de9eb-961a-44d3-ab64-db35d11d87dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a15d604-72ce-4908-962d-13b997ea715c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cb9de9eb-961a-44d3-ab64-db35d11d87dc" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a15d604-72ce-4908-962d-13b997ea715c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3f3a61e1-20cd-4f20-935b-683fa5e6c7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cb9de9eb-961a-44d3-ab64-db35d11d87dc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3f3a61e1-20cd-4f20-935b-683fa5e6c7f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0abf2d88-fb7a-450a-9815-58700bbc7e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7a5c3c24-3de1-487d-aeac-134159bf1593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0abf2d88-fb7a-450a-9815-58700bbc7e4c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7a5c3c24-3de1-487d-aeac-134159bf1593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8b3ba6e1-9623-4829-9963-51c7cbd35ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0abf2d88-fb7a-450a-9815-58700bbc7e4c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8b3ba6e1-9623-4829-9963-51c7cbd35ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_99c912ad-01e8-4ece-8906-9e7e3c829658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0abf2d88-fb7a-450a-9815-58700bbc7e4c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_99c912ad-01e8-4ece-8906-9e7e3c829658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6967e9e0-d515-456e-bc64-73bc016fd520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9dc0907d-d1d1-43d2-9009-8466dc5e93da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6967e9e0-d515-456e-bc64-73bc016fd520" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9dc0907d-d1d1-43d2-9009-8466dc5e93da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_af9c0a6f-ad7d-4466-af22-8d2836bf2b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6967e9e0-d515-456e-bc64-73bc016fd520" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_af9c0a6f-ad7d-4466-af22-8d2836bf2b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f304f10e-7059-4a18-8100-066eb905d13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6967e9e0-d515-456e-bc64-73bc016fd520" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f304f10e-7059-4a18-8100-066eb905d13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c8000f1-a656-4d47-811c-afd6a7670eda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ba6fea30-d7bc-46fd-8687-6d0a9186fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c8000f1-a656-4d47-811c-afd6a7670eda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ba6fea30-d7bc-46fd-8687-6d0a9186fd81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_00780cf0-5f1a-4965-9c04-451340a92abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c8000f1-a656-4d47-811c-afd6a7670eda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_00780cf0-5f1a-4965-9c04-451340a92abd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_dfea1370-3b0d-46f1-b081-3bfa36825f79" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_dfea1370-3b0d-46f1-b081-3bfa36825f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_a4c865bf-f28f-44ab-ae0d-b4864d9afbde" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_a4c865bf-f28f-44ab-ae0d-b4864d9afbde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_24cc8139-4234-461b-a968-8c225c6354c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_24cc8139-4234-461b-a968-8c225c6354c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_83eae443-525c-4754-8f51-5c55db17b142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_83eae443-525c-4754-8f51-5c55db17b142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1b1fa818-031c-42df-88fe-a63c8971d1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1b1fa818-031c-42df-88fe-a63c8971d1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8bbd003f-2e8a-4da6-ac72-edfdf5c37ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8bbd003f-2e8a-4da6-ac72-edfdf5c37ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_d4f63bb9-9871-4a9b-8500-4a014420454e" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_d4f63bb9-9871-4a9b-8500-4a014420454e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_222ab1b6-20e4-4b6b-a4c3-8dac9b5b0664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_222ab1b6-20e4-4b6b-a4c3-8dac9b5b0664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee0560b2-1da4-4528-9336-341df7ce111b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee0560b2-1da4-4528-9336-341df7ce111b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_b5f236b8-ea6c-4e8e-97d0-2cdff7a970ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_b5f236b8-ea6c-4e8e-97d0-2cdff7a970ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9eaf34ac-1df6-4c48-8b0f-b8398ebeb889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9eaf34ac-1df6-4c48-8b0f-b8398ebeb889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_bf44d81f-0302-4168-a9ad-854b077ccbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_bf44d81f-0302-4168-a9ad-854b077ccbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_c9780be7-7729-4503-acd9-e84555150c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_c9780be7-7729-4503-acd9-e84555150c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_16ad4258-345d-490c-bd96-68007099a58c" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_16ad4258-345d-490c-bd96-68007099a58c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_42ce4328-6f09-4e5d-a9e7-0031493f3e7c" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_42ce4328-6f09-4e5d-a9e7-0031493f3e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27160459-817e-449c-b40d-04db436f62f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27160459-817e-449c-b40d-04db436f62f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0ae634df-1bb7-4c1a-a311-1839a5d1bced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0ae634df-1bb7-4c1a-a311-1839a5d1bced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_06bbd8ae-28e8-4745-9ec7-674047de5100" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34857b23-b0e9-4f99-8632-3c70470094e7" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_06bbd8ae-28e8-4745-9ec7-674047de5100" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_657e836e-cd36-4fad-974f-7b2e806f0226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e0e6c21-a61a-439c-8a6d-0ac386330622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_657e836e-cd36-4fad-974f-7b2e806f0226" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e0e6c21-a61a-439c-8a6d-0ac386330622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_83946296-9ba5-41b8-919f-d9c413998e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_657e836e-cd36-4fad-974f-7b2e806f0226" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_83946296-9ba5-41b8-919f-d9c413998e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4ed80a33-bdc6-4d1b-924e-9973ffa79f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_657e836e-cd36-4fad-974f-7b2e806f0226" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4ed80a33-bdc6-4d1b-924e-9973ffa79f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eb8fe131-6aea-4571-b3a6-6183cdd96e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eb8fe131-6aea-4571-b3a6-6183cdd96e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_c87392c7-d3ec-4825-b7d4-82dea67aa757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_c87392c7-d3ec-4825-b7d4-82dea67aa757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DeferredTaxAssetsLeasingArrangements_605fe296-86e4-4a58-9426-fc1891f67e85" xlink:href="lfvn-20240630.xsd#lfvn_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:to="loc_lfvn_DeferredTaxAssetsLeasingArrangements_605fe296-86e4-4a58-9426-fc1891f67e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e6e22998-dce5-4540-a3bf-5076b2b88f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e6e22998-dce5-4540-a3bf-5076b2b88f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_97a5365b-5418-40d1-995a-5a18067b6ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fbfc364b-7d61-42d0-8e49-15fea97cfc66" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_97a5365b-5418-40d1-995a-5a18067b6ba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b6f54560-dacb-4842-b6a7-e2774268abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5dbc2759-27b6-4d61-ad97-0e2e79f24ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b6f54560-dacb-4842-b6a7-e2774268abdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5dbc2759-27b6-4d61-ad97-0e2e79f24ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_83d1fd79-bf9c-45d0-b014-1ce0defb0db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b6f54560-dacb-4842-b6a7-e2774268abdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_83d1fd79-bf9c-45d0-b014-1ce0defb0db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ec6c3eea-2241-42c7-a87f-69d1a306ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b6f54560-dacb-4842-b6a7-e2774268abdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ec6c3eea-2241-42c7-a87f-69d1a306ec21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0b4a36d4-a932-4244-8150-ddb38356c6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b6f54560-dacb-4842-b6a7-e2774268abdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0b4a36d4-a932-4244-8150-ddb38356c6b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a074e32a-a0af-4c44-95f6-fc7b58edb95d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_75663d28-911c-4e83-93b1-f3c812dcdc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a074e32a-a0af-4c44-95f6-fc7b58edb95d" xlink:to="loc_us-gaap_OperatingLeaseCost_75663d28-911c-4e83-93b1-f3c812dcdc75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_47188673-49a6-4d8f-ad2f-14b98e0fd07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a074e32a-a0af-4c44-95f6-fc7b58edb95d" xlink:to="loc_us-gaap_ShortTermLeaseCost_47188673-49a6-4d8f-ad2f-14b98e0fd07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_827a3f89-e7b8-412b-bfef-dfe6af3709fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a074e32a-a0af-4c44-95f6-fc7b58edb95d" xlink:to="loc_us-gaap_VariableLeaseCost_827a3f89-e7b8-412b-bfef-dfe6af3709fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_893ddb84-cac6-41fc-a5b3-a3943e94883f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_893ddb84-cac6-41fc-a5b3-a3943e94883f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54c977e0-e9a7-4a4e-93f9-71e42b5a1c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54c977e0-e9a7-4a4e-93f9-71e42b5a1c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_42d08ce0-eb7f-4e8d-acbe-49d6e6a76a67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_42d08ce0-eb7f-4e8d-acbe-49d6e6a76a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6bdc9bcb-5ea8-4e2a-9b11-c9f44bab61d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6bdc9bcb-5ea8-4e2a-9b11-c9f44bab61d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cfe7ee11-a21e-428a-9c0d-a42295434fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cfe7ee11-a21e-428a-9c0d-a42295434fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7aca603a-17c8-4dea-b6fc-db7bbd24bc43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb9b5233-f43b-46bf-ab06-f1876cbcc11d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7aca603a-17c8-4dea-b6fc-db7bbd24bc43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ff0e66c-4f1b-486e-92f8-05636d6d6013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e6db18ad-de8f-4ffa-8475-b103d6105eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ff0e66c-4f1b-486e-92f8-05636d6d6013" xlink:to="loc_us-gaap_OperatingLeaseLiability_e6db18ad-de8f-4ffa-8475-b103d6105eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2818f648-7d93-4b5c-ae39-db96c819ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ff0e66c-4f1b-486e-92f8-05636d6d6013" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2818f648-7d93-4b5c-ae39-db96c819ad96" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>lfvn-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:to="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_270af150-7ec6-434a-8b7c-a04f8a8a7735_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:to="loc_us-gaap_EquityComponentDomain_270af150-7ec6-434a-8b7c-a04f8a8a7735_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:to="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a28c62f2-f0f1-432b-a212-9bac06de7877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_CommonStockMember_a28c62f2-f0f1-432b-a212-9bac06de7877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2377a0a-4384-43fa-96ef-713b59a77186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2377a0a-4384-43fa-96ef-713b59a77186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad1e6bc8-229d-492a-b8b4-06762cd8111e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_RetainedEarningsMember_ad1e6bc8-229d-492a-b8b4-06762cd8111e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d09221f0-6e90-438d-83e5-f2ded62283c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d09221f0-6e90-438d-83e5-f2ded62283c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_36b59fae-2d65-481f-a893-b20fa3c91b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_36b59fae-2d65-481f-a893-b20fa3c91b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07da13f1-5449-4823-b602-8397d125bf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockholdersEquity_07da13f1-5449-4823-b602-8397d125bf3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb409cd0-fc85-4abf-8611-2a81a30499db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb409cd0-fc85-4abf-8611-2a81a30499db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e05a89c5-bf6f-4cab-9887-cc00f537094b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e05a89c5-bf6f-4cab-9887-cc00f537094b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c075d848-af90-45e7-ba87-d97405ffb6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c075d848-af90-45e7-ba87-d97405ffb6f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_90e3fcba-c96b-459f-a0d3-12fb504d5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_90e3fcba-c96b-459f-a0d3-12fb504d5f11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_91a26e28-2971-48eb-b093-df1d1cc68030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_91a26e28-2971-48eb-b093-df1d1cc68030" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b7d63ff-9461-4549-864b-4677492ae003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b7d63ff-9461-4549-864b-4677492ae003" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8f0770da-6727-42ae-92ea-cbbf024d22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8f0770da-6727-42ae-92ea-cbbf024d22fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c98ac6f5-f3e3-4f85-af10-4b7bdd034565" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c98ac6f5-f3e3-4f85-af10-4b7bdd034565" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_0f77ee0f-9730-40de-af41-7c55a40a818a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_DividendsCash_0f77ee0f-9730-40de-af41-7c55a40a818a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fd39ed17-668a-49ad-8098-62ccdcda6aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fd39ed17-668a-49ad-8098-62ccdcda6aac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3b992bd-4e6f-4c6c-98e3-2ee792df1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_NetIncomeLoss_c3b992bd-4e6f-4c6c-98e3-2ee792df1bdc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cc29c38-1e18-4fc1-8e64-a3fdc75584d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_28a9bdea-08c1-4956-acda-c27875354c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:to="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_05fb255b-4bd5-4fbb-b7e5-a74781851990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_05fb255b-4bd5-4fbb-b7e5-a74781851990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_60bc175e-bf42-4be4-9e3b-4419bd8eee9b" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:to="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_60bc175e-bf42-4be4-9e3b-4419bd8eee9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_a4e6b35d-3163-4044-8768-dbbb486c3662" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:to="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_a4e6b35d-3163-4044-8768-dbbb486c3662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:href="lfvn-20240630.xsd#lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:to="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_55c30e90-d1d6-4ab9-acc0-a6f8b08c1ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_55c30e90-d1d6-4ab9-acc0-a6f8b08c1ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryAdjustments_dbbd00a2-1d3c-4848-9bbe-38fd9a1be897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_InventoryAdjustments_dbbd00a2-1d3c-4848-9bbe-38fd9a1be897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_eec5c8e7-a9c1-4140-b5a4-aac74ef26ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_eec5c8e7-a9c1-4140-b5a4-aac74ef26ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5aace631-57b0-4cda-b1c8-2986f8526d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5aace631-57b0-4cda-b1c8-2986f8526d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1106fe67-0aa5-4ffc-84b9-58c58091eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1106fe67-0aa5-4ffc-84b9-58c58091eae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfFinanceLeases_97663a1f-c6d3-484a-bddf-3fbda021b6d4" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_lfvn_NumberOfFinanceLeases_97663a1f-c6d3-484a-bddf-3fbda021b6d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_695c3724-a612-4cf8-a3a8-b404e1d00051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_695c3724-a612-4cf8-a3a8-b404e1d00051" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfGeographicSegments_91b558c5-5901-4b02-9d9c-51de77b4b98e" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfGeographicSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_lfvn_NumberOfGeographicSegments_91b558c5-5901-4b02-9d9c-51de77b4b98e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:to="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_83c8dee9-85ba-4934-ae50-9dde24501802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:to="loc_us-gaap_InventoryValuationReserveMember_83c8dee9-85ba-4934-ae50-9dde24501802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_cc6bf26b-dd8b-455a-8960-5543ec5d0f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_cc6bf26b-dd8b-455a-8960-5543ec5d0f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_dddceba5-cb34-43df-b897-f6c9a37c15f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_dddceba5-cb34-43df-b897-f6c9a37c15f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_341f7917-77cf-4a19-94ec-465df3d366c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_341f7917-77cf-4a19-94ec-465df3d366c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_94d8181b-dc6e-41d8-94d7-567b2fc1d330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:to="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_069464f8-e706-4f1a-9e2d-9b809ce2a76b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:to="loc_srt_RangeMember_069464f8-e706-4f1a-9e2d-9b809ce2a76b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:to="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3e9316b2-c526-4190-b1b6-cc20cc26681f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:to="loc_srt_MinimumMember_3e9316b2-c526-4190-b1b6-cc20cc26681f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63eaa845-a463-47d8-89bb-df05eb6479c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:to="loc_srt_MaximumMember_63eaa845-a463-47d8-89bb-df05eb6479c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9db99f81-f730-453f-b708-ba2b95822286_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9db99f81-f730-453f-b708-ba2b95822286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_e2a30942-677c-4ccb-8b1b-e1f4933e4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_EquipmentMember_e2a30942-677c-4ccb-8b1b-e1f4933e4f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f3e69974-1b8a-4ca6-89a6-0a46512ea18e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f3e69974-1b8a-4ca6-89a6-0a46512ea18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_1c1a7d7b-3b4e-488f-abf6-dbab74f06608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_VehiclesMember_1c1a7d7b-3b4e-488f-abf6-dbab74f06608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0ef58510-d3d1-46e4-9b05-83e8c12bb57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0ef58510-d3d1-46e4-9b05-83e8c12bb57f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:to="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28f4fd3e-a487-4735-9f0b-d96083e9007e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:to="loc_srt_SegmentGeographicalDomain_28f4fd3e-a487-4735-9f0b-d96083e9007e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:to="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e2b75535-f902-4a2e-a064-c14f03ec9097" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:to="loc_country_US_e2b75535-f902-4a2e-a064-c14f03ec9097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_17409438-979b-4a67-a2c6-7600262114b3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:to="loc_country_JP_17409438-979b-4a67-a2c6-7600262114b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a647551c-a8bc-46b5-9874-ade30fc15bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:to="loc_us-gaap_NoncurrentAssets_a647551c-a8bc-46b5-9874-ade30fc15bb3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_a3cfe0cc-d861-4063-8894-01feba57b3db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_a3cfe0cc-d861-4063-8894-01feba57b3db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9566e6b3-02b8-4332-a71f-ab25481458b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9566e6b3-02b8-4332-a71f-ab25481458b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a5a85a67-44d3-4dbc-af61-cff36aa28865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:to="loc_us-gaap_SalesRevenueNetMember_a5a85a67-44d3-4dbc-af61-cff36aa28865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_77e265f9-9a14-4c31-848a-9adbd820b711_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:to="loc_srt_ProductsAndServicesDomain_77e265f9-9a14-4c31-848a-9adbd820b711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:to="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimandTrueScienceProductLineMember_98ae5198-d702-486c-88d8-f2deaccff421" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimandTrueScienceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:to="loc_lfvn_ProtandimandTrueScienceProductLineMember_98ae5198-d702-486c-88d8-f2deaccff421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_MoneyBackGuaranteePeriod_9f09522b-826d-4c4b-81b3-10df398aa050" xlink:href="lfvn-20240630.xsd#lfvn_MoneyBackGuaranteePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_MoneyBackGuaranteePeriod_9f09522b-826d-4c4b-81b3-10df398aa050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_HandlingAndRestockingFeePercentage_e2f0c723-6b3b-4383-a1f5-a8ffa1a77fd5" xlink:href="lfvn-20240630.xsd#lfvn_HandlingAndRestockingFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_HandlingAndRestockingFeePercentage_e2f0c723-6b3b-4383-a1f5-a8ffa1a77fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ReturnLiabilityReserve_4fef9145-f2eb-4737-b300-6742b84fd82d" xlink:href="lfvn-20240630.xsd#lfvn_ReturnLiabilityReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_ReturnLiabilityReserve_4fef9145-f2eb-4737-b300-6742b84fd82d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfGeographicSegments_49120487-6ab5-47a5-9de5-3e85fa6a7866" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfGeographicSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_NumberOfGeographicSegments_49120487-6ab5-47a5-9de5-3e85fa6a7866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfProductLines_62848e9d-2979-4796-abff-9227466e9dea" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfProductLines"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_NumberOfProductLines_62848e9d-2979-4796-abff-9227466e9dea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e1442506-57e5-4a5f-a60a-3381e40ab8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e1442506-57e5-4a5f-a60a-3381e40ab8c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a8daad28-c179-4516-8db6-785bbab50ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a8daad28-c179-4516-8db6-785bbab50ad4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f26c9458-9f9f-4946-8e4d-86d2c1d16fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f26c9458-9f9f-4946-8e4d-86d2c1d16fd3" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueSalesReturnDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueSalesReturnDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/RevenueSalesReturnDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_25ff3b96-0539-4732-8768-79bfc71a7d73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_25ff3b96-0539-4732-8768-79bfc71a7d73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_99255ad7-40ac-49e5-bd5f-d001a2eac46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_99255ad7-40ac-49e5-bd5f-d001a2eac46d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d7d81f43-501b-4a30-86dc-4d52fb283ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d7d81f43-501b-4a30-86dc-4d52fb283ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c0dfe7f9-67d1-40f6-8da1-9b821492ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c0dfe7f9-67d1-40f6-8da1-9b821492ab56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4164df9e-7c6a-4aea-81cd-e9dc5efd47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4164df9e-7c6a-4aea-81cd-e9dc5efd47c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_312361a2-9338-4232-8360-492e9c7faf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:to="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:to="loc_srt_SegmentGeographicalDomain_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:to="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_7466cfe3-c79a-4762-91eb-83e0458963c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_srt_AmericasMember_7466cfe3-c79a-4762-91eb-83e0458963c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AsiaPacificAndEuropeMember_5e6dd844-a4fa-4f1a-8c69-9303ece5c606" xlink:href="lfvn-20240630.xsd#lfvn_AsiaPacificAndEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_lfvn_AsiaPacificAndEuropeMember_5e6dd844-a4fa-4f1a-8c69-9303ece5c606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_958ae3ce-0ba7-41a4-ad7d-5cf6d5cd1ed9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_country_US_958ae3ce-0ba7-41a4-ad7d-5cf6d5cd1ed9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_e6abef0f-e04b-4415-bf1e-76ed45d49983" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_country_JP_e6abef0f-e04b-4415-bf1e-76ed45d49983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3687a1e0-8c23-4c49-a182-4e2ffc4e2540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3687a1e0-8c23-4c49-a182-4e2ffc4e2540" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueMajorProductsDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueMajorProductsDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/RevenueMajorProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1942a3e-eafe-41ab-b399-56fadcbce7a0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:to="loc_srt_ProductsAndServicesDomain_e1942a3e-eafe-41ab-b399-56fadcbce7a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:to="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimMember_1fc048a9-8d73-4be1-83be-9e8c479feb94" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_lfvn_ProtandimMember_1fc048a9-8d73-4be1-83be-9e8c479feb94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_1b7ae259-4685-454b-991d-4e3924824e53" xlink:href="lfvn-20240630.xsd#lfvn_LifeVantageTrueScienceSkinCareRegimenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_1b7ae259-4685-454b-991d-4e3924824e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_f3847fa6-aca0-4edd-9ca4-6d987dea7151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_f3847fa6-aca0-4edd-9ca4-6d987dea7151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6d761bd0-203c-4151-a383-1fe634a3b6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6d761bd0-203c-4151-a383-1fe634a3b6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_28ad83c6-7b94-4417-a804-2450b04d892c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_28ad83c6-7b94-4417-a804-2450b04d892c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59f04211-d617-4b87-a71f-9f2ac6218968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59f04211-d617-4b87-a71f-9f2ac6218968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f2a12000-7d96-4f2f-af0b-035ae56efa08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:to="loc_us-gaap_SalesRevenueNetMember_f2a12000-7d96-4f2f-af0b-035ae56efa08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24251741-8f9c-474c-b70f-3895e1e22984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24251741-8f9c-474c-b70f-3895e1e22984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_15466eea-35ac-4478-8e56-6fa6e7432886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_15466eea-35ac-4478-8e56-6fa6e7432886" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ed9de84-03dc-4410-bba7-c58a7313b5fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ed9de84-03dc-4410-bba7-c58a7313b5fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c77f2049-c066-43dc-a3f1-131a069500b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_EquipmentMember_c77f2049-c066-43dc-a3f1-131a069500b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1903c643-8f8c-408c-a6a1-e3d30a585508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1903c643-8f8c-408c-a6a1-e3d30a585508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1dc3181e-5ded-43c8-8b60-779537d30bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1dc3181e-5ded-43c8-8b60-779537d30bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_ce5a1e96-2643-4968-b69b-5bc9d3cf0a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_VehiclesMember_ce5a1e96-2643-4968-b69b-5bc9d3cf0a86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e450cf66-f057-48f4-b886-fe0ebc038d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e450cf66-f057-48f4-b886-fe0ebc038d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ec54932a-1d12-4529-89a1-cd74fc9d6417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ec54932a-1d12-4529-89a1-cd74fc9d6417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b0561f9-dfcb-4cb4-a3fc-8dbcd3f1e090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b0561f9-dfcb-4cb4-a3fc-8dbcd3f1e090" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_69200a1c-ff85-4255-b26f-604d373dfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_Depreciation_69200a1c-ff85-4255-b26f-604d373dfe46" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7d0be832-5dd0-4113-aff3-6e39c69b6c18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7d0be832-5dd0-4113-aff3-6e39c69b6c18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_caf1497c-00da-45d2-bfac-a10683632b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:to="loc_us-gaap_PatentsMember_caf1497c-00da-45d2-bfac-a10683632b9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad7c1f6a-3f5e-438a-8446-3db2997f508f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad7c1f6a-3f5e-438a-8446-3db2997f508f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9497519-1bc2-43df-9c97-2c5f6b2fdb25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9497519-1bc2-43df-9c97-2c5f6b2fdb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_130e8441-e0af-4e53-b565-25bd60f97cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_130e8441-e0af-4e53-b565-25bd60f97cca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_64b9ae69-ed6f-47fc-8cfa-d7bbd582db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:to="loc_us-gaap_TrademarksMember_64b9ae69-ed6f-47fc-8cfa-d7bbd582db1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_136bf123-7cfe-492c-a8f7-7f2e81cc8843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_136bf123-7cfe-492c-a8f7-7f2e81cc8843" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6c849da-7010-4677-85b9-c456f62dbc63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6c849da-7010-4677-85b9-c456f62dbc63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016RevolvingLoanMember_979d1d62-366d-4543-b36e-a882fa40fa82" xlink:href="lfvn-20240630.xsd#lfvn_March2016RevolvingLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:to="loc_lfvn_March2016RevolvingLoanMember_979d1d62-366d-4543-b36e-a882fa40fa82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016TermLoanMember_0fe9a535-544f-46fe-ba9e-5c6bd8425d5d" xlink:href="lfvn-20240630.xsd#lfvn_March2016TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:to="loc_lfvn_March2016TermLoanMember_0fe9a535-544f-46fe-ba9e-5c6bd8425d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_04864867-53f6-4420-888a-1c4bff050581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:to="loc_us-gaap_CreditFacilityDomain_04864867-53f6-4420-888a-1c4bff050581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:to="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4e949b75-e49d-4b5b-8101-ff8777c082c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4e949b75-e49d-4b5b-8101-ff8777c082c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_41ceffb7-8ee3-46d3-8706-3d5a96dc85fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:to="loc_us-gaap_SecuredDebtMember_41ceffb7-8ee3-46d3-8706-3d5a96dc85fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3270d2fc-0079-4940-b1c9-e46b7f9df2f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3270d2fc-0079-4940-b1c9-e46b7f9df2f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_57722aa4-fc55-4826-b44d-fcf58bf552c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:to="loc_us-gaap_LineOfCreditMember_57722aa4-fc55-4826-b44d-fcf58bf552c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40a6d374-2fc9-49ae-b548-47153fb08482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40a6d374-2fc9-49ae-b548-47153fb08482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d482cf37-356c-488b-9377-52fed34e70c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d482cf37-356c-488b-9377-52fed34e70c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentFloorInterestRate_14009850-1119-499c-96b0-f63273eda874" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentFloorInterestRate_14009850-1119-499c-96b0-f63273eda874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_8cd913dd-8a33-47a3-8de3-5847055ef567" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_8cd913dd-8a33-47a3-8de3-5847055ef567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_c123674e-87fe-45a6-989d-751ade3b102c" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_c123674e-87fe-45a6-989d-751ade3b102c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_1067fe12-fbae-4eb5-abcf-0eff20e5f2dc" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_1067fe12-fbae-4eb5-abcf-0eff20e5f2dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantMaximumDividend_e33da5e7-97c9-4d95-81ae-2f16b0791048" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantMaximumDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantMaximumDividend_e33da5e7-97c9-4d95-81ae-2f16b0791048" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_d6ad3273-28b1-463b-8f9c-6c166c89f96f" xlink:href="lfvn-20240630.xsd#lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_d6ad3273-28b1-463b-8f9c-6c166c89f96f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17990e0e-94de-4137-97c1-1ca257487246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17990e0e-94de-4137-97c1-1ca257487246" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92ffb862-c90f-46cf-ad62-1e92e7b66585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:to="loc_us-gaap_EquityComponentDomain_92ffb862-c90f-46cf-ad62-1e92e7b66585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:to="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_949d0404-8273-4f18-8f04-6258d37d7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:to="loc_us-gaap_CommonStockMember_949d0404-8273-4f18-8f04-6258d37d7b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18cb908b-e6b4-4239-8cd5-70ce9df1bc19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18cb908b-e6b4-4239-8cd5-70ce9df1bc19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2e99ba0b-4acf-4b73-b2db-d89644a4dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:to="loc_us-gaap_RestrictedStockMember_2e99ba0b-4acf-4b73-b2db-d89644a4dc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2839c68-6923-4ee2-92c6-8d3f145b08f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:to="loc_us-gaap_PlanNameDomain_b2839c68-6923-4ee2-92c6-8d3f145b08f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:to="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EmployeeStockPurchasePlanMember_32d4cebf-638a-48b3-80ce-a113434c003b" xlink:href="lfvn-20240630.xsd#lfvn_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:to="loc_lfvn_EmployeeStockPurchasePlanMember_32d4cebf-638a-48b3-80ce-a113434c003b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_62932888-a089-4589-8f74-4fec4da12265" xlink:href="lfvn-20240630.xsd#lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_62932888-a089-4589-8f74-4fec4da12265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_18781960-8c39-4e74-bf38-607c255d4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_18781960-8c39-4e74-bf38-607c255d4d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_aa4d961d-7fdc-49a1-949d-e68e395456df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_aa4d961d-7fdc-49a1-949d-e68e395456df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a76cb8b-5133-467e-89dd-6fbb917c67fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a76cb8b-5133-467e-89dd-6fbb917c67fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8b22bf41-111e-4b93-8d3a-fd2917e1112a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8b22bf41-111e-4b93-8d3a-fd2917e1112a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_37ab9a49-08f2-4548-8ca2-de34bd2a2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_37ab9a49-08f2-4548-8ca2-de34bd2a2e81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0646696f-a913-4c1a-84e0-f0040132f428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0646696f-a913-4c1a-84e0-f0040132f428" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d6bd9ecc-3019-4fd0-b2aa-fe7773f7c551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d6bd9ecc-3019-4fd0-b2aa-fe7773f7c551" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_66a746ed-bea9-4343-89ba-e3adf8711e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_DividendsCommonStockCash_66a746ed-bea9-4343-89ba-e3adf8711e1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b0c598a2-f059-4452-b1b1-8ed7fdce8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b0c598a2-f059-4452-b1b1-8ed7fdce8a80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantMaximumDividend_b9e88ce8-9004-49bd-8e9e-b1e3dcfc1594" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantMaximumDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_DebtInstrumentCovenantMaximumDividend_b9e88ce8-9004-49bd-8e9e-b1e3dcfc1594" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_f1799671-2848-4c0f-afde-f3be45971a84" xlink:href="lfvn-20240630.xsd#lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_f1799671-2848-4c0f-afde-f3be45971a84" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationEquitySettledPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:to="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:to="loc_us-gaap_PlanNameDomain_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:to="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_04571c61-a084-4c1a-a57d-dbc16caba3d3" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_04571c61-a084-4c1a-a57d-dbc16caba3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_5bab8b5e-3382-4785-9c3b-1f75825beee4" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_5bab8b5e-3382-4785-9c3b-1f75825beee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_9e12970a-a1c9-44ae-95e6-8d85ac1af816" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_9e12970a-a1c9-44ae-95e6-8d85ac1af816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bd0d7c80-03f7-4433-80e0-99bc9f10bb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bd0d7c80-03f7-4433-80e0-99bc9f10bb03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4655db72-6dca-4b13-86d6-b9a6352d57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4655db72-6dca-4b13-86d6-b9a6352d57a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2c7cd416-ad3b-4e70-9271-764408cb9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2c7cd416-ad3b-4e70-9271-764408cb9d2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6a8ace45-26df-44db-80ed-182399610a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6a8ace45-26df-44db-80ed-182399610a4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_ca27782b-dbe0-448a-a9f5-c63a69ba1c10" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_ca27782b-dbe0-448a-a9f5-c63a69ba1c10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5efc748b-ec5c-4467-83b8-ad8c01830fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5efc748b-ec5c-4467-83b8-ad8c01830fd1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:to="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bc040768-8017-4544-9a91-78fe193218ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:to="loc_us-gaap_PlanNameDomain_bc040768-8017-4544-9a91-78fe193218ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:to="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EmployeeStockPurchasePlanMember_2237ebfa-f6ab-40fa-bb61-2612081f679e" xlink:href="lfvn-20240630.xsd#lfvn_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:to="loc_lfvn_EmployeeStockPurchasePlanMember_2237ebfa-f6ab-40fa-bb61-2612081f679e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21d85fa2-9761-441d-a4f9-94fccd7252ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21d85fa2-9761-441d-a4f9-94fccd7252ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ced7cea-46a8-44e3-b50b-ddcc0d88409f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ced7cea-46a8-44e3-b50b-ddcc0d88409f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4db27761-f017-419e-a265-6af4ac48f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4db27761-f017-419e-a265-6af4ac48f08d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48311f52-7220-44c8-9f9a-5d9f49d517e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48311f52-7220-44c8-9f9a-5d9f49d517e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9da9b5c5-330d-45e1-a2b3-2761863fb035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9da9b5c5-330d-45e1-a2b3-2761863fb035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_90393448-7430-4cee-9356-d25ccd0275cc" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_90393448-7430-4cee-9356-d25ccd0275cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ea73cc22-aa0d-4c15-96f1-a5319615af38" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ea73cc22-aa0d-4c15-96f1-a5319615af38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_35e9878c-5051-433b-a69b-bb13ef96f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_35e9878c-5051-433b-a69b-bb13ef96f91c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationStockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:to="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2165209-1f7f-4e8d-9dc0-8d8b989682ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2165209-1f7f-4e8d-9dc0-8d8b989682ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_537a75ce-bdb8-419c-99e5-6eeb017edf47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:to="loc_us-gaap_RestrictedStockMember_537a75ce-bdb8-419c-99e5-6eeb017edf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:to="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fa595383-6b50-4a2a-8129-3fa3bf9de585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:to="loc_us-gaap_PlanNameDomain_fa595383-6b50-4a2a-8129-3fa3bf9de585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:to="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_5ed8b2bf-a220-4b78-8512-50c1f862af4e" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:to="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_5ed8b2bf-a220-4b78-8512-50c1f862af4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ca3a50ac-f0d6-43ad-b5a4-aa52452728ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ca3a50ac-f0d6-43ad-b5a4-aa52452728ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7b6bb06d-37fd-44d7-8153-65c1fe5b8128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7b6bb06d-37fd-44d7-8153-65c1fe5b8128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c24aa54-263e-4255-b863-34cacf8f0bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c24aa54-263e-4255-b863-34cacf8f0bb0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationStockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:to="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b9d822e1-279d-4678-a536-25d5d0329943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:to="loc_us-gaap_VestingDomain_b9d822e1-279d-4678-a536-25d5d0329943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:to="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_826f4db4-c9b8-4388-9f9c-fb7f4c625833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_826f4db4-c9b8-4388-9f9c-fb7f4c625833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a2cf968b-b284-46f7-b6b2-b8f7e4bc5f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a2cf968b-b284-46f7-b6b2-b8f7e4bc5f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:to="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4636330-799e-405b-b4e3-76b0eace1633_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4636330-799e-405b-b4e3-76b0eace1633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32125f01-44e7-4782-bef8-e1a6b12e10c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32125f01-44e7-4782-bef8-e1a6b12e10c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7d3324e9-1b8a-42c9-ba36-66d0b404b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7d3324e9-1b8a-42c9-ba36-66d0b404b7b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ee408fda-007f-4838-bb20-9177b16067ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ee408fda-007f-4838-bb20-9177b16067ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9b9626c-23fe-4849-8dd8-419632c7e244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9b9626c-23fe-4849-8dd8-419632c7e244" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationRestrictedSharesDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:to="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a0f43c5a-b76e-4f6d-9026-90647fd0182b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:to="loc_us-gaap_RestrictedStockMember_a0f43c5a-b76e-4f6d-9026-90647fd0182b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_01544b59-c31e-4bb3-afb5-3ccb90b32b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_01544b59-c31e-4bb3-afb5-3ccb90b32b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32fe7ac6-3095-4e53-820a-2a717ad158c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32fe7ac6-3095-4e53-820a-2a717ad158c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ccdbc25-42de-4748-9c94-9d21095dd974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ccdbc25-42de-4748-9c94-9d21095dd974" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_95a42774-2e8c-4aff-a2b0-8b372b189cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_95a42774-2e8c-4aff-a2b0-8b372b189cc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4757bb70-91ac-46d9-bbaf-65d129b34181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4757bb70-91ac-46d9-bbaf-65d129b34181" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20b27bc8-a100-402c-883f-7237ce66575e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d77c3ed-2577-42b6-b7cf-e224235988bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d77c3ed-2577-42b6-b7cf-e224235988bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50c03ded-acfc-403a-abc0-7e68daba3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50c03ded-acfc-403a-abc0-7e68daba3a96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7b921d3f-c8bd-401d-ad28-f96b18b5aee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7b921d3f-c8bd-401d-ad28-f96b18b5aee1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7c12922e-9c55-484a-8953-61522706ba49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7c12922e-9c55-484a-8953-61522706ba49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_68277001-efd9-4b39-bb94-40dd36bc9172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationRestrictedStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:to="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a10a74f7-d019-4ad6-8935-a1fd81b45cd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a10a74f7-d019-4ad6-8935-a1fd81b45cd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_32f657ba-c248-4413-a75d-543628c47b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:to="loc_us-gaap_RestrictedStockMember_32f657ba-c248-4413-a75d-543628c47b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3babe1f5-2f62-458d-83f6-f34fc02221c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3babe1f5-2f62-458d-83f6-f34fc02221c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8da77e29-8ca5-46ec-8667-50da5711b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8da77e29-8ca5-46ec-8667-50da5711b7e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:to="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67dfa6d6-7e90-4287-84fe-561c4c1bf190_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67dfa6d6-7e90-4287-84fe-561c4c1bf190_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember_c9cab3c1-ed6e-43a4-aca5-21a01bbeeb19" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:to="loc_lfvn_PerformanceStockUnitsMember_c9cab3c1-ed6e-43a4-aca5-21a01bbeeb19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:to="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e59ac95-475b-4547-bb12-932ab7e2214d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:to="loc_srt_RangeMember_8e59ac95-475b-4547-bb12-932ab7e2214d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:to="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b36a0ddb-a9b6-45f4-9e45-16092a628448" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:to="loc_srt_MinimumMember_b36a0ddb-a9b6-45f4-9e45-16092a628448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_41425434-2cc7-4af7-a507-3c9085dac744" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:to="loc_srt_MaximumMember_41425434-2cc7-4af7-a507-3c9085dac744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_4d985260-8c2e-45eb-8209-bf2948103fe4" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:to="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_4d985260-8c2e-45eb-8209-bf2948103fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f69b1c1a-a76a-4a60-a512-7f0fac2da839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f69b1c1a-a76a-4a60-a512-7f0fac2da839" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationPerformanceRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:to="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_684b069e-4eb6-4a72-97b7-96cf66ab872d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_684b069e-4eb6-4a72-97b7-96cf66ab872d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember_52a855e7-9dd4-4427-8487-8e4ac9a130db" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:to="loc_lfvn_PerformanceStockUnitsMember_52a855e7-9dd4-4427-8487-8e4ac9a130db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93562aea-275a-4ce7-875e-5079de10a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93562aea-275a-4ce7-875e-5079de10a13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a1ff155-9706-4e66-b8e0-30d8014465d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a1ff155-9706-4e66-b8e0-30d8014465d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bef0666-ebf6-4068-a434-fec29df1af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bef0666-ebf6-4068-a434-fec29df1af0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0f91f00-45c7-498e-abcd-63bdcd0a7368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0f91f00-45c7-498e-abcd-63bdcd0a7368" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2ffc6ee-ffca-49f6-b74a-e0a89cf565dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3dd0e113-974f-4817-8345-a1a0a7f0217a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3dd0e113-974f-4817-8345-a1a0a7f0217a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9174c5ec-f3a4-41c9-924f-8fe34e2622d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9174c5ec-f3a4-41c9-924f-8fe34e2622d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_529c1910-0387-4f2b-8cf8-5b5133644e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_529c1910-0387-4f2b-8cf8-5b5133644e09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_669599d1-5a72-4e7e-9bfd-036475fef8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_669599d1-5a72-4e7e-9bfd-036475fef8ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4be241a7-97cf-45b9-9a36-3466c6898fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5b6c79fe-7d98-4532-8e3a-df82f3268223_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5b6c79fe-7d98-4532-8e3a-df82f3268223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0d82de53-58e1-4715-9847-c62b9499977b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0d82de53-58e1-4715-9847-c62b9499977b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_884f62d0-236f-4e54-969e-aef181193576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:to="loc_us-gaap_ForeignCountryMember_884f62d0-236f-4e54-969e-aef181193576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_69826b71-3bc9-4817-a74b-5b895ec2f6a7" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_69826b71-3bc9-4817-a74b-5b895ec2f6a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_49c15478-0656-49c4-abe6-a033be117cc4" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_49c15478-0656-49c4-abe6-a033be117cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPosition_0aa18d87-f1cb-4976-b0c3-646388102623" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPosition_0aa18d87-f1cb-4976-b0c3-646388102623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_75a20c79-c697-4955-b336-883b523c8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_75a20c79-c697-4955-b336-883b523c8cb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8ecc966d-09e3-4105-a563-46adfcc3197e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8ecc966d-09e3-4105-a563-46adfcc3197e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_47b0a006-8945-4a66-9f2d-8ee41cf8d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_47b0a006-8945-4a66-9f2d-8ee41cf8d8da" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lifevantage.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:to="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:to="loc_srt_RangeMember_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:to="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21bdc4e-71b0-4a48-8ba5-98bb63e656d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:to="loc_srt_MinimumMember_b21bdc4e-71b0-4a48-8ba5-98bb63e656d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_260299f3-1735-4d18-9b32-68c23e3836f2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:to="loc_srt_MaximumMember_260299f3-1735-4d18-9b32-68c23e3836f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cdd3ef3-d9a5-40bf-b541-0bdf0efc00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cdd3ef3-d9a5-40bf-b541-0bdf0efc00b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3dcad26e-8ac9-4a59-b35a-b00a1c4c4f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3dcad26e-8ac9-4a59-b35a-b00a1c4c4f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0a6bf28b-ad71-44c4-8f86-3c17327d14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0a6bf28b-ad71-44c4-8f86-3c17327d14bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseLeasedArea_6c2cafd4-4886-45b6-b581-4b9a7596109a" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseLeasedArea_6c2cafd4-4886-45b6-b581-4b9a7596109a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0198c612-105f-4074-b1c5-36e175362685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0198c612-105f-4074-b1c5-36e175362685" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseMonthlyPayments_eb1c80a7-1abd-4cb3-800d-2a342cae27b6" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseMonthlyPayments_eb1c80a7-1abd-4cb3-800d-2a342cae27b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseAnnualAmount_56022f62-c39f-4f66-81a6-853d8237c492" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseAnnualAmount_56022f62-c39f-4f66-81a6-853d8237c492" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember_3d168681-f90c-4a1f-9ae3-f65c70291ca4" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lfvn_PerformanceStockUnitsMember_3d168681-f90c-4a1f-9ae3-f65c70291ca4" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>lfvn-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_50fd0f97-80c2-4b88-a37d-7733ce03a7e5_terseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8212; current year section 162(m) limitation</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Current Year Section 162(m) Limitation, Percent</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Current Year Section 162(m) Limitation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48c89da5-1674-4abe-b0d8-ab65f815b8e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of employee compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b0dabc23-3617-47a6-8fb6-f175acedc4ff_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_53f7801a-d6f0-4a3a-956e-e6061a78a617_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized amount of common stock repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_b9deebbb-c38c-4ed7-a16c-c71241609950_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_91997a2c-b9c3-45ba-bdf3-633e65dc4ac3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bddfc6e7-9900-459b-8d40-e649bf3974ff_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_86ac4634-83c5-442b-9d93-17dcfcba590e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4889bd4-ae56-4bad-b382-c7c36e9142a7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ea951a0-b046-4a18-b444-1bf42a7cd41c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_131f7bff-b06c-4012-bccf-1d0047c9e06e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_95f90ddf-6ad6-4809-b40d-43dec78f4e50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_63468466-1b96-4c75-a266-4cfe0f310f93_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_7db1bf96-00d4-4cc6-a7c1-c9e9e9f83cf9_terseLabel_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities to tangible net worth ratio (not greater than)</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_label_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Total Liabilities To Tangible Net Worth Ratio</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_documentation_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Total Liabilities To Tangible Net Worth Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:to="lab_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0ff000f9-54aa-49a6-a739-c447ccac6ee4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8261a02b-1c82-4be6-9a8c-45902e30b5cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Computation of Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_733740f6-9d10-4dab-84cf-3832a2f934ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_1fed5db7-0827-4ecb-b518-976320ae7de5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_32c82a13-d9e3-45be-8dbf-07e22abeb04c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b36acf9f-54b8-4cdb-a615-c3a571d050d6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_eb2aa9b4-c8b3-4fd0-98e5-bdc22bf06028_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f40a1b70-f021-4cfb-90b6-d60ac462d083_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd9466a2-9a0f-4db3-84e5-caaf49723e7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2232f6d8-f233-4771-8c8f-bc97f644f648_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1aaf1128-ed95-4f35-acb6-7ddbbed3d3c1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under equity award plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1e875116-29c9-4edd-ab11-46fa4e33bc20_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted common stock to employees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b29f6fd9-cf8d-45fe-94d1-5cd61e2279d7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_AuditorInformationAbstract_label_en-US" xlink:label="lab_lfvn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_lfvn_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_lfvn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AuditorInformationAbstract" xlink:href="lfvn-20240630.xsd#lfvn_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_AuditorInformationAbstract" xlink:to="lab_lfvn_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_b4ece389-20c8-4b96-86e0-2026b2ec264a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Nonvested Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_799d24be-8cbf-43e9-ad2e-17ff0df3fc3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_63bf7904-3ba6-4178-9530-c77f82950c74_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1d99fc18-b0b1-4ee6-af2e-a4fef19bfda9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b0896af6-c97b-422f-ba0b-c6ecd6bfc48c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0b191dae-5241-4d22-9792-385989b65e0c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6ad60da5-ea1b-445e-97a7-29c65c4114af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DebtInstrumentCovenantMaximumDividend_9918778e-ee04-4946-9fa2-f72bc4cdbffe_terseLabel_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum dividend</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantMaximumDividend_label_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument. Covenant, Maximum Dividend</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantMaximumDividend_documentation_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument. Covenant, Maximum Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantMaximumDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:to="lab_lfvn_DebtInstrumentCovenantMaximumDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_83f0da15-0356-4398-a4de-e3972a717029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_cbac0810-eaf8-44bf-a7d8-661cc4cf3b89_verboseLabel_en-US" xlink:label="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies Additional Information [Abstract]</link:label>
    <link:label id="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_label_en-US" xlink:label="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies (Textual) [Abstract]</link:label>
    <link:label id="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_documentation_en-US" xlink:label="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:href="lfvn-20240630.xsd#lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_02454a0f-f615-495b-b352-22ac862da954_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_50b4969c-b7d9-4219-b31c-2995a370dfd9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7bc50a83-9114-4baf-8576-f16de1ed2845_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_8e128c64-1296-452d-a0a0-0b9093cbbc6a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_107bbe5e-0a0f-4329-8602-e4e349aaa544_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_49d3853b-008a-4905-aee2-e229edd8b30f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3b5a98e3-1067-4be2-bf82-e359eb43d9ab_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8f4a8dba-d66c-4d74-9c69-21c779b54d44_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_abbc52d2-853c-4dc7-96b2-3d769fdc7e1d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_cc421401-ba68-4127-99f2-e3c504e98c45_terseLabel_en-US" xlink:label="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:href="lfvn-20240630.xsd#lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:to="lab_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dd2850e9-d738-44f6-b9ad-58f401ab80ae_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f84c1bf7-1a41-48a4-ae15-ec4000b2e66d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a6ef9a74-200a-4dbe-9647-4175befd3275_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d42d4fd4-cffa-4cae-a990-5e8c14764c19_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent costs</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3289245d-0985-4416-9a03-b6b911153729_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d0c2903d-0b1e-4f88-af1d-f929cb89c78b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a46435b7-a598-4832-a318-61b045d1c704_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The effective income tax rate differs from the U.S. Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_19286376-7db7-46cd-ab4b-d5189e3c763e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_2bd45178-840e-4e1d-a895-16905e8693bf_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1179a66-0650-43f0-9947-96839db5d6e9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_c9104d0b-fb8c-4d3d-85f9-dba91ee0c87e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_CommissionAndIncentives_3956a3e7-8056-4056-9a50-af4b54a8038a_verboseLabel_en-US" xlink:label="lab_lfvn_CommissionAndIncentives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commissions and incentives</link:label>
    <link:label id="lab_lfvn_CommissionAndIncentives_label_en-US" xlink:label="lab_lfvn_CommissionAndIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commission And Incentives</link:label>
    <link:label id="lab_lfvn_CommissionAndIncentives_documentation_en-US" xlink:label="lab_lfvn_CommissionAndIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses related to commissions and other incentives earned by independent distributors. Commission and incentive expenses include sales commissions paid to our independent distributors, special incentives, costs for incentive trip and other rewards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommissionAndIncentives" xlink:href="lfvn-20240630.xsd#lfvn_CommissionAndIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_CommissionAndIncentives" xlink:to="lab_lfvn_CommissionAndIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_01e94599-2591-4ad5-a68e-c83d3bef6df1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_52944b17-b81a-44ff-914f-4bf12d5bc7cf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_d62330a9-66c7-4900-b8b5-b62268c91bd0_terseLabel_en-US" xlink:label="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One time dividend (dollars per share)</link:label>
    <link:label id="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_label_en-US" xlink:label="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend</link:label>
    <link:label id="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_documentation_en-US" xlink:label="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:href="lfvn-20240630.xsd#lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:to="lab_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6b6872f7-2d80-41ce-a429-709c6174f578_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e2f09bd0-4f82-4ed7-8ce4-a017529cd4e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8454201d-f27c-492d-98c0-521a4c06b096_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6e987a5e-1e3e-40a6-aa3d-c500fc8960b2_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dc949ed9-0bc5-4ed6-b793-64b19d304957_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_8765cb7a-2fac-4f61-a127-a579387bb072_terseLabel_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount in excess of fair market value of stock for option not to be granted</link:label>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_label_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Amount In Excess Of Fair Market Value Of Stock For Option Not To Be Granted</link:label>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_documentation_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Amount In Excess Of Fair Market Value Of Stock For Option Not To Be Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:to="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_247a72c5-c4c8-4094-86c1-d0d5a921ff22_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_5565c1ce-9b54-48af-b1c8-1f277384e0dc_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_fbfe96be-8699-4f71-a102-7d9f9d0bdf56_terseLabel_en-US" xlink:label="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Accounts Held Primarily At Financial Institution</link:label>
    <link:label id="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_label_en-US" xlink:label="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Accounts Held Primarily At Financial Institution [Member]</link:label>
    <link:label id="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_documentation_en-US" xlink:label="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Accounts Held Primarily At Financial Institution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:to="lab_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d8a3b586-8e13-476b-992e-94e06d565753_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_65c48aa2-893a-4ab1-8501-a7d54fa5d0f1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a87b1f0e-6dca-46b4-a944-ada66831d6c7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_40a3d2e9-73c6-4bcb-abae-57ee8dc349a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5e9c1c7b-491b-4980-8672-df401dd3a899_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c96267a-7a46-491d-8943-82f1024b33fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_715cca1d-af76-4536-87d4-44afdeeb7960_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_a7827839-bdda-42b3-a994-05ea8ee0f1f0_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_1b3b4537-a9e8-464f-9d9e-454769165a2c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of company stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_713e9c43-b987-4e00-9442-1d03806a923f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5a4a6831-cf86-496f-8b1a-5aa902975df0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1231dca2-ff1d-4c7f-95dc-c4955f152ebc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_66988b93-d343-4afd-bccf-f2dffde60034_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed8f1188-90bd-4385-b2a4-fdc32c639c6e_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8e05660f-0c79-4e86-a40d-73e43e5a87bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting on January 1, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ProtandimMember_eac99b5f-5f30-4c31-a652-13c813a2b6ab_terseLabel_en-US" xlink:label="lab_lfvn_ProtandimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Protandim&#174; product line</link:label>
    <link:label id="lab_lfvn_ProtandimMember_label_en-US" xlink:label="lab_lfvn_ProtandimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Protandim [Member]</link:label>
    <link:label id="lab_lfvn_ProtandimMember_documentation_en-US" xlink:label="lab_lfvn_ProtandimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Protandim [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimMember" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ProtandimMember" xlink:to="lab_lfvn_ProtandimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c3d6324a-2a2a-437f-bc2c-23f6a5154633_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d1ac1ffc-ffaf-48db-9a1b-4fbc7c029f34_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ProtandimandTrueScienceProductLineMember_cab59c0b-8867-4a92-b42f-22d712c1dfcb_terseLabel_en-US" xlink:label="lab_lfvn_ProtandimandTrueScienceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Protandim and TrueScience Product Line</link:label>
    <link:label id="lab_lfvn_ProtandimandTrueScienceProductLineMember_label_en-US" xlink:label="lab_lfvn_ProtandimandTrueScienceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Protandim and TrueScience Product Line [Member]</link:label>
    <link:label id="lab_lfvn_ProtandimandTrueScienceProductLineMember_documentation_en-US" xlink:label="lab_lfvn_ProtandimandTrueScienceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Protandim and TrueScience Product Line [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimandTrueScienceProductLineMember" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimandTrueScienceProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ProtandimandTrueScienceProductLineMember" xlink:to="lab_lfvn_ProtandimandTrueScienceProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b718061-b983-413a-ad7f-99fca486a8ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e04d38e4-7c7d-480e-a02c-cf3766b3199a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_5b3c4eac-fbbf-4115-92e2-b26c53f938fd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued incentives and promotions to consultants</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_f56bf6e9-2ca9-46e7-8aba-f5396838a025_terseLabel_en-US" xlink:label="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TrueScience&#174; product line</link:label>
    <link:label id="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_label_en-US" xlink:label="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LifeVantage TrueScience Skin Care Regimen [Member]</link:label>
    <link:label id="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_documentation_en-US" xlink:label="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LifeVantage TrueScience Skin Care Regimen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:href="lfvn-20240630.xsd#lfvn_LifeVantageTrueScienceSkinCareRegimenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:to="lab_lfvn_LifeVantageTrueScienceSkinCareRegimenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_03f16b6d-454c-4cc7-b53d-96480e03d661_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9cf95f60-8b22-4489-acce-2a58f0abff8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_88b265b9-b995-4c1e-b320-9dfe5b73e8df_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb09c77f-33c0-403c-b48d-a4d47fdb1603_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_983a3654-0fe6-4566-a26e-051d43334cf8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0f676bcd-88f0-47bc-9185-287a21946642_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares purchased as payment of tax withholding and other</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9c071d2a-ebe1-4dbd-9a69-0c247c562dd8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_3aca81a6-3ccb-4920-a205-37c78776aa65_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase common stock amount authorized (up to)</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_21f722fa-a63a-411b-9bac-00d849960e86_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_a9bb9c70-03bc-4ece-b9b2-5820498b23b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_94329c4a-9cce-4373-aeeb-943e54c2e616_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_21e16530-852e-4211-9ca0-74a29069bcad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2f310fb6-9bba-45c3-9a37-f1e637a960d3_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_NumberOfFinanceLeases_fd767a38-af9d-4ded-8abb-b9460835257d_terseLabel_en-US" xlink:label="lab_lfvn_NumberOfFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of finance leases</link:label>
    <link:label id="lab_lfvn_NumberOfFinanceLeases_label_en-US" xlink:label="lab_lfvn_NumberOfFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Finance Leases</link:label>
    <link:label id="lab_lfvn_NumberOfFinanceLeases_documentation_en-US" xlink:label="lab_lfvn_NumberOfFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfFinanceLeases" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_NumberOfFinanceLeases" xlink:to="lab_lfvn_NumberOfFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f089fe5-d978-4824-8d31-499aabcd1dd0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_d6bdf466-3964-4c21-8eae-93c6c6301cc5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_aed1bada-0156-49e6-973b-cca12084bf6e_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b316b15a-2fa3-4cd6-9d05-43d05fc536b9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4fe0e5f7-3f56-4dff-b5bf-2c579675cf55_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_547c2515-fa18-45b7-b050-93aee07428b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2c1de953-e4d4-41e0-8762-25d3b393032f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a9826c91-a4cb-4929-8ec6-733ee580b391_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of earnings per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_597f1267-ab36-4240-b498-006c9e84ccae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c6204203-dc9b-490b-9c85-325c6b6963ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d5a07117-7da4-423d-a9ee-6fe8d6450217_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ce5556da-6f92-4033-91af-42b917c00bdb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c005340a-2255-4f78-9b8b-a19a54419950_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7939d88d-c43f-47b2-81c0-daed124eb8a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1e1a2f0d-9e0b-4b94-a1e6-364acee9aae7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_HandlingAndRestockingFeePercentage_a37ad6a9-dd0d-422f-befb-0640e40d15ea_terseLabel_en-US" xlink:label="lab_lfvn_HandlingAndRestockingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Handling and restocking fee, percentage</link:label>
    <link:label id="lab_lfvn_HandlingAndRestockingFeePercentage_label_en-US" xlink:label="lab_lfvn_HandlingAndRestockingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Handling and Restocking Fee, Percentage</link:label>
    <link:label id="lab_lfvn_HandlingAndRestockingFeePercentage_documentation_en-US" xlink:label="lab_lfvn_HandlingAndRestockingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Handling and Restocking Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_HandlingAndRestockingFeePercentage" xlink:href="lfvn-20240630.xsd#lfvn_HandlingAndRestockingFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_HandlingAndRestockingFeePercentage" xlink:to="lab_lfvn_HandlingAndRestockingFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_37db4a85-7d43-4bdc-bcd5-5d9cf582b4f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividend, common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_59038149-8e75-4532-baba-99589f0943d1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_PerformanceStockUnitsMember_550f02f4-00db-4b02-82d4-d4753e2eb705_terseLabel_en-US" xlink:label="lab_lfvn_PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:label id="lab_lfvn_PerformanceStockUnitsMember_label_en-US" xlink:label="lab_lfvn_PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units [Member]</link:label>
    <link:label id="lab_lfvn_PerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_lfvn_PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_PerformanceStockUnitsMember" xlink:to="lab_lfvn_PerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6ae9f60a-7ab4-4df0-bacc-1148e9235c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c8808f89-d172-491a-873a-45cc861c2ad1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4e9cfd1c-73d6-44ac-ab00-d1d0f3f27e6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abfa13f2-afad-4701-abf9-46d94e3a96ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7f8269a0-b4c6-465a-b12b-25338ea60b62_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_7f0bfafa-0f3a-4cf7-a3e8-e37fe3cd29ed_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_ad12b691-38fa-4a6a-99cb-c0cb8baf50ef_terseLabel_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Long Term Incentive Plan Excluding 2010 Long Term Incentive Plan</link:label>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_label_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Long Term Incentive Plan, Excluding Two Thousand And Ten Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Long Term Incentive Plan, Excluding Two Thousand And Ten Long Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:to="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c23be90-88e3-4df8-8795-482f49fc3db8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0cffdc3-ff23-4d36-b2a3-c1845ce4a0b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c05bf7b2-ac2b-4afc-b04a-379240e70b44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d08c4f24-ceb6-49ec-8d8a-29282fba2690_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d9b93f92-2c70-4c7c-84f5-f8627fa3f796_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Shares</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_41a2325a-43ad-4aed-b947-7d334770c010_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a3af6970-7334-48ab-975a-fdee316366f0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_5638a20b-ce3c-43ce-aa2b-a58f79bca129_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_88efe37a-9c17-496d-b73b-fc0d24ed1936_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal, state, and foreign net operating loss carryovers</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_RawMaterialsPercentOfTotalInventory_aa11173f-e9d2-4d14-a039-e15328d25a64_terseLabel_en-US" xlink:label="lab_lfvn_RawMaterialsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_lfvn_RawMaterialsPercentOfTotalInventory_label_en-US" xlink:label="lab_lfvn_RawMaterialsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw Materials, Percent Of Total Inventory</link:label>
    <link:label id="lab_lfvn_RawMaterialsPercentOfTotalInventory_documentation_en-US" xlink:label="lab_lfvn_RawMaterialsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raw Materials, Percent Of Total Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_RawMaterialsPercentOfTotalInventory" xlink:href="lfvn-20240630.xsd#lfvn_RawMaterialsPercentOfTotalInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_RawMaterialsPercentOfTotalInventory" xlink:to="lab_lfvn_RawMaterialsPercentOfTotalInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_b5f86cc8-8948-4576-8acd-8dc088042bc3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equipment (includes computer hardware and software)</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_26958171-3712-4486-b1cc-15b4416a5599_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment (includes computer hardware and software)</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1ef2466-e43c-4cf8-98db-493270876113_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_109f7850-41e5-49ee-a77f-2d8413276a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3cf2d40d-5b7a-44fa-b47c-4253d162c242_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b17d671e-2a34-4f5f-b46c-524e5f795861_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_59fb1628-8056-477d-b9b3-a167de48a419_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_401dd18f-7824-4d90-bec8-61b1c8360fff_terseLabel_en-US" xlink:label="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_label_en-US" xlink:label="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Percent Of Total Inventory</link:label>
    <link:label id="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_documentation_en-US" xlink:label="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Percent Of Total Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:href="lfvn-20240630.xsd#lfvn_InventoryFinishedGoodsPercentOfTotalInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:to="lab_lfvn_InventoryFinishedGoodsPercentOfTotalInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b3e0eaf-2f17-49cb-94d9-5a88f32d9c5d_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_40b52218-555d-461b-9bf0-a87a3962faed_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_439a698a-fa2a-46b5-ae53-f687f0a0b165_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f85ae438-3db8-4aec-8b1a-41ddb134d618_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5f5b653b-88a2-4620-ab32-f513a75b52d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6e121633-5bfd-43c0-8c2b-3c3d9520074e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ecb0472f-7f08-4c51-b132-ab2312054a35_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_079d1162-3c26-4a58-8241-73fe6a036921_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_MoneyBackGuaranteePeriod_3d6bb8c9-0b27-4f90-8880-567a54540748_terseLabel_en-US" xlink:label="lab_lfvn_MoneyBackGuaranteePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money back guarantee period</link:label>
    <link:label id="lab_lfvn_MoneyBackGuaranteePeriod_label_en-US" xlink:label="lab_lfvn_MoneyBackGuaranteePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Back Guarantee Period</link:label>
    <link:label id="lab_lfvn_MoneyBackGuaranteePeriod_documentation_en-US" xlink:label="lab_lfvn_MoneyBackGuaranteePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Money Back Guarantee Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_MoneyBackGuaranteePeriod" xlink:href="lfvn-20240630.xsd#lfvn_MoneyBackGuaranteePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_MoneyBackGuaranteePeriod" xlink:to="lab_lfvn_MoneyBackGuaranteePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_22a03e47-c28d-45dd-b500-cad50e6089a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_92501e75-a2eb-4708-8ec5-0ff3f6d0b9f3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6b5bb6d3-f05a-4bb4-a87f-dba5e180af9b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_f473712a-4088-46ce-b9a1-9cec0e9e8cd5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4d94e778-29f9-4933-b176-b69fd3d89b1b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_dba44706-5aa0-4dd5-bd57-02afcc31de8c_terseLabel_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Long-Term Incentive Plan</link:label>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_label_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Long Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:to="lab_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_OtherMiscellaneousIncomeExpensesNet_c4ab4436-bf9b-4d30-8c13-cb51f964e4c1_terseLabel_en-US" xlink:label="lab_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_lfvn_OtherMiscellaneousIncomeExpensesNet_label_en-US" xlink:label="lab_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expenses), Net</link:label>
    <link:label id="lab_lfvn_OtherMiscellaneousIncomeExpensesNet_documentation_en-US" xlink:label="lab_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expenses), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:href="lfvn-20240630.xsd#lfvn_OtherMiscellaneousIncomeExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:to="lab_lfvn_OtherMiscellaneousIncomeExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c1f04111-4a60-4539-b575-81e7e176e354_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_fbaa5c9d-4a45-4b78-a64e-acf84c84d14d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares that can be purchased during any offering period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ae74a08-5e98-44d7-9f98-6ab2b3241f90_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4e5bdc51-d598-499d-93c9-4eef38b1e8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c51353f3-6a01-4c79-98cd-7564ed2911e6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_11482169-8c4c-42b2-adb9-2b0776c7339b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum common stock issued under Long-Term Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_01a5198e-1a8e-4441-a223-56414eb7d0f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_02b40dcb-73f3-475f-99bf-c74030748081_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c3820927-08a6-4b8f-9695-d3620a297595_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28d94dfd-eaef-4d3d-b899-ccfb4d27db62_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a8f3092-0fd5-41d9-ae97-c28b3e31cf9f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_de9efd64-3831-42bf-9322-9ea369505a75_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_UnrecognizedTaxPosition_8b5cff05-1835-46bd-ac74-3bfc0b13edf9_terseLabel_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax position</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPosition_label_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPosition_documentation_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPosition" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_UnrecognizedTaxPosition" xlink:to="lab_lfvn_UnrecognizedTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7c8c823-438a-4966-8430-81aa10747149_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2e74214f-9c9c-4639-9267-45d5af2b9902_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_1f706b78-6b67-4776-b5c0-9b830fa1baa3_verboseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax return to provision true-up</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Return To Provisions True Up</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation tax return to provisions true up.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c8821dea-099c-41ac-aa4c-877b5947e5e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3816b202-e7ce-4180-a71d-4dd0900ea825_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_49916a5a-d502-4715-86f6-d8badbf0fa35_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_e2b9278e-d25f-4d22-89a4-e30e78b32e64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommissionsExpensePolicyPolicyTextBlock_f9c94b36-8992-426b-bf9e-b29c859f03cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions and Incentives</link:label>
    <link:label id="lab_us-gaap_CommissionsExpensePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commissions Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommissionsExpensePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:to="lab_us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c54319e5-2fc6-4683-a685-03ca21f471b0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_a517909b-095a-43c7-a6c7-937dd44dbd34_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3ff3e01c-86fd-4f27-a769-4a188bd437b8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and other indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d3ef2c39-adfc-4ebd-bb92-d7fd00b290a6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e2ff629a-e88b-4bac-a792-229c413aa800_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_91f37b06-7301-438a-944d-d68c479d8d86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred financing fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9aa6da9e-71d6-4d83-8c99-646acb6e7f48_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bedb0314-7e96-4ed6-9da0-0b5eaa0bcbb5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1c62cae6-7db8-483c-a34b-486f59bcb839_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_90ed66c0-8601-486a-9c91-c52234606120_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ca545c1d-8ba2-44f6-8a05-f61bc275b446_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_bb565b08-9b0e-48a8-aa4c-b00ef7f590e7_terseLabel_en-US" xlink:label="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of options and warrants, shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:href="lfvn-20240630.xsd#lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9d85c884-bd22-4e76-a33a-8ca5d0e92cd2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_64142a7c-d88b-405b-b48b-a17db231603a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired or Canceled (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_632f6d2d-dce4-415e-9777-5c7061e4705d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dd57a417-369e-4b1d-a1fe-a7b0d11a38cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2b4b9316-e3e0-472d-8035-8f7374338db7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c4254e67-c8a9-462e-9993-43144cd7ea28_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b7fee779-64f2-4a1e-a510-0141703fa919_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_2bf8f9ab-6a24-420b-80b1-09ac75b73bde_terseLabel_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase resulting from settlements with tax authorities</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_label_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position, Increase Resulting From Settlements With Tax Authorities</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_documentation_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position, Increase Resulting From Settlements With Tax Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:to="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_503c6cea-9587-4d27-acbb-693bae60fb8b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2fbf2e7f-d074-45c8-afce-7b3db7208b00_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4f18b3d-a7dd-42dc-abb8-65434a38be35_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_de326b0a-e7da-4ef5-b572-515be883f256_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9e1a44-6d29-478f-82c7-5b2fc594018e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9303dac6-3d1d-44ec-9899-bfe890319232_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property&#160;&amp; equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_fbe9e164-f828-45a3-8da7-a061c41d68e3_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_978740f4-8345-4e7a-b1e3-957b6845b2ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cc9c32b3-01f1-4986-8e51-b27637d572ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock option compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_2bbab73f-5ad2-414a-a575-ac33c5df1bb6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_b3bd0900-3730-4786-976d-d3b4dda4b2b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ReturnLiabilityReserve_60b57366-62c4-4366-a8e8-bec6411485d0_terseLabel_en-US" xlink:label="lab_lfvn_ReturnLiabilityReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return liability reserve</link:label>
    <link:label id="lab_lfvn_ReturnLiabilityReserve_label_en-US" xlink:label="lab_lfvn_ReturnLiabilityReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return Liability Reserve</link:label>
    <link:label id="lab_lfvn_ReturnLiabilityReserve_documentation_en-US" xlink:label="lab_lfvn_ReturnLiabilityReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Return Liability Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ReturnLiabilityReserve" xlink:href="lfvn-20240630.xsd#lfvn_ReturnLiabilityReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ReturnLiabilityReserve" xlink:to="lab_lfvn_ReturnLiabilityReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_baca0b1c-d793-41be-9f5d-2be80b63a213_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_cd4ab2c7-73e6-4b62-9971-65f4155518e4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b90bf459-6ac4-49a8-8283-d155ff4e30fe_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8b5ee095-8b52-4064-a40b-75ab085e69f6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c5fc4960-d393-4130-871e-d4460e051f53_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income per share, diluted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bd879873-80fa-4352-bf95-2dd28573585f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2328d32e-ffa8-4f11-a174-049f32cdad33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3308dc71-bb6d-464a-94f9-c441874bb2ad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling, Revenue And Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ba6363cb-99fc-4ac1-8048-041397b1b984_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_34943d69-230b-40c3-be4b-893fd727157f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_467ba1f6-616b-4d24-b1b4-d7871f724096_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_203fd5f6-0727-4a0f-a9a9-9303f76389e9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_21204749-83bb-47ab-b2d2-2b066b7f0eed_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3035555d-3906-4b6c-a2b4-50a36e2fa170_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting right percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_0adf8ad1-d537-4118-8fc3-f5b6fb35262f_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e50bce61-6e3a-46f6-98a6-4bd0c81c94ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_d5271271-8228-4c5b-b372-bda9633c2648_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_82415b5a-5ae9-43be-be3c-2386743ea362_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction loss, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_bf74ed73-59ef-44b3-9e14-65b1b24d4ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e30800cb-daca-45d1-8738-b8c95f985718_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_78b591c5-a608-4d84-83ef-dba586cd6b24_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">&#8212; foreign derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a4423c36-dcbe-4a81-811a-59ce966b3425_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7c250780-63af-42e2-94db-a1f646a1e671_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_bd8a30d2-3c7b-45b3-be18-e064dc8798e1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding stock options (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_89e40268-9ec8-48cf-8e2d-1641bd23410f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_cb70584f-0cc6-4a12-acc1-5ebbf1b8e4ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6410d517-e8e1-485e-891a-bb9bedb50eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4ecade08-2c9d-429d-ab06-6fe1c7adfe27_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting on the last day of each fiscal quarter following January 1, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6f0c4d04-097e-488c-8de6-5473ffb17ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_df64ecc5-087e-4a96-a482-9b251157f0cf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3ee4c205-1acc-483f-b4c0-3956ea2490b8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_45c1ee54-7476-4663-9937-8b9fca4c7352_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8212; accrual for foreign tax audits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_437ec2b7-d80a-4f36-b9fa-c5970f45029c_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_ec06f1a2-107c-44e1-b1cf-072b1264eadb_terseLabel_en-US" xlink:label="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2010 and 2017 Long Term Incentive Plan</link:label>
    <link:label id="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_label_en-US" xlink:label="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Ten and Two Thousand Seventeen Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Ten and Two Thousand Seventeen Long Term Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:to="lab_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6c542b37-5cc4-4a27-8b2f-7f2ca911dfc5_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2cb01385-80f6-48c4-b124-1098f12ae88a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for recognition of unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b84c0b89-104d-4779-a3c6-6f8d4ddfb815_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_976e3d8d-d0e8-4294-8de9-c5c362821a98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_68f6ce6f-f628-4221-b41c-4d68839d11cd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b38e2c7e-fa1d-41ac-998d-9407bad5321d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_30e41bac-cdce-45a6-b937-9945ee3cf8da_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e4cc2d73-f3d1-41fe-899e-5e69b9cc272e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc65c517-f965-4948-9369-41ef59598ba1_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income tax provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_InventoryPercentOfTotalInventory_7a330cc1-1310-4a56-8c6c-916711843bec_totalLabel_en-US" xlink:label="lab_lfvn_InventoryPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_lfvn_InventoryPercentOfTotalInventory_label_en-US" xlink:label="lab_lfvn_InventoryPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Percent Of Total Inventory</link:label>
    <link:label id="lab_lfvn_InventoryPercentOfTotalInventory_documentation_en-US" xlink:label="lab_lfvn_InventoryPercentOfTotalInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Percent Of Total Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryPercentOfTotalInventory" xlink:href="lfvn-20240630.xsd#lfvn_InventoryPercentOfTotalInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_InventoryPercentOfTotalInventory" xlink:to="lab_lfvn_InventoryPercentOfTotalInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39413e4f-06dc-4d91-8ad7-c8bdf26e9a84_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3633e7a2-60c5-4175-8035-5e8e6ac6644a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_be3f200c-b3d8-4a57-9305-1ad57836cccf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2e95f961-4185-4cb3-9078-98ab5ac7999c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7526021f-baed-45e4-a571-444615e75861_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d118c94e-81d6-448d-8419-5d6e2540d2ae_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">&#8212; stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cd83c13b-2bca-4a05-a665-2029c3434398_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5e195304-0fab-4d53-9e46-950a9db6cd12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_941fdfbb-b4f7-464d-b293-b7c6924e21f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_b774f403-cfa4-4139-9e11-00b264989734_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of cash dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_959b4548-f975-4568-8e24-2a1633333463_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_38ac76a3-c250-4f32-b08f-5c5f53f65456_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryAdjustments_b0722d7b-ee6e-4498-909d-367963d07342_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in inventory</link:label>
    <link:label id="lab_us-gaap_InventoryAdjustments_label_en-US" xlink:label="lab_us-gaap_InventoryAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryAdjustments" xlink:to="lab_us-gaap_InventoryAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d12a152-1a9a-48fc-8e63-4c0552e49b90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled or surrendered as payment of tax withholding and other</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72bf1a99-8b0a-4c72-9676-5b7a640e0d8e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_555baca0-a9d3-4bf3-9146-989f3ea90302_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d74924ea-25df-470a-8b26-c7f51d8aefc5_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7b0b81d4-8004-4cd3-9af2-041bf492258f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_PermanentDifferencesAbstract_9cc80802-a3d9-420e-9dc2-32ead1feb8bf_verboseLabel_en-US" xlink:label="lab_lfvn_PermanentDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences:</link:label>
    <link:label id="lab_lfvn_PermanentDifferencesAbstract_label_en-US" xlink:label="lab_lfvn_PermanentDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent Differences [Abstract]</link:label>
    <link:label id="lab_lfvn_PermanentDifferencesAbstract_documentation_en-US" xlink:label="lab_lfvn_PermanentDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Permanent differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PermanentDifferencesAbstract" xlink:href="lfvn-20240630.xsd#lfvn_PermanentDifferencesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_PermanentDifferencesAbstract" xlink:to="lab_lfvn_PermanentDifferencesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0f5afd9a-4231-4707-8692-462cd057e5ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_437e412a-7f16-46c4-9b68-9b5516272b0c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_07ba23ad-9e1f-4d6a-b0da-465e391e5fa6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_304c8349-c621-4082-800a-195e14df266b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8d207194-0cfa-49a4-95a8-7deabbd66775_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_a5161e70-1494-4cc6-93c7-f4d2a7841861_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6c844f3a-fd83-4f3d-977f-c05bc095c1dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e1fc5a10-267a-4e83-97d7-4dc528f453a7_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4bce7fec-a7f3-407b-8c29-20299328994b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2717d3e-c9d5-4940-9c26-d04c50593913_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_482a9f97-dc28-4d7c-9ec4-d9aaeacb0c62_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0973b3b-a4b2-4863-a374-e8ff73e1c5f2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2843a409-b84d-49c1-912b-d92f8e0e767f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DeferredTaxAssetsLeasingArrangements_0be25868-4aeb-4318-8203-e5220d5dc9a5_terseLabel_en-US" xlink:label="lab_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_lfvn_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_lfvn_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:href="lfvn-20240630.xsd#lfvn_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_lfvn_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a4bdaa19-fa88-4c3f-8085-1d4ad4707654_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_a0d594c1-5da4-4097-9a00-eaf9ac91d311_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent_3320baa5-4e0e-428c-a060-8ba950560683_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued incentive compensation</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1c41f72b-d519-4046-b846-76a6ed92856e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b06dd6c-72a2-45c1-b853-7aa10af2d9cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c120a3dc-45a0-4606-b151-bcdb04016ce0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6eb501a4-14ef-4fd6-bc6f-42bfde74fd7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_80e415f4-3620-4ceb-8dec-1541d5e7bca5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_26929d7a-ca7a-4d30-932f-cc09fe90ce90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4a30698f-9c29-4935-801a-14359d6365b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's common stock purchased in aggregate (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d7b37312-af6e-4a9b-bb3a-f872440bf684_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_653aa069-cde5-4e75-8342-fb3271cf6656_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_3e218049-606b-40a4-91aa-1b63346d271c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Recorded bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fa76a6ba-f431-4c9e-b171-3903cbcfad3f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_0320a4e9-0899-4941-9f0f-7dca02fcf758_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_01c1eb21-7e3d-472c-9ca8-4bf07db968ed_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1bf17f10-0b7a-4646-b637-b89e1dceecd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of The Components of the Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6c5f3c87-a554-46c7-a180-4e59c7e57c8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_e1736795-61ca-4c4c-b195-3105d24a8619_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_03a16e26-f388-46c9-b882-d3a58b6fddff_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ffbb024-f7a5-4653-ab54-4db0110c0a13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_527bc7d5-1d92-482c-a035-9d2e4cb3b98d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_533060df-2622-4a71-b02b-86a0e840bd12_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d1609327-7c3c-43b3-bb07-f6fe3b1e8cff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_d963a025-d5d9-4969-a1f1-9a8668f77d5a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8212; meals and entertainment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_16aa0e2e-4778-4c75-b463-06f17a2f0993_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c1dc23f8-5a04-4cb5-b7e5-1f6564dcb3f0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_LesseeOperatingLeaseMonthlyPayments_9e3ff81b-355a-478d-8332-910800cf6b59_terseLabel_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly payments</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseMonthlyPayments_label_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Payments</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseMonthlyPayments_documentation_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:to="lab_lfvn_LesseeOperatingLeaseMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_LesseeOperatingLeaseAnnualAmount_ed821c59-b8fd-4e14-af4f-2506f2ffdf23_terseLabel_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual amount</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseAnnualAmount_label_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Amount</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseAnnualAmount_documentation_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:to="lab_lfvn_LesseeOperatingLeaseAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5e935c47-1c4c-4b63-ab74-1b24e7f4b79f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c0cdf573-64e6-4c5e-920e-6026afaded50_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14931354-d883-4368-88e0-d21895f25622_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_59bc4737-296a-4299-a1d8-865528fbd8ed_terseLabel_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed charge coverage ratio, minimum</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_label_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:to="lab_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e224abc-9efe-4c35-9eac-930557f9fd73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c22cf75d-93e0-437b-8443-970aeb25714c_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_457b5e3b-0b5b-41f9-9328-10f1cf5f94d0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_7f2f28c5-ca44-4ca5-848a-21964e0dbca4_terseLabel_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum working capital</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_label_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Required Minimum Working Capital</link:label>
    <link:label id="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_documentation_en-US" xlink:label="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Required Minimum Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:to="lab_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_14994036-8ac8-41ce-9235-dcf67cb7b674_terseLabel_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average&#160;Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_de90eb08-ffff-43cd-b95e-3e778a96109d_terseLabel_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term of stock options granted</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_label_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Contractual Term</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_documentation_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:to="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2874fc13-8162-4bf9-999d-806ed42d7e43_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock subject for purchase</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_8fa45da0-6f55-40b5-a1d6-e2b7184bd132_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commissions payable</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e4c321e8-c0f1-469c-a76f-4bf69c90be0e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_26f90e3b-51b2-48e7-a1b4-b6d8ab0a5c44_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_231b6312-45d6-4bce-85b3-0a6903b28e51_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d87c73a0-c95c-4936-978b-48c902ad4ea5_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c9e6bb28-2416-4cb0-9341-9604ebf8a741_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_b5407f1e-fc83-4bbb-bb6e-d04fd756c95a_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_DebtInstrumentFloorInterestRate_8fd750b0-8f95-4ea3-8eda-2c2e6d76a7f4_terseLabel_en-US" xlink:label="lab_lfvn_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floor interest rate</link:label>
    <link:label id="lab_lfvn_DebtInstrumentFloorInterestRate_label_en-US" xlink:label="lab_lfvn_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_lfvn_DebtInstrumentFloorInterestRate_documentation_en-US" xlink:label="lab_lfvn_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentFloorInterestRate" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_DebtInstrumentFloorInterestRate" xlink:to="lab_lfvn_DebtInstrumentFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9396dcc3-c75c-45bd-a843-9f6e1da56760_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of company stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a014b7ba-10b7-4c10-a542-025540f97ac8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c6032e1a-505c-4677-ad59-a387201e717a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_87fa5509-fc84-45b0-8ef2-0ee71cc72fec_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax rate difference</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5784d968-97ab-4a02-8c5b-c1d2e2a4595e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b00b9feb-78e1-4487-8b45-9f610e19ac0c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of stock fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2b1c51a4-af30-4d3f-b247-9631cf768ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e05b697e-604b-4bdd-adeb-c65029febc47_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fa80c40c-033c-4937-a866-7fa3d1462848_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f04d5c00-52f1-4243-9f1a-21ad34dbfbd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3de2f45e-6b31-402e-96af-818d17811b1b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_61f067eb-98e5-40d6-b8b8-0dd5e0a52d66_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3772bf73-ec8f-4e05-9173-1ce51fa5dd5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_db53d5b4-aaf3-42a7-a4b6-58ba655d8ebd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_d0a080d6-0291-4c96-9ffc-d238c10041ba_terseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign withholding tax</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_9ec9fbba-0f80-41e3-83fd-e866a2783029_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1ddbcac9-1287-426c-b437-74545c121fcc_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_9f6412e3-0c6b-4ef6-aa14-1674fcd06345_terseLabel_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase resulting from foreign tax audits</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_label_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position, Increase Resulting From Foreign Tax Audits</link:label>
    <link:label id="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_documentation_en-US" xlink:label="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Position, Increase Resulting From Foreign Tax Audits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:to="lab_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_b133c7a9-122c-4e07-977f-16816c0e1809_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b6c36dc6-e6b7-4c1e-9a26-1266b7b54de0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5ab736f2-2736-489f-b6b9-b180bb679322_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_274f2b57-e7f9-4b48-ba60-1fd4477dfc21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled or surrendered as payment of tax withholding and other (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_33c6e18d-58fc-4c09-97c6-f2bbdfd3f208_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled or surrendered as payment of tax withholding and other (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_20ce0654-4635-4a1d-9a0e-f3bb4792a3b5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_NumberOfProductLines_cf0903df-0027-4e0f-8311-473885e5fb95_terseLabel_en-US" xlink:label="lab_lfvn_NumberOfProductLines" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product lines</link:label>
    <link:label id="lab_lfvn_NumberOfProductLines_label_en-US" xlink:label="lab_lfvn_NumberOfProductLines" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Lines</link:label>
    <link:label id="lab_lfvn_NumberOfProductLines_documentation_en-US" xlink:label="lab_lfvn_NumberOfProductLines" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfProductLines" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfProductLines"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_NumberOfProductLines" xlink:to="lab_lfvn_NumberOfProductLines" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_599bc7fa-c359-4e43-8b89-1a288fdfaf9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ff8a6a50-6d83-434e-af96-41dff2f825e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_3ab3bcef-883c-4350-a6f4-13da39039864_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_470cbb81-3c0d-45c6-9886-dbf1f619b4e9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2f132eb5-a928-4ff7-94bf-91d8d84d399d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0ac625ac-f0fb-4a25-9c4a-518cb261fe1d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_LesseeOperatingLeaseLeasedArea_8e754f6a-e4e3-489c-998e-88431c9a2aa0_terseLabel_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease area</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_lfvn_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_lfvn_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseLeasedArea" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_LesseeOperatingLeaseLeasedArea" xlink:to="lab_lfvn_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_94dd144f-4c37-4f2d-9ab0-5a25ce64eb7f_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88935c56-60a4-428e-9841-72dc4b23a0fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ddacf21f-aa5e-4118-a93e-0c0c2ea8faf8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e3e3841c-c00f-465e-bb67-e21b8768ea2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_e734f0eb-699c-43f4-959b-df1f62c35cef_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_45064974-1997-46c8-a966-3fa5181223ed_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bb143d04-c8cd-4445-a1cc-56465354bda0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_NumberOfGeographicSegments_fb48fca4-7a57-4ab0-ab8d-eb4506eb541e_terseLabel_en-US" xlink:label="lab_lfvn_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of geographic segments</link:label>
    <link:label id="lab_lfvn_NumberOfGeographicSegments_label_en-US" xlink:label="lab_lfvn_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Geographic Segments</link:label>
    <link:label id="lab_lfvn_NumberOfGeographicSegments_documentation_en-US" xlink:label="lab_lfvn_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of geographic segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfGeographicSegments" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfGeographicSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_NumberOfGeographicSegments" xlink:to="lab_lfvn_NumberOfGeographicSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7a9bb724-c81f-4899-8a6a-5b77c7cdb92f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f3a7d348-3b30-4784-9624-898516abbe79_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_72c8e7f8-92b8-473c-9add-4d187bdf5f5c_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2d1ba661-06eb-44c2-aec8-6087b4185864_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_8ef900a1-639b-4795-a6af-b729e1c03e50_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e627cd08-e089-45fd-ab8d-a2ca2b746763_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_801b3a9d-40bf-4178-8beb-d50d409db26c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_59dd4820-1568-48ff-b1dd-9ca712acb0e4_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_53d72efd-a99a-4ed5-8a73-dfb99bcdb7ba_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revalue of deferred for change in federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3fb93282-b938-4ba8-81da-9f40df05099f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_525eee51-12a9-45c1-9d2f-7adbe1b3cac4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d899d04a-a239-49db-b6d9-625dc43a658a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70f06f5b-d1ab-4cdc-b337-80216e123d53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_533e4b2b-f733-4fcf-b55a-7c06ffbbef3c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_31bceae7-73a8-4607-8395-8a48b0e90539_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_907e3ed0-6630-4b25-a10f-9f0ec3c6e528_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4d4db569-f3df-4429-9c1d-f986528cd212_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_d350c89a-7c77-4ee3-9c6f-7c3b32406d8a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_058b7c6b-654e-485d-9c7a-ff788335bcc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_d0e0a261-a101-4909-a206-9a5e5f093caf_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f6bca848-ad5c-41f4-8696-f6f7910464be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e8e3a7e0-148a-46e6-bd1b-f1f495e27da1_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f1fefe82-5df6-4c5b-92ed-0e0640129ef9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3cad8703-1c2d-4e44-82ea-93dcff6a8c6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1fcbaed4-3cd1-49e4-9513-50d183625b56_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5061c8c4-6ad6-4c52-ab9e-f306155311d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues by Major Product Line</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_595a589a-5d57-4b48-bba9-2aa24299661d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_99825360-78eb-468f-9871-bf0dbc7ce172_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_7f42ddec-18f8-440e-b5a0-96e839235cce_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Before Income Taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_aa6eca62-1bb7-4b2f-acdc-12df7029a8e0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_afc65769-d801-4064-aad2-2115ae8b3ba6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_486a855d-43d8-466e-a1d2-973a623c1a59_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_de8c6b11-c964-486a-b432-c140b1ef090c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_36588802-ccbb-4132-8610-439a0e533890_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c21ee291-3f32-419f-b3fa-2703ff01b76c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_2e960566-d2b1-4008-b586-e5ecc54a0018_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued vacation, allowance for returns, bonuses&#160;&amp; other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_636dc10f-f7dd-41de-8d7c-5aa898f9d555_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_bd8f7a6e-4157-4e41-9db7-3c9c26d90f9e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_65b9a649-8c95-48c2-b939-03927cbeaa29_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividend, common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2b6593b1-5b63-4557-809a-ecc9bb13d968_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f791b300-fea6-42de-b2ee-0e17b9582b52_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1eb354a7-07eb-4ee5-850b-630324ad3a36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_857180d0-cc44-4ace-8343-a29dcdfd1a3f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_b68719b1-0bf6-4742-9cff-40f8a167f03c_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_69fa1b20-8678-4e65-a06e-ea3553657c4f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_717a2f8e-5665-40de-b4a7-153844ffdca3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_d6739803-c74e-4791-8e8b-07440d5df17b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2a889c91-dac6-441b-8cd3-3af07f5aa84f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_c6c45443-c26c-4ac5-bf71-540922a2ec90_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_950f1001-5f34-4c59-a476-6ce2127d70aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a1a0e45d-0d2a-4ada-9e27-3673e9911cc1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a72efa3b-2d8f-48df-82e2-8efa7b0ab020_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_acf3e4fe-d06f-4105-8874-9933532b0fad_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_83655825-2d11-45b8-a1c4-e623b756839e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_75ed9c01-de33-4777-b48a-3613502d98f4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d7d86296-5e32-4017-9d84-410fa4108527_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_cd232e06-2f84-4328-be25-505f95dc115c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6cd6619d-3987-4ec3-a366-5d8fc9abfcf4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock &#8212; par value $0.0001 per share, 40,000 shares authorized and 12,510 and 12,622 issued and outstanding as of June&#160;30, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_012df46c-58ea-4ea4-8e9c-05947c002776_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96d8b38b-c6b2-477e-bf89-cc842f7537df_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7186bb30-7d19-4e45-acff-8cefeb2017f2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_74298558-78b8-47c1-bd30-36b9145eee47_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_0a595e4a-d8cb-4835-bd85-f59c9cad225b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_5c9b8617-0cef-47a2-b978-f9fcadfac063_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4e43714f-ee81-4c1e-bd27-d1e685be6aae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_374fd38c-f324-4dba-a248-cfe5e4c192c3_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_654fabc2-9a50-481b-aeaa-3f20cb7d000e_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Taxes:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0912f064-047d-4d50-b659-299457cdfaae_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_93b1aef4-c45c-4ddc-a4a7-1edc3474ce67_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd14b775-cd7e-4e07-9afd-59912d99719c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_65b13eb6-b97a-469f-bdd1-125fce796b71_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ef55bf1a-b8cc-4478-b035-0d798aff20ce_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock &#8212; par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_409e3849-ebd7-4e6c-880d-710d4683d003_terseLabel_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0033dcda-1720-4d6b-b245-06d6cab7800f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated service lives of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_61cc8094-9773-46bb-b73c-ac187ef32742_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_496ca3a7-4f47-4e56-aaab-99cf925b1cea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7732d3fe-f535-4213-9ad0-0092d5d4278b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_91c3c009-30bd-443f-bbcf-5ae72333a575_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8da4cc61-e07a-4fc8-a33d-87198a4a0c66_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income per share, basic (dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_70722f7a-cc05-4c6e-8d91-ff7b11b28fa9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_0d229ead-ed1e-42ee-952b-3acb0a159569_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from settlement of stock based awards</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7f7823e5-c2f2-491c-889c-3ecc250e23b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_March2016RevolvingLoanMember_ad81dda5-019e-49df-aa6d-0d02b4da954e_terseLabel_en-US" xlink:label="lab_lfvn_March2016RevolvingLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2016 Revolving Loan</link:label>
    <link:label id="lab_lfvn_March2016RevolvingLoanMember_label_en-US" xlink:label="lab_lfvn_March2016RevolvingLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2016 Revolving Loan [Member]</link:label>
    <link:label id="lab_lfvn_March2016RevolvingLoanMember_documentation_en-US" xlink:label="lab_lfvn_March2016RevolvingLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2016 Revolving Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016RevolvingLoanMember" xlink:href="lfvn-20240630.xsd#lfvn_March2016RevolvingLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_March2016RevolvingLoanMember" xlink:to="lab_lfvn_March2016RevolvingLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_4664bb7b-1037-4e3e-bf6f-729ed203d2e6_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_d549d16e-3f5f-4a4e-920c-c690a810c883_terseLabel_en-US" xlink:label="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Accounts Held at Other Financial Institutions</link:label>
    <link:label id="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_label_en-US" xlink:label="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Accounts Held at Other Financial Institutions [Member]</link:label>
    <link:label id="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Accounts Held At Other Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:to="lab_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3c3e9888-45cf-4b00-9081-54a986558cce_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_720d83c9-44a8-461b-ad34-e1a55be8b36c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Patents and trademarks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EmployeeStockPurchasePlanMember_99fc319a-a3b7-4607-adbf-b2a6d7b14273_terseLabel_en-US" xlink:label="lab_lfvn_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_lfvn_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_lfvn_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_lfvn_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_lfvn_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EmployeeStockPurchasePlanMember" xlink:href="lfvn-20240630.xsd#lfvn_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EmployeeStockPurchasePlanMember" xlink:to="lab_lfvn_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0c792a7e-ab14-4dbf-8124-93cc233003e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1f4338b1-81cf-4aae-a740-b908c83117ef_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_46ac5ace-6d46-410c-b699-8e3c1a6ffd32_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7e7148fb-6c7b-4b25-b291-104b25aa3c1f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ed0da426-e93c-4ef5-afad-d8721d202b2b_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c22d648-a468-4899-96d8-e407147bf01c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8f9d6450-a5cc-4950-9bde-0e47dd61be2c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f23e7e78-a879-4b9d-97d3-ba0257377d86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7c7a1562-5acc-4030-bd6d-e2133cf731ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_53e0faf1-5587-4e2c-a6d8-96512ebd3175_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d2a91a0-6d37-4940-a0bc-4576ce46febb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d2275f57-5084-4838-bc62-6a57c0a1c33f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d02f1dd1-3c2c-4d7e-a7c9-43179c066bef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies &#8212; Note 13</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2174585e-3b9e-4b22-b803-6b623cfd99a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e023dcbf-a94d-4a9c-bc49-1824d807c2f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of The Effective Income Tax Rate Differs from the U.S. Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_e8e856a4-cfae-4201-9676-0066048231f7_terseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8212; change in uncertain tax positions</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In UncertainTax Positions</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In UncertainTax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_e3b686d0-bd0e-4d5c-bcb7-3520d6d8ad75_terseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limit on future stock compensation due to 162(m)</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Future Stock Based Compensation Expense, Percent</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Future Stock Based Compensation Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a624ce80-bc34-4d66-91c8-f455d520db38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81eb3e0e-d23d-45bb-86b3-9606b55584ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_14287005-60ee-4a28-8838-c52815965d11_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c14e1d78-4529-4af9-a594-3d8bd73ffea1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_41514d46-48cc-4f23-bdc2-228357498487_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_173fe8b9-c1a6-4ca4-9147-cdb99aedc3c3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_08e44e83-cd7a-42cb-8890-8ad35b8e1bb6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserveMember" xlink:to="lab_us-gaap_InventoryValuationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_167a754d-4387-46a9-a1c5-f1ff1e217f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_71d9b91a-953b-4b5f-9280-90ae26957714_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_402cae39-6ed3-4bcf-ae74-c874c384f8a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38c8504c-4470-4e0a-bdfd-5528ab522d4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3f862caa-c343-41f5-a311-361ba66c18bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_726b0654-3ee4-4dbf-82fe-bd5631ca9f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_a5fb0a9e-da87-4b4f-8d85-cdb09a25c75c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_23b8514f-1fa0-4d7a-b9b2-e75199c16b02_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_92714489-3e2b-4921-87e5-88054bdb2098_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_562b5bb9-a565-45c4-9a5b-f0266675c21d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3de5d52c-7111-4fdb-88af-757dc93e5b90_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_78db3163-415d-47f9-8ee6-6888859246fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c1ce0427-c3d7-4e36-87a4-a86fc2f1e037_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0ebb270a-9f05-4eec-a60d-2f4821c8d81d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_6dbbfbfa-6e99-4fc1-9ac6-9fb7a17dcf28_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_542a15d0-0e6a-483e-84e5-cbd2dc7608e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product concentration risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_b41d08ed-5b38-4fa3-9367-60a710b14c1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0b8d49d9-156b-4720-89da-7f67191a46f6_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e904162b-99e1-420d-872b-5c75f24fd350_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_58ff1f65-3421-4d2b-b572-3bcae69bdc12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a2e2873-1783-4912-8f43-f17955ed49f5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Effect on Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1655a622-8745-478b-887b-b9eb45892039_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_73a65672-885e-43e7-b97a-a6c407c9a6ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7d8ef7ff-a653-4fba-88aa-410b8bcdcf09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4c67721f-d9fb-4503-a119-1ae1bacc4ffc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_092182f3-1ebd-4e59-98e9-b184ae2d0d22_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f29c0459-fc2c-446e-84d9-2ddb402f3aa6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_ee4f52ac-c9a0-46a8-b029-8ea5525b18d7_terseLabel_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution percentage of target number of Performance Stock Units</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_label_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Distribution Percentage</link:label>
    <link:label id="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_documentation_en-US" xlink:label="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Distribution Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:to="lab_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c837fa8a-e8b5-486a-8427-137469ecc9cd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c03e3864-01a7-4224-ad3f-b9ca55b5f594_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_7e2e9182-731b-470a-94cc-32e45a20760a_verboseLabel_en-US" xlink:label="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2010 Long-Term Incentive Plan</link:label>
    <link:label id="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_label_en-US" xlink:label="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Ten Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and ten long term incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:to="lab_lfvn_TwoThousandAndTenLongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02a00b14-7b3b-413f-9a8f-b413408c9ec8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_951e9642-075c-4ff6-b601-a5e199935fff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0882cb2f-2d58-4792-baae-25000c65abd9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired or Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_0094728a-87f1-4327-8172-aedb6dade466_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_AsiaPacificAndEuropeMember_5a21e167-1d2b-4407-b2d9-579366563c03_terseLabel_en-US" xlink:label="lab_lfvn_AsiaPacificAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia/Pacific &amp; Europe</link:label>
    <link:label id="lab_lfvn_AsiaPacificAndEuropeMember_label_en-US" xlink:label="lab_lfvn_AsiaPacificAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia Pacific And Europe [Member]</link:label>
    <link:label id="lab_lfvn_AsiaPacificAndEuropeMember_documentation_en-US" xlink:label="lab_lfvn_AsiaPacificAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asia Pacific And Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AsiaPacificAndEuropeMember" xlink:href="lfvn-20240630.xsd#lfvn_AsiaPacificAndEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_AsiaPacificAndEuropeMember" xlink:to="lab_lfvn_AsiaPacificAndEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_AccruedPayableToVendors_a2245809-7d19-4a78-8356-ec553c9a165f_terseLabel_en-US" xlink:label="lab_lfvn_AccruedPayableToVendors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payable to vendors</link:label>
    <link:label id="lab_lfvn_AccruedPayableToVendors_label_en-US" xlink:label="lab_lfvn_AccruedPayableToVendors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payable to Vendors</link:label>
    <link:label id="lab_lfvn_AccruedPayableToVendors_documentation_en-US" xlink:label="lab_lfvn_AccruedPayableToVendors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payable to Vendors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AccruedPayableToVendors" xlink:href="lfvn-20240630.xsd#lfvn_AccruedPayableToVendors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_AccruedPayableToVendors" xlink:to="lab_lfvn_AccruedPayableToVendors" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_March2016TermLoanMember_d9f06dcd-0d96-4686-968b-af265d90d22f_terseLabel_en-US" xlink:label="lab_lfvn_March2016TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2016 Term Loan</link:label>
    <link:label id="lab_lfvn_March2016TermLoanMember_label_en-US" xlink:label="lab_lfvn_March2016TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2016 Term Loan [Member]</link:label>
    <link:label id="lab_lfvn_March2016TermLoanMember_documentation_en-US" xlink:label="lab_lfvn_March2016TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2016 Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016TermLoanMember" xlink:href="lfvn-20240630.xsd#lfvn_March2016TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_March2016TermLoanMember" xlink:to="lab_lfvn_March2016TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b8b5577-6459-4777-ab83-031c0a094163_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_cff8f8d5-c728-4838-8203-91383bb9b464_terseLabel_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8212; removal of additional permanent reinvestment assertions</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_label_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Removal Of Permanent Reinvestment Assertion</link:label>
    <link:label id="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_documentation_en-US" xlink:label="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Removal Of Permanent Reinvestment Assertion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:to="lab_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_6e30bb92-c57d-4684-af8e-15fc186fec2e_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f26ec48-392e-4dd0-9957-7236f18a4dd7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in revenue from recognition of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7fc7890-bdcd-4a0d-9d96-b78b5bba4c31_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ba95c0d1-21bc-4039-a760-4ef6aa7744b5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_9077335e-c36f-4373-8fdb-d42b186a53ea_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">&#8212; other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4ad733d6-a3d5-4604-96ad-aaa5f1d95337_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">&#8212; tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f25937c3-52df-411a-a028-b85da6ef57f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4cd56456-6b2c-4773-bb49-f4007b58d51e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_503b9717-6631-42de-a41f-fd9457548759_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_bea44f91-b07b-496f-9cea-cc31ecf60ab2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fa3e338-75c8-4479-ac6b-6166f220a201_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3052f67b-edfb-47d5-aab7-e947fb508d4a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_97f8d05c-352f-488f-ad77-ff5011bcc502_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_cc951b1e-c416-4081-857c-02a29580f11a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dbdac59e-4b3c-4ac4-9b50-c9b720c92301_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_ecbf54b3-9179-4666-a910-e4e4df052ffe_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The components of the deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_b54fd17b-f14a-4be9-8d40-9be30d34f474_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_432ee989-1733-4cfd-9187-dadb9c72486b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_e40baaf0-cb4a-45f0-99ad-b224fba6f368_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued severance</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_eb735dbf-f9ea-4a9a-b081-ed3a31ca37dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0655aae4-bbbb-44de-a6b2-7f8b8bb57bc3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>lfvn-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ede0a258-2789-4f71-b00d-72c836a1040e,g:5e4071bc-2678-48be-a35c-6711906edf66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lifevantage.com/role/CoverPage" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c563426c-0cb5-4050-b5ee-0a42f142261b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentType_c563426c-0cb5-4050-b5ee-0a42f142261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_36d87650-a36c-4148-91c0-0b55f3ca8298" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentAnnualReport_36d87650-a36c-4148-91c0-0b55f3ca8298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6c9a47e7-7ac1-4a26-834b-00c5b1c6f918" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentPeriodEndDate_6c9a47e7-7ac1-4a26-834b-00c5b1c6f918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ea62219f-564b-4fc6-b99b-d85626c5d3ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_CurrentFiscalYearEndDate_ea62219f-564b-4fc6-b99b-d85626c5d3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c7f92f41-2fe1-4341-8611-629174f70634" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentTransitionReport_c7f92f41-2fe1-4341-8611-629174f70634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_15caca76-c6dc-4124-b643-cf94b4f4fec0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityFileNumber_15caca76-c6dc-4124-b643-cf94b4f4fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_72e966fe-f0bc-4073-a50c-5e63a015b196" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityRegistrantName_72e966fe-f0bc-4073-a50c-5e63a015b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_37e07a17-68d1-4325-a9b1-02d8da6b284e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityIncorporationStateCountryCode_37e07a17-68d1-4325-a9b1-02d8da6b284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c8d76578-9e92-4378-931d-db62ba9e9ad5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityTaxIdentificationNumber_c8d76578-9e92-4378-931d-db62ba9e9ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_858164ab-23a5-4537-90dc-f555bbbf7d28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityAddressAddressLine1_858164ab-23a5-4537-90dc-f555bbbf7d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1c6b9ea3-e1f1-40b2-a96c-aea612f5ef37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityAddressAddressLine2_1c6b9ea3-e1f1-40b2-a96c-aea612f5ef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dff8dc35-a787-4217-a638-879f56a80708" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityAddressCityOrTown_dff8dc35-a787-4217-a638-879f56a80708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_45a6e366-e3cb-4c1a-8856-ad481f8e8a55" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityAddressStateOrProvince_45a6e366-e3cb-4c1a-8856-ad481f8e8a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_355693b7-3838-4aac-8d13-a6bb52476eeb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityAddressPostalZipCode_355693b7-3838-4aac-8d13-a6bb52476eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eb97b663-abb0-4805-80f3-3d39ab64951d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_CityAreaCode_eb97b663-abb0-4805-80f3-3d39ab64951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6949e50f-edbe-4607-8b9b-21f371f419d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_LocalPhoneNumber_6949e50f-edbe-4607-8b9b-21f371f419d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3dd25c60-9b3f-42e0-b057-46166e5f6856" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_Security12bTitle_3dd25c60-9b3f-42e0-b057-46166e5f6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_16ce7aff-5039-409e-bee9-cfd4b73c59db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_TradingSymbol_16ce7aff-5039-409e-bee9-cfd4b73c59db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bf51076d-6d80-425e-80d1-5d033527b12f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_SecurityExchangeName_bf51076d-6d80-425e-80d1-5d033527b12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_18b5f867-0c02-419a-9870-fa6fc91098f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_18b5f867-0c02-419a-9870-fa6fc91098f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c716ea21-c5b4-40af-a894-bfcfdb44772f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityVoluntaryFilers_c716ea21-c5b4-40af-a894-bfcfdb44772f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_73eca788-c363-4b65-a868-68d3b5e2823c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityCurrentReportingStatus_73eca788-c363-4b65-a868-68d3b5e2823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8e9d8959-6935-4710-a559-8d57ee096bef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityInteractiveDataCurrent_8e9d8959-6935-4710-a559-8d57ee096bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7e4925b3-82ce-434f-bfa2-41ee3defa076" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityFilerCategory_7e4925b3-82ce-434f-bfa2-41ee3defa076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_83c4134a-8125-4f22-8e4b-47a7339f5e4f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntitySmallBusiness_83c4134a-8125-4f22-8e4b-47a7339f5e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_51d6e526-6251-4215-9425-d645c6226ab8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityEmergingGrowthCompany_51d6e526-6251-4215-9425-d645c6226ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9dbaaee4-6dbc-4617-bce8-71045de1615d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9dbaaee4-6dbc-4617-bce8-71045de1615d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_817579d7-2361-4e02-bfe2-db907b09777f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityShellCompany_817579d7-2361-4e02-bfe2-db907b09777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_989071eb-0374-4d98-99ab-a6eac8ffc4ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityPublicFloat_989071eb-0374-4d98-99ab-a6eac8ffc4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1fe47370-f481-4260-b35f-b80d3f71a48c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1fe47370-f481-4260-b35f-b80d3f71a48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_22f2631e-6a36-4e61-8d9d-7f7654e9d55f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_22f2631e-6a36-4e61-8d9d-7f7654e9d55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8c33bc94-3e28-4b8a-b92b-9f2c00cc8890" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_EntityCentralIndexKey_8c33bc94-3e28-4b8a-b92b-9f2c00cc8890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f75ce584-2c38-4f85-8ccd-4ab712c5198b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_AmendmentFlag_f75ce584-2c38-4f85-8ccd-4ab712c5198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1bfaf626-44fd-44a6-b0eb-7ff66673c571" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentFiscalYearFocus_1bfaf626-44fd-44a6-b0eb-7ff66673c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_298752f4-6ba2-4b90-bda8-e4326bd1e1a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentFiscalPeriodFocus_298752f4-6ba2-4b90-bda8-e4326bd1e1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_74647a51-183b-4803-bcca-a369746e3b93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46119772-f847-43aa-b533-fff3e462bb52" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_74647a51-183b-4803-bcca-a369746e3b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/AuditInformation" xlink:type="simple" xlink:href="lfvn-20240630.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AuditorInformationAbstract_83c93c78-e25c-474f-802b-e0f6f60b2013" xlink:href="lfvn-20240630.xsd#lfvn_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9c9abad6-7ae9-4c07-95c2-feedb3b9b95e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_AuditorInformationAbstract_83c93c78-e25c-474f-802b-e0f6f60b2013" xlink:to="loc_dei_AuditorName_9c9abad6-7ae9-4c07-95c2-feedb3b9b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_32e184ce-7de0-4343-99cd-4a128778fdb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_AuditorInformationAbstract_83c93c78-e25c-474f-802b-e0f6f60b2013" xlink:to="loc_dei_AuditorLocation_32e184ce-7de0-4343-99cd-4a128778fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_3b3a03f5-907d-4052-9dc2-d91205af5afe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_AuditorInformationAbstract_83c93c78-e25c-474f-802b-e0f6f60b2013" xlink:to="loc_dei_AuditorFirmId_3b3a03f5-907d-4052-9dc2-d91205af5afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59f403ef-1ec8-4c95-8d86-175e7a8059d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c53178b4-ac94-4979-8525-f8ca539d774f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59f403ef-1ec8-4c95-8d86-175e7a8059d9" xlink:to="loc_us-gaap_AssetsAbstract_c53178b4-ac94-4979-8525-f8ca539d774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c53178b4-ac94-4979-8525-f8ca539d774f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ccfa296-05bc-42b8-8e38-118fd1a77526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ccfa296-05bc-42b8-8e38-118fd1a77526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e1c7735e-79b6-43d5-88c2-8aeed0d74600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e1c7735e-79b6-43d5-88c2-8aeed0d74600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_14dfce67-4134-45f1-a70f-e9a2fff39008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_14dfce67-4134-45f1-a70f-e9a2fff39008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0f4a272d-9078-4210-bb88-1bb6e01a260d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_InventoryNet_0f4a272d-9078-4210-bb88-1bb6e01a260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_807a5fea-484e-45fa-9836-e06471857b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_807a5fea-484e-45fa-9836-e06471857b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4f5aa0bb-0038-46e4-b5ef-a18c41eac321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2780771d-ba2c-4f02-b82c-e338eaa373b0" xlink:to="loc_us-gaap_AssetsCurrent_4f5aa0bb-0038-46e4-b5ef-a18c41eac321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c53178b4-ac94-4979-8525-f8ca539d774f" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34999ac2-50a3-4656-acd1-bdfb4f4c0dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34999ac2-50a3-4656-acd1-bdfb4f4c0dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f5338d5-a7bb-4239-aa67-e322aca57c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f5338d5-a7bb-4239-aa67-e322aca57c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc98992-d277-4447-89f8-5fd40f991b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc98992-d277-4447-89f8-5fd40f991b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbfa34a4-b04e-4548-b577-6dff22ccf9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbfa34a4-b04e-4548-b577-6dff22ccf9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_51592288-fab4-483a-8d15-afddc0372a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_b1679261-75bc-4a05-b2d5-a81e535ec39e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_51592288-fab4-483a-8d15-afddc0372a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7a0201c5-0633-44a1-9de1-740060cd6323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c53178b4-ac94-4979-8525-f8ca539d774f" xlink:to="loc_us-gaap_Assets_7a0201c5-0633-44a1-9de1-740060cd6323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59f403ef-1ec8-4c95-8d86-175e7a8059d9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8231fbb-4dbd-42dc-9aa3-ce84e7cedcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8231fbb-4dbd-42dc-9aa3-ce84e7cedcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_5231c067-9f47-4a8b-877a-becf92aa86cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_5231c067-9f47-4a8b-877a-becf92aa86cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_fdd0c992-eb73-4bb7-8a9c-bd38e81577c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_fdd0c992-eb73-4bb7-8a9c-bd38e81577c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96597f85-b0d2-4532-ae5c-a3819a8a1342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96597f85-b0d2-4532-ae5c-a3819a8a1342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b074c6c4-5961-4ec4-bcb4-23e28602f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b074c6c4-5961-4ec4-bcb4-23e28602f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dba4538f-88d5-44b7-bd3f-43883394072c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_LiabilitiesCurrent_dba4538f-88d5-44b7-bd3f-43883394072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91d7f2b8-4b53-4b6b-a8ae-a901d23f3599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91d7f2b8-4b53-4b6b-a8ae-a901d23f3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a3c72579-29d4-43a3-bdee-b1ded570a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2dd65b0a-6411-45ce-a68f-206a2bb74dda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a3c72579-29d4-43a3-bdee-b1ded570a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ce32b113-31d8-4998-adbf-6c68c5c40f54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:to="loc_us-gaap_Liabilities_ce32b113-31d8-4998-adbf-6c68c5c40f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02829bf8-7435-4e4b-98de-8a6379ec71c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02829bf8-7435-4e4b-98de-8a6379ec71c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2181b62b-8fa8-4943-b539-66879c439b24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_PreferredStockValue_2181b62b-8fa8-4943-b539-66879c439b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b7f88a9e-72ce-4dc1-a6de-268d8379092f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_CommonStockValue_b7f88a9e-72ce-4dc1-a6de-268d8379092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e950546f-8f0d-4079-ada6-7abb1fbd4d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e950546f-8f0d-4079-ada6-7abb1fbd4d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a3a248ad-a76f-4530-9d61-3a55213c423d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a3a248ad-a76f-4530-9d61-3a55213c423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_558040af-acb9-4963-9b4f-ef1fdb144d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_558040af-acb9-4963-9b4f-ef1fdb144d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8af9f85-8767-4745-bb97-a9d36b0c702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2118bc74-f4d2-40f5-a7b0-bd06302dcd56" xlink:to="loc_us-gaap_StockholdersEquity_a8af9f85-8767-4745-bb97-a9d36b0c702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3d96f6-cc42-46c7-b6f3-18dbc8fb1f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7f9a6b8-ceb3-4090-9af9-a506a1e7eb47" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3d96f6-cc42-46c7-b6f3-18dbc8fb1f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_82342681-615c-4ce9-9967-3387e67354da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_82342681-615c-4ce9-9967-3387e67354da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7368e716-1388-4d17-9798-d455f84e691d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7368e716-1388-4d17-9798-d455f84e691d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2b26a959-db28-44a4-bb9e-76be55d389ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2b26a959-db28-44a4-bb9e-76be55d389ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d76c5804-0048-439e-b2bd-3b3f321b9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d76c5804-0048-439e-b2bd-3b3f321b9d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c2476c99-257b-453d-b738-1d182e31c547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c2476c99-257b-453d-b738-1d182e31c547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8d4cfa21-76eb-441b-a14b-7447ed53a38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8d4cfa21-76eb-441b-a14b-7447ed53a38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_af222c90-72cb-4a2f-959f-42b31afa0bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_CommonStockSharesIssued_af222c90-72cb-4a2f-959f-42b31afa0bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2be5301-0584-427e-99f2-1dee770e8fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e44bd8-291e-44a4-97d7-aeec7a174916" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2be5301-0584-427e-99f2-1dee770e8fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8390a5-35c3-4a8c-83f2-8b0030237b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8390a5-35c3-4a8c-83f2-8b0030237b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_242c2356-c587-43e2-9592-ef40630afa34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_242c2356-c587-43e2-9592-ef40630afa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2a03293b-fb7e-4323-94c2-984c9e8f8f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2a03293b-fb7e-4323-94c2-984c9e8f8f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a4129149-9dbc-49c8-88f0-14fe45caa088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_GrossProfit_a4129149-9dbc-49c8-88f0-14fe45caa088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fe572fea-3500-46f7-8632-62d82217ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fe572fea-3500-46f7-8632-62d82217ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommissionAndIncentives_f716365b-4f86-417d-88de-263da34590aa" xlink:href="lfvn-20240630.xsd#lfvn_CommissionAndIncentives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fe572fea-3500-46f7-8632-62d82217ee89" xlink:to="loc_lfvn_CommissionAndIncentives_f716365b-4f86-417d-88de-263da34590aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4a09b113-9357-4a9d-8fe9-32080dfe1fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fe572fea-3500-46f7-8632-62d82217ee89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4a09b113-9357-4a9d-8fe9-32080dfe1fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ddfa193c-9e68-42c2-9e36-7bf89569ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fe572fea-3500-46f7-8632-62d82217ee89" xlink:to="loc_us-gaap_OperatingExpenses_ddfa193c-9e68-42c2-9e36-7bf89569ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49642ad3-219b-4308-86da-896efb27a6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_OperatingIncomeLoss_49642ad3-219b-4308-86da-896efb27a6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6fcf1560-48ed-4680-97fc-651a97e997ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6fcf1560-48ed-4680-97fc-651a97e997ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d95f93d9-4664-475a-b42d-5ed585e76356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6fcf1560-48ed-4680-97fc-651a97e997ff" xlink:to="loc_us-gaap_InterestExpense_d95f93d9-4664-475a-b42d-5ed585e76356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8f0ed030-d192-4d63-b561-dce95f491b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6fcf1560-48ed-4680-97fc-651a97e997ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8f0ed030-d192-4d63-b561-dce95f491b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c8ebd2a6-fc12-4762-acd6-af3c4e063e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6fcf1560-48ed-4680-97fc-651a97e997ff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c8ebd2a6-fc12-4762-acd6-af3c4e063e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0af72f22-c596-40ef-99a2-93e01c05800c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0af72f22-c596-40ef-99a2-93e01c05800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_faf9da24-c58d-442e-987d-5e2d8a2189ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_faf9da24-c58d-442e-987d-5e2d8a2189ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dce1dbd3-38b2-4f04-b65f-6d29ba3f8b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_NetIncomeLoss_dce1dbd3-38b2-4f04-b65f-6d29ba3f8b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9b9405f3-d6cf-4499-9c45-ecbe11d7dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9b9405f3-d6cf-4499-9c45-ecbe11d7dab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d11f903-1912-4a9f-95ff-0e590d5cd3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b9405f3-d6cf-4499-9c45-ecbe11d7dab0" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d11f903-1912-4a9f-95ff-0e590d5cd3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_280baadf-35ac-47a8-b8aa-474708017e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b9405f3-d6cf-4499-9c45-ecbe11d7dab0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_280baadf-35ac-47a8-b8aa-474708017e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1f011c48-7675-4eaa-b1d6-9259c12ff60b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1f011c48-7675-4eaa-b1d6-9259c12ff60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fde8418-7170-4fd4-bcf5-8beedb42de18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1f011c48-7675-4eaa-b1d6-9259c12ff60b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fde8418-7170-4fd4-bcf5-8beedb42de18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7adb14fb-7f71-4262-9acc-cc18486afe18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1f011c48-7675-4eaa-b1d6-9259c12ff60b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7adb14fb-7f71-4262-9acc-cc18486afe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d6902c32-9651-4035-a8ac-96063797edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d6902c32-9651-4035-a8ac-96063797edbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_199bd2c0-8ccb-445b-974a-fb1fcc16a9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d6902c32-9651-4035-a8ac-96063797edbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_199bd2c0-8ccb-445b-974a-fb1fcc16a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_850dca0f-8445-43a7-9f6f-1fc7b54ab999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d6902c32-9651-4035-a8ac-96063797edbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_850dca0f-8445-43a7-9f6f-1fc7b54ab999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d0f2a14e-8b7b-40eb-8b16-34b90ee04f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06e23c9e-e1d6-45a0-8cdd-5be03d522f5d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d0f2a14e-8b7b-40eb-8b16-34b90ee04f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6b33be48-09b5-4da8-a64b-84d7b6c719b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6b33be48-09b5-4da8-a64b-84d7b6c719b1" xlink:to="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270af150-7ec6-434a-8b7c-a04f8a8a7735" xlink:to="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a28c62f2-f0f1-432b-a212-9bac06de7877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_CommonStockMember_a28c62f2-f0f1-432b-a212-9bac06de7877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2377a0a-4384-43fa-96ef-713b59a77186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2377a0a-4384-43fa-96ef-713b59a77186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad1e6bc8-229d-492a-b8b4-06762cd8111e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_RetainedEarningsMember_ad1e6bc8-229d-492a-b8b4-06762cd8111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d09221f0-6e90-438d-83e5-f2ded62283c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76638778-0bc8-4eaa-826b-a75c36bbd3da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d09221f0-6e90-438d-83e5-f2ded62283c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16089112-fc9a-460d-a58a-0dd7936a8c54" xlink:to="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2e6b502-9b9f-424c-86c7-a0a7036b8946" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_36b59fae-2d65-481f-a893-b20fa3c91b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_36b59fae-2d65-481f-a893-b20fa3c91b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07da13f1-5449-4823-b602-8397d125bf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockholdersEquity_07da13f1-5449-4823-b602-8397d125bf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb409cd0-fc85-4abf-8611-2a81a30499db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb409cd0-fc85-4abf-8611-2a81a30499db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e05a89c5-bf6f-4cab-9887-cc00f537094b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e05a89c5-bf6f-4cab-9887-cc00f537094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c075d848-af90-45e7-ba87-d97405ffb6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c075d848-af90-45e7-ba87-d97405ffb6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_90e3fcba-c96b-459f-a0d3-12fb504d5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_90e3fcba-c96b-459f-a0d3-12fb504d5f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_91a26e28-2971-48eb-b093-df1d1cc68030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_91a26e28-2971-48eb-b093-df1d1cc68030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b7d63ff-9461-4549-864b-4677492ae003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b7d63ff-9461-4549-864b-4677492ae003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8f0770da-6727-42ae-92ea-cbbf024d22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8f0770da-6727-42ae-92ea-cbbf024d22fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c98ac6f5-f3e3-4f85-af10-4b7bdd034565" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c98ac6f5-f3e3-4f85-af10-4b7bdd034565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_0f77ee0f-9730-40de-af41-7c55a40a818a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_DividendsCash_0f77ee0f-9730-40de-af41-7c55a40a818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fd39ed17-668a-49ad-8098-62ccdcda6aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fd39ed17-668a-49ad-8098-62ccdcda6aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3b992bd-4e6f-4c6c-98e3-2ee792df1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_NetIncomeLoss_c3b992bd-4e6f-4c6c-98e3-2ee792df1bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cc29c38-1e18-4fc1-8e64-a3fdc75584d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6cc29c38-1e18-4fc1-8e64-a3fdc75584d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_28a9bdea-08c1-4956-acda-c27875354c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ccba9312-56ea-4977-876d-9431ef49279f" xlink:to="loc_us-gaap_StockholdersEquity_28a9bdea-08c1-4956-acda-c27875354c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d91646a5-fb4d-4577-abe9-f9200d261930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d91646a5-fb4d-4577-abe9-f9200d261930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33381a9e-8026-4801-9277-10bc182c06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d91646a5-fb4d-4577-abe9-f9200d261930" xlink:to="loc_us-gaap_NetIncomeLoss_33381a9e-8026-4801-9277-10bc182c06b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d91646a5-fb4d-4577-abe9-f9200d261930" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4f9c5b30-feb4-4616-9088-7c7c03eb7b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4f9c5b30-feb4-4616-9088-7c7c03eb7b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8bf765a8-a9fd-4509-a8f7-18e828a88afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_ShareBasedCompensation_8bf765a8-a9fd-4509-a8f7-18e828a88afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_20caad30-b0ac-420a-9750-3e680fdad8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_20caad30-b0ac-420a-9750-3e680fdad8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1c7cc424-ac31-4ff5-bfbd-86f4345039c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1c7cc424-ac31-4ff5-bfbd-86f4345039c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bb80921f-987a-4daf-984e-65c70630fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bb80921f-987a-4daf-984e-65c70630fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_19bbba11-7188-4583-8528-10ab66aa30c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_19bbba11-7188-4583-8528-10ab66aa30c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56ae904-a54f-4912-a09b-7e9e0b2b31d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2eace56c-12ba-4e37-9c52-280ef751ddad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2eace56c-12ba-4e37-9c52-280ef751ddad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_cab5f356-a736-419e-8725-d1933ab8df4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_cab5f356-a736-419e-8725-d1933ab8df4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0793f91a-fe3f-4d9a-b6e9-41a6714f3fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0793f91a-fe3f-4d9a-b6e9-41a6714f3fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_67ba2431-8203-49cc-8fd5-304fa2adc1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_67ba2431-8203-49cc-8fd5-304fa2adc1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_04afb981-7823-43db-84ab-b3cf07b83659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_04afb981-7823-43db-84ab-b3cf07b83659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1ac28249-273f-4bee-9aee-26f759cf9de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1ac28249-273f-4bee-9aee-26f759cf9de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7b57adec-e87a-418a-a7f0-53a5f34e1f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7b57adec-e87a-418a-a7f0-53a5f34e1f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_05e5cae7-fa8f-44d0-9508-3271a43ff7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_05e5cae7-fa8f-44d0-9508-3271a43ff7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_93c2b399-ece5-49a3-bb64-7ac5c0a618aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_93c2b399-ece5-49a3-bb64-7ac5c0a618aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c529ba4d-ee41-4ff3-840d-65a380825f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bb5e6b2a-47ce-4b49-8068-904cafde151d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c529ba4d-ee41-4ff3-840d-65a380825f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca8c2158-1370-4d44-ab11-24690071d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d91646a5-fb4d-4577-abe9-f9200d261930" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca8c2158-1370-4d44-ab11-24690071d5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53762863-abab-4678-a950-6014596bed27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53762863-abab-4678-a950-6014596bed27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1dca5bbc-dc40-480a-b488-57fa6c4df00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53762863-abab-4678-a950-6014596bed27" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1dca5bbc-dc40-480a-b488-57fa6c4df00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cb67760d-eccf-4db1-92ea-c0d6edffa949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53762863-abab-4678-a950-6014596bed27" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cb67760d-eccf-4db1-92ea-c0d6edffa949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88391e8-ee73-49a0-9176-de1f6a211a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53762863-abab-4678-a950-6014596bed27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88391e8-ee73-49a0-9176-de1f6a211a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1db7485a-7d59-474e-a569-0c60b89e74f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_1db7485a-7d59-474e-a569-0c60b89e74f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f0534a0a-0c0b-4a28-bbcb-aaf073115569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f0534a0a-0c0b-4a28-bbcb-aaf073115569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_3a516f41-f781-4281-a838-54a296ff1445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_us-gaap_PaymentsOfDividends_3a516f41-f781-4281-a838-54a296ff1445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_491b51b4-d895-4f99-900e-ff9697aaf941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_491b51b4-d895-4f99-900e-ff9697aaf941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_24b91ead-0561-452a-8827-2d409485d077" xlink:href="lfvn-20240630.xsd#lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_24b91ead-0561-452a-8827-2d409485d077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_831e1633-77b1-42d1-9cbc-ca4384fa2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9323a598-e76e-4ec9-a37c-b78525cda5f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_831e1633-77b1-42d1-9cbc-ca4384fa2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cea77ed5-18cc-4c3f-a2d8-e2d7f82119f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cea77ed5-18cc-4c3f-a2d8-e2d7f82119f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ddbb519d-50f4-4bc3-9b09-6d803a0d6eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ddbb519d-50f4-4bc3-9b09-6d803a0d6eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d260446-3109-44b3-b91f-58f99c6d36ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d260446-3109-44b3-b91f-58f99c6d36ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ccb4eea-5cbc-45cc-93ac-aaffa16b6505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ccb4eea-5cbc-45cc-93ac-aaffa16b6505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ad0170f-0e91-4572-9266-3d85685dd4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_11411eac-ef31-4788-93a3-d64576eebec0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ad0170f-0e91-4572-9266-3d85685dd4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9ec140b3-6958-413b-b7b8-a7478924f9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ad0170f-0e91-4572-9266-3d85685dd4ac" xlink:to="loc_us-gaap_InterestPaidNet_9ec140b3-6958-413b-b7b8-a7478924f9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_50e5bce5-553d-4188-9a7d-3c5a2d30071d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ad0170f-0e91-4572-9266-3d85685dd4ac" xlink:to="loc_us-gaap_IncomeTaxesPaid_50e5bce5-553d-4188-9a7d-3c5a2d30071d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/TheCompany" xlink:type="simple" xlink:href="lfvn-20240630.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b8cbf6b-bf31-4e2f-a86a-714f12d727dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_10b97dee-ca20-44f7-8884-6790358a89ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b8cbf6b-bf31-4e2f-a86a-714f12d727dd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_10b97dee-ca20-44f7-8884-6790358a89ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25b70939-5b18-4e23-9539-b3011304de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_353fed50-485d-4143-a196-21d6f898dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25b70939-5b18-4e23-9539-b3011304de3c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_353fed50-485d-4143-a196-21d6f898dd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/Revenue" xlink:type="simple" xlink:href="lfvn-20240630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9be03218-c0a6-47d1-861f-d2b466bc801e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_928cdf6d-39d8-4d83-abd2-a7a716bddf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9be03218-c0a6-47d1-861f-d2b466bc801e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_928cdf6d-39d8-4d83-abd2-a7a716bddf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="lfvn-20240630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4254558f-9781-4b24-bbd0-4825e5df2c86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99ed254c-7663-44ee-b6c7-aabd7d6207e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4254558f-9781-4b24-bbd0-4825e5df2c86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99ed254c-7663-44ee-b6c7-aabd7d6207e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b901e78-e686-4a72-bdc0-f4d9a550a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_93d3ea6e-d4eb-41fc-86d4-77ffdcbb7f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b901e78-e686-4a72-bdc0-f4d9a550a2c3" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_93d3ea6e-d4eb-41fc-86d4-77ffdcbb7f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherAccruedExpenses" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_34c8d3dc-c186-415a-9ce1-5a5a367df5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f3d2c017-251c-4a3e-97fc-41a3bc7bb7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_34c8d3dc-c186-415a-9ce1-5a5a367df5e1" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f3d2c017-251c-4a3e-97fc-41a3bc7bb7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LongTermDebt" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f702b0c8-90f2-4c77-aa1f-275c51a7ebc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e9e0f80e-ffb8-48e7-a7f5-4fca9509d572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f702b0c8-90f2-4c77-aa1f-275c51a7ebc2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e9e0f80e-ffb8-48e7-a7f5-4fca9509d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lfvn-20240630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cad08494-be91-4748-9282-565a007f4081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eef8594b-a884-4e3a-aab1-ecdd9393fe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cad08494-be91-4748-9282-565a007f4081" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eef8594b-a884-4e3a-aab1-ecdd9393fe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82061582-4a65-404c-931c-004afa3e40a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f45efc98-5ba4-47fe-8683-621b3e35bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82061582-4a65-404c-931c-004afa3e40a1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f45efc98-5ba4-47fe-8683-621b3e35bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherExpenseNet" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherExpenseNet"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2cbd4b57-e72f-4e27-93a5-b296618301d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_57fda5e0-d04c-428f-8ba4-e0f1ef213b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2cbd4b57-e72f-4e27-93a5-b296618301d7" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_57fda5e0-d04c-428f-8ba4-e0f1ef213b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_33917d8a-6772-4c0b-9dd0-e89ad7420fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7430a5a3-24db-46d2-aaf6-2907d6655617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33917d8a-6772-4c0b-9dd0-e89ad7420fe1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7430a5a3-24db-46d2-aaf6-2907d6655617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/Leases" xlink:type="simple" xlink:href="lfvn-20240630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_99cd29f9-0354-4d81-8025-3e312841ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0cf0a27c-1882-479a-9301-4298a4aed902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99cd29f9-0354-4d81-8025-3e312841ff08" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0cf0a27c-1882-479a-9301-4298a4aed902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lfvn-20240630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da9f5ddd-bee2-4234-8554-7b0c7d9fcc85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5da07432-641b-4f4f-8062-2b5b4212eb69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da9f5ddd-bee2-4234-8554-7b0c7d9fcc85" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5da07432-641b-4f4f-8062-2b5b4212eb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e242acbb-8e05-4f0e-bd4d-02f772bd22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e242acbb-8e05-4f0e-bd4d-02f772bd22d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1670c878-9942-4384-bc7a-f6a7f20c4253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_UseOfEstimates_1670c878-9942-4384-bc7a-f6a7f20c4253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_493c8faa-3134-4803-bd7f-79bfc7290221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_493c8faa-3134-4803-bd7f-79bfc7290221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3e4e4383-083a-423d-9fef-b85c4bd1f587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3e4e4383-083a-423d-9fef-b85c4bd1f587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0de9edee-2c3b-46a1-8e21-08cd435c73c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0de9edee-2c3b-46a1-8e21-08cd435c73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_7c9dab24-7b53-4e6e-8d04-6014b79c72dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_7c9dab24-7b53-4e6e-8d04-6014b79c72dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7d2688af-a208-4f12-8672-92decc3b55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7d2688af-a208-4f12-8672-92decc3b55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c81240dc-103a-4fc1-b198-ccb76e13ce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c81240dc-103a-4fc1-b198-ccb76e13ce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3c7d6236-061a-4ffd-85e9-379526da2c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3c7d6236-061a-4ffd-85e9-379526da2c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_28cd8746-e3eb-45e9-ab7f-44e74276a80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_28cd8746-e3eb-45e9-ab7f-44e74276a80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e8953e46-4f6c-4e8c-946d-b0a680fb4ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e8953e46-4f6c-4e8c-946d-b0a680fb4ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommissionsExpensePolicyPolicyTextBlock_6a690a7a-322b-4318-8e24-627f738c1466" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommissionsExpensePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_CommissionsExpensePolicyPolicyTextBlock_6a690a7a-322b-4318-8e24-627f738c1466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c1368be9-f19b-46ac-a22f-1d99d45580fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c1368be9-f19b-46ac-a22f-1d99d45580fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_78232eb8-bc50-44a3-a271-3320096510b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_78232eb8-bc50-44a3-a271-3320096510b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_fe86a127-adec-407a-a42f-c22611dff616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_fe86a127-adec-407a-a42f-c22611dff616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ab085e55-ba0b-45fa-8a2a-a15a8324528f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ab085e55-ba0b-45fa-8a2a-a15a8324528f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9ed0af83-f133-4b1d-b54e-cb623e73d832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9ed0af83-f133-4b1d-b54e-cb623e73d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ea77339d-a3ac-48ce-9fc3-7f12c5f8c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ea77339d-a3ac-48ce-9fc3-7f12c5f8c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b22e77f8-62e5-4719-bfe1-3f7817ab7f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b22e77f8-62e5-4719-bfe1-3f7817ab7f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d10f509-1ea3-4391-a4db-73e3dcdab85f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d97721a-b2ea-4e74-95d4-31d11a3dc8ef" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d10f509-1ea3-4391-a4db-73e3dcdab85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07593930-83aa-43b8-81f8-02739f25a225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e2968ac-a59a-4b2d-82c5-f7f744431bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07593930-83aa-43b8-81f8-02739f25a225" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e2968ac-a59a-4b2d-82c5-f7f744431bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ae4f182e-c221-40d3-bced-5fd5cd8d30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07593930-83aa-43b8-81f8-02739f25a225" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ae4f182e-c221-40d3-bced-5fd5cd8d30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_aa3411e3-272b-4328-b953-d2ad6e64b83b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07593930-83aa-43b8-81f8-02739f25a225" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_aa3411e3-272b-4328-b953-d2ad6e64b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_72ac36fd-2bc6-4566-9d39-49d16d44ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07593930-83aa-43b8-81f8-02739f25a225" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_72ac36fd-2bc6-4566-9d39-49d16d44ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_220cc4b0-7a1f-4799-b370-00efdb6d6714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7bbf1b16-8ca0-4b80-a3e6-6465754ae056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_220cc4b0-7a1f-4799-b370-00efdb6d6714" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7bbf1b16-8ca0-4b80-a3e6-6465754ae056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_24bfbb00-a2dd-4ab3-a2b6-5b09f6e478e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_220cc4b0-7a1f-4799-b370-00efdb6d6714" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_24bfbb00-a2dd-4ab3-a2b6-5b09f6e478e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64879561-cde4-4ba2-81a3-06784b727ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b3dc72f-153b-4f54-94d2-9f1e7b1ade47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64879561-cde4-4ba2-81a3-06784b727ca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b3dc72f-153b-4f54-94d2-9f1e7b1ade47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_874ccbd5-ea18-4f4c-b889-0c3e88f25203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fcf32c56-45c8-445b-8a6f-085fbf990a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_874ccbd5-ea18-4f4c-b889-0c3e88f25203" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fcf32c56-45c8-445b-8a6f-085fbf990a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherAccruedExpensesTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_01f1f14b-e603-4a96-a483-eecf535230d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c2a83603-359d-4317-aeac-0d3c7906c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_01f1f14b-e603-4a96-a483-eecf535230d7" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c2a83603-359d-4317-aeac-0d3c7906c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd440df-b901-4d83-903d-bbf1b1155926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1f1097a6-2a52-47d8-9b94-8b2d3c9348f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd440df-b901-4d83-903d-bbf1b1155926" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1f1097a6-2a52-47d8-9b94-8b2d3c9348f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2893042e-ae15-464b-9ef7-8f229ef0d4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd440df-b901-4d83-903d-bbf1b1155926" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2893042e-ae15-464b-9ef7-8f229ef0d4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_28229a0e-81f4-4d7e-a383-038c66a11a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd440df-b901-4d83-903d-bbf1b1155926" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_28229a0e-81f4-4d7e-a383-038c66a11a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d060ce03-9fd8-49a5-ad72-20b2d5018266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd440df-b901-4d83-903d-bbf1b1155926" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d060ce03-9fd8-49a5-ad72-20b2d5018266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherExpenseNetTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_893005aa-7370-47a6-a382-47555671fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_412b00dd-4537-409c-9937-4c638646c904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_893005aa-7370-47a6-a382-47555671fab3" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_412b00dd-4537-409c-9937-4c638646c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b06472ee-5ff3-482c-8ec3-5103603f5bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fae597dd-eeb7-4625-aed6-bef06457e482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b06472ee-5ff3-482c-8ec3-5103603f5bb5" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fae597dd-eeb7-4625-aed6-bef06457e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f71a3ad4-aaf2-498f-ba40-732b85390446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b06472ee-5ff3-482c-8ec3-5103603f5bb5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f71a3ad4-aaf2-498f-ba40-732b85390446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bb22ecb1-b7cd-4b38-abd6-592c9733a140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b06472ee-5ff3-482c-8ec3-5103603f5bb5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bb22ecb1-b7cd-4b38-abd6-592c9733a140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_f1bee92f-d8be-4f6d-9fa8-8c9743eeecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b06472ee-5ff3-482c-8ec3-5103603f5bb5" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_f1bee92f-d8be-4f6d-9fa8-8c9743eeecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesTables" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fffaa09a-eea4-4565-91d3-36967d7a3991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_bbafd8ff-fdd3-4295-9641-63c1c24ae5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fffaa09a-eea4-4565-91d3-36967d7a3991" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_bbafd8ff-fdd3-4295-9641-63c1c24ae5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f589c950-42af-405d-b14d-e000ce882259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fffaa09a-eea4-4565-91d3-36967d7a3991" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f589c950-42af-405d-b14d-e000ce882259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/TheCompanyDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#TheCompanyDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/TheCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a858055-28ba-4ad2-9c9d-8a6a19c31f38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bc604d02-5eaa-4d6f-bc7b-6828fa5f5a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a858055-28ba-4ad2-9c9d-8a6a19c31f38" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bc604d02-5eaa-4d6f-bc7b-6828fa5f5a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a69f9da6-8559-48de-acc9-9eff426ae662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a69f9da6-8559-48de-acc9-9eff426ae662" xlink:to="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_05fb255b-4bd5-4fbb-b7e5-a74781851990" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_60bc175e-bf42-4be4-9e3b-4419bd8eee9b" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:to="loc_lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember_60bc175e-bf42-4be4-9e3b-4419bd8eee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_a4e6b35d-3163-4044-8768-dbbb486c3662" xlink:href="lfvn-20240630.xsd#lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d8bf9e35-fd33-4091-9259-fd2dfe3114f5" xlink:to="loc_lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember_a4e6b35d-3163-4044-8768-dbbb486c3662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2f65186e-cd66-47d6-9cc2-29a4eb30c129" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:href="lfvn-20240630.xsd#lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_fa7f128b-4105-4143-b61e-e156427c6fd8" xlink:to="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_55c30e90-d1d6-4ab9-acc0-a6f8b08c1ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_55c30e90-d1d6-4ab9-acc0-a6f8b08c1ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryAdjustments_dbbd00a2-1d3c-4848-9bbe-38fd9a1be897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_InventoryAdjustments_dbbd00a2-1d3c-4848-9bbe-38fd9a1be897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_eec5c8e7-a9c1-4140-b5a4-aac74ef26ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_eec5c8e7-a9c1-4140-b5a4-aac74ef26ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5aace631-57b0-4cda-b1c8-2986f8526d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5aace631-57b0-4cda-b1c8-2986f8526d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1106fe67-0aa5-4ffc-84b9-58c58091eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1106fe67-0aa5-4ffc-84b9-58c58091eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfFinanceLeases_97663a1f-c6d3-484a-bddf-3fbda021b6d4" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfFinanceLeases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_lfvn_NumberOfFinanceLeases_97663a1f-c6d3-484a-bddf-3fbda021b6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_695c3724-a612-4cf8-a3a8-b404e1d00051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_695c3724-a612-4cf8-a3a8-b404e1d00051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfGeographicSegments_91b558c5-5901-4b02-9d9c-51de77b4b98e" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfGeographicSegments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract_63bf2c9f-73ae-4d23-a858-596db1256520" xlink:to="loc_lfvn_NumberOfGeographicSegments_91b558c5-5901-4b02-9d9c-51de77b4b98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a94f58dc-e344-4002-82d9-b4059a404bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a94f58dc-e344-4002-82d9-b4059a404bc1" xlink:to="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_800f80b4-a41b-4837-9e84-6bf81dc3f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_us-gaap_InventoryFinishedGoods_800f80b4-a41b-4837-9e84-6bf81dc3f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_e06a0019-72fa-45a9-9e8b-f6836d19ffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_us-gaap_InventoryRawMaterials_e06a0019-72fa-45a9-9e8b-f6836d19ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6aaf50b9-48ff-4b18-b5b9-bdcd3ecf59b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_us-gaap_InventoryNet_6aaf50b9-48ff-4b18-b5b9-bdcd3ecf59b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_b1981c43-6742-4bad-9bd3-66b77f68ef8b" xlink:href="lfvn-20240630.xsd#lfvn_InventoryFinishedGoodsPercentOfTotalInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_lfvn_InventoryFinishedGoodsPercentOfTotalInventory_b1981c43-6742-4bad-9bd3-66b77f68ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_RawMaterialsPercentOfTotalInventory_d785b526-8716-40f1-b11a-c9c46bf8cc48" xlink:href="lfvn-20240630.xsd#lfvn_RawMaterialsPercentOfTotalInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_lfvn_RawMaterialsPercentOfTotalInventory_d785b526-8716-40f1-b11a-c9c46bf8cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_InventoryPercentOfTotalInventory_1de3dac2-0521-4c4c-be7c-ccff35298652" xlink:href="lfvn-20240630.xsd#lfvn_InventoryPercentOfTotalInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_cc59bd1d-3f51-4999-ae90-03fc25753b87" xlink:to="loc_lfvn_InventoryPercentOfTotalInventory_1de3dac2-0521-4c4c-be7c-ccff35298652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1ade1a25-c005-46c2-adbc-1f20c9697893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ade1a25-c005-46c2-adbc-1f20c9697893" xlink:to="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b9e95ca7-e991-4a7b-adfa-aec3d9ff603a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_83c8dee9-85ba-4934-ae50-9dde24501802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9bea565-cc40-455b-9d7c-88fcae6ad81a" xlink:to="loc_us-gaap_InventoryValuationReserveMember_83c8dee9-85ba-4934-ae50-9dde24501802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e348ac1f-bb06-46ae-97d2-cc9fec805323" xlink:to="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_df922c95-88f9-417f-86d4-2b2a21e934cf" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_cc6bf26b-dd8b-455a-8960-5543ec5d0f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_cc6bf26b-dd8b-455a-8960-5543ec5d0f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_dddceba5-cb34-43df-b897-f6c9a37c15f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_dddceba5-cb34-43df-b897-f6c9a37c15f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_341f7917-77cf-4a19-94ec-465df3d366c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_341f7917-77cf-4a19-94ec-465df3d366c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_94d8181b-dc6e-41d8-94d7-567b2fc1d330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aa0eb6b5-2c8e-493b-b3bd-ada7ca67e958" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_94d8181b-dc6e-41d8-94d7-567b2fc1d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86ebe4a6-b87a-4535-a438-97a42a5a4bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86ebe4a6-b87a-4535-a438-97a42a5a4bfd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:to="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_069464f8-e706-4f1a-9e2d-9b809ce2a76b" xlink:to="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3e9316b2-c526-4190-b1b6-cc20cc26681f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:to="loc_srt_MinimumMember_3e9316b2-c526-4190-b1b6-cc20cc26681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63eaa845-a463-47d8-89bb-df05eb6479c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44d5a4c4-c5a9-4692-9cf2-425e0008aef1" xlink:to="loc_srt_MaximumMember_63eaa845-a463-47d8-89bb-df05eb6479c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9db99f81-f730-453f-b708-ba2b95822286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_e2a30942-677c-4ccb-8b1b-e1f4933e4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_EquipmentMember_e2a30942-677c-4ccb-8b1b-e1f4933e4f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f3e69974-1b8a-4ca6-89a6-0a46512ea18e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f3e69974-1b8a-4ca6-89a6-0a46512ea18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_1c1a7d7b-3b4e-488f-abf6-dbab74f06608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54c8f269-7c28-4509-9da7-35a8e9bc6e3f" xlink:to="loc_us-gaap_VehiclesMember_1c1a7d7b-3b4e-488f-abf6-dbab74f06608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62016052-c6e6-4df5-bc1f-203398d3bb04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0ef58510-d3d1-46e4-9b05-83e8c12bb57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c82071af-7c15-49c2-881d-117568907589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0ef58510-d3d1-46e4-9b05-83e8c12bb57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f66d3cd-a4e6-40f3-830e-73dfb2d7fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f66d3cd-a4e6-40f3-830e-73dfb2d7fd6d" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_24a08449-d409-4e0f-965c-0a326aee3789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_24a08449-d409-4e0f-965c-0a326aee3789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e5f8265-39cc-4785-9417-c0514650958f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_24a08449-d409-4e0f-965c-0a326aee3789" xlink:to="loc_us-gaap_NetIncomeLoss_2e5f8265-39cc-4785-9417-c0514650958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_40f74dc5-129f-49bc-85f9-6437eecd9d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_40f74dc5-129f-49bc-85f9-6437eecd9d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d133b42-a6e3-4e5b-b7e5-b0e2c55e8299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_40f74dc5-129f-49bc-85f9-6437eecd9d1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d133b42-a6e3-4e5b-b7e5-b0e2c55e8299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b38e06e2-5c0d-4c53-9a39-4f9566959d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b38e06e2-5c0d-4c53-9a39-4f9566959d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_83f0544c-9fba-4ac6-a932-f8011cf46271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b38e06e2-5c0d-4c53-9a39-4f9566959d04" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_83f0544c-9fba-4ac6-a932-f8011cf46271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_751d6e24-157f-49c5-8faf-b13aeaec26cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_751d6e24-157f-49c5-8faf-b13aeaec26cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9daf21cf-c5df-4250-84c7-c318d5b193af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_EarningsPerShareBasic_9daf21cf-c5df-4250-84c7-c318d5b193af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_27abadb4-9201-433d-b55b-0312ca423cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_95c69235-cae5-47cf-93c6-172883e0b832" xlink:to="loc_us-gaap_EarningsPerShareDiluted_27abadb4-9201-433d-b55b-0312ca423cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5fd47c27-039a-4caf-b83d-54acfc04867f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5fd47c27-039a-4caf-b83d-54acfc04867f" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:to="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_28f4fd3e-a487-4735-9f0b-d96083e9007e" xlink:to="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e2b75535-f902-4a2e-a064-c14f03ec9097" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:to="loc_country_US_e2b75535-f902-4a2e-a064-c14f03ec9097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_17409438-979b-4a67-a2c6-7600262114b3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b2cb50ca-08ba-4fef-b096-cb2dee30c418" xlink:to="loc_country_JP_17409438-979b-4a67-a2c6-7600262114b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dbd9b9a8-9b56-470f-9123-52b032fb25bc" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a647551c-a8bc-46b5-9874-ade30fc15bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60e82329-38b2-4542-8f14-ab57a9650481" xlink:to="loc_us-gaap_NoncurrentAssets_a647551c-a8bc-46b5-9874-ade30fc15bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b5fcb0da-8df3-40eb-9882-7951f6153acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b5fcb0da-8df3-40eb-9882-7951f6153acd" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5a52937-ea25-437f-a7b4-6d1e01d6a4a4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_a3cfe0cc-d861-4063-8894-01feba57b3db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_924faa37-8300-4706-ab8f-2d53aef2ccb1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_a3cfe0cc-d861-4063-8894-01feba57b3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9566e6b3-02b8-4332-a71f-ab25481458b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a5a85a67-44d3-4dbc-af61-cff36aa28865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b106ab84-ba37-4e37-a30d-74d1df53d6d6" xlink:to="loc_us-gaap_SalesRevenueNetMember_a5a85a67-44d3-4dbc-af61-cff36aa28865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_77e265f9-9a14-4c31-848a-9adbd820b711" xlink:to="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimandTrueScienceProductLineMember_98ae5198-d702-486c-88d8-f2deaccff421" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimandTrueScienceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_43da91f1-69fe-4a2e-9ff9-5eceda9dc814" xlink:to="loc_lfvn_ProtandimandTrueScienceProductLineMember_98ae5198-d702-486c-88d8-f2deaccff421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4333e7be-930e-4928-b43e-d5163d238a50" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_MoneyBackGuaranteePeriod_9f09522b-826d-4c4b-81b3-10df398aa050" xlink:href="lfvn-20240630.xsd#lfvn_MoneyBackGuaranteePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_MoneyBackGuaranteePeriod_9f09522b-826d-4c4b-81b3-10df398aa050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_HandlingAndRestockingFeePercentage_e2f0c723-6b3b-4383-a1f5-a8ffa1a77fd5" xlink:href="lfvn-20240630.xsd#lfvn_HandlingAndRestockingFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_HandlingAndRestockingFeePercentage_e2f0c723-6b3b-4383-a1f5-a8ffa1a77fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ReturnLiabilityReserve_4fef9145-f2eb-4737-b300-6742b84fd82d" xlink:href="lfvn-20240630.xsd#lfvn_ReturnLiabilityReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_ReturnLiabilityReserve_4fef9145-f2eb-4737-b300-6742b84fd82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfGeographicSegments_49120487-6ab5-47a5-9de5-3e85fa6a7866" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfGeographicSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_NumberOfGeographicSegments_49120487-6ab5-47a5-9de5-3e85fa6a7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_NumberOfProductLines_62848e9d-2979-4796-abff-9227466e9dea" xlink:href="lfvn-20240630.xsd#lfvn_NumberOfProductLines"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_lfvn_NumberOfProductLines_62848e9d-2979-4796-abff-9227466e9dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e1442506-57e5-4a5f-a60a-3381e40ab8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e1442506-57e5-4a5f-a60a-3381e40ab8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a8daad28-c179-4516-8db6-785bbab50ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a8daad28-c179-4516-8db6-785bbab50ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f26c9458-9f9f-4946-8e4d-86d2c1d16fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_66b90d07-436d-444f-8a48-007d3b2bb511" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f26c9458-9f9f-4946-8e4d-86d2c1d16fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueSalesReturnDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueSalesReturnDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/RevenueSalesReturnDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_602c1af4-5e0c-43a8-a99f-c998f6ac6a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_602c1af4-5e0c-43a8-a99f-c998f6ac6a39" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_25ff3b96-0539-4732-8768-79bfc71a7d73" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_99255ad7-40ac-49e5-bd5f-d001a2eac46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f9531d44-49e2-4dc1-b36a-17c5db329458" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_99255ad7-40ac-49e5-bd5f-d001a2eac46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a650bf25-d722-4622-83bd-51325c74558d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16da455e-583e-4f07-91b4-ac176e97fede" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d7d81f43-501b-4a30-86dc-4d52fb283ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d7d81f43-501b-4a30-86dc-4d52fb283ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c0dfe7f9-67d1-40f6-8da1-9b821492ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c0dfe7f9-67d1-40f6-8da1-9b821492ab56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4164df9e-7c6a-4aea-81cd-e9dc5efd47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4164df9e-7c6a-4aea-81cd-e9dc5efd47c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_312361a2-9338-4232-8360-492e9c7faf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3f4e4c1b-cde8-4233-ba44-03620121ce07" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_312361a2-9338-4232-8360-492e9c7faf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4636ad09-2981-48f8-a56b-6835cc0cba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4636ad09-2981-48f8-a56b-6835cc0cba0a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:to="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cb4be8ab-ec0b-4ac7-8b33-a447c38aaf4b" xlink:to="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_7466cfe3-c79a-4762-91eb-83e0458963c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_srt_AmericasMember_7466cfe3-c79a-4762-91eb-83e0458963c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AsiaPacificAndEuropeMember_5e6dd844-a4fa-4f1a-8c69-9303ece5c606" xlink:href="lfvn-20240630.xsd#lfvn_AsiaPacificAndEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_lfvn_AsiaPacificAndEuropeMember_5e6dd844-a4fa-4f1a-8c69-9303ece5c606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_958ae3ce-0ba7-41a4-ad7d-5cf6d5cd1ed9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_country_US_958ae3ce-0ba7-41a4-ad7d-5cf6d5cd1ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_e6abef0f-e04b-4415-bf1e-76ed45d49983" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_86de732f-7e09-4e75-9a08-1e2e78d25b28" xlink:to="loc_country_JP_e6abef0f-e04b-4415-bf1e-76ed45d49983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_476ab96c-e517-4015-b6ef-6fca774aa1ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3687a1e0-8c23-4c49-a182-4e2ffc4e2540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e54d8e39-2bdb-4544-acaa-d607f24841ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3687a1e0-8c23-4c49-a182-4e2ffc4e2540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/RevenueMajorProductsDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#RevenueMajorProductsDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/RevenueMajorProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90f82f3a-d07f-46ff-84b2-80ce64fd537a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90f82f3a-d07f-46ff-84b2-80ce64fd537a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e1942a3e-eafe-41ab-b399-56fadcbce7a0" xlink:to="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ProtandimMember_1fc048a9-8d73-4be1-83be-9e8c479feb94" xlink:href="lfvn-20240630.xsd#lfvn_ProtandimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_lfvn_ProtandimMember_1fc048a9-8d73-4be1-83be-9e8c479feb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_1b7ae259-4685-454b-991d-4e3924824e53" xlink:href="lfvn-20240630.xsd#lfvn_LifeVantageTrueScienceSkinCareRegimenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_lfvn_LifeVantageTrueScienceSkinCareRegimenMember_1b7ae259-4685-454b-991d-4e3924824e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_f3847fa6-aca0-4edd-9ca4-6d987dea7151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59701cb1-b337-4d7c-a7a1-4c879cddb664" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_f3847fa6-aca0-4edd-9ca4-6d987dea7151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6d761bd0-203c-4151-a383-1fe634a3b6cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_28ad83c6-7b94-4417-a804-2450b04d892c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_85143f9e-a09e-4dca-a33d-a8415edd192a" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_28ad83c6-7b94-4417-a804-2450b04d892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59f04211-d617-4b87-a71f-9f2ac6218968" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f2a12000-7d96-4f2f-af0b-035ae56efa08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f42a4fd1-af59-402f-a17b-c2107651db79" xlink:to="loc_us-gaap_SalesRevenueNetMember_f2a12000-7d96-4f2f-af0b-035ae56efa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51ad23ce-ce18-45d1-91cb-a20b71a58250" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24251741-8f9c-474c-b70f-3895e1e22984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24251741-8f9c-474c-b70f-3895e1e22984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_15466eea-35ac-4478-8e56-6fa6e7432886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_170f0ff6-d744-435d-8623-4ccd34451e88" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_15466eea-35ac-4478-8e56-6fa6e7432886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20f39f00-930a-4e88-a330-7133e67cfaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20f39f00-930a-4e88-a330-7133e67cfaa5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ed9de84-03dc-4410-bba7-c58a7313b5fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c77f2049-c066-43dc-a3f1-131a069500b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_EquipmentMember_c77f2049-c066-43dc-a3f1-131a069500b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1903c643-8f8c-408c-a6a1-e3d30a585508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1903c643-8f8c-408c-a6a1-e3d30a585508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1dc3181e-5ded-43c8-8b60-779537d30bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1dc3181e-5ded-43c8-8b60-779537d30bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_ce5a1e96-2643-4968-b69b-5bc9d3cf0a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf8dd6bf-4ddb-46ba-9996-6fcf460c1d39" xlink:to="loc_us-gaap_VehiclesMember_ce5a1e96-2643-4968-b69b-5bc9d3cf0a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_572f019b-be39-4470-bcdb-bc22b223159b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e450cf66-f057-48f4-b886-fe0ebc038d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e450cf66-f057-48f4-b886-fe0ebc038d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ec54932a-1d12-4529-89a1-cd74fc9d6417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ec54932a-1d12-4529-89a1-cd74fc9d6417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b0561f9-dfcb-4cb4-a3fc-8dbcd3f1e090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b0561f9-dfcb-4cb4-a3fc-8dbcd3f1e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_69200a1c-ff85-4255-b26f-604d373dfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_91696af3-29bd-4348-9a52-6a3d71d04a80" xlink:to="loc_us-gaap_Depreciation_69200a1c-ff85-4255-b26f-604d373dfe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7d0be832-5dd0-4113-aff3-6e39c69b6c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_caf1497c-00da-45d2-bfac-a10683632b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_493d9284-135f-48b2-98cb-5b9491afd443" xlink:to="loc_us-gaap_PatentsMember_caf1497c-00da-45d2-bfac-a10683632b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ae4d2d1-efdb-438e-b7bf-7144afb41c9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad7c1f6a-3f5e-438a-8446-3db2997f508f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad7c1f6a-3f5e-438a-8446-3db2997f508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9497519-1bc2-43df-9c97-2c5f6b2fdb25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9497519-1bc2-43df-9c97-2c5f6b2fdb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_130e8441-e0af-4e53-b565-25bd60f97cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e1da2641-eb1a-4ee1-8e7a-76b65cc1d1b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_130e8441-e0af-4e53-b565-25bd60f97cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44cc6f30-171f-4f8e-82a8-3a3ab57ef2e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_64b9ae69-ed6f-47fc-8cfa-d7bbd582db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_49dbe3ff-4a68-4423-8628-6493b93ab6e6" xlink:to="loc_us-gaap_TrademarksMember_64b9ae69-ed6f-47fc-8cfa-d7bbd582db1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_99659552-d31d-4dfa-a08e-485c6db167d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_136bf123-7cfe-492c-a8f7-7f2e81cc8843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_eaa81724-427a-4703-8809-abd59988f7db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_136bf123-7cfe-492c-a8f7-7f2e81cc8843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_328d085e-a8b9-45f0-ae92-9a5c308d3b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_328d085e-a8b9-45f0-ae92-9a5c308d3b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7e2bd7c5-fd4d-4ca6-9413-8116868104c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7e2bd7c5-fd4d-4ca6-9413-8116868104c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_15e0c28d-28f9-41e1-96bd-aff141abea93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_15e0c28d-28f9-41e1-96bd-aff141abea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_b2858b12-9ff4-46ec-82f6-b7992bb64455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a429dea3-053b-4fb4-89bd-cbff00db20ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_b2858b12-9ff4-46ec-82f6-b7992bb64455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7b2a3096-3714-4e3e-9407-0c4950531fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_b2858b12-9ff4-46ec-82f6-b7992bb64455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7b2a3096-3714-4e3e-9407-0c4950531fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_57dda138-8850-41a6-a58a-66b49945d029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_b2858b12-9ff4-46ec-82f6-b7992bb64455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_57dda138-8850-41a6-a58a-66b49945d029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherAccruedExpensesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_442d018a-4e46-408e-a4a5-cdce7f5532c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_442d018a-4e46-408e-a4a5-cdce7f5532c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_2a66f286-9271-45ad-ba82-231574ebd606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_2a66f286-9271-45ad-ba82-231574ebd606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7cb071cf-a206-444d-95a6-88b61bc1acc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_TaxesPayableCurrent_7cb071cf-a206-444d-95a6-88b61bc1acc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_AccruedPayableToVendors_ebd4e49a-549f-4c0a-8958-fe09a1d95469" xlink:href="lfvn-20240630.xsd#lfvn_AccruedPayableToVendors"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_lfvn_AccruedPayableToVendors_ebd4e49a-549f-4c0a-8958-fe09a1d95469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb1608e5-cf85-4b7b-9475-4aa06785ab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb1608e5-cf85-4b7b-9475-4aa06785ab4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_a20ea18a-cc88-4c3b-bc4f-e784279095f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_a20ea18a-cc88-4c3b-bc4f-e784279095f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a924dfe5-fe82-4124-9fe9-152b4e025d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a924dfe5-fe82-4124-9fe9-152b4e025d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c1f60679-b1f6-436b-9d51-dce5c09679fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7a86e789-20cc-4437-aa0e-7635e74640b2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c1f60679-b1f6-436b-9d51-dce5c09679fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6046e0ef-944b-4d1f-a81f-9c00676efdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6046e0ef-944b-4d1f-a81f-9c00676efdd6" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c849da-7010-4677-85b9-c456f62dbc63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016RevolvingLoanMember_979d1d62-366d-4543-b36e-a882fa40fa82" xlink:href="lfvn-20240630.xsd#lfvn_March2016RevolvingLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:to="loc_lfvn_March2016RevolvingLoanMember_979d1d62-366d-4543-b36e-a882fa40fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_March2016TermLoanMember_0fe9a535-544f-46fe-ba9e-5c6bd8425d5d" xlink:href="lfvn-20240630.xsd#lfvn_March2016TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9520d3af-05ce-487a-bcdb-a26268afb0d9" xlink:to="loc_lfvn_March2016TermLoanMember_0fe9a535-544f-46fe-ba9e-5c6bd8425d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_04864867-53f6-4420-888a-1c4bff050581" xlink:to="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4e949b75-e49d-4b5b-8101-ff8777c082c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4e949b75-e49d-4b5b-8101-ff8777c082c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_41ceffb7-8ee3-46d3-8706-3d5a96dc85fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3808e8d2-45a1-4bd7-8830-087adf2e7b91" xlink:to="loc_us-gaap_SecuredDebtMember_41ceffb7-8ee3-46d3-8706-3d5a96dc85fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3270d2fc-0079-4940-b1c9-e46b7f9df2f4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_57722aa4-fc55-4826-b44d-fcf58bf552c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efc7508e-275b-4f3e-9d7f-703188fe9d5b" xlink:to="loc_us-gaap_LineOfCreditMember_57722aa4-fc55-4826-b44d-fcf58bf552c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_25c2372a-4919-4904-ac3b-750e7e426063" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40a6d374-2fc9-49ae-b548-47153fb08482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40a6d374-2fc9-49ae-b548-47153fb08482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d482cf37-356c-488b-9377-52fed34e70c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d482cf37-356c-488b-9377-52fed34e70c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentFloorInterestRate_14009850-1119-499c-96b0-f63273eda874" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentFloorInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentFloorInterestRate_14009850-1119-499c-96b0-f63273eda874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_8cd913dd-8a33-47a3-8de3-5847055ef567" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio_8cd913dd-8a33-47a3-8de3-5847055ef567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_c123674e-87fe-45a6-989d-751ade3b102c" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio_c123674e-87fe-45a6-989d-751ade3b102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_1067fe12-fbae-4eb5-abcf-0eff20e5f2dc" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital_1067fe12-fbae-4eb5-abcf-0eff20e5f2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantMaximumDividend_e33da5e7-97c9-4d95-81ae-2f16b0791048" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantMaximumDividend"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_DebtInstrumentCovenantMaximumDividend_e33da5e7-97c9-4d95-81ae-2f16b0791048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_d6ad3273-28b1-463b-8f9c-6c166c89f96f" xlink:href="lfvn-20240630.xsd#lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_d6ad3273-28b1-463b-8f9c-6c166c89f96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17990e0e-94de-4137-97c1-1ca257487246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5e5f9cb9-111e-4705-b880-a55b1f1805af" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17990e0e-94de-4137-97c1-1ca257487246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4b3bb8e4-d0d1-4723-a260-abf03861969f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4b3bb8e4-d0d1-4723-a260-abf03861969f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92ffb862-c90f-46cf-ad62-1e92e7b66585" xlink:to="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_949d0404-8273-4f18-8f04-6258d37d7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0707a00b-64d4-439e-b513-3057231d7e73" xlink:to="loc_us-gaap_CommonStockMember_949d0404-8273-4f18-8f04-6258d37d7b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_18cb908b-e6b4-4239-8cd5-70ce9df1bc19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2e99ba0b-4acf-4b73-b2db-d89644a4dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0defc0-0a65-4427-bffe-31c269e6269c" xlink:to="loc_us-gaap_RestrictedStockMember_2e99ba0b-4acf-4b73-b2db-d89644a4dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b2839c68-6923-4ee2-92c6-8d3f145b08f0" xlink:to="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EmployeeStockPurchasePlanMember_32d4cebf-638a-48b3-80ce-a113434c003b" xlink:href="lfvn-20240630.xsd#lfvn_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5c28c708-7155-41ea-a823-00c1bb1878af" xlink:to="loc_lfvn_EmployeeStockPurchasePlanMember_32d4cebf-638a-48b3-80ce-a113434c003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f36e0f9b-2c7f-4db0-b75a-6213067f19de" xlink:to="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_62932888-a089-4589-8f74-4fec4da12265" xlink:href="lfvn-20240630.xsd#lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_62932888-a089-4589-8f74-4fec4da12265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_18781960-8c39-4e74-bf38-607c255d4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_18781960-8c39-4e74-bf38-607c255d4d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_aa4d961d-7fdc-49a1-949d-e68e395456df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_aa4d961d-7fdc-49a1-949d-e68e395456df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a76cb8b-5133-467e-89dd-6fbb917c67fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a76cb8b-5133-467e-89dd-6fbb917c67fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8b22bf41-111e-4b93-8d3a-fd2917e1112a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8b22bf41-111e-4b93-8d3a-fd2917e1112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_37ab9a49-08f2-4548-8ca2-de34bd2a2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_37ab9a49-08f2-4548-8ca2-de34bd2a2e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0646696f-a913-4c1a-84e0-f0040132f428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0646696f-a913-4c1a-84e0-f0040132f428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d6bd9ecc-3019-4fd0-b2aa-fe7773f7c551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d6bd9ecc-3019-4fd0-b2aa-fe7773f7c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_66a746ed-bea9-4343-89ba-e3adf8711e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_DividendsCommonStockCash_66a746ed-bea9-4343-89ba-e3adf8711e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b0c598a2-f059-4452-b1b1-8ed7fdce8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b0c598a2-f059-4452-b1b1-8ed7fdce8a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DebtInstrumentCovenantMaximumDividend_b9e88ce8-9004-49bd-8e9e-b1e3dcfc1594" xlink:href="lfvn-20240630.xsd#lfvn_DebtInstrumentCovenantMaximumDividend"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_DebtInstrumentCovenantMaximumDividend_b9e88ce8-9004-49bd-8e9e-b1e3dcfc1594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_f1799671-2848-4c0f-afde-f3be45971a84" xlink:href="lfvn-20240630.xsd#lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ace17d23-bd38-49b9-91d0-95eac532a035" xlink:to="loc_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend_f1799671-2848-4c0f-afde-f3be45971a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationEquitySettledPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_131b2729-eee3-4a0a-99c1-9105aa828f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_131b2729-eee3-4a0a-99c1-9105aa828f25" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:to="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0ae09ed9-6c0a-4d00-b6d5-adeb93cd191b" xlink:to="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_04571c61-a084-4c1a-a57d-dbc16caba3d3" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandAndTenLongTermIncentivePlanMember_04571c61-a084-4c1a-a57d-dbc16caba3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_5bab8b5e-3382-4785-9c3b-1f75825beee4" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanMember_5bab8b5e-3382-4785-9c3b-1f75825beee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_9e12970a-a1c9-44ae-95e6-8d85ac1af816" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cc68c2a-c05a-4669-a1e0-3c5bebbb9f18" xlink:to="loc_lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember_9e12970a-a1c9-44ae-95e6-8d85ac1af816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bf8077a-632d-40d1-a663-476dd10af81e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bd0d7c80-03f7-4433-80e0-99bc9f10bb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bd0d7c80-03f7-4433-80e0-99bc9f10bb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4655db72-6dca-4b13-86d6-b9a6352d57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4655db72-6dca-4b13-86d6-b9a6352d57a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2c7cd416-ad3b-4e70-9271-764408cb9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2c7cd416-ad3b-4e70-9271-764408cb9d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6a8ace45-26df-44db-80ed-182399610a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6a8ace45-26df-44db-80ed-182399610a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_ca27782b-dbe0-448a-a9f5-c63a69ba1c10" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm_ca27782b-dbe0-448a-a9f5-c63a69ba1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5efc748b-ec5c-4467-83b8-ad8c01830fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c04bfe3a-f141-4f0e-a95b-db65fbfc2cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5efc748b-ec5c-4467-83b8-ad8c01830fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_579f89f7-aee1-4d75-9800-2d1f392de754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_579f89f7-aee1-4d75-9800-2d1f392de754" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:to="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bc040768-8017-4544-9a91-78fe193218ac" xlink:to="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EmployeeStockPurchasePlanMember_2237ebfa-f6ab-40fa-bb61-2612081f679e" xlink:href="lfvn-20240630.xsd#lfvn_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d004018a-7545-4a53-ac9c-a3598ba60cd3" xlink:to="loc_lfvn_EmployeeStockPurchasePlanMember_2237ebfa-f6ab-40fa-bb61-2612081f679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05a17b97-dd2a-40b5-8f95-153074707946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21d85fa2-9761-441d-a4f9-94fccd7252ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21d85fa2-9761-441d-a4f9-94fccd7252ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ced7cea-46a8-44e3-b50b-ddcc0d88409f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ced7cea-46a8-44e3-b50b-ddcc0d88409f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4db27761-f017-419e-a265-6af4ac48f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4db27761-f017-419e-a265-6af4ac48f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48311f52-7220-44c8-9f9a-5d9f49d517e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48311f52-7220-44c8-9f9a-5d9f49d517e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9da9b5c5-330d-45e1-a2b3-2761863fb035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9da9b5c5-330d-45e1-a2b3-2761863fb035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_90393448-7430-4cee-9356-d25ccd0275cc" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted_90393448-7430-4cee-9356-d25ccd0275cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ea73cc22-aa0d-4c15-96f1-a5319615af38" xlink:href="lfvn-20240630.xsd#lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ea73cc22-aa0d-4c15-96f1-a5319615af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_35e9878c-5051-433b-a69b-bb13ef96f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1c04078-c411-4c8d-880b-7c8c7f1076b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_35e9878c-5051-433b-a69b-bb13ef96f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationStockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25ebea8-3b6e-46c3-8848-e6673f750c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25ebea8-3b6e-46c3-8848-e6673f750c1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:to="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f2165209-1f7f-4e8d-9dc0-8d8b989682ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_537a75ce-bdb8-419c-99e5-6eeb017edf47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e49f20a5-a814-4813-83b9-80d4a4794438" xlink:to="loc_us-gaap_RestrictedStockMember_537a75ce-bdb8-419c-99e5-6eeb017edf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:to="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fa595383-6b50-4a2a-8129-3fa3bf9de585" xlink:to="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_5ed8b2bf-a220-4b78-8512-50c1f862af4e" xlink:href="lfvn-20240630.xsd#lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b4e02db4-52f0-42cb-bd12-8943d7a43ee4" xlink:to="loc_lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember_5ed8b2bf-a220-4b78-8512-50c1f862af4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38cbbe05-8929-4de2-a478-bac0b37373bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ca3a50ac-f0d6-43ad-b5a4-aa52452728ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ca3a50ac-f0d6-43ad-b5a4-aa52452728ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7b6bb06d-37fd-44d7-8153-65c1fe5b8128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7b6bb06d-37fd-44d7-8153-65c1fe5b8128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c24aa54-263e-4255-b863-34cacf8f0bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e722693-7519-4395-a88a-efa09e58333a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c24aa54-263e-4255-b863-34cacf8f0bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationStockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_154c1ac6-a9e5-4031-864a-8ff3fe8ba666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_154c1ac6-a9e5-4031-864a-8ff3fe8ba666" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:to="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_b9d822e1-279d-4678-a536-25d5d0329943" xlink:to="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_826f4db4-c9b8-4388-9f9c-fb7f4c625833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_826f4db4-c9b8-4388-9f9c-fb7f4c625833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a2cf968b-b284-46f7-b6b2-b8f7e4bc5f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cedd25be-d90f-4539-bc1c-60b9f8fab35e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a2cf968b-b284-46f7-b6b2-b8f7e4bc5f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:to="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d4636330-799e-405b-b4e3-76b0eace1633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32125f01-44e7-4782-bef8-e1a6b12e10c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1210f77-c6d9-4980-910b-0b9ea7c3a48e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32125f01-44e7-4782-bef8-e1a6b12e10c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_207312eb-69e4-4780-a1d1-a211f8bd937e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7d3324e9-1b8a-42c9-ba36-66d0b404b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7d3324e9-1b8a-42c9-ba36-66d0b404b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ee408fda-007f-4838-bb20-9177b16067ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ee408fda-007f-4838-bb20-9177b16067ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9b9626c-23fe-4849-8dd8-419632c7e244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77350fac-ef82-4e9f-a835-7b6d2df392c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9b9626c-23fe-4849-8dd8-419632c7e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2229f34-68ac-4fd8-be3c-e6fd5ae66676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2229f34-68ac-4fd8-be3c-e6fd5ae66676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b5629fc9-33bf-4bb3-9c34-82b062978e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b5629fc9-33bf-4bb3-9c34-82b062978e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0a72228-207f-4b5a-8af3-a3402ea7dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0a72228-207f-4b5a-8af3-a3402ea7dddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eea171e9-ddf9-4190-ba3e-09044ad2f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eea171e9-ddf9-4190-ba3e-09044ad2f3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20bd37c-1e9f-49b4-90e1-4dc579b63626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20bd37c-1e9f-49b4-90e1-4dc579b63626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee92a666-a9bd-4237-9f82-01f984563a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5461daf1-3169-4373-8286-8524079b5af3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee92a666-a9bd-4237-9f82-01f984563a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d90ba342-3624-42f6-8a08-9ef93e54cb10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d90ba342-3624-42f6-8a08-9ef93e54cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3f8e64c-b5bc-42d8-a447-5bc788f1bc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3f8e64c-b5bc-42d8-a447-5bc788f1bc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_99588279-9ed5-45d8-8a2d-83e2d95b6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_99588279-9ed5-45d8-8a2d-83e2d95b6b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b581c22-7af8-468b-a79a-02d3bf92f642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b581c22-7af8-468b-a79a-02d3bf92f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dc54d8d5-68b7-4b50-8b13-7a9810f517c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dc54d8d5-68b7-4b50-8b13-7a9810f517c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b25ae2a2-18a1-4e87-9c92-72974f2e3969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b25ae2a2-18a1-4e87-9c92-72974f2e3969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e31407e0-e21e-4e10-932c-2a8b4c306a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bc5901c1-20b4-4232-aa7f-4bbe84d28a75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e31407e0-e21e-4e10-932c-2a8b4c306a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0e977891-2995-4ec1-89e6-5d19ac67e904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0e977891-2995-4ec1-89e6-5d19ac67e904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_40b07c77-36d7-48e2-b801-2bd8e0988878" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_40b07c77-36d7-48e2-b801-2bd8e0988878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56680aaf-245b-42ef-b02f-f6040866f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_40b07c77-36d7-48e2-b801-2bd8e0988878" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56680aaf-245b-42ef-b02f-f6040866f5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d1c2398-6374-4e2d-8c2e-a60905d5985f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_40b07c77-36d7-48e2-b801-2bd8e0988878" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d1c2398-6374-4e2d-8c2e-a60905d5985f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e4406bf1-0815-46ac-b3fe-db042ca2d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9471ca79-3126-4add-972c-3c9a30ebe125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e4406bf1-0815-46ac-b3fe-db042ca2d0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09aeda70-0f61-4dcc-bc16-ba2200480ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e4406bf1-0815-46ac-b3fe-db042ca2d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09aeda70-0f61-4dcc-bc16-ba2200480ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aea7b8c3-0af9-483b-8c7f-c05d404bfd05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e4406bf1-0815-46ac-b3fe-db042ca2d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aea7b8c3-0af9-483b-8c7f-c05d404bfd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f5c1c0f7-4d41-4d6f-83e4-12bd34400320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e4406bf1-0815-46ac-b3fe-db042ca2d0cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f5c1c0f7-4d41-4d6f-83e4-12bd34400320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationRestrictedSharesDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ce406aa-327d-4a30-a6d2-c465c1be885f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ce406aa-327d-4a30-a6d2-c465c1be885f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:to="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fe466dcd-2e0f-4dd0-b15f-1d38430d47f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a0f43c5a-b76e-4f6d-9026-90647fd0182b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:to="loc_us-gaap_RestrictedStockMember_a0f43c5a-b76e-4f6d-9026-90647fd0182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_01544b59-c31e-4bb3-afb5-3ccb90b32b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa50d954-d98f-4361-b306-c9fd2b542c24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_01544b59-c31e-4bb3-afb5-3ccb90b32b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad16543f-cdc0-447e-8ab0-bfad53386d4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32fe7ac6-3095-4e53-820a-2a717ad158c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32fe7ac6-3095-4e53-820a-2a717ad158c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ccdbc25-42de-4748-9c94-9d21095dd974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ccdbc25-42de-4748-9c94-9d21095dd974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_95a42774-2e8c-4aff-a2b0-8b372b189cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_95a42774-2e8c-4aff-a2b0-8b372b189cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4757bb70-91ac-46d9-bbaf-65d129b34181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4757bb70-91ac-46d9-bbaf-65d129b34181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20b27bc8-a100-402c-883f-7237ce66575e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780e5083-5e66-4379-b697-589d7084a9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20b27bc8-a100-402c-883f-7237ce66575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263b0e0a-195b-4fd6-b4f8-d48277d8e389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d77c3ed-2577-42b6-b7cf-e224235988bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d77c3ed-2577-42b6-b7cf-e224235988bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50c03ded-acfc-403a-abc0-7e68daba3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50c03ded-acfc-403a-abc0-7e68daba3a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7b921d3f-c8bd-401d-ad28-f96b18b5aee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7b921d3f-c8bd-401d-ad28-f96b18b5aee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7c12922e-9c55-484a-8953-61522706ba49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7c12922e-9c55-484a-8953-61522706ba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_68277001-efd9-4b39-bb94-40dd36bc9172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c17c4467-8d9b-4e26-898c-d296434efcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_68277001-efd9-4b39-bb94-40dd36bc9172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationRestrictedStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3356f442-c7d3-41eb-b152-ba38e1c646bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3356f442-c7d3-41eb-b152-ba38e1c646bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:to="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a10a74f7-d019-4ad6-8935-a1fd81b45cd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_32f657ba-c248-4413-a75d-543628c47b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:to="loc_us-gaap_RestrictedStockMember_32f657ba-c248-4413-a75d-543628c47b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3babe1f5-2f62-458d-83f6-f34fc02221c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29094f9-5398-42e1-9631-5a7cb32d0e60" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3babe1f5-2f62-458d-83f6-f34fc02221c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3546eed8-2edc-4d2e-8bfd-d5c81f6f1479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8da77e29-8ca5-46ec-8667-50da5711b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4854c21d-566c-4d41-babc-6396f7b533e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8da77e29-8ca5-46ec-8667-50da5711b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_704ef39e-b4a0-4ead-894b-d3dd6dca31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_704ef39e-b4a0-4ead-894b-d3dd6dca31ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:to="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_67dfa6d6-7e90-4287-84fe-561c4c1bf190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember_c9cab3c1-ed6e-43a4-aca5-21a01bbeeb19" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7240f119-6108-49e4-b030-4a7771bff2a4" xlink:to="loc_lfvn_PerformanceStockUnitsMember_c9cab3c1-ed6e-43a4-aca5-21a01bbeeb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:to="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8e59ac95-475b-4547-bb12-932ab7e2214d" xlink:to="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b36a0ddb-a9b6-45f4-9e45-16092a628448" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:to="loc_srt_MinimumMember_b36a0ddb-a9b6-45f4-9e45-16092a628448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_41425434-2cc7-4af7-a507-3c9085dac744" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9cb23abf-37d6-43a0-8156-58e040720e17" xlink:to="loc_srt_MaximumMember_41425434-2cc7-4af7-a507-3c9085dac744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c0a318d-9f51-4cd4-bd1f-10777099789f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_4d985260-8c2e-45eb-8209-bf2948103fe4" xlink:href="lfvn-20240630.xsd#lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:to="loc_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage_4d985260-8c2e-45eb-8209-bf2948103fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f69b1c1a-a76a-4a60-a512-7f0fac2da839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41dad0fe-abf6-4a49-a3bb-567961629a52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f69b1c1a-a76a-4a60-a512-7f0fac2da839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#ShareBasedCompensationPerformanceRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0714d4a-5d35-40c5-b72a-9f757b0d634c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0714d4a-5d35-40c5-b72a-9f757b0d634c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:to="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_684b069e-4eb6-4a72-97b7-96cf66ab872d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember_52a855e7-9dd4-4427-8487-8e4ac9a130db" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_285fc3c0-daf5-4356-8fa4-2e8cc7ef6eaf" xlink:to="loc_lfvn_PerformanceStockUnitsMember_52a855e7-9dd4-4427-8487-8e4ac9a130db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed6bac20-0cd7-4346-b956-a907d440f388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93562aea-275a-4ce7-875e-5079de10a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93562aea-275a-4ce7-875e-5079de10a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a1ff155-9706-4e66-b8e0-30d8014465d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a1ff155-9706-4e66-b8e0-30d8014465d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bef0666-ebf6-4068-a434-fec29df1af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bef0666-ebf6-4068-a434-fec29df1af0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0f91f00-45c7-498e-abcd-63bdcd0a7368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0f91f00-45c7-498e-abcd-63bdcd0a7368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2ffc6ee-ffca-49f6-b74a-e0a89cf565dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4432d97-21f5-40f3-a4bd-885a8196b67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2ffc6ee-ffca-49f6-b74a-e0a89cf565dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_491a7648-70f8-4fd7-8fba-368f6a9c1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3dd0e113-974f-4817-8345-a1a0a7f0217a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3dd0e113-974f-4817-8345-a1a0a7f0217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9174c5ec-f3a4-41c9-924f-8fe34e2622d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9174c5ec-f3a4-41c9-924f-8fe34e2622d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_529c1910-0387-4f2b-8cf8-5b5133644e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_529c1910-0387-4f2b-8cf8-5b5133644e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_669599d1-5a72-4e7e-9bfd-036475fef8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_669599d1-5a72-4e7e-9bfd-036475fef8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4be241a7-97cf-45b9-9a36-3466c6898fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7888c48-1771-4188-99eb-5b750c0b1809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4be241a7-97cf-45b9-9a36-3466c6898fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/OtherExpenseNetDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#OtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/OtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_04b62954-b015-4aa2-86cc-e1b8ba4fb850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_603114e2-ceec-43ef-85c6-0e84801ddd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_04b62954-b015-4aa2-86cc-e1b8ba4fb850" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_603114e2-ceec-43ef-85c6-0e84801ddd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_OtherMiscellaneousIncomeExpensesNet_d7746e7c-4569-4003-bd39-66bd7001d439" xlink:href="lfvn-20240630.xsd#lfvn_OtherMiscellaneousIncomeExpensesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_04b62954-b015-4aa2-86cc-e1b8ba4fb850" xlink:to="loc_lfvn_OtherMiscellaneousIncomeExpensesNet_d7746e7c-4569-4003-bd39-66bd7001d439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9b3abf58-d6ce-49b8-befc-d733395f65b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_04b62954-b015-4aa2-86cc-e1b8ba4fb850" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9b3abf58-d6ce-49b8-befc-d733395f65b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77e7845e-c4f3-4c9e-bda3-f73ba64036c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e7845e-c4f3-4c9e-bda3-f73ba64036c4" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_b16c5cf6-a692-47aa-8f68-7e3faed7d532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_b16c5cf6-a692-47aa-8f68-7e3faed7d532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e66c1356-4801-4945-a12e-6341bb216e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_b16c5cf6-a692-47aa-8f68-7e3faed7d532" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e66c1356-4801-4945-a12e-6341bb216e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_74cdc473-ff4d-4845-8c8c-7af88921b7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_b16c5cf6-a692-47aa-8f68-7e3faed7d532" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_74cdc473-ff4d-4845-8c8c-7af88921b7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16920b6-2530-4352-8a15-e5dee32c2d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_b16c5cf6-a692-47aa-8f68-7e3faed7d532" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16920b6-2530-4352-8a15-e5dee32c2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cc7b77cb-805a-431c-8042-4c8b76389b40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cc7b77cb-805a-431c-8042-4c8b76389b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9a99cc28-c113-4d59-8953-234d0b69c543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9a99cc28-c113-4d59-8953-234d0b69c543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d521b60-63a9-4464-8249-60ea68b490dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d521b60-63a9-4464-8249-60ea68b490dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d39ad9e3-8731-4a47-80f5-d21561407754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc675014-ed67-4be5-8ce9-93b796c5a105" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d39ad9e3-8731-4a47-80f5-d21561407754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_eb5688bb-12b0-433a-835d-61b29d878f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_eb5688bb-12b0-433a-835d-61b29d878f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_793ed0c8-9a51-4899-af44-40497de21b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_793ed0c8-9a51-4899-af44-40497de21b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c186a7df-e2db-4ac8-abc7-4acc7dc517eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c186a7df-e2db-4ac8-abc7-4acc7dc517eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e09936d8-8d60-4a60-af01-86e422240908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_30c0e880-39b9-4ab4-85a0-0408935d9176" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e09936d8-8d60-4a60-af01-86e422240908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b002e011-4c96-48f8-b9bf-9851f556e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_bdf16474-a7bc-4e8d-acc0-39226283a316" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b002e011-4c96-48f8-b9bf-9851f556e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ac40e50b-9af4-45f2-9808-05175e163f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac40e50b-9af4-45f2-9808-05175e163f43" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3b67523-a7ab-4a0a-a8fe-93c9366c0e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3b67523-a7ab-4a0a-a8fe-93c9366c0e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0014411d-54a2-4c61-92b1-58b714557b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0014411d-54a2-4c61-92b1-58b714557b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7a3b676a-2098-4291-a7c1-806865fd8506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7a3b676a-2098-4291-a7c1-806865fd8506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_53064c7f-3700-46b7-a75f-6001c572d9b5" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp_53064c7f-3700-46b7-a75f-6001c572d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_7e5df1eb-08f6-4b4d-a497-a18728607815" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent_7e5df1eb-08f6-4b4d-a497-a18728607815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_4ba74905-e1c3-492e-8430-bbcafed1113e" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent_4ba74905-e1c3-492e-8430-bbcafed1113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0516e03b-7d54-422c-8507-c9a3120b50db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0516e03b-7d54-422c-8507-c9a3120b50db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_88568c7f-4795-4109-bfd7-13b275f35cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_88568c7f-4795-4109-bfd7-13b275f35cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:href="lfvn-20240630.xsd#lfvn_PermanentDifferencesAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b690ff65-3dbe-493f-a4bc-0916c6979d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b690ff65-3dbe-493f-a4bc-0916c6979d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_24894db9-131c-4ade-b08e-183afaf7bc9d" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent_24894db9-131c-4ade-b08e-183afaf7bc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_9773a5aa-2a9d-41cc-94d8-4e37f2642419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_9773a5aa-2a9d-41cc-94d8-4e37f2642419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_34c0c314-9127-49a5-81df-dae87b265647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_34c0c314-9127-49a5-81df-dae87b265647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_0f5cf166-1ff7-42cd-b20d-ef92c98c45a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_0f5cf166-1ff7-42cd-b20d-ef92c98c45a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_12329320-c372-42d8-b477-f2a2ee23dafc" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion_12329320-c372-42d8-b477-f2a2ee23dafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d412838c-4710-45ab-902b-86f80e107581" xlink:href="lfvn-20240630.xsd#lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d412838c-4710-45ab-902b-86f80e107581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_185164f9-e7ef-4976-bb1f-f4092c0afedf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_185164f9-e7ef-4976-bb1f-f4092c0afedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_ed8f2e5d-1976-4bed-90c1-70a4ec1cf55c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lfvn_PermanentDifferencesAbstract_85d28410-fdeb-4b61-9514-6e417ce47d8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_ed8f2e5d-1976-4bed-90c1-70a4ec1cf55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d0b409f9-c65b-49ca-a67b-50943bf0a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d0b409f9-c65b-49ca-a67b-50943bf0a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_47f457c0-6162-4df0-b8bf-4638b7109d64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ea7fc8a6-7619-45a5-8d14-d6d06da3a85c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_47f457c0-6162-4df0-b8bf-4638b7109d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_222966e9-1704-4bbf-add6-8e07645b6286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_222966e9-1704-4bbf-add6-8e07645b6286" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7613078d-af5d-4258-8904-25abdc428e05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7613078d-af5d-4258-8904-25abdc428e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_978ec872-98e9-4862-8279-ae4da6092180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_978ec872-98e9-4862-8279-ae4da6092180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2911af97-0ed7-46be-b03a-3590b88b2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2911af97-0ed7-46be-b03a-3590b88b2b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_DeferredTaxAssetsLeasingArrangements_683771ca-e94c-4c3d-bb5b-de322fb3857f" xlink:href="lfvn-20240630.xsd#lfvn_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_lfvn_DeferredTaxAssetsLeasingArrangements_683771ca-e94c-4c3d-bb5b-de322fb3857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5a0ec6ab-677d-45f2-b8f2-5350c5fc9ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5a0ec6ab-677d-45f2-b8f2-5350c5fc9ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9da3f6b9-f5d4-48c6-814b-b2c064f30943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c5b2cc2c-6639-4d7a-be3b-2611f23e8967" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9da3f6b9-f5d4-48c6-814b-b2c064f30943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4d1965cb-5d76-4568-9973-94daa7dcfd01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4d1965cb-5d76-4568-9973-94daa7dcfd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_253710f7-aac3-4319-956f-4a976f5b0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_253710f7-aac3-4319-956f-4a976f5b0a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e7fdb3e4-1d93-4375-bdce-8dd6ccdbb21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e7fdb3e4-1d93-4375-bdce-8dd6ccdbb21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5a2ae11b-ae0f-4346-9117-ea14853114f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5a2ae11b-ae0f-4346-9117-ea14853114f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f51cd72d-e843-4d88-886d-a515f8597658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_31fa3e7c-a615-4907-b614-1c04b27182c2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f51cd72d-e843-4d88-886d-a515f8597658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_62173cab-8174-4f69-9270-2d502345bfac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_62173cab-8174-4f69-9270-2d502345bfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df7c832b-095f-41f7-b3bd-d03ad1d84e55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_fa6c834f-d115-4e41-9281-84a05fe99540" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df7c832b-095f-41f7-b3bd-d03ad1d84e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4dca7a9b-84ee-4f7d-a200-6be581072ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dca7a9b-84ee-4f7d-a200-6be581072ccb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b6c79fe-7d98-4532-8e3a-df82f3268223" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0d82de53-58e1-4715-9847-c62b9499977b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0d82de53-58e1-4715-9847-c62b9499977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_884f62d0-236f-4e54-969e-aef181193576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b91be6a2-f4be-4b3f-ab5f-4d132926f5da" xlink:to="loc_us-gaap_ForeignCountryMember_884f62d0-236f-4e54-969e-aef181193576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_91b3178f-251b-4d43-b4dc-c6f5eb352cab" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_69826b71-3bc9-4817-a74b-5b895ec2f6a7" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities_69826b71-3bc9-4817-a74b-5b895ec2f6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_49c15478-0656-49c4-abe6-a033be117cc4" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits_49c15478-0656-49c4-abe6-a033be117cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_UnrecognizedTaxPosition_0aa18d87-f1cb-4976-b0c3-646388102623" xlink:href="lfvn-20240630.xsd#lfvn_UnrecognizedTaxPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_lfvn_UnrecognizedTaxPosition_0aa18d87-f1cb-4976-b0c3-646388102623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_75a20c79-c697-4955-b336-883b523c8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_75a20c79-c697-4955-b336-883b523c8cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8ecc966d-09e3-4105-a563-46adfcc3197e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8ecc966d-09e3-4105-a563-46adfcc3197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_47b0a006-8945-4a66-9f2d-8ee41cf8d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c1b83363-7509-4e92-b6be-fff41dc328c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_47b0a006-8945-4a66-9f2d-8ee41cf8d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9a217f2a-0cc9-4520-a39d-1bc967d3f6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1359f76b-dc5b-4727-b215-3f5bbebd398f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9a217f2a-0cc9-4520-a39d-1bc967d3f6e9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1359f76b-dc5b-4727-b215-3f5bbebd398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46b5024a-50a5-43aa-9dea-a389b39f9ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1359f76b-dc5b-4727-b215-3f5bbebd398f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46b5024a-50a5-43aa-9dea-a389b39f9ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e14eceea-0146-4464-82ef-03e999906b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1359f76b-dc5b-4727-b215-3f5bbebd398f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e14eceea-0146-4464-82ef-03e999906b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aaa1d14d-c698-4de9-a5cd-a8890bc8115c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1359f76b-dc5b-4727-b215-3f5bbebd398f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aaa1d14d-c698-4de9-a5cd-a8890bc8115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a11f309f-774e-4436-b01a-3557e1346b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a11f309f-774e-4436-b01a-3557e1346b90" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:to="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3752fa6-b0d6-4dfc-9fbb-c4daf633bd28" xlink:to="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21bdc4e-71b0-4a48-8ba5-98bb63e656d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:to="loc_srt_MinimumMember_b21bdc4e-71b0-4a48-8ba5-98bb63e656d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_260299f3-1735-4d18-9b32-68c23e3836f2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba5de963-36b0-4916-b364-1b041577cdce" xlink:to="loc_srt_MaximumMember_260299f3-1735-4d18-9b32-68c23e3836f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_158f84e5-e171-4686-8625-d98e574081b7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cdd3ef3-d9a5-40bf-b541-0bdf0efc00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cdd3ef3-d9a5-40bf-b541-0bdf0efc00b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3dcad26e-8ac9-4a59-b35a-b00a1c4c4f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3dcad26e-8ac9-4a59-b35a-b00a1c4c4f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0a6bf28b-ad71-44c4-8f86-3c17327d14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0a6bf28b-ad71-44c4-8f86-3c17327d14bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseLeasedArea_6c2cafd4-4886-45b6-b581-4b9a7596109a" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseLeasedArea_6c2cafd4-4886-45b6-b581-4b9a7596109a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0198c612-105f-4074-b1c5-36e175362685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0198c612-105f-4074-b1c5-36e175362685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseMonthlyPayments_eb1c80a7-1abd-4cb3-800d-2a342cae27b6" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseMonthlyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseMonthlyPayments_eb1c80a7-1abd-4cb3-800d-2a342cae27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_LesseeOperatingLeaseAnnualAmount_56022f62-c39f-4f66-81a6-853d8237c492" xlink:href="lfvn-20240630.xsd#lfvn_LesseeOperatingLeaseAnnualAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_99f019c2-ec0a-4a24-bc20-941ffb207b84" xlink:to="loc_lfvn_LesseeOperatingLeaseAnnualAmount_56022f62-c39f-4f66-81a6-853d8237c492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5ba2ee4e-9923-4440-91c0-f45b8ea72a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_10be9e5f-bfa2-42f1-b218-e5d6a6f7dfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ba2ee4e-9923-4440-91c0-f45b8ea72a99" xlink:to="loc_us-gaap_OperatingLeaseCost_10be9e5f-bfa2-42f1-b218-e5d6a6f7dfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_936e1c6b-9fc2-41a6-aee8-9e660c52a02d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ba2ee4e-9923-4440-91c0-f45b8ea72a99" xlink:to="loc_us-gaap_VariableLeaseCost_936e1c6b-9fc2-41a6-aee8-9e660c52a02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_bc45dd48-60ff-421a-baa8-7c18e2338409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ba2ee4e-9923-4440-91c0-f45b8ea72a99" xlink:to="loc_us-gaap_ShortTermLeaseCost_bc45dd48-60ff-421a-baa8-7c18e2338409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c06f64d5-570a-4473-979a-f4c92bbcd74b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ba2ee4e-9923-4440-91c0-f45b8ea72a99" xlink:to="loc_us-gaap_LeaseCost_c06f64d5-570a-4473-979a-f4c92bbcd74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1955ba7e-c791-4d68-8005-337427296601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e82cc85b-1b97-4d80-871d-d9b877418168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1955ba7e-c791-4d68-8005-337427296601" xlink:to="loc_us-gaap_OperatingLeasePayments_e82cc85b-1b97-4d80-871d-d9b877418168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7a312ceb-11a3-49b7-86a2-e10daf3a5a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1955ba7e-c791-4d68-8005-337427296601" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7a312ceb-11a3-49b7-86a2-e10daf3a5a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lfvn-20240630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_69a9da54-cd41-4a12-808f-c0a12b844dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_69a9da54-cd41-4a12-808f-c0a12b844dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd929039-8192-4e5a-a25a-f00d85845fee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd929039-8192-4e5a-a25a-f00d85845fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cfc7986c-00ff-4f42-829f-2422efb6af01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cfc7986c-00ff-4f42-829f-2422efb6af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d376dd89-e027-4d9e-87e2-3d1b967083c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d376dd89-e027-4d9e-87e2-3d1b967083c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b0e3ea73-9d40-412a-a546-d1111cc94d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b0e3ea73-9d40-412a-a546-d1111cc94d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e7e7e28c-b875-4668-8472-d6364a14dc54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e7e7e28c-b875-4668-8472-d6364a14dc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1eb3cbc0-9b8a-403d-8d23-93b8ef4b7b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1eb3cbc0-9b8a-403d-8d23-93b8ef4b7b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe850773-423e-4784-9465-eedd6dac3947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe850773-423e-4784-9465-eedd6dac3947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ecb0d2df-1e8f-47d3-943f-9a1fb4fc7dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8fb1a45b-0aa3-4681-ad4d-78f64c0f4589" xlink:to="loc_us-gaap_OperatingLeaseLiability_ecb0d2df-1e8f-47d3-943f-9a1fb4fc7dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_lfvn_PerformanceStockUnitsMember" xlink:href="lfvn-20240630.xsd#lfvn_PerformanceStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lfvn_PerformanceStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex109keyexecutivebenefit001.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$\?PC\ZW)9HH(S)-(D:#JSL /S- #Z*0$, 000>012T %%%% !1110 4444
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M[O'3&.,5;LM'L[32X[ PQ2PJS.5:-=NYF+$A>@Y)P.U:   P!@4 <(KIX?\
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M6&/3BQZ6I+ *I_N9SCL1CMBNL\*Q6MGXU\6V5DD,,"/:N((0%56,7S$*.!G
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M7>^&=$AT+2V@BA\DS3R7+Q;MPC+MG:#[# _"J]CX>NWU%;W7;^+4I+:>22Q
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M 'T&&'8A?85W_P!G@-P+CR8_/ V^9M&['IGK2+:6R7!N%MXA,1@R! &/X]:
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M@P& 0@SC&/Y4 <;X6:>RUFST^Y6RO8SI[&RU.T&TO"&3Y95['D$$''7WJ_\
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M&![$?$VRGN#;^9<:'&8G<#,DGF]5/=L8Z=J[7[':\_Z-#\W7Y!S3A!$I0B)
M4!"$*/ESUQZ4 <U\2%G?X=:X+?._[,2<?W006_\ '<U3\<BR.E^'+B98?LR:
MM:$R2 ;5C)YR3T'2NSDC2:)XI$5XW4JRL,@@]0:IV&FI9:>E@S">VB 2(2#)
M5!]U23UQT!]AGGD@'#SVNDZEXK\5B>*UN($TBV,:N 54;9>0.@X(Y[9]ZS]/
MU6WBB\(G6M0^S:=/H:I%<2A&C^T87<K%P0"5QR?<=S7J!M;=F9C;Q%F^\2@R
M?K0]G;20>0]M"T.<^6R KGZ4 97A*RL=/\.P6VF7,]S8HS^1+,0=REB?E( ^
M3KCCIC'&*VZ    !@#H** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7*C 'SE>"QQV]ADXK.UU-6?7].$-C+=Z28I%G6"58V$I*[2Y)!,>-V0,^X/
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M@$P"HW'/)Z<<R)KNH:EK-SI%C';6MW96D,]T;A3*%DEW;8QM9<XVG+9[C H
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MU*".VNM2D20+'ODV-$BLRMNP,C(!(."._2M2\\$-++J:6>IFULM0T]+"2#R
MYC5$95V,3P,,<C!SZ@\UUU% '-67ABZM-7T[4&U-)7L]/-CM:VQO!*G=PW'*
MCCT[]ZH/;Z=X6\--X?U:X:^_M%K@0Q16KAIBY+L@QN .7P"2/TKM** ,OPYI
M1T3P_9:>\C2RQ1CS9&.2\AY9L^Y)I^I6%U>2PM!<PI"$=)K>>#S8Y@V.HW#&
M,>_4UHT4 9GA_1H?#^B6^F0.7CAW$'&!EF+$ =ADD =ABM.BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4C6J[86W,K*.XW @D>QSU-/U3PKH>M1VL=_IT4BVHQ!MRAC&,84J00.!QTH
MD\/1W=OH5K;W^H)?W<0:.2Y48\PJQ'3U&,'W!K4J@-$TT7-A<+9QK)IZ-':E
M<@1*P ( ''0 5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5\3W<4^IPZ59&ZFTX*'C\B5S,Y0/L5D4A3M*\G/)Z#K6X+J>XT5;N"$P7$D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_;?YCEN.V ,GKV9J6AWMSXEL]7M+^*(16SVSQ30F0 ,02Z?,-K<8R<\5O44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *9*LC1,L3A)",*Q7=@^N*?39'$4;.P8A1DA5+'\ .30!@
M^"-2O-7\':=?W\HENIE<R.%"Y(=AT' X%=!7)^"1<:3\/;5+FQNQ<VD4K/;>
M41(Q#,P50<9)&,?6NFM9S=6<-P8983+&KF*48=,C.&'8CH: )J*** "BBB@
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MZ\UZD %4   #@ =JHKHFF)>M>+80"X9_,9P@Y?IN_P![WZT <KI^EPZEX_\
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M"6!+\C).2,XIMX;?S->TBYM]772[K5?M,CPZ9)/DAD9]LJ9 !9/0E>>_0 ]
MO/$&F6, FGN3Y?E"8M'&\FR,]';:#M7KR<#@^AJ.?Q1HMO<"W?4(VF-O]I5(
MP9"T>0 P"@YSD8 Y-<I>3"#Q1?75WIFJ:EI&L6\+VTVGB1U&$VE'5", @Y!/
M')]ZN6-FUCXZTYDTR>VLX-#:W 2%WCB;S$81[P""0H/?M0!M0^,- G-EY6I1
M.+U@L#*K%68]%)QA6..AP:LW_B#2],=EO+KR@C*LC[&*1EN@=P-J9R/O$=1Z
MUP,=I>+\/K*U_LV^%PFN"=HOLDFX)]K,F[&WILY_2K;0FWU?6]+UC0=6U"#4
M+HW%M);^88)D=5^23#!4*D8^;'% '67GBW0K":[AN-002V@5IT5&=D!S@D*#
MQP<^G?%,N_%5C;ZQI6GHLTQU"-IHY8HG=/+ !!! .<Y7IT!R<<9PH[>6#Q)X
MJ=K&Y$4NF6\,++;2,KLJR!E4X^;&Y:IZ7;WMG_P@,\FG7Q6TT^6UN%6W;=%(
M8XP P(^494C)X]Z /1JS#X@TL7T5F;K$LSM'$3&P21QU57QM+#!X!SP?2M(C
M((!Q[UYQX9M<6VG:'J_A_5)-2TV=2)Y3(;7*-Q,KEMN<<@ 9R<8ZT =C'XGT
MB99C'=,WDW MI%$+[EE/1"-N<U-J.O:;I6_[9<&,1J&D81LXB4\ N5!"#KRV
M!P:X^^BN;7Q1#XNL],NG@DF%G<V:VLGFN@!47.W'WAD@<<H>N3@)=JUIXFUJ
M'5-%U>_T_5O+EMWLUD9&'E+&T4B@@+]W^+C!.<4 =C?:[ING(7N+GY1%YS&-
M&DVQ_P!\[0<+UY/'!I8M;TZ>\%I#<B2=K?[4JHI.^+CYU(&&'(Z9ZUR,!N/#
M7B2]CNM#O+C3-1L[:. 6<)N%A,:%#"WH.<@GCD^]695FTOQMI5^^E7"VKZ0]
MFL=G 9%AD\Q&"':,*, C)PO':@#3O?&>F6]OI<]N9;J+4;G[/$\4+L 03NS@
M=1M;CJ<>@-3)J]E'J^INVKO(EK;QO-9B+(MQ\WS\+NR>X[;:XJPM-0M_"?A=
MI=+OP]CKDDUQ$+=C(L;-/AMHY(^=>1ZUTVFQRM\0]9GDL[E()[&VC622%@C,
MID++NQM)&X=Z -R+6K">SL[N*8O!>D+;NL;'S,C(QQTP"<GM4;^(-+CO8K1[
MK;)+*88V*,(WD'5 ^-I;@C&<Y!%8/A/2+[3KVXTVYB(TW2II!ISG_EHDGS#_
M +X!9/\ @1]*Q_#]J5AM] UC0-4GU"SNMZ7#F0VC8<LLP;=M!P<XZYXQ0!Z3
M68_B'2H[E8'NPI>;R%<HWEF7ILWXV[L\8SG/'6M,]*\P32]0G^&LO@^>SNAJ
MZ3>4)3"WEM^^WB828VXQ\W7.01C- '0ZIK4UYXM/AVWN[NRQ8F83PVQ9O-+A
M5ZJ1M&"<]#GKQ731M)::<C7<IGEBB'FR1Q'+D#DA!D\^@S7.*LJ_%!IS;71M
M_P"R%@^T>0_EF3S2VW=C&<'-=70!P=]XQ>_T+0M8T^XFLK>XU6&&998@H>%I
M"#DLOH,DJ>,D9KJ;+Q!I6H0W<MO>(4LSBX,@,9BXSE@P! QSGH:\_L[:]C\"
M^%M/ETO4%N+#58#<(;1SM5)&+-P.5 P<]#GC/.+>LZ;J=_J/C,6-G<^9/'8R
M6Q>-XUG,)+.BN0!DX Z]Z .YLM:L+^[EM()F^TQ*'>&6)HW"GHVU@"1[CBH?
M$FNP>&O#M[K%PI>.VCW! <%V) 5?Q) K)\.26>IZG_:<6AZG9W*6YADGU(2*
MZ@L#Y:[R=PR"21QP/6KGC;0)/$_A#4-)A<)/,@:)FZ;U8,H/L2,?C0 MK9Z]
M-IB7%QJYBU"2/?Y*P(;>-B,[<$;R!T)W GVZ5935DL;"S35)&^WM;K)-'#$T
MC9 &]MJ G;D]<8JKIGB1KBSB2\TS4K?40H66V-I(1O[[9,;"N>C;L>N*SQ]M
MTKQ[<ZC>VL\EG?V$4:26\3S""2,L2A"@D [\@XP?K0!M2^)M%AALIGU*W\J]
M_P"/9PV1)P3P1]#55O&WAU;66Y;40(XI#'*#$X:,C&=R[=RCD<D <]:Y*WT:
M]TZW\.J]G<E?[?FOC$D#/]FA<2[0V =OWEX[$GTJW<V]PS?$/;87A^VPA;;%
MK)^^/V8)A>.?FX_7I0!U-]XIT33IS!=:C$DPA\_RUR[%,@9 4'/4<#FI(O$>
MD3Z?:7T%ZDUO=MMMS$K.TK<DA5 ))&#D8XP<UQ^G7*V?C/0#<P7*LOALQLOV
M=RZ,)(P<J!D=".G\ZAL[*^T9;1_[+N%M+W6+NZ\R"U\V>RC<$1@+@E-W<X^4
M$C@] #LV\4Z)'8V]Z^HPI;W$WD1N^1F3=M*D$9!!X.<8[TU?%FB/9WMV+X>3
M9,!<DQ.#%D9!((S@CG.,>]<'#9WL>@PVKZ3J2O%XI%R5>W=SY7GE]V1G("X^
M;D'L374:=:?:/''B<7-G/]CO+6VB#20,L<NU9 X!(P?O ?C0!T/]J6?^A_O&
M_P!-_P"/?]VWS\;O3CCGG%6G=8T9W8*BC+,QP /4UQ_@RPOX)IK:_;S(M&+V
M%E+NR9$)#;C[A/+3ZJWK73:JTRZ/>M;VJW4PMY#';OTE;:<*?8GC\: (++Q!
MI>HW"P6USND>'[0@:-DWQ9QO4L &7D<C(Y'K4EGK-A?SI#;RLSO$9DS$ZAT!
M W*2 &'S#D>HKA-,%V_B#0[Y]*U1X_[)GMY5DM#"D;_NSY83 "* "!QSC@L:
MT?"EI?:=K%M;6<E]-H;6C$0ZC;LDM@V5Q&KL 64\C;SC8.>F0#L-1GBMM-N9
MIKH6L:1L6GX_=\?>YXXK"'BFSL3X>L3-<W[:E#O2[%NQ\Q%CW;R%7J3C@#C.
M>*UM=#'0-158WD9K:152-"S,2I   Y-<9;07EK!\/[EM.O66RMF@N42W8O$Y
M@" ,N,@;AC)X]\4 =F-:L#>):B9C(\K0J1$^PNH)*A\;<C:<C/8^E:%<#;VE
M]9^)HY]'%^MO<:E)]NTZ\MV,* EMUQ%(1\N?O8!(.ZN^H YSP7=7VI:%'J-]
M?S7$DSS+Y;)&J(%E91C:H/11U)KHZYGX??\ (EVG_7:X_P#1\E=-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<YJMU?67BW08
MHK^8VM_/+'+;,D90!8'88.W</F4'[U='7,^(?^1O\(_]?=Q_Z324 =*S*B,[
M$*JC))Z 5BVGB_P_?2;+;4X7_=239P0H1&VN22,#!_QZ5M,P52QS@#/ R?RK
MSFQTO4KCX47=A;64\6HK<RS+!-&T+2 7)E !('WEP,^] '8?\)/HX%UYEX(#
M:1B:99XVB94/1L, 2ON.*;9>+-"U'44T^TU**2ZDC\Q(\$;UQD[21@D=P.1W
MKEKB2SU/0=;U*+0]3L[E-(N(9)]2$BNH*D^6N\G<,Y)(XX'K3K6T.MVO@C['
M;3Q-IPCGFF>!D$:"$J5!( .YBO SP,]* .M;Q#I27*0-=@,\WD*Y1O+,G39O
MQMW9R,9SD8ZU!<>+M!M;Y[*748Q<QRI"T2JS$._W1P#U_P /45Q4>E:C<?#1
MO!\]G=+J\<PA$IA;RS^^WB<28VXQ\W7.1C&:Z30XI$\>^)YGM;A(YUM1%,\#
M*DFQ&#88C!P2* &'Q=8:MX4O=0&H7&CQ)*\0NGMSN7;(5! 9<$G:>.2,\X-;
M%[XFT?3KR2SN;Y5NHXO.:%59GVYQD!02?H.>OI7"3VE^/A;KFC_V7?F]6ZG"
MQBV8^9NN"ZE,#YAM.<CCWKI 7/Q+^W?9+O[-_8WE>=]EDV[_ #=VW.WKCM^'
M6@#=77--?3[6^CNTDM[L@6[("QE)&0% &2< G&.,'TI=.UK3M6:9;&Z69X6V
MRH 0T;9P0P(R#[&O.;..?3/"?A*:2PU&._L;V<B-;-W9582[LQ<,P*D $=,Y
M]CU?@R:R;^U!"UV+RXNC>7,=U:/;%2XP-JO_  X3&<GD&@#H[N\M[&V:XNI5
MBB7 +'U)P !W))  '))KE++Q"T_BOQ#!+J4L>GVEE#(OG0B,V[-OW'#*#T"G
MYLU8\;PWWD:1?6EM-=QZ?J,=S<6\*[G>,!@2J_Q$%@<>U9L4TEUXI\0WT>GZ
M@+6YTF%(I'LY$WLOF9 4@'/S#C&?PH VX/$VCZ=I6F"\UI9VN;;S(9Y$(:X4
M+N+[0.,CG&/;K5F7Q3HT-E'>/>9MGB6?S5B=E2-ONLY ^0'U;'0^E<?I=M=1
M#X=K+I]Z#8V\B7.;23]RQ@V#=\O'S<?KTJ>^1K#Q5K4&J:-JU_I^J^6]O)9"
M1XR/*6-HI K +]WJW!!.30!V%[KNFZ>F^XN?E$7G'RT:3;'_ 'SM!PON>*IM
MXJL3XAL])A$LQNK4W23QQ,R%=R!<, 00=V<]!CGK7/0FX\,^);M;G0[NXTS4
M+&VBA%G";A8#$I4PM_L_-D$\=?>KC07%GXWT2Z_LN:.U.ERVFRVBW);N7C8(
MQ7A0 IYX''% #M$\2BSLM;N-=U!FAM=8EM(YGB^Z@";5.Q<=3UQR373M?VZW
ML%FSL+B>-I(T\MN57&3G&!C(Z^H]:Y/0-)75-,\5Z;J-I<107VIW#+YT+)NC
M=5 ==P&>02/I5OP5'J4]F][K&UKR$&P5U.0ZQ,5:3ZNP)/\ NK0!O:MJ<&C:
M3=:C<K(T-M&9'$2%VP!G@#_]0[U4M/$-G/I-E?2F2)KI5*0^4Y=F*[B%7&YL
M#/('09I_B6VFO/"VKVMNADFFLIHXT'5F*$ ?G7)VWVV"_P#"FLO87WV&WL'L
MKB-K=_,@=E3Y_+QNQE-I./?IS0!VUAJ-IJEM]HLIUEC#%&(!!5@<%6!Y!'<'
MFJ/B#Q#;^'XK)IXII&N[J.V01Q,V"S $G /09('4XP*I>&-/F@U;Q#J31R0V
MVHW:R012*5.%C56<J>1N8'KS@"F^-X+B2QTJ>"VGN!:ZK;7$JP1F1Q&K?,0H
MY.,]J *8\4)IOB[68]3U"0:=%9VT\,;0_-'N\S=\JKNQA1G/3OBNEEUBPBMH
M+CSS)'<)YD/D(TK2+@'<JJ"2,$<X[CUKEU$S>+O$=V]C>K%/I<$<;&U<AF'F
M;E! P2-R\"L*PBO]'M/"]]>:5JT]G'I(L;F*T259K:4%3N*+ABIQC\![4 >E
M6%_::I917MC.D]M*,I(AR#V_GQBK-97AZUM[3256UT]["&1VD6"0G>,G.6!)
MP3UQ[\\YK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP&QU!H [ZBN;L;>RLEO_ !9J%O'!-+$969D^:&!5) /^T1DM[G'.!2?\)5+
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M/9L+@2+.%(W*2 -K#(XY'O7,7D]CJ?@CPM?6FF0V$7]M6QBMTP?*_P!((."
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MVFW=XEU)=QP,I;#)]/\ 4U3C\4/!K=YI^JV*V2061OTF$_F PJV&W  ;6''
M+#WK!UF\N-3U?P5J$FFQ00SWX>&0R[I55H7(5AM&,C!P">10!U?]D7W_ $,>
MI_\ ?NV_^,T?V1??]#'J?_?NV_\ C-3:KJ$]@+9;>S:X:>786+;8X5"EB[M@
M[1QCIU(%8,7C@2Z3!?+8HP;51IDH2XW*K&0)O1MOSKR#VH V/[(OO^ACU/\
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MI-*7$B+YPE*,H&#@YPV?P';M]0ODTZR>ZDAGF52HV01&1SE@.%'/?)]LU:H
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MAG0LZIYD$D:[MZD*!@C(P00#CZ5R-HMR_P -_"\KWLLLTVMVS!I@&VM]I//
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MS8R:@UW;W?E1(P+1*XWKN!QRN?3V.*]!LX9K>R@AN+EKF9$"O.RA3(0.6('
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M,[L"H#98;509.22,D@<]*TM*TN'2;4PQ2W$S,VZ2:YE,DDAZ99C[ #TJO?\
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M/AG\PKCJVST]JV]%M?"VMZJM[IVI?;S-8F":VB6(1^23D"5%48(/ !YZ^AH
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MS]XXZ#-<3;"RD\:>)-/UJ*W%O]D@^QI. $^R["'V9X #YSCV]!7.Z98I=O\
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M:-%X(\97FD:HU[%=P*\K(T9@63&/DV #<1@M^'K6OX@AL)_&?@SSH[:3S3<
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M,<,=Y)=I$\XQO93%("I;J1P!CZ4 =[XPU^7P[X=N[^U6WEN8$#K#,Y&1D G
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MB*,0?:"X+AMRE02N,'CN.]1#3$M++1XO#6J0W+6\5T;:WU3#17<)9=X5@!@
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MJ-LO('08&,'MGWJA8:K;QQ^$O[;OQ;:?<:$BQ7$P1HC<87>&+@@$KCD^X[T
M>J @@$'(/0BEK$\)6=EI_AVWMM-NI[JQ0MY$LQ!W*6)^4@#Y?3VQCC%;= !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %-DC26-HY$5T8896&01[BG5S_B[7)]%TVV2S"&^O[N.RMBX
MRJNY^\1W  )_*@#;AMH+<8@@CB& OR(%X'0<40VT%MO\B".+>=S;$"[CZG'4
MUDW6BW:Z=(++5KU;_;Q-)+N#GT*GY5!_V0,=JFO=?L[)[H,L\HM%#W30Q[A
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ML22#[/*87++@%AUQZCG^G8UF^)?$!T"+3RMI+<->7L5L-@R%W,,D\]<9Q[T
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MU@/<W+H\UT;;CY65@$0,-H^4=SU/K0!NVEH(6>>5+<WDH FFABV>9C.W/)/
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M=/DMA"1E"Q8G=N]2>W3\Z@T'PQJ&DP165WKCWVFVRE+:!K<(P7& )'!.\ '
MX'8T 5K'Q/JU])I-U;Z<9[#4,%U%O(C6RLN4<R'Y7'0' &,\9J;PUK6NZY-)
M//;Z?%8P75Q;2A&<R%HW*J5[8XYS2:%X5U'1/+LQX@DGT>W;-M:M;@.@ZJK2
M9RRCTP.@&<<5H^'-$ET*TNH)+M+D3W4MR"L/E[3(Q8C[QR,GB@"OX@UC4--G
M9;=;6*$6KRK+.#(991TB5%8-TR2W./2LY?%>IWDOAA;*SM%76[-[@F9V/E,(
MU?' Y'S?CCMUK0U/PU<7NOOJ=OJAMUFL3931& 2';N+;D)/RGGG@@X''%5=.
M\'W5C)X<9M624:+ \"@VN/-5E"_W^,!1Z\Y^@ (;3QC=OIJ17$%O_:KZL^E*
M$W>474DF3!YVA03C.<\9&<T:$MTOQ)\1"[:%Y/L5IAX4*!AF7J"3@]1U/3\*
M23P)+)9SK_:VR\_M5M5M;F.WQY,IZJ5+'<N,C&16GI>@7MGXBN]9O-2BN);J
MWBADBBMO+4;"V",LQ_B/'/U[4 4KN\U4_%"QT^*\A2P.F2SF%H222)8U.3N'
M..AQQD\'-<SH6M:GH&@RWD,%H^G?\)#/;SJY;S2)+HIN7' P6'!SGVKM[_0)
MKCQ39:[:WXMY(+=[66-H0XDC9E;@Y&TY4<\\'MUK&/@6Y;PW-I!U>+$FI?V@
M9?LAX;SO-VX\SIN&,^GYT /U+Q7J;-JAT2R%T^G3^0;<VTKFY8!68+(ORI][
M R#R.P-7_&.L76E^ M3U2T1XKE+7<@8?-&S8&3[C.?PJJ_A'4K?7KR_TCQ"]
MA;:@RR7MK]E60&0*%+QL3\A( ZAJZ6XL;:[TZ2PN(Q+;2Q&%T<D[E(P03UZ4
M 9OAS2[2T\*6-FD:2126ZF4N-WG,RY9FSU+$DG/K7.WMA)I?C7PW8Z2L0,.F
M744/GDE44&+&<<G [<?6MK2M#U?1K./3K?68I;"$;(?M%H6FC0=%WAPIP. 2
MOUS4LOA^9O$>GZK'? "RMY(!')$79]Y4EBVX<Y4=O6@#.L/$^I7N@6UVT%G#
M.+Z6TO)G?]S#Y;,I< L"V2J@+G.6]JI7'C"\?P5J.IFRM)IK+4#9R)(K*C@2
MJ@<(>0?F!P3QCK5F+P1>6\5F8-91;BUU&:_1FM-T;&7=N5DW\XWG!SQ1+X&N
M)-!U;2O[9RFH7WVSS'M02A+JY& PSDJ.>..U %B]UK7F\67.AZ;;:=^[LX[M
M9;EWY#2,I!VCK\IQ_D5EW7C'78-%US51::?Y6D7[V\L99RTL:[,[3QAOF)R0
M?3'<]'#H=Q'XMDUU[V-A)9I:- L!'"LS!@VX]V/;I^=9<_@JXN-!U[2VU2,+
MJ]T]RT@M3F/=MRH&_G[HY^M %J'7-5B\5-I%[;6KK-8O>6_V=F# JRJ48MP<
M[A\V!]*JZ;XIU"?7+#3;F.S:2\LY9BL.[%O*FW,;/EE?&[!(Q@CIS5R^\,W&
MH:TNH2:BL?\ Q+Y;!EB@*MB3!+JV_@@J,<&J>G^#K^SN]$N'UM)&TJV>U15L
M@BO&P4#(W'!^09/?L%ZT 4K+QEK<VEZ/JMQ:6"VEYJ/V"6-"Y<$RM&'4G@8(
M&0<Y]NE=/XAUI="TO[5Y8EEDFCMX8R<!I'8*N3V&3D^P-8D7@FYB\/:=I(U6
M(BRU 7PE-J?G(E,@4C?TR2,^E;GB#0X?$.C2:?/(\1)62.:/[T<BD,K#Z$4
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MWKJ#G!QP>V:YF+PQ.FH6VJW5_%)J-I9R6ZW4-IL>3< -T@W'?C&0OJ3]*U=
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M:.0X8;.FX==W7@YJY<:C=+>:9?V6H7=Q#/X@^S/</,R1O&6=3$L62I5<8W$
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M9:MIVI1RR65];7*1-MD:*4,$/OCI0!G7?@WP]?:TNL7.EQ27XVYERPW[>FX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9&5I8B^X%"V.1E<CN!6Y>O>Z;J^E:6-2N;G^UWEE<W%QY6"D:_NT95RH));
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M[2>>.VU)+F=HI50H@1QD$L#G+#I6OIDM[%I\LNJW5E*JNSQW$&51H<95FR<
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M[X/?FHI?#6E316$1MV5+"3SK=8YG78_/S<'YCR>3G.3ZU<74K%[TV2WML;L
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MR,22P4G /S'V&>*N7=]:6$8DO+J"W0G ::0(#^)I)+^SBCBDDNX$2; C9I
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MF<S.0P7.WY2<#&3C [UH5EZ1JO\ :\$M_$46PWO' W>0*2I?/8$@X'H,]\
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M9J*3PAHLMC?V3V\S6^H2F:Z0W,O[QSC)^]D=!T]!6LUW;)*\37$2R(GF.A<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QOQ5D1?AQJT;, \BHJ+GECYB\ =Z[*B@#$MM%T47']M
M'%S*8#&MS/.TJK%U(7<2 /7'7O7 :9:11_""TOM/LUDNH)%-T;>-3.T*W(:1
M.1S\J@[3P0.F*]:HH \ZD;PUK=IJFJVNKWTJW%K';W-^BA5B_>#9D;5!8$DG
M@D $'J*I:I=W5SX.\86VJFPO)8;11'J5JN$NB5;:"O($B\9Q_>'M7J6,=*
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M. KPX7!!4.0W0],]J];HH \J\1KH-UX.\0:IIUS+>"]EM6>YE "22*ZCY!M
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M3Q$7!'F!?W>T.3WP#U]#7=8S10!QOP]M=/;1GN(H+<W"7ET/,51O53*V!GJ
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MH;?R_(P0<#)]JU;O683='3[:WGO)S;^>Z6[!2D;9"DL6&"V#C!SP>G6N:N]
MU>?3?&ENME\^L,3:_O4QS$L?S<\<KGZ58M-,UO2/$S:I;6*W5OJ%E!!<1&=4
M>WDB! //!4ACTY]J +/PWF>?P#IDLCR.[>:2TK$L?WK]2><U<D\56RM')':7
M<UF]W]C^U1(&02;BIXSNVA@5+8QGVYIG@C3+_1_"EKI^HQ1Q7$329$<F\89V
M8<X]ZS?#UAXDT$RZ&MI;2:<MS))!J)GY2)W+E3'C)<9(!Z?ER 4+#Q"/#MYX
MMGN+;4+NTMM2#22(P<01F*/)R[ D D\+DCT%=+JGBFWTQKS%I=7*V5J+NY>(
M* D9W8QN(W'"L<#T^E<_>>']7N-(\9VJ67[S5Y2UKF5,8,:I\W/'*Y_&C6M$
M\0:HNIVKV4-Q:W&F"&S$MP%6VEV,&)4 [F)(PW;'4<T ;5]XPM[2_BLH--U"
M]GFLS>0BVC4^8@*@@98<_-WQ^9 -237[6SG\4WMKIMZU_86T4US'-( KC8S+
MM&XA0 #G !]B:9INE:M%XDT6^N+%4BMM):RF*3*VURR$8Z$C"<^YXSUHET'4
M;G4_&), CAU:S2"VD9P1N6)T.X#D#+#'MZ4 7['Q++)I^D"73[I[^_M_-$:[
M "%52S9W8 )88&<\]*PM7UZ'4;CP;K=BMZT-Q=RC[.A.Y\12#:4SM)##&3P/
M7'-68]/\1F+0(9].@DLK>U,%U9_:@!Y@50KN<89>&^7GJ#@D<4M,\-:YI^B>
M&TDLH7FT>^FE>&*<9DC<2#*D@#/S@X)'3K0!/XA\1Q:WX%\3QQQ7VGZAIUNW
MG6\K>7+&=I93E&(*D=,'!K>F\00:?!!;"*2YNEM%G:)'12$Z Y=@,D@X'L:Q
MM6\-ZAJ&G>*KI+<+>ZS;I;0VY=?W:(I +MG&268G&<# YI;O2]<L==M]8L-+
MM]0CGL8[2[LYYEC>-D+%75B""/F8$4 =1H^KV>NZ/;:I8N7M;A-Z%A@CL01Z
M@@C\*RSXQL5M[:]:"X73+F<017V%\LL6VJ2,[@I/ 8C'3H"#6O:V\K:8(+M8
MTD=&$BP?=7.>%.!G&<9P,XS@5QD'A?59?!4'@Z\@7R898T-^LB['@20."%SN
M#D +C&,\YH W8_%D<^MW.E0:5J,LMK<1P3R+&FR/>NX.3N^[C'O[5$?&UE]G
ML;J.SO);34+@VUK-&$Q(X)QP6! .UL$]<=N,NTBSN]/\2^)-1O(1#9WCQ2Q2
MM(IPL<01MP!XZ9^GI7)Z2E]9:;875SX=DFTBUG:^MC!?QF.(.6*ND; .<*YP
MI)//3., '87'BVTMKAE>TNOLZWRZ>UQM4*)6P!P3N*Y8#..OMS4%[XU@M+C5
MX5TG4IWTE5>Y\M8\!"I;<"7&1M&<=?;K6'JV@>(]0:Z,UC;W4T6K175K</<@
M?Z.LBLL:+CY" .>F>O-7Y-'U5[OQA*;+C5;:.*VQ*I!98BASSP,G/T]^* -*
M;5=,N/$7A\&*Z>:[@EFLIE8K%MV MN&[DX*XR#C-%QXNCM;C3K>;2-2674)/
M+MTQ"6;C)8J),A0.22..]9UOHVJ1ZAX.E:S(32K.2"Z/F)PS1J@V\\C*D_0C
MZ4:78ZU'JU[K6HZ69-4N#Y,'[Y#%:V^>%'.2?XF..3QVH TSXMM%NH4:TNEM
MYKYM/2X*J%,PR,8SNVY4C..H].:IV_B6:]G\2P7FF7*VNG,8CY3IN*^6&/1@
M=Q#9&.@[YK'N= \2W<EK+<V%M<7EIK*W0NGNL>9 &;:J#!V *1D>HS@DUJQ:
M1JUK?>*@+2.2#4SYL$BS $L85CVE3TY&<YZ4 7M-URPBT?0X;""YD-[:+):6
MS,#((@BG+LS=@5!.3R>]13>.-/@TN2]>VO,P7BV5Q $4R02E@H##/(^8$%<Y
M!XK+T_P]JVEGPOJ,=L);C3M._LZ]M1(N63"_-&2=N0R@X)&0>U1ZGX6U*XLM
M4N8;8&\U+5+:[:'S% BBA*8!.<%B$)XR,G&>,T ;B^,+-&U9+ZTN[%]-@%S*
MDX0EXCG#+M8C^$C!P1WK4L=1:\GEA>SGMS&B2!G*LKAMV-I4G.-O/U%<]=Z9
MJ;^)M7U"/38Y[>YTR.UCCGD3;(RLY96&3A2'QGFIO"N@3:)J%]]F2XM-'EC3
MR;">82>5+EMY3!.U""O&>N>!Q0!=U;Q/!I4EZAL[JX^PVHN[EH@H"1G=TW$;
MC\K' ]/I2W'B6VCD,=K;SWDHLUO3'#M#>4V=I 8C).T\#^HSB^)M&US5;S6+
M<6L%W8W6GF*R,D^Q;>4JP8E,'+$E<-VQC(YJMJ/AJ]U/3+**YTDQZA:Z>B6E
M]9W026VG&X$%L@E.$/ /5N#UH [B6ZAM[-[N=Q%!'&9'=^ J@9)/T%<7J6J2
MWWB[P=,EK?6T%Q-,RF1P$D3R'(W(&.#T(R,_J*Z'5='N-7\'W.CW%R/M5Q9F
M!YP, N5P6QZ9YQ7/1V'B6\O/"\MWI4$+Z5*WVE_M0*R Q-'N0 $X.<X//;WH
M UIO&VF07%J&60VMS=?9([H,A7S,E1E=VX*2"-V,?@0:ATSQ<TW]O3:C9R6M
MKIUXUNKED;HL>%X;)8L_'&.0,YJEX>TKQ!HNW19--L9;&&9C#JAE&[RBQ8 Q
MXR7 .,YQWYQS%=>%M8N;/Q1IZ"");Z^&H6=RTF07'E%59<9 S'R??C- &LWC
M>QBGU"WFM;E+BRM#?-$IC<R0C@LI5B,@CD$@_6HSXZMTM+>[ET?58[:YEMXX
M9FB7$AF^Z0 V<#OQGI@'-0F#7]3\/:G#=Z':6$\ME+;I%#.KF61UQNS@!4'I
MDGGVY;J.CZI<>$_#UC'9YN;*XLY)T\U< 0E2V#GG../UQ0!<_P"$Q'VC4+0:
M'JAOK)5DDM@(MQC8$APV_;C@\9SGM23:[I.H7'ABY\F\D&H.9+*5&VHK&)CB
M0!AGY<\8/--33M03Q;K6I?8F-O=6,4$.)$R73?G(SP#O'Y&LO3_#VKVVF^"[
M>2S^?1W)NL2IC'E,GR\\\MF@#1N/'MI;V^H7#:7J1M].NC;7DH1,1?=^;[_S
M#YA]W)XR0.,Z&K>*;32FNE\F6Y:TB$TZQ,@**02/O,,G )P/ZC/-WOAW6+CP
MWXOL$LL3:M>/-;9E3&UE1?F.>/N'\Q5N?3M=T[Q-<ZE8Z1:ZC:ZE%%YT,\ZQ
M/;2HNW.<,"I&,XR>/S -D>)+._6"+3HI[Y[FT%V%@8(5B;A6)8C!/( ZY!Z8
MS5#X;S/<>!+&21Y69I+CF9B7_P!<_4GG-1+I>MZ3XM.K6UM#?07MG%;W4:2"
M(PR1DX90>J?,1CK]:O>"=,O]'\,0V.HPQQ3QRS-B.3>,-(SCG _O4 <WH_B=
M?#L'B"2ZL]4N[.#69Q+<H/-6WC^4#<6;<0/;.!776WB*VNO$$FCK;W"RK;+=
M),VSRY8R<!D(;)Y]OYBL :%JZ:=XFT<6J%-7NIY([OS%,<<<JA3N7[VX#/ !
M!..14GB;1#Y6A1Z5=_9]0M9!91OU8P.FV0?4(N\>Z"@#I]+U!=5L$O(X)88Y
M"=@EVY8 X##:2,'J.>E7*9##';01P0H$BC4(BCHH P!3Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***Y7Q[/>V^CV1LKK[.9-2M8Y/DW;E:51CKT]?7I0!O1:I8S:G-IL5RCWD*
M"22)>2BDX!-7*X6>/5&^(U^EC=6T5T-#@W3R0%UR)9>B;AU/OQ[U+IOBZ]UF
MPT-+>#9>7]@UY,8E5M@4JN%#,!RS=R< >^0 =K5>\O[33H1+>7$<",P52[8W
M,>@'J?852\/7&KW.E!M;LUM;U)&0A""LB@_*X 9L9';/%<[:2-?_ !AU%+KE
M=.TZ,6:-T'F'+N!Z\!<^G% '56NKZ?>7'V:"[C:XV%S"3B0*" 25/('([=ZN
MUEZU)9Z7;3^(+B+=)I]K*VY?O%,!F7\2@_*L.7Q!JNG1^'KZ[:WFM=6FBMY8
MHXR# \JY0J<_,H/!SUSD8Z4 =A17GEUXI\10:!KFKB73R-(U*2W,7V=OW\:L
MJXSO^0X8G//-;']K:U:^*+C2;B>RE$NFO>P,L#*(F5PI4_-\X^8<\=* .KHK
MSRT\5>(TTKPWKUX;"33]3EAMY[>*%E>(R\!PY8YYQQC@<9/6KUUXGU.SU2S2
M1[9UGU?["\$49=8XFW!29!P). 2OH>G>@#M:*X#4/$GB.&U\57,,VGJNAS95
M3;L?.01J^T_/\IP3SS]!WV9-=O;7Q5IL%T\":1J5LS0-L(=9U ;8S9Q@KDCC
ML10!TU5CJ%HNIKIIF'VQH3.L6#DH" 3Z=2*KZ'<W5[I<=W=%,SLTD05"N(B?
MDR"3\VW!/N:SY=5U >.UT96MQ:R:9)=(3$2ZR"1%Y.[D?,>!CZT =#5>^L;;
M4K*6SNX_,MY5*R1[B P/4'';VKAM.\5:_+I'AW5[I[$P:A?BRFMXX&!^9W4.
M&+<8*CC!^M>@,&*,$(#8X)&0#]* *6CW%A<Z7"VF2>99INBC.6.-I*D?-SP0
M1^%7J\WGUW6=5\*^';TW4-O/<ZXMO.(H3M8+.ZKP6R!\@)&>?6M>\\37-IXE
M.CW5U#8S&2$6IN("(KU"%,FU\X#Y+ +GL.N: .QHILC,L3LB;W"DJN<9/I7#
MZ;XY#Z=>W]U<H9;"QDGOM-> PW$$JX.T GE/O#//;GG% '=54L-4L=4^T&QN
M4G%O,8)2G(5P 2N?H17.3:]JFF/X?NKUK>>UU::.VE2.,J8))%+(5.3E<@@Y
MY[\=*S--U=M&3Q/+%&))Y_$8MH5/3?(D*@GD9QDG&1G&,CK0!Z#16%HUSKS:
MM>6^I6G^@A%>VNB$1B3]Y&57;IP0>*=K>L2V>IZ3I-J46ZU*5U61UR(TC0NY
MQW/0#ZY[8(!9.OZ4$U%_ML9731F[*Y/E<;N<>P[5?BE2>%)HF#1R*&5AW!Y!
MKSN.\U+1[KXAWR36\MY:+%,K/$=CA;?(!4,.<#&<]><=JTM6\67&GM8+=7$>
MGPW=BDL5[- 7@:X/_+-V!^0=#VSGJ,<@'37NBZ9J-[:7MY8PSW-H2UO)(N3&
M3CD?D/RJY+#',%$J!PK!@&Y&1T-<X^K:GJ>H:II^E2VT4^G6\3;I$WB6:12R
MCKPF .1R<]L<T[K5/$\OB.VT:WDTVUFFTHW;EXFD$<H=%89W#<N20.!USSC%
M '94C,$4LQP ,DUQDNO^(KV"ZNM%L5N?LMXUL+<JBK,$?9(=[2 J>&(X[#.<
MT[2[C5I/&'BM3?1,ML(%A22 D*#&7 X8< L<^OM0!U5A?6VIV,-[9RB6VF4/
M'( 0&'KS5BN*TGQ9>ZG8>%[?]S%?:Q;R7$L@3*QH@!.U<]26 &3QSUJKJ?B_
M6-/T[Q# !:-J&C7%NOF-$VR:*8KM.-WRL 3GJ,CIS0!W]%<WIVJ:I'XRN=%U
M"6VGC-DM["\,1C,>7*%#ECNZ YX[\5TE $<L\4)02.%,C;$'=CZ ?K] :HOX
M@TM+34;IKQ1!IKLEV^T_NF4!B#QSP1TS67IERU_X]UQ9#\FFP06\*^GF R.?
MJ?D'_ :R)_%6M1>%_&-\#9&ZT:[FCA_<-L9$C1AD;\Y^8\Y_"@#MHKRWFE$4
M<JF0QB0+T)0]&'J*GKC/&E_+8:!H^OIQ<6MY;,Q7^))2$D3Z$/\ F >U=9>W
M26-C<7<H)C@B:5L=<*,G^5 $](RAT*G.",'!(/YBN2T_5?$M[<:5<I8J]A>Q
M%YR50"VW+N1E/F9<9X(P">HQTK+L_%7B!]&TC6+B2P,-QJOV":".!@64SM$'
M#%OE(P.,'IUYX .UTO2+'1K8VVGP^3"7+E-[,-Q.2>2>I))J[7$ZSXIU*V3Q
M-+:^1$^BB,Q031EOM 90V3R#@Y*KCN._03ZSK>LZ?;NQFM(WCTYKE52!G>28
M9)!CW$K& !EL]6ZC% '7U6OM0M-,MQ/>3"*(R)&&()^9B%4<>I(KG8_$=W?7
M7AVU0):#5;!KMIBN[#!4/EKGC/S$G/9?Q&8OBK7CX-M]9D^PB6344MBJV[A6
MC,_E;E)<]?O ].?QH [:^L+34[.2SOK:*YMI1AXI5#*WU!JIIGA[2=&8O86,
M<+D;=_+,!Z DD@>U8-YJ_B"77]?TZSN;"&.PM(KF&1[=G/S!SM(WC/W.O;TY
MX=;>*+O45\+1JB6IUFT:XDFV[@C"-6\M,\9.XGG/"GZ@ Z^JT^H6EM>VMG-,
M$N+O>($(.7VC+?D*R/"&JZCK.E2W6H_9\K<2PQF")D5U1RN\$L<@XSV_&EU7
M5;VS\6Z#IT1@^R7_ )XEW1DN"D>X8.<8_#MUH WZ*\\F\4^(H=&U/5FET\Q:
M;JS6;PK;MF:,2K'P=_R'#9[\UZ'0 54T_5+'54F>QN4G2"5H9&3HKC&1G\16
M#I6K:UKEAINLV!M#974Y\RVD4@I;Y8!@V>7X!QC')';-<S%JFJZ'I?BK5K*2
MU$%IKLK2PR1%FF!,8(#;AMX/H>: /3Z*XSQ9XDU/1(]6N()+8+901S00",RM
M*.=YDQ_JUXP#QR#R>E2WVJ>(+CQ:^C:9<6$$;::MXDD\#.5)DVE3AAGIUXQG
MO0!TMOJ%I=W5U;03!YK1U2= #\A*A@/R(-6:\_US7=8?0_',*W,,,NEJ%@EA
MB(.UH0YZL?F^;&?TK6N+_5+.*PM_M=LBO9N_F)"7E>0;=JK$"3M )+-].E &
M_-JEC;ZE;:=+<HMY<AC##_$X49)^F*-3U2QT>R>\U"Y2WMT(!=_4]![UP3ZI
M?^(+OP#J4/V>WO;N"Y<ET+1HQA&3MR"1UP,CZU#XAU?4;SP/XMTK5Q U]IDD
M4;30*529'*.C;23@X/(S0!Z=17+ZEK6JW&J:EINC19FL88WW&-7#R.&*J=SK
MA< =.3GMCG=TN>\N=+M9M0M?LMX\8,T <,(WQR 02",T 6Z*XK6/$^IZ9=NY
M>V94U.&U^S1QF3]S(57<[CA),L2 >P'!ZU=?5=9U8ZR=#:U5]-N?LL<5PI(G
M=55GW,#\H^; QZ9[XH ZBJVGZA::I9I=V4PFMW+*K@$ E25/7W!%<S8S:I-\
M1=8@:]C$,5C;LD1BW*FXR<#YAW&2>_3BJ">*]:_X0*Q\1L;0;+IEU!5@8@0"
M=HV9!NX*@ \Y[T =S=7,-E:375PXC@A1I)'/\*@9)_*E@GBNK>*XA</%*@=&
M'=2,@U@:MJVH06&O7UC);&&PM2T(DB+!I50NV2&&5P5''?/I62]_JMYXG\($
M7J1Q7>GRW$D7E94N$CR>O^V0/3WH ["UU"TO9KJ&VF$DEK+Y4R@'Y'P#C\B*
MLUQ8\67]M#KOVA()9K758M/M1&A4'S!&%+ MS@OD\C..U2S:MXIL(]6=]*>Y
M@AMUFM90B"0OG#H8U<EL#YAC&<8ZT =?16#X8UN/7(;BXM]2@OK9654*QF.2
M,X^99%/1L^PX_.I=;OKNTNK&*":&""8N)9"IDER!E5CC'+$\D\' 'X@ V:*X
M&#Q=K5WH'AF]B6R2;4M0:RG#Q-@$&4;E^;C_ %><<]>HJ8^+M1TR#7+:_P#L
MUS>V5[!:6TD<9C20SA"FY<G&TL<\\@4 =8=2L)-4.D&XC:],)F:WZGR\@$GV
MRP_.J=EX5T+3[@3VFEV\3JVY0H^5#ZJO13]!6'#%>1?%BW%U<QS@Z'*598MA
M'[^/(ZGCT_K6[XAU=M'L;=HE1KBZNHK2'?\ =5Y&"[FQU &3COC'&: ->BN5
MU;6=8\-V&IW=\+6ZMU,*6+@%&:21@A$@Z8#$'([>]/FU;4]-\4:?H]U-!/'J
M<,IMYQ"5,4L8#$,N[E2#QR#QC)H Z>BO.[3Q5XCFT'P]K#OIY74;Q;26W$+#
M!=F4.&W<8('&.G>K=SXCUS3[;Q=#+-93W6C6R74,WV=E5U9&;:5W]BA&<]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA>Z>.QMU:[_X^"(Q^^XQ\W][CUJM:>&-"L+*XLK72+.&VN?]=$D("R?[P[T
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M@@DN)I8[>VB)QOE=@J@^V3D^P-:=<EX[A<Q^'[P9\FSUJVEG/94)*;C]"XH
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M\=SQ0!V+>+- 6]^QG5;?[1YWD; V<28SMSTZ4S3-9LH]$BNY=9&H137#QQ7
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MG!IJ:T]YY@TV:3[LN\@2H"NTN"<]0.#SR #T*Y\1Z1:2%)KU%V[-[@$I'O\
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MZ6^LW4;0"%B\!D;*7"+C+*1E2><#IW% 'H][K6F:=C[9>PP9 ;,C8V@G )]
M3QDU)'JMA-J$FGQWD+WD:AW@5P753T)'I7"7D]E!XCUVQUZTU.:SU8I):26J
MS/'<1F)4,6(^A!4]?[V:O:_97>AMHNMZ/9_Z3#$FFRVK2;MT<F%C!8]=DFWG
MT+4 =C:WEM?1&6UF2:,,4+(<@,#@CZ@\5/573K)-.TZWLT8L(D"ESU<]V/N3
MDGZU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#&JA6\H9*[0#CV.3QUK6M/!ME%IUQ8WU[J&J0SPFW/VZ;>4C/55P!CH.>O
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MF((+'*E2"IQC;C  %02>!-/DL]0M/M^HB*^NENYAYJM^\4J<C*GJ44_AZ<4
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M: .XCW)^\F9BN0 6.S^(D9/3M726/@RTL;S3+K^T=2GETZ)H(3+,N#&=ORL
MHR!M'3!/<FHV\!Z6VAOI+7%\;?[1]HMV$P#VK[BP,1 XP6;DY/- %"YUOQ!H
MT,L%\%/VS4;>STZXG\LR 2G#&18_E^7#8QC/&>]26,$]O\5KE9[R2ZSHL95I
M%56 \YN/E !YR>G>M"7P;8W>BRZ=?7E_>/(R/]LFF_?HR'*%6  7:<XP.YSG
M)J>P\,QV>MC5Y=2O[N\^RBU9IV3#(&+#(50,Y- %?QSJE_HWALWVG3I%*ES
MC%HP^5>54(&>G#>]9UY>Z_=>,=8TBUU9+2W@TZ*ZA9;579&9G&/FR#]P9S^&
M.M=#X@T*#Q%I9T^YGN(83(DA,!4,2C!EY8'N ?PJ#_A&HAK5YJPO[P7-U;+:
MO_J]H1<D$#9URS'\: %\(ZK/KGA#2=4N0HGNK5))-HP-Q'./QK:K.T+1X/#^
MBVNE6TLTMO;)Y<9F(+!1T&0!6C0 4444 %%%% !1110 4444 %%%% !1110
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M#@X&<$$5FP>*[&[\9S>&[;][/;VK7%Q(IXC.Y0$]S\Q)],#\'ZC<2J#HVAK
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MX0LN5=<C./2K-OJ$#77AJ&YU*ZCO9[9G2!5/EW/[H%BYVX^7J.1R>] '1@
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MMV,4$$J.\XN(O.A6WC:1G3 .X!03CD<^X]: +D$$-M"L-O%'%$@PJ1J%51[
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MO;722RK&2J,_E[03[[3]*YJ[TW49? WB2R33KLW-UK$D\$7E$%XVG5PP_P"
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MS)+D;4+$@JA&22I&2!DX%>E44 >8Z1INIV^B^#[6?2KR*33]3EDN 4W;4(E
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MK:O?M>"78Q$09E)7&?F^X.<CK1K7@K5M6;Q$HU2UCAUFWCC.^!G> JN-BMN
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M1QE!AF+8Y)SUZ\?2LI/!]U!I6J:%!>1#1]0ED?YE/FP)(<R(O8@Y."<8ST-
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MO[AC:HWW5B/+;1V5I"[#U&VH;;P9<1^'X_#4]W%+HT4ZNC%3YS1+()%B/;J
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MU=%E%[-&(I&,K%2HS@;<XXR>W>LN?P+H-PMY&T-PMO=RB::WCNI$B:0,&W!
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M% !129'J*6@ HHHH **** "BC(]:* "BBB@ HHHH **1G5 "S!03@9..:6@
MHHHH ***8)HF9E61"RG# ,,CZT /HHHH **** "BBB@ HHHH ***0LH8*6 +
M= 3UH 6BBB@ HHHH **,YIN]=^S<-^,[<\X]: '4444 %%%% !1102!U/6@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M89(]$D_?EKS;OCV!R5^0_-@]#@>]:LWB)Y-773-.MDFN#8?;R9I"B[2VU5&
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MZ5=SQ32VR%=\2D#&2>_7KUX^E;= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8?B34Y[ :9;VS*
MCW]XMMYC-MVC8S<'!P3M"]#UH W**\^\27'B;0_#.KW!U1(S'<6S691EED6-
MY%1TDR@R.3@CGWXJR4U8^.[K03X@OOLD^FK>[PD7F1OYA0A#LP%(QP03QUH
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MM?L]PYN Y$L<9,<>T9^=OX<]O6O._%5[?SZ#X^M)+^?RK%X5@V[5(5XD9D)
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M#"1/+).X9.<\9&,8Y[U"612<9(SP<B@!:R(/$5I=)JQ@ANI'TMRDT:PG>[!
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MN;>*5(I)XTDD^XC. 6^@[U(<X." >V: ,=O#.GRW]_>3&:634+86MR'?Y7B
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M R3@'C%:<,\5Q$)8)4EC;HZ,&!_$54O]9L--N[*UNKA(YKR0I"A8 G"EB?H
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M2%R/Q/\ +I6A2*P90RD%2,@CO2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7Q-D2/X>:N'=5+1
MJ%R<9.]>E=;3617^\H;ZC- '-PR:':W]E<PZJTT[K]GC@^W-/O+E>BLQZ;<Y
M';-<5?6^F#P1XQF2.U$L.K2^2Z[<QG>A&T]N_2O6!%&IRL:@^H%'DQ8QY:8_
MW10!Q-Q;Z9#X^%O;Q6JQ7&B3>9&@7$O[Q2,CN<9_6L'2].L)O"G@RZTQ(?[8
M%U!^]BQYA4?ZT,>I4*#D'@8 KU"XM_,MY%A6-964JK,O XQ6?X;T7^PM$M+"
M1HI9;>(1&=(]I<#IGK_.@#SS6;BX:V^(_P#9K&65;RU:5(3ES"(HA+C'^R''
MYUT$RVE_X]\-WFA/!+;/97"WQM\%&MBJ^4&QQ]\_*#_M>AKN%C16)5%!/4@5
M$;98[>5+01V\C@D,L8P&(^\1QF@#C-'L9+75)/"+VY_L^SN!?PN5^4P%BR1_
M42Y_!*SO,TO4)-7TG7=1N;;4EU)Y(X(PBRR /NA:(E"Q^4*!@]NPKN=(TZYL
MTDFU"\%Y?3!1),L0C7:N=JA<G &2>O5C]*OF*,RK*8U,BC <CD#ZT ><W4NE
M7E_X@T?Q%J,]I<RW8>*(*@>:+"^48B4))&,84]<^IKT:+Y8$W%N%&2Y&>G?W
MH:*-Y%D:-2Z_=8CD?0T\C(P: /-?#\6CW\7BR*[U4VQEU>Z4%+]HAM(4;MH8
M ]^2.<5IW>OV'_"7Z5=7UQ''H\UC+]CGG(6)I]X!;)XR4'RD]B<=:[3R8O\
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M:3<F*1"L/F+A1R06QW(% %ZY\665K827KVUZ8((DENB(<-;*RAOWBD@Y .2
M"0.HZ5%#XH^T^*SI4-G*]L+)+L7*88.'8A6'.=O![9)[>N/<:9J6G>*=5D_X
M1J#6K'4Y$FCF9XPT#A%1E??SM^4'(SCT-:$.G:C8^.$OEL%ELY-*BM6D@942
M)T=F(VDYP0W& ?0XZT 3Z1KFE1:"+N">]EAEO)((Q<DM,\ID8;%!YQD' .,
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M%PL:GD Y7  Y)XZU2GTO48->\-7]OI40BMHKF*>"V=$6W\W:5ZXR!M() SW
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M^U&RT^XTY1+<Z=?Q7JP%@OG!<ADR> 2&.,\9%,@L+FY\8/XCDLYX$BT[[''
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MVB:Y<0V5P;_2T4RVT@4%=XRC$AB"OT)/!XS6Q)K<<<D-O]EN7O98VE%HH7S
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MD+98. 6'S+Z&J6E^,=9NK'PSJ=U;6"V>L3BV:.+?YB,RN58$G&/DP1@^N>P
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M_M&"5[2XAB90LD8!974L<C!!!!'0CWH UI-7TZ*_CL9+ZW2ZD.U(FD 9FQG
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M82T*L0KG!QGG'09->C:EI=EK%DUGJ%LEQ;L0Q1_4'((/4$>HJ@?"6@,MTO\
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M/K@9H YV]N+GP]XLNVM;B[N4;0I[UX)YVD5YHV7:0"<+D$C"X'M5">)+G3O
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M7D^H+A;I%")( A8R8&0 <8 SWXK6M]9TV[6Y:WOK>5;4D3E) ?*(ZAO0_6N
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M$GTZ)K*XN#?7 MXS$5P'*E@#DCJ%/MZD5DR>-IHX-6)T&[-QI)S=Q"6/"Q[
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M09" CJP/S*<]AG/&*M0>-((]0U"RU>PN-*EM+4WO[]E<20 X+ H2,@\$?SH
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MUVL#:3<2VT,+1JRS-$@9O,SSAB2!M(P.>:Z'0]3&M:#8:HL9C%W;I-L/\.X
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MX^;!W YSC''3FM>\O-;N?&UUHEKJ,-K;C34ND<6P=T8R,O<X/W?_ *W>HX-
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M+ZG'#=W<%CJCF2\LXROER,PPY!*[EW#AL'Z8-=%'&D4:QQJ$1 %55&  .@%
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M-T;4@C/:Z9JUO>7:J,XB4D,V.^,YH V+K5]8L=-DOY]%B*(N]HHKO=*H]QL
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MB+(&Q&X Z,1N''4+[5H_#_2;*V\*Z3J44;?;+K3K<3RM(S%P$R!@G'&2/TH
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M:ZD\DZWGA]FG5I6Q,P6$\C//4D^O>L]]/AATJ"TG19M.L_%T<%DT_P ^R#<
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MA,WEV'_"5307<D@+JD&\@;N0=NX(#ST..E:DFDP+:ZK'H^O66Z[FMI$@6/\
MT-) W"$*3@2;<, ><CCGD ]!K*\2:Y#X;\/7FK31M*MO'N6)/O2-T"CZG%9O
M@RY\R/5+:72QIM[;W8%U!&X:+>8T(:,@#Y2NTXZ@DT[4S<ZIXCBM;2&VN(=-
M3S9TGE*J99%*H.%;.$WD@_WU- &[8WL&I:?;WUJX>WN(EEC8=U89'Z&K%>:>
M&+S4-!\/^*/"T87^U-$CEFT]%;?NAD0O$!D MM8E>GI5[PU%X7U:WT#4;6Z6
M2]ELVCECCD#-<[D'F?:%Y+8(/+=&/O0!VEC?VVI6HNK2598"[H'7H2K%3CU&
M0>:LUQ/PIBLHO MF+>.!)BTOG", -Q-(!NQSV(&?2J:K;ZPGC5=8PM[97$@A
M=CA[: 1 Q.AZKR&;(ZG- '7:KJ_V"[T^QBC5[O4)6CA#G"C:C.S,1VPOYD?6
MI]-N+Z?3EEU&Q6UNP6#PQRB0'!(!5N." ",XQGFN#-N=1O\ X>3:U:0R7UQ%
M+]I\V,%G(MB?F!'KSCL:]) P,"@#$T7Q%'JNF7U]/;M9QV=Q-!*)'#$>4<,Q
MQQV/3-5H?%;;=(N;JQ$%AJSK':S"7<RLZ[HQ(NT;=P'8G!P*I>#[:*^T3Q#:
M3#=#/JU_$X!ZJTA!_0UCS:+J1N_#GA0:A%>V^EW,5W+*MN4>*&+/EK(VXC<Q
MP  !D F@#I=4\2WVE:A;>=HKMID]TEI]J$X\Q7=MJMY>/N[N,YSWQ4WB+7-1
MT:UGNK31C>VUK$9;AS<"(A0,G8"#N( SV'8$GIF>-4N9M/M]5TC5#]JL+I/*
MM5V/%/(6"%&&,[L,1UX_6M3Q/9Q:QHE]8+J[6+I$6E:-D.T8R/,# _(<<CC(
MS0!KVEREY9P74881S1K(H88(!&1D>O-35E^&[F]O/#.F7.I1^7>RVT;S+MVX
M8J,\=OIVK4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEEG>V\./#(T,;2;6$L>3@ G&1CIW%=M8:)!I^IW^H133O-?LK3AR"I*@*I
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M*-/OCK6E:CIA\BYOE;3;M2V&$3J7WC'&Z/:Q'U-=A##';P1PPH$BC4(BCHH
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MQQP&QQ70444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4UD1]N]%;:=PR,X/K3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LGQ/K9\.>'+[5Q9R78M(FE:)'"D@#).3V_,^U:U<Q\1O^2;>)
M/^P=-_Z : .BMIOM%I#/MV^8BOC.<9&:EJKIG_(*L_\ K@G_ *"*M4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4%U9VM_ 8+RVAN(3UCF0.I_
M \444 /@@AMH4AMXDBB085(U"JH]@.E2444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex109keyexecutivebenefit002.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JM?WJ6%HT[*SMD+'&OWI'/"J/<G_'I5FLO
M6-"M]:%OYUS>0-;N7C>UN&B8$C'4>Q(_$T 8_@VXU&;4?$D6I71GEAU!5 !.
MR,&&-MJ#LH)/UZGDUUE<7X=\-7WAV^\1WZF]NWFD+6D,][N$X$:8+$G 8LI7
M<>@]JZZTDFFLX)+B#R)WC5I(=X;RV(Y7(X.#QF@":BBB@ HHHH *XGXK:U+H
M?@6>:UGF@O9IHX;9X9"C!R<GIU^4-Q7;5Y_XXT76M>\4>'FATN2?2--N/M-Q
MB:(&5LC "LPX&.^/O&@"SH=M;ZDME;VVNZE-J&FB"2_E%W*T<K$<HP8[><$X
M XX]:DG^)_AZWANI)!>XMKO[$X6#),G<#!Z#U]^,UH176O3:A>S)H:V<"VS-
M&99XVEN9@/D4[20JCGJ>XZ<UPEA\-]4_L[PUIU[;J8OMTFHZS(95.Z09V+P<
MD8R./4F@#O;7QGI%Y>ZO:6[3N^E1B6X;R\*5()RI/7@?0]LBJ>G?$71-2NM)
M@CBOHO[5WBUDFMRJ.4.",Y_EGJ.E</J]EK'AOPGXNN+ZWBCU'Q!J MK81R!B
MZ.=JJ,= $WX[\]L<]+;^$[]]0TBZ^RB"W\/:>T6GV\CJ6GN"@!9MI("\#OG/
M- #/#^N;_$_C#7K_ %.6+0["46D*RS,8D90/,(&<9) QC^]@5T,?C/3&NI[6
M2.[BN(;(7_E/#EW@/&Y0"3^!P1Z5PD/@373\/]%TRXLP9H]62\U*W$R%YTW'
M<<YVDX(XSVZYXKJ;'0)5\3:SXBU>2*&ZOH#:V=KO!,4"C)SV+' 8@9 ]: -.
MP\9Z5J)T;[,+EDU=9&MG,1VC8"6#'L>#^5(GC71Y=3L+*!IIA?3206]Q&F8G
M>,9< YR0.FX C/>N-\(^'=;G^$2VQ3[/?FRGCL4<X*B1F;<?[I8$ >@^IK0\
M/^&-0@\*"#^Q_P"S]8@TQ[2*YN+I92LA4C,84D(I;DG@^QZT =%+XVT=-0M;
M2-IIQ<W9LDGB3='YP&2N<Y..Y ('<UH>(;^'2O#FI:A.6$5M;22G:Y4G"DX!
M'()Z<5R?@#PW<Z9IVFQZEH7V:[L(GC\^>Y64 L228E4D+NSDG@]N>UCXH:7K
MFO\ A&71=#LVFDNY$$TAE1 L8.X_>8$DD#CTS0!YQHFJ^)M0\/\ AR#1];U"
M[\47-R;FZ$MPS116N2!Y@8[<'"GCGK[5Z[KWC/2?#XNQ<-+-)9PBXN8[=0QB
MC)P"V2 ,D\#.3V!KE;CPCJ^L>,?"]TEG_9.C^'H\1F25&GFX VX0D!<*!R>A
M-5]#\(:K'XD\0?VWHGVZ*^U+[5#=R7:_9VC!^0/&#N8J.BE2,^G6@#JKKQ]H
MMIJT>FRB[\][(7P*P$CRCTX'.2>, 9S4UCXVT2^\*P>(Q/)#83L4C\V,B1WW
M% H49+,2#@#.:X_4?"'B"\U7QOKBVB'4+RV%CI"F9>(MNUFSG"DCD9QW]:@U
M#P9KUM9>!([;3C=6NC;C>6EM<I&XD(&) S$ D'<>#P2<>M '1ZM\2;"P\/Z[
MJ,-E>/-I,OV>6%T&!*1\N6!(VY(!.<C/2N6BDN;N'PD-5\0>);'6]7<RF*W.
MV.0AE9@4SA45< 8['.#DU/XXTL2:+X?\(6=A'9MK6J!YX8Y#(WE)\TC._5F^
MZ2>>G4]:WKS0=8N/BU::S]BC;2K#36BM9#*H"RL3N^7KG:2.F.G/:@"[X?\
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M^I.."?6@#I=+\6Z?K,D7V&*YE@EN)+=+D*OEET!)SSD<*<9 S6]7!:%X;O\
M0?$^M:OIUC+!87=GYO\ 9CS(-]WG/RD$A1CC)[MZ"NY@>22WC>6+RI&0%X]P
M;8<<C(ZX]: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#)].: )**** "BBB@ HHHH ***Y>'7]7N_%.K:+;V=D1I\<4GFR3.N\2 D#
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M5B75YKMG8-=O9V<Q4 O;Q2-N0=R&(^?'7&%SBMAYHHW1))45G.%5F +?3UH
M?137ECC^^ZKP6^8XX'4TWSX28P)8_P!YRGS#YOIZT 245&\\,7^LE1,$#YF
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MD25 \;JZ'HRG(- #J*C>>&.1(WE17?[JLP!;Z#O1)<0PAC+-&@4;CN8# ]:
M)** 01D'(-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKM-+4.;D[FE&UV40KGC!Y+#/...,TVWM])U?XCZ8]Q':7:S>'"[[PKB4B6,
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M'&ZJ/,:0._+$# Y YZ 4 69Y9U^)UK;"YG^SRZ1,[0^8=FX2Q@,%Z9P3S3O
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M?4&K%8_ABWU2UT""'5YFFNT9QYDF-Y3<=F_'!;;MSCOZ]:V* "BBB@ HHHH
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M@[6=2TCPIX15HK1M-O9OL9 W>:K-YA5\],97&,?CVH ]*\M#()-B^8!M#8Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)['X5>([RSN[R"XBGO2DB7,F5*S/C&3P?4CD]ZW3:QS?%#3)7>?>=$DD.)W
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MDKGUKHT\*Z-'9V=FEHRV]G+YUO&)I (G[$?-P>3^9]:GBT#38;@3I;MN$S7
M5I79%D;)+A"=H/)Y [F@#1!!Z$&N;\9ZI-IUII<,4K0KJ&I06<LRG!C1LDX/
M8G;MSVW>M:>C:/!H\=TEN@C6XG:<QJQ*J2 #C/KC/XU/J6F66L6$MCJ%LEQ;
M2CYXW'![@^Q]Z //]7FD\->)O%-[8/,\L.@Q31^;(TNP^9(,C<2<#&['UK?T
M_3KK^U;6\76-VFWEJT;0+=RR^>2,K(C$Y0@9Y7'7Z5JVGA?1K*Y:YAL5,[P_
M9WDE=I6:/GY26)SU/7MQ3=(\)Z'H+3-I>GI;-,"K,CMD G)"DGY1GG Q0!PF
MD71T3P';303RQ"[UJ2UFEDN'VQQFYD!.23LS@ L,'YLYSS5[Q-:ZMHOAKQ-.
MNM2HIMTGMH(KB1I+=@<,1(QW;6]/4'%=A%X8T:'29]*6Q1K"<DR6\C,ZDDY)
MPQ.#GG([\U##X.T"WT>;28M.5;*<@RQ^8Y\S'0,V<D>Q.* .?UW3;C3M1T"*
M#6M6QJ&I[;C==,<J87)5?[HRH.!T)XQ31!=W>M:EX9AU*Y'V&SB^S237LBS'
M?N)ERN"Y!P.>!@>ISUMSH6GWALS<0R2&R8/;DS/E& QG.>3CC)J#6/"VB:]<
M07&IZ?'// ,1R996 ],J1D>QXH Y_3+NZU'Q-%H.I:B\XM-)CG,EM(T/VJ1G
M*-)E2#@;1P#C+$^F+?PU3RO!D<>]GV7EVNYCDG%Q)R?>MB^\-Z1J,MI+<62^
M;:+M@>)FB:-?[H*$';[=*L:7I&GZ+:FVTZU2VA+ERB9Y8G)/- &/XFU)[?6/
M#^FM,\%KJ%T\<TJ.4)VQEE0,.1N;'3DXQWK+U>:XT V.FQZM<S0:AK4<,CO(
M2]M$ZEA$'SNY*X!)R W&.#75ZMH^GZ[8M9:G:QW-N2&V/G@CH01R#[BH5\.:
M.NC'2181&Q)W&(Y.6SG<6)SNR!\V<\=: .1UF>_TS4_$FF6M[=_8QH3:A$YF
M9GMI@67"N22 VW.,]CBF10W0U3P<!JVIXU6SD6\!NF(DVPJX('1#G^)<'D\Y
MYKL_[!TW['=6K0.\=TNR<R3.SRKC&UG)W$8)&,]SZTU?#VEK+82"W??IZE;4
M^<_[H$8('/IQ]..E ' W%WJ,'AS4H(=5OD-EXECLX93.6D$3/%\K,<E@-YZY
M]ZGUB\U3P?K&M)8W][>6S:+)?!;N4S&"97"[@3T4@D[>GRFMGQ1X4271GM=(
MT]Y'NM0ANKD>?P^UU9F.]NI"XX]JZ2VTJRMQ,RVY9[A DQG<RLR@'"DL22!D
M\9QR?6@#FHK"]6Y2_AUHBQNK)U\I+J28S-MW+(C,?E('7'!!^E8NBSWT-EX#
MU-M4OYI]1(ANEFN&9)%,+MRG3(*@[L9]2:['3?!^@:.MPNGZ<EN+A2C[';.T
M\E5.?E'L,5*GAC1XX;&%+5ECL&W6JB9\1'&./F]"1]#0!S-CJ5W8^);6WUL7
M:>?=3-::A#<L]K=*0Y6-TSB-@N,#'\'!JKIE_=_VUX4EAO[RYM-1>Z62XFF8
M?:U\MG#"+)" $#;C!QV%=I;^'],M9DDBMSF-VDC5Y7=$9L[F522 3N;D#N?4
MU4M_!GAVU:W,.E0J;:4RP\L?+8YSC)X')^7I[4 <5!"UA\/O&EU9W5Y!<07M
M_P"7(ES)E=CG'4]?4]3ZUT4-Y+J?C"/1;J:=+:+2([I%CF:-IG9MK,64@G:
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M3(SQFII=5T^""&>2]@6*9=\3[QAUQG(/<8(.>E<L&M&^)NHW,GE&$Z+$@E8
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M/_:%UYULD*2E+N)E4*HV]&7: <XQ@4 =S=>(]$L6G6ZU:RA:W*B8/.H,9;.
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MIV'E[E8D$A?EX'RCKFI+WP>MQK1U:TU?4-/NY8UBNFM60"Y5>A8%2 P'&1C
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MMS>2O>W%PMQ*)%CE(*PC &U,#IQG\:N4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;>H.,_6@#I:*\MO#(O@#Q[BYN=T&HW/E/Y[[E 6/ W9SCVZ5Z;"Q%I&V"Q"
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MD\2W,GC*+2%T^46IT\79EW)GYG !(+9 &".Y)/3C-7=)\01ZQ]EDM[2<6MU
MUQ!<DH4905&#@DACNS@CL>X(H V**H:EJJ:=):0^1-//=RF*&.,#J%+$DG
M 4UG0>+K*XL8)UAF6::]?3UMY"JL)TW;E)SM_@8YSSQCDXH Z"BL4^(HU^R1
M/9W$=W=RRQ16TA16)CSN.=V,<9&"<Y'OA3XAB/V.);.Y^VW8D9+1MH=0APQ8
MYP #@=3U&,T ;-%8$'B[3Y[*2;RYTN([O["]FRCS1/V3K@Y'.<XQSG@U2UGQ
M%8R>'M>74],U%(K%=EW"F%9D9<AD<, 1CT.1Z4 =916%?^(X=-+PQV5W<&WL
MOMLOE[?EB&1U8C+?*>/;GMFI-XJE?Q!H-I964LUGJ=J]T)@4!*@*0,$C&-X)
M[^F>: .HHKFKGQOIEK-"760VDMU]D%TK(5$FXKRN[=MW C=C].:R?'NN"Y\&
M>(4L8;R1;1&ADNH) @248R/O L%R W&/K@X .[HJ")V6Q1PC2,(P0JD98XZ#
M) _.N?C\<64FEZ;J L;X0W]W]C4,(P8I=Q7#C?QRI'?]: .GHKF/$^MV$6A:
MV-0L+^6RLPJ7#0.JEL@-\I#@C 9<].O>GRZ[<_\ ";1: MA*;5K W#3+(N3E
MU4'[P( ^;/<D\#C- '245YYX1\2#2M!M(;NVOY89M4GM/MK$,J.UPZH&+-N/
M89 ('K7;:O?/IFCWE]';M<-;PM*(E8+NP,]3T_SUH NT5YW=ZO=7A\":K/!=
MI-<29DAC<8FW6S-D*&VX)/&[!'? KH[7Q?93Z==W,]O<6LMK=_8Y;:;9O\T[
M=J@ABISN4YSCU(P: .AHK%T?Q+::OJ-]IRQO#>6>QI(W96!5A\K*RD@C@CU!
MK,\7ZC<PZMX?TZ.TGFMKR[(G6-D F58G;R_F8=P"<\$#&>U '6T5RMMJECX?
ML+^WL+34+NUTURUR1()#!D;RB[FRVU6!P,X' R>*@O;N*\\=>$KNSN7DM;RT
MNY!MD;8Z[$*G;TS\QYQGF@#L:*XCPWJD.D6?B6>[FFDCCUV6&)6<R.Q81JB+
MN.222 .:VO\ A)HTOKJPFL+N._AMOM26WR,T\><$H0V"0>""0: -VBN<@\96
M5R-!>.TN_*UH$V\I\O:AVEMK_/P< \#/IUJ+7M;T]M-9KZPOVM8]1BM@\3A=
MT@D4!@5<':'P#]",4 =117.7OB^.UU'4K"+2=1NKC3X4GD$2Q@,C;N068#^$
M\'D]@>:L+XGLITTG[(DEQ+JL)GMHQA3Y84,6;)XQN4?4_6@#;HK)T'7H/$%K
M+<6]M<P+%*T+B<*"'4D,.&/0C%8BWLWB+Q]JFCO-+%INCPPF6**0H9YI06&Y
MA@[0H^[T)/.: .QHK$:Q@T2\DU9KZ:'3H;23SH99F>-,%6W@$G'"L#CVP.N6
MQ^*(/MMA;75E=6G]H*6M'E"[9"!NV'#':V.0#U^O% &[17)-X^M$L7OVTO4E
MLH;PV=Q,43$+A_+R1NR1N(^Z#_2KB>+(1>7]I<:;?6\]I:_;!&X0F:')&Y<,
M>X/!P: .AHKE+/QY975SI*2:=J%M;:JJ_9+N>-1&[E=P3AB0?3(P<<$CFK4?
MBZU>ZLT-I=);WEW)9P7#JH5I4W9!7.X [&P<=NU '0T5R5QX]M;:WU&Y;2M2
M-OIMT;>\D")B+ 4[_O\ S#YA]W)XR0.,Z\>OPOXF?0FM;F.X6W^TK*P3RY$S
MMRI#9.#P>/YB@#6HJGIFH+JED+N."6*-F8*)=N6 )&X;21@XR/:KE !1110
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MU738-8TB[TVY&8;J%HG]@1C/U'6KE% ' 1^#-6E71+R[N8SJ>#;ZLXZ2VS(
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MBTMT,%Y!';33*O\ I$4CJIRJ.=K*6Z]#QQ6I>^"K*]TIK;[3<Q7AN_MXOXV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT5M>W5S-:F[B6"'(D3('!) S\PZX'J: -VBL2T\5:??:78WULL\AOG:."WV
M2LZYWJ03@;=K9)...O2BV\465U:M(D5RLZW;67V5D D,RC)4<[3P"V<XP,YH
M VZ*S-(UVUUE[R*))8;FSE\FXMY@ \;8R,X)!!!R""16G0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9?VBMP\.AZCY5M>FRG<F']VX8*Q($F2HR"2 >*Z>N-^'O^K\3?\ 8P7G\UH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,9]1ZU-+J^G074UK->0Q30Q>?(DC;=L><;SGMGC- $-_X>TO4[V&]O+42W,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6/<ZX;3Q/8Z-+:X6]CD>&X\S@E "R8Q
M][!S],^E;%87BK0Y];T^W^PW"VVH6ES'<6TY&0C X;/J"I88]Z -'3KU[^&6
M4PB-%F>-"'W;PK%=W08&0:N5G2P7EE:Z?;:3';F**2..83LP*P 8)7'5^F,\
M=:T: "BBB@ HHHH **** &R1I+&T<B*Z,,%6&017GO@'0;#5?!6^Y23SWN;A
M?M$<K)*H$K!<.#D8 'Y5Z%(7$;&-59\<!C@$_7!KCO#6C^)O#_AO^S%ATEI_
M-ED6<W4C*N]RWW/+&<9Z9&<=10!3\+^+YK?2+NRU>X6XOK+59=*BGE<)Y^T%
M@SMT'R@Y/MW)YO2>/X8=.OKAM.EDELKN*VF6"570^80%='XW*=W89SP0*KOX
M%N]-T2R_L:^C?6K2^;46N+I2$NI7!60.!]T,&QQTP/K5K6=(\1Z]X;>VN1IT
M5Y)<02"%)G\N-8Y%<_-LRS'&.@ X^I )I?%EU&VM6K:28+^PLQ>11RS@K+&=
MV"2N<$%3D<_6ETKQ!J,NA:')-8>;=W]L)6E\PK"H$:L6=PIV9)X&#3;KP_J-
MYXEU2^?[+':WNDBP&)69U8%SNQM Q\_KVJE!X?\ $<=GX<AE73)HM-A,%Q:-
M._ER81527.SYF&TG:1@;NN1F@"KKFK6WB3PUX9U>*$Q[]<M5"L02I6?8PR."
M,J>>_%=OJ,,=QIMS%,BNC1-E6&0>*XJ#PCKL/AC3=++:>\MEJXOMWFNH>,3M
M+_=."=V,=L=37;WJSR6$R0)&T[1D*LCE5R1W(!/Z4 >>^$-?7P]\,O"URUC/
M=R:C+';N\;+NWNY 9BQR3_G(K?'C>.W@UTZGI\EG-I'E-+&95<,DOW&W#@=\
M^F.]9%IX.UVV\%>&M%(TYKC2;Z"XE<7#['2-RWR_N\Y.>XK2;0M:CU[Q'J$4
M.FR1ZE':QQ132L0RQ9#JXV$ ,K$<9Q0!:U/Q7/I&BW>J7.FJ\%N8L-!<[UE2
M1@H9&VC."1D''\LV;GQ']F\0W.D&QDDDBL/MZ-&X^==VW;@XP<^^*YF3X?W
M\/>(].T_R;"#4##):6/FL\,$B-N8]/E#D#@#C&?8:*Z-XBN/%,FMW,&FQB72
M39&W2Y=MC[RP.[9R/P&,]\9( _3O&MYJ.D6^IQ^&[T6MW'";9Q(K;WD;;A@.
M55<Y+$8QS]4NO'L=GHVOWLFG/)-HDHBN(H)E96RH8,KG'&&YXR"#Q59/#.OV
M_P /-(T2&6S%Y8M )XQ,XANHD/S1E]NY0PZ\'TY!JC?>"]>NM.\6VD:Z5$NM
M"'R%65U6$K&B$'Y.@V\$#GT7I0!T</BP+KL^FZCI\E@J637\<TDBL&A5@'+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7O&AG5].A2.-,*#NE(W,0W<!63\2?2@#5JGJFJV6BZ=+?ZA.(+6(9>0J3C\
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M[=7%CH&H7=HT:SP6\DJ&1"RY52>0"/3UKDH-?\1VC^&+^]N+.XL=:\J"2&.
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M+0PJ0F)%90IW_+SP!TQ6:OP^@CT]=,AUC4(M,BNENK>V7RR(65]X"L5)VYZ
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MAU,:F=.M/MX&/M7DKYN,8^]C/2E;2-,>VEMGTZT:WE?S)(C"I5V_O$8P3[T
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MD+'%BZ:7>5:%R6R4.<8Q@ #&,5WVCV-Q:0S37TD4E_=/YEPT*D(#@*%7/.
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M0P+B7_>&/F_&A=%TI%=5TRR"R1"%P(%PT8Z*>.5'ITH J^$O^1,T/_L'V_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K%O?#5O=:H^I0WM_974B*DK6L^T2A<[=RD$<9/.,\UM44 06E
MG%90>5#N()W,SL69SZDGDFIZ** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBJ]]>1Z?8S7<H)2)=VU>K'LH]23@ >IH L45E:+JE_J7G&]T2YTS9C;
MY\L;>9G.<;">F._K6K0 4444 %%%% !1167K&K3::UI%:Z=/J%S<R%5BA95V
MJ!EG8L0 HX'U84 :E%<)H?Q(;Q!";FQ\/WKVB7ZV$DXEC*H[$#=C.2HW#D>M
M=W0 4444 %%174S6UI-.D+S-'&SB*,99R!G:/<]*J:'J4NKZ+:W\^GW&GRSK
MN:UN1B2/DC!'X9_&@#0HHHH **Q=8\0KI^C7U]I]E/J\MI((GM;,;G+Y7(_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5#6--T[5]/;3]5B2:UG8*8G8J'(Y X(YXS^%7ZJ:CI=AJ]L+?4
M;2&YA#APDJY 8="/0^] '/>%[*30=4UG2TNY9M&MEBEMS/(6-N6#%XMQYP $
M;GH&%=4CK(BNC!D895E.01ZBJZZ;9+I[V"VD*V;HR/ $ 1E;J"/?)S4UO;PV
MMM%;V\:Q0Q($C1!@*H&  /3% $E%%% !1110 5S?C[6_^$=\"ZOJ0?;*EN4B
M/_31_E7]2#^%=)5'4]%TS6H5AU2PM[R)3E4GC#J#ZX- ' ^''_X5W\#(M1,
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M,-Q>7!T^V,UZ@CNI#$-TR 8VN>XQQ@U-8V%IIEG'9V-M#;6T8PD4*!57Z 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB%\I]CI@<XWY!S[UTFN>,[R'Q/+H.FQK]H@TUKUW-N\Y=\@)&%3D YR6]\4
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M@'TK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9B,<#/3@5-X/\(CPC!?Q+J$EX+RY:Y8R1A2&/7I]!72T4 <YXT\*?\)CH?\
M93WOV6$R+([+%O8D= .1BMFSM9+?38K268.\<8C\Q%V9P,9QDX-6J* /.;3X
M4"TBTE/^$ANY#IE\UY"6@3J2"0>Y)('))^E79+;2_&/C2POTMKJ*YT"YFCF\
MZ+8'P!M^HW'<O^ZU=S10!3:VNSJZ70OB+,0&,V?E+AGW A]_7@<8Z<U<HHH
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M&R@/51DXYP!^5 'GD2ZA'X"L/$<.JZC)J<%YM57N69)E-R8_+9<X;(/4\^^
M,6-8U2[T75_B-J5@NZZM].LGCXSM.R7YL>W7\*Z+PAX;&G:);1:C9[;R":27
M!EWIN+L0P7.W.& SC-;<>BZ=%?W=\ELOVF[4)<.6)\U0, ,"<$ $@>F: .3O
M/-TS6/"<^EWEU/#J<AMKI'N'D$\9B+B7DG##;G<,=<>E):R7-M>WWA*:ZNWN
M9;I9K:X:X<R&T8[F(;.1MV,F?4KZUU-AX?TS2F5K&T6,QH4B!=F$2GJJ DA
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M>\@0I%-R&53S@$>_(]#R* /+=)CEL?"/A_5;>\O([@^(3;E%N&$9B>[D5D*
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MY-&"B=[1HD!60DJ!M&T >OYFN>L5DC^&G@N%X)UF@UBV>:,Q-NC59F9BPQD
M @Y/J* /5+V^M-.M7NKVYBMK=!EI97"J/Q-5;/Q!H^HW\UA9ZE:SW<(S)#'*
M"RCZ?YQ6=X^P?A]KYZC[#+_Z":PI[)=8U?PQ/HH$<MC:3>;,L940JT.U4;C@
M[R#MZC!.* .Q76M,>\6T6^@,[LR(F_[S+]Y0>A([@<BG-J^GI>"T:[C$Y?RP
MN>KXSMSTW8YQUQ7GD5O/J/P^T70$MYH-=LKJW5HV0AH'CD!>4G^Z5#$-T.[
MY-7\75EXE$FDW$EQ;7.J$7FDW4))B.XAKB)L9"\;NZG)&<\4 ;=UXGLM&TO6
M]6N=7AO[>UF(6*!1F%MHQ#D$Y;/.3TSSTJ\^IV]QJ^F);:U;(LJRL;,!6>Y
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MX*1RQ@HDB'&T@$DY.<8R>>!7,^"+M?"NAQ^&M:#VUU8R2)%*T;>7<QERRNC
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M(JW44 A\H/ J!'PWRC&>.OY8J6@ HHHH **** "BBB@ HHHH **** "BBB@
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MTMXEE6^@-QO23A$ 4[NG(.]1^-2:GJ\>GW%E:+'YUY?2,EO%NV@[5+,S'LH
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M"K@CJHY&#Q6%:W-II/CSQ;?7#"*WAT^TGF;T \TD_I6H/$[0WFFPWU@UJFJ
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MZ-L:>W25&W(Z[E8-D#&,Y'48[U8M_%1F\0P:-J&DW%D+Z)Y+.61U99PHRRD
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MTK3[M(EBDOKJ2S1)Y@J+(F_.7 (P=AQ@<Y''I=?7W0V-J]DR:E>R2I';/)@
M1D[G+8^[@ @@$_,.* -NBN2N_'4-EI>IW$VG3_:M,N(X+NV5U)3>0$<'NIW
M@@9]JTM/\0/=>(+G1KK3I;.XCMUNHB\BN)(BQ7/R]"".G/UH VZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *P?&.D7NN^&I].L/($TLD39G<JH"2*YZ*3_#CIWK>HH X;Q!X9
MU[6)]<0?8)8+^Q$-JT\K[K-MA#*J[<$,3G=D'U!P!2ZUX5U#7+!+>[LK W,5
MLBVE[%.R2VDX!R0P7)7[IZ\X/ [=Q10!S=KHNI6?C&34Q);S6MQ8PV\SNQ60
M/&6.0H&#NW>HQ[T>(]&U&YUC1];TDP/=Z:TJM;W#E$FCD ##< <$;01Q7244
M <%-X:\2NNN2Q/8127]]!=");A\21HJ*\3-L! 8*1D#GTYK0T?3+G0M9UK4M
M3.EVFGWP@VK'*0L3*@39\R@8]^_H*Z'5=4M-%TV?4+YVCMH%W2.L;/M'KA03
M3KBULM6L/*N[:&ZM90K&.>,.K=QD'\* .=\#:.FG6MW-%<&>T:=XK GHELKL
M54'N-S/@]U"^U7/$.B7=[JFCZQIS1?;-,E<B*9BJ2QR+M=<@'!P 0<=16\JI
M%&$10J*,!5&  .P%8LGB_1HM'N]6:XE%G:3M;S/]GDRDBG!!7;D<G&2,4 4)
MO#E[.GB2]VVZZAJ]L+:.(RG9$BHRKEMN2<L2<#T'O6UH-I<Z?H&GV5V(A/;6
M\<+&)RRDJH&02 >WI6C10!QVF:/XFT6\N]/LYK!]&GN9+B*XD9A/;B1BS($Q
MM;DG!)[\YZ43>'-6D_X3'"V7_$ZCV6^9V^3]R(OG^3CIGC/I78T4 <DF@:J-
M2\*7#+9A-)@DBN,3MEBT83*?)STSSBL'P]I5YXA^'[:.T<"6-Q?S^9/YA+>6
M+IF8!<?>)!'7&#GVKTIE5T*L 588(/<5FZ"NE_V:)-(LTM;5W?Y%MS#\P8@G
M:0.X/..: ,*_\)W6JZMXD-TT$=AJUC%:HT<A,B% _P Q7:!U?U[5+'H>JZBF
M@Q:RMJ@TF9;AI()2WGR(C(I *C:/FW'KR,>]=710!QL.GVFI>/SJ6G7T<UG]
MG26\CA8.CSJ66$DCOM+Y'^PE61HFJ+KWB2^5;0Q:E:Q0P S,&!17&6^3@'?V
MSTKH++3[+3(#!86D%K"6+&.",(N3U.!WJS0!Q5OX8UB&P\'VY%D6T0K]H(G;
M#@1&/Y?D]\\XJ30]'\3:'(^D136$FC"=Y(;IF;[1'&S%BFS&TGD@-GWP>E=C
M10!PMWX4UFYT/Q;8*+$2:S<M+ QG?"*R(OS?)U^3/&>M:L>CZI'XRM]846GD
M/IJ6=PIE;<C*Y?*_+\P.['.,=?:NEHH YOQ19L+_ $/65!*Z;=%IO:*1"C-^
M&03[ U-=:7?_ /"86VLVGV9X/L36LJR.59<N'#+@$'ICMZ\]*WJ:B)&@2-55
M%& JC % '$KX6UE?#$&FXL?/CU3[:6\]]I3SS+C[F<\XZ5<ATKQ'I6L7XTU[
M"33K^<W!-PS"2VD8 /@ 8<<9 R*ZL$'H0:6@!%!50"Q8@8R>II3G''6BHKBX
MCM;:2XF+".-2S%5+$ >P!)_"@#DM)\,ZK%\0]1\2ZE]C:*> 06Z13,S1*,=B
M@'.WU[FH+_PIJ4GCR[UD6]A?V-W:I 8KJ9E\K&,_*%(<9&<'N>U=?IVH6VJZ
M;;ZA9N7MKB,21,5(RIZ'!Y%6J .7;PU=W'CNRUJYDMVL[&Q,,,:9#><3RVW&
M ,=.3T%4-5\):K?^)=8UE);3S7T[[%IF]VS"6!W.WR\');&,]:[>B@#SZP\
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M;BVU07K-]H?84%P9L [,YYQTJ_<>']6DU7Q/=(MGY>JV,=M #.V595=<M\G
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MH_"VJVNBZWX>@:V?3M1DF:&X>0AX$FSO4ICYB,M@YYSSBNVHH YG3M N]/\
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ML4<5PP.]8R2IP2,KGG!'(SZU=JIIFI6NKZ;;ZA92&2VN$#QN5*[E]<'D5;H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K#\63ZE9:')?Z9*RR6I$LL:HK&6('YP,@X;;DCZ5N5GZM
MJ1TV")AIUY?&5_+V6L8<C(/+9( 7C&?>@##U7Q.UIIVJ:Y:2_:+"SLT:-,#;
M),XW#G&<!6C/7^+VJ2[O]2TC6=%@FO3=VVILUO(3&BF*3865DP/N\$8;/;FK
MFD^&[.S\*)HDUM&8)(F6>($E27R6 /7 S@>P%2V7AZ&TDLWEN[J\-DI2V^T%
M3Y0(VY^51DXXR<G&?4T <Y'XBU4^$[#4#= W#:N+20^6N'C^TF/D8X.T=1BN
MMU>6]AT:]ETV%9KY(':WC8\,X!VC\ZQ7\#V+Q/!]OU!;8W8O(X%D4+%)OWG;
M\N<%N<$G';%;U]9+?Z?-9O++&LJ%#)&V'7W![&@#S[4]>CUGP-XL5;^YD>'3
MB)+*]@6*XMGVONW *,@C;@\]#S6Q8ZAJMAXFT[3KB^CN+6]TR2=8S$$$+QE!
MP1R5(;G.>GX5HWGA"TU&&_6\O+N6:^MEM)I_W:OY0).T83')8Y.,_2I)?"MK
M<7UK=SW=W(UM:O:!"4"O&X ;=A0<G Y!'2@##TG7]4;7]!M9[P7<.HVT[3.D
M2K#YB!6S"V S+\Q&3D$8(/6L+4/^2:>.?^PO=?\ HY:Z^Q\$6=C-I,HU+4Y6
MTI6CMO,F7 C8 ;" HR  /?CDD4Z3P392Z)J>DO?7QM]2N&N9SNCW;F;<V#LX
M!(% '1L&,9",%8C@D9P?I7GFG^(M?C\'+XDO=2BG#.]J+86RJ-YN?*20MD=!
MVX!&.<\UZ$L;" 1F5RVW'F$#=GUZ8S^&*P[;PAIL'A>;P[,\]UI\V_<L[+N&
MYBYP5 _B.1Z4 9&I:UK_ (;M]5U&Z1I]-BLQ) ;LQ+(L^X+M/E<&/D'/48-7
M]2N]7\.6U_JL]]'?Z?;Z>\QBD14D\]>1MV@#81GKDCUJ6S\'6<.G7%E?7NH:
MK%/";<F_FWE8SU5< 8Z#GKP.>*=IGA&TT^TDM;B]O]2A:%K=4OI@X2(C!08
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MWX<?:9/",5Q<WL]R\MQ<$F7;P1/)DY !YZ\_ABIQJ-[K/B36M)M+UK$:9'"
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M#D$'L00"*SX?"-D=)NM/U&ZO=52YC\F22^E#/L[ 8  YYR!G(!)X% %2ZO\
M4M)\4Z3I<M])=6NK1S1B1HT5X)8TW[EPH!4C/!!P0.:JZ-K.J7EG)I5U>D:W
M;ZDUM/(L: >6#OWA<8"M%C!_O,*W;+0(K6ZMKFXO+J^FM8FBMWN2A,:MC)^5
M1DD #)R>/<YFBT2QA\07&MI&1>W$"02-G@JI)SCU.0#[** .9DUCQ#JL-_=:
M&K>99W[VZ0R>2()%C?:X<D[P3AB",8^7@\DSVEUK^I>,-9L8]6BM[33YK9U0
M6JL71T+,A)/&?7KTZ=[;^";$ZS<ZA#>ZC;1W;^9=V<,^V"=NA++C//?!&>]:
M%EH45CK6HZI'=7+3:AL\U'*;!L&%V@*",#WH Y"7Q)KR^%;N\6]A^U0:Z;'>
M8!@Q_:!&!CMP?<UIQZOK6GZUX@T^24:F]MIR7UH@A$;%SY@\OY>H)08[\]35
MMO!%DVESZ>;^_P#)FOOM[G='N\W?O_N=-P!Q2:SH<EN-6UFR:\O-1N+#[*+<
M2(@91G&T@ @@LQZC^5 &;I>N:I?ZMX>2UU-+NVO;)KF_ A0^0RA<#Y<%=Q9E
MPV3\OL:N_$5KA/"3O;W<UNWVJV5O+Q\ZM,BD'(/&#V_ED5G:!97<5S:#3M2\
M3>7$RB6#5;9$B$8X(R8U)..!M)YQGC-=;K>CVVOZ3-IUT\J12%6WQ, ZLK!E
M()!&05':@#EKJUO9?B6+>VU%X)O["P;DQ([_ .O[# 7/X?AWJ/2?%FI:II?A
MR!MXO=1@N))I;98PQ\E@AVA_E!)(/?@'CN.CB\.11:V-7&H7K70M/LF69""F
M[=G[O7=SZ=L8XK.;P!IO]C6&GQWNH1/I\KRVEY'*JSPEB2P#!<$')R"#0!J>
M'6UDV$R:VJ?:(YW6)U*[I(NJ,X7@-@\@<<5@O%*GQ7FE:^G$::,LI0*A&WSF
MRGW<XX^OO74Z9IR:9:>0LT\[EMTDUP^Z21NF6/T '    JJ-!B'B5M=^UW7V
MAK<6QCRGE^6&W8QMSU)YS0!RLGBC54\$6GC)+@-"\B22V'EKL\EY-FU6QNW@
M$'.<$@\>E^R_Y'[Q;_UX6?\ *:M"V\'6%K;BR2>Y.F+<?:$L&93$K!MX ^7=
MM#?-MSC/MQ5E?#L*:OJ6I)>7:SZA$D,H!3:JJ"%V_+P1N/7/6@#DO"NK31Z!
MX)T.WE,#7U@\LDX4%E2-1PN01DEAU!X!]<B:\UWQ!%9>*+."X\R^T)XYTF$2
M9N8&7>588QO"AAD <@<5N1>"["#3=*M(;J[2323FRN@R>;&",%?N[2I'!!'-
M:EAI-O8?:G!>:>[?S+B:7!:0X"C. !@*    /UH Y;_A+C%XJ96O9)='N=.-
MQ:LL:?ZY5#L@.,D^6R,![GKVN2W^LV'B#PMIUQ>)(+V.?[6/*7+2)'NX(Z $
M]@.G6KD/@O1H--TNP2!O)TRY%S;Y;)#C/4]Q\W3V'I5R^T.&_P!:T[5'N;B.
M;3]_DI&5V'>,-NRI)X]Z .*F\0^(H=!U76&U.(_V;K#6OD"V4+-$)ECPQZCA
MLC'.>Y[:NN>(+ZWU37;47BZ?]BL$N+'<BG[4Y#%OO Y (5<+@\^XJ])X)LI=
M'O\ 3'O[\P7UV;R8[H]WF%PYP=G W ''M6)J=M</XHO9)Y?$]BQ$44$VG1":
M*=%7.YOD8(VYF&/E'?O0!TVF)K=W9:+=W5XL#^5YE];?9@#(63A,YRFTG\<5
M1^(=[-9^#+H0.T<ES)%:[U."JR2*C'_ODFKVFZ9?/!ID^H:C>FXM#*2F]5$Z
MMD+YRJ-K,%QTXW9-3^(M&3Q!H%WICOY9F4;),9V.I#*WX, : ,_Q+?7>CG0(
M]/DCA@GU*&TEC\L',; \ ]ONU7UBX>P^(WALQ<#48+FVG']X(HD0_@=W_?1K
M0N])_P"$AM=.>_:YL[BRN$N?+A*X\U.G+*=R\G&/7GG@#:8VH>*[?59T*PZ=
M#)%;!A@O)(1O?'H H4>N6[8) )/$-W<6EM:&WNXK82W21R,REI&0@DK$N#N<
MX'&#QD]JXG6M5O=4^&?BU+YF:2RO'M49U57*!HV&X+\N[YL<>E=SK>@P:X+-
MI+BYMI[.<3P3VS*'1L$?Q @@@D$$5F2>!=/DTS5M/-[J @U2;SY_WRDAN,[2
M5.,[1G.3Z8H 9>?\E2TG_L$W/_HR*K'C'4[W2;33)[*?RS+J=M;2*4#!TDD"
ML.1QP>HJZV@Q/KUKK#WETUS;0-;JOR;65B"V1MZDJ.A'2GZ]H=MX@TLV-S)-
M$!(DL<T# /'(C!E9201D$=P: .:U37M7M=1\96]O=J%TW3(KRUWQ*VQBLI(X
MQD?(.N:9I^KZ['K7AF.ZU&.XAUJPDD>+[.JB&1(T<,I')SN.03CTQ6F? ]H\
MFJ2RZGJ4DVIVBVEU(TB99 &&0-F <,W08&> *L#PM:P7.C79OKYFT6%HK<?(
M=RE0IW )DG  XQT]: .*_P"$E\60>!XO%KZG;S1VMW)'<60M543Q"Y:(_-U5
M@,8QZ<Y-:WB3Q'JVE-J-U;WR2"TO[:);>")6B6)VC5A,S+D2$N3A6R!M.,$T
MWP3X=:[\)Q6VJG4(XDOYIWL+B+RT)\]G3.4#%?NMC.,]>XK5O?A_IU\NJ1M?
MZG%;ZC<+=RP13*$28%3O7*DY)0<$D>W2@"+4/$MYI'BW68KF02Z;9:'_ &DL
M*1@-N#N"-W4\)^M8^I-J%X_@'4[R_,OVO48IG@6-1'&SP2,-A W8 )').>#Q
M76GPM9OK4VIS3W,[SV(L)(965HWA!)P?ER3ECSGO6;;_  _L[>+38/[7U:2V
MTRX%Q90O*A$.%90N=FXKAB.22 , ]<@&UXBNK^RT*XN-,MY+BY0H?+B +E-P
MW[ >"P7<0#W ZUSUMXD:^T2:ZL-<1E^WQ0L;J#9<0(=H>+RPG,N=VT;3G(ZX
MKJM1L1J-F;<W$]N=Z2++ 0'4JP88R".HY!'(K&N_!=C>B666ZO%O9+J*[^V1
MLBR"2-=J8&W;@ D8(.<F@#F]3U:]U#P/XZM;UI'^PB6*)Y459"AA5QN"\9^8
M]AQC/-:VKZEJ%K"([2^$0CTHSQPV\:R3&0#[SAE*K& .N02<BKC^"+%[;6;=
MK[4"FK@?:<RJ3G:%)&5X) 'T[8%23^#K.>]^U&^U!'>S%E.(Y%43QC.-V%X(
MR>5Q0!BMK>O:G<>%8K2_ALQK&F27$K"W#^7((T;(R>>7Z?SJT-:U#0=?O+'6
M[]KF!]/^TV4BPHA=TXE0 #ELE2!Z-WQ6A9>#K2QGT:6._OV.DPM!;AW0@HP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMPX,JNICXA'!1<$G.3D[^,<UJ376CZGXB\1:?K]S D9AB-F\LBJ! 8^7B8\
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MLX7S6Q^E '6T5QWQ$BB?3]&,K,BC6+12RN4P#( >0>/K7.ZSHD&EW_B^STJ
M)IK^'VN)H%Y2.Z^?8P'9BJD\>@- 'J=&:\[CN["?Q7X*\NX@=I=,G20JXRV8
MX]H)'_ L?C5+P_H.G7'@&>]6=+2_::ZM8[V0EA&K73 (1G&PD $>Y]30!ZCG
M/2BO)M:D<>$_$UK?Z/;6&IV36DDSVAS!(#(,2)QE3@-D'G'UK7U/4]-M_'NJ
M7/VK$2^''>9K1QYAVN22N/XPO3\* /0L@T9%>9: UC'XSTF&)[**VN]"93##
M("7^>/9YC#&]R"><#J>O6LW1K*UMO"?@;5(D OGU9(3<;B7,;-*&3/\ =/IT
MH ]6MK^VN[BZ@@E5WM9!%,!_"Q4-CZX(_.IY)$AB>65U2- 69F.  .I)KC/!
MUOI]OXG\5K'#;1W0U([0JJ'V&*,G'?!//UKH?$D,<_AC58Y(UD4VDIVLN1D*
M2./K0!>M+J*]LX+N!MT,\:R(Q&,JPR/T-35YSITMH!X)LMEO_9=Q:GSE4#RW
MN?)0J'QP6QN(!ZG'<"M[PM%):ZYXCLX>-+AN8_LJC[L;M&&D5?0 D<#@$F@#
MH+^^MM,L)[Z\E6*W@0R2.W8"LR?6YH?%UCHWV:/R+JUEN!/YAW H5&-N/]KK
MFL[XF0QS?#K6?,C1]D&]=RYVD$<CT/O6??6.E7OCGP]:1PVTE@=.O/W,6/*;
MYX\@@<$9SD>M '>=LT=:\DLK]=/T31[6YG2#15UJ]M9'F7?%&%:3R5<$XVYZ
M9X&!Z5W'A*QL;"+4$T[41>6TER9-L0'DPL0,I'C@#H<#H30!T=%<?\2TC/A'
MS)&*;+VU.\.5V@S("<_0FL35+*Q\,>)M6DLA<VVF2:%+-J*6CG<'W821<])"
M-^#[$^M 'I>0>E5=/>]DL4?4888;K+;TAD+H!DXP2!VQVK@O#[6D7CV*UB>Q
MC@N="&8+60$,1(-NXC&]]I/.!P:S-'O4M_"_@JVNW"Z/<ZA=)=LY^1F#RF)'
M)[%\<'K@4 >@:5K<VH>(-:TR6VCB73FA".DA;S!(I;)X&.W'/UK6N+B&TMI;
MBXD6*&)2[NQP%4#))KCO":6-MXZ\7V]EY")OM6$<1& ?+.[ '3G]:U_&\,<_
M@77DDC60"PG8!ES\P0D'Z@@&@#0:[NKA=/GL(HI+:<AIFE<JR1E205&#DYQQ
MQ5[(KSJ6.P0^ 'LA H^U!6\G &3;,3D#C.<&LK4M+L9?#_Q"G>%6EM+R26W=
MF),+B&-@R_W3GN.>U 'K5&><5Y]);)IGC/1I],B5+N^TFZ:8@Y-PZB,H7/\
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M_$&%;6,0Z>SRV<8^[;/]G5]T8Z*=W.16^,3>./"LTC%I+C1[@R$M][B+_$T
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MIXQT.[BU!UO&B_L]=]TMQ"\31IC(;:P!P1T(%2IXGTQOM89YTDM(5N)8GMY
MXB.<.%QDC@],XQS0!2\)>&1H>F)'>VUB]ZDTL@N85W,0[LW4J",!L?A6S+I6
MG32322Z?:R23@+*S0J3(!T#''.,#KZ5!'K^G3:?87T<LCV]^RK;,L+DON!(X
MQD# )R>PK/;QSH"1M*UU*(4N#:R2FVD"12 [<.VW"<G'S8H VUL+-+LW:VD"
MW)&#,(P'QZ9ZU#'HNE0S&:+3+))3)YI=8%#%^?FSCKR>?<U!9>(],O[ZXLHI
MI$G@C$S+-"\68R<;U+ ;ER#R.*9%XFTN6\CM1+,LLT330!X'7ST7J4R/FQD'
M YP<]* -BFM'&TB2,BETSM8CE<]<>E8-GXUT*_DL5M[J5DOF*6\IMY%C=QGY
M=Y7 ;Y3P3FF6'B^SN[G65ECGMX=-G\II)(' ;"J3VZDM@+U/''- &U-IUE<7
M'VB:SMY)@AC\QXE+;#U7)&<')XID^DZ;=6\-O<:?:300X\J.2%66/'3:",#\
M*9%K%I*EVW[V,VB[IA+$R%1@G/(YX':N3.NW.C>,;=-3O+M[>72'N6M$B,I6
M8RKPJHI8X!([X ["@#M);&TN)H9IK6"26 YB=XP6C/\ LD]/PI@TS3Q;Q6XL
M;;R8GWQQ^4NU&ZY Q@'D\U4MO$FE7NEVVHVESY]O<L4A\M&9W89RH7&<C!R,
M<8.:K'QEH26<=T]XR1O=?8COA<%)LXV.,?(>>^* -:*QLX+B2XBM8(YI?]9(
MD8#/]3U-,MM+T^R$@M;&U@\S_6>5"J[_ *X'/4U4LO$NE7T=\Z3O%]@(^TK<
M0O"T8(R"5< X(Y![TL'B+3Y[N>S!N%NH8A.T#VTBR-&3@,JD989XXZ'K0!/_
M &+I7DB'^S+/R@V\)Y"X#>N,=:O    # ':O-;35_P"UO#-KXBO]?U;2U>0B
M<6\+>6P:4B-5RA QA5W#KD@GFNM_X2:#_A+9M",$ZF&V6=YC$VWYF('., ?*
M>3QGCM0!IRZ9832RRRV-M))*NR1WB4EU]"<<CVI9].L;J2&2XLK>5X.8FDB5
MC'_NDCC\*KV6MV6H3QQ0&;,L/GQ%X659(\@;@2,'[P]^:J:MXDBTO7M*TIK>
MXD>^,A+I"SA512>, Y.<?09)QQ0!IW6GV5\T9N[.WN#$=T9FB5]A]1D<4YK&
MT>Z6Z:U@:X7@2F,%Q^/6L^[\3:58M,9YW6*"0133B)C%$YQ@,X&!U&?3/.*T
M;N[BLK.6[F+>3$A=RB%S@=2  2?PH CFTRPN)VGFL;:69XS$TCQ*S%#U4DCI
M[47.F6%Y'''=6-M/'$<QK+$K!/H".*HQ>*-)F?2TCGD8ZJA>S/D28E&-W7;@
M<<\XXK&\5ZZ85TR6ROI[=(M:@M;OY"JNI/S*2PY&,?=.* .HN]/LK]$2\M+>
MX1#N59HPX4^HR.*D@MH+5&2WACB5F+$1J%!)ZGCO6,WB72K[2M6=;NZMA9(R
M7+&WD2:WRN0X1ESTY!P1Q4]OJ]E;Z9IV+FXNVN+=7@_=EYID"@ERH'N,G &2
M!W H K>+-%NM=M+""W%L5@OH;J07#$!E1L[<!3UZ?XULVUE;6D)BM[6"!&Y9
M(D"J3WX YKD-3\30S:MX3U#3]3D;2KV6=9$C3B7;$Y *XW;@PQM]1TS73Z3K
M-EK=J]Q9.[+'*T,BR1M&\;KU5E8 @].OK0 Z#1M+ME18--LXA'NV".!5V[L;
ML8'&<#/KBG)I>GQVTELEA:K;R'+Q+"H5OJ,8-10ZW8W&LW&DQR2?;;=!)+&8
M74!3T(8C!!YZ'M4:^(=.>WMYHY)7^TLZPQK"^^3;]XA<9P/7ITYY% %N/3K&
M&VDMHK.W2WDR'B6)0K9&#D8P>*;!I6G6H46]A:P[8_*7RX57"9)VC Z9)X]Z
MHCQ5HQLHKS[4WDRW(M,^2^4F+;=CC&4.2!\V*N0:M9W.J76FQR,;NU1'EC:-
MEPK9VD$C!!P>GI0 1Z1ID*QK%IUHBQAE0+ H"AOO <<9[^M)_8VE^4D7]FV?
MEQMN1/(7"GU QP:CU#7+'39Q;SO(TYA:?RH8FD81J0"Q"@X&2/KVJK<^+]$M
M$L7>[=EOXC-:F*!W\U0N[Y< Y..W7D<4 :R6MO'<R7*6\2SR *\H0!F Z GJ
M:F(!&",@UB3^*])M[$7CRSFW$23R.MO(WE(PR"^!\O'.#R!STK7$\36XN!*A
MA*[Q)N&W;C.<^F* (3IE@;/[&;&V-KG/D&)=G7/W<8ZU-#!%;0K%!$D4:_=1
M%"@?0"LN+Q-I<MXEKYDR320M/"'MW7SD'4ID?-C(X'/.<57LO&NA:A)8K;74
MC+?$K;RFWD6-V&3MWE<!L G!.: -Z2..:)XI45XW!5D89# ]0155=*TY7C==
M/M0\2[(V$*Y1?0<<"L.'Q9::C!X@247ME#ISO"UP+=]R@(I+CY2 06) ZX&<
M4#Q3;65QX=TZ/[9>+J-OYB730LQ=%C!#' Y8DJ3QQDYQQ0!N#2=-%K+:C3[4
M6\O,D(A78_U&,&I[:VM[.W2WM8(X(4&%CB0*JCV X%<SH>J2Q:OXK&HWSR6U
ME=H(VEQ^[0Q(V  !W8^Y]ZUK?Q%ID]S=6[3-!/:Q">:.YC:(K$<_/\P&5X//
M;'- %;Q?HUUKVB"PM?LX8SPRL9V(&$D5\< YSMQ^-:EMI]I;6[1165M"D@_>
M1Q1@*W&#G@9].E<O<:^]SX\\.VUI<WB6ES!<R20R0F-) $!1AE03U/&?3@=^
MDO\ 5[+3)[.&\E:-KR86\'[MF#2$$A<@8'0]<=* '1:5IT 00Z?:QB-&C0)"
MHVJ>JC X![BC^R=-^Q/9?V?:?9'.6@\E=C?5<8-4+KQ=HME%JDEQ<R(NE%1>
M?Z/(3'N&5XV\@CG(R*DL/$^E:EJCZ;;32?:1#YZK) Z"2/.-Z,P <9(&03UH
M O6NGV5CN^R6=O;[@ ?*B5,@# ' ["K#*KJ58 J1@@C@BN&\2>)Q)>>&_P"R
MKVZ2*YUB*!W2$B&XC^;< Y7GD#H>><9%=%>^*-)TZ7;<SND8F6W>?RF,4<C8
M 5G V@Y(')X)P<4 7!I.FA(4&GVFV#_4CR5Q'W^7CC\*0Z1IA653IUIME.9!
MY"X<^IXYK./C'11J[Z6)YVO(YTMY(UM9#L=QE=QVX (Q\QXYZT_Q#XBCT%].
M1[>>5KZ[2W4QQ,X7.22<#K@' ZG\#0!HKIFGI+%*MC;"2(8C<0KE!Z XXHAT
MVPM[R6\ALK:.ZE_UDZ1*'?ZL!DUR,/BA-*\5>)AJ=Y=R65O':RPQB!I#"K([
M.=J+D*.,D^V373W&MV,$4,@>2?SHO.C6WB:5FCX^;"@G'(_.@#1JJVFV#WHO
M6LK9KL8Q.8E+C'3YL9HT[4;35M/@O[&=9[6==T<B]"/Z?2J3^)=+CO(+=YW7
M[1,;>&4Q-Y3RC/R!\;<\$=>2".M %YM.LGNQ=O9V[7(Z3&)2X_X%C-$&G65K
M,\UO9V\,K_?>.)59OJ0.:SH_%FCRO<HD\QDMKA+:6/[-+O61ONC;MR<]<CC'
M-1:AXRT33+F[MKBXF-Q:(KS11VTCLJMG#853D<')' []: -;489;C3;F" (9
M9(F1=[$+DC') /\ *LOPKX?CT+0["VEMK,7MO;K!)/ G,FT 9S@'G&<4EQXR
MT*WCLI#>-(M]$TUL8H7?S549.W:#D^W7VI\_BO2;:R%Y)+-]G$2322+;R$0H
MPR"^!\O'.#R!R>* -%M-L'O1>M96QNQC$YB7?QT^;&:5M/LFN6N6L[<W#+M,
MIB7<1C&,XSC%5+CQ!IULS@R22+&J/(\,32*@;[I)4'KU^G)P*=+KMC#=- S2
MLR3);NZ0LR)(^W:I8# /S+],C- $XTK3A9O9BPM1:R??@\E=C?5<8-5;^SU&
M"QMK;PZ=.LU1P'6: E%CP<[%0CG.#Z4SQ1KR>&O#UWJCP23&%?E1%)RQX&<=
M!GJ?ZU-<:[96T2NRW+,T9E\I+:0R! <%BF,@?4<]LT 6K"SCT^P@M(B2D2!=
MS=6/<GW)Y/N:L5S\_C70(([23[8TBWD#3V_DP2/YJ*,MMPO)&>G4>E(_C;0U
M%SB:Y=K:*.:9$LY69$<%@Q7;G& 23T'?K0!J#1]+"QJ--LPL1+1@0+A"3DD<
M<4C:-I;^9OTVS;S#N?,"G<?4\<U3MO%FC7=]9VD%R[M>(7MI/)<1387<0KD;
M20.<9SUJQ!KMC<744$32L9G>.*3R6\MV3.X!L8XVGZXXS0!:FL+.YM1:SVD$
MML,8A>,,@QTX/%+]AM!9FS^RP?92I4P>6-A!ZC;TQ3;V_MM.B22YDVAW$<:A
M2S.YZ*H')/7IZ&J#>)+%]/U&X@,KRV (GMS"XD1L9 *8S@CG.,8YS0 ^\T.!
MM+N;?3$@TZY>V-O%<0P+F)><  8X!)./>L2Q\(LT]N]]I?AZW-O(DBS6%J1*
MQ4@C!(&T''/WLC([YJ7P>]UJVGZ=KLNHWI:XLD-S;2QD1-(P#;DW#@#)'R\$
M5IOXHTE+L6[7#9-T++S!$QC$YZ1[L8SV^O'7B@"U_8NE>4T7]F6?ELVYD\A<
M%O4C'6KJJJ*%4 *!@ #@"L"[\:Z'927T<UQ.7L"!=!+65O*!&=S87A<<[NGO
M5Y=>TY]8BTI9F-W+!]HC41/M>/CY@^-I'([]Z +4UC:7$PFFM8))0A0.\8+!
M3U&3V/I40T;2Q''&--LPD;;D7R%PI]0,<&I+._M[\3&W9V$,K0N6C9?F4X(&
M0,X/&1Q5!_%&DQW8MVN&S]J%GY@B8QB<](RV,9[?7CKQ0!>;3;![];][*V:\
M086X,2F0#T#8S5JN<OO'7A_3Y+N.XNIMUFX2Y"6LK>5D9RV%X7!'S=.:GN_%
M^B6=PEN]T\DSVWVJ-(('E,D9( *;0=W4=,\9/0&@#4NK"SOE5;RT@N%4Y431
MAP/IFI&MX'MS;M#&T!7:8RH*E?3'3%<AKOB)+_1M!U30]2?[-<ZM;0N8QCS$
M:0*RL",CTQQ6S!J%D?$NHQ#4K@S6]M&TUM(-L4*Y;#@D#D\Y.3TH NKH^EI9
M"R33;-;0-N$ @4(#Z[<8S3WTVPE\GS+*V?R>(MT2GR_]WCC\*I0>)M*N+M+4
M7#1R20&XB\Z)HQ)&.K*6 ! R/PYZ4EGXBTW59H[2UN)DEN;<W%NS0LGF1\#>
MA88.,C\P<8H N'2--(E!TZTQ-_K?W*_/_O<<_C2C2M.5XW%A:AXUVQL(5R@]
M!QP*X[P=XVLCH&D6^KZA,^H73O%Y\L+;'D\Q@J&0#8&P!\N?3VK2TK4IHO%W
MBN.^OG:RLTMI(_-("PJR,S= ...I]* -S^Q=*\GR?[,L_*W;]GD+MW>N,=:=
M)I.FRO*\FGVCO,H25FA4EU&,!N.0,#KZ5!::_87NI-IR/+'>"(3"&>%XV:/.
M-R[@,C/'MWK,\0:W=)XATGPYIT@ANK\/+-<;0Q@A0<E0>-Q/ SD#G@T ;[V-
MI)/Y[VL#3>68O,,8+;#U7/I[5&-+T];-[-;&U%J_WH!"NQOJN,&J3Z;J-O=V
M4EKJEQ+ LO\ I,,^QO,0J1D' (()!]..E+)XGTJ*5%>X81O/]F%QY3>5YN<;
M-^-N<C'7&>.O% %W^S-/^Q_8_L-M]ESGR?*79G_=QBA=,L$GCG2QMEEC&U)!
M$H91Z XX%9=WXPT:RGOX)9KAI; *URD=K*YC!!.X@+]W )STZ<\U);^*]'NK
M^VLX;EV>Z0R6\GDN(Y@!N(1\;6(') - &RRAE*L 5(P0>]4%T'1TD$BZ38JX
M.=PMT!S]<5DMX_\ #:%=U]($,YMVE-M($CD!V[7;;A.>.<5>OO%&DZ=-<1W-
MPP^S&-;AUB9DA+_=WL!@9R/ID$X% &G<VMO>6[6]U!%/"WWHY4#*?J#Q4:Z?
M9)YNRSMU\U!')B)1O4# 4\<@#C%9M[XKTFPOKBQFEG:[MXA,\,5M)(VPDC<
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M-XI\-:JNG>&IM)OY;(P>9>(J22'<K>4I!)*'!R3@<CWQZ#/<06L?F7$T<29
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MC1P^[8N!T Z<>W7BL6VTZ_C\%>'[1M/NA<VVK)/-%Y1RD8G9RW_?)'2O1J*
M.!MI3)<>-[)+.>XDN;DQQJL9*N6@0;2W1>V=V.M/AT6\L/$_A>#RYY(;'1Y;
M.:Z1"560B,+S_P  /TXS75:=HT&F7=[<PRS.][)YLPD((+8 R, 8X 'X5HT
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MT@NOL<=G>17$+20S!,[7 # AAD]^_P"8 X^-7=M/@:U33KR]LS<1P:DQBWR
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MB&\OHHH8GM\D6PB;>A!.-QWG<>G8=LE_]B^(K[0K^RU;5;.:>XM'M8S! T:
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MOFBB9#Y@;T5D.WZLM '1:3=SW^F07<\*Q-,N]44D_*?NDY Y(P<=LXJ[0
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MRC%Y V9#@@L%PHQTZYSD8AM;RZO_ !3'X>N]1DE2VTI+AY[<F$W,I<H7^4Y
M&WH#C+<YP* .QHKS,:SK<UCIT$FISI+!XE;2I)T50;F)=V&;CKP!QQD'(-6'
MCU$W7C#3QKNI"'38H[BV82CS%9XBQ!;&2H*\#IR: /1**\]@O-4UK5O#4+ZO
M=VT6HZ&;JX6WVK\^(CE3MX/S'UQVQ573M>UB(PZ%=79N&&MSZ>+R63RFFB2+
MS%4NJG#$D+D#)P1P3F@#TRBO/-9_X2'1M'D6362I.JVPMQ%+YLD<,DBJ4=F4
M%AUP>O8DU9\W6;76O$VD6.IRSRBPAN+1KQP?+F<NI ., $J,#& >U '=4$@
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MR)*[6=N2CRX"@,9 1L52>?4D=>E<]8ZKK=SX/T6^,=QJ.UYA>PV\NRXD169
MRD8W8P,@8SQ0!W]%97AR]@U#0;:ZMKJ6YB?=B288DX8C##U'0_2M6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J.KZ/8:[8-9:C )H"P<#<5*L.0RL,$$>HJ]3)98X(FEED6.-!E
MG<X 'J30!D6WA32+:XN+CR99YKF 6\[7-Q)+YL8SPVYB#U/6IM/\/:=IKP-
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MCO/[<.JVD<[JT<R\81L$XR 1^(H ZS2O$5KJNHWNGK%-;WMGM,L,NTG:PRK
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M[#J,]N-<N+4W9/F+"#-L0,S-N(Z#(!QWJW8>&-0T#5/#36D2WEO8Z;)8SN9
MA5B4;?@]1\IX'M5*;P]K4G@_5M.&GM]INM9:]C4RQX\LW"R\G=UP,8]: .FU
M;Q99:0EY(\%Q/%8X^UR0["(<@-R"P)PI!.T'@U#-XSLTU-["VT_4;V988K@&
MVA#!HI#@."6' QS^F:RSIFMZ9XDU*6VT.SU2QU.5;A9)IDC>UDV*K!\@EE^4
M'Y<]ZT;#3;^#QU<W\MM_HDFG0VHF4J 71G8G;G(!W<?2@#HYYA;V\DQ1W"*6
M*H,DX]!7+VGQ!TR[;2W-EJ,-IJ;+';7DT($1D;HA.[()^F/>NHN/^/:7_</\
MJ\X\-:==^(/A]X4L6M&AMX'@N9+AG4J4C.X!0#NR2 .0,<\],@'67GBZQLX+
MJ[-O=2V%G,8;F[B52D3 @-D;MQ"DX) ..?0XFN/$=M%<7,,%O<7?V5$>=K?8
M0@?E3@L">.> >*YR/P]J]IX>U_PTEJ)H+^2X-K>^8NR-)LD^8"=VY2S= <\=
M*;K/A.ZE9?[-LY[;4K***'3]6@G5,HJJ"LR[LLN0>,'(Z>X!O:;X@N;[Q=J^
MDMI\L<%BL($NY""6#-N/S9P0%  !Z<XS6KJ&HP:9;K-.2=[K'&BXW.[' 49P
M/SX')/%8$.BWH\6Z\]Q;[]-U6"!3/'.8V38C*PP/F!.1@@CZYJKK?@PPZ/%_
M8 >6[MKR.\2&^NI)4F* J4)<G:"K'\<4 6[CQYIMI9ZK-<6UXDNEE!<VX5&<
M*_W&!#%2I^O'?%3MXNB75I=+_LG4S>"'[1!'Y:#[1'G!926PN#C._:>161K.
MFZUKG@S5+5=!M]/NKI$CBM4FC8Y#9+.XP,>@&?UXTY+*_?Q[:ZN+&3[(FF26
MS$NFX.SHX&-WHI&?7\Z $_X3G3#IFF7PMKYDU&=K:-%ARZ2KN!1AGKE&'&>E
M9^K^)H-;\'^*888[_3M1TVTD:6"8^5+&?++(P*,<@X['M6++9:AHVE^%[>ZL
MF%ROB2241"1#O5Q.XP<XSAN^.1^-;>I>']0OX_%5^MH4N=4T\6-M;LZ;@ K#
M<Y!VC+/V)X7U.* -BSUF.WLM+LEBGN[Z6Q6?R8BN[8 H+$L0!R0.N2?H<0MX
MVTT6%I>+;W;Q3WGV%\(H-O/NV[)06&WGC/(_,9H6^D:KINOZ7K<5F\Z_V4NG
M7=JLB"2,J=RNI+!2,Y!&1P0>>E20>%H3X:U^VU5TA&KW,]Y)\P_T?<!M.>F5
M"*Q/J#VH U=6\36VCKJ#SVMW)'86RW,SPJK#:=V /F!S\I/T^HJK_P )C;_V
MC%8G2]3$US 9[0&)<7 &,A?FX(W#[^T5EKI.K7WPQO89U%QK6K6A,I!" NR!
M5SNQC"A<^^:N/INHOXE\-7WV%Q!8V<\,Y,B95G$8&!NY^X<_44 7K3Q987FE
MI>+%<1R/<M9BUD"B43*3N0\[<@*3G.,#.:J2^/=,@LKV>:VO%>RN8[:Y@"*S
MQLY 0_*Q!4[A@@FL%_#.NK8RW4%C"U[;:[/J4-K<2+LN(9-P*$@D*VUN_ -:
M&L:;K.L>%I84T."RN);FW=;6.:,E5CE5V9G& 20" !GMSR< &HWB^(?VM$-,
MODO-/MA=?9Y@B&:,YPRG<1CY3G."/3/%7O#>I3ZQX<T_4+FW:&6XMXY&!VX8
ML@)9<$\<\9P?:L:[T?4;WQ5JMT+4QVUWHPLDD=UXDW.>0"3CYQS[&M7PI;WU
MGX7TVSU"U%O<6MO' 4$@?.Q N<CCD@_A0!7U/Q;;Z;K3:.NG:C=WWV4W21VT
M(;>@8+P2P&<GO@<=<D QV7C?3=2L-.N;&&[FDOY9((K;RPLB.@)=7W$!2H4Y
MR?3&<UG7L\UO\7H&ALY;K.A.&6)D# >>O/S$#]>]4X?#NO:8EH8;9;BWO-3N
MK[5+**X$>/-.8UW'&Y5_B'?T(XH VV\<Z>NE6>H_8[XP7-Y]A;Y$!@FWF/$F
M6P!N&,@D>_(JUK'BFUT1=1>>TO)8]/M5NIWA56 4EL 98'/RL?H/<5@Z-X7D
M3P3K6@Z];V]G;3W%TZ-',&"H[LZN.!C;P1WXZ"FQZ/K&H?"J^AG476N:O9GS
M2"$!9HPBYW8QA0N??/'- &O_ ,)K;_VE#8'2=4$]S;FXM 8DQ<@8W!?F^4C<
M/O[1[U-9^,-/O=*CO5AN8Y7NGLQ:2!5E$Z$[D/S;<@*QSNQ@=:H/IFIOXH\,
M7_V"006%E/#<$R1Y5I!&!@;N<;#GZBL%O"VOI927EOI\+WUKKUQJ4-I<RILN
M89=P*$@D*V&[\ B@#H9?B#I4%C>7$UM>K)97<=I<P"-6>)W("$[6(*G<,$$U
M+)XSB5-9C&E7R7NF6PNC;3A$,T9#893N(Q\ISG!&.F>*R]:TO6]9\+/$FA06
M5Q+=VT@M(IHR56.579G<8!)P0 ,]N>3BQ>Z)J5]XIUNZ%J8[:^T46,4KR)Q(
M#(>0"3CYQS[&@"[I/BIKG2-$:YL9SJ.I6HG2!#&"X5$9W7+XQEQ@$YYZ<&MZ
MPNQ?V$%VL4L0F0.(Y1AUSV8=C7#GP[=:CX8T#3-:\/._V*U\HRVMVBW%M*BQ
MJKH^Y<9P_0GHN?0=7X;M=2LO#EC;:O<FYOXX]LLI.2QSQD]SC )[D9H JZKX
MML])>_\ ,MKN:/3XTDNY(E7;$KYQU8%N!D[0>/RI;SQ5!;:R^DQ:??W=X+47
M2K!&N'3=MX+,!USUQT]<5SWBO0_$&M'Q#9_8H[NVN;55TYWN J0G;\P*'^,M
MG#>G&16G:6.J+XSBU:?3F6 :0+5MDR,1()-^.H[<9]?;F@"_;^*]/O-,TR\M
M4GF;4L_9K=5 D8@$MD$@#;@Y)./KD9S/!-S+<:GXH\T72"/4MJQ7,A=HQY29
M&<GC.<8..:QM+\-Z_I%GX9OH[ 376E&YAN;/ST!DCF;.Y&SMR,#@D9YKH_"]
MAJ=KJVOW5]9K;Q7UVL\(\X.V/+1<$#I]WU_/K0!6\:W+V6I^&+A&NB#J6QXH
M&8^8OE2'&P'!.0.O3VJ[9>,].NH+]IH+NRN+"1(Y[2YC"RAG.(\ $@[B<#!H
M\4Z=>WD^B7=E!]H.GWXN9(0X5G38ZG;NP,_,#R1]:QM8\)ZCK']L:I$L5M?S
MM:M:6\Y#*/L[;P)-N1\Q)& 2 ,<]: -.Y\=:=9+J8NK6\BGTZ 7,L&$=FB.?
MG4JQ4C(P>1BK=GXIM;O5UTZ2TO+5Y+8W4,EPBJDL8(#$?,2,;APP%8E_8ZYK
M7A+5K9O#MMIMS<VCV\<$<\;L[M_$6& %'XDYZ#',]WHM_?Z_I4SVDD=K'I<]
MG._F)E&D"#@;N<;3^8H T(O&&GR7VGVS0W$::CG['.P39,0-P'#;E)'(W 9^
MM<TDXU[_ (22ZU:WU:&/3;YA&]K.J/%''&A,8VOU.6)['/7@8TO"MCKUC#9Z
M9J.AV$0L5$9U..16\]5&%*IC<&/&<X[GVIVGZ7JD-AXLBET]U?4KF::V'FQG
M<'C5 #\W!RN?I0 Z/Q*;63PG8Z;IUW-9ZE;&1'DD0R>6L6X*=S<MRI))[<9)
MK9MO$$-W=)%;VMS)"US):_:%V%%DCW;@1NW 90C..N.Q!KGH=$UBVB\%3)9*
M\NDV[6UU$TRKM+0JFX'D$97MS@]*6/P[>KXHAU6RLI=+N6O'-\\<ZFWNX/FP
M2@8GS"-O.T8.>: .RN;B*TM9KF9ML4*-(Y SA0,G@5CV7BNSN[M+:6VNK1I+
M+[?&9U7#P@@$_*QP1D9!P>:TM56]?2+Q--=$OF@<6[O]U9-IVD^V<5Q6GZ+K
ML6O6.JG2(XY!I<MK<--=B1VE)1@SG^($J0.>G]V@#J],UQ-3>#R[.YCBN+?[
M1#,^PHZ?+W5C@_,#@TOB'7K7PUH\NIWL<[V\;*K>2@8C<P4=2.,D5@^&O#US
MI.N_:+*UGTO3);=OM.GO.LD0G+*0T0!.T8WYZ9RO'H[XHEA\.M3*@%MT& 3C
M)\Y* +=MXULIM5N=,ET_4K6[AMS=11W$ 4W,0."T?)_(X/MUJ*Q\>Z??::FH
MBPU*&REBC>":6$!9VD;:L:88Y?=@8Z=\XYIMYI=[JOB2VUJ2PDMUL+&>&*%I
M(S)-)+MST8@* O<CEO;G)3PIK$GPTT+35B2#5]&EM[B.*20%)7A.=NY<\,,\
M^N* .F3Q/ ;^ZTZ6QO(=0M[?[4+5PA>:+.-R$,5.#P1D'/U%2V?B&VO]-TV^
MMX)WBU!@L*_+N'!.6^;C 4YZGBJ%OI=UJ/C&V\075I)9):V+VT<,KHSN[L"Q
M.PD;0% '.22>!CEWA_0+C2=4O_,=3IZ3.^GH.L8EPT@/L&&![$^M "Z?K>E6
M]KK5ZHNXD@OFCG$Y+%IL(,(,G@Y4 #')Z50BU&0?$B0W*7=I FC-*\=Q*"@Q
M*OS@!BHX&#TZ54N?#6L7.G:T(H%ANGUA=3LQ)(NV0+LPK8)QG8?S%6+K2=6U
MW7)KBYTXV-M<Z-+8.7G1WC=VSG"YR/Q_*@#9@\4V4NIVEC)#/ U[&TEK)+MV
MRA1DCAB5..<,!_2L/Q#K7V__ (1VXLX[U+6;5X%2Y5]L<R;CU4-D@XR-P[>X
MS8T?3]:GL1INIZ/961C@:&2^AD5S-\I4%% RN<Y.?3'?C/CTGQ'_ &%H.DRZ
M7&9-)O;=FG%RHCEBBR RC[P.,9! _&@#T G )KC[3Q3I&EZ/<7T=OJ9@;57M
MI5D!D=9FD"G@L<+N/ 'X"NOYQG'/H*\\?P]K3>'KRT&G-YTNO_V@J^='CRO/
M$G7=UP,8]: .MTKQ!#JFI7NGFTN[2[M CO'<JH+(^=KKM8\':?0CN*A\7ZY/
MX>\.S:A;VK7$@=(P 5 0NP4,<D9Y(X'\LD0V5A?)X\U'4Y+5DL[BRA@20NI.
MY&<G(!S_ !C\C4GC32[O6?"EW96**]RS1.B,VT-LD5\9[9"F@#&N-2N+3XC^
M8+349O,T7S/L*.&(?S@,@%]BG ZY&?K5VZ\1:1J>F^'M09+\P7U[$+8Q$H4E
MY $F&' (;(Y''>G16FJ-XZ369=.9+?\ LHVQ"S(Q$GF;\=1VXSZ^W-8EIX=U
MJ#PGX9T]]//VC3]56ZG ECP(P[MD'=R<../8_B =:/$$,EW+#!:W,T<-TMI+
M-'L*I(<=1NW8&X<XK7KB+SP[>S^)$U6QLI=.U%;U?.NX9U$-U;!N1*F[);;D
M#Y>N#D=NUD9DB9EC:1@,A%(!;V&2!0!Q7C37=1TR^M;ZR<_V=I$T<NIJO.])
M,IC_ ("IWD>ZFNHU/5[32M/%[.Q:-W2.,1\F1W(557W)(]JQ;3PU!J&C73:U
M8R_;;TR/=1BX)#%N HPVT@+M49[*,U@-9ZQ!\.+/1-6L5?4XKB&"TS<JK2[7
MW*R,,XD5%)YX^7)R,B@#IW\7VL5QJ=O+8WZ3:;")[A/+5L(02""&(.0#^1I+
M3QC:7=K'<?8-0ACF$1MFFC51<F12P"'=C( .<X  SG'-8D2:A*-:M[K0+R'5
M=4L71)Y;J"02!%VA?D("@>9GISD\YP*FO]!U>7PAX=%K:PMJ>C&%S:7#KLFV
MQF-TW#(&0QP?I0!KV_C#39TO5=)H;JSG2WEM7VER[_< (8J0V>#G'7.,&JUS
MX\TVSM-6FN+6\272@C7-N%1GVO\ =92&*D'Z\=\50U31]:UG0EN(=)L=.OK:
MZBNH+%W5UE*9RLCJ,?,&('7&!SSPFL:;K6N>"]6M1H%OIUU=0B&*V2:-F)SD
MLSC QZ 9/] #7;Q=$NK/IG]E:F;LP&>W3RD'VA 0"5);"X)'W]O6I;3Q987N
MDVE]#'/NNI7@CMF"K+YB%MZG)VC&ULG...O(JM+97\GCG3]6%C(+6+3I;=R9
M$R'=D8#&[_9(_&N<C\,Z];:997<.G0S7MAJ=U<_8KB5-MQ#,S$@-R P##KW%
M '0'Q[I:6;3O;WH>.^6PFA$89XI6( SM8@@Y!!4G/;GBEN/&:1Z?KLB:7>+>
M:1!Y\EK/L4LA4LK@AB-ORGOG@\9XJEJNFZQJ>C6>W1H;69=2MKDVL,J$I'&X
M8EFX!8X. ..G-+?Z%J=]JOBMEMO+AU32DM+>1Y%QO"R#D D@?./R- '2Z)>S
M:CHMG=W$#PRRPH[*VWDE0<C:3P?SJ_6#I$FL6UAHMI-I*(OE^5=-]I4F *@P
M< ?-N88X/ YK>H J:C8_VC;+;FXG@3S%9V@D:-V .=NY2" >^.U<3I6F-J7B
MOQ=ICZGJR0VAMEM2NHSYAWQ;B1\_///.:]!KEM TW4+3QEXEU"YLVBM=1>W:
M!S(A/[N/:<@'(R>G]* +&J>+;'1X;F2:*XG@LF5+N>$(1$2 3D%@QP&!.T'&
M?K39?&-JNK3Z=;Z=J5W-"L+L;>$,NR0D!P=PRHQSW],X.,I=*UO2?$.J+;Z)
M8ZG8ZC<?:8KF:54:V=E 97!!++D9&W_]6EIFG7]KXVU2_EM3]DN+2WACE#(,
MM'OS\H.0#N&/I0!"_C[3TLY+UM/U(6<-X;.XG\E=L#A]F6&[)&XX^4'WQ6C:
M>)8;O5+K37L+ZWNH8!<JDR*#-$21N3#'N,8.#STKEKCP]K,O@O7--73V^U7F
MK/=Q*98\>6TXEY.[@X&,>M;QLK__ (3[^V/L,GV/^ROLV?,3=YGF;\8W>G&?
M7VYH JZ9XJTC3_#FAR6MOJ;VFH2&"UW@RR;LL<.2Q/.UNYJ]%XQL6L-0N9[2
M]MI;"=+>>UD13+O?;L VL5(;>N#G'/.*YW3_  [K-MX<\(V4FGGSM+O_ #[D
M"5,! )!P=W/WQ^1JQ>:5XDCN_$]SIML8WOKJVEB_?HC21(B)(H8'Y&(4X/OV
M- &IJ7C%;32-?GAT^X-[H\8>6VE*#@IN5MP8@KCT.>#Q0^K6TU_X:74+6_BO
M;IG-OM<"/<(F+;]KX((S@<]NE8C>%]6F3QA#'IMO:0ZQ8HEO^_#8D$;+AL#J
M2<D_J:TIM/U>ZOO"5R^FF/\ L^1VN5$Z-L!A:,=QDY.>.WY4 :5WXNL;.WN;
MMH+J33[68P7%Y&JF.-@<-D;MQ"DX) ..?0TV[\76]OJ=UIT.G:A>7-O;K<E;
M>-2'C8D J2P'\)ZXSVS6''X=U>U\-:YX76U$L%[+/]EO?,78D<Q).\$[MREF
MZ @\=*OV>C7NG>*KNYCLY)+(:3#90OYB;G:,N>A/<,.?K0!T>EZE;:QI5KJ5
MHQ:WN8EEC+#!P1GD>M6ZP?!>G7>D>#M,TZ^A\JYMH1$Z[@PR.X(/2MZ@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBL;Q+J\FB:=%=JC^29U2XF6(R>1&0<OM') ( ]LYYQB@"_=
M:E9V4UO#<W,<4MR_EPHQY=O0"K) (((R#U!KA=:OIM1L/#-U#=6=VSZVODS0
MY$;+MEVDC).<=1GKGI5Z'7=82+7[64V$M[IDT2K.088BCJK;F!8XV@G^+G%
M%X>&_#6B*]_]CM[6&']Z2SD11GKN"$[1SZ"M$:UII>Q07D6^_7=:KGF4;=V0
M/3'-<W_;=QJ-IXKT^<K(EE:!HI1"T1=9(F/*GT*GGN#5.+_4?#C_ '5_])&H
M [ZBFR!S&PB*K)CY2PR ?<9&:X'3/%NO3Z7X:U:[_L_[-JEX+26WBB<,I8N
MX8MQ@J/EP?K0!Z!17&S>)M3N=%UK6M-%L;?2YYHUMY4),ZP_ZP[@?E)PVW@]
M!G.>&:?JE]JGC^WDANU&G3:+'>10/#R!(_/.[[WRCG\,=Z .LO[^TTRRDO+Z
MXCM[>(9>21L "IXY$FB26-MR.H93Z@]*P?'7_(@^(/\ L'S_ /H!K'MM<UG1
M;_0X-3^Q2Z7J,)CC,$;+);NL6\ DDAP0IYP.>U '<45QVG>(-?U(Z-J%OIXE
MTZ_*M,GEA3!$XRKA]_S8XR-O.>,5T^IS36^EW4]L8_.BB9T\Q25R!GD C^=
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M,K2>0\149&UL,#NR!G/O18>*-9FL+NWO%L(;^PU,65W<9(B\L@,)$4G)8@J
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MA@ V 01D'(-%-1%CC6.,!5484>@K@=0\8:UIVBZW)+]B.HZ5?"-H5MW(EMR
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MSG(7S,;BH/(&>PZUT-[;M=V,]LLGEF6-DW[<[<C&<5G66O+-K4FC7ELUK?K
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MS2=3%UY1TYI&2/R\ARZ[3DY]#Q[^M9VG^#GTR^G%KK%TFD33FX.F[$VAR=Q
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M!B.A;YCG\,#VK*7P7%'97NE1WKKHUY,TTEH8P67<=SHKYX1CG(P3R<$5U%%
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MMG"9+.]*6FJ6\> 78G$4HS_$"=I]C^-;%S<Q^$?#6I:[J$:R797[3=>7_&^
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MME;_ )8Q*,G;Z;CR?7 K7UZXLO#,-[X@2W#7<ZPVY4';YS[]L>X^Q<Y/I]*
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MN&3DY_SFLO\ X5=$WP_C\*OJSE8;G[3#<B  JV2<%=W/4]QVKM[VXN+?[/\
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MPS5C2-375]#LM4CB9%N[=)UC)!(#*#C/KS4&@:VFO6$MTEO);^7<2VYCD(+
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MYU&VN+.*Q6S>*XL]Z.%X#XW\''7UKJ:* *>EZ=%I6CV>FQ.[Q6L"0*SG+$*
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M.B?3V8N;=\LH8G)(R>#DDY'<TY?"^B)HC:,--@_L]SEH"N0Q]23SG@<YSP*
M,+1K.*R^)VMQQ-(4;3;9@))&?;\\@P,DX'&<>YIWB.&6Y\=:!8B_O8+6[MKO
MSXX+AHP^P1XZ'@_,>1@^];MAX<TC3+PWEI8QI=&,1&8DLY4= 6))[UE:YHMS
MJ7C+0KW[+(]G917"R2I,(V5I FTKA@W&TYQZ]Z .6@U34=*$FC3:C*]@GB#[
M E[<RL6$1A,BQF0'/W]JYSGG%6O$=GJ6B^&]:VZ[-G[3:RV\4,K[K4/*J,NY
MF)96Y(4\#FNWFT'2KC27TJ>QAEL9"2\+C(8DY+$GDMGG/7/-5D\):%'HYTE-
M.B6Q+B1H06PS#&"QSECP.N>@]* ,/5[)]$U?PU':ZAJ+)<ZLWFK-=NX8-$YV
MG)Y&5! [51:[N=7\->+-4>]N;;4=-NKI8#',RBW$(R@VYVD$ $Y!SN/MCMKK
M1[&]DM)+F$R/:-O@9I&RC8QN!SUQWJ*;P]I5Q>2W<EFIEFV^=AF"S;>F]0=K
MX_V@: .9T74KCQ-X@GL]5::V,&EVDZVT4K19>52TC_*03M.U1Z?4U=^&@V_#
MS21DG"R#)ZG]XU;5_P"']*U.]AO+RR22YA4JDN2K;3U4D$97V.14VF:58Z-9
M+9Z=:QVUNI)$<8P,GJ: .$>]NM4\(>)]::^N;;4].N;KR=DS*(/)Y1"F=I!
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MT\:U?SM<:JOE6ROER"I;[/YA.53 W$DYQQSD \]=7FHKX+\1C[=<PS6.NK!
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MPBANWC"N7D&1M((^Z.!P>^:Z!O"VBM9SVC60-O/-]HEC,CD/)G.X\\G.#GU
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MYA;:Z-;HH(;&"201@'.>U5[%0;GX<!XF_P!'LG67=&?W3>0J@-Q\IW#'/<4
M=>/%GA\P6\W]LV7EW#^7$WG#YFSC'Y\5;O\ 6-.TL9OKR&W&-Q\QL87IN/H/
M<\5YM?0A_!7C^..W<S7.I2M"JQ'=*"(]I48RPR&P1[UHWUW:6GBC4TURWU*3
M3=6MH1:S6JS.C@(5>)A'SG)) (_B- 'HBLKH&5@RL,@@Y!%5KW4K+3O)^VW<
M-OYSB.+S7"[W/11GJ?:LO3-2T[3I].\.1V]Q:R_8U>"%U9U1!D!#(<@L IXR
M>E/\6Z3)K/AJ[M;<[;Q )[5^ZS(0R'_OH ?C0!>CU?3I;BZMX[V!IK09N(U<
M%HA_M#M^-4_[5M9]8M3!KEH8&M7F-HNUFE7Y<2ALY"@9[8.:Y!(-9NM7L]66
MUEAC\2VWV:\@Q@VJJ R,3_>\OS>O0L!6W>JJ?$W1BD9$<>G7$994.U26C*J3
MT!(4X'M0!4U3QJ+SPM_:VA74:[+^.W<.FYBAG$6<'[N1DC(KJM/UC3=5>=-/
MOK>Y:W8+*(I VPGIG'K7FL@;_A6TNERVMS]IAUC][$UN_(^V;^./F&SDXR,5
MU=B5_P"%GZE)&#Y,FEVZAPIV,RO(2 >A(!'X&@#I[J[M[*(2W,R1(2%!8XR3
MT ]3["JC:_I":>;]]2M5M%?RS*TH"A^FT_[6>W6L3Q0;BT\4>&M5=)'TRVDG
M2Y**6\II$VI(0.PY!/;=7+^)+&672_&]];Q2/9:B]HMM&D9/G2)M\QU7&2#Q
MR.NTF@#TFQU.QU1)GL+N&Y6&0Q2&)PP5QU4X[\BH'\0:/''=2/J=JJ6C;+EC
M* (3Z-_=_&KMNL B#VZHL;X;*# /'7\@*XS6]'NF\67-K! S:?XBL_)O74<1
M-'P6/H6C8J/<"@#K&U6P0Q!KR!3-&98]S@;D R6'L..:Q%\4V.E:1I37NKPZ
MC)?3^3'=1*$23YCEN,@  >O./>H/!<>H)IYEUI"DVG(VGH[_ /+18V.Z4>S@
M)_WQ7,:<DEOX#\&2/;7 6RU</<*('+Q+F89*@9'WE[=Q0!TUOXLCL_$NOP:S
MJEI#86WV8VK/B, 2(S'G//0<_P JZ6YU*RLXXWN+F-%DYCYR7XSP!R>.>*X:
M;RY=8\>RM"_[_3X4B+1',G[EPRKQR<D @=\4S0YIM,UGP_J%^LBZ?+X?BLUF
M93B"X4AG5_[I( Y..5Q0!W UG3#':2#4+8I>,%MF$HQ,3V4]S["JNJ>*-)TK
M3=1O9;N-QIZ_OXXVW.K8R%('()[?G7"RV%QINEP:A)!.M@/%9OT01,3#;'<N
M[:!D L=V,=&IVI";4XOB*+6SNV^U6D+6^ZW=?-Q!@XR.OMU]J /2+*\AO[..
MY@=7CD&05.1[C-0'6],%Z+,WT'VAI/*";^KXSLSTW8YV]:=I-U'>:5;3Q"0(
MT:X\R-D)X]& ->;7UVTYMF%C>6S6OB5)9K.&S<JB^8<RLVTEF;.?E./FP!QF
M@#LO&'B&/1O#VJ2VU_;PZA;VS2HKC?@X)4$=MQ&!GK[UH:=K-I<?9;.2]A.H
MR6R3-!N&_! RVWTR>M<#>74EKH/CO2-1MKG^T;M[JXMO]'=Q/$\8$94@$?*
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MI.,#!SW[5?T^6*7Q[IEX\;K&N@%/,EB9=K^8IP21P=H)QUQ0!U_]K:>=/BU
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M-=,TR;3!X)M[V"0+%?W<PC>,G[/$ZR>4&X^7[R]>AX[5ZBB)&BHBJJ*,!5&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:SFBAN LH#IY@4A@G=0'!)R.AQG% &W17/7GBI((=2NK:QEN[33',=W)&X#
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M;\WBV."S\03M92$Z(?WZ!Q\X\L294_[IZ'% &SJED=2TJZL?-\H7,31,X7)
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MLH5P'Y!5?X@ <D\>V36-J]Q875SXNM5L)8;Z'2U::X9^)5VR%-H!XP0?0\T
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MXC8&R *P^5Y0 /(7&/Y5/10!YW%X9\3Q^'=)T)HM/D32KZ"6*Z-PR^=%$^X
MKL.TXX/)_&K6J>&]=E;Q9;6<5D]OKD.4FDG8-$_DB,J5V\Y('.1C/?&#W5%
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MXK6*02%F1XV9@2N.F6'?M7<51M-7LK[4;VPMY2US9%!<(49=FX$KR1SD ]*
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MP.8PBNVS;T4^G2MN;P9921VAAO+RWN[:[>\%W$R>8\K@ARV5*G(.,8X  &*
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MHKZ&0+.)F)+N3C!W9.1C'MP*?/X1ANK&TMYM3U!Y;>[2\-PSH9)94QM+94C
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MRGV@H8MC$E3R,-DC@YK2C\/6[S2SZA+)J$\MN;4O.% $3?>4!0 -W&3U.!V
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ML()8X E:,J5QCJX'TZ4 ;5WJVNW]QK%KH^_[5IK)#&52+RY93&KGS [;@IW
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M^RM.\NXC^P6NRY $Z^2N)<# W#'S<<<U8CABBA6&.-$B5=JHJ@*!Z >E/HH
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M9O4C')]ZL165I!<-<16T,<S(L;2)& Q5>BD^@R<"IZ* "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K NM2NKOQ++H=E.MLT-D+IYB@9B6
M8JJ@'C VDGZC&*WZP-9\+KJ>KV^KVFHW>FZC#$8#/;;3YD1.=C*P(//(XX-
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M+&8X 53YP4V'?Q_=],4 94'B75(]:T:">>"87UW/;7$<,9,,6U79-DG&YAL
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M/H\;:Y:I;WZLRNL; JP!^5A@G&1@XSQ6I573[(6%HL'G2SODL\TQ!>1CU)P
M/P   P!P*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 50UC6+/0M,EU"^<K#'@84;F=B<!5'<DD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K'UO4]3LC'#I&C_P!I73*797N!!&BCU<@\D] !V.<5L5DZ[KUIHD,:
MRSVZ75P2EO'-*(PQ[DD]%'4G\!DD @$?A;Q%'XGT?[:+66TFCF>WN+:4@M#*
MAPRY'!Y[UM5A^%8M-MM*:WTZ_AOBLSR75Q"P8/.YWN3@D DMG&> 16Y0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %4;[1=*U.59+_3+*[D4;5:
M>!9"!Z D=*** )K.PL].@\BQM(+6'.[RX(PBY]<"K%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex109keyexecutivebenefit003.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]TBQU*WAN'BO9!'"@"[\G/4;N,8.>XP:V*Y/0]'>U\4ZFJ2JVF6\QFMX@/\
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M)J<^H2V5OJ4R$Q2NTJ1^7&<*V<@#)[\5MOXCFB\4Z?HL&G7$L$U@USYN]"2
MR*/O,#QN.<\\C&>:Q9]"UB7PUXTLAISB?5;J:2U!ECPRO&J@D[N.5)YK3.G:
MI'XKT75([$O"FG/9S@RJ#"Q:-LGDY'RD?+F@"]:^*[.[T:[U)+6[5+2=K>2%
ME42^8&"E0-W7)'?GM6ZI+*"5*DC.#U%<>=%D'Q"E:WF7^SIXH[Z\@Q_RW0E(
MS[!L;OK"*[&@#G+7Q-)+XHUG39[*2"TTV&)VN7=-HW!V+-\V0I"C'!/!SBIX
M?%-E)<Z?'+!=6\>H_P#'G/,BA)CC<!P25)'(# 9^O%8]]X=U"]USQ1 8=MCK
M=A' MV)!^Z94D4@KU)RP/IC/-(FD:KJ^G^&['4; VCZ5=0W%Q/YJ,DAB4@>7
M@D_,2#R!@9H [6LNVUV"[N(DAM[AX99I(%N %,>]-VX'YMPY1ADC^8K4KB[7
M0KZ'Q##J5A:3:9))<2'4$$RM;7*8;#[ Q.\G:<X'\6?< V+3Q58WES911PW*
MQWYD6UF95"2E,D@<Y' )&0,XK*_X29+_ ,/:_<:G8WUM9VLTUNY@9?,"IA3@
MJV0V<G/3W-4+32?$4E_X?OK[3-][9W,IO)WND.\,C*&0#HG(^48/MWJ>31=8
M'AOQ7I2V&][ZXN9+:03)B02G*\$\8R<YQ[9H Z&77;:T40Q6]U<O%:+<ND>T
MNL9R 3N8$D[3TR>/<9RM;U">X\5:5I!M+M[*>WFED$4BIYA 0 YW@X7<<].<
M8SBJ^MZ%<ZE' ZZ;=0W]O9(+2^M;A$DBEYRC_-RGW3W')J[)8ZJ?%>B7LUL9
MDM;*6&YG1D ,C[.0I(.,J>W>@!^G:]8V4-G8AM0G@-RVGQ7MP5;S)5S\I.=Q
MY5ADKCCKWJW=^)[*S\V1H;F2VAN%MIKF) R1R$@8/.XX) ) .#]#CF;C2?$5
MV]E-=:8)[RTU<7#3FY0*\(+;1&O\("E<C@G&>36AI5MXAT6]U#38M/CGL[F[
MDN;>^\]0(A(VY@Z'YB02<8Z^HH OVOB5I-;UNVNK1[:TTQ4+SNR;0"A<L<-G
M!&,8!Z<XZ59B\1VK7EI;3V]U;->H7M6F08FP,D#!)#8YPP!K#U#PYJ&H7WBN
MT,02UUB&/R;KS!A&6+;@KUZ@>V,\]JL'3]2UDZ!]OL&M'TR87$[>8C"1U0J%
M3!)P2V><<"@"4>+["_M+K98ZJ;=%G2::. @(8^&&0<AO3^E8]W=1O%\/KG3;
MF^6SN;F-56:=BTD1MW8>8,D,> <G/-:6D:;J5KX6UJTFL)%N)Y[J2&/S$.\2
MLQ7G=@=><FLR+0M8CT;P);'39#+I$D9O )8_D"PM&<?-SRV>.WY4 =':^*K.
MY366-O=0MI#%;I)@BGA=^1\W(*\@\ UL6TQN+:*8Q20F10WER !ESV.">:Y#
M6]#DN/'=A+:3(D.H6Y35(<?ZR*%E9&^NYMASU5SZ5T+:E=)XC336T\_99+<R
MI=B4'+ @%2G4#D<^^* -)FV(S$$X&< 9-<CIWBK1M/\ #VGW,*:F]K>WTEM$
M95:602&5@0V23C(; ZXQQVKKF)"DA2Q Z#J:\ZMM UN+PUH=FVF2>?::X;V9
M1-%Q%YLCY!W<G#CCV- '8Z/K]OK%Q?6R6]S;7-DZI-!<H%8;AN5N"001[T[Q
M#JKZ'X>O]42V:Y-K \WEJP&=HSR21QZ]_0&L[1["^M_&7B&^GM'CM;P6X@D+
MH=WEH5;@$D=>.*T/$MA-JOA?5M/M]OGW5G+#'N.!N9"!D_4T <M>:O=?\))X
M1O)(KY#<VUR9;2-]PE81H5(16*]6."<8SSBNAL_%5A>Z6MZD=PCFY:T^RR(!
M*)E)!CQG&>"<YQ@9SBL>*PUB;6?"=W-I3Q1Z?;S1W(\^-BA=%4?Q<\J>F>,?
M09<OAG7&T^YN(M-B>[@U^74X;6YD0I<Q.&4H2"0K88]>AH [32->M=8GO;:.
M.:"[L9!'<6\P&]"1E3\I(((Y!!J/Q5=V=EX8U"?4/M8M%B/FFT)$@7N5((Q]
M<TGA]+DPRSW&C0:3YFT"W1D9^,Y+,G'?@<XQ[X%3X@_\D^U[_KRD_E0!>BUR
MV_M=-'6&X-P;+[7&6P0\8(7KN^]EAU_.H+7Q7I]YI=E?01W#&]F>"WM]H\UW
M1F##&< #8Q))Q@5GW-CJEIXMTS6+73VO(?[,:RE5950Q,71PQW$97Y2#C)]C
M6#IWAWQ%I=EX=OETY9;K2KJ\,UFLZ9EBG=CN5B=NX9'!(SSTH T=#UV.PU'Q
ME>ZC)=PVEI<PXBN7+M%F)<JHR>K'@ XY&*WE\46PU:32Y;*^BO$@^TF,Q!LQ
M\_,"I(Z@CZUR>IZ=?M:>,9;_ $I4CU>2W%G#+<J&DDV1HJY4G#;AD<XR.N.:
MT=*FO8==-SJF@ZFE_<V_V6&YFN+>0$(&?8/+(QG!.2.2.HX% %V#Q[ID\&F7
M(L]16UU([;>X-OE6?!(3 );<0#C (]ZNVGBNPN(=1>:*YLY=/D6.X@N$ <%P
M"F I(.[(Q@\FN9L] UF#PIX.L'TUS<:7>Q372B6/"JJN"0=W/WA^M/U;PSJ^
MIW?BMH;983>26<]D\[(R2/!M.U@"2 2N.1T- &[-XSL+5]1BN[:\M[BPM?MD
MD#(K,T/.778Q! ((//%26?BVSO=0MK-;.^B>[MFN;5IH@JSJH!8*<]1N'7 [
M@D<UCRV>K:GX8UB(^%[?2[FXL);9(8Y8F>61UP#N7 "#W.3GH,<S1Z7J9UKP
MC<'3Y%BT^SFANF,D?R,Z(H_BYY0]/:@#3\):_/XBTAKZ>QDM<S2HNYE((61U
M X).0%&<XYZ9%:>HZE;:7:?:+EB%+K&BJ,L[L0JJH[DD@5C>"M/U#2-'ETZ_
MM1%Y-S.T<@D5A*KRNX( Z###K@^U/\8:1>:MIMG)I^UKS3[Z&^BB=MJRE#RA
M/;()Y]<4 2_\)39QS7UO<V]U;W=G;_:7MW0,[Q?WTVDAAD$<'@]<5)H7B*#Q
M!&);:ROHH'@CGCFN(=B2*XSA3DY([_ID'-8U]I-]JFKW6LFPF@9-)DL8;=WC
M\R1Y#DDD,5 & .O<^@SM>%K6YL?"FDV5Y 8;FUM(H)$+*WS(@4X()&.* )=;
MUJ#0;);RYAG> R+&S1 '86. 6R1@9(&:==:S;65S)%<!XTAMC<RS'&R-!GKS
MG/![=C4^HV-OJ>FW-C=*&@N(VC<>Q&*Y"Q\/7NM?#^\M;V\5[Z_@$27.#@QI
MQ$3WPV-Y_P!\T =!'XBMVOK:SFM;JVENXVDM?.50)L#) PQPV.<-@_D:A7Q9
M8-I5OJ7DW(@GN_LG*KE)/,\OD9Z;NXS50V&HZW=Z#+?V+6;:;(9YV:1&#OL*
M@)M)."3G)QP!Z\8C:)KT>A?V1'I6_P"SZN+M9S<(%EC^T>;P,Y!P>0<>V: .
MG_X2JU;6)]+BLM0FGMYHXIC'!E8]XR&)SPOO_P#7K=KGM'LKZ#Q7K]Y<6C16
M]YY!AD+H<[$VG@'(YZ<5T- &1:>((;U89+>SNI(9XFE@F 3;*%QT^;@G/ ;'
M?TJ*'Q583V6D7B1W'D:K((K=BHX8@D!AG(X4^O2L?0]!O;+6K:[M;2?2[>:-
MSJ-F9E>!I"!@Q*&.T[LG/'%9]EHNOPZ+X9TU])P=(U!'ED-PF)$59!O7!SCY
MAP<'GIU( -NX\>:9;Q74S6>I-;VEP;>YF6V^6$C&6;G..>V3[=,Z-_XCM+&.
M>1(9[M+>$3S&W"GRT()!Y89X!.!DX[<C/+6$5Y?Z9XRTNVLFD-WJ5S"LQ=1&
MF]%4ELG=QG/ .:G.A:CH>N2/:Z+;ZU87,$$>9)$1X'C0)D[^JD 'CG.>* -B
M?QGIZ3QPVUM?WKRV8O8A:P;_ #(B0,KR,GG_ "<"K-MXDM;@:H/L]S$^F?\
M'PDH4'[N[CYNF.<U1M].OX?&EK>O9J+5-+-J\D3*$60N&P%SG;P1TIVHZ!<S
M>++>_MF5;.YA$6HJ3]_RV#QD#ODY4_[)H ?_ &E82^,;&WD34(=0:PDF1'8K
M"(]R;MP!P7!(]<<\U<LO$%M?+#*D,\=K- US%<OM\MHUQSD,2.&!P0._I6=>
MZ?J#_$33]3CLV:RAT^:W>;>F [LC#C.<?(>W<5D6OA.\?SH;:"XTBSO[&:*_
MM#,KPB5UP&B4,=O)8GH,8XH Z2+Q/9O+8"2&Y@AU XM+B50$E)&0."2I(Y 8
M#/UJOIWC&SU74WL;33]38Q74EI-,;;$<+HH;YCG@'.![]<9&<Z/2-4U+2= T
MR_LC;OIES#+-.)$9)/)'&S!W?,<=0,#/XS^&;/5-*C\2RS:8XDN=1FO;6,S1
M_O59%"KD$[22O?ID4 =916=H.I3ZOHMO>W-F;.>3<)+<R"38RL5.&'##C((Z
M@BM&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBN=\8:WJ&A66GS:?%;2O<:A!:NL^X#$CA>".AY
MZ\_0T =%17 S^--6\/ZEJ]AK\%G/);V O[26S5HUD4OY>Q@Q;!#E>1V.<5?.
ML^)8+N[1[**6T6Q>>.Z:W:$1S+_ RER6!'((QB@#KF8*I9B H&22> *HV.MZ
M9J=Q-;V5[%--"%9XU/S!6^ZV.ZGL1P:X'6-3\2ZM\)M2U>ZFTV"WN]&698X(
MI"XW1G>,EL#.1@\XY!SUK>@U"YCUK3-$A-C_ &G-I[7,MW]F("0(554"[\DE
MG_O8&#QS0!U]%>>W7CC6(--ND6VLCJ5AK$.G7 8,(Y5D90KISE<JXX).#ZU?
MGU?Q39>(=(T:X?1VDU!+I_.CADP@CVE3M+\\.,C/;J* .SHKSB3QEXDM_#6H
MZM*FEG^Q]0>SND6*3_20L@0LGS?N^&!YW\^E>CT 5H=0M+B^NK*&XC>ZM0AG
MB!^:/<,KGZ@&K-<7=>)M4M[KQHB0V6[1K6*XMR4;]X#&[D/SS]W'&*73?$FM
M'6O#T&H+8-:ZU9/,BP(X>%T1'Y8L0P(8]ACWZD [.BHKEY8K6:2"(2S*C,D9
M;:'8#@9[9/>N4TGQ-J-WK\&ERO92FXTUKH20Q,$CE5E5E#;B)%^;JI[>_ !V
M%%<!IGB_7;C3/#>K74>GBUU2[%I+!$C[U+%P'#%L8!4?+@_7TT4\2ZC;77B&
MQOQ:_;+%4DL5CB8"XC?B,X+')+_(0,<_6@#KJ*CMQ,+>,7+1M/M'F&-2%+=\
M DG'XUQ]YK_B!M0\3VMF=-C&D11S1-+$[^8&C9]I 8<\8SV]#G@ [2BN-LO$
MVK2ZCX:DN([,6.NPEEBC5O,@80^:"7)PP(!&-HQZFD7Q3J<.LZ7;72VF+V]E
MM);>)68V^ Y0F4,5+84$K@'YNV* .SHK@-,\0:EIUGXDOKZXBNS%K)LX8UA*
M_.WE1I_$<*-PXQGJ<Y-7;S7_ !'I]MK<SV4,D%II[7EO=/ T2EU!+1,F\DG
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M@XR#_$ <CC.#4NJ&<:7=-;2)',(F*NZ%@./0$?SKC?#M_+9^'?"%IBUDOK^
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MYRI_[4D^)-S]@-K;WC:%"6-PK2(A\Z3C"E<\\9R/7GI0!W*JJ*%4!5 P !@
M4M9'A;6'\0>%].U:2)8I+J$.Z+T#=#CVR*UZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXE/\
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M$L8K>)8D+')(48&?RKG-2\%O?C68EU>:&VU1UE>,1*Q210HSN/)7Y1Q^M=/
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M39(XV9V!W[TW@C';!%7)KBYCO[:".S:6"4.9;@.H$) &T$'DYR>G3% &%?\
M@Z.]T*]TX7I2:^NENKJY,89G=65A@9  &Q0!SP/7FKIT.8^*5UW[8F\61L_)
M\GY<%@V[.[.<C\OSK/F\:I#X>US5CIEQC2;F2WDAWIN;8%);.< ?-[UU"-OC
M5\8W '% '*)X)*>'8=+&IL)+>_&H07 A'RR>:9,%<X(R3Z<5>?PSY^ORZE=7
M?GQS:?\ V?+ T6-Z9+$D@]22>@QCM6_10!S&A^%;W2(TM9?$-U=Z?;J5M+>2
M)5,8Q@;G'+[0>.G;T&+%EX::/5[+5+Z[2ZO+.V:W29(/+:0-MR9#D[C\O'0
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M37?B.[MH1L9@&,CL257DX56.!UX''6@#T&BN-N?%FJ:7I.M7=_INY;)XA;7
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MI6#6-X=RRP'/!!(R,\X(Y&?6M.@ HHHH **** "BBB@ HHHH **** "BBB@
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MK6LW\]W'/'JACWP^3MV;$V#G<<Y'7BJ6@>%=0T,Q6?\ ;\UQH]NV;:T:!0Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?(AD3<2X &XKM4G&,YXXZT =?17&R^,KRPL+^;4M.>W2UNHH1>O!(D#QR?\
M+7:P# +R"/7'.#FH]<UW5QI>ESV4]B4N=8MK<7$#%DFB9UP5(/&3D'KQD>]
M';45SL6O7<'BF71]2CMH(OL?VJ"=6.)0#B0<]-O![\$'BM+2[Z:XT2&_OD2
MO'YQ49^1.HSGOCKZ4 :%%<>_C&YAT/3_ !%+:Q?V/>2HI )\V&.1MJ2'L>2N
M5XQGJ<5/9:]K>H>(M1T^'3K);?3[N.*>1[AMQC:,/E1MY;D<' ]SU !U-%9.
MHZL\&KV6D6BH;R[227=)DK'&FT%B!R3EE &1W.>*SQXBU&(Z;87FGQVVK7]Q
M-#&ADW1[(P6,O'." ,+P<L!QUH Z:BN)U/QM>Z5I_B%9+&!]1T98Y&7S"L<T
M3_==>"0>H*^HZU?7Q-=67B"YL-7MK>"W73GU%)89"Y5$8*P?('/(/'O0!T,U
MW;6\D4<]Q%$\S;(U=P"[>@!ZFIJ\\UJ\OM4F\%:E-;V\5O=:G%+&HR98@T4A
M4,>AR#DXQ@C'/6M"Z\97EMX:\0:I]D@:72+Y[8IN(655V<_[)^?WZ4 =G17/
MW>MW\][JMGHUM#-/IL2-(LS$>;(REEC7^[QCYCQ\PXZU1CU769_']G9.L5O:
MMI/VI[9R2R,9$# D<%AR!VZ^M '75 +ZT::*%;J$RRH9(T$@W.HQE@.XY'/O
M7/\ BF]=M5T#0E.$U.Z;S_\ :BB0NR_1B%!]B1WJ>XU'R_'-CI;V%L5ELII4
MNB<R*%9 4 QP#D=^<4 :AU73A;/<F_M1;H_EM+YR[0W]TG.,^U7*\FO(HQ\,
M_%"[%PFO3;1C[O\ I:]/2NSU;Q+=0WFH6>EVOGW%A$KNI@E?S'8%A&"@.TXQ
MR?4<4 =-17-1>)+J_P!1LM-MK+[)>3Z;_:#K>*08_F"B,@8.<DY/; X.:K:9
MXLU#5?#^F:I]@MK.*]=Q)-)/OCMD4'!;(4DLPV@#CD'/:@#J+B[MK-%>YN(H
M59@BF1PH+'@ 9[FIJ\YUO6?^$B\!6M_+;I'-'K$$+!>1N2Z5"5)Y .,_CBNU
MU[68/#^AW6J7"L\<"@[%."[$A57\20/QH T:*YR37;_3M?T_2]1M[9CJ4<GV
M:6%F"K*B[C&V<\$=&'H?EJ/PIKVL>(;:"_N+"SM["195)2=FD$B2%1@;0-N
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M.I]J .YIID02",NOF$%@N>2!WQ^(KG)?$=S&]E9&&(7]S#).S1))/&D:,%#
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MMI,;I1_RPPQR2>,-P/85GV7BVX?5[C3YX(+B2/33?C[&Q)#!MK0]P6!(Y!_
M4 =;17(V7C2.;0[C6S+:75A#:^<_V5CYD<G_ #R92<@\XR<9]!5S3]<U.;7T
ML+G39#;2P&1;J.WE1(G!YC;>HSD=&&,XZ"@#HJ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HICRQQ;?,=5W,%7)QDGH*?0 4455LKM[O[1NM+BW\F9HAYP \P#'
MSK@GY3GC^5 %JBJ6KZE'H^D76I312RQ6L32R+$ 6VJ,G&2!T'K5/_A)+87^C
M6AM[C=JT;20/A=JA4WD-SG.,=J -FBBD8[4+!2V!G ZF@!:*KV%TU[807+VT
M]JTJ!C#. '3V8 D9I-0NVL;">Z2UGNFB7<(( "[^R@D#- &=XFT6?7;*VMX+
MF.W,-W#<EGC+Y\MPP& 1U(ZTR/1+N/Q;=:X+J K-9):B'RC\NUF8-NSSRQXQ
M6XIW*#@C(S@]12T <UH?A_5-"\/Z7I4&I6Y^RS[IY#;G]]$2S%0-WRG+#G)Z
M5TM57NW74XK,6EPR/$TAN !Y:D$#:3G.3G(X[&K5 !1110 4444 %%%(QVJ2
M%+$#.!U- $%]9PZCI]S8W +07,30R '&58$']#6#H.AZ]I<<5K>Z[%>6EHFV
MV MMDCC&%\UMQW #T R0"36IH6M0:_I:ZA;Q311M))'LF # HY0YP2.JGO6E
M0!Q=OX+OH/#NB:4-2MV.F7ZWGF_9V_>8=F"XW<?>(SD]*P;B[6Y\1:M<1ZWH
M$,INPGV+5;9O.S'A5^42+N&064[2>0>O ](L;M[R.5GM+BV,<SQ!9P 7"G&\
M8)^4]15@HA<.57<. V.: .,G\,ZMK)OKV2^AM#J^EI:W,#VYD:!MK B-BPP"
M7.01V]>F3K0:QU+2-,N=>TNSN=/T_ EU&W*13%B%_=L'4Y 3!&X\,..3CTNF
MNB. '56 YY&: .'BT;4==TBRGM[VQL;[2KDG3[NQ@/V:6,H 1Y9/W#DKP?X<
M@UHZAX;U;5=+M8KS58'O([V&[=UMR(QY;!@B)NR!D<DDGD^P'4T4 <^N@WJ>
M(]2U9;NW_P!,M([98C$?DV;B&SNY^^>,"L>#P/J6G6&B-IFL10ZGI5NUKYKV
MY:*XA)!VNF[(Y .0?_K=E=7 M;26X,;R"-"Y2/&XX],D"H-'U2'6M&L]3MT=
M(;J)9460 , 1D9QWH Q[KPYJ%W=:+=3:G')/I]RUS*S0D"5F0IM4!OD4!N.O
M3G)R33N_!=S>6'B.VDU")3J]PEPC+"?W+)LP#\WS#]V/3J:V+7Q%%>#6%@LK
MMIM+<QR0[5WRML#@)SSD$8SBM6"0S6\<IC>(NH8QN,,N1T/N* &0K<I9JLTL
M<ESM^9U0JA;V7)('X_C7)6W@J^M_#^AZ6-2MV.EWXO/,^SG][AF8+C=Q]\\Y
M/2NTK,U[6X/#VE-J%S!/+"CHC"$ D;F"@G)'&2* *^F:+<6/B36=4DN8I(]1
M\K$2QD&/RUVCG)SD>PJM-X>O[?Q5<ZUI-_!"+Z)([R"XA,@8ID*ZD,,$ XQT
MK:6[<ZH]G]DN BPB7[20/*))(V YSN&,].AJU0!Q=GX*OK31/#NG'4[=SH]V
M+G?]G(\S 8;?O<??//L.*N7GA:;4M2L[J]GMG:ROOM5O<I$5G5-Q(AW9^[S@
MGN!C&>:ZBB@#BY_!5]/X=UK2CJ5N#J=^UYYOV=OW>75RN-W/W0,Y'6M%/#]]
M8Z]?ZKIMW;QG48XQ=131%E$J#:)$P1VX*GK@<BNCHH Y2U\&G3KSPZUC=(MM
MH\4R;)(R6F,H&YB00 <C/3O563P-=R6%TJZLD-\=5?5;2YB@XAD;(*LI8[EP
M2.W6NUHH P(],UXV8:ZU6VEO3(I=1;%8#& 04V;B>=W+9]..,5EGP)Y6E206
M5S!:3'58]4BC2$F")T*_(%R#M.W)P1R3TZ5V=% '%:_%IOB75=/T5;PRZK87
M :Z,*E2D31GS WHKJ0N,_P 0]#79R1I+$\3J&1U*LI[@]JSM?UFW\.Z-<ZM<
M6\TL4 #2"!06QTSR15G[8W]IK9_9+C88/-^TX'E YQLSG.[OTZ4 <U:^#)XM
M#M_#UQ?1SZ/;3I)&#&1*T:/O2-CG& 0!D#D#&!UK4T?1+G3=<UK4);J*6/4I
M4E$:QE3&50)C.3GA1V%;=% '/>(O#UWJ6H:=JVE7Z66IV&]4:6+S(Y8W W(Z
M@@XX!!!XJ*]\,WEY_9E\VI*=9L)VG2<Q?NFW+M>/9G(0K@=<C&>3G/344 <C
MJW@V;5M.UQ9+R&._U=(XI)1$62*-/NJHSD]2<Y[].*LWOAB;4M>^WW=S";=]
M,ETZ:!(R"RR$%F#9X^[TQ72TQ)8Y&D5'5FC;:X!^Z< X/X$'\: .,B\'ZT++
M1+*;6K62#1KM)H'-HV^1$1E57^?&<-C(],TFI>"-0O+/Q!IT&JP0V&K3FYPU
ML6DC<[=PSNP5^3/3//6NWHH Y2?PUJ\'B&;5])UBWMY+Z*.._CFM3(CL@PLB
M#>"K8XP21]:N-X>N$\36.KV]^ (;(V4Z31[VE3>&R&R,-D<G!Z]*W(Y8Y5+1
MNKJ&*DJ<\@D$?@01^%/H YWQ-ILDM[HVLP(TDNE71D=%&6:%U*28'<@$-COM
MP.:EFTB6\\56&O07D)MX+62!8PA8N'*G<&!Q_".U;3RHCHC. SDA%)Y8@9X_
M"L_1=;@UN*\>"":'[)=26DBS  [TQGH3QS0!STW@J]F\+ZMHYU*W#:A?M>>=
M]G.$W2B0KC=SR,9S5N\\.:O'XADUC1M6@M)+N)([V&>V,L;E!A77Y@0P!QUP
M>*ZFB@#SGQ+*B>);6T?7=/LI;.RP'UB(XG+GYBCATR<*-P!QR!CK6A::7JVK
MQ:1>Q7>FP-I4\BP^1;,;6XB9 H=4W J5R0""1UQP:W(]?MM0:0V-C<ZA!"Y1
MKB%4\O<O!"EF&['JH//'6K^F:E;ZM8)>6OF>2[.H\Q"C95BIRIY'*G@\T <I
M_P (1?#P]+I7]K0L&U/[>LC6QR!YWF[2 W))XSQQVKH]>T6#Q%H%UI-XS+'<
MQA2Z=58$$,/H0#^%:=% '/Q:%?7%]IU]JMU;SW&FQN(#%$5#R,NTR-DGMG@>
MIYZ8F\*Z+/X>T*/39[F.Y,<DCK(D93(=V?!!)Z%B*VJ* .?DT"ZMO$USK>EW
M,,;WL*174$Z%E<IG8X((((!(QT(]*I?\(6UK;Z(-.ODBN-,N9;AI)H=XF:4,
M)"0&&"2Y(YXX'-=;10!R-QX0O;BT\40'4( -<_B\@_N?W8C_ +WS<#/;FB;P
MMJ]MJD&IZ/J]O;736L=K>1S6QDBF"9VN!N!##)[]ZZZB@#GO^$>NQXETW53J
M"R+:6LENZR1DO*7*LS9!P.5&!C':IK_PY#?>)=/UDRLC6T31R1 <3C<K(&_W
M6&X>];=% &'X=\.)X;L+JVM9=_F3R21;QQ$A8E(Q_LKD_F:H:5X6O]+\.V&D
M&[L[R"W66.>*>W/EW"LVX9&3@@Y]?I70_:W_ +4%E]DN-GD^;]IP/*SNQLSG
M.[OTZ=ZGCECF3=&ZNN2N5.1D'!'X$$4 <6G@2ZTVTTI]$U5;74-.\Y%:2$O#
M)%*^\Q%<Y"@XV\Y&*OZ[97TOA*ZT9KK[7JFIHT!<)M50_P K,%R=J*I/?MU)
M//444 85I;ZE8Z[;6=O,C:+#8B/RC"0T;K@*=^><CMVQVXS/XCT4:_HTED)V
MMY@Z2P7"C+12(P96'XBFZGXABTZ>>WBLKN_N+>%;B:&T56=(R2 <$C).UL 9
M/!]LU+GQ?'&CRVFD:GJ$22M SVD2L5E R5*E@PY^4G& >#0 ^U\*6EEXECU:
MW=D1+1+?[/\ PEDR%D/JP1F7Z&JEQX4O)_\ A*1]O@ UV,(/W)_<XB\O^]\W
M'/;FM6;7H8-9TS2Y;:Y2;4(Y)(V(7:NQ06#<YSR.WXU<L[M[IKD-:7%OY,QB
M!F  E  .]<$Y4Y[XZ&@##C\-7:ZMH-Z]Y RZ7:/;,@A/[W>%!.=W'W!QSU-0
MZ!X7U700FG1ZRCZ'!(9+>'R")U7=N$9DW8*@^V2..!75.Z11M([!44%F8G
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M[=U5<MYA*CY?NG;@CJ>YXJM::G>?V)K:W.LW"2)K[6D,FT/*Z;T A0# !89
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M:'JNH17]W:.UU'&(C*D\B&1!_"^UAO'US6XJJB*B*%51@ #  H YGX=/;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRYU2QMO[*8PWT3O'+&9"(6"[@LI*  $=P3R,<]: .IILDB11M)(ZHBC+,QP
M/<UQ%OXZU&;2-(U9M$C%G?W?V0JMWF1'+LBD J 5RHR20>>G%0>)=7GU/PQX
MRTG5-/MX;G3[#S@8I3,C*Z.5()52&!4]J ._5@RAE(*D9!'>EKC[#Q->V%_I
M.G:KI:6UG?0$6MTEQO.Y$W%9%VC:2H)X)';-/M/&4UW<Z5)%IDDEAJ+!5DB#
MEX0PRCN-FT*>^#QGO0!UM%<M/XFU6#5],TLZ1:R7E[^\>*.\8M;PC[TC_N\
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M6,RD$]-ORXP >O4>M9$K:A'\2HY[;3K7^TIM!S)&T^V-6\X?><+DXZ?=_(4
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M$FGSVNFR7&GWMP(0\0=I(U)(65ALV[..?FX!!]0 #JY9HH(FEFD2.-1EG=@
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M@WXSMW*5SC\:P$\,ZI#=:-JJ7-HVIV%N;25-K+%/"0/ESR005# X/IBNMHH
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M8D8Z0K)M;Y>5R2,<=><UUEGX4TNQ\J.%)?LL$QG@M6D)BBDR3E5]B20.@/(
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M"77A75+C3_%EL'LP=;<F)O,;]T#&L?S?+SPN>/7'O792.(HVD8,0HR0JEC^
M')JGH^K6NNZ3;ZE9%S;3@F,NNTD D=.W2@#(UOPU/K&D:9$MPMIJ%C+&ZSQ$
MG:,;) #C/*%NW7%2^(=#N=0318[ 6\<>GWT5T5D8J"J @*N ?7]*Z"@G R:
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M6B@#E9-,\4:GX>U*RU:XTS[1<6DEK&MJ'$>77!D8L"<CLH'KSSPT^&]0EO\
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MH.H*$E)!ZX#,#^'H:C_X1'30UTBF=;.[F^T3V0<>2\F02<8R 2 2 0#W')H
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MZ@CO?+#?LKS0I<L$,BXP^/[WRCKGI0!D/=3Z;XU\6ZBUW<RQV.EP7 MR5VL
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M7GD6!XE-O>1 ,5\EP.H&TX)!ZYS6]#X5LH9-'=)[K.D1F.T!<852NT@\<_*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2_/N;N:/R9UD!6*4Q$[ST.2-W&,>] '945S=YXL$%IJ5_;6+W5AIDK174J2
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M8O$I9RHV]<'!&?7\ZW-2\=66G^=,L:3VEO<_9IRDX\Y6#;698NK*K<'D'@D
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MT]Z .=NO#3S>,X-9BF"6KP!;R#'^N>-MT+?\!)8Y]EJ.^\.W6H>+;F]F$/\
M9MQI+Z<^)#YN6;<3C;C&#CK73T4 <7;>&-4GT'2-!U(VIM=-GA8W,<A+3I"<
MQC81\I.%SR>AQG/#;[PWK\C^*I+.>UMY=4E@DMV$SY C5%97(4%=P4C(SC=7
M;44 <1'X4U1[O7B\>FVEMJNF):+';NS>0ZK(N/N@$?/G/'3&.]2MH&MSV7A:
M.5+!9-)N$DF"SN0RK$T?RG9R3NSSC'3GK7951_MBR_MP:-YC_;C ;@(8V \L
M$*3NQ@\L.AH YJ/PSJME9:_I%HUK)8:K+-+%-)(0]N9AAP5Q\P!)(Y&<X..M
M6;'P[>:7XHAO+5+=M/M](33HE:9A(2C;@2-N,=NM=!87\&HP/- ) J2/$?,C
M9#N4D'@@<9'6EU"^ATRPFO;@2&&%=S>7&SMCV502: ,OP=I%YH7A:STR^\@S
MP;P6A<LI!8L.H![^E:>I6,6J:7=Z?,2(KJ%X7*]0K*0<?G5H'(!]:* .-M_#
M6JW.D:)H^J&U,&E3PRFXBD):<0_ZOY2HVDX7=R>AQG/&CI.E:C9^+-=U*X6V
M^RZAY'E;)6+KY:%>05 Y]C70T4 %<[-I.I1>-VUJU%K);2Z>MK(LLC*ZLKLX
M( 4@@[L=1CKSTK;O+R&PLIKNX9E@A0N[*A8A1U. "326-Y#J.GVU];,6@N(E
MEC8C&58 @X[<&@#BK3PEK5OX8\-Z8PL3-I>H+=2L)WVNJESA?DZ_/W]*N6&C
M>)M'U&^L[&:P?2+NZDN4FE9A-;&1MSJ%QM;DDC)'7GTKL"0,9(&>*6@ K"\5
M>'3X@L+<03BVO[*X2[LYRNX)(O3<.ZGD$5K7MY!I]E->7+,L$*%Y&5"Y"CJ<
M $FBRO(=0L+:]MF+07$2RQL1C*L 0<?0T 9]M+KUPBQW=I9VC<"2:&X,OUV*
M4'7WZ>AK'B\/:KILGB"UL/LLMEJ\LEPCS2%6MY)%VOD!3N7C(P1Z>]=<""2
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MT;K)N#1O\H(RK'D9KT"B@#FYK/7=1TO9JEGI4YED43V!<M$8@#GYRN2^2#T
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M]W?WK2LCF[GFS.K(<H58 !=IR1@=SG.34UAX8CL];75Y=2O[N\%J+4M.Z89
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M6YU^'6$N)XYH;4VB1)L\L1D@D8VYZJ._:@#F=.\4ZE+I=C#<7"&\O=:GT\7
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MR<@C*C)Q],54AU"_UK6/ EX]]-!]NL)KB6*()L\P1H<@%3UWD<]!TQS74?\
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M:QLI?.M;25E*1,,[<';N(7)P&)QQZ#%NST&*RUV_U9+NZ>:^"":-RFS" A<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %,EABN(7BFC22)QAD=00P]"#UI]% %1-+T^
M*T:TCL;9+9CEH5A4(?JN,5/!!#;0K#!$D42_=2-0JCZ 5)10!5GTRPN;C[1/
M8VTL_EF+S)(E9MAZKDC.#D\>]']F:?YJ2_8;;S$78C>4N57T!QP*M44 5!I6
MG"UDM186HMY?]9"(5V/]1C!IPTZQ%B+$65O]C Q]G\I?+QG.-N,=:LT4 5#I
M>GF5I38VID==C/Y*Y*],$XZ4@TC3 L2C3K0+$<QCR%PA]1QQ5RB@"LVG6+WR
MWS6=NUXHVK<&)3(!Z!L9ILFE:=-)-)+86KO. )6:%29 .@8XYQ@=?2K=% %=
M;&S2Z-TMK MR1@S",!R/KUI;BRM;MHFN;:&9H6WQF2,,4;U&>AJ>B@"J^F:?
M):/:/8VS6TC%GA,2E&).22N,$YYIS:?9/9"S:T@:U  $!C!0 =/EQBK%% %=
M;&S6Z^U+:0"XQM\X1C?CTSUJ81HLC2!%#L &8#D@=,G\3^=.HH K)IUC$9C'
M9VZ&<$2E8E'F ]=W'/XTT:7IX,!%A:@P#$/[E?W8_P!GCC\*MT4 5?[-L3?_
M &_[%;?;,;?M'E+YF/3=C-$>F6$5TUU'96R7#$L95B4.2>ISC/-6J* *.FZ5
M;:8;IH(XT:YF,TGEQA%+8 X ^GXG)J273+">:2::QMI)94\N1WB4ET_NDD<C
MVJU10!4_LO3S*TOV&U\QEV%_)7)7&,9QTQVIKZ/IDEG]CDTZT:UW;O(:!2F?
M7;C&:NT4 0V]G;6@86UO#"'.6$:!<GU.*CN=-L;V:*:ZLK:>6$YB>6)6*'U4
MD<?A5JB@""6SM9YDFFMH9)44JKN@+*#U )Z U#_8VE^4L7]FV?EJVY4\A< ^
MH&.M7:* *\5C9PW$EQ%:P1S2??D6,!F^IZFFVVF6%E'+':V-M DI)D6*)5#G
MW '-6J* *D6E:= (Q#86L8C5D0)"HVJW4# X![CO4MM9VME&8[6VA@0G)6)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;5*JI^3D!21Z\\F@#,7Q3J>G1ZQ97<B7EW:ZG;V5O,(@FX3!""RY RN\]QG
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M0E$TRS;-H8#'R[5!'  ZU)-H4<WB6WUS[7<K/! UNL2[/+*,03G*YSE1W[4
M8 UO5M2TO7[^PNHXI-(GEMXX3$"D[0J"Y?/(W'(&TC P>:@M_$&M^(-9L[;3
MKRWL+:]T5-01GMO,>)F8#'+ -U]A[&MN3PG;FYU)[>\NK:#4^;RWB*[78C:S
M D$J6'!(/OP>:R)+"5/B5;K9?:K.U@T7[,DL=L3$"),A-Q4KPO/7M^% %"W\
M5^(;JRT>(RVD-Z^KRZ5>-Y)969 _SKSP/E''KW%;,>J:OIOBFRTO4;Z&[@_L
MN:YFDCMO+9W1T&?O'LW05;?P=9&+3(XKN[A^P737BLA0F69MVYG)4Y)WMTQU
M^E79M!AG\20:VUS<":&W>V$(V>648@G.5SG*COVH P=+U7Q)JD>BZI;0,UE?
M*KW44GE!(HW7*M&0VXE<C(;KSPO2J&@WNJ6_AG4[LZJC2_VO-"TMV -JB?82
MH ^9]O"KTS@ =JW-'\%V^B7 6WU/47TZ-S)!ITDH,,39SQQN(!Y )P#SUJ.7
MP+9O:W$":CJ$2O?_ -HP[&3_ $>;?O)3Y>023PV[VQ0!C7WBO6;;0?%\D$P\
M_1V1K>6YMP'9&C5\,HP,\G!QTQD5H:S>>(= M8=6NM4AGL!=QF[CCM0IAMVP
M"0223M8Y)]"?2K%QX$M+J'68Y=4U)AJZHMT=\>254+D?)@$@#V'8"K>O7/V7
M34TAM/OM4>^AD@!6'<A.W'[UA@(#GKCL: +FFW,][J.H2^=NL8Y!# H4<LH^
M=L]QN.WZJWM6#XN_Y'#P7_U_3?\ HEJZ31M,BT71K/38"3';1+'N/5B.K'W)
MR3]:J:OX<BU?5--U"2]NH9-.D:6%(=FTL1M.=RDGC(ZT <UJ.M>(O.\8"WU"
MUA3142: ?9=Q<>3YFTY;IV)_+'=VK276I>)/!%TETUO]I6:4(J*P1C;DD\CG
MKCFMN7PE;ROKS-J%Z/[:01W('E_* FSY/DX^7CG-*?"D1GT2;^T;T-HZ%(,>
M7A\IL)?Y.?EXXQ0!F-KFIZCIGB'4=,N(X/[)N9H(;=H@RS&( OYAZ_,<@;2,
M<'FJ\>O:YK^LV5MI=[;V%O?:(NHQF2V\UHF+J,'YANZX[5MR>$K8W&IM;WEU
M;6^J$M>6\17:[$;68$@E2PX)!_(\U/%X;MH/$$&KP7$\306?V)+9=GE"+(.,
M;<]0.] '*WNO>(TTWQ9=1ZA:HVB3L8U%KD2JL2/M.6. <GGK].E:T&KZM!XK
MTJUNKF&:UU6SFG6)8MGD,FP@!LDL"'P<^F>.E69?!UM+::Y;-J%]Y>LL6N<>
M7E<J$.WY./E '.:FE\*V\]]IUU-?7CM8V\ELB?(%=' #;L+G)"CH1TH Q-.\
M1:H^N:%:S7<=PNI1W G:*(>3'(B[AY+X!<#D$G<#ZUEVNJZSI?PY\0ZQ%J7G
M7=O>76UKB)6^[,RYXQSC'L,=*Z.Q\#6]C)H[#5M2E_LG<MJ'>/ C9=NPX09&
M,<]?>G2^"+.71]5TG^T+];/497E>-63]UO;<P0E.A/KDCMB@"1M4NM3\3W>B
M6MR;06=I'/)*J*S.\A;: &!&T!<GC)R.1CG!A\6ZY>V^B*C6D%S+JLVF7F82
MREXU?YU^;I\@./PS73S>'(WU6'5;>]N+>_2W^S23($/G1YR ZE<9!Y! '7TX
MJ%_"%ELTM(KFZA&G7+7:;"A,LK;MS.2IR3O;ICK]* &^%]2U"YO=;T[49TN9
M-.NQ$DZQA"Z-&KC('&1N(JO)<O=_%.&Q<_N+'2C=(O;S9)-F[\%4C_@1K6TS
M0HM+U+4[Y+JXEDU"5995EV;58*%&W"@] !R35>_TQX/%%IX@@1G*V[6=TBC+
M&(L&5@.Y5@>/1CZ8(!AZWXCU33;B>9+F*01:G!;?9X8]\:PNR*?,<C*RY8G
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M]M)H4DLAH4 6)&PF/-E X''';TK%T?5GN-+\%VNK7=NMG=Z;(-]]'YD4LZE
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M?W<9-M\^T?7KTY[#.*[K1;VU32M)M'N85N9;.-XX2X#NH09(7J0* -:BN/\
M'\2R)X>#2RQA]9MXV,<K)E6W9'!]A].U<SK>F+H[>-;'36FCTL:,+LQ+*VV&
MY._H<\950Q'T]J /5J*\\N[.UTBZ\+QHCK8:M<K_ &C(\C,)I! ?*5LG&&;'
M'0X%9?BF&6QLO'-E:-)'ID-G!/''&Y58)VSN5<= 0 Q7ISTYH ]7J"]>YBL9
MWLX4GN50F*)WV*[8X!;!Q7$R:-!IOC[1CIC3"/4;6Y_M)?.9A*BJI20\\'<P
M&?>L+3M(L_\ A3%UK/[XZ@VDSJ9_M#Y(#,P&,XX(';^9H ]8C+M$AD4+(5!9
M0<@'N,]ZAFO;>"ZMK:255GN2PB3NVT9/X ?S'K7"75U#<^(K+2-3N+**SET>
M*2V6]BWQR/DB3'S*-X&SU(&<8R:K)INGVWB#P4EQ=QZE'';WT?VZY5<RJ@4K
MDGJ!S@^G/>@#TRBO*KF]M#=:5J=E.J"3Q(8VN)Y!]HD&YU=3C&V,= ISQMSB
MM?0]!TW5?%'B9KV-[@6VHHT*O,Y5,P)GC/.=QZT =]17G>A6S+='P3<Q%UTZ
M[-V977/FVN=\1+=VWD(?4(U=[;WEK=/,EO<PS- _ERK&X8QM_=;'0^QH GHK
MS;QM-9W#>*@C@W=EI:LSW+C;;MM=D\A>H<G&6SU"]>E3QVUMK/C?2ENG:YAN
M/#[/*AE8I(PDC!R <'OD>M 'H58VD:W+J.LZUI\MJL)TV6.,,LF_S Z!P>@Q
MP1QS7!:-J#+I?@[3KV4G2Y[^]@E,K95S&\@@B8GJ.!@'KM%:.F""QUOQI8:<
M4B>>[MH(5B/^K:2)06 [;<LV.VTT =UIEX=0L$N]@5)2QCP<[DW'8WXK@_C5
MNN-G$,OQ"M]#O8(VTQ=)WV=O(N8WD#[7X/!95"X] 3ZUS#Q3R:9I]K//<-:P
M>+3:6C^<P+6P+ +G/(!!4'K\O% 'K-5[*]M]0MA<6LJRPEF0.O0E6*G'X@U%
M8Z38Z=I8TVVMPMF P$3$N,,22/F)XY/%>5V-K9K\-/#OD;89FUB!93 ^QL&Z
M9?FQ[ @9Z8XH ]AHKS[5M.T6QU5M'MHU7RM-FN#%=REK>)7?F15;),FX$<$
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MK.G?@D9%7:* *5WI&F:A<PW%YI]K<SP',4DT*NT?^Z2.*D_LZQ^W_;OL5O\
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MW.(8E3<?4X')JS110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%5K[4+33(%FO)A%&\B1*Q!.68A5''J2*!J%HVIOIHF!O
M$A$[18.0A) /IU!H LT56T_4+35;&.]L9A-;R9V2 $ X)!Z^X-6: "BBB@ H
MHHH **** "BBB@ HHHH **** "BJQU"T&IKIIF'VQH3.(L')0$*6].I JS0
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M6E])<QVTPD:UE,,P /R. #C\B*LT %%%1)<P27$L"2HTT04R(#RF>F1VS@T
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MF6C( *,F-I7@<>O-6IO"[33Z3.VISO/I\[7'F2(K-/(RE26Q@ 8)   QQZ4
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MCJ U&1I;ZU2U??$IP$#888QS\S9[>PK'U+3[:T\,0>!A'>7DLUH(;>86[;$
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MK&HD8.X'+ 8R?I3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^>*3,A&0<G[ORXX %1>'@^O:9HVN/KL5M?I=#[6J1MYDCEBKV[_O.F3Q\O&
M0!0!Z317DE_ R>#?%>HK>7OVO3]9F^R2FZD)BVN@&,GG@XYSQ6Y?^=H'C&_&
MEO.[R>'[B[,4DK2"2='4(V&)YY(XH [^BN"T&TBU!M"UFW\01E;B!HY8H%<-
M>%DR0Y\PX=2"<XR,$<5AZ7&\/A;PEJPN[QKU]96W:5[EVW1-/(K*03@@C\:
M/4XKJ":XG@CD5I8"!*H_@)&0#^'/XUG2ZX8O%EMH9M#B>UDN5N-XQ\C*"NW_
M (%UK#\(V=K!XL\6NB!9!J"!?F/>%&/&><G)INO:?!J?Q'TFUN3+Y+Z7<[UC
ME:,L/,BX)4@X_&@#M:ANKJ"S@,UQ(L<8*KN;U)  _$D#\:\PM=0N]-B@TJXU
M!AH_]OSV4=U=EG!B6,E(V;<"1YF5Z_PX/&14WB+1H[+0Y8)-26^B&LV<D<*J
MRK:;Y4!126;@CG&>-WO0!Z?17!ZX(M!\36\VV:73]5LWL1"LK8%ROS1A3GY6
M<97([J*9X/:YNH[?1KTN][X?ED6[DW-^^?I$23U#*Q;GNHH [^BO-_#H?7-,
MT/7FUZ*WOEN5^UJD3>9*Y)5[=P9.F3Q\ORX!  I-(\S7]/M]6DUV*RU&VU%O
MM&V-C*K"0K]G8>9@J1@!=OH<9YH ])HKR75+=E\->.+\7E[]IT[4G>T<W4A\
MHJD1&.>>N.<\5ZI+"EW:-#*"4E3:V"0<$=B.10!-17GWAXSRS1>$;MIGN=)N
MVEN)V8YF@'S0L6]6WJ".^QQ5-[F74O OB+6I;B6'6[&ZNBDBN0UNT3'RXP/[
MI4*"O1MQSG- 'IM%<+93ROXLUA+YC")-$MKB6$N0B.3)O(&>.@Y]JV/ 4\MS
MX"T.::5Y97M$+.[%F8XZDGK0!T5%>8)>K]L\.:G97,C0W6M2Q-=S3?O;B,B7
M<K*.!&I4  ],#@54U.!E\,>.+\7E[]IT[4Y&M'-U(?**I$1CGGKCG/% 'J\K
M.D3M''YC@$JF<;CZ9K.\-ZR/$/AZRU98# MU'O$9;<5Y(ZX'I6#!-'K?CC7=
M,U)CY=G:VYM8MY7Y74EY5Q_$&PN[MCC&3F?X:8/PXT/G_EW_ /9C0!?\0>)8
M=%T#4M4@A^VG3SMFB20+AL D9^C#UK;!RH/K7D=U:6MM\/?'QB4*XU"[0#<?
MNAD[9]^OO6]>>?H7C&Z_LUYY'E\/W%T8I)6D$D\;KL;!)Y^8CC% '?UGZSK-
MIH=B+F[+G?(L,448W/-(QPJ*.Y-<GX=MX[U_#^NVWB"(^;$5EBB1BUX63)$F
M9#\RD$YQQ@C@4_Q]FUUSPEJDYQIUIJ)%RY^[&77:CMZ 'OVS0!O3ZS?V4<$M
MYH[K%--'#F&=9#%O<+EQ@8 SSM+?UK;J*>:&*(-,RA&(49YR2> /4YKSUIFU
M;PUXOU"ZN)8-4TZZNA#(LA5K81+F(+Z @ G^]DYS0!Z/17GUE!+K/C*UBU5K
MD?:?#L4]S:B=T02F0!N >/3 QTK(T]94\(^%-7-Y=O?C5XK7S7N'.83.T90C
M.""H';- 'K%%>93:3%J;>.#<:A?QFPN#):N+R0?9V$"/N'S>O8Y '3'-1W=[
M-J>ASR74DKZG!X<CGN%ED\N.U=D9A(@'/FDCVQ@<\XH ]1HKSN%6U;Q#X46Z
MN[IX[O1))+A%N'59& BY(!X/S'.,9[\56MK.]N_ ,L]I+<37>BZG</;(TS$S
M113-^Y8YRP*#'/M0!Z;17.:!?VNKFZ\3)*4LIXUCMVD;:OEJ,LY!X!+%@3Z(
M*Z($, 000>010 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$9&#TH
MHH K)I]G%':1I;1*EI_Q[J%&(OE*_+Z?*2/H::=+L&U(:D;2$WH38+C:-X7^
M[GKCVJW10!131]-26[E6QMQ)>#;<MY8S,,8P_P#>XXYJ/_A'M&%M:6_]EV?D
MVC;[>/R5Q$WJHQP:TJ* ,Q_#NC2ZPNKOI=HVHKTN3$-X/0'/K[TYM TAQ=AM
M.MB+S_CY!C'[[_?_ +WXUHT4 116T$%JMM%$BP*NQ8P/E"^F/2LV'POHEF(6
MLM)L8);<L]NZVZ_NF8<D?I^5:]% 'G5KX#>6,0W_ (?T2.[_ (]6MYW$K.>3
M(J!!A\\_>P#[<5W5MI=A9W<]W;VD,5S<8\Z5% :3'3<>]6Z* ,RU\.Z-8ZG+
MJ5KI=I#>S9WSQQ .V>O/OW]:(O#NBP:N^K1:7:)J#YW7*Q .<]3GU/K6G10!
MF'PYHK6L]J=+M3;W$GFS1&(;9'_O,.Y]S4RZ3IZWR7PLX1=QIY:3;?G5/[H/
M7'M5VB@#+LO#>B:==W%U9:5:6]Q< B62*(*S ]1D>M \-Z*MK#:KI=H+>"3S
M8HA$-J/G.Y1T!SWK4HH J1Z780ZC+J,=G E[,H22X6,!W Z GJ>@_(4E[I-A
MJ+Q27EI%+)"28I&'S)GKANHS5RB@"E<:1IMUIATV>QMY+' 7[.T8*8'3CI42
M>'M'CT<Z0FF6HTX];;RAL/.<D>N><UI44 0&RM3';Q_9XMENP:%=@Q&0, J.
MV 2*=';PPRS2QQ(LDS!I& Y<@  GUX %2T4 9D/AW1K?5WU:'2[2/4),[KA8
M@'.>ISZGN>] \.Z,-9.KC2[0:B?^7GRAO],Y]<<9ZUIT4 9C>'=&>&YA;3+4
MQ73[[A#&,2MZL.Y^M6YHY8-/D33XXO.2(B!)"0FX#Y02.0,XZ58HH R=%LKV
M(SW^J+;C4;H()%MR2D:*/E0$@$\ECG'5CZ5.^B:7)?->O80&X<JSN4^^5^Z3
MZD=B>15^B@"A=Z)I=_?0WMW86\]U"-L<LD8+*,YQGZ\U/8V%GIEHEI8VT5M;
MI]V.) JC\!5BB@#('A;0 [.-&L=S3"X)\A>9!G#=.O)_.I&\.Z,T%S"VF6IB
MNGWW"&,8E;U8=S]:TZ* ,VY\/:/>S6\USIMM-);+MB=XP2B^GT]NE6;#3K+2
MK1+2PM8;6W3[L<*!5'X"K-% &9-X=T6X-V9=*LW-V0;C="I\XCIN]?QJ9=(T
MY+V.\6SA%U%'Y:3;?F5/[H/I[5=HH S+'P[HVEWTU]8Z7:6UU/GS)8H@K-GD
M\CWJ_/!#<P/!<1)+#(-KQR*&5AZ$'K4E% &=8Z#I6F.K6=C#"5&$VC[@]%_N
MCZ4Z;1-+N+UKR:P@>X;;O<IR^W[N[^]CMGI5^B@"FVE6#W[7[6D)O&C\HS[?
MG*?W<]<>U5QX;T46D5H-+M!;PR>;'$(AM1\YW = <\YK4HH Y/2?"^-<UV\U
M2QMWBOKE)8OGW9545=KC&#RN<<CFMR[T+2;^]6\N]-M9[E8S$)9(@S;#VR>W
M)_.M"B@#-A\/Z/;/;O!IMK$]LACA9(P#&IZA<= :J76G7NFPQP>&+/3+9)I&
M:X:7<H3(^^JJ/F;/)!QGU[UNT4 4(]'L4T--'>!);)81 8I!D,H&.:NQQI#$
MD4:A$0!551@ #H!3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBJ=UJ^FV-Q%;W>H6MO/+Q''+,JL_P! 3DT 7***
M* "BJEYJ=CI\EM'=W44,ES((H$=L&1ST"CO5N@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BJMEJ-EJ2S-97,5PL$IAD,;;@K@ E<^O(JU0 4
M444 %%%% !1110 456EU"T@O[:QEN$2ZN0[0Q$_,X7!;'TR*LT %%%% !111
M0 44C,%4LQ  &23VJ"QOK74[&&]LITGMIEW1R(>&% %BBBB@ HHHH **J6.I
MV.IK,UC=17*P2F&1HFW!7 !*Y]1D46NIV-]<W-M:W44TUJP6=(VR8R>0#Z'V
MH MT444 %%5[V^M=-LY+N]N(K>WB&7EE8*JCZU+%*D\*31,&CD4,K#N#R#0
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MV<-\^P$#<1V&2* +=%%% !1110 4456MM0M+R>Z@M[A));601SJIYC8@'!_
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M)Y!+Y$2Q;PNW< ,9QDT >8QW6I7W@+P5>W4\5S=7&KVLJEE*?,2Y.XY.>>X
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M7R*MU&\7F*S*,*Z\C:P''<'CBJTGA"*!-%_LJ\>R?25>.)C&)-Z. '# XY.
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M[=?,#+)%@&5B/FME8\$X/.?IVK,T.^D.C^!='>X2"UO-*9QYA8+-*JQ[4RK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !112$A5+,0 !DD]J %HJ"SOK74(//L[F*XAW%?,B<,N0
M<$9'H:GH **** "BBB@ HHJE'K&F2S/#'J-H\J ED6=2R@=<C/&* +M%5+75
M=.OG9+2_M;AE&6$4RN0/4X--&KZ84C<:C:%99?)C;SUP\G]P<\M[=: +M%(S
M!5+,0% R2>U0VM[:WT1EM+F&XC#;2\,@< ^F1WY% $]%%% !1110 44R::*W
MA::>1(HD&6=V"JH]R:J6FM:5J )LM3LKD @$PSJ^"3@#@^M %ZBBB@ HHHH
M**** "BH;F[MK*+S;JXB@C)QOE<*,^F355=>T=V"KJUBS,< "X0DG\Z -"BJ
M]K?6E]YOV2ZAG\E_+D\IPVQL [3CH>1Q5B@ HHJO=7]G8*K7EW!;JQPIFD"
MGT&: +%%0P7=M=+NM[B*9< YC<,,'.#Q]#^534 %%%% !1110 4444 %%%%
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MZ!IRZG&1H]PDZN;8_O=H8 $;^.&-9'CC26TWPWXOU*6]B<:G%$%B\K85* *
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MP>!;BVT#3-/CU@>?IVHF_@G>VR"2SDJRAAG_ %C<@CM79("J*K,6(&"Q[^]
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MUCX?\01ZTL<<Z*;L?:9)%N"ZX*",_*C!NFWIC'- '?5&)HFG> .IE159DSR
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M:)O;47)MC<PB=4\PQ%QN"?WL=<>]5HM=TB=)WBU.S=;<!IB)UQ&#T+<\ ^M
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MR1Z*NL-=7K")E\PO&5^T%2,[0QZX[;NG->B44 >7>);<70\;:G9$2:==:1'
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M\:)<VJ%&V/N4\D@@_C5GQ/;:I>>'+R#19EAU!U'EL7*<;@6&X<J2N0#VSF@
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MQ\Q\JQ1578^.F0I]>HK2U/3M?\1:!,L\=KIM\DD4UI$)?.59(W#@NVT<$@#
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M;/#JER;J&X>?;C<$!0KCJ"G7.,'\* /0.HKG[V]L4\:Z=:RV5RU^;2=[>=7
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M6XM=/%U#(BJ &5O+<+DEN,C'?O71VV@7-[<:+JNJ7UQ_:&G+*%"K&H</P2X
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M\<@;:DB%B<2$%L'OMSVJ318K;_A.?[-9;2.SN]!4O:PR[@Q\P!6<C 9]I/S
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MD :=%/\ "N2O Z!SBMG6E\.Z7I>LS6M_<)#>?9A+!83*L<;%PJ[>-J;^C'N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTO4[2%$:R1R\+IN!1T!!"D-G)Z'/O0!U%QXGT>WBCD-YYBR6YNE,$;S?N?\
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M#:L2)F=AN;*D% $'HIR>3VN:7XCTG3] @N;WQ"U['-=M;K=SQ;-TA<KLP%&
M#QD\<=:CM5F3XF:G=-:W0MGTZ"%)C ^QG5Y"P!QCHPKF4L;X>$+6W.FWWG+X
MD%TT?V9\B'[29-^,=-IS^E '>V/B32=06]:"[ ^P_P#'R)HVB,0(R"0X'RD
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M4CC.560C:3P> >Q]*DMM?TV[EOXH)G:2P.+E3"X,9QGN.>.>,\5PL.EZA?\
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M9^4'8W)KT%F"J6.< 9X&30!Q6H^*$TKX>W.K:=J,^IL7D2"ZDMR<,92O("@
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MB+M*H#E#+M"8*Y'][..?:@#KZ*Y2R\3:SJ.J7]I::%"T=A>&VFD>]V\>6'#
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MVMO+L,L42QML)VD@8XX]JM44 <EH^AZ[H]YK<\3Z<_\ :=XUTN]G/E94+@C
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MH[^&2-(F8"24XZ1CJ6R1@#G.*S_^$1N+OP##H]Q?21ZH1'</>X#,MRK!]_N
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M((SC#*01D8KO:* *NGPW<-FHOKA)[IB6D>-=J GLH). .G7/>K5%% !1110
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MK^ZN5DG:_MQ;7*2-E)(QG QVQD\CGFJMIX)TJUN-/F,U_.VGAUMA/=NPC5@
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MRB_XMAX7URT59;K1[6"X&S!+($"RI_WSN_$"I?'D4#?"_6;V[CC66[VW \P
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M<I_9CM'<1NJAMP7<<#=SP00>ASQFI9]>BAEDACM+JXN(85FGAA52T*MG&[+
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MC%I)6+,WSMU)YKI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ7+;/<!E"><S(P^7=NV_*>W>L;3]+\0/JWAK4;W29/M5H9DOII+J-B2Z8W*
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M IP2-N<8.!V[4 <FFC:YIZ":"TDDBO\ 5IKV_M()T258V7:@#E@."JEL'GD
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MK$CD?6NAHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/-#=12V;WEJ4EC##?"77!&?49Z^U9-UX7OCKCZMIFN/I\]S&D=ZBVZR)-M&
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M7VP1VZDD3,23P5 (&>2<9[U(WA"8Z&-&.I+)8FP%F\4UL&'&<.H##:0,8Z]
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MP9Y((EC\UD"[L# .!_GWKGE\#QS:%J^DWU\9H=1NY+SS(HO+>&5F#@J=QZ,
M1^N: )Y=;U/3O$]GHMZ+2;^T;>5[2>*-HPLD8!9'4LV1@Y!!'3&.]<\/&7B@
M^ )/%AM]($/V3S5AQ)N#^9MYYQMQVZY[UU46A73ZA;:CJ-_%=7MG \-LZVWE
MHA?&YV7<<L=H'! QGCFLX>"7_P"%>GPD=2!C*>5]I\CYMF[=]W=C/O\ I0 2
M:QXB3Q9_8>-+'VFR:[@E\N0^1M=5*L-W[S[PP1L[UI>$M9N-=T!+R\CBCNEF
ME@F$6=A:.1D)7/.#MSSZT/H-R_B>VUMKZ+S(+-[3RA;G#!F5BV=W'*C\*D\-
MZ&_A_39+-KH7(:XEG#"+9@R.7(ZGN30!S5SXF\521^(I;"UTHKHMRRE)?,+3
MH(U<@$$8;!//3H,=ZE7Q5KFKZM:6FB0Z<D=YHZ:E"]X'.W<RC:VT^_;Z]L&I
MH=K-J^J^-+.WU.*&WNKXHX6+>^PPHK,C;@!W&2" 171VOAD67B2VU.VN$CM[
M?3QI\=KY6<1A@P^;=UR!VZ?G0!FS^*M3FT36-;TV*T>TTN:6,P2*V^=8?]80
MX;"GAL?*>@]>+$'B>=_$NF02?9UTC5; W5G*4(D+@*Q1CNQ]P[NG8^E*?!S1
M1ZQ96FHF'2]6D>2XMS#N=&D&)/+?<-H;W4X).*NZWX5L=:TRQL&W0164T<D/
ME]0J_*4^C(67\: ,V\U[4[>'P[/+!9NFIZBL',;!HXW5V1@"QPVU>?0G&*S?
M%&L7NN>#?&#6)MH[*QCN+-A+&S/*43]X00P"X)('!^[GO73Z[H3ZS-I3I=K;
MC3[Q;Q08M^]E5E ZC PQ_2L:[\#3NFO6MCK)M=.UKS'GMVMA(4ED7#.C;A@'
MJ00?8B@ 37[WRAIFE(GVBTTZ"9FDMGF#,ZG:F$(V_<Y)/?IP:L67B/4]3O[+
M2EM(].U%K#[;>)<J9!#EM@0 ,,Y(8YSP!TYXCG\&WL=_::AI6ORV-[':I:7+
MFV65+F-?NDH2 &&3@U/<^$YEUFRUC3=5>WU"&W-K/)/$)EN8RV[YERN&W$D$
M$8SC&.* *WPW\T>'+OS]GF_VI>;]GW=WG-G&>V:Q;>[U^PO/&EYHL6GR+;:B
M9I8[G?NE @C)5=I 4X'4YY/0=:[#PUH+^'K&XMFOGN_.NI;G<T83:9&+$<>Y
M_P#U53?PK.+C61;ZGY5IJ[[[F,P9D4E C>6^X 951U4XH @L_%=U<:WHGF)!
M'I&M6/VBU<H?,$NT-Y;'=C[I)!QS@CWK;T.\N=0TQ;RX\K;,[/!Y:%<PY.PG
M)/)7!_&N<\1VND:O':^#;>.=+FV>WDC$4;J+:)3RPDQ@?(&7KG+8KM$18T5$
M4*JC  & !0!Y?J%UJEYX,^(9O[R&>.":Y@15A*E=L4>,'<0!CMC.<G-=!:^(
M=1TW6;:PU1;0V4NEO>1- K;XO*V[E8DX;(;.0%Z=*DNO!4D]IXBLX]5:.UUI
MWD>,P!C$SJJL0<C/"C'ID]:MR>&'GUFPO[B\CD6ULI+-H1 0)5?;N.=W'W1^
MM %/3O$6MWUUI$Z:>)=.OTW3;;=T:U#+N0[V.)!V. /45%X_G>27P]I))6TU
M+4DBNL'&^,<^6?9CC\JM>'_"E]H?DVK>(+BZTFV/^BVCPJK(!]U6D'+!>PXZ
M#L,5K:]H=KX@TX6ERTD;)(LT,T1P\,BG*NI]10!8OM,M-0LA:3Q*8E*L@ 'R
M,I!4CT((%8$OB'4;NTUN]TM+4Q:5-)#Y4R,6G:-07PP8!.I X/3/>M6VL-5*
M+%J&JPSQ#&3#:F%W_P!X[V'/? 'X51/A:2&?5A8ZA]GM-58R7,)AWE9&7:[Q
MMN&TD>H;GGVH IP>)]1U;6+&UTQ+2.VOM*^WQ2W"LS(=R#!4$9^]TR/KQ@TX
M/%VMMH>G:O-!IZP-?"QNHD#EF/G&(NC9PHSSM(/UK=@\-"SURTO[2X2*&UL/
ML$5N8B0$RI!W;NORC\*HCP9*/#L>D?VFNV.^^VB7[/R6\WS=N-W3=^GYT 07
M.O>)I[_Q!:Z;;Z9G2F0KYV\F4-&'V\$8/.,]/8YX)?%U[<Z/;:G9QVMO!/II
MNX_/4RO)+U,816#8 '+8(Y'2J^EQ7%]XO\80VNHPPK,T"L1%O;_4JI9#N&"#
MD<[AD#\=%O!20W(.GZA):6K:<NG/!Y0<^6N<%6/W3\QSP<_7F@"+_A)=5N[O
MP[%906<::Q8/=9FW,8F"(W8C(^?IQG'457?Q7K$?AB75&ALS)I^H26NH;8W*
M^6DFQI(QNR,#YL$GOS6A8^$Y[*?093J8E_LBU:V0-;X\Q655[-QPB^O?K48C
ML?">GW=OJEP]W'JMY-((XK1V+/+EFCPN[@\@9Q0!LVM]-=ZS<Q1-"UC!%'EP
MI+&5ANQG.,!=IZ?Q"JUQJUQ/XC?1+!H(YH;47,LTT9D W,550H9?0DG/IZ\.
M\+:.-"\.6=@=QD1 9"[;CN/8GOCA1[ 4E[H+R>((M;L+M;:\$!MI1)%YD<L>
M=P! 92"#T(/<]: ,$>,]3EL]/,-G:K=MJ[:3=QNS;5D4,2R$=B%!YSUK:T#5
MK^\U+6--U(6S7&GS1J);=&171T#CY6)((S@\U7E\(*8+!(;S8]OJ)U*61HMQ
MGF.[.<$8'S'CT ]*OZ;HLEAKFK:DUTLG]HM&QC$6W9L7:,')SP/SH @?5KR^
MU[4-)TQK:*2PAC>62XC9P7DW%5 #+@87).>XXK%A\9ZGJ$.@FRM+6*74)Y[6
MX2<LWE2QJ^<$8R,KGW'''6MV?094\0RZSIUXMM<7$*PW*20^8DH7[K8#*0PR
M1G.,=JJ+X02W;1?LEYY:Z9-)/\\6XS/(&#EB",9WL>!U_*@"]J N_P#A$+T:
MAY!N_L4GG>0#Y>[8<[<\X^M<QHFM:SH^D^$A=0V4FDW\-M:+Y6[SHG:(;&)/
M!!QR !C/4UW-W;)>64]K(6"31M&Q7J 1@X_.L.P\,/#!I5M?7JW5MI6TVJ+!
MY9+*NQ&<[CN(!/0 9YQTH I0>)M5OTLK_3K$7-C<7/EO"('#K#N*^8)"=I(P
M"5QWQGC-4%N7M/$GC.[U-[:XL+6V@>>$VY.^,1NP498@>^0<Y[5K:9X2NM)N
MGBMM<G71C,9ET_R5RA+;BHDZ[,]L?CUJPOA@/J6MW%W<I/;ZO$D4UOY6W:JH
M4 #;NX//'Y4 59/$.I:>="N+Z.U>SU65+<K"K!K>21<IR20XXVDX7U]JIP>*
M=9%KJVIW<6GKIVE7-U#.B!_-D$:_+L.< DXSGU[8YU+3PQ+'!I=M?:A]LMM+
M<26RF':Y95*H9&W$-M![!<G!IUEX62'3=9T^]N!=6^J3S32!8]A7S/O ')_"
M@!MCJFM/K=O;W%FLMC-"S-/';O%Y$@Y"G<3N!YP0!R.G-0^);G4HO$OAJVLK
MN*&&XN)1(KPE]Q6%R,X89'MZX.>,59T+0=1TORTOM>FU&"W7;;H\*QE1C +L
M.7('&>/7&>EC6M$?5;O3+N&\:UN+"=I4<1AP0R%&&#[-U[>AH Y"34=4TB\\
M<:EIRV96SN4GE6=6)D"VZ$J,$;3C/)S]*W[OQ%=W%U<6FE1J)H+6.<F2W>8,
MT@8JGRD;>%ZGUZ<4D_A*6>W\0PMJ*@:U_K#]GYC^0)Q\W/R@?C^5)<>$[Q=0
MM]1TS6WL+Q;9+:Y86XDCN$7[I*$\,,GG)H VM/OYIM#AO]0M6LIO)\R>%CDQ
M$#YAGOTKB]9U&_UG2/#&JM]GCL[O5[25( A\Q$+Y0EMV"<=1@=>O'/=Q6:1V
M(M)&>92A5VD.3)GJ3]<GI7*1^!KN+3;+3%UUS86%W'<VJM; R($;<J,^[# >
MN!^- $FK>*-1TN\/F1V@C&HPVHMP"\AA<JHD+JV$)+'"L.WO4(UN^T[Q#XMN
M[VYCEL=,MX9%@6(@[?+=P =V <GDD'/M4MSX(GFBO8$UN1(+C4%U%%-NK%)
MZL03GYERO XQ[@8J])X4CGU+59YKQY+75+=(+JW,8RQ5"F0W;@] .H'TH +'
M5=:DUJV@GLUEL9X69YX[=XOL[CD EB=X/(! '(Z<T[Q)XA&@SV"S21VMK<EU
M>]FB:2.)AC:K8(QNR>2<?+[\&A:!J.E>5'>Z]/J%O;KMMXWA6,J,8&]ARY X
M[>N,XQ?U&PN;R:)H;J)(1&\<MO/!YL<H;;U&X<C!_,T 8<^NZ[_:FCZ=;IIC
M2W]E),TQ+,BNFSD8/*_-P,\^HJO8>,[V2'[#>VT,>L+J+Z>_DHSQ';&9/,5<
M[B"HZ9SD]:I-IB:)XM\*Z587L:&ULKI-TR;P2Q0@%01C/.!GMWQ6S=^"X[G3
MV6._EM]3^VG4%OHT&5GQM^Z>-NWY=I/0<D]: (U\2ZK;(UO?6*)<37\=G93F
M-HXY@X)WE"2PVA6R,\D#!&>)-9U37=*T#7KJZM;"86<7F6TF"$G3;E@R;B00
M>.O/M3[WPG/JFC_9]0UB>744F2>&]CB6/R9$SM*H.,<G.22<GGIB2Y\.7M_X
M>O\ 3M0UAKBXO8O)DN/LX143GA4!X/)Y)/Y "@#-UV2_G\4>#S#<01K*\SA6
MA9@'^SMR<.,C!( XQZFG_P#"0_V-=^*$DL;2.#3$AEC%NFPRM*&/S'U+8[=R
M>:T[KP_<7.H:+>?;XU?2P^%^SDB0LFPY^;C@_G44_A**]N]>>\N?-M]8ACBD
MB6/:8P@(4ALGGG/3J!0!7E\1ZGID]U/J5IYNEPV;W#7,5N\)C=>2A#L=V1T(
MQ6?J$NI7/B'P7<WIM0DUQ))Y<2,#&3;N=NXD[A@]<#I[\:UIX7NWTZ?3]<UN
M;5+:2!K=%,*Q$*PP2Q&2S8[_ %XS4%OX1OT?1OM.O-.FDR%H,6H5W784PYW'
M)P>H ^G>@!?'^\:1IQC56D&K694,< GS1C)YQ3$UKQ''K%_HD\.G/J LC>V,
ML2N(Y%#;2C@MD')'(..<X[5M:]HPURPCM_M#0213QW$4@4, Z,&7([C(Z9%5
MI((-%EN_$6KW/FS);K"TD,#!8X@V<*@+-RQR3D]!T H @TGQ#<:Q9:'+;&#S
M;M&DNU,;?NE08< ;N"'*KSGN>U,\:76H6L6C"QND@$^J6\,NZ,MN!;('##C(
MY'?ID4_PMIEM#<:KJ]M'+''J5QYL22 KA,#)"GE=S;F_$5>U_13K=I;1I<FV
MFMKJ.ZBDV;P'0Y&1D9'XT <S))JMOXT\22Z>UG]ICTVU=WGC8HQ'FG 4,#SZ
M[N/>M"W\5SZE!IB6<:PW-WIR7[EH'G$8; "[5()YW<Y[>_%Q?#EPNJ:G??VB
MK/?VL=LP:#[NP, W##)^8YX';I6>/!-Q;6^D/IVM/9ZAIMM]C%R+<.LT/'RN
MA//3.<]: -[0;V_O]'AGU.Q-E>'*RPYXR"1D>Q'//K6E5:QM7M+1(I+B2XEY
M+S28!=CR3@< >@'059H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ6I6FD:?-?7TPBMXAEF(S[
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M2M#TG?<[)R5,K*2N <@L5.!D=1GK0!ZC6;K&L#1Q:,]G=7$<\ZPL\"!A#N.
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MY++RI4MM5E;)X'&".E5=,O;@:UX5G@O;J>UOVN0]Q/,<W:^6SAC%RJ@$#;W
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MF 1DL2>3G@8]<Y^A7<UY!X6T$SK%!)X<@N(T,KQ^<^%4@%""2H .,_Q$]A@
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M3@C(RL(5^&;<3]W./7FDACB^W_#G]SQ;V\@E_=G$1-N -W'RG>,<XY%>CT4
M>3S"ZCLM;NK>UNIX;;Q2+V:&W#+)+;^6@+IC!;#?-QW6IO$4>D:AX+\2:CHM
MG?R27\<$;SSK-NN'5AA523D[1W Q]<''J5% '%2>6_Q,1K=/W+Z"\*NB_)N\
MU65<],XR0/2L+28TN/ WA>W-[?:-J5BA2.\:W(2&55VLDBN,%2"1SQD 9S7J
M5% &'X1N+ZZ\.02ZE;1071DE#^2I5)/WC?O%!Y ?[W/]ZMRBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK<@3'=F14&5^7D#9WQUI/#%AXKTJUM=&OO[/>PL5$<=['(WFS1KPBF,KA3@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK/5]-U"5HK._MKB15WE(I0Q"GHV!V]ZEN[ZTL(A+>7,4"$[0TCA<GT&>IXH
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M!O)E;_8Y4[NA]:^C:* /!M:M+RPE^*=IJ,<CWNK&!M.7:6:Y0E@JQ_WBN5!
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M]:]KHH \A^$.I6_A_P #:W<:D)H(DUJ0A?)=FVR"-4(4#.">^,<&O7J** .
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M5Y)A(F%W!O(PP +GYNF<>O(S=T^^\-:^TFL6@U&6]M].EAG:[61!;(PYB?<
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M#SQE"@!+>(VDA11DLIGB;<H[C 8Y''!KUZPLH]/M1!&SO\S.\CXW.[$LS'
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MXID[E>5.X< *<XQ6_HUK:R_%'6TO8X+B;^S;)=[Q@AY$+E\9[@["?3BO0**
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M"6<;U,8<G<O;._\ 2@!C_$/24N[!2&-I?77V.&Y65&'F$D+E VX*2" V/3.
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M7#QM&C*5VXYR2#G..M.\1:5J$WB7P]K5E ERFFFX$T'F!'82H%!7/!QCH2*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOC-;=<7?:]K5_?ZIIVAH6N-/MXF#QK$ZR32(7 ;>Z_)C'W>>3R,<[Z7FK?\
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M%<=I.KZ]XBTVPUW3)K06DUZRO:3+@"U5V0MN'/F_+N_N]L=ZR[[Q=K5KX/\
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MUM]FQHT5E3&5)7 8C@BI/^$.8:8-._MBZDM7L%L)DFCC<.B[OF V@!L,1Z8
MR#BKFD:_)J?B'7-)DLQ =+>%1()=WFB1-X.,#'&..:W* .0N? ,"ZC;7VC:O
MJ&CS1VL=G+]E*,)XD&$#!U8;@. W6NAETR-]$ETN*6:&-[=H!*C9D7*D;@QS
MEN<Y/>J-UK\EKXQT[039@I>VTTZW'F]/+VY7;C_;'.:W* .2U+P'::VE\VJ7
ML\UU=60L3<1(L;+&'#@\#!;< ?3C  R<SVOA![?7'UA];OY[V6R%G(TBQ!7
M+$-M"C!&X\#CUS7344 <=;?#^&RL] AM-8OX9=$$D=M.JQEFCD #*P*E3T&#
MCBFQ_#RWAL;>SCUB_$5MJAU2+<(V*R;V<+G;RN6.<\GUKLZ* ./\7I;^(O\
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M0$1^7O&5SG;QC.,\XI(?!L<,WAR0:C<'^P8C%;@HG[Q2GEG?Q_=],<\UTU%
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MI\]M:_\ 'O#);H5B_P!T8P!]*LR:/IDUW!=RZ?:O<VZ[89FA4O&/13C('TH
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M5A_X^4PI#G*[AMZCIG=WKFM=\<R:CX%U'5]%FNK&2TOD@W26Y7>GVA8FSO7
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M -3QC8:3X>TFY&H76M)J%_\ 98;M;<_,3*0V=BX&T @#&6V\9ZUIV/BVSO\
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M]+;3+;48[V.6UN2%@>++F4G/"A<ECP> ,\'TI+?Q!I5U875['>QBWM&9;EI
M8S"5Y(=6 *GV(%><V.@:MH5UH6MM9W#V,6KZA<RV449>2WAN<B-M@R3M') !
M(WGCK2^(= U>_F\3:[I=G.\,]SITJ6;(8WNUMSND^5L'G@#(&=GN* .DM/$4
MU[\4ETR"\N#8'1WN6M9K8Q;9/-10PW*&(()]1UI_CG4M3TV[\.)IVH26JZAJ
MD=E.%CC;Y&5B2-RG#?*/;VJG97DFJ?%"RU6#3-3CLFT62W,UQ9R0A)#,C;6W
M 8.%/MZ9IWQ&M'O[KPM"NGW%Y%#K,5Q<K':M*BQ!7!+8!&,L.* +&A:]J9^(
M&K^&;FX34+6TM8[E+L1A7B9CCRI-N%)Q\PP!Q6X_B72([^&R>[VRS3&")C&X
MC>49R@DQL+<$;<YR".U<SX=L[CP3K]SHL=C<S:!?.UU97,,#.;9V/SPRX!(&
M3E6/;()XK(\-6C)!:^&];\-ZM<:C87>]+F1I&LWQ(66=7W; 0#G&,YXQS0!W
MG_"3Z-]N2S^VCS7N#:JWEOY;3 $F,28V[N#QG/!':I3KVFB]6T\]S*TWD B%
MRADQG9OQMSUXSVKS6]&IW;6$DF@ZG#/9^)EGEMK:S*P)%YC_ +Q2 /-+ AB_
M."3]T==1;/4+3Q4MWH8U&*.YU4C4=+O+9FMRNX[KF*0C"' #<'!)QUH [*X\
M3:/:W!AFO F)A;M(8V\I93T0R8V!N0,$YR0*AO\ QCH&FW5U:W6HJMQ:H))H
MDC=V53G!PH)/0YQTQS7"+I>I'X<:WX+NM/NI=5DGN$@E,#&*<2RF1)O,QM &
M[)R<C;TSC.W;6T]KX]UB::VO)8?[$M[=;G[*Y65T,A8 @<GYEZ>M ';6EU!?
M6<-W:RK-;SH)(I$.0ZD9!'X5-7,?#N"XM/A]H=K=6\UO<06J12Q31E&5AP00
M173T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5D:_X?@\0P6L-Q=7,"VUS'=)Y!0$R(VY<[E/ (Z5
MKU@^+/$,WAK3K:[BL/M@FNX;8H)0A7S'"@C(.>3TX^M &Z!@ $DX[GO2UR;^
M*]0@G33KO3;6VU5HWG,37;/$L0?:AWK&3EN>-O&#GL#7M_'ZW$&C++8KIUYJ
M:3%8M2E,*J\;*IC#;3DMNRO R!GVH [%IHDE2)I$623.Q2P!;'7 [T^N3N-7
MSXG\*07^A0K>7T$TB3O(&>S<1!I$'R\YR%R",XZ55O/'TL.FSZI;:8D]C#J?
M]F'=<%)"_F"/?C:<#><8ZXY]J .VHKC+OQAK":GKFGVF@P2S:5;0W+-)?;5=
M75R0"$)#?)@<8/.2.,V6\733Z9IU_9:>HMKS3OMYN+R;RH8\A2L18 _.=WY
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M%E%:^7ME;<H<2-NQMY)P >0  .M=3-#%<1-%-&DD;C#(Z@@CW!H ?D$9SQ2
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MGH..N> #HZ*R/#&MGQ'X=L]8^S?9DNXQ+''YF\A2.,G YK7H **** "BBB@
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MN598SQN'<$$@_6M^B@#CM2\&-XFGOKG6S##+<:8VFQQVKEQ$K-N9]S!<G(7
MQQM[YI^G^'_$-[HLVD>)]2LKBT:U>TW64;(\X92F^0L< X)X QDYSQBNNHH
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M=N$1.=N.V[DX[#C&IXPT2]U_2[>TLI+>-H[R"Y9IB<?NW#X& >N,>WO70T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex109keyexecutivebenefit004.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9@,O./F!.#V'<@<U8L/'.D:CH_V^);F.3[7]A-G+%MG6XS_JBN<!N_7 ').
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M_&=IQCU_.@#K+WQIIUC/<K)!=O;VEW'97-TB+Y<4K[< Y8,1\Z9(4CYOKBC
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M7=I)!&@95^9E(!)8@8YJQX>M9;?0=+CN[4P7=M:) RL58J0JA@"I(P2H_(4
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M"KE=XVE2756S_>XYP1B7.GWNI>"/%.@VOA^_M=9O5-Q(MU<0-Y[S$C?O1MH
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M#[7=A(FN4C.[8 H5ER"0QSGC '.<C:\-WVIZCH5O<:SI_P!@U [EF@!R 02
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MA+N"J<AF (/ QU/%?4/%7B:-/&#VHTI!X?8.HDAD;SD\D2E3AQ@X.-W/T[T
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M -LO^C_ZD>6(OE^;GY1W[\^U=710!S'_  B<C:AX>NI-01O[&@D@5/L_$P=
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M:UA>'$GR',:N^<,JG&,*#\HR3SG8\-ZTOB+PYI^L)"8$O(5E$;-N*@]LUJ4
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M%1:CH>FZM+;RW]I'</;N)(2^?W;#HR^A]QS0!RDNGV[_ !JC=O-W?V&9N)G
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M9R.& /0@T ;4GB31XCJ >_B4Z< ;S.?W /(+<<#'/TYJ8:UIQ2T?[6FV[0O
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ML;'/&X'!YH Z(D*,D@#U-+7FC>*I;_X8ZIJWB31(KVT%S+&]M#.,%5N&0 Y
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MX'/7IQFIHWB?2K/1)[BUTI[.2?69;)+0."TUT9"&)/09(9CUP >O2@#M:0D
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MG?$(WFC?VU<:)<6FE;9!]IDGC/[U9O*6/;G^(_Q= <\XYIY^(=I;3:I%>VZ
MV%E]N$EI.)XI(\[2-^!M8'&01T.<XH [,D $DX ZDUC:+X?31K[5+M+R:=M2
MN/M,JR!<*^T+\N .,*.N:S-7UT-X4UJYU'1TO-/BL3,PM;D21743*VX*Y"]
MO/U&*LQ^(8HYM(TG3[)6NKNQ-U'"TFQ(H5"CEL$]64  >O2@#HZ*XB/XBK+H
MNFZDFA7NR^U$:<J&2/*R;BA_B_O*P[=.PYK:T'Q%)J^HZKIMUI[V-[IKQB2,
MRB1661=R,&'L#D=L4 3ZWH?]MBW1M3O[2&-F\V*TE""=2,%7."<?0@\]:U$1
M8XUC10J* %4#  ':L&;Q)/'XEO-#&G SQ6/VV!VG %PN[:0.."#USZCUJ'1?
M%PUW2-$U"SLU9=4+'R_.R844'<3QS@C:1_>(&>] '2@@]"#CBC(SC(SZ5YO=
M^*&T[P?K6HZ!H\=E,FMM:W"S2C/FM*B/+P""26Z9QWYZ5-<S7EI\6?M%MI2S
MW\OA_+01SA5+"<<ER!V &<9Z<4 >A$@8R0,\"EKA[CQ5IFLZ+X4U2?1I9X]0
MU*)( [J/LEQE@&//)!#C@?E4FH>/;BTD\0K#X?N9UT+:UTQGC3,9C\PLO7)V
M\@?GCC(!VE-+HIP6 (&<$]JABNOM6G)=VBB02Q"6)6.W=D9&3SBO(T^P7OP^
MOO$_B?P\FIO:W=W(7CN,2./.="K'Y?D4  #)X XXH ]C)"@EB !U)I0<C(Z5
MPOBNXO9/&7A;2ULK>XL+@7,C02RX24K$,!AM(PNXD=<GTQ5;PSK@T"T\26]Q
M916FBZ'=F"!([@R,H*HP0;ASN:3C) &0O09H ]#HKCX_B!8PWU];:A'%$EK8
MM??:+6X%Q$T:G#*2 ,../E[YX)IT'CE'U;^SGL5DEDM7N8#:723!MO6-SP$?
M'/4@\X- '745QFE^/FU ^'YI=%GMK'7!MM[AIE8K)L+A2HYP0IY]1TQS5[QG
MJ\VG6>G65K(8[G5K^*P25>L:MDNP]PBMCW(H Z6BN(^)UK';?#'5%MC) ((T
M,?DR,F/G7.<'D')SG.<UM^+HM6G\.7$&C6R7-U*51HVN/(S&3\X#X^4E<@'M
MG/:@#<HK@_ MKH-WI.J:?;Z1>:7>1RB+4+*ZNI)9(9 ,JRNS'C!RK+CUK9\$
MZU/K6@O]L;?>V-U-87+XQO>)RN[\1@_4T =$2 "2< =2:6O,/B+K7]N?#S5Y
M[.P6;3H;E8!=&7#%TF56=%QRH;*YR#UX(Z]+XB\9'P^FI7,FF2O9::L33SR/
MY?F;^T((Q(5'7D>E '545A#Q$P\8IH$MGY8FM#=6]R9?EF4$!E Q]X9!(]#F
MJ:^,0S:;#]F@CN-2>?[()KK8DJ1$#<&VGEMP*KCD<\=* .IKF;+P@^G[H+;Q
M#JZ:>SL_V,M$0-Q)8"0Q^8!DG^+/O6W:7K3:5%>W<+6;&(22Q2,,Q<9()]JY
M[_A-XTL]*U2>P>+1M4E2*WNO,RR[_P#5M(F/E5N,$$XR,@=@#J(TBMH8X8U6
M.- $11P !P *DKSQ[5_$_P 0?$.D:SIL%SIT-G:HBM.<PJQE.],+D,Q5<D$$
M;1R<5L:[K6IZ9XK\-Z186T,EM>F<R-),0S>7&3M^Z>.0<]21B@#J@020"..M
M+7E>D>(#X1A\8WB:3)/I]OK\C7$D<BIY2%(02JGEB,YQQQWKK-<\9V^E3WT$
M$<%Q/8PK-/%)=+"S @D+&"#N? SC@<CGF@#J**S(]>L7\-#7W=XK#[+]K9I%
MPR1[=QR/4#M6+9^-TNM;M=+%I"9+V!YK5X;M95!49*2[1^[;!_V@<'!XH ZV
MBN4T'QF^O70M(M+>&[AFEBOX))OFL]A !; P=V<KCJ.>QQGW7Q&N(+/5KV+P
MS?36FD7;V]]()HP8U0*2ZC/S8#9P.PZT =UD9QD9ZXI:Y2/6=-NO'-ND&EM-
M=R:,UU;WX91YD!D3]VHSW+ Y..E5=-\>WFIZ)_;$7A>_-BT3%&21'=Y1+Y83
M8.?<MT !],D [6D) (!(&>GO7&W_ (VN8=.\5)!8P?VGH-L)W3[1OB8,C,"&
MV@Y&ULJ0.1UYS3&U=)/^$-.LZ0)[R\E'D7*R@K#)Y+-OZ Y*[N,8&>M ';45
MRM[XT%O8:GJEMI[W6EZ9,\-U,DH#_)_K&1,?,%YSD@_*< \92?QE+)KCZ5I>
MCRWTO]GI?PRB=(XY8V8@<G..GIGIQCF@#JZ*S/#VMP>(_#UCK%NCQQ740D"/
MU3U!^A!%8DOCN&'2;?7FLF_L":<0B]$OS*"^Q963'^K+8YW9P0<4 =:S*HRQ
M '3DTM>?ZE%+KOQ,NM#U/3K>ZTL:.K>5)-D*'F=6D V\-A .#D8X-:?B'5=0
MT"_\,:5I5M%);W=S]F8S3D-M2)F"Y()YV\L>>/?( .LR,D9&1VI:\P@UB;PQ
MXC\?WUKI#W<%M-;W%PL<JQA$%LK.1G[S=3C'//(XSU.H^,[6V<0V8MIKC[(E
MX4N+I;<&-\[ "0<L=K<8QQR1D9 .FI-R[@N1N/.,\UG:+K,6O>'[75K.*14N
M8O,2*8;&4]-K>A!&.]>>Z3=VLMIJOB'Q'IZ23V&NSK:S13$S>:)?*CA7A<KR
M%P3M/4B@#U2D(RI&2,CJ.U<\/%$EOKG]C:AIQAO9;9KFU$,PD2X"_>4,P7#C
M(R#Q@YS7+ZE\0]8N/ <_B'3- :WMI+5)(;JXN4P&:0(0$ ))&<C( /\ , [/
M0M 31(Y"^H7NHW,N%>ZO9 \A5<[5X   W-V[FM>N>_X2.X@\4V&AWVG+ U[!
M)-%<+<;D9DQNC'R@EL$'Z9],5HZ3J;:G;S3M (8UGDAC;S-WF!&*EN@P"0<4
M 7R0H)8@ =2: P/0@_2N'\6W-[+XV\,:6+."YL;C[3(\,LN$F*Q#&X;2,+N)
M'7)],5!I%UI?A=/%<&@^&I(Y-(\MYX_/R]POEEQM)+=%. ,^W% 'H%%8=MXC
M2[@TBXABC:'4+8W;.)N(H@JDMTY^\H[<GZUEVGQ M+K4=)A6!&M=5)%O-#<"
M1XSC<OFQ@90,.G)P>#B@#IKW3X+\0F3<LL#^9#*G#1M@C(/T)!'0@D&K5<SX
MKU26&^T+0[=VCEU>[,;NIPRPQH9),'L2 %SVW$CD"HO%TTC:'J&DZ8QM_)L9
M);B6+Y?)C"':BXZ,Q&/90QX.W(!U=5;RPAOFA%QEXXG$@B/W6<'*DCO@C('3
M.#V&.*DAUB\^$V@6^E6*W[36-J+F$W9MFDA\M2RK)V+8 [<$\BI_!MIH>J>$
M[NUTNRO-+E2X>.YAN)GDGM+E0!D,[$\#:00<$'W(H [BD) &2<#WK!\%:])X
MD\(V.I7"JMRP:.X"\ 2HQ1\>Q*DCV-<?XXUDZ_X1MK^TL%?33JULD%V9?G.V
MX52X3'W"00#G)R#C!H ]/K'7P^I\0OJ\^H7TXR&ALY)!Y$#;=A9% SD@GJ3]
MXUF:WXT.B&\GGTR7[#9W,-O+-(_EM(9-O,2D8<+O&>1T/I5Z#Q$S^+KKP_/9
M^0\5J+N*9I<B>,MM)48XP>#GID=<T ;M%4-&U!]6TBWOWM_(%POF(F_=\A^Z
M<X'48/XU?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KG/&6BW^NZ99VVG_9M\-_;W3&>1D&V.0/@
M84\G&*Z.B@#@]:\$7OB#4_$OVM[>&RU?3H;6-XY&:2-XV9@Q4J 1EAQGM[UH
M)H>K:M?Z#=:ZMI&VD,TQ-O*S_:)BA0-RHVK@EL<G.!VR>LHH \YF\%Z^WP^U
MCPPC:<3<7,KVTS3.,H\YERXV?*1G&!GZUIW>B>);#Q=<:[H?]FRIJ5O%%?6M
MY*ZB-X\A71E4Y&&(((&?Y=/J6I6^E:=-?7 E:&$?.(8FE;KCA5!)ZU<H XK4
M-!\3V/B.#7=$N;"[GFLTM-0@O2T22;69ED0J&VD%V&#G@^M=;8QW4=E&M[*D
MMS@F1D7:N2<X4>@S@9YP.:L4V2-)HVCD171AAE89!% 'EG@W1K[Q)\+= TR>
M.WCTX3K/+,)27=(YRX4+MX)90"<],GV&]8Z%XKT35M2M=-N--?1;^[DNUFG+
MB>T:0[I J@;7&22N2.O-==8:=8Z7:BUT^S@M+<$D101A%!/7@<59H YK1M&U
M*P\7^(M4G6U-KJ1@,(25BZ^6FSY@5 &>O!-<^O@76&T5E,UE%J5MKSZU9%9&
M>-BSLWEN=H(!#%20#Z^U>BU4LM1@OWNTA68&UG,$GF1,F6 !^7(^8<CD<4 <
MCK?@B?Q9)JEUJ;16<UUI?]G0)"YE\L%_,+L2%S\P7@#HIYYX(M&\5WNN>&-0
MU.+2D;2?.6X:&Y=O/WQ[-R@QC;ZX)/UKN:SK_6['3+^PLKJ1UGOY3%;@1,59
M@"V"P&!P#U- %;PU?ZK?V5TVKPV:317+QQO9NS12Q@ A@6YSR5/;*FL#4=/L
M-=^(.G76G:C%(8H735(H'5PZ1R*T2O@_*PE['D@..QKKM3U&#2=.FOKE93#"
M 6$,32-UQPJ@D]>U+9Z=8Z>9C96=O;&=S+*88@GF.>K-@<GW- & VAZGIGC6
M^U[2UM[B'4[>**ZMYY3&5DCR$=6"MD88@C'OSTK)'@C4=*L_#\VEM:7-_IM_
M/>3I/(T4<QG#B3:P5B,%^..@KOZ* .9\)Z+JFD7FO3:BUHRZC?F[C^SLQ*Y1
M%(((_P!CUY]JJGP]JZZYXLO56R,6KVL,-N#.P92B.N7^3@'?GC/2NPK.UO6[
M'P]I<FHZE(\=K&0&=(F?!)P.%!QR0,GCF@#EK;PIK4-KX'A(L"=  6Y(G?\
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MF#=^E6?$G@_Q)KA\1Q%],DCU.U2.TEGE<M9D( T:KLQM9LG<"#SR#@"O1:*
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MEMX2Q0SE2PW$L1D =R:SG\$Z<6U*..XNXK#4Y3->6*,ODRNWWSRNY=V/F"L
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MLQR,*VTL5SC''J#5O6_#?]A:#HFC6*Z]-IEM=O.]U8,K7-N<,5^4+\REG/\
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MQ*@4@32^3MDV  A7YX R,CKS71+X$T:/P[::-#]HBCL[C[5;W"R?OHIMQ;S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOI_BG1[:VT.[BL'L+'"1:@DI\R6%?NIY97AL  G.!VR:SYO"VMR>$-5TL6\
MN;O5S?1DS_*(S<++@G'7"XZ=:]"JE:ZO8WNI7FGV\^^ZLMGVB/:1LW9V\D8.
M=IZ4 9%CI>I6GC?4]3\J V.H6]N&8RD/$T8<;=N,'.X<Y[&I?%>BW6L6-J^G
M3)!J5E=1W%M,XR%(.UP?4%&88[UOT4 <II/A$Z1XJN+N"4#2VBCD2 G)%R%,
M;2?C&!GU+$U6N/#6I7DWC962&*/6[=8K5S)G!$/E_,,<<\\9XKM** .-CT?6
MI=4\*7EQ:6\8TN*5+A4N-WWXP@VY49Y&3TZ]ZSV\(:Q);74Z+!%>P^(#K%HC
M2Y212,&-R!\I*YYP<'%>A44 <C>>&[K6]0U34KE%LY;G2'TN",N'*AR69V(X
MZ[< 9X!]<"G8:+XB?4O"ES=65E!'I$$L$X%T6+;HU3</E[[<X_,UW5% '.>$
M-*U'1;.\LKV.#ROMD\T,L<A8R+)(SC(P-N-V.I_QKKH%_HGBV_UK24CN+34P
MAO;-WV,LBC DC/0Y'53CUSVKJZ* .-D\,WFL^)=6U*^C6TM+[2#I8B\P-+RS
M$N<?*.&XY-1P>'=6O=%T+1=4B@1-*N(99+F.3(G6'[FU<9!.%SG&.<9KMJ*
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MEPOMC]:V_%&I7FDZ.+NTMYY@LR"<V\?F21Q$_,ZK_$0/KZX.*=9Z EGXBO\
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M0:C!#,-2O8;N1I2T;10>4$0XPN,G.#GFKU-12L:JSEV P6( )]^*=0 4444
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MC-"+>-I6>,8RP"@G'(Y]P.] &F    , = *8D4<;2,D:JTC;G*C!8X R?4X
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M[+0ZFP2TD$3[96() SC@X!ZXZ5#;^+]#NM2&GP7C27/VAK8H(9/ED5=Q!.W
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M6EN)K97DD;JQ/>MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,S+]TR1AL?3-3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M96V?OF=N3MR,;_0YQVIEKX;U6"\\)2L;,KHMH]O/B5LR%HU3*_)_LYY]<>]
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M;S7_ '@$31_+\G^UGGTQ[U57P?XAV60DNM,DFM-7^WFZ?S#)<K\^-_'!4/@
M$C  R,4 ;<'BMV'B!+JQ6WN-'/S1>?N,RE=RL/EZ-T'4Y!&*Z&W>5[>-YXA%
M*R@O&&W!3W&<#-<?=V>G:]X[L+O3M0BE-M$Z:DD#JZLJ.K1(^/NL) 2!U(#"
MNTH XVU\57MOJ?BF758K=-/TF1$7RI26P8U<8!4 EMWJ,' YZU.GC-QJ$]F^
MGI(ZV;744EI<^:C;>J,Q5=C=^X([U7O?!UY?7/BB"2Y@2PUH(Z2+N,L4BQJ@
MXZ8!4-G/MCO5NRL_%L^FSV^LW&E/((&BC^REP)F(QOD)'R_10>3UXH H'QY?
MIX<AUZ3PY(MA/';/$WVM"6,K!<$8R,%ASW![5>_X2C5#K=WHRZ OV^.W6Z@!
MO (Y(BQ7+-M^5LKC #?7'-5+CPMJLWPYT_PXK60NK46R-(96V$0NC9'RYR=G
M3'&>]:2Z3J2^-I=<VVGD-IJV@C\YMVX.SY^YC&6Q^OM0!FR^)['5M+\*ZE+H
M_G)J%]&D/FN,VLV'&[W(VN.*=?>.+NU&OM%H+RIHCC[2S72KNCV!RR\')VG.
M/U%5+/P?K%MX<\-::7L6DTG4!=R.)GQ(H+\#Y.O[S]/?BS=>%]6G@\8Q!K(?
MVZNV$F5_W?[D1?-\GMGCZ>] %_6/%4FG6\]S!IQEM8+$7K3SR^2C@YQ&AVD,
M^%/''5?6JS^(]1NO%6@VUE!!_9]_827G[R4JY'R=0%(& _3/)[C'-2Z\*:[<
M2S*9]/>&;218J)6=C:OM96:,8 (;(R3@\#KC%6+3PUK%K>>&;L36)ETVQ>RN
M5^?:58)\R<<D;.AQUH ?+X[@62WEAMDN+&6[^REXI]TR_,4\PQ!?N9'7=G&#
MBNLD+B-C&JLX!VJS8!/;)P<?E7(:+H/B70YI-+@OK!M"\]Y89&5_M,2,Q8Q@
M?=/)(#9XST[5U[NL:,[L%102S,< #U- '-:?XMEO] ^W+IRQW@O38M9-/\R2
M"3806"]A\W0_+S3KKQ7(EMJMY9:=]KM-*D:.Z83;7+( TGEKM(;:#W*Y((JC
MH]A8ZAXYOM;TR^2YTXQ1R,L+!XC=E60NK#C<(L _[PI\?AG5-/\ ^$@LK"6T
M>PUB62X#S.PDMI)5Q)A0I#C/S 97T]Z -"S\4)J&N1Z?:P+)'<::NHV]QYI
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M,5#,=P";<$XS@[AUZ<<[UUX4FO?$6H33>0NEWFD#3"B2-YBC+'.-N/X\=>U
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M)XIY"C B7#1, IXRI!/IV(-=EI6E6FEPS?9K2*U>YD\^>.%B4\P@!B,X]!T
MSUQDUS$W@V\M] T;3K&2VDDL]334;B29F02,)#(P4 '&2Q ST '6NU7<5&X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKBVNI(U5]DD4F4;: #@J<'%;-CJ=Q>:WIOAV*YDM8H]$CO7>(+OD)8( "P.
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MQ4FI7VNO=^-EAUV>W32(HY[4)!$2#Y!DVL2IRN?Q]Z /0Z*IZ1=O?Z+87D@
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M<'()Z<]:HZ1K.J/X@T2SDU"XN+?4=.FDDG:)%1Y$V?O(1@,%^<XW#!&#@]:
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M>ZNFN;"-XH6++C:V-V1MYSM'Y52E\#:1/I=QI\S73QS79OA)YNV2*<G)D1@
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MI1K6M76F:YH5G'#"UOJ%P\,KNQW)B-GX'3^'O0!M1Q)#$D4:*D:*%50,  <
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MMH/M;6$FY/)5QN&%. _EE_< =N,SZ@WA'5=(UK4-(>UN'?19(Y3;L#$D:@E
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MZUFZK8:G.D,6CWT&GH78W!-OO9E(ZKR &SSDY_H0"CX5FCUU)/$YMC$U^B)
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M48DY(&>< \<5UZ0Q1EC'&B%L;MJ@9P,#/X<4V"V@M4*6\$<*D[BL:!03Z\4
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M9+=E\V+.-R<989X_$52T/7--'A_3I+*XO[Y+R65+;[0<SRE6<MG=C &UNN.
M!UJ)[:^;XB6^JC3[C[$ND26[293B0R*X7&[/13STS6#IWAV=_!6D:5K&C7R2
M0W$\AEMIE6>T8N[)(C*W/#8P,]>G% '?V%['J%HMS$LB*69=LB[6!5BI!';D
M&K-8OA6#5;;0(8=9F::Z1Y )) -[1[SL+XXW;<9QWK:H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIZ9XH ]-HK@M4\3ZY%H_C"V;['!J.CVRSQSPJS(R/&S#@G(8;2,].AQVJ_\
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MB:^2;Q7"L5N6T6%)H6PV)0T1DPPSQTQD?7':@#J8XTBC2.-%2- %55&  .@
MIU<1'K6KW_BKPRL<UO#:WVEO>20>6Q^;]WGG<,\.<>G.<]NA\0ZTNAV,,HC$
MD]S<Q6EO&3@-)(P5<GL!R3["@"6PT2STW4+Z^MQ+Y]\P>X+RLP=@  <$X&
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MU% &/J^DW.I.R":U>RDA,4UI=6YE1SGAOO#!'Z^V*LZ+I<>BZ'9:7'*\L=I
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M!N7*NH!!!XY'4$"\GA^.XDOY]4>.ZGOK86DVR,QH(1N^0#)/5V).>_L*V:*
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M K6%M+:6:13W+W,_+23, -S'DX Z#L!V%6:** "BBB@ HHHH **** "BBB@
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MLHO)M8DV(BL?E7V.<_K6>OA'1%T^&P6TD%K!/]ICC%Q+A9-V[</FZ[LGZ\T
M<XMW=Z[I_BZZ-_=6=WIEW/!:B*9D6$1("K% </N.2=P.0<=J@_MNYMY?#FOZ
MK/<PV&KZ:8KJ%975(;@QB164 \%@KJ,=\=ZZ^X\-:3=7D]U+:GS;A EQLE=%
MG4< 2*" _''S \<=*NW>G6=]#%%=6Z2QQ2I-&K#A70@J1]"* .'\)7E_>QP:
M!J-Q=C5--O)'OF:Y8N\8 :/)!Y#>8G'0[&INCSZOXATS3M?@U-+21;PFY#74
MC(4#E6@,.-H., 'KD Y.:[N*PM8+ZXO8H%6YN519I!U<)G;GZ9-9</@[0+?6
MWUB+38TOG?S&<.VTO_?V9V[O?&: .=6ZN]-U_6_#<M[=O-J'ESZ7(\[LR1O\
MKA23QY9!;U((S4MT]]K/B#6M!M;N2!K&VA6V;[;+$Z[T)\WY1F3YL#YB1\ON
M<]A+I]I-J%O?R0(UU;HZ12GJBOC<!]=HK.U?PEH>O7L-YJ-@LMS"NQ)5D9&V
M_P!TE2-P]CD4 <M]GU+4_%ECI5UXAO1'+H1EFDL)?*5Y5E1?,3CC/7].A(KT
M)1A0N2<#&3UK/&A::NJQ:FEN4NXH?L\;K(P"Q_W H.W' XQVJ'2M!M]+U;5;
M^!!&VH2*\B*[,"PS\_/0G=R!Q\HH RYYKK_A9T5D+VX%K+HTLAA#_(KB5%#
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ME(A?VPD:%M\,BLR21-ZJZD,I^AH 9K]\-,T:\ODC26ZMK::>",]694)P._\
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MTL8IFEWR&$R1_*S');&\]>O?-2:WJ6K^"]4UV.SO[S4+?^Q6OXUO)/--O,)
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MZ,* /2)-<TF%+IY-4LD6T(6X+3J/))Z!^?E/UJ2RU2PU%IULKVWN6@?9*(I
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MY<>%Y)!S_&HXSUKD_ ?B8V7A/PM:7=E=F*^S;I?,RE3,=[!2,[N0IYQC/YT
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MV%Q.$NKUF6WCVD[R%+'D# X!ZT6.KV.I7%Y!:3B66SD$4ZA2-C$9QR.>#VH
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MJ.H6NE6$M]>2&.WB +L$+$9..@!)ZT <G::!J,6GZW;7>EVEY!J&K/=-;2R
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M,6JV4LRG[+S;-'LZ?-\V0^.>_/M5#_A*M?&BV96:S:\7Q =(FD> A95$A4.
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M>*? T=M>W5U 8;J,2SREC,JQ#:QZ!B>N['.: .VMKVWO#.+>59/(E,,A7H'
M!(_#-3UYEH?AFPUCPSXHTVW6*UNVU6]2"2/Y6B*R?)TYV@D<>AQWK<\)W_\
MPD\UOJLUK]G?3[<V;Q%=NRYS^]7'HNU0#_MM0!V-%<MXFDM)?$&BV$W[V>19
MY$MYG MF55 9I 0=Q7/R@>IZ=:Y31#J.H^"=#%A<65_=6UQ=,;"\<[+N)9'0
M*#S@J"-N<C\J /5**PO!]Y;WWAFVFMK:>U0/*C6\[;FB=9&#+GN P(!] *W:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB>#QC(P?0T +_P (]HIMWM_[(L/(=_,>/[,FUG_O$8P3[UHJJHH50 H& !T
MKE?"6L7&J:WXECDNYKBVM;R..W$L7EM&#$K,N-H/#$CD9K1U_P 26^@2Z=%-
M#<2/?7*P)Y4+N%X)).T'G .!U/T!H LSZ!H]U/)//I=I)++_ *QVA7,G^]Q\
MWXU/-IEA<6(L9K*WDM  ! T0*#'3"XQQ7)0>+(M*\4>)H]8U*7[#;?9GMU:
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M6-G>)=K)!>X%L8P7,V03\J@9/ )/'&#GI0!8BT^R@O9KV*T@CNYP!+.L8#R
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M9-+OW@TZZOUO+9+=C*@F=MD@3&6 !YQDX8^]>KTUY$CV[W5=S!5W'&2>P]Z
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MR).822Z!B,<_=_'TKTRB@#CY(I?$/BSPYJMO:7=M'IT=P]P;F!HB/,0*(_F
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MM;W,RPH781J3N8*.3C(X&34=GI0U3QAJFL26KII]QIT=@4GB,9N#N8LQ5@"
M P7D<\]L5UE4]4T\:KITMDUU=6HDQ^^M)3'(N"#PPZ=/RH Y?P3I]_;RSV^H
M,)8M&+Z=8R[LF2/(;<?<+Y2>Q1O6MGQ>UVGA34&L=/34+C8-ML\8D#C<,_*?
MO$#) [D"M*PL8-.LH[6W#>6F>78LS$G)9B>22222>I-6: .'\.QW*^/M0O&L
M]4^S7>G0!+F\C*[F5I-V0<;3R/EP/7&.:T/',%\VG:;>6-K+=_V?J,-W/;0C
M+RQKG(4=R,A@/]FNHHH \Z:637?&&NBWM;F![GPVL<4=S'Y;DEY0,J>1R<<X
MJ+3&O;B[\!8T?4XUTV&2"[:6V9!&_P!G"=^V[OT/8GG';1Z%#'XDEUP7-P;B
M6W6V:,E?+V E@,;<]23G/>M2@#RRU75+BY\,W4^AZC!/::G*;FVBMO+@MPR2
M@! ,!E)8'?SU.2,XJ]-:W;Z3\0XA87A>^:7[*OV9_P!]FW6,;>.?F!'Z]*]%
MHH X6^CN#/X&=;*]9;1]]QMMG/E#R&3YN./F(%5M7TC4-4UCQK;VL$\;7^EP
M06TSQ,L<CJ)-R[B,?Q ?C7H=% 'GD<#>)]+NE@\/:EIVL"PG@%SJ&\"%W0KM
MC9F.X%L<CC SUP*KI<7M[:^"H?["U.&?3+R-;R-K5@L6V%T)#'AER1@@D8ZX
MKTNB@!&8(C,<X R< D_D.M>6V%E?1^#O"-M)IM\)K76_/GC-J^8X_,E.XC'3
M#K^?L:]3HH \PU_2M5O[GQI]@L;AGFEL9X%>)D6Z6$*716(P?NX]ZNWKW7B+
MQ7:W-GIVI6T4VC75J9KBU>+R97*8#;@.F#R./3->A44 >?\ A1!=#2K34/#&
MI0:IIBA7GNMQ@B*KM+Q,6(;=T 7U]!6+I5HVO_"NUT.UM9_M<M^Q64P,$C"W
M;.TF_&WA0>ASGBO6'4LC*'*$C 9<9'OSQ6=H&AP>'=*33K6>>6!&=E,Y4L-S
M%CR .Y- '$_99+;5-;T;5_#NI:E%?7CW%K+"6:VE1\$+(=VU-IXY'0?3-PVU
MQ'K7C9OL-UY=S8016[+;N5E98I%(4XYY8"N]HH \UT9=0T/5/#FHW>FW\EDV
M@1:=*(K9W>UG4@G<@&X XQD#^$=JHPV6KVVFP:B-%U&2.RUZ\N)K- 8YI(93
M( \8!!8C<#@=<GM7K%% 'G&LV:7?AXW&FZ!?VYN=3M)G66%S/*(Y%+.Z\D *
M,#/)QTZ5:U*RN[SQ'XK\BSN2EYH:V\$C0LJ22 2_*&(QGYU_.N]HH QO"DDC
M^%M,26UN+:2*VCB:.XC*,&5 #P>>N1^'I6S110 4444 %%%% !1110 4444
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ME1E1=P(&01L!Q[GF@"#4O&.J3Z1;SV-G!!+_ &\FF3!YR<A9@AVG9T;!&2.
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M_!>M+I'B'0[&\L3IFJR2S1-.'\RW:3EEP.&7/0Y!&>AH [FU_P"/2'_KFO\
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M%S=%2P@B:0J.^T$X_2N0\!6,&M>%;;7-7@AO=1U,---+,@?:I8[8US]U0,#
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MZ3' NIV;W-FXNMQ+(%+*X"_+]\<@M_2C3_%MQ?:$]W_9L<>H1WYL'L3<DE9
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M%R6,Q8 QD'8,!\@#@\U8;7[R>^OK'3K""XN]/BC:Y5[DHOF.I81J=AR<#.2
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M&L7,\V8&),8E4#'('(QG/Z4:7HGB*73GTOQ#J-E<62P-;A[6-EEN%*E,R$G
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M4\L/"I *CIU[_E6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIFT6^M)#"I"XAGC&XKP,G<@)&2>5([T =A56:]$.H6MI]FN7-P'/FI'F./:
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M0!V2.LB*Z,&1@"K*<@CU%.K*\-1&'PUIJF:27-M&<R$9&5'' '%:M !1110
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M,5K26RMK:&>&6!BQ;>7!!.<<;.U #M(\&Z1HT,L$*W,\+Q&!8KNY>9(XCU1
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M#-?.QO&>_MA:W3-=2,94 (YR>N&(SV!XQ5I/#5BEUI=R&N#+ID;16I,IPJL
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MR?4DFK'VJ&&)3<W$"/Y>]CO &!C+#/;GK3GO+:.U%R]Q"MN0")2X"$'H<]*
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MNQ>WET]]$F&HLA5HF&1Y.[MN^_CV!KOE1%SM51GK@4B0Q11E(XD1"<[54 4
M>3:*FFVNF_#2ZA%M'=2.$DE4@.P-NX()ZGG:,'V%=C\1'N8_"4DD*.\"7$#7
MB("2UN) 9!@=1MSGVS74>5'Q^[7CIQ3Z .*86]U\1;"]TJ6"2S?3)1J+Q,#&
MR97R=V.,\OCV![4[X9M:/X:G:W,+-]ON]QCQG'GN5SCMC&*[".&*)"D<:(I.
M2JJ #2JB)]U57/H,4 <1XFNK>/XH^"D>>-65;[(+@$9B7&?KVKE=3M=(/ASX
MD2B*S,L-XYA8!<QGRHR"OH=P/3J1[5["8T8Y**3ZD4GE1_\ /->?:@#SR36=
M)B\6:I;^)KB%++4-,@6QFG;$<D6UA*BMTW%B"0.3QZ"J>N76DPG4=,@064B>
M'5CC^VEGDFAP^V.-&/WACYB<GH,<9'I[0Q/MW1HVPY7*@[3ZBE*(6#%5+ 8!
M(YQ0!Y9IRZ-J/B/P?)>BTN(Y_#[*S38*RNOE<'/#$?-P<X(]146G/9:):VT,
MHCBTZ3Q'</I-Q<2%;:WC$9PQY 92WF!!D D@YKN[KP])<^+;/5S+;_9K>T>U
M^S-#G<&96SG.!@H.,5NF-&4*R*5&, C@8H \>MM4BLM'ED>7SM-M/%<KZ@$3
MA(&+%691T3>5;'M6QXO/AR[\ >+;_2C#,ERBR27"/NBDF "C9SC< !G;Z^N:
M])V)AAM7#?>&.OUI!%&L8C6- @Z*%X'X4 <3+-81_%/39IV@"W.BLD#MC$LG
MG)@*>YQZ=JJV6FRZ?X@N_!RVO_$IN+@:G"X7Y$@W;I(O3_6A1C^[(?2O0&C!
M7Y0JL =IQG;67HFE7MEYEQJNHC4+^15C,RP"%0BDD *"<<L23GGCT% #_$BP
M-X8U1;D1F'[+)N$F-OW3US7G-I:Z/]C^&;&*TWS1!)C\N9 ;4Y5O4;@!@^PK
MUD@,,$ CT--\J/C]VO'3B@#RE[W2=.B\40/'";,>(+;8BR>7#"Q$1\Q]O1 P
M)/J1CWJKJ&HNL'CL6=TMUNN+*>;[*N-]N4C$S(H)^4KD9R<C/)ZU[ 88B"#&
MA#=1M'-."J"2% )ZG'6@#S:]U'3;SQY:3^'[JSDN)M NHK=X'7!?<AC7CN.>
M.U-\)S>']9?P[-%J=V^LZ?&4-D%C22%MNV42@(&VY!Y8\G'4FO2(X(HL>7$B
M8X&U0*58HT=G6-5=_O,!@GZT <A\4A;_ /"OM0:?R_E>$H7QPWFKTSWQFJ<M
MMHUW\6;L7,5E,C:'&[B0*RL?-?YB#P3MQSZ5WK*KC#*"/<4WRH\_ZM?RH Y7
MX8S";X<:*1()-L)3.[.,,0!^ Q6+K>B,WB+6/#L5N/L?B>W$XDV96"6/"RL?
M?;Y9'^U7HRJJC"J /848&0<#(XS0!Y_I<KZUX/O]2UNU2.:UL)-/=9E&/,3(
MF89[,ZJ/^ 5AZAI^BP_ JWOX[:S6YDT^R#SA5WLZE."W7();Z<BO7-B[2NT8
M/)&*3RTV[=B[?3% '%22V$7Q;#7#6X%SHJ"$MC]ZWG-G;ZG!'X>U<@W]F-X#
M5";;RX_%1$>"!L4W?\/H-OIVKV38N1\HX&!QT%)Y4>,>6F/]T4 ><S16%OXD
M\:V5E<1:?%)HD3%K90/+8+*"X5>I QTYZ5'X;ET77M?\.70OM%^TZ;IQ@%M%
M<1RR2.0N-J]0%VDCODGZGO=8TO\ M32+JRBN&LY)TV">)067\#U'8CT)K-M-
M OI+B"35[G39Q XDC^R6!A8L.A9B[?7 Q]<<4 4OB8L?_"%RRRJNR*ZM79F'
M"J)X\GV&,YJI:WUE_P + U%=1>W_ +/N=-A_LQY,>2\0+><%)X.25)QU !Z5
MW+*&4JP!!X(/>FR0Q2J%DC1P#D!E!P: .9^'D%S;>$(8IRYA$TWV3?G(M_,;
MR^O;;C'MBNIHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K"\5Z_+X>TZVGALY+EY[N&V&TC"[W"
MY.2/7CWQG YK=KG/&NG7NI:'"MA;FXGM[VVN?)#JI=8Y59@"Q S@'J10!D2Z
MU-IWQ!OB\6ISPMH\-P+&/,A1S)(&(7.U3A1GG\\UT4/B2QN["PNK%9;LW\)G
MMX8@ [H ,GYB ,;@#DCD@=367#:ZG_PG=WJ\FES+;2Z3%;J1+&3YBN[E<;O1
M@,],Y^M<Q8>&]=TC2/#%VV@QZA+I]G)97NG221%MK,K"2,DE<@KZ]#0!Z'HN
MM6>O:<+VR9RF]HW1UVO&ZG#*P[$&N=T*]G\8:KK5S+<W$.F:?>-86T%O,T1=
MD WR.RD,<DX S@ =":Z'1(9(M/S)IT&GM(Y?[+#M_=@_WBO!;C)QZXYQD\[I
M.FZEX0UG5DM]/EU#2-2NFO8VMW026\KXWJRNRY4D @@G'<4 :P_XIPW]Y?:C
M/+I["(0)*Q=XV)*[%[MDE<9R23CL*>GB:S%W=6=Q!=6UY;P?:3;R1AG>+.-R
M;"P89X.#D=ZSO%&F:MK^AJ]K L%U:7<%Y;6TSC,C1-N*NP)49[8SC )//#+G
M3KW5?$46N-I\]LMIITT$<$CQ^9+)(1QPQ& %[GDGVH FA\>Z5,NFR"WU!8-2
M7-K,;8[7;:6V<9.X@''&#ZTZ3QSI4&DZC?W,-[;C3I1#=020?O(V(!4D D8(
M8$'..:PK30]9A\/>![1]+E\[2KB-[L"6+Y%6)T)!W\\L.G:J'B^QO[;1?']Y
M<63Q6]ZUJ]N[.AWA%C0\!B1R.XZ4 =E:^,M+N-5GTV5+NTGB@-RINH#&)HAU
M=,]0/P/M3[#Q78W]S;P+#=1-=6AO;8R1C]_$,9*[23GYE^4@'GI6;J>G:IJ^
MO6NK6MF;.;3;&Y6W^TE3YD\JJ%!"D_*NWD^XQWK+TG3-=3Q'H.JW.BW"O%8S
M07LDUU&\AD;RSGAB-I*MM Z9Z** -NS\>:3>KITL<-\MM?SFVBN)+<K&)=S*
M%)]25..OO@U?M?$MG=2:M&(;B)]*.+E9552/EW#'/((Y!Z5Q]KH&N1>#/#NG
MOI,WVJRUA+N=!-%\L8F9R<[\'AAQZUK>(-$EN/&6GRVDBI'J4#6^IPG_ ):0
M1D.&_,F,GTEH ZJ"\CFTY+UD>&)H_-(E&&5<9Y';BLJP\66&H7%I"D-U']MM
M6N[1Y(QB>(8R5P2<X93@@'GI6O>_:?L%Q]CV?:O*;R?,^[OP=N?;.*X+2]+U
MX:_X<U2ZT6X66WM)X;^26ZC9S(P3YAAB-F5;:!TST4<T ;EKX]TF[2PEC@OU
MMKVY-K'</;E467<5"L>Q)4XZ]LXJ#QGKR+X9\0Q6(O6FLK9Q)<VC;1;R[-R@
MMN!R,J3MS@'FL6#0=<C\%:/I[:3-]JMM:6\E3SHN(A<M+G._!^4CCUI]QI.O
MV6G>,=&BTF6]BU=KFYL[J.:,!3*F#&X9@00> 0"#[4 =OI!:;0+ R,S,]K'N
M;<<DE1DYZY]ZX'P]J^FMINLR:WXAN5GMM2NH8T.I.D@C5\( H89/8<<UWVD)
M/;Z#91W$#1SQ6Z(\6Y20P4 C(..WK7*>%K75-)TO5[34/#MY*+O4+FX5$EMR
M&CD;(!S*.<=: -V77+?0KG2](U!KAYKF/RX[MU41R.B9;<V>&."<'KVS5A->
MMWTZTN_L]RIO&VVT#*!)*<%N!G X!/)' YK&UW1[_P 6Z7#I6I6;6D;Q&YDG
MC:-S%,/]7&O.<J3DM@ [<=&-9NHV?B;5-&T+4[O0X9M6TN8FYT^66,I=(R%&
M9#DJ#R& .,'(^H!T=OXMTRXMIW_?1SP70LY+1T'FB8]$ !(.1R"#C&3G .(9
M?&FG6]M>RW$%W$UC<1V]U$R*6B:0J$)PQ!!W#D$]:Q=3TG6+K3;'5=,T&VL+
MRQOTNTTW?&K3H%9&#.ORAB'..3C'7G M^(;;7/$O@R_C&E?9;EFADM[.29#(
MWER*YW,#M!.W &>W)YP #8O/$EO:7U]8_9KF2[M+/[:8U"_O(\D?*2<9R".<
M=*QHO$EOJ?A[PW?ZI%J%G+?W-L81;DA7D8 @,5/^K.3PV,XZ4Q;'6-2\7WFH
MRZ3):6MUH@M%,LT99)-[G#!6/][MD=.>H%)=(UQO!_A*P?1Y5N-+O+1KA//B
M.$A&&8'=@Y[#.?7% '6VOB&VN]3U/3UAG2XTY5:<2!5!# E2ISR" >>GKBF'
MQ' ;:*2&RO)YI+<77V:-%\Q(CT9@6 &>PSDX/'!QFZ_X>O+SQ-8:A8E5AN(6
ML=3!/WK?[X/UR&7_ +:>U5->TS4;3Q@NLVVA0ZW97-HEK-;EHUDA9&9E=?,P
M"#O((S[T =5I6J6>MZ7;ZE82B6UN$WQOC&1].Q!XJG:Z[;:J88X8;H6]VK^3
M<C 1PO4@AMRGTR ?RJYI<+V^FPQR6T%JV"3! !LCR2=HQC.,\G')R:X[0]"U
M#3==M;^PL+O3;:5)7U/3C,CV[2$<&$;CM8MSV&.N* &^!_%D<?AG0+;4C?RS
MWKO"M[*A9&EW.0A<G)) ]QQC-= _B[3DNA$4N#";X:<;D(/+%P>-G7=U.,XQ
MGO7*V6@:W!X/\)V#Z5+]IT[5$N+E!-%\L:LY)!WX/#C@>]&J:3XEU"0O<Z1)
M<7%IKD5W#*+F,1M;)*& C4MPVT<[@"?4]* ->U>>3QEXPM6N[HPI9VKQKY[?
MNBRRY*<_+G Z5H>!+B:[\!:'/<S23326<;/)(Q9F)'))/)-5+:PU.+Q9XEOG
MTZ7R+RSMXX&62,[W17##[V1RXP2!^%7_  58W>E^#-)T^_MV@NK:W6*1"RMR
M!C@J2,4 <QHOB^#0(M<_M0ZI<6T&LSQFZ\MYDMH\J%W.>@'H,X_&NLU+Q+9Z
M='<2"&XNH[6(3W#6RJPBC()#')&> 3A<G'..1GFO[%U==)\5:)_9S%M7O+AX
M+HR(85CF &YOFW97DXV\\8]1&V@ZAH/B*Y:'P[#KVG7D,"J[/$LEN\<8CPV_
MJI"@Y'3GB@#NH+R&[T^.]M6\^"6(2Q&/_EHI&1C/J*\Y%^FL:%K&M:S/KUC'
M97MTIDL9RO[E&*>7M5B. ,DX'(SNKT:TC:WL(8VBB5XXP#' ,("!T4=AZ5PL
M>B:RWP]\3:4VE2I>WT]X]O&98OF$KL5Y#X'7G- '13>*;"RO;;3%@OY[J6T^
MTQ)'"7+H-H^\>"WS#OCU(I;?Q?IMWING7ENMQ(VH2M!;VX0+(9$W;U() 4KL
M;.3CCZ5GPV&ICQCH^H-ILPMK?29+:5O,CRLC-&0,;LG[AY''(K(T[3?$NG:3
MIUM_9=P;<:E=2WL$-Q$LK1R.[1E6WX RPW $'MR,Y +OBO74U+P-)J6FW%U;
M20W\,#@.8W1Q<)&Z-@\]2.XKL[NZAL;.>[N7$<$$;2R.1]U5&2?R%><-X=UU
M?!6K:4FC%9I=9^U0)'/'M,7VA9<@DC "C'.#GL*[W6/[0?0;W^RU1=1:W?[.
MLN,"3;\H/;K^% %.S\4V=W=&V-O=PS&S%]&CQ@F6$G&Y=I/.2.#@\CBJMAXZ
MTK46TLQ0WJ0:F2EM<20%8V?!.S.>I"GVXQG/%8VD:;K$'BRSUB30[E(SI+VT
M[37<;R^;O1OF.XY!VD#!Q_NBJUAH&MVWA3P582:5+]HTN^CENE$L6$15D!(.
M_G[XZ>] %SXA>(1_PA>NG3C?A[3]TUY:ML6*4$97(8,<9P< @9YZ''<231P6
M[S3.J11J7=V. H R237F=YH7B*#P?XC\+1Z1)=FZFFEL[Q)HPCK(^_#[F#!@
M21T(]Z[O6=/DUSPM?Z<<VTMY:/#\Q!\LLI'..N,]J (;?Q38SW]M:217-N;N
M!KBVDG0*DT:X+$<Y7 (.& .#38O%FGR2V&^.XBM]1;9974B 13L1E0#G(+ 9
M&X#/:LO3D\1:SX??1-6TK^S3]C>UGNO/21924* QA3D#G=\V,8QSU%.+1-7U
M/P[X>T._T]K:32[FW>>Y\Q#&RP=#'@[B6P.H&,G/09 -2;Q_I,$-Y.T&H&"R
MNOLMU*+8A83\OS-G^'YA[^V.:T=3\1VFF&Z!AN+DV</VBZ%NH;R8^2"<D9X4
MG R<#ITKD+[0=;N/"GC.P32I?M&J7\DUJIEB^=&6, D[^/N'K[5HB+Q!HOBW
M4=0M-&?4++5XX6*K<1QO:RHFS#9."I !RN<<\&@"6;4&G\?Z%-:7-Q)97>E7
M$XB60A),&,HVTD '#'D^M:,?C'39-)L=36.Y^S7EW]C0E!E9?,,>&&>FX$9&
M:JSV&J/XYT34)+0R06]A-#<3QNH19'*'@%MV/D/;TKFUT3Q!#X=M=%319':Q
MUQ;SS_/C"31?:3+E/FSG!Y# ?C0!W!\06YNGAC@N)8X[E;22>-5*)*<<'G/\
M0R<8YK,3Q#IE@WB2_7^TYA8RJ;U&!818C!S&C$87;@G'KFLV[T'4)/$BZKIE
ME=:9J!O4^T2QS*;:\MPPR9$W'YMF0. <X[<C3T+3+N/Q#XIEOK!DM-0GC:(N
MR,)$$*QMD!B1RIZCI0!KIK,#M8!8I2+V(S(PVX1  26YX'S#D9ZBJD7BNPDO
M["V:.XB340397$B 1W&!G (.02.1N R.E97AOPQ?66C7VFZC-E(XY+"QD!RR
MVN3M8_[6& /_ %S6JWA/3]5M8['3M1\+65M-8*$?4U:)EE"C 9 /G#-@9SC'
M)]J -7QYK%WHGA"]N[))//PJ+(FW]WN8+NY/OQUYQ26<MOI&H2I"-6GNKV/S
M_P"S99Q*850[2X+-A0Q(XW<GH.M+X]L+[5?!]Y8:=:-<W,S1[45T7[LBL22Q
M Z U!<66I6?CB/Q!!8S7-I<V LYX%=!) RN75N6P0=Q!P?0T 69/&^C)I]C>
MAKF2*\N?LB!(&+)-D@HP_A8$$8Z^F:U]/U%-0TU+XV]S:JP8F.ZB,<B8)!W*
M>G3/TKAI/#&JVUO9RPV#RRS>)3K%Q$DD8\B,Y&W)8 MC:3C/.?Q] N?/^R3?
M9M@N/+;RM_W=V.,^V: ,;3_%FGZG=6-O''<QC4('GLY9$ 6=%QDK@DCA@<,
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M%& 68L?Q)Y-.HHH *S=.T#2])N[R[LK18KB\D,D\A9F+$G)ZDX&3G P*TJ*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (YX4N8'ADW;'4JVUBIQ]1R*KZ5I=IHNG0Z?81M':PC;&C2,^T>@+
M$G%7** "D(R"/7TI:* ,_2]%L=&6X6QCD07$S3R[YGDW2,<LWS$X)]JT***
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M(()P",T +17*P^*[O5M5O[;0=/CO+?3KB.WN)WFV!W)&\)_N+R3W/ '>NI#
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M,8IH/.+X7&0^2H^4CH?:M'1+Z]U'3Q=WEK%;+(2T2I(7+)GACE1C(P<=L\T
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M3RE[?PMH@6YE4D/-,R$XW#D%@2,]1SC!Y'6_".R6R^&^F@2>8\VZ=SU +MG
M^@P#[Y[UV?V6W_>_N(OWW^M^0?/]?7\:>B+&BHBA548"J, "@#$\9:U+X>\'
M:KJMNFZ>W@)C!&0&/ )]@2#^%>6: =/U+QMX0M!<B=K2Q;4[VZ9LF[N7]3_%
ML;\@#TP:]MEBCFB>*5%DC<%61QD,/0BHTL;2.02):P*XC$098P"$'\.?3VH
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M'PZM)]5T?4)+6PL[G3IEG>XLE82714=&ST!/))W$],\DT 8 \.V7BWXE^(+
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M;*V7QSX<D#F)M1:2TO%5L"XB5=X5AW&X ?0D=ZT?'5P]M8:6[\:>=3@6_/\
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M+$FKSJH7@ ?:%P*]3"("Q"J"YRW'4XQS^ %0?V?9",Q_8[?83DKY2X)]<8H
MYZX9?^%IZ>-PR='GP,_]-8ZZJH!9VJR+(+:$2*,*PC&0/8U/0!P,NF:+J7C7
MQ7'K<-O) MK:N!.>%78^YQGH1_>'(_&LC3+J2T7PY:>*+O[-;RZ6XADO$4H9
M-_W7W@@-Y>SKSU'>O3IK*UN)8Y9[:&62,Y1WC#%?H3TIUQ:V]Y%Y5S!%/'G.
MR5 PS]#0!E>%+.TL/#UO;6%W-=V:%A#-*0=R[C]T@#*CH/;&.,5M4@ 50J@
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MPK?2=5C\$Z'8MIEP+JVU=+F6+Y<K&MP9"<YP?E(Z&@#K[3Q+IMW]O&^6W:P
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MJAXGN[NP\+:K>V,D<=S;VLDT;2)N *J3TR/2L"+5[ZTL?!R7<%I=F_DCC,[
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M+J=IH?GM)J5C<))<F%&7RHRAW@GIM=3MQD_>'H:[&B@ HHHH **** "BBB@
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M97:.%FSDHA)5.IZ =3ZFD/AC2#=3S_93FXE$TT0E<122#'S-'G83P.2.P]*
M,"REEN_B/933J89IO#>]U'5&,RDCGT-9EAJ>KGP+I\_VNZGSK;P7DH<M,UN+
MAU(7')/"C"\XSBNY?1;!]8_M8Q/]N\GR/-$SC]WG.W .,9YZ=>:YS7O"D<6D
MV=AI>CK>:<EV;BXM#>.DA)#8:-V/!W-D\C///)H IRMJ%E:^*;V?5]0L=,W)
M'ITTZM(Z;@N\JC?,3O)523WXXQ56YENVF\9Z9.]W%:IH\=S%#)>/(\3%9<_/
MG(SL&5#$<>YK6TKP?:2P74%WIES:Z;=0^7+87-^]QO;<"'^\P0C'!5LG/; K
M:M_"FB6MS)<QV*F:2#[/(\DCN9(^>&W$[CR1D\X.,XH Y13/IOA_P ;2\NHT
MN;JUBF3SF82*T#,0<DG&5''3VJ3[;>:UHWBW4!?W5I>Z9>7,-J(I2JPB%05W
M)]U@W4[@<AL=A72IX2T2.UL;9+1UAL91-;*+B3]VX& <[LG X&<X''2I;CPU
MI-U>7%U+:GS+D!;@)*ZI.!P/,0$*_''(/''2@#DK"XU#Q#XGTZ.[O[ZTAO?#
ML=Y-;6\QC"RLZ@X(Y7KUSGWQD57T[4]>N?!F@7ZI<:J(_M"WMO#<F*YF1'**
MZD$%BN.1GDL.]=V^AZ>^K?VH8G%[Y'V?S5F=<1YSM !P!GGIUYJK;^%-'M(+
M:&V@FA2U,AA\NZE4IO(+@$-G!(!QTS0 [PU>6^I^&+.YM+JYGADC(6:<8ER"
M00V?X@00?<5YVLVM1?#N'Q3%KNI2ZA:7KJL+S9BG3[4T?ELN/FR#P>HX Q7J
MEK:0:;8I;6<&R&)3LC3OWZD\DGN3R3S7*>#/"WV+0H8]7L98[N*[EN/+DN-\
M>XRLZ,%5BN0"O;@C/O0!1O+Z\CA^(J+?72BPA$MH?.;,+?91)\ISD#=SCI32
ME]J_B31K!]9U*WM[O0&FE%M-L.\-$-P..#\QY_#H374W_A+1-2O+J[N[+?+=
MP^3<8E=5E7! W*" 2 3@XR.QJ2#PUI-K>VMY!;,D]K#]GA83/A(_[N-V,<#J
M.PH Y9]0O--\21V^L&_%K<7ZQV6I6UPSP-SM$$J @*V01G')_&L^]U/4(O G
MBFX34+M9['6I(K>7SVW(@EC4+G.2,,1@^M=VOA[3%N3/Y#EC/]IV-,[1^;G.
M_83MSGGIUYJI=^"O#]]+>O<Z?O\ MK![A/.<([C'S;0V W R0 3^)H YCQIJ
M-W#;^)[G3]1NWN-.MXG412&&.S8#=@X/[UFR#@K@#C(K0N8[K4OB')ISZI?P
MV4FC+.8K><QX<RE<@CD< =.?PR*V+OP9X?OIKJ6YTY9&NXEAG'F.%D4#"Y4'
M!8#@-C(]:LP^&]*M[X7L,$D=RMO]F$BSR B/KM^]Z\YZYYZT >>V<DVMZ?\
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M._(%=/'X1T.)[MTLMKWD(@N'\Y]TB $<G=G."<GJ<\FI!X9TD+IJBWDQIO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'%O>>%[N0-Y$&K*TKJI;8#%(H)Q[D#\:P+W[)/>_$B1UC9I;*-8BZ\M_HQ!
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M<P6T&JV,L]PI:&-+A2T@&<E0#R.#T]#4.E^)=+UC4;^RLKJ*2:RE\IU#C).
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M>]:>E6EC)\2=5CGMXG(TVT51* YW*SEAD]6'R$]^AH [ ZMIPOUL#?VHO&)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM/S<[L=.YP*@A\?6LUA9W_\ 9>H)9SW(M)IG5 +>4OY>UANR?FX)4$<]>HH
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MU!QD$=#GVH [VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[:P6-[E)X)T21]H?RY5<C/;(4UOT4 <M#8ZH/'3:U-8J(#I2VI$<RL?,$A?
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M!TR03Q7?44 4[::_?4;R.XM(XK-!']FF$NYI<CY]RX^7!XZG-7*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'(*H^[:?FQP00,!>N>*['P!X7A\)>%8;43P7,\N9I[J%0%E+'(P>X /!/Z4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***YZY\::-9L@G-ZHDN?LD;BQF*R2[BNU2%PW(/3KB@#H:*HZ=JMMJGG
MBW$ZM X21)X'B8$@$<. 2,'KTJ]0 45#/<Q6T4LCDGRTWLJ*6;'LHY/0U!I&
MJ6VMZ3:ZG9ES;W,8DC+C!P?44 7:*** "BBB@ HI%97171@RL,@@Y!%+0 44
MC,J*68A5 R23@ 4O6@ HHHH **0.I<H&&X $KGD YP?T/Y4M !1110 4444
M%%%% !12%U4J&8 L<*">IQG _ &EH **J:IJ5OI&EW.HW7F?9[:-I)/+0N0H
M&2<"H;G6K2UT!M:E\W[&MO\ :3MC+,$V[N@]J -&BH;2YCO;*"ZBSY<\:R)N
M&#AAD9_.IJ "BH[BXBM;:6XGD6.&)"\CL<!5 R2?PJC8:U#J%Y):K;W4,B1K
M,#-%M5T;HRD9'X'!'<4 :5%%9^F:Q:ZM)>QVWF[K.<V\OF1E/G"AN ><884
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MMY?,C*?. #P#SC#"DT[6[34[[4+.W\T2V$BQ3B2,IABH88SU&".: -&BBB@
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MW"7,(B<+B5<[6Z<XR>.GM0!1\2ZK+8:CHFGVS>1)JMWY$EP%!*(J,Y R,9.
M!GU-1:1J%];^--3\/W,[W5O':Q7EM-(!O169E*,0!GE<@]<=<UKZMHMGK5G'
M;WH=C%(LT4J-MDCD7HZD=#_CZ4^PTJ"PFGN \DUU<;1-<2D%W"C"C@  #)X
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M,<<?+QQ_/F@#"L]3U5=7\*SS:C)-%K-N[3VQC01H1") 4P-PYR.2<YI-*O\
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M^NUIHVH_$#63-%9W$,FD0RG<%96):3YO0G&.?0^] '=R310Q&621$C R79@
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M)AC!B3D8[$YIDL=E_P +=E21(/WN@'SE8#YQYP^]Z\>O:@#L%N8&D6-9XR[
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MOV_P[-XF\ 7.ESV6P)/&IC9=RJ8" K=P=W&#WS0!Z0MS \[0+/&TRC+1AP6
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MD@6-&N^9'3&!NX')'J/K7G-S87=GIUUI=I:!I?"UZ=0MW9,^9 3O2,'N2K2
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M/7]%GU>[TJ6.2!8[&Z^T.DJD^9\C+M]N&/K6RD,44(ACB1(@,!%4 8^E/HH
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MJ",@TM% $7V:WPH\B/"MN4;!P?4>]/$4:J55%"L22 .#GK3J* $V+D':,J,
MXZ5&UO TRS-#&95Z.5&X?C4M% !445M! &$,,<8<Y8(H&X^^*EHH CC@AB),
M<2(3U*J!3I(TFC:.1%=&X*L,@_A3J* (X+>"UC\NWACB3.=L:A1^0H:")@X:
M)")/O@J/F^OK4E% $9MX2"##&<@ Y4=!TI!;0*P80Q@KT(4<5+10 U(TB0)&
MBHH[*,"G444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#V*GD&H;+6+/4+^^LK=I#/8LJ3AXV7!89&,CGCG(XH OT444 %%%% !1110
M4444 %%%4'UBU6WBN$$TL4LZP(\43."6.-W'\.?XNE %^BBB@ HJA=ZO:66I
MV.GS-(+B^9E@ C8J2JECEL8' />K] !13)I5@A>5]VU 6.U2QQ[ <G\*SK7Q
M!97MEIMY;">2#4&VP.L+''!.6X^4<=30!J4444 %%%% !1156SOX;V"25%EC
M6.5XCYT9C.5."1GJ/0]Z +5%4(]8LY=:FTA&D^V0PK.ZM&P&PD@$$C!Y!Z>E
M7Z "BBB@ HI%8,H92"",@CO5%-7M'UQ]'5I/MB0"X93&P783M!#$8//IZ4 7
MZ*K6%]'J-HMS$DR(69=LT9C;Y6(/!Y[59H **K3WT=O>6MJZ3%[DL$9(RRKM
M&3N8<+[9ZU8# D@$$@X/M0 M%%59[^*WGM(F65S=.4C:.,LH^4MEB. ,#J:
M+5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&\Q2%+,I!X!.3W'7-;5SX4T^XTN"Q5[B$P7/VN.XB?$HFR27)(().YLY&.:
M.5\3ZCJ,VB^.[1K^98[ 1" HJ*P5XE9E) Y!+$>N.];=Q?7YUI-!MKFZ+QV
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MQD 5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNG"*82I$FPG@-NSG'/ ]*(6T[3_'EDTKK#;2^'_+5[L@-(%D7ABW5MN,YYH
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M P!0!(716"EE#-T!/)H:1$SN=1C&<FO,YCI>K7.O6&N:M]AU&+4"T2A46XV
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M='(D%NY:,')Z$@&IS+&%#&10K=#G@UY186]I<>"_  F5'#:D(SD]5(FROT)
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MD?B;3;62\O([IHYFBMT5O*F  W%N,$KQ@9R,^]51XWT5@&$ESY7VK[(\IM9
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M1:+J-O)I]U:VX19967]W+'RL@()X# '/'>MWPJEV^BQW^HJJW]^!<3JO125
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M /XUA>)++7-2M]=MFTFZED%Y#):&!T6%X5:,Y(W M)\K9W XP,8KT55"J%4
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M5U.UM(9+?3;\6+PR,5>0[E4L&&<<N,#!R!G/.*ZLFX-H"%B6Y*#(W%D#=^<
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M#E<[-QZD#-8>G>)KR_T6*0V\$>J&_-C+:DDB-U8[N>^$!?W%=&TOV>T::Z=
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M*G>1P1VK1>*UT*YOO$NMW<*.T,<#2*I"11AC@#J3EGY/T]* %LM?EU2#1Y+
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M1F! '+$\G'ZU:G_M&/XD3?8H;1KUM#C+-*S+'GSGYX!)_P \U8;P;=-X>O\
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M2I[;3X_#>DZ4@TB>!H9;B2YR+=3P0$;);Y2<<XS71Q1)!"D,2!(T4*JCH .
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M03:II]M<K;3WUM%.Q 6-Y5#$GH,$]ZQ]<\116FN6&BQWUM:S72RN\TC*3$%
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M7L&(&>F>*;O1=$\8Z-JRYU&XN;F2")A\]RCJ/),8_BQA5&.A7M7HU% ' Z9
MEOXYLDU1H7NH?#T<<\LF#^]#_-R>^,GZ'TK5^')'_"":<@/,?F*5[K^\; QV
MXQ74T4 >87RW<FA^-M/M(9GO3JAN3 J',D&(2V.,'<H8 =^:WGD@UKQKX?U+
M1Y5EB@M[@7DD?01LJ[$?T.[D*>1@UV-% ')>,UA&H^&KB[139PZ@6G>1<I&#
M$X!8] -Q')KG=3L9XI/$6K:1;R/I;W5C,T=JO^O$39F:,=#QMY'!*GK7I]%
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MN+4)S][;&0V/7'?TI?'4,HAT34$B>2'3]5AN+C8I8K%AE9L#DXW G':NLHH
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MD!YVY (*Y/M0!K/XBMI/+73XI-0D>U%V%@('[H_=.6(^]@X'?!Z51;6M-O\
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M^ YZ\!ATSGU'6I/&W@B;5O"[V6E6WFZC<2))-<7$VW)&"2W.,G & ,#M@ 4
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MW<Z2+&Z:YAM?M2XV8F3.WY/FZYXYQ^HJ/3_$UOJFG:7?6MK<M'J+$1K\FY
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M-I6"82F5N/F' VKP>,D\^W,>MZ?>W7B3P_>V]OYD%C+*\QW@'#QE!@'KR<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex109keyexecutivebenefit005.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZCJL.FM:QR)++-=2^3#%$!N=MI8]2 ,!2>3VI-(U:WUFT>>W61#%,\$L<H
M:.1#AE."1U]"15#Q)'JTDNF_8('N+03G[;#%,(I'3:=N&)' ;!(R"1QTS4'@
MW3+[2;?5(+RRCMDDU":>$1R!E*.V1C'0#ISCZ4 .\1:S&--UBTMHKR::UM6:
M:2T8*8"5)7G<#G'.%R<8]1FCHVH6IM_!D-V]\U]<6 >%E=O+<^2"YDYPQQTS
MGDYJ*33-:TZ^\2V\&G&]M-7W303I,B^5(8PA5PQ!QP,$9HLM'U:*;P49; @:
M7;/%=E94(0F$1C'//(SQVH W[?Q!!=/$8;:Z>WE>2..X55*,R;LCAMW\+8R.
M<5EP_$#298K*X-MJ$=G=S>0MW);XB23<5"L<\9(ZXQSSCFJNFZ#>VWB.UU&S
MLY]+$LDC:G")U:VG!4X94#$ARVTYP.,Y]\G0M/NO$'PWL]&6S=(I;MB]TSIL
M5%N6<D#.[=\N ,=?:@#KY?%-G#:ZQ.]O=8T@XNEVKD#8'R/FP1M(/K4(\22R
M>++728;"9K>:P-V9LIT+H <%LX&3GOTP#6+JVCZUN\8VEKIOVB/6(MUO/YZ*
MH;R!&58$YSD<<8YY(J]!I>J0^)=*OVL@T/\ 91L;C;,H,+;U;)]1@'IGG\Z
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MJ,UE83R:-?0H\C&=69;A<C(#-D@KC)/?VJW8Z$NH6EY<:Q9W$=U>2.9H?M1
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M@[2&;D8W#.!R!ZXJQ)XBU*P30;R]2U>SU66.!DB1@]N\BY3YBQ##/!X'K[4
M=916%XFU:\T2&RO(1 ;,W<<-X9$),<;MMW@AAC!(SD'K[5FQ^*+TZGX@T]S:
M-<60C-CMB8";?\HSEN<2?(<8P?RH Z^BN=35=2U#5=2TRPEM$GTV*(2R2PLR
MR2NI8  ,-J@8[D\^W-#2O&-SJMQX;9+>**'5%N5GC8$O%)"#D!LX(W ]NE '
M3W^HV6EVQN+ZZBMX<A=\C  D] /4^U6))(X8FDE=4C499F. !ZDUY]XBU:ZU
M7P%XD6[6$/9ZD+13$I4,JRQ8)!)YYKI6U6\O]>U#2M->WB.GQ1M-)/&7W22
ME5 ##  &2?\ :'I0!KV=[;:C:1W=G,D]O(,I(ARK#ID&IZY;X<?\D]T7_K@?
M_0C74T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6]DL!-"S#A4=>0&^9B"2!QZ].Q.M;?%4>AFU<%[-KH3EA@A65=N.O\7Z5JT
M<_X5-Z+>:.:ZBN[- OV:>.S^S9Z[E"YP0/EPPP#D^E1W7A62YF\0O]O"C6H%
M@D'DY\I0A3(^;DX8]>_Y5TE96E:U_:>I:K9&U>!M/F6)BS []R!@>.G!% %5
M/#DJZCHEVU\I.E0/ JB''F!E523\W!PH_6I=3T*6^UNPU2WU"2UFM8Y(B!&K
MAT?&< ]#\HYY^AK:HH R/#>A_P#"/:.FG"[DN8T=V1G0*0&8MCCKR3S6:W@J
M.;3=1M+B^9FNK\ZA%-''L:WFR""N2<@$#K[UU-5M0OX-+TVYO[IBL%M$TLA
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M"'H9&8NC+GYE.XCJ#TYKK*HRW[R6EO<Z=;_;HYI44E) H5"<%\GJ .<#KVH
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M5Y]K>1X5)0[E; QCJ5'MUP!5V3PY<)XADUFQU,VL]S$D5[&(0Z3;?NL 3\K
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MH&E+':1K91A+,YME&<0G_9]/PILOAS1[A+M)M/AD6[8-<!QGS&'0GU(QP>U
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M7ETUS<6<;S,GENW3S%_NMC[P]CD4 <5IDMYK6L>&6U*>Z0WNB22W,,<[QJ[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\GN:ZY0H7Y0 #SP,=:\POX)I/!WC6)+.Z:>YU1WA06S[I5S'M*C&2/E/(]*
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MW.W>$#;6#!64JW0C/0CBN=T^::R\-:>LFFW&!K<[/,;-WDM59Y"LBIMSDA@
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M 7_=OD<D#F@#M000"#D'O17)6/B6"TT[PQ;V&CRB'5+?-M&DBXB"Q;PI)//
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M8HX^Z<#Y@??';NVZ\6I!I]YJD5DT^EV<S13SI)\_RG:[*F/F53G/(/!P#QD
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MO8%MMMW:IY2R @NT:J,,<##$@Y.,9YQS0!WU%<E+XXCMX]6$EEYLNGVOVO\
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M!RH(VX)Z$KZUUK1HT1B*C85VX'I5*=-,TA+W5Y8K>V.SS+FY$8#,JCJQ R<
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M)86T4C21HC.[R;L?>!&T!1VY)Z\5R^I:G>Z]X3TF>ZF:"ZAUV&TG\A5V.Z7
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M@?'EJXZ-@#YB.V2<'GK3;S1X+O4(-0666WO(4:-9H=N2C8)1@P((R >G!'%
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MF@AFPCQHI5,Y!.0#C@\]\U.GA6W@DL)K:^O8;FRMC:I.'5F>(D$JP92.H!X
MZ4 <XGB37%T2+SKF+[9::\FF7,R0C%PGF*-P'120W..^<8K6A#M\2]5$;A'.
MD6^&(S@^9+SBK]SX5L+C3;>Q66XACANA=[HV7?),&W[F)!R=W/\ ]:K"Z'$F
MN7&KK=W(N9[=;=AE-H522,#;U!)/XT <2-1U/6?#W@J]N-1FCGN]1"3F%44/
MQ*0<%3TVC Z>H)P:V+WQ'?:1JOB;SI!<6VFZ;%=01; IW'S,Y(ZYVC_"M!/!
MMA%HFGZ7'=7JQZ?<"XMI0Z^8C#/?;@CYFZCO5G_A&K)M1OKR62>;[=;+:SPR
ML"C1@$ =,_Q-SGO0!GPR^)4OHY8C]ILY;5RRW)B7$VW*&/9R5)X(8G P<]:9
MX6UY]4OGMKB\N4O8;<&ZT^\@6.2-\CYUVJ-R'D9R>WK5G3?!MGIMM);#4-3N
M(#$T,,=Q<;UMU88.SCK@X!.2!QZU?M-$BMM02_EN;B[NHX#;I+/MRJ$@D?*H
MR20.3GI]: )M9U Z9I-Q=(ADE5=L48!)>1CA%XYY8@5Q.@-'X<\<+9(+D6FM
M6X8R7$#Q[KR,?.WS <NN2?<5VU]IBW]S9S/<SQ_99?-5(RNUFP1\V5.>"?Y]
M0*KZ[X?M]?6S%Q<7,!L[A;F%K=E4B1<X.2#ZGC\Z ,UK[5-:O==M=+OELYM.
MD2" ,BLKR% Y,F03M.['RX/!/TKVHO)/B7(LNH2E%TF*7RDVF/+2,&"Y7.#M
M!SG/OC J_=^$+2YUA]3COM0M+B9%CNA:S^6MR%&!O '7'&5P:N'0+3^W(=6B
MDGAFCMQ;&.)P(WC!+*",=B3T(]\T 0>)M8ETJ#3XH"%FU"^BLDD(R(]^26QW
M. <>Y%5(;[4(/%\WA^>\DFAGL?MEO<[$$D1#A&4X7:1R"#CU'-;&L:/::Y8&
MSNP^T.LB/&VUXW4Y5E/8@TRVT9(+F6[>ZN)[V2(0_:9-F]4!)  "A1R2>G/?
MH* ,3X;12)X'T]WN)90X<A7"X3]XV<8 //N34GC[_D7K?_L(V?\ Z/2M?0M%
M@T#2HM.MIIY+>+.SSBI(R23R .Y-&M:+#KMI';7$\\4:2I,/)*@ED8,N<@]"
M!0!F>(K/41X@T+6+*V:[ALFF2XMXV4.5D4 .NX@$@CIGH:Y,66IZ]/XGOM+M
MR%35K2:&VD=0)I+<+YBY!*Y) YSC*]:](NK1[FW$/VNXA&,,T14,P^N./J,&
MFP:=#9Z<EC8?Z)#&-J>4!E?^^@03[F@#SSQ!?7MYXAU>ZL[2XM);/PW.)A(5
M+!G.Z-3M8C/RL1S5S4 +?P[\/C:<,M]9(A7KL,+!_P -N:[6QTJTT^&:.*/<
M9V+SR2'<TS'@EB>O''H!P,"J=EX:LK*6S99)Y8K$,+.&5@4MP1CY< $X'RC)
M.!0!LUR4ZW+_ !2MXQ?W"PC2GE$(V;1^]0$<KGG R>O'!%:^B:=<Z>U^9KNZ
MGCGN6EB6YE$C1@]0".BYSA>PQW)IUWH5O=:W;ZMY]S#=01-#^Z<!70D-A@0>
MX!XQ[Y'% '"Z5>ZGI/AVWU"VO0MO_;LD$EKY2D2))=,C98\@C.1C'3G-;EQJ
MFO:J=6.B%TFL;LVT*$1>4Y4*6\S=\_.3]W&!CWJ^/!ED-(73/MM[Y"W?VP'<
MF[S-_F==G3=SBEN/!ME-K$VI17NH6KW(7[5#;3[([G QEQCKCC*D4 ;\3,\*
M,X"LR@D Y /U[UYYXQ$FK&]U"TBNFO-'D5M-:.W=D,D9W2_,!CG[A'JE>AM'
MF$QQL8OEVJR 97Z9!'Z55TW34TO3$L8KB:14! DE*E^3G)( !.3G)'UH Q=4
M\2NW@NWUW3!^[N/)9I"-WD1NP#N1ZJ"?88YX%9L_B/4=.E\1W8NUOM,TZV22
M!RBX>1@<H77 .TA3P.C<T[4?#0T+PLFEZ=_:UU9->))(()%,UNN[>6C  S\P
M'R\]2<<8J?1],FO&GAGN]9O-)G@>*>'5XU7<3@ *-JN.-V2>.G?H 7K Z^FN
M1&9WETN6$^8;CR@Z2CD%/+ZJ1G@Y(]:I?$[_ )$2[_Z[VW_H]*T]#\+V^AE=
ME_J-VD:[($NY]ZP+Z*,#MQDY..,]:L:_H5OXBTTZ?=SSQP,ZNPA*@L5(8<D'
MH0#0!C?$V*W?X?ZI)/A6A1987Z%)0PVE3V.>/QHL=5U?_A)["PN)%*2Z)]J>
M$H 1.&13ENO<UJ3>&[:]GMY=2NKK4!;N)(H[AE$:N.C%450Q';.<5)<:#;W&
MN?VLUQ<"?[*UIL4KL\MB">-N<Y .<]J .6LO&,T%I?3:A-<IJ5AITD]UI=U"
ML9+K@AHV"_-'PPSD\$5OV<6MO)977]K0RVMQ;$S(\2_+(0"IBP!QUX8GC%21
M^&+,O$UY-/?F*V>U3[25.(WP&!VJ,Y"@9.?U-1Z/X3M]%0)!J&HS1QJ4MDN)
M@ZVP/'R#'8< MG X[F@#FK/5O$DOPZG\32:Q&91ITLJP"T3"NI)#9^@QC&/Z
MZTVH:O/XETG3XM0$$%YIDD\A6!68.ICY!/&?F/;'L:T(?"EG!X3?PVMS=FQ>
M-HMQ9=X1LY7.WW/;-3)X=@34[+4/MET9K.W-M'DI@H<9R-O7Y1^5 '(C7O$$
M7AAM7DU17>QU/[')&+= MR@N!$2W<'!S\N.G>MV74]3'BO6-/6Z00PZ9'<P#
MRA\CEG!SW/W14S>#;)]&N-+-Y>_9Y[K[6YW)N\S?YG79TW '_P"M5M_#L+ZK
M=:B;R[%Q<VHM7P4P$&2,#;URQ/XT <UI.MZV8_"%]=ZBL\>KKY<\ @50"8F<
M,".<Y7GMST%2R:_JEOJ6F-]M6YCN=6>SF6*-?LZH1)M"L0&+C8,D$C.X>@K9
MB\)6D-OH\"7=YY>D-NMLLG]TK\WR\_*2*K)X%TZ.&WA6]U$06UY]LMXA. L+
MDL2%XZ'<>N2,\$4 9>FRZC;P^-KN/4YWFMKJ7RO.1&4%88V!P .G3&<>V>:N
M:?KU[J=UH.E_:6AFNM(74+FX1%W,?D4*H(*C)8D\=ABM0^%[3S-69+F[C75
M?/C60;0Q4*S*".I  YS[8I/^$5LUBTORKFZBN-,C\FWN4*^9Y> "C97:PP!U
M';/6@#FKGQ-KD5C<VRW,2WECK<-@\YA!$\4C)@D= =K<X_#%;VB7NHKXIUC2
M+V\^UQP0P7$,AB5&7?O!7Y0,C*\=^>IJ>X\*6-S8K:F>Y3_2UO9)59=\LP((
M9B5QU X  P .E6K;1(;;7+K5EN+A[BYB2*16*[-J9VX 7/\ $>_>@##^(?\
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M*FF0RZEXX>_N;BVO1(LT<T=P\92$1?NW&" <$,/P(H ZO5-2UNUGBATW0UU
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M8MR"(G:+B( 'KTW*1]2!0!W.0"!D9/057AO[:XO;FSBE#S6P0S*/X-V2 ??
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M[;4-(LKUU"-<01RE1T!90<?K5H$'."#CK7.Z?>6\/PXMKMY)#;Q:4KN]N?G
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MHH ]2R#THJEINE6&E),+&W6(3R>;*02=[D %CGN<"KM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M0W-I;7B!+JWBG0'(65 P'YU-5+4=5L]*6W:\D:-;B9((V$;,"['"@X!QDGJ>
M* %ATC3;>598=/M(Y%^ZZ0J"/H0*/[)TWRWC_L^TV.=S+Y*X8^I&.35:?Q'I
M=M)J,<TTBMIT2S70\ASL0YPPP.1\IZ9Z4RQ\4:5J%]!9P2R^;<0^?"7@=%E4
M8SL8C#8R,X/>@"U-IML$:2WLK7[2L>R-R@7'& -P!(%9WA3PZF@:'96LT%H;
MRWB$37$*<N!WR0#^'M67XJ\1#[-IYTV[NDW:K!;M+%&?+E_>A73?CZC@XX(R
M>E;NH>(]-TOS6NI9%BA=4GF6)FCA+8P'8# ZCZ9&<9H OQ6-I!)))#:P1R2?
M?9(P"WU(ZU%'I\%E;S+IEM:VLKJ<%(0JENQ8+C(S5";Q9I$&I2Z>TL[743Q(
MZ);2-M\PD*<A?N\?>Z<CGFIXM?L9W01>>XD5WB=8&*RA>NTXY]O7MD4 &C6%
M];B6ZU6>"?4)@JR-;H4C55SA5!)/4L<GNQJR=*TXB0&PM<2G,@\E?G^O'-8^
MD>,;+4=#MM3FCF@^U3&&&)HFW.Q9@JKQ\QPN3C@<U8D\6Z/#IKW\MPZ01W'V
M60M"^8Y=P7:PQ\O)')XYZT :*Z;8+)%(ME;!XAB-A$N4'L<<4J:=9174EU'9
MVZ7$HQ)*L2AW'H3C)JI9>(M-OY[R".62.2S4/,MQ"T1"'.'^<#*\'GVK"O->
M:Y\9>&(K.XNTM;OSV:-HBD<RB(E6!(R><<9]#CO0!TO]D:;Y1B_LZT\LMN*>
M2N,^N,=:G6UMUG$ZP1"8)Y8D"#<%_NYZX]JS?$^N+X<\/7FJ-"\QA3*HBDY;
MH,^@SU-8U_KCVOC;32;B\^PSZ?._V00-N9U= "$"[B<$_ASTH ZDV=JUT+HV
MT)N ,"4QC>!]>M-FT^RN9EFGL[>65?NO)$K,/H2*H1>)]*N-/L[R&=I$O9#%
M;HL;;W<9W+MQD$;6SGIBJ>H>,K&VTJUOK5)KA;B^2RPL+9C<R!'##&01SQU)
MQB@#<-A9F]%Z;2#[6!M$_EC?CTW8SBGK;0+</<+#&)W4*T@4;F Z GKBE$RF
MW\_;)MV;]NP[L8S]WKGVZUPFH^+)=3\)V6KVDES8#^U(HW!38&B^T;,%B.?E
M'.T\'B@#M[JPL[X(+NT@N ARHFC#[3ZC/2B>QM+I$2XM8)E3[@DC#!?IGI6;
M'XCTV]@U)$FN86LDS<!K>1)(U8$API7)& 2" >E&GZQ8Q:1I@BN;J]^T6HEA
M=HR\TL8"YD8 ?[2YXZF@#95510JJ%4#  & !4$%C:6LCR6]K!"[_ 'FCC"EO
MJ13K2YBO;."Z@),,T:R(2I!*D9'!Y%9P\3:6;M+<3/\ O+DVBR^6WEF89RF[
M&,\'VR,=: -*&V@M@P@ACB#'<PC0+D^IQ39K*UN94EGMH99(_N.\88K]">E9
M]]XFTO3OM37$SB.T95N9$B9UA+8P&('7D?3(SC-07GC'1K&<P327/G>0+CRU
MM)2WEYQG&W/7KZ8.: -N2*.8*)(T<*P9=RYP1T(]Q574=+M]4$"W*(Z0RK*-
MR D,IR,$]/?';BJUWXETRRD GED6+SA T_E,8DD/ 5FQ@<D#T!X.*-0\1Z9I
MAD-U+(L4+K'-,L3-'"S8P'8# ZCZ9&<9H TYH8KB%H9XTEB<89'4,&'N#4']
MF6'F>9]AMO,V[-WE+G;C&,XZ8XQ6;=>+=)M+B^MWDN'FL55[A(K61RJL"0W"
M\C )R..G/-/M_%6D7=]:6L$\C&\0M;2^2XBEPNXA7(VDXYQGU[T 7CI>GM9F
MS:PM3:L<F$PKL)]=N,58BBC@B6*&-8XT&%1!@*/0"LR;Q)IEO<Q12RNJRS_9
MDF\IO*,N<;-^,9R"/3(QUXJI-XVT. 7+///LM9_(N&%K)B%N.7.WY1\PY/'I
MTH V+O3K&_V_;+.WN-OW?.B5\?3(J1K6W>V^S-!$T&-OE% 5QZ8Z5D_\)%&?
M%IT(6\^Y;83F7RF*G+8&"!TX.2>*?XEUU/#ND&]:"28F1(E5$+ %F"@G';G\
M>E %V72]/FM5M9;"UDMT.5B>%2BGU QBGBPLU@E@%I (923)&(QM<GKD=\U5
MGURS@94(N'F,7G&&.!VD5,XW%<9'.<9Y.#C.*M6-]:ZG8PWME,DUM,NZ.1.A
M% #!I6G"T2T%A:_9D.5A\E=BGV7&!5I$6-%1%"JHP% P *R;OQ-I=E/-%-,X
M$$J0SR+&Q2)WQM5F P,[A],C.*CN_%>DVNH3:=)+<?:XO+#I';2,5#G"MPI&
M,]^G3UH V2B,ZN44LN=K$<C/7% C179U10S8W,!R<=,UPWA[QC:6-E-#K5_<
M/)_:5Q;BYDA9D0"4JBNX7:O '!Q^5;SZI90:_J ^UWLEQ;6:R262QDHJY;#J
M-O+'D<$]* -2XT^RNY8Y;FSMYI(_N/)$K%?H2.*<]E:27*W,EK"\Z?=E:,%E
M^AZU@6/C;3IM$TS4;T3VQU JL2&WD(+D9"@[<'C\\<58/C#2!;&??<%5@-S(
MOV9]\40)4LZXR!E6]^": -0Z9IY:5C8VQ,W^L)B7Y^_/'/XTV72M.GMDMI=/
MM9((SN2)X5*J?4#&!6;/XGMX_$.G:7'#-*MY;M<+.D3,NT;0,$#_ &LD]!^-
M6)?$FF0W4,,DKJL\_P!FCF,3>4TN2-F_&,Y!'U!'7B@"\]C9R3QSR6D#2QXV
M2-&"RXZ8/:D.G6)N_M1L[<W.<^=Y2[\_7&:=>WMMIUE->WDRPV\"%Y)&Z*!5
M&/6+746O+*"6>WO(81(RO$4=58':PW#!'!]>G- %^XM+>[C\NYMXIDSG;*@8
M9^AJ.WTRPM)/,MK&VA?INCB53^8%8'A37"_@[0YK^::XOKNWWX52[R8^\W'8
M9'Y@=Q6O_;MB8+61&ED:[4O!$L3>8ZCJ=N,@#(SG&,@=30!:N-/LKJ:*:XM+
M>:6$YC>2,,R'V)'%(VGV3S/,]G;M*XVLYB4LP]"<<TW3=3M-6M/M-E+YD8=D
M;*E61@<%64\@@]C574?$6G:7+-'<22%X(?M$XBB9_*BR1O; X'!]^#0!:;2M
M.>S-F]A:M:DY,)A4IGUVXQ3I=.LIX8X9;.WDBBXC1XE*I]!CBLZ\\5Z197*6
MTD\KSR6_VF..&WDD,B9 RNT'=U' ]SVJ(>--!;3K._%Z3;WDAAA81/RXSE3Q
M\IX/!P>* -<6%F)TG%I )D&U9/+&Y1Z ]J?#;06YD,,,<9D8N^Q0-S'J3CJ?
M>N8U/Q-:ZIX2\0SZ1>3P7FGVLK.K1&*6)PA9<JZY ..N*LV^H0-<>&HKG4+N
M.\GMRZ0JI\NY/E9;><8XZCD')H VDT^RCN3<QV=NLYZRK$H8_CC-.FLK2YE2
M6>UAEDC^X[QABOT)Z50F\2:9;W,44LKJLL_V9)O*;RC+G&S?C&<@CTR,=>*E
M37+*2[2W0RL7F:W601,4,B@[EW8QQM;VR,=: +%UI]E>E#=VEO<&/E#+&'V_
M3(XJ2:V@N/+\Z".3RV#IO0':PZ$9Z&L[Q+K:^'?#U[JK0O-]GC+*B*3D]L^@
MSU-2OK=I&(%(G::96=(! _F%5X)VXR ,CDXZCU% %EM/LGO5O6M+=KM1A9S&
M"X'H&QFA["SEO$O)+2![F,829HP74>S8R*;IVI6FK627=E,)86)&<$$$'!!!
MY!!X(/-4M0\2Z9IDERES*_\ HJ+)<M'$SB!6SM+$#C.#^ STH T7L[629II+
M:%Y63RR[("2O]W/I[5'_ &;8_9&M/L5M]F;EH?*78?JN,51O/$^F66H-82/.
M]V(/M AAMY)&=,XRNT'=^&>AS34\5Z/)'IDB7#M'J9VVC+"Y#MZ$XPIX/!QT
M- &B=.L3:"U-G;FV4Y$/E+L!^F,4)I]E'.LZ6=NLR#:L@B4,!TP#BB*_@GOK
MBSC+F:W"F3,;!1N&1\V,'\#4=[J5O9RQ6[M(UQ,&,<42%W('5L#H!D<GCD#N
M* )GL[62Y6Y>VA:X4864Q@L/H>M-N-/LKN19+FSMYG7A6DB#$?0D5Q>C:VD_
MA9[C4M7U"-7UB2&&X1#YC 381&^7Y0> 00.IZ5UEQKEE;W#PL96,<B12-'$S
M+&[XVAB!QG<I]@1G% %EK"S>]6\:T@:Z0;5G,8+@>@;&:2>QMYC,YMX#-+$8
MF=X@VY?[I]1[5C7GCC0;%[I9KB?-I(([G9:RMY/ .6PO"X(YZ>E:,>N:?-J
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M (EV#_@.,4ITZQ+QN;.WWQ*4C;RERBGJ!QP/:L=O&^A+$9C<3"%;@VTDIMI
MD4@;;AR5PG/'.*MVWB72[FZN[<32126L7GR">%XOW7/SC<!E>#R* +G]FV ,
M)%E;9@&(CY2_NQZ+QQ^%-_LG3?+>/^S[3RW;<R^2N&/J1CDU4M?$NFW<OE1-
M/YAMOM<:- X,D/3<HQD]1QUY'%+!XDTRZT:#5H)99+.>18XW$#Y9BVP#;C/W
MN.E %S^S+#S!)]AMMX78&\I<A<8QG'3'&*(=-L;>.2."RMHDE&)%2)5#CT(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6PCNYIX)[^W2:1I98(;R1(V=CECM!XR>N,5M1QI#$D42*D:*%55&  .@% '
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MA['L:Z,W-N+H6IGC^T%#((MXWE0<;L=<9.,TEQ=6]J$-Q<10B1PB>8X7<Q.
M!GJ2>U '!G2+^X\*:WX;>PF6ZO;ZX:.1TS$(Y)2PDW]. <X^]D8Q6LEC<_\
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MVF^M9(\Q LT2JBNT8;@N-I(SWP>:] HH \YET?4[F/QK##IEZBZE91_96N)
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MY2WGM;N*[B=X]ZED.<$ @X/UH YIIM1LO&OB2;3[>T>X73K623S6*H2/-)Z
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M% 'I*R([.J.K-&=K@'[IP#@_@0?QIU>=:?BPT[QC<C5+BS==5>%9W9IBN5B
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M*1-3L)())X[ZV:&,X>195*J?0G.!U% %4^'-*\^PF6T"/81^5;^6[(%3CY2
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M"L]YDQ@R ?*%)W'V. !ZDTNF>(=,U>YO8+.[BD>TE,3[7!S@*21[ MC/J#0
MDEG_ &19W5UIMB]]?,H^62X^>;'1=[DX R<#IR?6DT2PD@^V7]U;1V][?RB6
M:-"&V *%52PZD!1D^I-7+;4K&\\S[+>VT_EC+^5*K;?K@\5%_;FD88_VI985
M/,)^T)PF<;NO3/&?6@!VJ:39:S:K;7T;R1*ZR!5E9/F4Y!RI'0@&L^\\'Z'?
MS7DMS:.YO4"7"^?(%EP, E0V-P'1L9]ZU8-0LKJXFM[>[@EGAXECCD#-'_O
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MS<$D,3UJAI_A72/#Z3S:78R"0HP2/SF<+GJ$#MA<GTQ6K/J=A:M&MQ?6T+2
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M5?CU73IK>6XCO[5X8N))%F4JGU.<"J%_XLT/3_*$NI6K/).D 1)E)#,1UYX
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M^JWD7C:RTH&$V5Q92S\(=X9&0=<XQ\WI6G%J5A/=-;0WMM)<+G=$DJEA@X/
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MM&!YJ;9/G9L<A0@/7CI[5ZW*':)A&RJY'RLR[@#],C/YUF>&]&;P_H%KI37
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M;3]2LGN8/^)K;Q,A<HP(G".K!3@\@^HK3UJ#6+F;1VMK3S;)2_VZT:<1EB5
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M]:2W,&^^\FX@69XVC81N6C< CH0.OM6A>>*;6TBOK@6US/:6#F.ZN(54K$0
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M;XCF<> -7,,JI^X(?*D[E/! Y&.OO0!MV.L6&HSSP6MP'F@VF2,J590W*G!
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M$&X+Y:%B79BHQCLW0U'!XOOF\.174D40N&U;^S7F,;*B+YI3S&4G(XQP3U-
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M)/,K;U0$+E6*G /(Z9J2ZT-;K6DU+[;=Q?Z.;>6WC<".5?FP6&,Y&YB"#Z4
M007'AWPY:J$N[>T@NI"Z&2<[9').2I8\DG)XZUIV6HV6HQM)8W<%RBMM9H9
MX4^AQT-</XFTYM$TOPE9BYNK\PZ[!M>9E,C##X7/ X' I]U::OI6I>*/%\<$
M-F/[/_<VTQ$AE:-2Q=PC8!XP.3Q0!WU%<@FN:S =*ANI;)I]9D06WEQ,! HB
M+R%LM\YX '3D_A5#Q#X@U:VT_P 4:4T\<=Y96'VNWNXH\%XF!!!&>&!!&1]<
M"@#OJ*Y7^UM0CGL]'@97NC8_:9)HX <+D*H"LX[YR<]NG/#=/UW6KRYT_2+V
MUBT_5);:6YN20'4(CA%V -_%N!Y)P 1S0!UE%<1JESXB6Z\+PW=Q:VUQ-?R1
MS+#&7CDVQR%6/S XP =N>IZ\5/=:_KMVE_+HEDMPUE=&W6!D4"<H0'RY<;3R
M<<'H,YSP =7<W,%E;27-S*D4$2EGD<X"CU-%K<PWMI#=6\@D@F19(W'1E(R#
M^5<KJ&JWNLV?B2&R>*WAT^)H&$L>\R2>5N8'!&  P''?)Z<'5\(?\B5H7_8/
M@_\ 1:T ;)(4$D@ <DFF03Q7-O'/!(LD,JAT=3D,I&00?2L?Q/=1I91:>S.O
MV^3R7**S%8NLA^7G[ORY[%A6/\/;U8+34/#KR.QTB<K TBE6:V?+1G!YX&5_
M"@#M*R]?L=&O--,NN6\,UG:'[23,N53:#\V._&:S-*U76M:L=,UBR%H;*[E)
MDMW!#1P'.&#9Y?@9&,<D=LUCV6JZU:>'/%VIM>6]Q-97EUL$L!P?+48'#=,#
M&/U- '>0O'+!')$08V4,A'0@CBL36=)\.)<KJ6IVT,<TKI"9OF4R,3M56V_>
M[#FJT^N:C::KX>\XVXTW4T\N1O*.])RFY1G=C#88=.H]ZBU37=4M-(MM0B:T
M:*XU**% T+9,#RA P.[J1\P/H1Q0!U,44<$*10QK'&@VJB# 4>@%/KD+276)
M_''B."*_@"0VUMY*2P%E3<)".C#OU/?VI^C^(M0U73--0_9X]5>YD@OHO*)6
M'R\^9@;LC^$ Y/WUH V%\2:(T,<RZK:&*2X^RHXE&#+_ '/K[5J5D-X;T]X)
MH6A0I/<BYE'EJ,L  ,<<<*!D<]><DFM>@ HKC8O$NI1ZSI-O<-;.+V[FMIHH
M4++#M#LF)<X+84;A[]!BIM+\337_ (@.FS7$-K=QSRK+83PE',0W;'C8G#YP
MI.,\$],<@'654NM3LK*XMK>YN8XYKI_+A0GEVZX IVH7L6FZ;=7T^?*MH7F?
M'7:H)/\ *N)U2?4;Y_!>H74L CNM1CE\B.,YC+0R%0&SS@$@\<GD8Z4 =_5#
M4=:T[25+7URL*A=S':3L7.-S8!VKGC)P*YU?$&NZA"FH:18"XMOMC0F JHWQ
M+(49@Y<8;Y2V,8[<]:2RBO)_B+K\;W%N\7V*V4H\!8%"9<+][ZY]?04 =1I^
MHV>K6:WEA<)/;L659$Z$J2#^H-6JX.'Q3K+>&-&OHUL1<76K&QE3RF";?.=
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M,G.3SVQ69K7B2+2](.HV\(O(UNEMGVR;0K&01GG!SAC^E #]>T$ZY)IS&[,
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M0YPV?RK<H YN?PC%):VL45X\;Q:@-2DE*!FFFSG)Z #G&!V YXKI!TYZT44
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MX<I,5N'7S!Y+GG!ZY'7K[U,[75CX>\86>GW3Q)::BBP!YB"J,L3-&K$Y!;+
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M)'&NU5'H!VJO<:-IEU=FZGL8))R K.R E@.@/KCMGI0!Q;Q-J>M^!+G4X/\
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MI(6W&2PF9VDX(*_<0!3GG.>.,=ZZBUTO3[&U>UM;*WAMY,EXHXP%;/7(Z<T
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MZ(\<T;:19%)RIE7R%PY487(QSCMZ58NM*L+Z&**ZM(94A(,6Y<F,^JGJ#]*
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MQ6Q8Z!I&F7DUY8Z9:6US-_K)8H@K-WZCWJEXRTJ[USPM>:99+$9K@*H,K[5
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M9_X&U=35:QT^STRU6VL;6&V@7D1Q(%&?7 [U9H **** "BBB@ HHHH ****
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MEO\ _CU(C;$OTX].?ISTJ#6=7LDL+I/[7.G/#-'$\_EY*,2IV@,,$D$#C/#
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M"!W$:#!9G8]%4#DGKP/2N.\,F"_?2X[K0-4@U33DVN]WYGE0';M8QLQ*L&Z
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M*3>9*767?C: -V3DY&WZ5M:YIFIVFKZ3J6EAI;F2(Z;=N.H1AE93_N.,_P#
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M4+!R?G+8SSTQGM2V?BC1;^ZMK:UU"*66YC\R$ '$@QDX.,9QSCKCM6)+YO\
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M1< DOMSU8 87G\*YC6[V:]O/"6HRZ3+;WPU*2,V\F XQ'(,!CCY20"#Z<XH
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MV-)G:"K!AG';BMBB@#D[G1_$<&N+K6ESZ;Y]S;I!?6MQO\L[2Q5D8#.1N(Y
MS[=G:WX<N]:M#:7T-A?Q&#Y9)6:)X9\L2Z$*2!RN!G/R]ZZ"XOXK=[12DT@N
MI/+1HHRZC@G+$=!QU-6J .9MO#^I67B#3]02[AN5BTQ+"X>?<)'*L&WC'4GG
M.3QG//2LUO">KMX>N=/W67FS:N=0#>:^T+YPEV_<Z\8_6NXHH Y]-*U%/%]U
MK.VU,4M@EJL?FMNW*S-D_+T.['X?A6/I?@_4])M?#\\4MHVH:5');R(781W$
M3G)^;;E2#@C@UU.F:Q::LUXMJ9";2<V\OF1E"' !(P>>C"K] '&:GX1O;ZPU
M9T>U74-4O+>>7<[>7&D)3:H.W).$ZX'+'TK1>SGLO%ESXBO9K.WL/[/2V=GF
M(*;79]Q)4#'S8Z]JZ%F"J6.< 9X&3^59^GZAI_B/23/"GG6<K/$RS18W;6*L
M"K>X/6@#%\*Z7;QZMJ^I6=SYVGRW#?8PI!1-P5IBA'56D'YJ:U=!NM3NH;O^
MTUM=T=RR0R6N[9)'@$'YNXR0>V0:U(XHX8EBB14C085%& !Z 4Z@#E[S1=;M
M/%%QJ^ASV)COHHX[N"\W@!DR%=2OL<$''U](M1\.ZS=:F\JWEI<02Z>;7=<A
MMT,AW;I$4<?-G!Y&,#D@8KK"P! ) ). ">M+0!Q;^%+ZZ\.66CZE:Z7?0V]B
MD W.Z-%*HVAT;:3R,>G3\W+X<\0:1?VU[I%_:74CV4-I?+?[P)6C!"R@KD[N
M3D&NQ9@HRQ 'J32T 0VL<T5K&EQ*)I@/G<+M!/? [#T'IZUQUSX3U6X\->(M
M,WV2RZK>O<1OYK816*\'Y.HV_K776M['=RW4:1S(;>7RF,D94,< Y4G[PYZB
MK- ',W^B:K>>(EU**:WMA_9DMD&61F>-W*L''R@'!4>F:H:9X9UNTU'1+R5M
M,4V%M+;S)&7)E+;/GW$<LQ3G/3.<M72W6LV=IJ-A8RL_G7[,L&U"5;:I8_-T
M' ]:T* .(@\)ZM%X9TC3"UD9;'4EO7?S7VLHE:3:/DZ_-C\*9?\ A/7;H:@O
MVC3Y#-J,=[#/*7\PHCJPB;CY0N,#&?H,DUW5% 'G-^L^H^(=:>U?0YHP([6Z
MBNKJ6V+;%R0RID.OS$9;MD=.NG]AUVZO+'Q'HWV""YDM?LMU9W#,8717)5D=
M1GN2#CD,.E=//I.FW5RMS<:?:33K]V62%68?0D9I^GWL>HV,=W%'-&DF<)/&
M8W&"1RIY'2@#$GT;59]<T'4)9K:7[ )S<'+(6,HQA!@\+VR<D?G6;<^%-5N/
M#GB33=UDLFK7CW$;^:Q$:MMX/R=1M_6NVHH Y.;1O$-EX@N-4T>?3O+OXXQ>
M6]V7(21%VAT*CGC (.,XJU'HVHQ>+8M6,EO-$FF_8R7<J[OO#[L!2 ,C&,_X
M5T*L&4,I!!&01WI: .(MO"6K6WAW1+19;(W>EZBUWR[^7(I,F1G;D'$GIV]Z
MZO4M/35='NM.NF^2Z@:&1D&/O#!(_.KE% '*0>'=2N;+1;'57M6BTJ:.830N
MQ:X:-2(\J5 3J">3TQWI+7PK<RZ'XATO47A6/5;F>9'@<L4$G8@@<C'XUU;,
M$4L<X SP,G\A5+2-6M=;TY+^R9V@=G12Z%3E6*G@\CD&@#FXM#\1SW?AZ6^D
MTW.DR-ODC=R9U,93=@J-IYSC)^M2Z%H?B'1"-*2]L7T2.4M#*5;[2L9;=Y>/
MN]\;L].WIUM% '-Z3H^JZ=;Z^-]HL]_=2W5LZNS!&9 JA@5'0J#QZU3MO#UW
MHUWJ>KZ?%IVG33VFW[,LCFV>8'/F.-JX].!SDUV%0W=W!86DUW=2K%!"A>1V
MZ "@"+2YKJXTJTFO8EBNGB5I47("L1SC/(^AYKB[CP=KB>'-5\.6D]@VGW,S
M2VTTSN)(@TF\HRA2#SGG/X5TUMXDM;G6/[*%M?1W0R6$ELP11C()?[H!YQSU
M!'6K6KZQ::'8_;+TR"'>J92,MRQ"C..G)')H PI-&\16/B&ZU+2+G3FBU!8S
M=PW0?$<BJ%WQ[>N0!D''3K1-H6NV'B%]5T>[LYOM=O'#>QWH89:/(61=HZX)
MRO ]_3K** .>N=%U"7Q'H>H>=!+'813),SL5>1I H)"@$#&WIGO[53L_#%TO
MB&RUJ:*RMKV%'6ZEM)&'VW*X ==H YPV>3D?EUA8 @$@$G R>IJO!>QW%Y=6
MRQS*UL5#,\956W#/RL>&]\=#0!R$/@[4H]'M$\^U34;'4Y-0MV5F:-][L2C?
M*" 0Y&0#T!]JN:EX:O=5&LWDOV:._OM-.G0H)&9(D.XEBVT$DENF/X1ZUU%Q
M.EK;R3R[O+C4LVU"QP/0#DU#IFHV^K:9;:A:EC;W$8DC+#!*GIQ0!@C0M3.J
M^'KLFT"Z;:RP2@2L2Q=57*_+VV9Y]:@LO#5W::PFMF.PLKU;61+IK:1O+NY"
M!M9UV@  @G/)YZ\5U]9.H>)=+TM[A;N2X7[-&))GCM)9$C7&<LRJ0.!GK0!)
MH-QJ%UHT$VJ1P)>$L)/L^[RVPQ 9=W." #SZUS&J^$]<ODUB);BPD%W>17,$
M\V_S%1'1A"<#Y5&TX(SU/'.:W&\7Z.EM)<%[L1QVS766L9EW1+C++E!D#<.G
MKFMBVN$N[6&YBSY<R+(N1@X(R* .<&AZH-6UZ\8V;#4;2*! )&&UD5ADC:<
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MO7+>>">91Y$2G3I5E(=)QSYK87@Y QC/&[UK8L]8M+_4;^Q@,GGV+(LX>,J
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M!&1_.I: ,/POI-WH]C=07A@+2WDURIA<L )'+8.0.F<4EOI-[%XTO=7;[/\
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MR-Z2;?,3.X;@!@X//_UN* .5TJ_UZX\(RZY<>(HHG47$($]N@C!$Y57.T9+
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M<ET5_?Z]J.OV]E?O9'3G6"#8B-N<H'WON!R"3C QP#W/%J?P?ILVL3ZDLMY
MUS@W4$,Y2&X(& 74=>.#TSWS5B?P[:RZE<7\$]S:3W48CN?L[@"90,#=D'!
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MP9]>%/I45U;Z=H^B>%KI8(H=/OIK8:I..DH$1\OS#W7>1DGVS0!U^EZW-?\
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M2MCX;U?4]+$-U)IK&.17<A=P )&1UQN [<@UL:?I=AI<4D=A:Q6\<TAE<1C
M9R "Q]S@5YC>+I]OX)\>PQK;1W2WMR-BA0XCRF/?;D\=J /5TD5\@,I88W '
MIFE62-G9%=2Z_>4'D?6N"O;9=-\:2#188XKJX\/W#@1@9EE#KL9O[S9)Y//)
MJ/PO_8&J3:#?VFK.VIP1,C6L0C63E?W@F 7<0",Y;O@Y)/(!TWBS7;CP[I"W
M\%K%<_OHXBCR%/OL%!R >YJ#5/$EYX>6&YUG3HETYW6.2[M;@R>06. 74JIV
MYXR"?I5+XF.J>$ 78*/MMMU./^6JG^E,^(-]!J'AFXT*P=+O4]1VQ06\3!CC
M<"7;'W5 &<GB@#JM]V=4"@6WV$P;@=Q\TR;O3IMQWZYJ5[JWCBDD>>-4B!,C
M%AA0.N?3%<2+:#3_ !ZT32[&3PWMEECX<[9 -WUP*HV44MO'<:3?VEA>AM%E
M:SU*T4 3PKMP)$[-DJ002.N.] 'H%E?V]_86U[ X,%Q&LD9/&0PR/TIOFW3:
ME&$^S&P:$L6WGS"^1C Z;<$\^N*\V@MM'N]'^'RI':.KR)'/L"_,QMCN5L=<
MG&0>O0ULR6%OI7C^&WTBWA@D70)Q#&@ Y$J;1^= '<B1#(8PZEP,E<\@?2JV
MGZE::I \UG*LL22/%O4Y!920<>V0:XOPK/X<U;3= E:17UNW0K+$'Q/YI7;-
MYJ]2,Y)W<=/45=^':V4>DWL4"P+<I?W2RJ@ =0)GVAL<CCIF@#L'D2/&]U7<
M<#<<9/I6;K>KC2H[-5"F:\NDM8MW16;)W'V !.._3CK7/P_9;WQGXEL==CA:
M/[/";9;C&TVVP[RN?]O.2/;T%8(@:;PIX%.L1I+<MJD<>^X4%WBQ+L!SR<KL
MH [V*YU:+2;N:]M[3[5"7,?E.0DJ#D-W*D^G./>H_#>L7&O^&K357MXH'NH_
M,2(.6"CMDX'\JTKB -I\MO$JJ#$410, <8 KEO 6I6=M\/\ 3UN;F*![*(PW
M*RN%,+J2"&!Z&@#5L?$"-IME<ZB(;::]F\F&&.3=N;)'!(&> 2>.*V#+&LBQ
MF10[?=4GD_05Y]K%O;1Z1X-EU"&)$_M)#(;A0-BNDK;6STZC@]ZS/$]_ILEG
MK\MI+;P30:C:Y,S9F9E:+#1C(\N,+TZY^;I0!W=IK<TOBG5=+N(X8H+."&5)
M0YRWF%QSG 'W?_KUN5Y_<VFFZOXO\3?:HH+J$:3;N@?#+R)?F Z9P1@]L^];
M?@_5+?\ X1/PW!<7<?VNZL4\I'?YY=J#=CUQWH Z6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$([("5SUP>U--C:,(PUK 1&,(#&/E'MZ5/10!"UI;-<K<M;Q&X4;5E*#<!Z
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MG):6T9C*6\2F/.PJ@&W/7'IFIJ* "BBB@ HHHH **** "BBB@ HHHH ****
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MD\<T 7J**HZ;J]GJXNC9N["VG:WEWQLA610"1A@#_$* +U%%% !136<*#D]
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M<3/;@A&8<9&:N5FIHT<,]A)#=WD:6:N/)68E)RXY,F>7.<D'/4DUI4 %%%%
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MB/'>@#TP$'.#THR,XS7"S06BZIX1O- 6-1=EDF\K@36QB)8OCK@[>3W/O3_
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M . ,D\#I5NN?\#WEQJ'@G2;N[F::XF@#22.>6.3S704 %%%% !1110 4444
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MI%?07MS<75HDP^Q7%VFV=X]HSOX!.#D D G'IBNBHH YSQ?:75Q#I$]M;27
ML]3AN9DB +"-0P) []1P.:R-7L=4FNM;U_3=/+O)906D$$L8WS!9"SR;&[A6
MPH;J5Z8QGNJ* //H["X;6->EGT+4;FPO].@3;<."\NTON4_-D-AN ,8]JAGT
M+7'TC4[*QFNKZRB-M<6*:D-LK/')O:$LP!9<*,%NYQG@FO1Z* //M2TN;Q)X
M:U3^S?#;Z5?26PC#W:(DDI#J_E@@GY#M(R<#)'O5TW%_JWBWPWJ(T2_MXH(;
ME+CSD5?*9Q'@=>1D'D=>V><=H3@9/2HX+B&ZB$MO-'+&20'C8,"0<'D>X(H
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MG_[:&KNJ:=I^N.EG<7,H>W82M%;W31M@@C#!2#M//6M-$2*-8XU"HH"JJC
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M9A<K ;?&X;/+SNQC'J,YZT <8^A7UII%CMLIB\WB,:F\$:[C!"9"V#CC(7'
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M(_(G_&NBHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K%\3:S<:#IL=_'!'+ LT:7)=B/*C9@I<8
M'.,Y(]*VJK:A8PZGIMS8W*[H;B)HG'LPP: ,+_A*'CUW6]-GC@3^S[5;F)E<
ML95().1C@C@8Y^\/6BZ\17T<DME#:1MJ%O:I/.@621 [[L1@HI_NGYC[<'G$
M,/@I$&@R2WCR7.GDFYFQS=9 )!]MZH1[+BI]3T#51XA.M:'J,%M-/"L%U#<P
MF2.0*25888$,-Q'7F@#-FNCJ7BSP7J$EE+9SSPW9>&9-LD9\M<J<C/!S4-F+
MJ\U;QA]NTZWU&.":(BU!)+,D*NBKD8ZG/U)K=N-!NY=;T2_^VI(-.642>8AW
M3&0 $C!PN,9 _#BJDGA:^FC\2H=02'^V<%7A0AH"(P@[_-P!GIWH ?9^*+F;
M5KK3&AM)KB*P%XIAF.T'<5:-C@X(/<?D*K6'C#49M$L]6N]-@BM[](5M5CF9
MW:5SC# +PH&3QDX'3)P);;PUJL6KQZC)?6.X::;%H8K9D0#=D%?F.!_^KB@>
M#YV\$V&AMJ BO-/,;VUY%']UXSE6*D_@1GO0!HZ+K%[?:A?6=Y821"WV-%="
M)TCG5AT&\ A@>".:AU;7=2M?$5KH]C86\TEU;231RS7!15*%0=P"D@?-VR3[
M=:NZ/;:O$C2:S?07$Y 55MHC'&H'?!))8^OY#KG"UF28?$K0A;/!YHL+K*2D
M@,-T?&1T/?H>AH RM:UIM?\ !\CWEDMMJ%AK-O:SQAMX1UFCY5L=""/SK<\1
M^*KK04O[AK2$6UFJ,@EEP]V#]_R\=-H/<')].M,O/"$T^BW%K'=Q+=7>H+J%
MQ,T9VEE=6"J,],(J]>V>]0ZQX/U+4VUY$U.W2#5HD4[X"[Q%5 VJVX#9D9Z=
MSZYH OW>NZK_ ,)-/HMA86KNMBMW'--<,JD%RN" I(Y!Z9^HJG%XXBFTS0KJ
M006/]JQNPDNF/E1NN!Y>X8Y))P3CA3]*T(-$U"+Q,VLR75M(QT];,H(V7D,7
MW=3QDXQZ=ZI:?X6O;'P]8:--)87UI!%+%/#/$0DVY@5;O@K\WKG/:@#IK*6>
M:Q@EN8EBG>,-)&K;@K8Y /<>]><ZQ>ZCJG@?QL=2%NZ6UQ/#$%R=FQ4  !'3
MJ<^I-=YH.E#0]"L],$S3"VC";V[_ ,\#L!Z8K N_!]]-IGB+3H]0@6VU>9YE
MW0DM$7"ALG=SC;QTZT 7+/7;^/7UTF\L8E$EBUW;F&4LQ"E5*,"  WS#H<>_
M>H;#Q3=SZS9:;<VULEQ>6DDXB24EK:1-N8Y/?YNHQT/%37?AZ]N]:AO_ +9'
M#LTZ6R/EJ=P+[3O4YX(*C _6J>F>$]4L[S09YM1LR-*@DMRD5J5\Q&"C/WOO
M';DGISTH N>!]1U+5?#PO-2:)W>><!HR>TSC&#T P .3P*L7>LW<FH7]AI-O
M%-<6,"RR^:Y4,S@E8QCN0O)/ R.#SA?#.BW.@V$EC+=1SP+-))!MB*LJN[.=
MQR<G+8XQTJI?>']4B\22ZSHFHV]LUW$D-W#<P&1&V9VNN&!# $C&<4 3IKMW
M>7\6FV]HD%_]B6[N$N&R(-QP$^7J<AN>V,\YK,_X3>XELM/D@TQ#<3:FVF7,
M+SX\F9=V<';\P^7KQP1P>E:#^'KJVUZ#6;"[5[G[*+2Z2Y!Q.H.X-D?=8$GM
MC!QQ563PA*L-@(+J+S8=5;5+EWC/[Z1MV0 #\H^; Z\ =: *&M>*=8B\->*%
M$-M;:GI053)'(SIL= P9<@'< >_<9]JVM1UG4M/C0/;VL8%L\S7$LI\MG!^6
M)>Y8C)SVQT-4[[PA<:@OBA);R)$UI$5=L9)A*($&>?FSC/:I)_#NKSZM#?OJ
M=KO-BUG,IMF*IEB2\0W<$\ YSG ^E #/^$C2^/A*Z.F0.FJG>CRME[9C$S_+
M\OH",Y'TJI=^,]5M]/UN_&E6I@T>\,,X-RVYT 0DI\O7#9YP.@YJQ:>$[^VL
MO#,#WUNYT5LDB(KY@\LQ@=3C@YSZ]A27/A"]N=%\1Z>;RW7^V;AI@_EG]T&5
M5(QGYN$'IUH Z_/R[@,\9KEK/Q5=2:SINGW5I!%+?QRMY"RYDM60!@LG49(/
M;&/0UTGE2/9&)Y-DC1[2\?8XQD5R.G>$-5LY- >34[-_[($J#;;,#*KK@LQW
M??/4GU)/- #8_&FIG3DU*72[9+--2-C.!<%G'[WRMRC;@@''7&>>!UKL;J5X
M+2::.%IGC1F6)/O.0,A1GN>E<D?!]^?#DNE?;;;=)J/V[S?+; _?>;MQGUXS
MGI73:I9R:CHUW9)<-;2W$#Q":/K&64C</IF@##T_Q/=7.M?V5);VK7+6!NP(
MICB)PP5HG.#R"PY'OQ6;:^.-3?3M%UBZTB"+2=1D2%G2X+2PLYPK%=N-N>.N
M>_'2KMAX;U&QU33]2N=0L@MGI[63Q0VQ12F5(();@_+SV]N]97@S2I]:\ ^'
M8;F:#[# 8[@B,'?(48LJ'L,,!D\YQC S0!;N/&&MK9:S>V^B6LD&D74D5P#=
MG<Z(JL2GR=<$GG';&:NW/BUYTG.CVIN6AMH[C#1R'S"Z[U0;%."5QR?4<'G&
M5HMI=:LGC'3X+FW2VNM4FBD?!,D8:- Q Z'(X&<8(SSTK4E\+ZCIVL?;O#FH
MV]I'+!';W%O=0&5"(QM1UPP(8+QUP: %O_%-[;Z<+U=.%K&+#[61?,4+2<GR
M .H8 ')P>HXJK>7,6I>*? VI)$$-S%<2#/W@K0;@,_C5F]\+:A/J-Q/%JJ-%
M<Z=]BE-Q"7=/O99"& &[=R,8X'H!2VWAB_AE\,O)>V[G1HFC;$17S=T?E\<G
M& ,]\GTH TO%.LS>'_#EWJL-LEPUNH8QO(4R,@=<'UZ?K6>OB/5;?Q)%I.H:
M9;Q?;89);%X[@L&* %DD^7Y3@YR,CZTWXD,%^'NL98+F$ $^NX5=&DW5YJEI
MJMW+;-+9P2):K$#M+. &<GZ   =,GD]@#'L?&FH3>'[?6[K3+>*TNT1+:-+@
MF1YWDV*I^7 7G.>>!T[5HW'BAM'U62QUF*-$^QR7L5Q 2598^9%(/(8#!]QZ
M55A\%N? EOX=N+U1-:E7@NXH\;'5MRMM)]>",\CTJY/X;?6+DW&MO"["RELU
MCMP0H$H D;)YR0  .W/)S0!);ZQJ>^TN+K3XUTZXMFGDFCDR;7"A@'S][(/5
M>A'XU3L_%5Y<W6F.-+E:POUR9$BDS; KN4N2NT@]R#P?4<U)HN@ZQ:V::=JN
MJPWEA!$88A' 8Y)4VE1YC;B#@'L!S@YIN@^']:TJ*+3;K6(KG2;8;8%$!6=D
M'"H[[L8 QT&3CTR* ,/Q)J<^N^'-*U2*V@%A+JML82Q/FA// #],?-C[O8'K
MVK=F\3742^)Q]EA+Z(@D7YSB8&+S,'CY3CCO6:O@K5H="AT*+5;7^S[2ZCGM
M7DMV:5520.$;# ''3/?VJYJ'A;4KB[UYK74+:.WUFV$<P>$ET<1F/*G=C!&,
MY!- !-XGU:6_L++3],M9);W33>QM+<E0"-F5.%Z?-U&<\=*2\\77L<-U/8Z6
M]X+.?R)8(8Y'>1@0)-C!=ORDG@]<'I5BR\.7UKK.DWSWEO(MC8&R91$5,@)4
M[AR<?<''/>HX_#FL6&KWSZ7J\,.F7\QGFAE@+R1.WWS$V0!GKR" >QH Z&]O
MH+#3;B_N"5@@B::0XY"J,GCZ"L%O$UW:C1KF^LXDLM6D2%#&Y+P2.,H&XPP/
M0D8P?7K6]?V,&HZ9<Z?< M!<1-#(,\E6&#SZ\U@VOAF\:STBQU*[AN+;2I4E
MB=$*O,8P1'OYP,9!.,Y('3I0 NB:]J^L:A<)_9MK%:6M[-:3R?:2S?(!@J-H
MSDGG..OM6CJFKFRU#3M-@17O+]G$>\X5%1=S,<<G' QW)'3K47A[1[G1SJ?G
MSQ2B\O9+M?+4KLWX^7D\XQUI-<T.34;[3-3M)UAO].D9HC(NY'1QM=& ]1CG
ML10!SWB#Q9J,/A_Q';Q1Q6VJZ7Y:NX8E6CD^[(G<'&>#T([U-?B^C^(FFR06
MUJU^^E7 ;+E8^)(\$G&2,>W?\:N:AX0;5-.UT37*1WVK+&K2(A*1",?(H!.3
MSDD\9SVJT-%U)O$EEK$]U:N\%I);NB1LH8NRMD<G &T#O0!3LO&+7>DZ=(UJ
M([^\FF@,2[I%1HBP=OE&2/EXX_B'3DU#-XPU.VT]99=$99AJ<=B?,+Q+*KL
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MKS3O%^HZE8#1UT]HE%UJ4,$I<D$@G.!CH#MP?:K6@Z/<Z5=ZM+-/%*M_>&Z
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MK6\,JIC$B,W(/&>W8BL/49=4FO/&BKK5[$FFPQS6JQE5V-Y)?!^7D9[=^^:
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MQ'RP[(HYV@X!Y(-17_B+4M(MO&$WVN24VEY;PV[RA2(%D6/)P !@;R>?09H
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MKG%79[^SM94BN+N"&23[B22!2WT!/-+/?6EJQ6XNH(B$,A$D@7"CJW/;D<T
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MQ$Z6AM?$<,D]N<M)D2H#,Y.=JD#Y<8&.YSBM2XDT\^)_&(9K<))I,+,K8&6
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M0XSM19D+-] ,FL'4-1TV_P#$GB.1)X9K:7P^FV3JDF&EY!Z'MR.]>C]1@T@
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M?ST!'?-=/1@9SWHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D8[5).< 9X&:6N:N=0FOO&YT!;B2W@@T\7;F([7E9G*@9[!<$\=21
MV&" :NC:S;:[8&\M%E6(2R0D2IM;<C%3Q]0:T*Y'X<HT?AB9'D,KKJ-V&=@
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MZC=S2:7>VCO:H0O[N:/EHQ@9)9<$9/4$5T.DPW4&E6Z7T[37>P&9VQ]X\D#
M' Z#Z4 7::[B.-G(8A1G"C)/T%<'J6LZA;WD5Q;ZA+<+_;D5H[1J! D3.$,.
M#RS#/+#H>,\8J]8#5-0\8ZW;OK=TEKIUS;O%"B1X96C#,C';]WGM@^YH Z'1
MM7MM=TF#4K02"";=L\Q=K<,5.1]14T-X)KZZM?L]PAMPA\UX\1R;@3\C=\8Y
M]*\QTJ35='^'NE:]9:I,5@N0CV!1/*EC>X*$=-V[YLYS^%;FIWE_,_CRT?4+
MCRK2QCDMMNU3%NB=B 0!U('/7WH [E'61%=&#(PRK*<@CU%.KS]3J4,?@JPM
M=8NH(;^!DFPL;' M]PP2O!';J/8TSQ%J&J:1IFL&WUBYN[G3+2)D9$11$P&2
MTV>&+_W0#@8X&<D ]!+J'"%AO()"YY(&,G]1^=065X+V*1Q;W$&R5XML\>PM
MM.-P]5/4'N*Y98Y9OBB&^V7"J=&641JPV@F7! !'0X'O6?;>(]2BTF"&:\>2
M>[\12:9]J95W1QB1AP -N<)@<=3F@#T*BN&U34M4TK5=;TJ&^G:(:,^HVL[!
M6>!T)4KD@[@>#SD]:--OM4@U?PFTVJ3W,>K63FXAD5 BLL2N&7 R#DG.2<YH
M [FBL;Q6FI'PU>R:1<20WT,9EBV '>5Y*8(/4 C\:YE?%P7Q';7@NKB71+W3
MRT2_+A;D()-@.,Y,9'&>O'T .VGO!!>6MM]GN)/M!8>9''N2/"YRY_AST'J:
MS&\5Z<MCK%V4NO*TEV2Y'DG=D*&) ZXP>IQ6;/-JNG:]X2LIM1ED^U&=;Q"$
MQ(RPLV<A<\'I]!61<?\ ("^)G^]/_P"DJ4 >@6TZ75K%<1@A)4#KD<X(S532
M-9MM:CNGM5E46UR]M()4VG>N,\>G-/T;_D!Z?_U[1_\ H(KSU8M3@T7Q=JVG
M:Q-9R6&J7=PD*HACEV ,0^02<@8X(Q0!Z?17#C4M9\27&IVVGS+93VMO 8AY
MVPI))$) S#8VX9.W!X^4UU^G-<MIMJ;QX7NC$OG- 28R^.2N>V<XH LUG:WK
M-KH&F/J%XLS0HRJ?*3<<L0!].2.M<E;ZSJ"ZKH$B:A+=PWU]/!-,%"V\J[9&
M41J>1MV@;N^#R<UFZY>W'B'X:7^MR7<R>9=;4MEQL2-;@($(QR> Q/7)].*
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M/$/PTN==DO)D\V\7;;+C8D:W(0(1CD\!B>N?;B@#TV:00PO*RLP4$D(I)/T
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ME])+,?$(TF&[E52Z1L%?)XP6 ) ..N.* .RBUFUFUZ?1U6874$"SL63"E6)
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBF2RQP1M)+(L<:C+,YP!]30
M^BH5N[9[<7"W$30'I*'!7\^E8E_X@DMO$VD6,3VCV5V+@32;LM&T2;L9S@=>
M<^E '0T50OKJ5](DN=,N;+S" 8YKAB8>O))4^F>_6@ZU8#6AI'VF/[;Y7G&/
M<,JN0!GW.>![&@"_14"WEJ[;5N868*7P'!.T'!/T!XJ*75M.AT^:_>]M_LD
M+23"0%5QUR10!<K)U/PY8:IJ%MJ$AGAO;=2B7%M,T;E#U0D=5]C^%6K;5+.Y
MTR+4!/&EM(BOO=P N0#@G. >:G^TP>0LWG1^4V,/N&TYZ<T 8]KX2TRSM(K:
MW-W'''>?;1BZDR9,D\\\J23D=#WK=ID4T4Z%H94D4$J2C C(ZCBD>X@CE6)Y
MHUD;[J,P!/T% $E%0"]M&C:1;J$HF-S"08&?4U5:>^^UW@CELFA6!6@3+>8&
M^;)?G&TX&,>] &C17&6_BW49O#OA;4_)M0VK744%PN&P@?<<KS_L]\UV= !6
M=K>B6?B#37T^_P#,:UD(+HCE-V"",D<]0*S[#Q!(_B'7+#4'M8(+%X%A?=M+
M>8A;!).,_2MRXNK>TB\VYGBACSC=(X49^IH 1K:.2T:UF'G1.A1Q+SO4C!!]
M>*SK#PW8:<;7RS/(EF"+6.:4NL (Q\N?;@$Y(' XK65@RAE(((R".]1SW,%K
M&)+B:.%"<;I&"C/IS0!@S^"-&N1=I(+KR;FX%R\*W+JBR[@Q90#\I)')'OC&
M:W9[6&YLY+29/,@DC,;JQ)W*1@@GKTHEO+6"W%Q+<PQPG&)'<!3^/2LC6M9N
M=/U+0HK98)+?4+O[/(S9) V,P*X./X??K0!%;^#]-L'LKFV%U)<Z?&Z6IFNY
M" I PAY^[\HXQ7-:7H-^+>.&*W\2:;J ^9C_ &@#9I(3DD+O;<F2?EVY/0^M
M>@O=VT=PEN]Q$L[C*1LX#-]!U-$MW;0RQQ2W$4<DG"([@%OH.] %2RT6TL+^
M^O83*9KY@]QO<L&(&T'';@ <51TKP=I&BWAN+);E$#,\=LUP[0PL>I2,G:#R
M?SXK0AUJPN-8N=*BN8VN[9$>1 PXW[L#ZX4DCT(]:LQ7=M/-)#%<122Q_?1'
M!9?J.U &-8>#=(TS4GO+1+B-6D,HMOM#^0LAZN(\[0?PX[8K6U"PMM4TZXL+
MR/S+:XC,<BY(RI&#R.E8^O\ B%],O=*M[22TE>YOXK6XC9LNBOGD '@\=_6N
MAH QX_#5C%>6-V)+II[*-HX7>=G(#8W9SG.<#KZ#&*K'P7I)A6,?:E9+MKU)
M$N&5TE;.XAAR,Y.1TK5CEN1JETDLMI]D2-&C12?-4\[B_.-O Q]#4T=W;2RB
M..XB>0H) JN"2IZ-CT]Z ,8^#-&^PW]GY4_DWLXN)1]H<D2 @AE)/!RH.>_>
MMN&!(;=85W,BC;\[%B?J3R3]:DJ$7EL;HVHN(3< 9\K>-^/IUH PK;P/HMH+
M(1+=A;&4R6P-W(1%D$%5&>%P3QW[U(_A#2Y-,O-/<W)MKRX-S.OG'+2%@Q.>
MHY .!QQ6_4$M[:P;O.N88]I ;?(!@GH#GUH P[NVN-:UBWLKO276RTZY2Y6\
MG=&$S*IV[ #D'<<DD#@$=ZZ.HA<P-<-;K-&9U&YHPPW >I'7%(EY;27#6Z7$
M+3IRT0<%A]1UH PI?!&BRF8%;I4ENA>>6EU(JI-NW%E .%)/I^&*T;'1+33]
M2O+^ S>?>;?.WR%@VT;5X[8''%6S>VJNJ-<PAV?RU4R#);^[]?:EFO+6WW^=
M<PQ[ "V]P-H/ SGIF@#+L_"VFV0BBB$QM893/#;/*6CC?).0#[DD D@'D8J4
M>'K#[9J=RRR.^IQB*Z5I"5=0"H&.V 2./6M">Y@MH?.GGCBB_OR.%7\S0US
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MA551@*!P *8+RV9U07,)=QE5#C+#VJM=W4K+;FPN;+'VE$F,S$Y3^)5P?O\
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M@^SHZW#\IG(#9/S8//.:TY9HH$WRR)&G]YV %,%W;-(L:W$1=AE5#C)'7@4
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MG!S@A!D5T%(%"C"@ >@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV7S-+E5KL>;'\@$3)D?-SRPZ=J .OU#5H-.FM('226XNW*00Q ;G(4L>20
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M#5IWFNT+C?(07*;CLWD<%MNW.._KUK7H **** "BBB@ HHHH **** "BBB@
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MV32I7A>&16)N'C4&3:P(V<D@9!Z9/6I+3Q-<:^YCT,0(RV$-X6ND+9,H8HF
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MH3Q;@H.#\H)/3[O_ (]74?;A#H<_BO5=/2UOK2VN L>=Q2,-D*6[D[%/X\4
M:L7B'19Y5BAUC3Y)&.T(ERA)/I@&M%W5$+NP55&22< "OGS1;&77O#=EX06(
M6^IZO,=7FO+D#;Y>2!Y>,DL0I.#COZUV6O/-XB^)>E^#))I#I%C;K<WB%N;D
M@9 ?U'W>/<^U 'H,'B#1KF988-6L99&.%1+A&+'.. #S2/XAT2*9H9-8T])5
M.UD:Y0,#Z$9J6XTNRN)+&62% ;&3S8,  (=A7\L,?R'I7C^CQ:CXGM/&FJ6&
MDO>RZW,UG;3.\:QQ1#C<2S9X!4\ \J* /8'UC3(OM/F:C:+]E4//NF4>4I&0
M6YX![9JQ#<P7!(AFCDP%8[&!X(R#]".AKE?#?@:VT?0XK:[%M<W9LQ;32- K
M*XSG#9^^!P!GH%' YHU]8_#,?AF:R!2."\ATYA_>@D&S!]<$(WU% '7T45EZ
MU?7=B+3[.+=(I9=DUQ.?EB7:2,+D%B6 4 'O0!J45PP\9:F^@VMY%:VK7!UC
M^S)0X=%8>;LW 'E2?0YQ[U8D\7W>D'Q$FKQ6\K:7'#+$;4,@E$N0J'<3@[AC
M/OG% '4/J%G'?QV#W4(NY%+I 7&]E'4XZX]ZLUQ5VNHK\1?#1OY+5\VMV1Y$
M;+M.(]P.6.1TP>._%=-K<UQ;Z'?SVDB1W$4#O&[IO (!/3(S0!-/J%G;75O:
MSW4,=Q<$B&)G :0@9.!U/ JS7F[2:A-IWP^GDEAN+N6575V4J.;5OO'))/4D
MC&?:MNU\1:N^GZNDL-BU]IU\ML\H8QPB,A&,I#-D;5<DKNYQP>: .MHKSW6?
M%&IS>%_%JV\T,=SI8 CN8X&7>CQALA6;*MR<')'0@5W=F)Q:1BXDCDEQRT:%
M ?P)/\Z )Z*Y#Q1XHU'08]2N%BM!#9Q1RQ1."\ERO\9^5LQ@=,D$9J6_UG7G
M\52Z+ID6G "Q2[22YW]Y"I!V_0_YXH Z&SU"SU%)'LKJ&X2.0Q.T3A@&&,C(
M[C(IWVVU%^+#[1']K,7G"'=\VS.-V/3/%>>6>HZYI%AXIU+3;>QFM;35[J:>
M*8L))% 4L%(X4@#/.<^@[])!KMQ?>*8K*WBMD@N-(^VP3NA:0$NH 89''.<
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MC+M=HVW#:2/4-SS[5%<>#WM]2M;[0=3;2Y(K5+.1/($R2Q)]T8)&&'8UU-%
M',7_ (3N7U&TU/2M:FL=0B@^SS2R1+,+B/);YU) SN).1C&?2G77A:<ZAI^J
M6.JO#J=K$\,D\T0E6XC8[F#J"N/FY&",?2NAFGBMT#S.J*SJ@)/5F( 'XD@5
M)0!R'_"$R_V3>6IU=C<3:E_:<4YMQB*4.''RY^8<>HJ23PA=3RZU--K&^75K
M-;2;_1@%3 894;O1S@9^I-=7535-2M](TRXU"[8B"!"[;1DGV'N3Q0!C:AX5
M>_T+3;-=1>WO]-*/:WL48RK*NW)0D@@@D$9YK4TJQN[.!C?Z@U]=/C?+Y8C4
M = J#H.O<GGKT +"_NKFZNK>ZTV:U,.TK(6#1RA@?ND=QC!&...N:T* ,#7]
M-D?5-'UJ!&DDTV5_,C49+0R+M? [D?*V.^T@<U(^BO+XE77K34!'YEFML\1B
M#JZABZD'(QRQSZCTZUMT4 <E!X+F@T+2-+74T*Z;>B[60VW+D,S!2-_ RQ_2
MI(_"5W::K>26&N36VF7TQGN+(0JQWM]\I(3E W?@]\8KJ:* "BBHXYXIGE2-
MU9HGV2 '[K8#8/X,#^- '-:9X0EL?&M_XFFU%;B>\B$+1_9]HC0;<!3N./NB
MKGBWP_+XHT&;25O_ +'#.1YKK%O9@"#@<C'(K=HH Y"X\"B2^\.7]O?BVN]$
MB\E&6#*RI@#:1NR!C/?^(U/J_A W?B:V\1Z9?_8-4BC\EV:'S8YD]&7(/X@^
MGI7444 8UQI.H76DW=O+JH^U7,9B,RP82-2"/D3=P><Y)/Y<4WPEX=7PKX>@
MTA+@3I"6(D\O86W,6YY//-;=% !7/Z[8-K>IZ59J#Y%G=I>W#]@4!V)]2Q!]
M@O/49Z"B@#)TB/5([[4S?7AN;5ILVNZ 1F-><IQ]Y1QACR>>V*9K>AS:G?:9
M>VU]]EN+"5W3=%YB.&4J05R.<'@YXYK9)P,GI7)77CE;>"QO4TB[GTV_D2."
M[C9=HW.$!<$Y4'.1US[4 ,7P1,EF;8:PS+_:W]IJ9+8$AM^_:<$9R>I_("K%
M_P"#8]5N=;:]N]T&K6\4+QQQ;3'Y>2C!MQYR<].PK?%S.=3:V-G(+<0B076Y
M=I8DC9C.<X&<XQS5F@#F;?PUJ1U?2=1U#7!<RZ='+&-EH(_-5PH);YCS\O)'
MY#OT%W;)>64]K(2$FC:-B.H!&/ZTZ&>*XC,D+JZ!F3*GC*DJ1^!!%24 <K;^
M$;J&WT")]667^QG#1DVV-X$9C .&X^4GGGGVXJ.Z\%S7']H.NJ^7+=:A%J",
M+?*I)'M !!;YE^4<<<\UN:EJPLKJVLH83<7URLCPP[PH*H 6))Z=0/J1[D4[
M_P 2_P!G:!;:K<:9=IYTD<;0/M5X2[A!NY]3VS0!1F\%/=1^($NM6DD&M1(L
MF(%7RW5 NX>HX&!^9/6NDL89[>SBBN;C[1,HPTH0(&/LHZ?F:L44 <EJW@J7
M4Y-=5-7>&VUB-!+'Y =D95"@AB?N\?=Q]"*T+70;F'Q*NLRZ@LS?8ELVC\C;
MN 8MNR&X.2>W3\ZW:* .9/A.3R]6LUU'&G:I.\]Q%Y/[T;P ZJ^[ ! Q]TD9
M//>KB:"8O%$6L17")%%9?8EMA%T3<&SNSUR!VZ5M44 <?%X)G@T2PTI-7S#8
M7J74!>V!(".753AAGD\GN .!WT-1\-SWFNG4X=3:W\VR-E/'Y(?*[BV4)/RG
M)]#GCTKH** .4M?!TUK;^'ECU=O/T9&B63[.N)(V0(1C/!PHP>>>QZ4__A#V
MCMM4TZWU#R])U*1Y)K<PY=-_^L5'W8 ;GJIQDXK?T^XGN[&*>YLY+.9QEH)&
M5F3GN5)'O1=7,\$]JD5G).DLFR1U90(5P3N.3R,@#CUH S;;0&M?$SZM'<H(
MFLTLUMA#C:B$E<-NZY8]NE;=%% ',W/@JPN1KX:1\:NO*XX@;: 64>I958^Z
MCTJQJ_AH:EX4&@Q79@CVQJ9F3>QV,&SU')*\GW-;U% &,VB3MXIBUPWD>Z.R
M:T,/D'!!8,6SN]5''I^=.\.Z*^@Z?+:-="X#W$LX81;,%V+$=3W)K7K$O_$+
M6]U=6]EI\]_+9"-KE(2 RA\XV@_>.!DCCC'TH -3T*>\UZQU:UU%K66VBD@9
M#$) R.5)QD_*WRCGGZ5R-[I#>')?!^E)JJ.\.HRNDLT0&U620X*@C(RV,Y')
M[5Z310!P'C?2TT_PAKMY-=*]_J$MMOD"[!A)$"JJDG@#)ZGJ3].F@TF2?5(]
M7N;R&XN([=H;8QPE8T#D%FQN)).U>XX'OFMFB@#C3;Z=X6\)P>&M2EDOQ=1S
M001QVS;I\Y)7C< ?FX)('Y&M_P /Z5_8N@6>GF0R211CS9&.2[GEFS[DFK37
M,XU..V%G(T#1,[7(9=JL" $QG.3DGICBK- %'4;2ZNF@:UNT@\MCYB21>8DJ
MD$;2,CZ]>U8(\$K;6%A'IUZMK<V5[)>QOY&Z(&3=N01[AA,.0 #QBNLJM87,
M]U;&2XLY+1][+Y<C*QP&(#9!(Y S^- '-OX(:;3]:M9]6E?^T[F.Z+^2H,<B
M;"..XS&.../SK0?0+BYGFO;J_4Z@;1[6":"'8L ;DLJEB2Q(4]?X0..<[M8<
M'B)[L:TMMIEQ)<:9+Y7D%T#3-L##:<X&0PZF@"M+X12\GU*YO+B(W.H6#6$K
MVT'E J<Y8@LV6YX/8"F1>%;Z&[TJ[76V^T65LUHY-LI5XSM^Z,_(WRCGGZ8X
MKIT)9%)4J2,E3V]J8\\4<L<3NHDE)"*3RV!DX_"@#E+#P3-86FAVZZMYB:3<
M/-'OMA\^X,-IPP[.>?7\JDNO!C7EEK]M+J.!J\R3[D@P874+CJQW#Y%].]=%
M:W,\\UTDMG) L4NR-W92)EP#N&#P,DCGTJS0!A/H-S+KVEZK-J"O)8PRQ%?(
MQYGF;=Q^]Q]T8Z^^:F'AZV'BIM>#L)6MQ"T0^ZS G$A_V@K,OT)K7HH YB3P
MK>PZY=WVEZ[-8VU\XDN[40+)N? !9&/W"0!G@UTJ((T5%^ZH '.>*=10!@OX
M?N;;7[O5]*OH[>6^1%NHIX#*CE!A6&&4J<<=2#Z5-_80FTO4K:[NFFGU*-DG
MF5 N 4V *O. !T!)[Y)S4E_K:6&MZ5IKVTKG47D1)@5VH40N0><YP/3\:T)9
MXH%4RNJ!G"+D]6)P!0!S4/A.^@GTBY36S]HT^W:U+&U4J\9VCY5S\K?(.>?I
MCBH;+P3-966C6JZMYB:7=O<QE[89;=O^4X8=G//KZ=*Z^B@#(TG19--U35KU
M[I9?[1F68H(MNPJ@0#.XYX44>(-%?7+:UA2Z6W^SW45UDQ;]QC8,!U'&12:E
MXBM[ Z84A>XBU"[6U26-EVJQSR><X^4] >E;% ''ZEX(GU!-;A767BM]5D29
MT^SAF210H^\3ROR#Y>,>OKK:GX=AU:?29[J=S-I\ID+@ >:"N&0@?PD[21_L
MXK:HH R-(\/VVCZAJEW S$ZA/YQ0](^.0/JQ9O\ @7M6A?6J7UA<V<A(2>)H
MF(Z@,"#_ #J>HY9XH AE=4WN$7)ZL>@% ',Q>$)H;;1775,ZCI"F."X-N-C1
M%0A1D#<@@ YW9SR/2MC2](73[B^NY)!->7TBR3RA-H.U0JJHR<  >IY)/>M*
MB@#%UG0YM2U/2]0M;\VL]@TA :(2*ZNNTY&1@XZ'MSUS63%X(FAL;>U76"Z0
M:I_:2&2V!.=Y?:<$=V.3], 5UCSQ1211NZJ\I*QJ3RQ )./P!HFGBMT#S.J*
M65 6/\3$*!^)('XT 8$D$'AG4=8\1ZA?_P"C78A61$MF)CV?*N-I).=W/'Y4
MOA+2+>P@OKV"*6)+^Y>:..0$&.,DE0 ?N@DL^.V^KUKK:77B*^T?[-+'):0Q
MRF1RNUPY8#&"?[IZXK4H H:WI%MKVBW>EW>[R+F,HQ4X([@CW! /X5C0>&-3
M.IZ1?W^NBYETQ947;:!/-#@#+'<>>.2,?05TDD\4+1K(ZJ97V("?O-@G _ $
M_A1//%;0/-,ZQQ(,LS'@"@# L/#=[IMM,EOJJ"274);YB;;Y6\S=NC*[^1EN
M.>PKG-?T>#0(=%@M[F"&:Y\1)>,1&%CC)1@<)GA.%SSU/49KLAK:'Q2="-M*
MLGV0W8F)78R[@N!@YSD]\=*U* .<N_"<>I6^L"_N=]SJEN+9Y8H]HBC4':%!
M)[L2<GDFDL_#5]'KMCJU[K'VB>VM7MF5+81JZL5.>I(/RC/7\*Z2N;_X3",W
MFJVL>C:G*^E[?M)00G 9=P('F9;CG@9H I+X$>/P_:Z;'K,T<VGW'GZ?=)"H
M: Y;AAGY\AB#T!&.!WZ'2K&\LX6.H:@U]=/C=+Y0C4 = J#H.3W)YZ] )=+U
M.TUG3+?4;"42VMPF^-P,9'T['/%3W$I@MY)A&\I12VQ,9;'89('ZT 9>LZ%_
M:5]IVHV]S]FU#3W8PRE-ZE7&'1ER,@C'<$$"L[4?!QU'3-4A>^5+O4Y8I+BX
M$&1B/;L55W< ;1U)ZGUXV=#U6/7-#L]4BC:*.ZB$BHYR5!]:T* &H&"*'(9\
M<E1@$_3)IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<YXLU)[ Z-!YS06]]J"6T\RMM(4JQ #
M#[NYE49]":Z.JNHZ;9:O8R66H6T=Q;2?>CD&0?\  ^] '&^,+$:?X(\51+J$
M]PCQ"5()G+_9P<# 8DG!()P>E/\ %%Q))+K"6MY=-/9Z3YIBCF:%+5L.1)N4
MY9SMX&, +R1GGHT\,:,FCOI"V*"QD.9(MS?O#_M'.6Z#J>PI+CPQHMW<BXN;
M".:;R?(+R$L63T;)^;KQG.* ,!;V[FUSP1(UW/B]LYFN$$A"2,(58$KTSEC6
M#=O>1^$=>U-=5U+[7I^LR);/]J?"J)U7:1G##!QALUZ!%X<TF![%XK,1FP4K
M:[78>4#UQSW[^O>F-X7T=K&XLFL\VUS+YTT9E<B1\Y+'GDYY^H% &39+)IWQ
M%DL([R[EMI]+^TR)<3M(/-$H7<-Q^7(/08'3BNK.V6/ALJPZJV.#Z$5G3:#I
M\UR]V]L9+EK<VQ=YG^:,]4//0_SYZT_0])AT/1X-.M\"*+<549PNYBV!DDX&
M<#V% 'GE]>:E8Z;?:7'=:A/J6BW[79/VN0-/9#$GS'/S J=F/4?6MO6[I[SP
M7XBU^ROKN-)+=FLWBG=0%1?O 9P"6W<CJ,5V'V&U^US77D)Y\T:Q2/CED4D@
M'V^8_G4,NC:?-HXTE[9?L C$0@!(78!@+P>F* .5^S1S?$?1II'GWG19')$[
MKDB2+T/3GD=#WS6"BRV?AN\U>WO+N*XM_$<BHJ3LL95KL*RL@.&!#'J#[5Z+
M+H.F32V<LMHKRV:E;=V8ED!QQG//0=?05 ?"^C&R>R-F3;23>>\9E?#29SN/
M/7//UYH Q())?$&H^*;>XO+FUEL)1!;"&=H_)7RPRR8!&26)/.>!CI5'P]JV
MHZGJ_A>>\FG1K_1YI;B(2,J.X,8#[<X!P2>/6NON= TR[N3<S6V9FC$4CK(R
MF5!_"^"-X]FSUI;_ $'2]3:U:[LTD-J3Y!!*[ 1@@8(X( R.AQ0!YX^[4= T
M9KJZNIBGBDPH[7+EM@F< 9SG@ 8/4=J['QLTMKX#U:6UN)X)8+1GCECE8."!
MQ\V<U<_X1;0_L#V(TV$6SS_:&09'[S.=V>H.:N7FF6=_IS:?<P*]HRA&A!*J
M5]..WM0!R-Z)=+OM%LEU&Z9-7D9IGNKI\%UB&U%(Y0,<G QDC'3BJ'BC3+FS
M^'^NV][J;WGE7"R0JLLF8%9TQ&S%LOC.1NSP1[5VU]H&EZGI2Z9?6:7%FF-L
M<A+;<="#G((]<U&?#.C-HW]D?84_L_.3 &8!CG.6YRW//.: ,2^:2;Q8/#B7
M#I NGBXB62[E5Y&:1@QWAMS%0%P">,_3&;)9ZA_:?A72KO7[NX,L=[#=3VTK
M1>=L'RYP?O#.-W7(-=;JGAG1M:BMX]2L5N1;G,3.[;T]<-G=^M2G0=,-Q93B
MT5)+%2EKL9E$0(P0H!P,C@^HH Y%8;W6+G7-(@U:6VN-,:."WE>YD$D:")&6
M5@" Y+%B2W7I4B6T^I^+KNQN=6O7MVT:WG/V:X>)3(S."ZX.5SM!P#]<UT>H
M^%=#U?4([^_TV">ZC&T2,#DCT;'WA['-66T6P:_EOO)874T7DO(LK@E.R\'I
MR: .)\/:W<ZJGA.PU*[E"7FER3LXD*-<3*5 !8$$X4LQ'?O5RYFGTZ_T3P__
M &M)=0W$ET&GN)65F9-I2(NIR<!SWR=O/<5OS^$=!N=*M],FTZ-[2W;=!&6;
M]T?]DYROX&I;SPUHM_I$>E7.G0/8Q$&.+& A'<$<@\GD<\F@"+PW9W>GVEU:
M7>I?;C'<L8R2S-"A 98RS$EB,]3S@BN'2Z?P_P"'/%M]9RSQRKK;P&1IG<1(
MS1*SX8D;@"?F(STKTFPT^TTNS2TL8$@MT^ZB^_4^Y]S5<:!I*S7LOV" O? B
MYW+D2Y !R#QS@9]<#- &)-]HTCQSHUK9SW$EEJ%O.+B&69I0AC"E9 6)()+;
M3V.1WJ;7'^T^(+:PCN;AY?L<LILXY3"F-R@2O(ISQR  #R<\8S6Q8:/8Z:P:
MVA(8((U9Y&D*H/X06)(7V'%-OM#TS4KR"[O+..:X@!6-VSD*>H/J/8Y% '!Z
M;>7^IV'@%Y]2O0]Z)8[EHYBOF@0N?FQU/'7KWZ\U:M['4K_0?$^FV.I7RW.G
MZDXL'-U)OP$1Q&SYRRDDCDGK[5U5OX6T2T%H+>P6(6;,]N$=AY;-P2,'J1Q]
M..E,N+&;1HI9] TR*XNKJX#W"3731ALC!<DAN>!VZ?3% %3PYJB>)KF/5[=Y
MTM(K98O*,K ><WS.&7."4&T9]2WI3+JY_M'QQ/H5S<30P)IJSPI%*T9D9G96
M;*D$[0%P.V2?3&WI&G#2]-CMOD,A+22LBX#2.Q9R!V!8FH=7\.Z1KK0-J=C'
M</ 28G)*LN>H!!!P?3I0!SUO/,_B;2_#MSJ5Q=6J:;+,;C>8VNI5D"8)4@G:
M,G&><Y.<5C7%YJBV,EF=1O%6S\3064%PLIWO"SH=K$_?QNQDYSCG/-=]<Z)I
MMW':QR6JJ+3_ (]S$3&T/&,(RD%1CC --FT#2Y[2&UDM0889?.10[#$F<[\@
MY+9YR><\T <]IL+1^(O%&D&[O9+-+>VGC66ZD9D9Q)NVN6W '8#C..M<_!;I
M#\(?#SJTA,EQ8,V^5F /G)T!)"CV&*]"_L/3Q=75T(7$]T@CGD$S@NHZ \]L
MG\S47_",Z1_9D.F_9/\ 0H6#QP^:^U"#D8YXP>10!S^JZE>Z9XMUR2WEFE6#
M0/M<5NSED\T._(7H,[0.*N:1:0WEMHNJ)K5VRW5J5EC,[%;IG3.>OR,N&/RX
MQR.*W%TBQ34VU(0G[8T0A:4R,24'\)!.,9Y^O-5]+\,:)HMU+<Z;IT-M+)G+
M)G@$Y(4'A0?08H Q_AI D/@>Q=&D)<R9#2LP&)7' )P/PZUEM>W6J>%?$^KF
M^N;;4=.N;H0[)F58/)Y12F=I! !.0<[OICM=.TBPTE)4L+6.W65R[A.Y))_
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MQ1-93QEK'4RFJ3L/NQ3*?GC'KEO*^H5JDDBDF\7>+$CBD)GTN&.([#AW ER
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M]H^(1\N3$\:^3^[;]YBV"?+Q\WS<<=Z .NT.ZEO/#VFW=PX:6:TBED; &6*
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M7+00M"06+R9CESC&T#!W= !6[#%(OQ$N5(=_^)''!YI0[7D$CDC/3."#CWH
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MK(/ ?BC36M+K[2=6E<1_9W.]6N0X*\?-E>>,\4 >BV6LZ;J-Q<6]E?03S6Y
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MF*>5-&-H*G:<J0<'@'C..U:/AK11H&@P:>9!(ZEY)' P"[L6;'MECCVK6HH
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MZ2I,Y7Y9%4;A@')&WIQG/45OU2&K61UK^R/-;[=Y!N/+*,!Y8(7.[&#R1WH
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MC577KFXLO#^HW=HZ)/!;22HSIN&54GID>E4[/0Y-/UJU>SNKJ/3;:Q%J+5I
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M=P ,#@#]2<@&GIMO?VZ3#4+Y+MGE+QE(!&(U('R=3G!SR>>:NTV-2D:JSLY
MP6;&3[G  IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWA\32&^<&!58("^T\M)D8SD8!///(!Z517E.F)!K-I\.UNY6N/-BGBG!E/S
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MV9"&&#[#\SZT =7)J+76GWDND"&ZN(&:)5=]J-(O52P!Z'CZBKZD[06 #8Y
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MUM]0^'7B'74C*_;K<RPMC:WEJ $S]<%O^!>U:=Z1_P )_P"%N?\ EPN_Y14
M:WA[6IM:BU!IK9('M+Z6TVI(7!V8YS@=<^E)I&M3:CJVLV,ULD)TZ=(@R2%]
MX9 X/08X8<5G>"""OB''_0<NOYK6#<:/I.J:OXY?5!Q;R12))YA7R2+9"'&#
MP>.OM0!Z117F%I=RW=WIVF>*;BVA:;1('C&H1;E>0EA*>6 $F-F>_P!.:ZZQ
M$NF^!"-/NY=2EMK23[-/*,M,5#;/J.  >XP>] %C7-:FTBZTF-+9)8[Z]6T9
MS(08]P8Y QS]T]Q6S7EI;29M%\":I%) ]W+J$!GN"P\QW,;^9O/4G?USTJ2
MV>MK??VCJ\%EK%GJDG(C'VI"LI\M4);)5DVJ !@Y(Y/- 'IU5DDO#J4L;P1"
MR$:F.42$NSY.X%<< #'.>]<+#+I&KR^(;?7KKR-1M=2;RV#A)XXE*F'RNX!
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ME\5Z+#I<VHRW92V@E\F8M$X:*3(&UEQE3DCJ.X]: ->**.&)(HD6.- %5%&
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M\CS4\[;N\O<-VWUQZ5)0!R4>B7MOXSNDBC_XDMZT=_*<\+<)P5 _VB(W_P"
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M?+= ^Y1MY(!'''U/:K;>#[I/#\/AJXNH9M(AF5UDP?.:)9 ZQD=.H W9Y Z
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M@%PIY.-N<9Y]>:Z?0K75;.]U&*_NXIK9F22UB\YI9(5((8,Q4$@D<9R>H[4
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M\NI;'5+:<.'D+/#)& 1(K'D9W8QTSCBN=;Q#J-GI5@]Q>7,EUI%^\.LX? >
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M>O:@!Z64"6 L=A>W$?E;'8ME<8P2>3Q619^#=%L9;"6&&XWV&X6Q>ZE?RU(
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MY9FUB2-DC4XDBR#N,A)Q@XXX'0U-#J%E<3^1#>6\DVP2>6D@+;3T; /0Y'-
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M.<[1U))[].E>F8I  .@H \H@AM;7X6>']1MK6)HTDM!JDD,8:1K=7S(K$<D
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M]]YF.0-H((/? ]*M:A/)(GCS[ 3/(E[:R/% 0SO$J1>8 .<_*''YBO3@H!)
M )ZGUI: .1\-S:'JVNR:SI6HW-_.]H(9I=H6-5# JK *OS\GW S[4WQ%=VVF
M^//#E[>S1V]L;>[A\Z0[5WGRRJD^IP<>N*Z\*%&  /I00#C(!QSS0!Y"TNGS
MZ%")C%QXP)Q*-I5#<$G@\@;>OZU;UPM%=>.[?10OFFSLV\FVP"RC<)=H'?9Q
MQ[5ZH !THH \\N=5TG4O&?AJXT2YMG+6%Y%&T6,*=L>Q#Z8Y^4]*J^&9]&U:
MVT.VO+R].M:60)+)D57AD VRER$!V'DDD\Y[FO3 JCH /H*-H!)P,GJ: .)^
M'EII<EC>W,$%H]Q%J5V%E55+(ID; !Z@%<=.,5-XAO[.'Q=;VLNRVN)=.E"7
M4@+>8I=<PQIT+D@'H3C P<\=C1@4 >1:0^F7%K\.7O?(:-8)X9&F VY6(84D
M\'![>OO1JVG6EKIFNW$,<2Z*VNV;VI480'=&)F3T7=D9'H:]#U+0Y;_7])U-
M;J.--/\ -_<M"6\SS%VGG<,<>QI?$>B2Z[IT5I%=);".XBG+-#YF?+<,!C<,
M<B@#G8K2PM_&][?Z2+>'3ET<I>/!M6(R;\QYQQN"AOH,>HK%MI[,>#?AV[20
M"6.^MU+%AE0(W##VYQG\*]31=J ?+GOM&!FG4 >=6=_I,DVO:!XBC9]1EU-Y
MH[<A@]RFX&$QD<D *HZ\;><"L[Q7J5F]IXFBC9+2>'4;9Y86RTLQ5H?WQS]R
M/ P,#^'KSBO5<#.<#([T8'I0!P)&AR^./$+ZTEH8+BQM6@^U*/WB;9-^P-R>
MJYQSR*H:;'-I<?P\M-2D,5Q'+<929L,B&*0(#GH0"J_7BO32H)!(!(Z9[4M
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M!V  #. ,D#D^X-9,<B>&/B3K%[J;B&PUJ& P7<G$:21*5,;-T4D'(SUKN0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+"V\@NX9([<R?("%X<@!MHSD@'N:ZGQ=IU[J%A8M8P">:TU"WNC%O"EU1\D
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M\/ZGJ5IKL5I.L6GMJ%K+:*T88!@IC8,3SDKSZ5?74_$<=^\;VD4EHUJ\@N#
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M:%2459/,"\8S\W4GMZ5UM% &$WA^6'7+G5M/OA;3WD21W:-#O20H,*X&X;6
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M\LY[60L$FC:-BO7!&#C\Z?+*D,3RRN$C12S,QP !U)I8Y%EC61#E' 93Z@T
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M(=R,,5<\INQSC\".,32>&7>\UVX%\!_:\*PNOD_ZH*I4$?-R<,>O?'TKH:*
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M_11JMJ5C!+\4-)9C+EM/N'.V9UY#Q < \#VZ'O73V^EV5K?7%[! $N;G'G2
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MIMG;V:7(M[B6<2W#RN9)C)M8GE1GH!Z=JX.;3FU(^,S+JVI0M87!>U9+R11
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MRPM&75F^5AN R".]2^)KF2WUK1/]$F,+-,'OH+8S26YVC"J #MW\@G!X'X@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP=KKZ+X8T>!].<V-QJ$MI]H$@&QWGD"X3J5S@$\?0T >@V]O%:6T5M @2&)
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M9&&58/T*D?CQTJ^VLZBOC6STFWM8?L+::]R1YN&.'C7^[C@$@#/.>HQ0!TS
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M '61\#/H1C(- '8T52TV[O+M)FO-.>R*2E8U:57,B8!#?+TZD8]JNT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5B>)](N=8T^V2T>(3VUY#=HLI(5_+<-M) )&<=<&MNB@# CL_L
MVM7'B36);:T*VJVJ*)<I&F_<2SL!R6P.G&!US5/P?I,-I<ZG=VUQYVGM<.E@
M!C;'&3ND"'T,A8?1!737-M;WEN]O=01SP2##QRH&5A[@\&GQQI#$L<2*D: *
MJJ,!0.P% &'K>DW]WKNBZG8M;[K!IA(D[, 5D0+D8!R1C..,^HK%N_"FKW.@
M>*=/!L5DUBZ:>)C,^$5E1<-\G7Y,\>M=Q10!R4VD>(['Q#/JFD/ISQW\<8N[
M>Z=P(Y$&T.C*O(QP00.E6O%Z21_#S6TFE\V4:;,'DQC<=AR<=OI6U8WT6H0O
M+"LJJDKQ$2QLARIP< CIQUIUW:VMY;M!>00SP/PT<R!E;Z@\4 <W;:1?:L-!
MNKOR+=-/@,D9B<R%Y6CV X*C  )..<G'ISG:=X6U^VNM N+AM,:;39)OM$HD
MD9[G>A4R$E?O>QS]>U=Q!!%;0I#!$D42#"HBA54>@ Z5)0!RVE^';^'PWK>E
MW;6R/?S74D;PNSA1,6/.5'3=^-0-X?UN73O#,$HT\2:3<1R2[9GPRI&8_E.S
MDG.><8Z<]:Z\D @$@$\#WI: .1M-%\1Z3J=_;Z?<V#:3>W+W(DFW>=;,YRX5
M0-K#))&2.O.:35/"]UJFKPWS0VD%W;W:20:C#(RS>2&!,;J% ;(RN"2,'/UZ
M^JU]?1:?;K-,LK*TB1@11LYRQ ' '3)ZT 9?BG2;W5[:PCLOL^ZWOX+I_.<J
M"L;AL#"GDXQ5)]!U1M2\3W(%GLU6VCA@!F;*E49<M\G^UGC/2NFGGCMXI)9"
M=L:[F"J6./H.3^%0:9J-MJ^F6^H6;E[:X0/&Q4@D'V- $.@64^F^'M.L+GR_
M.M;:.%S$Q9254+D$@'G'I7+R^ YQI=_!;WB).EY]ITER.+0!_,Q^+,X/MBNY
MJA>:S96-W8VL\CB6^D\N#;&Q5FP3]X# X!ZF@#*UK0+JXMM!M]-%OY>FWD5P
MWGRLI944K@84Y)W9R:FOM)OKCQCI6JQ_9_LMI!-$X:1@Y,FWD#;CC9Z]ZWJ*
M .%F\):R_@S6?#Z/8'[5<2O;RM(X^5Y3)EOEX(SC SGU%;(TK4_^$S&M%+3R
M/[-^R;/.;=OW[\_<QCM^N.U:.JZW8:)%%+J$KQ)+((T*PN^7/1?E!Y/:BQUS
M3M0NY;2WN#]JB4.\$L;12*IZ':P!Q[XH X672[[2='\.: \FEG5(;F:YC\RX
M>-64%CE9 H93F11@ Y&>V:T[6]UC3=(U6&TT_28=0A=9]XNY)XIF<G<&.T/Y
MF%X'/5?I777NG6.IPB&_L[>ZB!R$GB5P#ZX(JI:WNE66JKX?M(EMYUMS<+#'
M 4C$>X+D$ +U(Z4 6I[NWM[!9M1D@MHW 5_/D 4$_P .3P?3WKE_"_AR#_A&
M=0M7N))[.]$MM;.>JV>7$:@]QAF(/<,*ZN[L[6_@,%Y;0W$)()CF0.I(Y!P>
M*F "@   #@ 4 <C;^&M3N-)T;2-3:U:WTN>*3[1$[%IQ%_JQM*_*3A<\GH<=
M>*6I^$]<GTWQ'I5J]A]EU2Z-U%/+(^]2VS*%0N,?+][)^GIWE% &+XBT_4]4
M\//:V,T4%XS1LP9V". P+(6 R P!&0.]<U?:;>:);>)M3O?[*@M+^RAA2(!F
M2.0!HU0@@ J2XYX^@KIX_%&E37-Q;PO=RS6S[)DCLIF,;8S@X3TJ];W%IJU@
M)8P)K:4,I62,C."00589Z@C!% ''Z(FI:7J=B+G3]+G:2'[+#/!J4DTB(!NX
M#K]W(&2#Z=<"I[7PC?M\/W\/W-Q!!=K*TT-Q Q=5?SC*A.5'0X!KIK'2-,TL
MN=/TZTM"_P![[/"L>[ZX'-7: .4FT?7_ !!H%[I^O3V-LTL'EQFP+.-^01(=
MP&,%1A1ZGGIB_H:>)25_MY]/ B7:/L98^<W]YMP&WZ#/)Z\8J]J.KV>E/:+=
MNZF[G6WAVQLP+L> 2!@?C5Z@# N-)U!?&D>M6IMF@:Q^R2I*[*RD.7!7 (.<
MXYQCKSTK$A\)ZS%X7TK3"; S6>J"]=O/?:RB9I,#Y,Y^;'X5W5% '!ZEX4U^
M]&I+YFG2M+J,=W!<32/O\M)%80GY?E"[3@@G/H"2:W+#2-1L_%NI:D7M7M+^
M*#?@L'5XU9<!<8P<YSGC&,=ZZ"B@# N=)U >-(M:M3;- ;$VDJ2LRLN'W@K@
M$'/3G&.O/2L2+PGK,?A;3=+)L#-::H+YF\]]K*)S+@?)G/./UKNJ* .1M]&\
M2:5J^H)IEQI[:7?W#7):XW^;;._W]H PXSR 2*T_$VFZAJ6EP0:=+%YD=Q')
M+%.Y5+B-3\T;$ D _0],$8-;=% ' WW@_6[K3O$]HC:8@U<Q-$%=U$6U$4@_
M+T&SC'7/\/2M_6M*U"^N]$U&W6V^T:=.TKP/*P5PT;(0'V]MV?N\^U;]% ''
MZIX5OM0TKQ&0ULNHZU&D."[>7"B+M4;MN6/+$\#KCMFKCZ/JB^)]-U>'[(1'
M8-9W$;R-\N71MR$+\WW<<XZY]JZ2HY9DAC=W)PBEB%4LV/8#D_A0!R5MX<UN
M#P;JNE1W5M;7US//-!/#*Y"^9(7P3M!'4KD?6BU\,ZI_;-S=RQZ;:VUSI0LF
MAMF9O*8,YXRH!'SYSQZ8[UTNEZG:ZSID&HV3E[:==T;%2I(SZ'FKE '$VOA?
M6+:T\-7.^R_M'1(S;^6LC>5/"4"-EMN0WRAAQ@=.>M+K'A'4-2T[7Y(S:)J&
MKO "K2-Y<4<6-HW!<L3ACT'7';)[3(R1D9'44$A1DD =.: $C+F-3(JJ^/F"
MMD ^QP,_E7&WG@8W2^((_M($-ZQFL4_Y]YV"LS_BZ*WMSZUTUMJ]G=ZM>:9$
M[FZM%1YE:-E #YVX)'/W3TJ]0!S&M^';V^\#2:);2P->2JIDFF8JK/O#NW /
M5LG&.]3R:5J$GC.UUG;:BWBL'MG3S6W[F96R/EP0-N.O>N@J.XG2VMY)Y=WE
MQJ6;:I8X'L,D_A0!C>%=)O='L+J"]^SEY;R>Y4PN6&)'+8.5'(SBN?;PIX@<
M6_F2:;+-;ZN+[[4[N9)XPS85OE^7:&P "1QV[]GINH6VK:;;ZA:,7M[A!)&Q
M4@E3TX-6J .#N?"FNQ:7XCT:R>PEL-5>::&6:5TD@:7[RE0I##/0Y&,]ZUK3
M1M5A\4P:K(MF8H]+%D569MQ<-NS]SIQCK_A6[>WT5@D3S+*PEE2%?*C9R&8X
M&<#@>IZ"K- '"P^$]9B\)Z5I6; SV>I+>.WGOM91,9<#Y,YYQ5ZX\/ZK+J'B
MB=19[-6LX[> &9LH51URWR=/GSQGI71P7T5Q>W5JBRB2U*ART;*IW#(VL1AN
M.N.E6: .3A\/ZI'=>%)6%GMTB!XI\3-ERT8CROR>V><4VR\/ZK;6&IV\UOIE
MRE[J<MT\$LC,CPOU0Y3AAP>A'%==10!PP\%WMKH:VMC) GD:M'J%K:2S.T<2
M(5/E!\$@$ACTXSCWJXVD>)-.\07=_I4NFRV^I"-[J*Z+KY,JH$+IM!W @#@X
MZ=176UE:IXAT_2/-^TM*WDHLLWDQ-)Y2$D!FP.!D'\CZ&@"G;Z/J,7C,:M(]
MO);?V:MFS%R)68.6W[=N.<],T_Q%IFI7]UI<MD;:6"VF9[BTN79$F!7"DD*<
ME3R 1C/T%;N]=F_<-N,Y/3%4AJ]F=<.C!W^VBW-R5,;!=FX+D,1@\GM0!R*^
M$M<331:&33G*ZY_::L'= 4\WS,8VG!/3'./4U/J_@^^UJZ\2":6W@@U2VMXX
M71V9XWB)8%AM P21T/:NUHH Y./2_$5YXAT/5-1CTV,V$4\<XAF=O,WA1N7*
M#'W>GZU-K>CZN/$5IKVAR6C7$=NUI<6]VS*DD9;<"&4$A@?;O7344 <O>:%J
MKZGI.MQSVTNI68ECGB8E(I(Y,953@D;2!@D<XYQFJ6J>$;^^T_6)(S:+J&JW
M=O-(&D81QI"4VJ"%))PAYP.6]N>GL=7L]0O;ZTMW<S63K'.KQLFUB,CJ!GCG
M(XJ6:^B@O[:S993+<ARA6-BHV@$[F PO7C/6@#F=7\*WFMZSJ<MPUO%9WVDB
MPRDC-(C;F;=C: 1EO7M4<6B^);B\\.S7XTP'29'\QXYG)G!C,>X H-IYSC)^
MHKL@020"#C@^U+0!P-UX3UY](U/2;=M/^SSZG]OAF>1]Q!G64HRA<#&#R"<\
M<#J-%-&\0Z7K^H7.E2Z>]EJ;K-,ER7W6\H4*S* /G! '!(Z=176$A1DD#MS2
MT <^FC7]OXR_M6*6"2UEL8[68RL1(&1V;< !@YW>HQ[]*AUG1=5O?$*74#V<
MMD;-H!'<LV;>4D_O54 AB00.H/'7DUTU% '%:3X8UFRE\*M.;!ET>UEMY=DK
MY;<JJ"N4Y^YGG'7';)GM-.M](T?6;3Q)<Z?#:ZG>7$H_TC *29)7Y@O(&>F:
MZZL[63I\5D+O4;,7,=NZN@^S^<RL2 &50"<\]1TH H^#=.N-.\-VPO)I)KN9
M5DEDD7#'Y0J CL0BJ#[@UB^(?"NMZN_B"));"2'4(%2UEG9]]L H!C"A<!21
MG(/?D&NJ.LV8UHZ06D^V"W-SL\IL>6"!D'&#R1P,TNE:M::U9?:[)V>'S'CR
MZ%#N5BIX.".0: ,JUTG5%\9#6;@68@;3EM'6.5BP8.7R 5P1SCKVS[52_P"$
M;U5;/7]+1K7[)J]S-+]I\QM\22@*PV;<$@ X.['/MST1U>S&MIHY=_MKP-<!
M3&P4H" 3NQ@\L. :O4 <Y!H-S:^+[;4(1;C3H-,^P*ID;S/OA@<;<8^7'6L:
M'PGKD/AC2](#:>QT_4([E7\UQYB)*7Y^0X)R!CH,9R<X'>56GOHK>]M;1UE,
MESOV%8V91M&3N8#"^V>M &%K&C:M>^($NX6LY+(V;0>5<,W^CRDD^:@ PQ((
M')4\=>36?8^%]:L[7PHPDL&N-&C>"5=[[&1HPFX';DD8SC SG&1UKMJ* .+O
MO!UYJB^*(;F:""/59(9;:2)V9HFB50I8%0.J \'VK1&DZEJ&K:7J>IQ6D<VF
MQRF-()6822NH4G)4;5QGC!/S>W/1T4 <-;^$]9@\,:%IA-@9M.U%;N1O/?:R
MB1GP/DSGYL?A6YXKTF]UG2X+:R^SB1+N&=C,Y48C</@84\G&*U+R^BL?L_FK
M*WGS+"GEQL^&;H3@<#CJ>!4[R*BL2<[5W$ 9./I^% '-?V)J@UW7K\+9F/4+
M.*")3,V59 XRWR=#O[9Z5/I^CZC:> XM%6YBM]0BL/LL=Q$Q95<)M#C(!ZX/
M2MBQO(]0L8+N%9%CF0.HD0HP!]0>15B@#C='\.:Q9Z]IFHS1Z9#'!8/:3QP.
M[$DLC;P2HW$E><XQGJU:EYI5]-XRT_5HA;FUMK6:!@TC!R7*G(&TCC9Z]ZWJ
M* .%E\)ZS)X2U+2<V GNM2-XK>>^U5,XEP?DSGC'ZTFN^%->U9=>B$FGNM^L
M9MIIG<O %"YB "X"DJ3N![\@]N[HH YN'2=63Q7=:Q(MD4FT^.U"+,X.]69L
M_<Z?-C\,X[5EZ3X4U?3XO"4<AL6&BK*LQ69_GWH4!7Y/?/-=5>:O9V.H6-C.
M[K/>NR0 1L0Q"ECEL8' /4U>H X:7PCK$EKJ+Q7%G;WQUC^U;)P[.@;:%V2#
M:#@@$'&>OM5O6-(\2:_X4O[&\.FQ7ER$1(XY'\J,*P8L6*Y)..F,#%==10 V
M,N8U,BJKX^8*V0#[' S^5.I 0R@@@@\@CO2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>(=5ET
M]]+M('$4FHWBVWG$ ^6-K,2 >,D+@9[GOC%;=9NN:%9^(=/^QWOF*%D66*6)
M]DD4B_==6[$4 8>JZEJ_A^'RI[Z*Y-]J5O:64S( \*2'#%P %)&&V\>F:9?:
MKJNEZ_=:3]L:>.;3)+RVGEB3?"\9 92% !4Y!''7UK4;PG83Z/-IUY-=WGFE
M6:YGFS-N4Y4AAC;M/(P .OJ<S#P_"WVB2>[NKBZGM_LIN9-F]8^I"X4*,GDG
M&3QZ# !S6DZSK?F^#KF[U$7$6LP$3P>0BJK>09 RD#.<CGG'/ %6=(\07=QK
MZ:9J5U<66H[Y2;.>%?*GC&=K0N!\P VDC.>OI6K%X4M(4T94N[O;HXQ:@LG3
M;L^;Y>?E./\ Z]2V_ANWAELGDN[JX%B6:U68H?*+*5R"%!. 2!DGK]* .=MM
M?UQO"[WI6>\>'59H+AK2)/-$".ZY1",$C"\8)QGO5;4-1?5K#PS<V6O3SPSZ
MV(C(B(A(VR, ZE.&7:!C&.^.F.FM?"T%E:K!;7]]&5O'O%D#)N\Q]VX?=P5.
M\\$4DWA'3YK-(?-N4D2^_M#[1&X60S\@MTQT)&,8Q0!ESZEKVJMJ\>BR2)<:
M?<_9H0PB\N1E56/FY^;G<?NXXQ3)+[7KW7]8L(]5%G'!I\%S'Y4".4=M^0"P
M((RHZCZ8K3N?!EA-J\FI0WFHVDDZJMS';7)1+D*,#?W)QQD$&K8\.6RZG>7\
M=S<QRW=NMLZKLVJBYVA1MXQN/YT <I!?WVM:GX$O)+Z>!KVSFFECA";-XB7Y
M@"IZ[B.>@Z8KO;N.::SFCMIS!.R$1RA0VQNQP00:Q(O!]A#;Z1#'<WB_V2&6
MV=9 &V,-I1B!R" /?CK70T >=0>+=0%OX;N;B[D ,[6NL1B./$<@;RPQ.WY1
MYF![CZ9K3UC5M5M- 35+:^(6XU*%(E:)#^X>54 !QW!W9//(K6G\)Z3<6NLV
M[PD)J[[[D@X.=H *^F"-WU)-6-6T&UU?3H;"226""&2.1%@*C!0@KU!X! _*
M@#"LTN6^(7B+??W#1165L5A.S;AO-^7[N0 >>#GU)K$\+7FIZ7X?\$.M]OL[
MXK:26GE*% ,;L&#?>W KZXYZ5VLGAZW?6)M42YNXKB>!8)?+<!7"YVL1CJ-Q
M]N>E58?!]E!8Z19I=W@ATF42VPW)D$ @9^7D88C\: -/6?,&B7QAGD@D$#E9
M8\;E(!.1D$5P,<5R?#?P[Q>.TTLT++)*JMLS:OP  ,X]\GU)KTF:))X9(9!N
M212K#U!&#6!!X.L[>VTJW6]ORFER"2VWR*V"%*@'*] I(Q_7F@#%7Q)J>G1:
MM97%R;NX@U:"Q@N&C16VRA#D@87(W''09QFM_1_[<CU6\CU!C)I[(KVS3&/S
ME;HRD1@ KT(/6F3^#M,NXM6BNGN)X]4=9)U=@-KJ %92 ""-J_E5S1M#CT=&
M_P!.OKZ5@%\Z]F\QPHZ*.  /PR>^: ,+XD%AH>G% "_]K6FT,< GS!U/.*KZ
M()-9^(E_J.HA;._TR#[''8H=VZ-CN$V_ W*>PP,=^:Z37=!M]?MX(+FXN(HX
M9DG40E1\ZG*DY!Z&DO?#UM>ZG9ZGY]Q!?VJ&-;B%E#.AZJX((89YQC@],4 <
MM>^(=7M_"?BV\2]/VG2K^2*VD,2?<58R 1C!^\><9J_?7 M/B0MRREEBT">0
M@=3B9#5J^\$:??\ ]J))=WZ6VIMON+>.4+&7P 7'&<D*.^/:M >'[<:U%JIN
M+EIX[4VFUV4JT9()!R,DD@'.: ,72;[Q%J']BZI&VZRNXUDNXI3$(U5URIB*
M_-D$@88G(]Z;X=\075YK,>GZI<W%IJ:QR&:PN(55).1AX7"_,HY[DX//2M#1
M_!MAHEP&M;O4&M48O#92W!:"$G^ZN/<XR3CKUJS9^&[>UFL9)+JZNFL(VCM?
M/928PP"GD*"3@8Y)H V:*J:;8C3=.ALQ<W-SY0(\ZZD\R1LDGYF[]:MT <'H
M+:D/%OC+^SX[1S]KB_X^)&7GR5QT!XJ]JM]JUI<>&+:"YCMGO9S%>*(5;YS$
MSD^QW#-:%MX72RO[^\MM5U"*:^D$DY'E$,P&!@%#CCCBG-X7MG?3Y&O+UI;&
M=[E)&=2SR-D$ME>>&(QP ,>@H YBXU+Q##IOBO;K;&30F:2&4VT>Z8>2)0K\
M8QR1\H!]ZOOJ.MZIXG@TZUU-;&WN-'6\RENKLCEP.-WU[^_'<:TGA2TECUF-
MKN[VZP,77S)TV[/E^7CY1C_Z]8XTF>+Q_:K!+J,5M;Z/]E6[6$$,PD!"EBA7
M[O/3M0!ER:K?:IH6BC4RCWMGXFBLYI47:LICD(W =LUN#5-2UE/$4MA>FT;2
M[A[:"/RT979$5B7W G!+8X(X'K6C-X4L);"QLTEN(8[.Z%XC(R[GF#%M[$@Y
M)8DGZTZ;PQ:O>WMU#<W5J;]0MW' RA9L#&3E25;'&5(/XT 8=MXEOI9O#.L3
MS&'2-7A$4L&Q<0W#+E/FQG:Q##KUQZXJ=M;U#.E0K-,[:Q/-)"56,/' JED"
M[@!DC:?FSP3]:GUVTBU*!/"::+<&R=(LW&P"WBC5AP&SG< O  ZD=LUIZYX=
ML=>LX;>X,T#6\@EMY[9_+DA8< J>W''I0!@MJVOZ:+73]0.Z>]U!H;:=3'YO
MD>6SC</N;\KM].<XS6UH/]M)+?1:LP>)9 UI(Y3S3&1R'"?+D$'!'45#<^#]
M/O=&_LZZGO9G$JSB\><_:%E7A7#]B!P,#'M6AI.DQZ5 R"YNKN5R"]Q=2;Y&
MQT&>  /0 #D]R: *&MW=XFJ6UK;WQA22"5_)MD5[AW!4*?F!4(,G)..2HSS6
M)9>*-0NM"\)W5S*MM%J1*WMXJ@",A&*CG(7<PQD_0=171W_AZUO]8@U0W%W!
M<Q0M Q@EVB2,G.UN,XSSD8/O7,:GX?71K?1M-M5UTZ=:>:ZW5C)YDT3D;54K
MC[NTMR%/0>IR 0W.N>(H/"6JZDNH*3!J2VUI*UNN)H?-5-_'!SN/('\.1UK7
MEN]6M=:AT)]0GNI9X9KSSX8H8W5 R*J -\I W$DX)Z>],M?#LVL:5=6.H:CK
M#Z=*T4D7VSRUGW(VX]%R%R$P",Y!['G5UOPQ::X;.6:YN[>\LR3#>6L@CE7(
MPPSC&#CD8H QHM6U^"72]&U'C4+G[0[S6QCWM''MV\-\H8AP3U^Z<=>&W&I^
M)=*TJ*34H9YHX[R19YK%$DN!;;24=D *YR1NVCH,BM6_\':??V%I;O/>QW%I
M(98;Z.<BX5S]YMYSG/0@C&,#' JS'X>C@CMO)U"_2>%F8W!D5WE+  []RD'@
M#C'&!C&!0!+X>OH]2T.WNXM06_CDW%;E5"[UW'&0 ,$# (P.0:P[-;EOB7K
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MV$JNT, 1UV\>GMF@#E[77=;O-/\ !4BZ@D;ZLK"Z8P*=Q\EGR/3D=OUZ4_\
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M;C>+PWIP>>28FVC.YPH(&T<?*!Q6I5/2].32M.ALHYYYDB4*KSON; &!V Z
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M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5#;7=O>([VTR2JDC1,5.<.IPP/N"* )J*** "BBB@ HHHH **** "BCOBB@
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M1U"]U6.: V^;QU)6(]5&T#DX&6.3P.:K1>&_[$T>[WZIJ>HK%;/';1W!$GE
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MU4:'XF\:ZF8_,^S:?9R!,XW$"7 )],XK0/@2V, M1JFH):)>B]@@4H!#)O\
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M6MU\A?R]H4HPVX8$ =NV:6[\(6EYITUH]W=(]Q=)=SSILWRR*5*YRI  VJ,
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MDD<9)H ]1DD2&)Y)'5(T!9F8X  ZDFJ9O9[B&PN-/@CN+>Y96D=Y-A2(J3N
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MLY-,$MG;,@\IF,A$A"]"P&WW )]37-B.>;3=&M[F>X>WB\426=M(9FS);#S
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M;83V4%WI>I64279T>=[?4K"4B.\C4+EF ^8/G:<Y.=QYH ],HKS"TTN.UL_
MFJZ>\IU"[,$-R3*S>? T),@8$XPH7CTJ"YGAA\!ZHK3(DL'B%HX@6PR#[6O
M]/DSQZ4 >GI>6\E]-9I*K7$*))(@ZJ&+!<_7::GKSN=8[+Q3XVO+&"#^TDTZ
M&:T(0;C*8I>5]2<#ZU9\.PZ=>7^BZO8ZS;&22!E>"UCPUR"F3YV78DJ1G)YR
M<=Z .CU_6I=%_LTI;+,EW?16C$R;3'O;&X#!S],BMBN3\?(LMCHL;LRJVLVB
MDJQ4@%^Q'(^M<YK$4WA>_P#$BZ"9H[%=,BN)XT9G$,IE(9EYR"8PS'![ ^E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D90ZE6 *D8(/<4M4-4UBQT:.&2_E>))I5A1EB=P78X ^4'&3Z
MT 63:6QL_L9@B-KY?E>24&S9C&W'3&.,57NM%TN^M(;2[TVTGMH<>5%+"K(F
M!@;01@<<4Z75+."Z>VEF\N1(3<.61@JQC^(MC:.AZGM4%OX@TZYNDM4ED6>2
M(S1)) Z&5!U*;@-V,C@<\B@"XUC:/+;RM:PM);9\AS&,Q9&#M/;(XXI;JTMK
MZV>VN[>*X@D&'BE0,K?4'@UG+XGTA["UOENF-M=7'V:*3R7YDW[-IXROS CG
M%:] %.+2=-@+F'3[6,O&(6*0J-R#HIP.0/3I3K+3+#3@PL;*WM@V 1#$$R!T
MZ"K5<CXO\2W>A7EC);H&LK>6.35'_N0R$QK_ ./$M_P#WH Z*+2M.@O&NXK"
MVCN7)9IEB4.2>ISC.35EH8GDCD>-&>/)1B,E<C!P>W%1W5Y;V5L;FXE"1# W
M=<DG   Y))(  Y)-4H?$6ES)>M]I\LV)47*2HT;1[AE<JP!Y'3U[4 6+_2--
MU7R_[0T^UN_*.Z/SX5?:?;(XJ.?1[6XUBTU)XHO/M%(B<1C>,@C&[KMPQ^7U
MYJ.'Q#I<S7B&Y\E[)!)<+<(T1C0C(8A@., \TL&OZ=<736JRR)<"+SA%+ \;
M.G=E# ;A].E %N\L+/4;<V]]:P74)()CGC#KD=#@\5 ^AZ1*DJ2:78NLI4R!
MK="'*C"D\<X' ]*HV?C+0;]6>WOLQK"\[2M$ZH$1MK$L0 "#VSGD&LT:[)/\
M0;.TBN;I;-M-FGDMY8&C&0R!6&5!/!/K^% '2W.FV%Y;I!<V5O-#&04CDB#*
MI'3 (XI)-+T^:R%E+8VSV@Z0-"I0?\!QBL:Q\2:/9:);74VL37-O<W3P17-Q
M&02YD(VG"C !R,D#@5?L_$>E7T=])%<E!8_\?(GB:$Q#&X$AP#@CG/2@"V^F
M6$LL,LEC;/) I2)VB4F-2,$*<<#'84R/2-,BLI+*/3K1+67/F0+"H1\]<KC!
MJM%XCTRXO8K!)Y4NIXQ+$CP.I9#_ !#*XQ_DUA^'_$J6>ARSZW?32$ZK<6D<
MS0EB2)2J*=BX'0#H* .F@TC3;5@UOI]I"PB\D&.%5(CSG9P/NY/3I3%T/25B
M@B72[(1V[;H4%NF(SURHQP?I4WV^W_M 6.Y_M!B\W;Y;8VYQG=C Y[9S5F@"
MG-I6G7%V+N:PMI+D  2O$I?CD<XSQ3GTRPDNS=O96S7+)L,S1*7*^F[&<>U5
M#XCTL7D%JUPRM<2&*%S$XCD<9RJOC:3P>,\X.*9%XITB?SA'<2LT-R+61/LT
MFY92,A=NW/3G/2@#1M+*TL(/(L[6&VA!SY<,81<_05(T,;RI*T:F1,[&(Y7/
M7![5GZCX@TW2O.^USLH@023%(G<1*>A<J#M'!Z^A-%[K^G:?$TDTSLBQ"=VA
MB>79&<X=MH.!P>3Z'T- %Y;>!8Y(UAC"2$EU"C#$]21WS57^P](^S1VW]EV/
MD1OO2+[.FU6]0,8!]ZI7/B_0[258GO=\CVXN42&)Y"\9QAEV@[NO;MD]C5:Z
M\:Z8EII%U9F6\@U.X$,4L,+L!U+9 &<_*1MZY[<&@#<33K**\:\CL[=+IAM:
M98E#D>A;&:==V-IJ$'DWEM#<19#;)D#C(Z'![TEU?6UC8RWMU*(;:)#(\C\;
M5]ZIQ>(M,D-X#.T36<0FG6>)XV1""0V& R.#T],4 78[*TBM#:1VT*6Q!!B5
M $(/7CIS3+#3+#2H##IUE;VD1;<4@B5 3ZX IMIJ5O>SS01><LL*JSI+"\9
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M=79TZ326G6U^SL6\P2JN0@7>3C/!SW[4 =;'#%$TC1QJAD;>Y48W-@#)]3@
M?A56'1],M]0DOX-/M8KR7_67"0J)&^K 9-11:]IMQIMK?P7!FM[K_4>7&S-)
MP3@*!G(P<\<8.:FTS5;/5[4W%E-YD:NT;@J59'4X*LI *D>A% $UW9VU_;/;
M7EO%<0/]Z*9 ZM]0>*K'0](99%.EV16151P;=,,J_=!XY [#M7-M=ZE/XXUC
M3FUVXM+*VLHKA"(X<1EBP.2R'@8[FI?#/BUY_ XUW7B(DC=U:XCA;;(BL0)
MH!(!_*@#HUTK3DN(KA+"U6:)=D<@A4,B^@.,@5 /#NB+.\XT>P$KR>:S_9DR
M7_O$XZ\GFI#JEFVIKI8G9;R2 SHOEMR@(!8$C:<$CCWK#\):S(WA5+O5+N2>
M8WEQ"'9<O(1,ZJ JCDX'0#M0!T\T,5Q"\,\22Q.,,CJ&5AZ$&J9T323:I:G2
M[(VZ-N2+[.FQ3Z@8P#4$/B32[B"26.=B8Y_LSQ&)Q*)>NW81NSCGITYZ5=LK
MZ#4(6EMRY57:-@\;(0PX((8 T 1G2-,,DTATZT+SKME8P+F0>C''(^M-&B:2
M#;$:999M?^/<^0O[K_=X^7\*@D\2Z5%=_9WN3N%R+0N(F,8F.,(7QM!Y'?J<
M=:@N_&.AV,M[%-=2>998^TJEO(YB!&=QPI^7'.[H..>: +RZ)I*QP1KI=D$M
MR6A46Z8C/7*C''X5:N+:"\@:"Y@CGA<8:.5 RM]0:JW.KV4(A7SG=[A"\*P1
MF5F4 98!0>!D<].1ZUD>!-1N-5\.-=7-U)<N;NX199% 8HLK!> !C@#L* -Q
M]-L)-/\ [/>RMFLMNW[.8E\O'IMQBHAHFDBQCL?[,LOLD9W)!Y"[%/J%Q@&L
M&_\ %!O+;Q/:67VNUN-,@;;/Y!'SB,OG+*5 Z8SR>H[&K/ASQ-8WMGI=E+=.
M^H36*3$O$X$I"KO*N1M8@GD G% &Q_96G?:&N/[/M?.=/+:3R5W%?0G&<>U,
M?0M(DT_^SWTNR:RW;OLY@7R\^NW&,U0TS6-/6SO+E=3N+N/[<\/[R,[DD) \
MI%"@D#MP>_-:ME?P7\<CP%\1N8W#QLA5AC(PP![B@!DVDZ=<:>NGS6%K)9*
M%MVA4Q@#IA<8XJG<Z9)I]H[>&[+2K:\=D#&:(HC(,#!V<Y ''TJ/Q7?7]GH<
ML>D*&U6X!CM%/][:6)_!5)^N!WJSH&LPZ]X?LM5BPJ7$0=ES]QNC+^!!'X4
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M2PZ#H]OL\G2K&/9(94V6Z#:Y&"PP."1WIVJZQ8Z+;I/?RM%$\BQAA$[C<3@
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M+"6\CO+*-2LP260LKJ,C=C X'][ZUW?AZ&%+.:>#2FTU+B8R^5(H61R0 7<
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M6+(XSR"&(XZ>]:6IZ!JVL^'9K:]O[8:@\L4R&*)A!&8W5PH!.3G')SGGV H
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M#71RL8C#[U&WGKR..W7G&3K5[<ZK/X-U*2Q@BM[C4XI(6WYE16C<J&XQR.2
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M\B%R!&3MRHR">_6L67P3JZ>';[PY::A9C3))_.MGEB8R1 RB0H<'! .<'_\
M6-LZ+J'_  E,^L>;;,)-.6S"?,OS!BV[OQEL8_6@#.TWQG?7D7A^\N-*BAL=
M8;RD9;@M)'(59AE=N-IVD9SGV'2I+_QG-;:=J>I6]C'-:Z=??89%>4H[-N52
MPPIP SCCN.?:H[7PEJ%MHWAFP^T6S'1KA96?YAYH"LN ,<<.?7I6"ETUSJ.H
MWUKJ/AQD>^9_LU\9(Y0\9VKNC5L%OE!!*YZ'K0!Z;$9&B0RHJ2%0656W 'N
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M %%%% $45K;P.[PP11N_WF1 "WUQ4M%% !1110 4444 11VMO%*TL<$22/\
M>=4 +?4U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<L$
M5PFR:))%SG:Z@C/KS4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%]EMS<?:/(B\
M[IYFP;OSZU+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5E:_K+:-91O!:B\O;B40VUKYRQ>:Y!)&YN!A0Q_#WK5K#\0Z-X
M<\0B'3==M[.Y=E9X8IF D XW,G.X8XR1[4 7-&N]2O;#SM4TL:;<EB/L_P!H
M6;"]CN48Y]*T*Y?P%!=6N@36DUW+=VMO=S16-Q*VYY+<-\F6_BQR >X /2NH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5_HVEZJT3:CIMG>
M-"28C<0+(4/JNX''X444 7  JA5   P .U+110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex109keyexecutivebenefit006.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIYL>/+^T"7.=V,[1C'K0!TM]XLL+"6[$D-R\-G-'!<W"*NR)WV[0<D,?OKG
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MW3KF![3^U;FXD@E9U8;9(U4$[2<<CD>E5DM/$5V/"R7.B&&32K@?:7^TQE'
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MJH@\PY970_,<'.,=?:@#7U3Q19:4EU++#<2V]FP6ZFA52L!(!Y!()P&!.T'
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MK9"X\^0.@QO0*N 6!/(YH ALM>T_1?#NHL?[3GAT:5H;@W#+)*. _7=\P 8
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M>*;*W<,8;F2U^U"S:ZC0&-92=N#SNP&^4D @'OP:DMO$=K<R:M'Y%Q$^E_\
M'PLH5?X=P(^;H1R#P*Q=!M?$6AR7&BC3HYK(W4LMOJ/GJ%2.1RY#)]XL"QZ<
M'CD4_7M&>Y\7Z?):RJB7T+0:C%C_ %D$9#@_F=A]I* .IM;C[5:17'E21>:@
M<)* &7/8@$X-5M1U:'3I;2!HY9KB[D,<$40&6(4L>20   3R:BDU.ZB\20::
M=/)M)H&D6\$R\.#RI3KC&/FZ9(%5/$<6K276E_8;=[FQ$K?;8(IA$[+M^3DD
M?*#U //N,B@!C^,],33;6^:*[V3WGV'8(=S1S;]A5@#V([9SVS4UMXKT^5-4
M-REQ8MI@#7*W2!2J,"588)R" <=^,8KE(/#VMP:/!9_V2JF'Q"+\+%.A7R1,
M7XR1VP .OL*LZYX9U76+KQ6D4!MUU"WM1:S.ZE6>%BV" 20"<#IZT 6YM1GN
M/B)H*>1J%I'+9W+O%.^$DQLVG:&(R,G.0#R*UO$VNSZ'%IY@LY+AKN]AMLJ5
M 4,PSU(Y(R!VSUQ68L>N:EXJT#4[G1'LX[6"XCN0]Q&VUG"8*[2<CY3COZ@=
M[_B[3[V_LM/>Q@^T2V>HP731!PI=4;) )P,X]30!C)K;Z5XQ\1RRP:E<Q)9V
MLWV:,^88AB0N0"VU>@X!Y[9KI#X@M)+>TDM(YKQKNW^TPQ0[0QCP/F.XJ!]X
M#DYY]C6,NGZI_;WB.\?3G$=]80PP[98SET5P1]X<9<<D#H:R(= UK3(?#]ZN
MB0ZD]MIB:?>6,LL892N")$8G:><]^A_( [?1M8M-=TN+4+%V:"3(PR[64@X*
MD=B""*OU2TJ*6*P036L%K(Q+&"#&V/)X&0!D^I]<U=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHK,UR]NK&SBEM?LZ[IT266X;"Q1D\MC(W'H  >2: -.JLNHV4-_!82742W<X
M)B@+#>X R2!Z>]<=/XRU2/POK&H10VKW.FZD+/\ >1/&)4+1@':3E3B3OZ>]
M-U==='BWPT)WTXWIDO?(9$<1JAB7&X$Y)'/0C/'2@#M;Z^M=,LI+R]G2"VB
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M.ZCJVOMXMET33!IRC[ +M)+E'.#YFT@[3ST/Y]Z .JHKCV\2ZS=PF]TFP%U
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MB-S!S(5W8#?-T^8]/:FI'IWB;Q=::E;1W'_$J$L4TCQ/$KON&U/F WX(+<9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<3\2E>/3]$O7!-E9:Q;7%YCHL0)!8^P)%=M39(TFB>*5%>-P596&0P/4$4
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M#/([:/9EI)O/8F(',F<[OSH YLW5UI_B:(ZE#)/9W6I%;34K6<D*Q)402IZ
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MN!Y8_>XQC)ZGH* ->N*\5Q23>/\ P;'%</;N?MN)$521^Z7LP(_2NU    &
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M.7:\F,EU#B?]\W[X?923NY^;YL')[U!8Z3'?Z)XFNKN[OYGM+S4(8E>\D*A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%N_[X_9@F%X^;YN.*6YU!='UK1M1V7?F-HWV>4-9RRJ!N4C(0%E8'.<CD<4
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M,87_ '9C+9C88RI.[< 0,].O%85II=QIT/A:.>TG\M=9N+H1"!F^S0N)-F[
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M);FXNVN[B.2WDA\LN   K@'&$Z]R#]*F\>VL]YX%UBWMH7FF: [8XURS8(/
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M,D6L1W#1)$SF"$R.P#8!P%#*#Z4 =WI$5Y%:R?:]0^W*\A>"4Q"-A&0"%;&
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MSF<*=QPI& >-O0]:TTNY;#Q!XF2_M+PKJ<4<ME*ML[AT$6TQG .T@YX..I-
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M]]1M7N#"(D\UTC(?=O56*[N@X.,CVQ0!=HJIJFI6^D:9/?W180PKN(49)/0
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M2PCDWJ_,GS X'TY Z5T.H:LMG?6>GPQ":]N]YBC+[5"H 69C@X R!P#R1[X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8/BO2KW6-.MK>Q%OYD5Y#<,9Y"HQ&X; PIY.,5O56O[Z'3;-[J<2F-
M"H(BC9VY( X4$]30!@ZUI.MKX@M==T1[-K@6YM;FUNG94D3=N!5E!(()/;D&
MC5=#O-8LX+;5;+3]2A9',R,[1F*0D;3$VTD #(SD'O[5T]% 'G]O::CI/C#P
MY9M*M_=0:-.DLDLA4OAX^0<')Z=>HJTW@V\B-OJ=M- -7BU23461F(B;S%V-
M'NQD?( -V.HSCFMW6IM$T>.37]1MX@]LN&N5M_,D0'MD D#I[5LT <;J_A:_
MU:WU^Y(MH[_4[);*)#*Q2*,;CDMMR22Q[=A5J;1M6?Q!IFHQBT1;73Y;9OWK
M$[WVX(&S! *=_6NHHH X9? S75Q>N\-OIB7]A+;7L5E(S1SRMC$@4@ ;?FYZ
MG/YZ>E6_BY;/[/J4^FAH(62*> LQG?:0K.&&%'0G&<GT'7IJHMJ]FFM1Z07<
M7DD+3JGEM@H" 3NQCJ1QF@#F[+P[=Z1J-[K%E;V&G2263K):QSL;::XR"LC#
M:-H&",@9(8^G/2:/<W=YI%K<7T*173IF1(\[<^HSS@]1GGFI;Z^AT^W6:<2E
M&D2,>7&SG+, . #QD]:L9&<9&>N* . NO"6O)H&N^'K,V$MA?R2RVT\LS*\7
MF-N*,H4@X.<'/X=JTI-)\2:?K\VIZ2VG2I?Q1+=V]S(ZB.1!M#HP4Y&.""!T
MKKJ"0 23@"@#BG^W6_Q,MUC$5U,-#(E+OY>X^<.1@'OV]._'*)X-O+*33=4M
M)8'U2VO;F[FC=BL4HN/]8@."1@;<''\/(YXZ.>/2X-<M)7LD.H709([E;?<P
M"C)#.!\H^IYK3H Y9M O6N-6U%H+&6ZU)H$DM9F+1>1&,%2VTY)!8_=QT';)
MS)O!5\GA75](T[R((KRYCEMK62=VCME4HS -M)Y*DX P,UWE% '/-I6I)XS7
M681:F"6P6UF1Y&W(RNSY7Y<,#NQSC'7GI6-%X/U5-&MAYEHFHV.JR:C;XD9H
MW#NQ*,=H(R'(R >E=U10!R.I^&[_ %5M9OW2VBOKS2SIL$7FDHBG<2S-MY.6
M' '1??B1-"U0:KX:NF%H$TNUDAGQ,Q+%T5<K\G(&W/..M=510!QNG>&;VRUF
M/6A!8V-V+61;T6TS>3>2D#:S+M 4 Y.<9YQSUKH- N[^]T:"?4XH(KLE@XMR
M3&V&(#+GG! !'UK2JM8WT.HV[30"4(LCQGS(V0Y4D'@@<9'6@#F;WPI>7U]X
MFADF@2PUF./;*K-YL3K&$'RXP1D!LY]L=Q:T^+Q>]C+%J4FEI/% R0R0%V$\
MFW"LX*_*N>2!G)] ,'7MM7L[O5;S387<W5FJ-,K1LH ?.W!(P?NGI5Z@#BH?
M!DBMK)MHK?3(=2T][:2UMY6>(S,"/-Q@!< XX'.>W>9]!UJ:U\,+*M@LFE3I
M),%F?#*L9C^4[.2=V><>G/6NANM7L[/4[+3IG=;F]+"!1&Q#;5+'YL8' ]:O
M4 <9<>&=6FT[Q;; 60;678P'SFP@,2Q_-\G^SGC-69_#^H7>KZ'<3):BVL[.
M:VN%$S;F\Q57Y?DYQM[XZUU5% '%6_A34G\,6OAB]>V>PMIH_P#2E<[Y(8W#
MJNS;@-\H4G.,<^U/NO#6K3V_B^)19C^VAM@)F;Y/W0C^;Y/;/&?2NGU/4K72
M-.GO[UW2V@4O(RQLY '?"@FK$,J3P1S1G*2*&4^Q&: .-\0VBW.DZ3IL=_!;
M>(;26#[/Y$@=T)^5S@X)79O)XZ#VK:U"2]TA-(M=)@M7MO.2"6*5F#B+A<Q@
M=2HY.>PK3%A9B^:^%K +MDV&?RQYA7TW=<>U6* ,KQ+HW_"0>';S2Q,8'G4;
M)0,['4AE/Y@5F&S\6ZCH5Y;WEU86-ZULT4,EF[L#(1_K"2 5Z< 9QG.>!744
MA( R2!VYH XNT\/:[;:PNHQ1:5:G^RFLQ%$[L$EW;E;)4;@3USS]:B;P&;C^
MU5C2'28-0L_*DM[24O&;C<&$H7"@8QCC&<GIW[$7T)U-M/ E\Y81,3Y;;-I)
M'WL8SD=,YJS0!AZ&OB4E1KK:>HB7;FS9F,[?WCN VCV&>3U&,%OB72K[59-'
M-F+?%GJ$=W)YTA7*J&&!A3S\WZ5O44 <JV@ZH=1\47 6TV:K!'% #,V5*QE/
MF^3CKGC/2J4/AG78AI43MI\UO;:4MDT<DCE89EX\Y!M^8D8&#M(['DUV]% '
M$Z5X8UJS/A+S_L)&C0R13;)GRVY @*Y3GIGG'7'O4;>&-?2TO$B:Q/GZT=0>
MW:=PD\+#!B<[..0#T(.,&NLU?5[/0M,EU"_=TMHL;V2-GQGCHH/YU>H \ZU/
M2;S2=#UZ"^;2E36+^,VRLS! S"-=I.!MP$)##/8X&,&U#I]Y>R7VDZK86:/J
MMF\#WEK?O<2*@4@9#J"%&XX(XR>>N:[:YMK>\MWM[J".>%QAHY4#*WU!XJ&P
MTK3]*C:/3[&VM$8Y9;>)4!/O@4 8^AP^*X8HX-7?376V3:LEN[[KD@8!?*X3
MU.,\^@ZY%KX4UBW\+^'-+/V%IM+OH[F5O/?:ZJ6.%^3.3N[^E=U10!Q>H^$M
M0U.\\2LT\%NFI+;&UE1RSQ20'*EE*@8+8Z'M5QK/Q1J6@ZA:ZH-,CGFM)+>-
M+>1RCLPQO8E<J!V !ZGFNHHH Y.'0-42]\*3,+39I-N\5QB9LL6C"97Y.>F>
M<5=\+:3?Z+:75G=&W:'[5-- \3,699)&?Y@0 I&[&!FM^B@#G;C1[ZT\7/KN
MG"&9+FU6VN;>60IRI)1U(!]2"/QK,/A&_@CTLV[6KRQ:N^JW9>1E!9]^53"G
MIO !./N^]=K2$A022 !R2: .:FT?5K#QA<ZSI8M9X+^".*Z@N)6C*-'G:ZD*
MV1AB",#ZUBV7A+Q#I>DZ)-9SV']JZ6TZ&-V?R9XI6W,I.,J1A<<'I79#5[,Z
MX='#O]M$!N=AC8#R]P7(;&#R1T-7J .5U+2->U./1I9C8&XM=12]E02LJ(JH
MR[$.TEC\V<G'--\4^&[CQ"TT;6EFV(A]BO/-:.>UEYRP(7)7[IQGG%=910!C
M6=UJB>('T^<6TU@EJK+<(Q\T2#:#Y@Z#=DD8_NFJWB/1M0N]4TC6-*: WFFO
M(/(N&*I-'(H##< 2#P"#@UT)(!&2 3T]Z6@#A9_"6M7QUR9Y[.TN;N[M[VS>
M-VD$4L2H &RHR,KC/OT[5=O]%U_Q)X<N[+5YK*RN75#!]C+.JR(P<.Q8 ]5'
M Z#/)[=;10!@6L7B2ZT^X755TZ.<P-%'%;2.4=B/OLQ7(]@ >IY/;*3PM=2>
M&-(T34M/TZ_MK6T\F96F92)%"A'C;9D<!L]#R.M=I10!R%MX;U:WNO"KR7,-
MT-)CE6XEEE;?(73;\ORG./4D9Q4,?A34H/#^I^&8WMFTR[ED\JY+D20Q2-N9
M2FW!89;!SSGG&*ZN]U"WL!%YQ8O*Q2*-%+/(P!. !UX!/X5G6/BO2M1L;N]M
MWN?L]HNZ9FM9%QUR "N21@@@9QB@"E#H-_:^(-3O($M?LL]A%:0(9F# Q[L%
MOEX'S>IZ5GQ^$;N3PQINB:GI^G7T%K:"$GSV5HY1P'C;9D<=>A'O786-[!J.
MGVU];,6@N8EFC8C!*L 1QVX-6* .;TXZUI5WHVD326][;+9A+FX9F\_S%!^?
M'38< 9/))]C5CQ/IVHZE9VB:<\!\JZ26>WG=D2XC&<HQ )QD@]"#CFKVGZO9
MZG/>0VKNSV<ODS!HV3:^ <<@9X(YJ]0!P-SX1UR71_$%BATT?VE?1W46)'4(
M!Y>5/RGIY>!ZYSQTK1U;PO>:UKE]-.8(K*\T<Z>Q21FD1BQ;<!M (&?7M76T
M4 <5%HGB6>3PX;U--!TB8EY(YW/GKY;1[@NSY3SG&3]16UXKT27Q!H,EG;3K
M!=))'/!(PRHD1@RY'IQBKL6KV<VLS:2CO]LAB69T,; !"< @D8/(/3TJ]0!Q
MLN@:SK&N+>:K#8P6\NES:?/'!<.[?O"I+*2@_N].WJ:=;^&M4N-'T;1M3:U-
MOID\4AN(G8M.L7^K&TK\I.%SR>AQUX["B@#D=(T3Q#HMS=:=;3V+:-+<O/%.
M[-Y\*NVYD"XVGDG!)XSD@]*K:IX9UJ8^*;6R^PFUUI-R2RR,'C?RA&5*A<$'
M:#G/&>AKMZ* .8M-%U6'Q/9ZG(MF8H=+^Q,JS-N+[E;(^3I\N/QK,3PIK*>$
M;32?]!,\&IB\+>>^TKYYFQ]S.><=/>NL.KV8UM='+O\ ;6@-P$,; % 0"=V,
M'EAP#5Z@#D8=(\2:5K.H?V7+I[Z;J$YN2;@OYEM(P ?: ,..,@$BI?["U--:
M\07B_97BU"SBMX=TS!@R*XRWR8&=_;/2NIHH XRS\-:O9CPG(ALFETBUDM+@
M&1MK*R(N]3MY(V9P<=>M21^%[J3Q'9:P\%I9WD,SFYN;65LW<1#!4=-H!/*D
MDYQMX]NOHH Q/%&CW6LZ7$MA<);W]K<)=6TD@)3S$/ 8#G!!(/UJ.$>*)=.F
M>X&FPWK@)''#(QCC'\3EBN2WHN,<<DYK?HH Y&T\*7-C<:MIL#Q_\(]J4!!C
M:9C+#*RE79<K@ANIR>N3WJQX=LO$]A:V]CJ4FGO;V4?EI-"S;[D 87<",)V)
MQGD5TU% '"P>%-9A\+Z-IA^PF>QU1;V1O/?:R"5I,#Y,Y^;'X4S4?"OB"\^W
M@MITSOJ4=Y!<2ROO,2R*PA/RG: %Z@D'TR2:[VB@#DFT#5FO?%$Q%D1JUM'#
M#^^8;66,H2PV\#YL\9Z5D7%IJ$%]H&F6O]F/JFEZ9B57NWA.#M0%7"Y8'8WR
MXXX)[5Z)5*_T?3-5V?VCIUI=[/N_:(5DV_3(XH X^/2]3OM,LGTFVL=.U'0[
MMA%&)VFMYU9/G!? ;)WG)()W _6K^K:'K^L:?97<DUE#JUC>)=P0(6,'R@@H
MS8W'<&/.....YZN&&*WA2&&-(HD&%1%"JH] !TI] '-:5IFKIXLO=8OHK.**
MZM(8?*AF:1D9"QZE0"/F]JEUK1KN;7M+US3FB:YLA)%)!*Q598G R-P!PP(!
M''-=!10!Q.K>$M0O].UJ2+[(NH:M=6TSAY6$<:0E-JY"DDD(<G Y;VY[5"Q1
M2X ;'(!R ?K2T4 <_9:7J-MXOU;572U-M>00Q1@3-O!CW\D;<<[O7C'>L5?"
MFLKX*MM&_P!!^TQ:@+HMYS["HG,V,[,YYQT]Z[JB@#DWTGQ'IOB*^O='?3Y;
M/4BDD\5VS@P2A0A9=H^8$*.#CIVIT>BZSI7BFZU.P>UNX-0@A2Z6YD,;))&N
MT.NU2""#RO'/>NJHH PO!VDWFA>%+'3+XPM/;H5+0L2IY)[@>M;M%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<]XUU&^TGPQ/?:?.L4T4L(R4#9#2*I'/LU=#6=KFC0:_I;Z?<
MS31PNRLQA(#':P8<D'N!0!AW=SK5UXSO]'MM5%I;KIT=S&R6Z,R,SNO\60?N
MCK^G6M/PEJD^M^$=+U*ZVBXN+=7D*C +="0*D&@QC6IM6%[="ZEMEM6/R;0@
M)(P-O7))_&IM$TB#0=(M],M9)7M[==L9E(+ >F0!0!YSJ"W+?#SQS)<7]Q<E
M;ZXB EV?PL@!X4'. !CI[5TMSK6I:'XDOH+R[^VVJZ1+J(C$2IY;1L 54CG!
M![Y/'6KMSX*T^YL]6LVNKY+;5)6EGB21=H9B"VW*G&2!Z^V,FKK^'K>;64U.
M>XN)IA:M:,C[-CQL06! 7N0* ,O2[GQ#<7FE7FXR:=<P[KM9O*55+*"C1;/F
MQGC#$\8[UI:]=W%L^GQP7B6ZS3E9 J;YI!L8A8EVD$Y R2,!03Q5?1/"%GH4
MJ&WOM1FMXL_9[6XN-\5OGCY!C/0D#).,U<U?08-7N;&Y:XN;:YLI&>&:W<!A
MN&U@<@@@CVH Y'_A)-=?PY;SI=)'=)KW]G.\L*DNGG;/F X!QUV_ABI;JPU9
M?'&DVK:UNNSIUV?MGV5 P4RQD +]W(&!DCMTK8_X0?3UM7MTO-06-K_^T /-
M#%90VX8W*>-W/J>Y-:-]H45[J5KJ*W5S;7MM&T2S0E?F1L%E(92#RH/3M0!R
M)\2:]#X>N/.NHC>Z?K4>G2W"P@"XC+QC=CHI*OSCTK1MEO7^('B()J4X$5E;
M-&C*C(N?-XQC. >>N?4FM6Z\*6%SI2Z?YMQ%']I%T\B,N^64-OW,2#D[@#^G
M3BII/#T#:S-JJ75W#<3P+!*(W4*X7.UB".HW'V]J .9TG4M?N?!UEKMUKMNA
MO(808WM@ A:0!F3 )9RO 7!&[%4M;U?4[GPOXVM)+NYC.GJGDRLB)*4>(,5;
M:,8Y/0 X/8UU'_"'6'_"-6FABYO!!9R)+;3!U$L3(<J0=N#CW!I#X,TZ1=76
M:XO9AJT2QW7F39SA=NX<<' 'L.P XH BN;W4-/\ $7AC3UO6EM;P3B<21IN?
M;&67D 8P<= .E9<OB35+CP7=^++2Y"BWEE=;)D7RVACD*%6.-P8A2<@\$CBN
MB_X1J%KO2KJ2^O9)M-W^4SNIWEAM8M\O.1QQC':H1X0L%6[@6:Y6PNYO/GL0
MR^4S$@M_#N )&2 0/;DT 9$NI:WJ&N:U:VNJ?9+>"P@NH,6R,Z%PYP=V<_=&
M<_ABNC\-:C+J_AC2]1G"B:YM8Y9 HP-Q4$X_&HSX=@.J:AJ"W=TLU] L$H!3
M:%7.-H*\$;CZ]:J0>&I-/FT.*PO[];734:,HTR^7)'MP%=0!N8<8/89.<T '
MC#4=1TVSTZ33IXXI)M1M[=_,CW@J[A3]/Y_2L2\UCQ#HU]KVFSZDETT6DOJ=
MI=-;JIC*D@H5'!&0,'^=:GCRWFN]-TV&"*Z=AJ=M(S6T3.T:*X+-P#C YYK0
MF\-VUW#?_:+FZEFO[?[-+.VP.(L'Y%&W"CYF[9R?I@ PH]5UFW70H[G5!++K
MK1A2+=5^R@1%WVG^(M@ 9'&3QVJ9[_7#JNN>'X+W==PV:7EA=-$F3NW#9(,;
M3\R]0!P?:M>X\,V=UH]CI\LUP?L+(]M<AE$L3)PK XQG''(P>^:MV.E165S<
M71EEN+NX"B6>7;N95SM7Y0  ,G@#N: ,?0M9GU^VTJ>VN70&T,UX&12?,SL"
M'CCYEDZ8^Y[UE6/BC4I-&TZ&:X5KZ_U>:Q%QY8 C1'?)"],[4P,YY.3FNKTS
M1;+2/MILD,9O+AKF4]?G;KCT'?'N:RV\$::VC?V:UQ>%5NS>0SB11+#,6+%D
M(4=R>H/6@#GYM0G\-^(O&%\\YNY(K.R\MI548W-(HW;< @$Y[<?G6G?:MKOA
MY-0U.[62XTJ&Q:4+<F)91.O0+Y?5".N>16@O@ZP>;4);VYN[YM0MUMKD7#KA
MU7.#A5 !Y/3'YTNG^#[*SLIK2YO+_4H)(6MPE]/Y@2(\%5P![<]>!S0!BWL5
MZ/%?@JXNM0:Y,KSLZ>6BJK&W8_)@ XZC!)[<]<]!XHO[[3=/@N;.WN9HQ.HN
MOLJ*\R18;+(IR"<[<C!XS56U\%VUM+ICMJFISC3&8VBRRKA 5V[<A02,''))
M]ZV=0T_[?]G(NKBV>WE\U'A*Y)VLN"&!!&&/&/2@#E4\13RP^';BPU<7MM?:
MD]M(YB52T>V1@&&T%7&U0>GTYIMSXHO["XU^!YED,&I6ME:O(@ B$RIDMC&0
MN\G\ *V)_"%A-8I L]U#,EZ;\743*)//.<M]W;R"1C&,5&W@C2IH=6AN9+NX
M35"C7 EES\RJ &7 X/R@_7VXH H^*;?5+;PMXH6ZOTNK%],D, D55F1@C;@=
MJ@%>F._6ETR]U.Q\1:+83WHN+2_TYY!%Y*J(6C\O&TCD@AN<D_TK07PC;MH]
MWIUSJ6I78NHC!)/<3!Y!&>J@[<#W.,GN>!5E?#L"ZEIU^;NZ:73X6@B!*8*M
MC.["\D[5].E %3Q9J&HZ?)HHL+E(1=:E':R[X@^58,?_ &7_ .O6,][X@\_Q
M18KKA!TJ-+B"<VL9=MT9?8W&W:"IZ#)SUXKJM7T6'66LFFGGB^QW"W,?E%1E
MUR 3D'(Y/'O59O#5NUUJ]Q]KNP^JQK'. 4P JE1M^7C@D=Z ,K3O$-WKFHZ7
MIZS&S:?1H]3GDA52Q9R %7<"  =Q/![>]8E]JVIZG8V5M<7DL-Q9>)8]/FD@
M556X 8,KD$'!^Z<=,CITQUB>$K. :8]O=7<%SIT'V:&Y0IO,. -C94JPX'49
MR,TZX\*6%QIB67F7$92[%Z+B-P)3.&W;R2""2>V,8X '% &=>:]>Z1XDU2&X
MF-Q8V6B_;Q'L56+!F!R0.I">PYZ5!+K>JV&G^'-7DNQ<Q:G-!#<VWEJ%3SAP
MT9 W?*2."3D>];R^';7^V)-2DFN)9)+06;Q2,K(T0).#QDG)/.>]0V/A6SL8
M[.#[1=3VEB_F6EM,RLD) (7!VACM!.-Q./P& #E;S7O$,&A>(=5&J)G2-3>)
M(A;)MEC4Q_*Q/.,,>1@Y[GH.]U.:6WTJ[GAD@BECA=D>X;$:L 2"Y[+GK[5C
M2^#+*?2]4TY[R],&IW!N+CYDSO.,X.W@?*/RK7U#3(-4TBXTR\+RP7$1BD.0
M&((P3QT- '+Z9K.J2^(6TTWDLL4ND_:TFGMU7$@<*2H 4[#GHPSQZ51TG7M=
M?3_".J76HK,FJRBWN+<0(J_,CL&!'.05^GM70V_A&WM[^&^_M+4I+N*U-IYL
MDRDLA((R-N,@@=OKFDA\'64&GZ19)>7HATJ42VWS)G< 0-WR\C#$?C0!ROB?
M4+OQ#\-]>U1;QH;=99(H[944J8TEV?,2-VXX)X(QQQUSZ%J3S1:9=26\@CF2
M)F1BNX @9Z5@77@/3KF'4K9;W4(+'47,L]I#(HCWD@EERI*Y(Y ./:NAFM!-
MI[VAFE >,QF0$%\$8SD@C/X4 <39:WKD7AS1-3N]1%S)K(MH$B2W1/)=U+,P
M)(!) Q@\ ^W%7I[OQ586>J.8);N-'A>UP(C=&,L/.&U?D+ 9*\<]\UI2>$=.
MF\+0^'IWN)+2!56&0N!+%L^X58 8(QP?YTL'AB."R,)U34YK@NC_ &R68-*-
MARHY7;CKQCG)SF@#G;CQ1=RZ#'>Z/K G+ZM!;$7-L%DB5RBM'(N%P02QSCH1
MSWINI>)]9\):AK%OJ-RNIQ1Z8=0M9#"(BC!Q'Y;;>JY8'/7&:L>+=!\G35^R
MI>W%W>:I:W%S-%%O?",H+81<#:J\<?F:Z+_A'K*X^UR7IDO7O(!;RM<  ^5S
M\@"@ #))Z9S]!@ R[O4-4T;6-#BEOC>6VINUO('B0>5)L+*Z;0/EX((.>,<U
MB0:]X@70K36)=31PNL?8I(!;H%EC-P8N3U! QC&.G.:ZVR\-P6C6;27EW=&R
M0I:?:&4^3D;<C"C)V\9;)QGU-5!X,LAHXTS[;>^0+O[8#N3=YF_S.NSINYQ0
M!1N?$-U;>*#IVH7,^G>9=QK9,T*M;74?RY3?M)$A^<8)';%,75_$&KVTM_HX
M8&&^DA$$GE"!HXY"C!B?G#$ MD8QD<8Y.W-X;M[EF6XN[J:V:Y6Z-NY39YBL
M&&/EW ;@#@''YFJP\&6$>KW%]#=W\$5U)YUQ913XMYG[LRXSSW (![T 4'\0
MW,/BDZ;J%S/I[R7:K9AX5-M=1<?*LFTD2'G@D<X JQ\16G3P7=/!=2P,)(58
MQX^96E52IR#QANW\LBM&3PW;SRCS[JZFMQ=B\6W<H460-N&#MW8#<XS5K6=)
MMM=TF?3;LR+#,!EHVVLI!# @^H(!H YB[M;N3XD6]O!J,D4O]AR!KDQHSX\]
M.@QMST[8]N]1:5XIU*_TKP];R,QO=0^U"6:!4#$0,5.T/\H)X/?@' ].CC\.
MQ1ZQ'JOVZ]:Z2U-KN=D(*%@Q)^7KN /Z8QQ6>W@336T:UTY;J^C-G.\]K=1R
MA9H78DMM8+C!+'@@]?I0!F7VH^*M.L;".YN88IYM9CM%D:-':2W<_*7"\!NQ
MVXSVQ5O[9K(U.70!J%Q/=6UHMPUW!# CN9'<+E7^7"A0#@<Y[=]&;PG:SV=I
M!)?7[-;72WGGM(K222K]UF)4YQTP !3M8\*VNKZA;ZB+R^L;^!#$+FSE".\9
M.=C9!!&>>E '/DZW-XG\))JEXUO=O;71N(;8HT6]-HW#*GJ&.?3/&.<NE\1:
MI=>$-1\46=T$%I-,R6;1J8WBB<J0QQNW$*3D$8R./7H9_#-E-/IDRS744NG[
MQ&\<OS.'QO#DY)W8R3USSFHCX1L/]-A2:Y2QO93-<62LOE.QQNZKN ;'(! /
MXF@#0GO7;0);^W:&%S:F:-KD[40[<@N>P'>N;TG6-3F\1C3&O)989M)^U)--
M;JN) X4L@ 4[#NZ,,\>E=1J6G6^JZ7<Z==*3;W$31.%.#M(QQZ5DVWA&WMK^
M"^&I:E)=PVIM1+),I+(2",C;C@@=N>^: .=TS7]='A+2M<O-16=]3\BV2W6W
M11'(\F-X;(R=N>#QG%=-HYUQ-5O(]0+2:>RJ]L\YC$RM_$I$?!7H0>OK34\'
MZ8/"8\-RF>>P50J&1QO3!R"& '(/(-6M&T--'1LW]]?S, OG7LWF.%'11@
M?AD]\X% &'XDMYI?'?A8)>SPAS=8"*AVD1=1E3UZ<Y]L4XZC?7%[XRL+F=9(
M+.W3R%"!=H>%F.?7FMN_T.*_U>PU-[JYCFL=_DK&5V_.-K9!4YXJ+_A&[<7>
MKW(N[H/JJ*D_*84*NT;?EXX..] '.:)JMR-'\+:+:><C2Z)'<O)!Y>_"K&H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9)4)5]VW.S.[;N&,_CC'-:?B#78O#U@EY-;3SQM-'"?) )4NP4$@G.,GMDT
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MN[\6^3J.H6%MI%Y=3V4"7#;&C"NC;N02W^R>.I].]:]CJ4>IZ+;ZG9H\D=Q
MLT2'"L01D ]@: +M%>:7NMW6M^#] U>[MY(9&UFW95C?(9?/(V@ \X  Y'-=
M5#XMMA_:PO[6>PDTP(\R2E6+(X)0@J2"3@C&>M '0T5@Z;XJM;_77T=H_+NO
M(^T1E94D1TS@\J3A@<9'Y9JS?:U]GO)K*TM9+RZA@^T2QQL!M0DA1D_Q-M;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB5N(F4H_.T;6(.1UZ<]>.BTO29E\0ZCKET@BENHHH(X0VXHB9.6(XR2QZ9P
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M;=;,9,@8C5,-QQRO;/6NGL-8L=3GN;>VE<SVI43121/&Z;AE20P!P1T/2K]
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M8Z[!JL5FFG.T#_VC!;S9ANI2!M95Z YR<D \XYR379T4 <#9>$]7M-$T)U6
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MI.H16'V2R41K?12DO/&HPH\LK\IP!DD^N/6LZY\,:Q<>#_$NEB&!;G4[Z:>
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M'5$TY/M$ULFGW"7$*PA<%D!"@Y!XP3P,54N?!MC?2:T;R>XFCU<1B:,E0$*
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M-NMR_E\C9L ;"= O'&/7K0!EP>*-2M;2^M+EDNKV'6$TV&9(PFX.JL&*D@9
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M9")=V\C&$!  4YP O3I4VH6\FJ'Q#IPG@DU)]30VU]]H13;I^[.SE@XVC<"
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M8$$#@X#J 2%9ADG'IFM3Q);F*9KC2[73]2L+:Q(N-,W!&C0LY,L+#@-PP/\
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M:<UN/L4=I;SI;[SL61DDW.%SC=\HYJ.PNK74[#PW;WTBSW;:%Y\GVUP8 A"
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MX93(HYXPQ SQ[5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J.>"&Z@>"XB26%QM>.10RL/0@]:D
MJ"[O+>Q@\ZYDV)N"C@DLQ.  !R23T YH 9#IMA;VKVT-E;QV[_?B6)0K=N1C
M!I]I96EA#Y-G;0V\779#&$7\A5*+Q%I4UO=SBZV+9N([A9$9'C8XP"I .3D8
MXYSQFA/$.F.;M3.\<EH@DFCEB='5#T;:0"1P>0* -2J#:)I+JZOI=DRO)YK
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MN2Z,<=B<72O$ZO%QD;D(W<CD''- %32O">GVT4_VK2M+07!0M:V]N/)4KG!
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ME?SK# \I=XO.3?"Z!TR!N!8 $<CIZU)J>H1:5IES?SI*\5O&9&6)"S$ =@*
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M^!FM#5]&@UF.&.>XO(DB?>5MKAHO,&,%6VGE3GI5]$6.-8T4*B@!5 P !VH
MQ?&-C<ZEX-U>RLXC+<36KI&@(!8D=.:S6@?5]>\/ZC':W,,.E1S23/- T;$M
M'L$:J1ENY. 1\HYYKKJ* /.K/2-4E^%"6$%E*FHV\_G_ &68&,R;;CS=N3_>
M Z^IJQ.[WFC:EJ6E^$KB._%GY.W4H07DRP)158G<H^8\X!.,9R<=O]KMO),W
MVB+R@VTOO&W.<8SZYXI_G1^=Y/F)YNW=LW#=CIG'I0!YO>:1J6K:CK<=M::D
MBZCH:P17-X-N9 TA(;GY,Y V@#KG&.:Z/2=7N-3MXY+GP]>65Q;0,L[W$ &T
MXP4BQDL"1G(XP/7%=110!YOI]A?0^&O MN]A=K-8W:-=+Y#9B41R*2>.F6%>
MD444 ><II>HKX'UCPG/8W$E]+-.D$WEDQ3+)(764OC:,;LD$Y^7H>*VM(M)[
M;QWJ+R0W#0MI]M ER\3!79"^[YO^!"NLHH *\SN['41X(\0:3_9=ZUR^J22Q
M[8B1(K7(D!4CJ-N3^&.M>F44 <;?QSOXUO+Q+2[:V?0S L@MWP9-Y;;TZX-9
M[:;J8^&WAU8-/GDN]+:WEN+$@QR2!%*NHSCGG(]<5Z%3$FBDDDC21&>,@.JL
M"5)&1D=N* .&NFDDT>[U+2?"]S#++);K+]JMPURZJX+,L;$Y*#E<]^V!S1FT
MO4;F+QQ##INH8U&QC-J]SR92(BI&2>I/;MZ#I7HYFB658C(@D8$JA89('4@4
M^@#S^]:\@U32=:DT34KJP>P^R300J1/ X8,'* @D'D'Z5.]@8=8\*26FC36=
MK#<W$TD21%O)5XV4%\9 8D@D9XS^-=S10!YI<Z;JC6VL7%MIUS*T/B!=06W9
M6C-S (U4["<<]2/I]*L:KI\VK:%<W^C>'[JUN%GMIWBNUV3W8B<,4()/  XS
MU/3W]#HH XZTGN-0^(-KJ::7J$-H=*>!I+B Q[7,JMM(//0'^E=1J$3SZ;=0
MQC+R0NJC/4D$"K-,EEC@B:6:1(XU&6=VP /<F@#@K+3;G4?#WA'2S97,%SI4
MUM-=/-"R"+R5Y"L1ABQX&W/!)J6RTF]O_#'C'3D@FMKB_O+M[<S1L@=9  IR
M1T.,>HKNZ* .%TZ22_M_M"^$;F#5K2VE&;\?N_,*$;(V+'<&.!D<8Z]JH6-I
MJ-WK&AW!T_4X=VF7%K-))$(T@D81X 0$!%&#C &<#J:])HH XOPG<WL>EZ9H
MU_X?N8;S3$6%[B6(&$!%V[XW_B+#T&>3GBL<V-\?!,UJ-/O/M!UW[2(_L[;O
M+^U>9NZ=-O/Z5Z910 @.X C///(Q7$V\%YI4WBFPN[&YNEU&>2YM)(HBZRB2
M,+Y9(X4@KCYL#!KMZ* .#CTJ\TFY\"VLD-Q<?V9'(MU-%$SJF8"@Y Z;CCZ5
MWE%% '""PO;?Q*MWHZW\ GU$_;[&XB+6TB;CF=&(PK$ -P>3QBLO4;34T\.>
M)='32+^6YFU<W4;)%E'B:='!5NA. <@<CO@<UZ?10!Q"37VD>)M:2ZT*]O[+
M5S'- \,:R 'RU1HI,G"_=')XP35J"*XA^(,EY+9RK NC1P&2*%C'YBR,Q52!
MSP1C_&NJEEC@B:6618XU&6=S@ >YIX.1D4 <WX MKBR\#Z9:7<$L%Q#&4DCE
M0J5.X^OU%=)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5#5KZXL+>)[:T-P\DRQDEMJ1*>KN>R
M@#^7UJ_6)XETB\U:"R%E<0QO;7:7#13J6CF !^5@/<@CW H S8_&\?\ 8.I:
MA);H[V-\+'$,NY)7)0*P;'"GS%SP<<]:G?Q+?PZOJ6FOIL#R65H+OS%N2HD4
M[L#&PX.5(_(_3#UG3+C1-"UM+_4;#R]9U"-E>6W/E(S[ PDRWRKA" <Y&<YS
MBK&DG4)9KRR5]"NVO+=E>YLIY7=,+A3(6+';R<#/T[D %RT\7WLFDV6I7>EQ
M00Z@D'V,+<%V>1U+$, OR@ $Y&<CMG@/3QA)"E\E[ITD<L$\,,#J'\JY,IPN
MTE0>#G<,'&.,TV7PG>2^#=*TI+Z.WU'2O)>VND4LF^,;02I[$$@CWI][X>UG
M6]#DBU/4[>'45DCFMI+.)A'!)&VY6PQ)8D]?;''<@$-WXRO;*RUJ:71RYTZ
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M.HP<=LU>IJ(L:*B*%10 J@8 %.H **** "BBB@ HHHH **** "BBB@ HHHH
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M]B,8ZT =O17 6^H:OXCUO3H8]5NM.@O]!6^:.%$)BD+I]TLI/?OG\,UWP&%
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MV+5+C2;R"VGL=0DMX_-GQ&JQL PD38<AADYSD9&,4 =Q5:&\\Z_N;7[/<)Y
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M>^*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV*VTNW0W BTM]]HOG']V<$?CP2.<]:;#X/TBWU>7484N(VEE\^2!;AQ TO\
M?,>=I;//3KSUK5?4+*.&*:2\MUBE_P!6[2J%?Z'/-9EYJ]W;>,-+TI4A-K>0
M3R,Q!WAH]OOC'S>G:@!DG@W1WUF75 EQ'+.P>>*.X=(9V'0N@.&/UZ]\UOU2
ML9K@K=M>36C!)W$9@)PD8Q@/D_>'?M27&L6,&E3ZB+F*2VA1F9XY 0<#. <X
MS0!4F\,:;-<WDNV:-+['VN&.0K'.<8RR^XX.,9'7-37.A6=UJMGJ+F9;BS5D
M@V/M5 P 8;>AR .OI530-2U355M[Z1M/?3KFU64"'=YL,IP=AY(88/7Y3D=.
M:W6941G=@JJ,DDX % "US@\#:(JQHJ70CBNOM<48NI L3Y).P9^4$L>!ZUM?
MVA9;5;[7;X;A3Y@Y^G-1:C=2+8W8L+FR2\B3(-RW[M#ZO@Y H O5BMX4T>1=
M322W:2'4F+7,+RL49CC)"YPI.T'(YX%6)-;LH]732#<Q?;W@,PC+#@ J!GOR
M6X'?!JCX7\0/J^DQ37[VT5W)<3Q+%&V-PCD9> 3D\+S0 MMX/TRVTNZT_?>S
M17,1AD:>Z>1_+Z;%)/RK[#%6!X<LA=:;<;[@R::ACMB93\JD $'UR !SZ5HR
MW=M!+'%-<11R2'"([@%OH#UI3<P"1XS/&'1=SKO&5'J1V% '&^)?#*PZ4MOI
MD%Y.UUJT-[<A9"2,.#(X.1M.!T'IQ72QZ)9$73SHUT]Y$(9WN/F+Q\X3&  .
M3P .I[T7VO:9IZVC3W<0%W,(8<./G8GG'L.<FM$$, 000>010!E6/AVRL#;F
M-[B3[*ACMO.E+^0I&"%S[<9.3CC.*A3PGI2Z%=Z,T<LEC=.SR(\K$[F;<2#U
M!W<_6M5KVT618VNH1([%%4R#+,.H ]?:EGN[:U*"XN(H=YPGF.%W'T&>M &.
MOA#2Q/+<%KQIYK;[++*]T[,Z<]<GD_,1GMGC%22B7PWH]E9Z3IESJ$<96!(E
MF4&- ."6<C@8 ]:U9[JWM55KB>*%6.U3(X4$^@S5.37=.CU>WTPW47VJ>$S(
M@<?=!4 _B6&/7!]* $T#28]$T6WL8TC0H"T@C&%WL2S8]LDX]L5/J>G0:MIL
M]A=;S;W"&.0(VTLIX(R/6F6ES,JWCWUQ9[([AEC:$D!(^,!\G[_//;D59BN(
M)GD2*:.1XCMD5&!*'T/I0!F:AX9TW5-&@TN\262&W*M"_F$21LOW65QR"/6B
M+PU90V<$$<UX'AF^T+<&X9I6DVE<LS9W?*2,'C':M*.[MII7BBN(GD3[Z*X)
M7ZCM4U &+-X6TNXLTMY$F^2[^VB5)620S<Y?<"#DY(],<5/::#966I7E]%YI
MFO%5)P\A96"C"C!Z8'%7(;RUN))(X+F&62/AU1PQ7Z@=*%O;1I(XUNH2\F=B
MB09;'!P.^,'- &':^"-%LS8^4MWBPD9[8-=R$1 @@J.?NX/3OWJ27P?I<UCJ
M%E(;DP:C/]HN5\XC>_'.>WW5X&.@K92\M9/,V7,+>6,OAP=H]_2I(Y$EC$D;
MJZ'HRG(- &=_85L=7&J^;<?;!;_9A)YG_+/.<8Z9SSFJ<7@_2X;#3[*,W*P:
M?/\ :+9?.)V2<\Y[_>;@YZFFZ?X@D?7]<L-0DM((;&6!(7W;=_F)NP23R>W%
M;EQ<V]I%YMS/'#'G&^1PHS]30!S6O^'0-/U>:PM9KNYU-HQ=Q&XV%T4@'820
M P0$#D#IG-0Z!I=S'J<%S!_PD-M F[SH]4O1*L@*D *N]CD'!SQT[YKK#/"J
M(YE0*Y 1BPPQ/3'KFD@N8+E"\$T<JJQ4F-@P!'4<=Z 'R1I+&T<B*Z."K*PR
M"#U!K)L?#.GZ?]F6+SWBM"3:Q2RET@R"/E!]B0,YP#@8JL?$+R>,K/2;:2TF
MLYK6:5GC;<ZNA08)!P/O>E=#0!E67A[3[&VO[=$>6&_D>6XCF<N'9_O'GIGT
MZ52M?!6DVDE@R/?.-/<M:*]W(1#D8P.>F#C'IQTK<AN[:Y>1(+B&5HSAUC<,
M5/OCI0EW;2RB*.XB>0@D*K@D@'!X]CQ0!C6W@W1[/5I-0MTN(S)+Y[6ZW#B
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M#Q\2Z?+X:2":6%S!XLP-X"E%-QD\?PY&3CTK2U0+:ZCXWMM%1%?[#9R?9[4
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MOP!SNQGWS[UKW#V&I>(/"MWH;P-$(I1<>5C:+0Q_=<#H-VT 'H<^]=P%4'(
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M6%L00?7G /OQ5-[N*QTS6S;OMTZU\3![I;95;RK?8A+!<$;0^">.QKU;RT
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MY&J\MK=7-QK,<.@WE]HUWJ!F<6=Y (YF0J&.'(;)9#N ('''<D ]&BD\V%)
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M2>16D"X9L$LV2QVG&3C'?H*@AU_^Q/$GBV6YBU*ZMK<V\ICCS+Y"&+<Y^9L
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M <QR?-\R9P>A&">_4 [ZL.[\56-G%<W#17,EE:2^3<W<:@QQ," V>=Q )&2
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M(+DM<1DY,03<-I.1D<=^O [@'0?\)38F:T AN3;7EP;:"[" Q/(,\<'=@E2
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M'^[61RY#J1N)4DXQUXZ=:6'2-6TW6M3MU\/V6I6E[=/<P7TKH/(W\LLBGYB
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M6X:?<F#N8C/WL[1M(Z9SVQR;FG:Y#J;V_DVURL-S ;B"=PNR1,KZ,2#\P."
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M$N0-RX92"05([$$$5>JEI44L6GH)K6"U=B6,$&-L>3P,@ $^I]<U=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHK)UO5GTTV%O"J&YO[H6T1DR54[2Q8@=<*IXR,G'2@#6HKF+W
M7-6T:!TU""U>6XOX;/3Y8\JLOF8&77)(V_-GGG'&,TRZ\0:EIVL76DW"VLLQ
ML'O;2=8V13L.&1UW$]P00>AH ZJJ6J:59:U8M97\32V[$%D$C)D@Y&=I'< U
MS&E^)M9FG\+RWJ6/V76X22D*.'B<1>9G<6P0<$8QQZFI]'\3W&L:D]DMQ:6]
MW$\JW%C-"RS0@9V,,L-Z_=R0.<]10!UB*$15&< 8&22?S/6EKSG3/$.O67@2
MPU-I;2\GN=1\AA+&RG#W+(>0Q]>., =C6_#JNN6OB73M(U)M/D^V0W,N^WB=
M=OEE=O5CU#<_3K0!T]%<;:>+KN:TBCDBB-[/JEQ81F*)BH6+>2^W=DG"=,]3
M3CXFU>SA:"_L42ZGU".RL9BA2.8.,[RFXL-H#9&><#&,\ '31ZC937\MC%=1
M/=PJ'EA5@60'ID=JSQX2T-;J2X6Q"-(Q>2-)76)V/4F,'8<^XK(TM;M/B=J@
MNY(9&_LNWVM%&4!7S).H)/.<]_2K'B>YU*+Q)X9M[*[CABN+F42*\1?<5A<C
M.&&1[<<X/;% '4@   # %9VG:'I>CS7<]C:1P273F6=P22[$DGDG@9)..G-8
MDOB+4KJPUO4-+6U,6E3RP^3*C%IS$ 7^8,-N3D#@],GK@=#I>H1:KI-GJ, 8
M174*3(&Z@, 0#^= $/\ ;^D_V;/J/]H6YLH'*2SAP45@0",_4@5HUYQ;ZI<Z
M)X,\3ZC:1V\DD&M71V3J2I!F Z CUKHKO5=9?Q?+H=D;&./^SQ=1S31NY5M^
MW! 89''J.OM@@'2U7BOK6>\N+.*='N;8*9HP>4W#*Y^H%<99^+M;FTC0M7FB
ML%MKV\2RG@17+[F<Q[U;. -P^Z0>.]6=0UW5 ?&4$+6T$FEVB36\RQ%F.Z-W
M^;)Y/RX'8>AZ4 =E56[U*RL"@N[N& R<()' +?0=ZJ>&S<-X;TUKJ9)9&MHV
MW*A7@H.N2<GW_2N?\#2MJ>L>*=4NOFNTU22Q3=UCAB VJ/0'))]3S0!UMK?6
MEZ&-I=0SA0"?*<-C.>N/H?RJQ7/ZY<VWAN.?58(%-Y?RP6H4\*\A;:A;'INY
M/HH%0S:WJ5AXA71[K[+*UU:27%I.D;(-Z8W(Z[CV((((]/>@#IJ*X.T\5Z_-
MIOAK4GCTTQ:PZP-"$<-&[(S!MV3Q\OW<?C2W_BW6M,TGQ,94L)K[1GBVNL;I
M'(DBJP^7<2",_P!Z@#K8]'LHM7EU5(W%[+&(WD,KD%1D@;<XP,GMWJ]7*?VY
MKEAXJM]+U*WLI8=0@EDLS;;E9'C )C<L<'@CYL#Z5%IGB;49]<T_3K@V<C7E
ME),Q@1ML,J;<IOW%9 -V"1W'O0!T&G:%IFDSW4]C9I#+=R&2=P22[$D]3T&2
M>!QS6A7!6/BW79=)T75KB/3Q;7FH_89H8T??S*T8=6+8&-HX(.>3D=!J#Q'>
MVFJ:[8ZB+99+2!;FR\J)@9XVR!P6Y(?Y<#')'K0!U-4;G6=-L[J.VN;V&*:1
MQ&JLV/F/W5ST!/8'KVJ>T^T_8HOM9B^U;!YGE*0F['. 23C\:\_L[G4;/2O&
MVHR-8W;6=_--Y<UNV&>.&-@1\YP %&!U!YS0!Z/17(IK^LPOID%W]@\_6)%%
MH(T?$*B(O(7R?F(Q@8QUJOJ?BS5-+B\16LD5H]_I=HM[!)L81S1$'JNXD,"I
M'7GKQ0!VU%<BVM>($U^PTXG3=NI6DDT+>6^8&39G=\W[P8?MMK2\+:O=:OID
M[7RPBZM;N:TE:$$(YC<KN )) /'&30!N45Q_BGQ-J6A1ZG<1K:"*SA2:&)E:
M1[@?QD[3^[ Z D8S^56+K5]:E\62Z+8&PBC.GK=QS3QNY4ERN" PST]1U[XP
M0#:ET>RFU:'5)(W-Y"A2.02N JG&1M!Q@X';M5ZN)M_%^I2Z-X<UF6*TBL;Z
M407QV,3"Y)564[L!2X YSC(ZUTNFWEQ>75^S&+[)%.88"J$,Q4 .2<X.&W+T
M'W30!HT5@R:M=WOB&]T?37MX7LK>.6:6>,R M)NVJ &7C"DDY[BN;;Q)JFLM
MX9DMY8K*2749K6\@,9D7S8TDSSN&5RN0/<<\4 =Q:ZC97LUQ#:W44TELP298
MV#;&/.#CO5JO.9K[5=+U;QWJ.G&S_P!#:&XD%PC-Y@2V5BH (VY ///TK=G\
M1WEY<O:Z5&JS1V45TQ>!IANDW;5PK+C[IR?<4 =317%OX@\2S7VCV,=C965W
M?V4TSQW09_)ECVC!VGE3N^O\JZ74+B[L]!N+E1 UW#;F0@@^66"Y/OCB@"_5
M:_U"STNS>[O[F*VMT^])*P4"N4M?$NM+I&E7UZEB?[76W6UC@C=FC=XV=RPS
M\PPN0!CT)[U2\3WVK77@;Q9!J=F$CA@_T:Y6,QB=2,GY"205(P>>>,4 =P]_
M:)>P637""YG1I(HB?F=5QDCZ9%6:YZXU:XMO%NEZ:8[<VMQ9S2F0J?,4ILX!
MSC!W>G:J-CXDUG41I-_9V GT^^D'F1B%E:&)L[9/,+8;'&0!WXZ4 =#>ZSIN
MG2I'>7L,#L5 WMC!8X7)[9((&>N*O5QGAZ"YNO%GBN.]DM;B 7,"O&;<X;$"
M%<98@ ?0\\\5M:KK$MOK6FZ/:^6+F]$LGF2*66-(P"3@$9)) '([GM@@&S17
M"ZCXQU73]-UZ,P6CZEH]Q CG:PCFCF*[& SE3@G(R>1[UUNFC4Q#+_:C6C2>
M:3']F5@!'Q@'<3\W7GITH DO]0L]+LWN[ZYBMK=/O22L% JP"&4,#D$9!KSW
MQ9JUYKG@/Q-<VC6Z6,!EM@CQEGD"':[;MP"\YP,'I[\:GB#Q#J6C6MY+"+1(
M[2Q6XA216E>X(!+C"L"B@ #<1C+>U '7T5RTFN:M<^)+73+(6445UIAO5DF1
MG:-@R#! 8;A\W3CZ\8.7#XMUTZ%8ZQ-%IXA^WBQNH41RSGSC$71MWR\\[2&^
MM '1MX3T1KV6[%ELDF<O*L<KHDC'J60$*Q/?(YK95510J@*H&  , "N/U_Q1
MJ6C/>3%+3RK>Y@C2WVM))+$[(I=F5L1\L0-PYV]\U8U/Q%?1:AKEK:"VB.E6
M*70-PA/GE@YXP1A1LQGGD^W(!U-%<E!XEU"[33K98DAO;JP%](1;O*(U8@*N
MS<#GDY.>WOQ!-XNU"PL=+?7+:/1VN?-2>XEB:2&.12 @.&&T."3DGC&/>@#M
M**K:?+-/IEM+.T+3O$K.T)S&6(Y*\\C/3FN)TWQ%J.G:5K-[?7$-W,=9>QMT
M\HH-Y=8UR=QPH'.,9X/)- '?T5SR:S?67BNVT74?(E2]MWFMIX8RF&0C>C*6
M;L00<^V.]2>)M6O-$CL+N$0&R:[CAO&D0DQHYVAP0PQ@D Y!ZY[4 ;M58M1L
MI[^:QBNHI+J!0TL2L"R ],CMTKFHO%%Z=1\0Z>YM&N;+R_L6V)@)MYVKG+<X
MD^0XQ@C\*IS'54\>ZN;"2S6Z72+=FDFB8H2'EZ*&!Y_WN/>@#L[B^M;2>V@N
M)TCEN7,<*L<%V )P/P!JQ7'P>*;N\A\(72V]LL>L'$P8$M&WE,_R'/J,<]JL
MV^LZQJMNU_I,-I);)?-;^1*"'>-'*.^_. <@D#!X'J> #=M-1LK^2XCM+J*=
MK=_+E$;!MC8S@X[U:KSB34-4TB[\<:EIWV/;9W23R)<(S&0+!&2HP1M.._/T
MKT.&7S[:.9!CS$#@'W&: ([2^M;])7M)TF6*5H7*'.UU.&4^X-6*\[U+7]7N
MO"-Y<1RVUI/#K8L7,41(=!.J'JW!.<GUZ<=:] 43"W =XVGV\L$*J6^F20/Q
MH K:II-EK-J+:_B:6$.K[1(R?,IR#\I'0@&KBJ%4*,X QR<G\ZX&#Q;X@?0=
M*UEXM-,=S?\ V*6W"N"<S-&&#Y.W! XP<\G/:M.+7=;BOM>TZ:&RNKRQM8[F
MV,684<.'^5]S'&"G7/3TH ZRBN2L/$&I7NKW^E02V4\J6,=U;7 @=(V9F92"
M"WS+E>&4]^^*DT?Q'>:OIFCM&+=+ZXD=+V(QMB'R\B4 ;L@AMJY)/W@<4 ;]
M]J-EID GOKJ*WC+! TC 98\ #U-6JY7XCY_X0>\V@%O.ML G'/VB.J]SXIU3
MP_JUS;Z]%:2VQL)KZWELU93^ZP7C8,3DX(PW'TH [*BN:L-5UR76+*.:R66P
MN86:65(6C^S.!D EF.\'D9 '(]ZNZWK#Z=/I]I FZYOI61"8RX4*A9CM!!/0
M#&1USVH TKNSM[^TEM+N".>WE7:\<BY5A[BJ.G^'=+TN59+6W<.OW#+,\NSM
M\N\G;^&*YV\\2^([#3&EGT^W65=2AM8Y)$9%N(I'50P7<2A&2#G/3//2EO==
MUR"+Q18RS6:7>GV O+:XAA;&UE<[2K,>04X.<<YQVH ZVYOK6SDMX[B=(GN9
M/*A5C@N^"<#WP#3[FY@L[:2XN9HX8(QN>21@JJ/4DUR4.K:EI^G>$$E-K<+?
MR10R.T;!E!A+ CYCS\I!/?/2J]K<ZE<Q^-UO+N*:&!Y(D00E2H\A2 #N.!R>
M,<GG/:@#M;:XAN[6*YMY%DAF021NO1E(R"/PJ6N)T;69H-"\-:39C%Q)HT5P
MTAA:7:H1% V@CJ6ZYXQ[U9M/$>K3-I6FW=E'9:M>-,9-ZED6.+JX7.?FRN 3
MQDYSCD Z.TU&RU!IUL[J*<V\GE2^6P;8^,X.._(H74;)]2;3ENHFO4C\UH P
M+JF0,D=AR*YOP6)UU7Q4+EHVF&J?,T:E5/[F/!P2<<8[FH-3746^)@72VM4N
M3HA^>Y5F51Y_]U2"?S']* .UHKBM/\9WE[;VEI+;)#JSW%Q;7 C1I41H" Y5
M002#N7'/&3UQS8M_$>K@VFGWUE';ZC=WTEO!*R$1O$B%_-V;LC(&-N>O?% '
M6T5SDVH:_96,S7<6GHRWJQ+=%]L?V<X_>%"V=PZ;=W)_*LB3QEJ4?A[6+Y8[
M9IM-U)+3YX'02HS1@':6RIQ)[]/>@#NJ*YN]U[4+7Q'J.G16T=RL&E?;H(T4
MB1WW,H3.2#G;Z=ZH6OC5)-%OM52[M+V&WBC'E11M#+',S;=DBLQ(&2O./7K0
M!V=%8&FZAK3ZZUK=V@>P:#S$NU@:'9(#@H59CG(Y!'TJ;5=8DMM9TS1[7RQ=
M7PE?S)%++&D8!)P",DD@#D=SVP0#9)P,FJ-GK.G7]U);6MY%+/&@D9%;G8>C
M#U4^HXKD]5US4+KP]XQTR8P17^E6SEIHXVV2Q/$S*RC=E6P".IP1WKH_#ML4
MT73YIQ ]Q]EC198X=A";00O))_7'M0!KT5RB^([ZUO\ 7K'4!;"XLXEGLA'$
MP\^-LA3@MR=_R$#'./6K$6K:E>:O<:-;R6<=W96L4MU,T+,ADDSA57<" -I)
M))ZB@#HZ*XO3_&5Y?OH/^CP1&\O)[*\B(),<D2N24;/3*=QT-1ZCXNU:ST?Q
M'=1Q6;S:5?);QY1@'1A'U&[K^\]<<4 =Q15+31J8BF_M1K1I#*3%]F5@!'@8
M#;CRV<\CCI5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "L?Q'H">(+&*'[3+:7-O,MQ;7,0!:*1<
MX.#P1R00>N:V*RM<UM=$2Q9K:29;J\BM,HP 0R,%!.><<]J *-UX5?4]'>VU
M35)KF],D<T=XD:QF%XSE"B#@8.>N2<GGIB9_#TMS//>7EY'+?26;6<<J0;4C
M1CEB%W$DDX[]A[YW:* .9@\)R01^'4&H*1H@VQ_N/]:/+,?/S<?*>W?\JFA\
M,NVHZ9>WUXES+II<P2"#9(=RE<.VXY&">,#) )]^@HH Y$>"9$T./28]6;[/
M#>B[AWP E,2F4+P1GYCR?0#I6GJVA3:AJFFZE;7_ -DN[)9$W>2'5T<#<,$\
M'Y00<\>]6=?U8:%H=YJC6\EPEM&9&CC(!('7K5^&3SH(Y0,;U#8],B@#DCX#
M']EO;)J]RETNH/J%K=JBAH)&))XZ,"&((/7VJS>^$IM3TE8;_6)YM2CGCN8;
MY8E3RI$SMVH.,<G(.<Y//3'3TV218HVD=@J("S$]@* ,+3O#]U;>(9-:N]4-
MS/+:I;/&D C0A68@CDG^+IG_  %C6M#;5KG3;J*\>UN+"<RQNJ!\AD*,,'V8
M\]J;I6NS:I+;2)ILRV%W;"YM[O>""IQ@..JL000.?TK9H YL^%&ADU:.RU P
M66JLTES"8MS*[#:[1MD;2PZY#<\UO6MM%96<-K;H(X88UCC4=%4# 'Y"IJ*
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MR1:2V]N]NGEA%E #N.3EB ,'H/3FJECX/NK.ZT>Y;6GEDTRW>VC'V9%5HR%
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MIG&+'B+P^-=@MC%>2V-[9S>=:W40#&-L$'(/# @D$=ZM:?>W=S/=0WFG/:M
MP"OY@>.8$9RIX/'0@@5;FN(K=5::14#.L:D]V8X _$F@#GKSPO=ZAI<5O>:R
M\URMS%<O<-  "8V#*JH" JY'N>3S4L_AC[5J6K74]YE-3LA9R1I%C:H# $')
MY^<]O2K=AK:WVOZII7V62)]/6%C([ B02!B" .@^7OZUJT <S_PBMPUIH<,F
MJ^8VDS+*C&W W[4* 8!X&TGUY_*I?^$8DCN-<>'462+5LLT31!A&Y0(6SG)X
M X]?6NAHH Y.7P9,MIHQL=8DL]1TJW%K%=I"&$D6 -KH3@_=!Z]>:GO?"DMR
MVFWD6K31ZO8N[K>/&KB3> '5D&!M(   QC KI:* ,70]!DTB\U.ZEOWN7OYA
M.ZF((JMM"\8Y_A'^>:6\T2:3Q!%K5E>K!<K;&U=)8?,1D+;N@92#GOG\*V:*
M .6N_!,+V5F+#4)[+4;2XDN8[X*KLTDA)D+J>&#9Y''0>E/O_"4NHZ=;";6+
MC^UK:X%S%J"QJ"CXVX"=-F.-O?N>M;DMQ<)J$,"6;R6[H[/<!U C88PN#R<Y
M/3TK+LO$4VI:5J-W9Z5-)<6=U):BU,J*TC(0#\V=H[]^U $%YX6N[ZRM/.UJ
M5M1MKM+M;HPKM+*" OECC;ACQG.3G-02>"/.T_7+275IW75)EN-QB0&*5=F&
MXZ\QKQQQQ[UUE% ',CPM>OJD^IS:Y*;N;3C8EHX%0+RQ#J.<8)SC/4=>P2Y\
M&6VIRW\VJ2I+->V8M)'MXO)RH;<&/+9<'&#VQTKIZ* ,31-&U'3R#J6N3ZF8
MTV0[X5CVCU;'WFX R??U-/UG0AJ=YI^H07!MM0T]V:";9O4JPPZ,N1E2/<'@
M<UL44 <_/X8^T:=K4+78%WK"%+FX$7 79L 5<\ +TR3R2>:UM.M7L=.M[624
M2F&-8PX3;D 8SC)]*F-Q$MREL9%$SHTBIW*J0"?S8?G4E ')21Z=XG\665S;
MQW!;1WE6XD:)XU+9&V/Y@-_S .,9 V#U%:5SH$@\0'6M/NUMKJ6 07"21>9'
M*H.5) 92&&3SGH>E;=% ',S>#HUL--BL+U[:ZL+IKM+AXQ)YCON\PLO&=V\]
M,8XQ5:X\#R7&G:S:-K$I&JW"7$CM I*%=O3&.NP>V.W>NFO+BX@-O]GLWN?,
MF5)-KJOE(<Y<YZ@<<#GFLV/Q$)-3UJQ%C/OTN*.0_,O[X.&(V\\?=[GO0!LH
M'"*)&#/CYBHP"?IDXIU4-$U--:T.RU-(FB2ZA68(QR5!&<5?H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KE/'R&33-)0.R%M8LQN7JO[T<CWKJZK7VGVFIVIMKVWCGA)#;7&<$<@
MCT(]10!P6I076C:CXCT^RU#4&LCH;WP\RZD=[><%@I5R=P#8)QG^$T]R^E:;
MX=D.HW0767@CNYKFX=D!$#%0.1LW-M!P1G%=F-$T[['<6AM]T-R,3[G9FE&,
M89B<L,<<GIQ1-H>F7.CC29[**6P"A1!)\R@#H!GICMZ4 <K<V\NC0RV=SKD\
MJW6HP?9[2#=O7=DF'>S$A6VD]1@9]<5F-K=[I=AKD,MR\-O%KD%L[B=G^RP2
M",OM<X('S'GMNXKM5\*Z$NDKI:Z9 +)9!*(@.CCHV>N[WSFI(_#6B1)=HFEV
MH6\4)<+Y8Q( ,8(_ 4 <WXLT^&P\+^*3#?SR)<:<7%H\A=8L*1N4G)&[]<'W
MI]C&^F^-])ABNKIXKW2Y7G26=G5G0Q[6"DX4_,1\H ]JW;?PKH=KI4VF0:;#
M'9S?ZV)<XD]F.<D>QJRNBZ>EY;W8M_\ 2+>/RX9"[$HG=1STZ?E0!D>)[^6#
M5_#NGEWBL[^[>.XD1BI.V-F1,CD;F ^N,=ZRW2>/4_%6C&6XDTR.Q2YB#3-F
M%V5\H&SG!VYQG ^AKL;_ $^TU.V-M>P)-%N#;6'1AR"#U!'8CFHETBQ6SGM1
M!^ZN/]=EV+2<8^9B<G@ <GIQ0!F>!K=(/ ^B%#(?,L8';?(S<F->F2<#V'%<
MSKE],HO=0L;RYE:#6X(#.TQ01_/&C0H@X91DY)QDD]<9KO[&QMM-M([2TC\J
M",82,$D*/09Z#VK.N/">@W4MS+/I5L[W3AYB5^\P(.[V/ Y'6@#E[VV>]UOQ
MI%)?Z@L5M:030)'=R((W,<C9&#QR,XZ>W2G37MU9Z7X4\67%W<-;&WA34T\Y
MA'ME10)2N<95R,\=&/I76_\ "/Z6)+J06@5KM!'.5=AYB@8"G!Z < =AQ6=?
M:5=R)%H-I8VB: T*I+(\Q+JH;F-4(/!4  Y&,GT H O>'TD:P:]E:8O>R-<!
M)'8^6C?<4 GY?EQD#N37+-IC:SXD\6V<VK:E!%;BW:#RKQT$+-$6W#!Z \XZ
M>W3'?=*Y.T\.-/XKU^^U"R/V6^$*Q$38WJB;65U4\@GL<C'7% '.Z:]]XAN/
M"B:C?7\7V_1YWN5AN'C\PJ8PK\'@D'.1CKZ<5I6N_5[?Q3'<7EW!<:9.UO:L
MMPRM"B1*4DX/)8Y8DYSTZ5USZ/82:A!?-;C[3;KLAD#$;%[@ ' !]*9=:%IE
MY=O=3VB--(@CE8$KYJCHK@'#CV;- '&_VK>6EIX4\6:E//%;W$*0:E'YK")3
M(HV2E,[1AN#Q_'[5;UU+JTT/2+K[1=PW%SK%M)(GGOPLDH_=D9Q@*0,=./>N
MQN;.VO;4VUS"DL#8S&PR#@@CCZ@5'J&EV6J1QI>P"98I!(@+$;7'1N#U'8]J
M ./U>\N],\02W.H1SS:3)>P>5?6EPP-F04'E21Y'R,W4C/W^>U5-7U?4-';Q
M]<6D\\CVL=LT =RXAWI\S*#G &2V.G%=J=#TUKE[AK;+R2+*X+MM=UQM9ES@
MD8&"1G@>E/BT?3XKJ[N4ME\Z\&VY9B6\T 8 8'@X''TXH YR\5]-\2^'1IMS
M<26NHB6&Y1IW<2((RZRY)X8$?>'7/TKG;)KJ+POH>K?VC?O>#7!;%I+IV5HF
MNF0J5SALCN03[\"O0[+0]-T['V6V$>U#&GSL?+0]53)^4<#A<#@>E0CPQHPL
MH[,62BVCE\](@[;5DSG<!GKGG/KS0!5\;ZI=:-X-U&_LR5GC10' R4#,%+?@
M"3^%4+M)-,\7Z!%I\\[VFHQSQW433M(&54W+("2<-G@D==P]JZR2&.:%H946
M2)U*LCC<&!X(.>M4['1=/TW!M+<1E4\M"79BB?W5R3M7@<# X% '.^ [.*!_
M$$B&4L-8N8QNF=A@%>Q)&??K[T7=I"_Q8LI',@;^R)7R)6496:/' /3GIT/>
MNDL-)L=+,QLH/)\]S)+AF.]SU8Y/4^O6BZTG3[Z\M[NYM(Y;BVSY,K#YDSUP
M?P!_"@#S:.-[3PS/JT%U=1W,'B)U0).RIM:[VLI0':P(8]03713O=_\ "7>)
MK:#49(/^)1%)"\LA:."0F4;P#P!P"<>E;W_",:,;-K,V2_9FE\]HM[;3)G.[
M&>N><^O-2OH.F2SW,\EJKRW4/D3LS,?,CQC:<GD<G\Z ,'PK>RC6;K3M1LKF
MQU..V1GB:X::"5 Q'FQL3W)Y!P>F<UJ>)9)I;*/3+9/,GOW\HKOV_NAS(<]O
ME^7/JPJ_9Z79V+M);Q$2,H0N[L[;1T4%B2 ,GCIS2OIMI)J,>H/%FZC0HDFX
MY53U'7&#@?D* .0T-YM!\?7VFW%LMK::TAO+6-7W*)D $H' Y(PWX57U./6+
M]/$=M;R79U5;Y%T^:WD=8XX]L9VEE.%P"Q8'DY[\5V=]HFG:E=V]W=VPEGMC
MF"0L08SW*X/!]ZX^7PC)=:I>2ZAX;TZ\GGG>1;Y+QX<J3\NY57((7 XSG&<\
MT 3W.E_;?'TFE/J.II9C2(Y=D=[(#O$Q&[.<YP!GU[U5M#>^(+&YU%=:6PO+
M+4I5D.7)A"2D")DW!2"@'&.<YZUUMAH-G92VUTP::_BMEMS=.[%W4#H<GIGG
M'KSUYI'\+Z')K0UA],MCJ (/G[>21T)[$CUZT <H3>>(4UR1-:73KO3]0D19
M,OFW2-AM)0,%*LHR<CG)].%N+5[W6?&<,U_?B.WMH)85CNI$$;F)VRN#D<C.
M.GM757/A?0[S5TU:XTRWDOTQB9EY)'0GL2.,$],5*="TUI[R<VW[V]4)<L'8
M&4#@ \] ./IQ0!QNGRW,=SX%U$WUY)<:I#MO/,G9DE!MB_W,[1A@#P![YI=(
M-[K^FV>MC6EM+J&^/V@9=CQ(5-NR;MN", #&>AZG)Z]?#VE(+(+: "Q_X]1O
M;]SQCY>>../IQ3$\+Z''K3:PFEVRZ@QW&<+SN_O8Z9]^M ' ZB+E/#7C'45U
M+41<:9JDAM#]KDQ'M6(XQGYAR1ALC'3&3716]I"?BO>2DR!O[)@DXE8 MYL@
MZ9P1P..E;K>&M'>VN[=K)6AO)/,N$+L1*WJPSR>!^0]*F.C:<;^"^:TC:[@C
M\J.9N65>N,GK^- %Y65U#(P93W!S5;4O^07>?]<'_P#031I^G6>DV,=E86Z0
M6T>2D:=!DDG]2:EN;>*[MW@F4M%(-K*&(R/3B@#S":!)O@3I;.7!2.UQMD91
MS,@Y //XUZ:L8M+,I"KOY:DJ'<NQ/7&2235 ^&M';2ETLV2FP4@K;[FV#!R.
M,^O/UK4C01H$7=@# W,2?S/- '!>'Q=ZSIN@^(5UQ(I&=3=J"["9FX>$J7V@
MACQ@?+BLK6%>X\#>,4N+BXF%MK96(R3NQ508<+DGH,GBN^M?"^AV6K2:K;:9
M;Q7TA):95P<GJ0.@)[D=:>/#VDBUO;4V4;07K%[F-B6$K'JQR>O YZ\"@#G+
MW38+CXC6-D9;@0?V-.&V7#AV'G1\%\[NOH>V.G%9.E:Q>/H_AFPN;YO+NKJ\
MMWGG=LR&)W6-&8$'D#UY*@<YP>ZCT#2X;F*YBM1'-%$88W1V!5#U48/0GGZ\
M]:BD\+:'+I+:5)IL+V+.9/);)4,3DL.>#DGD>IH Y'5;*^TNPL[4Z[<2DZ_;
MHODR.I@BD89B)+'<!U&[. 17<Z?IL6G6'V.*6YDC!8AIYVD?YB3C<3GC/'-5
M?^$9T86%O8KI\2VMM()8HE) 5P<AN#][/.>M:A^2,E5+$#@ \G\Z /*%COT^
M'T7B.#5M2?5;2]=8@]T[)(OVHIY;+G#9!ZG)Z<X %:7B*^F6+5-0L+RYD>UU
M:WA,[3&-83OB5H40<,,,=Q.,[N^*V_"'AD:=I$4>I686[CN99P/-WIEI&96"
MYQN (&<9XK4N?"F@W<UU+<:5;2/=$-,67[Y&,'Z\#GK0!@PZ>=4\>Z];3ZAJ
M*V]O'93Q117;HJL?,)Q@]#CITY^F,S1="DO?!&L0Z9=75M?KJ%V;=H[J1?F2
M9MH/S=#T/USUKN[;1M/L[Z2]M[98[B1 CNI/S*/NC&<8'8=NU4KG3Y-(2:Y\
M/:39R7EU.'N!)*8@V<[FR ><\XQW)H I>&]47Q/<1:O"9HK>"V6$PF1@//;F
M167."4^49/=FI?%9U-+FQGL+;[?#$DIN-/2X,4L@^7$B$=2O/!_O>N*V=(T\
M:9IR6Y*&4LTLS(N TCL6<@>A8G\*==Z79WT\4\\;&:$,L<B2,C*&QN *D'!P
M/RH XJSU6/6[_2=+@O)192Z2)H?M3NLDSARC;BK EU"CN>I/O3H9+V#4=&\.
M7NM)>*UM<$7,F]/M,B2*H0E6R652W?G&3R*ZF_\ #&AZI96]G>:9;RP6W^H3
M;CR_]TCD4M]X;T74].AT^\TVWEM(,>3%MP(\=-N.GX4 <3K4>IZ/:>'HH[K^
MVKZUU2;R0Q*EL0R%8RQ))(SC)/UK7C>34O!J7FAW[SWES,LCK=SNGF.'R\'4
M^5T*X'3WZUT/_"/Z5Y=E&+*-$LCFV5"5$1]5 /!Y//O3?^$:T<?:,62K]HF\
M^7:[#=)G._@_>SWZT 4?".H1WMM?I]FO+2YAN=MQ:74F\P-L7Y5;)RA'(QZU
M4E,K?$#4[7[5<B!M&241B=@$<R."R\_*<*.GI736EE;V*.MO'M\QM[L6+,[8
M RS'DG  R>P%02:+I\M]+?-;_P"E2Q>2\H=@63^[UZ>U ' :,]S#IG@35#J%
M]+=7TJP7)EN799$:)VP5)V\%0<XS[FI-5N+N'0OB 8[V\#VDX:W<7#[HOW*-
MA3G(&2>.E===^'[*WTR%;#3(II+$^996[SM&B-['G;QGM3=)T/8NLRZC#&W]
MK3^9+;D[U5/+5-A/0\*2?K0!0EE=_B!I]J+J<0SZ1,\D2SL%)#Q@-@'@X)Y'
M-<UI#W47ASP=JYU&_DO+C4EMYFDN797C9I 5*D[3T!R1GCK7=6WA;0[-X9+?
M3HDDA1HXY!G<H.,X;.>PYZ\4Y?#.CI:6UHMDJV]K)YL$8=@L3_WE&>#R?S/K
M0!SFG2+X@LM4O+G5;FRO;'5)$9HI2/(2-\*FSH0R@9R.2Q]J-*L81XK\;%9)
MT8/#M*W#@@M;@D]>N<X].U=')X9T2761J[Z9;MJ P?/*\DCH3V)'8]14SZ)I
MLE]/>M9Q_:KB,1RRC(9E Q@D>W&?3B@#AUGO(OAYX9\2?:[R1K%(9[U1._[^
M$\2%AGYB,[N?[M:.LZG):Z2-5CNWBMM2U*&'SFE;9%;D[0PY^4-C.X8.'Z\5
MU=OI5C:Z7_9D-LBV6PQ^1R5VD8*\]O:GSZ=9W6G-I\]K%)9L@C,+J"I4=!B@
M#)T/3;C3=7OP^J">"=$ECLQN80'D%@S,2 WITR#CO65JUDVI_$./3I+Z_AM9
MM'DD>.WNGC&X2Q@$8/!Y[=>_&:Z32-#TS0K9K;2[.*UB8[F"#[Q]R>33VTJR
M?5$U-H,WJ)Y:S;CD+_=Z]/:@#B4%YK]OK$L>MC3[O3M0DC$I9RUND;?+E=X4
MJR#)R.=QZXK4M4\WQ]XE0LZ[M.M!N1BI'^MZ$<BMFX\+Z'=:PFK3Z9;O?I@B
M<KR2.A/8D<8)Z8J?^QK#[;<7@@Q<W*".:0.P+J.@//0=O2@#A-'U:[N-&\%V
M-S>$+J-K*\DL\C9FE4+M4L""<AF.,\D"G>)-*EM/ 5_;7>J27S0:E#Y1#NIA
M1IXB(V.XE]H/!/(R/2NQF\+:'<:.FD3:;#)81G=' V2$/^SW7OT]:>_AS1Y-
M*CTMK"+[!&0RP#(7.<Y('4YYR>_- %Z%(K=4MD<DJN0KR%VQGKDDDURWCNVB
MGD\-F3S,_P!LPI\DC+P0V>A'/ YZULOH-J_B"UU?RU%Q;0F%9,DNRG/RDD_=
M&2?<D>G-O4-,LM6MA;W]M'<1!Q(%<=&'0CT- '#W>GQW7B/QF/M%U&(=/M7C
M,%P\9W".4JQ92"<8[G'J#3K'4[K6KG0=-N[I5^U:'%=_.[IY\K8#\JRDD#!Q
MG^(GMQUXT#2Q+=2+:!7NHQ%.5=AO0# 4X/0#@#L.*@N_"FA7^GVUA=:9#+;6
MO^H1L_NAZ*<Y Z<>U #_  Y;W%IH<-K=ZG_:4T)>-KK;@OAB,'DY(Z$YYQ7!
M7%K<R^%_%.J+K.IQW>E:A=-:-]K?:@CP0I&<,#TPV?;OGTZWMX;.VCM[:%(H
M8E"I'&  H'0 5R_AWPUY,NK2:I8X:YU.6\C4R[D96(*;E!P6&.X..,&@"A;6
MD^L>-+N"]O-0A0:=:71@ANG0)*6?. #P/EQCH?RQ#I)O=?TVVUH:TMG=07[?
M:!EV(Q(5,#)NVX(P ,9Z'J<GM4TJRCU234D@Q>2($>7<<LHZ \]/:JR^%]#3
M6CK"Z9;C4"=QG"\EO[V.F??K0!S32W&E^(]7T!KJZ<ZLB3::[SNQC!^255)/
M&S[^!V-5_%<S1V_B,6-Y=R3:;I\;#-RT:V;!692I!R[MP3GL ,\XKO9+2WEN
MH;J2%&GA#+'(1R@;&['UP/RJA>>&M%U"[FNKO3;>:>:+R9'=<[UQC!]>#UZB
M@#%:YG;QQX=/VF;9<Z;.\L7F'8S#R\';TS\QYKG;R2:#X?>,I[>>:":+6+ID
MDAD*,#YH'4'I@FN_CT'2X;BUGBLTCEM8S' RDCRU/4#GH>_K49\-:.UC<V36
M2FVNI/-GB+L5D?.2S#/))Y/K@4 8E[:&_P#B/)837=ZMG)I E:"*Z=%+>;MR
M-I!' '3&<<UE:5J&I7'A;PA+/<3W$$ES)%>!6)FF51($Z?,P!4%@.2!DY&:[
M<:+8"^^W"%OM7D^1YWFMN\O^[G/3O]>>M<[KGA1##IUK8Z+8WNE6S2.]C+,8
MBKMC#(V#C'S97C.[- %[PG8WMJ-3EO)+HQ2WCFS2XF=BD'&T;6/R\[O?&,UF
MWM@=5^(5YIL]_J$=FVE1S&&"Z>,;S*ZY&#QP!TX..<UJ^&=!71_M$D=HEC'.
M$ M([AYE4C.6RW )R!@#^$<GM6FT*:[\>RZG<6KBS.GK:I*D^QMP=F/W2#M(
M8#ZCI0!@:%>W=]8:+87M[<W=TLMY&D9D*+=QQN4$DKCG"\= 220<<9%:UNKV
M]\)^$'EU&\$LNLO:2O'<L#)$&G !.>>$7D\\5WUSX>T>[2S2?3K=UL^+<;,"
M,8P0,=B ..E1+X5T-(XHX].BC2*<W$:IE0LI_C&#UY//:@#F[;1+2R^),%JL
MUXZIHK,'ENY&<_OQC+;LD<].E,L)+F"\N_!T]U>/=?;%GAN6N',C6;'?NWYS
MQM,7'<K78W6E65S>PW\EG#+>VRD0R..5SSC/ID ^W6J6C6FH37;ZKK%K;6]Z
MT0@2*"0R!$!))W$#EB1QVVCWH NZO8-J6CW5E%<36\DL16.:*1D:-L<,"#G@
MXKSRW\22QOH&MSR7*6EHOV#6%,[E$G.5!*YQE73DGM(M>HU3;2K!K>6W:TB,
M,TOGR)MX>3<&W'U.0#^% ')ZO%=V%GX9D:YNX[BXUF(SH;AR,2;F,9&<%1@
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MS9W21:?J<YN3+;M^ZSYNUCQTRR_-T&>M '6ZYXEBF\$:KK'A_4;>5[6%V65
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YXS-;RQ+*\3.A4
M2)C<F1U&>XJEI&DC2K9D>[N+RXD(,MS<$%W(&!T    Z ?J2:T:* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M75[U]&M76QLLW!)#*,R.&/).<$'T;TKL=9\-Z/XA-H=6L8[K[))YL.\D;6_
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MWL%]=_Z5<+:RP&4^4T;)(<;.F05!SU]Z]$L-'L=,TP:=91/#:*"JQB5SM![
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M;"&&S*)8-OM@LSCRVQC/WN>..<\<=* ,_P .?\CEXO\ ^OFV_P#2=*3XE?\
M)-]?_P"O1JW;32+*QOKN]MXF6XNR&G<R,V\@8!P3C@<?2EU/2[/6=/EL+^(S
M6LHQ)'O90P]#@@XH Y+SI]&\;>0VK77V2XT6:ZF-S(9$BDC=!YBKT488Y P.
M*J:-=WH\2>'H#>7TMGJ.ESO+)<3MNN67RR)0F3Y6=Q("D'!P0,5U[^'-*EO$
MNY;=Y)TMVM@TDSM^Z/52"V"#QG/6JUGX,\/V$UE-;Z>%EL@1;NTKN8P<<?,Q
MR.!@'@=L4 <]HMS=F>]\)75[=R:A;:AO^T-._F-9G]XK[LYQC]T<=S3&FU?Q
M&FNO9:FMA=:=J#PQRM=R*L"1D8WQ ;75E!)+9^][#'<C3[1=2?41 @O'A$#3
M?Q% 20OTR2:S+OP=X?OM:&L7&FQO??+ND#LHDQTWJ#M?'^T#TH VD),:DXR0
M,XZ5P"6D::S\0) \Y*0I@-.Y'S6V3P3@\GCT[8KT&LN?P[I5S>75W+:YGNXA
M%.ZR,N]0,<X/7!(SUP<=* ./T/[3I\_@0Q7UV\>H6!CGA>4F,A;<.N$Z*01U
M')[YJ719M6U[3-)U^+4DMG-R&N@UR[(ZEBK0F+&U3R #UR!UR:ZI/#FEQMI[
M);N#IR[;3]_)^Z&,8'S>G'/;BHK?PEH5KK#ZM!IR1WCN9&8,VW>>K;,[=WOC
M- &R1D$9(]Q7G_ARTO;[3]7U"XUW56EM+V_MXE%Q\FQ7*KD8Y(QP>U>@D9!'
MKZ5F6?A_3;"SNK2VADCANW:29?/D.YF^\<EL@GOB@#C[#4]3E\->!9I[BZEM
M;M!_:#Q,QFD8PDH?E^<C<,MCTYXS6?KEMJD?P[U^34+B]9)-4A%D+IB66W%S
M'L)#<@]?O<D 9K<\0>%5$>D6=GH0O]'LE<"VCO6AFB<X"E'+#Y0-PV[AU'I5
MC2_!UG)875K?6=S%I]PT;K82ZA+-L9"3N+;N"3M^4$CY >O0 SKM)[7Q'XAT
M=M0OI[.;0Q>;9KEBR2[I%)0@@J" .!@>U;O@*!(/ 6A;&D/F6$#G?(SX)C7I
MDG ]AQ6B-!TX:F^HF!FNW@^S-(\SMNB_ND$X(Y)Z=34FE:18Z)8K9:=!Y-NO
MW4WLV/Q8DX[ =J .9\76D=SXR\'!WG4-=7"GRYWCX^SN?X2,'WZXXZ52%[>:
MWHWBV_\ [0NK2]TR[N(;413,JPB%04+)G:P;J=P.0V.PKLM3T73]8%O]OMA-
M]GD\V([F4HV".H(/0D$=#WJ"X\,Z1<W<]S):$27*JMP$E=$G X D0$*_''S
M\<=* )= OI]3\.Z9?W,?E3W-K%-(@&-K,H)'YFN>UVZ?1_%2M<W5X=/U.RDA
MCCCG8;+E/F 3GAG7('NOO79    # ':J]U8VMZUN;F%93;RB:+=_ X! 8>_)
MH X_PE>7FI06>F7MQ<?VAI,LJZBPG8[W4[4R<\JX.\=OEQC%8NJM/>>!M?%W
M=W4[6WB#RHV:9@0@N(U"\$< $\?CUKTJ&QMK>YN;F&%4FNF5IG'5R%"C/T
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M '16.L:9JBSM8:A:W2P-ME,,JN$/H<'BHXM>TB<3F+5+-A H>4B9?D4]&//
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M/),B#S!MW*%/WOI7EVE7L<NI>#;E()[>&&2YC>T2U<1VA:)@$)*Y+9ZDG'?
M% 'H(\1Z(TL,2ZO8F2>0Q1*+A27<'! YY.>/K5F'4]/N+J>U@OK:6XM_]=$D
MJL\7^\ <C\:\RG6$>!==\N,><_B RH%3YV7[4K!@.I&W)SZ9KI/$4-[IWB&T
MU;1UWMJT?]G3[<85B"T4WOM^;/L: .NMKJWO;=9[6>*>%ONR1.&4_0CBN;T#
MQ%(ZZ^^MWMI%%8ZJUI'*V(4"[(RH.3U)8]^<UT=I:Q65G#:P+MBAC6-!Z #
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MT=%,BECGA2:)P\<BAD9>0P/((K!M/%D5S>Z; UC<PIJ8E-HTF 6\L9.Y>JY
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MF$6T_<! )SC'4CO0!P_B3PQXBUF/7X#;V5R+EXWL+B:X(,"+L)B";2%.5;+
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M,9K@@)E20H(7Y>!A1US3KOPBLVKKJEKJU_8W;PK#<O;E,7"KTW J0&'8@#%
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MXB25-A_=-QO3YL9YS@8-4;3Q+X@;1=)U>XNK5HYM5^PS0);XWJT[1;@V[@C
MP/;G-;=EX,2SN-)G_MC4)9-,B>" OY>#&P4;2 HZ;1SU/<T)X*MTT6UTL:C>
M>3;7@O4?$>XN)#)@_+C&XD]* ,O7-2O-=\,^,'MKA;>VL%N+,1^6&\TI'F0L
M3R.I QC&,G.<5U>A?\B]IO\ UZQ?^@"LBZ\%PS2ZM]GU.\M+?5D87=O$$*.Y
M7:7&Y25)'7'6M[3[,:?IUO9K+)*L$:QJ\F-Q &!G  _2@#F/[>U&ROM>TV^F
M1[R%$ETW;&%\U)/D3ZD2?*>W(]:M0:AJ&I:WJ.C07JP2Z9;PF6<0@F660$CY
M3P$  X')SU&.6)%;^(_%-I?G3;N#^R#,GG7,)C\QR0 %!^\O!;/3.W'>M&X\
M/HVMOJ]G=S6=W+"()S&JLLJ@_*2&!^89.#[\YH Y_2O%VH:E/X99TCB^W375
MM>0A<@/"K\H>H!*^_%;7AK4[O49-;BNW5_L6I/:Q,%VDH$1AGW^8TR?PC:&S
MTN&RN;BRETV5I8)X]K-E@0^[<"#NW$GCJ:MZ)H$6AR7[Q7=S/]MN#<R"8J<.
M0 2, 'D*/;TQ0!G^*-?DT2[M#<//::9(C^9?10>:L4F5V!^#M4@MSCKCD5E3
M&]O/&NA-;WMN+B71)BUTB>8AR\6609P<GIVY[UU5]IDEU=">*]EA!A,+Q;%=
M'4GJ01U';ZG(-4++PE::=?:=<VES<1BPLS90Q':5V'!).1DG*@]: ,O3?$.I
MWOA[39Y[FWAE>\FM;J5$R[B-G4>5'@Y9BHXP<#/'IEZMJUUK'PWU![S!FMM5
M2U+;-I81W:*"1V.,9]ZWHO \%O%8BWU2^BFLKJ:YAF'EE@9<^8I!7:0=Q[<4
MK>![5M(OM,_M*^\B[O/MC$E"ROO$F 2O3< ><F@ /_)5E_[ 9_\ 1XJ/XFY_
MX0#4-N,^9;XS_P!=XZV!H:#Q(NN&[G,XM?LACPNPINW9Z9SGWJ37=&M_$&C7
M&F73R)#-MR\1 92K!@1D$=0.HH Y:_\ $FL^%=;FBUB:WU"RETZYOH6@@\EH
MVA 9DZG*D$8)YS6AIEYXEEU7399+<RZ9=0LUTS^4GD/M!0Q[7)93R,')Z'-:
M*>'()IY+C4YGU">2V:TW2JJJL3??4*H ^; R?8=!530/"(T%HD_MC4;RUM@1
M:6URZE8!C'!"@M@$@9)P* +_ (BOKS3M%FNK&VEN)49-R1)O<1E@'95_B8+D
M@>HKGT\7B33;:2QU&*^.H:FEE;RM'M: %06$B<?.-K\8'5:ZK4;)KZV$274M
MLZR+(LL6,@J<XY!!!Z$>AK'N/!MA=PW?GRR_:[FYCNS<Q (T<T8 1D&,# '?
M.<G/6@"N^JWMOK^I>'[R07$;::U[;W&P*P7)1D;'!.<$$ <&LSP[JUQ%X<\*
M:/:++YMQI7VAY(@A950(,+O(7)+^_ Z<Y'3IH*F6ZN9[N6:]N+<6QN-J@I&,
MG"C&!R23G.3[ "LV7P/;'2])M;?4;VVN=)79:7L942*I !5N-K @#(([4 96
MKRZO+H^A#6[=(KM/$-L@*%?WB"3Y7(!(4D=1GK6G)KUWI7B/5++5)P;;[']K
ML#'& SJ,AT]W!*X'<,*N77A:*[LK*WEU"\:2VNTO#.2A>65>A;*XQTX '  J
MK>0V_B3Q%91/IUVG]CW1F:YGA,:.0N J'^($D-QQ\GN* .@TY;M=.MQ?R*]W
MY8\YD7"[\<X'IFN2@UC7IM<U\27]I'8:+<H71;4EIHC")"N2WRGGKSGT'0]M
M6/I_AZ&PU+5KTW,T_P#:CJ\\4H78"%"#& #C: .2: ,;2M4\37\VBZ@EKYFG
M7L8DNT?RE6%67<C1D.6."0#D'/7CI4&@^*+S5;Q[.:]%GJT4$C7.F7=MM,;@
MC:T>,;X^O.3G(.16CH?@R+0I$CBU?49].A8M;6$TBF.$]L'&Y@.P)('U -/3
MPW#9&SO;R]N+V33+>2*V>1%W@,H4EBHRQP,?XGF@#F+/Q3XG30?#?B2ZN+*:
MRU":&"ZLX[<JR"5MH=7SR0<<8QCCWK2F\3:K=^&=9\1Z=+$L>FS3B.T>,%98
MX20^YNH9MK$8P!QD'FH_ N@/<^"O#T>IRW16Q"3"SFB\LI*N<;L@$A2<@>N.
MN*V&\&VH&IV\-Y<PZ=J<C2W=FNW:S-P^TXRH;N >YQB@#.CUO6]9\226&GWM
MO:6LVD0W\#O;;W0R,PP<M@].OZ=ZIQ^.+MO#'AW6-0$MI8WMLSWE[;0>:L$H
MVA=PP=J'Y^<'H!D=:ZA?#D<7B"76(;N>*62T6S$2JGEI&I)7 VYR"Q[U5TSP
ME_8^G6%E8ZK=K#9P/;JLJ1N)$8@_,-HR1C@C'4YS0!5_MS44UGPC;"\L[FVU
M."4W$D,>1(Z1!MR-G&TDYQC\:Y:TO=?T;PYXBUO3+JT^S6&LWTTMG+ 29T$Q
M+_/GY3CI@=N>O':6_@VRLYM!:UN;F)-%1TMXQM(?>,,6RN>1Z8IJ^#;81WUH
MU[<OIM[=/=3V;!<,SMN9=V-VPGJ,^V<<4 9%SJD=CX]U/5V1FB@\,I<E.A(6
M21L?7BM#3+[Q+<:EI<[VYETR[A+79?RE$#%0R&/:Y9E)X(.3T.>U:4GAJVG\
M07&K33RR?:++[#);,%\HQ9)QTSG+'OWJKH'A!=!>)%UC4;NSMLBTM;EU*0#&
M." &; ) R2 * +WB<2GPOJAAF,3BUE.X#/1#Q7.Z1J-S::=X1T=)U\_4;/>)
MS&,Q11PH2JCH225Y/OQ77:E9#4M-N;%I7B2XC:)GCQN 88.,@CH:R7\)V[6.
MDPK>7"7.DX%G=C;O4!=I4C&""O!&.: ,#5O%6LZ;IWB6V62W:^T=X&CN'BXF
MBEQC(!P&'()Z<=*[+38=1ACF&HWD-R[2EHS%#Y81,#"]3G!SS65?>$+74=,U
M&TGN[@2ZBZ/=7*!0[;,;5&00 -HXQZ]R3701JRQJK.78#!8@ GWXH Y&T>^D
M^*>IPM?N;:+3H)$A*#: SR @?BH.>OX 5S?A#4M6TCPGX+E6Y@:PO;D63VOD
M_, WF$/OSU!7IC&#^-=W+X>1O$CZW#?74$\ELMM)''L*.%+%2<J3D%CT(SWK
M.@\#6UOH^C:8FHWODZ3<BYMV(CW,PW8#?+R/F;IB@"D==\1ZI;RZAH=HTJPW
M[P"W?RA')%'(8W)8N&#\%AQCH,'K7:2J[PNL<GEN5(5\9VGUP:YE/!,$&KW=
MU:ZKJ%O97DIGNM.C=?)ED/WCR-RANX!&?I74T >8Z5K6M:=\*M/UA+])KB:Z
MC$AGAW$B2YV-@@CGYLY(-;ESJ6OW7BC7=)M;^UMHK2SAN()/LV]@6\S@Y;!^
MZ.?3MWJ8> [5?#0T$:I?_8EG6:,?N]T863S%4';TW>N3[UHKX<5-:U#5%O[D
M3WUNEO(NU-JJF<%?EZ_,>N>M '-:?XGUR:U\(ZM<3VIMM:D2":T2$C86B9@X
M<G.<ITQC!QVR;,6N^(]6MH]4T:T:6$7KQ&W?RA&\*2&-CN+[P_RENF.V#U.A
M#X*MX=-T*P34;SRM&E66W)$>6*J5 ;Y>1AB.,4VW\$P6FJW-Q:ZKJ$-A=3&X
MGTU77R7D)RW4;@">2H(!^G% &?:I?OXL\=#2Y8XK[99F!I%W*7$)P"/0]*NZ
M%XAN->MM":WFVR21/+J"M&,H4^1D(_A/F<#V5OK5N2Q@\-WFM>(R^H7;7@B,
MUM#$)"-@VKL51N/!YY/K1X6TF&T?4]52S>TDU6Y-P8I!AE4# R.Q)W.1V+F@
M!_C35+W1?!^IZGI[Q+<VL)D7S4+KQ[9'^>U9/]K^(-+\6Z59:A/:7=EK$4WE
M+'"8S;2QIOP6R=RD9&<=>PZ5=^(D<DWP_P!:@ABEFFFMFCCCB0NS,>@  S4U
MOX?@OTMKN_NI[PI:/!#YBB/RUD4!S@ '>0,9[=@,F@#&TOQ'JDNNZ)93W<4Z
MZG:W#3/%%B**6,*?W+X^=?F(R<C@<U)I_B#5I;.]TNZN(QK\&I+:#;$ I1OG
M60+Z>4&;KU4BK5EX(BTZ31K@ZOJ4YT:-XK=6\OF(J!L("#/"CGJ?6ET6WM]<
M\2OXI&FW=F1:+:Q_:XC%(YW$LQ0^@( /NW:@#.O-9\1-=^+H+?4+2$:-''+
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M4EO-+)^QZB'3ST!&"I.W# @ '(YQ6A%X?EMTMFBU>\-U$S/+/)L8W!8 '>,
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M&[(DXW=E!.>O4YK1U(+I.GZQJ^B:O;R-)IN[[+I\6(P PS/@.<-M)YXSCVH
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M#E<'!'\)]: -A++5+K6_.U%K+[#:RF2S2 -O8E2H:0GC(!;@>N>U:%YIUEJ
MC%Y:0W'EMN3S4#;3ZC/2GW5U!96[3W#[(P0,X)))(   Y))(  Y)-<QXKU]H
M_#TEYIE[-;R6U];P3[H=A 9X]RL'7(^5P<C'7K0!T5QI>GW>G_8+BQMY;/
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M<1/M#D[0KG;A#D8PV#5J\\2Z187$L%S=[&A9$F81NR1,^-H=P"JYR.I'4>M
M%VWTZRM+B:XM[.WAFF.99(XPK/\ [Q'7\:6]L+/4K<V]]:074!(;RYXPZY'0
MX/%9M]XMT/3KJYM;F^Q<6T8DEB2)Y&53GG"@D]#G'3'-+-XKT.W^P^9J,?\
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M@JI Y.77_(J"\LM23P!X3GMM.NYI=)-O)=V*!HIF586C<*."6!;('?%>B44
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M]R8_+7<!N)8CID87KTS1\*6K"UTO0]6\-:B=2TJ1!]IF+M:CR^!,CEMN2O0
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M C/NII9%FC^*+7K6MT;5=&\DS+ [)O\ -W;00.3CG].M=910!Y9IUA?0>"?
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MHKO3[V:YMH&9FA2*48:$'J!CH<<'M6]I>D26^KZAJ]T8_M=Z(T*1$LL:(#@
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M  ;J3R1[\ &5K?C+5D\)>(I8K*WM-4TN=;:4"X,B .%(=&V@DX<<$#!_(]W
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M(YKE/$5O:W^EZ7X?74X8?$=K+;M +:0-+$1PS@'G;Y>\G(_I7;6]O%:6T5M
M@2&)!&BCHJ@8 _*@#!UGQ'>Z?X@LM'L]*6[FO()98G:X$:@IMR&^4X'S#GGZ
M5D+\09_[*2=]$9;V/54TJ[M/M S%(S  JV,."&!'3^M2Z^UROQ,\,FT6%Y!9
M7N4E<H"/W7< X/X'I3;OP;?26FZ&6U-[/K,>K7+.S!,H5VQK@9(PH&3CN<<X
M !I0>(=2EOXM)DTRWBU<P/<RQ&[W1QQ!]B'>$R2QZ#;Q@YZ8-"7QXR:(-273
M !;ZB-/U))+C;]C?>%+9"G<HW YXX(_#1O\ 0KU?%=MXCTYX#<"T-G<V\[E4
MDCW;U(8 D,K9['(/:BT\)VXT'5]/O2LK:O--/=E!@!I!C"Y_N@* ?;/% #M:
MU9XK/7%;38;RSLK,O*K38\TE2S1$%2!\F#U/WAQ5.+Q5!;Q:'86MK:6\M]IZ
MW%O!//Y,> %Q$AVG)^;I@<#I4\'AZ\@\"3Z*]TEQJ-Q:O%-=2$@/(R[2QXS@
M# 'L *J77A:[O= M-'OK33+^TBL4MVCF9ALE48$B,%)'';@^_J 6I-40^+M$
MMKO1XDNKFQFF2Y=P7@P$WQ]/]H<Y[=*K2^./*T.'Q$;%3H4DPC-P)OWJ1E]@
ME*;<;<XXW9P0?:GV_A>^M]7\/3O=1W,.EV#V<KRLWF3EP@+="/X/7G/6J=OX
M*O(_"Y\)33V\FBK,"D^6\[R!)YGE%<8S_#NW=.V: )K_ ,9:E;S^(H[;0XYA
MHBK)*SWFP21F/S#M^0_-CMT]_7J[*ZCOK"WO(@1'/$LJ@]<, 1_.N7G\,ZE+
M/XN=7M NN0K%%EVS%B+RLM\O/'/'T]ZZ'1K2:PT2QLYRAEMX$B8QDE25 &1D
M#KB@"A/KUS-J>HZ?I-E%=SZ=&C3^;.8@7<%E1<*W.T Y. ,CKSCFM<\1RZ]I
M/A*_TJ&-K/4-4B#QSRE&+*)"8V 4C 9.3SRO3O6Z-"U#3?%&I:OI3VTD>IQQ
M_:(+EV39+&NU74@'(*X!7CIUJB_@RYM-)\-Z=I\L#1Z3>K>2O,2IF;Y]P  .
M,F1C[=.: .FTW3+33()$M;6*V\^0SRI$<KYC8W$=/3T'TK@M6U'4=9\,?$&#
M4K>T:WLEGBAVR%BA6!67 *\\G=NR.>W>O21G R #WQ7&W?A/5'M_%EI!<V9M
MM<WLA<,'C9XEC.<<8&W(]<]J )M%\0WD5]I.C7FFI#'=Z>9K29;C>S>6$W*Z
M[<*?F!&"U5;#Q;8Z?X?^V#3;734EU::R=3+MB23>P:1W"\ E3SCJ0,]ZO+H&
MI?VYX>OV-ILTRSEMY$$C9<N$&1\O;8/S]J@T[PWJECHTUC(NFW23ZC-=3P3%
MC'+%*78H<J<$,R\X.=M '2:;<W%W:>;=6Z0/O8 1R^8K*#\K!L#((P>G>FZQ
MJ TO2I[O"EU 6)6. TC$*BY[98@51\*:!_PC>E2V2L!$]S)-' C%DMU8\1J3
MR0/H.2>*FU+3[F_U2P+);/I\#-))'(QW.^"JG&,$#).#U..F* .>\#7,FGZG
MJ_AFZO?MDMO)]LMYRP)EBE.6Z>DF[/\ O5=U/QBUE;:W=V]@)[?1Y%CN-TVQ
MG.U6;:-IX 8=3SS^+]4\-W)\3:3K&CI9VS6BR1SJV5\^-\?(=H[$9!]>U<W<
MR/?:YK=Q;W7AYX#<B*:"_FDA;,0 PZJ<,-P)!8'(QVP* .BNO$^JIK"Z5::'
M'/=/8?;5!O BD;PI4DKQUZ_3IU$=YXU\A9+BVL/M5M!=?9I5B=C,<-L=E0*0
MP5L]QD FI["QU&\\26?B*:*""-],%M)!O8NK%@Y(^4<9&,'![\=*@L_#^OZ5
MJ-[!8:C9C1KNX>XQ+&QGMRYRZH0=I!))!/3/0]P!^I^,C9B\DL['[9'93^3*
MB.WFN1C=Y:A2#C/<C.#[$NG\4:@VIZM8V.D1S26%O%<!I;KRQ(KACC[A(/R\
M#\R.\<>@Z_INLW[:3J%DNF:A.;B1+B)FEMY& #F/!P<XS@]#^MA-#OXM>UG4
M%:W:.^M8K>-6D;<I0,,M\O??^E $%GXQGN9-"G?2Q%I^LX6&4W&9$<QEP&0+
MC!VD9#9]0*23QK\T,UM8FYLI+K[,6B=C*HW%/,V!<%<C^]G'/M45OX6U*#2_
M"UGYEH3HLJO(V]OWH5&3CY>.&S^%2:3X?U_1KB73[;4;,Z&T[RQ[HV^T1*S%
MC&ISMQDG#'D9Z4 0W?C:^MK36KI=$1X-'N3%<$W>"R!58L@V\G#=#@<=:NKJ
M^I2>/_[,2.W-@NG+<C]X0QW2;=Q&WDC;@#WZ\X%*Z\*:E<:3XHLO-M%.LS-(
MC;V_= HJ<_+SPN?QK1CT34(_%5MK"S6RI]@6SN(R&8C:Y;*'CKDCGI[T ;&I
MWRZ9I5W?O&\B6T+S,B#+,%!.![\5R?B#4O[<\ Z_*T-G-9_V:\T%Q;S^<C-M
M?(Y489< _CVKKKY+F6PN$LY$CN6C81.XRJOC@D>F:Y&?P5,\.NM:165@^JV/
MV5[>!V,)<[LRD;1S@XP!]3S0!=TC7KJ._P!,TB\TY88[FP,UM*D^]FV!0RLN
M %/S C!-.LO%DL^L:9IUWIZVTFHQ22)$9LRP[ #B5-HVDJ?4\C'O22>']2EU
M71KOS;>(6%E+;.4=BQ+A1N7Y>VP'!]:H:9X3UJTN/#TLUWIY.E>:LA2-RTX=
M0"Y)/WSC)]R3D]* .?O[6W'PW\<1B",1QZK<E%VC"$,F,#M7JR_='TKBY_"6
MIS^&/$.E&6T635;R2X1][$1AR"0?EY(Q^.>U=E%O\I/-"B3 W!3D9]C@4 <'
M%<:AIOC3Q<^CZ/'>R;;222,SB$']VQ..#EC],>I]=:'QK:W]II\FGHC2WMJ;
MH+<.4$:@[<$JK'.[(X&/E//3,_\ 8^J6?B+5=1L)+1TU*.)3YQ8&!HU*@@ $
M..<XROUK./@^^T9M)N/#5Y D]C:FSECO58QW$9.[)*\AMV3QZT =!H&KMKFC
MPWSV<UG(Y97@E!RC D'G R.,@]P:TZK6$5U%:*+V=9KDY:1D7:N3V49. .E6
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***Y_Q1JTVGR:/:0R^0=2OTM6GP,HI5FXSQN.T*/K0!
MT%%<5K5]J?AJ#R?[5\]=0U2VM;9Y$!DLXY3AB2?O?=;:2.O7.*;J%_J>D^);
MK2(;^=[:YTF6\AD<*\EM+&0#@D<J=PX;.#TH [>BO.M'U+6$D\#7EQJ]Q<C6
M8"EU!(J!/^/<R!EP,ALKR<\Y/3I5K1]<O#XD@TO69;ZRU"228Q@A7M;V/#%3
M$P& 57:<'!XYR: .QL+T7\,D@MKF#9*\6VXCV,VTXW =U.,@]Q5>VUNUNM=O
M='C687-I$DLA=,*5<D#![_=-<59^)M371K2WFOG>ZOO$,VF"[95#1QK(_0 ;
M=VU-HXZG-0W]]-X7\2^,+^*=YWATJT>(W!W>7EY ,GJ0"<\\T >FT5QLEOXE
MLY[FY_M2)=/DL7(!G$THG W*\>8@N" <KT] *R;/4]9M?"OAW4YM9FN+C7/L
M=N5F"(D+,A8LI"$@MC;DYY.<=  #TBLT:W:GQ&="VS"[%J;K)3";-P7@]SD]
MJY+4M1\1>&;:\%U>V[17EY:V]@QE\V6U\UMKLY**& Y*YSSP<U9M;1K3XN*I
MNIYU;0F(\Y@Q4^>N<''0]<?_ *J .VHK'\274EKIT1CO1:-)<Q1Y";WD!89C
M0?WF&0#VZ\8R*/A34+VYO]>L[MIBEG>*D*SE6=$:-'VDKP<$GN?K0!O"PLQ=
MF[%I +DC!F$8W_\ ?76K%<]XGOK[3Y+.>*WNY]/ D^UK9$><GW=K@=64?-D#
MU'TK.M]7N-6NK#3;&_\ M$;Z:+HW(D\EYR6V9^X<8(R1@<G\* .NBMX(&D:&
M&.-I6W2%% +MZG'4U)7#M)XB34/#NF7NL*D]RMS'=26BHP;8N58;E&&P>>,9
M[4RUU/4[<:CI-WJK.]GJ4,$=R8P9KB-U#^4,#&_!QNQP,GC&: .[HKSR\UK5
MXO#'B1X[R>"?3]06*!G",ZHWEG:QP0?OGD'/O6Y=1WEE?VMF^LW=T;AYI3 J
MHLSC"X"L  J*<G)]0,GH0#I7=$ +L%!( R<9)Z"G5YA-=7VL:7X'N;J_N%GE
MU5X9&C*KNVK, Q&,$_(/;K6G+=>(M?.M#1KV&VN-/O3;0&6?:J[ I)D3RVW!
MLGOT(QC&2 =Y1441:6V1F90[H"6C.0"1U!/4>E>62:IXEA\"3>*5UZXEN-/O
M9E-JT48CN(EN"A5L+G<1T((Q@<9YH ]8HKSSQ1KFI6,>KWUEJ,TK65[;1JL*
MJ(;=2T8:.3/WV.\DXSC*_=K1U+6+CPWXQ=M2O9I-(OK-WMD(7$4\8W,@P,G<
MO*Y/4$"@#LJ*X:Z;7+76?"6G2ZQ<(]\EP+T*L9^98BWRG;V)P.W )!K&N]1U
MVV\*>*+U=?NS+H-]+';$I'F55".!+\OS<,1QB@#U*BN*O;[6=<UG6M+TNY6U
MEL(8?);S_+(DD0N'8>6VY<X&.G!_"&.77;SQ=9Z3=ZVT*RZ(9[@6(0J)A(J,
MT;,F0#SU!QSC% '<LZ( 78*"0!DXR3T%.KRM+S4-:T;P+<WFHW'VA]6EMY7C
M(7S-@F4,1C&[Y![<FO46(BA8EP JY+OT&!U- #Z*X+2]6U(ZYX=B-_<7,&I6
M]P9IV55CF955E>)3RH&3C( ((X/6J,6J:W'X>M]8DUFYDEBUHVC1%(PDL1N3
M$0P"]<'J,8P./4 ]"U&^BTS3KB^G$AAMXS(_EJ6; &3@"H=,CT^>WBU2SM(H
MC>1++O$2J[!@"-Q'UKD]1O;C7])\8G[9-;QZ=YUI#%'@?=B#,S9'S;BQ&.F!
MQSS73>&?^14T?_KQA_\ 0!0!JU&UO UPEPT,9F0%5D*C<H/4 ]17G.J7NN&/
MQS+'KUW%_8V)K14CB[0++M;Y>5R<8X/J36S::O<Z_P")7TIKF6TBATN"Z/D$
M*TDDI/.2#\JX''J><T =>[I& 78*"0!DXR3P!3J\J?4-2UF'PVM]>SI<VWB*
M73Y98<(L_EK*!)MQC/RCVSG KTV[G^Q:?/<%6D\B)GP.K;1G\^* +%%>=/KN
MJP>#="\6)?232W4MN;JUP#$Z3,%**,94J6&#G/'.:KZG?ZX+'QO=1Z]=QG1I
MM]JJQQXP(4DVM\O*Y)&..O)/8 ]-HKB9]2U;7M8OM+L)UM7MK&"9"L_EMYDH
M8[_N-N48 QTZYSD8ZC1C?_V-:C5);>6_5 MP]L28V<<$C('<=,<4 7JI:AJD
M.GM;QLCRW%RQ2""+&^0A2QQD@# !.20/S%<E_:FI:UIGBF_M=0ELY]*NY[>U
MC0+L7R5!RX(^;<<YST!&,'FJ4\\VO>(/ &IO/<6KWUK/,8XR,1DP*QVY!]>_
M:@#N]+U&+5M.BO8HIX4DR/+N(S&ZD$@@J>G(-7*KW\QM].NIA/% 8XG?S9?N
M)@$[F]AU-<9H.K:C_P )9I=E)=74]K>:2]P[W"JHEE5HQYB+U12'/RG';B@#
MNZ*RO$<FHQ:),^E1^9=JR$1APK.N\;U4G@,5W >^*Y:/Q49+"..QNKH3W6K1
MV;PWX\N:SW1YV$E3U*'!PWW_ &H [9;"S2[:[2T@6Y;K,(P'/_ NM)=W@M)+
M9#;W$OGRB+,,>X1\$[G]%XQGW%<1KTOB;1/#NN3MJD:+&\$EELD$LL:LP5U<
ML@RN2<'K[\5H:K_:FBWNAH-:NKE+W5Q'*LJ1@>6T;'8,*" "G'U[T =A17#-
M>>(=<@U*[TF\M[::RU"2!!-/MB58GPPD01G.Y03G.1N&,4^\UJ[LO$IM]4DO
M+.WFO(ULKN(![:1/E!A?'*L3N&3Z]<<4 =M15#6]0.DZ#J&HK'YC6MM),$_O
M%5)Q^E<O-J6I:=:>%]42^DNUU*>""[B8#8PF7.] !\NT]AU'7/6@#H-0\16N
MGS31>1=7)M_+^T&VCW^2'^Z6&<GU^4$@<FM>N.\-6KIXY\5L;NX<)/;Y5BN&
MS O7CMVJSXYO=0L-,T^73KUK6634K:!B$5@RO(%(((SCGL10!U%%>>7&H:QX
M?U[6=+F\0&6U?2&U"WO;^-";20/L((10&4Y! QVQCUMZ;=ZG<>*;_1/ME_!!
M)I,=S#)<!#+'(79"X'. < [6Z8Z#I0!W%%<-X=UC4-6M=-TJ>\E35[.XE356
M7;D^5P>V,.7C(P.A..E8UWJNO0^%-?UA==NC<:5K$D,*F./8\:RJFUP%Y&">
MF* /4J*X2]U?4O#?B358WOI]0MTT*74Q%.JC;+&V,+M PI!Z<]*LZ9%XCN+O
M2K\:I!_9UW;G[4#<!V=F3<CPCR@%(.>,D8[$B@#KA;P"Y-P(8Q.5V&7:-Q7T
MSUQ3@Z,S*&!9?O 'D?6O,=*U?7/^$?\ "6M3ZU<3RWNI+9W$+)&(WC9Y%R0%
MSN&T$'...E6]-CU6*7QS+IEW//?I?[((YI%PQ,41 !(P#SA>PXXH [U["SEN
MENI+2![A/NRM&"Z_0]:2_OX-.MA/<,0&=8D4<EW9@JJ/<D@5@>$=:BU:;4$6
M6_CG@,:S6&H)B6U8@]_XE;J#D]#]*@\>P-+%H)%Q-'_Q.;5<(1CE^O(/([4
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M'<#)'I5VZ\Y;"?[/EIQ$WEY[MCC]:Y;X7&-OAYIC*<R'S#,3][S/,;=N]\T
M=+IVI6NJVS7%HS-&LC1G>A0AE.""& (P?6GOI]E)=+=26D#7"])6C!<?CC-8
M6LZA]EU_1M'M7\@:I<3-<2QXW#RXMVT>A;Y>>N,XY.:PM1\3:EH5QKNF&<S>
M1+:+:74J@F(7#;2'[';@D9Z\9S0!V)UFU'B%=$VR_:FMFN02F$V!E4\]SEAT
MK1K@;\OH?CU[WSY[H0>'KF8),P)RLD9."!WP..W:K^D?\)!<7&C:I]OMGL+F
M'==H\^X2;ERAC'EC:0>V>GJ>: .HO+RWT^SFO+N58K>%2\CMT %48?$%K+>V
MUG)!>6\]UGR1/ RAP%+'GH.!T.#[4[Q!IUIJ^A76G7TK107($1=3@JQ8!2/?
M=BN7L=1U[0-;TS2/$R0ZC;3S&.QU:$;6$FQL+(G9BNX9'Z\D '=T5PNG7GB'
M7;"RUNQO+:&,W3&:.:X_=^0'96C*^7PP Z[LY]N*M:==:CX@T^;5+?5C920:
MA)&8F4&)(8Y"I1AZE1NSG()XP* .L>9$63&7:-=Q1.6QSCCWP:9970O;*"Z$
M,T(E0/Y4Z;'3(Z,.Q]JXW2XKE-=\:R1ZC=*\4J>625;:3 K#@J1P3P.E-TC7
MK[48O".G3W4BOJ.G-=W,ZX#RE57Y0<<9+$G'/% '=T5YOJFN:U9:;XALTU"0
M3Z5?VL<-T44F2*9H_D?CDJ'(R,$\5T&F3WUIXYOM)GU">\MFL(KM//"YC<NZ
MD#:!\I '% '45FV.NZ=J+Z@+:X5ET^4PW#GA58*&//MGD_6JOB;4I;"SABB@
MOG^TOY<DMG;O*T28R2 H)!/0'L3GM@^<S7Z2>&OB!;:;9WMN.'19+5XPD8BB
M5E.1P=N?E/..: /3['7K'4)XHHC(C3Q&:W\V,H)XQC++GJ.1[X(.,&HQXETX
MS0KOD$,TYMXKDH?*>4$C:&^H(!Z$C )-8&N@'7/ ZVAY\^3:5_YY>0=WX8Q^
ME8.I6&KZ;X'L/"$UJCW3WT4%I=1R@B15E$F\+]X$*#G/ ]: /2M2U&UTC3;C
M4+V416UNA>1\9P!_6K".LB*Z,&5AD$'((KF_$@75+V'1I+&>]M!&9[R.+;R#
ME8U.YAP3N;ZQBJWP\OIVT.71;X.M]H\IM)%DQN,8YB8X)ZIC\C0!U]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9VMZ'8>(=-:PU&$R0E@ZE6*LCCD,K#D$>HK1K#\7:O>Z!X
M=N=5LK>*Y-J \D3Y&4R,D$>@Y_"@ 'A+2FT6?2KA)[N&<@RR7-P\DKL/NG>3
MN!&!C!&.U3)X>M EP99;F>>X@^S/<2R9D\KGY0>PY/09/4]JSM1\1W5CK?A^
MW46LFGZL2@N?F!5]FY0!GD-T'I[U;O\ 4]0AO=0CM4MFBM+,3[I V=YW84X/
MHI/XCUS0 D7A/384TA$:Y"Z1Q9CS3^[^7;S_ 'OE..<\5+;>&K*UDM6$EQ*M
MF6:U2:3>(68$$KGGH2!DD 'C%.\/:P-7T/3;F:2!;RZLX[F2&-NFY03@$YQD
MU2UO5]4TCPYKFI*=/FELR[P(NX@(%!Q)S]_KTP,$4 *W@G1I-'FTN2.=[>6Y
M-WDS-OCF+;O,1ARIR<\4^#P?I,5S=7$PN;N6[MA:W!NKAY!+&,\$$X/4]OIB
MM7[=!#90W%W/# )%7YG<*,D=.:M @@$'(- '.Z9X+TK2;6:VMI+YHY(C OG7
M;R>3&>J1[B=@Z=.>!Z"II/"6D3^&$\.SPO-IT:*D:/(2R!?NX;J",<&K$VI'
M3FU.ZU*[LH]/ME5T*DAT7;\WF9.,D],5=L[N&_LXKJ!@T<BAA@@XR,X..] &
M,G@S1SHESI5RES>P7( FDN[AY96V\K\Y.1MZC&,?B:DL/"FGV&J1:F)KZ>]B
MMS;++<7;N2F<X(S@\XZ^F>O-:$$MR=2O$FEM#;(J&%4)\U<@[B^3C!(XQZ&I
MK>[MKI2UO<13 =3&X;'Y4 5=8T:SURTCM[P28BE6>)XI"CQR+T92.AZ_G4>F
M^'[#2;V[N[43B:[*F8R3NX8@ 9P2>< 9/6I[R2[2[L5MY;1(7E(G6?.]EVG
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M=)DCTVXU%@ 9?,YR2  3&%VYP=IQW(KTB2*.50LD:. <@,H.#1)%'*H61%<
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M.FV7-R2R,C.H:.-,X:0X'N .AS7':$VF7]C\,EN#;3,HG@D\P@G @?Y#GMG
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M!4^^:DCU,Z?#:Z=*D]]J<=HLDZ08+8 P7)8@<L#CG)P>.#46FZGK7V..WO\
M0YQ?(H1Y4EC,#L.-P;=N"GKC;D>AJG]AU/2_&4^KK;-?6U]9QPS" J&BEC)P
M0&8?*0Q[D@_G0!I1>)M-N=/LKRUD>X%ZYCMXHU_>.XSN7!Q@KM.<XQBL/PYK
M'E:CXIFO)+M88;^***&X8NZ%HT&Q1D]7/ '!R,5GQ>&=7T6XTC6+:U^URPWE
MY/=6,<BAE2X.?D+$*2F!WYYQ27GA_7-0_P"$AN(]-6&66_MK^TBN9$99O+1
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M[=@$E<XV\ ]<T >FT5R&I^)]3>35DT2T6XETV40^2UM(_P!H?8KLH=2%3AP
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M/'(88&>HYR..*CNM0U^#Q=-HVF6VB_:YM.%X]U+$Z"1E<)\P4D].!R<>O&"
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M0>G4FJL_@N:?0-8TIM30+J=XUT\@MCF,LP8J!OYY4?K775'//%;1&6:18T!
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MJS K%_O'L/>KG]JV'EVDGVN+9>$+;-NXE)&0%]> 3]!7-6NFP:MX[O\ 588
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M77GW1EE@ @<B16MD5=K8P26!& <_E0!V>B>(=/U-(;1=0MYM16V26:%'&X9
MR<#W//I5I=<TMKU;-;Z SNS(B[OO,O50>A8<Y Y&*XMD9M?\'BT5HBFDW,)D
M$9"Q,R1A W''*G@^E9T5M<:A\.-)\.+;S0>(+.ZMT9&0AH7CE!:;=TVE0QW9
MP=V.IQ0!WS^*-!2[%HVL60G,OD>7YRY\S&=OUQ68?%=AI&BVUW=ZQ#J:W=_]
MFAG@0*IW2[<?+D80'D]]OJ:K>&DA/C+Q?-)#@/=021R/&0&5854E21SAMPXZ
M5S,,<J> [*3[-<8M/$JW4R"!BZQ?:R^_;C)&T@\"@#TJUUK3;V\DM+:]AEN8
MT#O$C995/()'8&I[2\MK^W$]I,DT1)4.AR,@X(_ \5R'BB.^LM6TSQ'HL):Y
MND_LZ>)UVDK)S$[ _P!Q\$]\,U=3#8?8M%73[-RAB@\J)VY(.,!CZG/)H 1=
M9TU[Q;1;V$SNQ1%W?>8=5!Z$CN!R*A_X2/1?MBV?]JVAN6F\A8Q*"QDQG;]?
M;WKAHK>?4/ &D: EO-#KEG<VZLC(0T+QR M*3TVE0QW=#NQU-;_AN.)O%WBJ
M1H>9+N%XW>,@.%A5<J2.<-N'% &UJ-VL6J:9;C5X+2265LVKJK/=+M/RKDY&
M#SD>F*LC5+%KM;47,9F9V15S]Y@"2H/0D '([8KG/%G_ ",WA%@CL(K]WD94
M)"*877+$=!D@<U4L1<V?B"W_ +-GDN;&>^F,^GW,7SVC'?NE1NH0DGKP=_!Y
MH ["XU&SM;JWMKBYBBGN&VPH[8,AQG"^IP*P_$VO^1X3UV]T:^@-YIT+L_ ?
MRW5=VUAV./6JWC@FWNO#>H/'*UM9ZHKW#QQLYC4Q2*&(4$XRP'XUS5Z\ESI/
MQ)V6EX#=@&W#VSJ9<VR* O')SVZCN!0!V<?BJQBU73='N)A]MNK3[03T ^Z
M/3)+=/;Z4ZTUW3[:TU"]O/$-E<6J7C1K*"B+!PN(<@_,PS]>:PQ(8/&GAF]:
M"X:WDTB6V#QPLP$A:(A6P/EX!ZXZ&N?U)&D\$>.(%MYGDN-;:2&,0L3*I:'#
M*,?,/E;D>AH ]"/BK0%-T#J]GFUQYP\T93/ ^O/'%6?[;TPV-O>K?0O;7.!
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MS03K]K2UDAD\EMC*L;!CNQ@8/'7O4FJ%[;XB:-=/#.T#V-Q 'CB9P)"\9 )
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MISA5SU8[3Q],D9% &]17/V_B>WU5;2+3(&N);NT^U^7(WE^7$3CYC@X).0
M>A]*I?#<D^$03&T?^F77R,<E?WS\'Z4 =;17,ZQXSM-*-Z5C6X6P8"Y43JLF
M2 Q"(>7(# GIZ#)R*<_BQY-1N;&PTFYNY8;6.[0^8B+(CYP02>/N]^?;O0!T
ME%<M:>-8[M=&N1IMS'I^JLL4-R[+Q(5+!2H.<?*1GU'IS5>Y\>-!:ZC=KH-_
M):Z;=/!>2!X\QA0I+ ;OFZYP.@&30!V-%<<LUNWQ-@O8Y!Y,N@O+YF?E*^:F
M#^571XNB6WTZ^FLY(]+U&18K>Z+ D%_N%U_A5NQR>HSB@#I**P(/$Z2'7%GM
M&MY=(YE1W!+KMW!AC^$CI^/'%1ZAXLCL5EC-O&;N"W6XGMY+E49002$7/WGX
M/'3ISR* .CHKFG\9V,MM!)9!)9);1;L1SS+ 0C9VCG^(E6&.G!R1QEME!:>*
M;C2_$]J]Q%$]J\94RNA93N!0H#@$,2=W7*C% '3T5F>'])_L/1HK 2.ZQLY4
M/(7V L2%W'D@ XR?3MTK-T;4O[5OM:U*4,T&GW4EG;QJ,X\M1YC =V+$CZ
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ML:"RGGE8-;@ 9C"[2!D@G<#WYSC%=Q"93 AG5%E(^=48E0?0$@9^N!]*DHH
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MZL<'9G)V^E=;>:Q8V%_965S*R7%\YCMU\MB'8 L1D# X!ZFKU ')G1-5&O\
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M\8;=E23Q[BLRY\$V5S8:K8F^OTM=2G:>6-'3",S!FVY4]2 ><X[8R: "RO\
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M'SX\Y =2I7(/(( Z^G%0MX/L-NDK#<74"Z9.US$$*GS)&W;F<LIR3O;.,=:
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M%5,\UQ%;1%QE5:1PNX^PR3[XJD^H:AI_BVVT6>[>XMM1M99()VC020R1XW=
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MF)5>0 [59MH)]"<''Y5@:'K^H:_X7TO5[6P@62[D'G1/.0(H]Y#$';\Q '3
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M,JVT#(# 'UP30!V;6MN]L;9H(FMRNWRB@*X],=,4D=G:Q6OV6.VA2WQM\I4
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M%U8"60W5K$)Y8A"Y(0D@,./FZ'IGI5"3QIH$=OI\YO6,>HHTEH5@D/FA5+'
M"YS@=.IX '- &B='TU1"4TRRW6X_<?N5'E_[IQ\OX5B^%?"W]D0W#ZA::>]X
M][-<QSQ#>P$CLP&XJ""-V*VX[H:IHPNM-FV_:8-]O*Z$8)'RDJPSZ<$5RURV
ML6_C73-%'B*_:WN+.::1S#;;MR%0,?NL <F@#JKK2=-O;J&ZN]/M9[B#F*66
M%6>/_=)&1^%*^EZ<]Q)</86K32KMDD,*EG'H3C)%5$O?['LX[?4KN:]NP'?=
M' 7D= W#%8UXP"H)  S]:@E\9:#%#9R_;MZ7L;2VYCB=_,51EL8'4>G7/&*
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MUGO-JGS=SG##.$ZCY0 /;'-=U8WFFRQQ0:?=6LB+'^[2"16 0?+P >@Z5<H
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M,^4_]R0<HWX, ?PKD5T;7;N^TS5IH3'/JT!M-6AW<018#+CT("N/]Z2O0J*
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M6>K07,J0KN?RQN!('?&173JZNH9&#*>A!R*6@#A?(NSXA\87+V%VL=YIUO'
M3"3O=4D#*,9!(+J/3TK(M+/4=&3PW?W6AW]]:)HL6GW5O;H?.MIDP=VS(RIY
M!QZ _7U&B@#,T"UBM-(BCATU=-C8LZVJ@ H"2?FQQN/4X[GOUK3HHH ****
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M+"L&[:\C@*SG/3@$!><9/)H Q_"5N^K-JLNJVEK-Y&MSR1N7+LDJ,%7&5'
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MQGWH ZO4KU--TN[OY!E+:%YF'J%4G^E86BZ7!KG@RS.KI]H.H1I>7:DX$C,
MX4_[(^4 >B@=*W;ZS74=+N;*?Y5N86B?:<X#*0<?G6=X3$MOX=L].NAMO+")
M;:9?=!M##V8 $'W^M &#8:+I^D:SKVI:%IEG;-8VHM8\+M5I<>8Y..H ,8_
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M_P!%U#Q=)'.SQV=E:RP))\RQ/(75FQZ< X]J .VO;I+&RGNI$=TA0NRQC+$
M9X%1Z9J$6K:5::C KK#=0I,@< ,%8 C.._-8MW83VL=Y.NL2SV<VG2+]FF.\
MO(!GS5;/ QP5 QTZ5SWAZ6]TZ+P%LU"X>#4+00S6[8\L*MOO7:,<$%>N><F@
M#T:LS3M<MM3U+4["**=)M.D2.;S% !++N&WGD8(].M9OB+5)HO$'A[1(Y6@3
M4Y9O-E0X;9''NV ]BQ(Y'. <<\UR;7\_AO4O&3P7#L[:EI\ GN'SY2R)&I)8
M@_=#'!(/09SW /1]1OH],TVYOI4D>*WC:1UC7+$ 9.!1IM]%JFEVFH0JZQ74
M*3H'&&"LH89QWP:Y2[L]9LK3Q!]KO(FTZ?3)6AMFN6FECD52&(9E!V$$<<X/
M3K5?3)I9=(\*6$5Y<$OHJ2&RM3LD8[(P)6DR-J+DC'<D<'&* .]HKS2#6]7;
MP'X9\63WT[I 4;5(TX$T))4N0!U4X;C&0#FM/4]<NK>S?4;:Z/D:CJD5C;,\
MN$CBSM9P<'&YE;!P1@J: .XK,.N6R^)4T(Q3BZ>U:Z5]H\LHK*I&<YSEAVKD
M=8OM?\*6.ISS7T!M[F2WCLT>=IY+0NX1W+,HRHSD9S@\=*M1V/V+XM60%S<3
M*VB3\3R%R")HLD$\\\<=.. * .WHKC_$+ZA-XXT72[?5KJTM+RTNFF6$)G*>
M7@J2IP?F/)S[8/-8^G:IJD=M=:1?:Q/+)9ZY]CBE5 9[V+RQ((@1@!\'E^,
M'IUH ](HKSB&X\0:AX4\0FTO+I;_ $G5)5MX_,#-)$@1_)9OXB0S 'KG'-:4
MFL/KNDZIK6D:A<0V<&F9@9"#F8H9"2"",JI0?4MW% ':T5YQ;3ZOY_@E_P"W
M;XG6;4I=@[".+?S R@KPV1UYZTV+Q!J6FV6H6#7TDY3Q"FFPW-S( Z1.J/@O
MM//)4$@XR/2@#TFBO.?$G_"2:%X9\27/]KB&-84FLDCG,TT)SAP6= 2I[=QZ
MUI(;ZW\=2:3)JMY/:WND27+!V ,<BR*N8RH&WAS^0[T =BCQRJ)(V5QDC<IS
MT."/S'Z4^O,/#\FJ6?PU\-W5C%>:A&RB6]MH;C;.\>UA^[.0>&*D@$$],\UV
MOA;4;?5/#T-U:WD]U&SR#?<KMD4AV^1QV*_=/TH UII!;V[R;&8(I.Q!DG'8
M"JNC:K!KFCVNIVJR+!<H)$$@ ;'N 37*>']7NCJL6G:R;VVU0VLA9'?S+:]/
MRGS8F' P,_*,8#=.*R/#,M[IOA[P+<Q:A<&.\D6TEMCCRMACD88&,Y!4'.?7
MMQ0!ZA6,/$MH9]9A\BZWZ2JM.-@^8,I8;>>>![5S%SJU]%?:==6VH3W,<^N?
M9))A\L#1$LOE*A/)7&"^!R#R:LQ_\A_Q]_U[0?\ I.U '6Z9?Q:KI5IJ$"NL
M-U"DR!P P5@",X[\U:K$\&_\B/H'_8.M_P#T6M;= !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9?B
M#1UUO3! '$=Q#+'<VTI&?+EC8,IQZ9&#[$UJ5A>)]6O-(BTV2U$)6XU&WM91
M(I)V2.%)7!&#]<T 6M0TNW\0Z*]CJUNZPS#$T"S$9]MRD$C\OIVJ>ZTNTO=.
M%C<HTL(VD;G.X%2"K!LY# @$'.>*EMKVTO5=K2ZAG5&VL8I P4^AQWI+:_L[
MQI%M;N"=HSAQ%(&*GWQTH K0Z?%I4-S+96[374[!Y&DDRTK8P-S'L!CZ#H.U
M,T#1TT/2EM0_F3/(\]Q+C'F2NQ9VQ]2<>V*U"0 23@#O55-3L))HX4OK9I95
M+1HLJDN!U(&>1P: ,2Z\!Z!>&_$D%PL-^_F7-O%=2)%(^02Q0,!N.!D_CUYJ
M2\\$:%?37LEQ;SM]MA6&Y7[5*%F"KM4L-V"P'1CS6S!?V=U \]O=P311DAY(
MY RJ1UR1TQ2VM[:7J,]I=0W"J<,8I X!]#B@#G;_ $Z?49H?#S:,?[%@:&5K
MV><2>8$8/L"DEBQ90"3V+'/3.W>Z5!?75O=.\\4]NKK')#*R$!L;@0."#M7J
M#TK)NO$9'B[1]+L[FRGMKOSQ.$.Z2-D3(Y!P,GU':MP7]FUX;-;N W0&3")!
MO _W<YH CM]+LK32QID-NJV80Q^4<D$'.<D\G.3DGKFLRT\&Z+936$L,5QYE
M@&6V9[J5MBG'R\M]T8&%Z#%;]5/[5TX1-+]OM?+5MK-YRX#>A.>M %.#PSI<
M%KJ-LL4C0:DSM=)),["1G&&/)X) QQBJ]WX,T6]LK.VFBN,V1S;SK<R":/(P
M<29W= !U[#T%:[WD',<=U )FC,B!G!R/[V,\CWK*'B*STZ#28-5U&R:\OA@/
M"X6-B%+%QD\+QC.>I% $W_",Z6)=.E6*57T\L;8K.XVEL[B>?F)R<DYSDU?O
M[&VU/3[BPO(A+;7$;12H21N4C!&1S6'I7B)I-5UJUU2XLX$L[Q+>W;/E[]T:
MN!\QY;YNU;MU>VEB@>[NH;="<!I9 @)_&@#,B\*Z7#=6%TJW)GL(VCMY'NI&
M*AL;LY;YLX'7/0>E02^"=!GTJZTV:T>2VN;@W;AYW+"8G)=6)RK9]"*VS=VR
MRQ1&XB$DHS&A<9<>P[U1U/Q%I>E:7<:A<7L/D0':VV0$E^R#G[Q]* )=(T:S
MT2T-O:"4AFW/)-*TLCGIEF8DG@8]JAOO#UA?:@FH%9H+Y4\O[1;2M$[+_=;!
M^8>QS6E#-%<1++#(DL;?==&# _0BJEU-<)JEA'%=6D<+F3SHI<^;+A<KY?/8
M\G@\4 -?1+";3[BQN(#<07*[9A.Y=I![DG/T].V*;:Z%9VC;U:XDE$7D+++.
MSND?]U23D=!SU.!DG J<ZKIRR)&;^U$CR&)%,RY9QU4#/)Y'%5HO$.ESZ_/H
ML=W$U]!&KO'O&1NW87ZX4DCL"/6@"NGA'2(].L;!(IUMK"83VR"XD_=N,X.<
MY.,G@^M9OBOPTLN@^()-,M9Y]3U2W$3J)B0Y PO#-M&!FNEBU&QN+F2VAO+>
M2>+F2))5+)]0#D4D.I6-Q)Y<-[;2/L+[4E4G:#@G /0$8SZT 4K'1+,1133P
MS22_9S %N9"YC0XW(,D]<#)ZG Y.*K6O@O1+-[%X8KC?8[A;,UW*QC4C&T9;
M[O XZ<5K6VI6-Y')):WMO.D7$C12JP3ZD'BJ6H^*-&TS1[K5)M0MGMK9<N8Y
M5;)[*,'J<8 H A'A#1QIJZ>(I_LJ7'VI4^TR<2[MV[.<_>Y],U&;:[UC78#?
M:2+>TTN=I;>>257:=MI564#E1AF)SSD+[UNP7$-U"LUO*DL3?=>-@P/XBI*
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MTN$LUD5;B9IY-\K/F1CEF^8G&359_#&E/<74GDNJ7;B2Y@65A%,_'S,F<$G
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MW)D$$\4IC;9($<-L;T..A]JK:M-<0VB-:W5I;R&:,%[O.PJ6&X#!'S$9 ]Z
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MUBX\0>$=-U:[6-9[J+S'6($*#D],DUN4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R?Q!2-M%T]I
MU!MDU6T><L/E6,2#<6]!CJ3764=: /,M:T]FO_$-YX7A0VSZ.L<PLP DTPDS
MA<<%_+W#C^\/6MKPY<Z!K>N0ZMIFH75Y=I:&%\HJ+#'D$)(%51G/0'GKCBNR
M "@!0 !V% 4+G  R<G% #)_)\B3[1L\G:=_F8VX[YSVKR.PCTL> O!+.MJ'.
MJ1+(QVY*Y<,&]L8!![8KV"B@#R_4[K3+&^\=H]M'/:A+(O;1.4!)&UF.WD ?
M*6QV%0:A>W,]YXQ_LJ\%W>W6DV[PO;)M$@'F!C'C.0%X!R><#.:]7ZT8 [4
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MAMV6419)Z \8SV(J/5+B"[T#Q^8#O'VV&884\IMARWTX)SZ5ZN0&&" 1Z&C
MYXZT 16MS!=VT=Q:R+) XRCI]UAZCU'O7(^)7M(_B/X.:1H5F)NU)8@-M,1
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M1@  =>!0%51A0 /0"@#,MM?TFXN+.UM[R-Y;R)YK<("1(BX#,#C&.1]:U*3
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M<>3N!\M0JJH)'&[Y<G''..<9IGC33+W4]%MUT^$3W%M?6UT(2X0N(Y%8@$\
MX!ZT 8C:S-IGC[6)&M=3N4_LJWG^Q1MYAC.Z3=@%MB\ < \XXS6M<Z]I%_-X
M8N0;UEU"7S+)X240DQL<2<C/RYX.>14$5CJO_"8:IJDFFNL%SID5NFV:,YD4
MN2/O#^^!GV-96G^']9MM'\#VLFG/YFD3!KO$L>% B=,CYN>6!^E '5P>(8+J
M[6*"UN9(3=26GVE0AC61-VX'YMPP5(R1U^HK8KA4\.WR^*HM6T^RGTNX:^<W
MS1SJ;:\M\MAFC#$^81MYV@@DYKN2< D G'8=Z .-\?:MJUE9@Z(<S6 74;M1
M_' C#,?_  (;S](R.]=#-KVG6_AW^WI+@#3OLXN/- SE",C [DY'%9FGZ)_:
M,E_>ZS97$-S<S,/+^TG'DK\J+\CXZ<G/=F[5S,&F:AI7PZUKP]J>FJULLDD&
MEB>X7]['(^(HR58D.&8 =NG(H ZY?%,']L_V3+87\5Z;?[4(S&K9CZ9RK$=>
M,>N/6JFG>.M.U.R2]BLM1CLY(@\5Q+!A)&+B,1J<\N6(X]^O6LW1Y;ZUU^&X
MU;0-46]FMS9P74UU;RC"@R;,1E<;MI.2.H'(JM;^%M9?X66&CFWB@U:PDCGC
MBG97BD>.7>%)4GY6'% '21^+].^T:A;7:3V=S8QI++%,%)9&.%9=A8-D\8!S
MGC%1R>,[&WN+^VN[6\M[FSM/MK0LJ,TD(."R;&(.",$$@UCWNBZOXC\+W]N=
M#LM"NF1&AC+I+YDJ2+(-Q08"90#N3D\#',R6VLZAH&II-X7M=+N9+&6W6.*:
M)VFD9< AA@*@]SDYZ<<@%Z/QQ923Z?%_9VIK_:,!FLV, Q.0H8H,-D, >X"\
M$YQS5FR\6V%YILUWY-S!)#=FR>UE51*)^,)@$@YR#G.,'.0 :QH='U5+GP.Y
MT^3;I,+)=GS8_D)@\OCYN>>>.WOQ6==>%]<GM=8FAL8Q<C71JMI#<NACN$"*
MA1L$[20&Z^WX &_=>/=,LK359KJVO8I=+*?:K?8K.JO]QAM8J5/KGCOBK47B
MJ"74;S3UT^_2[@MOM<<<J*GVB/.,IEN.<##;3R.*P-9TO6=;\$ZK;1>'+?3K
MJZ1(XK6.:(L2&!+.XPN/0#)_/C5DT[4)_'T>I_8G2S.D/:&1G3*R-(K\@-G&
M 1D=_P Z +OA'6Y_$/AJSU2>T>W:XC$@!*D$'D;<$\=N<'VJ_?ZI%836L#(\
MMQ=.R0Q1E06PI8_>(' 'K63X&L=0TKPCI^F:E:"WGLXA <2A]^/XACH#^?TJ
M3Q1I4>L16UM<:6][;;F9GAE$<L#@?*Z$L.>O0_X4 9.LZJQ\1^%+R-+^-)9K
MJ.2T!.7*Q. "@.TG<.OZXK6@\76$VFM=F"[CD2]%@UJZ#S1.2 $X.WN#G.,'
MK6-:Z-KT=UX5>\66\.GS7+3S/*A<1NKI&&.1N8 KDCT/6HAIGB.UM]6-I92+
M]JUP7;QK<(CRVI5%958-\K97U''0YH M^)=:34O!'B4VQN[2[T^.2.1=^QXY
M @8<HV"""#P:?<R2IXS\)A9Y@D]G<^;'YK;&*I'@E<XR-QY]ZRW\.ZQ_8_C&
MSBTJ.(:I\UJJ3IC+1*F#TQ@@Y)_#/6MF;3]1E\2^&;T6+B"RMIX[AC(F49U0
M#C=S]TYQ[4 =2RAE*G.",<'!_.O-_"_C&#1/#ZC5(]4EM_[1N87U!T,D469W
M5 [L=V.@S@@=S7I->>)X9U:?PAJ'A2>R,:W=Y,S7OFH8A"\QD) SNW;3C!4<
M]\4 =5J?B6TTQ+J62&XF@LR!<RPA2(<@'D$@G ()V@\&M>.1)HDEC8,CJ&5A
MT(/0UQW]EZIIFOZCY.B6FIV5_*)XYY)45K=BH5E?<"2ORY&W-=A$ACA1"5)5
M0"5&!^ [4 9D^OP17=Q;QVUQ<&V>..=H@I$1?!&06!QA@20#P?8U!+XJLX;7
M6;A[>ZQI#8NEVKD#8'ROS8(VD'KFL?7] O;[69K_ $ZSFLM4CDB%MJ,$ZJDL
M>%W+,N[+ '<,;3P!BJ^K:+K>?&-I::<)XM9BW6\_GHJ@^2(RI!.<Y''&.>2*
M );K6'L_'XGBBU&\AFT43+:09?+&4<A2=JG Z\?F:NW'B71M5TS1K[-_Y-SJ
M$<40BW1LDX;&V49& #G(.0<=Z9#8:K8^([#56TYIXQI(LI8X)4W1R!PV3N*@
MCW!_"LN_T:;2M*TA)MIN;OQ+%>2I&<JA>0MM![@# S[$T =+JGBJQTJ.ZFEA
MN);:T<)=3Q!2L).#R"P8X# G:#C/UIU_XGL[%+N1(+F[CLT62Y>V56$2L,C.
M2,G;\V%R<8]1G"72=7TO7]32+0;+5+*_N#<PW<LB*;=F #*X(R5!&1MS_A-!
M9^(- \1ZFUCIT6HV.I-',LGGK#]GD"!&W \E3M!^4''3% &C#XCFN/&!TB*Q
ME-L+)+D3Y7Y@[$!L%L@#:1TSGMZ[TKM'$[K&TC*I(12,L?09(&?J:YU=.U.#
MQTNI>0D]M-IL=K+,'";'61F)V]<$-QC/OCK72T <IH/C(:AX8M=6OK.:![N<
MPV\*E6,S%V"HN&Z@+R3M'!/2M?3==MM1U"[T\Q36U]:;6EMYPH;:WW7!4D,I
MP>0>V#BN)LO"^OVWAG0HOL:"]T'4#.D7GJ1=QEG#;3T4E7&-V.<@XZUT^GZ5
M<3^,;KQ'<V[VH:QCLHH)&4N0'9V9MI(') ')Z&@#1U_5'T70+_4TMFN#:P/+
MY:L!D*,\DGI^OH#7+7NJW)U[P?>R17J-<17!EM4?(E/D@J=BL5ZDX)QCOBNI
M\16,VJ>&=5T^WV^==6<L,>XX&YD(&?Q-<_'I^KS:IX3NI=,:)-/BE2Y'G1L4
MW1!!WYY!/&>,=^* ->S\4V-YIINUBN(W%RUF;:10)1,#@IC.,]\YQCG-3Z3K
MUMJUS?6B1RP7=BZI<03!=R;AE3E2001T(-<?-X:UM[&]GBL(C=1:\^IV]O<2
M(4N(V7:4)!(4D$]>AQ76:"MTT4L]UH\&E;]H6W1D=N,Y+,O'?@<]/?  &^+=
M2N=(\*:G?VD;O/#;2,C+M^0A20QR1D _4^U9VF26^G36LP34VO\ 4+<#["TZ
MOOV %I<%BJGY@"=PSD<9K1\6V=UJ/A/5+"R@,UQ<VSPQJ&"\L",DDCBLN;3-
M3@UK1-<@LWD-O9M97=IYB!PK;2&4EMIPR\\]* *OBS7(M4\!:I=6,US;7%I.
MD,J;S')%()%#*VT\\'U((-:$DDD?Q1@C\^7R7T:5VB,C%-PFC&X+G ..]96K
M>&-2N=!\1O!:EK[6+N*5+?S%'EHFP#<<XR0A)P3U ]ZU+S2KV]\9QWC6LJ6+
MZ3+9O+O3*.[JW3=G@*>1WH MCQ;8;;.=HKA+&]E$-O>LJ^4[$X7ON ;'!( /
MXBF3^,+.WM-8N)+.] TEPET@1"P! ;<!NY7!!S_@:Q(?#VK77A#3_"U[:>6+
M2:%7O5D4QO%$X8%1G=N(4#! P2>?73U/PS+>^*OM*[#I=]:B+4HC_P M#&V8
M_P ]Q!]EQWH UWU:+S(X1;7#^9;&XS'M;:O'!PV<G/&,YYYX-8NG>*-)L="T
M+[-%J4MOJ \NU+J99"0"<,22<G!]:G\*Z/?Z+HDL5^WVFZC!MX=I&3!&2(AD
MG&2"3_P*L33= UBUT7P;:R:>WFZ5<%[K$L> -CKD?-S]X'\#0!T,/B[3GTO4
M+ZXCN;0:?-Y%Q#.@\Q7.W: %)!W;EQ@]ZL6WB&"?7'T=[2[@O$B$Q615*[#G
M#;E)&,@CZBN4U;3+M+#Q8MU8 C5;R'[$CSJID;;&BX()PP9=PSQP,]ZT]#DN
MH_$7GZKHU_!>W<(MTNY[B"4;4R^S$>-O5CG')[]!0!UDTT=O!)/,ZQQ1J7=V
M. J@9)-9%OXEM9[ZVM7MKJW^UPM/;RS( DB+@GH25."#A@*MZYIW]L:#J&F^
M9Y9N[>2$/_=+*1G]:P]+C\0ZCHW]D:QIT=BJVS6\UREPLGG90J"BCD==W.,8
MQ@YR "\GBNQ8V$CPW,5IJ$@CM;MU7RY6/W1P=PW8XR!G\JJ7'CK3[:+4)FL=
M1:'3[CR+N18!B+A3N.2,K\PZ9/MBLZ'0=6O?#.C>'K^S\DZ?/!YMVLBF-XX2
M"I3!W98*HY QD^V8KW0M7GT+QE9II[^;JMPSVN98\,IC1,GYN.5)H ZF]U>
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M>IJ,616*%"1DJV,CV..*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M&H^)O$<3^+?LITQ4T$+*OF0NQF3R?-*G#C!P<;OTH [RH;FZ@LX3-<2"-,@
MGN3T '4D^@KF)O$][?W)M-*B"3I80W;,\!F&Z7=L7 9<#Y#D^XK)UFZUR_E\
M$3744.FW4U]F6UDC,GERB&7DD.,KCH.O/7M0!V&E^(M'UJ66+3=0@N9(E#2)
M&V2@)(Y'8Y4\=>*TZXR35=0@UCQ-IMNMC;M:6$=W#/%;G)=_,+%ANP>5_7G-
M4++Q/>:+X+\+7.IW4:V]Y:QF;4&MG=8,Q*5$F&ZL2<OP..@SF@#T*D) !).
M.M5-)N);K2K:XGEMYI)$W&2V.8G]"O)X(YZFK$_F""3R2@EVG:7!(S[@4 16
M%_:ZI8Q7MC.D]M,NZ.5#D,*LUP%IXNUFYT#PC>00Z>LFLS>3,A1@J':[ K@]
M!LZ'.?:M[PSJ^H7UWK.GZF;=[G3;L0^=;QF-)%:-74[2S$'YL=30!T-4%T73
MUU1]2%N/M;D,SEV(W!=H;;G .W(SC.#5^N0F\2ZE<:/K.LZ:ML;?3)ID%O*C
M%IUB_P!8=P/RDX;'!Z#/7@ Z^BN03Q!J^JZ\ECI;V4-M<:5'J$,T\+NR[VP
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MO[3>T=S*3%]F5E CP,!MQ.3G//?C@5=H **** "BBB@ HHHH **** "BBB@
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MU9^(;.#5(I7%S<RFTU&WG+17 (<B.1,_*0O3@CY>.]=.^B:9(MFLEE$XLO\
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M]KX9TZXTI=0M)M5^W*+@O''M;_1E8 ^7N9F) Z@$\ CMBIG\*Z%+I,NER:9
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M,J&)R6'H<D\CU- '&:M87VDV-A:?\)!<SD^([=%\F1T,$4C F$DLV\#@C=G
M(JOK5N(+#XCZ4)[J2RM]/BN88YKF20H[12%L,Q)P2@."<5WH\,:(MA:V":="
MEK:R"6") 5".#D.,?Q9YSUJ7^PM,^T7D[6:-)>Q^5<LY+><F,;6R>1@D>V:
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M#(2-L8Z* . /I7+:_P"$8FM=%L='TN-;*UU-+V>)9 BA0K@[03]XE@>,=.M
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M;S&"N,R>60&?RQ@CW]@:Q;VSO+RW\=P6]IJ4[WUI UN\]NRF;$>#C@#.?X<
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MDGB"W\'1VMI<VMYIUU%-="2!H_LR)$RNA) 'S$A0!U'/09H [JYNH+.'S9Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117.>,]8U#1=+M)M/BB=Y[ZWMV:1RNU7D53C@YSG'MG/.,4 =%D9QD9ZXI:
MX"2>\L?B9J,UGI2W%Y)HD$CPI,$7=YLF<N1[ #CGCIVV[;Q8=1TS2;W3]/DD
M34;=KG?,YCB@50,AW ;!R<#CG!]* .DHKD(_'D<^EZ!?6VE7$JZQ,8$42(#&
MX#9!R>>4//2M70->?67U&WN+(V=YI]QY$T7F"0<J&5@P R"&':@#:I"0.I [
M<U'<O+':RO!&LDJJ2B.VT,>P)P<?D:\QN]5O-:\*>"];O[2-KJ76+>1/);+,
M&WG:,@;>PQGL,F@#U.BN7A\9Q11:S_:EDUE<:7+%')&)5</YH'E[6X')('.,
M'O5C2/%":CKMQI$D$:S1P"X2:VG\^%T)VD;L## XRI'0@T =!117*KXXM9+C
M3VBA2:SOIQ!%)#.'D4G.UGC ^5#CKGC(R!0!U5%<=)XZDCL[N^;19UL[*_-G
M=2&=,IAU3< /O<L./3N>U[6-5^UQZOIMI9+>?9+?_2M\FP LI(1>#N;'/.!R
M.>> #H@01D$$'N*6N?\  O\ R(6@_P#7C#_Z"*T-6U:+28(&=#)+<SI;P1 X
M+R-T&>PP"2?0'K0!H4FY2Q7<-PY(SS6+;:]++JUWH\MFD6IP0K<1Q^=F.:(G
M&Y7VYX/!!7KCK6)X!LH]3T+2M>OK2+^T?+D9;M9#ODWL=V_@9]@<X[8H [:D
M) (!(YZ>]9^OW]QI?A[4+^UBCEFMK=YE21BJG:I/) /I^/M7'75S=S:OX$U&
M>T66^D2;B-QF3-L3R2 !R<GTYZT >A45S-MXQ@?3)KB[MA:W4-^=/:!Y@5\X
M8/W^!MVG=G'3/!-6]#\0IK%Y?V;0+'/9,FYHI?-BD5AD%'P,]"",<&@#;HJ.
M=Y8[>1X8A+*JDK&6V[CZ9[5A6'BC^TM$T_4(+/\ >WEQ]G%LTN&C8%@P)QU4
M*Q(]C0!T-%<K=>.+6W998XHY[/[5]E=HYP9E(;87\K&2@8'G.<<XQ4U]XL-A
M<KY^GO':MJ"6 DD?9([,0-ZH1\R98#.?7B@#I**YQ/$UW/X@O-)M=$FE-G-"
MD\IG10J2#.\ ]<#G YZ]._1T %(S*B[F8*/4G%<YJ_BPZ0;F:;3W%G;7$5N\
MLC[&D+[?FC4CYP-XSR.A]*H:N;C4/B!:Z5<65O=6!TV:3R99?E;+QJ7(VGY@
M"0!Z$\C- &YJ^@IJ][IET]W-"VGS_:(EC"X9]I7YL@\88],5KUP_ASQ ^G^'
MKIKZWA@MK2^;3[:-;@M@JXC5-S@<<9+$^IP*LW'CM+2TUB233_-ETR%9S]FG
M$D4J'NKD#D=QC(]Z .OHK/TJ^O+])GNM->S0,/)+RJYE4@'=@?=],&J'C;5K
MS0O!VJ:G81QO<6\#,OF-@+_M=#DCKCOZT ;Q(! )&3TK)UC04UB\TVX>[FA.
MGW'VB)8PN&?:5^;(/&&/3%<QJTEU%X_\,W0T])+^2PO%,4<HPV/*QER!QR3T
MXSP#6K:^-K:?1[>ZF@%K=S7DEC]GFF4*DT9;>"_3: A.<>G&3B@#J:*Q/#WB
M)-=:^B,'DSV4WE2;)/,C<$9#(^!N!'L""""*U+V::WLIIK>W-Q+&A980VTN1
MV!]: *&BZ$FC^:[7][?W$O!GO) [A020HP  !D]N_P!*TE@C6=I]N9& 4L3G
M ]!Z5BV'B0:EI>C7MM;*QU-L"/S>8@%+-GC^':0??BJ9\;VOGV;QQ1S6=U<_
M9EDBG#2J22 [1@<(2.N<@$$B@#JJ*YN?Q8;6]MH[C3WBM[G4#81O(^V1FR0'
M"$<H2.H/0@XI;7Q-=WNN7>G6^B3,MG=)!<3-.@"*R!@^._4<#F@#HZR=2T2/
M5KH_:+VY-J519;(%/*<JVX$_+N!R.<$9 K6KDVUVTL+_ ,5W4>CN+G3HHI;E
MU==URHC9E/7 PH^OM0!UE%<Y8>*9+K5=-L[G3)+6/4K9I[64RJV[:%+*5'W>
M&!'KZ"NCH **YJY\526SZ]&VG9ETB)9V3SP/.B*EMR\>BD<]QBK*:JFK6UG&
MMM'+;W]DURY\S(1"!@8QSG=[=#Z4 ;8((R""/:@$$D @D=?:O/\ P3K\MAX9
M\*64^GN+6]B%O'=>:/\ 6;68 IUP0IYSU[=ZUK77]-LI?$5T=.>UEMKN.*?:
M07N965 F.<9.Y0.?KB@#JZ 00"#D'O7(^)+VYN_#OB/3[_2FA\K2Y9XYU8R0
MO\C<!BHPX(SCZ&G:!K\L;Z)I%SI[P)=V >VG,@;?Y:)N!4?=X8$<_E0!UE%%
M82^(C/JMU96ELD[6=Q'!<+YV)5#[3O"8Y0!^N1T/I0!NT5S$_C#[/H^NW[6!
M)T:=H9HQ+]\!5;*G'HPX-7+K7I1/=6VG6)O+BTMUGG3S-F-P)5%X.7(4\<#I
MSS0!M9&0,C)[4$$@@'!]:X6XNI7^(&EZA::9*;FYT25OL\N(G4^9$0),_=QT
M/6NH\/ZRFOZ+#J"0M 7+H\3D$HZ,589'7E3S0 S0="308;N*.ZFN!<W4ETQE
M"Y#N=S8V@<9K6JCJ^JV^BZ9+?71Q&A50,@;F9@JC)X&20,GBL6U\6RW=_?:=
M#I\4][;VPN8A;70DBG7."HDVC#@_PD=QSCF@#J*R=5T)-6O+>6:_O8[>($26
MD4@6*X!(.)!C)''J.,CH:H^'O%?_  D<,<]G8MY0AW3YDPT,N2/)(('SC'/(
MQD>HSDI\1G_LNSUB;0+J'2)K@V\UT9D/D-YAC!*CDKD#)[9[T =U17)ZOXYM
MM-%Y+%!'=0V,PAN%6X G)XW>7'CY]N>>1T.,XHNO&5PE]K-I9:)-<MID$5PS
M&=$61'5FR.N#A>!W[XH ZRFN&9&"MM8CA@,XKG!XO@N7TV*QACDGU"Q%]!%/
M,(2Z$#"KP<OST[>M%_XM2U+01P0&]CM4NI8+FZ$)4-G" D'+_*W& ..2,B@#
M2\/Z+'X>T>+3(;B6>*(L4:7;NY8L>@ ZDTW2M#72K[4KM;J:9K^832+(%PK!
M0ORX XPHZYJ?1M4AUO1[34H$DCCN8PX25=K+Z@CU!XJOKNM'0X[.9K;S8)[F
M.WDD\S:(=YVJQX/&3C\10!K45SR^*!]OUVSDM52728EE8>=GS592RD#''3'U
MJ/5O%,^D6UY<3:6PBL;9)[AGFV*=V<I&2N'8!3GIU'K0!TM%<_=^)U2]DLK*
MV2YNDLUO!"\WEO*C;L",8.X_*<],9'K704 (2!C) R<#WI:Y[Q'>V=MJGA^*
M[TTW1GOPEO,6 $$NQR&]2<!JS;WQW/:PZW.F@SR0Z--LNF,Z*=FU6+*.<G#9
MQ[=1TH [.LC3M!33]<U355NYI9-1,9EC<+M78NU=N!GIZDU#=>(7-S<VVE67
MVZXMK9;F53)Y8"MG8HX.7;:<# 'J1D4RU\3-=:S9::=.F@DO-/-]'YYV,F"H
M*.N,JV7'KTH Z"BN/_X3L'2--OUTB>0WNHMIPC25?DD#LF<G&02A_KBED\8:
MK'J$6F'PM<?VG)9R78M_MD6/DD"8W].00<GU QZ '7T5R&I>/+:PCN)UMTG@
MM9Q!<(EPOGAL@,4B .\*3@\@\' ('+?$^L?VEH7B2SLK%+R&RM7CN9'EV@.8
M]VU!@[F4%2<D=0,YS@ [ $$ @@@]"*6N;\-75W'H'ABWBL&EMI=-C,UT)% @
M(B7:"IY.[D<=,5TE $4UO%<;!*NX(P<+DXR.02.^#S4M<WKOBLZ&E_<2:>YL
M[ 1F6:1_+\S=U\H$8<@=>1Z4^\\2747B"?1K/2)+FY2T%TC&=41U+%>O..0?
M\,<T =#2 @D@$9'6N>L_%L&I6&CRV5NSW.JHSPP2/MV*H^<LV#@ X' .21^%
M#P(&%WXH#VZV[#5VS$K;@#Y4?0\9!Z]!UH [&BJNIWT>F:5>7\H)CM87F8#N
M%4D_RK(T6S&I^%;:?4B[S7\*7-UL)!;<-VSCG:,X '8>YR =#17$>"H]+>\\
M1V%F94LUN5 TVXC=3 I0 MM?D!V#$#T Z=*U_"NI2W0U/3KAVDFTN\>VWL<L
M\> T9)[G:P!/<C/>@#H*0D#&2!G@53UB[GL-&O;RVB26:"%I%CD<JK$#/) /
M\J\_N;Z\OH/AYJ]W:)+?S2JP\IP3)NM6;N %R><=!ZT >FT5RUOXTA_L^^EO
M[3['=6=\+%X&F5E:1MI4A^!M(8')Q@ ^E6]#\2IJ^J7VG/ D<]H$?S()O.AE
M1NA5\#D$8((&/>@#>I"0 23@#J322,RQLRH78#(4$ GVYKB_^$M?5_"=YJ5Q
MX;G?2&L9I)-UPGS[259-N<\@$Y]C[9 .VI"0.I [<UA1ZY%&^E:;8VBFXNK,
MW$<32;$BB4*.6P>[ # ]:YC6M;3Q!H^@:HNG31-%KT$:HS*7++(58#!]5QSC
ML: /1:*X_4/%]]#HWB1DTU(-2T>(2&.2;<A5D+*P('/ /R^HQGO72:7+<3Z9
M;2W2*LS1J6"ON!XZYP/Y4 7**YSQIK%_HFCP3Z?%$\DMY!;LTCE=JO(J\<')
MYQ[9SSC%3/KUS)?7.GV-A'<WUG DMTAN-BH7SM16VG<Q"D\@#&,D9H W:*SM
M"UJU\0Z+;:I9[Q#.#\L@PR,"0RL/4$$?A6C0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%XMT>[U
MO1HX+%H5N8;J"ZC$[%48QR!]I(!(SCK@UNT4 <Q#I&KIXQN=;D2Q,<NFQV@1
M9G!WJ[/G[G3Y\?AG':L?2O"7B#2[+PW;,^FW,.FP20SV\DK^67)!69?D^9E
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M:ZM9:9*[BZO YA7RVVMM&6^;&.!VSF@!FD+JQ@:76#:K</C$-J6:.,#_ &F
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MTEF5T#QSXP2ORXP1Q@@BE?P3ITEEJUH;J_\ *U5@UR#,&). #C(.,A1G],4
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M8H X^7Q7JK?#]/&\%R2@D\UM/,:>68/-V;,XW!PO.<XSGC'%=KK9SX>U$_\
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MX]>M=)K&D6FN:>UG>*Q3<KHZ-M>-U.593V(-5CX=@D6Z:>[N9[FYM_LKW+[
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MAB(3;%& 1A!MXZYYST'H*I7?@BRN[+3(FU#4DNM,!%K?1S 7"*1@J6VX8$
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MC: /3DD>G//SZMJ>L6^AI<7DL%S;^(7TZX:W50DQC#X?!!_NCCIG/'3'7_\
M"+VJ3V5U;W=W!>6EO]E6XC*;I(NR."I4@$9'&<T7'A33Y].M+-7N(?LMU]LC
MFB?$GG98EB2#DG<V>.] '+W(U&'7_&]Q8:BUK+:VUM,'$2.7986(!W#&#CG
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MGWJ<=3SSTX%=!8>'+>RELY);JZO&LHS':_:2G[D$8.-JC)QQDY.,\\G-+2_
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MC^UI&"C2XSA1G<1[@8I^J?$#2-'NYK:\AO5EALQ>,!",["0 ,9SNYZ8XP2<
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M^"V$OD037IAA$\@MRGRH<D'YF&20"0!D\>XRV'Q)97D5H^GK+>O=P?:(XXL
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MM]0,D^E;E% '.:1I3^$-!T_3K&T>_9[@"YD0K'@N27E(/8'^$<XP.U='110
M4444 %%0->VB-$K74(:9S'&#(,NPSE1ZD8/'M4] "$X!.,^PKS&VTS7S\6[_
M ,4W_AV]DLH[7[-8+'-;EAT!)!D&,_/_ -]5Z?44UU;V\D4<T\4;RMMC5W +
MGT /4T <5JG_  E&H>#?$4-IH!LKBX#0V5F9XC(WF$^9*S!MH)WL<9_A]ZQ(
MO NIV.L^![.WL%DTO2(FGNI3*H'VHCEB,Y." 1@'TXZCU6B@#RR#1/$\5Y\0
M-4&EO_:&HAH;!S,GS1JI5-O/7!!YQ]T>^(#X)UFX\)^"?#W]G&&SM;I;G4CY
MR9CVC<0>>2S,^-N<<9KT\ZGIZVTMR;ZV%O"VR64RKM1N."<X!Y'!]15N@#SS
MX@:)JUYX@\+WMC83WFF:?.\EQ;VCHDBMA0C ,0#C''I[9KK?#VG0Z;IS+%IH
ML/-D:5HVD\R1B>K2/D[G/<Y/U-:U% '/RV<^O:C,FI6=U;6%JRFV59PAG?KY
MF8WR,= #CN3SC')>'--O?"_BGQ5KFIV4EIIUPH^S375TC[L' #'>S9.1C.:]
M-JIJ6F6>KV$EE?PB:WDQN4DCD'(((Y!! .10!Y!X=CTU[S1_#OB/1=7TS%V]
MS:6L@'V1Y3D@9QN..@!)ZG-=OH.@7_\ PGWB+7]4MO+28QP6(+JV8U7!; )Q
MGWP>36W+IFEVEQ:WU_<,\ENVRVDO)\A&;Y>,G!8],\GGWK79@BEF("@9))X%
M 'F&F^&M2'BCQ(-9T2>^BU"\$T,QN%6W>-2=@D&[<0HQ\N&^G&:DG\.ZF?B'
MK-S?:/=7^FWUM'!;-;7"1QJ@ RC_ #!@N1R!G/H<UZ/;W$%W L]M-'-$V=LD
M;!E/.."*EH \]U#PUJ=UXXM-0_LN,:=HNF'[##'(@22YQPJC(('09( ^45SL
M/@#78?#?AZQ;3Q---J9O]8W3H,$'Y5)SR,$YQGG->R44 >:7F@:H_P 1]7O;
M_2;O4-.O;6.W@>VN%C55 &Y'RP8*2"3CKZ'-7[WPM>:EX]T.2;3XHM#T>S+1
MK&Z^69SQM"]< !>H ^6N\J(W5N+H6IGB^T%"XAWC>5'!..N.1S[T >3Q>&O%
M4/PX\20MIF-:U>[,DB"9"S*S#=R#C&W/?/)KT/14N--MM-TE=,DCM8;,+YWF
M*1&5PJH0#DL1R<9&<\GK6K!<V]T'-O/%*(W,;F-PVUAU4XZ$>E2T %<EXUL=
M1OKGP^UAITUTMEJ<5W,4>-<(H8'&YAD\UU%Q<V]G"9KF>*"($ O*X502<#D^
MI(%2T 8PO;Z34(S'H=S"A4^=/,\62J@E44*Y))8]\ #/-<__ &;K5EX@M?$]
MKILCW-^QAU.Q#Q QPC[C!MV"RX&>3NR>@ QW--DD2&)Y975(T!9F8X"@=23V
M% '&6::_X>U_5X8-&?4+'4KG[9!.DZ((795#+)DY &T<@'CL>E17NGZKI?BN
MZU Z#'KEIJ,,0<QF-7@F1=IP'/W6&#UX_GV\4L<\*30R))%(H9'1@58'D$$=
M13Z .$NGFL?'OAW?9#?_ &==;X;0#$0+1GCID#@<=>N*@U'PSJ<VC:U>0V9-
MW?:K!>I9AU#".)DXSG;N(4MU[XKL)M$M9];M]7=IOM=O&T<9#X4*V-PQT.<"
MM*@"*&266V61X3#(RY\MR"5]B1QGUP3]37FD>F>)KI_#M[?Z'/)JEEJ1DO9G
MN8L,I5U!B&[B,97C /LQR:]+GNK>U"&XGBA$CB-/,<+N8G  SU)/:I: //\
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M7/:L+Q;X9G2VT_4/#]K=7&JZ?=I- C79(*='4F1\ %?3G@5V]% '#Z[->_\
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M6I5KBVF436<RA I4JW0_-TST&17=W%S;VD8DN9XH4+! TCA06)P!D]R>*EH
MR?#,&IVWAVTAUB8S7R*0[L06(W';N(X+;=N<=\]:UJ** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?;M"HT_>1N.#YA+8Y! PH]^3VGT6#Q9&J+K-QIL@MT(0VQ<-<-C +DC"CN0
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MS-9"\G2[RGD(QP%88R6)R,>@)] :7PXW#0;_ 'Q+"_\ :MWNC0Y"'S#P#@9
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MUS5H]"T2[U2:":>*UB:61(=N[:!DGD@5:M+A;NS@N54JLT:R 'J 1F@#EX/
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M:RQSQW$4JJ&VNC!AE3PPR.E:U% ',P>%;F+4=6OFUAY)=2MDAE#6ZA0RAE#
M#MAC@9^I-,_X1"4:/H&G+J2A=&FCFC<V_,GEJ54$;O0G./TK0USQ);:)IT=\
MT,MS"URML6@*D(Y?R^<D<!N#C-;- !5>^M$O]/N;.4D1W$31,5Z@,"#C\ZL4
M4 <A'X,NDL?#]L^L^;_8LJ21,UJ!O"H8U4@,.-I/J2?RI]UX'AU&7Q%]NO#)
M#K8B+I''L:%HP C*V3R, \CJ/PKK*HZQJ::-H]WJ4D$TT5K$TSI#MW;5&3C)
M Z#UH S]!T35-.8/JVOS:L\:;(=T"Q!1W)"_>;@#)/KZFMZJ^GWBZAIMK>HI
M5+B%)55NH# '!_.F6=Y+=7%Y')93VZV\OEH\N,3# .Y<'ISCGTH H>(M!DUW
M^S=EV+?[#>QWHS%OWLF< \C Y.:S9_!][%X@N]2T?Q!<:;%?E6O;9($D5W Q
MO0M]QB!UP:ZRB@#S+Q*UJ?%9M)M=CT=+.TCA@74;%;B*;.26C+]_NJ<')Q[<
MZ]MHFK:V-+U*;6!'=Z9/+]FN4LMB7,+HJDF)C\IZ@'/09Q@UV<4L<Z%XG5U#
M,I*G/*D@C\""/PI] '%2^ 'D\.ZQHW]M2M%J=XUTTCP*6C)<.0,8R20.>F.@
M%:]QH4TOB:QUZ2^0-9VTD!B6 X<.06.=V1]T8Z_C6]10!Q>DKI/BGQ?%XITW
MS9(+:U,'G-&\:RR$G'RL 244N,_]-,=C7:4PRQB80[U\TJ7"9YP" 3^HHBFC
MF4M$ZNH9D)4YP02"/P((H )8Q+$\;9VNI4X]ZYNP\(M;Z;I^E75^+G3=/D1X
M8O(V.^PY02-N(8 X/ 7) S[]/10!SDGAB9[WQ!<C4%']L0I"R^1GR@JE 1\W
M)PQ_'\J8OA298_#J#45QH@ C_P!'_P!;B/R^?FX^4]N_Y5TU4M3U.#2[>.2;
M<S2S)!%&N,O(YPJC/'_U@: .7G\!2G2]5T>TUIX-(OW:3[.;<.T+,<L%?/W2
M>V/QK7_X1Z?_ (2"RU;^T SVMHUJ$>#[X8@EB01SE1T%7]+U&74$N/.L+FRE
M@E,3).HP^ #N1APRG/7ZU5UCQ);:1%82F&6YBO+V.R62$J51W?9ELD'&<] >
ME &2?!,K>%YM#.J#RY;O[49?L_S ^;YN,;NF[]/SK%UN>*X\67@NM?@TN:%(
MX8XK_3TE24 ;B\6[H"6Q@$G*\]J]'=BJ,P4L0,A1U/M5?3KJ2^T^"ZEM)K22
M5 S038WQGT."1F@"MH,M_-I2-J+K+-N8"583#YB9^5BA)*DCM_\ JK3HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KEO'=W=6&DV-S:7,L$O]I6L1,;$!D>558$=""#74UGZUHU
MGK^ERZ??!_)<JVZ-RKHRD,K*1T((!H YN[N[Y?'&M6$-_<10#1$ND4,&\N4R
M."RA@0.%''2L33+[5H=+\":Q)K-[/+J<T5M=0R,#$ZO$[9VX^\"H.<YZ]N*Z
MZ+P;IL5]+?">^:\FM/LDD[W+,S)DG)SP3\Q[<<8Q0O@W3DL-)LEFNQ!I,BRV
M:^8/D900N3CG )'.>M '(ZK=S>)OA_XPU.6[N(C UW;PPQ2%4CCB!&UEZ,6P
M2=V<;N,8%:5M>7NJ:E'H4#F..VTBVG4)>/;NS/N!<%5)(7:HQTRW(/&-:[\"
M:1=3:FP>]MXM3#?;+>"X9(I6(P7*_P!X]\=>X-.U#P+H]_\ 8'#WUK<V$7DP
M75M=NDPC_N%\Y(^OX4 <],/$D>H>#]*U'7V%S<F[@O9+$KMDV1L5;E0=V,9[
M C.*37+V]\.3R0:K=:N^E+;QQ6^L02[S;2 ?,;A%QG)(.X@\8Z'FNL?PKI[7
M6EW"-<1/I>XVP23H6&'+9R6+ G).>I/4TZ]\-6E_)>F:XNA!?J%NK=9!Y<H"
MA<8(R,@8.T@F@#G+.%!\3_$%U]MF5$TVVF5GG8QJ"9>HSC:,9QTZGO572]3U
M!/$'A2-;^]N(-3@N!<7,S82Z*QAUDCC).P9Z<+D'IBNMN/"VEW.K/J+QRB22
MV%K+&DK+')&,X#*#@XW''UJC:^ ]'M&TQTEU!FTPM]E9[QSY:E=NP<_=QQCV
MYR* .,NK_6H?!NOZU_;U^UUI6L31P+N4(R),J[7 'S @D8X'H/7K8+R77_&>
MO:5)=7%O;Z5%;I&EO*8V9Y5+F0D<G P #QP<@U9?P1I<FC7^DO+=M9W]PUS<
M+YHR[LVYCG&1D@' ]/K4USX3L+G5X]6$]Y!?"(0RS6\YC,Z#H'QP?J,'WH X
M/0[J]L/AOX):UOIHO,UF.WF"8 E1KAP0W&>W8BMJ9=2U#Q/XQLCKFH0V]I;6
MTMNL+JAC9DD/! Z9 ^O&2:VXO ND0:18:7"]XEM8W(NX1YY)$H8L&R<]"2<=
M.>E6QX:M%U#4[Y;BZ$^I1K%<D.,%5!"X&., D<>M ',6NOZC=Z9X(N+Z=X[#
M4+=FO[B,E"9?*!0%EP54G<3C'( Z=6VC>*1X;U*XBEO+UAJ96T@ED6*2:R1_
MX&P&W,N[DG) !&,YHUOP^NG2Z+8Q6>NOI5A;R)!=:7<$3Q.Q4;&"D$IM7K@\
M^G?4T;P_-/;RK<7NN"U\R*:U^W7 :XCD7=E@1DA2"HVMGH<C!Y +?@W5K75K
M.^>VGOBT=SMDM;\,)K0[%_=MN))&02#D_>ZUD^++Z[B'B*6TU"Y>:QL1+%';
M-Y:V;!6;=(<X<M@?+@\#H,YKK-/TJWTZ2ZFC+R7%U()+B>0C=(P4*,X  P !
M@ "LZ^\'Z5J%[J%U-]I4ZA"(KJ..X9$E 7:"5!Z@<4 8TMQJ.H>*]#MO[4NH
M+>]TF2>:.$JOS#R^5.,@_,>><=L5GV7B#48]*LM+DO97EGUZ;2_MCD&00HS'
MK_?( 7/OGK76V_A:QM;VRNXIKL365N;>$M+NPAQD'(.<X'7TXQ4#^"M(ETRX
MT^7[0\4UT;S<9</'.3DR(PP5.?PH SM+M!9_%+4XUFFD1M*@9?.D+E1YC\ G
M)(R">2>M:>OS-_:NEVJW<^)!*S65L2LMQ@#!W@C8JYR>1G('M4]AX9LK#5CJ
MHGO)[UH! TL]PS;E!)&1T[^E2:GX>LM5O[.^F:XBN;0,L<EO,T9*MC<I(Z@X
M% ''VFN:PW@33[F2>5R-6^RWLXYD6W$[(3D=\!02.<$GKS5EGU4'Q;<6^J7R
MZ9;6V[3Y,JXW^66?:S*2P! YSCDCMP_6_#,&EZ7:V>GV&ISV#7QN;@V=TWGP
M'YB#&"PXW-SCG&>">1-I.ARW7VF(W?B :;<6[PS1ZG.&9BV,; <LO&X$G'48
M]0 4([K4M.\/Z!>MJUU<3ZV;.WD$\H5(BT98E2%)4M@+GD\YZ\U-J=SKOA>R
MU.YFO8/LD\ENEHDERTSVQ>14D8NZ9*_-D9W8/Y5T<_A?3+OPVF@W4<D]C&BI
M&'?YT"_=PPYR,#!J.W\):9%I5UIUQ]IOXKI!',][.TKNHZ#<3P!U&,8//6@#
M)N[/7]/.J7"ZD(+%M/D9(OM33RI.HSO0NG"D<$?EBLN*;54L_!-Z-;OC+JB1
M0W*LRLI#0%]P4C&X$9W'/)YSTKIK'P=I]A8W%HESJ$RS0F#?<732M'$>J)N^
MZ/IZ#T%2_P#"*V/V?28!-="/2BIM!Y@^3"[1GCG"\<T <M/KE_X?3Q9;"^FN
M([&XLUMYKI]S1"?:&);'1<DC(./>M6:RUZQN+Z<:BL%A)8OMB-VT\JSKR'0N
MG QU'3N,5K-X6TV6?59+A9+@:JJI=QRME7"C"X '&!Z?SJ'3O!^GZ99S6T5S
M?RB6(P![BZ:5HHSU1-W"CIT'8>@H YG3KS4X+7P/J<FK7D[ZEY<-S%(P,;JT
M+-G&/O J#GK_ "IVC6M_%9^,Y-*GF?4%U26.%9K@X8[(N,MP&QP">G':NF7P
MG8+:Z5;K-="+2F#V@\P?(0-HSQS@$CFG-X4TUIM0E5KJ,W\BRRK'<,JB0;?G
M49X;Y5Y]J *7A/5X-2N[^)3J-M<PK&)M.ORS/ ?F^96).Y6]<]O>L_7K-[_X
MG:7;I>7%INTFYW2VY ?'F1\ D''UZUU5EI,%G>37ADEGNYD6-YY2-Q1<[5X
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M)<W>HV4\JB0^5\\@.P)T 7( (YXY)R:[AM MI-7M]4EFN)+F"$P*68;2C8W
MC&#G K+7P!HR6RVBR7ZV4=PMQ#:K=,(XG#;OE Y SSUX[8H T?%B>9X0U@"2
M1"+*5@T;E2"$)ZCZ5QTMHRZ9\/HHKF9&DFC;S"V]DS;-]W=D#V["O0[BUANK
M.6TF7?#+&8W4D_,I&",]>E8L7@_3X8M,C2>](TU]]L6G+%3MVCKG("\8Z8H
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MU=224WOE:C()KB)+EE0R\?O HX#':/RH SDL1-\7=1!N;M0='A?"SL "97&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3%XC6!6CE88C^TL !STP./3'%7M2FE\+WWC0:*K1B/2X+I(P2P20EU:0 ]\
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M7''4]S7!K,TOPE@5YO,,6K)&IW9P@O<*!D],# ]A76/_ ,E:B_[ 3_\ H]:
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MR=&T_2X/#FNZS?37D<EC>:A''<Q3.9(4+,OR#."<=,YYQ0!Z8V=IV@%L< G
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M/7 J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NM
M:W:Z':1RW DDEGE6"WMX@#)/(W1%![]3DX  )) %:5<'XHL1>?$[PI]M:9;'
M[/=K"T<K1_Z057C<I!!*!L<]C[T =I9O=R0!KR"*"0_P1RF0 >Y*CFK%<CX'
M-]%<>(;">YGNK"RU)HK&:>0R/LV*S)N/+!6)7))/!&>*ZZ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *ANK.VOH?)N[:&XBR&V2H'7(Z'!HHH
M=!!#;0K#;Q)%$@PJ1J%4?0"I*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex109keyexecutivebenefit007.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKQT8:K)=JMM8>>I"RE@!*K'*%EW?=R,D9/6O5X)X[FWBN(7#Q2H'1AW4C(-
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M'CJ<' XK-\?6EU=:#:O:6LMR]MJ%K<O%"NYRB2J6P.YQVK$OEGT_QA>ZA?\
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M-A2.22 J692^1M^]GYAQC-9=C8WT/ASP+;R:?>"6PND>Z7R&S$!&ZDGCU84
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M:P/;H?Q .MHK,&K%[S3H((DF%Y"TYD27A$ 7YNG()8 =.M:= !1110 4444
M%%%% !2$ @@]#2T4 <W8^#+;3HUMK?5=6&GJ,+8FYS&J_P!T'&_'MNKHT18T
M5$4*JC 4#  I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"CJVF#5K$VK7EY:?.K>;9S&*08.<9':I[.TAL+2.UMU*Q1C !))/
MJ23R23R2>2:GHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?4_#L&H
MZC'J"7M]97B1>3YUI*%W)G.UE8%3R2>F:NV.GQV"-MDFFE?'F33ON=\=,GL.
MO P.3QS5NB@ HHHH **** *6K:5;:UITEC=^9Y3E6S&Y1E92&5@1R"" ?PJM
M8Z"MI*DD^I:A?F,YC%W*"$/KA5 )]SFM:B@#.UC2$UB"&)[V^M1'()-UG<&)
MGX(VL1U4YZ5=@@BM;>.W@01Q1*$1%Z*H& *DHH **** "J>JZ>FK:5=:?+++
M%%<Q-%(T6-VUA@@9!'0^E7** *FF6":5I=M81RRRQVT2Q(TN-VU1@9P .@]*
MMT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XPT;4=5L;*XT>6)-
M2TZ[6[MUFSLD(#*48CH"K$9KHJ* .+UJR\3>)/!FK6=U86MI=7<'D0VJ7/F!
M3W=WVC\  <>ISQ9NM+U.X\6>'-3%H%M["WGBGS*NX-($ P.X&SGZUU=% 'E7
MB+3-2TKPCK[W-O&K7OB""\MQYH(*M-$ &QT/R\]>O>NQ_LN[U#Q7:Z[=6IMT
MT^TEB@@+JSR22%=Q)!P  H YYR<XQSK:II%CK5LMOJ$!FA5PX3>RC<#D'@C.
M",BKJJ$15&< 8&22?S/6@#SFQ\':U:^&- "QP+JVB7\MRL9ES'.DCN63=C@[
M7QDCJ/3FNDL]+FD\63^)KZ-;0BP6QBA9P2%WEV9B.!D[0 ">![X'1U6U#3[3
M5;":QOX$GM9EVR1..&% '*^$]#%CX@UJ:*<2:;!<NEC$!Q"T@5YP/4;\ >F&
M'K5"7PSK4OA+Q=IGV2,7&KWL\]OF8;0D@4#<>Q&WG&>M=W965KIME%9V5O';
MVT*[8XHUVJH]A4] '(WFCZC>>)O#E\;0+;65K/#<YE&X&157Y1W V\].M5_"
M^G^+=$MK?P_/#8R:=9D)%J8F.]H >%\K;]_'RYS@=><<]M10!Y]-X:UF7PUX
MRT\6D8FUF[FFMB9A@*Z(HW>A&S/&>M:::/J\/C#2]8BMX#"-+^P7*O-AHCO5
M]PP#NZ$8X_"NNHH J:IIT&K:5=Z=<C,-S$T3^P(QGZUQO_"%:G-9:)/<W:'5
M8F,6HS#I+;O&$=![X5,>^3WKO:* .=U[3+V\U[P_=6L"O!87#RS$N%.&C9 %
M'<\Y[5FR:#K$2^+K:*WMY(-6WO;R^=AMSPB/:5QP 1G.>G:NTHH XU=$U07/
M@Z0VJ8TB-ENOWHZF'R_E]>>>W%:OC+2;K6_"UW867EFY=HI(Q(VU24D5\9[9
MVXK=HH Y?[!JLOC2QUF:SC6&/3Y+>14F#$.SJPQD#( 7&>.:Q8_"VOV^E13V
MBV\6JV6K3W\$<DF8YHY2VY"1T.UB,^M>A44 9NCRZO<1O/JUM!9NV EM%+YN
MS&<DO@9)ST XQ[UD:IH5_;>*XO$VC+%+.UO]EO+25]@FCSE65L'# ^O!'I74
MT4 9B?;M21H[JU^QVS(RNC2*\CY!&.,@#G.<Y^E<M%X7U67P4O@Z\CC-NC+%
M]O608:W5PP^7J'P-N.G?/:N\HH Y6WTK48/$7B6^^RJ8+^"&.WQ*,DQHRG<.
MP.[CK6;'X=UB/PQX3T_[+&9])NX9KC$PP5C5@=I[D[N^.E=Y10!P.CF_DOO&
MEK9V:RF>_9$D:0*J,84'SCKCH>,D\]*E7POJMA<6-C;QV]]I=OIBVL7VB4H(
M9AG,NS!W$C&.XQCC.:ZNQT>QTV>YFM(6CDN7\R8F1FWMZG)//O5Z@#@M+\.Z
MW:P^#4N+6#_B3"1;CRYP<@Q&,8R!D\Y/MW-;&B:9<V>J>(9M0AC2VU&Z62+=
M(&RNQ4VL/4X]^M=+5+5-(T_6K/['J5I'=6^X/Y<@R,CH: ,#P+I#:=8W#M<F
MXA65[:Q8_P -JCML'OR6Y[@+70:7+J$U@CZG;0V]V6;='#)O4#)QS@=1@U9B
MBC@B2*)%CC10J(HP% Z #L*?0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!61XEUW_ (1S1)=3-G)=)&5#*C*N-S!023VR1T!K7KE/B3_R(&I_]LO_ $:E
M &SK.L1:1#;YC,MQ=3K;6\(.-\C>I[  $D]@#UZ4FF:PM]>WUA-$(+ZR91-$
M'WJ5<95E; R#R.@Y!K$\7PNOB'PE?,#]F@U%HY3V4R1LJ$_\"P/J13+!E3XC
M>)-2ED2*RMK.V@EE=@J!P&<Y)XX5AG_>% '8T4BLKJ&5@RL,@@Y!%+0 4444
M %<CXS\7W?AF^T>TL[*&\GU.?R(XWD*$'(&> >/F%==7C7BRSG\:?$^_T^TF
M=!HVE2%&C;'[XKQS]74'_=- 'I-CJ>J7^J.D%O:-ID0 :\WMEY/XE1<<@?WL
MXSQS@UMY&<9Y]*\MT+QO+:_ ]M7@Q)>Z=$+/!&=KA@B$_P# 64U;\-^&5U'4
M-%U/4;V":6&R>4K'*9);IY5 =Y6P,*,X51D#U[4 >D9'K17D7P^L(=;T6TT^
M5I6DT?6I+D.'/[M5((!]=S$C![!CVKUV@#D/%?BZ[T#7]$TFSLH+N;5)#&H>
M0J8\$#<< Y'S?H:U[6\UHZV+6[LK3[&86?[3!,S%7!7Y"I48R&R.>QK@DB3Q
M9\;+^5IY$M=#M!"DD3[2)#P>>W+./^ UT^F7?ARWT6XTJZU>"[A$TD<T]U.#
MYSL2Y7<3\S*I7..G'X '6Y'J*"0.IQFO(/ EOIKV5YIFNM--<^';QI+&WDD:
M-@O+JP0$;F.#US@ =.<F@V=QX^TJTU/5KZWC^UZCYQ(DW3*L;$)!$N/D'&XM
MG)ZD=Z /7R0.IQ2Y'YUY?H;6?CJU\1W&M7[0R27C6,$:R!7MHAC 0'.&<Y!.
M,GI67?:W;6'Q"\2ZRF)&T/35M;:,M\TDI7ES].5)^@ZD"@#U^YN8+.VDN+F9
M(8(U+/)(V%4#N361=ZQJ$@T6?1].%Y97TBF>5Y/+,,+ $/M/)X.<>V.]>2WE
ME$_PS\*:)+*LEWK-^)IIG;.Q2=SMGU"E ?H:Z;3+33;SXQ2PVL,,5EHNGK;Q
M1H,!I) 2>/\ =9Q^% 'J&1ZTA('4XKR'PII)U6/5]!99_*T_Q(URLV3B-8R.
M >Y.,8[9)[#,6EQ7'Q(TN[O-2O;>""\U 1+NDS)!$A!6*),?*S'JV<GT- 'L
ME<MX\\63>#](M[Z"UCNY)KA8%@9RI8D$C! /I74 !5 '0#%>7^-5;Q+\4O#W
MAV&8QI91M>S.H!V-U7(/'&U>O]Z@#HK'QE<_\)Q_PBNIZ?%%=/;_ &B.:WF+
MJ>,E6!4$'@^OZUUV0" 3R>E>2^ ]3CM/#_BCQ!J,'VGQ-IS3)=S2$EW"KE5_
MV5RI& !]VG^'-,D\06V@:[K.I6_F+*VI22"3=-,ZYPG3]W&@Z@9Y],T >KY
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MTU=1AOH)+-CM$JOD%LXV_7/&.N>*DT_5+'587EL;F.=$<QOM/*,.JL.H/L:
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MCL#7L5% 'F_BR4V^IZGJ6BZK$MZ+9!<:7=*'AU*/:2HC[[B&*_+G/&1SSZ)
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M]MBC$J6YM'#S(21N0=QD8R<8[U/:^*M-OM,L;VT\Z;[=(T4$ 3;(SKNWJ0Q
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MP^5!ZG;VZT >DQ2>;$DFQTW#.UQ@CZUCW?BG3K-+B:03M:6TODW%TD>Z.%^
M0>_&1D@$#N1@UKP2-+ DC1/$6&=CXW+[''>N"M-/U&P\*Z]X8FL+B>XG>Y6T
MF5"8YUFR0S/T4@L<AL=.,T =%J/C#3--OWL72\GN5MOM0CM[9Y"\>0,K@?-U
M[<<&MU75HQ)R%(S\PQ@>^>E<9I>EW.F>-=.0PSRVUKH26!NO+.PR*ZG&?<#.
M>E=5JEHVH:1>V22>6UQ \0?^Z64C/ZT 9Z^*M-9K-F\Y+6]D$5K=NF(I7/0
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M5;WQ-I"VMY;+I\(59U.P[C&S[MP.0#\N/_KUO:!_:7_"/V']KJBZAY*^>$
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M67&25!)')XYXK2K&\*O.?"^G1W%G/:2PV\<31S@!LJ@!. 3QG/Y5LT %%%%
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M7<J,HY /(![^@H W]>T&#Q!:16MS/<11QS)./)*@ED(9<Y!Z$ UJ*"J@%BQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5K^.TGLI;:],?V>=&B=78 ,"#D?EFK-4]1TG3]7CCCU&SANDB<2(LJ
MA@&'>@#F]!\/-=>"+BRO;IYFOX&A6<CYA"%V1?\ CN&^K&GKHFJ:CI>D:7J<
M4*+I\\4DL\<FX3>5]W:,9&2!G.,<XS76@ # & ** //=1\,^(#:^+],L[>SD
MMM:9YX;F2<JR,\2H4*;?5>N<8.?:NWTV*>#2K6&Y6-9XXE1Q&Y9<@8X) S^5
M6Z* .'MM UF/2?&%J]K )-8GGEMB)\A1)&L8#\<8QGC-27WA?4KWP?X?MXS!
M#J^BR6\\2LY,4CQ+M*E@,[6!/...*[2B@#E9=&OM0UYM=N+5(98-/>TMK;S0
MQ+.069F P!P .O4GVK)B\+ZU%X3\):9]GMS/H]Y!/<'S_E98PP.TXY)W=\=*
M] HH YO3-*U"W\<ZUJLT,:V=[!!%$1)E@8]V<C'0[O7M6=XHDGB^(G@][> 3
MN$OLQ[PI(V)G!/&?KCZUVM8U]!HDGB33OMF#JVR1[/+N&"@#?MP<#@C/K[T
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MT0V]M]KAU(7;'S_D*"X,V,XSG!QTKOK&^MM2L8+VSE$MM.@>.0 X93T/-6*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7/^,=4U31- EU33([>46I$ES'+&SDPY^=EPPY49//7%
M=!69KFM:1HMHC:Q=1007#>2OF D.2#\N #U - &=?^)OL;W-ZDD,NE66FF]N
M'5"6<G)C"-NQR%8\@_P^M4;GQ+JVE6^A:E?K:26.IS1031PQLKVS2CY"&+$.
M >#P/4>E2^&/"=K:^!Y-(NHYC#?(_FQS-\Z1N-J(3V*QA%^JT^U\)W1L=)T[
M4]1CN[+2Y8Y8=L!224QC]WO.XCY>"<#D@=.00"C+XMU:/PWXMO\ ;9&YT2ZE
MBB_=-LD1(T?YAOSD[B,@_A4E[K_B*;Q):Z1IBZ8ANM*:]22X1SL<,@P0#R/F
M_7/.,%-0\$7]S'XCL[;6(H-/UMFE>-K7=)'(R!#AMV-IV@XQGT(ZUH6WAF]@
M\2V&KOJ4,@M=/-BT0MB#("RL6SOX.5'8T =%%YGDIYVWS=HW[.F>^,]JY&]\
M63Q^*;K1%N;.RNHWB^RPWD3#[9&P4LR/N SDLH'/*]\\=C7+:]X4N/$,=Y9W
MMY;R6,\R2Q;K<F:UVA<B-]V,DJ2#@8W'K0!5U'Q/JTYU;^PK99I-.G,"0O:R
M2?:'559AO! 3[V!UZ9/!Q3)=?\3WGB632-/@TZU?^S8;Y?MB.QC+.5*-M/)^
M4\CI[U8D\)ZK:>(+V_T/7_L-KJ+B2[MI+838D  +QDD;6( Z@C/KTJ]:^')[
M7Q>VMB^1H38)8BW:(E]J,6#%]W)RQSQ0!0MO$NHPW_B.PU+[*+K3D26T$,+#
MSXW!V'!<Y.X;,#'/UJQ)K&JVGBW0M(NA9.E[:3R321QL"'C"YVY8X7YO<\5:
MU+PS;ZCXFTS6VE9)+-'C>->DZDAD#?[K@,/>B_T&>\\6:7K2WD:1V$4L7D&$
MDN)-N3NW#'W1CB@#/T_7-=UK3K#6M*@LY;&YNMIMG!61;?<5,F_=C=QNV[>^
M.O-5;SQ7K-Q;WUWH5D+K[)=O;K:&UD)N C['Q*"%4Y#8X/09Z\3Z+X.U'0Y&
ML;773_PC_G-+'9FW'FH"VXQB3/W,D]LX.,CK1'X0U6PUB^DTGQ ;32]0G:XN
M+1K8.Z2-]\Q/GY=WN#@T ,NO%TX\2W&C">UL+M6B-K;WL3#[6C!2Q1]P&X$L
MH7GE>^>.SKE=<\)3Z]!=V-Y=V[Z?-+')"&@)FM=H4$1ONZG:2#CC<>M=50!Q
M*ZCJ$'Q&UK[3?Q?V=9:;%/Y7D'Y4)<M@[OO?+R<'/ P,4RX\7ZI9>%M.\63Q
MVK:7<M$\]LJ-YD,,K *P?=AF&Y<C:,Y/3'.Q/X9>7Q7<:NMX@M;NS6TNK5X=
MQ=5+$8;/RYW$'@_A5"V\%3QZ#;^';K44N-%MYD=$,)$S1HX=(V;=C ( R ,@
M8XZT =A7'Z?<ZK+\3]9MI+V)K."SMV2$P'Y58R< [NN1R2#GC@8KL*Y]O#]W
M%XNN=<M-0CB2ZM8X)H)(-^2A8J0VX8'S<C'XB@#B?".LZOHG@GPG,@LFTVZO
M5L7B*,9?WDK@.'S@8./EVGCOZ=#?^*=8G35)-"M!.]A<M;I;M:R/]H9,;QY@
M("<D@<'ID]<!L/@2[@\+:+HBZM"?[,ODO%F-H?WFR0N%(W\<GKFK'_"):M9:
M[?7>C>(/L5CJ,OG75JUJ)"LA #/&Q/RDX[@C/KTH ZN"1IK>*5XVB9T#&-NJ
MDCH?<5PXE;4_C4]K=?-!I>E":UB/02.P#28]<?+7=11K%$D:YVHH49.3@>_>
ML#6O#+7VLVFN:;>?8=7M4,(E:/S(YHB<F.1<@D9Y&""#0!JWMG:2SVU_<*!)
M8L\L<G=<H5;\,'I[#TKD)_&6IP^#H?&(BMFTQF622S\MO-6W9]H8/NP7 (8C
M;CJ.V3U-O9ZA,RMJEU!(J@XAMHF1&)&/FRQ+<=!P/KQCG[?P-+#X?/AF34$E
MT'S=RQM"?.$6_?Y1?=@C/&<9QQ[T *VM^(+WQ)KNDV#Z;$ME;P3V\TL3OGS
MYPP##/W1R",>A[4+3QEK<^E^&-;EBL%L=6N8;66V5',BM)D;P^[&-P^[M/'>
MM^#P]=V_B35]7COH/^)A!%"L1MS^[\L-M.=_/WCG@5EQ>!KN'PSH&C+JT/\
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MN3Y8.1R4!D/MO6M1_#MS:>)[S6])O(H'OXDCNX)X3(CL@PD@PP((!P1T(]*
M,;3_ !S>ZB/#4B6T$(U"\FLKR%@6:*2-7)V-D#&4[@\&MS0]9O+_ %_Q!IUT
ML&W39XHXGB0J65XP_P V2>1G'%9\_@@PZ7I$.EWRP7NF7;7BSSP^8LSON\S>
MH(Z[ST/'%7]"\/7>DZWK&HW&HK='4GCD9!!LV,D83@Y/''3L,<GJ0#0UN748
M-%NYM)6%[Z.)GACF4LKL!G;P0>>F<URT7C:XEOO"3"6S-AK<7[UA"V^*7;E5
MSOP-S;E&<\KW[=S7&/\ #RT.@ZGID5W+&UU=_:;:91\UIB3S$5/0*Q<_\"-
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M,CHAA(F:-'#I&S;L8! &0.0,<=: #0;G59_B#XGAN+V*2UM3;(D?D$$*T;,
MIW<<L<D@Y]JZV42&)A$RK)CY69=P!]QD9_.L6ST">R\6ZEK,5\OV?4%B\ZV,
M/S;XT* A\],')&,Y'6MV@#@[;QGJEQX2\+ZR8K,2:I?PVMQ'Y;8"O(5RGS<$
M =\U8T6YUF?QMXLA>^MY([5K>.%'@8!0T6]0"'XP6.>#GV[5H? &I0Z/INDK
MKL(L],OTN[3_ $/YL*Y<+(=_S=<9&W\:W+;P]>67B;5M6M]1C$6I+$9('M\E
M9$CV [MP^7&"1C.1U]0#E-0UBX\0?#SPMJMU'%'/<ZO9NR1 A5_?XXR3Z5T[
M:UJ7_";WVB1Q6K1II0O+=L$,7+L@5CG&,KV'>LZ/P+=Q>#]'T!=6A_XEMW'<
MB<VA_>;'WJNW?QSU.:U)?#]^?%=QKT.HP1R2:<+%(S;%@A#%PY._GYFZ8''?
MO0!1CUO79?&$.AV\VG7:P()=3F2U=!;J?NH#YAR[<X!Z#GFJT'BW6=1MM.U3
M2[ W5E=7 #VPM7#+ 21Y@E)VD@8)&.^,\9-_0/"^HZ#8I:QZK;2%[@7%W<&T
M837+E@6);S" 3C'3@5!HW@[5-$E-C:^(&_X1\2F2.S-N/-C4G<8Q+G[F?;..
M,CK0!V-<JNN:KJ[ZX=$-HBZ5.ULJW$;.9Y50,PR&&T?,%'!YR?:NJKF8_#-Y
MIVK:K=:1J$5O!JC>;/#- 9/+FQM,B$,.HQD'/(_"@#'3QKJNL2>&3HL-E%'K
MEK<2#[4K,89(E&0<$9&3CWQVKM[(70L8!?&$W?EKYQA!"%\<[<\XSTS7-P^#
M!8ZAX<DT^[2&TT2&6%(7A+M*)% 8EMPP?ESTZDUU= '/-K%YJ/B74-&TR2WA
M.G0Q/<33Q&3,DF2B@!EX 7).>X ]:X[PSK-_HOPW\,R01VS&YU?[).) 3M$E
MTX)7!'(YZUUEQX9O8?%DVO:/J45J]Y$D5[!<6YE239PCC#*0P!QW%9L'@.\A
M\,:7HPUB)OL&HK?"5K0_,1*9 N X[D\^G:@">[\63IXINM$6YL[*[CDB^RP7
MD3#[9&P4LR/N SDLH'/*\YSQ/)K6M:HNLOH$=FS:;<FU2&X4DW$BA6<;MP"#
MYL#KR,].*77/"EQX@BNK._O+>2RFG2:(FW/G6VT+D1ONXR5)!QQN/6HCX2U.
MS\07]]HNN_8K/4I!+=VSVPE(DQ@O&Q/RD@#J",]CTH AN)O+^*ME/< 1;= F
M>09SMQ-&3SWQ4%QXRU.#P=;^,?*MFTMV626T$;>:L#/M#!]V"X!#$;<=1VR=
MI_#4C>++?6!=QFWAL&L/LSPEBR,P8DONZ_*.U9UOX'EB\/\ _",RZ@DN@B4,
ML;0GSO*#[_*+[L$9XSC../>@!;CQ;-_PE%SHJ7-G9W22Q?9H+N)A]LB8*6>-
M]P!/+  9Y7GKPS4/%&KSC56T*U6=]/N#;I UK(_VAE +CS 0$ZD#KTR>N*MZ
MWX4GU^.YM+Z\MY+*2X2>$FW/G6VW;D(^[OM/.!C<>M1/X2U6SU^^O=$U_P"P
MV>HR":ZM7MA+B3 !>,D_*2 .H(SV/2@#J;:5I[6&9XFA=T5FC?JA(S@^XKG/
M$FM:IIEQ<"W-I!;QV330O,AE>XF&<H(U8,%  );!^]VP:Z6*-884B4L510H+
M')P/4]ZYK4O"MY=^(+W4;;5E@AOK$6<\3V_F,H&[!C;< OWCD$$?T *!\6:Q
M=S^$19064::]:/,_G!F,3"(/Q@C(^;IWQU&<B'_A)_$A\+Z_<PPV$^J:)>R0
MR!87V7$:*KDJN_*MM;ID\C'>KEAX,OK.3PNSZO#+_84+P@?9"/-5HQ'_ '_E
MP /7G/TJ6WCM/! U74-;U>W6VU2_\X$P% CLH79G<V1A/;O0!H6NLR:EJ6GI
MI\UO+92V7VN>3RSG:V!'M^;C=ASR#]PUM2R)#$\LAVHBEF/H!UKFO VAPZ+H
MDAA25$NIY)XHY<[HH2Q\M,'D +@X[$FNF=%D1D<!E88(/<4 <+<>,M3A\'0>
M,1%;-I;,LDEGY;>:MNS[0P?=@N 0Q&W'4=LFQI-UJES\1?$<,E]"]E!;6A2+
MR#PK"4@ [N#GJ2#GCIBEM_ TL/A\^&9-02701+N6-H3YPBW[_*+[L$9XSC..
M/>M$>';N#Q5?ZS9ZC'''?6\44L$EOO\ FC#!2&W# ^8Y&.W44 <7X/UG5]%\
M&>#'Q9/IM[.EBT6QO-!<OAP^<=1]W;T[^F_?>*M8N(M1GT*S%R;&[:V6U:UD
M8W!1@K_O00J'.['!Z#/7 (/ MW!X:T#1UU:$C1[R.Z64VA_>["2%(W\?>/.:
MF7PCJMCK5]/I'B V>G:C,;BYM6MA(R2-]]HG)^4M[@X- #!KGB6_\5:CI-A'
MIL*6L-M<*URCEMLA;<IPWWL+UZ#'?/'9U@:?X>GL?%=_K/VV-X;N"*#[/Y)W
M((]VT[RQR?F.>*WZ .'N_%>LW-M=WNAV/VM;:[>W6T-JY,ZH^QR)<A5.0Q'!
MZ#/7A\VO>([G7O$&FV/]FPC3[>&>&2>)W)WJYVL PY^7&0>/0YXEA\'ZII^K
M7S:7X@:UTB_G:XGM#;AWC=N7\J3/R[C['':KD7AJ[AUW6]2COX<:E;Q0+$UN
M3Y0C# '._P";[QSTH YY]?U;6KWP%=VMS#:1ZFDLTD+0EU\P0,>3N!*\G X]
M3FM*XU_5I+WQE8QO:P/I5I%+:S+$6/SH['<"V"1M ';Z]*+?P1=VFG>&88-7
MC6YT(LJ3&URLJ,A0@KOX.#P<XSVJ_%X6E&L^(;V:_1X=9MXX&B6':T01&4'=
MN()PQ["@#!MM=UO1/ WA;5)I[.:QDCM4OI7@??#%(B@.3YG)!/)QWSCBNL@N
MKF_U?4[;_1VT^W1(>8B6:5EW,"=V"H5D[?Q$=JY^?^SO#7A"V\,>(M1CO6N+
M1K2VABMRC7"(@4*JY;Y^1SGJ>,5O^&-(;0O#=CI\DC2SQQ@SR,<EY#RQSWY)
M_#% &7K%]!X&T.PC@406+712XNC 76W#[W+E$Q@%\#C &[VQ6UH=Y-?Z6ES-
M<6ESO=S'/:?ZN1-QVD<GG&,\]<TNIVE[<FV:RNHH?+<F6.:(NDR%2-IP1CJ#
MGGITJMX:\/P^'-/GMH2F)[F2Y9(TV1QES]U%R<*,#]: ,OX@W6H6NCV!L+I+
M?S=2M89,Q[BRM*HQU&!Z^HXR*AO=8\4'Q9+X?T]M)\P::MXL\\4@7=YFP@J&
M)P<'OQGOCG9\3Z$_B'24M8KH6L\5Q%<Q2M'O4/&X897(R./45!;^'[V/Q>NO
M3:C#+FP%D\(MBN<.7W!M_')Z8/'YT 8^L>+-6TB9GG2R4+J45M]D53([0.RJ
M)2ZMA"220&'08Y-7+O6+_6'\0VNEO;10Z8I@9IHV<S2^7N8<,-J@$#//.?3F
MC=> =0GLM1LH]=C6VN-2&I1;[/<ZOYBOM=M_S+Q@8 /3G Q5W_A$=1L]7U.[
MTS5XHK?54'VR&>V\S]Z%VF2,AAM)'4$$9_*@#(\*Z[+;>%?"VCV@(N)=)%R\
MGV=IMB+M4?*I!R2W7.!CW%=9X9U#5-1TMWUBQ^R7<4[Q<*5690?ED5225!!Z
M$Y'-<\G@*_L]-T(Z=KHM]6TB VR7/V;,<T)QE'3=[ YS_P#6ZW2[2YL[3;>7
MAO+IVWRS;-BDX PJ_P (  XY]222: ,[Q9KS>'=.M[LC9;O<K%<7)B:1;:,A
MCO95Y(R OMNSVQ5!O%,\=IIRI<6=Y-J5S)';7-I&TD9B5"^_8K$DX&,9ZGT%
M;VJ6M[<K;&QNXX&BFWR++$729-K*4(!&.6!SZJ.#7+2?#M$TS;I]_P#V?J,>
MHOJ-O/;PCRX)&&TH(R?N%>",\G)]J 'CQ7K-E#/#J.GJ)Y+^&RT^Y:)HH[CS
M>C%"2PV8;(SS@8QFK.K:IXFT72]?NY8M/FALK0W-I<;642%5)=&3<3QC@Y'6
MB_\ "%[K>@R6NK:TSZEYL<\%W;PB-;>2,Y0HF3W)SDY.>V!A\WAO6=1\/:C8
M:KKD4]U>VS6HECM-D<2,"&(3=RQ]2<<# '.0"HOB/7+2WT][\6)?5GB6R2WA
MD=HOW322%QGY\!>-N.3SZUD^*-<\2KX,\3B6/[+]E$8M[X6S1_:(GP& 1FRC
M+G!//L!71:KX2FU/P[IED-3-MJ6F-'):WT,7"R(NW)0DY!!((S3+WPKJ.L^%
MM2TS6-9$]W>QB/SXK?9'$%.5PF3GGJ2>?;% $>M^)[C0]5L]-O[ZRLOM$#-'
M?3VSB"27=@1_?^3 P3EN<\8Z5U-F\TEE;O<A!.T:F0(<J&QSCVS6%>Z%JFH6
M\D%Y?V-W!<6HAG@GLR8R^6.]1OXX8#!S]T<UK:/IL>CZ+9:9%(\D=I D*NY^
M9@H R?RH SKW6KA_%4/AZP:*.X-FU[--*A<*F\(H"@C))SSG@+WSQS=[XYU>
MVT/4F%M9G5-+U**QN%(;RY5D=0KISE<AP<$G&.]='JGAZ6?Q'9^(-.NDM[^"
M%K:02QEXYX2=VT@$$$-R"/R-9NH^!Y+W1[VU34(X[R_OH[ZZN6MRP9D92JJN
MX84!%')/?UH Z+2EU58)1J\EF\WFMY9M%95\OC (8GYNN>W2K](FX(H<@OCY
MB!@$_2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I&56QN4'!R,CH:6N?\4:O-IITBTMY/)DU*_2
MT\_ )C4JS$C/&XA<#.>3WQ0!T%%<5K^HZOX2TO4[E]22[BGGMXM/\Y 7MR[!
M'+D8#*"=P_(U->WFI:)XQT73?M\]U9:ND\3>:J%X)8TWAU(4<$9!!&!QCTH
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M)%9&\>Y!BBF</*RJ/NXPH7L.21VX._X:&LKHD4>OO!)J,;,LDD)&'&?E)
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M8KLMY'9BR+P<9)Y&0#SG&* ,CQSJ4UC!HL"2/%;WVJP6MS*C%2(VR2,CD;B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *9+-% F^61(UR!N=@!D]!3ZXWXF0V\GAFW:=4.W4+7:S<%<RJ
M#@]N,]* .I;4;);9[EKRW$",5:4RKM4C@@G. :D^U6_V;[3Y\7D;=WF[QMQZ
MYZ8KA=:_LWPYXOTE)'CTC29X9]DL,<:1"Z)3EMRE02@(!^HSR:I7]OI&C^']
M.FTS5?,T^/7EN ;F9%AG)R61& "!0=S#MN4CTH ]'ANK>XC\R">*5.?F1PPX
MZ\BF6U]:7BNUK=03A.&,4@;;]<=*\YN5T2+3O&?B.;[+=V]ZB*T%E<(TJ)M"
M'<Z$[=[<G!(P,\U/9W-G/\0[J*>\TZXCN-!52D&/*;$C?*,D[L+W].PH ] B
MO;2=]D-U#(^S?M20$[<XSQVSWK /B.27QO8Z7:W-G<6$]K-*YB^9U="HP6#8
M_BZ8KA8+6ULO@QIVJVMI'YKQ0QWUQ$F93;>:/-4L.2,#!'8?2NCGN]'G^)V@
MRVEQ92+-IEQ&#&ZD,N4V+Q[;L#ZT =987,L=K-)J%]92;;AU62'Y55=WRJV2
M?F P#[U;ANK>XDE2&XBE>)MLBHX8H?0XZ&O)+B"S/PSU-=D(2+Q$PBQ@;!]K
M4?+Z?+Z=JZA;2ULOB==VUD(K))= W-Y*A0")B V!W /6@#L4OK22=X$NH&F3
M[T8D!9?J*==W=O86DMW=S)#;Q*7DD<X"@=S7EVA1Z7KUAX0LI+S27;3)"[EK
MB-VN!M( 6,G=EB0S!@"".YKT3Q(@D\,:JA4-FSEP,9YV'% &->>*I)#X9NM,
MDMWLM5N4BE#KET#1EQR#@'@9!!ZUTUO=6]W$9;:>*:,$J7C<,,CJ,BO-&?3[
MWPY\.X4:WFC-U;I,BD$%OLS95L=^0"#Z\U%JI.GGX@1:=$4AAFL99(;91Q&4
M0S87IRH;/'K0!Z?;7MI>;_LMU#/L.'\J0-M/H<=*Q/%6LWVCSZ%]D\@Q7NIP
MV<XD0EMKY.5(( /R]P>M4="'A_4/$L>KZ7K4FH7;6?E.(FBV+%D$>8$48.>!
MGGKQP<0?$LS_ &7PXMK+%%=-KEN(6E&5#[7P2.XSB@#K9;R*1;B&VN[?[4B-
MPS!MA]6 .< ]:CL+HKIMD;Z\M)+F6-<R0G;'*VW)* GD=3]*X_1[VQU+P7KM
MG>6T<6L6\4JZO#/AG:8(?WA/\2D %3T P!C%8=M:V5U8?"K[1##)OA\MMX!W
M+]E/RGU&<<=* /5+>[MKR'SK:XBGBR1OB<,O'7D5SC>)9)?'>GZ3:75E<:?<
M6D\KF+YG1T*#!8-C'S=,5PNKRG3-/\=PV,?EV,6KVINHH!C9 R1>=@#ID9!]
MLUT4]]HTGQ6\.W%E=63"72[A \4B_,,H4''MNP/K0!Z#4%S>VMDJM=7,, 8X
M4RR!<GT&:9I^I66JV@NK"ZBN8"2HDB;(R.HKC)=3TN'QSXDT_P 23P00W-I"
MMHUTX1'M]A$BJQ_VRV<<GCTH V[[6[JS\:6&FO);+IUQ9S7#LRD,I0KU;.,?
M-Z5MB\M3:?:Q<PFVQN\[>-F/7=TKAGL]-D\:^%+-(-UE'I=P(8;C+':#'MR&
MY/ SSS^(K)L;O3[#16MYDC$2^*YHK3=)LA@8.S*6Q_".2%[G'3J #TY+ZTDM
M#=)=0-; $F82 H,=>>E(VH621RR->6ZI"VR1C*H"-Z$YX->2:G-:3^%?B)"]
MS:W+BY$Z;  "3''\ZC)QSWS^-=9K$>A:-?\ A\06EI;3W=RTL5TYV0JZPD;Y
M,$;VVG"@GDGK0!V<=S!-;BXBFC>$C<)%8%2/7/2J5WK^E66D7&J27UN;.W4E
MY4D##([#!Z^U>7PZI%::!=N9TFL(/%;/?^6/E%L6SN*CHA?:<=#[UT/B<:#>
M^%_%U_I#Q74]Q8;KF:"3S(\JI"=#@-C/3G&,]10!VJ:I9-IZ7S74"6S 'S&D
M4*,]B<XJ;[7;>5'+]HB\N4@1OO&'STP>]>?WFL6%MX@\/R3ZDEII$NGR1PW4
M?EF(7&4)#,RE02N1GZCN:I:EI.A6VG^&XK"8WEE)XC79+,4*L'5RZQE0!Y>[
MC XSF@#T^">&YA6:WE26)ONO&P93]"*>2 "2< =2:S;:?1M)NX-"M6M+2=T:
M:&SCPA*Y)8A1[Y/YUC?$2::W\-12J&-FE[;M?A1G_1@XWY]NF?;- '2VU[:W
MB,UK<PSJIPQBD# 'T.*(KVTGD$<-U#)(5+A4D!)4'&<#MGBN3OK>*?XC:1-8
MB*2";3IQJ(7!1X?E\K=V/S%L>P-0_"[3=.7P7I6H16MO]L,4D9N H+[?,/R[
MNN.!Q[4 =I<7,%I"9KF>.&)>KR.%4?B:C;4+)(XY'O+=4E&8V,H <>QSS7)>
M*-1BT[QKH[:G?/8Z;+:S1Q7&$V+<%EX8NI"Y0$ \=QW-4YM#T&;P;/I>G74U
MT+J^>33I2Z?+<GYMT)4 !%(8G X >@#NI+E)([A+:Y@\^-3G+!A&V.-P!Z5!
M;7JV^DVLVI7UF9&C7?.C!(G8CJN3T/;FN3T:ZM[[PAKUEJ,47]L6ZRKJJ28.
M^7:<2=.4( *^@ ':J.G0WLWAKP;-HVH6L6JPZ5F*UNUS%<Q[(PZDCD$';R/?
MMF@#M+SQ%I5C>V%I->0B6^+>4/,&-JJ6+'GIQC/J15Z6^M(+B.WENH(YY/N1
MO( S?0=37G$=_8W%[X"U">SATZW/VQ&BE8;(R(R  QX(R#M]B*C\W1M4'B/1
MO$>L2V5W_:,C&WS&LDB;@86BW(68[0H&"3Q[T >E3WUG;>9Y]U!%Y8!?S) N
MT'H3GIFGRW,$%N9YIXXX0,F1W 7'U/%<)::9IMQX_P#$<=U:PRC^S;5F69%)
MW$2!F8=-V,9/O[UC>']7CT^R\ SZK.J:6UC-&LTK?NX[C@)N)X!VAE&?4T >
MIB[MFM?M0N(C;[=WFAQLQZYZ8I;>Y@NX1-;3QS1'H\;AE/XBO/-7N-(TF'2K
MK3YG@T!M8DDN[F$B2,2.C;7&[<NP2'TP"..171^%K72([[5KO2-2DOUNY$DG
MD5XVA$FT@[-@ W8P6_"@#H+FZM[.+S;J>*"/.-\KA1^9K-\0:_;:#X<N]79D
ME2&%I(U#@"4XR #[UCW-PT7Q5MHK[ M9=*86)?[IF\S]X!_M;=OX"N6O[?[/
M\.?'" +_ &:MY/\ 8 ?NJOR[@GHN\L!COF@#T#1Y=5GN9);B[T^ZT^2)6B>W
M4JZ2?Q*>2"OH<Y_G6@U]9I<BV>[@6<X_=&0!N>G'6ELUB6SA\E4"% 1L& >.
MM<#/+=:7J[7,;6VK:)<ZRJR1$;;FRN3(%RI_B4$=.#M/I0!WOV^S\DS?:X/*
M5MI?S!M!],YZTMQ>6MI");FYAAB)P'DD"@_B:\OU"[L[;PW\1[*::&.Y>[G=
M(&(#L&A0@A>IZ$Y]C6G::WIUMXOB76+JW2RN=%A%A-,X$)Y/FJ&/&X_+GV44
M =%JVM7=EXI\/V43VYL-0\_S6*G<-D9<$-G&.G;M6[;W,%W"LUM-'-$W1XV#
M*?Q%>?W-EI UKP'8V<6[3 UX(8YF+AT$1P?F))4]1GL16KX'6*#4/%5M J)#
M'J[[8T  7,<9.!VYS0!U37EJDWDO<PK*!G87 ;&,YQ]*8-0LFA:87EN8E.&<
M2KM!]"<US'C(#1]4T?Q2D3.+24VMV(URS02_+TZG:^P@>YK(T"SN[36;OPI>
M6ZB">=-7^5?D2)CN>(=N)E QW4F@#OYKZSMGC2>Z@B:7_5AY I?Z9ZT^:ZM[
M;'GSQ19!(WN%R ,D\^@KB-,>UN;[QM8Z_P"6)#.6838_X\S&!&1G^$8;IT)/
M>L/3=/\ M-Y\/(M>MXY;N6QNUF6X4%I%"*4#@]<#L>^: .UL=>N)O%^IZ?-+
M:G3[>SANH94&.'+9+-D@CY>HQ6_#/#<1^9!*DJ=-R,&'YBO+==$NF>,=473[
M9'TRTTZT%[90#:[6H,@94QTP,$CN!C(SSZ!;Z]H:VVF+!?6B0WXVV*JP42X
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M9],YJ:&2*:".2!T>%U#(R$%2#T(QVKS?4]&=]3\0>#H80L&L[=1MI=F5@/\
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M!N!(*GYNN,,>.G.>>,72 RE6 ((P0>]+10!6@T^RMH7A@L[>*)_OI'$%5OJ
M.:D@MH+9"D$,<2DY(C4*"?PJ6B@"*YM;>\A,-U!%/$>J2H&4_@:3[);?NO\
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MO+&<8QCIZ<4W^S+#9L^Q6VS.=OE+C/KTJU10!7EL+.X,)FM()/)YBWQ@[/\
M=R./PJQ110!7AT^RMYVGAM+>.9A@R)& Q'U I#IUDTDLC6=N7E(,C&)<N1R,
MG'.,#%6:* ()[*UN9(I+BVAE>(YC:2,,4/J">E#V5K)-YSVT+2]-[1@M^=3T
M4 106MO; BW@BB#<D1H%S^5/9%?&Y0VTY&1G!]:=10 T(@=G"@,P +8Y..E0
MO8V<ETEU):P-<(,+*T8+K]#U%6** (39VQN/M!MH3/\ \]-@W?GUIG]G6/S_
M .AV_P"\^_\ NE^;G//'/-6:* &10Q01B.&-(T'144 #\!2[%+A]HW@$!L<@
M'J/T'Y4ZB@!GDQ&)HO*3RVSN7:,')R<CW)-0?V;8F,1_8K?RP=P7REP#ZXQ5
MJB@"!;.U6<3K;0B4<"01C=TQUIT]M!=($N(8Y4!SMD4,,_C4M% %?[#:>9')
M]E@WQJ41O+&57T![#VJ.32M.FCCCET^U=(QA%:%2%'H!CBKE% $;V\$K1M)#
M&YB.Z,LH.P^H]*@M+"&TFN)D51)</N<JH4<=.!]2<]22:MT4 0W-I;7L7E75
MO%/'G.R5 PS]#2265K+$D4EM"\:<(C1@A?H.U3T4 (JJBA54*JC  & !2T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M()PMM#()CY+?NLVVP!N/E^;CFMKXB037'@B]2WADFD62"39$A9BJS(S8 Y.
M"?PKJ** .,:Y6Y^)6G7RP7"VW]DS)YDENZA6,B$ Y'!(!.#S7,01WMKHEIJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]TZ:RMKX6.IBRNY1#;7!M_EF9FVK@ Y )Z%@!20ZUIGC?2;S2I;74;);N-X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[4UJ9!*LCRYD1@200<8X)/;OSFNOHH QXO#5A&^HS$S/>:A'Y5Q=LP\TKC
M(&% '0  9YK.;X?Z&VD:1IFVY6VTJ;S[<),5;?DG+$=>3GL:ZFB@"O<V5O=Z
M=-82QC[--$T+(./D(P1^5<I9_#'0;)]*=);]VTS?Y)DN,[@W4'CIUX&!R?4U
MV=% '-MX(TA[?78F^T'^VWW7;^9\W? 4XX R>*BN_ &B7EIH]NWVN-=);=;/
M%<%7Z 8+=>BKTQC Q@5U-% &'X>\)Z;X9DO7L//S>3M.XD?(4MU"C P.![\#
MFKK:6K:VFJ&ZN?,2)H5BROEA6()XQG)*J<YSQZ5?HH HSZ197.KVFJ2Q W=H
MCQQ2>@?&?Y?J?6LB;P-H\]UJ4C_:/)U.5);RU#@1S,O3/&[!/) .#72T4 8\
MOAG3IO$-CK;(XN;& P6Z*<1HI!!PN.N#BFZ!X6TWPV;LV FW74S3R&60O\S=
M<>@X'UP,YQ6U10!6U"PM=4L)[&^@6>VG0I)&W1A6+I?@VUTJVCLX]2U.;3X^
M$LYYPT:C^[PH8K_LDD>U='10!SU[X-TR]U6^U!GN8I-0@6WO%BD"K,@['C(X
MX^4CBI;GPEI-S=:-,86C71R6M(8SMC4X Y'?&!BMRB@#E9OA[H<^DZIIT@N6
MBU.Z^UW+^;\[/D'KCID=/>N>@TBXU#XJ(Z0:E9:;I.GF"RN3 V))6/SD-(I!
MX9AD]<5Z710!S5[X$T*^\,OH+P2+:O+Y[2))^]:7.3(6.<L?4T^[\'6.H>'[
MK2+Z\U"Z2Y14DN)I]TN%(( .,#D#.!SWS7144 <S-X%TB>[TBYD>[+Z4C)"/
M.X<,,'=QSP,<8XXZ<4U? >D+_;O[R\QK1<W(\[[I;.=O''4]<XZ=":ZBB@#F
M1X%TA;#2+:-KE'TF026LX<&12 !SD$$$ #&.PJ:7P;I,NA7^D[9ECU!S)=S*
M_P"]F8D$EF]\=.F.!BN@HH Y^7P9H\VI:3?,DPDTJ#[/;(LA"!,8P1WXX]^^
M:F\/>%]/\,B^%@9S]MN&N)?-DW88]A[?K[UM44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9>HZ_9Z;<M;.LTUPMNUT\4*;F6)3
M@N>G?L.3V%:E<CXB@U>ZUV2W33Y[C39=/9(V@D5 )R3D2DL&VXQ@#(Y/!XP
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M,MM#%<!WNQ&'1V(/\/!&#QW]1WKWGCH00F\M;-;NR2Y,#K'(QG(#[&=4"D$
M@G&>1SQTH [&BN<NO$=ZZ:G+I&F"_CTZ7R95\TJ\K@ NL8VG. PZXR<CWJO%
MJVJW'Q!DTMH(!8+IJ7&QI"&&]R"6&T@M\N,=/?F@#IX;B"Y5F@FCE56*,8V#
M ,.H..]25YQHNKS>&O!^N:A:Z<EU#:ZU=^;$)?+\N/S2"PPIR .<>@-=J-4>
M75[6SMX8I8I+8W$LRR_ZL9 3 V_-N^;!R/NF@#2K,U'0[;4[^QO)Y)UEL7,D
M'EL %8@@DC'/!(YI=;UB+1+%)W0R2S31V\$0./,E=MJC/8=R>P!J@/$-U!K_
M /8M[8Q)=S6S7%H\<Q,<VW[R$E0589!Z'CGVH Z&HIKF"V\OSYXXO,<1IYCA
M=S'HHSU)]*Y_PKXCU+Q+:VNH/I"6NG7%N9%E^TAV#AL;=NT<8R<^W2G^*]3B
MTU]$$^EP7T=SJD%NK2L/W$C$[9%!!R1SZ4 :6L:-:ZY:);7;7"QI(LH,$[1-
MD9[J0<<]*N6\$5K;QV\$:QPQ*$1%& J@8 %<G=>+M6&J>(+"QT.":32(XI2\
MMYL6575F[(2&PN ,8ZY(XS:M_%R:DFBQ:;;![O5;/[<(Y7VK!#A<LQ .3E@H
M ')STQ0!NMJ-BL-Q,UY;B*W)6=S*NV(@ D,<_+P1U]:L A@"""#R"*\JTV__
M +&\*^/;RZT2UN4@U:4S6!D'E,OEQ9P2O([_ ':ZK4O%&I6>N6NC:;HD5U-<
MV#W4):Z$:Y0J-I^4X'S=?ITZ@ ZRBN,U#QS-;6]]+;:?#/+IY"7%M]H/F/)M
M5G2,!"&V[L9.,D$<=:OMXGN+Z2ZBT2P%S+:6L=Q*EQ(8CF12R1@;2=Q YS@#
M(Z\X .DJ**Y@GDECBGCD>)MLBHX)0^A'8UQ\WB'6Y_%WARTBL8[:VO;*6YEM
MKB4I(K*$!5L*1\N_@=SUQBJ.E75QHM]X^N]-TY+N2WO4E%JLGE;P($+8(4\]
M>,<F@#T.BL&U\1M?P:#+96\,PU2/SFQ.<0Q!02P^7YL$JN..6%7M<U:/0]$N
MM3E0NENFXJ#CN!R<' YY.#@9H T**YR;Q1]ATF[U.[A@DM(TC-M-9S^8MRSL
M5"J2!@[L#OUS3SK\]KX@LM'U6SBB.H1N;:6&4R(SH,M&V5&#CD'OSTH USJ%
MD+:6Y-Y;B"$E9)3*-J$=03G _&K(((R.17F=C>PZ+X#\573:9!?6T&KWF^TD
M(5&3S,8Z$8''&*[*?69FU)M+TRVBFNHK5;B7S9"B(K$A%R <DE6^@&?04 :T
MMQ! \22S1QM*VR,.P!=L9P/4X!XJ2N2N=?:0^&)+_P /B.6_N?+"W+#S+.7:
MQR!CGA3SQP:D\/:KJU_XG\0VUW';BVL[A(8]DK$H/+## *\D[N3D>G.* .IH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KC/B89!X=L/)"&7^UK/8'.%W><N,^U=G63XBCT4:8
M;K78(9;.V97S+$9 C$@ @ $YR1SB@#'U'PG+XDU&[NM6$5NDFFRZ=#'!(9"H
MD.7D)('/"@#ZYZX#_#UIXQMHH+369]+D@M$VK-;L_F76!A=X(PG8DC/(KJE4
M*H51@ 8 I: .2\/>']6TGP/=:-<"R:[8W!B:.9RA\UW;DE 1C?C@'I5"U\'Z
MM86GA2[@>S;5-#MC:2Q&5O*N8BH5L-MRI^4$<>QKK[75[&]U&\T^WN!)=6>S
M[1&%/R;L[><8.=IZ5=H X35_ ESK=OK=Y)<0VNK7\EO);E"72#R.8P3@%LG<
M2<=^^.;4.D^)+WQ;HVMZC#IENMG;3031P7#R%BY3YER@_N]#T]3V[&B@#&\5
M:#_PDGAZXTT3^1*Q62&;&=DBL&4X],CFJHTC4=4UC2=1U:*UA;3%D98[>5I!
M)*Z[<Y*C"@9P.3D^W/1T4 <[X9TC4M*N]:>]6U\N_OWNXS#*S%055=I!4?W<
MY]Z=XOT6]UK3[$:>T NK+4(+U%G8JC^6V=I(!(SZX-=!10!S'B+PQ<:[/HUU
M]H2"YM9&2Z9,XD@D0K+&._/RX/;&:=H?A8Z-XDU>_68&TNI/-MK<#_4LX7SC
M_P "9%/MSZUTM% '"VWA'5[#P[J_A>VDM&TN]:807+R,)+>*8DNI3;AB-S8.
MX9SSBNSLK2*PL+>S@!$-O$L48/95&!^@J>B@#C_"=G<Z$FO:-&D9N$O9KNS6
M5BJ212_,IR 3@-N4X!QCIR*9I5EXXM[H-=CP_P#OY5:ZN8Y9FE* ]$4J ,#(
M49P.IR2<]@T4;R)(R*73.QB.5SUQZ4^@#E+^Q;5_B-I%P@_<:);SR2/V\V90
MBI]0H9CZ97U%=-<7$%K"9;F:.*+(!>1@J\\#DTZ.*.%2L:*BDEB%&.3R345Y
M8VFHVS6U[;17,#$$QRH&4X.1P: .=\(:+#:V^H/',9K*6:2*S!Z);AF.U?;<
MSX/<!?:FZ!I/B32(H=(ENK&32K9@(KD;O/,0.0A7&T''&<]/>NJ1$CC6.-55
M% "JHP /04Z@#A)/"VOO;B-I-.DEBU5+\7,COOG59-P5_E^7 X&,C QQ6OHN
MC:G8^+=?U2Z%H;;4O(,?E2L74QILY!4#GKU./>MJVU*TN[V\LX)=T]FRK.NT
MC:67<.2,'CTJU0!Q-CX2O3XETO7+FWL;+4+=76^N+*5O].!0@!EVJ.N&R<D8
MP,]1O>*=-O\ 5O#EU9:;<I;W4FW:SDA6 8$J2.0& (./6GZIXDTG1M_V^Z\I
M8]OF,(W98MQPN\J"%SVSBK>FZE::OI\-_8S":UF&8Y "-PSCOSVH YS3-#UF
MS\4S:L\6F1036$=O]FA=_P!VR,Q"@[0,?-UP/3;WJC%X/U<_#.3PW+)9+>K)
MYD<B2.T;'S_. .5!'IT-=W10!Q]]H_B6#7HM>TE]--S/;+;WUG.[B(A6)1D<
M#.1N(Y SZ"I[S1-:N=:\.Z@\EG,VGO-)<DNR;C(A7:@VGA<\9/./QKJ:* "N
M,FT^RU?Q]:7^GWT<L26V[4(X6#I(8W!@W$=&#;R/]RNSJK8:98:7$\5A96]K
M&[EV6",(&8]2<=Z ,1M%U#3O%]YK>F"WGBU""..ZMYI3&0\>0CJP5LC!((Q[
M^U9L_@V^MM(L#826TNI6VK-JLJRLR1RNY?>H(!(&'P#@_=Z5V]% '#7'A?7K
MK_A+6=M.W:Y:QPQ@2N!$PB*')VG(&>O?'09XZW2H)[72+.WN1&)HH5C?RF++
MD#'!(![>E7** .5UK1M<B\31:]X?ELVE>V%K=6MXS*DB!BRLK*"0P+'MT-+?
M:)K5YJ7AZ]DELY9+"XDGN<NR [T9-J#:> &ZD\X]ZZFB@#D1X>U87/BV7;98
MUE5$ \]_D(B$?S?)[9XSZ>]9"6FHZ3XH\%V)BMI;JTTJX@D43,$8*(ER&VY[
M9P1_C7HM4Y=*L)]0BU"6SA>\B&(YV7+H/0'M0!R>J^#M0O\ PYXAAC>T&IZW
M.LDA>1A'$J[0J@A26PJ]<#))K1DT74[3Q8=?L5MI#=VJV]Y:R3,HW*<JZ/M.
M<9(((''-=/10!RD6CZ7I'A[4[37+NU0:O-<7%UND"J6DY8)GD[5 &>O&>*CT
M?0K]/AW+8R2B;4[ZT822W)*99HPB[L D%4"@]>172WFF6&H/ ][96]PUN_F0
MF:,,8V]1GH:9J&KV.EO:I>W B:ZF6"$%2=[L< <"@#F_^$<U?R?"*8L<Z+M\
M_P#?O\^(C'\OR>^><>GO4%]X-U+4IO$QDN+>V_M*6WGLY8G9VADA"[2P*@<E
M0>":[BB@#F(;7Q7?:3>0ZL=+29K9X8X[5WV2.PQO9BN5 [  ]:I1^&=82P\(
M6^+$MHA3SSY[XD"Q&/Y?D]\\X]/>NTHH Y[P_H^H:1JFM&5K9[&]O7O(F5F\
MP%E4%2,8 &WKDYSVIWBK1[W5H=,DT]H/M%AJ$5X$G8JKA0P*Y )'#>AZ5OT4
M <<=&\3:7XAO;[1IM-FM=2V27,-V77R9E4*73:#D$ <'TZU<31-43QK::NTE
MM-;1:<;.1VD9978NK%]H7'5>F>]=+10!R::!JRW_ (KGVV175T1;<>>^5*Q>
M7\_R<>O&?3WJN/#.L+IOA&VQ8[M%>-ISY[X<+$8_E^3OG/./3WKM** .*N?#
M&L3Q>,4'V$?VXNV F=_W?[H1_-\GMGC/I[U9;0=6?5?"UT19!-)ADCG F8EB
M\83Y?DYQC/.*ZRB@#SVW\(^)$M=(CFETM[C3]2^UR7)>0O= AQO?Y>& 8<<Y
MQU %7I_!]]=_\)18RSVZ6&L2">.9"QECDV* "N,8#(#G//3CK7:44 <SIL'C
M%[1X]5N-,CFBA98I+4N?.DVD*S[AA1W( .3Z 8-.S\-76GZW/KMM;:?IMPUE
M(D\,,S&"XFX*NPVC:!@\XR=Q].>RHZT 9GA^[O[[1+>XU.*".\;<)! 3Y;88
M@,N>=K  C/8UC^++2VUBYTZVM;Y8M4BN0@\IP9$C=2)01U *9.?4+75U6BTZ
MRAOIKV*T@2[F $LZQ@.X'0%NIZ"@#(UC0IY=3TC5-+,*W&F[T$$A*I)$X *Y
M .", CBL_5O"$^M:;XD\Z2&&]U>V6W0*2R1*@.W)P"<DDGC\\<]A10!QL&B^
M([GQ1H>LWZ:9"ME:S6\T,,SN?GV?,I*C/W>F!CU-=BRAU*L 5(P0>]4[C5[&
MTU.TTZ>X"7=YN\B+:27V@L>V!@ ]:?;:E:7EW=VL$NZ:S=4G7:1M+*&')&#P
M1TH XL?#^YB\._8X=0"7UK>K+I]SC/V>%)&*)[X1W'_ O05M>)- NK_2-,L-
M+6V1+.[MYL3R,HV1,"%&%/)QBNDJKINI6FK6$=]92^;;RYV.5*YP2#P0#U!H
M QUTC4E\=2ZWMM/LKZ<MH$\YM^X.SYQLQCYL=??VI_@[1[[0M!^P7_V<R">:
M4-!(S AY&?NHZ;L?A6_10!SE_HVHW'CG2]9A%J;2SM9H'5Y6$C&0J<@!2.-O
MKWKG_P#A!M7?3KAC-91:C#KKZS9,LCO&2S$^7)\H(!!(R,^M=S;ZE:7=[>6<
M,I:>S95G7:1M++N')&#QZ5:H YG_ (1^ZU+7I-9U)8;>4:>]C!##(90N\Y=R
MQ5>>  ,= >><"QX.TO4=%\,6.EZD;4R6<2P(ULS,&51@,2P&"?3''J:T=5U>
MQT2P>]U&X$%NI +E2>2<#@ FKM '+7.BZM8^,I==TC[)/%>VZ07=M<RM&04)
MVNK!6[$@@BLE?!^NCP@FD%]/:==4^V[_ #75=OG>;C[AY[?U-=_10!SMII&H
MQ>.+W695M1:7%G%;A5F8R H6.<; ,'=CKVK.TO0O$^B7%SIEE=:>VB2SR2Q3
M2;_M%NKL690N-K<DX)/?)STKLZ* ..AT/Q'HVNZFVCSZ>^F:G.;EOM1?S+:4
M@!RH PX. <$C_&Z=$U&#QJFL6\EO+;/IZ6<WG,PD!1V;< !@YW8ZC'7GI724
M4 <MH6G'0=*U*WUZ;3XX;Z_GF7]_E6$K%MAW*O.,CWH\!Z2=,T .UQ)<"5B+
M>23[PME)$*_3;S_P(UOW^FV.J0I#J%G!=1(XD5)XPX##H0#WY-6@ !@<"@#"
M\5Z#)K^DQ16TZP7EK<QW=K(XRHE0Y&X#L>1^-0_V3?WVO6NM7T%K%/8VTD5O
M!'.S@O)C<S/L&!A<#@]2?:NCHH P?!FD7F@>%+'2KXP--:J4W0.65ADD'E01
MUJ+Q;HVH:RNCBP^S?Z%J4-[)Y\K)E8R3M&%;DYKHZ* .130-7CUWQ3?!;$QZ
MM;Q10+Y[@J41E^;Y.,[L\9Z5EV/@_7M&/AO4+%K"74-,T_\ LVZMY)G6*>'@
M@J^S*L",\J:]"HH \]F\'Z_<^'?%NGNVFK-K=RTT1$S[8PRHI!.SG&WTY]JV
M/[$U9O&.DZPR60M[6P>TF43N7RY4DJ-F"!L[D9SVKJJ* .+70_%&C>(=2ET.
M?3)=+U.?[3(EZ7#VTI #,H4?.#@'!(Y[CJ2;P_XCTGQ3<:OH-Q8W46H011WL
M5^S(1)&NU95* YR.HP/\.JL-2M-3CF>TE\Q89G@<[2N'4X8<CL>_2K5 '*WV
M@:NWB/0=6M[BUGDLX)H+HS[DW>9M)=  >A7[I(XP,]Z=H]A<Z#J_B+4]5FL8
M+/4+I)HW%P?DPBQ@-N4 9P._?%7-4\8:#HQ;^T+\0(KF,R&)S&' R4W@%=V/
MX<YK0N+6PUO3?*N[>&[LIU5_+FC#*XX()!_ T <UX&T2'3Y=5NK:X,VGO=21
MZ<O&V*'<6<)[&0N/<*M=+JD=Y+ITJ6 @-P2NU;C/EL-PW*V >"N1T[U9BBC@
MB2*&-8XT4*B(,!0.@ '04^@#@)?AX+BSUN"W\K2HKX0R06UNY>.&>-BWF8P
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MAFC8_<)QSP>?PH ZB%VDAC=XS&S*"4)R5..E/K$MK?5(?%,I%XSZ/]E"K;-
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M&@(/##(YZ<=.HS63;^,M5LCJ>E:I%;S:K:7UO:12P1D1RB?E'VDYR &)&>2
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M"3R.><^E7J1 P10Y!;') P"?I2T %%%% !1110 4444 %%%% !1110 4444
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M$EUF783%*LBJ"@VX PW3&.*Y^&_U^V\%^'_%G]N7=Q.\D"W-HX7RI8Y'"$
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MWGG;G[W/_P!:NCJO?7MOIMA/>W<@CMX$+R.>P% &7>Z) FHMKCS7<EW%:-;
M* VY#@D;57DD@'C^58G@CP]_Q2&B1:E]N#V85_L=RNU8Y5S@X*AC@G(R2 >G
M08["SEFGMDEGA\EW&X1$Y*#L&]_7''UZU/0!CIX;L5U'4[V0RS'4XUCNHI2#
M&ZJ"H&,<8!(]\\YIMAX8L['[&OGW5Q#8_P#'G%<.&6#@KQP"< D L3@'BMJB
M@#E[*,^(?$-KJ]SHUS8_V8LL4+7B*KN[D E0"?E"@\GKNXZ59UCPCI^LZG#J
M;37MG?1IY7VBRN#"[QYSL8CJ,UOT4 <]JG@S2M3CL<&ZLY[$%;>YM)S'*@/4
M;N^>^<_J:2\\- KI$5C<7L)LKD3&07)_><@OYF>9"PR.?4_0]%10!#>6EO?V
M<UG=1++;SH8Y(VZ,I&"*Q]%\)6&B+MBGO;I%0Q1)>7#2K"AZJ@/ '0>N!C-;
MU96KZN;"[TZQA16N]0E:*'>3M7:A=F..P"]/4B@"M9>$M/L8[>WCDN7L;67S
MK>SD<-'"^201QN(!.0"2!V' I3X5LR=8S<W?_$W&+OYU^8;=G'R\?+QQ_/FK
M^E3:A/8AM4M([6Z#LK)%+YBL <!@?0CG!Y%.2:\6_N_M,4$=@B(T,PD.YC@[
M]PQ@ <=Z ,^/PQ!#'%'!?WT2I:+9D*ZG=$N=H(*D9&XC(Y]Z;-X1TUY=.DMV
MN;-M/@^S0FUF*9AX_=L>I'RCW]ZU[*\@U"Q@O+9]\$\:R1M_>4C(/Y5/0!S7
M_"#Z4-%DTE)+M+22Y^U,HFR=^_>,9' #8.!CISFKUQX;L;K6%U29IS<?9OLL
MF)2JS1@D@.HP#R2?QK7K.UW5X=!T.[U2=&>.WCW;%ZL>@'XD@4 9-MX$TJU&
MG!)]0;^SG+6NZ[8^6I!78/\ 9P<>O;.*D?P9I\FE:GIKW%XUMJ4[3W(+KEG;
M!;!V\ X' ]*9=:]JNF7L=K?V%M_I=Q%;V4T4Q*LS!BP92,C:%)SWR.G:YI=U
MXBFN[B/4],LX(8U(BEBN2WG,#P<8^52/7)!SUH >WAVT?6+756EN?MD$'V?>
M)=HE0-N <# .#S3_ !%HRZ]HD]@7\N1MLD,N,^7(I#(WX$#\,UGZ/KVIZYX5
M_M*TL+87QGDB%N\Q"824H?FVYZ GIUKI* ,6[TE/$%O82:@+BUGLYUN%CC88
M69>AS@[AR<=CGD9X!_PC-J+K5KD7-T)-514N3N7!"KM&/EXPI(_^OS6E-?6T
M%Y;6DDH%Q<;O*C[L%&2?H./S%6* .9N/ VEW%CIEN)KV"73$\NTNH)_+FC3&
M-NX#D8 '(JW=>%K"ZL;&T,MTD=G<+=1L)<NTJG(=F8$L<DGGKFMNL^WU-7U:
M;3)U$=TB>='@Y$L1.-P]P>".V1ZB@"E>>%+&\U6;4&FO(I;B$07"0S%$G49V
M[P.I&3_(Y%5SX'TD6.EVT,EY!)I>1:7,<Y\V,$8(R<@J1VQCVKI:KV5];:C;
M?:+642Q;WCWKT)1BK8_$&@#$_P"$*TS[%JMJ9KUDU5MUV6N"Q?@ ]>!D <CF
MK0\.6PU.QU#[5=&XLH#;Q$LN-AQD$;><X'/M6S10!Q&N^'1INCFWLX-4N[:Z
MU(7EXUK,!/$V2YDCQC)WA>!G R0*L^&[&ZCU);B"\\0-9;&$J:P^=QXV[%8;
MP1SST^O;K3G!QR>V:YW2/%*W6DZIJ&IQQ6:6%[-:OMD+@^6VW() R2>G'<4
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M[1W=$F0QL4(!P1@XS[5CGPE9&QTFS^T78ATETDM '7*E1M7/R\X!(Y]:WZ*
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MY.W4;/49OM"-]X[CE7]P1T/M7=UG7V@:5J-TEU=64;W*#:LXRL@'IN&#CVH
MP_'NK-8^'I#;S,@%S;Q7DL9(,,+N QW#H<<>H#9[BH+RR73/'^B0:7&(;34+
M:Y6^@@^5"J*I23 Z-N8+NZ\UU:Z=9+8M9"UA^RN"KPE 58'KD=\]\U#9Z+IU
M@C+:VJ1[D\LD$D[!T4$G( [ <"@#RRVL8E^&NA:JKS#4(]45$N?.;>JM=LA
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ME7-X]W-8PO/( )&(_P!9CIO'1L=LYQ4CZ382:FFI/:QM>HNQ)R/F5?0'T]J
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M+:?;_9+8AH80F$C(Z$ =_>I8=(T^WU&34(K5%O)%"O,/O,!T!/<4 7:\QTB
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M:*>,%$>/;DDY)P00<C/I7*?#NZM_#>DR^%M6GCM-0L)Y=HG8)Y\3,661"?O
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M97X&>A SQS]* ->BJ?\ :EI_:G]F[W^U[/,V>4WW?7.,8SQG/7BKE !1110
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MM;72C?1-);!W1@JG'4#JW?/%<SXL\6ZUKOP+TO5I+L037EW]ENQ"@ F4,X_
M'8,@=<^G%>BS^ _.\7:GXA74V2:_L6L6B,&51" ,@[LD_*#5!_A79R_#R+PA
M+J<YA@N/M$%RL8#*V2>1G!^\WIUH [FSBN(+5([JY^TS#.Z78$W<\<#CVJ#6
M;J:RT+4+NV7?/!;221KC.6520/S%6+2&6"UCCGN&N)0/FE90I8_0<"INHP:
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M=K,5,9$D>0R@#(*XSG))[]Z .KL?$::A%K!@L+KSM,E:%H#MWRN$#87!(YR
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M5U"_AGFDMT"H TJIL .3@!CSD$T >DT5Q<[7.G^*-*\/-JM_/#J+7%W++-(
M^$5<1(R@;5R2W'/&,XK%UW6-8TS3?&FG0ZC<C^RXH;FSNLAI%60',;,0<X(.
M#][!ZT >G4R5S'$[JC.54D(O5O89KB;D:MHOC'0U76;R[MM7\V&XAFVD1NL9
M=7C&/EQ@\<\=<U7\,Q:IJ'AF?5[CQ!J1GB-[$J@IL(61@I(*G+#;P?PQ0!W-
MC<O>6$%Q+;2VSRH&:"7&^,GL<<9J666.%-\KJB[@N6..20 /Q) K@=,UO4+W
M3O!^GO,7EU+3GN9Y'N&B:9D5/E#J"1]\L<8/R]<9S4U_3]6@TC3[;5M2,Q7Q
M#;" PW#%UA:1=JR'"[F'."1Z'K0!Z917!>)[JZMH]>%IJ5Y++I^FB6&."0I]
MD95=M\K$_.6P/E(/ Z<YI+J?4]5\0>'K0:Q>6D.HZ3+-.+?:I#@1_,IQP<L>
MN?;% '?45P\E_-X2\3R1:GJ%Y=Z=>6!>U::3)6:(9D08QEG&&'N"!74Z-;7-
MII%M%>3/+=; TS.Y;YSR0#Z#H/84 5;[Q'!8>(+'1I+2[>YO5=H&0)L8(,MD
ME@1@'T^E;-<9KW_)4O"'_7"^_P#0%K'O)=6EL_&\W]NZ@C:3(TEKY;*N"L"N
M <+RN>,>YSF@#O=2U2'33;1LK27%W+Y-O"I +MM+'D\  *23[4:3J#ZG9F:6
MQNK*19&C>&Y4!@5.,@C(*GL1P:X[6HSJ>M^!;J::=)+EG9_*E*@$V[-D8Z'G
M\JNV,USXDO/$</V^ZM&T^Y^QVHAD*F,J@/F,/X\L3PV1@=.N0#LJ*\RLM:U?
MQ'_PA;R:C<V7]J6]TMTEOM7<8UP'7(X)Z]P,\>M:=M9ZA+XQO=!EU_4WM8=+
M@<.)%63<6=2=P4<G:"3U]\<4 =U17EUGJ>L'P?X:\02ZQ=R7;W\-K+'D"*2,
MS&,[E Y) SGKFK?BO5KZSL]>U"QU&YFFL;B$1M"VR&U&4S$XSB1CN)/!QN'3
MB@#T,RQB982Z^8RE@F>2!@$_J/SJ"PNY+Q)FELY[4QS/$JS8RX4X#C!/RGM7
M*K:;_BY<G[1<C&D1R@"8X!\UAC'3' XZ9K*A\1:E::%-')?3233^)GTH74F"
MT41EVY'& =H('&,F@#TFBN.N)KW2_&MMI$%Y<M8ZE8S2#>_F/;R1X^96?)P0
MP&#D9Z5S^EZAJZ^'/!NMRZQ>37%[?16UQ$[#RWC<N#E<=> <Y_3@ 'J-%-D?
MRXV?!.T$X'4UYO)K6I3?#-?&D%],NH+FY,6\F$H),&$ITQMXS][(SF@#M]1U
ME;&ZBLH;>2[OI8GF2WC902B8!))( Y90/4GZXM:=>?VAI\%W]GN+;S4#>3<)
MLD3V8=C7(36JW'Q6L)3+=1E]'DE*B5AM/FQ_+]/45U6M_:?[!U'['N^U?99?
M)V]=^T[<?CB@"I#XCBO9ITTVRN[^.!S%)/!L$8<=5!=EW$=\9'O5O2]5@U>"
M66!)D$4K0NLR%&#+U&#6#\,C ?ASHOV<C:("&Q_?W'=^.[-2>(M2-IJ^C:7;
M/Y U2]9+F:,X8!8MVW/9FP@SUQT[&@#J**X#4K_4]+U;Q%H\%_<FW31FU*UF
M9M\ENX+*4W,"2"5SSDCG!J!)=5C;P7.NMWV[5HA%=*S*RD&#?N4$8# CKR>>
M<T >C45YAJNI:KIFA>.;6WU>\+:4\3VL\C!I5#QJQ4L1TR3CO[UKW#:IH/C/
M0B=7NKRTU7S8KF"XV[(V6,N'C  V@8((]/4\T =Q17G5CJE_'JWA9TU"ZNXK
M^>>*XN6.V&Z'ENP,<9)V@%1@@#(]0<U2O+K6!X9\7ZD->OQ/I.I3"UPR@818
MR P"\CDC'3D]Z /4J*X[4[^?1?%6DZG=7DPT?4(S;2QM(?+@G(W(_P!& 9?3
M.#6YX>$[Z6+NXDF9KMVG5)6),<;'*+STPN,^^: -6BN;UJ22;Q!;627EPP:U
MD?[#:,8Y"=R@2M("-JCD8[D]#BN<L=<URZ\$^&]6D@N]2B:-SJ$=G)LN' ^5
M74 @MCN 1G(H ]'HK(\,7UOJ/AZUNK6]DO87W;9I1AS\QX8'N.A^E:] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<A\1K.?4-"L[6WM[J=CJ-M(XMD9F5%D!9LKTP/Q]*Z^B@#*M
M]#LQ-/=7!EO)[F 0/)= $F+D[-H  ')R,<]\XJAHG@?2M EW6,U_L0,+>&:Z
M:2.VSD'RT;(!Y//)Y/J:L1:W</XUN-"DMXEACL5NTE5R6;<Y3!&!C[I]:W*
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MM([[4+Q)[I9M0C6*<^9G*J"%QD<8!//7FK][?VVG11R74HC66:.!,_Q.[!5
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M$$&MO+<"\MXS%&5<!50]1MQ@Y]^:EUO1;77].:PO6E%NS*[+$^TDJ0PYZ\$
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MC5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)'J5Q9Q7=P;*&6!4+F)0.A8''R^7R*EUSP]9Z/K?@_PCH*O"&N)+R:3=ECM
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MJT_6_#%S?:?KEKIN'=%N9MK>5MD90Q5B/O!20#ZU4\.:UX<\0'1GLX!)J-E
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MMEJ/C6X-Q#_R 1$<N/O^>3M^N.<5R]Q+8#X8>)'C>W$AUN1E*D;C_I2E2/\
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MU#4K2PCVW%];VLCJ2AE8=NK8R.!D9K&\(:^]]X(L-6U>[A$LV_?*<(I(D90
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M+RW1(@19U)EP2#MYYY!''H:Y+0-0\-:_>Z3>P7-U-J%A$^89"5^Q*4PXD&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@N,D#)P,]Z6@#&\*MJC>';8ZR!]NRX=A'Y9<;SM8K_"67!([$ULT44 %%%%
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MDVMHDEO>B=W8R!2WEI]WIP/F!SWQBEET_4)_&^E:J+-EM8+*6"4M(F59RI'
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MZ$[<'DC .<=^U6K?PWK-A_86H"5KRYTUYXV@EE!=K>0_*N\\%U 7K@'!&>E
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M;*:SNXEEMYT*21MT93U%<AH_B;Q-JOAU=;BTBQDB>"79;QSL)&E60J.2,!<
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MRP^GM=I/-(W!#A>0!TYZ#KZBJFG^,Y[W1M))MH4U;4+N6S$6XF-6B+>8_J5
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MYQG!XQU"P^&M=TS5[_\ LC5[:+2M0N&N98IH"\L#MRYB.0.3S\P(!['OU]%
M&+:OJR^*;F!YH9=)%N#& A\R*0;>&8GYBP+'VP/7G:JEJ^JVVB:7<:C>>8+>
M!"[F.,N0!["K,$RW%O'.F=DB!USUP1F@#D]&\,:[HDC:;;:Q;_V )6DC1H3]
MIB0MN,:OG&,D_-@G!XQQAS^%K][?Q5%]HMO^)YNVG#?N<Q"/G^]P,]JZZB@#
MC'\*:S9WNFZII&H6D-_!8I874=Q$SPSQKRK8!!# Y/XXSZW+SPU>R7NDZM!?
MH^K6'F!VE0B.X23[R$#)4 XV]<8YS73T4 <CJ/@QM4TSQ )[E(]0U@1[I$4E
M(A&!Y:C/) ())XSD\"I8-"UQO$UKKMY>V!FBLGM7@BA8(=S!N"3D<KU.?3'>
MNIHH XR'P=?I\.I/#!U"))^=EPB':P,GF;67/0\J>>0:)].U'1=2O_%-_?6W
ME)I?E316UJQ*["S#8"W3YN_7':NSHH \PT W^F)ILEO>>%M1"A4C2V:3SF#$
M;_+^9E4GDG"@<<X'3?M/#&NZ5J%Y!IFL6\>BWD[W#1R0%IK<N<N(F! Y.2"0
M<9Z'OT]OI]E:2/);6EO#(_WFCC"EOJ0.:LT 8UG+JW_"37\4TL$NEB)3"$C(
M>)^,JS'AB>3[<>M;-%% '#W'@S4;CPWKNE&[M5;5-0:\$NUB(@SJQ7'?[N,\
M=?:ME]&OI/&%MKA>W"16+VAARV2696+9QZKC&*W@RDD @E3@@'I2T <G9>&-
M0MO#VO:8]Q:L^J37,RR*& C\[J".^,GN,^U-E\,:FD/AJ:TNK07VBQF']ZC&
M.5&C",>""#\H(KKJ* .';P+>SZ?JT,VK(ES=:B-2M;B*#!@F 7!P3@CY>GOU
M-7;G0_$.J^'-1L=6U*R:YNK9K9/L\+)$@88+D$DLWY ?B:ZNB@#F7\/7TNK>
M';QY;;9I4,D4B?,?-WH$)'IC;GOUQ[U6T#PQK>A*NE1ZO ^@PR%X5\EOM*IN
MW>5OW8VYXSC....W7T4 <?:^&==TK4;V'3-8MX]&O)WN&CE@+36[.<N(F! Y
M.2,@XST/?7LY=6_X2>^AFE@ETL1*80D9#Q/Q\K,>&)^8^W'K6S10 A 92",@
M\$5QEOX+NX/#<WA8W<+:*\A"2$'SDA+[C%Z'N-V>AZ5VE(S*BEF(50,DDX %
M &#9:'<VGB^^U?S(/LUS;16ZPJ#N01EB#GISN/%;]59[](-0M+)H;AGN0Y61
M(BR)M )W-T7.>,]:M4 <1:-?#XF^(_L/V9C]BM RS,1@_O,'(!Z>G?/44Z7P
M/=6-II,VAZDD&J:<9299XMT=SYIW2!U!R 6Y&#Q^M=:EA9Q7+7,=I EPWWI5
MC 8_4]:G9@JECG &>!DT <MJ?A[6-4T^P6XU"U>\@U"*^D81LL8\L@B-%R2!
MQU))ZGO@7=:TFZU4R02PV%WI\T C>UN@<+)D_.I /KZ \#D58T?Q%INNR7::
M?+-(UI,T$^^WDC"2+U7+*.1D=*U: ./C\):AIT^@W&F:A"\VFV36,K7D;,)$
M.WYA@C!!7IGIQFJJ>"=6@L$CCU6U>6+6'U-5D@;RW#,QVO@\GY@00!@C\:ZC
M7==LO#NEOJ-_YHMT95)BB+G+$ =.G)')P*TJ .&N/ =[>VVN17.JQ*]_=QWM
MO+% 0T,Z!<'!8Y7*]/0]:N+X<UF^U^QU/5;O3R(;26UFA@A?$BOMS@EN/N_A
M[]:ZVB@#DO#WAWQ!HR0:9-K4$^C6I'D8@(N2@/RQLV=NT<#@9(&.*U-!EU:1
M]074Y8)HTN2+:6&,H#'UQSUQTSZY]*V:* *>K:9!K.D7>FW0/D7431/MZ@$8
MR/>L*#PWJ%Q::/9:O=6\\&E3),DD2D/<-&"(RP/"XX)P3DCM6OK&NV6AK:&\
M\W%W<QVL7EQEAO<@#)' &3WK2H PO#NBW>D7.KR7$L,BW]ZUXHC!!0LJKM.>
MOW1SQ6[12,RJ,LP ) Y/<T <))X)UEK-K5=5LRD>K+J44DENQD<B3?B0[N<=
M..H Z5M6_AZ\@\2ZKJ O(3:ZE#$LT?E'>&1"GRG. #G/0],5T1( ))P!U-8\
M?B;3IXVFM_M,]JI(-S#;.\7'7# ?,/<9'O0!SL?@G5H/#^CV\&KV\6J:*W^A
M7"P'8R8VE9%)).X=<=,<5>U7P[K>M^&Y;*^U"T-[/-%(S1Q,L,:QN'"JI)))
M(Y)/?V KI+&]M]2L8+VTD$EO.@DC<#&Y3T-6* , Z->GQE'KV^WV+IYLS#EL
MY+A]V['J,8Q[^U<CK&C7N@Z-HEH]Q;O-)XFCGC<*=N9'=MI'L3BO3:KW-C:7
MA4W5K!.4Y7S8PVWZ9H Q)?#<FHWNI7]_)''<W=@=/C6'++#&<DG) W$DYZ#H
M![U?\.Z?>:5H5G87L\,TEM$D*M"A5=JJ%'4GGC)^M:@  P!@"L[3];L]3OM0
MM+;S?-L)%CG$D93#$;AC/7CO0!!XIT5_$/AN\TN.<023A=DC+N"LK!AD>F5J
MC)H&I)K]KX@@N;5M0^RFUNXF5DBF3=N7:>2I4]SG(]*Z565U#*0RD9!!R"*6
M@#*T+1AI$=X[R"2ZOKE[JX=5P-S8  'H  /PSWJWJ,5W-8R)8SI!<Y4H[J64
M88'! Z@@$?C5JH9[NWMK5KJ655@4 [\Y!!Z8]<\8QUH X^Y^']OJ*:WYPAL#
MJ<42F.RR426-BPFY RV2.,#@=3G-:L>BW]]J.EWVLRVSR::':(6X;$LK+MWG
M/W>,_*,\GKQ6_&_F1J^UEW#.UA@CZU"M["UZ]F6*SJN\(PQN7^\OJ,\'TXSU
M% ')OX/U"3PQXATAKJV#ZM=37 E"MB(2')&.^,=>,YJ>^\-ZPFLVFMZ/?6D%
M^MH+.ZBN(V>&9 <@C!!!!)_/\^L)"@DD #DDU1?6+*/2VU)Y2MH,;9"I_>9(
M"[1U.20!ZY&.HH R=3\/:A?#1";V*273[T7DLDBD>:V&!50/NCYSCK@ =:0:
M)J.G:UK^J6FH6L<6H1K(HFB),4J1; 2<X*\ GC/:M;3=8AU.:[@6&X@GM'"2
MQ3Q[2,C((/((([@FM"@#.T*34)=%MGU39]M*GS"B% W)PVT\KD8..V<55\6Z
M+/XB\,W>DV\T<+W(53)("0H# ]!UZ5MT4 <^=&OSXQCUTR6VU=/-F8<MDDN'
MW;L>HQC%8B>!M0ATNQ$&H6\>IZ=?RWMM-Y;&-A(S%XW7K@AL9!KNZ* .13PK
MJ-UJ&NW.H7MJ$U>P6TDC@A;*85QD$M_MGMS[5%:>%M<^T^&Y[O4;'.C!T"Q0
M-B13'Y>3EOO$?@/>NB76[-_$#Z(/-^V);_:2#&0NS<%R&/!Y/;TK1H X_1O"
M^M:)))IMKJUN- ,S2QH86^T1*S;C&K9P%R3SC//&.H6/PUKNF:S?OH^KVT.F
M:A.UQ-%/ 7D@D;[YC(('/7YL@'L>_3WMY#I]G+=W!<0Q*7<I&SD #).%!-1Z
M5JMIK6GQ7]B[R6TPW1NT;)N'J P!Q0!0MGU9/%,UNTT,ND"V&P!#YD4@VX#.
M3\VX%C[8'KSMT5G7>MV=EK.GZ5-YOVJ_W^3B,[3L4L<MTZ#IUH P-)\,:[HL
MLFG6FL6_]@-*TB1M"?M$2LQ8QJ^<8R3R02,\5(WAB_8>*A]HMO\ B>+A.&_<
M_NA'S_>X&>U=910!Q;>$]8LKG2M2TC4+2+4;6P33[A)XV>&XC7D' (((.3^.
M,^MV]\,WLMWI.JPWZ/J^GM)N>5"(YTD^^F 25'3;UQCG-=/10!R=_P"#3JNG
M>(1=7")?:S&D;/&I*0J@PBC/+8.23QG/:EBT'79?$6G:W>WU@9K6UE@>&*%@
MK;BIX).1RO7\,=ZZNLZ36[.+7H-%;S?MDT+3)^[.S:N,_-T/4=* .>@\'WR?
M#^[\--J$<<TID*7,2G'SR&0@KGIR5//(-*VEZCI&K3>)[^]M/*@THP3PVMJW
MRA"7&P%O?O\ 3BNQHH \MT%[_3K;3[BVO?"^HX \N.$N)V+\OY8#%58Y.<*!
MZX%='!X9UW2]5OAI.L6T6DW]PUQ)%- 7E@=^7\H@@<GGD$#T/?I8+&PM;AG@
MM;:&:0$LT<:JS#OTY/457UK7M/\ #]JMUJ4LD4+.$#I \GS$X ^4'J: *]K)
MJR^*;J!Y8)=)$"F,*A$D,@V\,Q.&+98^P ]>=JL<>*-)%W!:S3RVLUP=L*W=
MM) )&]%+J 3[=:O2WZ1:E;V)AN&>='=9%B)C7;C(9N@)SQZT <C=>#-1N= \
M0Z9]KM5;5[XW8DVL?*!*?+C^+[@YXZULR:-?2^+[37#);A(;)[5H<MDEF5BP
M./50,8K?I RMG:0<'!P>AH Y6Q\-:A:Z'K^GO<6KOJD]Q,L@# 1F;@@COCUX
MS[4R3POJ4=KX9DM+JT%]HD9AS*C&.5#&(V/!R#@ BNDOK]+#[/OAN)//G6!?
M)B+[2W\38Z+QR>U06&MV>I:CJ%A;^;Y]@R+.'C* %AD8SUX[T <P_@6]N+#6
M(9]61)[S4%U&VGA@(:"90N#R<$?+T]#U-7Y-%\1:EH&HV>K:E9/<W5J]K']F
MB9(D#C!=@22S?D!^-=32,RHI9B%4#)). !0!R_\ PCE^;WPQ<&>VQHT;HZ_-
M^^W1^7D>G'/?T]Z@T/POK6A$Z7;ZM;G0%F:2)#"WVE%+;C$'W8VY)YQG!XQQ
MCL** .0@\-:[I>K7PTG6+:+2;^=KF2*: O+ [\OY1! Y//(('H>_7*H50HS@
M#')R:BNKN&R@,T[[4R%'&2Q)P  .22> !4JDLH)4J2,X/44 8&IZ#</XEL_$
M&FS1)>0P-:S139V3PD[@,CE2&Y!P:S=1\&7-YI&H0QW,"WVHWL5Y<3,AVKY;
M(511U( 0#)/<GO@=5%>PS74UL&(GAP6C88.T]&'J#@\^Q'4&BTO(;V-FA8Y1
MRDB,,,C#JI'8]/P(/0T 3INV+O #8Y .1FEHHH **** "BBB@ HHHH ****
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MF"C804V_PCD#/?D\U%%X#M8=/M;&/4[\0VNH?VA$"48JX<N%Y7D98GGDYZT
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MQN4NE:,)EY$Z;L@\<G@8J*3PWC5[_4+34KJU?4%1;E4"$'8NU64D$J<?A[4
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M ' >] '2T5F>'[2\L=$M[:_N9KFX3<#+,P:0KN)7<1P6"X!([CO6G0 4444
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M\4,FFR3P6L,\A:&6-3^\5R<@'(R.F: .WOKVWTZREN[J39#$NYFQG\ .Y)X
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MC&1@_+U[8/X$YIZ7=74=C)H]YJE]/]EU][2U ;,MY$J;_*9R1@#.6;/1<>U
M'IE%>47]WJ$?@3QBIO+F"6PU0I;F*Z=C$I\H[ _!*_.W!]:Z-;5K+XBKIZ7E
M[);7^E2RSI)=.V9%D0!UY^0X8CY<#T% ':45YYI$]UME\&75Y=OJ5M?Y:Y:X
M?S9+3/F"3=G/(Q&<'@FO0A@# [>]  Q*H2%+$#(4=ZR?#>N?\)#I/V[[,UL?
M.EA,;.&(*.5ZCZ5KUY#%82P_#G4=>M-3OK:_L+R[FM_+G81_+.WRF,?*P;IR
M">?3B@#UZBN,TV:XG\9Z];7$UPL3:=:S>29WQ&[>9NV\_+T'3'2L;3;O6Y_!
M7A;4(HYM746TCWMI]J*3S#( D4Y^8KSP3SN'?% 'H5W<7<,UHEM9&XCEEV3/
MYH3R4P3NP?O<@# ]:M5YZ^HQW,'@F[TV^OVMI]0:%A-*X9U"2960$_,P9<9.
M>E5+RVFN$\?,^I:D/[.)EM EY(OE,+<.",'D;NQX]J /3:*X*'4KO6]8T_2[
MB5<2:)#>;&F>+S7<D.V4P3C X[;B?HRXM_$&EZ;IB&<^(EL_/2[@BG,4TJY7
M:X.?G9!E2">2?7H >@45YY)J%S<:1H^IZ1#>:SI*6\@N+3[0T=V#N $G7+LI
M5UQG.>177^&[NVOO#6G7%G<37%NT"A)9L^8V!C+9_BR.?>@#4HKF/&.I363:
M':1R/##J&I1VT\J,5(0@G:".06( R.<$UE7QNM-\5:EI5K<W0T^XT:2\V^<Q
M-O*C;04;.5!!Z ]1]: .\HKE/ E@1X=TO5IKZ^N+J[T^#S?/N&=,[0<A3P#S
MC/?OR23MZ[>S:=X>U*^MTWS6UK+-&I&<LJD@?F* -"BN(TJPO+HZ'K4.LJEO
M-$!< 3R2?; Z\<$X5@>00..1TKG%-W#X$.M_VGJ+WUIK!CB9[MRNS[7Y95ES
MA@5)^]D_A0!ZJ+F%KIK42*9T02,G<*20#^)!_*JMOJ,BZ?\ :=4MAI[>:8_+
M:42=7VH<C^]E>/?%<QIEA WQ0\1OF8-]DM6^6=QRWF ]#^0[=L5S4BO?_#O2
M9+RXN9Y4\0*@DDG<L1]K*\G.2<< ]NU 'K=%<5K,H\)^*=.U:>[NO[&N8FLY
MUEN9'2"7&Z.3!)Z@%2?7'K70^'[>>#2DDNFF^T7+-<2)+(SF/>=P09)P%!"X
M'I0!HRRQP0O-*ZI'&I9V8X"@<DFLB[\0K;:_HVF+:M)'JBRLEQO "[$W].IS
MQZ=:I?$2%)OA]K@?=A;1W&&(Y R,XZ_2L;4K",^(/ UJLMPB.EUN99F+X, R
M Q)(_ C';% 'H%-=UC1G=@J*"68G  ]:\YM+IK72-<TZ75+Z.*#7EM+7:YDF
M=6\MA K,V?FRPR3P#UXJO??:)-,^(FG7/F);VUHDT-O]I>01%H&8@,<'!*@E
M>F<]: /389H[B".>)MT<BAT;U!&0:?67X<MTM_#FG+&7(-O&QWR,YR5'=B>/
M:M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "JE_IEKJ:0K<K(?)E$L;1RM&R. 1D%2#T8C\:MT$@
M DG '>@#(N/#.D76F3:?/:EX)I1/(3(V]I 00^_.[<,#G/& .E-MO"NBVMS/
M<1V>Z:>#[/,\DCN9$YX;<3NZGD\G-:T4T4\>^&1)$/\ $C C]*2*>&?=Y4J2
M;3AMC X/H: ,ZP\.Z9IKP-;PR'[.I6 2SO*(01C"!B0O''';CI1!X=TRVEC>
M.&0B*5IXT>=W1)#G+!22 ?F/;C)Q6C]HAW*OG1[G)"C<,DCJ!]*5)8Y&=4D1
MF0X8*P)4^A]* ,:+P?H,&LOJT5@J7<DGFMB1MAD_O[,[=WOC/>KEEHEAI]Y>
M7=M%(D]X0UPQG=MY P#@D@'''%7!<0M(L:S1EV&X*&&2/7%#SPQRI$\J+(_W
M5+ %OH.] '&>*O"R)X7DTW1-.GF^T7T5S-&LY.<2J[MEWX) /0\FNHLM*L[6
M5KI(I#/+&$:2>5I'"CD+EB<#GH.]+'J]E+K$VE1S*UW!$LLB CY0Q. ??@G'
MI]:M+/"TS0K*AE499 PW >XH Q5\&Z"NE#3%LF%F)!*(A<2 !@<C!W9 !Y Z
M ]!5NZT#3KN]CO9(Y4NTB\GSX9WC=DZ[692"PSSSFKXN(6E:)9HS(O5 PR/P
MJ3I0!E3>'-*G%@K6I5=/;=:K'*\8B.,9 4@9P3U]34UGHUC8:A>7]O$ZW-X5
M,[M,[;R!@<$D# XX[5;\^'&?-3'3.X4K2 @JCIO*Y4$_YXH ?6/+X8TN349;
M](I[:YFQYSVMS)!YONP1@&/N>:$U@:=8::NLW-I]ONY%A MB=CR'KMW'. .3
MFJVGZ]<3>*==TV\^S1VMA';/#(I()$@?.XDX_A'2@#0O-!TR_P!(?2[FV#VC
MD$IN8'<#G=N!W;L\YSG-5$\'Z&DD\GV-FDN+8VLSO/(S21G.0Q+9)Y/)Y]ZW
M*HW^K66FSV<%S,J2WDOE0ID98X)/X #D_P"- $<.A:?"TC>4\K20_9V:>5Y3
MY?\ <RQ)P>_KWJNOA/14TN#3ELR+>WD$D/[Y]\3#@%7SN! X&#TXZ5!IFO7$
M_B77].O?LT5OIYM_)D4D%A(I;YB3C/ '%;TLL<$9DED2-!U9V  _&@#-E\.:
M7-IUU8RV[R079S<;IG+S<8^9\[CP ,9Z<4I\/:8UW87312F:P4I;.;B3]V",
M$?>YR  <YK35@RAE(*D9!'0UE>(=>@\/::MS+&\TTTJ6]M;H<--*QPJ#/3Z]
M@#0 S_A%=%^S:A;/9>9!J+[[I)97<2-Q\WS$X/ Y&.@]*BM/!NA66E7.FP6;
MBUN5V3!KB1F=>1M+%MVW!/&<<GUIM]=^([#29[[[/I]U+'&7-I%O4K@9.').
M_'IM7/M6Y+/##M\V5(]QPN]@,GT% &3J7AVWN]"ATVW8PFT>.6SD=FD,4D9!
M0Y)R1Q@C/0D5,^E0:C+%>W<,]O>K$8B8;ITPN>1E",C/()&>G0UILZJ5#, 6
M.!D]347VNW\H2_:(O+)VA]XP3Z9H R+_ $"*\@L-)C@2#2;62.5T&,/Y9RD8
M'IN ))],<Y)&[37D2/[[JO!/)QP.M()HFA\X2(8L;MX88QZYH IZEHUCJK6[
MW<),MLY>"6.1HY(R1@[64@C(X(Z'O5>Y\,Z1=Z5)IL]JSVDLGFRKYS@R/D'<
MS [F.0.I[#TK32>&6'SHY4>+KO5@1^= GA9V194+* S ,,@'N: '1H(XU12Q
M"C W,6/XD\FJNJZ59ZUI\EAJ$1EM9<;XQ(R;O8E2#BK(EC*EA(A4=3N&!63<
M:CJ,7BFRLH[:VDTVXA9GE$A\U&&3G;TV<*,^K"@"74_#NE:SI2Z;J-K]HM4(
M*"21BRD="'SN!]\YJ(>%=%&AR:,;+=8RL&D1I'+,P((8OG<3D#G.>!6J+B$S
M&$31F4=4W#</PJ2@##E\(:%/="YDL=TOD?9W/FOB1.>'&[#]2<MDYIT7A/18
M8].CCM75=..;4"XD'EG&,_>YXXYSQQTK6:XA1@K31JQ;8 6 );T^M+)-%%GS
M)43 S\S <>OZB@"G::+86.I7FH6\3K=7A4SN9G;?M&!P21P.!@5?J-YX8Y$1
MY45WX168 M]/6B::."(R2R)&H_B=MH_.@#-NO#6EW6HMJ)BE@O&4*\]K<20M
M(!T#;"-WXYJ:;1-.N=*GTR>V$MI< B9'9F,F>Y8G<3P.<YX%9_A?7;C6+;4&
MOA;QR6VHSVB^5D!A&0 >3R36\'5F*A@6'4 \B@#%@\(:)!<)<+:NTZP-;^;)
M<2.Y1NH)9B3^/3 QTJU9Z#I]C+%+#%(SPQF&(S3/+Y:'&57<3@' _(>E7EN(
M7>1%FC+1_? 897Z^E5-.UFPU73S?VMPCVVYU\S<,?*Q4G/IE3@^E %./PAH4
M6DMI:6 %F7$BIYCDHP.04;.4P<D;2,9..M6!H&G"VNX&BE<7:>7<.\[M)(N,
M!2Y.[&">,]SZFM&.2.5=T;JZ^JG(I6944LS!5 R23@"@#(_X1?2/*TZ/R)=F
MG8^R#[3+^ZP,#'S<\<<]N*>/#>DB;496M?,;45"W8ED=UE &!E6)' XX%:*3
MPRP^='*CQ8SO5@5_.E6:)Y#&LB,Z@$J&!(!Z'% &)IO@W0M)M+BVLK-XXIT\
MM\SR,VS^ZK%LJ/8$4^Z\+Z?/X7?0(5>"TV!8?G9S"5(*%2Q)^4@$#VJ#Q?K\
M^@Z.UU9FU>X26%6BF))VO(J9 !!_BKHJ ,HZ8NI"UN-1B>*^ME9 ]O<.@^;&
M[!4C*G:.#Z56U+P_#>:3%H,$ ATQW#7!W9W(&WE1W)8]2>Q)SFMJ2XAB=5DF
MC1FSM#, 3CTHDGAA*B65(RYPNY@,GT% $@  P.!5#5-&L-9BACOX#(()1-$5
MD9&1QD @J01P35R2:*(9DD1."WS,!P.I_6A98VSMD0XY.&'% &9<>&]*N+Q[
MLV[Q321"&1H)GB\Q!T5@I ;'09[<5IPPQV\*0PQK'%&H5$08"@<  =A56YDO
M#=V)M);3[*SL+CS<EV&TX$>.,YZY[9JRT\*2K$TJ+(_W4+ $_04 4M=TB+7-
M(FL9',;,5>*4#)CD4AD8?0@5'/I,&LQV4NK6K"YM)!*@CG<*D@XW+M(SU.,\
MX/2M&2>&)D625$9SA S %C[>M$EQ#"RK+-&A;[H9@,_2@#,&EM=^)(]7NEVB
MTA>"TC)R1O(WR'W(50!V&?7 U)G>."1XXS+(JDK&"!N..!D\#-/JG*UZ-6MU
M1[46)B?S%;/G%\C;M[;<9S^% &-H]A=W7B2\UZ]LGLOM%E#:BVE=&8%6=F)*
MDC'S #GL>!5ZR\,:3I[Q&VMF5(9#)#"9G:*)CG)1"=J]3T'&3CK6F;B$,JF:
M/<S%5&X9)'4#WHEGAAV^;*D>XX7>P&3Z"@#-?PUI3SZC,T$OF:D@2[/VB0>:
MH& /O<<$CC'!I!X8TD#3@()<::,6G^DR?NN,<?-SQQSGCBJ]_K-W:>,M(TD)
M!]CO8)Y&<YW@QA??&/F_2MSSHMH;S$VDX!W#% #ZQKWPIHFHW]Q>W5EOFN8O
M)G_>NJRIC W*#@D \$C([5IW,RP1$F6*-V^5#*V 6["N=T#6]6UWPGI6J*+"
M&XGN,7"N&V>6)&4A.<[\ 8SQF@#0M_"VCVL]E/!;2))8Q&&W87$GR(>H^]SG
M SG/2J\MF_AJW9O#^BR7LEY=&2X0WI7#-DM(3(3WQG'-;DEQ#$&,DL:!<%MS
M 8STS2R2QPQF26140=68X _&@"CH>F+I&DPV@6,29:24QKA3([%G('IN)Q[8
MK1I%974,K!E(R"#D&@D*I)( '))[4 8A\'Z"=;?5_L"B\=Q(Y$C!'<=&9,[2
MPZY(SGFI[KPYIEW?2WLD,B7$\8BF:&9X_.4= X4@-CISVXJ74=;T_2])GU.X
MNH_LL*;F96!SZ >I)X ]:MR7-O%&)))XT0G 9G !/UH I2Z#ILU]8WC6Y6:P
M4I:E)718E(P0%! P0 .G2H/^$6T?[/J%O]GE,6HL6NU-S+^])&#GYNXXX[5K
MM(B ;G4;N!D]:I#6K!M6CTQ+F-[IX#<!58'"!@H)^I;CUP: .:E\/2?\)Y82
MQV5XNEVNEM:I<)<D%7+J0,[]Y&T$<Y[5N7/A;1KNPM[.6S/E6\WGQ%)71UDR
M27WJ0VXDG)SSGFM=F5%RS!1ZDXI/,3<%WKEAD#/6@#"?P5X>>WO8#I^(KUU>
MX19I%#D8YX;CH"<=2 3FK5QHUG'>#5XK:6?4;>W:.'-RX++UV<MCD@<GZFM%
MKB%&"M-&&+;0"PR6]/K1)<0PLJRS1H6^Z&8#/TH Q=$MKNZOYM<U/34L+V:!
M+=(/,61XXU)8[F7@DLQX'8#OFI=/T&"Q\0ZEJT2>6]\$$BB1F\PK_$0> <8
M ]_7C9J.6>&!0TTJ1J3@%V &?3F@"2L>+POI$$K/';,$:;SS!YSF'S,YW>7G
M;G//3KSUK6,D88*74,>@)YH$B$L ZDKUYZ4 9E[X;TK4-434KFV9KI8_*++*
MZATSG:Z@@.,D\,#4-MX3T>RM[."T@FMTLE=(/*N9%*J^-PR&R0=J]<]*UX[B
M&6(RQS1O&,Y=6! QUYI5FB=RB2HS@!BH8$@'H: ,Q_#.D.E@AM6"V#^9;!)G
M78_.6X;DG)R3DG)]:0^&-)(U$&"7&I<7?^DR?O>,<_-QQQQCCBM8YP<8SVS6
M!X8UZ?5K6\.H&VBGAU">S18R0'$;;>,G)- #K_P9H.I6=E;75DSI8C;;.)Y%
MDB'3 <-NQCMFK1\.Z8!:"*&2#['&T<!@F>,JK8+#Y2,Y*@\YY&>M:$L\, !F
ME2,,< NP&3Z<UE:]K?\ 94FG6L9C^TW]R+>-I.5C^5F+$9&1A2,9')% #QX;
MTQ/L_DPRP&WC:*,P7$D9"L<D':PSD\Y.3GGK6A:6EO86D5I:Q+%!$H5$7H!5
M+3;F^BM2NMR6*7!F9(GMV*K*G\)PQR&/<9/UK1>1(\;W5<],G&>,_P A0!6U
M+3+/5[)[._@6:!R"5)(P0<@@CD$'H1S4":#IZ0W,9CE<W,8BFDDGD:1T&<+O
M)W <G@'N?4U=:ZMTC21YXE1\;&+@!L],'O4M %73=.M=)L(K&RC:.VA7;&AD
M9]H] 6).*LD!@00"#P0>]-EFB@ ,LJ1@G +L!D^E EC8X$BDD9X/;UH Q-+\
M&:!HMX]UI]@()&W8Q*Y5-W78I.$S_L@4[_A#]#.E-IAM9?L3S>>T7VF7!?=N
MSG=G[W/UYK:5T9=RNI4=P>*Q/%&MS:5X2U#5],-M/);1&0;R60XZ_=/]: +;
M:!IK:J-4-NWVT1"'S1*X)49QD9P2,G!/(]:KCPEH@T9](^QM]A>7SC&9Y"0^
M[=N#;LJ=W/!'-:=M<I/&GSH9=BLZ*>5R,].U3-G:=N-V.,],T <U?6=WJ5VN
MA-HRIHL+PRF\DG5Q*$(?8$^]G< "3VR<YQ735S_A77IM8TV2:_-M%<B\GMU2
M(D!A&Y7@$Y/2MR6>&#;YLJ1[CA=[ 9/H* &WEI;W]E/9W42RV\Z&.2-NC*1@
MBLR+PKH\,MA*EO*)+ ,+9C<RDID8/\7.1QSG@8Z5K2S10)OFD2-.FYV 'ZU6
MU-[U=.=].DM%N,J5:ZSY>W<-V=O/3./?% &=+X.T*>WNX);-V2[G%S-FXDR9
M1C#@[LJW Y&*DA\*:)!+>2I8KOO8?(N2TC-YJ8(^;)Y."<GJ<]:UI)HHL^9(
MB87<=S 8'K]*1YX8X?->5%BX.]F '/O0!!INF6FD6,=G91F.",84,[.?3JQ)
M/  Z] !5ND5E==RL&4]P<TM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<EX^O186FCRW)QI9U.);
M\G[HBPV-_P#L[]F:ZVHYH(KF%X9XDEB<;71U#*P]"#UH \]\5-IMGH.O7^@2
M^8;A[9M2:UDW(L08*V O 8IG=CG')[5HZC:0)XZ\-2Z5'"(KFWN$O%A V2VP
M0%"P'! 8@#_>KK;6PL[&U^RVEI!;VXS^ZBC")SUX'%,M=*TZQ21+2PM;=)!A
MUAA5 P]\#GJ: /)ETRP3X417J6\2W4&K8AG48>,?;2N%;JHP3P/6NFDTRPL_
MB+>6=M:00V]QX?9YH40!9&$V S#N<$\UU_\ 8FD_9_L_]EV7D[MWE_9TVY]<
M8QFDNM*MBDL]M86?VWRC''(R!2!C &X*2!0!Y;:Z-9?\*Z\):MIT*+KGVBU6
M&X3_ %CDOM9">I4+NR.@"FM$C2M;/B33M>UA;&\BU&0E6$:S",,#"T98;ONA
M<8[_ %YZ[P?X:70-!L+:ZM+$:A;1>4UQ;KN+]L[BH/-;$VE:=<7T5[/86LMW
M%_JYWA5I$^C$9% '#HD5MXZ\0M#'%_:']DV[VOFJHD>7$O(_VB<9Q5?PVFAZ
MQ:>&M0CUH_VC;%<01"-9S(5Q*D@QN(^\6)],YKT5K.V:[2[:VA-RBE%F*#>J
MGL&Z@>U10:5IUM>RWL%A:Q74O^LGCA57?ZL!DT <+H[7&EZUHT5S#:ZGIMW<
M3'3M3@^6>-G5V995_BXW9([CGFO12 1@\BJEOI6G6<QFMK"U@E.<O%"JMSUY
M JW0!Y5J.ALTOB#P3:6T:M=RC5+"0Q_+$IY;V&)$"CVD':ND\/30>*=+DUV[
MLD4268M!')&/EVC,O7MO)7_MG77>5'YOF[%\S;MWXYQUQGTIOV6W^SM;^1%Y
M+9W1[!M.3DY'3DDT >4V<5HW@GX<RW,<)3[=&C-(HQM,<O!)[9QQ6P-.TW5/
M%_C!;FVM[F!=/M#&KJ&0 QR\@=,XZ'MGCK7;_P!DZ;]C%G_9]I]E#;Q#Y*[
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MF*66%69/]TD9'X43Z5IUS<"XGL+66<8_>20JS<=.2,T 3V\RW%M%.JLJR('
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M1UQSTSVKN1I]D(9X19VXBG8M,@B7;(3U+#')/?-1IH^EQV'V%--LUL\Y^SK
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "H+J\@LHA)<2;5+!5 !)9CT
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M$+F,-_".I!Z''?'3O50^-?#0E@C_ +:L]T[F./$F0S D=>@Y!&>^*P)9(?\
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MKOE<8X;Y@<''6N7T&[FT;0?!&KW5K=?V;9QW,%V1 Y,#2'Y)-N,E>",CU]Z
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M:/$1ZY!(XYW>]/M98O#'C.TDNK2>RTB?28[6R+!I!;LKEC$QYPQ!'7TQDXH
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M9SNW+C&<YH VV&Y2N2,C&0>:YO3_  SJ-A:IIX\17$FG(NQ8VMT\W9Z&3O\
M7&??/-.N?%]O;?VE ]C=I?V-J;PV<FP-)%S\RD,5(R,'G(]*CT[Q<LFG: ]_
M9W,,^K)&L;!5\LR% YYW< C)&>3B@#I(HDAB2*-0L:*%51T '04^L6'Q-9S'
M5QY%RC:5_P ?*NJ@CY=W'S<_+SGI4DNO1),+>*SNY[OR!<26T2KOB0\ ME@
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MY"L<#)X]Q6T#D CO0 M%85WXLL+.*YN6CN9+&UE\FYNXT#1Q,#AL\[B 3@D
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M&.>]HH XR6UO)/$OA"Y6QN?)L[:=+ERF!$SHBJ#^*GIFMKQ;87&J^$=7L+1
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MT_)SZ]/QKB],\/WMLVI6&EM?QZ'<Z;(B6E^3_HUPW"K&6YVXSGDCI@GMW]%
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M:^DP7IMI;9I-P>&7&Z-E8JP..O(/-7Z;'&D,2Q1(J1H JJHP /0"G4 %%%%
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MWFH_V>Z22X*,=V'7Y?G0A<@\4>(M&U9M>T[7]":V>[MHGMYK:Y8HDT3$' 8
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MK4/%8OU@2RUQ$C1HI2SQ@0^6205 SWZU-X?M_%MM%!9:LVG-!:+M%Q [&2Y
M&%!4C"=B3S[#F@"G:^-M3N]%GU>/PX?L5NER96-XH(:%B, ;>0=IY['CW-F'
MQA<C3[>]OM*2S@O1 +)I+M<2O(I8AN/D"@$YYR.V>*BTSP[JUIX#U/1)4M/M
M=Q]J$3+,Q3]\SD9.W(QN]#TIU_X;U:Y\(Z+;VTUM;ZSI#0RPL6+PN\:%""<
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M[F=KI?W90<$+CYLGCVR.O.*_AO3?%FE6]MH]Y+I\FG6>$CO(V;SI8E^ZA0C
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MQ!@!L2C: N0>Q/((]ZPO^$$%W>7\GV:'28=0T^2VO(;24NDLK8Q(%P -O/.
M3GMWTM$L?$S646FZ\; 6L$1A::VD9GNAM*C((&SCD\G)'84 ,E\:F#1;;7Y+
M #0YY%7[0)OWD<;-M61DVXVDX_BR 1QU 6Y\6:B-3UNPLM$6>32XXY2TEV$6
M165F_ND@X7@8/?)'>A#X2U63P<O@^\-N]@CK']M60[WMU<,!LQP^!MZX[^U:
M$>B:I%K_ (EOA':F'4K>**W'G,&!167YOEX!W=L]* *EQXIU&]U/PBVF00?8
M]6CDN&6:8HQQ"6V'"G &X'ODCMWLKKT5MJ?BN2+18UNM-BAEFD610UT-C,N3
MCC"C SGK5*U\+ZU96?A!HQ8O<Z(CPS(TS!'5H]FY3MSQUQ@?6K,OA_5FU'Q;
M.J6A35[:.&WS,P*E8V3+?+P/FSQGI0!)8^,+NXN]"6YT@6]MK,.ZWE^TAF5Q
M'YFUEV\ C.#G/J!39_&TD'AG6=8.FJ3I5Y):RPBX^_L8*65MOOT(J)/#NKJG
M@]=EI_Q)5 N/W[?-^Y,?R?)SUSSBJ&H^$]?FT;Q-HMJM@;;5+N2ZAN9)F##>
M5)0H%XP0?FR?I0!T&J^*4LKNZL[5+66YM85ED2XNO)SNR51?E.6P/8<CUXU-
M&U2/6M'M=1BBEA6XC#^7*NUD/<$>QS7.7.D^)=/\1RZQHZZ?.M_#''>VEQ,Z
MA)$!"NCA3D8."".WY=5:)/':1K=2K+/C,CJN%)/)P/0=![4 <K-KK6]SXP>Q
MTBVAU#388Y'FD?\ X^?W;,I8JN?E4<#\,CK3K'Q1<6VB^'4U!;47NIP*8Y);
MDJCXC5LLVSAV)X7![\TX>'=1EU3Q;)+]G2#6;=(8&60LR%8BF6&T>N>":CCT
M+4Y_#FEZ3J^EZ9?6L%OY%S;^<3DJJ*CHQ4<\-QQC=U.* .HL)[BYLDENK;[-
M.2P>+?NVX8C@X&0<9SCO5FL?PMI-QH?AZVTZYN#,\1?:2Y?8A8E4W'D[00N?
M:MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBN>\9:OJ&AZ/%>:>+=I#=0PLLRD@AW"\$'@\]<'
MZ4 =#5+4=6L-)6!KZX6$3RK#%D$[G8X &/<U@/JVM6NI1:-<S6\U[,DMUY]K
M:L0D*LJJ-A;[V6/.<8'3G-8^NWFK7GA.R.M68MKN+7+:,%1@3()EVR!<G;D'
MH3P0: /1**XSQ5XDU714U>XB>U1+*!)K:$H97N!C+EPIRBY^4'CGG)Z427>I
M7'Q*TZ..\2.T?2'N! T6X#,D8;G<,D]CV].M '4V>I6FH/=):R^8UK,8)AM(
MVN "1R.>".1Q5JN'7QE>VFE:[<7B6\MQ::M_9UJL:E%8MY84MDD]7)//05HS
MZQJ>E^*-.TB\EMYXM4BE%O.L)4Q31KN(8;N5(Z<@\8R>M &YJ&EV.JPK#?VR
M7$2L'"/R-PZ''J*M*H10HS@# R<UYY:>+?$+^'-*UZX;3_(FU 6D]ND+993.
MT6Y6+?*1@<8/3.><#4G\4S#Q1/HSW5O8W2W$0MH+J$A;N$[2[(^0"W+@ ="!
MP: .CL]7L-0N[NUM+A99K-E2=0#\A(R!GH>/2GW.I6EI>V=G/+LGO&98$VD[
MRJ[CR!@<#O7!R3ZM:>(_'MWI<UK$]M]GG/GQ-)OVVP.W 88SCKS]*V?^$EOI
M=0\(>4D"VFM1-),A0ET(@,@PV<8SCMVH ZVBO/G\0^+;C3?$%[9MI7_$FO9H
MO+:%\W"1JK$?>^4X)YYR3CC'/:Z3J":MHUCJ4:%$NX$G53U4,H./UH N45SE
M]JVH67C.STV22W33[^VE-O(8B76=,$J3NP1MR>@Z$5F>'_%.I:UHD?[VT&JG
M4#:N! PC"#Y]P4MG!B^8'/4@4 =9!J5I<ZA=V,,NZYM-GGIM(V;QE><8.0.U
M,N]7L+"\M+2YN%CN+Q_+@3!)=L9QQTX!ZUS-WKNKO)XSLTGMX6TJVCDM9HX3
MD;HV<Y!8Y/&,].^.U8\_VXZ)\/6::&6X>YA,;,A4 &V;&[DEB.O;/M0!Z717
M.^&]5U"ZU36]*U-X)I]-GC59X(C&'22,.,J6.",D=:=XYN+NT\$:Q<V-Q]GG
MBM7<2!<D #G'H??M0!ISZO86VJ6NFS7"K>788P18)+A02?88 [U=KS_44OQK
MW@55FMWNBESMD:(A%!@')7<2<#MD9]JLVWB[4+?3K^&]6"?4+?5UTN*2*(JD
MA;:5<IN)R Q^7/.,9&<T =O28&0<#(Z&L#1KW6Y-:N[74+4M8"-9+>\,0B);
M.&C9=QSZ@\<5%\0-1NM*\!:Q>63,MPD&$9>J[B%+#W )/X4 7KK6M%F6XM)[
MI)(US'<% S1IZAW487W!(JSH\6FPZ7"NDB(6.#Y7DG*8SCY>V/IQ4'AJSM[#
MPQIEK:JHA2VCQC^+*@D_4DD_C6?)=C3=:T_POI(CMS+#-=L[+N$48?[JKQR6
M?CL .AH Z6BO/]3\9:QI^C>)$VVAU31)HE9S&WES12XV,!N^5L$YY(R/?C2F
MU/Q%#XNCT4W&G%+RS>XAD^SOFW*,H((W_O.&'/R\\^U '745Y^WB_7$\/13A
M+&2]AUO^RIR494E EV;EY.W(]=U7H==\0V'B2\T34([&\FDL'O;"2!3"K,IP
M8GW,<<D?-GI^@!V5%<;I7B34+CQ';:5)<6MP+G3FN?.C@8)'*K*"%;.'3YNQ
M[=:S;3Q;XA?P[I.O7#:?Y$^H"TGMXX6RRM.T6Y6+?*1QQ@].O.  >B45RZ:_
M>6/BO4M-U>:VCLUL_MEE*D14M&N?,#$L<E>. !D'-;6CR7TVDVTNI"-;N1 \
MB(A4)GG;@D\CH>>M %ZBBB@#&_X2S0O/G@.I1"6W.)T((,7^\,?+^-:=I>6U
M_:QW5G<17%O(,I+$X=6'L1P:X#0[J]MOB)X[-GIQO#YMH<"98^?(&!\WK5/P
M5<:A!X6\3R:7Y*:XFI3W4^F2Q,5MF//E#!&<@<,.": /4:*P;'6I-6?2'L)H
MG@N+8W-PQC.0O  '/RDL3US]UO2MUB0A(7<0.!ZT +573]2M-5M3<V4OFPAW
MCW;2OS*Q5A@@="#7,^&/$\^OSJ@O;9+I(6^V:?+ 8YK67C P3ED'()[\<CI5
M:W\8ZC_PAD.IW$=O]KFU,V!=4(BB!G,>\C.< #UZ]Z .YI" 1@@$>]<C_;6N
M)KFNZ<LMG)%IUHEQ'*]NQ+%E8A6PX'&T]!R"/QIZ?XFUUH?"=_>-8M:ZULBD
M@BA8-&S1%PP<MZKTQQGJ>M '8VVI6EW>7EI!+OGLV5)TVD;"R[AR1@\'M5JN
M+N/$NKPQ>,L&S,FB*'MR8FVL/)\S##=G/;(/X4^RU[6DUOP[%?/9R6NLVSMY
M<43*T+I&'SN+'<#SV&.* .QHK@KOQ=JW]AW>KV@ME,&J_8!9R1%F(\T1Y.&!
MWY(;'3''O7=1"01()65I-HWE!@$]\#)P/QH 5W6.-G=@JJ"23V%5=*U6QUO3
MX[_3K@3VLC,J2 $ E6*GJ/4$5S$4VJ/\6;JU-\ALXM+BF2$P_=#2L& .[J=@
MYY],5S/AO5]8T+P/H]_ ]F=/;5I+:6W:)C(ZR7;J6#[@%()X&#TZ\X !ZS17
M%ZAXCUJ\;61H%N))=-F-O'$UOO%Q(J*S*S;AM!W;1Z8SWQ76V<TMQ8V\T\#6
M\TD:O)"Q!,;$9*DCK@\4 3U#:W4%]:Q75K*DT$JAXY$.0P/<5D>*KY+?3$LV
MF\E[^06V\9RB'F1N.A"!L'U(K ^'EY#976K^%HY=\5A,9[(\_-;2'( SUVMD
M'ZB@#O**X75/%NJ1:7XDU&T%O&VC7?V=+6:,L9@ F6)!!^;?\N/3OGBQ>:KX
MF;Q-#HEI-IJ23:6]V)9+=_DD5U7D;^1S^&<\XP0#LJ*XJX\0Z]=V^HR:/;I/
M/87!MQ#Y!*W#IC?EMPV9)('I@$YS@37?B'5KRXU*UTJW,5S8Q1YC>#S=TSQB
M38Q## P5&1W)].0#KZ*XT:[XAGUW2--,-I8O?:=)<2I-&9&@E4H".& 8?-P.
M/KVK,E\5^)(?"NJ:LTFG%]&O);>=! W^E"-PI(^;]WP?]KGTH ]%HKEM0UW4
M+C4]1T_25VRV4,;%C;^;OD<%E4_,,+@#W.>V.:?]O^))=5T"P>VL[";4;2:2
M>.9#(T$D>W/1L,/FR!Q]: .T(# @@$'@@TM>::MKVM7O@J\+W4,-W9ZRNG3R
M0Q$+.HF1<@%OE!##(R>XR,UZ/"LJPJ)I%DD ^9E7:"?89./SH DHIDHD:%Q$
MZI(0=K,NX ]B1D9_.N0TSQ)JMYH;PS&U37X]1^P21+$WEJV[.0N[)'E9?.>Q
MH [*F&*-I5E**9%!"OCD ]1G\JYF/6-4UB36QI$MM'_9DQMD$T1;SYE0,V[#
M#:N6"C'/!/M532O&5SK%_P"&'@CB2SUBUGEDC927B>(#(#9P1DGMVH [2FNB
MR(R.H96&"#T(K#\+ZO>:L-76\\DM9:E+:(T2%0R*%()!)Y^8U;UZ[O++2S/9
M?9U<2('DN7"I%&6 9SDC.!DXR,T :2JJ(%50JJ,  8 %,N+B*UMY+B=Q'%&I
M9V/0"N*7QM/9V_B0W"K<_P!ER0);N8FA,OG ;0P/3#'J.HYQ6VXUV*YN8KMK
M6XTYK)F\Y$,;I-_=VY.5(YSU&.] &M87]MJ=A!?6<HEMIT#QN 1N4]#@\U8K
MS_X=ZK/J7AS2+'39X$BL+2-;XRQEG+LH*JHR,<<ECD=AGG!=^)/$HL/%%U#+
MIJ#0YWVAK=SYR+&K[?O_ "G!///T&.0#T"D(# @@$'@@US<>OW&K:XFE6#QV
MQ6P2]FE=/,(\PX1 ,CT))^@]QBR>,]630Y;YX[6-]+U7[#JO[MF4Q[E!EC^;
MCAE.#GOZ4 =_5*;5K"WU6VTR6X5;VY#-#%@DL%&2?08'K7.+XIN(/%.N:9>3
M0&"TM!<VICA(9N/G4DMAB"4X&,[A45^+L>-/!'V]HFN_*O/.,2E4W>4N< D\
M?C0!VM07EY;Z?9RW=W*L5O"I>1VZ*!WKD!XEUV_LHM4T>Q-S UT4^R^3C?"'
M*%A(6&&XW=,=N>M&J:M?:[HGBHV$L$-KIXGLPLD98S.D>9,G(VCYMHQW&>>E
M '86EU#?6<%W;/O@GC66-\$;E89!P>>AJ:N(T;5[B&Q\&Z+ 5A%[I2RM<.N[
M_5Q)\BCID[L\]A[Y#;'Q?JC:3YMW';-<S:JVF6Y@A;:Q0N&DP6.X$(2 ".>,
M]Z .YI" P((!![&L+0[W6IM3O[;4K0_9(]C6MV8Q&9 1\RLNX\@]^XJ_K=S>
M6>C75QI\<#W4:903OLC'/)8Y' &3U'2@"_17&6WB:_DU'7+&*:"X^R6*7EM<
M/;L@;.[((R-R_+PP/?O5?3_$VNM'X3OKQ[%K76@L<D$4+!HV:(N&#EN>5Z8X
MSU/6@#L-2U.STBPEOK^=8+:(9>1@3@?0<U9CD66))$.4=0RGU!KSSQ+JU]X@
M^'_B6^M)8(K&)9[>.-HRS2HF5=BV>"2#@8XP,YSQWFG?\@RT_P"N*?\ H(H
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MX/TZ]L)[>:2Y,T]REV]XL@6;S4QM8$# P  !C ':@#G6UC58X/&]O'=7=O\
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M;Z^5KR\^W2/O3<LW'(^7I\H&.1@?6M*QTN&QN+JY5Y);FZ93--)C<VT84?*
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M3TLK12(E9G)8Y+,S%F8^Y))_&KM !1110 4444 %%%% !1110 4444 %%%%
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M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7'AW2+FZ:YDL8_-=!'(4)42(. K@$!P!QALBM.B@"C=:/87LUK-<6RO):G=
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M114,5Y;3AS#<0R!/O;'!V_7'2@":BBB@ HHHH **** "BD9E1"[L%51DDG
MH1UD171@RL,A@<@B@!:*9YL?FB+S%\PKNV9YQZX]*?0 4444 %%%1B>$OL$J
M%NF PS0!)13#-$)-AD0/_=W#-/H **** "BD)"J22 !R2>U,@GAN85F@E26)
MN5>-@RGZ$4 2445%]H@-R;?SH_/"[S%N&X+TSCKCWH EHJ."X@NHO-MYHYH\
ME=T;!AD'!&1Z$8J2@ HHHH **** "BHX;B&X#&&:.0(Q1BC X8=0<=ZDH **
MCFGBMH7FGE2*)!EGD8*JCU)/2G@@@$'(/0B@!:*** "BBB@ HHHH **** "B
MBB@ HHJ.>XAM86FN)HXHEZO(P4#\30!)1110 4444 %%%% !1110 4444 %%
M%1K<0O.\"S1M-& 7C# LH/0D=LX/Y4 245%<7-O9P-/<SQP0K]Z25PJCZDTZ
M*:.>))89$DC<95T8$,/4$4 /HHHH **** "BBB@ HJ*2X@ADBCEFC1YFVQJS
M %SC. .YP":EH ***CAN(+E6:":.558HQC8, PZ@X[T 2445%<7$%I T]S-'
M#$OWI)&"J/J30!+14'VVT^R+=?:8?LS $3>8-A!Z<]*DAFBN(A+#*DD9Z.C!
M@?Q% #Z*** "BBB@ HHJ*>Y@M4#W$\<*$X#2.%&?3F@"6BFQR)+&LD;JZ,,J
MRG((]C3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LJ]UAXM2.F65L+
MF]6W^TNC2>6JIG R<'DD' QV.2*U:Y;5M'UJ#Q5'K^A-9RM):BTNK6[=D5E#
M%E=64'!!8\8Z4 ;NE7QU/2[>]:UN+1IDW&"X3;)&>X85<K-C768I[!&:TFA(
MD-[(=RL&/*",=,9R.3G '>M*@ HHHH **** "O(/&_AO4;3Q!?>,O#7R:AIL
MR&:!%XEC\I2QP.O4Y'<?3GU^LK3K;4(=5U*6YBM5MKB17B,<S,_"*OS H .F
M>": .9\,>)=&\3WJ>(H8X8I8].87.0"\)#98$]<=P>XJ&#XFAM,TW6[C3UBT
M;4+XV43^:3+'R0'88Q@E3D \>]7])\ 66C>(=<NK7:FG:M;B-[=>/+8D[MO^
MR0<^WTQ6!'\-=2D\/Z1X9NI[4Z9IVH-=M<H[>9-'EB%V;< G>03D@>] &KJ/
MCW4;;Q/KFAVFC032:99&\\Y[HJK(%5L$;"<X;'U].M;7AWQ?8ZWX7T_6;F2&
MP^V*V(YI@,,K%6 )QGD?J*P;GP9K,GC7Q'K4;V'V?4]-:RA1IG#*Q50&;Y,8
M^7L3UJSX:^']I;^#M-T;Q)8V%_-8&7RW4EU =RQQD CJ!^% '/\ CS66UWQU
MX<\)0W7_ !*;S;/=-#)Q<+N8;-P[?(?S]J[K4/".CWME%;Q6-O:M Z/#)!$$
M,95@<#&.#C!'>L+Q)\.X;R32+_P\T&G:AI# VRLI\IUW;MC8Y R3R/4^O'16
M\GB&Y,2W%K8V*A@97CN&G+ =0H**!GU)X]#0!S]_X_D2\\1)IMA'<0>'XU>[
M>24H9&.<JF >@5N3W&/>DU3XB?9G\,-IVG"\@U\XB+3^6T9RHP1@C^+U[&JE
M[X$U*"[\6#2WM7M_$<:AC/(RM;O\VXX"G<#O8CIZ>]%_\/KY9?!<>F36K6WA
M]]\K7$C(\Q)0G "D#[I/7O0!&?B/JWV?Q(G]AVOVO06S<?Z6?+9.?NG9DMP>
M" /<=*MZA\19;:S\+7-KI*SKKY5%1KC8T3$J,?=((^;KQTJE_P ('KGF^-F#
MZ=CQ  (/W[_NN6^]^[]&[>GXU@^)]*OM#@^&NES&V:\M;Y8P4=C&Q#1X.2 <
M=.U ':6'CX)JFOZ9KEI'9W6CP_:I#!*9$DAVALJ2 <_,O&.]0Z3\0O[2O]*M
M#;6JR:O;236BI<[C&RC(27 ^7*\Y XY&#UJ"'P%=ZIK7B?5M:>""76+3[%%%
M;.9!"FU1N+$+DY13C%:'@G1O$FAZ=;:5JK::UK9 I%/ 6:25>=H(( 7&>O/3
M'O0!R6B>)=4U[X;^*-5UFSM[RS:2;?&+EXVP%0>6H"G:H7H<YSU'.:6]\2W]
MAX?\ V>A6L-I9ZE/ !&]PS-A74^66V\*<C+8)/(QZZ6D> M<TKP-KOAD3:=(
MMX\IMYC(X)#A1EAM^7 7H,YSVQRZZ\ ZS)H7@^**:Q^W>'[A)'1I7$<P!4\-
MLR#\H_A[T 3-?6J?&&UBO]+CCU,:47-Y'=LR(GS97:5&>0W/IVH7XH)_9$'B
M"2P5=#FU#[$LGFGS5&#B4KC&.#\N<CU/2K<_A'5;KXD0>(IVL6LA8&SEC61P
M[9#9(&W&,MTS6)_PK'47\,VWA26XMCI<&I&[-T'/F/%@_)LVX#?-USC^5 &W
MJ7CG4;;Q?J'AVST>">6ULC>+,]T44J #@C8<=>V><=.2-KP=XD7Q9X7M-8%O
M]G:;<KQ;MVUE8J<'N.,U@W/A#5W^(&I^((FL?LMUIK64<;3.'!(&&/R$ 9'J
M:G\(>'O$'A/P;9Z1&=-FNHKK,C&1RAA9\L1\H.[!X'2@#M:X'Q7IZ>&/$-OX
MXLK5&CC7R-5C1!EH6(_>C_:4XSZCZ5WU8WBO3;O6?"^H:99>0)KN%H0T[E57
M(QGA2: *^DVEM?W\OBBXMXUDFC"6KN@#1VXR0Q)Y!;);V&T=C5*;QJT&A0^(
MFL%_L.20 S"8^:D;-M64IMQC.#C.0#GVK>TRRFBT"VL+Y(MZ6ZP2")RRG"[3
M@D _I7*P^$-4_P"$0_X1"Y>V?3E<1B\$A\PVX?=M*;<;\#;G.._M0!M1>(YI
M=4UZP6QC\S2XHI4;[0=LP=689^7Y?N^_6KNBZP-7\-V>L&!HEN+=9_*!WE<C
M.,X&:Q;C0M8M_$NK7FG"R>UU2TBA=II&5H&C#*"%"D,"&]16CX:TN_T?P=9:
M7</!]LMK80AXF+)D# /('\J (=-UG_A([!)!:VLVG75L[LZ3>9L;Y?W;J5&#
MAC_WR:Y+P/XCO-'\&^#H)],0Z=?%+);G[1^\61MQ4^7MQM.W&=V?;UZ&U\-7
M<.M+J\5I965T;:2.ZCMYF$=W(<;21MX .3G!/-9EOX.UR#PGX4TG_B7--HU]
M%<S/]H?:ZINX7]WG)W=_2@#3U;QG<:0[S7.F"*S74$LE\Z;9-,&*J98TVX90
M6]>0">*ABMX1\8KT"*/$N@QF0;1\_P"_<<^O'%9FI^#O$M[::S;[],E>YU)+
MR"[FE?S&C6576%AM^4*%P""1[#)-=#%HVK+X\DUV1;(V[:6EGM69P^\.7SC9
M@+DXZYH J?#!%C\$1HBA56\NP !@ ?:)*BN?'&HQ6.MWD>A1M%HURT5QNO,%
MD558E/D.3ALX.![GI6IX*T:_T#P__9^H?9C*+B:4-;R,ZD22,_=5Y&['X5DR
M^%M9DT3Q;8_Z )-9GDDA;SWP@=%3YODZC;GC/6@#<?7WN=5_LW2X(Y[A;5;J
M1II#&B*QP@X4G)P>W &?05S^H^,[Z\TG39]-MXX)VUJ+3KV&:4AHI!(-R A2
M"#C[WH>F3Q?@T#5=-U^#6;1;65YK%+2]MFF91N3[KHVWGN""!Q56Y\&WRZ0I
MM9+9M2;6UUB59&98F</DH& ) "@#..<9P,T =K&7,2&5560@;E5MP![@' S^
M0K)O=88:TFBV4$<]VUN;F7S9"B1QYVC. 223D 8[$_5EM?:Q_P ).;&YBL6L
M/L@D\R!F,B2@@$,#P%.3CO\ *?PI:EHNJV_C&+Q#I'V6?S+7['=6MS*T8*AB
MRNK!6Y!)R,=* .<\,:U+H&@W,ITZ/$_B2:U>%9MHA,DH7Y?EPP!/MTKJKCQ+
M-!K6JZ:-/5WLK%;U&$^/-4EAM(V_*?E/K6#_ ,(?K9\/7]NSV/VQM:_M6V =
MMC?O0^QCMR.G;/6KW]AZ_-K^I:I,FG+]MTM;00K.Y\MP7/WMG(^;K@?3O0!5
MNO%E[=^";G6KWPS!+I;V"7(BENE;S<_>5E*]!U!YR/0\#5N?$=[#K]MHMEI,
M<KSV!NHI&N/+08*KM/RD@?-U&>W'I4E\-:K+\+AX9S9B^%DMIO\ .;R^ !NS
MLSVZ8_&K2:-JH\76&KLED(;?36M'03L6WLRMD?)C'RX_&@"*W\;++X?M;Z2Q
M,=Y<:A_9HMO-RJS^84.7Q]W@G./PJ[IFOW5[XDU'19[".)[%8W>9)MRN'!*D
M J#V(/ICO7*WND7VF>'DT:Y;2S?:AK+W%LCSN%8%S*1OV@HP QN&3Z<FMWPZ
M=1LM;GM=1TJRAGNXS,]S;7KSLVS"@/O4$#!X[<'B@#0EUZ>W\86^ASV2)!=6
M[S6]UYY_>,F-R;-OW@#GKT_*H#XI<+;H+.,W%[>R6MD@G.)0F[=(QV_*N%8\
M ]O6JWC:"#4K6UM;2_C@UN"[A>S*,#(C$X)*]=NPN3[ GM4VM>&9)8]#GTAH
MH[K19 UO',2$DCV[&0D D97O@\]J (KGQA-8_P!MVUUI\8U#2[0WWE+.=EQ!
M@G<K;<@Y4@@CKW-6CXF<:AX>M_L*E-9A>17\[F(K'YF,;>?3.1]*K77ABXU>
MYUF^O3%;W-]I9TR)(V+B*,[B6)P,DL_3' 4>M4;;0/$;WOA>XNDTR,:.LD<B
M1SNWF Q>7N!V#![[<<8Z\\ &AH?B;5-;OI$31$BM+>]GM+B<W8)1H^A"[?F!
M/';&>]6M5\1K9ZD^FVPMFNXX!._VF<Q( Q(49"L225;MQBF^%-(U#1X]42^%
MM_I6H37<9@E9\+(<X.5'(JIJ^CZ[;^)UUWP^]E(TUNMM=VMXS(KA6)5U90<$
M;B.G2@"&#QO<70\/^1HLJMJ_G)LFE\MH7C5B005Y&5Z^G.#TIA\9:N+'67&@
MP&YT9V^UI]M^1D"!P8VV9)*GH0/KVJW>:)K-UK/AV_DDLY6T^2:6Y)=DR9$*
M[4&T\+GN><57_P"$<U<IXN7;8YUD'R/W[_)F(1_-\GMGC/I[T 3S^+KI]3TZ
MRT[2?M+:C8&\@>2X$8 &WAN#@?-UY^E<[XGUU?$GPVUO[7I_V34-/NHX)[=V
M$GER"5.5;'((/!^M68[?4-,\8^%+3R;>6YMM%FAE59B%(4Q#*L5]@>0*MZGX
M.U&\\-:Y;PM:#4M8NUN)2\C".(*R;5!"DG"H.<#))H WI];FEUFZTK3+:*XN
M;2%)9VFF,:*7SL7(5B20I/3@8ZYK(/CO=I.GZG%IO^CS7HL;WS9]C64N[8=V
M%((W<9R.H]>+0T;4]/\ %EUKEBEM*FHV\<=Y;23%-LD>0KJVTY&"000/7VJN
MVB:5I7A#4-,UN\MT_M)KBYN6+!<NY+,4!Y.WC'?@&@"_K'B.XTQ-8EAT]+F#
M3+07$C_:-I9L,Q3&TX(4 ]?XEXYJC_PENI+?Z1;R:(FS5H6>U9;L;@ZH'(D&
MW"KC/(+'CIGBDMM U*3X;W&F22I+J^H6;K<37#%?WDB;<L0#]T8'3^&G/H&K
M-?>%+C;9;=(1UN!Y[Y8M%Y?R?)SZ\X]* '6_C/98:D^I6:6UY8WJV30QS;T=
MWV["'*C@[QG(XP:C;QI/$^K1/IJ2O8V1O8Y+><M%*@^\N\H-KCTP<@YJG=>#
M=5O5U\FXM;6>[OHK^QFCD9_*DC"A=X*CCY.V>M:+V7BG5= U&VU,:7#<3VDE
MM%%;R.8RSC!=F*Y&.P /4Y/H )9>+;V;4-#BNM)2"WUF O;R"YWLKB/S"&7;
M@ C."">G('2G^#M6U756UAM1CMPL&HS6Z&*5CMV$+M *CCC.<\DG@577P[JX
MF\(N18XT9"MQ^_?Y\Q>7\GR<^O./3WJ_X:T?4-&N]82X:V:TNK^:\A=&8R?O
M"#M8$ #'/0G.>V.0"MXA\6W&@Q:E=/IH^QV'EYDFF\LW.X L(OE(;:#Z\D$<
M=:FN_$E\OB8:)9:7'/))8F\BFDN?+4C>%PWRD@<]L]N.I&/KOA37M3;Q)"DF
MGR1:G$$MKB=W\R!0H!B"A<!203D'OD@UIV^C:PGBZVUF9;$QQZ6;-T29\[RX
M?(RG3C&<^^!TH 2R\9K>Z+IMPMEMU"_N7M([0R\+(A8.2^/N@(QSCTXYJGX:
M69?B/XI\^VA@D-O:$^2VY7_UGS9P#D]\CMWJG#X+URUTS39H9;$:KIFHSW<*
M^:YBECE9BZ,=H*G#8S@]*W-&TK6(?%NIZQ?1V44-[;P1^5#,TC(8]W<J 1\W
M7C^M %+Q#<:B/B#X;MH8+>2 Q7<B+)<,H=@B#+#8<$!F ZYR>E20:RFFZ/J3
MZ!H\+Z7I,TL;QI-Y;.5.Z7RUVD<$GJ1D@CC@F[JFDZE=>,=&U6!;3[+813HX
MDF97;S HX 0CC;Z]ZHVWAW5M*BUS3K VLMCJ<TL\,DLC*ULTH^<%0IW 'D<C
MT..M #I_&5S-J%E:Z-I2WPO]/:^MI'N1$& V\-\IV_>_/ ]QN:AJ%W9:5%<1
MZ=)<7<C1I]GC;(1F(!)8 _*N<DXZ"L2R\+7>E^(M%FL_L[:;IVFM8_/*PE;)
M4[L!<?P>O>M'Q9IFHZKI"0:;+")4N(Y9(IV*QW$:MEHV(!(#?0^G0T )H7B'
M^U]1U73WBA6;3I$1G@F\R.0.NX$' P1R".Q%4+WQ5JP\1:CHFF:"EU<VEO'<
M*\EX(T=7+#GY3@_+P.<]\5+H.BZII_B;6-1NA8I;7Z0%8[=F)C,:;=O( Q[]
M_05F127T?Q9ULV=O#/\ \2NUW+),8\'?)CG:>.N?ZT 6;'X@6FI:3IEQ% L%
MY?&53;W4NP0-$<2;F .<$@# YW#ISBM)\0;B+2/M;:([3)J::=+&LWRMN8!9
M(V*C>ISQT]#ZU"W@?5]*M=(OM$N[1M9L9KB:=;@,L-R+AMTBY&2,$#:?89J]
MK>B>)-;T6T2=M-%ZFH07;Q"5UBC2)@VQ6V$L3@Y) Z^U #KG6KM-7\/P:UX<
MM8[BZO98H)1<B;R-J,0ZG8#EE!';K4]SXMN&LM6U#3=-2[LM+EDBF)GV22F,
M9D\M=I!V\@9(R0>G!,NOZ-J6IZWX>O;9;01Z=<M/.)9F!.8V3"X0Y^]GG'2L
MZU\-:QI,.OZ98&TEL-4FEN(99I&5[9I1\X*A3N /(Y'H<=: -*/Q3%JUU:6>
MC0Q7;W-BM\S3.41(6X7. 268YXQQ@Y[ YGPP#+X=U$- MNPU>\!A0Y$9\T_*
M#@9 Z=*9;^$-1\-:YI]_X>^RW-O'IT>G7-M=RM$66,Y616"MSR<C%:O@W1=1
MT.QU"'43;,]QJ$]TAMV8C;(Y;!R!@\^] $5QXNF&DW^LV>GK<Z98RR)(PFVR
M.L9Q(Z+MP0"#C)&<'IQFAK6I7EWXO\(M81V\]G<)<7$.^=D$O[D88C8<8#G'
M7.>U/M_"^K:?HVL>'[5K5].OGF,%P\C![=)<[U*;?FP22.1GOBK=QX<O8=<\
M-3:>EK]@T:"6#;+,PD96C5!@!".-OKS0!7\8:;9:;X0@M+.VC@M_[2M6\I!A
M<M<H3Q[DFNP2-(D"1HJ*.BJ,"N9\??\ (NP_]A&S_P#2A*ZB@ HHHH ****
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M83'-;R<8"Y.2@Y&><\<CI6MKE]>6MW8Q0S0V]K,7$TQ&^7< -BQIU8GDG .
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M[>>\LK>XEMFWP/+&&,;>JD]#P/R%<C<^*M5L_"=AXMD\A[&<Q27%F(^8X9&
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M(_0FNET'68/$&AVNJVT<D<-RI9%D W 9(YQGTK1H R_#FDC0_#UEIQ<R20Q
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M%WB73X+=I);C1KIVNW6-T5 !@QDD8;<^PX&<A#78.&*,$(#XX+#(!^G%.HH
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M!SC+C)Q@]O7C&O?ZA=7QA*WUPTC:0+C[)9L8VBD;GSG?(&WL%.<X/!QQL?\
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M8*YY(^8*S8Y'H,5G:+IDWVNT;3KCQ9!Y,B>8FIS9A$8(W*0V<Y7(&WH<'(H
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M!Q\HV@# [?6KU-12J*I8N0,%FQD^_%.H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK!\52VXMM/
M@G:4M<7T210QL%6=N3L<D?<XR?IWZ4 ;U%>8RZC<:1IGB>-91!;PZK D@MV.
MVWB?R_,V>G4],8)SQ6UX@BM]"TS5]4T.=HKN332R6\!'E84_ZX*!]X!NO?%
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M;IPACQG!!!/&.WUH ]DHKRSQ3-$^F>(-3L'9YK35(8S>3OB2&17B4Q0@#(0
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M?X0@M[?PCI*V\<:!K2%W" #+&-<D^]97C=G_ +5\)1G/V=M80OZ%@C%!^?\
M*@#HFEU,36(6UMS&Y;[6?-.8A@E=O'S<X!Z4VSU-9[^YT^9!%>6X5RF<AXVS
MM=?8D$'T((]"<'Q&NWQYX.</(-T]RK*'.T@0.1\N<9]Z;J3/'\5]"\G/[W3K
ME9\?W R%<_\  J .PHI')",5&6 X'J:\_P##$>G:]X9T?7+N\DBU6.[#SSQL
M%E:;>5,#<$[#D#9Z8Q0!Z#17FT CUSPIXJU"_8IJMG=782;=B2T,0S&$/50
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MUH A_L#2O],_T*/_ $W_ (^N3^^_WN>>..>W%(= TH+:?Z"A^Q?\>HR?W/\
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M'%5F\1:,ME=7G]IVC6]H-T[I*K>7Z9QZ]O6@#3K''A701;F!=*M5A,WGE%3
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M210QC:B(,!1["I:KVE]:7Z2/9W4-PL;F-S%('"N.JG'0CTJQ0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7&?$M;?_A'K*2Z5/*34[4LSCA5\T;N?3%=G6'XHT6YUVQM;:WFBA,-W
M%<EI%+9\M@P7 ]<=: .9OK+3QXVNKW3UMDLDT21+]H]HB)+#RPV.-V 3ZX ]
MJR4MX4^$&AW]C;12"(6C:@T*!G>!7#2*2.2,\D?6O5(HDCB""-$'4J@XS3P
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M''&,(BJ, ?*,<"G=: /,=-EU.U2+2K"\MM8MYM)N!I-_%A9[90J[4DQQ@D(
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M6,WTJO")@<7-N8U4(F.200W YRQQS7H=-:-'969%++]TD<CZ4 <1I]S'IGQ
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M'/'7@#GVJQ1C P** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;XJ+="VNOLQT;R?/,#B/?YN[;NQC..:;HT#S?$KQ)?*#Y$=O;6N[LT@4N1^
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M!N^3*D''.TXXK5\(1ZK;7>I6MW=W%_I\0B%G>74)CF8$-N1B0"^WCYL?Q'\
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MF"+RC*H<[9"G\)88)'O6W0 4444 %%%% !1110 4444 %%%% !1110 4444
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M:0&SGC.>GY&NCH **S]0U6.RNK6S2-I[R[+>3"I R%&68D]%&1S[CBL^/Q7
M;$2S65U!=->FP2U=0&DF']TG@KC+;NF ?I0!T%%<\WBN*";4K2ZL9X[ZPM_M
M36Z,K&6'GYXR2 1D$'.#FH+'QG'>7.C+)I=W;V^KQ;K:XD*;2^S?M(!R.,X)
M'./3F@#J**P[/Q$-0EC-I9O-:O<RVOG+(OR/'NR77JH)3 [\C(&:IR^-K>+P
MY?:TUC<>58W;VL\0*[@RN$)'.",GUH ZC/.**XZ=!%\6HI8XRTC:'*2H/WB)
MDQUXHT'Q?=W7AE-4O].E\R:\:WA2$A@S&=HU7/8+@98XZ9H [&BN9F\90VMA
MKD\]A<>=HQ'VJ&-E;(*!PRDD C!^OM4EKXK$^KVFGS:7=V_VVW>>TDD*8FV@
M%EP#E3A@?FQ^% '145SG@[7;[7M/N;F]M/(VW4T2X<, $<KMXYXQU[UT= !1
M65>ZTMMJJ:9!!]HO&@:X\KS F4!QQGJ<]NGJ14,'B-)M8L],:RGCFN[$WL9<
MC  V@JW<,"PH V\XZT5YUXEUJ#6=+T;4$M9T>T\20V[1G!8LDN& P><D<5N1
M>-[>.;4[?5-.O--N=/M3>M%-L<R0#^)"I(//!&>IH ZFBL7_ (2)+>VNKK4+
M<VUI!;+<_:%D$B.ISPI'5N.GN,9IJ>()QJ(LKC1[V.22V-S$5VL& (!0G.%?
MD<$X]Z -SI17%?\ "8V^M>%KJ_F\/:C)HTFGR3R.3&!(@R&3&\'.,G\#C/&;
MC>*;?3_[&TZTTB\E:^L_-M(XBF-JJIV9+<$!AR<#WH ZFC/.*X34O'TK>%-0
MOK'3IH-0L[I+.YM[@J&MV9E4-U(8?,,8X-:]Q?V;>+M%M[S2IDU&2"=K><NI
M6, +O7AN2?E[?C0!TE%<U<^,;>WTZ75ELYY='AF,4EVA!QM;8SA>I0-D$]>"
M0".:=<>*RNMSZ39Z3=WEU':K=(8WC"2(Q(!#%L <'K@^QH Z.BL_0M8M]?T2
MUU2U5TAN$W!9!AE()!!]P013M4U2'2X86D5Y);B98((DQND<YP!GCH"23T -
M %ZBN7OO&0TS3M7NKS2KM&TID\]!@AU<<-&QP&'/(X(K2FUV*W\1Q:-+!('E
MMGN4F!!7:A 8'OGYAVH UJ*PM.\1/JD%O<VNGR26UW;M<6\JRJ0V,85O[K'/
M3G&#W&*S/#_C&6[\*6&J:C:LL]]/Y5M%&RGS79VPJ\\  <DXX!- '845S_\
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MMNBSM#A2,[L>_..V,YI^J>.K'3(+FY:!I(+-Q'=$2H'0\;MJ9RVW/./?&<4
M;UAIZV*NS3S7,\F/,N)R"[XZ#Y0  ,G@ #D^IJYG/2L*YUR&\EN;&QM'U#RK
M=9;@(X4!7!*J">K,!D#@8QDC(JA\,R3\.=%))),)Z_[[4 =915'4]4ATQ;<.
MC2SW,HA@A3&Z1R">_   ))] :QKSQDNG:=J5U>:5=QMITR13H,88.1M9&. P
M^89Z$>E '3T5D3>((+?Q$='FAD5A9/>B;@J45@I&.N<MZ5#9>(I=0MHKFVTU
MY(;BT:ZMY%F4JP&W",?X6.[W'!YXH W:R-6T%=6U#3;QKN:%M/F,T2QA2&8J
M5^;(/&">F*Q]!\7RW7A33-2U"U876HN([>*-E/FNQ) '/  !R3V%77\6Q6[Z
MI;W5C<1WVG6_VI[=&5C+#S\\9) (X(.<'(Z4 =%17*)XW4OI)?1K]8-5B#6L
M@*'>^S?LQNR.,\G X].:L6WC"U:UU5[^UFL9],E2*>"1E8DN 8]I!P=VX <]
M>M '1T5RZ^-[47UY8RVLANK>T-ZJ02QR"6('!VMD ,.X./;-7/#_ (ADU^*.
MX72KNVM)K:.XBGF*[9-P^Z #G(]QSUZ8R ;E%%9E[K"P:G%IEM";F_DA:?RP
MP4)&"!N8GIDG X.>?0F@#3HKE)O'=E#HS:@;*\8PWHL;F !=]O*6"X89Y'(P
M5SG(K>TN^N+^WDDN=.N+!TE9!'.RDL!T8%21@_6@"[16-K_B&/0/L'FV5S<"
M]NEM4,(4X=LXSD@]CV^N*J_\)7M2.&;3GMM1:-I6M+F>-"B!BH);)'S$'&/T
MH Z.BN(;QT^HOX:ET>S>6VU.>5)-[*KJ41R8\$XSE<YSC XSFM+4/%\6GK>7
M$EA<&RLKF.VN)^ 0[[>54_>4;UR?KC.* .ESSCO1G-<^;K3Y/'WV)]/E&HC3
M&<79(VM#YB@H,'^\<\@=*H_#M%CT34(U&%35KQ5'H!*0* .NHJIJ>I6^D:=+
M?73$11@<*,EB2 J@=R20![FLN3Q++;3WEO<Z3=1RVUF;T$$,DD8."H?H'&/N
M_K0!OT5SZ>*[=X_#\HM9_*UM5,#97]V6C\P!AGT';-26GB(7TRFULWFM3=26
MC3)(N4=-P)9>H&5P._(X - &Y17'Z1XPE>PUW4-7M3;6UA>RVZ[&5_NE4" #
MDL6/TRV*U%\1>5K-OI=]8RVMS=1/):_.K+-M&63(/#@<X/'N: -RBN.'Q A_
MLF/5FT>_73_M1MIYCLS"WF>7DJ&RWS8^[GKW-:5KXH1]:N=,OK&>PDBM3>(\
M[(5>$':6^4G!!['UH WZ*Y:+QQ8OJ&G6S0LL>I9%K(LJ,2V,A74'*$CIGZ'!
MJ71?%C:Y=*EOHM]';B>:"6XD*!8GC.,$!B3DCJ,CWZX .DHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3/"]T!+'@!(V0X^;GELCVKO** ."U/POJFJWWBY5C^S+J4=J;.=W4CS(.1N
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MGI^AJFGZS>W?AVZ;3TW6M\;FXBAE3;$A1D"@DC<1N!)QCK[5V%% '-2:??\
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MJ<\^W*6LVK>&OAU8A-+6>^L+6**6W>X5!A  S!^1C )]:ZRFO''* )$5P"&
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MM]H51@;4QD,<#.<8Y^E6/"ECJ>D:-J<=Q8E;A[RYN88S*N) [%E&03@\X/\
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M.<@KR  0<DXZ<FMKPO/J$6JS6EP=%N$E0S2W&FO(SAQM \PN6SD=,G/R^@X
M.HO+J*QL;B\G)$,$;2N1V51D_H*YZV\0ZG-?:<!I[R6M\IW,EK*#:'&5+,P
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M[]T8^./EX.>_I[TS3/#.O:-<3V%EJ]L-!EF>54>%C<0!F+,B,#C&2<$@D9H
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MV1O&S"\XA4;0?E3ELLV!T'!/H"VU\77\MM96MQIC6NKW=[):1),CI&RH"S3
M, Q3:,@=<G&>]4XO!>KZ?IVA2Z9J5K#JVDV[6I:2-FAN83C*L.".0#Q_^J]J
M?AC5M0ATV_\ [3@&NV%P;B.3RB("&7:T>W)(4KWR3G)[T 0>&A=#XB^*Q=^2
M91!9?/"I4,,28."3@]L9/2NJU*YEL],NKF"-)9(8F=4=RH; S@D X_*L;1M$
MU.T\3:GK%[=6C"^AAC:&&-OE,8;&&)_VCVY]JUM8XT2_)_Y]I/\ T$T <A#X
MTUJ.RT#5[[3+-=(U1H8G,4K&6%Y!\K$$8VY[9SC'TJU>^,+\V]Q>Z5ITE[!;
M730&VCM9FDG"/L=D<#8""&P#G('4$XJIX9T>ZUOP3X6AO6MUL;:.WNOW9)>4
MHH**01A0#C)R<X[9J[:^&M>TK4KV'2]7MH]&O;A[AHY86::W9SEQ$00.3DC(
M.,]#W )!K^O7GB;4])L+"PV6/V:0R3S."T<FXG@+PV!P.@QU-00^,#::;K]W
M=6$$<MGJ?V*.*!_]?(PC"EF(')+C)QP!WQ6IIVBWEGXLU;5GD@:WOHX8Q&"V
M]/+# $D]<[C]/>LJ3P1/?:9K]E>74<9U*^^W02P@EK>0!=O!QNQL'IG)Z4 :
M$OB"ZTGQ#9:9JXMS#?Q2/!<P*RA'C&YD8$G^'D-GL>*YKQ/JE]KGA#3-56.W
M33[K4;5XXB#YJQ^<NURV<9/'RXXW=3CGIFT"ZU74+&\UPVQ-E%*B1VQ8AWD7
M:SDD#'RY 7GJ>36&/!6O+X:@\/+JEBUE9W,4EM/)"QEV)('"L 0.,8R.OMUH
M [^HKCS_ +/)]F\OS]IV"3.TGMG':LJRFU@^);V&XEMIM-$2&(Q1E6B? RK$
MD@Y^8X'08]:UKBXAM;>2XN)4BAB4N[N<!5'4DT <YIWB.[U'0;*X2*!-1GN_
MLLENP.(G5CY@/.<JJLWOCWITGB"^NK35;[3(;>2#399(C')G=<-&,OM8'"]P
M,@YQVJ+0;&RNO$^IZYI]P)K*4*(]C QF8@>8ZXX/ C&?4,/6GQ>';[3VU>WT
M^X@%EJ<KS?O0=]O(XPY4#A@>H!(Q0 VR\5OJ'B+3+.VCC-EJ6F/?12,"'0J4
M&TC.#][VZ5<\*ZW/KMA=S7,4<<EM?3VA\O.&\MRN[GIG'2L^X\)W=EJFAWNA
M7%M%_9UH]BT=VC,&B;:=PVD?,"F??/:KOA+0;SP_9W\%W=Q7/VB^FND*1E2H
MD<M@\\GGL!^- %OQ#K"Z'I?VUP GFI&\C*2L09@"[ <X'^<5S?BN\FO?!<T[
MO:W""^MOL\UJV4E3S8SD<G!R6'7M76ZE#=S01BS>$.L@+I,"4D3!!4X]<]?Y
MUR\W@J7^R;^TLVM;07E[%=^0FXQ0["APHP,[BF2<#KTXH TK?7-237K[2KVS
M@>6.R%[;BV<G>NXKL);'S9'7@<U%IWB2ZEUZRTR[2U+W5J\S+ 3FVD7;NC8Y
M(8_-U&.G3FG7_A^^OM<N[];J.V6XTMK &,DO&Q);>#@=">G'KFJUCX9U:WU#
M0[J6\L -.MWMFBA@8!E(7D<]3M_#/0T <A>*/^%5_$$8&/[5O_\ T:*]9@_X
M]XO]P?RKB9/!6I3>$?$6BM<V@DU>\FN5E&[$0E;<01CG&,9XSGMCGM;994MH
MEF""15 ;821GVS0!F7NK3?V[#HECY0NGMVNI)9E++'&&"CY006))]1C!/L:"
M^(M20:3I]YI\5KK.H32QK&S[XU2,$M+P<D$ 87(.6'/>EU[P_J5QKMEKVAWD
M%OJ%O$UO(ERA:*:)CG:=I!!!&1BFZAX:O[MM*U+^T(VUK3IWF61HR(7#KM>/
M;DE5*X /)&,\DF@"I>^,+[38?$-M/:6\FHZ1;"[4AV2.XA()W <D$$$%<_C5
MBV\1ZM_;NDV=[:6:0:M:R2VYB=B\;HJL0^>""&[=/4]:;J/A2ZU.VUV>66W3
M4-5M!9#!)2"( C@X!8Y8GH.P[<S-X?U!]7\.7K26P7289(I%!8F3>@0D<<8V
MY[]<>] &'8:_K$/@77]8O4L[]K>XN@8G#(I".5([_+@<#\S6S=>(=437=*TN
MSLK,B_LGN%DDD8!&7;G( Z?-VSGVZU5_X1#4E\-:[HBWMJT&H2SM"QC8-&)6
M+'=SR1D@8Q5X:#J'_"0:-J;26VVPLWMGC#-ER^W+ XXQL''O0!G+XSU!="2\
MEM+87,.KC2[J-2VPGS0F]#U[YP:T;SQ2=,UW5K2\C3[)8::-0\Q,[R-S KCH
M3\OZUG/X,U"30=2L_M=LES/JO]J6\@5BBOY@<(PX)'&,CUZ<5._A*_U+6+^\
MU:\M6@O]+^P30P1,"O+'*L3VW=3G)["@">S\0ZK)K6GVTVFO)9WB,7EBM9D^
MR.!D!V<88'IN&.>U=0<X.,9[9KFO#^D^)+$06VK:O:W5G:#;$T,+)+, ,#S"
M21P.P') R>N>FH X#2?%&H6&BZYJ>J/#=-%JLMG#%&"FZ0.L:*"2<+T]2.3S
M6Z=<O=.\3:?H^II;NFI1R&VN+=64+(@W,C*2>W(;/..E9DG@:>YTO6],GU"-
M;:]OGOK62.(^9#*SAP3DX(!&,#J#VK6BT:]OM7TW4M8:V\W3DD$*6VXAY' 5
MG.0,<9 7GJ>30!OUY=I.L:WH7A[6M2L=/L[C3[/5;V2Y1Y665D$IW% !@8'/
M)YYX]?4:X^/PGJ":9JVBF[M_[.U*YFF>8*PF5)6)= O3."0&SQUQ0!)=^+)[
ME[N/1HO->V@CE^>UEE$K.F]4^0?+\I7DY^]TXKH-)O9-2TFUO)K2:SEFC#/;
MS AXV[J<^AKG;CPSJ^G:_)J7AJ_L[>*ZACAN;6\A9T_=C:CKM(.0O&,X.*ZB
MUA>WM8XI)FGD4?/*W!<]SCMSV[4 9FHZS)%KEEHEF(_MES%).SR@E8HTP,D
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MAD=0P/U!KDHENW^*]U&=0N/(32XI5APFT9E8%?NYP=H.>OOC KKY"PC8IMW
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MEB)SM=3UP>000156]\'VMYX;O=&^U31K?RM-=7 "F21V()/3 Z =. ,5T=%
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M@$CN'5F<;0<X4G')(P?2@"K;>'I[*VL8+74Y EK:"TVRQ*Z2H, %AQ\P ZC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWXK9U?0-.UT6XU&*606\JS1!)Y(]KKT;Y6'(J[-:Q7%F]K)O,3IL;$C!B/\
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M55\0)?:D7T"/26EL+R#9/?/*NR-2<,-I^8MMZ'U(]#701QI%&L<:A40!54#
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MF>-801M.%4@'CCD'B@#B!=ZS8>&/'%GIE[<S3:;>[;1[B8R21Q%(W=0[DDD
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MS@]P:FTW49];T_PHL]]=7%Y<Z3]HELH9##YI(0>=)(I!5021@ Y+9 XKK/\
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MG[+LG=1'D8)P&P203DG.<TW_ (1;2<:D/)GQJ?\ Q]_Z5+^]XV_WN...,<4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J.>WANHC%<11RQD@E)%# D'(X/H0#^%%% $E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex109keyexecutivebenefit008.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR1#YOD-MWB0MMZ=<'^G6L"UT_4(? GAY&TZZ,]AJB3SP"(^8$$KDD#OPP/%
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M<CFC\0^(Y9;>>*.YNDDA>2)E#J(U4D$CU!H WKR]M["V-Q<OLC!"C@DLQ.
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MZ1>VUNLG]I,H5!+]P%2Q)..P4Y]^*=XKN[:Q\,7]Q>6)OK5(B98 0-R^^>U
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MZY*C1:-/%:^9-%).\R?NW1B,;>ISCJ.!0!NS0QW$+12KNC;AER1D>A]O:G@
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MU- ')VUCXDT75M0BT^WL[K3KZX:Y26:8HUL[\N"H!WC/( Q]176(I6-59B[
M %B,9/K4=I=07UI%=6LJRP2J'C=>C ]#4U '*:!8:MX8L'TF.P6]MHYI&M9D
MG5/D9BV'#<@@D\C-)K6@ZA=^#[C3H5BEOKFX%Q(=^U%/FB0@$\X &T<<X[5U
ME% '/-8WQ\;1ZO\ 9?\ 15TYK8CS%W[RX?IZ<8Z]:QHO#6KQ^#+*P\F'[;9Z
MD+P(9?ED43F3 ;'!PV.G:NZHH Y*6R\1:9XBN-3TZTM+R'48X_M-M)<&/R94
M7:&5MIRN,9XSQ3KC2M:L_$UMKMLD%Z\EG]DO(=_E8^8N&0D= 21@]O4UU=%
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M:GJ8O([-;74H;E3!J<,H4F$,"5D Y;Y<C&".G(YKI-8@FNM%OK>W0/-- \:
MG RRD#)].:NT4 <?;Z)JD4GA M;)C286CN<2CDF+R_E]>>>W%:/A_3KVQU/7
M)[J%4CO;OSXB'#';L5<'T/RYK5EU&R@OX+&6YB6[N,F*$M\[@ DD#TP#5J@#
M!\2Z)<ZI)IUS83BWN[6<_O>XB<%9 /?!!'NHJ'2/#1TKQ'?7$3(NF.%EM[=>
MD<K*%D/Y(,?[[5TE% '%RZ#JLFE>++86R!]6E=K<^:, -&$^;TZ9XS5S^RM1
M;7O#MX;91#86LL,_[P9W.JC@=P-OZUU%% ''^']-\1:'"-#6*T?38I6,-_YQ
MWK$6+;3'CEN2,YQ]<8*/HFJ-#XN3[,F=6!%M^]'&8A'\WIR,]Z[&B@"EH\$U
MKHMC;SH$FA@2-P#D94 '!].*X^;PWK9\(ZEHB6]NS27QFAE\_P"\IG$N2,?+
MP,=^:[VB@#EK_1+O4_$\MS+#Y=C<:3)8.V\;U9VSG'H!QUZT[P]'XHMH;;3=
M2@LU@M5"&]BF+-.JC  0CY2>,DGUP/3IZ* ,7Q3H'_"0Z0+9)O(NH94N+:;&
M?+E4Y4D>G4?C3K6[UR6$17&F0P7&,-,+@/%G^\!]X^N"!]>];%% '-)I>H:3
MXJOM4M8OMEMJ,,2SIO".DD8VAAG *D'GN#VK._X1:_M+71TACCEEAU9M2NR'
MPN6WY5,]<;P!G&<=LUU]Y>VVGV<MW=S+#;Q#<\CGA14RL&4,I!!&01WH YJ'
M3=0BU_Q%>FV!AOX8HX,2#.45E.?3.ZL&*TOM&OO EE+;*]S:Q7,3HD@^;$0!
M*D\?GBO1*I7&DV5W?V]]-$6N;;/DOYC#9G@X ..1U]: .9OM UB1=5U&TV1W
ME_<V[/;>;MW6\0 ,9<=&8;LD<<XSWJ%O#VKAO$PCL+.&+5;%(88XIN(V$;)@
M_*!CYLD_D#7<T4 <G_9&I&^\*3?9E"Z9&ZW/[P=6B\OY?7GGMQ1-I*7/CR.Z
MM;A3;2VZS7T*\AWC;$+$^N=W_?NNLJCI>C:;HMNT&FV4-K$[;V6-<9/J: ':
MOIZZMHU[ISN46Z@>$L/X=P(S^M8NB0>(VLX=-UBWM(H((_*DN89R[7("[1A=
MHV>I)/;@<\=-10!Q$7AK5&\''PE<I&;=6$0OA(,& /N^[U#XXQT[YK1ATN_@
M\1:]>BV4V]Y;0PP8D&<QAAR.P.[]*Z:B@#@K#PYK>D1^';ZW@AFNM/M&LKJV
M,VT21G!W(V,9!&<'K3KCPSK-]I/BFWDBM89-2G6XMP)BW*A/E;Y1C[G7WZ5W
M=% '(2:1J^J^(H[^]L[>VM9--ELIHUN-[IO8'((7!/'3]>U3>&[;Q+86EKI%
M]#:"VL@(Q>QS%FFC7A0(\?*<  DGUQZCJ:KRWUK!>V]G+.B7-P&,,9/+A1EL
M?3- ',V>CZM8V>L6C6-E=07.H27"+)+D31R."RD%< A=W7OBKGA?0GT274%B
M62WTZ9T:VLGDW^1@?/CD@ GL">GOBNBHH YZZL+^W\9?VS;VRW-O)8"T9%D"
MNC"1FSSP1SCKGVK,N?"^H6^EVLMLL,^H1ZQ_:LT6_8CEMV45B.P8 $CG'O7:
M44 <A#I>N)JNO7[V5BZZA';A('FW [ 0R-E<$$$C/Z&H;?PO<65GKT.FVS6M
MG?6AB@L'F!5)B&#..2%4Y7@>AXZ"NUJO:7UK?B8VLZ3"&5H9-ASM=>JGW% '
M,PZ-J:7?A*1K9-NE6[Q7/[T=3$$^7U&1GMQ52;PSJ\]OJ[P^5;W;ZJNI6+.^
MY25"@*^.F=IZ9ZUW-17-S#9VLMS<2+'!$A>1VZ*H&230!AH_B*^TV=KW3;&&
M3:$%F9_-68;AO+,5P 5R ,'KS6;8^&[G3$U0:=8HFGW0AV:5<RAH\[OWI'4*
M&4X YY';BNPAECN(8YHG#QR*'1AT8$9!IY( ))P!WH YSPOH+Z)<ZCY*26VG
M3LC6]D\F_P E@#O(Y( )(X!/3\*)=,OK#Q?-K5G$+FWO+98;B$.%=60G:ZYX
M(P2",CUYK2_M[2?[/FU#^T(#9PR>5).'RBMD#&?J0*T: .(F\+ZA%96WD112
M7+ZX-6N0),*HW9V*2.3C Z#.#TKMQR <8]J*KP7UK<W-S;0SH\ULP69%/*$C
M(S^% '.W'A+[7K^IO.ZG2;^$-)!W-QM:,M]-A'XX/:DM]#UNU\"W%C%>J-<E
MBV_:<X&0 J\]OD4#/KDUU=% '%V^C:S!KIU*WTVPM5;2FMA$)RVV7=N!/R_-
MD]?SR:M:'X=?3O$+W]I:?V9:2VY6YLTE#1R39!#HHX  !&>,YZ"NJHH Y+Q*
M\L?C/PH\,/G.'NOD#!21Y7.">,_6H[_P[?7EAXGN%B1;W68E@CA+C$:*A52S
M=,\L3C/8<UTESI-E=WUO>SQ%KBVSY+^8PV9X.,''(X/K5V@#DYM+UF35+!VM
MK>>R2Q$)@FFP()P>9, $-Q@#N/;)JAIGA[6K73_"D$]M!NTF5FFV39RI1E&,
M@<_-G'ZUW=% '#:GX>U:\MO%L4=M&#JYC^SEI1@!45#N]/NYXS6K-I^H2^*=
M'U(6H$%K:RQ2@R#=N?;C [@;?UKI** .#E\.:Q)X4U331;1"XNM4-XF9AM"&
M99,$^N%Q6M=6]Q;^+)->N8HXM.CTIH)'DD'RG?O)('\.!BMZ*^M9[VXLXIT>
MYMPIFC!Y0,,KGZXJ:2-)HFCE17C<%65AD,#U!% 'GFDQ:GIEAIL][X>26SL_
MWL31:B&6(OU9(RH/1B I8D9P*ZWQ1HK>(/#MUIT<PAED"M%(>BNK!ES[9 IU
MEX9T73IUFM-.AB=3E,9(0_[(/"_A6M0!S;Z??ZOJ6D7FH6BVW]FEYF190_FR
ME=H"X_AY)R<'IQ4OA+3KW2M+GMKZ)8Y&NIIEV.&!5W+#\1G%;]0W=U!8VDMU
M=2K%!$I>1VZ*!U- ',>(Y)8O''A9X8?.8+>90,%)&Q<XSQGZXJKJ_AC4;_3/
M$$L4,8OM7F@*Q-( L4<6W;N;U(4DXSU [9KJ)--T^_N[74V3S)H5)MY1(PVA
MASC!QR,9]:OT <WX@T_5IKS2]:TB.)KVR$B26D[[5ECD W+N&<$%00>E9GBE
M]4?1M+GO8(([IM8M#';1R[E3Y^%+X&23U.,#\,GMZIZAI5GJBQ+>1&589!+&
M-[+M<=&X(Y'8]J ,'4=&U34K^]U6V(L;P:<]G9!V!8.QW%V*Y Z #&>YJMIV
MC:O;>(-/U,Z9:01QV,EO-&ESN?<65MQ)4;B=O<^Y-=3'J%DVH-IT=U&UW''Y
MC0A\LJYQD^GXTZ\OK6PCC>[G2%9)%B0N<;G8X ^IH YS1M'U*Q\ S:// GVS
MRYT4+("K&1F(.>V-W/TJ&WT35(G\(%K9,:1$R7.)1R3#Y?R^O//;BNQJJ-1L
MFU(Z<MS$;P1^:8 V6"9 R1V'(H XW4=.NK;3/$J75M;'^U[Q!:1S2\.S!$"G
M'1OER#R!U[5>TA]0M==A?5-#:*:Y3[,EY]O6X(507"XVJ0.#R!DG&:Z:^L+3
M4[1[6^MHKB!_O1R*&!JOI^B:;I3%K*T2)R-I?EFQZ9.3CVH I>*=,O-1M].>
MQ2.2:SOXKKRY'V!U7.1G!P>:JVNFZGI'B+4M0AMX[J#4TC>2-)0IAF1=I^]U
M0C'/48Z5NVFHV5])/':7,4[6[[)1&V[8W7!]ZM4 9/AK1SH6APV3NKR[GEE9
M>A=V+''L"<#Z5K444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5F:SJITU;.*)%:YO;E;:$/]T$@D
ML?8!2<=^!QG-:=8WB30FUVQA2"Z-I>6LZW-M.%W;)%SC([@@D$4 5+W7=3T2
MTU&;4[2"1(I(H[*6$[!<-)@8*DL5PQY/<<BGRZS?Z=X@L=+OEMIEU".3[--$
MC1A94&XHP);@CH1Z=*9=^&[S6]#N;/6M01[F8*8Y+6(HD#(=RLH)))SUR>>G
M%6$T>\NM1L=0U.:WDGL(W$"PH55I' 4N<GCC@ =,GD\8 ,*W\7:T^AV.LS6M
M@MK)??99XU+E\&8QAE.<#''!SGGI6I=ZK>:F=;MM.^SK%8*87:9&;S9"FXJ,
M$;0 0,\\D\<<TU\'WR^%8-%^W6^Z*\^U>=Y3<_O?-VXSZG&<]*L_\(WJ-KJN
MI7.G7UO';:F-UQ#-"7V2;=I9"".HZ@__ %J ,[POJUS9Z;X,TY5B:WO[)MQ(
M.]#'&&X.<<Y]*NQ^*[A(=16>&%[B'55TRV"9579@FTMDG&-Q)^E-A\)ZA:6'
MAX6VH6QO='#(KR0-Y<B,FT@@-G.,<Y[4R3P3<7%CJL$^J 2W=\M_!/'#AH)E
M"X/7!'R]/UH LZS>^(K+2===A:HMM9F>VO8TX8A264H7)!&.#G'/0]*UO#YN
M#H%@UU*DLC01G<J%>-HZY)R?>J0T;5+_ $B^M-9U*&66YMGME-M"41 P(+8)
M.YNGH..,<YT-&M+JPTFWM;N>*>6%%3?%&47   X)/I0!SFJ?;O\ A8]N--%O
M]I.CR -<;MBCSDY(')^F1UZTR'QAJ)LK<SVMM'>1:Q'I=Y&-Q4EF WH<\#!!
MYS6U?:/=-XCM]:LIX1)';-:O#,APRLP;((/!! [&J5WX1>32&B@NU746U!=2
M-P\>4:96! *YR%P N,YP.] #[GQ#>VNJ:[:BU2X%A8K=PI$I#R$[_E/)S]WM
MZ]*-/U^;4=-O+ZRNM.O[>.WWQM$&CQ)SN1U+,1P!Z=:;'X>U==6U#4SJMNES
M=VB0#9;G$;J6(8?-T&[H<Y]13X_#4@U'4-2'V6"[O+3[,RP(0CG)/F,.YYQ]
M.YSP 4H?$^IR6OA4V]I9#^UXCO!+*(V$1?"@=!Q[^GO4D/BNZM[34TU&&!KV
MSOH[)/LZMLE,FW8<<L/O\@9Z<4ZV\+7MO%X:3[9 PT4$9\L_OLH4]?EX.>_-
M-N/!TMZFMI/?+&=1N([F&2%"&MY$"A3R>?NCT[T .?Q%J]HVI^;IKW4-O9FY
M@GBM9(0[#@QE7R<]\CJ,TZ/Q/*^AW^K6L]GJ=K# KQ-:(P8-D[PZ;B1@;3C@
M]:M6NF^(39R_;M9MVO/+V0/!;E$4Y!W.N[YB<=!@8SZU!'X:N8M0OM4M9K:R
MOKJ*.,B",F-F5]Q=QD;B1Q].YH OZ%JK:LDMQ'>65Y9E4,,]J"O/.Y64L2"/
ME_.I]9O+NRM(Y+2.)BTRK++,P"01G[TAR1D =LCK532- 73]8O\ 4]L$,EXD
M:O#;*0F5W?.?5CN].W?K3O$6CW.K0V1M+I()K2Z2Y42H7CDVY^5@"/7/U H
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MBAC@C$<,:1H.BHH 'X"N)\3ZWJ>FV^LW=K?EWLGB,4,$:M'$GR[A,6'WCD\
MY *G JWJ$NLW?C2;2+36'L[<Z:MRI6!'*/YA7C(Y&!W]Z .E@O1/>W5J(+A#
M;[,R/&0DFX9^1OXL=#Z&K-<;)JFJI<>,H1?G.G01R6K>4G[LF)G/&.>1WJ.Q
MU'5X;[PG+<:F]Q%JT)6>!HD55(A\P,I SG(YR2#GH* .VHK@;_7]7:PU62"\
M:'5K;4A;6]@$0[XRRA?E(R=RDON_H#7<K'(+81-.QDV;3*  <X^]C&,]^F*
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M 7>OZO)I][+!>-#JT6J?98]/"(28RX4?*1DY0[]W].*[KRY#:^49W$FS;YP
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M7M0NFLM/N+I83,88V?RP0"V!GJ:CT?4/[6T6QU$1^4+J!)O+W9V[E!QGOUH
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MJ26XEU"'R+B9L!BF" HP  !N/;J>]:]% &.WARVF\-/H=S<7-Q \7E&65AO
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M8*JC)8G  H 1%*HJERY P6;&3[\<4ZF0S1W$$<T3;HY%#JWJ",@T^@ HHHH
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M5Y-.LQ"S C)D9]H)R0NXG:,]ABF?\(EH@TV33A9$6DD@D:)9G R#N'1N #R
M. >U %".;^V/&FL:7>/*MO9VT!@B21DW;PQ9^""2#@ ]L<=:YR.[U*ZTW0X[
MB_NP\>OOIYG24J9XE\P MV)^4#..U=W<Z)87=U#=21R+<Q1^4L\<SQR;/[I9
M2"1WYSSS39O#^ESQ6<3VQ$=DXDMUCD9 C#^+Y2,GD\GU/K0!D^&E:T\3^(]-
M2>=[2W:WDB2:9I"A="6PS$G!(SUIWCG_ )!6G?\ 85M/_1HK9MM(LK34;F_A
MC=;JZVB9S*[;]O X)QQVXI=2TFRU>.*.]C>1(I!(@65TPP.0?E(Y!H -8_Y
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MD''M2:CX9T;5;&WL[NQC:"VP8 A*&+']TJ01^!H Y34+._TVTT6SEUJXF?\
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MM!6U!M-$A2!;W&[RB3M]=F?7'&[UYQVK F2.ST_4+^QM]]KIRSW$2$EOM-R
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MQN^R5XP08?+_ (CP%  [_7G1TUHKKQ=XFM-6C0DQ0^2D^"#;%.<9[;MV?<T
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M';O.FJVG611HEFBE9W(7;M"DX"D$Y.",].M;WCF-9/ VM H&Q:2,,C."%/-
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MWD@B:$  1L@*@#IQTI8)XKFWCG@D62&50Z.IR&4C((/I5#_A(-+$-]*;GY+
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M4*H50 H& !T%+5'1]235])MKY$=/-C5BK(RX) ) R!D<]:O4 %%%% !1110
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M)9G"R!<98#=GC^E>L44 <+=V;ZOXJU/5M.#26AT)[,R*"%FE9BR@?WL#OVW
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MN_V@.Y99%8 @CG'7C%>M44 >;:X)/,N-2TB[N;/5$LHU>RN;9FAU% I(CV,
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MWCYOFR..]-^V+H^KZ9J&J0ZB=+N]'M[=;BU\[]Q,A8E76/YN=W<=1]:],HH
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MN83]GB2']W$%'^K+#Y5.!C'M]*W*@DM8IKF&>3+-"28P3PK$$;L>N"1^)]:
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MT]N@N[>9^##+'\ZL?3D8/L35OP[;7,.CQS7RA;^[/VFZ _AD;^'Z*-JCV44
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M%N&XJ#C..N,]ZYNV\72S-XAA>Q@6ZTAP@B2Y+>>6&4P=G&X_+WYR*E_M-_\
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MG$V)6C1RC2*NW& 03@GD#/'2@#K**P;7Q$]YXBN=)AMHF5;&.]@G$QQ(KL0
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M7+-)(HELMS& PX.X;BI)8YSTQP!ZD]%574=1M-)L);Z^F$-M"NYW()P/H.:
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M#';E2RGL#@COGCH+#1YSXEN-?OEBCN7M4LXH8G+A(PQ<DL0,DLWIP .M;M%
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M]NEGMM7MTMI8/*VE50, 0V[K\Q[>F,4EKX6G%OI=KJ.I+>6NER++;KY&QV9
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MDX_.EC\$W%FNB7%AJZP:CI=K]B$[6VY)X./E=-P] <AAS6IX>T";0Y=3DEU
MW1O[MKIAY00(S  @8)_NB@".?5+R^\07NC:=+%;O96T<TDLD>\L\A;8H&1P
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M^S$&,S9W8&_G&3C^M-D\'W"2Z/>V.JK;:GIMM]D,QMM\<\/'RNFX'L#D-UH
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MXOX+5UG4\AV X(/'UP:L6^B3OJMIJ>J7<5W=6<+Q0>5 8E7?C>Q!9LL0H'4
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MI3F.J:CXE\4V1UR\AM[:UMIH! 4'ELRR' .WID#W/&30!W+RQQM&KNJM(VU
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MC<W*C^Q1*$60[0?. P!TP<#([UF+XDU.QT/5?,O9)9V\1G3(KF15)AC9D7.
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M:)I72( MM49.,D#H/6N&?5[^"ZT.ZAU&XNQ=:R;2>Y7Y;:6-O,PB(3_#M W
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MYI)Y#+-*YR\KG W$_0 8'   %8^L^*19:/9ZEIT45W;SWL=J7,A4 -+Y99<
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MD6&GOOM;9(V">6IR253^ZN>B^PXIU]I=AJ8C^W6D-QY9)C,B@E#ZKZ'CJ.:
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M_@CX>3(UO'-_:< 9P5#<K(&R?R!_"@#U.?5=.M;J.UN+^UBN)" D4DRJ[$]
M 3DU;KRQ;G2+O_A(/#WB74;J"ZDU&63[& H:Y0ONA:,[2S' 4#!R-HKM_%,5
M\_@K5(M.\W[:;)UB .7)V] 1_%_6@#1M]4T^[N7MK:^MIIT&6CCE5F49QD@'
M/7BA=5T]KW[$M_:F[R1Y F7?D=?ESFN2TS5?#_B&UTZ?1!%)J]K921VZ(2&L
M\QX(<= ,A5Y_#N:P6>/4OA-IEA9L%U^WG@CCB)_?1W:RC>Q'4'&]B?0DT >C
MW.N:39^;]IU2R@\EE63S;A5V%LX!R>"<''TJ:YU&RLT1[J\MX$<91I954-],
MGFN!$>EOXF^()E6T)6T@!W;>,PMN_7&?PJMI[SRZ%X9N](UJUM]7@T5!]GO,
M-!<Q87<I.<J0RC)'2@#O9[OS-1TLVVJVD<$V]C <,UTI3*^6<]OO9 .169XU
M\1C0_#NH36>H64.I00F2.*8AF;CH%R#D\XZ].AKG4OK6ZUKX<W9M8[!Y(9]M
MNQ&8U\C"J">2.F/PK(NM4M#\.?%^FZI-$FMBXN6G@F($DC%LQLH/)&T+@CLO
MM0!ZA)JME96,$^HWMM;"1 =TTJH"<#/4^]23ZKIUJ$-Q?VL(=#(OF3*NY0,E
MAD\@#G-<!)K5A9^*)!J^JM9:??Z9 +.Y^0PR*N[S$+,I .6!QQG\J8;#1+7Q
M'X%L85#6BPWJQ+>$%W0J"F0>H/501TQ0!WTFN:3$(C)JED@F57C+7"C>K?=(
MYY!['O5>X\2Z7;>(8-$ENX5O)8FEVLX&T J #GNV[@>QK@/%EWID5OXSTNU6
MWT^6*RC1H0,R706+*;$Z+&HX^4>IR,5KPZE:+X\\/7;W,8AN=$DBAD+<2OYD
M?RK_ 'C["@#KM-G>1]0:74[6[C2X(40@#[.NT'8Y!.2.N3CK4UKJFGWQD%I?
M6UP8P"XBF5]H]\'BO+KIF/AOQLNFA94CUP23PP8): "+S  .V V?8&NFU![;
M5/''AJ^TJ>&:)+>X-Y)$P*FV9!M#^Q?& ?0^AH Z=-<TB26")-4LFDN"1"@N
M$)E()!VC/.""./2C7+BXM-"O[JT>-+B&W>1#(A9<JI/(!'IZUY5;G3HOA9IU
MQ&;9)5UQ6$@*A@1>'!S_ +OZ5Z?XCEC3PKJLC.JI]CE^8GC[A[T 0>'-?M]3
MTG2UGOK5M4GL(;F6!9%$GS("6V9R!DUHR:KIT5ZEE)?VJ7;G"P-,H=CUP%SF
MO.;-K"WM_AE)"UO'(4 9E*@G=;$-GZMC/O46GW&DZCIUSH&OZC>1ZM#J$CM8
M+M6267S2Z/&=NXY!'.>!Z"@#TF36=+BG\B34K-)O,6+RVG4-O;HN,]3C@=:<
M-5TXWXL1?VOVPYQ;^<OF<=?ESFN.T*UTR[\?>,%$-G+/'+:O$&56V,(A\P'8
MAAU'<5C^'+C1]6TG2-,U34;S^W-/NE9M/^595N58Y?A=Q4Y+$YQ@G)H ] M[
MU8KO5);K5[.2VB=<1C:IM1MY#MGN<GG%6(-6TVZNS:6^H6LMRJ"0PQS*SA3T
M;:#G'(Y]Z\YOI+'R?BA&'M]HB!5<C&[[*!D#UW?K5N)K"WU_X>&W:WC,EK."
M4*C<# .N.N6_6@#T>BJEAJ=EJD<SV-PDZPS-!(5_AD7AE_"K= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3719%*NH93U!&13J*
M &F-#G**<]>.M'EH""$7(Z'%.HH C\B'>S^4F]B"6VC)QTJ3J,&BB@!JQQIM
MVHJ[1A<#&!31!"'+B) [$$MM&21WJ2B@!C11O(LC1HSI]UB,E?H:2:,, ZQQ
MO*F3&7['ZXXJ2B@#"\+:#)H?ABVT>\>&Y\C<-ZK\K@L6Y!Z=??I6WY:88;%P
M_P!X8Z\8Y_"G44 -5$4@JJ@@;1@=O2@Q1F,QE%*'JN.#^%.HH 1$6- B*%4#
M  & *:\4<C*7C5BARI89P?44^B@!DL4<R;)8TD7KM9<BE*(P *J0.F13J* &
M^7'G.Q<_2FI!#&K+'$B*QR0J@ FI** &-#$\9C:-&0]5*@@_A2JB)G:JKGK@
M8SVIU% $:011H42)%4G)55 !/K3C%&4*%%*'JI'!IU% "!5!)"@$]3CK3?*C
MP!Y:X P!CI3Z* &-#$\BR/&C.GW6*@E?H:4HA;<44GU(IU% #514^ZH&?04T
MP1-*LK1(9%Z.5&1^-244 ,:*-W#M&C, 0&*@D ]16%JNA7&H>)-&U%#;"VT]
M9E:%P29!(H4]L#&/?/M7044 87BO0Y]>\.2:3:20V_F/&=[J2%".KX '^[BM
MB")8H^(HXV;EQ&.-W?L,U+10 P0Q+*TJQH)&&&<*,G\:4(BG(50?4"G44 ,,
M4;*RF-2&Y((ZTJ1I$@2-%1!T51@"G44 (45CDJ"<8R1VIOE1XQY:8^E/HH ;
MY:9)V+D]>*2.&*$$11H@8Y.U0,GUI]% #7C20$.BL",$,,Y'I21Q1PQB.)%1
M!T51@#\*?10 Q(HXRQCC1"YRQ48R?4T+%&CLZQJKO]Y@,%OK3Z* &F-#G*+\
MQR>.M(\,4D?EO&C1_P!UE!'Y4^B@!IC0J%**0.@QTH$: Y"*#ZXIU% "%0PP
MP!'H: JJ,!0!Z 4M% #51%^ZJJ?857L+"*PCD6/EI9#)(V -S$ 9P.!P /H!
M5JB@!IC0DDHN3U.*3RH\8\M,?2GT4 ,,4;2+(8U,BC"L1R![&EV)NW;5W>N.
M:=10 P0Q*Q81("6W$A1R?7ZT/#%(X=XD9@" 64$@'J*?10 TQH<913CIQTI/
M*C_YYK^5/HH YW4-$U9M9>_T^]LFAEB2)K6^M3(L>TDY0JPQG/(.<X'I6CI.
MEKID<Q)B:>XD\R9H8O*0M@+\JY.!@#J2?>M&B@!I12<E03C&2.U)Y4>,>6GY
M4^B@!ABC:19&C0R*,*Q'(^AI]%% #$BCC+%(U4N<L5&,GU- AB$IE$:"0C!<
M*,D?6GT4 -\J/).Q>>O'6FO;P2*%>&-E!R R@\U)10 THC$$JI([D4UH(7<N
MT2,Y&TL5!./2I** &211S "2-' .0&&<'UI2B,VXJI/J13J* &F-&8L44L1M
M)(ZCT^E+L7*G:/EZ<=*6B@!JHB_=51]!21PQ1*RQQ(@8Y(50,FGT4 ,\J/&/
M+3'TIQ52NT@$>F*6B@!GE1\?NUXZ<4&*,RB4QIY@& ^.<>F:?10 T(BG(50?
M4"D$48E,HC02$8+XY(],T^B@!GE1\_(O/7BE\J/CY%XZ<=*=10 BHJ A5"Y)
M)P,9/K2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !112,P52S$  9)/:@!:*K6&HV>J6WVFQN8[B
M#<R>9&V5)4X//U%6: "BBB@ HHHH ***QCXKT-=;717U!$U)SA;>165B<9XR
M/2@#9HK.UC7=+\/VB76JWL=K"[^6KR9Y;!../H:LV5[!J%I'=VKEX)5#(Y0K
MN!Y!&0./>@"Q116;<Z]IEIJ]OI5Q=K'?7/\ J8F5AYGT.,'\Z -*BLZRUW3-
M1U"^L;2\CENK%@MS&,YC)SUSUZ'I63/\1/"5KS-K4**5W*VQ]KC<4)4XPPW
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MUQ.R7=SGR8O*<F3 R=N!S@=?2DU37=/T=6-W))E(S,ZQ1-(R1@X+D*"0OO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<Z??&!;>YD$*2+<*O0LI& PR<$5:NO"XFOM(O(-1N(9].$JF0JKM,LF-^<C
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MXQ]X%0<]>O;BI-5U:^MY$O;74;FY(UV.W:9&V6ZQ-($,&PG#$ \L!USSD8H
M]&ICRQQO&CNJM(VU 3]XX)P/P!/X5PLRZC?^(_%]F=;OX8+.WMY;=8753&S(
M[<$#ID?CW)JC%+-K>H_#N]N[FX$]W:3/*8I2@+>0#N ' ))/\J /1KF5H+66
M9(GF:-"PB3&YR!G SQD]*2TF>YLX)W@D@>2-7:&3&Z,D9VG'&1TJEXB>:+PU
MJ<MM.\$T=K)(DL>,J0I(Z@CM7)S:KJL/A_PWJ,MO?W^GMIJ/?_8I2+A9&1"L
MI (+C[^0#WR<XH [^BLS0+F"^\.V$\%ZU[%) N+EN&EXP6/H<]?>N&O-7U*+
MX?>*+M-0N1<V&JSPV\WF'<B+*JA<]Q@D<YH ],HKC+I+Z^^(EUI1U>^@L6TI
M+CRX&52K&5E^4XR. /?WQQ6);ZOK-[X6\'3G5KB.>ZU,V=Q(@7,J RC)X^]A
M![9Z@T >G45PZK?G79O#,=_<W*6=BDXEGO6AGD:1W^8LB'<% 4#H.><]G1-J
MT:Z+INK:M]KOQ%/Y]OIS%'N"I 5S)E=@4'GIECWZ4 =M17G.GZQKUSX'T;4#
M%=:ELN)UOHK:79<2Q([HI4C!)!"D@8)_$U/:^(TOYO#.F6.HW4MKJ<]V9IY,
MI,!%EA"2>58;@">N$X/.: ._HKS?6=4U;3$\8:7#J%SY=C8)?6=P6#21;@V8
MRQ!)&5R"><=ZT;>:_P!/\6^'$?5+JYBU2RG:XBF8% R*C*R@#Y?O$>_?)YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKM_XWOQXRTC1-+M;6>'5;+[7#-,[)L&UCSC.1\N?QQ[T =S17E'_  M'7/\
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MBRRA-RY7D9(.#CZUO76L7<^JWVF:3#"]Q90)+,TY.TL^[9& .Y"DD]LC@YX
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M>U==?\.Z?JR1&(7ENDWEDYVDC)&>^*TJ "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *P/&-WJFG>'+C4=*D FM )9(R@;S(P?G ST(7)'TK?I&571D=
M0RL,$$<$4 8UO?3:G?!].O%-FMHK[VC#*[ORAXP>%Y(R/O+TYSSFD>+M0O\
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M05&W<ORC!P/QJMI_B#7O(\(:C=WEO+!K&R&:W6#;M+1%PX;/7*],8Y_&M?\
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M,D,UNL&W:6B9PX;/7*],8YQ[UV]W:FXT^:UC<1>9&8PVW.T$8Z5SR>#V33M
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M>2?<R;2"[%F'!Z9)Q577/"[:IJMIJ]AJ4^F:G;(81/$BN'B)R496X(SR/0T
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MFN"N_$7B@:-XMU"/4;-#H=Y(L:"TR)42-'V'+<#!//)R>HQ7I*!@BAR&;')
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MO%MFM;UK26"82AMF]7&UE*L,C(.[U!X% '*+XO,EAI:Z?JMOJ!U?4?LUM>!
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MC'I5J]\)3ZEH4FGWVLSW%Q-+')-=/$@)\M@RJJC"J,CWZGUH KI?ZS%XJO\
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MD#(P<9XS6K573[+[!9I 9Y9W&2\TI!>1B<ECC Z]@ !T'%6J "BBB@ HHHH
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MQ'#%*+03_:5LS*Q@23.[<$Z#YN<= ><9K9G@BN;>6WF0/%*A1U/1E(P14E%
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M<$8PN?;C)R0. <51N? &@W0U"-H[I+;4'\RYMHKJ1(7<G);8#@$XY_QKIZ*
M(XH$AMU@7<8U7:-[%R1[DY)_&LFS\+:78^2D*2_9H)?.@MFE9HHGY.54^A)(
M'0=@*VJ* ,V/0K.+7)=84S?;98Q$[&5BI0'(7;TP"3VK#\?6,^I6NBP06US.
M(]6MYYC;@Y2)2=S9'0C/;GTKKJ* ,C_A';&2&]$IGEDOHA#/,\A$C1C.$!&-
MHY/ QU)ZFAO#.E2>'$T":!I=.1%C2.21B4"XVX;.01@8.<C%:]% &=9:+:V5
MPUSNFN+EHQ"9[B0N^P'.T$]!GD^O?-9A\!^'V\/G1'M)'L0XDC5YW9H2"2NQ
MB<IC)P!ZGU-=)10!@KX.T7^PKC1Y[>2ZM;G'GM=3/+)(1T)<G=Q@8P>.U/L/
M">E6&F75@%N+F*[B,,[75P\KO&01LW,<A<$X QU-;=% &#_PA^E?9=.MS]J9
M-.E$UL6NI"RN!@$DG)P. #QCBI+CPMIMQ?W=X!/#)>H$NU@F9%N !@;@.^.,
MC!QQFMJB@#*D\.Z<^IV.H".2.>QB,-L(Y"J1H0 5"CC! ';L*?I.AV6B?:_L
M8E'VN=KF;S)6?=(WWFYZ9]N*TJ* ,V;0K.?6X=8<S?;(8S$C"5@H0\D;>G.!
MVJO)X5TN2>\<)*D5ZV^ZMTE(BG;N67W[XQGOFMJB@#-.AV1UU-9Q*+Q(?LZL
M)6"B/.=NWIC//2K=[9V^HV%Q97<8DM[B-HI4)QN5A@CCV-3T4 8,7A#2H9-,
MD7[69-,W&U=[J1BI*[3DD\_+QSVX%*W@_19+?5+>>W>>'5'WW:2RLPD;  8<
M_*1@=,8P*W:* ,?0O#6G^'HW6S-S(S +YES</,P4=%!8G"CT%6=6T:PUNU6W
MOX/,5'$D;!BKQN.C*PP5(]0:OT4 9UIH\-K(DCW%W=/']PW,Q?;VR!TS[]>3
MS59_"NEO-=N(Y4BO7\RZMTE(BF;N67IS@9QC/?-;5% &:VAV;:W_ &N/.6\\
MC[,&64@"/.=NWIUYZ52/@[2#HTFD%+@V4DWGO']H?E]V_.<Y^]SUZUOT4 <9
M:Z1--X]UFYD&H06\MK;PQ7"$J)-N[>"?Q'/7K@UL3^$](F.GE8)+<Z>I2W:V
MF>(JAQE25()!P,YK;HH YY/!.B16\4$<4Z117?VV-%N' 27)((YX )/'3FIK
MK3X=(GO]>L[.ZO-0EC57ACFYE"G@ ,=HQDG\ZVZ* ,;0;!HI+_5;BS%I>:E*
MLDD606154*BL1P3@$G'=B.<5=T_3+?3/M7V<R_Z3</<2>9(7^=L9QGH..@XJ
MY10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !11THH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M93PQ"@8#>I(Y%;_P]\+7OA^/6;W40L=UJU\]T8%8-Y2DDJI(X)Y.<<5I7_\
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M26.FV5J\]U/:^>D"N%$4(P-S,>@R0!U)/T)&=K6BZA<?#O4-,BA$^J7MO()
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD>DZ#ISZA8"+1KV.:)UA<F1$5P-PS][# 8''4Y[5WE% &#H.CWFF:IK-S</
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MQ'\2G>WJ,#VKLJBM[6WM(S';010H6+%8T"@D]3@=ZD=%D1D=0RL,%2,@CTH
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MP2;64.J2%PO?DYZ]O0UNPZ'>+XVN];D>#[/<6*6GEJQWKM9FW=,<[B,5T-%
M'%Z;9V7A'P9%H/BC5=.^R&)[6+=^[\V/!R#N/+$'H*TO!&CR:+X6M(+B262Y
MD422O-]_[H"JWNJ*B_\  :W)[6VN3&UQ!%*8FWQF1 VQO49Z'WK.M/$NGWM_
M!:0^<?M,;2V\QB/ES*O4JW3\\9'(R* #7+"]U$V44!M_LL=PDUPDI(,@0Y51
M@''S!3^&.]4/&/ANYUZRL1ILMO:WMG=QW4-Q(#\C+VP.H()!&:Z:B@#SKQ#-
M=7WC"*"WO]%M[ZQL0)(KUI$YD/)C=&5F&%&1T&1W)Q/%INJ>(-&TVWC31[==
M(U2*='LV<V\R1 $*G''+%3UP5/7MV5[I^G7Q3[=96UR4R4$T2N1],@_I4.BZ
MQ8:S:S2:=O$-M.]LP>(Q[73@C:0",=.E &/KOA_6)/$%KX@T"^M;>_2W^RW$
M-VC/#-%NW#[N"""3@^_YQ:MX8UNY;2]5LM6@37K$R$O+$?L\R28W1E0<A1M7
M')/'J<UU]% '):KX>UO5]*LH[J]LWO8M0AO9"JLD2B-@1&@Y.#CDDYR3[ 6X
M]&U"/QI=:[FV,4UBEHL.]@059F#$[>Y;'Z^U=%10!Y];^!-8L=!T1+'4K6'6
M=&EF:"8HS0S)*Q+HZ\$ Y'3/W?RTM6\/:[K.APP7E[9->_;(;ERBNL*"-@P1
M!R3DCEB>_P! .FO;^WT^%9+AB-[K'&H&6=VX"@=R:ATK5K;5X)9+=9D,,K0R
MQS1E&1QC((/U'(R.: ,A_#UY<>+;S5I9(%M[K3!8&-6)=<,S;NF#]XC'M^%6
M_">DWVA^'+/2[ZXMYVM(EAC:!"H**, G)/)[UMT4 <U<^&[F7Q?<ZHL\!L;V
MP6SNH'0ER%9C\I!QR'(.:SK?P9?GPQ#X4O;JWFTB&5,3C(FDA1PZQE<8!X"E
M@>@Z UVU% %74[62^TJ\M(KAK>2>%XDF3K&64@,/<9S7*V'A;6K:^T"ZDN].
M']EV\ELT44+@.K!1D'/4[>>.,]Z[2B@#AV\':FW@Z;0_M%IYDE]]K\W+8 \[
MS<8QZC'ZU+XF@TWQ)J.FZ;#?1?VK;7/[]+>4,\4+(1,K=PK*0N<=2M=G44=K
M;Q3RSQP1)-+CS)%0!GQTR>] $@      Z 4M(K!E#*001D$=Z6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "L3Q%JTNG?V9;0,J3:C>):K*PSY8(9BV.YPI SW(Z]*VZRO$.@6WB/
M31:7$DL+1RK-!/"VUX9%^ZRGUZ_G0!C:QJ>L^&-.U*YN;J"\BDFABTYY% D5
MG(5O-"A5(!.1CDC@U)=:CJ6C>*M)TV2\:\M=526-7EC0-!*B[@?D"Y4C/!YX
MZU9;PG#>Z+=Z?K%]=:D]TJK)<2[490IRNP* %P>>G7KFK%OH3B\MKR]OI+RZ
MM(FCMY'C5=FX ,Q ZL0 ,].N ,F@#CE\0>(U\%V_B!M3B:2*_,$D'V90DR&Y
M,7)ZC QC&.G.:VTO]9L_%E[I$NHI<H^EF]A=[=5\EP^TJ ,97D'DD\=:E_X0
MB'_A&/[!_M*Y^S?:?M/F;4W[O,\W'3&-WM5J^T9(=6F\037SB1+!K0QE5"%,
M[L^N=WO[4 <I%X@\36_A?0?%$^HPSVUP\*7=D+95RDC!=P8<[LD<<#\N;^N^
M(-5TS[7=1WR2-;ZE#"+>"(/"L+,BXD<KD2'<3@-Q\O&*7P5HAO\ P3H,=]=2
M206H27[*R!2)%.0KGJ0IP0,#H,YJ[=> X;BWU&U&KWT5K>WGVWR5V$1R[PY(
M)7)&1T)Q0 R:[UV]\6ZUI-OJJ6L%O:0SPLMLK,A8OQ\V0?NC.?PQUJBOB;5F
M\+>&O$LMR([*5HUU2-(UP%8[?,!(R &QD>AXQBNC@\.FWUF\U1-0G::ZMTMV
M#JI "9VD<=?F/MSTK(N+:S\/>&8?" AO-1-S;206ZF E6!XP[J-J_>ZG& ,T
M ;^FW%Q>:EJ,WGLUE'((($VKC<H^=@<9/S97KU4U3U#59Y?%MGX>MIFMC):2
M7DTRJI;:&"JJ[@1R2220>![UIZ1IL6CZ1::="24MX@FX]6(ZL?<G)/UJKJF@
M1ZAJ5EJ<-Q):ZA9[ECF0!@R-]Y&4_>4_@0>AH Y'5/%.N6.B^)+=;F+^T-&N
MH$6Y,(_?12E=N1T# ,<D#''2NWTRVU"V2<:AJ"WK/*7C*P"+RT('R<$YP<\G
MGFLF_P#!UMJ&CW]C)>3K)J$ZSW5RJKO=E*[0,C  V* ,=!ZDFNBC#+&H=][
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M>'+@=/N[B3SD^]69?"@&N76J66IW-D]ZBI>11*C),5& V&!VMCC(H C^'?\
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MW4GV*6Q64(L;^7)C<21U;@>@'/'-1VO@]K>^TR]?6KZ:XL('MT9UC 9#MP"
MO;:.>I]: ,K0)?%>O^'CJ*:]%%,#=1)$+--KNLC*C$GH/EP0.WOS5[1==NM<
ML="6&YDCNWWMJ"E$ROE_+(A&.#YA4#IQDU=L;2V\$>&YP\]W=6L,C3'$.^0;
MWR<!!R,L3TX%)X8TRWBN=5UJ*UDMSJLXE"2*58(% !*G[I8[FQU^89YH T];
M1Y-#OA'.\+>0Y#H 2, ^H(KC-!U*YTWPKX-TV&[<S:M'&BR.B?N(UBWMMP.3
MP -V>N><8KNKZV-Y8SVHE:+SD*%U )4$8.,\9K#/@ZV.@:;IAO)P^ELCV5T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%)N&[;D9QG%"L&&5((/<&@!:*3<-VW(W8SC/.*6@ HHHH **** "
MBFJZN,HP8=,@YIU !12!@PRI!'J* P+%01D=1GI0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44A(&,D#)QS2T %%%% !1110 4444 %%%% !
M1110 4444 %%)N&[;D;L9QGG%+0 4444 %%%-+JK*I8!FZ GK0 ZBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HI"0" 2 3T]Z6@ HHHH **** "BBB@
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M)7(7</<EASVP:]!KA/'GA'4=6UG0_$6C"&74-(FWFVF?8LZ9!P&['@]?7VH
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MM'G$':SX)R$!/7J<'BGW_P 1[#3]=UC2WL+QWTJV^T3.FTAOE# +S_=).3C
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M>./[Z$, =PR.>A]JL6WB/6GU>P@;3&GM;V)RTB6LT0M'"Y4.[C#*>FX <]J
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MX(QGL20.#0!W5%5-,FN;C3HI;Q81.V<^2VY",G!4^A&#^-6Z "BBB@ HHHH
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MMM:TJVU*S+&WN$WQEA@D?2@#-T&R\11,'U_4[2Y,:;(ULX6C#_[;Y)RW'0
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M!BIX);.?EZGZ8[UU%% !7%OX!C&B:E80WC1RS77VBQEQ_P >FV0R(J_1V?\
M!JZIK]%U5-/\F?S&A,PD$1\L $#!;INYZ>E6J .>\0^'9-3\-0Z-8210)&\)
M#2Y.%C96 XZYV@4]M'O6\91:[OMQ$E@;,PY.<EPY;./48QC_  K>HH P_#&C
M7.B6EY!<RPRF>\EN@T8(QYC%BO/IGK3/%>B7FNVMC#:300FVO8;LM*"=WEMN
M"X'J>];]% '-7VA:HWBRWU[3[JTB=K+[%<QSQLX"[]X9,$9()(YQ61#X'U.'
MPCI^B?VA:R/::B+X2F-AD"8R[>O)).,\?2N\HH YM],GL_&%QXGNKFUBLETT
M6TBDD%%5C(7+'C')&/3G/:J&@6.FZEXTU+Q'I=T+BQDBC4&-@T3W&"'D7'&0
MFQ21W+#KFNR95="CJ&5A@@C((ID$<,,0AMTCCCC^4)&  O?&!TZT /8;E(!(
MR,9'45PUGX+UFWM=$@?5;)O[*NVF1_LS;I@P8%G^;ESN_/DYKNJ* ..D\)ZA
M)H_B:P-Q:@ZU/)*KX;]SO14(Q_%@+[5*/#6J66N6^L:;=VB3O:):7L,R,T<@
M3[KJ1@AAZ'C'YUUE5=0OTTZU^T20SRKO5-L$1D;+,!G [<\T 9GA71+K0=,F
MM;JZAN&DN99U,493&]RV.2<]?_UTS7-"O-0U_1=6LKN&&33_ #D99HRX9)54
M'&".1M&.U=!10!Q\WA7499/%K"XM0->B$:<-^YQ%Y63_ 'N.>W/%2-X9U$S^
M%9//M?\ B2*0X^;]]F(Q<<?+P<]_3WKJV95&6( ]2:K/?HFJ16!AG,DD32B0
M1$Q@ @8+= >>E ')7?@:YU$>(A/?1P-J=S#=VTL )>VEB"A#S][[@/;O]:U-
M/T_Q*UE<#6=1L9[@P-#"MM$T<9SU=\DDMQT& .?7CHZ* .&GMM*T'X?P^$_$
M%];/(]DUM%&C8DN-HP/+4\E\E< 9YQ72>&]+ET?P_9V=Q*9KI4W7$K')DE;E
MVS_O$_ABM"2W@EFCEDAC>2+/ENR@E,]<'M4M &!XGT"XUE;&ZT^\6TU/3Y_.
MMI73<AR,,C#^Z0<<55U'PSJ&MZ+Y>I:C$NII/'<V\MO$1%!)&<KA223U.23D
MY[8%;M]J4%@84</)/.Q6&&, O(0"QQG X )R2!1I6IV^L:?'>VPE6-RPVRQE
M'4@D$$'H0010!FKH]Y<ZO#K%^;;[7:VSP6T418HI<C<Y)&>=H&,<#/)SQCP^
M#M1A\*Z%HPNK4OI=W%<F4AL2"-BP&.V<XSD]*[:B@#C==T>[AD\2ZU)+!Y-Q
MH[V_E#.Y=BN<YZ'.X\4FAZ1=:OX=\+&^>W%I8Q6]T@BR6E=8_DSGA0,Y."<D
M#ITKKYX(;F(Q3Q1RQMU210P/X&B""&UA$5O#'%&O1(U"@?@* .=LK9?#%UKF
MK:M?6D-I?7*S;V8J(CM5 I)X.<#GBH_!FD6UF-2O[21GM+RY=K,'[J0[B?D_
MV2[2,/4%:UM/U/3O$=O>I%$98K>Y:UF2XA(!=<$_*P]QU%:@    P!T% !7&
MS> HGTO7+1+HJU[,9K-L<6AW>8-O_;3<3CM@=J[*B@#G=?\ #<NI>#SH-E-'
M%E8U\V4$\(RMD@=22OZTZ?1;]O%MOKL%Q;I_H7V2>%T+9&_?E6R,<Y'(_"N@
MHH XAO!NI-X0N-#^UVN^:^^U^=M; _?"7;CZC&<UVR[MHW !L<@'(S2TA900
M"0"QP,GJ: .%/@K6?L4=J-5LV6WU8:C%*]NQDD/F%\2'=R1G''H.16W:Z+?V
MOB?5-7\VW=;RWBA6,Y!4Q[L$GWW'CM[UT%% &+X3T:?P_P"&K/2;B6.9[8%1
M)&" P))Z'IUJOJ7A^Y/BJV\1Z9-$MVEL;.XAGR$FB+;AR,E6#<YP<YQ7150U
MG5[70M*GU*]\P6\"[G,<9<@?0?SZ4 <[?>#9[GPQKNGQW,(OM;E:2YG93L3<
M  %'4@*H R?4^U=59)-%90QW'E^:B!6,9)4X'49J6-Q)&KKT8 C-*K*PRI!&
M2,@]QP: .?N="OO^$U37[2Z@6-K$6<T,L9)(60N"I!XSD@Y!Q6)_PA.I_P#"
M&?V#]KM-_P!O^V>?M;&//\[;M^O&<]*[RB@#CY?#>OV/B*\U+0=4L[>WU(H]
MY;74#2B.0*%,D9!7D@#@\<?EUEO$8+:*$R/*40*7<Y9L#J?<U)52\U".RN+.
M%X;B0W4OE*T41=4."<N1]T<=30!SL7AK6M,UK4)-'U6VATW4IC<3Q30%Y(9"
M,.T9! YQGYL@'L:LQ^'[S2_$-[JFE3PM'?QQK<07);B1!M616&<\=0>N,YKI
M** .=7PA:#P5/X<:0NDT;[YB,$RL2Q?';#'('; HO?"HO_!PT26]D6YPLGVQ
M1\WGAM_F8]WYQ[UT)95(!(!8X&3U-58=0CGU*ZL5AN%>V5&:1XB(WW9QM;HQ
M&.<=* ,2+2O$=SI-Y!JVI64T\EL]O$+>%HT^88,CY)RWL,#KZ\0)X8U!+?PM
M%Y]M_P 23;N/S?OL1F/C^[P<]ZZVB@#A#X*UD645H-5LV6WU4:C%*]NQDD/F
M%\2'=R1G''H.16D/#FH"[\2SF>V;^V(D1!\P\HK'Y>3ZY'/;T]ZZFB@#D8O"
MNH0+X7DAO;99]%MVM7+1LRRHR*FX#(P?D!QTYJ2Z\+W.I:G8W5\UH9;&]-S#
M>1 B8Q[B1">.F" 3G! Z=ZZJB@""\CFFL;B*WE\F=XV6.3&=C$<'\#7,2>"T
MU'4;N\U".V@>[L)+*Y^Q9'VC?C]XV1P1C@<]>IQ7744 <WH&D^(K'R+?5=8M
MKJTM1MB,,#)+, ,#S"21P.P')QD^L_A71+OP_IKZ?/=0SVZ32-!LC*L%=V?Y
MB2<GYL<8Z5NU5BOTFU&YLA#.KP*C-(T1$;;LXVMT)&.?2@#*\5:)>:Y%IL=I
M-!%]DOX;UC*"=WEMD+QTSZ_I4+Z!?6GBF?7],DMQ)>VZ0WMK,6VLR?<=6 SD
M D8(Y'I72T4 <7+X)N([/2HK2Z@,MKJQU:YED4CSY6+E@ /NCYSCK@ =:U-2
MT*]N/%>FZY9W4$1M[>2VFCEC+;D<JV5((P<KWR.:U;K4(K5[13'-*+J41(T,
M9=5R"=S$=%XZU;H X2?P3J5QX5\0Z,;NT5]7OI+H2@-B(.P8KCOC;C.1U]J[
MB+S/)3S0HDP-VTY&?:GT4 <E+X7U![[Q5<+/:A=;MTAC!W9AVQF/)_O9#9QQ
MTQ[TU?"VHK_PB?[^U_XD2[7^]^^_=&+CCY>#GOSQ77U6OKZWTZV-Q<OM3<J#
M R69B%50.Y)( ^M %AU#HRGH1BN#@\$ZO!X8T71CJ%G(-*O8;B-_*9=Z1/N"
MGD\GN>@QT-=;IFKPZH;E(X;B&:UE\J:*>/:RMC(]B""#D$TS5=>L=&%F;II"
M+NZ2TB,<9<>8S;0"1PO/KZ&@#,&@Z@OB;5]766UVWUG';)$2V4*;L,3CG.X\
M>U5]-\,ZEIWAS2M'=M/OK:UMWMKFWG4B.X4[=K=#M(P>H/7\NL=@B,Y!(49P
MHR3]!4&G7R:EIT%['%/$DR!PD\91U]F4\@T 4/"^A+X;\/V^EK+YBQ,[#&<*
M&<MM7/.T9P/85L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5!>7<5C93W<[;88(VD<^P&34]9^
MKZ6=6MHX#=S6Z+*DK"(*=^U@P4[@>,@9'>@#ST7(T+Q1HWB&2*[BDU%FM=6,
MMK+&BF1MT?S,H'R-A,_W0*[#7-5N;3Q#HVGB8VEG>>=YET OWU4%8P6! SDG
MID[>*N^(="@\2:'/I-U-+'#-MWO$%W<$$8R"!R!7+^)87@U#2K6[U'68(;:V
M?;J4%L)A)(Q VR*$8 X7.2HZ\'K0!4GU_P 1P^"M1U5=00R0ZB+:VE-NN)HA
M,(]_I\P;J!VXZUM3WFKV&L6NBR:A/>S7@GNO.@@AC>.-=@$:ACM/+$Y.3@8]
MZA@T*\\0Z+=:??ZSJ$^GN\3P7$MJD$Q*MN(VE!\N0F"5!//;%:^O>&(==6RE
M:]NK34+)BUO>VY"NI(PPQC!!QR,4 8RZQXAL$L=-U)&-W>7\L,$\?E>:UNJ%
MPQ&=@DXQZ=\56UK4O%>C>&-<NI)_+^SR1-8SS)$TK(S!65U3Y003P<<BMN]\
M&VNHZ/'9W-]>O=1SBY34!(!.LP& P(&!QQ@#&/SI+GP>E_H%SIE[JU_</=%/
M.NG*>8P4Y50-NU0#Z#N?6@"G--KD7C6/1_[:)M[VQDN-WV:/= R.H_=\="&_
MCW=*I6/BG4QI=O9SRM<7TFLSZ9]I1$5F6/>=P!P@8A0/3G.#T/32: )/$%MK
M+7T_VBWMVMU3:FQE8@DGC.<@=ZS9/ =C-I-U82WMXQFOFU".X5E62"<G.Y"
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MTES;@^62A1MR+]SD GOR?6@!EA?ZQ#XC\0:+/J9NO(LXKJVGD@16B+[P5PH
M(RH(SSZDUFP^*]63P5X:UF\-X]K<PE]2N[*!'DB./E;9M(V9SD@<8%=/_P (
MTHUR_P!6&H7(GO;9;9UVIM55S@CY<Y^8]<]:BT[PH=(T_2[2PU:[1=.B>&,N
MJ,)$;;PXP,XVC!&#0!?\/7BW^A6UTFHQZBDH9ENHP )%W'!P ,'& 1C@@UIU
MGZ+H]MH6F)86F[RU=Y"6QEF=BS'C ')/ &!6A0 4444 %%%% !1110 4444
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M33%\1[;3EU'4OLE_ILTMU']LD^=T= "#G*?>/W-OITXK(LM:O;/1K;36O9#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:1W6-"[L%4<DDX H =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYW,&9F(.T<A0 ">,GO@ '*^'KZQLOA=X.%_I9OHIKFWBC.5Q#*92$<Y.>#Z
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MCN+RWT_3K=;NYN+7[65D?RT2$\ L<$Y8\  'H>F*Q?AB /#^H@6_V<#5[O\
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MTB.43/102 3@=R.>N!TJU0 4444 %%%% !1110 4444 %%%% !1110 4444
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ME,XZ].>.?1UW!!O(+8Y(& 3]* %HJCK-S>6>CW5QI]HMW=QQDQ0M($#-[L>
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MG7;J;Q1#H5B(89'TXWQFG0N#\X0*%#+WY)SZ>M '145Y[#XXUV?PQH>K+86
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MKID>J6*W4-Q>QLT32, 1%N#*%(!SDGFNMLGGDL;=[I42X:)3*J'*AL<@>V:
M)Z*BNKF*SM)KJ9ML4,;2.?10,G^5<E/XLU&S\/:=XEN(;8Z7=-$98%5O-@BE
M("-OW88C<N1M'7@\<@'2ZCJUAI47F7MRL*[2YR"2%'5L#G R,GH,U:AFBN((
MYX)%DBD4.CH<AE/((/<5QRI?2?%:YC:XMFA&DQDHT!/[LS/E?O\ WN.O3IQ7
M9111PQ)%$BQQHH5448"@= !V% #JIPZK87.I3Z=!=Q27ENH::%&RT8/3/ITK
MGO'5WJ5JN@KI]W' MSJ]O!*&B+%@6W#D,.,KR._J.^8PU<?$G65TYK+[9_9%
MJ6EN$;R\AY/X0<\G_:X]Z .VO-1L]/-L+NX2$W,RV\.X_?D;.%'N<&K5<,GC
M.\N_#WA+58[.V U>\AMYU?),9;=DI_WR<9]:M?\ "633^)[K1HI[*VN[>ZC1
M;.ZC99+B [2TD;[@#P7P #]WGK0!U]%%!.!DT 0M+;R3-:,\;2&/<T1()*'C
M)'IU%9-GX.\/:?<">TTJ")E;>JC.Q&ZY5"=H/T%>?W>OV=IXMTOQC'JMO(EW
M<MI]S;K.I,=HQ B;;G@!EWGO^\QVKT#7M;ETR_T>P@1/-U.Y, FE!*1@(SG(
M!&2=N ,CK[8H W**X&Z\8Z[:Z/XJN?LNGO)H<C1J_P X67"J^<9..&&1GKWJ
M_)XAUFQ>TAU".R$NIR@68MHI93$@C+N9%'+$8 &W'7/&* .OHKBU\7:G9VUR
MFI:>RS?;HK2RN!;2)'<B3D,(SEP5 ;*]\#!YJ.[\4^(+"P\03/I\<J:?:&[M
M;M[:6WCE !+(R,2=PQV.#GM0!W%%<2WB/Q%'JVA6SP:8T>M6[M$!O!@=8P^6
M.?F!&> !Z9[TEOXTO;>RU&'4H;=]1M=4334:VC?RY"X5E?;DMP&)*@G.W@\T
M =O17$77BCQ!8VFO2OI\<T5C9&\MKM[:6WCDV@EHV1B3N&."#@@]L5+:>)-;
M&MZ!;7T5@+;6K61XA"'WPR)&'^8DX8$$\ #'J>M '945R'@*[U2^M=5FU*\B
MN"NIW,(VPE"-C[1CYC\N ,#''J:Z^@ HKD/%'B35-$75)HDLH8+.T%Q;B<&1
M[Q@&+@!6!0* !D@CYL]!1<>)=7F\0:1IUA;V21:EI[W:R3EF,9&SJ!C(^?IW
M]10!U]4XM5L)M3ETV*[B>]A022PJV612< GTKE+/QK>2:-"MQ;VW]L2ZM)I"
MA-PA,B,09,$YVA5)QG.>,\YI-+6]3XN:B+V2"1_[&AV/#&4!7SGZ@D\YSW]*
M .XHHKD]>NM43QQX<L[6\ABMIUN7:-X2V61!R2&&>&.!Q@\\]@#H;+4['4C.
M+*ZBN/L\GE2F-MP5\ XSZ\BK=>:QZCJNC_\ ";ZEIR6;)9Z@T\JW 8F0+#&2
MJX(P<#J<_2NCN?$LUQ>M9:=B.5+..Z9Y+26X \S=L7$>,?=)))], \X .GHK
M-T"_O-3T2UN]0L'L+MU/FV[]48$C\CC(]C6E0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67X@T*U
M\1Z1)IUV716(>.6,X>)U.593Z@UJ5'<7$-I;R7%Q*D4,:EGD=L*H'4DT 9-I
M:^(1"MO>:C9N -IN8;=ED<>N"Q56]^1[5 ?#US9>([C6-*N8D:\A2*Z@N%9@
MY081P0<Y ."#U]JFD\5:?%8/J$L=['8JA?[2UJX0KUSC&0/<@"MI6#HK*<AA
MD4 <FW@QXH-'BM;R-38WS7\SR1$F>5MV[H1M!WGUQ@5:B\/7L.J>(+U;RW)U
M5(U53"?W11-@)^;YN.>U='10!R$GA"]D\$6/AW^T( ;5H<7'D'YA$P8?+NX)
MVCO5EO#NHVGB>YUG2[^WA^WQQK>P3PEU+(,*Z88$''&#Q3Y/&=BCVPCLM2GB
MNN;::WMC(DPW $@J<@#.>0..1FNAD<11M(0Q"C)"J6/X <F@#AX/ >H66AZ/
M%::RD6JZ2\AM[D6_R,DARZ.N[D'UXZ=*T=1\-ZKJFE6\-UJL+W:7D5W)(("(
M_P!VP8(B[N!QR22>3[ ;6C:O:Z]I,&IV6_[//N*>8NT\,5Z?45?H YU_#EQ/
MXCO]3FNXO)O+ 631)&=R@%CNW9_VCQBJ'_"(:DWAK1M)?5+9FTRX@E206Q 9
M82-JD;^IQR<_05V-5+S4([."&;R9[A994B'V>,R8W'&XXZ*.Y[4 <MJG@O4-
M0'B&%-6A2VUE5+![<M)&P4*%#;L;..F.YQZUI?V!?-XBTO5I;Z!S9VKV[H("
M/,W[22/F^7&T8'/UKHJSI=;M(M>M]&82_:YXGF0^6=FU<9^;IGD=* .?D\%W
M$_A[Q#I<VH19U:[>Z61(2/*9BIP06^8#:/2D\42VU]I/_".7FH12>()A'+;K
M;H499-_R2*N20JD9//0&NGM-0CNA=L89X%MIFB9KB,H&V@$LI/5>>OL:L^7'
MYOF[%\S&W?CG'IF@"*RM(K"Q@M(01%!&L:Y.3@#'/O4]%5-3U.ST?3Y+Z_F6
M&VCQO=N@R0!^I% %6RTV\AUV_P!1NKB"5;A$CA1(BIB1<G&23G)8DG [>E9D
M?AZ[L/&U_P")(+V%+6[MTCN;00,6D*9VON#?> XZ=*ZBB@#R'2;V<P#5=/US
MPQ=3RS2726MS;'[7YC$G80CY$N#MX7/;D5WNF:)>VWBK4M<FN(=FH00QM;",
M[HO+#8^;.#]XYXK<6UMTG:=8(EF;K($ 8_C4M '&Z5X1UC1;B6QL]>5?#[S-
M*MLUOF>(,VYHTDW<*23SC(SQ@\TY/"FLZ=K5_+HVNQVNF:C.;B>WEMO,>*1O
MOM$V0 6Z\@@'L:["B@#GK;P_=VOBN^UF.[A*7%I':I"T;$KL+$,6W<_>.>*R
M(? U]#X0T?0EU.W)TV]CNA.;=OWFR3S NW=QR<9S7<44 <?_ ,(KK5AKM]=Z
M)KD5I8ZC)YUU;2VWFF.7 #/$<C!.!U!&>QZ5>@\/7=MXMFUJ.\B:-K!+)(9$
M8L C,P8ONY.6YXKHJ0LJE06 +'"@GJ<9X_(T <1;>!;ZT\.:%I\6J6_VK1[T
MW44[6Q*2 [\JR;\_\M#T/:NV0,J*&;<P !;&,GUIU9VIZW::5<V$%R)=]].+
M>$I&2N\Y(R>@Z&@"#Q3HK^(O#=YI4=T;5YU4"4+N PP;!'<'&"/0FLE/"VKG
M7KC5YM5M#+<::+*2)+0J@(9B"OSD@?-T.2<=1T'74V1Q%&SD,0HR0JEC^ ')
MH XZ/P9?1:+X9TX:C;G^P[B.;>8&_?;%90,;OEX8^M03>!]3BL=?TG3M5MX]
M)U<S2>7/;EY('D'S!6# ;2>>1Q6T/&6E-H5EK %R;2]F$,1\DYW%]@S_ '1G
MUKH* *NF6LMEI=K:33+-)#$L9D5-@; QG&3C\ZLMG:=N-V.,]*6B@#DH/!TY
M\,:WHMW?1NNIRSS"6*$J8VE.[H6.0#]*?#X=UE];TK5;S5+1YK&WE@:..U8(
MX?;R,MD'Y<D].F!Z]510!S6D^%YK+PK?:'<WD<JW7VC$L<14J)2Q/!)S@L:K
MIX5U/R/#J3:E;.VCR!P5MBHD C,8'WN."3GGGL!71V-\M^L[+!<0^3,\)$\9
M3<5.-RYZJ>Q[U:H Y"[\%/J#>(1=7P5-6>&6-H8RKV[Q!0C D\\J#VJU;Z-X
M@ETVZ@U;6;>YF>W:"(Q6QC0;A@NXW?,WTP!SZUTM% &;H&G2Z/H%CILTR3-:
M0)")$0J&"@ '&3@\>M:5%% '$:OX(U'46\211:Q#'::VB[A);%Y8F5 H4-NQ
MLXSC'<XQUK*U]W?Q-;6,VO:/:W=A8 $:G;;8Y3(?F:+YU/10#R>#CN:],J&X
M@MIE7[3%"X##;YJ@X)Z8SWH XF'2]4\2:/IT9NM*B32]2BN()[*W;R+A(P"H
M1=W R2N02/EXK4UWPUJ5UKMKKVB:G'8ZE% ;:99H?-BGBSN (R""#D@@]ZZ@
M# P** .1U7PEJ5X-,U"TUORM=L&=A=20[HI1)C>ACSPO QSD8[GFM_2;6]M;
M4G4;U;N[D;=(Z1^7&O& J+DX QW))))J_10 5RS^%[Y-6\0W5MJ,*P:Q&H:)
M[<LT;B/R\[MPRN.<8SGOZ[UG?K>7%Y"MO<Q&UE\HM-$463@'*$_>'.,^HJW0
M!Q\?@^^CL?"UM_:%N?[!96W>0W[[;&8_[WR\'/?FJ3> ]5^PBS76[?RH=6&I
MP.]H6=F\S?B0[_FZXXP>!S7>U#-<)#!/+AI/)4LR1#<YP,X '4XZ#WH Q;'P
M_=V'BS4M72_C:VU!(?.@:'Y]\:% 0V< $')&.M=!4%E="]L8+I8I8A-&L@CF
M38ZY&<,O8^HJ>@##UK0[G4=8TC4K2\CMYM/:7B2+S ZR+M;N,$8XK.?PG>O9
M^)K<W\'_ !/"QW>2?W.Z,1_WOFX&>W-=;10!Q\_A/5;>\L-2TC5H+;4(;-+*
MY$MN7AN(U^Z=NX$$$GOWQ746-O+:V:13W#7$W)DE88W,3DX'8>@[#%6** "O
M-/"NEW6O^$]9TS[7 FGW6J7B2LJDR",S'<HYQ\P[]L]#7I3*&4JP!4C!!'!%
M1P6MO;!A;P11!NOEH%S^5 &):>'I[3QC/K27$ MI+*.S6V6(@HJ,2#NS_M$8
MQ5"+P?=V5IK&E6.H11Z5JDDDA5XB9+;S!^\"'."#R1D<$]ZZ^JE_?KIZVY:W
MN9O/G2 >1$7V%OXFQT4=SVH R=<\)VVJ^'+/2+:5[+["\+VDT?WH?+P!C_@.
M5_&E\2^')-:T.WTNRGALXX9H9%+1%P!$P95 !']T"N@HH Y3Q#X6NO$=M?6-
M[/:26=T4:(O"3+:,%4$QG/4D$CI@D]>E3R^%WN/%-UJ=Q<126=SIO]G/;&,[
MBFYFR7SU.XCI70O*J+(>6*+N*KRWY?A4.GWJZCI\%XL,\"S('$5Q&4D7/9E/
M0T <Q:^#;L:'9>'[Z_BN=)LI8V0^41++'&P:.-CG'!"@D#D#H,YJ4^%;TW'B
MF7[=;_\ $\14 \D_N,1>7_>^;CGMS75T4 <FOA>_&BVVD3SV%[8II\=G)!<6
M[;69 0)!\QP<8R/8<BMW1-,71=#L=+29YEM($A$C]6VC&35^FR2)%&TDC!$0
M%F9C@ #J30 VX@CNK:6WF4/%*A1U/=2,$5RUMX0N1H=MX?O+Z.XTFVE1E_=D
M2R1HP9(V.<<$*"0.0.@ZUKV'B&VU&^2UCM[N/S;<7,$LD6(YH\CE2,XZCAL'
MGI4FLZ[9:%IK7]V9&A5UC)A0N0Q8*,XX') YH J)HEVGC.;73=0F*2T6T\CR
MCN 5RV[=GKR>U;M%5=.OEU&S6Y6"X@!9EV7$9C<;6(S@]CC(]L4 9OB?0IM=
MM+);:Z2VN;*]BO(GDC,B%D)X8 @X.3T-06WA_4+?Q1>ZT;ZWD:YLH[7RS 1@
MH6(;.[N6/'ZUT=5-1U.STJ".>]G6&.25(5+=W=@JC\S0!R5OX&OK?PYX=TE=
M3MS_ &->I=>:;=OWNW=A<;N/O'GGI5W6/"ESKI\F_N+62&.\6ZMIQ$1/;!7#
M;%;/?!&>, ]#BNKHH *S=>L;S4]&N+&RNH[62=3&TKH7PIX; !'..^>*TJ*
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M[='Y9(^;Y>.>]4+GP'/>PZVLNJ+%-?WT>H6TT$1#6LR!0IY8[A\H].IKMZ*
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M7%[>G^UEB$RAD 0Q<H4PN00?4G-3VOA9+?6AJ[:KJ$UZ;46KO(R8< D@D!0
M02>!@>H)H X>V_Y(]H'_ &$H/_2NO0O$ESJ-IH4\^EP23W*,A\N( R%-PW[
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M:IITMPJI=I:S +<[1@%L@D-CC<,'\>:O0^&;:W\21ZU#=7221V8LEMQL\H1
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M$?N\.&7:=_R<\ =,54L/!%IIM\[VNHZ@FGO*9_[-\T>0')SP,9VYYVYQ^'%
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MU220J, L1R<=N:VJS=!T:'P_HEKI5O//-!;)Y<;3E2VT= =H _2M*@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBN9\9ZC-8Q:/;QR/%#?:G#:SRHQ4K&V20".1D@#/N: .FK M?
M$-UJ$\,ECIAN-->YDMGN5G ="A*ERA'*;E(R&STXK.2.6Q^(']DV[S'3+W36
MGE@\UB(I%<+N4YRN0V,#'(S3?AK:10^%_-3S-[75RIW2,PP)WQP3@4 =E17'
M>()_^$;\5Z?KT]S,-*N%:SNU:9C'"YYCEVYP,X*D^XJI<3W5K/X:LKF2XABU
MJ]EFN]TK93Y&>.#.?E'*J0,9VGU- '>45YQK3W>FW?BS3+6XN/L*:*=0AQ,V
M;6;YQA&SD [=V,XX.*OO<3'7O O^DS_Z5:S>>HF;$N( 06&<$@G.: .XHKA_
M!>G?:KB_O[B^U"66RU>\AA5[IV38&*A6!/S8'KD\"KWB&]F?Q5H^C&6..WNX
M)Y,2,P$TB[,)\I!/#,<=^/2@#JJ*\XU6QO\ 2-,T^U?7+B9AXAMT0Q2NIABD
M=3Y+$D[P 01NSP15RVTB*3QQJ^C-=Z@=.>Q@N3!]ME_UA9U)W;MPX XSC/X4
M =W5+6-0;2M&O-06 S_9H6F,88*6"C)Y/L*\XL+F]U'0O C3:E?*]S<RV\[Q
MW#*9$59 -W/)^4<]>^<U<:"?27\;Z+%<W-QIL>E?:81/*TI@9XY 5#,2<';G
M!- '>Z9>_P!I:39WWE^7]I@2;9G.W<H.,]^M6ZX#2KM[K5/#&AW#.MBV@K=!
M0Q432@(NTXZA5R<>^>PJ$6&J:G9>*]#M;Z[#Z;=*VFSB=PP)C$GE%@<LHSMY
M)X;V% 'HM%<AHFH1>+VBU&%[B&V@L_*>-)G3$[X+J<$<H !G_;-<K9+<?\(5
MX/U<:EJ'V^>_@@DF^TN=T<CLK J3M/'<C.10!ZS17F^H7EUX8U#Q='ILUPT<
M&E17D233/-Y<I+J7&\D] "1[5LV.D3'5-.U&#656QN8&CDBBED;[6&3<K!BW
M##!.X<XS0!U]1)=0R74MLDBM-$JM(@ZJ&SC/UVFO+--^T1^#O"FM'4+^2^?5
M(H'>2Y=@T;SLK*5S@Y'<C/O72^'+*"/X@^+I%$@9);8C]ZV,M#DY&<'KWZ=J
M .SHKD_$%](_C;P]H<KO'8WD=Q+(%8KYSHHVH2.PR6([X%<EXBN+^PTKQ]ID
M%[>+::?#!<64BSN'A:126CW9R5XR >@/TH ]9HK,T?2(M+2:2.XNYGNF620W
M$[2?-@ [0?N@^@X_"N \5WDJZ=X@U33KRYGFLM2A3[6TQC%LP>)6AC4?>')W
M9 !W'KB@#U*BN%FT\:G\3-3TZYO+_P"Q-I4,I@CNY$7>9'!(P01P!P,#US6)
M;3ZE)\,O#WBC[7>3W&E-YMT@G<?:;=797# '#,%&[)_N^] 'JM%8/A^5-4N[
M[7(9GDM;EA#:_O&*&-."X7. 6;=R.H"UD>+I;^SU)[PV<VH:2EF%GBM)REQ:
M'+$S(N1NR..N1MX[T =K6/KFN-HUQI<?V0S)?WB6F_S OEE@3G&.>AK"TVZ6
MY\=VRV]W/+87/A]9U4R,%<F0 /MSPVT]>M<[&\U_X/\ "XFN[AW;Q(T?G&4L
MX423@88Y/   H ]7HKSQ[*_TOQ%K>AZ1J<Z6]SI2W,37=P\@MKAI"@ <DL V
M#WSD9%5I_$<VF:1KQ>RN](U>"WM_-MWE,L2QF0H9HFR0>&.>!RHSGF@#TRBN
M#U.._P##D%[X@LM2B:(:;*RV:L\B3.J[EE!9CT[D=1UIM_$EJW@Z[M;VY=[R
M]B6>7[0Y%PK1,Q+#.#R 1Q@=L"@#OJ*\UN+BX3PAX](N[D-9WL_V=_/?=%B)
M" ISD#)/'3FM$SSZSXC;19IT")I<$T4<DCJ9"Y8.X*D$D849[=NM '<U%=7,
M-E:RW5S(L<,2EW=N@ ZUP#V5[#JW@[3KO7+J\9C>07,\,SQB8(C8R ?O#[I;
MKP><UDZS#_Q0OC&QDEGE@T_5%6V$LS,44F([<DY(!9L9SUH ]:HJ*"!+:!8H
MRVQ<XWN6/YDDFN%TW4;O3;N"WU.UG_M'[/,]M=0S&2#4<)NR1GAL#(!'KC@X
MH [^BO.M!M;W6=*\.>(XM=CB=S&]U(K2-]IW_*\3#=M!W' P/E(X%/\ "FB)
MJ\VM37NH:I(;36;R"$"^E 6/ 7!YYP#P3R,"@#T*JEO<7DE_>0SV0AMHBGV>
M?S0WGY&6^7JN#QSUKA_#$]Q=VT7A6]N;A]0TJ^<7DQF</)$A#1N6SGY]\8P>
MH#^E5-3UB_T27XBW-K<W#M:+:M )':3R=\?S%0Q. -Q;'3B@#TZBN2N+.#24
M.N:9J5P^=.E\NV:8RI=L%WK(<DY;CKWS46DV=S=+HFMPZNBQN@\[#._VO>OW
M6!; 8'G@<8(X% '945R'Q',T?AVVDM[JXMI1J%J@>"4H<-*JD$#@C!Z'(JC=
M6PT_Q78>&X;J7[)=V]Q=A;VYED\Z7<@V!MVX@+N.W..<]0* .C\2:\WA^WLI
MA9FX6YO(;4XD"[/,8*&Z'/7I6U7FFMZ?=Z5X4L[&[U3^T&A\0VH1CDM$AE1E
MC)8DMM!ZD]"*3QI<R-;>+;JPN[F:XL((R)/.,26+JF[;'CEF.0QX P0">,4
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M2NS92"]D A\M%89Y^8=OFS@=,9- 'J]%96ASSZKX5TV>_4K<75E$\X4E2&9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI)M*O7M@[G+/%@-&2>YVG!/?;GO6AK6LQZ/#; QF:YNYUMK:$-CS)&R>3V
M))]!W/%9?@ZR=9-:U=P0NJ7[30Y[PJ B-^(!;Z$4[QAH=_JJ:9?:4\(U#2[L
M744<Y(248*LA(!QD'KB@#!L;F:P^(_B:]N-,"2Q:1#,T5F?-,^&D.5^526.,
M8(ZBMVR\4W-QKG]C3Z=%#?/I_P!NB1;G<,9"E'^0%&RP['O63=:%XIOM7UK4
MH19Z;-?:2MI RW+.\,JER#D(/[W4=.V:?I.@:Q9^)M,U:6RTRSMH=.DM+B.*
MX9BI+HY?)4;B=IZ_4DT :.G^+Y-0\,C5$TX)=_:_L9L6G^9)?,\LJQV\'//3
MIS4T/B>2\U*ZM+*TAG-G=I:W*?:<2IN*Y?9MY0;LYR,@&LW3='AD^(6H:A9W
M2R:=LCN7A3!07C*R;P1W\K!(_P!H&H]8\*WFKZM'??8[>TU.WO%>WU6WFVO]
MG#@E)% !8E<K@Y'0Y'(H [BN9N?%K)IM]JUKI_VG3+&5XYI5FQ(P0XD9$QA@
MISU89VGVSTU<5;>&]6T[1M9\/VZP2V5Z\QMKEI,&!)<[@ZXY*DDC!Y[XH 37
M-1NKSQ9X46SBMKBQN4N+B(/,567$0P2-AQ@.<=<Y[5UFG:;9Z39+9V%ND%NK
M,RQIG +$DX].2:YV;P_>6^M^&)+&*)K#1X)8&,DN'8-&J+@8QQMYY%=90!YE
MJ6IZCKO@OQZFJ6MIY-F]U#$%D+^68X4*@ J,\DMNR#D]*W]%\27$-YH>C7FF
M-;Q7UD7M+CS@Q<QHI8,@'R\'(Y/X51G\,:XNE^,=,ACLWAUB6>:WE:=@098U
M3#+MX P3G)SQQ5Q]"U676O"=VT%N(M+MY8KD>=R2\:I\O'(&W/..M #6^(-K
MOL)XH89]/O+D6ZR0W(:9,DA9&B X0D==V0",CL.RKB/#6D^+-!@BT FPDTBV
M?$&H>8WG"'.0ACVX+8XSG Z\UV] 'F7BKPOHFFZGX,M;?2[0(^IB*4F%2TR^
M6WWSCYLGGGO74SOI'@U1%96]M;-J=SE(=ZPQ!Q'\S$XPHVIS@')QQS4/BO1M
M3U76/#UQ8Q0-%IMZ+J8R2E2PVE<*,'GG/.*E\6:-JE^=,U/1)($U33)S+''<
M$^7*K*5="1TR#P?:@#,G^(HM]&U6];2FDETRXCAF2"</&XD8!723 W YZ8R"
M#5RY\6ZG8WMA:WOAN6)[Z\>V@Q=QMN4(7#<="<$8/3'4U6U_2O$WB/P?=VEQ
M!8PWMS)"4MUG)CB6.17)+[<LQQC@8''N3H>(-+U+4M6\.W=O!#LL+HW$ZO+@
MX,;)A>.3\V>W2@"C_P )IJA3685\.@WVD$&YB^VCRS&4WJ5?;DDCMM'3DBIK
MCQ!87NH>$9CI(G&J;I;2YD*YMB82_3DY*\<?G4::%JRZGXON?(MRFKQQK;#S
MN05B\OY_EX]>,U6M_#6LPP^"8VAMB=#7;=$3GYOW)B^3Y>>N><4 27/CR\AM
M-<NHO#\DD6BW#1W):Z524558LO!R<-G;[=>U:FI^)IK3S'M-.,T$5C]N:XGE
M,,14YPBMM8%S@G!QCCUK%E\,ZS)HWC.S\FV$FMRR/;'SSA0T:Q_/\O&-N>,T
MZ;P]XAEOXR\5C/:G2UM46:=L6<P!#.JA3NW CG@\8XH DNO%>HW>J>#SI5M#
M]BUB.2X(FF*.0(2P0X4@ ;@<C.2,<=39A\1:98ZSXKGN=.6R;3(X)+N[!!:X
M4HQ7IZ 8 )[]JS;/PQK]I9>#)!%8-=:)&\$T1G8*RM%Y>X-MY(QG&/;/>I[S
MP?>:O?>,([SRHK/6X((H)$?<Z-&A&67 [D'&>U &H_BF:RO=*BU331:P:HWE
M6\J3^85E*[ECD&T;21G&"PR,>]94_P 0;J'2]4U+_A'Y#::5>O:W;&Z4, I4
M%E&#N/S9QP,=ST%HZ)J^LQ:!!K,-O#_95S'=2RQ2[_M$L:E4VC P"3N.>1C'
M.<UEW/A/7)_"'BO2A#:K<:O?S7$!,YVJCE3\QV]1M[9ZT >A @@$=#7GVH:5
MIUY\:;5+JPM9T;1))&66%6!83 !B".N"1FN^M_,^SQ^:@23:-R@Y /U[URE[
MI&M?\+$A\06UI:RVD6G-9;'N2CDF0/NQM(QQB@#+U-!X-\?>'_[*+0Z;K,CV
MMU8J?W0< %9$7HIYYQ@$"M@^,I(KO3%NM+:WM]1O7LX?,EVS@@L [1%1A3L/
M(8\%?6E3P[?ZKXKM->UQ[=%T]7%C96[%U1F&&D=R!N;'  &![U@)X4\4-;:6
M+B+39KVQU<7DUX]PV^[4%\$_)\N X 7GIQB@#5L/%5]%J/BJ?5X[>/3M)E"Y
MBE+,JB,., J-Q.[U'/'/6KMCXP6X\16VD36T&;J%I(9K2Z$Z@KR4DPHV-CD=
M0<'FLVY\'ZC>S^+;*5[=+#6MLD=PKGS(W$:J 4QC 90<[NG'?C4T-O%[HB:W
M#IL7V="#);S,WVI\8!(*C8O<]3GT% '2UBZQKLFD:KI5L]FKVU_/]G^TF7:(
MI""0",'KC YZ\<5/H-[>W^E)/J$$,-SO96$+%D;!(RI/:J?C*"RO/#%_:75P
ML+F(RPD'YUD7E&4=20VWIUZ=Z %OO$R:?_:,D]OF"TDB@1DDRTTS[<1A2!@_
M,O.>_L:!X@G@UV'1[ZRC@NKJ%Y;1TG+QRE/O(3M!5@"#T(Q^54+_ ,*W>H^"
MHM/:Y1-661+PSL/E-R&WDD#^'=D>PQZ5;&EWNJ^(-*U;4;>.U_LV.79$DOF%
MY)%"DYP/E !QW.>@QR 5H?&@F\.Z1K(T\B+4+M+4QF;YHBTAC!Z?,,C/:NKK
MSJ+PMXCB\.:=HBP6&S3=22YCG:X;]^BRF09&WY.#CO7H@S@9 ![X- &#:^)'
MO[VXALK6*:.VO#:3XGQ+&0<%S'M^[GISR.:Y32]8E\,0>+KNUTD3V=KK$LD^
MR58MB>7'G:,'<1R<<#WK6O/#%W?Z[;:E]D@L]1M[[S/[1MY<&6V#D^6Z@#<2
MF%P<COGM4,OAK6)= \6V/DVPEUBYDE@/G'"JZ*OS?+P1MSQGK0!M:MXCFL/M
M#6^G^=!;V?VMYYI3#&P.<(K;2"W!X..H]:Q]7N;;5-;\":M#%M^U3-(C,HWA
M'MV8 G\:==Z#KUS?2EHK*:VETU;:(33-_H<N&#,JA3NW9'/!XQ26_A[6DM?!
MR20VF[1L"X"SGD"(QC;\O)YSV].>M %GPU%'#XZ\8K%&J*9;5B%&!DPY)_.M
MKQ%JYT#0+S5!:M<BVC,C1JX7('7DU2T?2[ZS\5:_J%Q'$+;4&A:$K)EAY:;#
MN&.,]>IJQXLTZZUCPKJ.FV2QF>ZA:)3(VU1GN3@T 4CXJG@2,WVFI9&ZD5+(
MS7:!904+LS$#Y  .X/)&.M8^K^.+UO#6L36-K#'>V$\4$CB<O&5D8*LD;A?F
MZ]P,$'TP=36]%U>ZL=&O=-:WBU?2WWK%*Q,4@*%'0L!GD'@XIFLZ5K_B+PC?
MVMTEG;7LQB:&W24O&FR17^9]H)+8QTP./<T :4>N7 \21Z)<64:3263W:R1S
MEU^5U7:<J#_$.:RW\<E-&M]0_LF1S)J?]G-&DP.UO,\O<"0,\C@8_*I;S3M<
M_P"$FTW7;>ULY)19R6EQ UR5$89U8,&V'=C;@\"L=/"NO)H,-D8[)YH]<_M'
M<)F4,@F,F,;3@GTR?K0!L/XJU2WU/3]-N?#KQ7=]Y_E*+M&7$>#G('0@@^H]
M">*TO#NN-KEI=/+:&UN;2ZDM9X?,WA77'1L#(((/055U/3+^[\7:%J<447V:
MQCG6;=)ALR*H&!CG&WU%+X7TN^TN76FO8XE%[J,EW%Y<F["L%&#P,'Y?UH ;
MXRU;4-)L;!]/CA9KC4+>W=I'*D*T@&!@'KR">P/>K#:W<RZA/IME90SWMK D
MMRK7!1$+YVH&V$DG:3T'&/6F>+=)O-7TJW2P$37-M>P72I*Y57\MPQ7(!QD>
MU5(=)U73/%-YK5O#!<1ZG!$MW )=IBEC!"E21\RX.#T/&<=J -;0-;M_$&DQ
MW]NCQ@LT<D4GWHG4X93[@BLGQ+K.JV'B7PY86$-N\-]/*)#),4+;8G;;PIP.
MASSR ,=ZT?#6BG0]*>"1U>XGN);J<I]W?(Q8@>PR!^%4_$ND:C>ZOH&IZ:EO
M))IMS([Q3R&,,KQLA((4\C.<8H YFVU&X\/>)O'EUI^CK=1V\EO<3(LRPJJB
MV5FQP<L>3C'/.2._37'C"UQ9):&V,]W9K>HMY<B!5C;&W+88Y)SP >A]LYQ\
M/ZP;GQG(8;8_VU$J6V)CP1 (OFXX]>,U5C\/>)M'DT34]*CLI[NVTR/3;ZSF
MF*I(J<JZ.%X(.>HZ&@#J?#6O1^)-$BU&.WDMRS,CPR=493@C/<=P>X(K"\37
M<FH>-="\,%V2RGCDN[Q5./.5!\L9/]TGJ.XXKJ-.6^%FK:BT1NG)9UASL3T5
M2>2!ZGJ<G Z#&\1^'[F^U+3=;TJ2*/5=.9MBS9$<T;##(Q'(]C@X/:@"Y=>&
MM,G-J\%K#:RVTT<J/!&$X5@=IQC((&,'Z]JI7/BQTT_4-3L]/^U:=I\KQSR"
M;;(VS_6,BXPP7GJPSM/MG2MYM7NB@GLXK%009#YXE8X[* ,8/J?R[CGK;P[J
MVFZ7K>AVJ6\ME?R3/;7#R8, ESN5UQSM))&.O?% %YO%DD^MQ:;ING&[^T:>
M+^WG,X1'4LH&>"0/FZXS[>E$>/)_[#CUA]$D2SCN/LUZ6N5W0OYGEG: /G .
M/[M6+#P[=Z5XHL;FVCC?3K/1QIR%I<2$AE8'&,8PN.O>LR7PKK4G@34=%$5J
M+JYOFN4;SSL"F<2\G;G.!CI0!L7?BF_76]1TG3]!DN[FSBCF&ZY2-75MW<YQ
M]WCU]J6P\7_VOINF7>G:=*YO?-#^<Q1+8Q_>$C '!R,#CFL^TGO8_B5KC06:
MS%M/M=Z>:%*MF3')'(ZY/7IP:CA\*:MID>C1VXM+Z"&2>:^MII3'&\LK;@X^
M4Y"$D $>AZ] "W_PG:MH%AJD>F22_:K\6+QI,I\M_,*9!_B&1D=,^U6H/$U]
M+=:M8/HVW4+"%+B.!;D,)T;.,-MX;Y2,8QG'/>L*/PIKT>AV]@T=DSP:V-0#
M+,P#1B8R?W>"<X Y^M;UOI]Y:^--1UJY6"*QFLXH QE^92A8DD8P!\WKVH D
MLO$W]HZ-HU_:VJ.VIN%6+SO]7PQ;)V\E0IR,#D8KH*Y'PQHR6WB'6;J"X\S3
MDN&%I&/NQ/(%:;![C<!CT.X>M==0!RZ^+I%O-+CNM-:VAU*Y>WA$DN)E*[L,
MT9484[3R">H]:R[.TMSX@\?P&"+RG2 LFP;23!DG'UYJO#X7\2^1I!N(M.DO
M+'4OM,]TUPQ:Z&'&X_)Q@.,+STP, 5M0:-J<.L^*;LPP&/4TC%N!-SE(]GS<
M<9Z\9H L^!/^1"T'_KQB_P#0170UC^%=/NM)\+Z;IUXL8GM8%A8QMN4[1C(.
M!6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !02 "2< 45Q7Q+N94T?2]/1VC@U/5(+.Y=3C]TQ)8
M9[9QCZ9H Z'_ (231=K/_:EJ(QG]X9!L..H#="?8&M,$, 0<@\BJ]QI]I=:;
M)ITMO&UH\7E&';\NS&,8^E8R:G>7>LW^BZ5+;Q'2X81+-<QF3<[J2JX#+@
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M43R2P=@H.XY*C SQNZ\<['AW4=4O1>Q:I9^4T$VV&<1-&MQ&1D,%8DJ>Q&:
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MQT+A=P(SC(SU]:MJBHNU%"CT Q2T 9?AS2I=#\/V6ERW"7'V6)8ED6,IN4#
MR,GG\:JZ7X?FL=4UNZN;J&XAU219&A$)79A F,[CD8'H*WJJ:AJ,&FQ1--N9
MYI5AAC3&Z1ST49P.Q/)Z T <Y;^#)H]!3PY/?I-HL<H95,1\XQ!]XB+9QC(
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M<2FU)\WRR<#&_CKSR:["B@#GWT"ZMO$<^MZ;=PQ37D"17D,L19)"GW7&&!!
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M%A+JL]Q;ZE832.C(@$,B%,&/"\##'@Y]\U9F\"Z=-!JT+7NH[-5V_:09@<D
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M>%82H&_!&3E3G@D?C0!ROBO5M3TVUUZXM-4FEET^&)X$@1<084%C,2 "6/\
M".<8( ZUKC4+G6O$=_I,=Y)9):64,H,.-SR2[OFR0?E7:..Y/-.OO ^GW\FJ
MF2[OTBU10+J".8*C,%"[P,9!P!WP>XIUYX+L[J[M+R+4-2M+ZWA\@W5O.!)-
M'G.U\@@C//08[=J ,W5M4U?1+?37U:6YN+)+=UOKW3(P3',",.R8)V8#9P,9
MZCH*D.JWG]L^"TM]6-U:7\4HG9$7;<%8"P?ID9/./TK<.@QQR1/:7UY:^7#Y
M)$;*X<9SEMZMELDG/7D^IJO'X2T^"71GMY;B!='5EMHT9=OS+M;=E23D9[T
M<I<ZAKK>'_%U\NNW*2Z1>S?9ML46&5$1@K_+R.3TQU.<]M=+W4[7Q7X?634I
M9X-7MYFFMV1 D3(BNICP,CJ1R36@?!]H=.U>Q-[>F'5I'EN?F3.6 #;?DXR
M!5AO#4#WVDWC7MV9=+1D@Y3!#*%;=\O.0 .U ')WE]>WO@#QTE[=/<M:W%W;
MQ.RJI$:HN!\H [FM4ZC>7.J6NAVK21K'I4=TQBD5'8L2HP6!X&WM_>'TJ_\
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M=]LZ_/&4=D9QMQO  [8[XYJQXOUG5=+L_$%U9ZK-+-IT<3P);HNV#"@MYY8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUUZ.Z\B*X@FM)C!/!<ILDC; /(R1@@@@@U7\:/<0^"]9N+6[FM9X+.69)82
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ML=3@FN(@HRB)*68YS@\$=#7J-% 'EWB>Q\0:QIWB*TFT:]GN/MD<EB8G58#
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M92"I&01T- &7X:>X;P[8+<V<UI+' D;13;=P*J 3P3WS6K110 4444 %%%%
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M>V$#QJGS?)VVYXSUJ]9Z'J\7B[3-4EBM!;V^E&QE"SL6W%E;<!LP1\N.HZT
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M!6#C VL-PZ%A[UT-<Q<:5JLOCBRUM8K46T&GR6SJ9SNWNRMD#;C VXZ]ZO\
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M=AAM!+8&.>">>E9R>,=8UJ?PT-&^Q6\6MV4\W^DQ,Y@DC"YZ,-PRV.@Z9]J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N)^)\R1^'K!3<QP2-JMIL=R.,2@YP3SCK7;4A4-U /U
M% &+!HLSZPVM7-W#->BU^S6YCA*QQ(3N)QN))) [C@ >I.':> [NPTK0+:UU
MM5N-%FD>&5K3<DBN&#!DW]<,<$'CTKMZ* .*?P#))H>MZ8^M2,-1OOMR2FW7
M,4F]7Y /S<H/3BM*]\.WU[K&B:D^JQ>;I9E;!M<B5I$VMT<8 !X'/N371T4
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MQXSGW-=/10!FZ!I;Z)H-EI;7 G^RQ+"L@CV;E48&1D\UI444 %%%% !1110
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MOA%Y+S6Y7]Y'G(5@RL#@]#C(]: .*'B#7;O2])0ZB\%TFOG2;F6.)-LZKO\
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MGZ2MQ>+#ITRSVLJR 21L,XYQ@CYB.1WH Q]6UJYTK79;?5;B^LK-YH5L=0C
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M]A]BU6S6XO$M]3>1YHQ*-J^9R^T$<9_'';% &)<I/=^,O!\CWUTIFT^=W"N
M-P6,YQCJ=QS3;GQ'J.E+XREDNS.+"XMX[8RA0(A(J>@' +YY]*Z.;PO9SR:5
M*UQ=B;3$:.&1) K,C  JV!R"%'3!XZT@\*Z>SZN;AIKF/5L?:HI2NTX7:,8
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MM/D6TOQ L+B<#>J1[65PK9()['(QUQ71S:'IMQ>6EW):(9[,8MG!*^2,8(4
MX&1QQU'%21ZOILI81ZA:.5C\YMLRG"=-QY^[[]*DM+^SOT9[.[@N44[6:&0.
M ?0XH S]7\*:#K]S#<ZKI5M=30C"/(O('H?4>QXJ:ZT#3+RX,\UJ/,,(@8H[
M)NC&2$(4C*\G@\<U/%JFGSRF**_M9)!U1)E)'..F?6A=4T]KA;=;ZU,S.T:Q
MB9=Q91EE SG(!!([4 4M6\*:#KJ6ZZGI5M<"V&(=RX*#T!&./;I4[Z%ICW5G
M<FS0362[+9E)7R5Q@A0#@ @ 'U%3VVIZ?>RO%:WUM/)&,ND4JL5'3D \4P:Q
MIAFAA&HVAEG)$2>>NZ0@X(49YP01Q0!6_P"$8T7[)>VIL(VM[YM]U&Y+"5N/
MF;)Y;@<]>!37\*:#+<03OI-JTL$7DQL4Z)G.T^HSSSWYK.M_$DL'C#7;#5+N
MS@T^R@MI(9&_=8\S?D,S-@GY1Z?2NH5E=%=&#*PR"#D$4 8__")Z!]@M+'^R
M;7[-:/YD$>SA&Z9_Q]:MV^D6%IJ-SJ$%N$N[G FE#',F.F>><=O3M5J>>&U@
MDGGE2*&-2SR.P"J!U))Z5QVH>-?M6FZ'J.A7-M);7NJ06DRNNY_+=R,C!^4D
M#/(/7M0!UT-G;07-Q<10HDUP5:9P.7(&T9^@&*S'\)>'Y-<&M/I-J=2!#>?L
MYW#HV.A/OUK2M+^SOU=K.[@N!&Q1S#('VMZ''0^U-M=3L+V62*TO;:XDB_UB
M12JY3Z@'B@"+^Q=.^T-/]F&]Y?.8;FVM(.C%<X+<#G&>!4>GZ+;Z?JNH7\,2
M1R7I4R*F<,5W?,?]H[OT'UI^MZU8^'](N-3U"98K>!"Q)."Q[*/4GH!3O[8T
MT:>E^]_:I:MTF:90F?3=G% $5WX>TB_OQ?7>G6\UR(_*\QUR2OH?7\>E<WKO
MA2,SZ?!;^'+'4-'M861+42B&2*1B,L">HP ,9'X\5UQU"R6*&5KRW$<W^J<R
MKB3O\ISS^%1C6=+:(2KJ5F8VC,H<3K@H#@MG/0'C/2@#&T/PM9VMC>V\VFQ6
M]E>*JMIYF:>,8SECNX!.1D#CY1S5VU\)Z%8Z7/IMMID,5G/_ *Z)<XD]F.<D
M>QJY_;&E[;9O[2L\71Q;GSU_?'_8Y^;\*NT 9PT+31/9S_9LRV2E;9R[$Q \
M$+SP"./IQ49\,Z*?M.-.@4W,HGE*C:6D!R&R.ASSQWYK ?Q]#'I$]]+#/&(-
M1-G.#:2,;<<X) Y?. ,CC+CTYW]>U>+2],N'%]9V]WY+/ MRPPS <?+N!//'
M![T 7+2PMK$2"WCVF1M\CLQ9G.,99B23P .3T%07FB:=?W8NKBV!N GEF169
M&9/[K%2-R^QR*R=&U6_U30O#%_)?V=O)>PI+<Q.G,^Z/)6/G@YY[\"MQM2L%
MN_LC7ML+G('DF5=^3T^7.: (9M$TVXGM)I+1/,LQBV*DKY/&/E X'''':K[*
MKJ58 J1@@C@BJ<FL:9"ZI+J-HC-)Y*JTZ@E^/E'/WN1QUY%/N]2L-/*B]O;:
MVW_=\Z54S],GWH IZ5X9T30YY9M,TVWM9)?OM&O.,YP/0>PXJ2#P_I5M<F>&
MR1'\PS!03L$AZN$SM#>X&:M7%_9VFW[3=P0[E++YD@7( R2,GH!S44FLZ7%Y
M/F:E9IYZAHMTZCS >A7GD'VH B.@Z89KV7[*/,O0%N6#MF4 8 ;GGCCZ<4UO
M#FCO;V<#Z?"\5D<VRL,B+C&%SVQVZ5=NKVULD#W=S#;H3@-+($![]ZI:G>%]
M+,NGZI8VS[TQ<3X>/&X9'4<D9 Y[T 2VNC:?9274EO;*C71S<$DGS3ZMD\FJ
MEOX1\/VAMS!I%JAMG,D)V9*,?3_#H*T+C4["S,@N;ZV@,:;W\V55VKG&3D\#
M/>I&O+5+4737,*VY 83%P$(/0YZ<T 9R>%]#CUIM832[9=08[C.$YW?WL=,^
M_6K*Z-IJ:E/J*V4(O)U"2S;>7 &.?PX^E4]8U29]!N;C0+S39+M%!C:=R\7#
M '.SDG&0,=\57L]0U^3Q!:0W-M9I836 EEC0L9K>;C(8_=VDD@=S@^AH T+'
M0=+TUT:TM%BV B,!B1$#U" G" _[.*6WT+3+6&[AAM%6.\+&X7<2)2PPQ;)Y
M)'4]:N7%S!:0M-<S1PQ+U>1@JC\34']KZ;NN5_M"TS:_\? \Y?W/^_S\OXT
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M]V^;GGCCZ<5'?>%-"U.QMK.]TV&>"UX@5\DQCT!SD#IQGL*M_P!L:9YD4?\
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M6$\-0Q7<MRY9[G*/^[B0G&0V<M@DD@8[UV7AOPW+I5SJD]]'9RR7>H2WL4B
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MO8YI'M[XJ+9U@<^9N&1QC(!'.3@8K!T*-S\0/%KRVMPL%PEH(WD@8))MC8,
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M6+XG0W$EC-%"F@^0SQP.8DD\T-L# 8X JQ\-XIK?P@D%Q;SV\J75R3'/"T;
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M.0._>KM9>AZ[;Z]!<R06]W;FWG:"2.ZA,;A@ <X/8@@@^]:E !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %1SPI<6\D$F[9(A1MK$'
M!&#@CD5)10!S5CX3EL[5+!]?U*YTR-!&MI*(L% ,;"X0.1CCKGWKI0,# HHH
M **** "BBB@ HHHH **** "N;MO"D]C-*+'Q#JEO92RO,UJ!$X5G8LVUV0L
M22>O>NDHH BMK>*TMH[>!=L4:A5&<\?4]?K4M%% !1110 5#':Q17$MPJDS2
MX#NQ).!G 'H!D\#U/K4U% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 0V]K%:JXB4YD<N[$DL[=,DGKP /8 #H*FHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LC5=<^P:KINEP0I+>ZAYIB62
M7RT"Q@%B3@G/S#  YYZ8K7KBO'-A!KVJZ%H,A>UEG>:YAU&([9;9XE! C/\
M>;=W_A5N.A !T.AZP-8@NB8/)FM+I[69 VY=ZXR5; R,$=AZ8XK4KD_A_)>Q
MZ+=Z7J$</VG2[R2T:X@7:EU@*_FX_O'?\W^T&KK* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J"ZLK6^B$5W;0W$88,%EC#@$=#@]Z** 'P00V
ML*PV\4<42_=2-0JCZ 5)110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex109keyexecutivebenefit009.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M85E)!C (#Y&"6P3DG) Q706)O=,\7^)[J32[R2&ZC@N(6B0$.$AP5!S][<,
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M%KITXD>_TR\C;RK5MI(,3,./G.,*2"">E '6ZYKUAX=L/MNHO)'!O6/>L;,
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M'* &! ]*Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBLW6M9AT6"V>79NN;A;>+S'V)O8$C<V#
M@8!['G [T :+.J#+L%!(&2<<GI2UPGC.:2YT[2+B[T_RKBVUZU5%4ARPWCE&
MP.#^'O6Q;^*F\_6+>]TNX@N=-@6Y,4;"9IHV#$;<?Q?*1CU[T ='3/-C",_F
M)L7(+;A@8ZUAV/B WFN?V)>V*P7$ED+P*)?,&PL%*L" 0P)'&"/>N#EMH/\
MA3%\/*3$.I/Y?R_<_P!,QQZ<<4 >MT45RMOXONKS6KW3[?0;ADL;M+>ZG:>-
M1$C*&\SKR,'H,G'Y4 =517+IXUM'N=.Q'&UKJ$HBADCG#2*6^Z7CQE0?7)QD
M9 J:3Q289[4S6$D5M=7QL8W=]LA?) ;81]TD=<YY!Q0!T5%8L>OM<WMQ#:6R
MSI;72VT^)L2(21EMF/NC=USV-1W'B1E@U"ZL[%KJUTYVCN&60*Q*@%PBX^;;
MGN1R"!0!O45R\WC$-J]CI^GZ;->F_LFO+>82*B.HV\'/(^\,D_@#19>,&O\
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MA)0RSB+[NP=06(&<XQSC--.A:L=/\8P?94WZPTAMOWHP-T0C&[TZ9XS7:T4
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M0@%Q_:O]J0R^22H?S/,VLN[)&>,@BK>M^&;W7;&\L+Z>RN+:Y5=CO 0]L^T
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M2>6:TBDWA"IY0'YB2<G.>>/I5:3Q'J5YIVL:EI45J]OILTL0AF5B]QY0^?#
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M\<L8;<I&""&!)^M98\":@/#]U9'5;=KMM6_M6VE^S$*DGF^9M8;N1],8SWH
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M!4DB7.T'()&,GD$57M_!=K;RZ)(FHZ@3HP=;<%HR"&780WR?W>.,?GS72T4
M<P;:U\&+J&IC^UM0_M&[626*&!9F5R N0J*"!A0.]6?"FBQ:/I<[):_99;ZY
MEO)(>\9=LA?J%P"!QG.*WJ* ,7PQIM[I>F26]Y?7EWF=GB>]D$DRH0.&8<'G
M<1Z @=JVJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *HWVJVNGL$E\UY"AD\N&)I'VCJ<*"<5>KBM?ANM/\
M9)JSZ-<ZKIMS9+:NMH TD$B.S [21E2'(]L4 =987]KJEA#?6,ZSVTZ[XY%Z
M,*LUB:9)_9L.F:=!H<EI!.)6VP*OE6H!W /@\,V>V1NS]:VZ "BBB@ HHHH
M*X+4I[OPGX]L[Z\O[R;P_J?^C!99V9+.Y/W203]UN1ST/IQ7>URGQ(LI]3\!
M:II]I:275U<1A8HHTW$L&!SZ#&,Y- %K28GU'5[K7/M=T+%@(K6#SV\IPN=T
MVW./F/ [84-_%3U\7:639R-YZ6=[+Y-M>,F(97/0 YR,X."0 >Q.15D6IO\
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MR!91*'1P2I4X')((P>_>D@\7B36!IK6D4DLMNTT#6ETLRL5ZHQP C=^X//-
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M=#TBZU.]8K;VR%WVC)/H .Y)P![F@"[17//XEGLM7T_3]5TX6QU$,+62.?S
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ME!+$2&&U@#A@1Z5U%% ')ZMI>N:G%HLLL5L9[;4DO9HTEPL:*I&Q21ECSG)
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MAJ^TW4M:CDNKQ%C:9+7;'&@.?E3=U/<D^G'%77T*ZE\3:?K#WL/^B6SV[1"
MC?O*DG.[C[H[&@#*\&)=Z[X%==6N4N1=M<*2(RK F60$D[B/I@#&*E\)ZMK.
MN>$=!OXGM3(S&._:<-N=4+(Q3'\1*@\\<FI]+TZX\(:!/:BZ%ZJO(;*%8=CE
MG9G"$Y.XY;KP !D]S3M#\/7VB>']$TRUOTB%H0UY^Z#^?G)=03]W+-G- '24
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4UXTE7;(BNOHPR*=10   # X%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(O4,E^N^T7!S,N,Y7CD8Y^G/2ICJ]@OVK=<HOV1Q'/NR-C'&%^IR, =<CU%
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M411$?^6:(,8_%B[#V852U29]+^(UCJ5Z2FES::]HD[?<AF\P.=QZ+N4 9/\
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M\6^*;Z73KE8;RRMXX&"@[W17#*,'U<#)X- &\GB*RN+.PN+)9;QK^'S[:&$
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MGF\F.^*CR2Q.T=]P!/ 8C'OR*CNO&-C;7>I6B6>H7$^G*CSI#;Y^5@3D9(R
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MD\V![V[=3AA"I"JH/;<S#)]%/KFEAOM._P"$PU""".^;4H+%&>/)$31[FV[
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MV;0V"?[IZ9QQFN?ET#6I-)U"XATDS3V_B235(K.YV@7<# K@9R 2&)YZ8Z4
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MTH W-4TZ+5M,N-/G>18+B,QR>60"5(P1D@XR*?9VBV5A#9QRR,D48C1WP6
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MIT%L[1W>'CF\QC^Z'RM\HZ?B.36E8WSZ=XRU+08TWQ/9KJ-K%G 7+%'0>@+
M$>FXT =11573I[JYTZ":]L_L=RZ R6_F"3RSZ;AP:M4 %%%% !1110 4444
M%%%% !1110 4444 %9*>';%?$$FM,;B2Z<#:LD[-%&0NW<J$[5..,X[GU.=:
MB@ HHHH *R]3T"RU>[M;B[-PWV?.(DG98Y <<.H.&' X-:E% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;0SQP2W$232?<C9P&;Z#O7 ^%[5X+N;P3-"3;:1>&Z5V7*O;$^9 ,_WMY_\
M(1K-+:-K'_"3:1XDUI[&\74I&:(F)96C# P-$64L?E"@;<G\Z /5'=8T9W8*
MB@EF)P /6L6+Q#%_PCL_B"XVQ:=Y1FA!X9H_X6)/'S<$#MD?A'XM2<^ =82
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MCV H ]4>[MH[E+9[B)9W&5B+@,P]AU-1:D]['8L=/CBDNBR*@ESM + $G'/
M)/X5YA;-HVMZ9JNFZ_K4UGJT&J2O) AB2X\P2EHC$64NV5V*N">.!Q7K0Z4
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MZ2Z-\1?$Y# C['9GKVQ)4GPV(/P[T4@Y_<'_ -"- '2-=VR2B-KB)9"P0*7
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M;0)=0:X/*G"C?&!>X 4]A@G@<<GUKK/$1D\)>+H]>L;/S8]8B^PSQHO6Y&3
MQQ_>.4)^AH [J*:*=-\,B2+G&Y&!'Z4^J6D:;'I.DVUC&0WE)AGQC>YY9C[D
MDG\:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4<5+'96D,[3Q6T*3/]Z18P&;ZFN2L?$+3_$/5+4ZC-_9L&EQSF*>+RO(D,C
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MRKM(P.%"[R<+G!R1S73+K>FR:;;ZA%=++:W('D-$"YER,@*H!). > ,\'TH
MO/&DD;1NBLC#:RL,@CTQ5:/2]/AADABL+5(I,;T6%0K8Z9&.:H'Q=H"V"WKZ
MG"D#3_9LOE6$N<;"I&0V2,@CBKFEZQI^MVSW&G7*W$4<K1,R@C#KU'(H ?\
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M!D>XH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S?C*[:SLM.D^R>;&;^,/.(#,;0<_O0H!
MY'0''&[OT/244 >8J772OB%!Y-\S7,;M"T\#AI=UN%&.!R3V'/L*T9Y ;SP"
MX5RL.XRG8?W?^CE/FX^7YN.>]=[10!#=VRWEE/:N2$FC:-B.N",?UKC/!FH+
MX;T.'P[KBO:7EB6C21HV\NX3<2KHV,'@].N1TKN:* ..\5R7DZZ+JL-I<-96
M.I)-/&$.]HMI7S-F,_*6SC&<<U5OXA?>)-4UNT):P70GM7D53MFE9BRA?[Q
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M()H9(Q(&26)D(_>,1C(&1@CD<4W5V:T^)NB7DD%PUO)I]Q;J\<+./,+QD*2
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M\A6B(0.>=I)XP3UXYQ7H-% 'E6FK8?9[SPMXBTG5;G4A>2O'$#<&"[#2F1)
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MXL;1B>)90C=5W#.#^=<Y!#J6C^*]8E&GSWEGJ?ERQ2PLN8W5-I5PQ&!P"#0
MWPCJZV_@S05F,UQ>7<9$<:G+R$$ECEB!@#J2?3N16M%XET][:]EE,EN]DXCN
M()5_>(QQM& 3G=D8P3G-<KHVC:OIMGX7OWL)?,T^*6VNK7<I?8_1UYP<$#(Z
M^U6-5\-ZEJ3:UJMI'Y5U/):R6D$I W^0=WS>FXY SZ#.* -]_$UO#+>PSV=Y
M#/:6WVIXF5"6BYRRD,0<8/&<U*/$-H9-)7RY\:JFZW?:,?<WX;G(./:J@GU/
M7](OH)=*ETX2VLD06X=2S2,N.-I/RCGDXSGI6+:V^KRGPCNT6YB&F9CN=[QY
M'[DID?-RN?H?04 :TOC:PBM+RZ^Q:@\%E<-!<NL(Q$1C+')Z<]LGVJ]!XBM9
M]8BTXV]U"\\;2V\LL85)U7&[;SGC(/(%<U)I>IOX7\6V@TZ?S[^[GDMD)3YU
M=5 .=V!T/6M"\L;VZU_P[,+*<06]M/'</E?W9=%4=^>0>F: -%O%%E'+9;XK
MA;6]E$-O=E5\J1SG:.NX9P<$C!JK+XVT^*WO+C['J#0V5P8+EQ!Q%C&6.3T^
M;MD^U9GANRO[&"UT>\\-0>?:%4_M+$9B>-3PX_BW8[8Z\G%1S:7J<GAKQ=:+
MIT_GZA=RR6RDI\ZLJ@'[W'W3UH WGUZ?_A,(M'CL97@-F;@S*R8.750>6SM'
M.>YSP*M6>NPWSVQAMK@P7)80W&%V-M!/9LC.#C(%926M_%XPT_4182O;OIGV
M1R&4>2_F!OFR>F >F:IZ/I%W::W97>GVMWIT4Q=M2LI&!MP2IPT8R<$MC[O;
MKCH0#M:HWVJ0V5Q!;".2>ZG#&*"+&YE7&YOF(  R.2>X'>H]$U275;262XL)
M;&>*4Q/#*P8@@ @Y'!X8?K6+XAM]5L/%&F^(=.L7U"&.WDM+JVB91($9E8.F
MX@'E1D9H T;3Q18WMC%<0QW!EDG>V6U* 2^:F=R\G' 4G.<>]<]XOUV#5O 7
MB+[,UU:7FG_)-$S^7)&V1C)1B"I![$@U-XAL]9OXM)UI-'CN);*X=WTN5T+-
M"Z;3D\KO'WL=.<9..8];L+[5? NL0V7AW[#/>(L<-HHC65B#RSD':/89[>^
M 7=2+Q_$3PT%EE"2VMWO3S&V$J(\';G&?F/.*ZBXG6VMI)W5V6-2Q"*6)QZ
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M'A\PQFVM[]MSPRY;<J$DML V]>_3-6_&>GZC=6>G7NE0K<7>FWJ78MRP7SE
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MFD)( Z[L$@C=MQ[XYJAX7NM?6PLM'U#19+62SC6&>[:1&BD51@&/!W$M@=0
M,GZ&KX3'B#1=/@\-W&CNWV1RB:CYB>0\.[(;&=V[!QMQUZD4 ;.I>++'3(9K
MF:&Y>QMYA#/=QJICB;(!S\VX@$@$@'!^AQ/+XAMTN+B.*VN;A;:5(9Y(0A6-
MG"D9!8$C#J20".?8XY6RT[4=*U'4=-F\+PZE'<7<MQ::@1&4"R,6Q+N^8;23
MT!SV%2:WHEY-J]Q?Z3:7=AK4<L2174# 07<0"Y\U<XP!N'(!X&,]* .F?Q!
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MYI@W[MI3;C=CY<YQW]J[>B@#FK;1M2MO$NN:BJ69@OK>&*!/.8,#&&'S?)@
M[NV<8[UEQ>%-9B\+^&M+'V S:3>0SRMY[[76//"_)G)SWZ5U]]J-KIRP&ZE\
ML3S);Q_*6W.WW1P./J>*M4 <'HXU*76O&<%C%;'S;P())92/+8PH,D!3D?B.
MGXU8A\)ZCIE]IT=A+:3Z=:Z<+-5NBP:&3)S,J@$$L.",K]:ZBTTJPL)YIK2T
MAAEG.Z5T7!D/JQ[FKE '"Z;X4URSL_"D,IT]CHSN9=LKC>I0H,?)R?FSV]/>
MM73+&;1M7U[4=4FL8;34;B-XSYYXP@3:VY0.<>O?%=+5:^T^SU.V-M?VL-U
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MCK70T4 5M0@GN=,NK>VG-O<2PND4P_Y9L00&_ \UR&G^&=>M[_P[=2)I4?\
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M$W\_G;#TBR/F"_5MS'Z^U9%QX*FN-&U[3FU1 NL7)N'<6W,>=H('S\\*/UH
MLV^JZM;^,K?2[^2UEM[VSDN(Q#$5:%D905)).X$-UP.1T%9 \6:S<Z)I&JVI
MMD;4=2^Q-:R0EO)!=E!X8$LNW+=NO3%;USHUP-=M-=DNU<V-K)$8(K8YD#8)
MQ\W7Y1@<UP^CW,OEK=Z9XETR?4W+2_89M,5KHNQ),;LK!\\[2V ./2@#TZ]>
M>+3IY(6C$Z1EE+J2N0.X!!Q^-<)-K&KZKIW@>\6[B@;4)U:=%ARK-Y3L/XLX
M&.F?QXKO;F*2XLI85=8Y)(RNXKN"DCTR,US:^#98M#T*QBU/9/HTJR0S_9\A
MP%*X9=WHQYS0!%>:]K5V-5_L6$22Z?-Y"1F#<L\BJK,&;<-H.[ ],9R<X#O[
M7UZ[\4_V1$;2R632DO?WL)D>%R^TJ<, V,=L?C4DGA._M];N;_2-?FL8KTJU
MY ;=)0[@ ;T)X1B!SP1[5=C\/2P>)AK$5XH5; 6*0O$6PH;<&+;LDY_3\Z .
M:C\5^(#X5LO$$K6 C2\6UN;=86)E_?\ DLRMN^7U P?KV&G?>)YH?$UQI#W4
M-A<"2/[&ES$=EVA"ERKY W9+*!Z@=<\)_P (3/\ \(G_ &#_ &HFS[5]I\[[
M-SGS?-QC?_>_3\ZN:MX8GUN"[M+Z^BELKB5)0AMOWD)4+GRWW<9*DYP2-QZT
M ;.J375MI5U-911RW4<3-$DK[$9@.,GL*YS3/$%_<^(Y=)6YM[A&TT7D5S]G
M95#[]I YPZ<@@@_B:W-?TA->T&]TIYG@6YC*>8G)7\._T[UEV_AG4(]=BUB;
M6A+=+9&S=1:*J,-VX$#.1SU&>?44 8FG>*M?ET?PUK-R]B;?4[N.UFMXX6##
M>6 <.6XP0.,?C5K5M5O=<\/>*GLIH8;6Q6XM KQ[C*R1_O"3G@<D#'IDYSBK
M,/@J:'P]HNDKJB%=*NDN4D-MS(48D C?QU.?Z4LO@VZCDUJ/3]7%M8ZOO>XM
MWMO,*2NNUG1MPQGN"#^% &OX9S_PB&C[2 WV"'!(S_RS%<DWBKQ%'X<N-<DD
MT_RK+4FM98%@;,R"<19!W?*><]_Z5VNDV#Z7HUIIYN#,UM"L(E9,9"C .!]*
MYU_!,\GAB]T0ZHFV[O#=-*+;E29!(0!O_O#\J +PU6^U;6]7T[39X;;^S1&A
MDDB\SS)77=@C(PH&/<DGD8YYMO$6I:__ ,(C<P3)9-/?30W,'E[U\V-) ><@
ME<KD#W&<XKI_^$>N;;7KG5].OXH)KV)$O(Y+<R1R,@PKJ P*D#CJ01^=5Y/!
ML<=CH\&GWKVTNF7#7"3/&)/,9@P<L..3O)]O2@#4U^\NM.\.:A?6K1?:+:V>
M9?-0E254G! (/./6N?BU[7+;3M-NKQ[25M7,$=K'#"V86:-G<MEOFX7CIR:Z
M75M/?4]$N].6?RS<P- TK)N(#+@G (YP:R;[PG_:'A>PTJ2_>*ZL#$]K>PQ[
M6CDC&%;:2<\9!&><GI0!@^)-3\2Q>$_$RSJ;>*"$-:WOE!6E1AAT*[CM8=-W
MH>@-;UY>:I:265LUW;1Q20.QG6$M(\@QM1(LDD8))(ST[4DWA>[U+P]J&G:Q
MK+WD]Y#Y)G2!8EC';:@/7/)YYXZ4?\(SJ']L6>J#6R+J*U-I.?LRE9$+!LH,
M_(<CJ=U &7%XNU.Y\+>%]61+9'U*^@MKE"C'AG*DISQ]WOGK[5//J_B&?6O$
M>GVEQ80IIL,,T,CV[,3N5VVD;O\ 9QGVZ<\+!X'GM_#^DZ2NK[DTV]2[C=[8
M?-L8LJX##CGD_P JT4\.W":MK=^M_'G5(8XBAMSB/8I4'._G[QH O>'M3?6?
M#FG:G(@C>ZMDE9%Z E02![9K'L]6UO6M.BU?21:F!KMHUM9006A60HS%\\-\
MI8<8[<UL:!I;:)H5GI;3B<6L2Q+($V;@!@9&3S6-8>#[K3+RXBL];ECT6>9I
MVL/)4LI8Y95DSD*3VQGG@CK0 Y=9U/5UUR729+>(:9</:QQRQE_.D106W'(P
M,G:,<\9YZ5G0>+=5UJZT!=*^QV\.KV,L^9XF=H73:#T8;ADGCCIUK87PU<6>
MH:G/I>HK;0:FWF3PO!YFR4C!=#N&"1C.01D?A6#>VD&D^./">E:9<P6PM;"X
MB191OR/W8 (R#DX)Z]10 VX\7Z[9^%_$33K9?VOHDZQNXB8Q3(V"K!=V5.&]
M3T]ZWM0UF]FUF[TK304DM;>.5Y!#YN7?=M&-PP/DY]<]L5%?^#A?Z!JU@;X)
M<ZK*);JZ\G.<8 "KNX "J!DGOUS3M3\+WUQK,.LZ9K1T[4/(%O<D6XDBG0'(
MRA/!!)P<T 4+CQ;J%A:Z0VO0C1#=0OY\[1^;''.& 5"0<*K#+<GVR,&NLTZ6
M672[66YDA>9H4:1X3E&8@9*^V>E9TFB7FQ(TU%)H6@:*XBO+?S5F8DDN0&4
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M7<22=H'4<?6@#F-/\5Z_+HGAW6KE[$P:A>I:36\<+ _.[*'#%N,$#C!^M=K
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 SG S2T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !169K=
MVEK!; ZM%IKRW,:(TBJQE^89C /=NF1R,YIB7\/]OW<9UF!D@ME:2RPN8#DY
MD9LY&1@8/IF@#6HK.T&?[3HMM-_:<>I[@W^F1H$67YCR ...G'I6C0 4444
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M6 T=[A[:>$PB-Q*@#895;H3R<CK6[:>)](OKB*"WNF:2:)IX08743(.K1DJ
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M>3:G=_8XU0G3UVB)W5MRL>-W7!QGL.W% $^AV4MEI42W./M<I:>X(Y'FN=S
M>P)P/8"M&BB@#CO N=-T;68+A7,MGJ=UY@52S,"=X( Y.58$>N:BN+/3M?\
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M/:JMQ&01L13DEAC&TY_3/6@#I;KQQ!9/"+G1M7B6XO%M(':%<2LR[E(^;."
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M !1110 4444 %,>&*1XW>-6:,Y0L,[3TR/2GT4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5[Z>:VL9Y[>
MU:ZFC0LD",%,A[ $\"ID9FC5F0HQ )4G.#Z<4 .HHHH **** "BBB@ HHHH
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M"E_'*_G"7E#&H)&W'/WASG\* -JBL;0=;EUB?5H9K5;=K"\-K\LF_?A5;=G
MQ][I6S0 4444 %%8FG:]+>^*M8T:2T6(:?'!(LJR[O-$F_J,#;C;[UMT %%%
M% !1110 4444 %%%% !1110 4444 %%%0/>01WD-HT@%Q,K.B=RJXR?PR/SH
M GHJ"YO(+,1&>0)YLBQ1@]6=CP!_GM6;I^MRWGB;5M(DM5B%C'"ZRK)N\P2;
MNV!C&WWH V:**@NKR"S2-[B0())4B3/\3L0% _$T 3T444 %%%% !1110 44
M44 %%%% !1110 45G:UJT>C6*W#H9'DFCMXDSC=([!5&>PR<D^@-9AU_4X-1
MBTNZTR&*]N976T<7&Z*6-$W,YXW+CA<$=3UQ0!TE%9.B7NLW@F.K:1'I^W C
M"W(E+GD,> ,#@$>Q[5K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!SWCIY8? VM3P3S0316DDB20R%&5@,CD<UE:U
M<R:)J'A_Q!->7*Z<P%K?(9W\I=ZCRY2N=O##!./XO:NMO["VU.RDL[R(2V\H
MVR1DD!AZ'':DETVSFT\6$T"RVH"CRI,L,*01U]"!^5 %;18WAT]9KEY1-=.9
MBDTC,8]QRJ#)XP,# [@UIU5O=-L]1-L;RW2;[-.MQ#N_@D7.&'N,FK5 !111
M0 4444 %%%% !7G^M:5J/BO2]8GMK2W<7)5;"X:Y*.@A)*,!L/5]S9SR&%=[
M-"EQ"\,@)1QM8!B,CZCFH;2PMK"Q2RM8S%;HNU$5C\H]!SD#Z=* .535+OQ7
M\/[.\L)8(K^5HP\,Y*H\J,/,A;'(#;6'T/O5SP=?17(U.W.G3:;>PW"_:K)V
M#)$Q1<>61P4(&>,<YJ_#X5T2WM9+:&P6.&243,BNP!D!R'Z\-GOUXJ_:6%M8
MB3[/&5:5M\CLQ9G.,99B23P .3T% '"V2KXDLO&$NHR/'?65_<06\@<J]I'&
M@\MD(^[G[V1UR<Y%4)@^N0?#F_U> ->W<@\\G(WCR'.<#IGK^-=]=>'=)O+R
M6[GLU,TR!)BK,HF4=!( 0''LP-27NAZ=J-Q:W%U;[Y;4[H&#LOE'U7!&#[T
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M-;V21D2&94#-Y:2'JZIG:K')Y !Y-,O/"VAZA?RWUUIT,MS-%Y4CG/SK@@9
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MQSEE4G"DY/(&>3ZU GA308]:.L)I=NNH%MQF"\[O[V.F??&: .'O=/CN-/\
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MP+^&0CY3;%BT<>?42_HAI+">U9/&UAKS1K.]U+(RS$ O:E (B,]0 "..A]Z
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MQC&VDW5AXLMXF=]/;RKM47+26KG#?4J<,/H: .F%]9E9F%U 5@.)CY@Q&?\
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MWM;&VN5\RV@D@:5S&?NLY#@9(YP.F>IJWXITR76?"NJ:= 0)KBV=(\G W$<
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M8D'WW/,#_P#?7R$^C#TH ["WN;>[C,EM/%,@)4M&X8 CJ,BI:IZ78C3=,@M
MV]HU^=\8WN>68^Y8D_C5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Y0/C:3P>,]CZ51\5Z]!9:'JZ6]Y/%>6UJS^9!"7\EMI*[CM*KGCKC@YXZT
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M;MNW:1NW9XVXSFL32]7EO/B+J%FEU<O:1Z='(+>:(Q^7(78' *@] .3GKUH
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M_5=7L[1)[9[F:.=83(Q@A:1HEYPQPK!1P>H['T-4O U[<ZCX(TF\O)FFN)H
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ME]39UA^RR;V4W0<$+MSC;SFM_4Y)_P#A/1=V]A/<H-#FC4&!_+DD+JRQEB,
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MRVR7D _A)P%)'?[V<5-8-(_B?PM<&SO$CBTB2*1WMG 1SY> QQP3M/6N]HH
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M<$%@>P.1OXS5T&\E\9>%KBZL989%TV5;D10L8H9'$9V;@,#D,.O:NVH(R"*
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M&'0;?4[*_NFNH+IYD0P,^-RR \D \C;G_#2LM/U"'Q[<7\MHWV-].BMA<!D
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MVPL<V#M+?,#C&[L15:Z\9I!<ZO;Q:/J-Q+I05K@((P-A7?N!+ 'Y>W4^E/\
M%MA?7\FA&RM'G%KJ<5U,5=%VHH8'[Q&3\PXJB-,U,:IXQG_LZ4QZC#&EJ1)'
M\Y6(H?XN.3W[4 =78WD.H6%O>V[%H+B)98R1C*L,C]#7&?;)-+^(>OR6]C=W
MSFPMY/)A89ZR9.78 =!QGGL*NZ=X1M[SP[H\.KPWD-W9V45LZ17KQ@%5 /\
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M]2U&2S=;*>RAA28NARR,Q/ ;/\0[5%XET[4QK^B:]IMM]L-AYL4]J'5&>.0
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M+]C&EM;%]\>1(9%?&-V>@QGU_.N4NK/4-)T'1XKNPD2?_A*%G2+S$)=7D=@
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M.1RI!ZBI[6U@LK6.VMHEBAB7:B+T J:B@ HHHH **** "BBB@ HHHH ****
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MNT %%%% !1110 4444 %%%% !116%XOUVX\->&KG5K>UCN3 4#))(4X9@N>
M<XSTX^M &[1110 4444 %%%% !16%XMUVX\.:&=1@M8[C;-%&ZO(5P'=4R,
MYY8<<5I-)?\ ]K)&L$)T\PDO,9#Y@DR,*%QC&,\YH MT454M)+][F\6[@AC@
M60"V:.0LSIM&2PQP<YH MT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<9>V-O+\6+!F#[FTJ:0XE8<B6(#H>GMTKLZI2:382
MZDFHO:H;U%V+/SN5?0'T]J +:2))N\MU;:Q4[3G!'4?6G56L]/L].686=O'
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MCI\ZX8' SU&!C'-4[G3]3M;+2VLI;?Q7%8V;Q7%K='9),A<@2QDY!8;"N3U
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MQ)8+;I:VUPLK\%B7/I]X+QVZ]<5S=GJVG_\ "&^!+?[7#YUMJ=NMPF[F$@2
MA_[ISZXH ]-M)I)-7U!#J-M/$@CV6T:C?;\'.\YYW$9&0.E8VJ>)2GB?0K#3
MM0LIH;JXDBN8D(=QB-F'(/ RN.G;K7-:D\W]H?$:/1V7[:;2V*+"1O)\MMV
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M[/[/]G> #&'5BP)R<G(Q^'05RTK:9HEWX:N;6:5O#9U&XEEN9C^Z\UT_=N.
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MW=M \P1GQOC<("5P0,'&".]7O&-O?^*/!>J6FE6\JNR(T/GJ8FF975RNU@"
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M@Y\M2H")^"A<^Y-3ZSH":W-;&;4+^&WB#++;6\VR.Y5L9608R1QV(ZFM<
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M<C./PZ5>KF_#EGJ.@Z1H&C?8A+#':[;NY\X#R7 ! "]6R21D=,5TE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZOHEAK
MD$4.H1R21Q2K,@29X\.IRI^4C.#S6A10 BJ%4*,X QR<FEHHH **** ,S6/#
MVE:_]F_M2S6Y%L_F1!F8 '&#D C(QV.16F    , 444 %%%% !1110 4444
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MW:NU7PWHB[]NDV:[X?(;$*C='UVGCI[4\:#I(^RXT^W_ -$_X]OW8_<_[O\
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MH4*EL]3DGGKS5#P_;6NM:5X?ULZQ;0WT<L9GDAAQ<32'B2&1MY)!).>., C
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MQ!I=EX.\+V-S=K'<WD'E0(5/SNN,C.,#J.OK6UXT:-? ^N^:5 -A.!N[L4(
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M+:V9L8$LH7J< \]!GBKI90I8D!0,D]L5YA<ZEI,'B'Q-H_BB]N;:/4I%DML
MF.[MVB1-J$*22"",#G)XKO[2QC_X1R"P1)88OLBPJLK;G1=F ">Y% &1H6K:
MAXKM7U2TN%LM,:1TM (@\DRJ2I=BW !(.% SQUK3L+F^MX;]];DMHT@GQ'.@
M\M&BV*0QW$XY+ \]17,> ]4M= \/Q>'-:N(;#4M.9XV2X<1B5-Q*NA/#*0>U
M6/&%\\EKH^HQ([Z7:ZK#+=.%X,0!_>>Z*Q!S[9Z<T =1#J^G7$$TT5];-% <
M3,)!B/\ WO3\:AC\0Z--<16\>JV3S2Q^;'&)U+,F,[@,\C'/TKE;_P BZ\8:
MAJEG/"^GKH;Q7DR.#&[ELQ@GH6 W?0$>HK%1M._X0WX>JYMN+VW\P';Q^[<-
MG\<9]\4 >BP:_H]S937D&J64EK"VV699U*(?0G.!3K;7-*O+YK*VU*TFNT7>
MT,<RLX'K@'/<?G7G^LRVS7GQ)C5XB3ID+!01RRQ2 GZCY<^G%6S;6%_<^"7T
M80&[MG625X,9C@\H^9OQTRQ4<]R?>@#MTUC39+T6:7]LUR691$)!N++U '<C
MN.U03>)-#MP3-K%A&!+Y)+7"C#\';UZ\CCWKS8:Q87%IX:GA=;2*#7OGL$4D
MVN?-SYC'+;R3G' ^;@'&:M3OI[:)\26W6Q=Y)0IR,G]PN,?\"S^- 'I/]IV
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MEU'[7?\ DF, N-S-C:>HW+P*U- O_#OB'5-*O;.XN[C4;.-P(FROV0,N&60
M =0  >_([F@#3'BBPUKPQ-?:?K=KIV7*+<3;6\O$A )5B/O!3@'GFMV\U&RT
M]5-Y=0P!@2/,<+G'7'TKRM[NU/P-N[-Y$^TV\C1R1MU1_M)(4^^.<=<<UU:7
M\=C\2+N?49XTL[W3XA87#L!&=K,70-TR<AL=P!Z4 =/)JVG11V\DE_;*ER0L
M#&5<2D]-O//X46&JZ?JJ2/I]];W:QML<P2!PK>AQ7F$EM%::)IJ77EK8S>+/
M.LHY< "V+MC /\)Y/IAAZUT=EJFG:9X\\674]S%%;Q6=K+*5Y^X)-QP.20,=
M/:@#N#G''6N1\/\ BN+_ (F$&NZM9QW":I/:6X=EBWJA   )YZ^_6NFL;VVU
M*Q@O;.42VTZ!XW'1@?K7FZQZ7)H'C;3[R*!]0GU"[\JW*CSI"W^J*KU.3R#^
M- 'HRZG8/J#:>M[;F]5=S6XE'F >I7.<5);WEM=^9]FN(IO*<I)Y;AMK#J#C
MH?:N)U>UOO#EGH'B(0O<WMA;QV.H1Q\M/&X4'ZD28(^IKKM'LGL-+AAF(:X.
M9)V'1I6)9R/;<3CVQ0 MQK&FVEQ]GN;^VBFRHV/( 06^[GTSV]:;=:YI-C)+
M'=:E:0/"GF2+),JE%R!D@GCDBO-O&.I6D^F^,[2(K9W*21F2W"EI;K 3]Z<Y
MPF  -H'W<D\XKH(KK3KGXJ"X$MNR_P!A@J[8Z^:3GG_9.?H?2@#J3K>DJMJS
M:G9@78S;DSK^^_W>?F_"K(O+9KQK,7$1N53>80XWA?7'7'O7G.A::=8^%5N-
M.=#J.GW4US9E2#LD2>1E7Z,O'T:NM\+3OJMF^ORPM"^HA&CC?[T<*C"K^)+M
M_P #H U;S4K+3PIO+J&#?G;YC@$XZX^G>F/J^FQK;L^H6JK<C,!,R_O1C.5Y
MY&.>*Y[7-2M+7QK86TQ2SGDL9-E\X+,X+KF&-?NER0#R">  .:XW1[FQD\,^
M 8I9(BT.I.LBR #;@2\'/N5_$B@#TK_A*- %D;S^VK#[,)/*,OVA=H?^[G/6
MKT]_:6T"3SW,4<3XV.SC#9&1CUX]*X6%]._X2;Q\SM;<V\())7IY)#?K@'WQ
M5'P]??8[GP7>WLRC3&T4VB3,WR17/R$ACT4E5VC/H10!Z$=9TL6<=X=1M!:R
M-M28S+L8YQ@'.,YXJ1M2L4NI+9KVW6XBC\V2(R@,B?WB,Y ]Z\TUFUD&@>-;
MVV!;2YM0MIX-@RK;&C,TBXZC(/(_NFMI-8TR\^)L=S#=PRVK:&ZB8',;?O@3
MANAX!_(^E '4P^(-&N+F"VAU6RDGN%+0QI.I:0#/*C//0_E4%EXHTJ_U:_TZ
M&[B\VRP)"7 R<$MCU &,G_"O.M.ELH/AWX(8/!'(NKV[.<@$$.P8G\",^U;C
M3Z<NM>/;+4IGCBN(XW81_?,/V8!G7V&",],\4 =O::G8WTCQVMW#,Z*&98W!
M(!Z$CT.#@]Z=+J-E!>1V<MY!'=2C,<+2 ._T'4URWA6[U!=>GT^\N[35HDLU
MDAU6W #%-Q CD )&[J01U&:T/&%I-_9\.L6:;K[29/M,8'5TQB1/^!+G\0*
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M59NJ7.HVL+,%(#RJ.&^Z>O0]O6N"TJUMT\?Z-I^K_9IKR/PPL$ZR[6W2[U#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !115:]OX+".-IBV99!'&BC+.YS@ ?0$_0$T 6%554!0
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M,#)R?J3W-2[5W;L#=TSCFN)^)&N:A8>&=271YS#<VT(EGN%ZQ*6 51_M-S]
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M I"JD@E02.A(Z4M%  1D8/2BBB@!"H;&0#@Y&1THVKMVX&W&,8XI:* $P ,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ"<@G!Y/&>G08%0Z)]KTNW^'<\.HWC)?V\=O/;O+F(I]FW+A.@(*CGJ>Y-
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MC<--'O.UF41[3CID;C7-WFH:HG@+Q+<)JMX+FTUF2&*;S/F""9$"Y],$],4
M>GT5Q=\+G2]>TW1H[^[N4U-KBX<W5XT9+(J8C1U7*KR6VC'3KCBJMQ<:QHBV
M.CWFI!QJ.K"%)4F9Y8("I;RS(P!+'&T,><'U H ZFWUQ)_$MUHGV66.6WMTN
M/-8KM=68@8P2>QZXK1EFB@56E=4#,J D]6)P!^)(KD-*M%L_BCJB)+-(K:7
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ME'1KEHR&3HW![YQ@8P.* /7**X(W%QHGB[6[#^VKE+,Z(+[SKV0S"WEWNI<
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M^T%N?Y9KHYY&A@DD6)Y2JDB-,;F]AD@?F:\NLO\ DE7@W_L)6?\ Z/KU-_\
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MI3>.JPB)L -$%VL"!D[B?O=L##UBO-4\6Z]92ZQ?);I8V\R+;3E C-OR5(Y
MX'U[YH [JBL'P5?W.J>"](O;N0R7$MLID<]6/3)]^*WJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>1^?;SRQ+#,UO,R>:@X ;'4@< ]1ZUKT4 16UM#9VL5M;1+%!$H2.-!@*HX
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M=/LE=;:$8C5W+;1Z9/-7:Q_"NL2^(/"VG:M-$D4EW")61"<+GL,UL4 %%%%
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M^;3[4W<B>6\YB7>R_P!TMC)'M59O"^@-:0VC:)IYMH9/,BB^S)L1CU(&, T
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ML-K;I]V*% BC\!5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JM[J5CIJ(]]=P6RR.$0RR!=S'@
M9ZGVJU7&?$]H!X4B28I\U_:X5\<@3(6_3.?:@#;_ .$K\/F.ZD&M6!2T($Y$
MZ_NR>F>>]6O[9TS^SX;\7]N;2? AE60%9">@7'4^PKE!+8#XP^9YEO\ +H(
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MG/ZT 6IM7TZWN?L\U[ DVY4VLX&&/13Z$]AWINI:I9V$9CGOX+65T+(9"#M
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M-$995P-JHI)/OEC@>F.]7[7Q!:7&K?V6Z3VUX8O/CCGCV^9'G!9?IW!P1Z4
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MG#$ G&0.O'3J>PJE_P )EI8TJ_U!TNXX]/D\N[C>W820\ Y*]<8(.?2@#H<
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MI'<>';672M0;3AI8CD-JFR47 VCRY&)!1, G@@$XR2*[VD9E1"[L%51DDG
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M#3([#<YGN+F=AM:>YDW-CT'0 ?0"@#FIX;J3Q+X2N([.Y,=K:SI,QA8"-G1
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M@ DYKF;32];L_">C7MOI=S)=Z3K$]W+8LNUY89'EY3/!;;("!]>]>K$@ DG
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M4FA:L]EXRA^R+NU@M]F_>K@9B$?S>G(SWXH V+WQ3:PRQP6QMY)Y+9;H+<7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6&:%(-^]69<MNSQCD8QTZ<]:JZ[XF.F:Y%IC7-I8F:W\R">\C8QS29(\O<&
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MXN?6_%5EKVCZ/<Q:.\VHBZ82Q^;M01@%3@\]&&1WQU'6M3PEK5YK-IJ":C'
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M[&".:=2H E<*B@L SL21PHRV,\XKFX_&XM$\1R7QAN(=(BBFCFMT9!.) <
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MLUO*,I(G1ATR*L5RWPW_ .2=Z)_U[_\ LQKJ: "BBB@ HHHH **** "BBB@
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MEGNY(&VS?9HBZQMZ%NF[_9!S[58T[5+358I9+-V=8I3"^Y&0JX )!# $$9H
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MMN!W'')/'ZU1M_"VKZ=J5ZNF:VL&D7L[7$EN]ONDB9CE_+?.!D^H./2NMHH
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M\#6XGN)%9XXVX(7Y<9/&203P*<OA.W5=#4:A>XT88M_]7\WR;/F^3GY>.,4
M8L&J^(];TV+5](+@_:FQ!(T0@:%9"I4G[X; SGU]JL6,NN:EXNUNS&M-#:Z=
M=6[(BVR'>C('9"2. <XSUJW!X)M+74[BXMM1U"&RN93--IR2CR'<\GC&0#W
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M \D@#/XBJMCXGN[ZQLKU-$F%M>P^;"_GH?X"X##MD"M#Q+_R*VK_ /7E-_Z
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MUQ811D2><8DL75 VV/'+,<ACP!S@GC%:/V2&X^+=E<2"0RMH)E)65ERPF3'
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M5;)VDCKD=Z .DN=2E?2)KS1[9=2F1F1(1,(P[*^QAN(P,$-^5:->.6\'V'X
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MN!Q0!WEI<"[LH+D*5$T:R!3VR,XJ:N"BUL^(M5T:T14MK2\TG[9';2,RAW+
M%?E(SM'0>^<<##8FN]+U+P_X<U#5VO+>>>Z#RAF4L456CA9LY.-Q[\[0#W%
M'=7-S#9P&:XD6.,$+N/J2 !^)(%1//=KJ<4"68:T:)F>Y\T#8X(PNSJ<@DY[
M8KA?%>CP6>A+;_;KBZ5=;MI$224G[,'D3]V"#T )(SR U:MQYEG\1=.@@EN6
M@.E3MY#3LREE= #@DC/.,T =?17F#7UU=?"Q?%D5W,NM(3<>8)&QN$N#$4SC
M;CY=N/?KS6F+$ZKXR\06EW=7ZVXL+:40)=R*$=O,SC!R.G0<>W2@#O**Y_P/
M>7&H>!]&NKJ5I9Y+9=\C')8CC)/<\5T% !1110 4444 %%%% !1110 4444
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M4<DAD93(SY8G)/S$]34&K>'=+UN6VFOK8M/:L6@FCE>*2//7#H0P!],UJ44
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M1J$[6GF/J*!+OS)&=9E P 5)(X' XXJK9^"O#]C/93PV3&2QW?9FEN))/*!
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M.<_]/HKU"/3[*((([2W01J40+&!M4]0.. :;_9EAY1B^PVWED[BGE+C/KC%
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ML_C3Q>MIY*ZE)IT#62G 9Y-DO*COSC-49?)O/AYX6N-+(_M6*XMEA*_ZP39
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M@CUJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-J.O:5I,T4-_J%O;S39,<;N-S =2!UQ[U-I^J6&K0M-IU[;W<2ML:2"0.H;
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M;\K?(,%>23U]N7VOB"_U/4;73(K9+"]-BMY>+<(9/)+':$ !&3D,<YZ <<\
M&YI^IV6JP//87,=Q$DC1EXSD;AU&:MUR'P\\W^R=5\_9YW]L7?F>6"%W>8<X
MSVS2-XFU,)XP7;:>;H8#0-Y38D'DB7##=[XR"* .PJGJFK6&BV+7NI74=M;J
M0"\AP,GH!ZGVKEO^$GUNXU'PU:6L6GJ-8TY[IGD5SY;JB,> >1\_3J<=16+X
MCUF\UGX4>)AJ*0"[L;MK*5H 0DA25,, 22,@CC)H ]/HKF-3\079UB\TK3-J
MSVEO'*\CVDEP"[[MJX0C PN22>_'0U4'B^\BM=(.KP1Z'->0N9&NXR\:3*V
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M_#>K-KOAO3M4:,1O=0+(R \*2.0/;-:E !1110 4444 %%%% !1110 4444
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M+R<C:OE0^4BCZ9.2?7\@.<Y6H^%KR[UC5+NWU1(8-2LUM9HWM_,= H8 QMN
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M%)Y2, 'YSVXX&3QUK9K+UO0K?78;9)IKBWDM9UN()K=@KHX!&1D$'@D8([T
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MA,MG'*HCB8.'^0E=P&1TR1SZ\T 1EM5U#QCKFE+K5S;VL-I!+#Y4<>Z-FWY
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M<>UU2:26PLDE@CMT7,)"DEIR1M.[ ^4<XY [U>N-4OSXI\+Q+=,MMJ%K.\\
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M5E?VD MQ=VDRQR2Q#^%_EP1WZ4 :OA[^UO[!M!KC6[ZFJE9VMSE&8$C(X'4
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M1Z!9;F6>[T<7]PT+K&SL2J\$@X&220/4=LYZ1/#$$>I:O?)?7@FU2-(Y^8\
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MF>4NKRHJE%('RC: , Y_.KU-12J*I<N0,%FQD^_'%.H **** "BBB@ HHHH
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M7?(YRS$<9)[GBNDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSBM.B@#,7P]I0-_FT5Q?_P#'T)'9Q+QCD$D=.*;I7AK1]$MI;?3[".**8;9
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M^O4O)H6%TJ&,312O$Y0\[24()&>QXK0HH S9_#^EW L@]J MB0;98W9!$0,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !61J6MFUU>STBT@2XU"ZCDF5
M))?+1(TP&9F 8]64  <Y]JUZYCQ)HI_M>R\46^J0Z=<:;#+',]S'OAD@;!8,
M RD8(!!!_.@#0\/Z]'KMM='R3;W=G<O:W4!;=Y<BXZ'C*D$$' R#T'2M>N,^
M'>GWT=GJ^LZBACGUF_>[2-HS&5BP%CRI)*DA<X))&0#S79T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !4$]E:W3QO<6T,KQ'=&TB!BA]1GH:**
M )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex109keyexecutivebenefit010.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSR6\:EF$DD>U8^/[HVKG_9S63>:2E]INB"2+6--U&TTU!!J-E#(7B< !HG0
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M6&RD\FXS:2_NY,X*D[<9!QGG R/45D^(+^26Y\-:M%IFHB^B,KF*.#S)(E*
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MU!H W+_5;?3Y+>&0/)<7+%8((ER\A R<=@ .I) ''/(K@M+UFW.B>-9]5O\
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M>>W*%'+HV"#S_">G7MF@ /BFRTKPO!?:;]OOXKC4/LZO<!F96:;:V=V" "2
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MWN(Q)&X&,J1D58KGO MO/:>"=)M;J"6"X@@$<D<J%2K#ZUT- !1110 4444
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M>3UZ '\* -JFNZ1HSNRJBC)9C@ 5RD'C68:I?Z7J&AW-G?6]H;V"+SHW^T1
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M>&34UE(S("8FC7+!AC\B*YGQEJT6M>"=<\RS$<VF:C#;]0_S"6([E.!U#XH
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M(V^N10!TE%8WB37SX;\,W.LS63W'V= \D,3CC\3CC/MGVK/B\82IXDM](O\
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M:"-<?P[.NG&"&<2FX3.U^IV@9PN1D^G- '945GG46.K6UC'"L@E@:=Y5DXC
M( XQSDGC_=/I6A0 QYHHW1'D17?A5+ %OIZT^O.[4C5+KQ7/KFE+=PV=TK!8
MI"\L?E1(RI'@ ]<G@CECZUTMCXCDGUO^R;JQ\FZ:R%ZBI,'RNX*5;(7:V2..
MGO0!N>=%Y9D\Q-@SEMPP,<'FGUYGKL^G:G\*+ZYM-+2RC2]^6$X)207(5FR.
MA)ST]:[4:VQ\33:']F'G)9B[23S/E92Y3!XR#D>] &O17(CQRK:+I.HII5PX
MU&\-FJ+(N4<,R_CG8?;U(JRWBN2(1VUS906>IF)IGMKJ]1%1-Q5?G .2V"0
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M3[:9;:%G#LTT@ ))' 4 8'<YYQCG)A\%M->W3PVG]CV]]836^H6\,H:*:1P
M'11P,?-S@'IQUKNZ* .3T.W\4FSBTC6+>RCMX(_*>]@G+-<*!@80K\I/&23]
M!SQS&IV>O:/X%M]&U&VM3;65Y:Q17D<Q)F03IM^3'RG&,Y/:O4ZIZEI5EJ]N
MMO?P^=$K!PF]E&X'(/!'0\T <]<Z3K%MXGUF[LK:WGMM5M8HS))-L,#QAUY7
M'S ANQ'3MUK+M/#OB31K#P[?6,-G+J&G69LKFT:<A9HCM/ROM^5@5!Z$>_KZ
M JA5"C. ,<G)_.EH Y+6-.UW5;71Y);: 3P:I%>RPQS96*- 1L#$#<W.<X Y
M/M3+C0-1N]6\5.8DC@U:P2U@=I 2&5'7+ = 2_OTKI=1U2PTF!9M0NX;:-F"
M*9&QN8\ #U-6Z ,OP[#>VV@65MJ$,4,\$*1%8Y-X^50,YP.N#7&2^%-?_P"%
M=ZQX9%M:M+-/+]FE$_#J\QDW,,?+@'&.23Z5Z/10!RS:;J3^/;36C: 6D>F/
M:./-7>'9U?@=Q\N,Y[UA3^%=<F\ ZWHHM8A>7VH27,69QL"/,).3Z@#'3K7H
MU% '%S6'B;2/%5]JFCV5I?6>K+$T]M<7/DM;RH@3<&"L"I &0.>/SZ2%M5CN
MK6&:.": PL;BX#;2).,!5_N]>_\ ]?0HH 1B0I(!) Z#O7*>'['6-'.K^;IT
M<HO=0ENTVW X5\8!XZ\5UE% &#-9ZAJ=E#8:A;1+:SES=K%)PJ<[8QP"01C)
M^N.O&0?#VMW/A:71Y946>SG673;IWW%EC<-&) .^!C(S7:T4 <S<6.M>(]"O
M;+588-.,T!C189O-R_!#DX& ".G/4\U/I4OB26,)K%K9VXA0AY8)M_VAL8R%
MP-@[]2>E;<\\5M"TT\BQQK]YF. *J6U]I^MVTZ6UR)D5C%,$8HR-W4]&4_E0
M!Y[X6TN]\2?"KP_H\EJ(;1O*DFN3("#$DF_"CKN)4#D #).3T/6:5I6I:?XT
MUZ\:*!M/U)H95E\T[U*1!"NW'J,YSTK9TS2[/1K".QT^'R;6/[D88D+[#).!
M[5<H Y'6]'UF^UV[98+6[L)['R;?SYBHM9?FW-LVG<3D<]>,<533PU=77AO2
MM(UO1+>[AM;)(LP3@2PRJ  R,=N,@9.#Q@=:[JB@#"M=$NI?!(T/5+QI[F2R
M:VGN =Q)92I.3UQGJ>N*I^'AXL@@M[#5;6R6*T4*UY#/N:Y"C"@(5&TGC))]
M<#G(ZFB@#B[G1=;&IV7B*TB0:OYICN[=IL1/:GI&#ZC 8''4MG@X#;"XNX?B
M+XE:WL3/NM;/*B15*MM?&<\8ZY(R1Z&NVJC!I%C;:E<:C#"RW=P )9/,8[P.
M@()QQV]* .3M?"FH:6WA=((XYQIT\]Q=N'"@M*KY" ]<%SUQP!5V]L/$&E>*
M[K5=&MK6_M=0CC6XMYYS"T<B @.K8/&#R,9XKK:JR:C9Q:C!I\EQ&MW.C210
MD_,ZKC<1],B@#F]=T&XUJ%+?5-,AOP(-T=Q!((I+>XR2=A."%^[SG/R\@U4U
M+PO>ZCI5K8:I9IJ-Q;V,:PZC',(YHKH;MS;C@[?N'//0\&NYJI#JEA<:C/I\
M-W#)=VZAIH48%HP>F?2@#GTT;5D\2>'[R<K<I8V#VUS<%P&DD8)E@/3*DGZU
M&^D)<?$$7=I<J;22W2XOH5Y#RH2L+$_]]'_MD*ZX@$$$9!ZBJ.E:+INAVK6V
MEV4-I"S%V6)<9/J?6@#!^)__ "337O\ KV_]F%2S:9?:OKNC:C=V8MX]*664
M)YBLTTKIL 7'10"3DX)..!S6YJ>EV6LV#V.H0^?:R??B+$!O8X(R/:K,,2P0
MI$F[:@P-S%CCZGDT <+9>#;Z\^&E_P"&-1"6T\[S,DJ/O4%I3*A_ D BM!])
MU77I] ;5[6.U.ESBZF9)0XFE5"J[,<A<L6.[!X QW'6T4 <M/X8G;QVNKPRJ
MNGW$*->P?\])HC^Y;\-Q/_;-:2^T.]O/'?\ :#0C^SGTF2P=Q( ^YW#9 ],#
M'U[5U5% 'F?_  C?BL>#;+PTUE92G3KJ!HKS[5M6:*.0,/EVDJ<#!_3-:T>G
M^*M!\0ZE)I5G8WVG:I,+DB:Y,36LQ4*Y^Z=ZG:#@ 'Z5VU% '&IH^NZ+XQNM
M7LHH-2M]3MH8KL/+Y+1RQ @.."-I!.0.15WP-I6HZ'X7CL-2BA6>.:9P(9=^
M0\C.,Y P?FQWKI:* /.+GPKKD_@CQ'I M(A=:EJ<MW#F<; CRB3YCV( QT/:
MM.>P\3:3XJO=6T>RM+ZTU5(C<6UQ<^2UO*B[-P8*P*E0,CKQ7:44 <H^DZNW
MC71]4ECCFAMK*6"XE5POSR%3E5_NC;CDY^M54T_Q1H/B/5&TBTL;_3-4G^T@
MSW!B:UE*A6)PIWJ=H.!S78W$\5K;RW$\BQPQ(7=VZ*H&23^%);7$-W:Q7-O(
MLD,R"2-UZ,I&01^% '-R:5J8\<Z?JQC$]M;Z;):RR[E5GD9E;<%]/E]>]8)\
M+:X?A^^B?9(OMC:E]J!\\;-GVGSNO7...G6N_O;VVTVREO+R9(;>%=TDCGA1
M3&U6P6^@L3=P_:KA2\4.X;G4#)('I[T 9WBW2KC7_"&HZ;;;4N+F':@D. &R
M#@D9],5GRZ9JZ>)K'Q*EK$TQLS97EDDV2$W;U9&( )!Z@XZUUE% &)X?T>33
M[C5;^Y"K<ZE<^>\:G(C4*%5<]S@9/N?;-8DF@ZS#<^,(X;>WEM]84O!)YV&#
M&$1[2N.,$9SGIVKMJ* .'CT#5U7P2#:I_P 25-MU^^'/[DQ?+Z\G/..*-"TS
MQ9H!DT*&&QFTD3N]MJ+3D20Q,Q8J8]IW,,D#D#IGTKK;35+"^NKJVM+N&>:U
M(6=(VW&,G. <=#P>*MT <_XNT:]U?3K5],EC34+"[CO+<2YV.RY!5L= 0Q%4
M=5TC6_%?AF\M-0CM],N'"-;11R^<$D1@P9VVC@D 8 X&3R3@==10!S+Z=J&L
MZMH]_J-FMK_9GF2M&LH?S963: I'\(R3DX/3BL0^&=:/@671_LL7VMM1^T@^
M<-FS[1YO7UQQTZUZ#10!S$.G:I9^+]4U.*VBEM+^U@!S-M>-XPXVXQ@YW#G.
M!S6?::#K]G\,[71;;RX=3M@B,%FPLJ!\LH<<KN7(SCC]:[>JE[JEAISVZ7EW
M# ]S*L,"NP!D<G 51W- '(1^']8BU#7)XM-LH(-0TU+>.&&?_5N XQ]T _?R
M3^6:W]&L/L_@^QTG58HU*6:6<R%P5?"!3@]P<&MNJ.JZ-INMVR6^IV<5W"D@
ME5)5R PS@_J?SH P?!6G76G^'))C.+V9@8[21SMWV\980 GT(^;/^W6SX?O[
MS4]&ANK^VCM[HLZO'$^],JQ7*GN#C-:/EIY?E[%\O&W;CC'IBE    & .@%
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MF9EPP7']WH/KGL=O2;6_M[9FU.]2ZO)#N=HHS'&OHJ*22![DDDD^P'-$W?\
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M1(;.-)((Y<O)=C&7(VME .F2IY]JFN==U>3Q7%HUC!9+'-IK7B33EB5(=5Y
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MQN=:^U1-;S6<=H(2K%P$+$,6)Y)W'/% %[Q!=7]CH-Y>:9%%+=01F58I02'
M&2O!'..E8B>+)7UWP_;K+:M8ZO:F59!&P97V[@OWL#=\V,_W2.>M==UKC/\
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MA%<2+)<02M$(?().57 WAEXP2>H.?2NE\17-Q::%<36UY!9R@H!/.,J@+ '
MP<M@D*,')Q0!J45RWAS5+VX\3ZWIMQ)</;6T=O+;_:459 '#YSM X^4$9&1D
MU8UV]O=-UK1YQ=NNFW$YM;B((A =@?+;)&1\W!Y[B@#H:*XG3-<O[K^U=.>_
MF:]^UHMC*8XP3 _*N %PP 5R<CD+VS2^)M6U/3H-9GMM19GLHHWAB@C5A&,
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MFG27$#64$15H#%GS)%+!FW@Y48 P/?/;&]HSZ@VC6IU985OPF)Q"<IN'!(H
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M^\O6&9KGF/(RH4[?DX^4 =ZZ*B@#D-:MH;^Q3P:;+4+D-'$#=R0XC5 PRWF
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M>Y)Y)]ZM53TF^_M31['4/+\O[5;QS[,YV[E#8SWQFKE !1110 4444 %%%%
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M><DX[[<>U>B6^D6=JLWEI)OG4+)*\SM(P'0;R2V!DXYXR:HR>#]!FT*/19+
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MJ2W+O^]$NW<I)RIP?X<#@5S5M<7LWP[\+S'4KY;B375A>87#;W0W3J0V3\W
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M@NC8(R"H/%<\/$ MO%,FH0///IFKVICL T[E'N4 .U1G"[MVWZH:]$90RE6
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M/&:5;RV>1HUN(3(J[V4.,A?4CT]Z\ETW1-'?X&76HFPM7NUT^[47!0%QAWP
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M[O-!DM?AY=64]H%6\C56#KN53"VX'O\ >QG/?WKH_B?_ ,DXUGT\M,_]_%H
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MCHL4T,,GE%;>W+ ,ZH!D@=\=ZT* "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BF1313QB2&1)$.<,C @X.#R
M*:US;K<+;M/$)V&5C+C<1Z@=: ):*** "BBB@ HHJGJ.JZ?I%L+C4KR"T@)V
M^9.X1<^F30!<HJF=6T]=+_M,WL L-N_[27'E[?7=TQ[U8M[B&ZMX[BWD66&1
M0R.AR&'J#0!)15'4=9TW23"NH7T%LT[A(ED< R-Z*.I//:KU !1110 4444
M%%%% !1110 45%'<P3330QRH\L) E53DH2,@'TXP:EH **** "BBB@ HHHH
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M=RRK(H."5)4]?<$5:H **** "BBJ=_JUAI;6RWMU'"UU,L$"L>9'8X"@?4T
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MDU*\2Z_LL$P%8MA=]NP._)Y"D\# R<^@ !OT54TZ&]@MG2_O$NI3*[*Z1>6
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MWR%VJ"SEB%&3A1G &>@K5H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP1MQ]WTQ6A+)J]]XLU[3(]:N+:VM[6":'RHH]R,V_@$J>/E&<C/N.X!V5%<
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MCI&TC(=X?&[=\O? Z8QCBK&CZ)#HIO3#<7$OVRY:ZD\XJ<.V,XPHXX'%:=%
M'+ZND/B75(M'FTJ[\JRNH[B2YGAVQ$*-PV-GYB20I'H6K5U;0[;5I;.X>26"
M[LY#);W,) >,D88<@@@C@@BM.B@#%E\,6%SIVI6ETTLYU(8NIW(#O@;5Q@ #
M  P ,?F:@M_"<4.HVFHR:IJ5Q>6L+PI++(G*MCJ H'&!V^N:Z&H+2[@OK9+F
MVD66%\[77HV#CC\J *>A:)#X?T[[#;W%Q-"'=U\\J2"S%CT [DFH]2\/V^H:
MI:ZHD\]IJ%LC1I<0%<M&W5&# AESSR.#TQ6O10!GV&CVEA9SVZ*THN7>6X>7
M!:9V^\6P .1Q@    "LZ'P9H\.EZ-IZPL8=(F6>V+-EMX!Y8]\DY/X5T-% &
M3>Z##?:]I^KO=7*3V"R+$B%-A#@!L@J2<X'?M2Z+H,.AO?M#<W,WVVY:ZE$Q
M4XD; )&U1@<#CVK5K%O]=DLO%.DZ,;0-'J*3,)_,QL,:@D;<<YR.<T /;P];
MOXE;7&N+AIVM?LC0G88C'NW8QMSUYZUGZ-X'L=#N%-M?ZF]E&YD@T^6XW00M
MG/RKC/!Y )(!YZ\UT]% 'E]A!<R23G[;XQTS4IKB69K**W\R!79R<+(T90KT
MY+@?3I72R>"8;_[;/?7UZD^J6B0:C%;2A8I7$>S>!MR#CT.#W!KJZ* .?C\)
MVT=WHMR+^^:32(WC@W.AW!@%;?E><@ <8QVQ5_7-$L_$&F/87P?RV8.KQMM>
M-P<AE/8BK&HW+V6FW-U'")GAC:01EMN[ SC.#BJ^@:H=;\/:?JAA\DWEND_E
M[MVS< <9P,]: *<?A6S;2KJPU"XN]36Z01RRWDFYRHZ 8  P>>!G/-36>@1V
M]S:W%Q>75]+:(R6[7)3,8(P3\JC+$#&3D]?4YUZK:C<O9:=<W4<(F>&-I!&6
MV[L#.,X.* .>E\!V$UI<V9U#45LYKG[4MNLJA8GWASM^7."1T).,\8/-:,?A
MV*+5;W44OKP3WD*0R9*$!5SMQE>HR>N>M6- U0ZWX?T_5##Y)O+=)_+W;MFX
M XSQGK3[G4HXA>QV^V>ZM81*\.[;P=VW)P<9VF@#.L/"T6EVMA;V6IW\2V43
MPQ\QMN1B#A@4P<;1@]>M07/@;3)K+3X;::\L9M/W?9[JUE"RKN.7!.""&)R1
MC\JT_#NKG7O#MAJQA\C[7"LOE;MVW/;.!FM.@#"NO"MK=Z=:V;WE[^XN4NO.
M\Q6DEE4Y#.64YY X&!P!T&*OZOI-MKFC76EWN]K>YC,<A4X;Z@^O>KU% '.6
MW@^"WU6WU,ZMJDM[#:M:^=+,IWH2"-PVXR" > ,]\U%'X&L8M"TW2$O[\6VG
M7*W,!W1[MZMN7)V<@$FNHHH YFY\$V<M[J5Q;ZAJ%FFIH5O8+=T$<Q*[=^"I
M*MCJ5(S6UI.FQ:/I-KIT$DLD-M$L4;2MN;:HP,G ["KE% '/1>#["&WELDGN
M1I<DWG&PROE [MQ ^7<%+<[<X_ XJW)X?@;7I-8BNKJ"XE@6&18G78X4DJ2"
M#R-Q]O4&M*XN(K6VEN)Y%CAB0N[L>%4#))IR.LD:NIRK $?2@#G(_!5E%HNG
MZ2E]?"WL+E;F$[H]V]6W#)V<@$DTMQX,LY=9FU*"_P!1LVN<?:H;6?9'<$#&
M6&,@XXRI%=)10!DP:!;V_B!]8CN+@2M;K;>3\GEB-22H VYX)/>GZ]H5MXAT
MX6=S+/#LE2:.:!@KQR(<JRD@C(/J#3X-0EBTY;C5H8[*1I?*\L2^8,L^U.<#
MELKQ[UH4 <T/!&FM<:E-=3WMW_:=ND%VD\H*R!00&P ,'YCTP!V J.V\$00S
MZ5-+K&JW)TMF-J)I4^4%=NTD("PQQD\^]=34'VN#[<++S5^T&,R^7W"9QG\_
MZ^E %2?0K&X\0VNMR1DWMK \$;9XVL0>?<8./]XU'-X?@F\21ZX;JY%PELUJ
M(P4\ORV()&-N<Y .<]JUJ* ,*T\+6UO-I\EQ=W5\=/C:.V^T[#L#+M))506.
MWCG/Y\U#:>#+"SM8K!;F[?2X9Q/%82,IB1@VY1G;N*AN0"Q''IQ71T4 9-AH
M$.GZ[J.K1W=R\VH;/.C<IL^087 "@C ]Z@M/"]O;RZ<\U[=W@TW)M%N"A\LE
M2N<JH)PI(&3^N*W:J6\UZ]_>13VB16L>S[/,)=QFR,ME<?+@\=\T 5];T*TU
MVVABN6ECDMYEGMYX6 DAD7HRD@CUX((/I26NB1VT]S=F[N);^XC6)KMPF]47
M.U5 7: "2>G4\YK4HH R_#VA0>&]'ATNUN+B:VAR(_/*EE!).,@#/)[UEZJD
M/B75H-)ETJ[\JPNTN9+F>';$=HR/+;/S9) (]-WM745!-=P6\]M#+*JR7+F.
M)3U=@I8@?@I- %+5=#M]5N;.[,LUO>6;%H+B @,F1AEY!!!'4$5!/X7L+K2]
M2L;EII?[1.;F=F D<@ *<@ #: , #''UI=%UV35=5UFQEM! VFSI#D2;_,W(
M'!Z#'!''-7[B:]34+.*"T26UDW_:)S+M,.!\N%Q\V3QU&* ,NW\*Q0ZI!J<F
MJ:C/>PV[6XEED3YE8@\@*!V'0?7-7-!T2'P_I::=;3SRP1LS)YY4D;F+$9 '
M<FM.B@# UOPG:ZSJ=MJ:7M]I^H6Z&(7-E($=HR<E&R"",\].M.E\*VDEUI-P
MMU>1MI;.\(#JV]G!#LY926)!.>>]2W7B.RM/$]CH,A/VF\A>5#V&WH#[D!\?
M[M;% './X*TR>'68;J6YN8M6D$MPDC*-K@ *R%5!!&U<?2KEIH$4-Y#=W=W<
MZA<00M#%)=;/D5L;L!549.T9)YX^M:]% '.6G@RPM+6.P6YNWTN*<3Q6#LIB
M1@V\#.W<5#<A2Q'X<5-=>%[>]%Q%<WMW+9W%PMQ):,4*;@P8 ';N RH.,_S-
M;M% &$WA:W;4-7O1?7BR:K"L,X!CPJJ"%V_)Q@,>N>M0KX.M%M=$MQ?WVS1F
M4VO,>>%V#=\G/RDBNCHH \RAAFEU*_:2\\8:5?SW<DAM;6W\V \X4JYC9,%0
MO5@!TX KO8;.:\\/)8ZN1++-;>5=%?EW$KANG3J>E:%% '-6O@NUMIM+F_M/
M4Y9=,5H[=I)E^X0!M("@$# ]SW)H;P59/H5SH[7U\;:XN#<R'='NWE]YP=G3
M< :WXKJ":XG@CD#2P$"51_"2,@'\.?QJ:@#"E\+0-K3ZM;W][:74T:QW7D,@
M6Y"\ N"IP0.,K@U;T'1;?P]HUOI=K+-)! ,(TS!FQU[ 5I55EFO%U&VBBM5>
MT=7,TYEP8R,;0%Q\V>?IB@#%F\%V,L>M1+>W\4&L%FN(4D7:&90KE<J<$@#K
MG';%3'PM;M>Z/=M?7C2:5&T< )CPRLH5MWR<Y  XQ3M?\1II'A_4=4M85O38
M$K+&)-G(QD9P>F16TC;D5NF1F@#DX/A[IUO:V%LFI:KY.GW/VBT0SKB'[WR#
M"\K\QY.6'8BMBP\/VVFZQ?ZC;W%R#?.)9;<N/*#[0I8#&<D =21[5K44 <=K
M$$UQ\1M(>)KR%(K.=&N(82R*S%,*6*E>0#^5:-UX1LKO2VL6N;M!)="[FF1D
M\R64,&#,2I'4#@ #  Z5T%% &5J>A1:I/ITTUW<H]A,)HO+*#<^",ME3V)Z8
MZU!)X7MOM=_-;7=W:IJ'-W#"R[)&Q@MRI*L1P2I'Y\UN44 8S>&[3^U--OHI
MIX/[.B:&W@BV",(P ((*D]%'?M6G=VT5[9SVDZEH9XVC< XRK#!_0U-5=+^U
M=[I5G3-H=L^3@1G:&Y/T(/XT 82^"K%=,TVT%[?F;3'#6=X9%,T.%V[1\NTK
MM&"",'OSS6KIVD0Z?/=7(DDGN[HJ9[B7&Y]HPHX   '0 =R>I-6[:XBN[6&Y
M@;=%,@D1L8RI&0?RJ6@#GM;\(6FLZI;ZHE[?Z=J$,9B^TV,H1GCSG8V001GG
MI4C>%;0W^DW:75XCZ7YGD@.K!S(,.SEE)8G)R<]3FMVB@#FI/!.GSZ?K-E-=
MWLD6KS>?/ED!63Y<,A"C&-J]<CBDU+P5:ZC/97?]IZG;:E:(8A?V\P6:1"<E
M7^4J1GG&,#MBNFHH P)?"=I)<:3.MY>H^F.\D1#JQ=W!#LY926)!.>>]69]
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M8Z<5Z''8VL-[/>QP(MS<*BRR <N%SMS]-QJO#H>FP7E[=I;#SKX!;EF=F$H
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M]_BU(UM/;,TVBKDQNIWL)3Z=3MQ^&*GU(.OQ1T)I/]2UA<K%Z;\H6_\ '<4
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M*=4@7S@ &Q]H8$;NO3(K;U&SLH/%?B2SAMH(X)/#RR/"B *S!I "5Z9 Q^E
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MWQM5<RCDGH,XK8U^XFT^\U?5K![35M(,MN=0TY_EEB8)'L>%AUX*$*>^<<T
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M&[]S'&%3YB2>!QR2: '"^M# 9Q=0>2#@R>8-N?3-$U]:6[QI-=01M)_JU>0
MO],]:X?2;.6TU.;P4T!^PV]R+^%RORFU+%PF?42C;[KFI=-:UN;GQI9:[Y8E
M-PS,)L?\>AC C(S_  C#=.A)[T =J;B 3^09H_-QGR]PW8]<4T7MJT!F%S"8
M@=I<2#:#Z9KSK29;BRO? <^MRB&<Z==))).VTYQ&5#$]]OK[UFWLEA=>#?$Q
MWPL4\2!U.0"H::+YAW&1GGZT >M0SPW 8PRQR!6*,48'##J#CO4E5K+3K+38
MWCL;2"VCD<R,L*! S$ 9('?@59H **** "BBB@ HHHH **** "BBB@ HHHH
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M5D (3:')Y/'/L* .K?3[*6V6WDL[=X%Y6)HE*CZ#&*FBAC@B6*&-(XU&%1%
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MNSQ6\A"%$+'HO)Z<#/!STH Z"WL;2UQ]GM8(<+L'EQA<+G...V2:@U+34O\
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MZJ+IG+$8R!M(.:];HH \G\737&H:7XNLUTZ]AG$R-#!:V;;;E!Y?[YY OSG
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M],U+>>+K6UM[Z[2TN[BQL)#%=7,(4K&5^_P6W,%SR0#C!ZX-4M,TB]L/'C7
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MYK(QH\-U:3%UD)+;EQC@KA?^^NW2EUC6DTR>SM5"M<W9?R]Y(55499C@$\9
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M:&4ZE:0VTHE8(L4WF!DXPV<#!Z\8[5=H **** "BBB@ HHHH **** "BBB@
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M1E?D[;.^.M0:;X?UK3[#4XBFF3&]U66\:&21FC>*0_-&V4Z^^#784C$*I8]
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MX;-SXNM-9CF"0B'R[J'_ )[%&#1'_@+9.?85T%% '.RZ+?67BR?6],-O*MY
MD-U;SR-'\R9V.K!6[$@C'XUG7/A"\&AQVEK);-=2:J-3N7D9E4OYF\JN 3C@
M*,^F:[.B@#F)]%U>+Q1>:E8M9>1?VD<$XF9MT3)NP5 &&&&Z$BL_3O"FL65I
MX4AD>Q<Z,SF4K(XW@H4POR_[6><5V]% '%WOA+4;^S\66\DMK&-9*M"RNS;"
MJ*H#?*.NW/&>M6Y-)U^77K#4WDTYQ':M#) Y<I!(6SYD?'S'''.WCN,UU-%
M'":?X1UNRTCPU9-)I\ATBZ,S,)'7>N&  ^4\_/G\,>];M]I-[<>,-+U:/[/]
MEM()HG5G8.WF;>0-N.-OKWK>HH YK1K-_#PUB;5[BQA@OM0>Y1C-P-X50AW
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MU8"586W1[L '#>W/?OC!M:?XBU>Y\..\UQ9I<VNK2:?=73+L!C20J71.<N>
M%YY/0]*V/^$99-?T[5(KYO\ 0;9[=4DCWF0.069FR,L2H/YUF_\ ""2"W CU
MAX[A-6?58I5@!"R/NW*5)P5^8X[CUH S;S6KK5? WCJVNV,GV".X@BD>(Q.Z
M& ,-R\8;YO0?04NO1W3Q> Q#=^4C7<("^6&PWD/\WOQQBM8^"7-KXAMSK$[K
MK8(EWPH=A*!&(QCG X[#T-6;SPO/=QZ$IU%4.D2+*A$&?-95*#/S<#:3T[T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\<7G/ H.Y5XZ\8!Y''49Z5!XSU1M$\&ZKJ23M!+;V[-$Z@$B0\)U!'WB!TH
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MOBA%<Z_KOAO0H[*]ETY;Q9[^:.UD:-5!  + 8Z%_S%>HT4 >7>!(;OP]X_\
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M;=D?+DNV-W7:.*]HHH \Y\':;<?\+*\3ZE<:;<VT,82RLWDC*IY2]2I/WMQ
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MWI=%\8JVC:@=0U/55M7F^S,RI;*?D5,#+# (X&,8YR17OE% 'E]YH4NK^/\
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M=,UYK;"X/@'P;9MIVH+/8ZG:?:4:SDR@C8[SC;T''/3GKUKU>B@#S37-.O\
M5-:\:06%O.)+O3+=+=VB9$E="Y9 Y &<$#KWK6\.W6FZWJ5G>1Z%JD%_:HPE
MDU 2C[-N&&16<X8DXZ=N3C@5VM% '(>,PS:QX59;>XE6'4Q+*8H'D$:^6Z[F
M*@X&2*75ED/Q+\/2K!<-%%:7222K"Q1"^S:"P&!G:>]==0>10!Y%]ITU+2_T
M.^?4K;2QJ\ESG^S)I&PLV\@2J"NTNI.>H!QUYKJK*=7^)6H:@L4[6<FD0+'<
M+ YC<AW8A6Q@\,#QZU>T_P )W&FPK9P>(M3_ +-3(2V81$JO]WS-F_'OG/O7
M1111P0I#$@2.-0J*HP% X % 'E6DP7=GX1\"33:??#^S[]OM48M9#)$"LH!*
M ;L?,O..]=YXNMY[_P $:U;V\+O/-83+'$!EBQ0X7'KVK<HH \\2:XBUCPIK
MQM+PZ9%8O93AK=P]N[*A#E"-P4E=I..V>G-;/AJPE'BCQ+K(1X[/4)8! KJ4
M+^7'M9]IY ).,]]N>F*ZJB@#D+DNGQ5MK@P7'V=-'EB:80.4#F5&"[@,9P"<
M5RJ07(^%MK:_8+X72ZP)3#]DDWA?M9DW8VYQLYS7K-% 'G.LPW4&MWNI>'Y+
MV*_>YB$^FSP,]O?C"#>N1\I"]6!XV<XZTM\\MAKOCFWDLKUWU.UC>T,5N[K*
M!;E&^8#:,$=R.W6O1:* /-M.68:E\.S)8WJ_9--EBN"]I(!"YAC4!CM^7)5A
MS3[QTTKQ=KEOK6EZK=6.JLDMK+9K+(CCREC:)U0X!^7OU!KT:B@"II=NEII5
MI;QVHM4CB55MPV1$ /NY[XZ5RFE:7=6?BNZT4(#HT,PU2$@_=+E@(L=@) SC
MZ"NQN8FGM985E>%I$*B2/&Y"1C(SW%4]'TD:3;,C7=Q>7$A!EN;@@NY P.@
M  [#W[DF@#F-.:31[GQ18:G:W$GVR[ENK9DA9UN(Y$ " @'YAMVX/MVJC9V%
MWX9F\%OJ$5Q(EK8SVT[P0M-Y<CA"JD("<<%0?:O1J* /*[J.YD\)>((6TV_$
MLWB#STB^RNQ:/SD8D8!!&%;IZ5ZFC!T5USAAD9&*6B@#SA$F_LCXB)]DO-UU
M+.;=?LTF9@UNJ#9Q\V6!'%2:EYIT'P&BVEXSV]Y:R3JMK(3$JQ,K%ACY<$@<
MUZ'10!YS>R)IGB_6DUC3-5NM/U7RI+6:S69T;$2HT3JAX/R\9'0FNYTJ".RT
M>U@CM1:111 +;@[O*&/N^^.E7:* /,SI^H:EX)\56=G;7"W<NK3W,,4T+1^=
M'YJN,;@,A@"*V[QAXAU_PY?6<-Q&MB\MQ</+"R&)3'M\LY ^8DC@=@?:NQHH
M Y7P"CQZ->1RV\\#G4+F3;-"T9*M(2I^8#((Q4?B,2V_CKPQ?_9;F:VCCNX7
M>"%I-K.J;0<#@':>3QZD5UU% 'E]Q%/)X8^(<*V5X9;RZF:W3[+)F8&)%4J-
MO(R#TJ::X?2/$<5_J-AJT^F:AIMO$DUFDVZ"6/=E'1,,,[\C(Z_C7I5% &9X
M?M+>QT.V@M-/.GVXW&.V/5%+$C/H3G)'8G%<?H]M>6FI6,>C37G]FW7F&>PO
M(&W:<Q1CN1R 0-QP!WSQ[>AT4 >9)9W=W\,/^$3DLYX]8C*VVPQ-MR)01*'Q
MC;CYMV?;K6M?6=S=^--7AA2=3/H(M8[EHF">;N<XWXQGY@>M=O10!P/AJ2TO
MUTNTN]!U./5M/VB3[4)?*MV48+JS':<XX ZY],FM/QY!-)8Z1/%;S3)::O:W
M,XBC+LL:MEFVC)./85U=% 'G/B+1+OQ-J>LZAI,;HCZ$]A'(ZF/[1*S[]HSC
M( &,]/GQV-7= OM-U>]LKUM!U6#4+)',KWR3?Z*2N&5"Y.XDX&%[<G&!7<T4
M >36<%S%\-O"MLUA>K<6^L0RRQ?9)-\:K<,S,1MR!M.<U>!AL=9UW2==T;5K
MV/4+M[BU>V65X;B-P/D8*0JD8P=V!CKQ7I=% '%7*-;_ !!\.A;.=(+;3IX7
M:.%WBB9O+VKOQC^$_E6=-:W5V_Q(BAL[DO>0 6VZ!E$Q%ML^0D8;YN.*]&HH
M R?#%P+GPUI["&>(I;QH5GB:-LA0#\K 'KD?AZ5K444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M2U/4X-*MTEG#,TLJPQ1H 6DD8X"C/&?KP ":NUSOB[2;W4K;3KG3PKW>G7L=
MXD+-M$P7(9,G@$AC@GO0!:M_$"2ZG<Z7+9SPZC#"+A;=BI\Z,G&Y&S@\\'.,
M'\ZY[PA;Q^(+:/6-0LYUOX;VX=+OS%!8"1U$?RMDJ  -I&..]:L6GW-[XLCU
M^:SEMTMK%K>*&1D,DC,P8GY6(    R>I/IRO@FQOM,T#[)J%F]O,MQ-)@NC
MAY&<<J3V:@!NL^(+W3_%FB:3!8230WJS2.Z,F6V+]T!B,8+ D\=.,\US>E:\
MOAF?QA<-I]]=VMOJK23/$0WDQ^5'DDNP+=S@9/TXKHO$&GZE)XK\.ZK8V8NH
MK,7,<R^:J%?,50K<]0"O.,GT!K%FT/69-$\<6HTN7S=6FD:T!EB^8-$J#/S\
M<KGGM0!T]]XCM[:7R+:)KNX\@7)C21$PASM.6(Y;!P/8]*LZ%K5GXBT6VU6P
M9FMKA=R[AA@02""/4$$?A7(2:9KNDZU;:M:Z$FIP7.GPVMW:/-&LL$D><,I8
M[2/F((!]Z[734G2PB%S###,<LT4/*QY)(4' S@<9QR>: .7TN=O%7BK6Q=LS
M:;I<PM(;4,0CR 9=W ^]S@ '@>F:V&L;70KJ?5C<O!I\5JWFPM(QCCP0VY5Z
M+P#D#VK,@TO4?#?B?4[^QLFO]-U1EFFBB=5E@F P6 8@,K=3SD5=UO3KSQ/X
M>U'3GB-BES 8XQ,5+[^H+;20%X]23D],<@$J^)HDO+""\LKFT74.+627:59L
M9V-@G:Q'(!Z_7BL^;QU!%87]Z-)U%K?3KEK>[8+'^ZVXRWWOF'/\.>G..*9+
MI^IZ]%H$.H:>]F^G74=W<2-(C*[QJ0 FTDD%B#R!Q[\5GRZ)K$GA3Q=8C39!
M<:E>3RVRF6/YE<* 2=W'0YH Z*+Q-&^M1:;)I]Y";F%YK260+MN F-P W94X
M(.& _"LL_$2R73X]2?2M3333,T,UTT:[8&#E/F&[)&1U&0,^O%37%AJ,WB?P
MS>KI\H@LK>=+AC)'\A=5 XW<_=.<5S^C6=YK?PZNM$ALW NKNXB^TLR>6J&X
M8LV,[LCG QR<=N0 =7JGBRWTPZBYL[F:#351KJ6,* H89&W)&[ Y./U/%/N_
M$\=OK8TB'3KRZNGM#=1^4$"R+N"X!+#'7OCI[BN;\1:)KNI0^(-/.G?:X9;=
M4TR5KA!'$ @!&TG(?=GYL=^H%:MK9:H/&5EJ<VFR);II+6KD2QMMD+JV/O9/
M"XSTSZCF@"7_ (3:S_L:PU3[#>F"ZN?LK<(#;R;]F),L,#<,9&?UK;&H*VL-
MIRP2EDA69Y1MV*"2 #SG)VGMVKFM%\/23>#-2T;6;9K9;F>X<EG1L*[LZL"I
M.",@_459\-KJEMX1.I7$8O\ 5[B$3%%;9YN$ C7)^[D $Y[L: .HKEH]7TRV
M\0>))8]-O!?65O"]VX(/G)ARFP%\< -Z=:W-(OWU/2;:]DMS;R3)N:(L&VGN
M PX(]#W%<P^F:H/$7BVZ&FRM!?V44-LPEC^=D5P>-V1RXZ^AH N6'C>WO9]&
M#:;?6]MJ\8-K<RA A?9OV$!MPX!YQ@XXR.:WM2U"#2M-N+^Z)$%NA=\=<"N*
MBT76$TGP-;G3)?,TAXS=CS8OE"PM&<?-SR<\=J[+5TEDTFYCBLX[QF3:;:0@
M+*#U4YXY&>M %"[\2?V?8ZA=W6FW2QV4"W#E&C8.AW<J=V"1M.1QU'6IF\06
MZZII=@;>?=J43RP287: JAB&YR#@CM7+Q>$[V/3/$&FZ<MS:Z7>6!CMK.[F#
M^5.0V=A#-M3&WOUS4\-GKEYK7A>[FT9[:&PAFAN ]Q&64LBKD;2<C(XQSUR!
MQD V/^$JMS]DFCL[J2QNKG[+%=1J&4N20&P#NV9!&['Z'-<YIVM#P[=^+K@V
M%[=V]OJ'F3-$0?*C\I"22[#/<X&3]*O>%K;Q)HEE#X=FTV-K>U<I'J?GKL:'
M=D?)][?CC&,=\^L,NCZL^E^-(!ILGF:J\AM1YL?S!H@@S\W'(SSVH [>*5)H
M4EC;<CJ&4^H/(K!;Q;;)-$6M+D6LM_\ V>MP0 /.R5^[G.W<",_ICFM728Y8
MM'LHIXFBEC@1'1B"5( !Y!(KA;S1_$=['"]WI/VB_M=8CN?M!N4P\"R9 B!/
MR@+C(..F>2: .BN/%RQ7>K6L&D:A<3:8$:94$8RK*6W EL'@=.ISTZT0>,;6
M>;2B+&\2RU0A;:\=5",Y4L%(W;AP#SC&1Z<U5M]/U./6_%5T^G2>7?PPK;E9
M8SO9(RI'WN.3QG''I5%-%U=/#W@ZS_LV0S:7<PR70$L?RJD;*<'=SRPH WKO
MQ3!;07UU%9W-S9V$ACNIXMN$*\O@$Y;;GG'H<9P:FA\16MQK,.FPQ2R-/9?;
M89EV^7)'D#@YSGYAU%8-GI.K:3I^OZ,EBUU%>S3RVER)$" 2CE9 3N&TD\@'
M(]^*6+0M0\/ZSH4]E9OJ%O:Z6=.D*2(C*<H0YW$?*=IZ9(]#0!>;QO9+I=O?
MFQOO+FO_ +!M"*623?LY 8Y&0>F:>?%A,>L1_P!E745]IL G-M,R R(02K!E
M8C'RG/<5SL>@ZZGA^UM'TPF:+7Q?,$GC(\H3&0G)(['@=?I6Q/I.HW/B;79_
ML;1VU[I:VL4K.F-XW]0"2!\X[4 6=)\323Z+HCW5K)_:&I0*Z1ED42$1AV8?
M-P.>!U]JW+"[-]9K.8)8"693%+C<I5BIS@D=NQKCX]%N+WPMHFDZUX=>2.UM
MQ$YBN$\V&1%55D1@PQG#=#GIGTJYI]SKGA_2M(M+ZUEU#S;EH9KA[A?,@C9\
M1;O^>C8(SCI@G)ZT =+?7D.G:?<7MQN\FWC:5]JY.%&3@=ZS+3Q(EQJ7]GR6
M%S#=-9_;8D8H=\>0,9!P&!(X/KUJWKJ:D^@WR:0ZIJ)A86[-C ?''7C\^*Y;
M3-,U2W\6V>K_ -AO#"=,>WGWW2/+YF]6RQR=Q.T@')[9VT 7K3QW:W=MIEX-
M,OX[+4)Q;I<2*@5)"Q55(W9Y(Z@$<]:7Q+K"7.AZ]:VMK<7*VENZ3RPN%$;[
M-V!R"2 02!Z]SQ6+;Z#K47@?0--;3)/M=EJ,=Q,@EBP$64N2#NP>#5A=,US3
M$\3Z;%ICWEMJLD]S;7"31KL:5,%'#,",$<$ T =+X5.?!^B$_P#/A!_Z+6J<
MGC"WBL]:N&TV^SH[[;F+$>\C;NWJ-_*[>>U7_#=O<V?AK3+2\A\FXM[6.*1-
MP;!50#R..U96I>')[KQ:MU'L_LR]MA'J49_Y:&-LQ\=\[B#_ +(([T :R:RD
MLEDD5K/)]KMVN%*%"%4!>OS=]R@8SUKEQXD@T[PC8W>@Z7.D%SJ7V?RY7&Z,
MM.5<\L<DG=CG SVQ6KX0T2]T.PFBO6\YH6-O:8()^S(S&,'G[WS'\AZ5A1>'
M]97P-;V?]GM]MM=5%[Y!FCS(GV@R8#;L9P>Y% %N6[EL_B5+-#87<\TNB(_V
M5'4MN\XYY+;%X []N,UU.B:O;Z[H]MJ=JLBQ3J2%D&&4@D$'W!!%8T5KJ1\>
M-J\FFR+;-I2VV1+&?W@D+X^]GH<9]?;FIO!&GWNE>%K>QO[9H+B*24E2ZMD-
M(S#!4GLPH M77B".&ZO;>"TFNFL0AN!$5RFX9& 2">.3^F3Q0GB&&34-6L5M
M+GS]-C220?)B17#$;3N_V3UQ6!XET"[U/4+J[L=/GM=6AV"QU.VF5 RX&5E&
M[)4-NR"IXZ58FL-7L_%6KW,&G_:X-3LX8UF6546)T#@A@3G!W9& : -.V\3V
MM]9:9/:03R3:E$9H+<[0X0 $LQS@ 9 ZGDC&:YWQ)JT6IV&A7ZV]W \&O0PR
M0R*0P96(88!PW08(S4%AHOB+1;/PUJ-OIJSW5A9-8WECYZ!F1MI#*Q.W(*CC
M-:^N6NM:K::/(VF_O8M5ANY($F0^3$G4%B0&;OQQSC/&2 :^D:\FJ7]_8R65
MQ9W=D4,D4^PDJX)5@58@YP>_&*I^*M?O-%GT:&ULGG%]?);NZLH(&"V &(Y(
M4CT'KTHTVQOHO'&LZA+9O':75O;QQ2ET.2F[/ ;(^\,<4WQAIU_>C1+G3[4W
M3V&IQW4D(D5&9 KJ<%B!D;@>M #]5\7VNF1WLGV6:<6"![L1O&&B^4,5 +#<
MP4@D#UZYXJO<>.;9;V.TL=,U#4))K :A!]F1")8B0!C+#GGOCIW)%9OV'7M&
M\2ZE-#X?M]6L=4D2X#?:$1K:78JLK%QDK\H(('X5H0:;J<7Q M=1DLMUHFD?
M8Y)XV14\WS%?A=V[;P>U "S>.43^UQ%HFIROI6TW2 1@JI3?N&7P?E[#GVJ>
MW\96UQJ&EP_8+V.UU5<V=Y(JA)&V;\8W;AD9P2!G''K68NE:J+OQM(=-EVZH
MJBT_>Q_O,0"/^]QR,\]ORJ(:/JXL? T7]F2[]),?VO\ >Q?)MA,9Q\W/)SQV
M_*@#H;3Q''?3Q?9K.>6UDN9+47*LI57CW;MPSD#*$ X[CID5MUP4/AV]7Q-:
MZM8:?/I-XUVQU(I.AMKN'YOF*!C\Y^7!P""3GUKIM#U:\U-]0BO=,:QEM+@Q
M!?.642+@%6R.A((..V10 [4-;%G?_88;.>ZN?L[7)5,* BD#JQ R2>!_*H(/
M%%G>6^ER6<<DSZG"T]O&2J':H!;.3C(W 8&?R!-4]:M=7N?$<:BQ^VZ.UH4$
M?G*B1S[C\TBGEEVXQ@-@YX[UBV7ANYF\):)I&M:!))]EA=3+;W"":WD&W8RM
MN&,_-T)Z#/L =U8W7VVRCN/)E@+CF*4 ,ASC!P2,_C7/?VK8P>(_$#6VEW+:
MK:6<3S,T@"SI\Y0+EB!T;)P#]:U/#=MJ-GX>M+?59VGO$4AY'(+$;CMW$=6"
MX!/J#6/'I6HOXS\0736C1VE[8Q6\,[.A!90^<@'<!\X[=C0!I>$=7NM<\+V&
MHW=NT,MQ"DAR5PV1G*X)XY[X-177BD0:[<Z+!I5]=7L-LMR%C\L+(I8J,,S
M#D'KCIQFD\$VNH:?X2T[3]2LOLL]G D!4RJ^[:,;AMR,'MSGV%0+9:A'\1KK
M5?L$K6+:6ELLHDC^9UD9\8W9QA@,D=: (8?']G/8:=J*Z9J TZ\F6W:Y=458
M9&;8%8;MQPW!(!'O5K5?&-KI7]HR/974EMICQI=SH% 0N ?E!(+8# G'KQFN
M9C\/:XGPXL='.E2_;H=16X=/.BQL%R9<YWX^Z<?7\Z7Q1HGB37+3Q)9RZ5]K
M,X4Z;*]RBQQ1X7*!2>),ALMCG/WL 4 =B/$,/_"4_P!@/:7,<[6QN8YFV>5(
M@(!VG=DD$CC%6],U)=3AEE2WFB2.:2$&3;\Y1BI9<$\9!ZXZ5SGC"QOKG3=)
MU.R*6>N6EU&+<.=X_>D(\9QU&TY./[OH,UU%A9Q:?86]G#GRX(UC7/4@#&3[
MT 9]]K$;7ESI=O9SWL\,(DN$A=5\M6SM&21\S8. /3DC(SS/@/6H;#X>>'XY
M-\MU=++Y49<!FP[%B2Q  &1D^XZYJ['9:QH?CG5]0M].?4-/U=86W12HK6\D
M:;,,'(RI'.1DCTKGM/\ #?B32_#_ (9NTTB&YO=)^T0W&G23I^^BE;.5;[H8
M84\^] &SJ'C_ 'Z.EQIEC*UPNJQ:=<Q.R9A8NH/?#9!^4@XYR2,5MZAXHBL?
M.C%G--<6\ GG@$D:M&ISA<EL%C@\ GIU&1G'UO3=9U;PW#+'H\5O=1:A;W::
M>DJ;BD;J2"_"[C@]\=.:BNK+7M-\5W6K6_A^+5;35(8O.@\^-9+65!MZMP5(
MQG'<?F 7W\>V+G318:??WQU*U>ZM?(1?W@0#<O+###/?CWIZ^-#+<WUI!H.J
M27EG!%/) 1&IVR GJ7QD;<8SG/0'FH9=-U5O&/AZ_;3U,%K;7$=P\#H$C:7:
M0%!(8@;2"<<]<5):V.HV_C3Q#J+:=*UK=VL$<#K)'\[1A\\;LC.X8SC\* %M
M_'5G<KI%PFGWRZ?JKI#!>.J!!*P)5"N[=V(SC&>YZT1:SIEIKGB>>/3;P7MC
M#"]ZP(/G)M8IL!?'"@^G6L&W\/ZW#X)\(Z:VER&ZTS4()KE!-%@)&Q)(._!S
MGC^E:4FEZK_;?C&Y&FRF+4K.*&U82Q_.R1NI_BXY8=?0T 7[#QK;WMUH\;:;
M?6\&KQ;[6XE"!&;9O*$!MPXSR1@XXR.:2_\ '.FZ<GVF6.1M/6Y^S27:LF$;
M=L)V[MQ4-P3C\QS65'HVL)8^!8CIDN[2-GVS][%\F(#&<?-SR<\=ORINBZ9X
M@T22?1#H-K=VOVB1[756E3"1NY;YT/S%EW'IP>!D=: ._HJE;7-[+J5]!/I_
MD6L.S[/<^<&^T9&6^4<KM/'/6KM &3XAFG&F_8[23R[R^;[-"X&2A8'<_P#P
M%0S?A5#P+JD^H>'$M[X_\3'3I&LKL$\[X^,_B,'/O4TVGR:KXCD?4+"9;*UA
MV6LGFJ [L?G;"MN' 0#(_O>M9MAH]]H?CRZGT_3Y3HU_;H+AO.0[)U)PX#-N
M(VG![Y]: ,81*/!OQ 0-)B*]NV0^8V01"A'.<UWNC?\ (#T__KVC_P#017)#
M1M6/AWQC:'3I!-J=Q<26JF6/YEDC5!D[N.1DYKKM)CEBT>RBGB:*6.!$=&()
M!  /()% '-W7Q @@34WCT/5KA-+F,5X8XT_=@*&+_>Y&#T'/!) JQ=>.+2.Z
MM+>RTZ^U![RR-[;&W5<2H,<#+#!^;OC\3@5B:1+>->^.;2TTZ2Y>;4'2-PZ*
M@8PH,-D@@#@Y /'OQ5K2_#=_HOB+PXD5K)/8Z=I3V4MR'0 NQ0YVEMV/E/;N
M* -+4/&UII]I<W36=Q)%9A3=A6C#PDJ&*[2V6*A@3C\"3Q3W\80/JITZQTV]
MO9VLEOH3%L"2QL< AF8 =^N/QK(33]=T3Q'JJV^@6^KZ?J-Q]JAN&G2,V[LH
M#*X;DKD9&T'Z5?@T[4H/'YU)[)GM%T=+3SHVC4-*LA<X7=D#GC_)H ;%\0+.
M;3;'4UTS4%T^YF6WDN'5 ()"^S:PW9.&X)4$>_:K0U#3U\:W\2:=='58=.1V
MEW#;+#O;:J@MC.[=R0*YD>'M<'PVCT;^RI?MRZC]H*>=%C9]J\[.=^/N\?7\
MZZ&+3[]_B)=:F]C)'8RZ7':B4NA^<2,QX#9QAL=.HH EB\:6,VDZ'J:6EW]F
MUB=((3A,QL^<;QNZ<'IFH;GQO'"^L)%HVI3OI!'VH((QA2F_<"7P1MYP.?:N
M:L]#\21>&?#.D-HI#Z-J4,DLAN8]LJ(7^9.<XP1UP<D<'G&PFE:L+KQM(=,E
MVZHBBT_>Q_.1 (_[W'///;\J -.W\96T^H:7#]@O8[755S9WDBJ$D;9OQC=N
M&1G!(&<<>M6;3Q''?3Q?9K.>6UDN9+47"LI573=NW#.0,H0#CN.F17/#1M7%
MAX&B_LR7?I)C^U_O8ODVPF,X^;GDYX[?E20^';U?$UKJUAI\^DWC7;'42DZ&
MVNX?F^8H&.7/RX. 02<^M '6:[K$6@:+=:I<0S30VR&1UA +8'4\D"LJU\:6
MTVNV>EW&G7]G]O0O97%PBB.? R0,$D''.& _E2_$+_DGFO\ _7E)_*J?]G7N
MO7/AJ>2R>TATS_27>5T.]_+*JJ[2>,MDDXX ]> "[;>,K6XGTW-G=1VVI3R6
M]K<.% 9TW=5SN4'8V./KBIK'Q5;7@UD/9W5L^D,5N$GV GY=P(PQX(Y!.*Y"
M+1?$]P= N[[1O-U2QU$RWES)=QGS5*N 4Y.V,;A\O!'93R:V=>T.2X\;Z?+:
M2JD6H0-%J<./];#$RNI_,^6?]F2@#3G\5K$-J:5?/.MC]OEA(16CCR0 26P7
M.#P#VY(KG]9U:&?Q9X+UJQ@NKF.[M;J2.&+[T@,2E1@D*#\QY) '/-7_ !!8
M:W?:]=0G3Q?:5-8>7; SJD<,YW;FD4\MQMP0&QCH,DUGZ?HNN65MX)NIM*9G
MT>VDMKJWBGC,@W1*@89(4C*DX#=,?2@ \2^(;;Q'\.?$ZK;W5E>V$3)<6L_R
M21/C()VG!!'(.<&NEEUV*PCMK..)KB[^RK,8ED1,)T!)8@<D$#Z'TKGM7\-:
MG>Z-XONH[,_;]<1(H;42)F-$38I9B=N3\Q."<<#FGZAIVMV/B"SURST1-3AF
ML([.[LGEC22)D8E74L=I^\01F@#J=!URS\1Z-!JE@7\B;/RN,,I!(*D>H((K
M2JGI:W"V"&Z@AMYF)8PPG*QY/"YXR0.I]<U<H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE_'N
MHZEIF@PRZ;)%&\EY;PR,^<[7D52!CIG/)],T = M_9M?M8K=0F[5/,: ."X7
M(&XKU Y'/O5BN#NCJ2?%)#:06CWSZ 0Q=RL8/GCDD D_3'Y5<L?&QO="TFX-
MJ(K_ %"66#R@&D6-HBP=OE&2/EX&/XATY- '845PMYXWU:PT+4KR;1#YMC=Q
M0;GWQ1W"2,JJ\>Y<DY;!4GCUK1D\0ZI:746G7UI:Q7]RTLD/D&2=%@3;\S *
M"6W.!C@=\]J .IHKC[7QE=26MO!=:6]OJEQJ#6$,<JND<NT%C,I8 [-H)Z9S
MQ[T^X\67EA>:QIEU9P/J%C8'4("DA2.YA&03T)4@C&.>HYH ZVBN.L/%NIRW
M?ALWNGVT5GKD.8VCF+21OY7F<C&,$ C@D]/I6UXBUR/0;&"XE*1QRW"0--+G
MRX=V?G;';C';DCD4 :%S?6EEY0NKF&$RN(XQ(X7>Q. !GJ>>E3UPOBNYN+K1
M-+GFB@D9=;M/(>W?*2KO&&!/3.?P]3UK4MO$6I+?ZSI]WIL4EY8VRW4$=I*6
M\Y6#87+ 8;*X_&@#I)-IC;<VU<'+ XP/KVK$TH^']#T8O8WT$>G&5OWCW>]-
MY8[@&8GG=GC/6J^F>(YKKQ)_8MTMJ\C67VHM;OGRV#!6C8<\C<.>/H*X^9%_
MX4[J@VC"ZC)CCI_I@H ]2FFBMX7FGE2*)!EG=@JJ/4D]*;;W$%W;1W-M*DT$
MJAXY(V#*RGH01U%5]757T6^5@"#;R9!'^R:X'P[XCU70?"?A22[TVW.BW$-M
M:&=)R9HV=0%=EVXVD]@2>?PH [G5M!TW7#;_ -HVWGBW<O&"[*,D8.0",CV.
M16@\<<D1C=%:,C!4C((],5Q]_P",[Q(+J\TS39+Z"UNFMV@CAE:68*^QV1@I
M48.< YR!U%;/BB_O-/\ ".IZAIYC6Y@M))D,JG VJ3T]>.E &A)?65M<V]G)
M<P13S9$,+. SX&3M7J< 'IZ59KSB^EOWN?A_<2QPSWK.^WYR V;9N68C/N>#
M^-:]OXSGALM5&IVD2W]A?1V(CMW9DF:39Y9!QD??&>">#C/2@#L**YW2-=O[
MK7[C3+NP<0K )X;V."2.)N<&,[QPPZ]3D>E6+S693XA30K!8OM?V4W<LDV2L
M<>[:O Y))SW& "?:@#2NK^SL?*^UW4,'FN(X_-<+O8G 49ZDD]*FDD2*-I)'
M5$499F. !ZDUYKXCU]M:T"$2V8BU+3?$-K;3P!\C>)5(*L0/E8$8)QUKI--\
M0:DWBB3P_KFGVT$TML;JUEMIC)'(@8*RG<H.X9';!H V_P"V--^Q17O]H6WV
M69Q'%-YJ['8G: #G!)/%7:\Q\.ZHVD?"KPO(+"WNXY;J*!A,W^KW3D!P,')!
M]QBNJO?$5T=6U;3]/@A,FEVB7,AG) E+ABJ+CH,(<MSR1Q0!TE%<G9^*-0U#
M1M(U!;"VM(-0B:>2XEF+Q6R;05#9"$LQ.,=.#R:R+WQ=JFI^%]"U"P6"V>ZU
MB*SN 6+ [9BIVG^ZVSGV.* .\-[:B^%B;B+[68_-$&\;RF<;L=<9XS4]<S_;
M3P>-AIUY96D>S26NVO48EL!U#+R!A<Y/4]JIS^-+FV\.VGB>6SB_L6=TWJ&/
MG0Q.VU9#V/525[9ZG% '945QUSXHUMM4\0V-CIED6TF.*4/+<-B161F[+U^7
M&.@YY-=%HNJ)K&@V&JJAB2[MTGV$YV[E!QGVS0!?JO>W]GIT'GWMU#;Q?WY7
M"CU[^U<I-XUN4\,CQ5%9Q2:*)/F0,?.\G?L\T=O?;Z=\\5'?3W\_Q1TM(C;/
M;'2YY(PQ;!4O$&/U]/:@#LX)X;J!)[>5)89%#))&P96!Z$$=14!NM/DU-;0S
MV[W\<9D$6X&1$X!;'4#D#/O7-^,YKGP[X1B30H[:TC6Y@@VJNT(CRJI"@=,[
MNOU[U2NSJ*?%* VL%J]\^@.&WN5C'[]>2<$D>V._:@#O**X^Q\;->:'ID[VH
MCU"^N);;REW2)&T18.WRC<5^3@8[CIR1I^'=:O=4DU"WOM/DMI+24(DWE.D=
MPA&0R;P#[$<X/?F@#8N+FWM(3-<SQ0Q#J\CA5'XFF6]]:7BAK:Z@G!S@Q2!L
MXQGI]1^=<EI$IUOXDZ\]V-\>C+#!9Q-R$+J6=\?WCC&?3BN@U"VT[3[J7Q'.
MHCDM;219957EHN&(/KC9Q]3ZT :M%<M+XHO+*VTC4;ZTA73]2DCC_=L3);&0
M?(6[,.@.,8SWJM<>*M9$/B&2WTVR_P")-(=XDN&_>((PYQA?O$'O@#CK0!V5
M%<M#XGOVU714FL8$LM8C8VY$Q,B,(_,&\8Q@C/3.*SI?&>NC2=1U6+1;1[73
M+J:&Z3[4=[+&V&*?+@X&3SCZ4 =U17*ZMXJN;2RN;^V@@6RALENX9+E]OVLE
M2WEICH0 .>>6''>G3^)K]]5TBSLK"!UU.S>YC>6<KLP%.& 7I\PZ9S[=: .H
MHKBY/&&I1^%[O53I]N9M.O7M;Z-9&*JJ-M:1#C) !S@]L^E=$FH2S:U':0"*
M2W%L)Y903D;CA .QW88_\!]Z -*H;F\M;-5:ZN88%8X!E<*#^=350UK1[37M
M(N=,OHP\$Z%3ZJ>S#W!Y% %@WMJMJ+IKF$6YZ2F0;/SZ4^&>*XB66"5)8VZ.
MC!@?Q%<)H=Q?:I:R^"]4B)N-/(AOI\?+-;8&PCWD'!] &/!Q7376J&'6;;0=
M/CA%RULUP2X^2&)2%'RC&<DX R.A^A -FBN,G\:W%OIE]*]E$+W3KZ.TNH-Y
MVD2,H5T;'0A@<$>HK:36)O\ A,7T-X8_*^PB[64$Y^_LVD?KF@#9J![ZTBO(
MK1[F%;F4$QPEP'< 9) ZGI63KGB&/2=2L+&2:WMC>+(4N+K(CW+MPG;YCNXR
M?X3UK$UB6^?Q7X.G-I"+]XKO=$9/D5O+7/S8S@?2@#N*@9K73[9Y',-M F69
MB0BC/4D]*YVQ\2ZE=:5>M_9L;ZA9ZA]AE2*0^4.5S+D\[0K9(Z\5 ^O?VSI'
MBJPE%O*;"W9?.@.8Y5>(L" <X(Y!Y/2@#I?[4L,6I^VV_P#I8!M_W@_?9&1M
M_O<<\4^]OK33K9KF^NH;:!?O23.$4?B:X1E']B_#AL#=YUN,_P#;LU:_Q-56
M^&^N;@#BWR,^NX4 =8#D9'2BN9M-?U&/Q3#HVH6,$<=S9O<VSPREF&PJ"K@@
M#/S \<=N>M5;3Q=>MK6C:?>VMO#+J@ES;+)F:S94+J).QR![8/K0!V%%<I9>
M*+R6'Q!%=VL$5_I4PB2!&)\X,H,39./ODX [&GW_ (EO8KF[L;."*2]LH$DF
M'E2NC2,"1&NP'' ^\?4<'G !U%%9^DZC-JNAVU^;*6TGFBW&UN04:-O[K<9'
M/?'3G%<C;>.M7DT/3];FTJTCL9K[['.HN&:1<S&(,ORX(! ZX)YX% '5+X=T
MM=??7/LN=1=0IE9V(  QD*3M!QQD#."?4UJ5SK:[?7]YJUOHMO;RG3&$;^>Q
M'G2[0Q1<?=P"!N.>3TXS5_P]K=OXC\/V>KVJLL5RFX(_56!(93]""/PH N6U
M[:WAF%M<13&"0Q2^6X;8XZJ<=",CBIZX.7QC=6'A?Q+J\.CV:3:9J,EO)$DQ
M DQL!D+;?F8[O0<#K6M%KVJKXI.BW=E:Q&XLGNK1TF9L%6"E9.!S\P/'N.>M
M '345P/AOQ7J">"]/U#4_*GNM0NY((-@<Y<R2$Y !(554X SP,5->^--5T_2
MM>N)='WOID:S13LLD,-RA'.-RY#*>J_K0!W%%<K)XDU2T>"*_L;:*6_EVV0B
M=Y2$";V:0!<Y'3"YR2.<<U4?QO<V6FWLVIZ>UH;:\CMOM<D4BV[(YXF^8 X'
M0CL<<\YH [6BN&\2Z[K4/AE;JTDLAYFHV\"7$+EEFA=D&Y<=,EB#R<8.,]:[
M-3<"URRQ-<;?NAB$+?7!('X4 )9WMKJ%JEU9W$5Q;OG;+$X96P<'!'N"*GK@
MK3QE=1^$?#^I6FC6J#4;\6;6\<NT1;I67*_+@_=//')S6YH>N7UYKNJZ/J5K
M;PW%DL4JO;R,Z.D@;'4 Y!4B@#H:*PM;UB^L+HQ00V\5NMLTQN[IL1M)G"Q
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ME)D5UA# L,8P0IZ'T^E;GBS7KCP[I45[;V:76^YB@9&EV$;W"Y'&">>Y'UH
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M0 @9QP2 >YBB\$ZO%X;AT\7UD]Q::N-1MV,;!&Q*9,/SD9W=NF.]=X %
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MC66)B""5(R#@]*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:MJ:W%Q<6UMN-KN(+$J-V8\(%P0?O<\&@#6T_4=6;QS=Z0;N.YTV"TCN3*T
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MQU7/\/3D\9KTG3IWN=,M;B3&^6%';'J0": +-%<I\1;B[M/!\US8WDUK.D\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_F$[MV0.<]L=*OV-R;K3;6ZD"JTL*2,!T!(!_K5F@#&M?"^EVE]+>JD\EQ-
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ+A27PW;%MP9=1M
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M$>HR:BEE;K?2($>X$8$C*.@+=<?X4DVEZ?<7T5[-8VTEW$,1SO$I=![-C(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ5[XSU/P=I5Q9QV]MJ-S_:1@W%I%@C!*[^WS*2>.G3FO67=8T9W8*BC+,3@
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MEP^0"2"O;&?:@#K**Y[P/=7U]X-TN[U"5)9I[=)-Z@Y.1DD^^?2J]KXHEO\
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MX7O-'M9886N@JF67)" ,&Z#KT]JTWL_MND/8WZ(1-"89EC8D$$8."0.U7**
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MC49!(PP(/!5AP1_*H9_"EI>:?J\%Y-++-JT8CN;@ *VT+M4*.@"\D#GDG.:
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MN-YER"MC;2#%S)U+29XW8(] >!V%8&HW%S<?"#Q3]JN9KAXKZXB5YG+-M6<
M#)] * /3);FX34K>W2R>2WD1VDN0ZA8B,8!'4YR>GI5JN4U.:YC^(^AVZ7=P
MMO<6=T9(0^$)79@XZ9^8]:Y&>;48?!>LZR-9U-KO3=8ECM\W+;=BW 3:R]&!
M4XP<CTQ0!ZS17&ZO<7+>*K^TO);Y++^S0]G]B:0$2;F#D[.=WW=N>.#CO6QX
M2@U*#PQ8#6))7U%X@]QYK;BKD<C_ .MZYH VJ*XKQ/-+-J.J16U]=R2V^F%Q
M;V\S0+:L=Y$KNK<DXP%P?NGH#70>&+N:_P#">C7ER^^>XL899'_O,R D_F:
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M<3,SX, R S$D>G'3MBM;P1-<?\3ZQFNKBYCL=4D@@>XD,CB/8C!2QY."QZT
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M9Y'VF8YW[0_)&-I] ?QH ZRBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBCI0!5U'3[?5+":Q
MN@[6\Z%)%21D+*1@C((."#2:;IUMI.GPV-FKK;PJ$C5Y&?:H& ,L2<"K,<B2
MIOC=74]U.10DL<F?+=6VG!VG.#0!0T[0['2KF\N+1)5DO)/-GWS.X=\8SAB0
M#@ <>E5K3PKI-D46"&1;>*;SXK8RL88Y,YW*A.!R<@= >0!6QYL?F>7O7S,9
MVYYQ]*1Y8XP2\BJ!C.3CKTH SO\ A'M,_M>YU3[.3<W48CGS(Q20 ;1N3.TG
M:2,XS@U5T7P;HF@7)FT^WE0C/EH\[ND6>NQ6)"Y]JW'=(T+R,JJ.K,< 4;UV
MAMPP<8.>N: ,+3?!FAZ3J+7ME:O&Q<R+%YSF&-SU98R=JGGJ!],5.OA;1@^I
M$VF]-2+&ZB>1FC<MC<0A. 3@9( / K4:XA5 [2QA&. Q88)JO=ZI9V-Y96D\
MRK/>R-' F>6*J6)^@"]?<>M &=I'A#1M%@F@M;>1XY8S"PN)GFQ&?X!O)POL
M.O>H(/ FA6XM%2.[,=E-YUK&U[*5A.",*-W Y/%;$+7W]IW2S&U^Q!$-N$+>
M;GG=OSQCIC'O5E98V8*LBDD;@ >H]?I0 2QB:)XV+J&&"48J1]".15;3M,MM
M*TZ.PM!(MO&NU TK.5'^\235HRQK((RZAV&0I/)_"G4 8-MX,T*UTV^TY+1W
MLKYB]Q#+.\BNQY+?,3@Y .1CI4NF^%=)TJRGM(899([B/RI3<3O*S1X(V98D
MA<$\#BMAF5%+,0JCDDG %()$:/S ZE,9W \8^M &&/!^CBPL;+RK@P6,RSVX
M-U*2CJ,*<[LG X / %:=YIEGJ$UG+=0+*]G-Y\!/\#X(S^1/Z>E65=7)"L#C
M@X/2D:6-#AI%7D#DXY/:@"C?Z)8ZE?65Y<I*T]DY>W99F4(Q&"< @'@XYJG=
M:9;Z-+J.N:=IL]WJ$^&>WBG($K#"Y"L=@;:.N,X'O6U)+'$ 9)%0$X!8XYIQ
M95QN8#/3)ZT 8^@Z>\+7VIW-HMK>ZE*)98@02BJH1%)'!.!D^['DULU275K)
M]573$G1[HP?:-JD'"9 !/U)X^AI;!KYEN/MYM2PG<1?9RW$7\.[/\6.N.* +
M;+N4J21D8R#@U@_\(;HO]C'2/)G^PF;S_*^U2??W;\YW9^]SUZUL22O+:2M9
M/"\NUA&6.4WXXSCMGK26;SFQMFO&@^TM&OF&$GRR^,G;GG'7'M0!4_L"P.LK
MJS)*UX+?[-O:9R#'G.TKG!YYZ52TGP5H6B7AN;"U>,Y8I$TSM%$6ZE$)VKG)
MZ#H2.E;RR(Z!T=60\[@<BH9KZU@LY;R6XB6VB4N\I8;5 ZDF@#"A\!^'H(K:
M)+6<1VL_GVZ&ZE(A;G(4;OE4Y.5'![YJR?"6D-:ZE;&*<PZFY>[7[3)^])&#
M_%QD #C' JTU[<WMEIUYI9MO)G>-Y?M.0?)89.W'\?*XSQUJ^TL:9WR*N,9R
M<8STH R7\,:<VX W2J]NMK(JW+XDB7.%;G_://7GK6M#%'!#'#"BI%&H5$48
M"@#  I7D2)"\CJBCJS' %*"" 0<@]"* ,V+0+"'6;C5HUG%[<((Y7\]R&4=!
MMS@8R>@JH?!VBMHUWI+03&QNY3-/&;F3YW)W$YW9Y/.,UIJU]_:[JQM?[/\
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M<0[OX9 " WX9-6))8X@#)(J G W'&35:ZU2SL[ZRLIIE6XO7984SR=JEB?H
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M[5IT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5R7CV^%A:Z.]RVW3'U.)+]C]T1$-C?_L[]N>W;
MO76U'<6\-W;O;W,,<T,@VO'(H96'H0>M 'GOBHZ=IFA:[>Z#,3]HDM6U'[+)
MF..+<%8J%X4E,[L<XY/:KNKVYL?&GA^X\/11(UQ:W(GCA "2Q+&#&6 XP'*@
M'_:Q77VFFV-A9_8[.RM[>UY_<Q1!4YZ\ 8I++2]/TT,+&QMK4,,'R8E3(].!
M0!YBX%W\(;+5K,?\5#%-&R3X_?&[,P5U)ZDDD@@]O:M2V\/Z+J_CCQG;:I:0
MRPA+1RCGA"T3;G ['_:ZCGU-=RFD:;'>M>II]JMVS;C.(5#DXQG.,YQWK L_
M##/XNUS4]4L;">UOA"(-Q\QTV(5.05P,\'@]J .-T&_GCM_"-KK]XL-K-I\X
MMY;M R/()!LW;N,^5C!/J1WJUJ6B:5::=X=M;6[-[:_\)(BI(<;45U<M%&5_
M@!XP.^1VKTF^TVPU.U^S7]E;W5OD'RIX@ZY'3@BF2:-I<T,$,NFV;Q6^/)1H
M%(CQ_=&./PH XK4K'0K#6I](LK:UMS;Z3([)<D?9XHGD8G9'QEBP.3D #'7I
M6/IXL;VR^&LUZ+:<>7)%,\P5NELQ"L3[X.#7J$^F6%S=0W4]C;2W$ Q%+)$K
M/'_NDC(_"H_[%TK[)#:?V;9_9H7WQ0^0NQ&]5&, \GD4 <4;6U;Q+X]C$49B
MDTZV=E &"?+E.?Y&L[3;"SLK'X;:A;P)'>3^5'+.!\\BM;-E6;J1P,#H,<5Z
M.VCZ8\L\K:=:-)<#;,Y@4F0>C''/XTW^Q-)VP+_9=EM@.81]G3$9_P!GCC\*
M /.M1LQJMMXJT8S6D][<ZH&@O7GC'D#Y"%()WC8 1@ @YQW->D6\^GVL\6DP
MSVT<Z0ATM5=0PCZ;@O7&>]<@/"5]+=7"ZEH?AK5#+,[_ -H7"D2X8DC<GEG.
M!@ !QP!TKH++PS9V=WI]R$C:6PMA;Q2^4!(1C'+=<8)PO09/7C !E^)K@KXS
M\+6EV =+G><.''R-.$'EANW][ ]?<5RWB2R$%E\0K2&-?[*CMH9XXP/DBN"I
M+[1V)&UC]1ZUZC=V5K?VYM[RVAN(6()CE0.IQTX-1'2=-:R^Q-I]J;0G)@,*
ME"?7;C% %;0]'T[2[8RV-K'#)=*CS.O65@OWF/<^_>N"B\/:'J0\>+J%O"5M
M[MV1F/\ Q[_N$.]?[IR.HZXKT^&&*VA2&")(HD&%1%"JH] !TKE]%\+M#K.M
MWNJV&GRB]NQ<0-_K&0!57!RHQRN>* .9LYTN[:PM]4V'5D\.*]R^H-F-(V/4
M(<$R$C#'(QQG/2JMA!9ZM8_#7[4([@LDD,VXY+ 6['8WJ.G!]?>O49],L+J[
MAN[BRMI;F'_5321*SI_NDC(_"H5T'1T6!5TJQ M_]2!;I^[YS\O''//% '(6
MND:-I?Q26UBLK2"&/18_)0HO#>>P!&>_09Z]*PUN4TKPMJ) \O3%\621WNP?
M*MMYHW X_A^Z"/0X[UZG+86<]U%=36D$EQ""(Y7C!= >H!/(S4<6DZ;;P300
MZ?:1PSY\Z-(5"R9Z[@!S^- ',7]CX>>Q\1SZ<\4KW6G%KA('#0C:C;&P. Q]
M?]FL".QLKV3X91W42.DVGO&X)P)!]F4A3ZCV[Y([UZ);Z+I=K8/86^FV<5F^
M2]ND"B-L]<J!@UA:OX7:[U[P_+:V&G_V7IQF,D#?*#O3:-J!2.#SVH Y.2WT
M_0I?%6G>7(NAOJ%C';6\4GEQK</AG0L00J9V;N. 2,4^40--\1[21[*3.GQR
M+% H""0029(7)^8;5R?8=*]);2M.>P:P:PMFLV^];F)3&><\KC'7FB'2M.MW
M+P6%K$YB$)9(54F,=%X'W?;I0!Y_>0:>N@> 9;6.V5QJ=F&:(*.6A).<=S\I
M_*FSZ+IEYK7Q#6YLH95CAA=%=<A&-N26 Z!L\YZUWO\ 86D>1#!_95CY,#;H
MH_LZ;8SURHQP?I3SHVEEYW.FV9:X&)SY"YE'^UQS^- '!Q7A2'P!>W=Q'/&V
MG$R6TLJJSL84_>C>0I(S@Y.?GXSS70>!M%32=,O) MNIN[R69%A96\J(L2D9
M9>#M![<#.!46M^&KB:^M6LM*T2]TV& QC3KU/+2-BV2Z$(PR0 ,;>W!Y-:7A
MW08M&^TS)9V5B]SLW6UBN(DVYYZ#+'/)P. !CC) ,=;6V;XK:G&T,92;0XC*
MI'#GSG!SZ\ 5R6D6%G;^"/ >IQ0(M\VJ6\9N?^6A1G=2F[KM([=*]6?2M.>Z
M>Z>PM6N)%V/*85+LOH3C)'M47]A:/Y$<']E6/DQ-OCC^SIM1O4#'!]Z ,WQQ
M<65OX7F&H"5H)98HML<GE[F,BX#,00$)^][9KD&$!U/Q]:3/9,KZ7%)Y4 P@
M<1RYP,\L,#)XZ#@5Z7<VEM>VKVUU;Q3V[C#Q2H&5A[@\&JPT/20I4:79 -$(
M"/LZ<Q@Y"=/N^W2@#@+#3[.RN/AS=VT$<=S<P^7/*!\TJFU)PQZL,@8!Z8XJ
M9[$:'KVJ>%;>U"VGB$_:+5DCXCSA;A<]MJ_,O;G%=U_8NE?N/^)99_Z/_J?W
M"_NO]WCC\*HZ38ZQ+?F_UUK'SXE>*VCL]Q559@2Q+<[B%4>V#ZT :PM+9;,6
M@@C%L$\L1!1MVXQC'I7DMC:V\_P[\ ^8@)_MB.,,#@[2\N0".><#\J]>DC26
M-HY$5T8896&01[BJ(T'1Q#'"-)L?*B;?&GV=-J-Z@8X/O0!R.EZ'ILWBKQEH
M0M(8]-FM[0M;QH%169'!8*. > <CN :/!H;48++2+ZW3SO#;O#,3'@-*N4B9
M?K&2Q]RIKM8M.L8+N2[ALK>.YDX>9(E#M]6 R:F2&*)Y'CC16E;=(5&"YP!D
M^IP /H!0!Y;HRZ=KVBVTVHZPEKK5I?EYD1$6Z6X$A&S)^8@\ #IC [5?G,^E
MZZMU/;VNJZ/=:P EU'\MU97!DV;6S]Y PV\<X]L5W(T;3!J?]IC3K3[?C'VG
MR5\ST^]C/2A-(TV.[-VFGVJW!<R&585#%CU;.,YYZT <'I-EI@M?'D36UHLO
MVRX55V*&">3&<#OC//UID,HM_#OP[N))HFMXX4\RTDD5/._T?AAN(4E#SR1U
MXYQ7H+Z5ITDMQ*]A:M)<J$G=H5)E4= QQ\P^M8&O>')YY; :=IVC76G6RN&T
MV\CV1%FQAU(5@" ",;?XC0!SCZ?IND^&M;O+V-/(U/5%\F*VF0;$9TVQNXRJ
MH6!+#D ,:B80-?\ Q!M)6LGW:;#((8% 3S!%+G"DG+#:N3QT' KK='\)V5LE
MVUSH^E6R7:)'+96D8:$A22"V5 8\]=HQBMJ#2M.MI/,@L+6)_*$.Z.%5/ECH
MG ^[[=* //+FWT]?"O@&6UCM@XU*PW-$%!W-'DYQW/!/X5IZ;%::UJWC*TUZ
M.-YHIP@$P'[NU,8V%<]!G<V1WYKJ_P"PM(^SPV_]E6/DPMOBC^SIMC;U48P#
M]*DNM(TV^G2>[T^UGE1=JO+"K,!Z9(Z4 >9Z5:R:G<?#MM;B\ZYGL[L3&4<R
MH$&S?_>^7!(/7)SUKJ/ ,4=K_P ))9VZ+';6^M3)#$@PL:E(SM4=ADGCWKIY
MM.L;BZBNIK*WDN(O]7*\2ET^A(R*+73K&Q:1K2SM[=I3ND,42H7/J<#F@#DM
M/2WU;QIXKL-:@BF,:0K!'.H(%LR<E<]BV[)'?'H*Y?3K0ZA:> !JZ_:&>YNH
M@\O+2P!)-@8]P5"_4'WKU*\TG3M0D22]L+:Y>,$(TT2N5!Z@$CI3I],T^ZEB
MEN+&VFDA_P!4\D2L4_W21Q^% &=JFF65EX,OM.M[:..TBLY%2(#Y5 4G^=<#
M#HMG!X:\!:OI<2IK#S6:&=#EY8RG[Q6/=0H/'8+QBO3-7@GN]&O;:V5&FFA>
M-!(VU<L".2 ?7TK-\*^'XM%T33H9[*SCO[:V2"2:!0=Q"@$AL \XS0!RFBZ+
M:,_C"]MK"*74;'5)Y+#C/ER>0F-H[9)_' ]!5>5(I_AMX;U;2L'6EGM?+F7_
M %DD[.%F5CU.<ON!].>E>D6NFV%C))):65M;O*<R-%$J%S[D#FFPZ1IMO>-=
MPZ?:QW+DLTR0J')/4YQG)H X2VDT36'\66'B6>.*[CU!AF1PDJ0#:83&>H&!
MD8[D^M%V]AJOBCQ#I&MWL-HK6\(MEO$3)@:(;BC/T(?=G'?'I7=3Z/IES?Q7
M\^G6DMY%_J[AX5:1/HQ&11?:/IFIR127^G6ET\)S&T\*N4/MD<4 <$DUFGB.
MTTC4M35K(Z/$+";4(U87'S,)#EN-Q79[D4EDMGINN^%-$DOGO=$$-S]EFN2"
MLTZL HST(52VW\,=J[_4-)T[58DBU&PM;N-#N5;B)9 I]0".*6\TK3M0M%M+
MRPMKBV7&V&6)608Z8!&!B@#S"YM[!?#/Q+MH$@\N.XDD2-,84^2AR!V^;-;-
MUIUE>^-_"J7-O'*LNDS^8K#(D $6 P_B')X/%=DNAZ0L,L*Z79"*7'F)]G3:
M^!@9&.< 4X:/IBRQ2C3K,20KMB<0+E!Z*<<#Z4 >:H@M_ ^L6T$T4%K:>)'C
M2V=PB21"=3Y )X ;..>/7 S73Z!IEO/XRU37HHK:.*6&*.*-7C=PX!W.=A(7
M(*KUYQSVJWKOALS:>D.C66E1K]I6:YM9X L5V #\KE1QS@YP>1SQ4>A^&$L]
M2CU%]&TC2IHT9 FF\F3=_?;8G'M@\X.>* *7BJWL&\?>$Y+R&V*,MX':95P0
M(P1DGTY(KG=2TVQO-$^(UU<6\<L]O=2O"[C)B80(0R_W3D#D<\5ZA=6-I>F(
MW=K!.8G$D?FQAMC#HPST/O4']AZ3LF3^R[+;.<RK]G3$A_VN.?QH X?5+FQO
M[JXCE,+7B: K3R7K!HE1\GY$XRQ/5L@#Y>O2J%G]@O#\-9[T6TX-G*D\DP5L
MD6P(#$^AYYKT@Z+I1E@E.FV9DMUV0OY"YC7T4XX'L*7^QM+^S06W]FV?V>W;
M?#%Y"[8V]5&, ^XH YWXGQ12_#C6#(JMLB5E)['<,$50OM#TM/B/HT*V4(CN
M]/N?M*;>+C:T9'F#^/DD_-FNWN[*UOX#!>6T-Q"3DQS1AU)^AJ+^R=-\^*?^
MS[3SHEVQR>2NY!Z XR!0!YO92:?9Z+=:?-&?(7Q7);65NLGEPJP;>J/P0(Q@
MG&.N,5:T;2;'Q _C;0+J6UDBFNE*"!0%C<PIET7)P0W4YZUW+:!HS6\MNVDV
M!@F8/)&;=-KL.Y&,$^]17]A<6=K-/X>LM,CU&38I:="BNJX&&*#/"\#TH YS
MPE/)X@DLO[0M$CN- 1K:<&/C[5G82OL$7=QQ^]'I4_CV&&XN?"T,XS%)K**P
M)QD&*3C\:Z32;%["S*SNLEU-(TUQ(@P&=CS@>@&%'L!4]W96NH6YM[RVAN(2
M<F.9 ZG\#0!Y?K5HWAN\\6CP[$UOIRZ?;RW$-L,+%*9"'V <*?)R3C'8^E=)
MHEGHDOB*TU;2]7AFEEM#'Y%DB*CQ=0SJO3:< $XQG%=9;V=K9P>1;6\4,/)\
MN- J\]>!4-AI&F:5YO\ 9VGVMIYIS)]GA6/>?? YH YK7]0M[?Q_HMMJS1II
MDUI.8/.P(S<AEQG/&0F[&?[QQ67=+IVFZEX9T^Q<R>'9M3N!,6??$9BA,: ]
M-H<G Z;E]17>7^FV.J6_V?4+.WNX,[O+GC#KGUP:633K&:P^PR6=N]F%"BW:
M(&/ Z#;C% 'F_B"R6WG\=VMO$HTO^QA<O$!\D=UM?E1T#%5#''L:N06%IIWB
MCP//9P1Q3W=G<+/(O#3@0HPWGJV"._2NY&DZ<+)K(6%K]E8Y:'R5V,?4KC!I
M!H^EB2!QIMF'MQB%O(7,0_V>./PH \HNIK+4_@U<:C>B%M7%XK7;R8\U)_M
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M%F"HH5068L< < 9)P.PJ[0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-S=P6</FW$JQID*">Y/0
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M\"N@M?$VGWVD6>HVIEE2\8I!$$Q([C.Y<'H1M;.>!@\T ;%%9ND:Y::S]J6
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M;>%&2.G7MCJ.^*I:IXZ@A\)WFL6-G<R26]Q]DDAE38T$NX+\X)Z LO3.<C\
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M7%MY,#,)$ !X..3@CZ9YQ5$^/](739;XP:AY5O*T5V/LK9M64X/F>F/;/'-
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M[=&D1&,[J@>0^O [XXSBNJU/Q)9Z4EU))%<S168#7<D$>X0 C.6YR>""0N2
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M? F/: =H"[B6YX&._P#B*-1U>WTV:TMY%DEN;QS';P1 ;I"%+'J0   3DD4
M7Z*YV3QKI$.CKJ<AN%A-U]D=?)):.4/L*MC@8/?./3-6;#Q-87]_>66VXM9[
M2,3.MU$8LQ'.'&?X>#UQCO0!LT5P>OZY]MU7PG+9C4(8+G4DVRDE(KB+8QY4
M'UVD;@"1R.];'CV::V\#ZM=VUQ-!<6]NTD4D,A1E8?0\_2@#I**\_P#$&N6<
M/PRGDM-= U".R61'2^)E,F ?[V3SGBNEL]0CL=)TV$BYN[N>W$BQ!M\DF%!9
MB6.  2.20.0.XH VZ*P(/&&E75G;3VYFDEN+EK2.V"8E\Y02R$$@*0 2<G'O
MR*Q/&6MQZG\-M;O=.GNK::T9HGVNT4D4J. RG:>>OJ0<T =U17.W'B*2/QE;
MZ MC.Z263W#S+C^^BC'.<#<V3],5SWASQ3;Z-8ZF-2>_GBCUJXMS<LKRK OF
M[$#N>@Z#OCCUH Z;4M$U&;65U33-8^R2^0('AFMA/$5#$Y W*5//)!YP/2K^
MGZ>UH99KB?[1=S;?-FV! 0O0!1T R>I)Y/-7JX;Q)XCO],\4:?=QOC0[2X6R
MU#_?F7(8^R?NSG_;(H [FBJFHZC;:7:_:+ER%+K&BJ,L[L<*JCN2:Y"UUAH?
MB)K#W U"&VM])CFDMI=TFUO,;+(JEARH7[OH?>@#NJ*YB/QWI$BZ=(8[U+?4
M5!MYVMFV.Q7<$R.K$#@#.3QUJ=/$VG:A8ZNLB7ULU@F+J)H669%920RA<GD9
M((].U '045S%KXHT?3=,T"!6OY(]0MU-F7B>5W41[AN;G+$#IR<FBZ\3Z3J/
MAC6+B?\ M"V@M \%XBQLD\)VY)^7D<$$'I0!T]%8ZZU:V\5K;V\5U=2-:BX$
M:8:01< ,VXC)_,DYJ@_BTMXDTS38+"Y>"\LFN_-VC[OR8 &<\;N?PQGF@#IZ
M*YNW\<:3<SRQQQWWEPS2PSSFU<1PM&NYMYQ\O /7T^E6++Q397UU!;K#=1R7
M-J;NV$B >?$,<K@GGYAP<'GI0!N45P__  EMIJW@74=3U:WU"RL@\L;-;@^8
M%61E&&0D@_*,G@9/7%=-<:O;VL\-G''/=7;PF58(L%_+&!N)8@#DXY/)Z9YH
M TJ1P61E#%21@,,9'OS7/R>-=%CTNUU RS-!<7(M!M@8M'*6VE7&/E(/7/X9
MJWI7B&SU:^O+***Y@NK3:TD5S"8V*MG:P!Z@X/OQSB@#0M;6*SMU@A!"@EB2
M<EF))8D^I))/UJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N:\=V5W?>&PME;/<RPW=O.8H\;
MF5)59L9ZG -=+10!R,:W3_$9-4?3[J*T.CF NT>=LGFA]IQGG;Z9&>,YKF+;
M1M6M/#VBWAT22\?3;^[>YTZ5!NDBF=R&4'@D J<?6O5:* ,3PZL<D4]W#H0T
MB.8KB-X4CFDQGYG"$@=< $YX/K6+<+=0?%0ZM_9U[+8KH_V,S1PDCS?.WXQU
M(QWZ5V<DL<*;Y'5%R!EC@9/2G4 </XDM]1UG0[V/2=)EA-M<07D<<X$9NY%D
M#LH&>!A1UZD_B8TU*75/B+X>N)--N[$&PN\1W:JKYS'G@$\?7K7=LRHI9B%4
M#)). !67-HMM>ZY9ZX+J<S6\3)"$9?+*/@MVYS@<Y[<4 >?K8:S%X+M-!&AW
MSW5AJZS.X"A)$^TF0%"3S\I]@,')'&;'BNTUW6+'Q/8R:/?22/M-AY)583'A
M>6PWS29!&#G'&,#FO3:* .1>.[G^(&DZ@;"ZCMETV6&1V3(C=V0A202,X4],
M@>M'Q(M+O4?"C6=C:3W5P]Q"X2)<\+(K$D]!P*ZZC- &))J337UJUOI%X;@M
MY7G30[%BC)!<DD^BC &><5R,VG:C)X.\;6:Z==?:-0OKB2UC,1S*KJH4CTZ'
MKC%>DTR66.",R2R+&@ZLYP!^- '(W,%U-XM\)726=SY%K;7"7#F(@1,Z(%!_
M%3]*YS2H)M;^&%[H%O:3-<7=W<Q)(T9\I0;AB7+],+SQUR.!R*]3<%D90Q4D
M8##&1[\UFZ%H=OX?L#96LT\D/F/(/.()!9BS<@#J230!SEWH]U=>,[^-(KB.
MUGT#^STNRAVB3>QZ_1@<]*H?V7J6K> ]+\+7&GSVU];/;0S2E?W:)"RDR*_1
MLJG '.6Y Y->BT4 <7XITBZ;Q-IUSIKJAU1&TV_7."8<%_,'^TH#@'_;%6M4
MM)_^$\\.3P6<QL[2"YCED2/Y(]X0(/\ QT].E:6F:)8VNHW6J07-S=2W#N0T
MURTJ19/S+&"<*,@9 ] .U;&: /-Y=.U"3PEXXM%T^Z\_4;VXDM$,1S*KHBJ1
MZ<J>N,5)/;7>E^(4U.?PW/J^GWUC!"RQPH\UK+'N&-KD?*=W7/45Z)10!Q,E
MA<1^)?"4L.C_ &2VM5NS-';1#R[?S% 0';QG/7&1G)Z<UD7ND:I=>%_&-O%I
MUR9[K5EO+>-DVF:,-"<KGO\ NVX//2O2DECD+A'5BC;6"G.T]<'T/(I] %)X
MDUC1Y8+F"6&.ZA:-XI,!PK CG!(!P:YWPLUYX8T"'0]3L[J62RS'!/;0M(EQ
M'D[2-N=AQ@$-CIUQ77T4 >5^(M#NM/\  OB[6;^,1WVK3Q3- &!\J-9%$:$C
M@MC.2.,G\:ZJXLY=;\9:'J<=M/!!I<=PTCSQF,L\BA @!Y..22..!R:U]>T6
MV\0Z3+IEW+-';RD;Q"P!;!! R0>X%7_*?[/Y7GR;MN/-PN[Z],9_"@#RS1;2
M7Q%\(=/T""UG$UQ( 96C(CC1;C>9-_0\ X .<]N]=)ID-]X>UCQ'#<6%S=V^
MH7)O;26%-X<L@5HF_N$%1@M@8/6NAT'1+?P]I,6F6DLSV\.?+\X@E0221D =
MR:OK+&[.J.K,APP!R5/7GTH \]TGP]?Z%>>![1[>:==-M[E;N:-2R1M*HP,]
MQG(X].<5MQ6U[:_$F]NS8S26EY80QI<)C8C(S[@V3D<,,<'-=53))8X0#+(B
M!F"@L<9)Z#ZT >6VUAK,/A#0=&_L*^:YTO5X99VPH1D69FRA)^8$'KP/>MQ;
M6\&J^.)C8702^@B6U/E$^:5A*$#_ ($<<_7I7<T4 >?6UC?I%\/U:PN@=-CV
MWG[L_N3]G,?/K\WIGUK6\-VEW9Z]XEMKJPE$%W?&YCG;:8G1HT7'7).5.1BN
MKJGJFGIJNFS64D]Q DH ,EM*8Y%P0>&'(Z4 <MX.TBZL-2OK.=UDT_2)7MM.
M.<G9)MD(/NH*H#_O"KGC;0;S5K;3K[3 CZEI5VEW!$[;5F ^]'GMD=_:M_3[
M"WTRRCM;<-Y:9.Z1R[,Q.2S,>22222:M4 8UMKDU[$%ATF_ANB,&.ZA*+&?4
MO]T@?[))K(L(;WP_XMUZ:XL[FYL]3:.XMYK>,R8=4"-&P'*]!@GC'>NPHH \
MWTWP[?Z*O@JV>UED^Q7-S/=&)=RP"59,+D=<%P./3-7!9WOF^.V^PW6-04?9
M/W1_??N!'Q_P+UQZ]*[RB@#@-.LKY-5\#N]A=*EAIDEO=,8CB*1HXU /XHW(
MXJM+IVH2>$?&]HNG77VC4+VXDM4,1S*KHH4CTY4]<8KT9)8Y-WENK;&VMM.<
M'T/O3J .--O=2>,O#=V+*Y%O;Z?-%-(8R!&[[, _]\FJ&B:5>6.N6%SI$%_8
MVLYD;4],N5)MXB5)W1$\ E\<*3P>0,8KT!75@"K @^AI<YZ4 <!X<TN[TW6K
M";2H=0LM,FCD?4=,NE)BMGVY'DD]RQZ*2,9Z<5GPZ'K!\-6TT5A.+K3O$#ZE
M]D<;6GB,CG"YXSM?(Y[8KTQ9HW+!9$8J<$!@<4^@#C;JRFU3Q,VO1VMS';VV
ME2VRK)$4DFD=@=H4\X&.I&,MQT-9,&G:A'X7\#6K:?=>?IUW"]VGE',2K&ZD
MGUY8=,UZ110!E:9K+:AJ6I6,EA<VLEDZ@-,!B9&+ .N#T)1OTK)F@O+7XE'4
M18SS64^E);^=$ 0CK*S'=SGHPQ@'/2NGBMXH6D:- &D;<[=2Q]S^GL*DH \O
M72]3'PWAT[^S;O[8NK>>8?+.=GVKS=V>GW?\*O/;3Z7XFU=;SPK)K5EJDPN+
M:XBAC<H2BJT<F\C:/EZ^]>A44 9ESI$>H>&9='N(XH(Y[0V[I;C"1@KMP@]!
MV^E8WARYO= \.VND:GI]W)=V,8MXWM83(EPB\(RL.%R .'*X/MS7644 >:3^
M$M:M-&EUB&W2;69-:76);)7&"BY A#="0K=?7IVK6UU=6\7>$[]++2I]/F B
MD@CO@J2321R*^T@$X7Y<#)Y)[ 9/:T4 <U::CJ'B+3[F-]$NM,W6SQN;T*"9
M",!4P22O4ECCM@=<<O9P:O)I7@FU.@WZ/I%Q&EUO"+C;"R$KEN5[YXZC&:]-
MI"1TS@F@#SG2YI)+'QUIT5C<7$USJES'$%C)1V:)%P6Z+C@G..#QFG2:5J]E
M&F@R6-U=V4.BQVUM+:L%2295*MYK$@XZ8!XP3P378Z/H4&BR7SP7%Q(;VX:Y
MF$I4CS& !(P!C@#CIQ6I0!YS8V.JVUOX"NFT>[)TVWDM[F$;-Z,T(0$C=P,@
M\]N].U+P_J&M7?CNTCAE@&IP6ZVDTBD)(T:889[#.!SV.1FO1** .*NH+SQ,
M/#2R:?<V4VGWD=Y>&:/:(RB,-BGH^YB.5R, Y["L:[TO4IO OC&Q33;LW5_J
M4\MM$8R#(CLI5O0< ]<8KTZF>;'YQA\Q?-"[BF?FQTSCTH X+Q!'K&ISZY9M
MI5]+:SZ8%T\PXC1G*-N\TD@DAB,*<C';-/AM;]K[P'*^FW<:V$,BW6Y,^5F#
MRQG!/5OR'7%=[10!G:Q=7UG;P36-G)>-YZB6&,J&,9SN(W$#(Z]><8[URD>A
M0S?$#3M;T33KC3PB2_VE(\+0)."N%7:<;FW<Y QQU)Q7="1"%(=2&X7GK]*5
M65U#*0RD9!!R#0!Y>+?7KQ/#]W>Z'J#:A9ZMYEV 4$2KB0#REW8V\K\V/J2:
MWX;&ZN/&?B4O;W$-M?V,-O#<F,[2RB0-^6X<GK7949H \_\ "MO<1P:?I.H>
M#4AU"PV*^H/#$8"$X\Q'SN+D#C X)YK2\+:?<0_\)%IFHZ=*L%SJ-S,)'VF.
M:*4\ <Y.03GCBNNJCJ^EQZQI[6<MQ=6ZLRMYEK,8I 0<\,* .;\#Z9>VHN$O
MI1-'IC/IUA)G):%6R6/OPB'_ *Y5=\42:DFH:.+:SN;C3VED%X;/ F7Y?D .
M054G.2"#P.:WK.S@L+..UMD*Q1C"@DDGU))Y))Y)/))J>@#RO^R=53PMJ%A_
M8UXDA\0B[C3 ;=%YX?(()Z*/Q[9K6U[1[[6?$VM+;PSQ17OA\V45RZ%4\W>[
M;3W'##G^M=VLL;R/&KJ73&Y0>5STR.U#2QK(L;.H=\[5)Y;'7 H \[EDU?4;
M'PE"WA[48KG3;^$W:E4"J$C=258M@KSD'I^.*Z7QW;W%[X)U6RM+>6XN;F!H
MHHXUR2Q_E^-;\<L<H8QR*X5BK;3G!'4'WH:6-94B:11(^2JD\MCK@=Z ./\
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MD23;E6^[GC^(CO1_95]J]EJ^@WVEQZ9>ZC#]I^W17GVDO(C(%+Y52,$+@=,
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MP4*0QQQV([$9-<]IWA#Q#I.F^&;J%;*34=%$L#V_G,$GADZ_/M^5N 1QCWH
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M%V@C@Y4C&>X(Z&LU?!VH:;I_A[[ ;:XNM/OI+NX660QI(90^[:0IQ@OQQT%
M%[5O&\6GK?/!!;W(L'"7$?VL)*S  L(TVG?@'N5R015N3Q+)<M=)H]C]N>UM
MDN)5>0Q'YU+(B_*27(&<' &1SS6;!I?BC0]<U'^RUTZZT[4I_M)-Q(R-;2L
M'. #O4XR!D?4=:631_$6C^*;O4]'%G?P:E%$MU'=RF%DEC7:) 54Y!'48H =
M)XBU:?Q5H5I!8I#:WME)=/%<R-'*"-@*L-IP5W=.Y],47OCZUM4%U%##<6(N
M?L[F.Y!G&'V%Q%CE01ZYQSBK%[HVKGQ+HFJPO;7#6UO-;W1D8Q_ZPJ=Z@ Y
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MH0#58K=K6Y)@(BN(BV[;MW97!Y!R??-:.BZ,NDK>2-();J]N&N;B4+M#,0
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M"B%(]R,9&4[25/\ ='7/X5T6CZ9%HNDVVFP2RRPVT8CC,I!8*!@#( Z"J_\
M8,(\12ZVMW<K=26PM2H*; @)88&WJ"2>M '#6^M:]_PA>C^(9=9E>=;]+66
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M7B:!KT&NQK'+&!-Y8<F]WKRK$O\ >!R<XRN#T H [NBO(9H94^'6I:NM]?\
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M?H6D"[LY(KZTMDC*2S&01OL"L4&XJN>>1C@^]69/!_A^;6_[9?2X3?[@QEY
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M2U^U)<1-;XW>:K@ICUSTQ0!RG@;PL-,\+Z7!JEC)%?6A+&.2?S(U?)PZJ&*
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M-D>J6N9&XV*91N.>W%=I6!XLT6[UW3[6VM3;J8KN&Y8S,0"(W#;> >N,?XT
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M:.,*6^N*5K*U>)XFMH6CD;>Z&,$,WJ1W- 'D6I3V<_AWXC0O=6UR_FK<(5
M),4?SJ,G'/&?U-=+=06]AX[T Z9#!%/-I5V,( /-(\MEW>O.3S[UW#6=J^_?
M;0MOP6S&#NQP,^N*!96BNKBUA#)]UA&,K]* /))=3TNX^%&E>?<0#48-0MVN
MEF8"5)Q./-9@>0>6)/H:[[QX%G^'NNL@$@-C(RD<_P ).16V=/LC,\QL[<RN
M07?REW,1R,G'.*L$!E*L 01@@]Z //;U]-U'Q#X#1&MKBW9;G(4AD8B ?@>?
MUK,%UING:?XE@GAC:U_X26-(XQ)Y<43GRB&<CH@8$GUQBO3OL-F-G^BP?NP
MG[L?*!Z>E']GV6QT^R0;)!AU\L8;Z\<T >8RW,-PWQ*A%Y;W4LNFI(OD@!7(
MMW!95R>AP,Y/;FN_\+W%K<^&=.:TDBDC%M&K&,@C=L&1QWK36WA1BR0QJQ4*
M2% ) Z#Z4L44<$2QQ1K'&O 5!@#\* /(=3ALQ\.OB!&L< 2+69C&H PA_=8Q
MZ'K75M;V5C\5-*6SBAA$VDSAQ& -^)$(SCKW/YUUO]GV6TK]CM]I.2/*7!_2
MG+96JR+(MM"'7[K",9'T- '*>*=3BTGQEX;N-3D$6DD7">=(<1QW!"["QZ#Y
M=X!/J:RM7DTNR32;K2@#H,FO>=?S*Y>%G8'#YR1L$A&<?*&%>ASV\-U"T-Q#
M'-$W5)%#*?P-'D0^1Y'E)Y.W;Y>T;<>F.F* //\ 6[6-_%7B22%8VT^3P^QO
M1P4-P"WED]MVP'\,>U4K*WLK6W^&=Q!%#'/*JJ\B@!G#6IR">IYQ7I4=C:16
MWV:.U@2#_GDL8"_ETI/L%E\O^B0?+]W]V./IQ0!Y->6.FCP)\0)EM[;S(=4N
M!$X49CQY9&WTY]*W+S4[&/QE?VNO:K]@MKS3H?LDLOEB*6/#>8NYU(!R0<9&
M>/05WG]GV04K]CM]I.2/*7!_2EEL+.>...:T@DCC.45XP0I]@>E 'GME=Z9X
M;\2Z#!<W<J:'_94D6GW5^P"^9YF3EC@#,>W:3CY>.].U2/0]/3PC)IXCATA-
M8<I+(^8R&CE)(9C]TL3CMZ<8KT.XM;>[B\JY@BFCSG9(@89^AI9((98Q')$C
MHI!"LH(!'3B@#SZ[\Q?&'BTZ,$%])H,;P>4 &:7]YM/U^[^E03FWO_!?@R;1
MRHU"*ZM5AV??0@8G5N^,;]WTYKT=;6W6<S+!$)3UD"#<?QIL=E:PW$EQ%;0I
M-)]^18P&;ZGJ: /,+G3],?2_B6S6MLS1/(8R47Y#]G4\>AW#MW'M7HNC%;OP
MWIYEQ*LMI'OW<A\H,Y]<U9^P6?S?Z)!\WWOW8Y^O%31QQPQB.)%1!T51@#\*
M /))K34+?1;C2+2 M<^$+PWL$C+GS81\\2 ]]T;.#C^X/6M_Q"L&H?#/Q#K$
MT*YU"V>XC$JC*H%Q%UZ' #8[%C7>>6F6.Q<O][CK]::]O#)$(I(8VC&,(R@@
M8]J .$N9K2#QGX0GN7A2.33)U5W( 9L18 /<^E8&H6UC-X+^(=R\4#SQZI<;
M)" 60A8R,'MSZ5ZS]EM\1CR(L1',8V#Y#[>E1_V?9!2OV.WVGDCREP?TH I:
ML;>X\(WQN[AHK:2Q?S9XSRB%#EA[@9-<8)-36#6M'U2&SOKC^PI7MM2LQ@3P
MX*JKIT#9.1C@\XKT80Q"'R1&@BQMV;1MQZ8IEO9VMH&%M;0PACEA&@7)]\4
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MZ<CUIIUS3_L=O=+*\D=RN^%8H7=W4<DA "V!QVXR*\_L?#LFG^'M!M+F[O\
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M%<GXTUB[M)]%T6PF:WN=8N_)-POWHHE&9"N?XL8 ^M7KWPO;OISQ6$]S:76
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M,V ,I4L"OS<@@'DXJM)J>GS^)]%6XT^^BU*:UFDMBY"JBX4NK -@M]WUQZT
M=+17F.OZ_>:_\.?%4T]G<69M)IH8V650!Y;!=I*MDG.2>,<]3786?B>WFU@:
M3-9WEK*;8W,,DZ*$FC4@,5P21C(X8 ^U &]16)9>(UU".WEMM.NWANK=KBVD
M!CVRJ,8'WOE8[A@''?.,$5EZ%XT:\\+V&JWUA<)+?W'DV\<>P^8S.VU0=W
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MTX*@XSR*-=\-ZGJ5CXNOK>QD^U:O;PVUM:ET#;4!^9CNVC))XSG '<X'H=%
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MM(TG*[W>0@DD*3A0!CW)]N<^R\/:E>_"Q-"N[-K+4+2V5("TB,?.C^9'!4D
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M$9&TJ ^$8'<H8^HX]1WE9.J^'-.UBYANKA9X[N%2D=Q;7#PR*IY*[D()'L:
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MQLW84[R #@9R0.N3S7;Z5J]S?:EJ=E=:;)9FSD C=I5<3QMNVN,?=SM/RGD
MCUJ.P\+:;ITB-&U[*L9!BBN+V6:./'3".Q'';CCM6O'#'#O\N-4WL7;:,;B>
MY]Z %=%D1D=0R,,,I&01Z5QO@S1)[-M0@GG\VSL9);#3F!.5A+;FY]0=J?\
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M\AR:XRT\0ZJMGKMA>30G7+.Z6"W"Q;4<28\E\9.0<G=SQM;TKLXU98D5WWN
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MU6STR:8K>7N[R(]C$/M4LW.,# '<UR4OBZ_T >*EU5X;TZ3'!- \<7E;_-!
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M@Q3C^$JDF64C\1ZF@#I;RRM=0MFM[VVAN8&()CFC#J<<C@\5,JJBA54*JC
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MNF00SWE^4\UH+<+F-,XW.6(51GIDY/8&G6NM+/JG]FS65W:W/DM.!,JE64$
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MZ^B@#C/$0TWQ3=P^&7,LVH6MS#-<-'"Z+"@&YCN(QAE)3 )^_P"QKLP !@#
M%%% &#IWAV6P\4:GK9OED;45C66'R=H41@A=IW>_.<_A4FLZ%)JVHZ5>)>"
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MQO!YB.RC"NHW#:V..X/'%6M#UV+75OS';36YLKQ[1UFVY+* 2?E)&/F]:U:
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M&+R'Q#'K<^M23W0LOLCJ;=%1QNW X'(&><9R?4#BNA$T9G,(=?-"ARF>0"2
M?T/Y4^@#D!X'<>#X_#O]J?NDN//$WV?YB?-\W&-V/O?I^=:-QHAB\2?\)%]O
MDB*V8M[F)(@1(J,7!'4CDG@9R*WJ8LT;R21JZL\>-Z@\KGD9H Y/1(M,\0>*
MI/%>GK*8/LB6Z2O&T:S29;+;6 .54[=W^TP[5TU_!/<V,T%M<_9II$*K,$W%
M,]P,CGTJS65K6NQZ(^G++;32B^NX[17CVX1G. 6R<XZ] : )(M*$?AY=)+1,
MBVWV?)B^4KMV_=SZ>]<;JVER>&?!FG:%/K%R;1;A(Q?_ &0.((URP$J\AD)
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M^U"+4<2V^H1+L6ZMWV/M_NGLR^S BBTT"TM=6?57>>YU!X?LYN)WR1'G=M
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MM:NBZ+::#IR6-D9O(C&$$LK2%5'102> .PIUEI,-A>WEU'+.\EVX>7S'W#(
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MT;V?S;XQ)='><3 V[,=PZ$[@#FLZ\FU9M \:7W]NZBLVDWTIM=KJH&V-& (
MY7DC'3D]ZZNW\!Z-;I8H&OG2PE\VU#W;GR< @*O/"X/3OQG.*G;PAIK66J6C
M271AU21I+M?-^^Q !YQQD #C'2@#/MM2EU[Q;+I4T\T%O:Z=#<%()6C:627.
M6W*0<* !C.,L<YXKF_#NH75CH>D:5#+DWVLWL,DLDIB+A&D;&\ [2Q Y SU
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M00XQ\P(.,'BM_P 6WMTG_"1R6FHW4DUCIPFBBMG,2V;!7?=(<X<M@87!X'0
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M2(=0L);BXE1BCSM'M 4,,$=2QQ@\>F:ZY?#]JFJW6IK/<B[NH5AE<2<%5S@
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M79&FC;.5SE0QP/FP1GCGK6O5:PL8--LX[6V5A$F?O,69B3DDL>22<DD]:LT
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M(YX [4 =#KVL+HFG+<&/S))9XK>),X!>1PHR?09R?84_3)-6:2ZCU2"V41R
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MSBLDRJ0G'S<GIR.?>J.I>+M&TW2[746OH);>[F2&!XY 5D+,%)!Z8&22>V*
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M)9-"6YB^V1Q"1@7 Y)P%'J>"<=N/6G:]XAT_P[;037TRI]HG2"-2V,EF S]
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M.Y 7)QTS6G<7,%I"TUQ-'#$O5Y&"@>G)H SI/#&@RO</)HU@[7+AYRUNI,C
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M+"2"2=<@V\3<[6 4?-GD#KP:P_#FH:-JJ^#[2;6M)2325Q'&)L2SDQ[%4HP
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MXHTCQ.0/[1F62W\Q6875N8U4(F.I!!&!SD\5<2>VL/B;8+,GV2.;05@@B?\
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M<8KD=?ABB\-^+KC?&-+N]7MGLP2-KG?%YS)Z@L&Y']TUZ\RJZE64,#U!&:7
MQC% $%K#:PQ$VD4*1R'?F)0 Q('/'7@#FIZ** "BBB@ HHHH **** "BBB@
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M,NMNLBR;5)7(X+@<>_:EU72]0O[/XA0V]C=%[[RVM=T+*)ML2J=I(Y.5(]Z
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M.[.FWKK::=):W"K$=T4ACC # XP,JPST]Z[:PU!KZ2\0V5U;?9IS"&G3:)<
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MB$.!,LA/WMHR !G/IR0 7GO7\1^*-=TF6YU2QBLXX%MIK8O%Y3%6=G8]#G
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M6',K.%*[<=OG&<].:<FL1ZK-K6BW=H(KFS@5I5#B1'216*D' /\ "<@@4 =
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M]G96VL:>D, CF!$;B)TP0%]6R3_.N_HH R_#L=[!H%E!?VR6]Q#"D1C63?\
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M7%:'B[1VU'6-&FL[CR+N5Y+*X ZR6KH6D''0C:"#V)'K7633Q6\9DFD6.,$
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M7TT[?)%L(64DG/)R?F[8Z4 -7Q1)%XKU?2;R2V2&SLQ=Q2*C$LO\0;G&5RO
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M8K$\):+/X=\-6NDSSQSM;[@)8U*A@6+=#TZUMT %%%% !1110 4444 %%%%
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M;(/RY./7WH ]!+*&"E@"W0$]:6N 2XN]4\;>%[HW]Q"MUH\ERT,>S8K'RB<
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M4]0",X_6N'\1:_JVF1ZE>0:CYK6M_#&L%O$K0QPLT:E969<^8=Q.%;(RO04
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M+J'3M1D:2YLD*["6^^%.-RANX![G&*Z)$2*-8XU"HH"JH&  .U.HH Y._P#
M5G?QZQ =2U"*TU63SIK>-T"++Q\X)7=_".,X]JZB",PP)&9'E*C!>0@LQ]3C
MC\N*DHH QT\/QIXGEU[[;<F>2W6V,)V>7Y88L!]W/4GG/>L[3/ ]KI-X3:ZE
MJ*Z;YIF33#*/(1\YXXW;<\[<XSZUU-% ')7'@*UECU:VM]3O[6PU4N]Q9Q%"
MF]A\S*64E<]2 <?AQ4M[X)@N+JRO;75M1L;^V@%L;J!T#31#HK@KM..W%=11
M0!@OX5MVU#2;Q+V\1],\SRAN5A(9!ARY9223]1S5?4/!5KJ%WJ\QU"_ABU>$
M1W=O$ZA'(38&!*E@0.P.#CD$<5TU% & GA6%;[1KPZC>O)I,3Q0[BA#AP V[
MY?0#IC&*FT#3[VP?4/M5[=W,4URTD NG#.BGJ!CHN>@[ >^!LTV21(HVDD8*
MB LQ/8"@"E?Z=)=W-M<0WL]K+;[L>6%*N&QD,"#D< \8Y%9,G@NQ:QM8(;JZ
MMYK:^;4%N(MF\S,6W$@J5P=Q&,>E6-*U^ZU66SECTIQIE[ 9X+L2@[1P0)$P
M-I(.1@M6[0!R5[X!LKR+5[<ZGJ,=IJA$D]NDB[?,  W@E2V?E'&<'TK2/AJ+
M^W+75Q?WHN8;;[+)\RXG0-N^?Y?[W/RX].G%;=% '+:7X'M=(NS]EU/41IHE
M\Y-,,H\A'SNXXW;<\[<XSZUH:+I][97^JRW%[=W%M<3^9!'<N&,77<$QT3E0
M >>">];-% &9KFA6NO6D4-P\L4D$RW%O/"0'AD7HRY!'KP00<U7?PU%.M])<
MWD\MY>VWV5[G"!DBY^5!MP.6)Z'D^PQK7%S#:Q"2>18T+J@+?WF8*H_$D#\:
MA:XNAJJ6XLB;1H2[7?FKA7! ";>IR,G/3B@!ND::FCZ1::;'/+-%:Q+#&\NW
M=M48 . !T'I5?7="BUZ&TBFNKB 6US'=(8=N2Z'*YW*>,UJT4 8<GAI%UFYU
M2QOKFRN+N-8[KR@A67:,*^&4X8#C(_$&JM]X'TZXM-+BLI[G39]+!%I<VKC>
M@(^8'<"&#=\]3^-=-10!SESX0@N$T^1=2OXKZQF:=+T.C2NS+M;=N4J05XQC
M   '%0/X#LGTG6--.HZA]GU68S39="58XW;25[[1US[8KJJ* (X8S# D;2-(
M54#>P&6]S@ 5Y_JY+^+=0DN-0\0:1)B.* VMF;B*X15SN!$;@'<S#;QTSWX[
MFVN+J6]O(IK(PP1,H@F,JMYX*Y)VCE<'CGK5N@#EK?P]<:I9Z==ZC>W*ZI8R
MR/:WOEHDOEMQB1,;?F7&1@=NAK9TW28=.ENK@.\UU=N'GGDQN<@!5&    !@
M ?S)-:%% &7H_A^PT."[ALX\1W5Q)<2*W(RYR0/1?:LO1_!%OHLX6WU34FTZ
M-S)!I\DH,,39R,<;B >0"<9YYKJ*B:YA6Z2U,BB>1&D5.Y52H)_ LOYT 9&F
M^&H]+M=3@BO[MQJ$\EQ(S^7E'?[Q7"@?@<U53P5;1Z7HNGKJ-Z(=(F2:W/[O
M<64$+N^3D88^E;=E<74[70NK(VHCF*0DRA_.0 8?C[N<G@\\5;H YW_A$8/(
MUR'^T+S;K)8W'^KRN4V';\G'R@#G-./A2$RZ')_:%YNT8$6_^K^?*;#O^7GY
M>.,5T%5);W-K>M9(+NXMMR^0KA=T@4,$W'@$Y'/;- &#:^![6QU&>:UU+48M
M/GF,\FFK*/(9R<GC&X*3R5!P?IQ5@^$H"==SJ%Y_Q.ABX_U?R_)L^3Y>/EXY
MS6Y;/++:Q230^3*R!GB+!MC$<KD<''3-2T <\OA&WCFT::._O4ETN VR.I0&
M6(A05?Y?]D<K@^]= RJZ,CJ&5A@@C((I:* .;M/!MI:646F_:[F728)A-%92
M;2JD-N5=V-Q4-@@$]ADD<5<'A]%\4/KPO;GSWMQ:F+Y/+\L-N ^[G.2><]ZV
M** ,.P\-)ITVJRQ:C>,VI2&67>(_E8J%RN%XX ZYZ50?P%8G0=,TR.^OHI=+
M;=97J.HFB[$9"X((X((YKJZ* .=O?",&H>'9M(NM1OI/M#K)/=%D,LA4@CJN
MT#Y1P .GN:;>>#K>\U&^NSJ5_%_:%LMM>11,@68*"H8_+E3AC]TBNDHH YR+
MP?!%_81&I7S-HJD6Y8QG?E-GS?+_ '>.,?GS71T44 <KI/AR"WT"\\)WT#2Z
M<3*(&YPT#L6"Y[,I;'X CV6W\%^5<:3-/KNIW+:4S&U\SRN 5VX8A/F^7C)Y
M^E=(MS"]U);+(IGC19'3NJL6"G\=K?E4M ',3>";6?3M:L7U&^\K6)C-<D>7
MD$@ A?DX&% []*M:SX6MM;TNTM+B[NDN+-UDM[V%@DT;@8W @8Z=1C%2^)-=
M_P"$=TM;XVCW*F:.(A7"[=[A03GW8=!6Q0!S=QX,L[_0Y=.U&]O;R65UD-[)
M(!,CKRC(0 %V\X '<]<FI8_"L3Z-?:?J.HWVH->P&WEN)W7>$((PH4 #KGID
MGKGBM^JAN+K^UEMA9$V9@+F[\U<!]V-FSKTYSTH R7\)I*FD"75;^1]+E\V*
M1O+R[;2OS?)C&TD8&/7KS5.1+7Q3XFL93IMW&-%N)6,]S 8PSXVJJ9^\"</D
M?W%]:ZVL>UUW[3XIOM$-H\;6MO'/YS.") Y8# '3[IZT ;%8L_AR,ZY-J]E>
M7%C=W$2Q7/E!668+]TD,#\PS@'TZYK:JC<Z@_P#9MS<:9 +^>$LBP+($WNIP
M5W'@<Y'X4 9;^#K+;HZ6]S<VT>E2&6!8RIWN00Q<LI))W-GIUKHJ122BEEVD
MCD9SBEH Q6\.1G7;W5EOKI9[NV%LRC9M5 21C*YR"QZD]:I)X)M8](T;35U&
M^$.DSI/;G]WN+*"%#?)R,,?2NGHH Y6Y\#6\CZNMMJ=]:6FK!S=VL10HSNN&
M<;E)4GO@\U:7PI"EYHMR-0O2^D1-# &\O#*RA3O^3DX Z8Z5T%8%MXCGOKF)
M['3'N=.>ZDM7N4E :-D)4N4(^YN4C(.?:@"32_#-KIMOJ=NUQ/=P:E/)//'<
M;,;I.' VJ.#Z55T/P=%H;QHNJZE=V<&?LUI<RAHX>,<8 )P#@9)Q^M7==UW^
MQ)=,0VCS+?7L=GO#A1&7S@GN>AK8H YC2/!-MHUQMMM2U Z:DIFATUI 88FS
MGCC=@'D G&>>:G7PG;QG6A%?WL<.K,[RQ IM1W4*S+E<Y( ZD@=A7044 <AJ
MD4&G>'X?!\=G?Z@;BR-K [0;HPH&P>8Z@!<#!SUX]<5NQ0)H6A06EE \WV>)
M88(QU=@,#)[9[D^YK2HH R?#.BCP_P"'[73O,$DJ O-(!]^1B6<_3<3CVQ2:
MGX?AO]4M-5BN);34+56C2>+!W1MU1@00R]_4'H:UZ* .<O?!MG>Z1/8-=W<?
MVBZ6[N)TV>9+*&# G*D #:HP . !71("J*K,6(&"QZGWXJI?:C'9/;P[?,N;
MERD$0."Q R23V4#DG^9(!IZ5KIU/6=8TUK1X'TUXT9F<-YF]-X(QTXQ0 M[X
M?AO-?L]86ZN;>YMHF@(B*A98V(8JV03U4<@@^]45\%V<=O>6$=W<II5W*99;
M ;=F6.653C<JL>H![G&,UL76I1V5Y;0W"E(KEO+CFS\OF<X0^F<<'N>.#C-V
M@!  H    X ':N3N_ -G=P:I;?VGJ,5KJ%S]K:"-TVQS;@Q925SR5'!)'MTQ
MT5G<74\MTMS9&V6*8I"QE5_.3 ._ ^[R2,'GBK= &)!X<2WUNXU9-1O#<SVR
M6S;MA 5<D'[O7))_&K'A[1(?#FB6^E6T\TT%N"(VFVE@"<XX '?TK3HH PK[
MPQ#>Z]_:Z7UY;2O;?99XX64+-&"2 <J2#DGE2#[U3A\#6EOI>CV<6I:@CZ3(
M7MK@,A< J5*G*[<;3CIGOG-=310!A?\ "*V1U;4[UYKAXM3B6.ZM&8&*3:GE
M@GC=G;QUQWZXIECX4@M8M/MYKZZN[73G#VD,^W"$ A22 "VT$@9_') -6-,U
MW^T==UC2S:/"VFF(%V<'S/,4L" .G K8H QM*\/)I$FIR0W]T[:A.UQ)Y@0[
M)" "5PH[ <'/2L^/P-:0Z%I>D)J-\+?3;E;F!OW>XLK%E#'9@@$GM70:C/<V
MVGSS6=F;RY1<QVXD$?F'TW'@584DJ"1@D<CTH YB;P3;G6KG4;35=2L5O"&O
M+:VE"QSL!C=TRI(ZE2#]*AUJ&S\27\/AQM+NC'97,4\D[P%(511NPC=&S]S
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MF]FQGW8DU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^M]9,'VZ-Y$5)\ BV$0\K;GMG<>.YSWKJ?!$D<O@303&ZN!I\"G:<X(C4$4
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M4GWA,H+@C=]S([@"@#TL'(R.E%8OA.RM-.\,V=G87<]W9Q!EAGG8,SIN.,$
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M@;L\XQ^E &E=V=K?V[6]Y;0W$#?>CF0.I^H/%,M]/LK3?]FM+>'> &\N,+N
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M5'_8VE^4D7]FV?EHVY4\A<*?4#'!J,^(-*%XMH;U/-:8VZ\':91UC#8V[O\
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M$BPZD8+8S;5(3RT./E X!;J?7K74_P!M:=_:D>FB[0WDD?FI$,DLG]X>WO0
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MGBC$KQALL%)P#@?RZT :,\$-S"T,\22Q-]Y)%#*?J#5=M(TQXXHWTZT9(O\
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MB=9E6-!(%]> R\=SBO4Z* //;G7=/UKQ;X,O+!)FBC:Y$@%N^82T.-K<<'.
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MQ()"WS_,3G!&,9_#MFC2M9/PKL-$;1KI;ZUFMU:/<AW".8,S AL8P.,\GTH
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M.*SEE \MYDWG!YZ98=>*H:78ZJWBGP]JDNC7Z!;.:"\FN94+B1MAR1N.%X;
M'X*!0!O#QOIQT6VU86U[]FN+K[(,HH9)-^S#@M\HW<9/X]16U'?K)JDM@(90
M\42RM(0-F&) &<YS\I[=O<5QEYX+NM0O_$&ER$1Z+>?Z; P/*W3J5/X*R[_J
MR^E='X5MM0BT2*XUA0NJ7(62Z Z!MH4#\E'XYH DU3Q'9Z3J=AI\\5T\]]O$
M(BA+ E%+$9]<#]>PYK,/CVP%C>W/]G:INL'9+R$6XWVX !+-\V,8.>"21VXI
MVOVMW-XP\+W<%I-+;V<MPUQ(@&$#Q%%[Y/)[5E'3]1,'CM?[.N<ZEN^R# _>
MY@$?KQ\P[XXH Z.Y\36<4T4-O%<7LTMH;U4MPN?)X&[YBHY)&!U]JB'B_3G&
MBO%'<R0ZQ@6LRH F2,[6)(VG /'?'&:P(8-;!TBQN-)NY=.72$A,<;HFVY'#
M"4[@2@ &,9!YX/&&6FA74GPAM]/OX7TV_P!.@$L,DK+F*6+YE?()P,C\LT =
MK!J*3ZG=6*12AK94+R$#9EAD '.<X[8]/44R^U:&RNH+,1RW%Y<!FCMX<;BJ
MXW,2Q  &0,DCD@57\-V]S'H\=Q?H$O[P_:;E1_"[ ?+_ ,!4*O\ P&L?6+;4
MM-\>V?B"WL9K^RDL&L)X[?!DA/F;PX!(R#T./2@#!TW5+*+P=XLN-8.J&Q36
M)HV59',\:CR\+NW9&#Q]['O7;WVO06,]Q;I;7-U+;6XN)D@"DHAW8.&8$D[&
MX&3Q[C/#7>D:U<^"O&-D-&NEN=1U&2:UC+1DNK%/1N,;3UX],UJ^*=)?5;U[
MRULM2L]5AM%^PZA9G#,QW'R9!G&W./O#'S'F@#H[WQ!;VCR1QV]S=S0P"YFC
MMPI:.,YP3N8#)P< $DX/%8&H:C%J/BKP/J%C<S&TO3<,%#LJNOV=B,ITR/<9
MJ*)?$/A[Q//J,NDS:K#JEI;K.;)D#0W$:E2,,0-AR3G/%7=5MM3N/$OA.\>Q
M=A:23R71AP5A#Q,JC)(+8) R!VSQ0!HWGBRQLXKNX,-U+964ABNKJ) R0L,;
MLC.XA<\E0<<^AQ+=^([6W>98(9[TP6RW4OV7:VV-MVT\L-V=K8 ST]QGF+/3
M-5TSP_XA\./I\UR]U+<FRN%P8Y4FR1O;/RE2QSGMTS4.I^%I(;2VM[2#48=6
MTW3HH+'5+)L><RJ1Y<@SC;D _,,88\]: .OO]?ALO.6.UNKMX(1/,ELJDQH<
MX)W,,DX/ R>.E7--U&UU;3;?4+*42VUP@DC<#&0?Y5PUQ8:KI?B674+_ ,.)
MKL&HVL E-NL;-;SHNU@ Y'R-USGBNXTR%H-.AC>V@M6"Y,$  2/)SM&../7N
M>: .)U/Q%=ZWX2\9;K.[LO[.^T10RK,%*F.)3@E&SG))],<9K;T/Q-:R/I>D
MRP7D4\]F)()IHL1S[57=M.<DC.>0,]1FL*;3-6BT;QSI@TJXD?49[B:UE1DV
M2"2)54#YLYR#G( &.M77LK^37?!DXL+@16-M-'=,0!Y3-$J@'GGD'IF@#8F\
M6Z?;R6K2Q7*V=U<?9H;W:ODM(20!UW $@@-MP?7&*O:[J;:-H5]J2VSW)M86
ME,2, 2%&3R2../KZ ]*XGPQIE]I<$&@7WA*"6>T?9'JI2(PO&&R)"?O;\=L9
MSW';M/$-G-J'AG5;*W4-/<6<T48)QEF0@<_4T 9$7C.&WT[16U&RO4NM2C'E
MK'"&#OY>[C:2.><#KZ@5*WC2S6WDD_L_4O,@M/MES T*I);QY89=68<_*QP,
MG ]QG$^S:I,G@IVT>[C_ +.D'VE6V$H! 8\\-_>/0<X&:G\26VM7^IZQ9-IM
MQ=6,VG[+$PR*D0E*L&\W+ DY*X&"/;/- '1R:_9[;$6RRW<M]%YUO%"!N:/
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M EN9E9Q(&<_O#N)R<CUX].E $B^.+\^&_#VH'2)S+JMQ!$2&CV@/\QV_/GD
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M* "BBB@ HHHH **** "LK4_#]CJ]]:W5YY[&VSMB6=EC?)!PZ@X89 X-:M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5G:QHMMKEM%;W4ERB1RB4&WG:)B0",$J0<<GBM&B@".""*
MVMXX((UCBB4(B*,!5 P *DHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q-&\0
MG5M:UK36L9+9]+ECC)=PQDWH'!P.!P1W-;=<=X7(_P"$_P#''_7S:?\ I,E
M$LOCB*.TNM5%H#H=K>?8Y;SSOF!#A&<)MP4#G!.[/!.,#GK*\:%M-!\!=5T%
MD+:FEY-IYA_B>9[G*@>N0ZM]#FO88(S%;Q1LVYD0*6]<#K0!)1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 55M],L+2XEN+:QMH9Y?]9+'$JL_P!2
M!DT44 !TVQ:^%\;*W-V!@7!B7S!QC[V,]*M444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex109keyexecutivebenefit011.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF16"GCK@'^76N7M=.U>STW2=1CTR\E.FZU=7,]GY1$CPRLX#HI^\0&S@<\T
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MSPKXC/B2PFNC:36X6XEC42)CA7*CGIGCG'2LF:*XE\6^$;E+.Z\FVM+A)Y#
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MFVX..!R!G/0 Z:D9U3&Y@-QP,GJ?2N;F\7;[476GZ?)/!_9XU!I9V,*;#G"
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M1O4@?-PZD=/TY .[HJ&)YVM@\L*)/@YC63<,]OFP/Y5R.A^+[IO#MQJFKVZ
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MD=Q6A10!E:?H:V4JRSZA?7\L>?+:[D!V9&"0%"C."1DC.">>36K110 4444
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M7"D;1QE>3^0-:36/B/5/$7AW4KW3+2V6Q6X2Y N]V?,15RN%Z<9 _/'?M**
M.*\-:=XJT."'P^\-E)IMLVV'4O./F>3G(4Q;>7QQG.!UYQSTFMPSW&E20V]I
M!>%V0/;W! 22/<-X.01]W./?%:-% 'G?_"#7\6EZC%I$AL$6[@O=+L[B7S$@
MECY8'!.%8]@3CK[5J7^E^(/%GAG4-/U:"UTIY80D20S^=F4,&#L=HP,J.!GJ
M<]J["B@#G-,F\47-L?[7L+2V>*(J5M[CS#<R8QGD (O?&2>GISD6_A357^&=
MCH9>*UU:P\N2"3=OC\R-PZDXYP<8Z<>]=U10!S,47B/6]'O[;5K.STYI;22W
M6.*<S;W9<;R=HVJ.PY/)STJM97/B#0="\/6<NF6CE6ALKD+<DLJ@*@=?E&3U
M8CL!]<=?32BEPY4%ER <<C/6@#'\5Z-/KWAVXL;6<6]UN26"5AD+(CAUS[94
M57TZZ\536TDNHZ996\T41"00W6\7$G8EBOR+[<GGVYZ*B@#C;/0M6T?Q);ZG
M9*)H[^+_ (G$<DH7,O59(QZC)7'3:!WYJ/1=*\3Z!+=:/:PV<NE2W,DUO?-,
M0]NDC%F4Q[3N8$G'('KZ5VU% '&1:?XGT+7]3_LJULK[3-2N/M(:>X,36LC
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M*@9W'/%7J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9GT/5[*/3=3V"6U&XLDZ%=P(SCG!!]Q]*;\.?B%%KNG2:;K4\5OK=AF.?S'
M$P7C>#TSQSCZ]#5+6_",?C#P+HFK:'<(NN:=:1-:W$+C+%5!,9([YZ>A^IH
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M1U]Z[*:/PS9>.O#MC>032^(8[$I9W 5MH158'/.,X#]CU^E ':T444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOL1B)L#>!@'++^8KV&B@#RGP%J.K>$-;N_!NKPW=SIL#D6&HK [1J#SL9@,
M<_@<CIC&1#I%IJ7Q.\6R:K:72V%U$/LMU]FD*^8I3#*0.<$9]\5[;10!E:/K
M2ZQ'>3I;SPVT,QBC:>)HVD 4$N%8 [<D@<=C7G/P^T]=.^)WB?;9SP6$DC-9
M%XG6(DM\Q3(QT].W3BO6Z* $=U1&=CA5&2?05XCX'TNR35]?O-9L[RWDCU9+
MVRF:TE)8*[$[<+SD<?C7M]% ',MXL+Z-!=)97,<]Y,T5M%+;N-B[RHDE&,JN
M!NYQP0.M<%;V-[\,OB(GV"&[OM U9 ;I88&?R'S]_"# Y.<#L2,<"O8Z* /(
M/%UK#J/QHT.ZN+*XN=(2P,5S*MO(T:DB; )4?[2_G717%E#X@\)WO@S3%N%@
MMM-2%;N>!XT,@QY:@L!G[GS$9ZBN]HH \]^'NL#0_"EMH6NVUU8ZE8%HC&]N
M["5=Q*LA4$/P<<9Z4?%/3-0\3?#B06%A.;A)EG%L5_>,BDC[H[X.['7MC/%>
MA44 <A:ZM;Z]HNE6=@EPTWF6LDRO Z>0(W1VWE@ #\F .I)XXR:H?&*&:[^'
MUU:6L$T]S++%LBAC+L<."> /2N^HH Y[3)E3X?VI<.I33D1E*$,&$8&W;C.<
M\8KF/@G;W%CX(DM+RWGMKA;N1S%-$R-M(7!P1TKTBB@#S'PUX1O]&^)&N6T:
M[?#LK1:BBX^5I26VH/3:VX_\ 2H_C=;7%_HFDVUI:W%S*E\LKI!"TA"!6!)P
M#ZUZE10!R&D76EZ1J*Z9HMM<NNI7C7#_ .C2K';CRQN)9ACDIP,]6]*Z^BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>X@MH_
M,N)HXDSC=(P49^IJM_;&F?\ 02L_^_Z_XT_4I88+":>XMS/%"ID9 H8X R2
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MW_[]+_A0!'_;&F?]!*S_ ._Z_P"-']L:9_T$K/\ [_K_ (U)_9]E_P ^=O\
M]^E_PH_L^R_Y\[?_ +]+_A0!'_;&F?\ 02L_^_Z_XT?VQIG_ $$;/_O^O^-2
M?V?9?\^=O_WZ7_"D:PLU0D6,#$#(41KD_G0 S^V-,_Z"5G_W_7_&C^V-,_Z"
M5G_W_7_&N;3Q;X;-C/?R:;-%8V\[6\UP]F"D3J=I#8R0 >,XQ73)9:?+&LD=
MK;,C ,K+&I!!Z$4 -_MC3/\ H)6?_?\ 7_&C^V-,_P"@E9_]_P!?\:K:L^F:
M-I=QJ-Q8(UO;H9)3'"I*J!DG'?'M5*#5-,G2SE_L2=(+LH(IFM4V?-]TG!.
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M$E(Q", ;5P.G&>?6KE4[+3+:PGO)K<.'NYO.EW2,P+8 X!/ P!P*N4 %%%%
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MA?\ L&/)FA,@(\]NP=?YUW=8TWAC3)]8DU9A=+?/$(6ECO)4^0'(7"L!C/-
M'-^!GDM_%WBNPU$"36?.BGN+B(_NI(V3]V%7JF%XP23[FJ]OI;:?X_NO#$$H
M&B:C"=6>WQ]PAPKQKZ([%21Z CO7:Z7HFG:,)S8V_EO</YDTK.SR2MZL[$L?
MQ-,?0-/?7DUMDE_M!(O)63SWP$SG;MSMQGGI0!/?64EY):-'>W%L()Q*RPD8
MF !&QL@_*<]O2KE4[[3+;49+22X#EK2<3Q;9&7#@$#.#R.3P>*N4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!4U)KY;%CIRPM=%D"^=G8 6 8G&"<+D_A7,VNL^)+SQ'K
M.C12:5YNG10R"1K>0"4R!B!_K/EQMZ\]:[&N'T"[MW^*OBM$GC9G@LPH# [B
MJON ]<9&?2@"_'KVJGQM;:'+':I%)IOVZ0[&WJ0X0IG=CJ>OZ54NM;\366L>
M'],N#I2SZMYH;;!(1 4CWD??^;T[5'+=VP^--NIGB#?V(\>-X^^9@0OUP"<4
M>*KNWB^(W@L23QJ4DNR^Y@-N8<#/ID\"@"QK6N^(-%ATE94T\S7NJI8,1&^W
M:^2L@^;/0<J>_>NMQ)Y. R^;M^]MXSZXST]LUQ/Q(O+:V/A<SW$<>S7;:5M[
M ;4 ?+'T [GI70Q>*-&N;V.TM-1M;J5E9W\B97$:*.68@X S@<^M &/X>UO7
MM>TBYOO/TNV,-Q-!M>V<@^6Q7);S!@''IQ73078V6L5V\,5[-'N,&\9) &[:
M.X!->9^$3X<N?#6HKJ.L);NVHW3[3J+1C'F$JVS> 1T/3GWKO(]2T6\U+2I9
M(XQJ%U!)+8F2']YY6 6(./ER"N02#0!!XVUR\\-^%;O6+-())+;:3',I(8%U
M7J",=<]ZKKXCOM/\76.@ZM%;.-0@DEM[JV#( T8RRLC$XXY!S^%4_BQ+&GPV
MU9'=5>01A%)Y8^8G '>MFWT31?M)UMB+J0P&,7-Q.956+J0NXD >I'7O0!I0
MZGI]PY2&^MI'"&0JDJD[,XW<'ID8S1;ZE87<,DUM>VTT46?,>.565,<G)!XK
MRS2[6"+X/66HZ?9I)<P2(;QK>-6G:!;@-(F<'/R@':>,#IBM:5O#.M6>K:M:
M:U>2+<VT4%SJ"* D6)%\LL-J@L"<GN%R#C(H [2\U**?2+N;3-3T]98T.V>6
M0/%&W8O@]/QJQ<7UO9VBR75Y;0;A@22N%0MCMD_CC->:ZO>7-SX*\8VVKC3[
MJ:"V0)J5J,1W9*MM^7D"1<#(!_B'M6NFL6MAX\MYM5N8HK"XTB--/N)& B+[
MB9%#=-Q&SZ@"@#<\*^()-4\++JNJ36L+>=-&\B'9& DK(#R3C@#O6RFHV,EO
M%<)>V[03,$BD$JE78G "G."2>.*\ETG48M+\/>';QY9K?1[74KY+F6&('[.S
M2/Y3,I4X&"1G'&ZKVL6WA]=*TZXLI3<6MWXCMYS/<8VR%F'F,G &SU(&,YH
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MM<>4JJX#DEF*C,@&/TZT>#M:L]+\'V.GZM<16%]IT(MKBWG<*X*?*" ?O!@
M01G.>* -KPUX@B\1:8]RL303P3/;75NQR89D.&7/?U!]"*V*Y#P!I=S9V>KZ
MC=0O VK:G-?1PR##)&Q&W<.S$#)'O77T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<?XFUWQ!H.G2ZB$T[R?MB6
M\4+Q.7*M($#%@X&><XQ785Q/Q2GBB\)1K)(BLU];$ G!($JD_D.: +FN:MX@
MT'0=8U&8:=-]C@6>%DB=1)][<I&\D$87!SWJP][K[Z?'=Q-IZ1BR%Q(SPNVY
MR"=J@.,  #DGO5?XB7$/_"N=:;S4Q+:,L9W#YR1P!ZU=2[MO^$'6X\^+R?L'
M^LWC;]SUH H^&]7\0:YI&E:JXTY;>^B+R(D3AH<J2IR7^89 !Z=:L>"];O\
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M<YHHH **** "D  &  !2T4 (  ,  #VH(!Z@&EHH 3 QC QZ4O2BB@ HHHH
M3: Q; R>IH  )( !/6EHH 0JI8,5!(Z''2EHHH *0JI() )'0XZ4M% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 '2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K$T;Q"=6UK6M-:QDMGTN6.,EW#&
M3>@<' X'!'<UMUQWA<C_ (3_ ,<?]?-I_P"DR4 :S>(2OC6/PZUC(OF6+WBW
M)<;2%=5VA1S_ !=3CIWK;KCKDC_A<>G#_J!7'_HZ*NQH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JMOIEA:7$MQ;6-M#/+_K)8XE5G^I R:**
M !M,L'OA?-8VS7BC N#$ID _WL9JU110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex109keyexecutivebenefit012.jpg
<TEXT>
begin 644 ex109keyexecutivebenefit012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>@.B0G'_ (]74:'9:AI^EI;ZGJ*:A<JS$SI;K "">!L7@8H T:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT*WS%I[;?F$GGHI''4]*;;>#++3HKFWTJ\O=.L[DLTEK;LAB!;J5#JVW/HI
MKHZ* .8B\!Z);^$Y/#-LMQ!ILI)E5)<LY)!.6.<=!TQ0G@>RCT6'1UU'4_[.
MA 5;<3@ J#G:2%R1[$UT]% &/XD\-V7BK2SINHO.+5F#,D3!=Q!R,G&?RJ_I
M]DFFZ?!91R221P((T,A!;:!@#( SP*LT4 4)-*276H=4-S<"6*)H5C##R]K$
M%N,=257G.>*S+[P7INH>*;;Q')-=1ZE;*$B>)PH"C/!&.1\QZYZUT5% %&QT
MQ;&YNYUNKB5KJ3S9%E*D!MH7(P!CA5&/:H%\/V,,NIS6H>VEU+:;AX2 2P!&
MX9! )!Y/X]>:U:* *<&F01Z2NF2[KFV$7DD3X;<F,8/ SQQ5&?PII%UX67PW
M<6YETU(EB5&8Y 7[N#UR,#FMJB@##TSPO!IT=K$^H:A>PVF/L\=W(K+'@8!^
M506('3=G%7;?2DM]7NM1%S</+<JB.CL"@5<[0HQD8W-W[\YJ_10!S=KX*TZR
M\477B*WN+N/4;I2LS!UV., ?=VX[ _45%I?@2PT2[O[K3K_4;>:_D\RY82J?
M,;).<%3CECTQUKJ:* ,_1](M]$L3:V\D\@:1Y7DGDWN[,<DD]ZS8O!NGP^+)
M?$J7%W_:<J>6[EUVE, ;=NW&.![\5T5% %'3=,731.$N;B832M,WG%3AF.3C
M &![4RQT+3M.74$MK9%BOYFGN(B,HS,H5N/0A>1ZDUHT4 <WIW@NST9)(-)U
M#4K&R=RYM(IE,8)Z[=REES_LD4:_X(TCQ'I5MIE[]H6RMW\Q(HI,9?!&XL02
M3\QZGG.>M=)10!B?\(U%)?6=U<:EJ-PUFV^*.25=F[:5R5"C) )QFKNG:8NF
MB<+<W$PFE:9O.*G#'KC &![5>HH H:;HUCI#WK6,(B%Y<&YE4=/,*JI(';.T
M'ZYK-LO!NGV/BFY\1Q3W9U&Z3RYG9U*NOR\;=N!]U>G/%=#10!SVN^#M.\1:
MII^H7TUT)]/?S+7RW"B-LJ<XQSRJ]<]*U[_3[?5-+N-.O 98+B)HI,]2",'\
M:M44 06MG#96$-E:KY4,,8BC"_PJ!@8KG=.\"6&D7VH7MA?ZC!<:B_F73K*I
M\QLDYY7CECTQUKJ:* *&CZ3!HMA]DMY)Y5,CR-)/(7=V8DDECUY-7Z** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWF1,K,&!X /R-D>W&:DLO%<MSJEA93:5);#4;5KBSD>92'*A2RL!DKPP(/Z
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MHR]G&FM11K;,)68H4C"?.-HP#C/!-7[C2-9O==\-ZE-'8(-/\XW*+.Y_UB;
M$^3YL=><4 2VGBIKFRUB1K#RKK3;G[,UL9LM(_R[<''1MPV^N>U1:OXSATO[
M:JPPSR:>JM=1?:E1\E0Q6-2,N0I!_ASD <Y EF\-.WC5-9CF"6DL"_:K?_GK
M-&?W3?@&;\56JDFD>)-+\3:A>Z(^G36.ILDDT5XSJT$JJ$++M!W A1P<<CJ*
M .HM+F.]LX+N$DQ3QK(F1@[6&1QVZU-3(4>."-))#(ZJ SD8+''7%/H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6H:-I>KJ@U
M+3;.\"<H+F!9-OTW XJS!;PVL"06\,<,*#"QQJ%51Z #I4E% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5B:-XA.K:UK6FM8R6SZ7+
M'&2[AC)O0.#@<#@CN:VZX[PN1_PG_CC_ *^;3_TF2@!+_P ;7^EWEK->^'98
MM#N;E+9+_P"TJ74NVU':'&0I..<YY&0#Q795QNKZSH6L:A';76K6$>GZ;<+-
M.'N$!FFC.50#.2%;!/\ M #GYJ[*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *J6^F:?:7$MQ;6-M#/+_K)(X55G^I R:** *B>%O#T<BR)H.E
MJZG<&%G&"#ZYQ6M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079273920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIFEVANTAGE CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-0224471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3300 N. Triumph Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lehi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">432-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,479,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s fiscal year 2025 annual meeting of stockholders are incorporated by reference into Part III of this report. Such definitive proxy statement will be filed with the Commission not later than 120 days after the end of the registrant&#8217;s fiscal year ended June 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000849146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080986368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Salt Lake City, Utah<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080149968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,886<span></span>
</td>
<td class="nump">$ 21,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">16,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,646<span></span>
</td>
<td class="nump">44,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,813<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">9,569<span></span>
</td>
<td class="nump">8,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">4,268<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">60,299<span></span>
</td>
<td class="nump">66,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Commissions payable</a></td>
<td class="nump">6,569<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">7,874<span></span>
</td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,309<span></span>
</td>
<td class="nump">19,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">11,801<span></span>
</td>
<td class="nump">11,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,308<span></span>
</td>
<td class="nump">31,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies &#8212; Note 13</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock &#8212; par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $0.0001 per share, 40,000 shares authorized and 12,510 and 12,622 issued and outstanding as of June&#160;30, 2024 and 2023, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">136,644<span></span>
</td>
<td class="nump">134,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(108,738)<span></span>
</td>
<td class="num">(98,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,916)<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">25,991<span></span>
</td>
<td class="nump">34,649<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 60,299<span></span>
</td>
<td class="nump">$ 66,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080299280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">12,510,000<span></span>
</td>
<td class="nump">12,622,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">12,510,000<span></span>
</td>
<td class="nump">12,622,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074376016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 200,164<span></span>
</td>
<td class="nump">$ 213,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">$ 41,440<span></span>
</td>
<td class="nump">$ 43,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">158,724<span></span>
</td>
<td class="nump">170,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_CommissionAndIncentives', window );">Commissions and incentives</a></td>
<td class="nump">85,920<span></span>
</td>
<td class="nump">94,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">68,472<span></span>
</td>
<td class="nump">71,065<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">154,392<span></span>
</td>
<td class="nump">165,752<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">4,332<span></span>
</td>
<td class="nump">4,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest income, net</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 2,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">12,458<span></span>
</td>
<td class="nump">12,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Diluted (in shares)</a></td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">12,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (555)<span></span>
</td>
<td class="num">$ (238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss, net of tax:</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 2,382<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_CommissionAndIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to commissions and other incentives earned by independent distributors. Commission and incentive expenses include sales commissions paid to our independent distributors, special incentives, costs for incentive trip and other rewards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_CommissionAndIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079531184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In&#160;Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balances (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balances at Jun. 30, 2022</a></td>
<td class="nump">$ 31,516<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 131,075<span></span>
</td>
<td class="num">$ (98,437)<span></span>
</td>
<td class="num">$ (1,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued under equity award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other (in shares)</a></td>
<td class="num">(47,000)<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other</a></td>
<td class="num">$ (201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of company stock (in shares)</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(173,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of company stock</a></td>
<td class="num">$ (822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends</a></td>
<td class="num">(1,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balances (in shares) at Jun. 30, 2023</a></td>
<td class="nump">12,622,000<span></span>
</td>
<td class="nump">12,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balances at Jun. 30, 2023</a></td>
<td class="nump">$ 34,649<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">134,314<span></span>
</td>
<td class="num">(98,305)<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued under equity award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other (in shares)</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(206,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other</a></td>
<td class="num">$ (1,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of company stock (in shares)</a></td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="num">(977,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of company stock</a></td>
<td class="num">$ (6,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends</a></td>
<td class="num">(6,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balances (in shares) at Jun. 30, 2024</a></td>
<td class="nump">12,510,000<span></span>
</td>
<td class="nump">12,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balances at Jun. 30, 2024</a></td>
<td class="nump">$ 25,991<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 136,644<span></span>
</td>
<td class="num">$ (108,738)<span></span>
</td>
<td class="num">$ (1,916)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079659664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 2,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,581<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income tax</a></td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(1,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,424)<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="num">(71)<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other</a></td>
<td class="nump">2,280<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="num">(3,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">202<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(1,586)<span></span>
</td>
<td class="num">(1,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">12,197<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(2,245)<span></span>
</td>
<td class="num">(3,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(2,245)<span></span>
</td>
<td class="num">(3,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of company stock</a></td>
<td class="num">(6,430)<span></span>
</td>
<td class="num">(822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of cash dividends</a></td>
<td class="num">(6,940)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares purchased as payment of tax withholding and other</a></td>
<td class="num">(1,221)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from common stock issued under employee stock purchase plan</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="num">(14,417)<span></span>
</td>
<td class="num">(2,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Foreign Currency Effect on Cash</a></td>
<td class="num">(254)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="num">(4,719)<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents &#8212; beginning of period</a></td>
<td class="nump">21,605<span></span>
</td>
<td class="nump">20,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents &#8212; end of period</a></td>
<td class="nump">16,886<span></span>
</td>
<td class="nump">21,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 2,306<span></span>
</td>
<td class="nump">$ 1,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084604432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company</a></td>
<td class="text">The Company<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeVantage Corporation (the "Company" or "we" or "our" or "us") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company is dedicated to helping people achieve their health, wellness, and financial goals. The Company provides quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to its independent consultants. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The Company sold its products in China through a China approved cross-border e-commerce business model until March 15, 2023, at which time the Company closed its e-commerce business in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's line of scientifically validated dietary supplements includes its flagship Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of products, LifeVantage&#174; Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the Company's line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, its companion pet supplement formulated to combat oxidative stress in dogs; and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, its nootropic energy drink mixes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Colorado in June 1988 under the name Andraplex Corporation. The Company changed its corporate name to Yaak River Resources, Inc. in January 1992, and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, the Company acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, the Company changed its name to LifeVantage Corporation.</span></div>In March 2018, the Company reincorporated from the state of Colorado to the state of Delaware. All outstanding shares of common stock, options and share units of the Colorado corporation were converted into an equivalent share, option or share unit of the Delaware corporation and the par value of the Company's common stock was adjusted to $0.0001.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084608800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, stock-based compensation, and loss contingencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company&#8217;s business operations occurs outside the United States.&#160;The local currency of each of the Company&#8217;s subsidiaries generally is its functional currency.&#160;All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders&#8217; equity is recorded at historical exchange rates.&#160;The resulting foreign currency translation adjustments are recorded as a separate component of stockholders&#8217; equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices for identical instruments in active markets; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable for the fiscal years ended June&#160;30, 2024 and 2023 consist primarily of credit card receivables. Based on the Company&#8217;s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June&#160;30, 2024 or 2023 is not necessary. There was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad debt expense for the fiscal year ended June&#160;30, 2024. Bad debt expense for the fiscal year ended June&#160;30, 2023 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 and 2023, inventory consisted of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,841&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method, which includes a reduction in inventory values of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $1.3 million at June&#160;30, 2024 and 2023, respectively, related to obsolete and slow-moving inventory. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves of inventories consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are stated at cost less accumulated amortization. Finite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset&#8217;s carrying value and estimated fair value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Annual impairment tests on intangible assets were completed for the fiscal years ended June&#160;30, 2024 and 2023, resulting in no impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow. For the fiscal years ended June&#160;30, 2024 and 2023, management has concluded that there are no indications of impairment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents. At June&#160;30, 2024, the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> had $12.6 million in cash accounts at one financial institution and $4.3 million i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n other financial institutions. As of June&#160;30, 2024 and 2023, and during the years then ended, the Company&#8217;s cash balances exceeded federally insured limits.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commissions and Incentives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions and incentives expenses are the Company&#8217;s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent consultants, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent consultants for personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with inbound freight and freight out to customers, including independent consultants, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all costs related to research and development activities as incurred. Research and development expenses for the fiscal years ended June&#160;30, 2024 and 2023 were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.6 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the consolidated balance sheets. The Company does not have any finance leases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Per Share</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended June&#160;30, 2024 and 2023, the effects of approximately 13,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.2 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock, are not included in the computations as their effect was anti-dilutive.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards and options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,567&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operates in an integrated manner from market to market.&#160;Commissions and incentives expenses are the Company&#8217;s largest expense comprised of the commissions paid to its independent consultants.&#160;The Company manages its business primarily by managing its international network of independent consultants.&#160;The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific and Europe region. See disaggregated revenue in Note 3.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,504&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072125472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates the majority of its revenue through product sales to customers. These products include the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">line of dietary supplements, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Daily Wellness, Rise AM, Reset PM, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skin and hair care products and Liquid Collagen, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also charges amounts to independent consultants to attend events that it holds. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis, adjusted for the probability of the tickets being redeemed for attendance at a future event. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched its Rewards Circle loyalty program in the United States, Australia, New Zealand, and Japan in March 2023 and in Canada, Europe, and Mexico in February 2024.  Contract liabilities, recorded as deferred revenue, include these loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits are redeemed for additional products at a later date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deferred revenue is included in accrued expenses in the consolidated balance sheets.  The balance of deferred revenue related to contract liabilities was $0.9 million and $0.8 million as of June&#160;30, 2024 and 2023, respectively. The contract liabilities impact to revenue for the years ended June&#160;30, 2024 and 2023 was a decrease of $26,000 and $0.7 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales Returns and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company&#8217;s return policy is to provide a full refund for product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of June&#160;30, 2024 and 2023, the Company&#8217;s return liability reserve, net was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.1 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for sales returns consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports revenue in two&#160;geographic regions: the Americas region and the Asia/Pacific and Europe region. The following table presents the Company's revenue disaggregated by these two&#160;geographic regions (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information as to the Company&#8217;s revenue from operations in the most significant geographical areas is set forth below (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,679&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,522&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue is largely attributed to two product lines, Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each of which accounted for more than 10% of total revenue for each of the fiscal years ended June&#160;30, 2024 and 2023. On a combined basis, the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines represent approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1% and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 79.3% of the Company's total revenue for the fiscal years ended June&#160;30, 2024 and 2023, respectively. The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,135&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,720&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200081105440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,766&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,976&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $3.4 million for the fiscal years ended June&#160;30, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072104608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent costs</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.1 million for the fiscal years ended June&#160;30, 2024 and 2023, respectively. As of June&#160;30, 2024, the remaining weighted-average amortization period for finite-lived intangible assets was 0.75 years. Annual estimated amortization expense is expected to approximate </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the succeeding fiscal year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072150576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Accrued Expenses</a></td>
<td class="text">Other Accrued Expenses<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentive compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payable to vendors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentives and promotions to consultants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072084064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;30, 2016,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "2016 Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $10.0 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $2.0 million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement, and the 2016 Security Agreement, and together with the amendments described below, the "2016 Credit Facility"). During the fiscal year ended June 30, 2020, the Company repaid, in full, the balance of the 2016 Term Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018 and February&#160;1, 2019, the Company entered into loan modification agreements (&#8220;Amendment No. 1&#8221; and &#8220;Amendment No. 2&#8221;, respectively).  These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2021, the Company entered into a loan modification agreement ("Amendment No. 3"), which amended the 2016 Credit Facility.  Amendment No. 3, with an available borrowing amount of $5.0 million, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of 2.00%, with an interest rate floor of 0.00%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that the Company maintain this ratio not in excess of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.00 to 1.00, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3).  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other changes to the minimum fixed charge coverage ratio of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1.10 to 1.00 or the minimum working capital of $6.0 million as set forth in previous amendments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the 2016 Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio (as defined in Amendment No. 4) and allowed the Company to declare and pay dividends, up to $500,000 per quarter, through September 30, 2023.  There were no other changes to the covenants or revolving loan facility as set forth in Amendment No. 3.  If the Company borrowed under the 2016 Revolving Loan, interest would have been payable quarterly in arrears on the last day of each fiscal quarter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2023, the Company received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of $0.40 per share of common stock, to be paid on September 22, 2023. The Company also received approval to declare and pay dividends, up to $750,000, per quarter, through September 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2024, the 2016 Credit Facility reached the maturity date and was terminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with Bank of America, N.A., as Lender (the &#8220;Lender&#8221;). In connection with the Loan Agreement and on the same date, the Company, Lifeline Nutraceuticals Corporation, as Guarantor (the &#8220;Guarantor&#8221;), and the Lender also entered into a Continuing and Unconditional Guaranty (the &#8220;Continuing and Unconditional Guaranty&#8221;) and a Security and Pledge Agreement (the &#8220;Security and Pledge Agreement&#8221;). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Line of Credit&#8221; and collectively with the Loan Agreement, Continuing and Unconditional Guaranty, and the Security and Pledge Agreement, the &#8220;2024 Credit Facility&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company borrows under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the &#8220;Expiration Date&#8221;). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date. As of June&#160;30, 2024, the effective interest rate is 7.34%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, and by a pledge of the membership interests of the Company's subsidiaries, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants, both affirmative and negative, that, among other things, restrict the Company&#8217;s ability to deal with the Company's assets outside of the ordinary course, incur additional indebtedness, grant liens on the Company's assets, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, and enter into consolidations, mergers or other combinations. The Loan Agreement requires that the Company maintain specified financial ratios and satisfy certain financial condition tests. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains certain customary events of default, including, among other things, failure of the Company to make required payments under the Loan Agreement, certain breaches of representations made by the Company or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or failure of the Company to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to the Company may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will, at the option of the Lender, bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement. </span></div>As of June&#160;30, 2024, the Company was in compliance with its financial covenants under the 2024 Credit Facility.  As of June&#160;30, 2024, there was no balance outstanding on the 2024 Credit Facility.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084600896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued zero shares of common stock as a result of the exercise of options. During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.3 million shares, respectively, under the Company's equity incentive plans. During the fiscal years ended June&#160;30, 2024 and 2023, 0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, respectively, of restricted stock were canceled or surrendered as payment of tax withholding upon vesting.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the fiscal years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold 0.1 million and 0.1 million shares under its 2019 Employee Stock Purchase Plan, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;27, 2017, the Company's board approved a stock repurchase program, which was subsequently amended on February&#160;1, 2019. Under the currently approved stock repurchase program, the Company is authorized to purchase up to </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60&#160;million through December 31, 2026. The stock repurchase program permits the Company to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the Company's management, in accordance with applicable securities laws. As part of the stock repurchase program, the Company may enter into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan would be completed in accordance with the terms of the plan, including specified price, volume, and timing conditions. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he stock repurchase program may be suspended or discontinued at any time. During the year ended June&#160;30, 2024, the Company purchased 1.0 million&#160;shares of its common stock at an aggregate purchase price of $6.4 million under this repurchase program. During the fiscal year ending June&#160;30, 2023, the Company purchased 0.2 million&#160;shares of its common stock at an aggregate purchase price of $0.8 million under this repurchase program. At&#160;June&#160;30, 2024, there is&#160;$20.4 million&#160;remaining under this stock repurch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ase program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2023, the board approved a stockholder rights agreement (the &#8220;Rights Plan&#8221;) and declared a dividend of one right for each outstanding share of common stock to stockholders of record on September 11, 2023. Each right entitles holders to purchase one newly issued share of preferred stock at an exercise price of $20 per right, subject to adjustment. Initially, the rights are not exercisable and trade with shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the rights become exercisable following a public announcement that a person acquires 12% (or, in the case of passive investors, 20%) or more of the outstanding shares of the Company&#8217;s common stock. If a person becomes an acquiring person, each holder of rights (except the acquiring person) will have the right to purchase, for the purchase price, a number of shares of the Company&#8217;s common stock at a 50% discount to the then-current trading price. Rather than allowing the rights to be exercised in those circumstances, the board may exchange each right, other than the rights owned by the acquiring person, for a share of the Company&#8217;s common stock. The agreement provides for exceptions and additional terms for other certain situations and circumstances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Rights Plan is intended to protect the interests of the Company and its stockholders by reducing the likelihood that any entity, person or group gains control of the Company through open-market accumulation or other means without payment of an adequate control premium and expires August 28, 2024. There is currently no impact to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Certificate of Incorporation authorizes the designation and issuance of shares of preferred stock. However, as of June&#160;30, 2024, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Company&#8217;s board.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid a one-time cash dividend of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.40 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share of common stock to stockholders of record in September 2023, quarterly cash dividends of $0.035 per share of common stock to stockholders of record in September 2023, December 2023 and March 2024, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock in June 2024 which were in the aggregate amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.9 million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.545 per share of common stock for the fiscal year ended June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the fiscal year ended June&#160;30, 2023, the Company paid to stockholders quarterly cash dividends totaling $1.6 million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.125</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share of common stock.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The declaration of dividends is subject to the discretion of the board and will depend upon various factors, including the Company's earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects, and other factors deemed relevant by the board.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084585088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Term Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Settled Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted, and the stockholders approved, the 2017 Long-Term Incentive Plan (the &#8220;2017 Plan&#8221;), effective February&#160;16, 2017, to provide incentives to eligible employees, directors, and consultants. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he initial share pool approved was 650,000 shares. On November 9, 2023, the stockholders approved amendments to the 2017 Plan to increase the number of shares of the Company's common stock that are available for issuance under the 2017 plan by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2024, a maximum of&#160;5.1 million&#160;shares of the Company's common stock can be issued under the 2017 Plan in connection with the grant of awards which is calculated as the sum of (i)&#160;4,630,000&#160;shares and (ii) up to&#160;475,000&#160;shares previously reserved for issuance under the Company's prior 2010 Long Term Incentive Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. Outstanding stock options awarded under the 2017 Plan have exercise prices of&#160;$4.44&#160;per share, vest over a&#160;<span style="-sec-ix-hidden:f-510">three&#160;year</span> vesting period, and have a contractual term of ten years. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back to the 2017 Plan. As of June&#160;30, 2024, under the 2017 Plan, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.1 million shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;The Company&#8217;s 2019 Employee Stock Purchase Plan ("ESPP") was adopted by the board in September 2018 and approved by its stockholders in November 2018. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Reserve.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;The Company has reserved 0.4 million shares of its common stock for issuance under the ESPP. As of June&#160;30, 2024, 0.1 million shares were available for issuance. The number of shares reserved under the ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Employees may purchase each share of common stock under the ESPP at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee&#8217;s contributions to the ESPP are limited to 15% of the compensation, and up to a maximum of 3,000 shares may be purchased by an employee during any offering period. A participant shall not be granted an option under the ESPP if such option would permit the participant&#8217;s rights to purchase stock to accrue at a rate exceeding $25,000 fair market value of stock for each calendar year in which such option is outstanding at any time.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offering Periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Unless otherwise determined by the compensation committee, the ESPP will be operated through a series of successive six-month offering periods, which will begin each year on March 1 and September 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June&#160;30, 2024 and 2023, 0.1 million and 0.1 million shares of common stock were purchased under the ESPP, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with accounting guidance for stock-based compensation, payments in equity instruments for goods or services are accounted for by the fair value method. For the fiscal year ended June&#160;30, 2024 and 2023, stock-based compensation of $3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $3.2 million, respectively, was reflected as an increase to additional paid in capital. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $2.5 million of unrecognized compensation cost related to non-vested stock-based compensation arrangements under the 2017 Plan, based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over a weighted-average period of 1.44 years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock option grants during the fiscal years ended June&#160;30, 2024 and 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Remaining<br/>Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock award activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 125,732 shares of restricted stock that were granted in exchange for the cancellation of 48,026 shares of stock units and 77,706 shares of performance restricted stock units on November 6, 2023.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of restricted shares that vested during the fiscal years ended June 30, 2024 and 2023 w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $0.7 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.3 million, respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 48,206 shares of restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was $1.9 million and $0.6 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Restricted Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended June 30, 2024 and 2023, the Company awarded performance restricted stock units (the "FY 2024 PRSUs" and "FY 2023 PRSUs," respectively) to certain employees (the "Recipients"). Each performance restricted stock unit represents a contingent right for the Recipients to receive a distribution of shares of common stock of the Company equal to 0% to 200% of the target number of performance restricted stock units subject to the award. The actual number of shares distributed will be based on the Company's achievement of specified financial performance metrics. For FY 2024 PRSUs, the performance period for 50% of the FY 2024 PRSUs ended on June&#160;30, 2024, the performance period for 30% of the FY 2024 PRSUs ends on June 30, 2025, and the performance period for the remaining 20% of the FY 2024 PRSUs ends on June 30, 2026. The financial performance metrics for the fiscal year ended June&#160;30, 2024, were deemed achieved at the 0% achievement level. The performance period for 100% of the FY 2023 PRSUs ended on June 30, 2023, and were deemed achieved at the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133.13% achievement level. The FY 2024 PRSUs and FY 2023 PRSUs will vest only to the extent the specified financial performance criteria are achieved and subject to the Recipient&#8217;s continued service with the Company, as follows: (i) a portion of the earned award will vest on the first anniversary of the grant date and (ii) an additional portion of the earned award will vest thereafter in a series of quarterly installments. The fair values of the performance restricted stock units are based on the grant date fair value which is the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes shares added based on achievement of performance goals in excess of target.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 77,706 shares of performance restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of performance restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was approximately $1.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4,000</span>, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084500336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Expense, Net</a></td>
<td class="text">Other Expense, Net<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency transaction loss, net</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/720/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072269280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the fiscal years ended June&#160;30, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Income Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Income Tax Provision</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,134&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Deferred Income Tax Provision</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,274)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,675)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Tax Provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate for the fiscal years ended June&#160;30, 2024 and 2023 differs from the U.S. Federal statutory income tax rate due to the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax return to provision true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limit on future stock compensation due to 162(m)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revalue of deferred for change in federal tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; current year section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; foreign derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; removal of additional permanent reinvestment assertions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; change in uncertain tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; accrual for foreign tax audits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax provision </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities as of June&#160;30, 2024 and 2023 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal, state, and foreign net operating loss carryovers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation, allowance for returns, bonuses&#160;&amp; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,859&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property&#160;&amp; equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,563)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,164)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted accounting guidance for uncertain tax positions ("UTPs") which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position. The measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year ending June&#160;30, 2024, the Company began recording a withholding tax obligation on its rebalanced commission payments to the U.S. parent company it has not obtained treaty rates for. The Company does not believe it will obtain treaty rates, but will also not be able to take a foreign tax credit at this time. Since the Company believes it is unlikely to receive treaty benefits, it has recorded the taxes, the foreign tax credit on those taxes, and a corresponding UTP against the foreign tax credit. The UTP totaling $0.1 million was recorded against the foreign tax credit as of June&#160;30, 2024. If the Company is successful with its treaty benefit application or receives an opinion through appeals, competent authority, etc., it will remove the UTP at that time. The UTP recorded is the foreign taxes that will not be credited, but reduced by the benefit the Company will receive from deducting the taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also currently undergoing income tax audits in foreign jurisdictions. For the fiscal year ending June&#160;30, 2024, the Company accrued a total $0.3 million related to foreign income tax audits. At this time, the Company believes this amount reflects the amount that is has more than 50% likelihood to be paid upon settlement including interest and penalties. The Company will continue to evaluate as the audits progress.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved $0.4 million for taxes related to the UTPs as of June&#160;30, 2024. There were no changes to the liability for UTPs for the fiscal year ended June&#160;30, 2023. There were no unrecognized tax benefits for the fiscal years ended June&#160;30, 2024 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2022, the Company removed its permanent reinvestment assertion in Japan. In fiscal 2024, the Company also removed its permanent reinvestment assertions in Taiwan and Australia and recorded the tax effects of that change.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Taiwan, the Company recorded provisions for withholding tax that it will pay to Taiwan upon payment of dividends. The Company did not record any unborn foreign tax credit related to Taiwan withholding tax. The Company believes any withholding tax paid on dividends will be ineligible for a foreign tax credit.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any withholding tax to Australia upon the payment of dividends. There is a 15% withholding rate on unfranked dividends between Australia and Singapore, but the Company does not anticipate paying any unfranked dividends, so it has not recorded any withholding tax to Australia.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also recorded income taxes to various states when the cash is repatriated from Taiwan and Australia. The Company did not record any federal income tax implications because any withholding tax on dividends will be ineligible for a foreign tax credit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years open for examination by the Internal Revenue Service (&#8220;IRS&#8221;) include returns for fiscal years June 30, 2021 through present and the open tax years by state tax authorities include returns for fiscal years June 30, 2020 through present. In addition, the IRS and state tax authorities may examine net operating losses ("NOLs") for any previous years if utilized by the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance were as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in valuation allowance during the fiscal year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on the Company converting from a blended rate to a state-by-state provision. During the fiscal year ended June&#160;30, 2023, the change in valuation allowance related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on updated projections and changes to the blended rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had utilized all of its Federal NOL carry-forwards.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2024, state NOLs were $5.6 million and foreign NOLs were $0.4 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total recognized tax benefit from settlement of stock-based awards for the fiscal years ending June&#160;30, 2024 and 2023, was $0.2 million and $0.2 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business globally. As a result, the Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions, and are subject to examination for the open tax years of June 30, 2020 through June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072170720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for current corporate offices and certain equipment. These leases have remaining terms of approximately <span style="-sec-ix-hidden:f-747">one</span> to eight years. As of June&#160;30, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was 6.90 years and 3.46%, respectively. As of June&#160;30, 2023, the weighted average remaining lease term and weighted average discount rate for operating leases was 8.27 years and 3.25%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, LifeVantage Japan entered into an operating lease agreement with Sumitomo Mitsui Trust Bank, Limited, for a new office located in the Shinagawa Grand Central Tower in Tokyo, Japan.  The lease is for approximately 5,200 square feet and has a lease term from July 1, 2023 through June 30, 2026 with the option to renew for an additional two years.  Lease payments began in November 2023 totaling approximately $28,000 per month, or $0.3 million per year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June&#160;30, 2024, the Company also entered into new operating leases with previous lessors in Thailand and Taiwan and extended the operating lease Philippines. Each of these leases have a lease term of three years, expiring in fiscal year 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the fiscal years ended June&#160;30, 2024 and 2023, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities at June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,847&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074356400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for contingent liabilities in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of June&#160;30, 2024, and based on the assessment there are no probable loss contingencies requiring accrual or disclosures within its financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Accruals</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable publicity or resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding or publicity related to such could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact of any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.   The Company may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this annual report on Form 10-K, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently </span></div>believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084461872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 2,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200083516944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073576992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div>The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, stock-based compensation, and loss contingencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company&#8217;s business operations occurs outside the United States.&#160;The local currency of each of the Company&#8217;s subsidiaries generally is its functional currency.&#160;All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders&#8217; equity is recorded at historical exchange rates.&#160;The resulting foreign currency translation adjustments are recorded as a separate component of stockholders&#8217; equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices for identical instruments in active markets; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></div>Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div>The Company&#8217;s accounts receivable for the fiscal years ended June&#160;30, 2024 and 2023 consist primarily of credit card receivables. Based on the Company&#8217;s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June&#160;30, 2024 or 2023 is not necessary.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are stated at cost less accumulated amortization. Finite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset&#8217;s carrying value and estimated fair value. </span></div>Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div>Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommissionsExpensePolicyPolicyTextBlock', window );">Commissions and Incentives</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commissions and Incentives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions and incentives expenses are the Company&#8217;s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent consultants, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent consultants for personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Shipping and Handling, Revenue And Deferred Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with inbound freight and freight out to customers, including independent consultants, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.</span></div>Revenue<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates the majority of its revenue through product sales to customers. These products include the Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">line of dietary supplements, LifeVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Omega+, ProBio, IC Bright</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Daily Wellness, Rise AM, Reset PM, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skin and hair care products and Liquid Collagen, Petandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and AXIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also charges amounts to independent consultants to attend events that it holds. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis, adjusted for the probability of the tickets being redeemed for attendance at a future event. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched its Rewards Circle loyalty program in the United States, Australia, New Zealand, and Japan in March 2023 and in Canada, Europe, and Mexico in February 2024.  Contract liabilities, recorded as deferred revenue, include these loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits are redeemed for additional products at a later date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deferred revenue is included in accrued expenses in the consolidated balance sheets.  The balance of deferred revenue related to contract liabilities was $0.9 million and $0.8 million as of June&#160;30, 2024 and 2023, respectively. The contract liabilities impact to revenue for the years ended June&#160;30, 2024 and 2023 was a decrease of $26,000 and $0.7 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div>The Company expenses all costs related to research and development activities as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities and long-term lease liabilities on the consolidated balance sheets. The Company does not have any finance leases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease agreements do not contain any residual value guarantees.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Per Share</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div>The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operates in an integrated manner from market to market.&#160;Commissions and incentives expenses are the Company&#8217;s largest expense comprised of the commissions paid to its independent consultants.&#160;The Company manages its business primarily by managing its international network of independent consultants.&#160;The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific and Europe region.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommissionsExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommissionsExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200187898208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventory</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 and 2023, inventory consisted of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,841&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves of inventories consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,766&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,976&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Net Income Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards and options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,567&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,504&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072150576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for sales returns consist of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The following table presents the Company's revenue disaggregated by these two&#160;geographic regions (in thousands):<div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia/Pacific &amp; Europe</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information as to the Company&#8217;s revenue from operations in the most significant geographical areas is set forth below (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,679&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,522&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenues by Major Product Line</a></td>
<td class="text">The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023:<div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protandim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,135&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,720&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TrueScience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">product line</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084498016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment (includes computer hardware and software)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,766&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,976&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200186647232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent costs</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072008784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentive compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payable to vendors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued incentives and promotions to consultants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200083545792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Remaining<br/>Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Nonvested Restricted Shares</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock award activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 125,732 shares of restricted stock that were granted in exchange for the cancellation of 48,026 shares of stock units and 77,706 shares of performance restricted stock units on November 6, 2023.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested Restricted Stock Units Roll Forward</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 48,206 shares of restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Nonvested Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of performance restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:2.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes shares added based on achievement of performance goals in excess of target.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">Includes 77,706 shares of performance restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200081081184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Expense, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency transaction loss, net</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072126336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the fiscal years ended June&#160;30, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Income Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Income Tax Provision</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,134&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Deferred Income Tax Provision</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,274)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,675)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Tax Provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of The Effective Income Tax Rate Differs from the U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate for the fiscal years ended June&#160;30, 2024 and 2023 differs from the U.S. Federal statutory income tax rate due to the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax return to provision true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limit on future stock compensation due to 162(m)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revalue of deferred for change in federal tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; current year section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; foreign derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; removal of additional permanent reinvestment assertions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; change in uncertain tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; accrual for foreign tax audits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax provision </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of The Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities as of June&#160;30, 2024 and 2023 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal, state, and foreign net operating loss carryovers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation, allowance for returns, bonuses&#160;&amp; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,859&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property&#160;&amp; equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,563)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,164)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance were as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200188526256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the fiscal years ended June&#160;30, 2024 and 2023, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities at June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,847&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200186739632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Company (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080337792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>region</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies Additional Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Recorded bad debt expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Reduction in inventory</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_NumberOfFinanceLeases', window );">Number of finance leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_NumberOfGeographicSegments', window );">Number of geographic segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember', window );">Cash Accounts Held Primarily At Financial Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies Additional Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Concentration of credit risk</a></td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember', window );">Cash Accounts Held at Other Financial Institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies Additional Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Concentration of credit risk</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_NumberOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_NumberOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_NumberOfGeographicSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of geographic segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_NumberOfGeographicSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200081022624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 11,841<span></span>
</td>
<td class="nump">$ 12,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 15,055<span></span>
</td>
<td class="nump">$ 16,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_InventoryFinishedGoodsPercentOfTotalInventory', window );">Finished goods</a></td>
<td class="nump">78.70%<span></span>
</td>
<td class="nump">75.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_RawMaterialsPercentOfTotalInventory', window );">Raw materials</a></td>
<td class="nump">21.30%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_InventoryPercentOfTotalInventory', window );">Total inventory</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_InventoryFinishedGoodsPercentOfTotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Finished Goods, Percent Of Total Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_InventoryFinishedGoodsPercentOfTotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_InventoryPercentOfTotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Percent Of Total Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_InventoryPercentOfTotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_RawMaterialsPercentOfTotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Raw Materials, Percent Of Total Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_RawMaterialsPercentOfTotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072629808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details) - SEC Schedule, 12-09, Reserve, Inventory - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Write-offs</a></td>
<td class="num">(892)<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 1,301<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084587120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated service lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated service lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Equipment (includes computer hardware and software)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated service lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment (includes computer hardware and software)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated service lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074197696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 2,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">12,458<span></span>
</td>
<td class="nump">12,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock awards and options (in shares)</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">12,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income per share, basic (dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income per share, diluted (dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084507600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 19,216<span></span>
</td>
<td class="nump">$ 20,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,925<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074400016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="7">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>region</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>productLine</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>productLine</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_MoneyBackGuaranteePeriod', window );">Money back guarantee period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_HandlingAndRestockingFeePercentage', window );">Handling and restocking fee, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_ReturnLiabilityReserve', window );">Return liability reserve</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_NumberOfGeographicSegments', window );">Number of geographic segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_NumberOfProductLines', window );">Number of product lines | productLine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Increase in revenue from recognition of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product concentration risk | Revenue benchmark | Protandim and TrueScience Product Line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_HandlingAndRestockingFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Handling and Restocking Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_HandlingAndRestockingFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_MoneyBackGuaranteePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Money Back Guarantee Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_MoneyBackGuaranteePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_NumberOfGeographicSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of geographic segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_NumberOfGeographicSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_NumberOfProductLines">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Lines</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_NumberOfProductLines</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_ReturnLiabilityReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Liability Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_ReturnLiabilityReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lfvn_ProtandimandTrueScienceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lfvn_ProtandimandTrueScienceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072171280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Sales Return (Details) - Sales Returns and Allowances - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Returns</a></td>
<td class="num">(1,618)<span></span>
</td>
<td class="num">(1,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080204080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 200,164<span></span>
</td>
<td class="nump">$ 213,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">152,907<span></span>
</td>
<td class="nump">155,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lfvn_AsiaPacificAndEuropeMember', window );">Asia/Pacific &amp; Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">47,257<span></span>
</td>
<td class="nump">58,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">145,679<span></span>
</td>
<td class="nump">148,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 26,989<span></span>
</td>
<td class="nump">$ 32,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lfvn_AsiaPacificAndEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lfvn_AsiaPacificAndEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080259504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Major Products (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 200,164<span></span>
</td>
<td class="nump">$ 213,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lfvn_ProtandimMember', window );">Protandim&#174; product line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 104,135<span></span>
</td>
<td class="nump">$ 119,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lfvn_ProtandimMember', window );">Protandim&#174; product line | Product concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">56.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lfvn_LifeVantageTrueScienceSkinCareRegimenMember', window );">TrueScience&#174; product line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 56,252<span></span>
</td>
<td class="nump">$ 49,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lfvn_LifeVantageTrueScienceSkinCareRegimenMember', window );">TrueScience&#174; product line | Product concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">28.10%<span></span>
</td>
<td class="nump">23.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 39,777<span></span>
</td>
<td class="nump">$ 44,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Product concentration risk | Revenue benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lfvn_ProtandimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lfvn_ProtandimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lfvn_LifeVantageTrueScienceSkinCareRegimenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lfvn_LifeVantageTrueScienceSkinCareRegimenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079572208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">$ (14,510)<span></span>
</td>
<td class="num">$ (14,151)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">7,813<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment (includes computer hardware and software)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">15,766<span></span>
</td>
<td class="nump">16,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,040<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200082794320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Definite-lived intangible assets weighted-average amortization period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Trademarks and other indefinite-lived intangible assets</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patent costs</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(2,120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total finite-lived intangible assets, net</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073163536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued incentive compensation</a></td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 3,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Accrued severance</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Other taxes payable</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_AccruedPayableToVendors', window );">Accrued payable to vendors</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued incentives and promotions to consultants</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other accrued expenses</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="nump">$ 7,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_AccruedPayableToVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payable to Vendors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_AccruedPayableToVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074318912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th">
<div>Aug. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend', window );">One time dividend (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio', window );">Total liabilities to tangible net worth ratio (not greater than)</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lfvn_March2016RevolvingLoanMember', window );">March 2016 Revolving Loan | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DebtInstrumentFloorInterestRate', window );">Floor interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DebtInstrumentCovenantMaximumDividend', window );">Maximum dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lfvn_March2016TermLoanMember', window );">March 2016 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio', window );">Fixed charge coverage ratio, minimum</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital', window );">Minimum working capital</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DebtInstrumentCovenantMaximumDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument. Covenant, Maximum Dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DebtInstrumentCovenantMaximumDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Required Minimum Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Liabilities To Tangible Net Worth Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lfvn_March2016RevolvingLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lfvn_March2016RevolvingLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lfvn_March2016TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lfvn_March2016TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073668000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase common stock amount authorized (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,430,000<span></span>
</td>
<td class="nump">$ 822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount of common stock repurchase program</a></td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividend, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividend, common stock (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
<td class="nump">$ 0.545<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend', window );">One time dividend (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lfvn_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted common stock to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted common stock to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,000<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares canceled or surrendered as payment of tax withholding and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977,000<span></span>
</td>
<td class="nump">173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of options and warrants, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079477344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Equity-Settled Plans, Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2017</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 02, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Company's common stock purchased in aggregate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lfvn_TwoThousandAndTenLongTermIncentivePlanMember', window );">2010 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum common stock issued under Long-Term Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanMember', window );">2017 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,000<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum common stock issued under Long-Term Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price of outstanding stock options (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Company's common stock purchased in aggregate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember', window );">2017 Long Term Incentive Plan Excluding 2010 Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum common stock issued under Long-Term Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm', window );">Contractual term of stock options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_TwoThousandAndTenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_TwoThousandAndTenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073427696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details) - ESPP - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock subject for purchase</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of stock fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employee compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares that can be purchased during any offering period</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted', window );">Amount in excess of fair market value of stock for option not to be granted</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Amount In Excess Of Fair Market Value Of Stock For Option Not To Be Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072791600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock-Based Compensation, Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,280<span></span>
</td>
<td class="nump">$ 3,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | 2010 and 2017 Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation cost</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073033600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options, Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting on January 1, 2019 | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting right percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting on the last day of each fiscal quarter following January 1, 2019 | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting right percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073421024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired or Canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (dollars per share)</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or Canceled (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (dollars per share)</a></td>
<td class="nump">4.44<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (dollars per share)</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average&#160;Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200082852672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Shares (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning period (in shares)</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending period (in shares)</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning period (dollars per share)</a></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 6.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (dollars per share)</a></td>
<td class="nump">4.74<span></span>
</td>
<td class="nump">3.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (dollars per share)</a></td>
<td class="nump">3.85<span></span>
</td>
<td class="nump">6.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending period (dollars per share)</a></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning period (in shares)</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending period (in shares)</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning period (dollars per share)</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (dollars per share)</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="nump">4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (dollars per share)</a></td>
<td class="nump">5.05<span></span>
</td>
<td class="nump">8.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (dollars per share)</a></td>
<td class="nump">4.48<span></span>
</td>
<td class="nump">6.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending period (dollars per share)</a></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200187474784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200079562336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details) - Performance Restricted Stock Units - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage', window );">Distribution percentage of target number of Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage', window );">Distribution percentage of target number of Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage', window );">Distribution percentage of target number of Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Distribution Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074327680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Performance Restricted Stock Units (Details) - Performance Restricted Stock Units - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning period (in shares)</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending period (in shares)</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning period (dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (dollars per share)</a></td>
<td class="nump">4.89<span></span>
</td>
<td class="nump">4.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (dollars per share)</a></td>
<td class="nump">4.24<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (dollars per share)</a></td>
<td class="nump">4.68<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending period (dollars per share)</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lfvn_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072066304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss, net</a></td>
<td class="num">$ (429)<span></span>
</td>
<td class="num">$ (373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_OtherMiscellaneousIncomeExpensesNet', window );">Other income (expense), net</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">$ (412)<span></span>
</td>
<td class="num">$ (458)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_OtherMiscellaneousIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Income (Expenses), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_OtherMiscellaneousIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200080120016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Income Before Income Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 2,940<span></span>
</td>
<td class="nump">$ 2,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Income Tax Provision</a></td>
<td class="nump">2,687<span></span>
</td>
<td class="nump">3,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred Income Tax Provision</a></td>
<td class="num">(1,274)<span></span>
</td>
<td class="num">(1,675)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net Income Tax Provision</a></td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200272106752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>The effective income tax rate differs from the U.S. Federal statutory income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate difference</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp', window );">Tax return to provision true-up</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent', window );">Limit on future stock compensation due to 162(m)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent', window );">Foreign withholding tax</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other differences</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Revalue of deferred for change in federal tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_PermanentDifferencesAbstract', window );"><strong>Permanent differences:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">&#8212; stock-based compensation</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent', window );">&#8212; current year section 162(m) limitation</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">&#8212; foreign derived intangible income deduction</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">&#8212; tax credits</a></td>
<td class="num">(12.10%)<span></span>
</td>
<td class="num">(5.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">&#8212; meals and entertainment</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion', window );">&#8212; removal of additional permanent reinvestment assertions</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">&#8212; change in uncertain tax positions</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">&#8212; accrual for foreign tax audits</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">&#8212; other permanent differences</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax provision</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In UncertainTax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Current Year Section 162(m) Limitation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Future Stock Based Compensation Expense, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Removal Of Permanent Reinvestment Assertion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax return to provisions true up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_PermanentDifferencesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_PermanentDifferencesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200070144704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal, state, and foreign net operating loss carryovers</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option compensation</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 costs</a></td>
<td class="nump">2,578<span></span>
</td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">3,223<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued vacation, allowance for returns, bonuses&#160;&amp; other</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">8,551<span></span>
</td>
<td class="nump">7,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Patents and trademarks</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property&#160;&amp; equipment</a></td>
<td class="num">(798)<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(2,263)<span></span>
</td>
<td class="num">(2,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(3,563)<span></span>
</td>
<td class="num">(4,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(720)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
<td class="num">$ (675)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 4,268<span></span>
</td>
<td class="nump">$ 2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200074777632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities', window );">Increase resulting from settlements with tax authorities</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits', window );">Increase resulting from foreign tax audits</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_UnrecognizedTaxPosition', window );">Unrecognized tax position</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefit from settlement of stock based awards</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_UnrecognizedTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_UnrecognizedTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Position, Increase Resulting From Foreign Tax Audits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Position, Increase Resulting From Settlements With Tax Authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072081216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balance</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balance</a></td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200073180592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.46%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_LesseeOperatingLeaseLeasedArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_LesseeOperatingLeaseMonthlyPayments', window );">Monthly payments</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lfvn_LesseeOperatingLeaseAnnualAmount', window );">Annual amount</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_LesseeOperatingLeaseAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_LesseeOperatingLeaseAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lfvn_LesseeOperatingLeaseMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lfvn_LesseeOperatingLeaseMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lfvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200084543072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">$ 2,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 2,134<span></span>
</td>
<td class="nump">$ 2,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200072160256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 2,187<span></span>
</td>
<td class="nump">$ 2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 2,475<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140200083537840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">14,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!$.*($^ XQO&Q'%#_D#QQLKD?U!+ P04    " "M@!Q9/!/X[4 "  #"!0
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MS4V3!64=S/Y>2CP9]H"N;2=_ 5!+ P04    " "M@!Q9]49<9'\&  !@&P
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U9VW+;-A#]%8R2R;0SED4
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M]J3(R)*O/F)YHVC-U"O*1&;*%%WN0;9F<A#*"=^2%.Q(E%/PWCJW+ L"T=&
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MHX$##1&F.%1& NF?)1YA2HV2YOA5B#KEFB9QO?VL?FG-:S,S)/&(T^\D4O'
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M<E6M?ZJUH]B\H:S><QS1>ZI(-'3&BD3ST\(6QAKU51(2C *!24IBJ]V46S]
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M56%V$B!-=3-5[ZZH.6%A61HW%I36!T6C4&BRNJTC0<R.Q(\QUXG&$M!:?_I
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M%">U@?I])41Y_*)?4/__A<G_ 5!+ P04    " "M@!Q95M"^G/@%  !0#0
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M.;H^??[ZG)[G!WXU^LYGGQ6=9&'M)_KRMOKF:$8(Z5J7+4$H\.]6O]%U38"
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MH3V9=XJUJJ_/KR:9QP$ID"!D^XK/1%KU=E /_]$VJ^,?F8G!TKWKG._(8<
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M_-+:+?\NT,*VB.SXXUH7E7;T .XO+3@5OM &Z8>B7OTO4$L#!!0    ( *V
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MU\,G8S>34XQ##L]W:BRE-("$$*?X/$ TWB7[[@C-)#=94_6:+5UU3(DG4N)
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M1<TW:V,;0:S:3>):BZ(*3HU*\C2=)HV0.EK.P]G*+N>F(R4UKBRXKFF$O;E
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MN&)7GV0$ME/O;D.F#HJY-,3Z&Y8E7WAHO0&_7QE#VXT/T%^A\U]02P,$%
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M\=Z68>W%KV6ABJ& ,RC3:C1K-'HU.RKQ;W4Y%N>33,PFL_D1>>>MA><L[_R
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M\>7%2+CXB39>!%OQ9U$T5T2+?ZX5,,?1 CQ?6AN:"SJ@_4Y^\V]02P,$%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;,U:;6_;1A+^*PLU*61
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M>#$;".M?P/L?E=GQ2^^5J2I3\->MDH",%N#YVIBJ^4$;M/\%<?5?4$L#!!0
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MM7+V:6HC5X/8  O'!)SQ*9<_GI_S@[D$.#/Q.5S]2"U6[O+NH-Z#B>K:R'R
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MQ<$&&+=-<6"?<0BT(,>ZD%S#"(6'U#5#_0DLIAIK1_D6(U.%M/9SWQ"6DV]
ML*"5+UW"03;FST'CZO@Q[2Y_0SJ*YR]Q'[1OT4?0Y!ILO5A\^WH&+,C7K?P0
MW5:^**U=C*Z7GQL"27L6P/O&H0.4!SY@_,1X^S]02P,$%     @ K8 <67WX
M@<=! @  F04  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK51A;],P
M$/TKEID02%"G2=I"22*M+0B0AJJ5P6<WN3;6$CO83K/]>VPG#=V45@CQI?'9
M]]Z]Y_HN:H2\5SF 1@]EP56,<ZVK.2$JS:&D:B0JX.9D)V1)M0GEGJA* LT<
MJ"R([WE34E+&<1*YO;5,(E'K@G%82Z3JLJ3R<0&%:&(\QL>-6[;/M=T@2531
M/6Q WU5K:2+2LV2L!*Z8X$C"+L;7X_DRM/DNX0>#1IVLD76R%>+>!E^R&'M6
M$!20:LM S>< 2R@*2V1D_.HX<5_2 D_71_9/SKOQLJ4*EJ+XR3*=Q_@=1AGL
M:%WH6]%\AL[/Q/*EHE#N%S5M[F2"45HK+<H.;!24C+=?^M#=PPE@/#T#\#N
M_QP0G@$$'2!P1EMESM:*:II$4C1(VFS#9A?N;AS:N&'<_HL;+<TI,SB=K.DC
M.BBT!NE>!$\!K9A*"Z%J">@MNMNLT*NKU^@*,8Z^YZ)6E&<J(MK4M@PD[>HL
MVCK^F3IC']T(KG.%/O(,LJ<$Q(CNE?M'Y0O_(N/7FH]0X+U!ON>' X*6?P\/
M+L@)^HL,'%_P+Q<Y=%\M73A,9YMWKBJ:0HQ-=RJ0!\#)RQ?CJ?=AR.M_(GOB
M/.R=AY?8DV]FUC">BG+09HN=.:P=*8?$?Q_,(G(XE3^0- F]/JF514Y>>0ER
M[YI?H5347+?/IM_MY\NU:ZMG^PLS=]HQ\8>F'5HW5.X95ZB G:'T1C/3YK(=
M!&V@1>5Z:2NTZ4RWS,WL!&D3S/E."'T,;(%^&B>_ 5!+ P04    " "M@!Q9
M.K5N-44"  "+!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R=E5MO
MFS 4@/^*Q:0]M>&2VY8!4M)M6BIUBM)N>W;P"5@U-K--:/_];$-8-B54R@O8
MYIS/WS'B$#="/JL"0*.7DG&5>(76U<+W559 B=5(5,#-D[V0)=9F*G-?51(P
M<4DE\Z,@F/DEIMQ+8[>VD6DL:LTHAXU$JBY++%]7P$23>*%W7-C2O-!VP4_C
M"N?P"/I'M9%FYO<40DO@B@J.).P3;QDN5G,;[P)^4FC4R1C92G9"/-O)FB1>
M8(6 0:8M 9O; >Z ,0LR&K\[IM=O:1-/QT?Z5U>[J66'%=P)]HL2723>!P\1
MV..:Z:UHOD%7S]3R,L&4NZ*FC1U_]%!6*RW*+MD8E)2W=_S2G<-)0CB[D!!U
M"9'S;C=REI^QQFDL18.DC38T.W"ENFPC1[E]*8]:FJ?4Y.ET;8Z7@$1/$A/*
M<[24$O,<S+%K%?O:[&#C_*RCK5I:=($61NA!<%TH](43(/\"?*/6^T5'OU4T
M2+RO^0B-@QL4!=%D@#?NZQT[WO@"[UR=-VCWBM:<T ,E-6;GRFZAD_-0^^$L
M5(4S2#SS92B0!_#2]^_"6?!I0'G2*T^&Z.FV9H#"8#>]#4^UT9*(2O]_R*WN
M,'"/F8(!L6DO-AWD?!?\]@JY8>A;<K->;G;5J3V!-)\1ON VS'S+;=Z[S:\^
MN&&_8>Y%/_^D090@<]<&%<I$S77;*_K5OM,NVP;S-[QMTP]8YI0KQ&!O4H/1
MW+Q.V;:^=J)%Y=K-3FC3O-RP,'\+D#; /-\+H8\3NT'__TG_ %!+ P04
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MK&IAJ$X$P%T4'K3E!@\)]UX$52P6H,X("*QA'2)3K'$+A V,UT* VA1S4YL
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MJXO>=;2]G%6G],0+S&YB;*75*<M3X%VVD6M-F2<4A4N\4)R(L0Z(NZ:6HR*
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M^Z,1-19EVP>P@SS[ ?:$.=\Q!Z8YEOQ,:7(HLQ@(C *1Y!SO9H(1U!I#7J#
M4)Y2^3TAF5!Q# TB\8[K9V%K#"^:$DI\",PN:)U%%-2L;'(7]ZIN$&BP9CK?
MD#(DVZC"TF(($9Q  N\:+85MMJ>%N*>YP8-O?"VRTDW[[?- <KN/KN=XZL'0
M_]'3(3^=3%K$S]+)2SH'7HQ4^(\D'SF^<FM5YB"J6J,7*U==,(5B'V(OC>(]
M P/Z8?5LJJ9T0>D"1&_N<1![2> /W21(@N$V-^L#7CF"U)L&$8XSSY].#J%Y
MTJ%Y<AC-CX_<E?-8JQTN/Z/ ]Q+=R.$:W;A /_(^9!_DWX_L+T^0)PPPAVB9
MB5)T\LE@T<I'AX!9[V)(N-VXEH+G)PR1C!T2A;O">XX*:U5CC65M*<#N#.I&
MU\JT1:P%1ELDC,C:U!%E0Q'JE?D$@![P^XS7=E^GBM['5Y2ZSTV%RF+]/'7.
MW0HZ@M";1:D;$X31&RX5=C,MW:53\2>LQ6<A3J8T)$D*;XL"6SRRVEF(N0V&
M9PT63T%9OK JNP6&"8%/#/E!U6VA34)D@:ILW?)S\F>(3)(_2??-[/SE;?U^
M!/X(/>,&_P7*75P<4;2C/0#[M(-]^NHB_E')U0G5O1R?8\,QGY</\"=7*\UJ
MS&6XP([>]"'_H(C7(-]2UPCNE,H( 9N2D,F'WPV4CVJQ5BU"LL"QHHIO]EK2
MU:.RF,RW1/N*JOD5JQTR7V#*<]=AS+!MH'H8^E[BQ_"!H2;NY9R%"8Y1$O>Z
M?KS78B/ 5^Y#@@HP9D7;;7>[W;?*1=NB/Y*W'SJ?F,9N &WG!5[U1RD^F[K]
M>&@75M6N85\JB^V_FZ[Q>XMK(L#S0BF[6Y" [@MN_A]02P,$%     @ K8 <
M60JO\Y+U P  ]P@  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULE59M
M;Z0V$/XK(^X:)1):P,#")KLK);FKVE.CBY)<JZKJ!R]XP3VP.=MD+__^QH:0
MI-ILVB]@#S/////B,<N=5%]US9B![VTC],JKC>E.@T 7-6NIGLF."?RRE:JE
M!K>J"G2G&"V=4=L$) SG04NY\-9+)[M6ZZ7L3<,%NU:@^[:EZN&"-7*W\B+O
M47##J]I80;!>=K1BM\Q\Z:X5[H()I>0M$YI+ 8IM5]YY='J16GVG\#MG._UL
M#3:2C91?[>;7<N6%EA!K6&$L L77/;MD36.!D,:W$=.;7%K#Y^M'])]=[!C+
MAFIV*9L_>&GJE9=[4+(M[1MS(W>_L#$>1["0C79/V VZ2>9!T6LCV]$8&;1<
M#&_Z?<S#,X,\?,6 C ;$\1X<.98?J*'KI9([4%8;T>S"A>JLD1P7MBBW1N%7
MCG9F?</NF>@9'-_13</TR3(PB&J_!<6(<#$@D%<0(@)74IA:PT=1LO(E0(!T
M)D[DD=,%.8CXJ1<SB$,?2$B2 WCQ%&/L\.(W8MPJV<(E<E78"YAG4\.ERS!3
M\-?Y1COYW_LR,. G^_'MN3G5'2W8RL.#H9FZ9][ZZ%TT#\\.L$\F]LDA]/4M
MGL.R;QC(+7S@FE:58A5U+8V2,;9]I _"[B=],RPTX&D'3;$A\."97@D-A<2#
MJ(WU:6K,I6SP/'-1P3$7*)&]IJ+4)Z?P)Z-* [.] %A)-E72/F*X8!47PAIN
M:$-%P> ]1&1AGW$$YV7);6@:(G]."#X768Y!#AR.41CE)_:]R,,3VW#_ HKC
M$>X-%N=8<UY0;;53XB_"S*U2/YXC"<UI<$T+ON4%'-&V.X./O<(Y"$GFDS2#
M-/?#.(,[:6B#"1JZZSTBAWXT3^PJBOUXD4_AH!H7PP1UHTB#D2Z-E[+MJ'@X
M>I>3*#O3$YAK5?2HZ) -EV,&K<0*:%X)2XT* Q63E:)=C;L&*$YE5-6@<9BC
M-^SOC9VZ_[=$7P0W^.764,-<AI+4GV>N1$GNIUB63Q19VSCG6 C[(29^F!,X
MT.[IU.[I?V[WL;DU;![@BOZ#/7FM9-GCX?T-K?;U_&'LNQ>-:^S$ UW+W5/>
MT5'K''6C(POA3H-K>JYMGA]>31_FUZ7PS11C' :5>0LX)[+D[*4_3'28^%&<
M0DIF(?QD!='"ST@(Z7P6H>!.]>RVX,RV_3Z$=(Z-2H#D3CM9^,D"/<<S@KO/
M&(J"&/&R#*+%;&$UT%UNN<TRB^X:^ZFAHS <:3PV]BC95^_@V66$IZQR5ZZ=
M'[TPP[TT2:=;_7RXS)[4AU^"*ZIP6&AHV!9-D1N65PW7[+ QLG-7VT8:'.-N
M6>.?"5-6 ;]OI32/&^M@^M=9_P!02P,$%     @ K8 <63GUH(H3 P  ] 8
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MH:G/V&E.C1VE,:#SE1!ZOS .^E]%\@]02P,$%     @ K8 <6:#M]G/M!
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M'I+Y%8-_:ITC]"&?KVO52NO,AUU#XMAM1DX<>J;G7O2G8Q('Q%X2KXC0>9X
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M.3[W7-MWN./B6:X!%'K)*),C9ZW4YMIU9;R&#,M+O@&FOZ1<9%CIJ5BY<B,
M)Q:443?PO)Z;8<*<:&C79B(:\EQ1PF FD,RS#(O?$Z!\-W)\9[\P)ZNU,@MN
M--S@%2Q /6QF0L_<BB4A&3!).$,"TI$S]J^G?1-O QX)[&1MC$PF2\Z?S>0N
M&3F>$0048F48L/[;PA0H-41:QJ^2TZFV-,#Z>,_^V>:N<UEB"5-.GTBBUB/G
MRD$)I#BG:LYW7Z#,IVOX8DZE_46[,M9S4)Q+Q;,2K!5DA!7_^*7TH0;P>T<
M00D(W@,Z1P!A"0AMHH4RF]8-5C@:"KY#PD1K-C.PWEBTSH8P4\6%$OHKT3@5
M+8KJ(9ZB!5DQDI(8,X7&<<QSI@A;H1FG)"8@41LM]!E*<@KH6XKNV!:8XAKZ
MB&F.;4WF($%L 9W?@,*$R@N#N9U6N!;R@[8W:.T#6S66-GI8W*#SLPMTA@A#
MW]<\EY@E<N@JG:81Z\9E2I,BI>!(2GZ [CE3:XEN60+)6P)7^U.9%.Q-F@0G
M&;_F[!*%7@L%7M!I$#3]=WAX0DY8U2RT?.&QFC59>L^WH&^7,N:]5F1,]37%
M+-;ETV;N?9?HQYQ3BO1%V&&1_&SRN)#0:99@WI9KN<$QC!S]>%A2)_KXP>]Y
MGYK\^4]D;]SJ5&YU3K%'$U@1QLQ)7F)JK&C*MJ#H6PKS\&WU*1H$0W=;SZ(I
MJ!M606_4=2MUW9/JQDE"3*4:SWD![=4V''C^.U&',;X_&#2+ZE6B>B=%/0FB
MH,W3M%%5[V#']M6!5PU!OBYHLZY^I:M_4I>^SW^I8_^P1.&!90U!]6(7TMS:
MFYJ!6-E6(Y%]%HN7HUJMNMG8/N+OUB>ZRQ5-Z96F:)'W6.BC*1&%5%-ZEWU=
M2U&TG6*B^,:^W$NN=!^PP[7NU"!,@/Z><J[V$[-!U?NC/U!+ P04    " "N
M@!Q9 <8ZX=("  "+"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RU
M5EEKW# 0_BO"A=)"&Q][)>FN(2=-:6#)TO2A]$&1QVL167(D.=Y ?WPEV^LX
ML*M B%]L7?/--X<T,Z^$O%<9@$:;G'&U\#*MBV/?5R2#'*L#40 W.ZF0.=9F
M*M>^*B3@I!;*F1\%P=3/,>5>/*_7EC*>BU(SRF$ID2KS',NG4V"B6GBAMUVX
MH>M,VP4_GA=X#2O0OXJE-#._0TEH#EQ1P9&$=.&=A,>GX<@*U"=N*52J-T;6
ME#LA[NWD*EEX@64$#(BV$-C\'N$,&+-(AL=#"^IU.JU@?[Q%OZR--\;<805G
M@OVFB<X6WJ&'$DAQR?2-J+Y#:]#$XA'!5/U%57-V9@Z34FF1M\*&04YY\\>;
MUA$]@7"\1R!J!:*:=Z.H9GF.-8[G4E1(VM,&S0YJ4VMI0XYR&Y65EF:7&CD=
MKYIH()&B%5USFE*"N48GA(B2:\K7:"D8)104^HJ6TF2#U$\(\P1=/)2T,/'1
MZ-,Y:$R9^CSWM:%D@7W2JC]MU$=[U/\H^0$:!5]0%$3CE^*^L:0S)^K,B6J\
M\1Z\RU)RJDL)-<64;NQ8[>+EQ+%WX5@5F,#",\FN0#Z"%W_\$$Z#;PZ6HX[E
MJ$8?[6&Y]>,7M&36VR_=^>>G.8ZN-.3J[R[FHP&8CSOF8Z=_+Y2FYBI @BPR
M)8"8N53*ID_13P[86K/+ +>*"7H"+)6#[*0C.W$BW4)&"=L=?J?D&YTX[7A-
M!PS_= #FLX[Y;/CPNU6\'O[#CNRA$^F:<IJ7.?K7?ZHH)ZQ,#&4B\J+4(%&&
M95+A]L50(M5VLO,I<ZI[H^>/.F..!LR9HP&8A\%SB0F&SYI7=(Q>39NP5Q)#
M=^+@S?LFCEO?6_W_7!/#:,#<"8>HE.%SJ0R=]>R=DL>MP_'F^+W6RK:IUUBN
M*5>(06J@@H.9*22RZ?R:B19%W6W="6UZMWJ8F6X9I#U@]E,A]'9B&[BN_X[_
M U!+ P04    " "N@!Q9K9ULKX,#  "0"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6RM5MMNVS@0_15"#18)D$8WRY>L+2"VN]@NT,*H-^TS(XTM
M(A*IDI3=_?L=4K(BN[*W"_C%YF7FZ)P9DC/3O9"O*@/0Y$>1<S5S,JW+1]=5
M208%50^B!(X[&R$+JG$JMZXJ)=#4.A6Y&WC>T"THXTX\M6LK&4]%I7/&826)
MJHJ"RG_FD(O]S/&=P\(7MLVT67#C:4FWL ;]7*XDSMP6)64%<,4$)Q(V,^?)
M?USXUL%:?&6P5YTQ,5)>A'@UDX_IS/$,(\@AT0:"XM\.%I#G!@EY?&] G?:;
MQK$[/J#_8<6CF!>J8"'R;RS5V<P9.R2%#:UR_47L_X1&4&3P$I$K^TOVC:WG
MD*126A2-,S(H&*__Z8\F$!T'?WC&(6@<@E.'P1F'L'$(K=":F96UI)K&4RGV
M1!IK1#,#&QOKC6H8-VE<:XF[#/UTO*[31\2&K-F6LPU+*-?D*4E$Q37C6[(2
M.4L8*/*>+$115IK:^*/#9SQE'WDB"B KD&2=40GD=@F:LES=H?WS>DEN;^[(
M#7&),KN*,$Z>.=/JOK/P=R8J17F*BS='\ZFK4:(AZB:-G'DM)S@CQP_()\%U
MIL@'GD)Z#.!B;-H !8< S8.+B']5_(&$WCT)O&#00VCQZ^[A!3IAFZ_0XH5G
M\#Y7!4BJA7SL"T[M.^CW-2_"HRII C,'K[P"N0,G_NV=/_1^[Q-V); CF8-6
MYN 2>FR.%K-'JT]F[3NRON:=VL7!)!Q-W5V7?H]1-/!:HR-:44LKNAC])7"!
ME_!L_*-KQO]*8$="AZW0X<7XSZEB"=G;1Q#2]W2'AVX+!!-2X-UOKBY6!:7Q
MGII7XI8=EN_Z E-_;=A)AA\,HO%)ROJLHFC4G[-1*V5T,6<?-ALL&>:]2EE>
MF:)!%"259!H?M=XLCJZ9Q2N!'4D?M]+'%[.XUB)Y)71/9:H()HJ(TKS=ZK^R
M-?XI#U%PFJN?;?PSEVO2LIU<9+LTZ8'TBJ=NTG.>)N/AB9(^JVAXYM3YWEMA
M]2[*:2ICB9714KPW[09>JMM4Y#F5ZFVGEWN#/NG0\AY,!3KBWF]UAGJG)_#_
M)_6TR<VODO?[:(6GY'NM3LB[G=X&2]_6MGR*V/:DKN+M:MM6/MEFZF1];MI-
MVS.]P=2]ZB<JMPQO10X;A/0>1OCRRKK]JR=:E+:#>A$:^S$[S+!E!FD,<'\C
MA#Y,S ?:)CS^%U!+ P04    " "N@!Q9VR>+'[$"  #9"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6S%5EU/VS 4_2M7&9I &B1-^K&Q-A*4H8&8
M5)&Q/4Q[,,E-:N'8F>VT[-_/=D+40ELQK=)>&G_<<W+/N==UQDLA']0<4<-C
MR;B:>'.MJU/?5^D<2Z).1(7<[.1"ED2;J2Q\54DDF0.5S ^#8.B7A'(O'KNU
MF8S'HM:,<IQ)4'59$OG[')E83KR>][1P2XNYM@M^/*Y(@0GJNVHFS<SO6#):
M(E=4<)"83[RSWNET9.-=P#>*2[4R!JOD7H@'.[G*)EY@$T*&J;8,Q#P6.$7&
M+)%)XU?+Z76OM,#5\1/[I=-NM-P3A5/!OM-,SR?>>P\RS$G-]*U8?L96S\#R
MI8(I]PO+-C;P(*V5%F4+-AF4E#=/\MCZL +H];< PA80OA80M8#("6TR<[(N
MB";Q6(HE2!MMV.S >>/01@WEMHJ)EF:7&IR.DZ9Z(')(:,%I3E/"-9REJ:BY
MIKR F6 TI:C@&!(L3 $U7/&F?6P=#B]0$\K4D=F_2R[@\. (#H!R^#H7M2(\
M4V-?FT3MZ_RT3>J\22K<DM1US4\@"MY!&(3]#?#IZ^'1.MPW]G0>A9U'H>/K
M;^&[XU1C!HDF&C>JV0FWY_!4523%B6<.FD*Y0"]^^Z8W##YNTK8GLC6E4:<T
M<NS1%J6WN$!>FUKG4I3PZ5&CY(3!U/4A2@6FGG C>'%\8PY?!F=*H5;PX\;P
MP)7&4OW<Y$^T3W_V1+;F3[_SI[^S$YQTYJ03)WV3VH9BY"CLG^@B[GT(>\.Q
MOUB5\3(J# 9!OXM:RV_0Y3?8F=\UJ0C?E--.V-]68$]D:PJ'G<+A_^C0X3[]
MV1/9FC^CSI_1OW?H:%.'#IXUZ,N@:/"\/?V5B\=>^E^(+"A7P# WJ.!D9%I%
M-A=I,]&B<G?1O="F7FXX-]\>*&V V<^%T$\3>[UU7S/Q'U!+ P04    " "N
M@!Q9L^[R<C@%   @)0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RU
MFEMOFT@4Q[_*R%NM6JF- =^[MJ4FW++:5E'2[CZL]F$,QS8R,-YAB!-I/_S.
M ,;&P01'IR\V#.?\YO9GSG TTQWCFV0-(,A3%,;)K+,68ONYVTV\-40TN6);
MB.63)>,1%?*6K[K)E@/U,Z<H[!J:-NQ&-(@[\VE6=L?G4Y:*,(CACI,DC2+*
MGZ\A9+M91^_L"^Z#U5JH@NY\NJ4K> #Q8WO'Y5VWI/A!!'$2L)AP6,XZ7_3/
MKCY4#IG%GP'LDJ-KHKJR8&RC;F[]64=3+8(0/*$05/X]P@V$H2+)=OQ;0#ME
MG<KQ^'I/M[/.R\XL: (W+/PK\,5ZUAEWB ]+FH;BGNU<*#HT4#R/A4GV2W:%
MK=8A7IH(%A7.L@51$.?_]*D8B",'PSCC8!0.QHE#[UP-O<*AU[:&?N'0;^LP
M*!P&IPZ3,P[#PF%XVH?^&8=1X3!JZS N',;9[.;3D<VE206=3SG;$:ZL)4U=
M9(+(O.44!K'2[H/@\FD@_<3\'AXA3H%\(M\HYU0)B;PW0= @3#Z0=R2(R?<U
M2Q,:^\FT*V2-RJ_K%?3KG&Z<H>L&^<IBL4Z(%?O@5P%=V=2RO<:^O==&(_'W
M-+XB/>TC,32C3WX\F.3]NP\U#;MY X8DL)*OI:C!F3BMLG P]ELZQV$E%XL:
MFO,6VI8S/_7$']*X!NFV1_9>1U:$TBN%W<OJZ+TB["5G$;&>!/"8AN0F>Z.
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M4NU[>1D3'!%>!*CW:\;D_J98H/EGQO(_4$L#!!0    ( *Z '%G2^B$?W0,
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M'Y0=R;+B"/[ I#K0%\T(2 A<&ZCG:\;D4T=/4-_B^/\#4$L#!!0    ( *Z
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MS*QN!\XM3#'HWQ&QH$RB%.8:,KCHZZT7Q>Q<+!1?V?%SRI4>9NWC$G1Y%$9
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M6RRM4:/KAV$?:.EL<1%)C:3L^-_O2-F*:BM*9C0?(I+BO3RGX_$\VDEUKU,
M0QYX)O382XW);WQ?QREPJJ]E#@+?K*7BU.!4;7R=*Z")$^*9'P5!W^>4"6\R
M<FL+-1G)PF1,P$(177!.U7X&F=R-O= [+GQEF]38!7\RRND&EF"^Y0N%,[_2
MDC .0C,IB(+UV)N&-_/0";@=?S+8Z=J86)25E/=V\C$9>X'U"#*(C55!\;&%
M.629U81^_'M0ZE4VK6!]?-3^NX-'F!75,)?9=Y:8=.P-/9+ FA:9^2IW'^
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MKY'RDXNG+>;DYEXE(@1+EJCJ$%CG]P8\$B%YM)+JB[82X,,G(G$4BX_JZX_
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M\.XYWMF7R5[(.Y4":'*?9UQ-G53K[:7KJCB%G*HSL06.;]9"YE3C4FY<M95
M$PO*,S?PO)&;4\:=<&+W%C*<B$)GC,-"$E7D.94/,\C$?NKXSN/&#=NDVFRX
MX61+-[ $?;M=2%RY-4O"<N"*"4XDK*?.E7\9^19@+?YAL%>-9V)"60EQ9Q9?
MDJGC&8\@@U@;"HH?.YA#EADF].-G1>K49QI@\_F1_;,-'H-9405SD7UGB4ZG
MSH5#$EC3(M,W8O\G5 &=&[Y89,K^)?O*UG-(7"@M\@J,'N2,EY_TOA*B ?!'
M+P"""A \!PQ?  PJP.!8P+ "#*TR92A6AXAJ&DZDV!-IK)'-/%@Q+1K#9]SD
M?:DEOF6(T^$RI1(^SE"YA,Q%CM=)49N0CV0!TMXK'@.Y :4EBS5:+;6([\@M
M9UI](%^IE-1DCKR+0%.6J?='(='H=AF1=V_>DS>$<?(M%86B/%$35V-4QC<W
MKB*8E1$$+T3@!^1:<)TJ\@=/(#DD<%&.6I/@49-9T,GX5\'/R,#[0 (O&+8X
M-#\>/FB!1\?#_8YH!G6&!Y9OT)GAU:\9OL+4\0U@$6NR>B!-NP5]L-M7>RH3
M\N-OI"1?-.3JW[;\E.</V\\WC>M2;6D,4P<[DP*Y R=\^YL_\GYOT[9/LJ@G
ML@/=A[7NPR[V,&+FXJ\*J_469(R"8B<E8DTTE1MLZ;S(5R#-1K-@&E72)G;G
MH:>*W2=95)+Y9:<QWS>[T)NXNQ8)SVL)SSLE_$R9)#N:%5:U'782O)O4W,E6
M:4JR<>-\=/7)A3+D7XV&AQ91IT__\]*,ZHA'G1%?,\[R(F^+KA-X:N+[)(MZ
M(CL0;%P+-G[E[C;N4_<^R:*>R YTOZAUOWB-[M9YZ*EB]TD671S=W3[5$G[J
MKG5Z_U*M=P)/E:%/LJ@GL@/!?._IQZKWRM5>.="3]+VR17VQ'8K?F!3\URCY
M[E-/5KQ/MJAB.ZCZX%G5NXWA*P?4P0RQBL2BX+J<.>K=>E"^LN/AL_V9?SDO
MQ]TGFG+ZOD9Y&5<D@S52>F=C_(DBRX&V7&BQM2/>2F@<&.UC"C0!:0SP_5H(
M_;@P!]3_5@C_ U!+ P04    " "N@!Q9@/I=RX4#   %#0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6RMEVUOVS80@/\*H0U%"RS6JV4[LP7$[KIN
M0(<@6=//C'2VB$BD2])V]^]+4K(LR[0B#/EBB?+=\;GCZ>XT/S#^(G( B7Z4
M!14+)Y=R>^NZ(LVAQ&+$MD#5/VO&2RS5DF]<L>6 ,Z-4%F[@>;%;8D*=9&Z>
MW?-DSG:R(!3N.1*[LL3\OR44[+!P?.?XX(%L<JD?N,E\BS?P"/+K]IZKE=M8
MR4@)5!!&$8?UPKGS;U=^I!6,Q!.!@VC=(^W*,V,O>O%7MG \300%I%*;P.JR
MAQ44A;:D.+[71IUF3ZW8OC]:_V2<5\X\8P$K5GPCF<P7SM1!&:SQKI /[/ 9
M:H?&VE[*"F%^T:&6]1R4[H1D9:VL"$I"JRO^40>BI>#'5Q2"6B'H*D17%,):
M(32.5F3&K8]8XF3.V0%Q+:VLZ1L3&Z.MO"%4'^.CY.I?HO1D\IAC#C=+%8@,
MK5BILD-@$]\;= _<I E- 3V D)RD4DD]2I:^H*^42('>?P2)22$^#!._0;\B
M%PF]I3A>"$7_YFPG,,W$W)7*)0WFIC7^LL(/KN#[ ?K"J,P%^H-FD)T;<%4L
MFH $QX L@UZ+?^_H"(7>;RCP@L@"M!JN'O;@A,WYA,9>V'<^UL!4>I%=3[_]
MMV*+4U@XZO46P/?@).]^\6/O=YM3;V3LS,6H<3'JLY[\P^A>Y8O*E6?8$$H)
MW: M<,(R]%YE1Y4G'VPAJ.S&QJZN5_LDF@5S=]_V[%+&;R3.<,<-[K@7]T^.
MJ89]A6U\L6\X]CILES)C?VJGBQNZN)?NJ8KD*W#QQ<8WP33JT%F$KH1NTL!-
M>N%4X5T#&< WL?!-NGPVH=@..&T IP-3$6@V/ ^G%R27T;R4:>?J&>VLH9WU
MUH9OID<IV+L]<-5SD4E-I/H H$^8</2$BQW8@&=O63O>R-A9"'SOU+^\_UT]
M,E84F N]KH[/>GKU!K/VT8R"[OG54N-V(1F/KIR@WVJ__K!J,I"U[N;!&>QT
MUH6UBK5\.J<-3K3!H.HR$#9XA:*&K<6B8:$]=4Z_MVNUJ\U WM#&&T^[O%:Q
M8'*%]]0&_:%]L%-\!M)'EC2.N^W0*G61&&YKH"R!;\R<+5#*=E16HU3SM)GE
M[\P$VWF^U#.^&51/9JH/A"^8J]=5H +6RJ0WFJ@WBU<S=[60;&O&UF<FU1!L
M;G/UG0)<"ZC_UXS)XT)OT'SY)#\!4$L#!!0    ( *Z '%GTCU&\K (   4'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;*U5R6[;,!#]%4(-B@1(
MHLV6TU06$#L)F@)I@RSMH>B!EL86$8I42<I._KY<9-5Q9:.'7B0N,V_>/'*&
MZ8J+9UD"*/1242;'7JE4?>[[,B^APO*4U\#TSIR+"BL]%0M?U@)P89TJZD=!
MD/@5)LS+4KMV)[*4-XH2!G<"R::JL'B= .6KL1=ZZX5[LBB56?"SM,8+> #U
M5-\)/?,[E()4P"3A# F8C[V+\'R:&'MK\(W 2FZ,D<EDQOFSF=P48R\PA(!"
MK@P"UK\E3(%2 Z1I_&HQO2ZD<=P<K]&O;>XZEQF6,.7T.RE4.?;./%3 '#=4
MW?/5)VCS&1J\G%-IOVCE;(<##^6-5+QJG36#BC#WQR^M#AL.8;+#(6H=HFV'
M71'BUB&VB3IF-JU+K'"6"KY"PEAK-#.PVEAOG0UAYA0?E-"[1/NI[*LJ0:"K
M%WTK)!RC+_K>'%Z"PH3*(W2"GAXNT>'!$3I A*''DC<2LT*FOM*A#8"?MV$F
M+DRT(TP8H5O.5"G1%2N@> O@:\X=\6A-?!+M1?S<L%,4!\<H"J)!#Z'IO[O'
M>^C$G8ZQQ8OWZGC#<EX!TAJM)97HQ\5,*J&OZ\\^V1SJH!_5E/"YK'$.8T_7
MJ 2Q!"][_RY,@H]]*?\GL#<"##H!!OO0,UU4NF28OK-" ,M?D<Z92>R*E7(I
MCQ$#U2>!PQU97--TEMG)(/J0^LO-U'J,XE'<&;VA/.PH#_=2=F=&W)D=@CNP
MHYT\'5BR02$<;;'\V^3D;-A/,NE()GM)/G*%*>*6*JS+= ?#I$?),-KBV&<T
M/-LBZ6]TE K$PC9:B7+>,.5JM%OM>OF%;6%;ZQ/=XUU+_@/C'HA;+!:$241A
MKB&#TY$63[BFZR:*U[9OS;C27= .2_U.@3 &>G_.N5I/3(#NY<M^ U!+ P04
M    " "N@!Q9A^1\/+8#  !1#@  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6RM5U&/FS@0_BL65YU:J5TP$"!["5*3M+H]J=6JN[U[]H9)@@IVSG:2
MO7]_-A!"P/AZ4EX2;,]\_F8\X_',3HS_$#L B5[+@HJYLY-R?^^Z8KV#DH@[
MM@>J5C:,ET2J(=^Z8L^!9)526;B^YT5N27+JI+-J[I&G,W:014[AD2-Q*$O"
M_UE P4YS!SOGB6_Y=B?UA)O.]F0+3R"_[Q^Y&KDM2I:70$7.*.*PF3L?\?T2
MQUJADO@SAY/H?"-MR@MC/_3@(9L[GF8$!:REAB#J[PA+* J-I'C\W8 Z[9Y:
ML?M]1O]<&:^,>2$"EJSX*\_D;NXD#LI@0PZ%_,9.OT-CT$3CK5DAJE]TJF6C
MJ8/6!R%9V2@K!F5.ZW_RVCBBHX"C$06_4?#["N&(0M H!)6A-;/*K!61))UQ
M=D)<2RLT_5'YIM)6UN14'^.3Y&HU5WHR?:!K5@)Z)J\@T =T&:)/KRI4!*"W
M*Y D+\0[M?S]:87>OGF'WJ"<HN<=.PA",S%SI6*B\=QUL^NBWM4?V17[Z NC
M<B?0)YI!=@W@*A-:._RS'0O?BOC'@=ZAP'N/?,\/#826/Z\>6.@$K5N#"B^P
MNW4!*M$ =9U\;_)6#1::P70FWXL]6</<4:DJ@!_!27_]!4?>;R9+;P1V97?8
MVAW:T-.5LE/(?&TRLM:,*TU]NQQ3?QIZ,_?8)6\0"J.P%;HB-6E)3:RD'J@$
M3HF^-DAA8E:K1YU-<8C[S Q"DV!B9A:US*+_8%8%QDL=)GD]DCI,3#2C 8,P
MF/1I#H6"Z71JIAFW-&-K-"\/G .5E@".;QG -P*[,C5I34VL)_(9,N#F*$D,
M43*)>^X?"OD>]LWNG[:<IE9.3Y)(,#&:#C<+HQZAH4P81&8^V+L4#<_N)16N
M^98:+WYOL.$T"7ND#$)1,L:J4\JPE=4SDZ1 YV#ME+)'SHZY?G@8">.A%Z.D
M?ZX&J0 '(Q<3]B^4?6MFK6 #BFYF2:T&X4:Y=2NT:WLO91%;JX\MO1K-KH<_
M8#_!_8,PB86>-W(2E\*%[95K-,D:O>L-)P-:!JG "T9872H7MI<N6Z*9"E+2
MIS44\I,14I>BA>U5J\ZS-G1_.M&&I4D=<#RX&TQB43Q2:?&EAF%KW4B_PO^X
M$^+!,T2]"((^4Y/4I%]KW<[CO 2^K7H6@=;L0&7]OFUGV[[H8]4-].87NE^J
M'OT7F+K9^D+X-J<"%;!1D-Y=K$Z=U_U+/9!L7[4 +TRJAJ+ZW*F>#[@64.L;
MQN1YH#=HN\CT7U!+ P04    " "N@!Q9O5?\MBH%  !'%   &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6RM6&UOVS80_BN$APT9T%@B_9K4,="X+=9A
MW8*DW3XSTLD6*I$>2=G)O]]1DB5;H>A@2#[$HG1W?.YXO.?(Q5ZJ'WH#8,A3
MG@E],]@8L[T. AUM(.=Z*+<@\$LB5<X-#M4ZT%L%/"Z5\BQ@83@-<IZ*P7)1
MOKM3RX4L3)8*N%-$%WG.U?,M9')_,Z"#PXO[=+TQ]D6P7&SY&A[ ?-_>*1P%
MC94XS4'H5 JB(+D9?*#7*S:R"J7$WRGL]=$SL:X\2OG##K[$-X/0(H(,(F--
M</S9P0JRS%I"'/_61@?-G%;Q^/E@_7/I/#KSR#6L9/9/&IO-S6 ^(#$DO,C,
MO=S_!K5#$VLODIDN_Y-]+1L.2%1H(_-:&1'DJ:A^^5,=B",%.NU18+4"ZRJ,
M>Q1&M4(9N:!"5KKUD1N^7"BY)\I*HS7[4,:FU$9O4F&7\<$H_)JBGEE^$9',
M@7SC3Z#))?F4)% &EK0?R#TW0"X^@N%IIG]=! ;GM=I!5,]Q6\W!>N:@C'R5
MPFPT^21BB$\-! BX0<T.J&^9U^+OA1B24?B.L)"-'8!6KU<?>>",FB".2GNC
M'GO?-D"@B5Q:1<Y@Y)2-7)SB)Z5)HF1.#(I^'SX,R6>(0?&,:,--8:1Z[NJY
MXES!&+MAV!U_K;<\@IL!;FD-:@>#Y2\_T6GXWA6C-S)V$K%Q$[&QS_KR?WE?
MF:15*MOZM%N&0T87P>[8K7-2)W@G#=Z)%^^#L2O98@3]C@@LLC(A2>W*(PA(
M4N,"7MFFX0FDD+(.<K=8.'=#GS;0I_Y02X6U3'3S$43D#/+4%;XC#!74J1/J
M?.2&.FN@SKQ0;;%18 J%:"79*KE+2[HPJH#+8NN"ZS=X,1Z.PI]=)6LU<WHP
M8FX/YHT'<^^$?Z1YBEDA2%*@&X#Y+:,?!+,&:5?SDKCB JQW=,HN<F<QG3N1
ML>X2N,7&/4MPU3AP]:ILV:=FLY%9G(JUS1P7SBLWSFD'IULL'+MQTK EKM"+
M]"\LI>HHF;63F$+WUNN"/#/71>C(HU/<1X1+O;;N8<<SS $L'=AN@%(0$VS'
M2+3A8FUK3%-1?+6PGN1TGW:=HN[0]]1"REH7F)?O[@ ;* '"'(?_V@F3O25C
MO96U4[=;EJ=>2D13<T;9^VI37]KF,3[9VLX ^$U>S'L+5*W97;U)#QW0EGJI
MGWL/;D0%YAZNX3-P[.OKMKHJ2R2S=:S?*2?'AK/PY*]+S$ZM'F=:7J9^8CXX
MD]1U"W<.]F Q;B.#VRE]S!K6QLZSB'H]\L^"^W_6MTQG-"?#^9G*T1(Y]3/Y
MP5=;%R(L&ZEQUSR_E0O*AK3/F3.JD[-EL*5ZZJ?F@S,Y\$P3+F*"N0@*SQ@"
M3XG.-HJZ.9N.NHGFENMKI&A+[M3/[@?,"G*)1=R6<![C,F!2X6C;5$5,1;$#
M;:PCA&NL1%;$O5AN&G_1&_;(A3UT3UN^IW[";ZI!0S\%5O-R'<I$VTJ=]J-W
MD_M+]%>OWOJL;0"8GY0/R'D4J0+C;TDT.6IV>=&W0YB[*YC-.K /<J^!W?(_
M\_/_ ;8L^Y>MBTJ=F-UD3KMM88]<WP&(M:3/O.RZ7#4)8ON7JI?E62;WO.<D
M4=M[D;*3+N(>N5D/XI:OF9]<_\0#VM&QLCE/.,$ZV7;$7H!URTTG';#!T95,
M#FI=WE1I;!<*8:I[CN9M<QOVH;P#ZKR_I=>KZDZK-5-=L7WE:IT*33)(T"0R
M%#*1JFZMJH&1V_+BYU$:(_/R<0,<&=(*X/=$2G,8V F:N\/E?U!+ P04
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MM4??CL26P'UO?H%Z;W<%%-H["L2NU)8CL9!*^+6+X JS3E%&(S'1"!>C41D
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MF>)C!M($X/Q2"+WKF 7JYS'Z#5!+ P04    " "N@!Q9+:0N7J #   O$
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M#//6\R(]E--#.9;E0T;-!\OCYV3F\L\TRY(D3;$5'8V\#D;8NJ4I_/C5,&_
MP/) IC];:WRW\0K97P?8GNZK$&RF>"5B,\77&A#_N@$CR_R[C>4!!K8+6.U
M?G\>J"D_)TE@5S%OV!.,(UF&(5"+_AI-4V1U4OCX]P=[2I(DR_P(8'X'28(A
M\#3B".8 /&!(DC3OP9WW4;1Z3T7K_^ .?P-02P,$%     @ KH <69>*NQS
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MKE= >J>C"/-+1.R7-\B4PQS.;H2KC'KE]#$QTT3$IGG#A%J+KU9&K-J$ L8
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( *V '%FDB&T8[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( *V '%F97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ K8 <
M68<"1-15"   O3(  !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( *V '%D\$_CM0 (  ,(%   8
M      " @9D0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" "M@!Q9]49<9'\&  !@&P  &               @($/$P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ K8 <68+"*Y'W @  40H  !@
M             ("!Q!D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( *V '%E/*X"'P04  $T8   8              " @?$<  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "M@!Q9I->.*VD'  "$
M-@  &               @('H(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ K8 <66_R_9)O!P  RR   !@              ("!ARH
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *V '%E6T+Z<
M^ 4  % -   8              " @2PR  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " "M@!Q9N/L;J&T8   T2@  &
M@(%:.   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ K8 <
M639ZQH*Y"@  EQL  !D              ("!_5   'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " "M@!Q96;/8Z>P"  "&!@  &0
M        @('M6P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( *V '%G2PGY?(@,  $X'   9              " @1!?  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ K8 <6<#AV7B[ @  . 8
M !D              ("!:6(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " "M@!Q9GS60.;H*   S'P  &0              @(%;90
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *V '%ER+KJH
M 0D  #<8   9              " @4QP  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ K8 <65X_NWQ"#   &B8  !D
M ("!A'D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "M
M@!Q9K&FS@'8"  ")!0  &0              @(']A0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *V '%DE).7-_ L  !$A   9
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M970R,BYX;6Q02P$"% ,4    " "M@!Q95+3N#0,8  #Y3   &0
M    @($CIP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M *V '%D25V=+; 4  ,T-   9              " @5V_  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ K8 <60JO\Y+U P  ]P@  !D
M             ("! ,4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " "M@!Q9.?6@BA,#  #T!@  &0              @($LR0  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *V '%EUF?<<IP(
M /X%   9              " @7;,  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ K8 <6<(PNO?( @  -@8  !D              ("!
M5,\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "M@!Q9
MH.WV<^T$   G$   &0              @(%3T@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *V '%E7X:0NA0(  (L%   9
M      " @7?7  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ K8 <68;<9U*<!@  )1$  !D              ("!,]H  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "M@!Q95DU0J)T#  "-"
M&0              @($&X0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( *V '%F)OK8.7P(  !L&   9              " @=KD  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ KH <674*NRHF
M!0  SB(  !D              ("!<.<  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " "N@!Q9$X2T1:X"   D"   &0
M@('-[   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *Z
M'%EM;QJ6^@(   <(   9              " @;+O  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ KH <60'&.N'2 @  BPL  !D
M         ("!X_(  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " "N@!Q9K9ULKX,#  "0"P  &0              @('L]0  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *Z '%G;)XL?L0(  -D(
M   9              " @:;Y  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ KH <6;/N\G(X!0  ("4  !D              ("!COP
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "N@!Q9[0NP
MU-D"  "Y!P  &0              @('] 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( *Z '%DJ4 XM<0,  /@/   9
M  " @0T% 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MKH <67A2\F=+!   V!@  !D              ("!M0@! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " "N@!Q9TOHA']T#  #1$0  &0
M            @($W#0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( *Z '%D0VBU1[0,  ,T0   9              " @4L1 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ KH <69I[[<P4 P
ME D  !D              ("!;Q4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " "N@!Q92E$+R(,%  #%*0  &0              @(&Z
M& $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( *Z '%G!
MC6+:H@8  .@Y   9              " @70> 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ KH <60"XP[Y;!0  +BD  !D
M     ("!324! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z '%F:]J.TH 0  ($7   9              "
M@1([ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ KH <
M63[9%!;> @  LPD  !D              ("!Z3\! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " "N@!Q9>9TC8F\#  !B$   &0
M        @('^0@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( *Z '%F ^EW+A0,   4-   9              " @:1& 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ KH <6?2/4;RL @  !0<
M !D              ("!8$H! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " "N@!Q9A^1\/+8#  !1#@  &0              @(%#30$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( *Z '%F]5_RV
M*@4  $<4   9              " @3!1 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ KH <6<U.?9Y?!   XQ(  !D
M ("!D58! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "N
M@!Q9PQ#1H)0#  #!#@  &0              @($G6P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( *Z '%F$/>M.PP(  "H'   9
M          " @?)> 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#
M%     @ KH <62VD+EZ@ P  +Q   !D              ("![&$! 'AL+W=O
M<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "N@!Q9,U>NB+<"  !_
M!P  &0              @('#90$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM
M;%!+ 0(4 Q0    ( *Z '%G%% K(J0(  ) &   9              " @;%H
M 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ KH <62GS
MF6VN @  L@<  !D              ("!D6L! 'AL+W=O<FMS:&5E=',O<VAE
M970V-RYX;6Q02P$"% ,4    " "N@!Q9=SQ505$#  #.%0  #0
M    @ %V;@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *Z '%F7BKL<P
M !,"   +              "  ?)Q 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M *Z '%F_</7\4 4  "<L   /              "  =MR 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "N@!Q9R%S!4B "  #0)P  &@
M@ %8> $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "N
M@!Q9XB$R0O$!   9)P  $P              @ &P>@$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     2P!+ (04  #2? $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Other Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherAccruedExpenses</Role>
      <ShortName>Other Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Other Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherExpenseNet</Role>
      <ShortName>Other Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/Revenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Other Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherAccruedExpensesTables</Role>
      <ShortName>Other Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/OtherAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Other Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherExpenseNetTables</Role>
      <ShortName>Other Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/OtherExpenseNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - The Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/TheCompanyDetails</Role>
      <ShortName>The Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/TheCompany</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Revenue - Sales Return (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/RevenueSalesReturnDetails</Role>
      <ShortName>Revenue - Sales Return (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Revenue - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Revenue - Major Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/RevenueMajorProductsDetails</Role>
      <ShortName>Revenue - Major Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Other Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherAccruedExpensesDetails</Role>
      <ShortName>Other Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/OtherAccruedExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/LongTermDebt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/StockholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Share-Based Compensation - Equity-Settled Plans, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Equity-Settled Plans, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Share-Based Compensation - Stock-Based Compensation, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Stock-Based Compensation, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Share-Based Compensation - Stock Options, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Share-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Share-Based Compensation - Restricted Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Share-Based Compensation - Restricted Stock, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Performance Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/OtherExpenseNetDetails</Role>
      <ShortName>Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lifevantage.com/role/OtherExpenseNetTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income Taxes - Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Leases - Schedule of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lfvn-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lfvn-20240630.htm">lfvn-20240630.htm</File>
    <File>lfvn-20240630.xsd</File>
    <File>lfvn-20240630_cal.xml</File>
    <File>lfvn-20240630_def.xml</File>
    <File>lfvn-20240630_lab.xml</File>
    <File>lfvn-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="676">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lfvn-20240630.htm": {
   "nsprefix": "lfvn",
   "nsuri": "http://www.lifevantage.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "lfvn-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "lfvn-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lfvn-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lfvn-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lfvn-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lfvn-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 329,
   "keyCustom": 37,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 14,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 6
   },
   "contextCount": 132,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 633,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 676,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.lifevantage.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.lifevantage.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.lifevantage.com/role/TheCompany",
     "longName": "9952156 - Disclosure - The Company",
     "shortName": "The Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.lifevantage.com/role/Revenue",
     "longName": "9952158 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.lifevantage.com/role/PropertyandEquipmentNet",
     "longName": "9952159 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.lifevantage.com/role/IntangibleAssetsNet",
     "longName": "9952160 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.lifevantage.com/role/OtherAccruedExpenses",
     "longName": "9952161 - Disclosure - Other Accrued Expenses",
     "shortName": "Other Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.lifevantage.com/role/LongTermDebt",
     "longName": "9952162 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.lifevantage.com/role/StockholdersEquity",
     "longName": "9952163 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensation",
     "longName": "9952164 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.lifevantage.com/role/OtherExpenseNet",
     "longName": "9952165 - Disclosure - Other Expense, Net",
     "shortName": "Other Expense, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.lifevantage.com/role/IncomeTaxes",
     "longName": "9952166 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.lifevantage.com/role/Leases",
     "longName": "9952167 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.lifevantage.com/role/CommitmentsandContingencies",
     "longName": "9952168 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.lifevantage.com/role/RevenueTables",
     "longName": "9954473 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.lifevantage.com/role/PropertyandEquipmentNetTables",
     "longName": "9954474 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.lifevantage.com/role/IntangibleAssetsNetTables",
     "longName": "9954475 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.lifevantage.com/role/OtherAccruedExpensesTables",
     "longName": "9954476 - Disclosure - Other Accrued Expenses (Tables)",
     "shortName": "Other Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationTables",
     "longName": "9954477 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.lifevantage.com/role/OtherExpenseNetTables",
     "longName": "9954478 - Disclosure - Other Expense, Net (Tables)",
     "shortName": "Other Expense, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesTables",
     "longName": "9954479 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.lifevantage.com/role/LeasesTables",
     "longName": "9954480 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.lifevantage.com/role/TheCompanyDetails",
     "longName": "9954481 - Disclosure - The Company (Details)",
     "shortName": "The Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)",
     "shortName": "Summary of Significant Accounting Policies - Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule Of Inventory Valuation Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Computation of Net Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.lifevantage.com/role/RevenueNarrativeDetails",
     "longName": "9954488 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lfvn:MoneyBackGuaranteePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lfvn:MoneyBackGuaranteePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
     "longName": "9954489 - Disclosure - Revenue - Sales Return (Details)",
     "shortName": "Revenue - Sales Return (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-45",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
     "longName": "9954490 - Disclosure - Revenue - Disaggregation of Revenue (Details)",
     "shortName": "Revenue - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-49",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
     "longName": "9954491 - Disclosure - Revenue - Major Products (Details)",
     "shortName": "Revenue - Major Products (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-59",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
     "longName": "9954492 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.lifevantage.com/role/IntangibleAssetsNetDetails",
     "longName": "9954493 - Disclosure - Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.lifevantage.com/role/OtherAccruedExpensesDetails",
     "longName": "9954494 - Disclosure - Other Accrued Expenses (Details)",
     "shortName": "Other Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.lifevantage.com/role/LongTermDebtDetails",
     "longName": "9954495 - Disclosure - Long-Term Debt (Details)",
     "shortName": "Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-90",
      "name": "lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "lfvn:DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.lifevantage.com/role/StockholdersEquityDetails",
     "longName": "9954496 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
     "longName": "9954497 - Disclosure - Share-Based Compensation - Equity-Settled Plans, Narrative (Details)",
     "shortName": "Share-Based Compensation - Equity-Settled Plans, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
     "longName": "9954498 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)",
     "shortName": "Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
     "longName": "9954499 - Disclosure - Share-Based Compensation - Stock-Based Compensation, Narrative (Details)",
     "shortName": "Share-Based Compensation - Stock-Based Compensation, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
     "longName": "9954500 - Disclosure - Share-Based Compensation - Stock Options, Narrative (Details)",
     "shortName": "Share-Based Compensation - Stock Options, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails",
     "longName": "9954501 - Disclosure - Share-Based Compensation - Stock Options (Details)",
     "shortName": "Share-Based Compensation - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
     "longName": "9954502 - Disclosure - Share-Based Compensation - Restricted Shares (Details)",
     "shortName": "Share-Based Compensation - Restricted Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-112",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
     "longName": "9954503 - Disclosure - Share-Based Compensation - Restricted Stock, Narrative (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
     "longName": "9954504 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details)",
     "shortName": "Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-121",
      "name": "lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
     "longName": "9954505 - Disclosure - Share-Based Compensation - Performance Restricted Stock Units (Details)",
     "shortName": "Share-Based Compensation - Performance Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.lifevantage.com/role/OtherExpenseNetDetails",
     "longName": "9954506 - Disclosure - Other Expense, Net (Details)",
     "shortName": "Other Expense, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails",
     "longName": "9954507 - Disclosure - Income Taxes - Income Tax Expense (Details)",
     "shortName": "Income Taxes - Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lfvn:UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lfvn:UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets, Valuation Allowance Schedule (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.lifevantage.com/role/LeasesNarrativeDetails",
     "longName": "9954512 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails",
     "longName": "9954513 - Disclosure - Leases - Schedule of Lease Cost (Details)",
     "shortName": "Leases - Schedule of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails",
     "longName": "9954514 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "longName": "9954515 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lfvn-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Accrued Expenses",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r762"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued incentive compensation",
        "label": "Accrued Bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance",
        "label": "Accrued Employee Benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r120"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "totalLabel": "Total other accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued incentives and promotions to consultants",
        "label": "Accrued Marketing Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_AccruedPayableToVendors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "AccruedPayableToVendors",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payable to vendors",
        "label": "Accrued Payable to Vendors",
        "documentation": "Accrued Payable to Vendors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalesCommissionCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commissions payable",
        "label": "Accrued Sales Commission, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r724"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r180",
      "r599"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r78",
      "r187",
      "r595",
      "r620",
      "r621"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r18",
      "r499",
      "r502",
      "r545",
      "r616",
      "r617",
      "r896",
      "r897",
      "r898",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In\u00a0Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r912",
      "r913",
      "r914",
      "r915",
      "r992",
      "r1040"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares canceled or surrendered as payment of tax withholding and other",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r400"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r809",
      "r819",
      "r852"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r812",
      "r822",
      "r855"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r847",
      "r856",
      "r860",
      "r868"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AmericasMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "Americas [Member]",
        "documentation": "Continents of North and South America."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r887",
      "r888",
      "r889",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred financing fees",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r351",
      "r900",
      "r996"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r290",
      "r297",
      "r737"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "lfvn_AsiaPacificAndEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "AsiaPacificAndEuropeMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia/Pacific &amp; Europe",
        "label": "Asia Pacific And Europe [Member]",
        "documentation": "Asia Pacific And Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r131",
      "r183",
      "r214",
      "r250",
      "r253",
      "r268",
      "r269",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r494",
      "r496",
      "r509",
      "r591",
      "r661",
      "r733",
      "r734",
      "r762",
      "r787",
      "r947",
      "r948",
      "r1001"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r190",
      "r214",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r494",
      "r496",
      "r509",
      "r762",
      "r947",
      "r948",
      "r1001"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.lifevantage.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805"
     ]
    },
    "lfvn_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.lifevantage.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.lifevantage.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "lfvn_CashAccountsHeldPrimarilyAtFinancialInstitutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "CashAccountsHeldPrimarilyAtFinancialInstitutionMember",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Accounts Held Primarily At Financial Institution",
        "label": "Cash Accounts Held Primarily At Financial Institution [Member]",
        "documentation": "Cash Accounts Held Primarily At Financial Institution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_CashAccountsHeldatOtherFinancialInstitutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "CashAccountsHeldatOtherFinancialInstitutionsMember",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Accounts Held at Other Financial Institutions",
        "label": "Cash Accounts Held at Other Financial Institutions [Member]",
        "documentation": "Cash Accounts Held At Other Financial Institutions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r178",
      "r722"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents \u2014 beginning of period",
        "periodEndLabel": "Cash and Cash Equivalents \u2014 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r92",
      "r210"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r92"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r252",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r369",
      "r371",
      "r628",
      "r629",
      "r630",
      "r631",
      "r743",
      "r879",
      "r902"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "lfvn_CommissionAndIncentives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "CommissionAndIncentives",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commissions and incentives",
        "label": "Commission And Incentives",
        "documentation": "Expenses related to commissions and other incentives earned by independent distributors. Commission and incentive expenses include sales commissions paid to our independent distributors, special incentives, costs for incentive trip and other rewards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommissionsExpensePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommissionsExpensePolicyPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions and Incentives",
        "label": "Commissions Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies \u2014 Note 13",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r124",
      "r592",
      "r648"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r312",
      "r313",
      "r705",
      "r937",
      "r942"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock subject for purchase",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend, common stock (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "lfvn_CommonStockDividendsPerShareCashPaidOneTimeDividend": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "CommonStockDividendsPerShareCashPaidOneTimeDividend",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One time dividend (dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend",
        "documentation": "Common Stock, Dividends, Per Share, Cash Paid, One Time Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r912",
      "r913",
      "r915",
      "r992",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.lifevantage.com/role/TheCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r649"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balances (in shares)",
        "periodEndLabel": "Ending balances (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r649",
      "r667",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock \u2014 par value $0.0001 per share, 40,000 shares authorized and 12,510 and 12,622 issued and outstanding as of June\u00a030, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r594",
      "r762"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "The components of the deferred tax assets and liabilities",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of income tax expense (benefit)",
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r115",
      "r193",
      "r195",
      "r201",
      "r587",
      "r604"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r50",
      "r51",
      "r274",
      "r704"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r50",
      "r51",
      "r274",
      "r623",
      "r704"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r50",
      "r51",
      "r274",
      "r704",
      "r882"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r136"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration of credit risk",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r50",
      "r51",
      "r274"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r50",
      "r116",
      "r704"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r50",
      "r51",
      "r274",
      "r704"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r725"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r393"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in revenue from recognition of deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r553"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r945"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r945",
      "r946"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r905",
      "r991"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r905"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Income Tax Provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r905"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Taxes:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r905",
      "r991"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r212",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r318",
      "r319",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r345",
      "r352",
      "r353",
      "r354",
      "r524"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r57",
      "r58",
      "r119",
      "r123",
      "r217",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r903",
      "r938",
      "r939",
      "r940",
      "r995",
      "r997"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_DebtInstrumentCovenantFixedChargeCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DebtInstrumentCovenantFixedChargeCoverageRatio",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed charge coverage ratio, minimum",
        "label": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio",
        "documentation": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_DebtInstrumentCovenantMaximumDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DebtInstrumentCovenantMaximumDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum dividend",
        "label": "Debt Instrument. Covenant, Maximum Dividend",
        "documentation": "Debt Instrument. Covenant, Maximum Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_DebtInstrumentCovenantRequiredMinimumWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DebtInstrumentCovenantRequiredMinimumWorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum working capital",
        "label": "Debt Instrument, Covenant, Required Minimum Working Capital",
        "documentation": "Debt Instrument, Covenant, Required Minimum Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities to tangible net worth ratio (not greater than)",
        "label": "Debt Instrument, Covenant, Total Liabilities To Tangible Net Worth Ratio",
        "documentation": "Debt Instrument, Covenant, Total Liabilities To Tangible Net Worth Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_DebtInstrumentFloorInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DebtInstrumentFloorInterestRate",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor interest rate",
        "label": "Debt Instrument, Floor Interest Rate",
        "documentation": "Debt Instrument, Floor Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r355",
      "r524",
      "r525",
      "r760"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r217",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r903",
      "r938",
      "r939",
      "r940",
      "r995",
      "r997"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r990",
      "r991"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r990"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax asset",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Income Tax Provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r142",
      "r905"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Taxes:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r121",
      "r470"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r990",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "lfvn_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Deferred Tax Assets, Leasing Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal, state, and foreign net operating loss carryovers",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock option compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued vacation, allowance for returns, bonuses\u00a0&amp; other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails",
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Patents and trademarks",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property\u00a0&amp; equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r250",
      "r257",
      "r269",
      "r733",
      "r734"
     ]
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r403",
      "r433",
      "r434",
      "r436",
      "r752"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCash",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash dividends",
        "label": "Dividends, Cash",
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r109"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend, common stock",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805",
      "r848"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (dollars per share)",
        "terseLabel": "Income per share, basic (dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r249",
      "r490",
      "r493",
      "r506",
      "r507",
      "r588",
      "r605",
      "r728"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of earnings per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (dollars per share)",
        "verboseLabel": "Income per share, diluted (dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239",
      "r244",
      "r245",
      "r246",
      "r249",
      "r490",
      "r493",
      "r506",
      "r507",
      "r588",
      "r605",
      "r728"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r248"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Effect on Cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income tax provision",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "The effective income tax rate differs from the U.S. Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r453",
      "r481",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r755",
      "r906",
      "r980"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revalue of deferred for change in federal tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r755",
      "r906",
      "r980"
     ]
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2014 change in uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Change In UncertainTax Positions",
        "documentation": "Effective Income Tax Rate Reconciliation, Change In UncertainTax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2014 current year section 162(m) limitation",
        "label": "Effective Income Tax Rate Reconciliation, Current Year Section 162(m) Limitation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Current Year Section 162(m) Limitation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "\u2014 foreign derived intangible income deduction",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r980",
      "r982"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax rate difference",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r457",
      "r755",
      "r906",
      "r980"
     ]
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign withholding tax",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limit on future stock compensation due to 162(m)",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Future Stock Based Compensation Expense, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Future Stock Based Compensation Expense, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2014 meals and entertainment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r980",
      "r982"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "\u2014 other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r906",
      "r980",
      "r982"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "\u2014 stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r906",
      "r980",
      "r982"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r906",
      "r980",
      "r981"
     ]
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2014 removal of additional permanent reinvestment assertions",
        "label": "Effective Income Tax Rate Reconciliation, Removal Of Permanent Reinvestment Assertion",
        "documentation": "Effective Income Tax Rate Reconciliation, Removal Of Permanent Reinvestment Assertion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit from settlement of stock based awards",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r980",
      "r981"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r755",
      "r906",
      "r980"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "\u2014 tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r461",
      "r906",
      "r980"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2014 accrual for foreign tax audits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r980",
      "r982"
     ]
    },
    "lfvn_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax return to provision true-up",
        "label": "Effective Income Tax Rate Reconciliation Tax Return To Provisions True Up",
        "documentation": "Effective income tax rate reconciliation tax return to provisions true up."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition of unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment (includes computer hardware and software)",
        "terseLabel": "Equipment (includes computer hardware and software)",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r173",
      "r197",
      "r198",
      "r199",
      "r223",
      "r224",
      "r225",
      "r227",
      "r232",
      "r234",
      "r236",
      "r251",
      "r281",
      "r282",
      "r306",
      "r372",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r526",
      "r528",
      "r545",
      "r603",
      "r616",
      "r617",
      "r618",
      "r634",
      "r687"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r809",
      "r819",
      "r852"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r806",
      "r816",
      "r849"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r287",
      "r296",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r300",
      "r301",
      "r554",
      "r555",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent costs",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r296",
      "r555",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296",
      "r300",
      "r301",
      "r304",
      "r554",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r300",
      "r301",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finite-lived intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r933"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets weighted-average amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction loss, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514",
      "r684"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r856"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r856"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r856"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r856"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r856"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r83",
      "r130",
      "r214",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r509",
      "r730",
      "r733",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r947"
     ]
    },
    "lfvn_HandlingAndRestockingFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "HandlingAndRestockingFeePercentage",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Handling and restocking fee, percentage",
        "label": "Handling and Restocking Fee, Percentage",
        "documentation": "Handling and Restocking Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r805"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r290",
      "r303"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r452"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r126",
      "r130",
      "r589",
      "r601",
      "r730",
      "r733",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Before Income Taxes:",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r452"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r453",
      "r454",
      "r465",
      "r475",
      "r755",
      "r987"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r453",
      "r454",
      "r465",
      "r475",
      "r755",
      "r987"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r445",
      "r453",
      "r462",
      "r463",
      "r464",
      "r467",
      "r474",
      "r482",
      "r484",
      "r485",
      "r486",
      "r633",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "totalLabel": "Net Income Tax Provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r235",
      "r236",
      "r250",
      "r258",
      "r269",
      "r451",
      "r453",
      "r483",
      "r606",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r447",
      "r448",
      "r467",
      "r468",
      "r473",
      "r477",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r94",
      "r901",
      "r985",
      "r986"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r891"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r899"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards and options (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r246",
      "r402"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r294",
      "r299",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r299",
      "r304",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and other indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r299",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r294",
      "r299",
      "r737"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r847",
      "r856",
      "r860",
      "r868"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r872"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r872"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r872"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r302",
      "r305",
      "r717",
      "r718"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r554",
      "r726",
      "r925"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "terseLabel": "Total intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r933",
      "r934"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income, net",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r253",
      "r256",
      "r259",
      "r269",
      "r523",
      "r733",
      "r734"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207",
      "r208"
     ]
    },
    "us-gaap_InventoryAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in inventory",
        "label": "Inventory Adjustments",
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r894"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "lfvn_InventoryFinishedGoodsPercentOfTotalInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "InventoryFinishedGoodsPercentOfTotalInventory",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "lfvn_InventoryPercentOfTotalInventory",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Percent Of Total Inventory",
        "documentation": "Inventory, Finished Goods, Percent Of Total Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r723",
      "r762"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of Inventory",
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_InventoryPercentOfTotalInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "InventoryPercentOfTotalInventory",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory",
        "label": "Inventory, Percent Of Total Inventory",
        "documentation": "Inventory, Percent Of Total Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r177",
      "r188",
      "r284",
      "r285",
      "r286",
      "r549",
      "r727"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_InventoryValuationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserveMember",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Reserve, Inventory",
        "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]",
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "JP",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan",
        "label": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r761"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r543"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r544"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r544"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "lfvn_LesseeOperatingLeaseAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "LesseeOperatingLeaseAnnualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual amount",
        "label": "Lessee, Operating Lease, Annual Amount",
        "documentation": "Lessee, Operating Lease, Annual Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_LesseeOperatingLeaseLeasedArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "LesseeOperatingLeaseLeasedArea",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease area",
        "label": "Lessee, Operating Lease, Leased Area",
        "documentation": "Lessee, Operating Lease, Leased Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "lfvn_LesseeOperatingLeaseMonthlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "LesseeOperatingLeaseMonthlyPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly payments",
        "label": "Lessee, Operating Lease, Monthly Payments",
        "documentation": "Lessee, Operating Lease, Monthly Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r57",
      "r58",
      "r59",
      "r62",
      "r63",
      "r64",
      "r67",
      "r214",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r495",
      "r496",
      "r497",
      "r509",
      "r647",
      "r729",
      "r787",
      "r947",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r125",
      "r597",
      "r762",
      "r904",
      "r924",
      "r994"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r176",
      "r214",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r495",
      "r496",
      "r497",
      "r509",
      "r762",
      "r947",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_LifeVantageTrueScienceSkinCareRegimenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "LifeVantageTrueScienceSkinCareRegimenMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TrueScience\u00ae product line",
        "label": "LifeVantage TrueScience Skin Care Regimen [Member]",
        "documentation": "LifeVantage TrueScience Skin Care Regimen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r903",
      "r945"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61",
      "r319",
      "r903",
      "r945"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-lived Assets by Geographic Areas",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r37",
      "r938",
      "r939",
      "r940"
     ]
    },
    "lfvn_March2016RevolvingLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "March2016RevolvingLoanMember",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2016 Revolving Loan",
        "label": "March 2016 Revolving Loan [Member]",
        "documentation": "March 2016 Revolving Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_March2016TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "March2016TermLoanMember",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2016 Term Loan",
        "label": "March 2016 Term Loan [Member]",
        "documentation": "March 2016 Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r149",
      "r150",
      "r152",
      "r171",
      "r172",
      "r314",
      "r315",
      "r316",
      "r317",
      "r397",
      "r441",
      "r508",
      "r548",
      "r614",
      "r615",
      "r622",
      "r639",
      "r640",
      "r692",
      "r694",
      "r696",
      "r697",
      "r699",
      "r715",
      "r716",
      "r736",
      "r743",
      "r751",
      "r756",
      "r757",
      "r758",
      "r759",
      "r772",
      "r949",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r149",
      "r150",
      "r152",
      "r171",
      "r172",
      "r314",
      "r315",
      "r316",
      "r317",
      "r397",
      "r441",
      "r508",
      "r548",
      "r614",
      "r615",
      "r622",
      "r639",
      "r640",
      "r692",
      "r694",
      "r696",
      "r697",
      "r699",
      "r715",
      "r716",
      "r736",
      "r743",
      "r751",
      "r756",
      "r757",
      "r758",
      "r772",
      "r949",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "lfvn_MoneyBackGuaranteePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "MoneyBackGuaranteePeriod",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money back guarantee period",
        "label": "Money Back Guarantee Period",
        "documentation": "Money Back Guarantee Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails",
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows from Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows from Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows from Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r127",
      "r174",
      "r191",
      "r194",
      "r199",
      "r214",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r243",
      "r280",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r490",
      "r493",
      "r507",
      "r509",
      "r602",
      "r669",
      "r685",
      "r686",
      "r785",
      "r947"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r813",
      "r823",
      "r847",
      "r856"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Restricted Shares",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "lfvn_NumberOfFinanceLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "NumberOfFinanceLeases",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of finance leases",
        "label": "Number of Finance Leases",
        "documentation": "Number of Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_NumberOfGeographicSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "NumberOfGeographicSegments",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of geographic segments",
        "label": "Number Of Geographic Segments",
        "documentation": "Number of geographic segments."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_NumberOfProductLines": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "NumberOfProductLines",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product lines",
        "label": "Number Of Product Lines",
        "documentation": "Number Of Product Lines"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r730",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r761"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash outflows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r538"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r761"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r761"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/TheCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "The Company",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r114",
      "r624",
      "r625"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment",
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r603"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r14",
      "r192",
      "r195",
      "r200",
      "r232",
      "r516",
      "r517",
      "r522",
      "r586",
      "r603",
      "r896",
      "r897"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive loss, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income and Expenses [Abstract]",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/OtherExpenseNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Expense, Net",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r979"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "lfvn_OtherMiscellaneousIncomeExpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "OtherMiscellaneousIncomeExpensesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Miscellaneous Income (Expenses), Net",
        "documentation": "Other Miscellaneous Income (Expenses), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lifevantage.com/role/OtherExpenseNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/OtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other expense, net",
        "totalLabel": "Total other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r811",
      "r821",
      "r854"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r814",
      "r824",
      "r857"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r814",
      "r824",
      "r857"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r926",
      "r927",
      "r928",
      "r929",
      "r931",
      "r933",
      "r935",
      "r936"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of company stock",
        "terseLabel": "Payments for repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of cash dividends",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred financing fees",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares purchased as payment of tax withholding and other",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "lfvn_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Units",
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_PermanentDifferencesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "PermanentDifferencesAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Permanent differences:",
        "label": "Permanent Differences [Abstract]",
        "documentation": "Permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r357"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r649"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r357"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r649",
      "r667",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock \u2014 par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r593",
      "r762"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "lfvn_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock issued under employee stock purchase plan",
        "label": "Proceeds From Issuance of Common Stock Under Employee Stock Purchase Plan",
        "documentation": "Proceeds From Issuance of Common Stock Under Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of fixed assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product concentration risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r170",
      "r271",
      "r553",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r720",
      "r744",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r890",
      "r943",
      "r944",
      "r951",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r170",
      "r271",
      "r553",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r720",
      "r744",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r890",
      "r943",
      "r944",
      "r951",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment by Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r137",
      "r140",
      "r141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r179",
      "r600"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543",
      "r590",
      "r600",
      "r762"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r137",
      "r140",
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetTables",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated service lives of property and equipment",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_ProtandimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ProtandimMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Protandim\u00ae product line",
        "label": "Protandim [Member]",
        "documentation": "Protandim [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_ProtandimandTrueScienceProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ProtandimandTrueScienceProductLineMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Protandim and TrueScience Product Line",
        "label": "Protandim and TrueScience Product Line [Member]",
        "documentation": "Protandim and TrueScience Product Line [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recorded bad debt expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r283"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r149",
      "r150",
      "r152",
      "r171",
      "r172",
      "r314",
      "r315",
      "r316",
      "r317",
      "r396",
      "r397",
      "r429",
      "r430",
      "r431",
      "r441",
      "r508",
      "r546",
      "r547",
      "r548",
      "r614",
      "r615",
      "r622",
      "r639",
      "r640",
      "r692",
      "r694",
      "r696",
      "r697",
      "r699",
      "r715",
      "r716",
      "r736",
      "r743",
      "r751",
      "r756",
      "r757",
      "r758",
      "r759",
      "r772",
      "r779",
      "r941",
      "r949",
      "r993",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r149",
      "r150",
      "r152",
      "r171",
      "r172",
      "r314",
      "r315",
      "r316",
      "r317",
      "r396",
      "r397",
      "r429",
      "r430",
      "r431",
      "r441",
      "r508",
      "r546",
      "r547",
      "r548",
      "r614",
      "r615",
      "r622",
      "r639",
      "r640",
      "r692",
      "r694",
      "r696",
      "r697",
      "r699",
      "r715",
      "r716",
      "r736",
      "r743",
      "r751",
      "r756",
      "r757",
      "r758",
      "r759",
      "r772",
      "r779",
      "r941",
      "r949",
      "r993",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "lfvn_RawMaterialsPercentOfTotalInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "RawMaterialsPercentOfTotalInventory",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "lfvn_InventoryPercentOfTotalInventory",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Raw Materials, Percent Of Total Inventory",
        "documentation": "Raw Materials, Percent Of Total Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r923"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r806",
      "r816",
      "r849"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r718",
      "r733",
      "r1009"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r807",
      "r817",
      "r850"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r808",
      "r818",
      "r851"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r815",
      "r825",
      "r858"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Restricted Shares",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r109",
      "r596",
      "r619",
      "r621",
      "r632",
      "r650",
      "r762"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r223",
      "r224",
      "r225",
      "r227",
      "r232",
      "r234",
      "r236",
      "r281",
      "r282",
      "r306",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r498",
      "r500",
      "r501",
      "r503",
      "r505",
      "r526",
      "r528",
      "r616",
      "r618",
      "r634",
      "r1040"
     ]
    },
    "lfvn_ReturnLiabilityReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ReturnLiabilityReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return liability reserve",
        "label": "Return Liability Reserve",
        "documentation": "Return Liability Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, net",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r250",
      "r254",
      "r255",
      "r267",
      "r269",
      "r271",
      "r272",
      "r274",
      "r391",
      "r392",
      "r553"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling, Revenue And Deferred Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r719"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r395"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r761"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Returns and Allowances",
        "label": "Sales Returns and Allowances [Member]",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r881"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Components of Income Tax Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of The Components of the Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Computation of Net Income Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of The Effective Income Tax Rate Differs from the U.S. Federal Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r755",
      "r980"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueMajorProductsDetails",
      "http://www.lifevantage.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues by Major Product Line",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296",
      "r300",
      "r301",
      "r304",
      "r554",
      "r718",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Net",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r932"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r299",
      "r304",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Components of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Nonvested Restricted Stock Units",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/OtherExpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Expense, Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r105",
      "r107",
      "r108",
      "r109",
      "r184",
      "r185",
      "r186",
      "r252",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r369",
      "r371",
      "r628",
      "r629",
      "r630",
      "r631",
      "r743",
      "r879",
      "r902"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unvested Restricted Stock Units Roll Forward",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.lifevantage.com/role/LongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r151",
      "r153",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r272",
      "r273",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r636",
      "r637",
      "r638",
      "r693",
      "r695",
      "r698",
      "r700",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r721",
      "r745",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r779",
      "r951",
      "r1010",
      "r1011",
      "r1012",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r270",
      "r272",
      "r731",
      "r732",
      "r735"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount in excess of fair market value of stock for option not to be granted",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Amount In Excess Of Fair Market Value Of Stock For Option Not To Be Granted",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Amount In Excess Of Fair Market Value Of Stock For Option Not To Be Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning period (in shares)",
        "periodEndLabel": "Nonvested ending period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning period (dollars per share)",
        "periodEndLabel": "Nonvested ending period (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of employee compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares that can be purchased during any offering period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum common stock issued under Long-Term Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "lfvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired or Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's common stock purchased in aggregate (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options (in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning balance (dollars per share)",
        "periodEndLabel": "Outstanding ending balance (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise\u00a0Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedSharesDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationRestrictedStockNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails",
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired or Canceled (dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting on January 1, 2019",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting on the last day of each fiscal quarter following January 1, 2019",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r407",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting right percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of outstanding stock options (dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of stock fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationPerformanceRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution percentage of target number of Performance Stock Units",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Distribution Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Distribution Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term of stock options granted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Contractual Term",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average\u00a0Remaining Contractual Term (in years)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares canceled or surrendered as payment of tax withholding and other (in shares)",
        "terseLabel": "Shares canceled or surrendered as payment of tax withholding and other (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r761"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r211"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r72",
      "r73",
      "r173",
      "r197",
      "r198",
      "r199",
      "r223",
      "r224",
      "r225",
      "r227",
      "r232",
      "r234",
      "r236",
      "r251",
      "r281",
      "r282",
      "r306",
      "r372",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r526",
      "r528",
      "r545",
      "r603",
      "r616",
      "r617",
      "r618",
      "r634",
      "r687"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r151",
      "r153",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r272",
      "r273",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r636",
      "r637",
      "r638",
      "r693",
      "r695",
      "r698",
      "r700",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r721",
      "r745",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r779",
      "r951",
      "r1010",
      "r1011",
      "r1012",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r251",
      "r528",
      "r553",
      "r626",
      "r635",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r687",
      "r780"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r251",
      "r275",
      "r528",
      "r553",
      "r626",
      "r635",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r687",
      "r780"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r810",
      "r820",
      "r853"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/ShareBasedCompensationEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued under equity award plans (in shares)",
        "terseLabel": "Restricted common stock to employees (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109"
     ]
    },
    "lfvn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued (in shares)",
        "label": "Stock Issued During Period Shares Stock Options and Warrants Exercised",
        "documentation": "Exercise of options and warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109",
      "r413"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase common stock amount authorized (up to)",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized amount of common stock repurchase program",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.lifevantage.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of company stock (in shares)",
        "terseLabel": "Stock repurchased during period (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109",
      "r631",
      "r687",
      "r701"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of company stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r69",
      "r109",
      "r634",
      "r687",
      "r701",
      "r786"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balances",
        "periodEndLabel": "Ending balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r99",
      "r651",
      "r667",
      "r688",
      "r689",
      "r762",
      "r787",
      "r904",
      "r924",
      "r994",
      "r1040"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r213",
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r504",
      "r690",
      "r691",
      "r702"
     ]
    },
    "lfvn_SummaryOfSignificantAccountingPoliciesTextualAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "SummaryOfSignificantAccountingPoliciesTextualAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Significant Accounting Policies Additional Information [Abstract]",
        "label": "Summary of Significant Accounting Policies (Textual) [Abstract]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/OtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.lifevantage.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r737",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lifevantage.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "lfvn_TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 and 2017 Long Term Incentive Plan",
        "label": "Two Thousand And Ten and Two Thousand Seventeen Long Term Incentive Plan [Member]",
        "documentation": "Two Thousand And Ten and Two Thousand Seventeen Long Term Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_TwoThousandAndTenLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "TwoThousandAndTenLongTermIncentivePlanMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2010 Long-Term Incentive Plan",
        "label": "Two Thousand And Ten Long Term Incentive Plan [Member]",
        "documentation": "Two thousand and ten long term incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Long Term Incentive Plan Excluding 2010 Long Term Incentive Plan",
        "label": "Two Thousand Seventeen Long Term Incentive Plan, Excluding Two Thousand And Ten Long Term Incentive Plan [Member]",
        "documentation": "Two Thousand Seventeen Long Term Incentive Plan, Excluding Two Thousand And Ten Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_TwoThousandSeventeenLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "TwoThousandSeventeenLongTermIncentivePlanMember",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationEquitySettledPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Long-Term Incentive Plan",
        "label": "Two Thousand Seventeen Long Term Incentive Plan [Member]",
        "documentation": "Two Thousand Seventeen Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r466",
      "r754"
     ]
    },
    "lfvn_UnrecognizedTaxPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "UnrecognizedTaxPosition",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax position",
        "label": "Unrecognized Tax Position",
        "documentation": "Unrecognized Tax Position"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase resulting from foreign tax audits",
        "label": "Unrecognized Tax Position, Increase Resulting From Foreign Tax Audits",
        "documentation": "Unrecognized Tax Position, Increase Resulting From Foreign Tax Audits"
       }
      }
     },
     "auth_ref": []
    },
    "lfvn_UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lifevantage.com/20240630",
     "localname": "UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase resulting from settlements with tax authorities",
        "label": "Unrecognized Tax Position, Increase Resulting From Settlements With Tax Authorities",
        "documentation": "Unrecognized Tax Position, Increase Resulting From Settlements With Tax Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r134",
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/IncomeTaxesDeferredTaxAssetsValuationAllowanceScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r222"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write-offs",
        "negatedLabel": "Returns",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.lifevantage.com/role/RevenueSalesReturnDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesScheduleOfInventoryValuationReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r761"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.lifevantage.com/role/PropertyandEquipmentNetDetails",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vehicles",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.lifevantage.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r246"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.lifevantage.com/role/SummaryofSignificantAccountingPoliciesComputationofNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r246"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.lifevantage.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0000849146-24-000073-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000849146-24-000073-xbrl.zip
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MM5H#2SNX-C;L9SLY69Z<3L/I8[*91>!KX48@?EZ RJ<ZWPW#\6V)!O3KAFI
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M)^&T6T[WIJ"_-WQG%O0HL5,EB--B/&[*B'FN5)Q2%6M:5@@,EZ?$^4O7S3H
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MM-8S!*H4@%%^E38]1L9#O:+U@1L"5C2?6E@L&9&UF02\:TN.\W QWWH>Y^^
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MK1*YGIG??*S)\&A;*JD^PF/LR&M9::@W *M'<ZKKS$B&9]#G;DFI0#T7R>J
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MG$MWX?IY<6.H(N#P91P='1R^BJ-_)GF#B'>'K^G*UW%T:18UWW5T8*\=-]=
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M$A8UA#7(859#V;:HU03\1<4)4V-F4>$C?Z'PYY/@*DEO(A5.25B_2[-8R**
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MI44!"4^3=9 (%G@]"A;7PN_*RA6@".!7&1 +J&6;5;["=Z%J"..#^JBN@WQ
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M],RB(PH5:2ATQ&%&6UF.VAQT,-ADA_U?(M^3U,VO0=CGHEL2K /%!OH<WL%
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M*_&1A<:K9ZR5W8RG5F8:X_Y\0S42@9&?SG): QKQVSTT1^36V<J*LU[JJO/
MU'7#9;C(2NV[K-1=SDKW0%N;4'%:'1!8D[73"@VN^5;JM)O7 '%:%X8&Z\IT
M-\)8-I1A0-\[O8<N89R<N7W[V78O<\S_5WX#OES7".@?7P[(5XK%C@9*AIV!
M2PX_=UZ$[M6I;P&0!1;/16"=8@,S0A_ODD%B%/5Y8BW3R[5]?M-".]6#F7-M
M$\/2<7"0YH93PUW2-RS'1\$0#:48^CP7I"<:=WUHF9_EG?E;,/+ ?)L*RFC.
M&<] R /=6.%G->ZF[,]/V;_$_V>)3_N]]*T/$1C.\DOZ+11YX/T+14=(CXX2
M'< 5X!7H@)(/O=['_$: !24/[ ^X";@*J6":'.8ZTR\AD0_BI^1W3E-_7S+A
MO\U?>Y; V/S@<R],;I]U-P_^.7OP/Z<PQ<)@0WLK0R(7G <4[(G0EA&Z--L\
M"BP0R0/[%[T-WQ<B]9_TT%XFHW5E_51)@T&=1.0T@!#B&&>\^!\Z;[,47 )D
M4PJV3I.93/X$K ,^?$JHF'P/9/*1G',_$&C!9(8QXVZ]6'GP-B.F'8#X=_\3
M%VUGX4JGY],]L']I38ZE!MNZI'AH&W96FI7OVAUMYZ)W)T)'6H:)617YF_[F
M^7O6;5VT7=X_ %!+ P04    " "N@!Q9SC;JE\4"  #O"   '@   &5X,C,Q
M9&5L;VET=&5C;VYS96YT,#8S,#(P+FAT;=U6;4_;,!#^OE]Q:S7XTI2\I[19
M)58*ZM85U);Q<7*32^.1VE7L -FOGQ.G8@S8B[0AM'RPSKI[[IZ[^,X.4[G)
MAF&*)!Z^"E\;!ASSJ-@@DQ#E2"3&4 C*UG 9H[@"PVBL1GQ;YG2=2K!-VX5+
MGE_1:Z+UDLH,ASL_X8'>AP=UD'#%XW(8QO0::/RV1?W8Q0B=V',BW[7BU>K0
M,>T@<@\CS^OUT/]LM114F6N,D&6&;UL;RHP4J_A]U^X&WE8.;F@LT[YEFF]:
MM>DP3#B3*EZN\%K4;AXXDW@K#9+1->O7*;4T=*>.>,;S?MNLOT&E,1*RH5G9
MWU_2#0J8X0W,^8:P_8X@3!@"<YIH0T&_HN*DZ-7;&TTY4'XRRG"7@N54I,>W
M*5U155"G:]UG_#C72!47\]:3>;XPU#.6TZ[*.3J;+<:S)9R=P&1V/#X?JT5M
MY^/3R6(YGH^/X?SBW70R@J/1Z.QBMIS,3N%D,O_XE\KQKY-V'SU#EP@19Z)J
M7\E!I@B413S?\IQ(RAFL2L@QP1Q95*E@CFLJ9*-<2-7O=>O/N.B"XSB&[=FF
MY72T;/=\.VADRS_T=K)I.GYC8_4<U[<:.? LTVUDKQ=4,F&QWKNN[0:@@I[P
M? ,+HZ=U%>,G.364 LOTK>^@#O $>)&KS%2>$N)Z:AT5ZT+(O;;EFP-;>:_&
M5$>99,JO&F=-=1+*"(LHR=2/:@*)RMV4)OB),$G6J$;=7?W(=HLDKQRHXLF4
M"CABK%#PN8Z]8V69Q@=(>%X'*14$D,6*U?N"H>;DF)I3]W?.VQ>5"DW*/^V_
M^[#G/HM[;3<8B'J%8\PXE1)AK^WT!K#D191B!Z;3\_\V_07))$S)E3I 5)8=
MN) D??FL'VN;)V;;S__##[?SE@M:=5!?=^ U/KBO=\ 5EY)O^N8=A*P$SPKY
M$/*+*[Y9]8/CH'[H? -02P,$%     @ KH <66IY%:4:"   CB8  !X   !E
M>#,Q,6-E;W-E8S,P,F-E<G1I9FEC871I;RYH=&WM6F%SVK@6_;Z_0IO,9I,9
M(!A"0B#-#$WHEGF=)$/H;M^G'6')H(EM>249POOU[T@R@4#2I9-N0SO;F1+;
MNKJZ5_?HW"O99V.3Q.=G8T[9^4]G/Y?+Y%*&><)30T+%J>&,Y%JD(_('X_J.
ME,N%U(7,9DJ,QH;4JK4C\H=4=V)"?;L1)N;G<SUGA_[^[- -<C:4;'9^QL2$
M"/9F1]"(,MH\CAI10(^J=7YZVCPYKM-J>,("U@P:?P8[Z IQWT>;6<S?["0B
M+8^Y';]U5*N<-#+3G@IFQJV@6OUEQXF>GT4R-1A/H;^_]&K6E!E^;\HT%J.T
MY5S:\5WGS:&,I6KM5MV_MFTI1S01\:SUZT D7),K/B5]F=#TUY*FJ2YKKD3D
M!;7X'X=-,,_=3KW))] 3BY3/70AJUNCNI_>]M[T!J0>5X+'%RXY3-8+O1F:M
M4VA=,CW$7'/U2K9?=/N#WKO>16?0N[XBU^_(3;]W==&[Z7P@W4_=BX^#WN]=
M/(9$M_^L;]OBS,W'_NW'SM6 #*[)+8SO]P:][BT<N7C?N?JM2SH7 ]+_^ &/
M@CHM!T?[](!TKBY)T-AG!_Y^ZWWLW)+.Y?7-H'M)5MQU$:Q7:S:*@_==<MOI
MO^U<=6_+UY\^=/_KG$=+K5JM;0+2X"C[Y]?3T9,N]DKDUO )3TF_0MZ)B)=(
MR)41T8R8,35[NXUF>U,7VAEE##18CGED6K5:I3%??")EB&.K[)^]DJM!9>[(
MMQ_]\=0$;A)Z9$PGG"@^$7R*%&+&0I-.FN8T)GV>266(3,D[J1(25,O_(3(B
M'Q"@WVEJZ(@CN2C(4"-DBBB=_BA1JFU9E-Y2C=@@$,F,W*5R&G,VPB)QP5(^
M2DS"@%2B&(!^*E)"TQG)4Z-R#OM1'KA* >&C),&=$@AP1$,\4D0FPA CO=R:
M0,I#KC55,RN2T#N.<9=T:CQC, 9#QJ[,P!A6(!0*907$4G2')8PK,AV+<$QT
M;G\6_:=<\4*)=2 1.D;]84N9J3!C.*@S'CH#K=X,IDD&-R?HQLAPMCP-/Q((
MZ]\+"#F)1(HP6\0LPEH" B&.9K74+M((7.(( ]=AG#/H!'268E@"[(2*9R1#
MY"UH+9CC>('* A!Z96@ GPFKN&0E\A@"@*($7MQPVMD34CTF42RG>HY3Q4="
M&P5"(]0^]';#RM(2W/3<F#5K?R3$'6T9X@:/PK.WVZP%)VU=8*JH$"Q-R"@2
MN-W7!RYV/4(5=RA!U,4PYC::A .:PUCHL>UAQ1*PI&5*>\^$#F.I<_2S_*ED
M[.&2*1ERAL>:[ ,=C -N'@+=^W!,4Z3 #JBIG\>0<#5F8Y][*X(&\W?^5M@2
M,O4PM?J)Y:\E]'HT65LV'BAZ-%"$@:R?JYB&A$WQ+RBBZL>K* WJKXA2NC4H
M/:XT3NPT7'*-;0+"Y3+;WV.I9)-N2'.]>1>;_88<N"A&\OE4Y@H*0%$3H1WQ
M08JG3H\MG!>4N4R[BL?4 :U(J NPE I*MHT"] E;M(P%<X<+.A]JP015PCH@
M?-IWB2"UFG)M4[%;FMKE;4>34G,89$#+ME-&@? PCZEE=[CEC%BD=/3P!<)R
M78.K(;>"(&#TY^P%A+ME0!YN#Y#74;PQ7ZV!>7.FVQC36 <3P2Q4J98IM91.
M-6!N:TN+7ZK8'$M MZ!#$0LSLQG^J6'MRG*P<XCRB^*1Z%)MZC+'?>%0EF.W
MHQ$"6Y&$H53,&>"JU!%/46C$ #9:>&97C!5!!>[!BY4E,I#WUX5O\]7 &VX-
M>(.@4G4TW)W0.'=<9:/+HPA%HI@@+OJ)8N^AFMB >_WMT_6?PRLZ@C>UKS*'
M,C?/6[!)=J /TMR6T-'?[WO(<%Z<NR7(_4S,=^5V@!\ <FQ[(%?U:>/2!W,=
M%';S791MKN5)Y'T!4=ID+L,P5S;T2YGS":V)U ;/[9DE=.D0BO[*D7BA>O^9
M+A$P# I;D2X,QXZ)NW,#>Z3@SH6\70?>JC'5#V6&)3^'><Y<5G#S43#VC,3B
MCL?%(<**?.G%4_1"G&_=5JRQ/5A_V5;,'2^R^3HI+8C*\N8R5A><9='V!>7'
M6AG[8!U%*6NDT@\9WSV RB01QG#^F:PPE*@I;#L3L,\IV0>B0<+:DCS^VH)Z
MO@SY7[F ^6[)Y6GHCAL._MUQ_7,[KDZ,*@U5HP#:["[7[I=#P8&-(ET_['RF
MG-[9_.NK-I>!7;WISCWG9T-?A+ABD^+/&)Y@-\K04?,'<GL6G465BBZ &(K)
MDB\"-"H G2< "";).5,DE2=/T;Y^@O]W2_2P)>H@C4<*K%%"T+GC.L#&'5(7
M^"KY+"C2B8PGW*;"E(Z*LW95T"-/LEC..%JG8^D)D3Y"+]#V5>J$RB88\,$U
M;A-5M X!/J[*F.:89IJWYA=M\'86TUE+I&ZR7*=VH6LHC9&)5=>>6/Y'Z5"\
M+G5P\LW%N_[31N7DV+WN-PK_V7S@XDN BFLZ-&R]K7%:.3UN/MM<K03/MGU.
M;?VDTJS7-E)[Z$SV9F-B=$;3-SOUG7F' C2M6G9/@L?O^2V.5N?&3\NW7UWN
M8XM./LJ1<&O-DOL6Y $MQ11\Y][M[1YAM;C?E=?)CQS=,)Y5Z^_.9R>G6#:.
M6#.X:X_*R-S/+YPY*'FE:?LF4_7=S,8--N#")L*]W>"XVM[;K3?;Y&(L>$2Z
M]SS,[7:>7/LBUWZPM'_C3W9 PVOM!^N3>>@H] F"7OE$*I/:O<IJ^</:"5_[
M:&H!0D?#U447.@02<_-\E^>^;'GV"ZSBUW\/=NB^0_L_4$L#!!0    ( *Z
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M+<GCKZVIRU7(_\@%S'<K+D]#=^!P^/6;KL[)CJ%QA[9=G5K')?L@1J&&PE$
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M*&)">/;VMH!\A'X2QFF5@A\8T)//'Z;OIPMH!FZPC7@S<2*O,7<MLGX/O6Y
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MU%HG?^VMK?TZ.63K(RF3]@)X,CN/V(,F+WW>'E39D^O5^MHOM>=4]@1Y*:'
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MAQ[:[L?N5KO5:7]I=D  %V;C1U*C^RAJU+;&ZYSX)$,1!-9Z9>]FI!N63CA
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M)$X\2;)P9(YX2,JMGI_>76;N&K1V?7TS2I:+;Q6)92X.QHS?<!@FR@.E@[1
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MZ9G3B"'<A^D%9"U9BU8+4DVJ%4F33.+,.*TF=D.%!!@L, XG[%21 #)EB;9
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MC=6(E,4H%DUZ)I"JV9,JI6_U+ I-BC7!DVM35@5L%S,/FZM;"K<8-C[$*>/
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MR"! E!K3;C9$U#C0_@%"%0+E";D)8;QM<Q."2H/5)/3I7M[=#SLJS@<3Q+Z
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MXL4A()5K]G0UQ%.Z,,-(26I;06/R<#*4?0O(-8F&-YMF6IQ%"A_[=OO4""#
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M\C?>;$P1,ULB(J:[_[W*2Q1[E@P#FR2K:IH7(#+D]E%@_-+_5KERD!_7W)@
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MK=)BXA"WNO8AFARNY2>N*YD<I-\-2C^:#+VA*-CVK/-*1-2TJF";;V WY"4
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MIG"6DS!7"D),HO&3@ YM^ZZ1J3\U3&,]LPKFQ.7ZQ*<EV&H^)_/O2-W.,)R
M ];77"=D?[@<'^URO/8RF/?]10E!A]/TAAR\3QWVON*)US81P:KR6L.;0[F-
MVWPJFT:+:6@D(5]QCI__/T)O-3C6Z ]ZV"\&_C!'*'.FY,TRD(3*F!85>5>'
M WT;#O1+D/R[Y&1-&S7K!=)OYA /R?: .$ WZA[Y+ )F0._7$A^H2G&UV4L(
MT22$R>"L%QSV;3G=K:#AS3DC6-2W/J_J(COV-><<0+1NUS5CN7"=H K(P5^
MK$E!#[,E(IH%H@2,03AWW,!Z%L R,GX@EZ?T;X0C:<"+#FI$Q@]R4_YNE33+
MM':(O[O2_V>2MZ)L.6QZOJPX0+A*W^4KP%WC:(=WCPYVU*VX6:\$&7!:\>EY
MZ;(\37X"E.*&U40<*=4*F$;&N.(QVEU1.N:J >$53X6!($W<*H[C"AI1N"R
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MM"&C^GLEE/A(1+'>F?<47T?N2Q&1<2!TGX<Y ZO9X(-)$$[1>:$Y_<[=B<_
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M'*%-UV!'Z'IN%!]$!W:YR>JJV/S)'6N:9=@M/B%Z'IKD 6U\CJI*E!^UF[5
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MQ&G@X^15X D58$R*O.Q@V3V,,08 T#*?:91HQFA@Z7-,IAXW<^$^,,A>'U+
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M+O \._&0"&L.23#872'-RB"J5)/1D.#VTCZ6"7=9DU8H)3 )\=GBOM4DU6R
MAH*11PB[)M]S;0[<^ZH>!Y(FP.&HI$[1%D7O\R18L'R%1N^L7G1Z@A>MHQ#$
MZ 9$MN087\5=D<)691EA*&DA& ;.C8%K!R*N&3HJU)XX=:?RNT3V:"U?4V
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M,;9(=Z(MTIV!Z9C/>Y:VF2DV;XZ4O7F&&?Y.'H<\BF,%%HE1!"X#)CP%I>2
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M?%!3^MM&$6W_O$R8+J+SY%,WG(2;ND3S3[AGUOUNUU4R7%\3#2E3EBFL^0%
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MM4F$ 4MDB-:Z6FO!?B%]?OOUA,;(BIOI6:U]2>!!E5Q' L9J6=L*'63:1ZR
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M4U*J&I(U8U GII'&F:,:28RS1>N6<R,JGV'?O31)*@MNSBLYUI_A!X&:F3$
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MW<,#%$#&HTJZV@;A*HA&4#$?*_\@H+Q B8^X0>/.M!BH$$2^&)0J1^3A42K
MP5U,WUV2XC(7B%.&^34@\B2B9K5JT;-BDD_@L?!72O& 86\N8[4G2("9:FPP
M!8 > *QF^BBWWM-G*(Q#@:_/\Q3;F@"2!*<A/5KXV$""6R8H -SM&#G\@'K
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MEC%6MT%3B1.>,>G4&M8ZL?NXK;J<D&_C4KG^!=AM6)T40FY25 GB=%WG2\%
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M_5%WMH.DDZ'L4=,HI)5*4XZ0CJ8D*0WY)6"CD&8DG2(K]U4I:CB:(%:G$Z[
M+U_]'>+7E\X[$(EI>;:JC54XF[&Y9\X,D,NOL_FKG99?P)AW@U3C8&7.!'X7
MY#)5XK&;R2 PPI#6:ID[MJK+AB<PQ4Z .1":AH> 5B]FGD3BNW.3[XB6);LS
M_O@F-Z% >0^37#]72GH(PLK)"2!"H6.JR@0P=#7@2^J8JNEX==,F%QIU(QN.
MYZ)HJ/DEADY4AI>P^#%-(B9N\XK5YC<?F62M]U$SA>-[?V__ #<R D1(@+6P
M;_Z1*%Z/A.%QT-VY"?AA1.=!6 REQ1Q-'Q#UJ&00]B>YSB**Y+^/HT=XDT<_
MX"10N:_MO/:2?_C; 1!\'B^$H//46$.$/81#:@4]D,)?N&V P=Q.+W;#H7.>
ML;B-;ZKLNMAN] H>%)^<MQ!R3SH7^SS@:. (<0L'TG"@YYL*![JG 0.G63:/
MZW0X%H5*X,2RWX DJ+V)?7?F")+M<VI0$.H(VIQ2N]$^>'DCN\L^N%UZ2O[.
MW/7<?K>W:]]K"!X-76T@_IK<&_L9'[4N8?<S>O#.%G^WOX?7N/))EYY%>8VD
M[4<TD$?$THQ!N+4B\R*%TLD\S;+!(WR^MO%";PL]%4^'1OX[1P_LVREFZ:[J
MR@C0!S/ 8W+F&N2&D.P-9;;LV=+D@ :T<="8JN= &N08,S%(FB[% HYWHIB;
M7$!-\7C<S!JO8>%:-RC7;>T=/B30NVBK!CDG3T+D[F/?:Y8V,VQ0X2N@R:/,
M5N 9D''E 22RA<]SR&,4_LAX1DUR//VOT1E]!9^BQWUI;_WHAPZG[WK4F?O/
M#X8;Q)TI(0MP:$:OJ?=_\XOKOPM<;LQ(/M"N2@@,/B6&5\;U*+^11*SLJ34@
MJBRBW&!T+B$V?/=/@B@3=(11+JZ&X[.740;69R"<\C#4 -]X#EJAM:7^,C>4
M5$,+1].A=C#ET5)JD 9+#]^GL9TYRM]X%D\% D:?#:MA*X<\.D&H$D)1BXIT
MZDBLS=%-3E)1ILD:IS3H7[1-_,%KC,3L%P.' Q#JAN#+>MU)_<0A8+H54$/-
M'8^-<35!X1#=_.7T&IT#6"S@\A*]@^B+^ATLHARTDSD--[#FOSZG3,X\@Q9)
M&W+BV-$*B^'@=4HA(Y.EYD($KB%#$ #OC#MF;"R8UDP+1BF0JJ9L(5W6*]NY
M/C#LJS1)2)EAYS6=B4"( 2@RXHPA J&>0/XM(10Z%+-YU2/51 ^$Z@%@HFA(
M1$'1=;J*[B8(#8J@E4<7BI 6X3]""2,D-P%GI!0V'%A6V4+M*-_IY+<4[%T8
M_4&/YIM]Z[%C46AI@O'$W_4<K<L>Q1ZZH"O*-\[I1>LF;VF>(@1&:=,L('S&
M6] O$'[J^)$O;2"5(XF[DZQ9NO"NR\T>[ATZ''!<CF+[S9WWGS.CA#_W]D,Z
MDZ6/"8N)DT?K=IYEFQO4T^)%%B)&W)JEL-P+2MU@6$2))-;";#Q0W.)S_2MN
M_BK\O4-M;_G]H;O:9//(NB(LM>4:M!R?%!F'L:L.KEB7,*OCFJ>#D'B3,FZ2
M!C4[) T)1P<G5?VU^$[ 8D.0(%8D:-416<[ *>6YUW.!E N)M)2@JG7YUD^U
M)!C$Z^6M^<L#+W1MH\ B!YYQ+%#A"Y<L,>RR6R3[O7 R27 'U%W6>KSV/'/&
M+LBT]YR06N J,23/0_"2LF_W=VV?_MWCU%$P+1O2,)(*91>Y B6$,]EG;-=R
MNWH+5H*^,(D^>KB)0!+=*;'VV7>!03.B>)26K3D=+)\M-QN0 5.1-('X,)]R
M4''LZO1%Y]LW#"OET0CUI?DNL[12I^/2HM8]PC".:)5E,)4"4B>_IG)VW<,I
MT\;FU'G #$6QNPT6*98H*]X5TKSLE[[J#G:V0-SR:QGC_M7DE@*QS?:<,'*S
ML@'"4;M89DTV)7$*P%7C=SMJ!?'R!"\M#U.64+!=,1DZ,M*<:%RX87GTSJ]>
M;S'UKR'ZMF^<JZ'_M\)90"6IL6O7IFL8'=JH#NW0[Z*KQH[L(^WGJ_7%DCZU
M:>VY!8JTE2#LH)/<N75:9H%8 9FD0\RV4FT")D>[>?4'$:"L6X$=.U.2)FR5
MG&S'"H>G<Y':U_RQZ%ZF7O)F\X."7[R$L)X"B+W_U<#\<2 --)!232 !-ZAY
M3;#<F8Z)[HD/35BJE!XEFRQ2\S$S;NHM%!!1^? #[H9!10"=>*@./Q[S@G)/
M"NR'$V_"^_CL9]#&](EA:+1,DQ0H1JLN1(4$]#"D0@I>RLUD[J@K3;M+8%BH
MSD0Y)3S6@5D'C%L#O5[2QJDA^JZ?4SW4+E(-MA>7/450("X4M_,K3#Q_2LP3
M;!).*MAVE6Z>LN^%Q)^]V0T\U1CB"\M*;(XC^ Z5*&F,R/ZSR>$AQZ2"^KH3
M4US>( -5'*[JLD$UVL'RGO%"K&0QU=3(9ZN!SX7I>47=;')0XX4<.Z,8R-MA
M1 9].XH[T'#7>0(GE1+C6\%F _ZEWPV_<YDM9/B1\X XHJR[2DTIKAJ/XTUV
MM<13O(WQ5T4([28$ ZB\VWYJK2 ))'D(2@*Y?&/?\_E4(BO/]KY(P/_D3I"0
M.[:=9@RSC#V"])B.!3)8V%>\34I<@Q?0T,J@-(H*D"L'_SEP^?*ZM:WT*,=.
M<7,BDY&;H&>0.%6-$1U/61-)6U_5 =21F949N;&Z)/L#'F0,8UZK?#_Q"]<^
MS8.S=(6])[?-"0,WUN, C6+A/-.'\_)F(L ,NZ4I>+3 7@!?=/3.R_RON.?L
M@O%!X%2=B%.*#G 7M&3 W'@Y<3I04*4G;GDS;J!H"AE'6 (ZHJK2R4*FRNG0
M^2,OH!]&?74L3382 D'VL@@UJ'>CE]W*>3"7EUQ-%0E 1[X$T86G>:;A)B)F
M.3/<(%6T)8N)[,T4N1F@Q"4[<@MI4&?\X=X6TG"C 1/CH_F,R9IR4V9(S>C6
MKMNF8M8(%Z /./'>*9_3TIC#"\G21RL;L(X$I.IP&U \AE S@+LFS+^\E"!"
M(4\72ZG6[%[/19FJTERDAO& ?"Z1/X.F35D;N/QR?WB01!*U8_<N[$I*Y?^R
M*+.'(#WQBM$6 PQ-:H!=:#7D$G4MVUWW*A;D>5.NT8KZL]!:.7/IOC\MB\L:
M&L$*9)9[&$$+E&/;2QD\73N04RI9=(L/88,=05UA7#J&&X#-!O4*WZ^:BM;^
MB)6<&$ULFL/91(A$O_F[#F.O]*W:_TJ9MS")M?P@H5OCDV#*D<0'$IBZ/!V$
M6B:H>E3;SN5OU]#B3 (5/ME4(,&LZFAJ18#;+KQO-T$R]-X==ZT^PG N?%_&
MY9ZV$_3M)BB#7$,!F((LVX'L]RA+JW-";%EW/L6XD6 DU:*JS0R]$,GTQ& O
M [>$/;SM%'Z[*81&%'O>52B!QO&C9+CX%*R:Q(X>;;"%<XY'"Y^/G_H*FMJK
MVVG\M@W+Z4P"XP@"\T)I/*08E=3HZ7!N4.4XRF)!T!K\$K"@UG$)\"ZRK*.X
MM#[2M@']6\ZGJW,O*-S-H..4O%?MA#+DH4*"W/0"[2WF@Z7CRT8H0! ,*3).
M$8\7XVQ[2G[KO4E86$;.$9G LG>C:/E:2+O2S..:,?MQ=;Z=O6]Z0'*2ESCZ
M$+]!();E_4A! I:M*>FZG:EO&,^5A;5_LXI:%?LFA^D*P,!2<@"L;(,RB"00
MAVEQ@-)C7<%12VWI)KYQ\,<:FY*[=#D;;#0>+WQ%" MF#R"EEB]:^:*>NN.R
M\,S*[)34=SF9)1FZ!Y#=_37W9+/3K!C9]W99'*U?ZD$-Y_;;@(/*8E]_I53P
M+!Z71<>W">=B .W@F@2ABX[GH*\&O-08,Q @Z4/) +_/IPA3F9K")]*$LP6'
M"2NUZ:AA21//4= [UIB'^QR/33G"=#SHG%(!-R4A>./*ZYS)U6!.=\4FYQ1#
M#7 %S$[ ?Y5TJX!4W2SQV3!0G""9^UB #MF-3K%&Y)\:UH4O",B*N-ER((Q%
MAI5<=_H S+(TN*-+E,!E5<*3B9/N[1I%G6Q'0$!**!3:(AF1,>1>4M>=BUC)
M]6F85<(X:@]=\;@$]5$R8HF98<L5\UJYHK?3<T==)R!&T2*S5]WE4B$9288^
M#6OB2CN0DOVK9@S'F%!-X/-Y%35L1=-P1[7^W)C @R$Y2U.::C66@G5BL>P(
MQLG(+07;)>XG5RJYPE2%OQ\7V,(EPK2$(,%EB?!@.B=D!%T.%<H6=NBH_E<0
MH4@XNEXV=PE@0)49ER</%/22 H1I;D)$/5C!1/T@V#1\<1BGNM<",B32KT@5
M!-I@7Y!7W!\D.S<FTXGB@KJ_&[(Y!KX4,WXH+JF]H WXXKW(OH&]\K2(LT"
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MG%\\ZZMS:HZJ[.0 #U8IOP8G3-JO47O$A\3NTUZ.T3MA;?$KAM,RP6'6S,1
M7*D._Z?$<PXW%<^Y+D;X3(F=K!)J(V%Y V&>4'9*/[9?W[G( %>R+:C9XZH-
M1AO#JQ+Y\._4?Y/@?$M[TXG9RT;TFS-HB$%+VMK28RCYL+YG0_KA+>67SK%P
M)_82N2%X<"=$JZ>(2TDMA>\,:KAX7WC?I+C,IUC<7;K)W9B6X)+T2I<LYJ9U
MQ7N>NC*K1TSB322A<,-/"Z! 53G7KS)HYQLZ1E3R#(XX&,G[Z*#M>9D.<^GS
M"UT^TO6XK8;/]S:(VNKD[-7;__R/X9.]%\.?D>=AN/\B^O7=QU>G[]_\]NIE
M='IV]/JU#07>OGWU[NQTX_W&=T7G,7A=UK+AX89-;30\=K-Z_,^?7WT\?77\
MZ\>3LW_>-@0(-*CN93+I.1(@^$27]B?L&(=//?HK$K6]]9WRL-5/N6BR\6NX
MB]>#1/:8E\%&,XL19 ?P_%M03*)X VQH; ^.F2<E)(EC^G!5&RJ\@L4$=0QG
M4E/H38,PA+LRJ(F0JES4Y1;<%32PXMJ39G"%RRN,"YQP$M ;7S09I,4Q9>90
MW<@FS-I!_"U-58L&/KBY9N_@+F])USLR#WHK8LZR"P.[W(@:%_,Q<%B!>&[W
MX%&+VPR)8UWOXXI!A+,-(?%U*',%7;AC00+!"?93ZTW(=9F4L6M ?:&Z4O'I
MZ+W2BWB\>,$B8[G)7BA6-#KLD(A%O0N]PZJ'!M"2=0\H&<T::'*%2M%>TD15
M.G$Y4&NDEU.B-6E,S>D#2>KID2EW-"[8M,] _. AI"T60/GM<<1'0;5*S*)G
M$.E6NGP(23[B#@B^B$$XU1Z@S\_3HP!9 _.!8T0-.5/_$ZI862N9>%J:I4U)
M@R:U+6Q=FA.MDV]GF2EBO"S.*\H0NY2P'08D\:JE@Z5SAZW8G="DA!4&NY"P
MT]"EW43.PU&/M*X@W#?,) &>EK1\^@\5R#$DW:3:?B#K$(^A=?$,\#]PQ4H8
M)\R Y3.-%!?(^\7W<?>P\XV7878"8>) DH+-ST#_KOCW9<79 51F]U,.@A6=
MTRLM;-ZQ]^5 U11'K:3((U"T-Z4;7:;QPH<1'(,*7C#=C?QFL;4_-L)82)R
M=:G6YW&I'0LUFG^HGD:DSJH29G8["E$0^9'3C]9Q@GRMPF'VE2$RO0FDWLEM
M=4 98<RG+EY_CC&F"974L='=T\H0PP-7Z.,ZEL, OR,3J4<YF&'/'B!71BHD
MP*("]8PO"2XU&NM'Z/N2<TJDDW):*IDA?%H*X*R9+1RK#OX^*RJ\KLY:NBRB
M/4X;88>2X:/OZD2I9U> 1@;,D@Y:.BY^.?I-XFKZ*PJ=OAE-:%,?W1_\ZM%?
MP?8!ZW=T,HA.K-&/AD>[T?>\Z#5OL:/L0^IJ3\"1&#M-F6:(ZCBO0F"R*RZU
MH#-WJF^[=K'%<3 L1+P#+M;&GS3OG7)(2B443$YI5EE,1J$?17(1!=8%L)"2
M:\=2$E<.[D:+1Q$&*9*S8RT+0O<?8[="A55NJ+*@'>^]&?N)J80,D#7T1'WT
M95)Q0NH3@&TWUN.B6V%_.*%F0N=5L!M('<+^,&,FZ)M04DH,=$:QZ<71@:9N
MY4!CJ=T]>/"DV'NCMI5W8S1A3X_7IFQYJXU>\;HI]3OT>MW129\$'1I6.:?I
M)!>+CA+7_9JW&!I5US5-6?N5)8D7,'5A3TJ-><=>]P*DW9'T65R]&2CJR%G?
M$5T01Z&;2BP":X4ZFJUC%-T[,^/SW&ZDZ2)Z3ZI[T?>/CL_>@Y(!N+\<G%5]
M$\GTEO6Y4_MK/Q"\;S-'2;2!=%@-%!,BDW/G>M&[$MJU O;-=V9Q/L[>#[A)
M'WSY_6>LDPTE?\W+$IV<Z8.66*+\+'KW!38B"P/-H)[:VF7@:B!6PC@AHFME
M1SQ/E00Y^"'Z8=&V;<H%Z]RRO!;/WD.,9\J+%!!9BM4%HR$.@ ?,HCJ0X,^%
M/S.34 -)S]'L;8C8+XG(9B;.*ZVJ)U'RR [X!+<=!A..0*\KCG2YA;!<0Q32
MNEHC@5]B,)ATAP?.'Z),37Z1ED5.:0C[?U^>;3_8L)0L9=OW75KVP\?W'UY]
M/#MY]>79]7MZFV.7AB*3^N6:&.MBGT[RZ!V8:J"@V-\;/N]2S<JPF!4[W1DT
M96=E3&#RCVDRM>8=OQ.=G)Q$;]X<#X <L([/"0AE5##BV<&EM 7LN3Z]=V[B
MY%^-=>LAR9@5)*5AG:B#@[V]Z)T]?\NTF<W/HY^SBV1W$)TVP!=E)VL0O3'G
MZ8#N^NQP[_" SFIZ]I3U#.<HA\F4^X^'@R=/#Z,*;F>/5> QI82?5^6>I&4%
M3LRD <%7X"VENI[T@OM@PLZ=![R-FI2D;#%SQ:*T\'>"XEK+!:S^X!O00P+]
MF7B0=(>1=;)0Q?GO<=Z B2>AKB$K"T!YV0&F29''*S0"^,;>EA Q6P"$!D#L
M;P$0MS87?V_LWB&!O8 QTV[I-^G$_!;G-92\_Q[#X_UC]Q]VEU['GIPVUE(4
MLR)Z:P.0)K4;'1BP?H[S3W!=M")D,U!I&HRO,P^\ZT[/K=L^C2_CZ)<2=@F8
M).@V."LNB6G[K/BT* ;T9/8(OLH\#/:MR='6 2YZCN$4?0VW+?H0."9.F(\=
MD;\WN8D.]O"W3S;?D_U="Z2PO. D'DL(2LS7L"(R0OA3FF]"5.68Z7-4T4!S
M1D-.E2&(1 R&2DS OFE^P>_V94'_S4#.B4=DXR?\-(6P)*2I'MKE_#:V9_.G
MZ-7.,<2KH)+^I@!I2,"#?P\NM($NI-]2DE$Z)2#R,79#M0K4)U2%M%Z5]?>M
MV_ #;B\6M4@@TIW8DPX_7D$$,:8:31.D ]Q?=!(!BF9-R5'^)<\.BA@@]!K_
MQ84U)VU0G:?S.;8J204"X^30>)4EA+DS"9R)P<"CS-W# "<[:G]VL7 )+^^7
MAP!/-C($.' AP)M7OQR]@4#@^-6KER?O?ME\G U48-X5UAD=.@%P^-&E5XYM
M@%Y@<=2NI=<NP72J=8:P;L"$?GBHV8/IB"0./CI1E]=VAT7#O9U_L.,'Z:^F
M$K"RJ)E8%_M_5<NR=K=8<L\W<LD=NB7W]N3=J^CTZ/6KLW]&+T].C]^\/_WU
MXRU"T'59>':5@>>2I6,,*+X8ZK6W_R43_.+;^_;=4_[AZ..9#3^__/4?;^3Z
M?NS7]]''?[PZBUZ__QA]?/7+R>G9QZ-W9YQN/44\X_MWT:O__>O)V3\']A-O
MCLX0[/C^^!]_>__FY:N/]@)G9Z\^GD9'[UY&)Z>GO]I???CUX_'?CDY?G4;O
M7_-W(\;3=69OKCO6SS9HK-\2SOM$90?!6_@;B=-NO/EXWX8*(WV62]N_BZLD
M_E=T',^AQ!_Q8'B9FVHQ&Q59].C-Z]_>/=K\(&=I-.P)C"W\"?4:.0ET6 R.
MB=]CVW0..:U8_\&I6Y,VN\>"$1K?$\(#)9WU5Z%4TD "#"6D*1!VR)&3?+P;
M'>$U(,!DQXJB3-*0.8^[RO*@L#"U@6F>[/!@3O#_7GRKH4VB9\^B/K5Z.Y##
M_=W'T0RZNV'P21D:I<TTS+^IH5^+" 6P^RPI#.FV2G;?OG&3$T#(,^M2&I_:
M">#N<GUH :M+"$OS>.;9W^]CY4G68%06GTCT&B#^<2;_AD>'Y0#OFL$J3 2$
MH,945MB7>P'#35*I?IE"H)@GFV^%?X?.SA1:#U%+'I6106$CX3>$1;R6N_J[
MO=W#O7O=.* !2Y:R;2VPZ[K3WMA]?VKFM90]()?)10?HF=8#C]^R+[EW\#BZ
MHSN]-&/_(^[MM]B51 8<?E[7F=X[O%? U_7'/\TI^\IG(I,UE*Y $T^G)<)8
M@,:\(?C.>@[ZD]WG<B@BM.*[^YR!O=W'AZNV@<OHJIRAW4/VJ%IV5=9RN'<A
MNW+=5S@8D)!-FBRMOUYC4A< E+6.XG?#W2?!Q-[GO-JM/=Q_O)8STK_:=KL@
M%'=T[-_[:Y^A[.\XBTO73.$7D75[6V)0G@#):5L(UB_H16[F]A,"D"&8>-4&
MH]L5GY.(=2<2V''8(\,AD#<3#@800C"@(^N9LCA+7 L)B_+;![0E0J0>E7T\
M"EGA[O@I[1L %LA32XP6ZCUQ> #O6)2*>NF>'#G?9 WHKG$MU+F8EJ5.Y-"W
MPQD:L2G!J@';CYN5R*[KX6]21^<'S^4UB5[9)5,O=)<[:[.>0(1>;GP0\-YC
M<1@R]10.FN'3@=[2<U:9COG0A;X &B3?J?<KYV?22GZ'9Q6[0"ES;+/\TK\)
MQ*>NT\SA%]\-'^_NN8B<:PMJ)TL0+9%KU[/O[^U&]K6.FFE3U>$?NE\JMQZ9
MW1,S+AECBJGG-8G13^G7J/>A$T-]A_T\3,7@B]'#R-O!ZQXL_98AL,B%19D>
M(0V3X6@WEJ[E&1I.C'@OUM=I2C"Q ZPJF5%)0".:GOW[FYY[]826%P$LC2=[
MK=^NY3S?[\GWGF.NX<% P8-NN8!NL/5<6'TP9,@--?OV77T.FJ/6U: >*O=G
M-FI+XG;N/C$Z4(9PUC-CUW02^% <8A;6X>)"O^^MP#8U1!?E9EK4U.^*Z=_8
MZX\SM2_ EZ-8J:,FXO-XZ/8 &T#'D&GP_1"^&*BI9$AG4"F@44*Z/2R.^)/P
MG(S8FI=FAZ$/2<>(9K'(X3 ):]7U7-/&NCL9]J<QBZN]&%42/C;V88=[H\<[
M0WDT=<J_$L[LHS$^^?#YP2%U(\PP-+.OA;>RHY\MJ"TA&%.Z!\$PNY]=*&JP
MM<0PIJS]_#4C-2NW NUW R2*>RND6QDPQPHW]*<S:EX16DF[/-?2BJS:,T[-
M&1ELJ0468@^&HB)2%X??/M#]6J.7CMR1[#8T)1AHDJK/J]Z<!"Y^_]I)M+=[
MT%&2:+/KT$543:QKD:V@(/Q30G$/ME#<VZ<(?.&1.LT8.E<%=<@V"S9P?#B.
M9/9J4#%IH=%#FAZU9_,(N/70&F!]3:E/C8Q]. HZ\ 8Q$O("]%WQIZ&I] 4K
M>@^WO@&LMX.<'//*_"3_>&%MCMU3BY_2',<%O_0BG#A8!1>F1(9W7O X<?1G
M7B#/G^\.]_=AC=2E_?]$;LS+9]>.\X_+O[>^\]ZS9YU_VML=WO#WCP^>WN@;
M?0\U?+J[=WC3F_]9'VKX[/D:/M3S@Y67^A'7**U3NQ-@O_SWHX-'WE:B'LE/
M^_//T; +F-7>#K03OGUB!XWR!VQ7<::X3JYZK3UX*1Z>C7_[,R@#1.\</N&4
M? O)=OUIQ^6(^1(_(%WA!\B'VH5"P_-G'9.KU@H$0A]43/<!6?9MB'F4YT6#
M3,H?D$;)^NH?R(^OOLE8@C!2[TC>JTO:/=!OX\_IK)E%+\'+**/?XJPQ:L Q
MB__6!D#_M%[+ST9-P*_.\^\=Z#M]GR>@-77E"W7$$>#![ASL=KA&H")&9!_?
M#W]H.<BP1JXX>Y:#UO'8&!NTL@<'-]Z#^T:(@8_@Y5]\Z=+YQLXV&2;KIF;1
M,-J)Z%\'>]?80KVCLG)O[=_=J.Y%'6.+S:UK-;C[SP;/#Y]1)-(>UCM<8#@8
M>]<=BEZ+=Z-9_:HSN7:[Y+NO-7O7GK7[>>\GNP=/'N3RW1JEASBK6Z/T9S!*
M^_N#O2?/!WL'P_5;Q#=V)[D&LDDN(X0*X##"?P^&7^0NMM[ZQI:Y8]0VQ/H.
M#Y\/GCV]Z<KM7B5?S<2NF)Y;3\G:+>?KF]&N5USOU0:YUXU=:EM+L-;3L[4$
MFV0)]O<&SY\/!P=/;AK/W=&"^](\VR8Y1H02LYX1UY#O,Y.V@0;QZ>%@[_'>
ME_GT&Q!\/F1[V/6*:[[8=I]N[E+;&H)UGIVM(=@D0V =H\/]X>#Q_M/[67 /
M*V.THM)_GXDB3ODQ@N[ 3E-2-(#'DW=_:#G^Q_N#9T^^,/2_L\&Z[[S!?7]_
MNS"W"_/.%A:>$S\B('@=L=W+T)U.,9Y;0W?N Y#^=?H]ONJ(;3MNMQVWZ[,:
MMWVZ7WF U[.[]ZN^\E?JPOO:5GG=.HF_G&WCZ0:Q;7PT ,".3N,,@<^_YHKP
MTO?C;CS/QKLBOP5_RO[>!LTH4Z8 >ZC)*UKU %+7=+8/F44IK=J4K/:H$[$A
M;*@OS<2N;VCRMD:"]$1/G*+H/IF(M&+IKUNLFLT4[7KBZ*7_OX^O3E]]_.W5
MR___R\=@,U4+GBJ*[7='O[QZ^TKQ:@.3_*^GIR?OWR%OMOW FW^>GB!?]NN3
M=T?OCD^.WD3'[]^]/#F3S]B!_/7-&7X$=-".X _KJ(2&5[R^LG/8CZQ4"5!6
M,(^S196Z]OD.:C%6V.N0O;9NJ! T6"\5N1GLM_YH\K'O;Z;.926QX.]0>8D%
MK?>9%ZA;2;P5,89IR"#,>D(KI1=N80<V24;A_07(F9C+C3_Q674\=LWMD\*N
M3J)0SINZ3*<F+V;I&"7?P8]L$J1W.2\NZ>]N@>9Q;;U'B.6+,1"]B2 MG'*5
MB/R>-_:)(WM-DO^HFCFNH&E1)"!PE]7GJ#$#CV376SH6'4V0Q(0+SDTQMRY8
M/#YGN263EOQ%R"ID&8EVP_/X93XMXJS"ZS(+ +#(D?YWA1),*!$.3WX1RR8A
M(4N2LK$#8B>1Z*;7DI@D07Y!)![):]SLUE3$N*VK>^4:@1EAF669C0P<BTN1
M%0=-7;2%.R-L&"2NPJBR?K8U=;@XFIPT1%DMJ/,]<7)-/H4.6=&73V1B'3NC
M 3)A$%2],%DQ)Y8@\(":S(L75.SAQ\E%C!VB>A.0$G9,W)!):FI(-\ :SH2N
M,2^*NBSFN%^ &HA$TLMB9Y06-?Z6QBM@*L+[?DISEE&S*WH<$^<C+D%\.4^=
M6,&8PECT+='^U0!#<UG8[0=1W=R:=^3MAW,$6S@O6=QIG,5V3I"NA^5TC^RE
M[4A6_'E'[W]4I?&/'V+@]AGC+U\U]NT-?VSS10^0)JL9@Q@6OI[=Y9>UDZX2
MC?L(4YL@.&R?(**%S"(1))UMPWO\G).\ZIX>8""IZ](NLO7ENBX-ZGOZ]69_
MP*()FO.EI8ELI?87HG':>D6^6O^N!I702\.*>3@/DR9#"BJZBL@QTX6(9*S'
M$MI/N:<>1&D-LY;950><8R,SCD&CKIC\].5KEBLN.U ]_^G@26L5[ZQC& C.
M^OZ3%VNXTL+1'!Y"7HQ$2&1MM=EY)UD\!:$ZZ##'JL#L 24K;;SU]' =Y^G1
M7R.Z*ABW7F^J\ZQ4FJC;F=K<,N1U23!G9AK_UP!VY\]I,8A.CJ.?L6*^>5GX
M_BG^5H,YB#ZF]K@Z>FO_8?W:.OI@__4RAFWXNPN"7A[\%_F6'\X7U<G_CEY;
M%^_GIB3O[4-IR"7MWINH5FMO"[OZK&S,*>SL<><^W<[5%;MNA6N/OWZ3_JM)
MD^@8R%5LH&&WB.D_O[:C?=7.8 Y*>V^(5.9V<_B5[<(]RBK8CXWLIB@^PS&%
M8K5UB?Y\'B7%E/,(1__OR?OM3'SI3+B V(;GIIPNHJ1,\T_1+/ULJA??TM=>
M Y?ZOCUGRJJ,=<4+27Z]I 1]@E YL-0DG0#%3_CQ!?R\G;5O.FO #&VW.3G8
MS1S8 4L7R8JL]N:G6HX@2TA%#HG.+U!8DS-_DH:13%5FF!%/Y1MT:@^N9?_$
MPNC\!U[.-7Z<"%VMNR1)A#3/BPLZ"((#6K+&/A\)W-N@0')%-@?S(79C5>J"
MX L$/.FL> Y)ON7\"2<S?[7W!*0!U&OLL?36?$['UH?^>SP'GNTCNQA*>P#$
M@^AOA7V7?Q0@)G,<YW%B?W5FW0Z[RY.!OM(_[#LGQ8Q^]\[ YH?/V&O_8LH9
MRFF>Q>FENSI<^W0>I_;G$SB'X'(_FVR:-O8:L +^CXGIMZ?VRO$<=>LE2_CA
M/,U00-[P:X+.9/LUC\_3/%94\O2S [6,RZ*J=@B?&YD=2!P;.[D^!S<K[$:)
M&FNG,E:-&SX6D(Q=,5N*:;77#@_#X=@<BNE[&C JA:+8P27DQU':"26A.E:B
M+.;=Z,3N]43DH2Y[]G>LU%C'@"$LQ;J0-BM5@JMF-B=D5IXM=J-7L'K0;D6Y
M?45FC&;IJ K+>7EE;1:)*GDI/WB%@3*-F!4MA*.>RW'VP2>2=6URO +H0$!F
M'X3;I&AGI\':H0ISL/9I_7.0YU=:DVNO*CES)LC/05S0;BM[G=3ZZ&-KC+Z\
M9'RP2<KD<)9_X'G?^-/Z?9#D+PD>NS+QN@V7KD@32+KE3I.HVU&_8M2W:<FO
MGI:$-&0[-_F%:<EM*O(.4C+.T&SSDMN\Y)]U)E;E)4D>;>O-W$J<F#,R:&P8
M/UIMQ_168_KNX^MA=+J ]6J_5F['\$LV_W8)WFH)EI/][1*\Y1(D1W>[#&^Q
M#(]>;E?A+15QMS[.]CR^_S%,JU;LXQKNQR;+&I ;8@<=*W&FQ)9%:$H<+:)1
M45#Z>9;6Q?B\R*T3'XOKR3WLZ0PK2/YRI9E#O(N@>U!A='^(I_92VWVQ=1+6
M80RA*!.GH'.-A9>2LV&C#%KUBXG=)M/2)*GKW3N/JVAD#(CQ%I?YJB0"?-KD
MY[B'>&NI'6-W%>] D3@=%<F"FSHK:?*R%[&?ABOGH%-:U(:^;>\'7X'^+LCA
M08T^ YRVO;I<3MW+OD97TYA<SSZROHW)_[V8F0#VC7 (^+N!KLI94]L9'$3C
MN(XS_!>V;&3VU_6YO9\=@45> _O!=I-O7; U&,++V.F]4ZTG/ EK:$ZI\7R*
M*OOP,0)5YG8Q0QG>;H.+(KN0IEQ>W 8ZB:DA9KP8XQ>@F<W=)IH5F1F#ICS<
MT7X9IO'[/!T7]ARU+PE:Q(G)(6EC=U@SSHS]0V)^H+V4UAUVABG4JK2L&]2&
MMU- O954)Z:F'#K4$]>KB6VF S9 @PB2H%#HMN<P?A?N-BN*9#?Z%=MRE-CR
M=MO>05X.X$E30]Q)5+3WS7[; ;[- )^5Z<[6+MXN0;)L9.:,V*MH9"OP+D;6
M>$Q2NY2M)V1M)G#,V8=MG.,"_\A438M:,JWK;Z^YNRV<WTGA'.*WN*-62S!-
M<$$!$Q6]_-L1M0=_.*(O[AQ$D[BN;50W3@%U6. OGX:_A&\ !G1FCY67!YHO
M8%Q, 85I/40Y3\;045Y<Q-488SGY-=8XY0?!(Z:S68/>8%6;V78EW'8E$'2B
M=R4D!IP7<FED_HIYG<[L>9^D4U.YWOM@7J()LYAL)^BV$Q2"+VXT43PE0LVQ
M1<?<,M?5;2N)W\0-NED8W ^C,E;6RX;[< +"'ZV53*<-?0B@WP#+7C:-LH'8
MD@( ,[A-#IDT&UIDQLPAK+!':%[M+L%R;K)<>L@M^)(>W'.3:\8\ @NQ%L#[
M KW_NQ&@$#'9Q/F,9 L0NB,0(B1>=C ANA(FY K[VW&_;=30F./,V#M_M#XM
M$EG@CQ4$:-O!O?W@?C2 3Z>3\'5:SG"$BYDU/)^W WP7 VR=M#HZR;+&#FV,
M29]7]J0ZMJ'9;#O =S' ?ULD0,W)#IA!&_&VL*%P XS46S-Q)X-\!F6"#Z9$
MUB8[P&\*:M[9CNWMQ_8#U778"+^U'X)*TFF30S;G4W3ZX74$S.[;H;YE.+Y=
MO7<]I'\#]W=[E-W)6)[D%^D42*9A@9Z>Q[-Y46Q']=;5V,)Z =4Y>;5,&[SU
M"6X_KJ?VN>;1J2FASQVLP'9 ;S>@K::BW>V WNV "D4M &5*8\/;W)H%XU*
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M<J0S>(UYBQHE:*I).G"/< :?P+-TLV$K8)+]<FA.EM#S_?0@&C6)A>[#] B
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ME7<DYE.($<=P%-CG*3&X^#$F.R85"C1JU[^3$1V)4B!"Z>S;(AS*.),EK/V
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M\)WG=N4=^^#VQ8 2S87O8(-89HTG_)WRR:GJC$\C[ A=<L99G/$DZ6'=5_V
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MGY: 6S=:)@Q#U[,:Q_Q]F0NP)B[ S<=6P-+CTJ#;'8-./M1KQS_E2#Y(.\$
M?$?Z( G&0OF_RY%UIJ^P/O$ET2.=8.N%.F7&\.[<OT4!G'JMC.!L*,M]8I%<
M\_B=%PA_+.GJ&WQESGXE!\E.V#$S@*+4Y'IC]Z:]%@-DEQPAL\"P2]Z/&7#8
M-9?'+%:!=/%)^#]1W3T9P,IM4;$NJB?5M0GPKD-JTI00K^*SA\O.%]V50.]&
M:9;U4K/<6<W2AC6X?@)G!OPP\>%/AP8;J.AL^BNQRQ_9[\*SOB8"B\A&2O?<
M+>$Z&VX[K8;.!LTN:J2S(2(& =!7"9 4(+NJI<Z&2L42D?4I",/@7H85:MN
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M\^+4+-C6(I*C54J.4G+4/IR*T+-.P&!,PE)N3/7ZORR0-@<.Q0G JP?)0LF
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M! ;)$S?Z&4U%;WT21<0Q!_4K)F&.+P'IER63PXP9<8264K5N\'R,B]/MR <
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M@$42!2F/7VOO8_VP<G1TJ'U\>J4?V4?VE*/1A+?P$3V/L"@)9%L)Y& %!'(
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M%O5;9V1PH!=: ;)"$#B>;F':Z-A\IYGE0!6[3>0X$Z5QV]9WO^JFC7"^MY^
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M7HKITRNEZ?,T,6<S\J@ 8?T#_H&OO)1>>,1.-1&G$APUDH] !H1I#U%UQ_
MKL SZ,3/V!T;O2X"'X K<^[)G>$KF#FR)S,PV%&M%7D8Q,FJ2OK>QHS%\C!
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MI_'_9J4/ITR6]K^$*^-$6;R"+W0G R)2W1.?AN7< \_4?WG01SBD@3Z\GKN
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M1FTY) ^JY ?Z9C 90VG4Z%=2GN:@LP,L5( %J*US&_1TW'!P NX'$*UB@&9
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M3?^GXRH/8IA(Z0<+/:>6Z9F>8F&[.APX[?NN.9R+"6XKZ49,5Z$AW;M4ZPF
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M(MI^_(JBBCX@&5>TN(*/2A@#NH6[P%AY//@&*]DKM7T>9D.;AI'Q#6_W0;S
MPL1&1 8"?AV,Q AW "78\V%U?.7J#?- %SPXMTDGC' 7VU@<QYACS"\NV3HQ
M9+U^GYF<YRM7P*:66%_LK0%P='?Q MU''DC\#7;*DS#^FG-5DX^MF/+&^C_3
MKX"6.L)"^( HR^+I_N81W@WXH-R 78=%B12&7#:PDZ3R,QJ%A>0'QPXT=EJK
M HW'%#0BL/R3"=A0I(AR9V5$&;V:-"ID)2F"SOR!#(-G%HE(U$7H8*!0/MFG
M2!#X7\X&<*$ETMLTO6GAK8U'MTTO*S![L1FWB1%-<5!&4>TZV (8O>C_U%_2
ML0^+AJLIK2+^=C@#X@C^=\KF[GR%2QM:YHO.&QY$\&1),0>CFQ)<,<7M(YKM
M&EXG,#EO/D3N[YO VS^(P0M6*09N.7%'5J #A$HY%TRT_HRK H&[G2Q@;V+.
MPO<MK_:_/7J]:9A ,,PC&R!P_PNMEP\%$\QXK>)151[FKC<7X7W^EJW4FMAQ
ME!?^$XMTEC ][AY$[P7^/O.MC^ =H07R_]K[TB>UL2S??T7!ZYJNBB I)'9[
MAH@LEUW/\ZILA^WJCOXT(>"2J;:0*"V9SOGKWSGG7NT")"1 @ONAJYV9(-WE
M[,OOF#1$?0$^JR5J!.+']HR*&W3C%1@].1X*,KMN "TN"=Q%=UZB,&H7C"&T
M'-9K Z,N*$WP7"WT4>"'+A5@=-%%@6OB$5GO$:[,I6(\#[S6A&D5LH! C^$1
M)KC/T+B-:"N@8+!O@)*"*[$=L'3X$H%>&)IB0%4*-I\(THA?9!<L""0ITV!6
M&&A-OZ(+,OD;"RL #>L)5DYY05! OK-\U%U\+]_>,Y"3HB]Y]0GQFY/#A'$.
M) LGSK=$7B)Z34OAS /'2DXP=X$1!06;:[B8@"4RYX$Y;K@._.H"HRSXYUS'
M4Y3(N'MJ9+!:DA>#166/I&$X]^!0"G?]DEL;*5A1\7!#U\X78O\1?Y#/0/<(
M!J?NF^02B!FN^=RP!H/5=UA:LL!-$_&)RUH%]OYNQ= -E[/@H3A:!I@3<-6H
M8KE:V>C ,B#6X^\2R?V8[#>0QF K2_KC0K>^.?[66[ZD5YG]9K =6#]E.6"%
MS )9OV3D!H&T<#G7$7_D:2Y\+HAC< /@#P\@2T2F7GPTF&^9WCS.F-QYE,A.
M@:<<98(2N9[L,WN8[<'UDQ\87:EB+V$M^RZ"Y%&HRX/U")T2W"RIW4@ZB6A/
M5)<::KN -\D\C&*H4?6QL"SC#A__-&P;S#IP/$$3>Q@J0#=.!.Q%A2<O<S)<
M>'UVK=U(79.L,.*.,7SR>#)!68C2V-WEIB8YCAQ&W4<FHQBC&>XNM:.>\N<V
M*%%=<N1O7I"/RPCO#]0">=)!F)JO)^\<]ZZHJPCY:6_SSFZ7@\OK(<I;VZ=U
M77;5\?V@/((TI$/0^<'2)NCVQ=8B_1>2RZYS2RN$O049;5$1>\H6!IWY?F<L
MM"1!QJ$F04%E4!<)"2L#Z#&O\R">;\[&XK#P?=];,5D.[[/LJ&4E1O."?W(?
MG+TP)4?%%^V\';6M\W9Z9.<M97H?;1,NS7U+1A\^;E\O[F26+7B9S+*]N/$G
M"R-:X6\XJB^7OR+GQ37WY9Z+-?/[NPH-Q(YSI^&ZB/NR4V!3KMW-3$8?[$EJ
MT\6]I^?R1?(!U50"X-(?/Y)6P1FR_]0=5)SNV^_,66(M7#+9395O=__+G+S:
MSFE_3Q0Q?]U:(AG?O\RRU<X<_U1@N#+?1+K2 8U&S*JYI/%%Z;=8"/E96^$A
MU4PBK8HBY]__+$FWF?G9>VG@L_#NV8H^=O^L.ZL/S/NX?F<[:V: P<7R1GQ/
M-2Q!WE>M:UTVMUGV# _,(#_)&=(\\L'N,^1+3;9#=F.V1!0 "2,3P33*+=@)
MU9BEK/#<CY7"#PKKI.!,ONK?$8,8U2"L#GY!?_T%&];>Q*9HYAW9$(\LBY/2
M["3QQ7FAB:=2DK[&N3JN&GF5JT";@OD[G.06H%WT=O.E!,62 K$D5"Q5W"[1
M@3"Q-10#GNAQKYCHN IRU*A^]>_DT8A#5'QTTS&>"C_T&DE/!V3=):]HCYQM
MY%$F+2472*"T.AU54*?!>#CZT"<1N/^$"BU/(XQ1(V2GVL8-D=*K'Y]M]9,#
MJQ?&,M?Y&%U 8 8E>(="+U&"MRCXFJ0@N(*(_D=+^6 _41J3,Y$V(7R*23=E
M!"ULL+M$T3,C7"$Z'8>%R1_XRX.C;X(>)PRJ8,X'K"?8(Z9\1+,3''PN(D9/
M^3,TOL2<0OQ6\,;=[TMZ'A@:?;0=.(,5)32#C_-";-D"M;\%:M*&%JCR(9@+
M'6>YLO]=O>JNXW&I^#DD_D^<]N]#4N<5-6HQLRLF(J>=^<YY-8&8#$K^?V5+
M4?'/"_;&/*.ZBS&Q>&V#4C65?PH_)\1OMIHG>*%.\!O,HQS*AL%>L:,BS"$&
M*1@;K$Z$U?C&O*@_8>L83SS/8[$'VS,H2^0Y<)E\C[$D\8;!;Q6JB^,9)5Y,
MDI1_0 M ]3REA8FYY=)V5E%L&L24:2PICR2R<P9LS=2?7:I VNI.&'@I)L@P
M:17+=.O8D7M',:2'7&$(RDD(7LP6$OY(SC(??&-%9>IN+*W-]=]G']:N]A>C
M.S58Z9=H)V^_\QXRY7Y)&U%G@R'5L@BI#KND5\&UF%1&^Y(\;/X.UX?U[5@[
M-8,M&(_Z,X^7)Z;7CZO".PJ+3[8F;RD+2"+:%1# DG65)Q"\&R9*2XT--6H'
M>7DL"6BDC;B/JT3NT_5AJUR?.I2S#,+4E%S#XX<%)6(4*3"O?0F8X*7EH[P%
M;+M(BN48>'DR:K8_&L8W$@4^4>0D@Y]>JFD@.E*#)T1+R>D#>_PD:A/ -8YV
M^G$=ZW++V>.,^O.SM7VAJ1K$I1"N)4,3^Z#;\->9ZQ[4=-U%3/FRUSU3]T>A
MSGW=!_9XW'53LV)VA$'1Z[[W^"GL3FD:+O]]J:T6"=-F;)#/#"NEX%XC8R3Z
M3&B69(]@T)EK_3TDS]?O!$^/'TE"-EXR]A"_E&MP!45_<5)*Y'M^/,VJ$%ZU
MF\:6%6T0G_D?T7%.])2)=EE\5KRWV+88?Q[5-5&_1SP5G]O#BS9C;#VBS N-
MAF1'KZH&';UO\;G\-1C.]TPXP>#+<>L45V.Q9S/,9H7O!TM,S-F,"YPPGQ:)
M&:U/#1STLBXZP_]F2ZK<U5?_]GGU)'8@&KPFDI]V<*#4ON\%3R7#DDP8!VO6
MR!:*1&!>[6C\D-I/F^\MY8%98->:B5,2=4_Q0UK;B Y!]=!PEPLPRN'<+)!"
M2TZ?5+NEX[VX&+]:BO)/5?M!^9%7^PEL%9X9W>JNR[L#,#YK.RZ2T0_4([.Q
MH_*Z#)T6NQ<JJ@O6PC?CDO*B9>'#^-^ZG!L$SR&)\_W_B'V.6UYWE?[.3[Q0
MC H/PR.+4W@W+!],:DB$4.1%5_BFXKOA55VC_@_<'/6C(G5LZ;H3(1VB8%HE
MOJN'34EA094>7%WLBGF+?L!<HF?)AK4N#6?I;_#4EQB@CR05>4Z!N\)";N^&
MM:9!Z19_@?T<\_>R!\\;4D/>/WREZ!+K^8VM_+;('Z+6VJC@D?LTZZAN652O
MNH;GZ]$W$GMN/U?C4<5T! ;OL(Z.0R+9>'8>$Z7QN]HK>&>>YR:5P ([\%?^
M,J ET_@&7N^C;8O:3=%\3M6.@ONP+0)<OJWRP*N98?&.;:;?%D07,.1PQT,.
MZ*/ZFQ"'*1E4"  X8LD?I/,5MO-Y+'P+:)2-X6]X>3LV,,$9)[$^ACT![&*X
ML>"H92L&+&SII0ID0])\$Q;(PY&^"VOG"*#TQ*!>E^P=>H/S,PBPBYCVO;6,
MNO"C^#"/3 %S&@^6'N(:HK8/D*LCX9?2^3WE_]K/[(E@$G<6%^+0VAB\C3 C
M+" 140W^$LH@1[P *W1=_G%4/ \6YP02TBFK(QFA"K=.,K 5MTI/?(6 =<:R
M2/5:@*G2AKT51IOC_8U[ '<:&9]J+ K0;+@+!>B2;N).!*(]WHN1P",B9RS"
MQ4I0B5L_+E,TU/SPI>3=PFC_**B=Z]F%A%EU/>,CUS,[T7HX8O5@=+B@LP2<
M53EB"I,Y^",I/HZ$'@$Q7(_D4?NG(O0I760VB'71FJ7=% )T0',\J$I&I.G)
MJ.0>410SC=#_VT<%)>/UX7W': "O/"]F.<,H_6S/\($=T!D7+_O;QQPG88T1
ML!RPQFB8E7%[Z#,(2.2/GTG:UXTDS)[RKO@6TED8- 73,GRGSJ>Q >C?UIG,
M*,X+H[Z*6;EQ<WGA*$UQJ*OP6&:@?(^JY2G\!E+Q;@[MY76X70M:X5>*!F!J
M(FQ5COC-<.,!_/Q&89$I081'@WIZ,4,OJGMUA^#4UW#O%$6.2A92S0:Z8XEF
M^"R00(0702%!8[.U78%\@K5O<7 .BG.)6H%8=+K+Y8CHI!?X#6L?NR@PWD:U
MC0)G@<>QQ()A,_!IA.$QV1."18CP0UZX(;^JKF@?Y+1M?9"S8R>0AAV/E"X.
M2^<_8WTA5M.[GAL5UP=YYDQWY*@_R#0IPN]V=$?>T<.4^/N.Z8T4+\AY;97>
M2$W#>;D7B<KP=:S07:)]OJ)T,WXJ/N+U?=@"1#7']8C",^TZGX)Y>^S=%^9Y
MV+90X[8:$F#35S8XOJL(V3%A7@59[1#*=Z+LNNU$9IL^&<]KQ^<^I*J;QV%!
MM1VD@Z)>,DIP,=/@PYZ8*#T'";P"\2Q4!0>YM+!Y$SM(&URT9O!<MK =MK9M
M1G4#6 ]>MIJL?\@YR6\^NN=ED@3\\)(1H;R#D!*<']?W80Z.%R1%12PE.YA&
M_2$XASLPM$4BH:?$RNV56=P)R*7*^"A/872$A(>_ "K"$7,\OWL@9?OW5+*6
MY\&<^+Q&0B$+LA\)$/\)K]$$G=]([W87]6@MHIX1N%-==3 MW )W<7X/B?JB
M0_:0SG<7P^&X10))#C]5FH@.#:*N3$19TLDZVV.$;][=R92NB=S#]TOD8Q8D
M(U-<SK/P^9#H'",.$]BX>#="[@G&$/$V1Q)F(3[MD6=^:+#S"<Z\)+M..O-A
M=SS(%_>)ZT#M3>"LU(!TY($<@@>__(%,L7]W=/@X@L%B)I9H -,_!?"76<43
M4? 6G&?,5*A],L^4'/,LT03 7P7.N>]@!IT\<-Z::PHD_@ Z3-1LK$,L@1B%
MDXJD^'ALT<0&,<Z!CZ!N!-4>+P$C5K.#6A]\W YFHTJ 9.E@)-&.3'8D)):6
M2RJ+PZ2R2).*P#+Y8%,I'%O]D^0P^'Y\NMAO># (N?M.-YQ_Z*;/\LAD!F32
M&V83)GS#8=RI2^W0"@XN4W3!,W'U NIB>6=\OWLT5N!LO((GJWT<4.\PH0(P
M[BKT4M!9C5$MPQ:> *_ X 4XL 1?U&#%YMGN\.)!%"<@8 Z=YF+_:<:HYDVT
M%J3O! ?B?E^M?.?9!L)D5GB>J@J[9A9OQDX[\CWEGA,R+RDZV$]#M7)$K'A$
M7<XV+,)3#D!S\1/":N6,E@J,B4>@;;F*=X?+GLO\GLMI"WHN>6@G+^!3;>S<
MN0X9K>6,#[4/'#Q'6(=P<?B?N(@/%$8BSHJ#FR-=PEEP)>I)X^TI^R9H%[))
M<QHUCK4&LD+I@T!?S)BDJE:LN?[*RM-W1-'V0 :T87,E2_%^XZ7XN5 EYV)H
MSJ_Q_^85@AX$=%!^[+S]\NE3YR>*3XE@82*YD2Z>4:>\>#N(T<!G,_7'1BS,
M@]_@5>'XHG2-,X[U,-8O0MQ\$4[74!L$C$.3 K!$_#,BS?JXQ15K!<>4)"J2
M2+!+\@F:2UI@.;J1YU):<N_J\<]),(MISB$*&KWQG>V\HVS=>^$OY8EF@C[;
MTTRZIWERARN&I+M/6]9^#G4YM$%P$\Z-')2\XQH6TV2D]O.CI9R_,Q'8D$R2
M!YF/X"R:PJ*Q/"&R=("UXFY-G%+$?XAJA,7 -) [+/Y!Y<?((::>@Z#E+"PH
M9\Y=U/E#OI$(W)O&QO!^ND8A$\E^ZCYJEI0)])1+>?OP:L@MRZ^72M$5[VRC
M]L-P7E39*3:%(DW'A ]"M"9<7Z)!6LR]R4'B'JFCSGR:K9KY(=".. @Z''RU
MU@U'X( H3QB "*W/$ 0U*-1@0*W452RJM42Q/7W6^'['QXS9ZS5SHL !(GE8
M88HN9LF"VVXL?![K$;S%KR-@):[J2][$"66D&!P8@FGY"W?I&&3[[YA]-5+'
MG;FZYR*6L17P" O'6XH'X*OAG)W@ )*Z L@P.)&RT4]UTID/]F7^@DJ<"&F!
M:G9":E)6',"!!@0DR0ZHCN!C#)Q$!](;'@C: WN#%RR,1L*CA"N:$@G&FH.N
MB+]RE!4.S,.50/3DD**CSLL(JB<H,->72P>G#(0 _GS29NE"Q-W4'875CKE9
M#CCPWGH+RW+=CVL,1OY!(H%"DG#7N!.P!KBK^\'VOMJ_\-AE^:"WBG,"\F/>
M66%$=D%H8Y%0Q^=9*UV,^#," )_XA1G)$0QQ;!<1%KT^)?TQ8(!/0NXV2TW_
M:9DT_2H<])"%C8I+0]+8AN<Q,3$XL@ 7+,!J6L4@KW"=7',!'2 18X9C;TQZ
M-JJ'=X)SY\=>+/X\Z\Q#A9F./V<4: @-R'</Q,CY@,C?%C.V%9741PRZH16&
MZ*F0]YN*#3K2^BW&!AUI:N'P9<+BYNG 4(LGM>V5H8/NJXG<74S:ZBT3TD@&
MVV]):!;(P8B?1W] '4X4<4>.3LK^#>>3H80+T..#640<Y^'!ME<NG_OE/%'6
MEQ)F_%4B)RZT"9D2W(;@((BENDSBPF37BNO&0+L/@PWN5SLJDL+NB/=6/*Z5
M<20_XW&YX#)]X<?"&?PST."#14])9I9C#*V!";X'[[^9)51X-74V\%SBX =X
M\+OQVM+8Z<\4/UWCR'9>,40E1T$AHQU'1:&.*"Q'X@MOO4#MS.^] V.H2CI1
MT_WD$*I$?J?YEF%8T,&K!;YB8UG\[]B( '[2OY@GJ"&_1DT;XM"TG':_0*."
MC/$M)WQ$VDC&R<N\\P&I )YPQU>U6VCID4GKYN=K^9=L*X;>BBTV+OA/(O4:
MJV+@Y3YHFOHF_X#Y0K4C/+H;Q/_9=^J1P46&F^$N&^[!%34KRK.HCKG3>7E,
M$&$]7& R.]LM<AXGY,*0S=5<NQ\53'336*L:*^()[7TR:EO%I?GI7)XG%,GP
M%NUF9S=$4+10!<VUSOB;.%H*N[CO+4Z'OSFVZQ:?BC72]J$Z%, K;=Z&)N5K
MW-5#R 87WM*T,[<*S"W+B9O&ZVLHS.D&0=+R;G1:)I6;5[A\9"O?9").G#G+
MQ* W-'/ W/^**<)LJYXV2S?EM52@Q& 6<>("5GS3R.<PQAD41HGSR.OL+W!O
MKXX3ONJ SL;C<.Q!@: #!@+:^::^==FKX!^O5X:[-?675X9%.Z4OO4X^'LOH
MGA!2#)8N*@;I*OB?187=;-:;C@989.<Y\+]5\&)1?]>#D_LY^_O!M#?1AKE_
MZO?4W-_O>I0*[L^LW*-V_WXTT.2BSK^HZ=Y'_4R4Q:D+Z!=9X[\Z@TY4(KK"
M),&KOJ("_?]\Z&/:]CM^\'6F#C9-ZYS,ZQ8VTT.F&%6L"KF*Q0R(^^G#HU;N
M3Z%8\%:W=!A!Q3W5[HJR>_IW,%24BU'*L,LC"H^(GTJ(4TY_BA7;\VX2)##2
M2K=*7/=A1?)[+&BP7+",*.:SC_<.2*1 MR(2YNYCNL5/R8.3!R</KA6?D@<G
M#ZY1!Y=-6RV7C*W7K_?8&R9;9WU8>WO^" *WZI,E381)*9Q_;:?YI1T^ .'D
M8PR@CZ Z"H&?*[BAQ.'TE9PCHK*W\UAD!8^I=#"PP)CPD[2%#<((UZ#?F<^R
MR<!4K9JXVKJN$RZ2+K1?]#IW<N)!UHI;_">EQCR&O2@Q_NU4MU?XUAK&A/MZ
M\-7#+?CU,&*J"3\(!% (("<>/U 1P5;+EDE<)8.6^7Z1K1S[[+.N31@/P4/#
MR#T/B1=\L:B#.7KA\OO-_/[56Y:BDK^*$7G]AN+XM';B,2GCF 6I8=$] :K6
MI*4:H(DJTUS[S<$K-_G&U2P^MQ1/[;?Z"E=G# 97R&JM_GYI_9Q2](W7SP&I
M'J>A<W9[FQIZ7Q],O!XI/.XR"GA8FU3(I\Z3284B5O.-D=?E-%9 >K4KK=$U
MD^>%OE^9)5ILG^9ML;W<?F9?+\/EU'@05I"(IJ'BNF?<-.:^^HC).PY]*V,F
M%XV9O L!B$-.*L,VDVMVY&Z,_BYGLN4085U&V_2:";2-W[^!2 ,A[F*+_1N"
M?K^YF,./S5)Q;T,D\9B*RZJR66>N9?&4,E79;7+JKI.\&JC <DBL9('$L-^9
MJUIOF!UL*F,+,F%]WE+(@2R%/-9;&UV^$G*H=N:3&ZF$E*Y:1M.-&EH!.-3V
M3N"1;MA%W+!&5.N=I 2RJ89%V[]_]8:1K.0KB]#3M$J^X366%\E*OFO)E.YL
MWFAA)=^POIJ=YK!:J[]_ _%U6<E7@X8^927?\*I+I6Z,O"ZGL4Y5R3=L7+'/
MI9TZ6<DG*_D*8JXWO9)O6%])DJSDDY5\[8F95*OD&UYUH=2-T=_E3+;35?(-
M9]=,H&W\_@U$&FZ]DJ]9&BZWD*^PAAOUFV88RJ!$"S5<Z5*_PAINI%XS@;;Q
M^U?ON>TI AS*(L!CU>#P\D6 (TT6 =ZPES=L:!'@:""+ '/50F/)KNBLHMS9
MCEF26I0FJ7!\0FQR @Y.T [/BQL-<4+D:):>%U=@T((LS;G)TIS+:?)TOB.K
MT7'XX; NE7[VG$;[8C^DR6B25RV6<;+660SX&L#1KVP?7Q)L29K.I\\UXJWN
M-IW'=9C.=5_WA=QWF=6_%M5V&5<AQG!E785)/:Y"NT-A;9+Q9W(5=I/4+E>A
MP&CIT;1&5T'*TQN0I\=8+O50?=)54/-,F%DMOD*=]4\_TWS;8*!NALO@9SQ.
MP_)U/I<Y-G)77,E0ZTUP(.[6=FE@_"N'F?#A)R;FX(HKBWU16%W]Z"OZ LPK
MW]O]E<RDQ N-.I[,DA.(X_]]#+LVMR#T[A8.T[_=Z6M8["O=?-9?7#ST^,AB
MP[I+G6%Z^WR3<YI0F??BU/4$=-8?(*&+OX 8]H+?#DL,F!Y<8L!T9A0EG?IG
MY@)K+4&C*%0"KQ 'NA5F>'^PK2=X*%M%CZ8G\SK[ U.[Q_WKG]KM1$?.!WCK
M>.31_.ZC1Z]?_PCOL=H;JOL'-Q?_?6W3I,>]6;^)BU+S_W2:$=?7-)^7BRI2
M#7(8=FS2LR*\#H4:*Y5?<8+Q.]UP^/#B:YQ6++?1I$_);33I4V<J%;JH.QP:
ML\5GIYZAI..V$R;JR8:OOOW+!P/\O07VN4^%D1_!"'>^/NJ6"$F$Y+ SE3+&
MJ8^5$0W;485T4C)MG"B00UG+#&4]T536XAR:"I23Q8H&*]JKR8*#* $SUG!D
MZW34 O:]+ALB%?>4$U3;5,M]4>ET"+I,%MC68''-3E6C<E"<)Q&<\NRM06>N
MJI.&U(C)RDI967G0.)J=J/ZD)#,=92!1>7%M!E)+2C(O2F'_X.&'NJLRRA1P
MME#!E9W'<3D-Q^]WGX8;Y484Y)2.QA%=JY1!DNZ.4@;C>KSE.FMNKMS;.0P[
M)/V=5OL[X04?@?8PEI,)KX<PFZ@R8DA'!?1%81"(<>-PN&[!K]B9V=P]"ND,
M5M^M9S:U!F<V9[5$VDI>M/14FJ)V4L39EIS>I%]/R.H\7LKE,W)GS-LU!.7O
M)+.86HY &$JGL%/BPHF]6I<PQFL^N(:<MANDD;M!+Z?"'9N8\ &=^8_J3ZE^
M$AFR/86//FAL3G*B@LJ9-:473;9PRA;.PS&%06MSDA.:LCEI2M?\+82A>>Y
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MWW4["4+Z"029L@2-HJ/DWVQ-^X6QX&&?@7&V!A)WYZ>>\E9?/AY>"/QV"W_
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M\P!K+P1O2R&FQN&_'FP0TP) GKD<'HX 7W<"PU\'76F2KLK0U632G22&$Q2
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M5,3:$=.16(0C,_6MRUX%_W@=B 7#HHW3EUXG'X^DF3:K\6;XGP75SF:]Z6B
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MBO%NIOAY8:]>X/\>O8TY__]02P,$%     @ KH <64':K[DT$   HK0  !$
M  !L9G9N+3(P,C0P-C,P+GAS9.U=6W?B.!)^GU_A9<_9G3UGZ !)Y[:3WD,3
MTIVS26"!GIYYFB/L K1M+$:6<]E?OR79!H-M9''9T.O,0T^P55^IZBO=2I;]
M\S^>IZ[U"-RGS+NJU-_5*A9X-G.H-[ZJ?!G<5,\K__CPPP\__ZE:_?5C[\ZZ
M9G8P!4]8+0Y$@&,]43&QQ 2LKXQ_HX_$ZKI$C!B?5JL?E%B+S5XX'4^$U:@U
M3N)B\5U^"0[42./]>;5Q=GY1/1F=U:O#6LVIGC7L\^-34J^=U."G\>5[.*F=
MU8=VM7%Z=EX].1]"E1R_MZNG9_7Z1>T4G-'IJ0)]]B]]>P)38J%IGG_Y[%]5
M)D+,+H^.GIZ>WCT=OV-\?-2HU>I'O][?]5712E36I=ZWI=+/0^[&Y8^/Y.TA
M\6%>?/3H+15WZ0@>B2?(&-[9;'HD+:Z='M=B 0E'URB@GB^(9\\5.()7Q<L,
M_'JV$-X_DO>EHEJU5J\VZBE1O62C6CNN'J,D$8+382#@!OF[AA$)7'%5";P_
M H*647 P.%R0]"\52-P6A(]!/) I^#-B0S'G?/C!LB1M=#IC7%A>2GI$_*&J
MM<^%$JM8(<5WS"9"1:XLZ6-196"J_!&XPI>_JO+7NV??J1P5UQKXU3$A,R/-
M29E0>W3%I :)>*U?7%P</<L S*Y!9CBI\E7Y9[7>0(8-U.;%97'=^*L:R^VB
M#HO&9U:'6&[+.F0VM;Q8T$FJW_ZVU9BW6^-J1))&U5! /MCOQNSQR&:!)_A+
MD2:1)1+_,&D,2V .4!/=<7'YQ\8ZP79,=,;%Y1\9.HGG,:'DY97HVFQ&O1$+
M+^ E&;J7<?SV8!2/(JEA*J.34/^[)-SFS-7T*$<SSF; !04_.<0I@ F'T55%
M#G35N+_^?<;A'=8D+I)2L-P(Y6W4 #X.&\K>NX5!,82,PZN*CSRX$+KHD.UW
M8&1J/XI0C_Y?6.^2H:GU* +N=V^X35Q3PU'$#MQ-HEZ*#_"^19VK2HOA#+V+
M\Z:*):]_Z=VNG5@IU0N9&#B&7L3BAYKZKVY5%_/ZJJ4D+2GZ\]&JP I4X(/3
M\3ZHOU>;>"0<%5DCN.*DPG++;2I3++H8.W.-BYN!0\6M)Q<NJB8&GDZ):AW>
M6':X K 2""7R>ZOST._<W5XW!^WKC\V[YD.KW?_<;@_Z)J&>B[&&B8N+]XWZ
M>QGZ??0=Q+&?@+(B+"L$>R-ET.\2CE9-0%"LYRX86@;4TM4H3I?UXQ+VWTI*
M7W^ _]ZW'P;]SDVGV^XU![=XM_EPW>K<=WOMS^V'_NTO[=L'_-G>D% C%5J*
MC]=1O%!E=6ZLA3(+M5E+ZJQ0WQOK-_U!I_7/SYV[ZW:OW_[7E]O!;SO@.0-4
MR^Q)<6:3\'_Y\WFC?O9W*U3S1NA-J]G_?'/7^;KI$)F-I:7O?7'Z)*JE8$M$
MUV "+3:=$>_%@)>$D): 4SEKI+[M,C_@@#]0V(JD2^3G?C"=$O["1GTZ]N@(
M!W=/-&V54*+>N,M<:N.*SH"#@H!:?LY6^8F +3:R$M#6 MN*P4M$7P\>P0M,
M5K*QA): \U4"(LD2>;<;IC1>B.>T_PCH3/;5#R ,O)V'H/7^Q:KW8R0+H:PY
MUD\6HI6(D5NLN3>F0Q>:O@_"-V,C2UK'Q&EME8D%BA7"E(V$#BX#.?:[/ "G
M_3P#SS<:(3+%M3345VE0,%:$8\5 ):+ACGGC <B=XZ%)(U@2T[J]L>IV*5Z5
M\I8$*)&[^X+9WR;,=8#[LO\5)C/3#&&MZX]3,Z $R%^M$*9,!$P(AX\$I>4T
M'5N[:6HY!T!+Q$F*" E454A6$JI$9*C>-^ITS0;A54FM^]]G]_P11-D&WUL/
M/0D#\FPTYB:EM Y/+8U#:4N)E\C5=T#,9C:1@-;!J;5M*%@BUV*O.:5"KF!\
M7,^TF%K @V>8:UB'HB4AM;Y-H*E%UA)>B;@IEL'96VJH8(KHY.0LM20HGB*R
M?HS_*M-65C$"!@27MKOG-8+5LII:<9BP&BHI$Z=15LZ8M&4Y+2NIQ4@D7T:7
MYR3UC"E8CZ.E)+4L69,B+"--&=D^8XKR,;3TI)8MV7G#,C*3E0$TIF8-B):;
MU HG.YE81FZRDR3F<X)U,%I^TIM_.1F7,C*TDD#9K.&DY+6<I-9+Z31,&=E(
M9%8V&%U69;4LI/8%D[F9,OH_3)T8NWY)3.?U\]0>8"A>1G\OGK&Y!D&H:^+T
MM*S6\ZDU?N(Q'>O'"*9,_B^VV'X@G&-%'\&<I T5:)G<9EU?M>;ZWDC/Y>36
MPR6Y8'R#EKFA BWIZ3U,$]+G^MY(S^5$'KEW A<ZH[FW?B%NH.K>0_/Y_OH
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M['SZ$R-,7/[:Y4_'?TTQ$<>D ::-!9$U!4](!,V"X<I1(DCZ?\[^*I,@FOH
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MP^/VXA=4AF=N\-)/D%MAVE/<9Q9L!LU= A$9!V>D 6E5])1))1G9""9;O?X
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M?#S51;LI=':4RYX@Y+.)4?D,(I9:"^4=6&N+_A:R4"30R&L[>_8&G37^GD-
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ME:CW=+);6/"1I]4)"6Y*;J5PX-M"9WK?_Y;BW3=? R31Z% A16O44P<BE2K
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M\3KY7;)W'GI,G;2=M016RM<IH/B07XU3[$_?NM ?]*<_KH$BD\PV> N4TE2
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M"@ 5    ;&9V;BTR,#(T,#8S,%]L86(N>&ULU+W[C]LXLB_^^_DK^-T%#F:
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M)B=65"=V)G=\@#XCND_KCA7S<;#F4 [K_F0 V1D! VP\NZ!.@CL-H36G,MN
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MXUOE ZQN"[H4;5G:JZ)BRW6U*<5.AWC I.0LAE)&VES%*:01B2$+<Y0P@4A
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M:T/3:XC"<Z][.M'/P9I*:IB+U1/2*"E[2I)1R=F]!2=/TIX2YU2R]N3G7J<
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M^T&FE65SR:1C$ZX)>XJR]WM#$&C'3EZ,GD-X;74#;ZD FIZP$^^R*EZ]VVZ
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M0N/3AD>NS=,3*5_NBN-6C=T$JX(*>89*,"JR,$,X)A'*.$D1\9. X8 GF8A
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M>$"<UT!$9*$B\=OE>_(\7Y-%NR=1PHA/ X9XJH!D RI07L32#U.1^32)2!B
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MR-ZLLO4"[8F]A5&:A4'HXQ3G*(NH##M20A$->8A"ZB<)30M?*,A*_7F&P^1
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MNBH4R8[%1CFX#FQUR $H3]L:!U?)44^<P1)C*N/J(A0%?#BC18H%3R,4YZ)
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M%D&[S#1A"\P+2'U:D"\SU1R!?QDN8W4T^H,:%C@C&(<1BQ+$&14(DTQ&'T%
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MD9\IMT+R!!&<A2BG81PH$'6?%;!2US$X?6-*6F^W'21FDT?.:2@2 K/0CU%
M&)..-RH0Q<Q'41XG@H0X]U5&0Q_@\760'3\+&WB.XX <)T=PG :Y<1K(QC>!
MU0@$:;2+S@@IS)6_?%\*/E]7;8O>#,<L$"+&*,5I@G"21"C/HQ1E-"\8P2R-
M8E 3KA$7CB.IKJI?.JIR(P]QJK&NJ_"O83PVBA?[A?S'VM9S",YU"',7^D7]
MZA\:KK:]O*]4XW]6/1-6^A_S\.;J_<^JR:3J__QB9@[M\VJYG9W6D&W]Y;:2
M%4>I8"%-$<]\@G 1)4BZ+8)8G*=^@6,_S!DL)761IO-$5)/X;KN,?FI#MK\
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M:::^!<=1*G 0$I0602+-DF&4TR23?\1QD(1I2'TM_-]S!!R;9DNRODALJ8*
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M%H-LRO"ZKYU2T9):(Z^BMXZ!!Z_A).D XB1]V7VDCSC9XDK>;=;5FBQ5^OT
M5/*+>"*26\GE:EE??6Y(C="SO8X/<)YC/TI01E@FPTFFKBFC&'%6)"FC*4U2
M_8W@]>1PO)\<0M[^^[\%B?_7+5->CZL:?,K[249I+X*4E2;4\FM_#32VKC_'
MRX7M@ T\,M6$4::G8)2W0,D]^4Y@) ]\5Z#U-J_]70%LSG^.[XS9'O]G^>[
MXH;7?V.#X<<KLC==%//Z[V O&'H#[+QN3'7 W8R+W!?4SU A_P?AB'%$\UB@
M2*1I1O(D\'/]>@-W?#J.B?J^J,[7K8IVY-ZJX<Q[; 90O,ZN=OC2IHUP1KR*
M-Q+!'&XU;^,MOD[L,>)MOK'80ONMOEK4<$;74T4%A^3_E+O^&1VZVM7/D3/
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MI4BMENI27"R9#)IVU8V[KWX2%'Z2"HKR3"@849X@FM$,^9S'PB=QR),$Z#]
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MF7,9],N OW?=+']Q&OE[%J:X"&F<(I$6.<(49XB2Q$=!P3%.4UZP,.CFWCP
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M3$VD_*,JJJGH&ES.<%X#KY$%]L/OIRX>=>]G+BWD^HIF2]^3#/ST_2^](D?
M[<Q%=6A<T-C4!-0_GE>"B^L974G-;F@NKC[=)8VNH'OW--H/C0X@'U8[8JK
MXW;YGCS/UV11IXOH80/\%_&OS;R:K\5747Z?,Y57FJ_XEP:047V@SC;-.">L
M"(,"$1(+A(,@0R2/!/*9ST)!LH(4(,0.UPP[]C!U2@[5O'FLQYQQ#.CFK8%C
MP%=_%T ?=W_[O@7X&$( V4+%*NB/]ZMJ[?58=!+/.=6C_7C.#;NO%<\Y5?Y
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M!;C^RAZ6L@RUJ+^@1[:0@R1PY/N ,Y0 &(I+)0X9 SX+4IS'68CC4 _7>I^
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M]KRIY ;X%6."34"Q.+GLS%@68Z(=(UJ,/FV(.3@<<W@G_D1>=H=/&C.:$S\
ME$41@&F: @PS!*(DB&(_I'G&H5ZE[1@YG=^J467M'G%-",(Q-:F=T;9$U]NF
M>U3E+I5TO=^[?SHYEU4$M859.$9J7O1"!:&/< Q5WC&Y?E;]4%)9\-?@92I6
MO)YXU7EIW):B]X&)!1Z717>G%'_]/]4K7D])K7+'GB2P[I5Z3%9KB*$7Y#*\
M(A^O-^.-^*PP^Q?@\X_I>ZX=_O=+$.+[9;UB"YK2+ GS!,1,3A;R@Q3D-(/R
M@LN1^']9'*:J_NKAXHXW64-#7LN"\!?\YQY#_OQ K,O*N.R33A%1;UOI2J?E
M@9X3P\CO/%IL-F_SG!A#'_/L,\:>I9S75W:P#-4?[U[NQ4J-828TC$+F)R#D
M<@=%808P$U?!V(]Y'E,2!+'6G,\16HZWUAYE3Y+V)&4SG.L1C2G[F#;TH.UB
MFJC Q*^\))P]M_(LI;F]RDLBGW J+[YBNJ&W\+UM,U%":)($.051GDEP>A(!
M%"7B@*09)SG"G.A?#_=)S' EW$%A>W_ZKRP,PK]Z3ZCLIF?^7_Y??-\/9+F#
M5WU');ORH'\E_JK]M\I#F_K[NES^6Z(?%E2<0%=QX/=_3,+06U;5ION/ZTTM
M')2B&1K?=G;]GTW!VC%9D7_ER9]A\Z#X0W3EB>6?F!QNQE:*)_79#Z5J/,R5
MKVLQAE#<#;$K[U.C*9OFXK0XUFS$P?(S&X;3PAU;@S//Z3O$']9DT^ 4+\5Z
MC[7,"9;OUV4I?Z/KHH&B]H.0<I@0$&<,"8. (,A83H ?YS EOA^F::+J(E\F
MY[I"JF.@'QF)5FT7<O-W#3O>CA_O=\F1XGFOJ,W+/K9='6GF?&RJ1\LE5Y?:
MR$E76'XVMUU=U*$CK_&6<1ZXRRS?\F$=P%>VDJ#"[]=577V3!R1&%:-WZ$5R
M4UWCJFFJ6N0)S7"484 2',JP,@.89SD@)(,A3^,HI5K=2]/8<9TYEH1!0]GK
M2'O792D>:;?*[ST?FI>%B=] S2683[-ZQJ=5ZKLI2C5)-UO0A;T\]!1FYDY0
M6U#<B<RUC54-KT*H^GY=4/D/B0<M+@O-XG4S%DSX]ZW;G099@G'D@Y0&N1S>
M%0,DH> RPCC#H1^D7&GZ@A95U_$..4I(7E*(_ /;L:%Y15%2H.*]Q;9:-"\S
MO4::/PPXN/)0[?5,V *T,!+:UI5'B>:\]R =-1Q=CK1>-K,4-YRWE_@MNLU7
M89YDK5XAQY<U)NLT"@ZK%BD,\RR.,Y!F.!..$@D IL*>1 G. Q@SQF"J%V"9
MPH[S8$P+\K1LVYMK2?+**UC=#)A@0N7BBH%;3" ]8S/I&ZC9H+GTJF>:MEP-
M\;(D8]X^9U<C^%KR(]RQDE@=5&%#79:,VB169K5U-I1V: *MK*E?HO#^>_'P
MJ?@H@8AN^>VFKFCQ("C\5CQ7-;WY[_KE^D=)J[^514T_%7=E^<^R4L?5GT3
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M,:VIN5:6=*%GU#H<XU;PK2HN:4 ?<.6R;+904T8HS0M]<EGD(_P2A5?,]O3
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M8CLEXB2O\1K)B?$,PZ0T0;_(T12S]\)G6];R3PM&?8I@F "61P1 QF. .**
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M!&>U$NH*.#0)&F^:[?\&:NJ:D'+#Z*!7NLNJ+5*:,9YR+C9[+"Z@'"/9F8@
M#'R<84()][4<EG%RCO=]1]=;-SA<736>8H.BHK[4]K\]+>CM_1: K%?#'L!!
M1]O>IE>3T=*&OT!LULVN)OCA1E=\2Q\K\:.08UVPKXQ(F+B73P65$2]5^,/3
M;SO>IY*$.LK@&0''=Z(=V?1V7T?/ZPG*@;A4X@-NT,H;E5D+LV]<+",8OC-+
MSH:L-R[2$"SOPI-3FLCDJ,8>'."P>/0=X^N2;:M-6=6%+1>0)&D:!AS0G&,
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ME>S9_N!@O:.GH2D[Z$KOO:P/6+'7.'9&/I/C V:BZM] (>N6<7$YZ[)*;^#
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M]- +?H3S-$A!DD0!@"%E ,&  TYS&*<QS-(XUTF[G";C.J$Y.-L^,+XD2\5
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MTO%+G*G2P/RUBOS1<010RY(,,#ZN>^5ZZP%$X4PZ5W-GG&E2SZCV;'@=']V
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ME#JZA=>KU>J,>!%1F% 'G>=8YT!M'IC&FN@S$;7.TGELG07;3<W8V:\18'6
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MLGE/A5LDC.M*-U;QW8$M!TO[Z7#QYW"9X\=:(/.A;6^IG8*:N,(P,\D@<R]
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MR=(T?YD]_&$PF+?3)\2?I,0CNZ*3!);K#G K4HH*,8"N/IW2=-R1L%/-#I;
M332:M4ZL#8_;P5YI=(K;IRBQE[$09U^^S#:B#+-+4;Z:E\7R\[DRKZZC0V;<
ML@(,?0V&K0 O#.W0[+2A6#BKYE.9]B1MW#<;@R%Q",5T<5_Z:DX.-VVA.A"7
MPM^)Q\05(Q-OO':@N(P4.4<'P9+ O%#%8^O:XULDC-S ?PA%WRET/USF'<15
M-Q[%3?-$,]2QO@G16N;Z(H[V5; 99-(4'LI-\7/[QQ/;)(Q<]'L2R!PN\X9V
MIOV<F@^?L-Y%A/GWF^3N-Y!FZU^WFCRSBZ!&(V;>+#^&^47KP^>+^6HQF^9P
MT:7[[1;=5^42879UJ&TE.:-+L1BR$YNC#$6!X$R VF6$BVR%S:VW7!/"CV[#
M? P1+Z:K-%NLSI;X@93YRZR6 7 6O<V(D()@%-L4"\XY!<9Z)K4+SK<?;]F8
MAW'/R]/C^4ZOYC$QT;5M?7_V^7-8?E^4]]./\VF9IEK]?-Y:H8Y*)D&E>L-S
M@-W=\Y-;V>1#&&EDK^\N<P5:H:-E7GK0L8X=1"'!:_HV2L:Y9"JC;&T[=E-S
M=.3YD&2O]X;4LF#6]?F&KGZ'DA"X-R!X-L5YE[.1C7G>C[*1AX*T0<F=J+.]
M4KHV6._P*\[/\!"+=/E/6YF<>TEI9%,N/KM60M"!M8%)K=-Y?K9:DY._W#H5
MD4E!J*G/ZT'9S,$97B"+J(R)R3'>NC/,GJ0=:VT>6>8:VEZXE(NAP,9GVCW9
MU1<865!H'"PW,><B6S>@VY>V<2W.$!BZ;7X&T5*S!$9[\W/Y3"QLO1"K":D#
MS-&NCVIEGO8BM9&YVOEZ[@ID2FBEM2O@-P6P42B(,=?S2&C4N8CD6L_'>Y2H
M!H\_[U_@OI#!>\PD@P36&$DA P4/T20+@;:!S48PBZT;*#V%OG%-55O\W//:
M<Q@]=>TIO:+OYQ^G<78^DFAUH)FZ[V-:F:A'26QDGOZR6.0_IK,9Z?[VDM<0
MN$["1D\GGG6 QM%Y&*R F!.#4MOU:LV"2*T#F"<1V. ^9\<*6[M 9HG!(&2%
MD>*%DL@GR JL+26G&&VQ[1/VCY(UKI$:#D7WW/XTU5#'#M6F?]-%.[N+SL4'
MI9ON_9Q6=NIQ(EOY4><=).L\F<UR87:=)9 JN2QS@L0KH+@.X!-RT$$':6PN
M&@=X4[.+G*/'=-WLWWJWH2&MN1'[UH^NM\'S\VY?U[NAR"P2XQ:$YHEVFT1R
M%&A+*!YD3):V0_-9BFTY&-G_:H2[.U.\QM-RQS;O]6+^\0,N/[_ >)!+=N/?
MM[)QNXEJ9-OJ!]]S3A;+1&2I]O\K E2JO=<"+R"L3IH'BS&UKB:YGY+CI[S%
M>P.*.IZIN,U;N>@H7D%;NP'71W2I]@?Q6=MA&>S$QC30_]U);,>+O&,[L7GA
M5I]FTDHU9ET?5 !QSZ<TNW1[A,!&EN/\HZ\0DT)F3GD%<5,D8Q5A1S@!VNC
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MW=3B/CK&.0='@M71BNC P=H:9EYNM\YY^2W-SC()[[*ESP0QZ>300O")UQ.
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M/X7E1\P?%K7CY_60DTG..6$,Y'M$<@V4K$.:G+=03/)!VL1U:3TAYB!"QSV
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M2XFJ-.\'>(N$3B%TJ(H7[>3=Q2N_7\^6\^FZ#@&=YU^GW^I7ESVBBT3CO57
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MOE!XB*Z./,-?SO,IKL)N^NF+2S_]^&NQ1SZX\1794]@X\769,M*$S#P([^@
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M^25B;[Q\[<+*;;NJ?F4R,*Z9 V&IQ1^( %?.6BU)TDDP!'KM8^E)8H9-+E;
MP*.FZ%7$WL Y5&3S9HH2N5R->BH/1)P*1MCH0!-*0"BMP4AO(0BILF+1A^K
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MGA23@0)970R.=$@1_UMJ)IU!.20.7J+48PR!1&,$J3Y8L"]>SK\,XX@=T 1
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M8W2,F%N$S8OI]-)-UE?_4A'&LF(0N,VET5;I9>[P!\FC85P'8=G!F+G[I;T
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M?XN^_H/R@W>+]/_^7_\_4$L! A0#%     @ KH <6<(H$'$470  ;Y4" !0
M             ( !     &$R,#$W;'1I<&%M96YD960N:'1M4$L! A0#%
M  @ KH <6;2RA?M;'P  "+\  !(              ( !1ET  &-L87=B86-K
M<&]L:6-Y+FAT;5!+ 0(4 Q0    ( *Z '%EPO?3S4C4  *ZT   <
M      "  =%\  !E>#$P.6ME>65X96-U=&EV96)E;F5F:70N:'1M4$L! A0#
M%     @ KH <65%5-9%N!   ["T  !X              ( !7;(  &5X,C$Q
M;&ES=&]F<W5B<VED:6%R:65S,#8S+FAT;5!+ 0(4 Q0    ( *Z '%G.-NJ7
MQ0(  .\(   >              "  0>W  !E>#(S,61E;&]I='1E8V]N<V5N
M=# V,S R,"YH=&U02P$"% ,4    " "N@!Q9:GD5I1H(  ".)@  '@
M        @ $(N@  97@S,3%C96]S96,S,#)C97)T:69I8V%T:6\N:'1M4$L!
M A0#%     @ KH <64$^G5$7"   *28  !X              ( !7L(  &5X
M,S$R8V9O<V5C,S R8V5R=&EF:6-A=&EO+FAT;5!+ 0(4 Q0    ( *Z '%F2
MQG6A9P0   4/   >              "  ;'*  !E>#,R,6-E;W-E8SDP-F-E
M<G1I9FEC871I;RYH=&U02P$"% ,4    " "N@!Q90G.D[W@$  "F$   '@
M            @ %4SP  97@S,C)C9F]S96,Y,#9C97)T:69I8V%T:6\N:'1M
M4$L! A0#%     @ KH <6=IRL'',@0( %J09 !$              ( !"-0
M &QF=FXM,C R-# V,S N:'1M4$L! A0#%     @ KH <64':K[DT$   HK0
M !$              ( ! U8# &QF=FXM,C R-# V,S N>'-D4$L! A0#%
M  @ KH <6;>I: [:)0  0'@! !4              ( !9F8# &QF=FXM,C R
M-# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( *Z '%GWO3!S3D4  !8\ P 5
M          "  7., P!L9G9N+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4
M" "N@!Q9)RQX"^ 4 0"I[PH %0              @ 'TT0, ;&9V;BTR,#(T
M,#8S,%]L86(N>&UL4$L! A0#%     @ KH <60@TI1KMH   I]$' !4
M         ( !!^<$ &QF=FXM,C R-# V,S!?<')E+GAM;%!+!08     #P /
+ !X$   GB 4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>lfvn-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lfvn="http://www.lifevantage.com/20240630"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lfvn-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2024-08-27</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">lfvn:CashAccountsHeldPrimarilyAtFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">lfvn:CashAccountsHeldatOtherFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lfvn:AsiaPacificAndEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lfvn:AsiaPacificAndEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimandTrueScienceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimandTrueScienceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:ProtandimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lfvn:LifeVantageTrueScienceSkinCareRegimenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lfvn:March2016RevolvingLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-29</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-02</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-02</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandSeventeenLongTermIncentivePlanExcludingTwoThousandAndTenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-16</startDate>
            <endDate>2017-02-16</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lfvn:TwoThousandAndTenAndTwoThousandSeventeenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lfvn:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000849146</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>lfvn:lease</measure>
    </unit>
    <unit id="segment">
        <measure>lfvn:segment</measure>
    </unit>
    <unit id="region">
        <measure>lfvn:region</measure>
    </unit>
    <unit id="productline">
        <measure>lfvn:productLine</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0000849146</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-36">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-118">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-119">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-102" id="f-510">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-127" decimals="4" id="f-626" unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-128" decimals="4" id="f-627" unitRef="number">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-131" id="f-747">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-35647</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">LIFEVANTAGE CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">90-0224471</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3300 N. Triumph Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Lehi</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">84043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">432-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">LFVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">68100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">12479185</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">Portions of the registrant&#x2019;s definitive proxy statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s fiscal year 2025 annual meeting of stockholders are incorporated by reference into Part III of this report. Such definitive proxy statement will be filed with the Commission not later than 120 days after the end of the registrant&#x2019;s fiscal year ended June 30, 2024.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-37">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-38">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-39">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-40">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-41">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-42">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-43">Salt Lake City, Utah</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">16886000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">21605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">2949000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">1612000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">313000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">241000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">15055000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">16073000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">2443000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">4753000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">37646000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">44284000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">7813000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">9086000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">9569000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">8738000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">323000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">455000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">4268000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">2991000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">680000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">569000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">60299000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">66123000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">5853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">3505000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">6569000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">6651000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">202000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">1811000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">1521000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">7874000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">7932000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">22309000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">19609000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">11801000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">11566000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">198000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">299000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">34308000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">31474000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-86" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-87" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-88"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-91" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-92" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-93" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-94" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-95" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-98"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-99"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-101" unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-102" unitRef="shares">12510000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-103" unitRef="shares">12510000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-104" unitRef="shares">12622000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-105" unitRef="shares">12622000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-106" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">136644000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">134314000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">-108738000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">-98305000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">-1916000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">-1361000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">25991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">34649000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">60299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">66123000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">200164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">213398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">41440000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">43387000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">158724000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">170011000</us-gaap:GrossProfit>
    <lfvn:CommissionAndIncentives contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">85920000</lfvn:CommissionAndIncentives>
    <lfvn:CommissionAndIncentives contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">94687000</lfvn:CommissionAndIncentives>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">68472000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">71065000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">154392000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">165752000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">4332000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">4259000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-430000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">-198000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-412000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">-458000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">18000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">-260000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">4350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">3999000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">1413000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">1459000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">2937000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">2540000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-150" unitRef="shares">12458000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-151" unitRef="shares">12557000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-152" unitRef="shares">12986000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-6" decimals="-3" id="f-153" unitRef="shares">12567000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-555000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">-238000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">-555000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">-238000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">2382000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">2302000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-160" unitRef="shares">12493000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-161" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-162" unitRef="usd">131075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-163" unitRef="usd">-98437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-164" unitRef="usd">-1123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-165" unitRef="usd">31516000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-166" unitRef="usd">3188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">3188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-13" decimals="-3" id="f-168" unitRef="shares">76000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-169" unitRef="usd">252000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-170" unitRef="usd">252000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-171" unitRef="shares">273000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-172" unitRef="shares">47000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-173" unitRef="usd">201000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-174" unitRef="usd">201000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-13" decimals="-3" id="f-175" unitRef="shares">173000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-14" decimals="-3" id="f-176" unitRef="usd">822000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-6" decimals="-3" id="f-177" unitRef="usd">822000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DividendsCash contextRef="c-14" decimals="-3" id="f-178" unitRef="usd">1586000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash contextRef="c-6" decimals="-3" id="f-179" unitRef="usd">1586000</us-gaap:DividendsCash>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-180" unitRef="usd">-238000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-181" unitRef="usd">-238000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-182" unitRef="usd">2540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">2540000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-184" unitRef="shares">12622000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-185" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-186" unitRef="usd">134314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-187" unitRef="usd">-98305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-188" unitRef="usd">-1361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">34649000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-190" unitRef="usd">3280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">3280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-21" decimals="-3" id="f-192" unitRef="shares">64000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-193" unitRef="usd">271000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">271000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-195" unitRef="shares">1007000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-3" id="f-196" unitRef="shares">206000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-197" unitRef="usd">1221000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">1221000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-21" decimals="-3" id="f-199" unitRef="shares">977000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-22" decimals="-3" id="f-200" unitRef="usd">6430000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">6430000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DividendsCash contextRef="c-22" decimals="-3" id="f-202" unitRef="usd">6940000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">6940000</us-gaap:DividendsCash>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-23" decimals="-3" id="f-204" unitRef="usd">-555000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">-555000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-206" unitRef="usd">2937000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">2937000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-3" id="f-208" unitRef="shares">12510000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-209" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-210" unitRef="usd">136644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-211" unitRef="usd">-108738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-212" unitRef="usd">-1916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-213" unitRef="usd">25991000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">2937000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-215" unitRef="usd">2540000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">3581000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">3579000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">3280000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">3188000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">1287000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">1748000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-6" decimals="-3" id="f-223" unitRef="usd">-33000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">7000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">-1277000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-6" decimals="-3" id="f-227" unitRef="usd">-1702000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">1424000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">-1558000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">71000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-6" decimals="-3" id="f-231" unitRef="usd">-1510000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-662000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">-61000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">-2280000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">-1276000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">55000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">157000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">2301000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">-3982000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">202000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">-453000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">-176000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">-770000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">-1586000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">-1858000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">247000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">257000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">12197000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">6828000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">2245000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-251" unitRef="usd">3067000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-253" unitRef="usd">8000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">-2245000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-255" unitRef="usd">-3059000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">97000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-6" decimals="-3" id="f-257" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">6430000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-6" decimals="-3" id="f-259" unitRef="usd">822000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">6940000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">1586000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">1221000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-263" unitRef="usd">201000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">271000</lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">252000</lfvn:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-14417000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">-2357000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">-254000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-269" unitRef="usd">3000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">-4719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-271" unitRef="usd">1415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-272" unitRef="usd">21605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-273" unitRef="usd">20190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-274" unitRef="usd">16886000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-275" unitRef="usd">21605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">21000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-3" id="f-277" unitRef="usd">5000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">2306000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-6" decimals="-3" id="f-279" unitRef="usd">1873000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-280">The Company&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LifeVantage Corporation (the "Company" or "we" or "our" or "us") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company is dedicated to helping people achieve their health, wellness, and financial goals. The Company provides quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to its independent consultants. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The Company sold its products in China through a China approved cross-border e-commerce business model until March 15, 2023, at which time the Company closed its e-commerce business in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's line of scientifically validated dietary supplements includes its flagship Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; family of products, LifeVantage&#xae; Omega+, ProBio, IC Bright&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is the Company's line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, its companion pet supplement formulated to combat oxidative stress in dogs; and AXIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, its nootropic energy drink mixes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in Colorado in June 1988 under the name Andraplex Corporation. The Company changed its corporate name to Yaak River Resources, Inc. in January 1992, and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, the Company acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, the Company changed its name to LifeVantage Corporation.&lt;/span&gt;&lt;/div&gt;In March 2018, the Company reincorporated from the state of Colorado to the state of Delaware. All outstanding shares of common stock, options and share units of the Colorado corporation were converted into an equivalent share, option or share unit of the Delaware corporation and the par value of the Company's common stock was adjusted to $0.0001.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-28"
      decimals="INF"
      id="f-281"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-282">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, stock-based compensation, and loss contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Company&#x2019;s business operations occurs outside the United States.&#160;The local currency of each of the Company&#x2019;s subsidiaries generally is its functional currency.&#160;All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders&#x2019; equity is recorded at historical exchange rates.&#160;The resulting foreign currency translation adjustments are recorded as a separate component of stockholders&#x2019; equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices for identical instruments in active markets; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable for the fiscal years ended June&#160;30, 2024 and 2023 consist primarily of credit card receivables. Based on the Company&#x2019;s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June&#160;30, 2024 or 2023 is not necessary. There was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no b&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ad debt expense for the fiscal year ended June&#160;30, 2024. Bad debt expense for the fiscal year ended June&#160;30, 2023 was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024 and 2023, inventory consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method, which includes a reduction in inventory values of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $1.3 million at June&#160;30, 2024 and 2023, respectively, related to obsolete and slow-moving inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves of inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment (includes computer hardware and software)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are stated at cost less accumulated amortization. Finite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset&#x2019;s carrying value and estimated fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Annual impairment tests on intangible assets were completed for the fiscal years ended June&#160;30, 2024 and 2023, resulting in no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow. For the fiscal years ended June&#160;30, 2024 and 2023, management has concluded that there are no indications of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents. At June&#160;30, 2024, the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; had $12.6 million in cash accounts at one financial institution and $4.3 million i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n other financial institutions. As of June&#160;30, 2024 and 2023, and during the years then ended, the Company&#x2019;s cash balances exceeded federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commissions and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commissions and incentives expenses are the Company&#x2019;s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent consultants, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent consultants for personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs associated with inbound freight and freight out to customers, including independent consultants, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all costs related to research and development activities as incurred. Research and development expenses for the fiscal years ended June&#160;30, 2024 and 2023 were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.7 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities and long-term lease liabilities on the consolidated balance sheets. The Company does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#x2019;s lease agreements do not contain any residual value guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal years ended June&#160;30, 2024 and 2023, the effects of approximately 13,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 0.2 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock, are not included in the computations as their effect was anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock awards and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operates in an integrated manner from market to market.&#160;Commissions and incentives expenses are the Company&#x2019;s largest expense comprised of the commissions paid to its independent consultants.&#160;The Company manages its business primarily by managing its international network of independent consultants.&#160;The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific and Europe region. See disaggregated revenue in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company&#x2019;s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company&#x2019;s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-284">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, stock-based compensation, and loss contingencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Company&#x2019;s business operations occurs outside the United States.&#160;The local currency of each of the Company&#x2019;s subsidiaries generally is its functional currency.&#160;All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders&#x2019; equity is recorded at historical exchange rates.&#160;The resulting foreign currency translation adjustments are recorded as a separate component of stockholders&#x2019; equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-286">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices for identical instruments in active markets; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/div&gt;Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-288">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s accounts receivable for the fiscal years ended June&#160;30, 2024 and 2023 consist primarily of credit card receivables. Based on the Company&#x2019;s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June&#160;30, 2024 or 2023 is not necessary.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="INF" id="f-289" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-6" decimals="INF" id="f-290" unitRef="usd">100000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-291">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024 and 2023, inventory consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves of inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">11841000</us-gaap:InventoryFinishedGoods>
    <lfvn:InventoryFinishedGoodsPercentOfTotalInventory contextRef="c-4" decimals="3" id="f-293" unitRef="number">0.787</lfvn:InventoryFinishedGoodsPercentOfTotalInventory>
    <us-gaap:InventoryFinishedGoods contextRef="c-5" decimals="-3" id="f-294" unitRef="usd">12153000</us-gaap:InventoryFinishedGoods>
    <lfvn:InventoryFinishedGoodsPercentOfTotalInventory contextRef="c-5" decimals="3" id="f-295" unitRef="number">0.756</lfvn:InventoryFinishedGoodsPercentOfTotalInventory>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">3214000</us-gaap:InventoryRawMaterials>
    <lfvn:RawMaterialsPercentOfTotalInventory contextRef="c-4" decimals="3" id="f-297" unitRef="number">0.213</lfvn:RawMaterialsPercentOfTotalInventory>
    <us-gaap:InventoryRawMaterials contextRef="c-5" decimals="-3" id="f-298" unitRef="usd">3920000</us-gaap:InventoryRawMaterials>
    <lfvn:RawMaterialsPercentOfTotalInventory contextRef="c-5" decimals="3" id="f-299" unitRef="number">0.244</lfvn:RawMaterialsPercentOfTotalInventory>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">15055000</us-gaap:InventoryNet>
    <lfvn:InventoryPercentOfTotalInventory contextRef="c-4" decimals="INF" id="f-301" unitRef="number">1.000</lfvn:InventoryPercentOfTotalInventory>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-302" unitRef="usd">16073000</us-gaap:InventoryNet>
    <lfvn:InventoryPercentOfTotalInventory contextRef="c-5" decimals="INF" id="f-303" unitRef="number">1.000</lfvn:InventoryPercentOfTotalInventory>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-304">Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryAdjustments contextRef="c-4" decimals="-5" id="f-305" unitRef="usd">1300000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments contextRef="c-5" decimals="-5" id="f-306" unitRef="usd">1300000</us-gaap:InventoryAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-29" decimals="-3" id="f-307" unitRef="usd">1292000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-30" decimals="-3" id="f-308" unitRef="usd">1253000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-31" decimals="-3" id="f-309" unitRef="usd">901000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-32" decimals="-3" id="f-310" unitRef="usd">1199000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-31" decimals="-3" id="f-311" unitRef="usd">892000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-32" decimals="-3" id="f-312" unitRef="usd">1160000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-33" decimals="-3" id="f-313" unitRef="usd">1301000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-29" decimals="-3" id="f-314" unitRef="usd">1292000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-315">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment (includes computer hardware and software)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment (includes computer hardware and software)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment (includes computer hardware and software)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-34" id="f-317">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-35" id="f-318">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-36" id="f-319">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-37" id="f-320">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-321">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are stated at cost less accumulated amortization. Finite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset&#x2019;s carrying value and estimated fair value. &lt;/span&gt;&lt;/div&gt;Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="INF" id="f-322" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="INF" id="f-323" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-325">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure contextRef="c-38" decimals="-5" id="f-326" unitRef="usd">12600000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure contextRef="c-39" decimals="-5" id="f-327" unitRef="usd">4300000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:CommissionsExpensePolicyPolicyTextBlock contextRef="c-1" id="f-328">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commissions and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commissions and incentives expenses are the Company&#x2019;s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent consultants, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent consultants for personal purchases. Commissions paid to independent consultants on personal purchases are considered a sales discount and are reported as a reduction to net revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommissionsExpensePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-329">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs associated with inbound freight and freight out to customers, including independent consultants, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.&lt;/span&gt;&lt;/div&gt;Revenue&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates the majority of its revenue through product sales to customers. These products include the Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;line of dietary supplements, LifeVantage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Omega+, ProBio, IC Bright&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Daily Wellness, Rise AM, Reset PM, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; skin and hair care products and Liquid Collagen, Petandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and AXIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also charges amounts to independent consultants to attend events that it holds. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis, adjusted for the probability of the tickets being redeemed for attendance at a future event. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company launched its Rewards Circle loyalty program in the United States, Australia, New Zealand, and Japan in March 2023 and in Canada, Europe, and Mexico in February 2024.  Contract liabilities, recorded as deferred revenue, include these loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits are redeemed for additional products at a later date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Deferred revenue is included in accrued expenses in the consolidated balance sheets.  The balance of deferred revenue related to contract liabilities was $0.9 million and $0.8 million as of June&#160;30, 2024 and 2023, respectively. The contract liabilities impact to revenue for the years ended June&#160;30, 2024 and 2023 was a decrease of $26,000 and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-330">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;The Company expenses all costs related to research and development activities as incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-331" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-5" id="f-332" unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities and long-term lease liabilities on the consolidated balance sheets. The Company does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company&#x2019;s lease agreements do not contain any residual value guarantees.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <lfvn:NumberOfFinanceLeases contextRef="c-1" decimals="INF" id="f-334" unitRef="lease">0</lfvn:NumberOfFinanceLeases>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-335">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-338" unitRef="shares">13000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-5" id="f-339" unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock awards and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">2937000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-342" unitRef="usd">2540000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-343" unitRef="shares">12458000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-344" unitRef="shares">12557000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-345" unitRef="shares">528000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-6" decimals="-3" id="f-346" unitRef="shares">10000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-347" unitRef="shares">12986000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-348" unitRef="shares">12567000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-350"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-351"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-352"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operates in an integrated manner from market to market.&#160;Commissions and incentives expenses are the Company&#x2019;s largest expense comprised of the commissions paid to its independent consultants.&#160;The Company manages its business primarily by managing its international network of independent consultants.&#160;The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific and Europe region.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <lfvn:NumberOfGeographicSegments
      contextRef="c-1"
      decimals="INF"
      id="f-354"
      unitRef="segment">2</lfvn:NumberOfGeographicSegments>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-40" decimals="-3" id="f-356" unitRef="usd">19216000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-41" decimals="-3" id="f-357" unitRef="usd">20504000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-42" decimals="-3" id="f-358" unitRef="usd">1925000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-43" decimals="-3" id="f-359" unitRef="usd">354000</us-gaap:NoncurrentAssets>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-360">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company&#x2019;s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company&#x2019;s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-361">Revenue&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates the majority of its revenue through product sales to customers. These products include the Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;line of dietary supplements, LifeVantage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Omega+, ProBio, IC Bright&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Daily Wellness, Rise AM, Reset PM, D3+, and PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; skin and hair care products and Liquid Collagen, Petandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and AXIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also charges amounts to independent consultants to attend events that it holds. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis, adjusted for the probability of the tickets being redeemed for attendance at a future event. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company launched its Rewards Circle loyalty program in the United States, Australia, New Zealand, and Japan in March 2023 and in Canada, Europe, and Mexico in February 2024.  Contract liabilities, recorded as deferred revenue, include these loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits are redeemed for additional products at a later date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Deferred revenue is included in accrued expenses in the consolidated balance sheets.  The balance of deferred revenue related to contract liabilities was $0.9 million and $0.8 million as of June&#160;30, 2024 and 2023, respectively. The contract liabilities impact to revenue for the years ended June&#160;30, 2024 and 2023 was a decrease of $26,000 and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales Returns and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company&#x2019;s return policy is to provide a full refund for product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of June&#160;30, 2024 and 2023, the Company&#x2019;s return liability reserve, net was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.1 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for sales returns consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports revenue in two&#160;geographic regions: the Americas region and the Asia/Pacific and Europe region. The following table presents the Company's revenue disaggregated by these two&#160;geographic regions (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia/Pacific &amp;amp; Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information as to the Company&#x2019;s revenue from operations in the most significant geographical areas is set forth below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue is largely attributed to two product lines, Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, each of which accounted for more than 10% of total revenue for each of the fiscal years ended June&#160;30, 2024 and 2023. On a combined basis, the Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product lines represent approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1% and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 79.3% of the Company's total revenue for the fiscal years ended June&#160;30, 2024 and 2023, respectively. The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;product line&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;product line&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-5" id="f-362" unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-5" id="f-363" unitRef="usd">800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">-26000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-6" decimals="-3" id="f-365" unitRef="usd">-700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <lfvn:MoneyBackGuaranteePeriod contextRef="c-1" id="f-366">P30D</lfvn:MoneyBackGuaranteePeriod>
    <lfvn:HandlingAndRestockingFeePercentage contextRef="c-4" decimals="INF" id="f-367" unitRef="number">0.10</lfvn:HandlingAndRestockingFeePercentage>
    <lfvn:ReturnLiabilityReserve contextRef="c-4" decimals="-5" id="f-368" unitRef="usd">100000</lfvn:ReturnLiabilityReserve>
    <lfvn:ReturnLiabilityReserve contextRef="c-5" decimals="-5" id="f-369" unitRef="usd">100000</lfvn:ReturnLiabilityReserve>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-370">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for sales returns consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table presents the Company's revenue disaggregated by these two&#160;geographic regions (in thousands):&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia/Pacific &amp;amp; Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information as to the Company&#x2019;s revenue from operations in the most significant geographical areas is set forth below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-44" decimals="-3" id="f-371" unitRef="usd">129000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-45" decimals="-3" id="f-372" unitRef="usd">131000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-46" decimals="-3" id="f-373" unitRef="usd">1622000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-47" decimals="-3" id="f-374" unitRef="usd">1978000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-46" decimals="-3" id="f-375" unitRef="usd">1618000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-47" decimals="-3" id="f-376" unitRef="usd">1980000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-48" decimals="-3" id="f-377" unitRef="usd">133000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-44" decimals="-3" id="f-378" unitRef="usd">129000</us-gaap:ValuationAllowancesAndReservesBalance>
    <lfvn:NumberOfGeographicSegments contextRef="c-1" decimals="INF" id="f-379" unitRef="region">2</lfvn:NumberOfGeographicSegments>
    <lfvn:NumberOfGeographicSegments contextRef="c-1" decimals="INF" id="f-380" unitRef="region">2</lfvn:NumberOfGeographicSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="-3" id="f-381" unitRef="usd">152907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-382" unitRef="usd">155361000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-51" decimals="-3" id="f-383" unitRef="usd">47257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-52" decimals="-3" id="f-384" unitRef="usd">58037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">200164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-386" unitRef="usd">213398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-53" decimals="-3" id="f-387" unitRef="usd">145679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-3" id="f-388" unitRef="usd">148522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-3" id="f-389" unitRef="usd">26989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-3" id="f-390" unitRef="usd">32082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lfvn:NumberOfProductLines
      contextRef="c-1"
      decimals="INF"
      id="f-391"
      unitRef="productline">2</lfvn:NumberOfProductLines>
    <lfvn:NumberOfProductLines
      contextRef="c-6"
      decimals="INF"
      id="f-392"
      unitRef="productline">2</lfvn:NumberOfProductLines>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-57" decimals="3" id="f-393" unitRef="number">0.801</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="3" id="f-394" unitRef="number">0.793</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-395">The following table shows revenue by major product line for the fiscal years ended June&#160;30, 2024 and 2023:&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protandim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;product line&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TrueScience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;product line&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-59" decimals="-3" id="f-396" unitRef="usd">104135000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="3" id="f-397" unitRef="number">0.520</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-61" decimals="-3" id="f-398" unitRef="usd">119720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="3" id="f-399" unitRef="number">0.561</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-3" id="f-400" unitRef="usd">56252000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="3" id="f-401" unitRef="number">0.281</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-65" decimals="-3" id="f-402" unitRef="usd">49494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="3" id="f-403" unitRef="number">0.232</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-404" unitRef="usd">39777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="3" id="f-405" unitRef="number">0.199</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-406" unitRef="usd">44184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="3" id="f-407" unitRef="number">0.207</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">200164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-71"
      decimals="INF"
      id="f-409"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-410" unitRef="usd">213398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-72"
      decimals="INF"
      id="f-411"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-412">Property and Equipment, Net&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment (includes computer hardware and software)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.4 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $3.4 million for the fiscal years ended June&#160;30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-413" unitRef="usd">15766000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-414" unitRef="usd">16976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-36" decimals="-3" id="f-415" unitRef="usd">1466000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-75" decimals="-3" id="f-416" unitRef="usd">1476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-76" decimals="-3" id="f-417" unitRef="usd">5040000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-418" unitRef="usd">4734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-37" decimals="-3" id="f-419" unitRef="usd">51000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-78" decimals="-3" id="f-420" unitRef="usd">51000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-421" unitRef="usd">14510000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-422" unitRef="usd">14151000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-423" unitRef="usd">7813000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-424" unitRef="usd">9086000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-425" unitRef="usd">3400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-5" id="f-426" unitRef="usd">3400000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-427">Intangible Assets, Net&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and other indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.1 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.1 million for the fiscal years ended June&#160;30, 2024 and 2023, respectively. As of June&#160;30, 2024, the remaining weighted-average amortization period for finite-lived intangible assets was 0.75 years. Annual estimated amortization expense is expected to approximate &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the succeeding fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and other indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-79" decimals="-3" id="f-429" unitRef="usd">2330000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-80" decimals="-3" id="f-430" unitRef="usd">2330000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-79" decimals="-3" id="f-431" unitRef="usd">2252000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-80" decimals="-3" id="f-432" unitRef="usd">2120000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-79" decimals="-3" id="f-433" unitRef="usd">78000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-80" decimals="-3" id="f-434" unitRef="usd">210000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-81" decimals="-3" id="f-435" unitRef="usd">245000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-82" decimals="-3" id="f-436" unitRef="usd">245000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-437" unitRef="usd">323000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-438" unitRef="usd">455000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-439" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-5" id="f-440" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-4" id="f-441">P0Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-5" id="f-442" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-5" id="f-443" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-444">Other Accrued Expenses&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payable to vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued incentives and promotions to consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payable to vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued incentives and promotions to consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-446" unitRef="usd">1521000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-447" unitRef="usd">3060000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-448" unitRef="usd">90000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-449" unitRef="usd">42000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-450" unitRef="usd">2258000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-5" decimals="-3" id="f-451" unitRef="usd">1730000</us-gaap:TaxesPayableCurrent>
    <lfvn:AccruedPayableToVendors contextRef="c-4" decimals="-3" id="f-452" unitRef="usd">434000</lfvn:AccruedPayableToVendors>
    <lfvn:AccruedPayableToVendors contextRef="c-5" decimals="-3" id="f-453" unitRef="usd">720000</lfvn:AccruedPayableToVendors>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">860000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-455" unitRef="usd">834000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">1454000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-5" decimals="-3" id="f-457" unitRef="usd">758000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">1257000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-459" unitRef="usd">788000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-460" unitRef="usd">7874000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-461" unitRef="usd">7932000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-462">Long-Term Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;30, 2016,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "2016 Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $10.0 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $2.0 million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement, and the 2016 Security Agreement, and together with the amendments described below, the "2016 Credit Facility"). During the fiscal year ended June 30, 2020, the Company repaid, in full, the balance of the 2016 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2018 and February&#160;1, 2019, the Company entered into loan modification agreements (&#x201c;Amendment No. 1&#x201d; and &#x201c;Amendment No. 2&#x201d;, respectively).  These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2021, the Company entered into a loan modification agreement ("Amendment No. 3"), which amended the 2016 Credit Facility.  Amendment No. 3, with an available borrowing amount of $5.0 million, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of 2.00%, with an interest rate floor of 0.00%. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that the Company maintain this ratio not in excess of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.00 to 1.00, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3).  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other changes to the minimum fixed charge coverage ratio of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 1.10 to 1.00 or the minimum working capital of $6.0 million as set forth in previous amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the 2016 Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ratio (as defined in Amendment No. 4) and allowed the Company to declare and pay dividends, up to $500,000 per quarter, through September 30, 2023.  There were no other changes to the covenants or revolving loan facility as set forth in Amendment No. 3.  If the Company borrowed under the 2016 Revolving Loan, interest would have been payable quarterly in arrears on the last day of each fiscal quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 28, 2023, the Company received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of $0.40 per share of common stock, to be paid on September 22, 2023. The Company also received approval to declare and pay dividends, up to $750,000, per quarter, through September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;31, 2024, the 2016 Credit Facility reached the maturity date and was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 12, 2024, the Company entered into a Loan Agreement (the &#x201c;Loan Agreement&#x201d;) with Bank of America, N.A., as Lender (the &#x201c;Lender&#x201d;). In connection with the Loan Agreement and on the same date, the Company, Lifeline Nutraceuticals Corporation, as Guarantor (the &#x201c;Guarantor&#x201d;), and the Lender also entered into a Continuing and Unconditional Guaranty (the &#x201c;Continuing and Unconditional Guaranty&#x201d;) and a Security and Pledge Agreement (the &#x201c;Security and Pledge Agreement&#x201d;). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Line of Credit&#x201d; and collectively with the Loan Agreement, Continuing and Unconditional Guaranty, and the Security and Pledge Agreement, the &#x201c;2024 Credit Facility&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event the Company borrows under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the &#x201c;Expiration Date&#x201d;). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date. As of June&#160;30, 2024, the effective interest rate is 7.34%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, and by a pledge of the membership interests of the Company's subsidiaries, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains customary covenants, both affirmative and negative, that, among other things, restrict the Company&#x2019;s ability to deal with the Company's assets outside of the ordinary course, incur additional indebtedness, grant liens on the Company's assets, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, and enter into consolidations, mergers or other combinations. The Loan Agreement requires that the Company maintain specified financial ratios and satisfy certain financial condition tests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains certain customary events of default, including, among other things, failure of the Company to make required payments under the Loan Agreement, certain breaches of representations made by the Company or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or failure of the Company to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to the Company may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will, at the option of the Lender, bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement. &lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2024, the Company was in compliance with its financial covenants under the 2024 Credit Facility.  As of June&#160;30, 2024, there was no balance outstanding on the 2024 Credit Facility.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-83" decimals="INF" id="f-463" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-84" decimals="INF" id="f-464" unitRef="usd">2000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-85" decimals="INF" id="f-465" unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-86"
      decimals="INF"
      id="f-466"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <lfvn:DebtInstrumentFloorInterestRate
      contextRef="c-86"
      decimals="INF"
      id="f-467"
      unitRef="number">0.0000</lfvn:DebtInstrumentFloorInterestRate>
    <lfvn:DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio
      contextRef="c-87"
      decimals="INF"
      id="f-468"
      unitRef="number">2.00</lfvn:DebtInstrumentCovenantTotalLiabilitiesToTangibleNetWorthRatio>
    <lfvn:DebtInstrumentCovenantFixedChargeCoverageRatio
      contextRef="c-88"
      decimals="INF"
      id="f-469"
      unitRef="number">1.10</lfvn:DebtInstrumentCovenantFixedChargeCoverageRatio>
    <lfvn:DebtInstrumentCovenantRequiredMinimumWorkingCapital contextRef="c-88" decimals="INF" id="f-470" unitRef="usd">6000000.0</lfvn:DebtInstrumentCovenantRequiredMinimumWorkingCapital>
    <lfvn:DebtInstrumentCovenantMaximumDividend contextRef="c-89" decimals="-3" id="f-471" unitRef="usd">500000</lfvn:DebtInstrumentCovenantMaximumDividend>
    <lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend
      contextRef="c-90"
      decimals="INF"
      id="f-472"
      unitRef="usdPerShare">0.40</lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend>
    <lfvn:DebtInstrumentCovenantMaximumDividend contextRef="c-91" decimals="-3" id="f-473" unitRef="usd">750000</lfvn:DebtInstrumentCovenantMaximumDividend>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-85" decimals="INF" id="f-474" unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <lfvn:DebtInstrumentFloorInterestRate
      contextRef="c-86"
      decimals="INF"
      id="f-475"
      unitRef="number">0.0000</lfvn:DebtInstrumentFloorInterestRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-86"
      decimals="INF"
      id="f-476"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-92" decimals="4" id="f-477" unitRef="number">0.0734</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-86"
      decimals="INF"
      id="f-478"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-479">Stockholders&#x2019; Equity&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued zero shares of common stock as a result of the exercise of options. During the fiscal years ended June&#160;30, 2024 and 2023, the Company issued &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 0.3 million shares, respectively, under the Company's equity incentive plans. During the fiscal years ended June&#160;30, 2024 and 2023, 0.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares, respectively, of restricted stock were canceled or surrendered as payment of tax withholding upon vesting.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the fiscal years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2024 and 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company sold 0.1 million and 0.1 million shares under its 2019 Employee Stock Purchase Plan, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;27, 2017, the Company's board approved a stock repurchase program, which was subsequently amended on February&#160;1, 2019. Under the currently approved stock repurchase program, the Company is authorized to purchase up to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60&#160;million through December 31, 2026. The stock repurchase program permits the Company to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the Company's management, in accordance with applicable securities laws. As part of the stock repurchase program, the Company may enter into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan would be completed in accordance with the terms of the plan, including specified price, volume, and timing conditions. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he stock repurchase program may be suspended or discontinued at any time. During the year ended June&#160;30, 2024, the Company purchased 1.0 million&#160;shares of its common stock at an aggregate purchase price of $6.4 million under this repurchase program. During the fiscal year ending June&#160;30, 2023, the Company purchased 0.2 million&#160;shares of its common stock at an aggregate purchase price of $0.8 million under this repurchase program. At&#160;June&#160;30, 2024, there is&#160;$20.4 million&#160;remaining under this stock repurch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2023, the board approved a stockholder rights agreement (the &#x201c;Rights Plan&#x201d;) and declared a dividend of one right for each outstanding share of common stock to stockholders of record on September 11, 2023. Each right entitles holders to purchase one newly issued share of preferred stock at an exercise price of $20 per right, subject to adjustment. Initially, the rights are not exercisable and trade with shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, the rights become exercisable following a public announcement that a person acquires 12% (or, in the case of passive investors, 20%) or more of the outstanding shares of the Company&#x2019;s common stock. If a person becomes an acquiring person, each holder of rights (except the acquiring person) will have the right to purchase, for the purchase price, a number of shares of the Company&#x2019;s common stock at a 50% discount to the then-current trading price. Rather than allowing the rights to be exercised in those circumstances, the board may exchange each right, other than the rights owned by the acquiring person, for a share of the Company&#x2019;s common stock. The agreement provides for exceptions and additional terms for other certain situations and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Rights Plan is intended to protect the interests of the Company and its stockholders by reducing the likelihood that any entity, person or group gains control of the Company through open-market accumulation or other means without payment of an adequate control premium and expires August 28, 2024. There is currently no impact to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Certificate of Incorporation authorizes the designation and issuance of shares of preferred stock. However, as of June&#160;30, 2024, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Company&#x2019;s board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid a one-time cash dividend of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.40 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share of common stock to stockholders of record in September 2023, quarterly cash dividends of $0.035 per share of common stock to stockholders of record in September 2023, December 2023 and March 2024, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share of common stock in June 2024 which were in the aggregate amount of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.9 million, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.545 per share of common stock for the fiscal year ended June&#160;30, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the fiscal year ended June&#160;30, 2023, the Company paid to stockholders quarterly cash dividends totaling $1.6 million, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.125&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share of common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The declaration of dividends is subject to the discretion of the board and will depend upon various factors, including the Company's earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects, and other factors deemed relevant by the board.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="c-13" decimals="-3" id="f-480" unitRef="shares">0</lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="c-21" decimals="0" id="f-481" unitRef="shares">0</lfvn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-93" decimals="-5" id="f-482" unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-94" decimals="-5" id="f-483" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-484" unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="0" id="f-485" unitRef="shares">47000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-95" decimals="-5" id="f-486" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-96" decimals="-5" id="f-487" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-97" decimals="INF" id="f-488" unitRef="usd">60000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-1" decimals="-5" id="f-489" unitRef="shares">1000000.0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-490" unitRef="usd">6400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-6" decimals="-5" id="f-491" unitRef="shares">200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-6" decimals="-5" id="f-492" unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-4" decimals="-5" id="f-493" unitRef="usd">20400000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend
      contextRef="c-90"
      decimals="INF"
      id="f-494"
      unitRef="usdPerShare">0.40</lfvn:CommonStockDividendsPerShareCashPaidOneTimeDividend>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-90"
      decimals="INF"
      id="f-495"
      unitRef="usdPerShare">0.035</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-98"
      decimals="INF"
      id="f-496"
      unitRef="usdPerShare">0.035</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-99"
      decimals="INF"
      id="f-497"
      unitRef="usdPerShare">0.035</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-100"
      decimals="INF"
      id="f-498"
      unitRef="usdPerShare">0.04</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-5" id="f-499" unitRef="usd">6900000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-500"
      unitRef="usdPerShare">0.545</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-6" decimals="-5" id="f-501" unitRef="usd">1600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-6"
      decimals="INF"
      id="f-502"
      unitRef="usdPerShare">0.125</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-503">Stock-Based Compensation&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-Term Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Settled Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted, and the stockholders approved, the 2017 Long-Term Incentive Plan (the &#x201c;2017 Plan&#x201d;), effective February&#160;16, 2017, to provide incentives to eligible employees, directors, and consultants. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he initial share pool approved was 650,000 shares. On November 9, 2023, the stockholders approved amendments to the 2017 Plan to increase the number of shares of the Company's common stock that are available for issuance under the 2017 plan by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;June&#160;30, 2024, a maximum of&#160;5.1 million&#160;shares of the Company's common stock can be issued under the 2017 Plan in connection with the grant of awards which is calculated as the sum of (i)&#160;4,630,000&#160;shares and (ii) up to&#160;475,000&#160;shares previously reserved for issuance under the Company's prior 2010 Long Term Incentive Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. Outstanding stock options awarded under the 2017 Plan have exercise prices of&#160;$4.44&#160;per share, vest over a&#160;&lt;span style="-sec-ix-hidden:f-510"&gt;three&#160;year&lt;/span&gt; vesting period, and have a contractual term of ten years. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;back to the 2017 Plan. As of June&#160;30, 2024, under the 2017 Plan, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.1 million shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;The Company&#x2019;s 2019 Employee Stock Purchase Plan ("ESPP") was adopted by the board in September 2018 and approved by its stockholders in November 2018. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Reserve.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;The Company has reserved 0.4 million shares of its common stock for issuance under the ESPP. As of June&#160;30, 2024, 0.1 million shares were available for issuance. The number of shares reserved under the ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Employees may purchase each share of common stock under the ESPP at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee&#x2019;s contributions to the ESPP are limited to 15% of the compensation, and up to a maximum of 3,000 shares may be purchased by an employee during any offering period. A participant shall not be granted an option under the ESPP if such option would permit the participant&#x2019;s rights to purchase stock to accrue at a rate exceeding $25,000 fair market value of stock for each calendar year in which such option is outstanding at any time.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Offering Periods.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Unless otherwise determined by the compensation committee, the ESPP will be operated through a series of successive six-month offering periods, which will begin each year on March 1 and September 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal years ended June&#160;30, 2024 and 2023, 0.1 million and 0.1 million shares of common stock were purchased under the ESPP, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with accounting guidance for stock-based compensation, payments in equity instruments for goods or services are accounted for by the fair value method. For the fiscal year ended June&#160;30, 2024 and 2023, stock-based compensation of $3.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $3.2 million, respectively, was reflected as an increase to additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2024, there was $2.5 million of unrecognized compensation cost related to non-vested stock-based compensation arrangements under the 2017 Plan, based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over a weighted-average period of 1.44 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no stock option grants during the fiscal years ended June&#160;30, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity for the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Remaining&lt;br/&gt;Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock award activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 125,732 shares of restricted stock that were granted in exchange for the cancellation of 48,026 shares of stock units and 77,706 shares of performance restricted stock units on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total vesting date fair value of restricted shares that vested during the fiscal years ended June 30, 2024 and 2023 w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as $0.7 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.3 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 48,206 shares of restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total vesting date fair value of restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was $1.9 million and $0.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal years ended June 30, 2024 and 2023, the Company awarded performance restricted stock units (the "FY 2024 PRSUs" and "FY 2023 PRSUs," respectively) to certain employees (the "Recipients"). Each performance restricted stock unit represents a contingent right for the Recipients to receive a distribution of shares of common stock of the Company equal to 0% to 200% of the target number of performance restricted stock units subject to the award. The actual number of shares distributed will be based on the Company's achievement of specified financial performance metrics. For FY 2024 PRSUs, the performance period for 50% of the FY 2024 PRSUs ended on June&#160;30, 2024, the performance period for 30% of the FY 2024 PRSUs ends on June 30, 2025, and the performance period for the remaining 20% of the FY 2024 PRSUs ends on June 30, 2026. The financial performance metrics for the fiscal year ended June&#160;30, 2024, were deemed achieved at the 0% achievement level. The performance period for 100% of the FY 2023 PRSUs ended on June 30, 2023, and were deemed achieved at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.13% achievement level. The FY 2024 PRSUs and FY 2023 PRSUs will vest only to the extent the specified financial performance criteria are achieved and subject to the Recipient&#x2019;s continued service with the Company, as follows: (i) a portion of the earned award will vest on the first anniversary of the grant date and (ii) an additional portion of the earned award will vest thereafter in a series of quarterly installments. The fair values of the performance restricted stock units are based on the grant date fair value which is the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of performance restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes shares added based on achievement of performance goals in excess of target.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 77,706 shares of performance restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total vesting date fair value of performance restricted stock units that vested during the fiscal years ended June 30, 2024 and 2023 was approximately $1.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4,000&lt;/span&gt;, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-101"
      decimals="INF"
      id="f-504"
      unitRef="shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-102"
      decimals="INF"
      id="f-505"
      unitRef="shares">1138000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-103"
      decimals="INF"
      id="f-506"
      unitRef="shares">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-104"
      decimals="INF"
      id="f-507"
      unitRef="shares">4630000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-105"
      decimals="INF"
      id="f-508"
      unitRef="shares">475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-103"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">4.44</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm contextRef="c-106" id="f-511">P10Y</lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-103"
      decimals="-5"
      id="f-512"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-513"
      unitRef="shares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-107"
      decimals="INF"
      id="f-514"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-95"
      decimals="INF"
      id="f-515"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-107"
      decimals="INF"
      id="f-516"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-95"
      decimals="INF"
      id="f-517"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted contextRef="c-107" decimals="INF" id="f-518" unitRef="usd">25000</lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountInExcessOfFairMarketValueOfStockForOptionNotToBeGranted>
    <lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-95" id="f-519">P6M</lfvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-95" decimals="-5" id="f-520" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-96" decimals="-5" id="f-521" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-522" unitRef="usd">3300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-5" id="f-523" unitRef="usd">3200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-108" decimals="-5" id="f-524" unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-109" id="f-525">P1Y5M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-526" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-6" decimals="INF" id="f-527" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-110"
      decimals="INF"
      id="f-528"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-529">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity for the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Remaining&lt;br/&gt;Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-11" decimals="-3" id="f-530" unitRef="shares">92000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-531"
      unitRef="usdPerShare">6.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-6" decimals="-3" id="f-532" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-6" decimals="-3" id="f-534" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-6" decimals="-3" id="f-537" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-538"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-6" decimals="-3" id="f-539" unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-540"
      unitRef="usdPerShare">12.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-3" id="f-541" unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-542"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-543" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-544"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-545" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-548" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-549"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="-3" id="f-550" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-551"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-3" id="f-552" unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-554">P3Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-555" unitRef="usd">142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="-3" id="f-556" unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-558">P3Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-559" unitRef="usd">142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-560">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock award activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 125,732 shares of restricted stock that were granted in exchange for the cancellation of 48,026 shares of stock units and 77,706 shares of performance restricted stock units on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-111"
      decimals="-3"
      id="f-561"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-111"
      decimals="2"
      id="f-562"
      unitRef="usdPerShare">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-94" decimals="-3" id="f-563" unitRef="shares">117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-94"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-94" decimals="-3" id="f-565" unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-94"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-94" decimals="-3" id="f-567" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-94"
      decimals="2"
      id="f-568"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-112"
      decimals="-3"
      id="f-569"
      unitRef="shares">117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-112"
      decimals="2"
      id="f-570"
      unitRef="usdPerShare">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-93" decimals="-3" id="f-571" unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-93"
      decimals="2"
      id="f-572"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-93" decimals="-3" id="f-573" unitRef="shares">117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-93"
      decimals="2"
      id="f-574"
      unitRef="usdPerShare">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-93" decimals="-3" id="f-575" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-93"
      decimals="2"
      id="f-576"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-113"
      decimals="-3"
      id="f-577"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-113"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-93" decimals="-5" id="f-579" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-94" decimals="-5" id="f-580" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c-1" id="f-581">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 48,206 shares of restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-114"
      decimals="-3"
      id="f-582"
      unitRef="shares">334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-114"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-115"
      decimals="-3"
      id="f-584"
      unitRef="shares">417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-115"
      decimals="-3"
      id="f-586"
      unitRef="shares">156000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-115"
      decimals="-3"
      id="f-588"
      unitRef="shares">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-116"
      decimals="-3"
      id="f-590"
      unitRef="shares">539000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-117"
      decimals="-3"
      id="f-592"
      unitRef="shares">214000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-117"
      decimals="-3"
      id="f-594"
      unitRef="shares">331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">5.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-117"
      decimals="-3"
      id="f-596"
      unitRef="shares">84000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-118"
      decimals="-3"
      id="f-598"
      unitRef="shares">338000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-599"
      unitRef="usdPerShare">4.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-117" decimals="-5" id="f-600" unitRef="usd">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-115" decimals="-5" id="f-601" unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage
      contextRef="c-119"
      decimals="INF"
      id="f-602"
      unitRef="number">0</lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage>
    <lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage
      contextRef="c-120"
      decimals="INF"
      id="f-603"
      unitRef="number">2</lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage>
    <lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage
      contextRef="c-121"
      decimals="INF"
      id="f-604"
      unitRef="number">0</lfvn:SharebasedCompensationArrangementbySharebasedPaymentAwardDistributionPercentage>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of performance restricted stock units activity during the fiscal years ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:95.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes shares added based on achievement of performance goals in excess of target.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;Includes 77,706 shares of performance restricted stock units that were canceled in exchange for restricted stock awards on November 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-122"
      decimals="-3"
      id="f-606"
      unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-122"
      decimals="2"
      id="f-607"
      unitRef="usdPerShare">15.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-123"
      decimals="-3"
      id="f-608"
      unitRef="shares">518000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-609"
      unitRef="usdPerShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-123"
      decimals="-3"
      id="f-610"
      unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">15.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-123"
      decimals="-3"
      id="f-612"
      unitRef="shares">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-124"
      decimals="-3"
      id="f-614"
      unitRef="shares">492000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-125"
      decimals="-3"
      id="f-616"
      unitRef="shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-125"
      decimals="-3"
      id="f-618"
      unitRef="shares">284000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-125"
      decimals="-3"
      id="f-620"
      unitRef="shares">274000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-621"
      unitRef="usdPerShare">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-126"
      decimals="-3"
      id="f-622"
      unitRef="shares">284000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-623"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-125" decimals="-3" id="f-624" unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-123" decimals="-3" id="f-625" unitRef="usd">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="c-1" id="f-628">Other Expense, Net&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency transaction loss, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-629">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency transaction loss, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-630" unitRef="usd">-429000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-6" decimals="-3" id="f-631" unitRef="usd">-373000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <lfvn:OtherMiscellaneousIncomeExpensesNet contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">17000</lfvn:OtherMiscellaneousIncomeExpensesNet>
    <lfvn:OtherMiscellaneousIncomeExpensesNet contextRef="c-6" decimals="-3" id="f-633" unitRef="usd">-85000</lfvn:OtherMiscellaneousIncomeExpensesNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-634" unitRef="usd">-412000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-635" unitRef="usd">-458000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-636">Income Taxes&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the fiscal years ended June&#160;30, 2024 and 2023 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Before Income Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Deferred Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate for the fiscal years ended June&#160;30, 2024 and 2023 differs from the U.S. Federal statutory income tax rate due to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax return to provision true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limit on future stock compensation due to 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revalue of deferred for change in federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; current year section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; foreign derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; removal of additional permanent reinvestment assertions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; change in uncertain tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; accrual for foreign tax audits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax provision &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the deferred tax assets and liabilities as of June&#160;30, 2024 and 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal, state, and foreign net operating loss carryovers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued vacation, allowance for returns, bonuses&#160;&amp;amp; other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property&#160;&amp;amp; equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted accounting guidance for uncertain tax positions ("UTPs") which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position. The measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal year ending June&#160;30, 2024, the Company began recording a withholding tax obligation on its rebalanced commission payments to the U.S. parent company it has not obtained treaty rates for. The Company does not believe it will obtain treaty rates, but will also not be able to take a foreign tax credit at this time. Since the Company believes it is unlikely to receive treaty benefits, it has recorded the taxes, the foreign tax credit on those taxes, and a corresponding UTP against the foreign tax credit. The UTP totaling $0.1 million was recorded against the foreign tax credit as of June&#160;30, 2024. If the Company is successful with its treaty benefit application or receives an opinion through appeals, competent authority, etc., it will remove the UTP at that time. The UTP recorded is the foreign taxes that will not be credited, but reduced by the benefit the Company will receive from deducting the taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also currently undergoing income tax audits in foreign jurisdictions. For the fiscal year ending June&#160;30, 2024, the Company accrued a total $0.3 million related to foreign income tax audits. At this time, the Company believes this amount reflects the amount that is has more than 50% likelihood to be paid upon settlement including interest and penalties. The Company will continue to evaluate as the audits progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reserved $0.4 million for taxes related to the UTPs as of June&#160;30, 2024. There were no changes to the liability for UTPs for the fiscal year ended June&#160;30, 2023. There were no unrecognized tax benefits for the fiscal years ended June&#160;30, 2024 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal 2022, the Company removed its permanent reinvestment assertion in Japan. In fiscal 2024, the Company also removed its permanent reinvestment assertions in Taiwan and Australia and recorded the tax effects of that change.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For Taiwan, the Company recorded provisions for withholding tax that it will pay to Taiwan upon payment of dividends. The Company did not record any unborn foreign tax credit related to Taiwan withholding tax. The Company believes any withholding tax paid on dividends will be ineligible for a foreign tax credit.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record any withholding tax to Australia upon the payment of dividends. There is a 15% withholding rate on unfranked dividends between Australia and Singapore, but the Company does not anticipate paying any unfranked dividends, so it has not recorded any withholding tax to Australia.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also recorded income taxes to various states when the cash is repatriated from Taiwan and Australia. The Company did not record any federal income tax implications because any withholding tax on dividends will be ineligible for a foreign tax credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax years open for examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) include returns for fiscal years June 30, 2021 through present and the open tax years by state tax authorities include returns for fiscal years June 30, 2020 through present. In addition, the IRS and state tax authorities may examine net operating losses ("NOLs") for any previous years if utilized by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in valuation allowance during the fiscal year ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on the Company converting from a blended rate to a state-by-state provision. During the fiscal year ended June&#160;30, 2023, the change in valuation allowance related to current year income in entities with a full valuation allowance along with a change to the United States valuation allowance based on updated projections and changes to the blended rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had utilized all of its Federal NOL carry-forwards.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of June&#160;30, 2024, state NOLs were $5.6 million and foreign NOLs were $0.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total recognized tax benefit from settlement of stock-based awards for the fiscal years ending June&#160;30, 2024 and 2023, was $0.2 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts its business globally. As a result, the Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions, and are subject to examination for the open tax years of June 30, 2020 through June 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the fiscal years ended June&#160;30, 2024 and 2023 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Before Income Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Deferred Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-638" unitRef="usd">2940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-6" decimals="-3" id="f-639" unitRef="usd">2464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-640" unitRef="usd">1410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-6" decimals="-3" id="f-641" unitRef="usd">1535000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-642" unitRef="usd">4350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-643" unitRef="usd">3999000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-644" unitRef="usd">1457000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-645" unitRef="usd">2012000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-646" unitRef="usd">246000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-647" unitRef="usd">436000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-648" unitRef="usd">984000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-649" unitRef="usd">686000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-650" unitRef="usd">2687000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-651" unitRef="usd">3134000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-652" unitRef="usd">-1281000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-653" unitRef="usd">-1400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-654" unitRef="usd">-151000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-655" unitRef="usd">-303000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">158000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-657" unitRef="usd">28000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-658" unitRef="usd">-1274000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-659" unitRef="usd">-1675000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-660" unitRef="usd">1413000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-661" unitRef="usd">1459000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-662">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate for the fiscal years ended June&#160;30, 2024 and 2023 differs from the U.S. Federal statutory income tax rate due to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax return to provision true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limit on future stock compensation due to 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revalue of deferred for change in federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; current year section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; foreign derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; removal of additional permanent reinvestment assertions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; change in uncertain tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; accrual for foreign tax audits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax provision &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-663" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="INF" id="f-664" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-665" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-666" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-667" unitRef="number">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-6" decimals="3" id="f-668" unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp contextRef="c-1" decimals="3" id="f-669" unitRef="number">-0.043</lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp>
    <lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp contextRef="c-6" decimals="3" id="f-670" unitRef="number">0.032</lfvn:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionsTrueUp>
    <lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent contextRef="c-1" decimals="3" id="f-671" unitRef="number">0.028</lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent>
    <lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent contextRef="c-6" decimals="3" id="f-672" unitRef="number">0.043</lfvn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnFutureStockBasedCompensationExpensePercent>
    <lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent contextRef="c-1" decimals="3" id="f-673" unitRef="number">0.026</lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent>
    <lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent contextRef="c-6" decimals="3" id="f-674" unitRef="number">0.004</lfvn:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-675" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-676" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-677" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-6" decimals="3" id="f-678" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-679" unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="3" id="f-680" unitRef="number">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent contextRef="c-1" decimals="3" id="f-681" unitRef="number">0.070</lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent>
    <lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent contextRef="c-6" decimals="3" id="f-682" unitRef="number">0.000</lfvn:EffectiveIncomeTaxRateReconciliationCurrentYearSection162mLimitationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-1" decimals="3" id="f-683" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-6" decimals="3" id="f-684" unitRef="number">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-685" unitRef="number">0.121</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-6" decimals="3" id="f-686" unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-1" decimals="3" id="f-687" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-6" decimals="3" id="f-688" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion contextRef="c-1" decimals="3" id="f-689" unitRef="number">0.012</lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion>
    <lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion contextRef="c-6" decimals="3" id="f-690" unitRef="number">0.003</lfvn:EffectiveIncomeTaxRateReconciliationRemovalOfPermanentReinvestmentAssertion>
    <lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-1" decimals="INF" id="f-691" unitRef="number">0.012</lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-6" decimals="INF" id="f-692" unitRef="number">0.000</lfvn:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign contextRef="c-1" decimals="INF" id="f-693" unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign contextRef="c-6" decimals="INF" id="f-694" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-695" unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-6" decimals="3" id="f-696" unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-697" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="3" id="f-698" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-699" unitRef="number">0.325</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-700" unitRef="number">0.365</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-701">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the deferred tax assets and liabilities as of June&#160;30, 2024 and 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal, state, and foreign net operating loss carryovers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued vacation, allowance for returns, bonuses&#160;&amp;amp; other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property&#160;&amp;amp; equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">271000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-703" unitRef="usd">250000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">360000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-705" unitRef="usd">549000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">2578000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-707" unitRef="usd">955000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lfvn:DeferredTaxAssetsLeasingArrangements contextRef="c-4" decimals="-3" id="f-708" unitRef="usd">3223000</lfvn:DeferredTaxAssetsLeasingArrangements>
    <lfvn:DeferredTaxAssetsLeasingArrangements contextRef="c-5" decimals="-3" id="f-709" unitRef="usd">3100000</lfvn:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-4" decimals="-3" id="f-710" unitRef="usd">2119000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-5" decimals="-3" id="f-711" unitRef="usd">3005000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-712" unitRef="usd">8551000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-713" unitRef="usd">7859000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-714" unitRef="usd">30000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-715" unitRef="usd">66000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-716" unitRef="usd">798000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-717" unitRef="usd">1571000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-718" unitRef="usd">2263000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-719" unitRef="usd">2057000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-3" id="f-720" unitRef="usd">472000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-3" id="f-721" unitRef="usd">470000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-722" unitRef="usd">3563000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-723" unitRef="usd">4164000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-724" unitRef="usd">720000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-725" unitRef="usd">704000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-726" unitRef="usd">4268000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-727" unitRef="usd">2991000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <lfvn:UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities contextRef="c-1" decimals="-5" id="f-728" unitRef="usd">100000</lfvn:UnrecognizedTaxPositionIncreaseResultingFromSettlementsWithTaxAuthorities>
    <lfvn:UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits contextRef="c-1" decimals="-5" id="f-729" unitRef="usd">300000</lfvn:UnrecognizedTaxPositionIncreaseResultingFromForeignTaxAudits>
    <lfvn:UnrecognizedTaxPosition contextRef="c-4" decimals="-5" id="f-730" unitRef="usd">400000</lfvn:UnrecognizedTaxPosition>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="INF" id="f-731" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="INF" id="f-732" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="INF" id="f-733" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="INF" id="f-734" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-735">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-736" unitRef="usd">704000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-737" unitRef="usd">675000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-738" unitRef="usd">16000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-3" id="f-739" unitRef="usd">29000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-740" unitRef="usd">720000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-741" unitRef="usd">704000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-129" decimals="-5" id="f-742" unitRef="usd">5600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-130" decimals="-5" id="f-743" unitRef="usd">400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-1" decimals="-5" id="f-744" unitRef="usd">200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-6" decimals="-3" id="f-745" unitRef="usd">200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-746">Leases&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for current corporate offices and certain equipment. These leases have remaining terms of approximately &lt;span style="-sec-ix-hidden:f-747"&gt;one&lt;/span&gt; to eight years. As of June&#160;30, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was 6.90 years and 3.46%, respectively. As of June&#160;30, 2023, the weighted average remaining lease term and weighted average discount rate for operating leases was 8.27 years and 3.25%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, LifeVantage Japan entered into an operating lease agreement with Sumitomo Mitsui Trust Bank, Limited, for a new office located in the Shinagawa Grand Central Tower in Tokyo, Japan.  The lease is for approximately 5,200 square feet and has a lease term from July 1, 2023 through June 30, 2026 with the option to renew for an additional two years.  Lease payments began in November 2023 totaling approximately $28,000 per month, or $0.3 million per year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal year ended June&#160;30, 2024, the Company also entered into new operating leases with previous lessors in Thailand and Taiwan and extended the operating lease Philippines. Each of these leases have a lease term of three years, expiring in fiscal year 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the fiscal years ended June&#160;30, 2024 and 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities at June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-132" id="f-748">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-749">P6Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="4" id="f-750" unitRef="number">0.0346</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-751">P8Y3M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="4" id="f-752" unitRef="number">0.0325</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <lfvn:LesseeOperatingLeaseLeasedArea contextRef="c-1" decimals="-2" id="f-753" unitRef="sqft">5200</lfvn:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-754">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <lfvn:LesseeOperatingLeaseMonthlyPayments contextRef="c-1" decimals="-3" id="f-755" unitRef="usd">28000</lfvn:LesseeOperatingLeaseMonthlyPayments>
    <lfvn:LesseeOperatingLeaseAnnualAmount contextRef="c-1" decimals="-5" id="f-756" unitRef="usd">300000</lfvn:LesseeOperatingLeaseAnnualAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-4" id="f-757">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-758">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the fiscal years ended June&#160;30, 2024 and 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-759" unitRef="usd">1913000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-760" unitRef="usd">2537000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-761" unitRef="usd">174000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-3" id="f-762" unitRef="usd">283000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-763" unitRef="usd">47000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-6" decimals="-3" id="f-764" unitRef="usd">76000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-765" unitRef="usd">2134000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-766" unitRef="usd">2896000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-767" unitRef="usd">2187000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-768" unitRef="usd">2973000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-769" unitRef="usd">2475000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-770" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-771">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities at June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-772" unitRef="usd">2111000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-773" unitRef="usd">2154000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-774" unitRef="usd">2151000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">2037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-776" unitRef="usd">1772000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-777" unitRef="usd">4622000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-778" unitRef="usd">14847000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-779" unitRef="usd">1235000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-780" unitRef="usd">13612000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-781">Commitments and Contingencies&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for contingent liabilities in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of June&#160;30, 2024, and based on the assessment there are no probable loss contingencies requiring accrual or disclosures within its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable publicity or resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding or publicity related to such could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact of any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.   The Company may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this annual report on Form 10-K, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently &lt;/span&gt;&lt;/div&gt;believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
